Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.46 - complement factor D

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
Effects of di(2-ethylhexyl)phthalate exposure on 1,2-dimethyhydrazine-induced colon tumor promotion in rats.
Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats.
Abortion, Habitual
Effect of the functional VEGFA-583C/T variant on vascular endothelial growth factor levels and the risk of recurrent spontaneous miscarriage.
Gene-gene interactions and risk of recurrent miscarriages in carriers of endocrine gland-derived vascular endothelial growth factor and prokineticin receptor polymorphisms.
Luteal phase defect is associated with impaired VEGF mRNA expression in the secretory phase endometrium.
miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9.
Recurrent miscarriage is associated with increased ghrelin mRNA expression in the endometrium- a case-control study.
Vascular endothelial growth factor gene polymorphisms and idiopathic recurrent pregnancy loss.
Vascular endothelial growth factor gene polymorphisms in North Indian patients with recurrent miscarriages.
Abortion, Incomplete
Factors related to completeness of medical abortion with mifepristone and misoprostol.
Abortion, Missed
Soluble fms-Like Tyrosine Kinase-1 (sFlt-1) and Serum Placental Growth Factor (PlGF) as Biomarkers for Ectopic Pregnancy and Missed Abortion.
Abortion, Spontaneous
An Increase in Vascular Endothelial Growth Factor (VEGF) and VEGF Soluble Receptor-1 (sFlt-1) Are Associated with Early Recurrent Spontaneous Abortion.
Assessment of the transcription levels for the complement activation control system in eutopic endometrium in women with two or more consecutive miscarriages of unknown etiology.
Association of angiogenic cytokines (VEGF-A and VEGF-C) and clinical characteristic in women with unexplained recurrent miscarriage.
Association of serum levels of vascular endothelial growth factor and early ectopic pregnancy.
Association of vascular endothelial growth factor A polymorphisms and aberrant expression of connexin 43 and VEGFA with idiopathic recurrent spontaneous miscarriage.
Association of Vascular Endothelial Growth Factor Gene Polymorphisms with Recurrent Spontaneous Abortion in Chinese Han Women.
Association of VEGF genetic polymorphisms with recurrent spontaneous abortion risk: a systematic review and meta-analysis.
Association study of vascular endothelial growth factor polymorphisms with the risk of recurrent spontaneous abortion.
Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction.
Dynamics and reproductive effects of complement factors in the spontaneous abortion model of CBA/J×DBA/2 mice.
Effect of the functional VEGFA-583C/T variant on vascular endothelial growth factor levels and the risk of recurrent spontaneous miscarriage.
Elevation of Adipsin, a Complement Activating Factor, in the Mouse Placenta During Spontaneous Abortion.
Expression of ATF4 and VEGF in chorionic villus tissue in early spontaneous abortion.
Gene-gene interactions and risk of recurrent miscarriages in carriers of endocrine gland-derived vascular endothelial growth factor and prokineticin receptor polymorphisms.
Genetic variation in vascular endothelial growth factor gene and its association with recurrent spontaneous abortion.
Identification of specific vascular endothelial growth factor susceptible and protective haplotypes associated with recurrent spontaneous miscarriages.
Involvement of heparanase in vaginal and cesarean section deliveries.
Low VEGF expression in conceptus material and maternal serum AFP and ?-hCG levels as indicators of defective angiogenesis in first-trimester miscarriages.
Maternal serum vascular endothelial growth factor levels in early ectopic and intrauterine pregnancies after in vitro fertilization treatment.
Mechanisms of Traditional Chinese Medicine Bushenantai granules in promoting angiogenesis at the maternal-fetal interface of recurrent spontaneous abortion mice.
MicroRNA-16 inhibits feto-maternal angiogenesis and causes recurrent spontaneous abortion by targeting vascular endothelial growth factor.
miR-219a suppresses human trophoblast cell invasion and proliferation by targeting vascular endothelial growth factor receptor 2 (VEGFR2).
Polymorphisms in the vascular endothelial growth factor gene associated with recurrent spontaneous miscarriage.
Prenatal depression and stress - risk factors for placental pathology and spontaneous abortion.
Production of vascular endothelial growth factor and endothelin in the placenta and umbilical cord during normal and complicated pregnancy.
Regulation of Complement Activity via the Alternative Pathway in Placentas of Mouse Spontaneous Abortions.
Regulation of natural-killer cell cytotoxicity and enhancement of complement factors in the spontaneously aborted mouse placenta.
Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage.
Soluble Flt-1 and PlGF: New Markers of Early Pregnancy Loss?
The -2549 insertion/deletion polymorphism in the promoter region of the VEGFA gene in couples with idiopathic recurrent spontaneous abortion.
The association of second trimester biomarkers in amniotic fluid and fetal outcome.
The prevalence of combined vascular endothelial growth factor, endothelial nitric oxide synthase and thrombin-activatable fibrinolysis inhibitor genetic polymorphisms among Egyptian patients with recurrent spontaneous abortion.
The role of VEGF and its receptors in the etiology of early pregnancy loss.
The value of vascular endothelial growth factor, pregnancy-associated plasma protein-A, and progesterone for early differentiation of ectopic pregnancies, normal intrauterine pregnancies, and spontaneous miscarriages.
Vascular Endothelial Growth Factor (VEGF) and the VEGF Soluble Receptor-1 (sFlt-1) in Chorionic Villus Tissue from Chinese Women with Early Recurrent Spontaneous Abortion.
Vascular endothelial growth factor and recurrent spontaneous abortion: A meta-analysis.
Vascular endothelial growth factor gene polymorphisms and recurrent pregnancy loss.
[Growth factors are markers of placental insufficiency in third-trimester miscarriage].
Abortion, Threatened
Production of vascular endothelial growth factor and endothelin in the placenta and umbilical cord during normal and complicated pregnancy.
Soluble Flt-1 and PlGF: New Markers of Early Pregnancy Loss?
The relationship between the VEGF/sVEGFR-1 ratio and threatened abortion.
Abscess
Imaging vascular endothelial growth factor (VEGF) receptors in turpentine-induced sterile thigh abscesses with radiolabeled single-chain VEGF.
Acidosis
Accomplices of the Hypoxic Tumor Microenvironment Compromising Antitumor Immunity: Adenosine, Lactate, Acidosis, Vascular Endothelial Growth Factor, Potassium Ions, and Phosphatidylserine.
Acidosis induces synovial fibroblasts to release vascular endothelial growth factor via acid-sensitive ion channel 1a.
Acidosis inhibits endothelial cell apoptosis and function and induces basic fibroblast growth factor and vascular endothelial growth factor expression.
Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo.
Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
Multifunctional Albumin-MnO2 Nanoparticles Modulate Solid Tumor Microenvironment by Attenuating Hypoxia, Acidosis, Vascular Endothelial Growth Factor and Enhance Radiation Response.
Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells.
Acquired Immunodeficiency Syndrome
AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor.
Androgens Induce the Expression of Vascular Endothelial Growth Factor in Human Fetal Prostatic Fibroblasts* *This work was supported by grants-in-aid from the T. J. Martell Foundation for Leukemia, Cancer, and Aids Research; and the Hans E. Schapira, M.D., Foundation for Urologic Research.
Complement levels and circulating immune complexes in a controlled, longitudinal, multicentre study on effects of intravenous immunoglobulin in adults with AIDS-related complex/Walter-Reed 5. The ARC-IVIG Study Group.
Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass.
Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells.
Involvement of vascular endothelial growth factor in Kaposi's sarcoma associated with acquired immunodeficiency syndrome.
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma.
Sequential delivery of vascular endothelial growth factor and sphingosine 1-phosphate for angiogenesis.
Vascular endothelial growth factor (VEGF165) plasma level increase with immunodepression in AIDS patients with Kaposi's sarcoma.
Acro-Osteolysis
Association of Acroosteolysis With Enhanced Osteoclastogenesis and Higher Blood Levels of Vascular Endothelial Growth Factor in Systemic Sclerosis.
Acromegaly
Plasma levels of vascular endothelial growth factor in patients with acromegaly.
Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.
The effects of growth hormone status on circulating levels of vascular growth factors.
Acute Coronary Syndrome
Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes.
Concentration of vascular endothelial growth factor in patients with acute coronary syndrome.
Gene electro transfer of plasmid encoding vascular endothelial growth factor for enhanced expression and perfusion in the ischemic swine heart.
Increased circulating placental growth factor during percutaneous coronary intervention is associated with applied radiocontrast agent.
Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay.
Peripheral Artery Disease and Stroke.
Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes.
Plasma haemoxygenase-1 in coronary artery disease. A comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor.
Prognostic value of placental growth factor in patients with acute chest pain.
Serum VEGF: Diagnostic Value of Acute Coronary Syndrome from Stable Angina Pectoris and Prognostic Value of Coronary Artery Disease.
The effect of bay leaf extract (Syzygium polyanthum) on vascular endothelial growth factor (VEGF) and CD31 (PECAM-1) expression in acute coronary syndrome.
Wenyang Huoxue Jiedu formula inhibits thin-cap fibroatheroma plaque formation via the VEGF/VEGFR signaling pathway.
[Evaluation of selected vascular active factors in patients after myocardial infarction subjected to cardiac rehabilitation].
Acute Kidney Injury
Acute renal failure during the "off" period after sunitinib administration: Possible mechanism of vascular endothelial growth factor cascade hyperactivation.
Complement depletion during haemofiltration with polyacrilonitrile membranes.
Effect of erythropoietin therapy on the progression of cisplatin induced renal injury in rats.
Effects of histamine and the h2 receptor antagonist ranitidine on ischemia-induced acute renal failure: involvement of IL-6 and vascular endothelial growth factor.
Enhanced vascular endothelial growth factor and inflammatory cytokine removal with online hemodiafiltration over high-flux hemodialysis in sepsis-related acute kidney injury patients.
Expression of syndecan-1, PKC and VEGF in rats with acute kidney injury and correlation between syndecan-1 and renal function.
Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury.
Kinetics of Vascular Endothelial Growth Factor and Endothelin 1 Levels in Acute Kidney Injury.
miR-195-5p alleviates acute kidney injury through repression of inflammation and oxidative stress by targeting vascular endothelial growth factor A.
Plasma protein extravasation and vascular endothelial growth factor expression with endothelial nitric oxide synthase induction in gentamicin-induced acute renal failure in rats.
Protective effect of vascular endothelial growth factor against cardiopulmonary bypass-associated acute kidney injury in beagles.
Significant reduction of factor D and immunosuppressive complement fragment Ba by hemofiltration.
Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use.
Acute Lung Injury
Bone marrow-derived mononuclear cell therapy in experimental pulmonary and extrapulmonary acute lung injury.
Effects of Vascular Endothelial Growth Factor in Recovery Phase of Acute Lung Injury in Mice.
Myeloperoxidase instigates proinflammatory responses in a cecal ligation and puncture rat model of sepsis.
Paxillin is involved in the differential regulation of endothelial barrier by HGF and VEGF.
Protective role of vascular endothelial growth factor in endotoxin-induced acute lung injury in mice.
Pulmonary microvascular hyperpermeability and expression of vascular endothelial growth factor in smoke inhalation- and pneumonia-induced acute lung injury.
Reduced vascular endothelial growth factor correlates with alveolar epithelial damage after experimental ischemia and reperfusion.
Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury.
Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants.
The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival.
Variations in the Vascular Endothelial Growth Factor Pathway Predict Pulmonary Complications.
Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?
Vascular endothelial growth factor and related molecules in acute lung injury.
Vascular endothelial growth factor contributes to lung vascular hyperpermeability in sepsis-associated acute lung injury.
Vascular endothelial growth factor in acute lung injury and acute respiratory distress syndrome.
Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury.
VEGF levels in the alveolar compartment do not distinguish between ARDS and hydrostatic pulmonary oedema.
Vegf-d promotes pulmonary oedema in hyperoxic acute lung injury.
[The protective effect of angiopoietin-1 on early acute lung injury induced by oleic acid in mice]
Adenocarcinoma
17beta-estradiol inhibits forskolin-induced vascular endothelial growth factor promoter in MCF-7 breast adenocarcinoma cells.
A case of adenocarcinoma of the endometrial type mixed with a clear cell component that metastasized to the vagina.
A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor.
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas.
A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis.
Activation of STAT3 signaling in human stomach adenocarcinoma drug-resistant cell line and its relationship with expression of vascular endothelial growth factor.
Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice.
Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review.
Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection.
Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma.
Angiogenic factors in normal endometrium and endometrial adenocarcinoma.
Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus.
Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor.
Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling.
Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma.
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.
Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease.
Association of vascular endothelial growth factor (VEGF) gene polymorphism and increased serum VEGF concentration with pancreatic adenocarcinoma.
Association of VEGF genotype with mRNA level in colorectal adenocarcinomas.
Betulinic acid inhibits the expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in human endometrial adenocarcinoma cells.
Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma.
Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers.
Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line.
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells.
CD105 microvessels density, VEGF, EGFR-1 and c-erbB-2 and their prognostic correlation in different subtypes of cervical adenocarcinoma.
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays.
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
Clinical significance of immunohistochemical expression of hypoxia-inducible factor-1alpha as a prognostic marker in rectal adenocarcinoma.
Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients.
Coexpression of vascular endothelial growth factor and its receptor KDR on gastric adenocarcinoma MGC803 cell line and stimulation of exogenous VEGF(165) to MGC803 cells.
Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6.
Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma.
Correlation between the immunohistochemical expressions of MMP-1, MMP-7 and VEGF and prognostic factors in colorectal adenocarcinoma.
Current status of novel agents in advanced gastroesophageal adenocarcinoma.
Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma.
Cytotoxic and Antimicrobial Evaluations of Novel Apoptotic and Anti-Angiogenic Spiro Cyclic 2-Oxindole Derivatives of 2-Amino-tetrahydroquinolin-5-one.
Determination of Pentraxin-3, Interleukin-8 and Vascular Endothelial Growth Factor Levels in Patients with Gastric Adenocarcinoma.
Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.
Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma.
Effect of chitosan oligosaccharide-conjugated selenium on improving immune function and blocking gastric cancer growth.
Effect of resection of localized pancreaticobiliary adenocarcinoma on angiogenic markers and tissue factor related pro-thrombotic and pro-angiogenic activity.
Effects of 3-Tetrazolyl Methyl-3-Hydroxy-Oxindole Hybrid (THOH) on Cell Proliferation, Apoptosis, and G2/M Cell Cycle Arrest Occurs by Targeting Platelet-Derived Growth Factor D (PDGF-D) and the MEK/ERK Signaling Pathway in Human Lung Cell Lines SK-LU-1, A549, and A-427.
Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3',5'-adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signaling pathways.
Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib.
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma.
Enhancement of prostate cancer xenograft growth with whole-body radiation and vascular endothelial growth factor.
Esophageal Adenocarcinoma: Treatment Modalities in the Era of Targeted Therapy.
Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation.
Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer.
Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer.
Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma.
Expression and localization of endocrine gland-derived vascular endothelial growth factor (EG-VEGF) in human pancreas and pancreatic adenocarcinoma.
Expression levels and significance of hypoxia inducible factor-1 alpha and vascular endothelial growth factor in human colorectal adenocarcinoma.
Expression of angiopoietin-2 is correlated with vascularization and tumor size in human colorectal adenocarcinoma.
Expression of CD44v3, erythropoietin and VEGF-C in gastric adenocarcinomas: correlations with clinicopathological features.
Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine.
Expression of IL-6 receptor in pancreatic cancer: involvement in VEGF induction.
Expression of liver-type fatty-acid-binding protein, fatty acid synthase and vascular endothelial growth factor in human lung carcinoma.
EXPRESSION OF MUC2 GLYCOPROTEIN ANTIBODY AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN BARRETT'S MUCOSA.
Expression of NOS and VEGF in feline mammary tumours and their correlation with angiogenesis.
Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma.
Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas.
Expression of vascular endothelial growth factor and epidermal growth factor receptor in pancreatic ductal adenocarcinomas, neuroendocrine tumours and chronic pancreatitis.
Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration.
Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression.
Expression of vascular endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma.
Expression of VEGF, EGFR, and IL-6 in Gastric Adenomas and Adenocarcinomas by Endoscopic Submucosal Dissection.
Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma.
First-line application of apatinib combined with S-1 based on peripheral circulating tumor cell screening to treat advanced gastric adenocarcinoma: a case report.
Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with a poor outcome in lung adenocarcinoma.
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk.
Heparanase regulates in vitro VEGF-C expression and its clinical significance to pancreatic ductal cell adenocarcinoma.
Hepatocyte Growth Factor Mediated Cell Invasion in Pancreatic Cancer Cells Is Dependent on Neuropilin-1.
High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma.
High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.
High serum levels of Transforming Growth Factor-b1, Interleukin-10 and Vascular Endothelial Growth Factor in pancreatic adenocarcinoma patients.
High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma.
Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers.
Hypoxia inducible factor 1 alpha and 2 alpha expression is independent of anemia in patients with stage I endometrial cancer.
Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in canine simple mammary gland adenocarcinomas.
Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma.
Immunohistochemical study of vascular endothelial growth factor (VEGF) and matrilysin (MMP-7) in T1 adenocarcinoma of the colon and rectum to predict lymph node metastases or distant metastases.
Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
Increased expression of alpha-1-antitrypsin, glutathione S-transferase pi and vascular endothelial growth factor in human pancreatic adenocarcinoma.
Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas.
Increased pro-angiogenic factors, infiltrating neutrophils and CD163(+) macrophages in bronchoalveolar lavage fluid from lung cancer patients.
Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine.
Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells.
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1.
Interrelationships between dietary restriction, the IGF-I axis, and expression of vascular endothelial growth factor by prostate adenocarcinoma in rats.
Lack of immunohistochemical detection of VEGF in prostate carcinoma.
Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer.
Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma.
Lymphangiogenesis of normal endometrium and endometrial adenocarcinoma.
Lymphatic vessel density in pulmonary adenocarcinoma immunohistochemically evaluated with anti-podoplanin or anti-D2-40 antibody is correlated with lymphatic invasion or lymph node metastases.
Macrophage migration inhibitory factor up-regulates alpha(v)beta(3) integrin and vascular endothelial growth factor expression in endometrial adenocarcinoma cell line Ishikawa.
Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus.
MARKERS OF THE LUNG CANCER COMPLICATIONS.
Markers of tumour angiogenesis and tumour cells in bone marrow in gastric cancer patients.
Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma.
Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer.
Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma.
Molecular determinants in targeted therapy for esophageal adenocarcinoma.
Molecular profiling of angiogenesis markers.
Neoadjuvant therapy and biliary decompression lower biliary and pancreatic juice vascular endothelial growth factor levels in patients with periampullary adenocarcinoma.
Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas.
Neoangiogenesis and relationship to nuclear p53 accumulation and vascular endothelial growth factor expression in advanced gastric carcinoma.
Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis.
Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial ?5 integrin.
Novel cis-restricted ?-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro.
Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival.
Optimization of Ultrasound-mediated Anti-angiogenic Cancer Gene Therapy.
Phosphatase of Regenerating Liver-3 Induces Angiogenesis by Increasing Extracellular Signal-Regulated Kinase Phosphorylation in Endometrial Adenocarcinoma.
Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study.
PlGF knockdown inhibited tumor survival and migration in gastric cancer cell via PI3K/Akt and p38MAPK pathways.
Possible involvement of tumor-producing VEGF-A in the recruitment of lymphatic endothelial progenitor cells from bone marrow.
Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer.
Progestins activate vascular endothelial growth factor gene transcription in endometrial adenocarcinoma cells.
Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer.
Prognostic Role of Protease-Activated Receptors 1 and 4 in Resected Stage IB Non-Small-Cell Lung Cancer.
Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma.
Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung.
Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma.
Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung.
Protein kinase B phosphorylation correlates with vascular endothelial growth factor a and microvessel density in gastric adenocarcinoma.
Pulmonary adenocarcinoma angiogenesis.
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
Ramucirumab: A Review in Advanced Gastric Cancer.
Regulation of vascular endothelial growth factor expression by insulin-like growth factor-I in endometrial adenocarcinoma cells.
Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue.
Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas.
Sanguinarine inhibits vascular endothelial growth factor release by generation of reactive oxygen species in MCF-7 human mammary adenocarcinoma cells.
Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix.
Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma.
Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.
SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review.
The ?-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor ?B signaling.
The changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma.
The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma: correlation with neovascularization.
The prognostic significance of growth factors and growth factor receptors in gastric adenocarcinoma.
The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A) expression with clinical-pathological features and survival in pancreatic adenocarcinomas.
The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer.
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.
Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
Tumor-Infiltrating Lymphocytes Express Vascular Endothelial Growth Factor in Renal Cell Carcinomas.
Vascular endothelial growth factor (VEGF) genotype and serum concentration in patients with pancreatic adenocarcinoma and chronic pancreatitis.
Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells.
Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus.
Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma.
Vascular endothelial growth factor and survivin immunostaining in gastric adenocarcinoma.
Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma.
Vascular Endothelial Growth Factor Expression and Neovascularization in Non-Small Cell Lung Carcinoma.
Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression.
Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: an in vitro and in vivo study.
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.
Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803.
VEGF and Id-1 in pancreatic adenocarcinoma: Prognostic significance and impact on angiogenesis.
VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations.
VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.
VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these malignant tumors.
Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma.
[Correlation of VEGF and Ki67 expression with sensitivity to neoadjuvant chemoradiation in rectal adenocarcinoma]
[Relationship of hypoxia-inducible factor 1 alpha (HIF-1alpha) gene expression with vascular endothelial growth factor (VEGF) and microvessel density (MVD) in human colorectal adenoma and adenocarcinoma]
[The relationship of MMP-9, VEGF and PCNA expressions and their clinical significance in gastric adenocarcinoma]
[VEGF-D expression in lung adenocarcinoma with or without acquired resistance to gefitinib and normal lung tissue.]
Adenocarcinoma of Lung
?-arrestin1 over-expression is associated with an unfavorable prognosis in lung adenocarcinomas and correlated with vascular endothelial growth factor.
Angiogenesis and phenotypic alteration of alveolar capillary endothelium in areas of neoplastic cell spread in primary lung adenocarcinoma.
Assessment of VEGF-D expression measured by immunohistochemical staining and F-18 FDG uptake on PET as biological prognostic factors for recurrence in patients with surgically resected lung adenocarcinoma.
Branched ?-(1,4) glucans from Lentinula edodes (L10) in combination with radiation enhance cytotoxic effect on human lung adenocarcinoma through the Toll-like receptor 4 mediated induction of THP-1 differentiation/activation.
Computed tomographic images reflect the biologic behavior of small lung adenocarcinoma: they correlate with cell proliferation, microvascularization, cell adhesion, degradation of extracellular matrix, and K-ras mutation.
Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma.
Correlation between matrix metalloproteinase-9 and vascular endothelial growth factor expression in lung adenocarcinoma.
Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis.
Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.
Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 in lung adenocarcinomas.
Haemoptysis as a prognostic factor in lung adenocarcinoma after curative resection.
HoxB7 PROMOTES GROWTH AND METASTASIS OF LUNG ADENOCARCINOMA CELLS THROUGH REGULATION OF THE TGF-?/SMAD3 SIGNALING.
Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma.
Mesenchymal stem cells stimulate angiogenesis in a murine xenograft model of A549 human adenocarcinoma through an LPA1 receptor-dependent mechanism.
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
PC4 induces lymphangiogenesis dependent VEGF-C/VEGF-D/VEGFR-3 axis activation in lung adenocarcinoma.
The Biophysical Property of A549 Cells Transferred by VEGF-D.
The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.
Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma.
Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma.
Vascular endothelial growth factor and basic fibroblast growth factor in primary lung carcinomas and the incidence of metastases.
Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma.
Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells.
VEGF-A and its isoform VEGF(121) mRNA expression measured by quantitative real-time RT-PCR: correlation with F-18 FDG uptake and aggressiveness of lung adenocarcinoma: preliminary study.
VEGFR3 inhibition chemosensitizes lung adenocarcinoma A549 cells in the tumor-associated macrophage microenvironment through upregulation of p53 and PTEN.
[Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]
[Overexpression of p73 gene inhibits VEGF and bFGF mRNA expression in lung adenocarcinoma cell.]
[Relation of vascular endothelial growth factor-D expression to microvessel density, microlymphatic vessel density, and lymph-node metastasis of lung adenocarcinoma]
[The effect of TNP-470 on the proliferation and apoptosis of lung adenocarcinoma cells]
[VEGF-D expression in lung adenocarcinoma with or without acquired resistance to gefitinib and normal lung tissue.]
Adenocarcinoma, Bronchiolo-Alveolar
Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung.
Stimulation of vascular endothelial growth factor gene transcription by all trans retinoic acid through Sp1 and Sp3 sites in human bronchioloalveolar carcinoma cells.
[Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]
Adenocarcinoma, Clear Cell
A case of adenocarcinoma of the endometrial type mixed with a clear cell component that metastasized to the vagina.
Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma.
Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
Adenocarcinoma, Follicular
Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration.
Adenocarcinoma, Mucinous
Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.
Adenoma
An immunohistochemical and ultrastructural study of pancreatic microcystic serous cyst adenoma with special reference to tumor-associated microvasculature and vascular endothelial growth factor in tumor cells.
Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour.
Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models.
Comparison of lymphatic vessel density and expression of VEGF-C and VEGF-D lymphangiogenic factors in Warthin's tumours and oncocytic adenomas.
Concurrent expression of angiogenic growth factors and neovascularization during tumourigenesis in colorectal carcinoma patients.
Effect of gamma knife radiosurgery on a pituitary gonadotroph adenoma: a histologic, immunohistochemical and electron microscopic study.
Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.
Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Expression of the von Hippel-Lindau Tumor Suppressor Gene in Nonneoplastic and Neoplastic Lesions of the Thyroid.
Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression.
Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.
Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways.
Potential Red-Flag Identification of Colorectal Adenomas with Wide-Field Fluorescence Molecular Endoscopy.
The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Tumoral angiogenesis in both adrenal adenomas and nonadenomas: a promising computed tomography biomarker for diagnosis.
Vascular endothelial growth factor 1498C/T, 936C/T polymorphisms associated with increased risk of colorectal adenoma: a Chinese case-control study.
Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma.
[Association of vascular endothelial growth factor 936C/T polymorphism and the susceptibility to colorectal adenoma.]
[Relationship of hypoxia-inducible factor 1 alpha (HIF-1alpha) gene expression with vascular endothelial growth factor (VEGF) and microvessel density (MVD) in human colorectal adenoma and adenocarcinoma]
Adenoma, Pleomorphic
Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
The role of the VEGF-C/-D/flt-4 autocrine loop in the pathogenesis of salivary neoplasms.
Vascular endothelial growth factor immunoexpression is increased in malignant salivary gland tumors.
Vascular endothelial growth factor in salivary pleomorphic adenomas: one of the reasons for their poorly vascularized stroma.
Adenomatous Polyposis Coli
Colon cancer: a civilization disorder.
Adenomatous Polyps
VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression.
Adenomyosis
Constitutive and tumor necrosis factor-?-induced activation of nuclear factor-?B in adenomyosis and its inhibition by andrographolide.
Effect of GnRHa on apoptosis and release of VEGF in endometrial cell cultures from patients with adenomyosis.
Effect of ovarian steroids on vascular endothelial growth factor a expression in bovine uterine endothelial cells during adenomyosis.
Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis.
Expression of Vascular Endothelial Growth Factor (VEGF), Hypoxia Inducible Factor-1alpha (HIF-1alpha), and Microvessel Density in Endometrial Tissue in Women With Adenomyosis.
Involvement of NADPH oxidase and NF-?B activation in CXCL1 induction by vascular endothelial growth factor in human endometrial epithelial cells of patients with adenomyosis.
Proangiogenic features in chronic pelvic pain caused by adenomyosis.
Serum levels of vascular endothelial growth factor and cancer antigen 125 are related to the prognosis of adenomyosis patients after interventional therapy.
Vascular endothelial growth factor gene polymorphisms are associated with the risk of developing adenomyosis.
[Expression of vascular endothelial growth factor (VEGF) in uterine tissues as one of the mechanisms of algogenezis in adenomyosis, associated with chronic pelvic pain].
[Study on the expression of vascular endothelial growth factor in patients with adenomyosis of the uterus]
Adrenal Insufficiency
Reduction of maternal adrenal steroids results in increased VEGF protein without increased eNOS in the ovine placenta.
Adrenocortical Carcinoma
Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy.
African Swine Fever
Serum Concentrations of Vascular Endothelial Growth Factor, Stromal Cell-Derived Factor, Nitric Oxide and Endothelial DNA Proliferation in Development of Microvascular Pathology in Acute African Swine Fever.
Agammaglobulinemia
Effects of circulating endothelial progenitor cells, serum vascular endothelial growth factor and hypogammaglobulinemia in Perthes disease.
Aggressive Periodontitis
Effect of non-surgical periodontal treatment on gingival crevicular fluid hypoxia inducible factor-1 alpha, vascular endothelial growth factor and tumor necrosis factor-alpha levels in generalized aggressive periodontitis patients.
Airway Obstruction
Combined neuronal and inducible nitric oxide synthase inhibition in ovine acute lung injury.
Effects of pranlukast administration on vascular endothelial growth factor levels in asthmatic patients.
Remodeling in asthma and chronic obstructive pulmonary disease.
Albuminuria
Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease.
Angiopoietins: vascular growth factors looking for roles in glomeruli.
Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice.
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy.
Differential response of bone and kidney to ACEI in db/db mice: A potential effect of captopril on accelerating bone loss.
Effects of previous physical training on adriamycin nephropathy and its relationship with endothelial lesions and angiogenesis in the renal cortex.
Endothelial glycocalyx restoration by growth factors in diabetic nephropathy.
Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy.
Increased urine podocyte-associated messenger RNAs in severe obesity are evidence of podocyte injury.
Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria.
Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.
Mesangial immune complex glomerulonephritis due to complement factor D deficiency.
Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor-beta1 in mouse podocytes.
Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
Rapamycin prevents early steps of the development of diabetic nephropathy in rats.
Role of Complement Component C1q in the Onset of Preeclampsia in Mice.
Silencing of hypoxia-inducible factor-1? gene attenuated angiotensin II-induced renal injury in Sprague-Dawley rats.
The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus.
The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes.
Urinary angiopoietin-2 is associated with albuminuria in patients with type 2 diabetes mellitus.
Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus.
Urocortin 1 improves renal function in rats with streptozotocin-induced diabetes by inhibiting overproduction of TGF-beta1 and VEGF.
VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy.
[Renal excretion of insulin-like growth factor 1 and vascular endothelial growth factor in patients with type 1 diabetes with nephropathy].
Alopecia
Alopecia in patients treated with molecularly targeted anticancer therapies.
Comparison between single- versus double-spin prepared platelet-rich plasma injection in treatment of female pattern hair loss: clinical effect and relation to vascular endothelial growth factor.
Fractional non-ablative laser-assisted drug delivery leads to improvement in male and female pattern hair loss.
Loss of vascular endothelial growth factor in human alopecia hair follicles.
Treatment review for male pattern hair-loss.
Vascular endothelial growth factor and its receptor may be one molecular mechanism for androgenetic alopecia.
Vascular Endothelial Growth Factor Protects CD200-Rich and CD34-Positive Hair Follicle Stem Cells Against Androgen-Induced Apoptosis Through the Phosphoinositide 3-Kinase/Akt Pathway in Patients With Androgenic Alopecia.
Alopecia Areata
Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study.
Altitude Sickness
Associations between Vascular Endothelial Growth Factor Gene Polymorphisms and Susceptibility to Acute Mountain Sickness.
B-type natriuretic peptide, vascular endothelial growth factor, endothelin-1, and nitric oxide synthase in chronic mountain sickness.
Cerebrovascular dynamics and vascular endothelial growth factor in acute mountain sickness.
Change in plasma vascular endothelial growth factor during onset and recovery from acute mountain sickness.
Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness.
No correlation between plasma levels of vascular endothelial growth factor or its soluble receptor and acute mountain sickness.
Overexpression of genes associated with hypoxia in cattle adapted to Trans Himalayan region of Ladakh.
Plasma vascular endothelial growth factor in acute mountain sickness.
Variability in pulmonary function following rapid altitude ascent to the Amundsen-Scott South Pole station.
Vascular endothelial growth factor and acute mountain sickness.
[The expressions of VEGF and VEGFR signaling pathway in the bone marrow mononuclear cells with chronic mountain sickness].
Alveolar Bone Loss
Effect of VEGFC on lymph flow and inflammation-induced alveolar bone loss.
Effects of formaldehyde on VEGF, MMP2, and Osteonectin levels in periodontal membrane and alveolar bone in the rats.
Role of Hyperplasia of Gingival Lymphatics in Periodontal Inflammation.
Alzheimer Disease
-1154G/A and -2578C/A polymorphisms of the vascular endothelial growth factor gene in Tunisian Alzheimer patients in relation to beta-amyloid (1-42) and total tau protein.
Amyloid-?(25-35), an amyloid-?(1-42) surrogate, and proinflammatory cytokines stimulate VEGF-A secretion by cultured, early passage, normoxic adult human cerebral astrocytes.
APOE ?4-specific associations of VEGF gene family expression with cognitive aging and Alzheimer's disease.
Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer's disease among Northern Chinese Han.
Association of serum vascular endothelial growth factor levels and cerebral microbleeds in patients with Alzheimer's disease.
Association of vascular endothelial growth factor levels in CSF and cerebral glucose metabolism across the Alzheimer's disease spectrum.
Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease.
Brain expression of the vascular endothelial growth factor gene family in cognitive aging and alzheimer's disease.
Case-control study of vascular endothelial growth factor (VEGF) genetic variability in Alzheimer's disease.
Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease.
CSF VEGF Was Positively Associated with Neurogranin Independent of ?-Amyloid Pathology.
Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate.
Dynamics of a heparin-binding domain of VEGF(165) complexed with its inhibitor triamterene.
Efficacy of the combined use of donepezil with either quetiapine or sodium valproate in patients with Alzheimer's disease with behavioral and psychological symptoms of dementia, and their effects on vascular endothelial growth factors.
Encapsulated VEGF-Secreting Cells Enhance Proliferation of Neuronal Progenitors in the Hippocampus of A?PP/Ps1 Mice.
Exercise training ameliorates cognitive dysfunction in amyloid beta-injected rat model: possible mechanisms of Angiostatin/VEGF signaling.
Expression level of vascular endothelial growth factor in hippocampus is associated with cognitive impairment in patients with Alzheimer's disease.
From angiogenesis to neuropathology.
Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease.
Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia.
Increased serum concentrations of transforming growth factor-?1 (TGF-?1) in patients with Guillain-Barré syndrome.
Insight into potent leads for alzheimer's disease by using several artificial intelligence algorithms.
IsoDA: Isoform-Disease Association Prediction by Multiomics Data Fusion.
Low serum VEGF levels are associated with Alzheimer's disease.
Melatonin ameliorates microvessel abnormalities in the cerebral cortex and hippocampus in a rat model of Alzheimer's disease.
No Association of VEGF Polymorphims with Alzheimer's Disease.
Reduction in Vascular Endothelial Growth Factor Expression in the Superior Temporal, Hippocampal, and Brainstem Regions in Alzheimer's Disease.
Serum VEGF predicts clinical improvement induced by Cerebrolysin plus donepezil in patients with advanced Alzheimer's disease.
Severity-Related Increase and Cognitive Correlates of Serum VEGF Levels in Alzheimer's Disease ApoE4 Carriers.
Sildenafil ameliorates Alzheimer disease via the modulation of vascular endothelial growth factor and vascular cell adhesion molecule-1 in rats.
The A? Peptides-Activated Calcium-Sensing Receptor Stimulates the Production and Secretion of Vascular Endothelial Growth Factor-A by Normoxic Adult Human Cortical Astrocytes.
The Amyloid-?42 Proxy, Amyloid-?25-35, Induces Normal Human Cerebral Astrocytes to Produce Amyloid-?42.
The role of Beta-adrenergic receptor blockers in Alzheimer's disease: potential genetic and cellular signaling mechanisms.
The Role of Mast Cells in Alzheimer's Disease.
The Role of Vascular Endothelial Growth Factor in Neurodegeneration and Cognitive Decline: Exploring Interactions With Biomarkers of Alzheimer Disease.
Vascular endothelial growth factor alleviates mitochondrial dysfunction and suppression of mitochondrial biogenesis in models of Alzheimer's disease.
Vascular endothelial growth factor associated dissimilar cerebrovascular phenotypes in two different mouse models of Alzheimer's Disease.
Vascular endothelial growth factor gene promoter polymorphisms and Alzheimer's disease risk: a meta-analysis.
Vascular endothelial growth factor improves the cognitive decline of Alzheimer's disease via concurrently inducing the expression of ADAM10 and reducing the expression of ?-site APP cleaving enzyme 1 in Tg2576 mice.
Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia.
Vascular endothelial growth factor polymorphisms and risk of Alzheimer's disease: A meta-analysis.
Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia.
VEGF counteracts amyloid-?-induced synaptic dysfunction.
VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment.
VEGF-induced angiogenesis ameliorates the memory impairment in APP transgenic mouse model of Alzheimer's disease.
[Levels of proinflammatory cytokines and vascular endothelial growth factor in patients with Alzheimer's disease and mild cognitive impairment].
Ameloblastoma
Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas.
Evaluation and Comparison of Vascular Endothelial Growth Factor Expression between Ameloblastoma and Keratocystic Odontogenic Tumor.
Expression of inducible nitric oxide synthase and vascular endothelial growth factor in ameloblastoma.
Amyloid Neuropathies
Serum vascular endothelial growth factor (VEGF) in the differential diagnosis of amyloid neuropathy and POEMS syndrome.
Amyloidosis
Effect of large-size dialysis membrane and hemofiltration/hemodiafiltration methods on long-term dialysis patients.
Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis.
Transthyretin Ala36Pro mutation in a Chinese pedigree of familial transthyretin amyloidosis with elevated vitreous and serum vascular endothelial growth factor.
Vascular endothelial growth factor helps differentiate neuropathies in rare plasma cell dyscrasias.
Amyotrophic Lateral Sclerosis
ALS and oxidative stress: the neurovascular scenario.
Amyotrophic lateral sclerosis in pregnancy is associated with a vascular endothelial growth factor promoter genotype.
Association of polymorphisms in vascular endothelial growth factor gene with the age of onset of amyotrophic lateral sclerosis.
Brain-Derived Neurotrophic Factor Facilitates Functional Recovery from ALS-Cerebral Spinal Fluid-Induced Neurodegenerative Changes in the NSC-34 Motor Neuron Cell Line.
Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis.
Clinical and fundamental aspects of angiogenesis and anti-angiogenesis.
CSF concentrations of adipsin and adiponectin in patients with amyotrophic lateral sclerosis.
Delayed administration of VEGF rescues spinal motor neurons from death with a short effective time frame in excitotoxic experimental models in vivo.
Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration.
Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis.
Extraocular motoneurons of the adult rat show higher levels of vascular endothelial growth factor and its receptor Flk-1 than other cranial motoneurons.
Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice.
Human umbilical cord blood cells transfected with VEGF and L(1)CAM do not differentiate into neurons but transform into vascular endothelial cells and secrete neuro-trophic factors to support neuro-genesis-a novel approach in stem cell therapy.
Immunohistochemical localization of vascular endothelial growth factor receptors-1, -2 and -3 in human spinal cord: altered expression in amyotrophic lateral sclerosis.
Immunohistochemical studies of vascular endothelial growth factor in skin of patients with amyotrophic lateral sclerosis.
Impaired Cytoplasmic-Nuclear Transport of Hypoxia-Inducible Factor-1? in Amyotrophic Lateral Sclerosis.
Intracerebroventricular delivery of vascular endothelial growth factor in patients with amyotrophic lateral sclerosis, a phase I study.
Mutant copper-zinc superoxide dismutase associated with amyotrophic lateral sclerosis binds to adenine/uridine-rich stability elements in the vascular endothelial growth factor 3'-untranslated region.
Mutant Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression.
Post-spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VEGF and Ad5-ANG.
Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis.
Screening of the regulatory and coding regions of vascular endothelial growth factor in amyotrophic lateral sclerosis.
Tandem Delivery of Multiple Therapeutic Genes Using Umbilical Cord Blood Cells Improves Symptomatic Outcomes in ALS.
Triple-Gene Therapy for Stroke: A Proof-of-Concept
Vascular endothelial growth factor and amyotrophic lateral sclerosis: The Interplay with exercise and non-invasive ventilation.
Vascular Endothelial Growth Factor Attenuates Neurodegenerative Changes in the NSC-34 Motor Neuron Cell Line Induced by Cerebrospinal Fluid of Sporadic Amyotrophic Lateral Sclerosis Patients.
Vascular endothelial growth factor counteracts the loss of phospho-Akt preceding motor neurone degeneration in amyotrophic lateral sclerosis.
Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases.
Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice.
Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration.
VEGF and ALS.
VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis.
VEGF protects spinal motor neurons against chronic excitotoxic degeneration in vivo by activation of PI3-K pathway and inhibition of p38MAPK.
Anal Gland Neoplasms
VEGF and 17-?-estradiol levels after tamoxifen administration in canine hepatoid gland adenomas and hepatoid gland epitheliomas.
Anaplasia
Prognostic significance of anaplasia and angiogenesis in childhood medulloblastoma: a pediatric oncology group study.
Tenascin in meningioma: expression is correlated with anaplasia, vascular endothelial growth factor expression, and peritumoral edema but not with tumor border shape.
Tenascin in Meningioma: Expression Is Correlated with Anaplasia, Vascular Endothelial Growth Factor Expression, and Peritumoral Edema But Not with Tumor Border Shape.
Androgen-Insensitivity Syndrome
Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice.
Anemia
Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF).
Cardiac hypertrophy in chronically anemic fetal sheep: Increased vascularization is associated with increased myocardial expression of vascular endothelial growth factor and hypoxia-inducible factor 1.
Effect of large-size dialysis membrane and hemofiltration/hemodiafiltration methods on long-term dialysis patients.
Endostatin improves cancer-associated systemic syndrome in a lung cancer model.
Hope on the horizon: promising novel therapies for necrotizing enterocolitis.
Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients.
Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure.
Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.
Levels of bone marrow microvessel density are crucial for evaluating the status of acute myeloid leukemia.
Liver cirrhosis in a child associated with Castleman's disease: A case report.
Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis?
Myocardial vascular and metabolic adaptations in chronically anemic fetal sheep.
Peliosis hepatis associated with follicular lymphoma with a rise in vascular endothelial growth factor and anaemia of inflammation.
Possibility of enhanced risk of retinal neovascularization in repeated blood donors: blood donation and retinal alteration.
Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells.
Study on the Effect of Severity of Maternal Iron Deficiency Anemia on Regulators of Angiogenesis in Placenta.
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis.
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.
[A case of POEMS syndrome associated with Waldenström's macroglobulinemia and treated with lenalidomide].
[Interleukin-6-producing paraganglioma mimicking multicentric Castleman disease].
[Molecular factors of angiogenesis in renal tissue of patients with chronic glomerulonephritis: association with nephrosclerosis and anemia]
Anemia, Aplastic
Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes.
Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia.
The regulatory roles of VEGF-Notch signaling pathway on aplastic anemia with kidney deficiency and blood stasis.
Vascular endothelial growth factor corrected for platelet count and hematocrit is associated with the clinical course of aplastic anemia in children.
[Bone marrow microvessel density and vascular endothelial growth factor expression in patients with aplastic anemia]
[Expression of vascular endothelial growth factor in patients with aplastic anemia and its significance]
[Serum Levels of sVCAM-1, IL-18 and VEGF in Patients with Aplastic Anemia and Their Clinical Significance.]
Anemia, Hemolytic
Effects of experimental asthma on inflammation and lung mechanics in sickle cell mice.
Anemia, Iron-Deficiency
Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia.
Possibility of enhanced risk of retinal neovascularization in repeated blood donors: blood donation and retinal alteration.
Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Anemia, Sickle Cell
Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.
Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia.
Clinical relevance of vascular endothelial growth factor levels in sickle cell disease.
Cytokines and plasma factors in sickle cell disease.
Expression of the angiogenic mediator, angiopoietin-like 4, in the eyes of patients with proliferative sickle retinopathy.
Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.
Recommendations for Serogroup B Meningococcal Vaccine for Persons 10 Years and Older.
Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells.
Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype.
The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment.
The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell disease.
Aneurysm
Abdominal aortic aneurysm rupture is associated with increased medial neovascularization and overexpression of proangiogenic cytokines.
Acceleration of aneurysm healing by P(DLLA-co-TMC)-coated coils enabling the controlled release of vascular endothelial growth factor.
Aneurysm embolization with biologically active coils: an animal study.
Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.
Concentration analysis of hypoxi-inducible factor-1?; and vascular endothelial growth factor in patients with aortic aneurysm at different stages and its clinical significance.
Delivery of human vascular endothelial growth factor with platinum coils enhances wall thickening and coil impregnation in a rat aneurysm model.
Embolization of a common carotid aneurysm with rhVEGF coupled to a pH-responsive chitosan in a rat model.
Endovascular treatment of aneurysms: healing mechanisms in a Swine model are associated with increased expression of matrix metalloproteinases, vascular cell adhesion molecule-1, and vascular endothelial growth factor, and decreased expression of tissue inhibitors of matrix metalloproteinases.
Erythropoietin Stimulates Endothelial Progenitor Cells to Induce Endothelialization in an Aneurysm Neck After Coil Embolization by Modulating Vascular Endothelial Growth Factor.
Expression of angiogenesis factors and selected vascular wall matrix proteins in intracranial saccular aneurysms.
Heparin and Vascular Endothelial Growth Factor Loaded Poly(L-lactide-co-caprolactone) Nanofiber Covered Stent-Graft for Aneurysm Treatment.
Heterogeneous histomorphology, yet homogeneous vascular smooth muscle cell dedifferentiation, characterize human aneurysm disease.
Hypoxia-inducible factor 1 in clinical and experimental aortic aneurysm disease.
Rosuvastatin- and Heparin-Loaded Poly(l-lactide- co-caprolactone) Nanofiber Aneurysm Stent Promotes Endothelialization via Vascular Endothelial Growth Factor Type A Modulation.
Vascular endothelial growth factor enhances angiotensin II-induced aneurysm formation in apolipoprotein E-deficient mice.
Vascular endothelial growth factor immobilized on platinum microcoils for the treatment of intracranial aneurysms: experimental rat model study.
Aneurysm, Dissecting
Association Between Aortic Dissection and Systemic Exposure of Vascular Endothelial Growth Factor Pathway Inhibitors in the Japanese Adverse Drug Event Report Database.
Successful treatment of aortic dissection during sorafenib therapy for hepatocellular carcinoma.
The multitasking role of macrophages in Stanford type A acute aortic dissection.
Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection-A pharmacovigilance analysis.
Aneurysm, Ruptured
Implications of vascular endothelial growth factor, sFlt-1, and sTie-2 in plasma, serum and cerebrospinal fluid during cerebral ischemia in man.
Angina Pectoris
Intraoperative multiplane transesophageal echocardiography for guiding direct myocardial gene transfer of vascular endothelial growth factor in patients with refractory angina pectoris.
Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.
Serum levels of vascular endothelial growth factor in patients with angina pectoris and acute myocardial infarction.
Angina, Stable
High frequency home-based exercise decreases levels of vascular endothelial growth factor in patients with stable angina pectoris.
Interleukin-8 is associated with circulating CD133+ progenitor cells in acute myocardial infarction.
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals.
Serum VEGF: Diagnostic Value of Acute Coronary Syndrome from Stable Angina Pectoris and Prognostic Value of Coronary Artery Disease.
Angina, Unstable
Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina.
Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes.
Influence of preinfarction angina on the release kinetics of endothelial progenitor cells and cytokines during the week after infarction.
Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.
[Concentration of plasma vascular endothelial growth factor and related factors in patients with unstable angina pectoris].
Angiodysplasia
Characterization of a Porcine Model for Von Willebrand Disease Type 1 and 3 Regarding Expression of Angiogenic Mediators in the Nonpregnant Female Reproductive Tract.
Increased expression of angiogenic factors in human colonic angiodysplasia.
Increased plasma vascular endothelial growth factor levels in patients with angiodysplasia.
Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
The role of VEGF in angiodysplasia: an intervention study with thalidomide.
Angioedema
Elevated serum levels of TARC/CCL17, eotaxin-3/CCL26 and vascular endothelial growth factor in a patient with non-episodic angioedema associated with eosinophilia and granulomatous cutaneous reaction.
Vascular endothelial growth factor is involved in angioedema associated with eosinophilia.
Angiofibroma
Expression of vascular endothelial growth factor in Juvenile Angiofibroma.
Hormonal receptors and vascular endothelial growth factor in juvenile nasopharyngeal angiofibroma: immunohistochemical and tissue microarray analysis.
Hypoxia-Inducible Factor-1? (HIF-1?) Expression on Endothelial Cells in Juvenile Nasopharyngeal Angiofibroma: A Review of 70 cases and Tissue Microarray Analysis.
Molecular angiogenic signaling in angiofibromas after embolization: implications for therapy.
Vessel density, proliferation, and immunolocalization of vascular endothelial growth factor in juvenile nasopharyngeal angiofibromas.
Angioid Streaks
Successful long-term management of choroidal neovascularization secondary to angioid streaks in a patient with pseudoxanthoma elasticum: a case report.
Angiolipoma
Angiolipoma of the buccal mucosa: a possible role of mast cell-derived VEGF in its enhanced vascularity.
Angiomatosis, Bacillary
Bartonella henselae Detected in Malignant Melanoma, a Preliminary Study.
Differential effects of Bartonella henselae on human and feline macro- and micro-vascular endothelial cells.
Angiomyolipoma
Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/-) Mice Is Superior to Everolimus Alone.
Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients.
Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Natural history of incidental sporadic and tuberous sclerosis complex associated lymphangioleiomyomatosis.
Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.
Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis.
Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms.
Aniridia
Analysis of protein composition and protein expression in the tear fluid of patients with congenital aniridia.
Anovulation
Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome.
Anthrax
A "dock and lock" approach to preparation of targeted liposomes.
A "Dock and Lock" Approach to Preparation of Targeted Liposomes.
Anthrax Lethal Toxin Inhibits Growth of and Vascular Endothelial Growth Factor Release from Endothelial Cells Expressing the Human Herpes Virus 8 Viral G Protein Coupled Receptor.
Anthrax lethal toxin suppresses high glucose induced VEGF over secretion through a post-translational mechanism.
Regulatory mechanisms of skeletal and connective tissue development and homeostasis - lessons from studies of human disorders.
Self-assembled "dock and lock" system for linking payloads to targeting proteins.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Elevated soluble Flt1 inhibits endothelial repair in PR3-ANCA-associated vasculitis.
Antiphospholipid Syndrome
IL-35, TNF-?, BAFF, and VEGF serum levels in patients with different rheumatic diseases.
Role of the Vitamin D in Leprosy.
Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome.
Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.
Aortic Aneurysm
Concentration analysis of hypoxi-inducible factor-1?; and vascular endothelial growth factor in patients with aortic aneurysm at different stages and its clinical significance.
Perivascular Adipose Tissue-Derived PDGF-D Contributes to Aortic Aneurysm Formation During Obesity.
Aortic Aneurysm, Abdominal
Expression and localization of vascular endothelial growth factor in normal abdominal aorta and abdominal aortic aneurysm.
Expression of angiogenesis and angiogenic factors in human aortic vascular disease.
Polymorphisms of genes involved in the hypoxia signaling pathway and the development of abdominal aortic aneurysms or large-artery atherosclerosis.
Quercetin Downregulates Cyclooxygenase-2 Expression and HIF-1?/VEGF Signaling-Related Angiogenesis in a Mouse Model of Abdominal Aortic Aneurysm.
Vascular endothelial growth factor enhances angiotensin II-induced aneurysm formation in apolipoprotein E-deficient mice.
Aortic Aneurysm, Thoracic
Curcumin attenuates the development of thoracic aortic aneurysm by inhibiting VEGF expression and inflammation.
Aortic Valve Stenosis
Chemically modified tetracyclines (CMT-3 and CMT-8) enable control of the pathologic remodellation of human aortic valve stenosis via MMP-9 and VEGF inhibition.
The role of VEGF in the diabetic patients undergoing endovascular therapy of symptomatic aortic valve stenosis.
Arrhythmias, Cardiac
Cardiotoxic effects of angiogenesis inhibitors.
Arsenic Poisoning
Effects of silencing epididymal vascular endothelial growth factor (VEGF) expression on hyaluronidase (HYD) activity in arsenic poisoning rats through downregulating VEGF receptor 2 (VEGFR2).
Arterial Occlusive Diseases
Designer zinc-finger proteins and their applications.
Oxidative stress and increase of vascular endothelial growth factor in plasma of patients with peripheral arterial occlusive disease.
Vascular endothelial growth factor overexpression in ischemic skeletal muscle enhances myoglobin expression in vivo.
Arteriosclerosis
Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis.
Molecular imaging of vascular endothelial growth factor receptors in graft arteriosclerosis.
The differentiation of mesenchymal stem cells to vascular cells regulated by the HMGB1/RAGE axis: its application in cell therapy for transplant arteriosclerosis.
Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis.
Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis.
[Effects of simvastatin on vasa vasorum and aortic endothelial function in rats]
Arteriovenous Fistula
Effects of brachytherapy on intimal hyperplasia in arteriovenous fistulas in a porcine model.
Evaluation of circulating vascular endothelial growth factor and soluble adhesion molecules as reliable predictors of native arteriovenous fistula thrombosis in chronic hemodialysis patients.
Investigation of the mechanism of dural arteriovenous fistula formation induced by high intracranial venous pressure in a rabbit model.
Arteriovenous Malformations
Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain.
Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia.
Characteristics of pial brain arteriovenous malformations with transdural arterial supply.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Effect of elevation of vascular endothelial growth factor level on exacerbation of hemorrhage in mouse brain arteriovenous malformation.
Effects of Cerebral Ischemia on Levels of Vascular Endothelial Growth Factor (VEGF) and its Soluble Receptors: A Possible Link to Angiogenesis in Arteriovenous Malformations.
Effects of VEGF on phenotypic severity in children with hereditary hemorrhagic telangiectasia.
Expression of endothelial cell angiogenesis receptors in human cerebrovascular malformations.
Expression of platelet-derived growth factor ligand and receptor in cerebral arteriovenous and cavernous malformations.
Focal neurons: another source of vascular endothelial growth factor in brain arteriovenous malformation tissues?
Increased expression of angiogenic factors in cultured human brain arteriovenous malformation endothelial cells.
Increased expression of vascular endothelial growth factor and its receptor in enlarging brain arteriovenous malformations - a case report.
Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage.
Neurological surgery at the National Institutes of Health.
Perlecan domain V is upregulated in human brain arteriovenous malformation and could mediate the vascular endothelial growth factor effect in lesional tissue.
Polymorphisms of the vascular endothelial growth factor A gene and susceptibility to sporadic brain arteriovenous malformation in a Chinese population.
Polymorphisms of VEGFA gene and susceptibility to hemorrhage risk of brain arteriovenous malformations in a Chinese population.
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Arteritis
A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis.
Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells.
Increased serum vascular endothelial growth factor level in Churg-Strauss syndrome.
Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia.
Vascular endothelial growth factor gene polymorphisms in giant cell arteritis.
Vascular endothelial growth factor levels and rheumatic diseases of the elderly.
Arthritis
Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction.
Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis.
Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome.
Complement factor D in serum. An indicator of glomerular filtration rate in chronic inflammatory arthritis.
Effect of Bone Marrow Mesenchymal Stem Cell Transplant on Synovial Proliferation in Rats With Type II Collagen-Induced Arthritis.
Effects of total saponins from Rhizoma Dioscoreae Nipponicae on expression of vascular endothelial growth factor and angiopoietin-2 and Tie-2 receptors in the synovium of rats with rheumatoid arthritis.
Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis.
Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis.
Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer.
Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis.
Fat-Produced Adipsin Regulates Inflammatory Arthritis.
Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice.
Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts.
Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models.
Intra-articular injection of platelet-richplasma reduces inflammation in a house swine model of rheumatoid arthritisof the knee joint.
Involvement of sphingosine-1-phosphate and S1P1 in angiogenesis: analyses using a new S1P1 antagonist of non-sphingosine-1-phosphate analog.
Key Components of the Complement Lectin Pathway Are Not Only Required for the Development of Inflammatory Arthritis but Also Regulate the Transcription of Factor D.
Local ice cryotherapy decreases synovial interleukin 6, interleukin 1?, vascular endothelial growth factor, prostaglandin-E2, and nuclear factor kappa B p65 in human knee arthritis: a controlled study.
Local synovial engagement of angiogenic Tie2 is associated with the development of persistent erosive rheumatoid arthritis in early arthritis patients.
Mannan-Binding Lectin-Associated Serine Protease 1/3 Cleavage of Pro-Factor D into Factor D In Vivo and Attenuation of Collagen Antibody-Induced Arthritis through Their Targeted Inhibition by RNA Interference-Mediated Gene Silencing.
Myelodysplastic Syndrome Precedes the Onset of Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome.
Placenta growth factor is not required for exercise-induced angiogenesis.
Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor.
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis.
S100A12 and vascular endothelial growth factor can differentiate Blau syndrome and familial Mediterranean fever from systemic juvenile idiopathic arthritis.
Serum and synovial fluid concentration of vascular endothelial growth factor in juvenile idiopathic arthritides.
Sphingosine-1-phosphate modulates expression of vascular endothelial growth factor in human articular chondrocytes: a possible new role in arthritis.
Synovial concentrations of the angiogenic peptides bFGF and VEGF do not discriminate rheumatoid arthritis from other forms of inflammatory arthritis.
The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis.
The Hypoxic Synovial Environment Regulates Expression of Vascular Endothelial Growth Factor and Osteopontin in Juvenile Idiopathic Arthritis.
The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor.
The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis.
Vascular endothelial growth factor and its inhibitors.
Vascular endothelial growth factor C attenuates joint damage in chronic inflammatory arthritis by accelerating local lymphatic drainage in mice.
Vascular endothelial growth factor expression in arthritic joint is regulated by SAF-1 transcription factor.
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis.
Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis.
ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity.
[Effects of qubi zhentong recipe on the expressions of IL-1beta, IL-8, and VEGF in the synovlal of rats with collagen-inducing arthritis].
[Relationship of tetramethylpyrazine on expression of vascular endothelial growth factor and development of adjuvant-induced arthritis in rats]
Arthritis, Experimental
An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor.
Effect of Bone Marrow Mesenchymal Stem Cell Transplant on Synovial Proliferation in Rats With Type II Collagen-Induced Arthritis.
Effects of cold-damp and hot-damp environment on VEGF and IL-1 expression in joint cartilage cells in adjuvant arthritis in rats.
Interleukin-35 attenuates collagen-induced arthritis through suppression of vascular endothelial growth factor and its receptors.
Interleukin-35 inhibits angiogenesis through STAT1 signalling in rheumatoid synoviocytes.
Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice.
Relationship between PI3K pathway and angiogenesis in CIA rat synovium.
Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF).
Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritis.
Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis.
Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis.
[Relations of synovial angiogenesis and PTEN/PI3K/AKT signaling pathway in rats with adjuvant arthritis].
[Up-regulated expressions of HIF-1?, VEGF and CD34 promote synovial angiogenesis in rats with adjuvant arthritis].
Arthritis, Infectious
TLR-2-mediated induction of vascular endothelial growth factor (VEGF) in cartilage in septic joint disease.
Arthritis, Juvenile
Increased circulating vascular endothelial growth factor is correlated with disease activity in polyarticular juvenile rheumatoid arthritis.
Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor.
S100A12 and vascular endothelial growth factor can differentiate Blau syndrome and familial Mediterranean fever from systemic juvenile idiopathic arthritis.
Serum and synovial fluid concentration of vascular endothelial growth factor in juvenile idiopathic arthritides.
The Hypoxic Synovial Environment Regulates Expression of Vascular Endothelial Growth Factor and Osteopontin in Juvenile Idiopathic Arthritis.
Arthritis, Psoriatic
Pathogenesis of psoriatic arthritis.
The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study.
Vascular endothelial growth factor in patients with psoriatic arthritis.
Arthritis, Rheumatoid
A new approach to studying angiogenesis in rheumatoid arthritis by means of power Doppler ultrasonography and measurement of serum vascular endothelial growth factor.
A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis.
Adeno-associated virus-delivered polycistronic microRNA-clusters for knockdown of vascular endothelial growth factor in vivo.
Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators.
Age at onset of rheumatoid arthritis: association with polymorphisms in the vascular endothelial growth factor A(VEGFA) gene and an intergenic locus between matrix metalloproteinase (MMP) 1 and 3 genes.
Amelioration of collagen-induced arthritis in rats by nanogold.
An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor.
An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.
Analysis of vascular endothelial growth factor (VEGF) functional variants in rheumatoid arthritis.
Anti-citrullinated protein antibody-positive rheumatoid arthritis associated with RS3PE syndrome-like symptoms and an elevated serum vascular endothelial growth factor level in a patient with myasthenia gravis.
Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study.
Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes.
Association of Circulating Vascular Endothelial Growth Factor Levels With Autoimmune Diseases: A Systematic Review and Meta-Analysis.
B cell activating factor-dependent expression of vascular endothelial growth factor in MH7A human synoviocytes stimulated with tumor necrosis factor-?.
Biomarkers in Rheumatoid Arthritis, what is new?
Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome.
Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis.
Body composition and serum levels of adiponectin, vascular endothelial growth factor, and interleukin-6 in patients with rheumatoid arthritis.
CD147 induces angiogenesis through vascular endothelial growth factor and hypoxiainducible transcription factor 1?-mediated pathway in rheumatoid arthritis.
CD147 induces up-regulation of vascular endothelial growth factor in U937-derived foam cells through PI3K/AKT pathway.
Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.
Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients.
Clinical Significance of Serum Levels of Vascular Endothelial Growth Factor, Angiopoietin-1, and Angiopoietin-2 in Patients with Rheumatoid Arthritis.
Cocoa polyphenols suppress TNF-?-induced vascular endothelial growth factor expression by inhibiting phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase kinase-1 (MEK1) activities in mouse epidermal cells.
Correlation between circulating VEGF levels and disease activity in rheumatoid arthritis: a meta-analysis.
Correlation between synovial blood flow signals and serum vascular endothelial growth factor levels in patients with refractory rheumatoid arthritis.
Differential Expression of Renin-Angiotensin System-related Components in Patients with Rheumatoid Arthritis and Osteoarthritis.
Effect of electro-acupuncture on tumor necrosis factor-? and vascular endothelial growth factor in peripheral blood and joint synovia of patients with rheumatoid arthritis.
Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis.
Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts.
Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis.
Effects of total saponins from Rhizoma Dioscoreae Nipponicae on expression of vascular endothelial growth factor and angiopoietin-2 and Tie-2 receptors in the synovium of rats with rheumatoid arthritis.
Electroacupuncture on ST36 and GB39 Acupoints Inhibits Synovial Angiogenesis via Downregulating HIF-1?/VEGF Expression in a Rat Model of Adjuvant Arthritis.
Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity.
Engagement of toll-like receptor 3 induces vascular endothelial growth factor and interleukin-8 in human rheumatoid synovial fibroblasts.
Expression of Galectin-9 and correlation with disease activity and vascular endothelial growth factor in rheumatoid arthritis.
Expression of platelet-derived growth factors C and D in the synovial membrane of patients with rheumatoid arthritis and osteoarthritis.
Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA).
Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis.
Gliostatin/thymidine phosphorylase-regulated vascular endothelial growth-factor production in human fibroblast-like synoviocytes.
Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy.
IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes.
IL-17, IL-1beta and TNF-alpha stimulate VEGF production by dedifferentiated chondrocytes.
IL-35 Inhibits Angiogenesis through VEGF/Ang2/Tie2 Pathway in Rheumatoid Arthritis.
IL-35 prevent bone loss through promotion of bone formation and angiogenesis in rheumatoid arthritis.
IL-35, TNF-?, BAFF, and VEGF serum levels in patients with different rheumatic diseases.
Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis.
Immunohistochemical analysis of vascular endothelial growth factor expression in severe and destructive rheumatoid arthritis.
Increased expression of endocan in arthritic synovial tissues: effects of adiponectin on the expression of endocan in fibroblast-like synoviocytes.
Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease.
Increasing production of matrix metalloproteinases, tumor necrosis factor-?, vascular endothelial growth factor and prostaglandin E2 in rheumatoid arthritis synovial fibroblasts by different adiponectin isoforms in a concentration-dependent manner.
Inflammation and Lymphatic Function.
Infliximab: a review of its use in the management of rheumatoid arthritis.
Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts.
Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells.
Interaction Between Smoking and Polymorphism in the Promoter Region of the VEGFA Gene Is Associated with Ischemic Heart Disease and Myocardial Infarction in Rheumatoid Arthritis.
Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways.
Interleukin-35 attenuates collagen-induced arthritis through suppression of vascular endothelial growth factor and its receptors.
Interleukin-35 inhibits angiogenesis through STAT1 signalling in rheumatoid synoviocytes.
Linking systemic angiogenic factors (VEGF, angiogenin, TIMP-2) and Doppler ultrasound to anti-inflammatory treatment in rheumatoid arthritis.
Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
Molecular mechanism of Wutou Decoction in the treatment of osteoarthritis: a bioinformatics and molecular docking study.
Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice.
Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.
Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions.
Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid.
Phosphatidylserine inhibits inflammatory responses in interleukin-1?-stimulated fibroblast-like synoviocytes and alleviates carrageenan-induced arthritis in rat.
Polymorphism in the vascular endothelial growth factor A (VEGFA) gene is associated with serum VEGF-A level and disease activity in rheumatoid arthritis: differential effect of cigarette smoking.
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate.
Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis.
Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention.
Recent data on the role for angiogenesis in rheumatoid arthritis.
Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab.
Regulation of vascular endothelial junction stability and remodeling through Rap1-Rasip1 signaling.
Relationship between PI3K pathway and angiogenesis in CIA rat synovium.
Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis.
Serum concentrations of vascular endothelial growth factor in collagen diseases.
Serum vascular endothelial growth factor in late rheumatoid arthritis.
Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages.
Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis.
Splice variants VEGF121 and VEGF165 of the angiogenic peptide vascular endothelial cell growth factor are expressed in the synovial tissue of patients with rheumatoid arthritis.
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
Subclinical gut inflammation in spondyloarthritis is associated with a pro-angiogenic intestinal mucosal phenotype.
Synovial concentrations of the angiogenic peptides bFGF and VEGF do not discriminate rheumatoid arthritis from other forms of inflammatory arthritis.
The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1alpha in human rheumatoid arthritis fibroblast-like synoviocyte.
The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis.
The Ets 1 transcription factor is upregulated during inflammatory angiogenesis in rheumatoid arthritis.
The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study.
The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis.
The VEGFA -1154G/A polymorphism is associated with reduced risk of rheumatoid arthritis but not with systemic lupus erythematosus in Mexican women.
Vascular endothelial growth factor A (VEGFA) polymorphisms in Chinese patients with rheumatoid arthritis.
Vascular endothelial growth factor A and cardiovascular disease in rheumatoid arthritis patients.
Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis: critical involvement of the interaction with synovial fibroblasts.
Vascular endothelial growth factor gene polymorphisms and rheumatoid arthritis.
Vascular endothelial growth factor in patients with rheumatoid arthritis.
Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells.
Vascular endothelial growth factor levels and rheumatic diseases of the elderly.
Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis.
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis.
Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.
Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation.
VEGF Gene Polymorphisms Affect Serum Protein Levels and Alter Disease Activity and Synovial Lesions in Rheumatoid Arthritis.
VEGF-C Gene Polymorphisms Increase Susceptibility to Rheumatoid Arthritis.
[Characteristics of vascular morphology and vascular endothelial growth factor in patients with osteoarthritis and rheumatoid arthritis].
[Effect of 10-hydroxycamptotbecine on the expression of VEGF in rheumatoid arthritis synovial fibroblasts].
[Effect of strengthening Pi and activating blood circulation therapy on serum levels of adrenocorticotrophic hormone and vascular endothelial growth factor in rheumatoid arthritis patients]
[Effects of dioscornin tablet containing serum on NF-kappaB p65, STAT3, and VEGF mRNA expressions in rats' synovial cell strain RSC-364 induced by IL-17 and TNF-alpha].
[Effects of RNAi on cyclooxygenase-2 expression and biologic activity of human rheumatoid arthritis synovial fibroblasts]
[Mechanism of Xinfeng Capsules improving rheumatoid arthritis based on CD19~+B cells regulating FAK/CAPN/PI3K pathway].
[Polymorphism in the regulatory regions -?2578A and +C936T of the vascular endothelial growth factor (VEGF-A) gene in Russian women with rheumatoid arthritis].
[Relations of synovial angiogenesis and PTEN/PI3K/AKT signaling pathway in rats with adjuvant arthritis].
[Serum tumor necrosis factor alpha (TNF-alpha) concentration correlates with soluble adhesion molecules and vascular endothelial growth factor (VEGF) in rheumatoid arthritis]
[Up-regulated expressions of HIF-1?, VEGF and CD34 promote synovial angiogenesis in rats with adjuvant arthritis].
Aspergillosis
Invasive aspergillosis associated with bevacizumab, a vascular endothelial growth factor inhibitor.
Asthma
A comparative study of two angiogenic factors: vascular endothelial growth factor and angiogenin in induced sputum from asthmatic children in acute attack.
A potent antiangiogenic factor, endostatin prevents the development of asthma in a murine model.
A prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, regulates vascular permeability by reducing vascular endothelial growth factor expression in asthma.
Abnormal histone methylation is responsible for increased vascular endothelial growth factor 165a secretion from airway smooth muscle cells in asthma.
Acute and chronic changes of vascular endothelial growth factor (VEGF) in induced sputum of toluene diisocyanate (TDI)-induced asthma patients.
Alveolar macrophage-derived VEGF contributes to allergic airway inflammation in a mouse asthma model.
Analysis of growth factors and inflammatory cytokines in exhaled breath condensate from asthmatic children.
Analysis of growth factors in serum and induced sputum from patients with asthma.
Analysis of vascular endothelial growth factor levels in induced sputum samples from patients with cough variant asthma.
Angiogenesis: a potentially critical part of remodelling in chronic airway diseases?
Anti-VEGF treatment suppresses remodeling factors and restores epithelial barrier function through the E-cadherin/?-catenin signaling axis in experimental asthma models.
Association of vascular endothelial growth factor polymorphisms with asthma in tunisian children.
Association of Vascular Endothelial Growth Factor polymorphisms with childhood asthma, lung function, and airways responsiveness.
Associations between Th17-related inflammatory cytokines and asthma in adults: A Case-Control Study.
Asthma Promotes Choroidal Neovascularization via the Transforming Growth Factor beta1/Smad Signaling Pathway in a Mouse Model.
Asthma treatment outcome in children is associated with vascular endothelial growth factor A (VEGFA) polymorphisms.
Azithromycin Attenuates Fibroblast Growth Factors Induced Vascular Endothelial Growth Factor Via p38(MAPK) Signaling in Human Airway Smooth Muscle Cells.
Biomarkers for Overweight in Adult-Onset Asthma.
Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma.
Chlamydophila pneumoniae triggers release of CCL20 and vascular endothelial growth factor from human bronchial epithelial cells through enhanced intracellular oxidative stress and MAPK activation.
Circulating and exhaled vascular endothelial growth factor in asthmatic pregnancy.
Clinical significance of plasma and serum vascular endothelial growth factor in asthma.
Clinical significance of serum vascular endothelial growth factor in young male asthma patients.
Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma.
Cough and asthma.
Effect of active vitamin D3 on VEGF-induced ADAM33 expression and proliferation in human airway smooth muscle cells: implications for asthma treatment.
Effects of academic exam stress on nasal leukotriene B4 and vascular endothelial growth factor in asthma and health.
Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma.
Effects of leukotriene receptor antagonists on vascular endothelial growth factor levels in asthma.
Evaluation of circulating vascular endothelial growth factor and its soluble receptors in patients suffering from persistent allergic rhinitis.
Evaluation of the PPAR-? Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial.
Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils.
Expression of semaphorin 3A and neuropilin 1 in asthma.
Expression of Serum MicroRNAs 221, 222, 15a and Level of VEGF-A in Children with Bronchial Asthma.
Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma.
High vascular endothelial growth factor levels in NZW mice do not correlate with collagen deposition in allergic asthma.
IL-9 Induces VEGF Secretion from Human Mast Cells and IL-9/IL-9 Receptor Genes Are Overexpressed in Atopic Dermatitis.
Impaired TNFalpha-induced VEGF expression in human airway smooth muscle cells from smokers with COPD: role of MAPkinases and histone acetylation--effect of dexamethasone.
Increased expression of tissue vascular endothelial growth factor and foetal liver kinase-1 receptor in seasonal allergic rhinitis and relevance to asthma component.
Increased synthesis of vascular endothelial growth factor in allergic airway inflammation in histidine decarboxylase knockout (HDC(-/-)) mice.
Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma.
Increased vascular permeability precedes cellular inflammation as asthma control deteriorates.
Inhibition of VEGF blocks TGF-beta1 production through a PI3K/Akt signalling pathway.
Is VEGF a potential therapeutic target in asthma?
L-2-Oxothiazolidine-4-Carboxylic Acid or ?-Lipoic Acid Attenuates Airway Remodeling: Involvement of Nuclear Factor-?B (NF-?B), Nuclear Factor Erythroid 2p45-Related Factor-2 (Nrf2), and Hypoxia-Inducible Factor (HIF).
Markers of autoreactivity, coagulation and angiogenesis in patients with nonallergic asthma.
MFG-E8/integrin ?3 signaling contributes to airway inflammation response and airway remodeling in an ovalbumin-induced murine model of asthma.
Microvascular theory of exercise-induced bronchoconstriction in asthma: potential implication of vascular endothelial growth factor.
Neovastat (AE-941) inhibits the airway inflammation via VEGF and HIF-2 alpha suppression.
Oncostatin M causes VEGF release from human airway smooth muscle: synergy with IL-1beta.
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation.
Polymorphisms in the vascular endothelial growth factor (VEGF) gene associated with asthma.
Predictive effect of exhaled NO and VEGF expression levels on the severity of bronchial asthma and airway inflammation.
Proangiogenic activity in bronchoalveolar lavage fluid from patients with asthma.
Recent advances in mechanisms and treatments of airway remodeling in asthma: a message from the bench side to the clinic.
Recombinant IGFBP-3 inhibits allergic lung inflammation, VEGF production, and vascular leak in a mouse model of asthma.
Relationship between neurokinin 2 receptor gene polymorphisms and serum vascular endothelial growth factor levels in patients with toluene diisocyanate-induced asthma.
Relationships of methacholine and adenosine monophosphate responsiveness with serum vascular endothelial growth factor in children with asthma.
Remodeling in asthma and chronic obstructive pulmonary disease.
Role of Inhaled Steroids in Vascular Airway Remodelling in Asthma and COPD.
Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants.
Role of the extracellular signal-regulated kinase 1/2 signaling pathway in regulating the secretion of bronchial smooth muscle cells in a rat model of chronic asthma.
Role of vascular endothelial growth factor antagonism on airway remodeling in asthma.
Roxithromycin inhibits VEGF-induced human airway smooth muscle cell proliferation: Opportunities for the treatment of asthma.
Serum vascular endothelial growth factor as a marker of asthma exacerbation.
Silver nanoparticles modify VEGF signaling pathway and mucus hypersecretion in allergic airway inflammation.
Studies of vascular endothelial growth factor in asthma and chronic obstructive pulmonary disease.
TH2 Cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids.
The indication and effectiveness of low-dose erythromycin therapy in pediatric patients with bronchial asthma.
Therapeutic perspectives in vascular remodeling in asthma and chronic obstructive pulmonary disease.
Thymoquinone inhibits inflammation, neoangiogenesis and vascular remodeling in asthma mice.
Up-regulation of thrombin activity induced by vascular endothelial growth factor in asthmatic airways.
Vascular biomarkers in asthma and COPD.
Vascular endothelial growth factor and cysteinyl leukotrienes in sputum supernatant of patients with asthma.
Vascular endothelial growth factor in patients with acute asthma.
Vascular endothelial growth factor induction by rhinovirus infection.
Vascular endothelial growth factor levels in induced sputum and emphysematous changes in smoking asthmatic patients.
Vascular endothelial growth factor modulates matrix metalloproteinase-9 expression in asthma.
Vascular endothelial growth factor overexpression in induced sputum of children with bronchial asthma.
Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma.
Vascular remodeling is airway generation-specific in a primate model of chronic asthma.
Vascular remodelling and angiogenesis in asthma: morphological aspects and pharmacological modulation.
Vascular remodelling in asthma.
VEGF -2549 -2567 del18 polymorphism and irreversible bronchoconstriction in asthmatics.
VEGF serum concentration and irreversible bronchoconstriction in adult asthmatics.
VEGFA variants are associated with pre-school lung function, but not neonatal lung function.
[Effects of bacterial lipopolysaccharide on serum IL-4, serum IL-8 and pulmonary VEGF expression in mice with asthma].
[Modulation of Toll-like signal path of allergic asthma by CpG-ODNs from Bordetella pertussis].
[Potential mechanisms of airway remodeling initiated by activated thrombin in asthma]
[The effect of a vascular endothelial growth factor receptor inhibitor on airway inflammation and airway remodeling in a murine model of asthma]
[The research progress of relationship between the obstructive sleep apnea hypopnea syndrome and asthma].
[Vascular endothelial growth factor - structure, function and role in airways inflammation and the clinical course of asthma]
Astrocytoma
Analysis of interleukin (IL)-8 expression in human astrocytomas: Associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry.
Angiogenesis and its role in the behavior of astrocytic brain tumors.
Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas.
Bevacizumab Use in Refractory Adult Pilocytic Astrocytoma: A Single-Center Case Series.
Blood-brain barrier breakdown in septic encephalopathy and brain tumours.
Co-existent pilocytic astrocytoma with acute B-cell leukemia within the cerebellum.
Correlation of bFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas.
Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance.
Decrease of endogenous vascular endothelial growth factor may not affect glioma cell proliferation and invasion.
Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Dynamic contrast-enhanced derived cerebral blood volume correlates better with leak correction than with no correction for vascular endothelial growth factor, microvascular density, and grading of astrocytoma.
Expression and hypoxic regulation of angiopoietins in human astrocytomas.
Expression and regulation of neuropilin-1 in human astrocytomas.
Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis.
Expression of brain-specific angiogenesis inhibitor 1 is inversely correlated with pathological grade, angiogenesis and peritumoral brain edema in human astrocytomas.
Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma.
Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
EXPRESSION OF INTERLEUKIN-8 (IL-8) RECEPTOR CXCR2 AND SUPPRESSOR OF CYTOKINE SIGNALING-3 (SOCS-3) IN ASTROCYTIC TUMORS.
Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors.
Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival.
Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.
Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors.
Expression of tissue factor signaling pathway elements correlates with the production of vascular endothelial growth factor and interleukin-8 in human astrocytoma patients.
Expression of vascular endothelial growth factor (VEGF) and its two receptors in diffusely infiltrating astrocytomas and relationship to proliferative activity of tumor cells.
Expression of vascular endothelial growth factor and its receptors in pilocytic astrocytoma.
Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.
Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.
Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis.
Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.
Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro.
Minimal change disease onset observed after bevacizumab administration.
miR-21 Is Linked to Glioma Angiogenesis: A Co-Localization Study.
Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras.
Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells.
Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model.
Phosphatidylinositol 3'-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells.
Production and interferon-gamma-mediated regulation of complement component C2 and factors B and D by the astroglioma cell line U105-MG.
Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines.
PTEN protein expression correlates with PTEN gene molecular changes but not with VEGF expression in astrocytomas.
Quantitation of angiogenesis and its correlation with vascular endothelial growth factor expression in astrocytic tumors.
Ras activation in astrocytomas and neurofibromas.
The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells.
The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis.
The importance of cell density in the interpretation of growth factor effects on collagenase IV activity release and extracellular matrix production from C6 astrocytoma cells.
The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.
Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?
Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma.
Vascular Endothelial Growth Factor as an Angiogenic Marker in Malignant Astrocytoma and Oligodendroglioma: An Indian Scenario.
Vascular endothelial growth factor expression and angiogenesis in various grades and subtypes of meningioma.
Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.
Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy.
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.
[A quantitative pathological study on angiogenesis, vascular endothelial growth factor and inducible nitric oxide synthase in astrocytomas]
[Expression of vascular endothelial growth factor in brain astrocytoma and its clinical evaluation]
[p53 and vascular endothelial growth factor expression in astrocytoma and their relation to angiogenesis]
Ataxia
Grafted human chorionic stem cells restore motor function and preclude cerebellar neurodegeneration in rat model of cerebellar ataxia.
Ataxia Telangiectasia
Circadian rhythm genes in cancer: insight into their functions and regulation involving noncoding RNAs.
Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival of gastric cancer.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Atherosclerosis
A study on the association of rs7950273 polymorphism in the PDGFD with ischaemic stroke in the Chinese Han population.
Adipsin deficiency does not impact atherosclerosis development in Ldlr-/- mice.
Altered in vitro endothelial repair and monocyte migration in obstructive sleep apnea: implication of VEGF and CRP.
Angiogenic Factors and Risks of Technique Failure and Cardiovascular Events in Patients Receiving Peritoneal Dialysis.
Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells.
Anti-inflammatory effect of glycosaminoglycan derived from Gryllus bimaculatus (a type of cricket, insect) on adjuvant-treated chronic arthritis rat model.
Anti-inflammatory Effect of Isaria sinclairii Glycosaminoglycan in an Adjuvant-treated Arthritis Rat Model.
Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor.
Atherosclerosis and the protective role played by different proteins in apolipoprotein E-deficient mice.
Basic fibrobrast growth factor induces the secretion of vascular endothelial growth factor by human aortic smooth muscle cells but not by endothelial cells.
Betaxolol stimulates eNOS production associated with LOX-1 and VEGF in Dahl salt-sensitive rats.
Both vascular endothelial growth factor and soluble Flt-1 are increased in type 2 diabetes but not in impaired fasting glucose.
C3 and alternative pathway components are associated with an adverse lipoprotein subclass profile: The CODAM study.
Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury.
Complement components as uremic toxins and their potential role as mediators of microinflammation.
Correlation between vascular endothelial growth factor and subclinical atherosclerosis in patients with psoriasis.
Cytokine-inducible growth factor gene expression in human umbilical endothelial cells.
Deletion of Lymphangiogenic and Angiogenic Growth Factor VEGF-D Leads to Severe Hyperlipidemia and Delayed Clearance of Chylomicron Remnants.
Diabetes mellitus-associated atherosclerosis : mechanisms involved and potential for pharmacological invention.
Effect of obstructive sleep apnea on carotid artery intima media thickness related to inflammation.
Effect of resveratrol on seric vascular endothelial growth factor concentrations during atherosclerosis.
Effect of simvastatin on expression of VEGF and TGF-?1 in atherosclerotic animal model of type 2 diabetes mellitus.
Effects of Lys-Glu-Trp peptide on cell-cell interactions and vascular endothelium proliferation under normal conditions and during atherosclerosis.
Effects of PDGF-C and PDGF-D on monocyte migration and MMP-2 and MMP-9 expression.
Headache in Children: Selected Factors of Vascular Changes Involved in Underlying Processes of Idiopathic Headaches.
Heritability for plasma VEGF concentration in the Stanislas family study.
High levels of oestrogen receptor-alpha in tumorigenesis: inhibition of cell growth and angiogenic factors.
HO-1 and VGEF gene expression in human arteries with advanced atherosclerosis.
Homocysteine induces vascular endothelial growth factor expression in differentiated THP-1 macrophages.
Identification of cis- and trans-Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels.
Increased placental growth factor (PlGF) concentrations in children and adolescents with obesity and the metabolic syndrome.
Induction of high mobility group box 1 release from serotonin-stimulated human umbilical vein endothelial cells.
Induction of vascular endothelial growth factor in balloon-injured baboon arteries. A novel role for reactive oxygen species in atherosclerosis.
Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis.
Influences of Pinpoint Plantar Long-Wavelength Infrared Light Irradiation (Stress-Free Therapy) on Chorioretinal Hemodynamics, Atherosclerosis Factors, and Vascular Endothelial Growth Factor.
Inhibitions of vascular endothelial growth factor expression and foam cell formation by EGb 761, a special extract of Ginkgo biloba, in oxidatively modified low-density lipoprotein-induced human THP-1 monocytes cells.
Intercellular adhesion molecule-1 and vascular endothelial growth factor expression kinetics in macrophage-derived foam cells.
Lipoprotein-associated phosphatidylethanol increases the plasma concentration of vascular endothelial growth factor.
LncRNA NORAD Promotes Vascular Endothelial Cell Injury and Atherosclerosis Through Suppressing VEGF Gene Transcription via Enhancing H3K9 Deacetylation by Recruiting HDAC6.
MicroRNA-9 overexpression suppresses vulnerable atherosclerotic plaque and enhances vascular remodeling through negative regulation of the p38MAPK pathway via OLR1 in acute coronary syndrome.
Modulation of Adhesion Process, E-Selectin and VEGF Production by Anthocyanins and Their Metabolites in an in vitro Model of Atherosclerosis.
Near-Infrared Light-Driven Multifunctional Tubular Micromotors for Treatment of Atherosclerosis.
Nicotine potentiates vascular endothelial growth factor expression in balloon-injured rabbit aortas.
Observation of human retinal remodeling in octogenarians with a resveratrol based nutritional supplement.
Oxidised LDL decreases VEGFR-1 expression in human monocyte-derived macrophages.
PDGF-C and PDGF-D signaling in vascular diseases and animal models.
Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3.
Phosphatidylethanol in high density lipoproteins increases the vascular endothelial growth factor in smooth muscle cells.
Phosphatidylethanol mediates its effects on the vascular endothelial growth factor via HDL receptor in endothelial cells.
Placenta growth factor is not required for exercise-induced angiogenesis.
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate.
Polymorphisms of the methylenetetrahydrofolate reductase, vascular endothelial growth factor, endothelial nitric oxide synthase, monocyte chemoattractant protein-1 and apolipoprotein E genes are not associated with carotid intima-media thickness.
Possible association between circulating vascular endothelial growth factor and oxidative stress markers in hemodialysis patients.
Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular disease.
Post-transcriptional regulation of VEGF expression by oxidised LDL in human macrophages.
Protective role of cytochrome P450 1A1 (CYP1A1) against benzo[a]pyrene-induced toxicity in mouse aorta.
Radiofrequency-enhanced vascular gene transduction and expression for intravascular MR imaging-guided therapy: feasibility study in pigs.
Reactive hyperemia and BOLD MRI demonstrate that VEGF inhibition, age, and atherosclerosis adversely affect functional recovery in a murine model of peripheral artery disease.
Reduction of atherosclerosis in cholesterol-fed rabbits and decrease of expressions of intracellular adhesion molecule-1 and vascular endothelial growth factor in foam cells by a water-soluble fraction of Polygonum multiflorum.
Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.
Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor.
Salusins and adropin: New peptides potentially involved in lipid metabolism and atherosclerosis.
Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia.
Serum Levels of Vascular Endothelial Growth Factor and Insulin-like Growth Factor Binding Protein-3 in Obstructive Sleep Apnea Patients: Effect of Continuous Positive Airway Pressure Treatment.
Serum VEGF--as a prognostic factor of atherosclerosis.
Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis.
Significance of nitric oxide and peroxynitrite in permeability changes of the retinal microvascular endothelial cell monolayer induced by vascular endothelial growth factor.
Soluble Fms-like tyrosine kinase 1 is a novel predictor of brain natriuretic peptide elevation.
Systemic lupus erythematosus and atherosclerosis: Review of the literature.
The effects of growth hormone status on circulating levels of vascular growth factors.
The effects of VEGF-A on atherosclerosis, lipoprotein profile, and lipoprotein lipase in hyperlipidaemic mouse models.
The impact of vascular endothelial growth factor +405 C/G polymorphism on long-term outcome and severity of coronary artery disease.
The NF-?B pathway: regulation of the instability of atherosclerotic plaques activated by Fg, Fb, and FDPs.
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study).
Transforming growth factor-?1 signalling triggers vascular endothelial growth factor resistance and monocyte dysfunction in type 2 diabetes mellitus.
Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study.
Variation in the vascular endothelial growth factor gene, carotid intima-media thickness and the risk of acute myocardial infarction.
Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis.
Vascular endothelial growth factor and its inhibitors.
Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes.
Vascular endothelial growth factor increases the migration and proliferation of smooth muscle cells through the mediation of growth factors released by endothelial cells.
Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells.
Vascular endothelial growth factor polymorphisms are involved in the late vascular complications in Type II diabetic patients.
Vascular endothelial growth factor promotes cell-cycle transition from G0 to G1 phase in subcultured endothelial cells of diabetic rat thoracic aorta.
Vascular endothelial growth factor-D expression in human atherosclerotic lesions.
Vascular endothelial growth factor-D is overexpressed in human cardiac allograft vasculopathy and diabetic atherosclerosis and induces endothelial permeability to low-density lipoproteins in vitro.
Vascular endothelial growth factor: angiogenesis, atherogenesis or both?
VEGF and therapeutic opportunities in cardiovascular diseases.
VEGF protects against oxidized LDL toxicity to endothelial cells by an intracellular glutathione-dependent mechanism through the KDR receptor.
VEGF regulates FGF-2 and TGF-beta1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration.
VEGF-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, NF-kappaB, and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits.
Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice.
Vitamins C and E prevent endothelial VEGF and VEGFR-2 overexpression induced by porcine hypercholesterolemic LDL.
[Role of anti-angiogenic factor chondromodulin-I for maintaining cardiac valvular function]
[What is new in the treatment of diabetes?--The importance of nephro- and cardioprotective management]
Atrial Fibrillation
Increased intracardiac vascular endothelial growth factor levels in patients with paroxysmal, but not persistent atrial fibrillation.
Increased vascular endothelial growth factor D is associated with atrial fibrillation and ischaemic stroke.
Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosis?
Serum levels of vascular endothelial growth factor and transforming growth factor-beta1 in patients with atrial fibrillation undergoing defibrillation therapy.
Atypical Hemolytic Uremic Syndrome
Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016.
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Autoimmune Diseases
Active Vaccination With EMMPRIN-Derived Multiple Antigenic Peptide (161-MAP) Reduces Angiogenesis in a Dextran Sodium Sulfate (DSS)-Induced Colitis Model.
Association of Circulating Vascular Endothelial Growth Factor Levels With Autoimmune Diseases: A Systematic Review and Meta-Analysis.
Chronic and non-healing wounds: The story of vascular endothelial growth factor.
Investigation on association between five common polymorphisms in vascular endothelial growth factor and prototypes of autoimmune diseases.
Luteolin inhibits human keratinocyte activation and decreases NF-?B induction that is increased in psoriatic skin.
Plasma VEGF-related polymorphisms are implied in autoimmune thyroid diseases.
Vascular endothelial growth factor (VEGF) in autoimmune diseases.
Axial Spondyloarthritis
Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis.
Relation of ?2-Antiplasmin Genotype and Genetic Determinants of Fibrinogen Synthesis and Fibrin Clot Formation with Vascular Endothelial Growth Factor Level in Axial Spondyloarthritis.
Azoospermia
Caspase-3 and VEGF immunopositivity in seminiferous tubule germ cells in cases of obstructive and non-obstructive azoospermia in smokers versus non-smokers.
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Bacteremia
Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome.
Bacterial Infections
Bacterial induction of pleural mesothelial monolayer barrier dysfunction.
Complement factor D haplodeficiency is associated with a reduced complement activation speed and diminished bacterial killing.
Functional deficiency of complement factor D in a monozygous twin.
HIF-1? is involved in blood-brain barrier dysfunction and paracellular migration of bacteria in pneumococcal meningitis.
Infection of human brain vascular pericytes (HBVPs) by Bartonella henselae.
Lipoprotein-associated phospholipase A2, myeloperoxidase and vascular endothelial growth factor - predictors of high vascular risk in respiratory bacterial infections.
Serum hemolytic factor D values in children with steroid-responsive idiopathic nephrotic syndrome.
Barrett Esophagus
Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus.
Bartonella Infections
Bartonella henselae Detected in Malignant Melanoma, a Preliminary Study.
Infectious angiogenesis: Bartonella bacilliformis infection results in endothelial production of angiopoetin-2 and epidermal production of vascular endothelial growth factor.
Behcet Syndrome
Association of vascular endothelial growth factor gene polymorphisms with behcet disease in a Korean population.
EFFECT OF INTRAVITREAL METHOTREXATE AND AQUEOUS HUMOR CYTOKINE LEVELS IN REFRACTORY RETINAL VASCULITIS IN BEHCET DISEASE.
The role of heat shock protein 60, vascular endothelial growth factor and antiphospholipid antibodies in Behçet disease.
beta-Thalassemia
Correlation of vascular endothelial growth factor with the severity of thalassemia intermedia.
Vascular endothelial growth factor and pulmonary hypertension in children with beta thalassemia major.
Vascular endothelial growth factor in children with thalassemia major.
Bicuspid Aortic Valve Disease
Increased macrophage infiltration and neovascularization in congenital bicuspid aortic valve stenosis.
Bile Duct Neoplasms
Overexpression of matriptase in tumor stroma is a poor prognostic indicator of extrahepatic bile duct cancer.
Biliary Atresia
Expression of vascular endothelial growth factor A in liver tissues of infants with biliary atresia.
Genetic Variation in the Vascular Endothelial Growth Factor Gene is Associated With Biliary Atresia.
Biliary Tract Neoplasms
A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma.
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Bisphosphonate-Associated Osteonecrosis of the Jaw
Genetic association between VEGF polymorphisms and BRONJ in the Korean population.
Blast Crisis
Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease.
Blindness
A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.
Adenosine receptors and caffeine in retinopathy of prematurity.
An endothelin type a receptor antagonist reverses upregulated VEGF and icam-1 levels in streptozotocin-induced diabetic rat retina.
Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity.
Clinical application of therapies targeting VEGF.
Curcumolide, a unique sesquiterpenoid from Curcuma wenyujin displays anti-angiogenic activity and attenuates ischemia-induced retinal neovascularization.
Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina.
Effects of HGF and KGF gene silencing on vascular endothelial growth factor and its receptors in rat ultraviolet radiation?induced corneal neovascularization.
Expression of the angiogenic mediator, angiopoietin-like 4, in the eyes of patients with proliferative sickle retinopathy.
Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide.
Inhibitory activity of bevacizumab to differentiation of retinoblastoma cells.
Regulation of tight junctions and loss of barrier function in pathophysiology.
Requirement of NOX2 expression in both retina and bone marrow for diabetes-induced retinal vascular injury.
RETHINKING STOP-ROP: IS IT WORTHWHILE TRYING TO MODULATE EXCESSIVE VEGF LEVELS IN PRETHRESHOLD ROP EYES BY SYSTEMIC INTERVENTION?: A Review of the Role of Oxygen, Light Adaptation State, and Anemia in Prethreshold ROP.
Retinal hypoxia induces vascular endothelial growth factor through induction of estrogen-related receptor ?.
Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells.
Streptozotocin induced diabetic retinopathy in rat and the expression of vascular endothelial growth factor and its receptor.
TCCR/WSX-1 is a novel angiogenic factor in age-related macular degeneration.
The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy.
The P2X7 Receptor: A Promising Pharmacological Target in Diabetic Retinopathy.
VEGF as a Trophic Factor for Müller Glia in Hypoxic Retinal Diseases.
VEGF-Production by CCR2-Dependent Macrophages Contributes to Laser-Induced Choroidal Neovascularization.
Vitreous TIMP-1 levels associate with neovascularization and TGF-?2 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathy.
[New drug treatment for age-related macular degeneration]
Blister
Distinct compartmentalization of immune cells and mediators characterizes bullous pemphigoid disease.
Histopathological and Molecular Changes in the Rabbit Cornea From Arsenical Vesicant Lewisite Exposure.
Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase.
Severe generalized pustular psoriasis accompanied by bullae formation with increased serum vascular endothelial growth factor level.
The efficiency of subconjunctival bevacizumab in refractory glaucoma - case report.
UV radiation induces the release of angiopoietin-2 from dermal microvascular endothelial cells.
Bone Diseases
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
Expression of human VEGF(121) cDNA in mouse bone marrow stromal cells.
Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Bone Neoplasms
Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer.
Bone Resorption
A Pilot, Randomized Study in Women of Nutrition-Related Clinical Chemistry at 6 Weeks after Roux en Y Gastric Bypass: Comparison of Two Nutrition Support Plans.
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice.
Histopathological and biochemical evaluation of paeoniflorin administration in an experimental periodontitis model.
IL6 receptor blockade preserves articular cartilage and increases bone volume following ischemic osteonecrosis in immature mice.
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts.
Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone.
Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption.
Bowen's Disease
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
Brain Contusion
Astrocytes co-express aquaporin-1, -4, and vascular endothelial growth factor in brain edema tissue associated with brain contusion.
Very early expression of vascular endothelial growth factor in brain oedema tissue associated with brain contusion.
Brain Death
Comparison of Vascular Endothelial Growth Factor Concentration in Porcine Kidneys Removed From Living Donors After Cardiac and Brain Death.
Brain Diseases
Apatinib-induced hyperammonemic encephalopathy.
Could increased vascular endothelial growth factor induced by interleukin 17 be the cause of posterior reversible encephalopathy syndrome in systemic lupus erythematosus?
Modulation of endoplasmic reticulum stress response in gut-origin encephalopathy: Impact of vascular endothelial growth factor receptor-2 manipulation.
Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability.
Plasma and Cerebrospinal Fluid Candidate Biomarkers of Neonatal Encephalopathy Severity and Neurodevelopmental Outcomes.
Posterior reversible encephalopathy syndrome (PRES) with immune system activation, VEGF up-regulation, and cerebral amyloid angiopathy.
Protective Effects of Tetramethylpyrazine on Cerebrovascular Regulations in Rats with Chronic Alcoholic Encephalopathy.
Reversible Encephalopathy after Cardiac Transplantation: Histologic Evidence of Endothelial Activation, T-cell Specific Trafficking, and Vascular Endothelial Growth Factor Expression.
Role of interleukin-6 and vascular endothelial growth factor in Henoch-Schönlein purpura with posterior reversible encephalopathy syndrome.
Vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) levels in the cerebrospinal fluid of children with influenza-associated encephalopathy.
Vascular endothelial growth factor mediates vasogenic edema in acute lead encephalopathy.
Brain Edema
13-Methyltetradecanoic acid mitigates cerebral ischemia/reperfusion injury.
A pre-injury high ethanol intake in rats promotes brain edema following traumatic brain injury.
Alterations in the expression of vascular endothelial growth factor in the rat brain following gamma knife surgery.
Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.
Anti-vasopermeability effects of PEDF in retinal-renal disorders.
Antiangiogenic therapy for glioblastoma.
Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis.
Apatinib and fractionated stereotactic radiotherapy for the treatment of limited brain metastases from primary lung mucoepidermoid carcinoma: A case report.
Apatinib in refractory radiation-induced brain edema: A case report.
AQP-4 in peritumoral edematous tissue is correlated with the degree of glioma and with expression of VEGF and HIF-alpha.
Association of pSTAT3-VEGF signaling pathway with peritumoral edema in newly diagnosed glioblastoma: an immunohistochemical study.
Astrocytes co-express aquaporin-1, -4, and vascular endothelial growth factor in brain edema tissue associated with brain contusion.
Bevacizumab for the Treatment of Gammaknife Radiosurgery-Induced Brain Radiation Necrosis.
Bevacizumab for the treatment of post-stereotactic radiosurgery adverse radiation effect.
Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression.
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas.
Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia.
Effects of intraventricular infusion of vascular endothelial growth factor on cerebral blood flow, edema, and infarct volume.
Endothelin systems in the brain: involvement in pathophysiological responses of damaged nerve tissues.
Evaluating the molecular basis for acute mountain sickness: hypoxia response gene expression patterns in warfighters and murine populations.
Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema.
Flt-1, but not Flk-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway.
Glucocorticoids in the management of peritumoral brain edema: a review of molecular mechanisms.
Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness.
Hypoxia-inducible factor and vascular endothelial growth factor are targets of dietary soy during acute stroke in female rats.
Intraventricular infusion of vascular endothelial growth factor promotes cerebral angiogenesis with minimal brain edema.
Lesion Size Is Exacerbated in Hypoxic Rats Whereas Hypoxia-Inducible Factor-1 Alpha and Vascular Endothelial Growth Factor Increase in Injured Normoxic Rats: A Prospective Cohort Study of Secondary Hypoxia in Focal Traumatic Brain Injury.
Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor.
No correlation between plasma levels of vascular endothelial growth factor or its soluble receptor and acute mountain sickness.
Pathophysiology of Meningioma Growth in Pregnancy.
Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply.
Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway.
Protection of Vascular Endothelial Growth Factor to Brain Edema Following Intracerebral Hemorrhage and Its Involved Mechanisms: Effect of Aquaporin-4.
Protective effect of albumin on VEGF and brain edema in acute ischemia in rats.
Regulations of astrocytic functions by endothelins: roles in the pathophysiological responses of damaged brains.
Stereotactic radiosurgery combined with anlotinib for limited brain metastases with perilesional edema in non-small cell lung cancer: Rvision-001 study protocol.
Surgical brain injury and edema prevention.
Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain.
The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas.
The Relationship Between Peritumoral Brain Edema and the Expression of Vascular Endothelial Growth Factor in Vestibular Schwannoma.
The role of vascular endothelial growth factor in ischemic stroke.
Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema.
Vascular endothelial growth factor and blood-brain barrier disruption in tuberculous meningitis.
Vascular endothelial growth factor antagonist reduces brain edema formation and venous infarction.
Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain.
Vascular Endothelial Growth Factor in Brain Edema Formation After Subarachnoid Hemorrhage.
Vascular endothelial growth factor in tuberculous meningitis.
Vascular endothelial growth factor is associated with blood brain barrier dysfunction in eosinophilic meningitis caused by Angiostrongylus cantonensis infection.
Vascular endothelial growth factor: an attractive target in the treatment of hypoxic/ischemic brain injury.
[Correlation between vascular endothelial growth factor and peritumoural edema in meningiomas]
[Efficiency of integrin ?v?3 inhibitor Cilengitide in acute cerebral ischemia in rats].
[Micro-ribonucleic acids participate in electroacupuncture intervention-induced improvement of ischemic stroke].
[Small interfering RNA (siRNA) targeting vascular endothelial growth factor inhibits vascular leakage in brain of rats exposed to high altitude]
[Vascular endothelial factor of meningomas and peritumoural vasogenic brain edema]
Brain Infarction
Association between kinase insert domain-containing receptor gene polymorphisms and silent brain infarction: a Korean study.
Evidence for telomerase involvement in the angiogenesis of astrocytic tumors: expression of human telomerase reverse transcriptase messenger RNA by vascular endothelial cells.
Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability.
Vascular protection and restorative therapy in ischemic stroke.
Brain Injuries
Adeno-associated viral vector-mediated hypoxia-inducible vascular endothelial growth factor gene expression attenuates ischemic brain injury after focal cerebral ischemia in mice.
Adenovirus-mediated brain-derived neurotrophic factor expression regulated by hypoxia response element protects brain from injury of transient middle cerebral artery occlusion in mice.
Anti-Vascular Endothelial Growth Factor Treatment Suppresses Early Brain Injury After Subarachnoid Hemorrhage in Mice.
Astrocytes-derived VEGF exacerbates the microvascular damage of late delayed RBI.
Carbon monoxide potentiation of L-type Ca2+ channel activity increases HIF-1?-independent VEGF expression via an AMPK?/SIRT1-mediated PGC-1?/ERR? axis.
Correlation between magnetic resonance perfusion weighted imaging of radiation brain injury and pathology.
Corrigendum to "Protection of Granulocyte-colony Stimulating Factor to Hemorrhagic Brain Injuries and Its Involved Mechanisms: Effects of Vascular Endothelial Growth Factor and Aquaporin-4" [Neuroscience 260 (2014) 59-72].
Differential Expression of Vascular Endothelial Growth Factor in the Cortex and Hippocampus upon Cerebral Hypoperfusion.
Differential expression of vascular endothelial growth factor-A (VEGF-A) and VEGF-B after brain injury.
Dynamic Changes of Vascular Endothelial Growth Factor and Angiopoietin-1 in Association With Circulating Endothelial Progenitor Cells After Severe Traumatic Brain Injury.
Dynamic Expression of Platelet-Derived Growth Factor-D and Phosphorylated Platelet-Derived Growth Factor Receptor-? after Traumatic Brain Injury in Rats.
Effect of Combination Therapy with Neuroprotective and Vasoprotective Agents on Cerebral Ischemia.
Exercise-induced overexpression of angiogenic factors and reduction of ischemia/reperfusion injury in stroke.
Expression of VEGF- and tight junction-related proteins in the neocortical microvasculature of patients with drug-resistant temporal lobe epilepsy.
Neurogenic effect of VEGF is related to increase of astrocytes transdifferentiation into new mature neurons in rat brains after stroke.
Neuroprotective Effects of Vascular Endothelial Growth Factor Following Hypoxic Ischemic Brain Injury in Neonatal Rats.
Neuroprotective effects of VEGF administration after focal cerebral ischemia/reperfusion: Dose response and time window.
Postacute ischemia vascular endothelial growth factor transfer by transferrin-targeted liposomes attenuates ischemic brain injury after experimental stroke in rats.
Promoting neuroregeneration after perinatal arterial ischemic stroke: neurotrophic factors and mesenchymal stem cells.
Protection of granulocyte-colony stimulating factor to hemorrhagic brain injuries and its involved mechanisms: effects of vascular endothelial growth factor and aquaporin-4.
Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor.
Role of PDGF-D and PDGFR-? in neuroinflammation in experimental ICH mice model.
Serum Biomarkers of Regeneration and Plasticity are Associated with Functional Outcome in Pediatric Neurocritical Illness: An Exploratory Study.
Signaling pathways for early brain injury after subarachnoid hemorrhage.
Transplantation of human umbilical cord blood mesenchymal stem cells to treat a rat model of traumatic brain injury.
Vascular endothelial growth factor (vascular permeability factor) expression in injured rat brain.
Vascular endothelial growth factor A promotes platelet adhesion to collagen IV and causes early brain injury after subarachnoid hemorrhage.
Vascular endothelial growth factor is neuroprotective against ischemic brain injury by inhibiting scavenger receptor A expression on microglia.
Vascular endothelial growth factor regulates focal adhesion assembly in human brain microvascular endothelial cells through activation of the focal adhesion kinase and related adhesion focal tyrosine kinase.
Vascular endothelial growth factor: an attractive target in the treatment of hypoxic/ischemic brain injury.
VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway.
VEGF overexpression in the astroglial cells of rat brainstem following ozone exposure.
[Expression changes of Ang-1, Ang-2, Tie-2 and VEGF in co-culturing of endothelial cells and astrocytes after irradiation by X-ray and their significances].
[The evaluation neuropsychological development in preterm infants with hypoxic brain injury].
Brain Injuries, Traumatic
Collagen-chitosan scaffold impregnated with bone marrow mesenchymal stem cells for treatment of traumatic brain injury.
Collagen/heparin scaffold combined with vascular endothelial growth factor promotes the repair of neurological function in rats with traumatic brain injury.
Delayed voluntary physical exercise restores "when" and "where" object recognition memory after traumatic brain injury.
Differential expression of capillary VEGF isoforms following traumatic brain injury.
Dynamic Changes of Vascular Endothelial Growth Factor and Angiopoietin-1 in Association With Circulating Endothelial Progenitor Cells After Severe Traumatic Brain Injury.
Early neutrophilic expression of vascular endothelial growth factor after traumatic brain injury.
Erythropoietin Mediates Neurobehavioral Recovery and Neurovascular Remodeling Following Traumatic Brain Injury in Rats by Increasing Expression of Vascular Endothelial Growth Factor.
HIF-1? and VEGF Are Involved in Deferoxamine-Ameliorated Traumatic Brain Injury.
Hippocampal Neurogenesis after Traumatic Brain Injury Is Mediated by Vascular Endothelial Growth Factor Receptor-2 and the Raf/MEK/ERK Cascade.
Histopathological changes in the choroid plexus after traumatic brain injury in the rats: a histologic and immunohistochemical study.
Increased Expression of Vascular Endothelial Growth Factor Attenuates Contusion Necrosis without Influencing Contusion Edema after Traumatic Brain Injury in Rats.
Lesion Size Is Exacerbated in Hypoxic Rats Whereas Hypoxia-Inducible Factor-1 Alpha and Vascular Endothelial Growth Factor Increase in Injured Normoxic Rats: A Prospective Cohort Study of Secondary Hypoxia in Focal Traumatic Brain Injury.
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Pathomorphology of inflammatory response following traumatic brain injury, serum values of interleukins, and gene polymorphisms.
Release of VEGF and FGF in the extracellular space following severe subarachnoidal haemorrhage or traumatic head injury in humans.
Role of vascular endothelial growth factor in blood-brain barrier breakdown and angiogenesis in brain trauma.
Subacute treatment with vascular endothelial growth factor after traumatic brain injury increases angiogenesis and gliogenesis.
The role of vascular endothelial growth factor and vascular endothelial growth inhibitor in clinical outcome of traumatic brain injury.
Time-dependent changes of protein biomarker levels in the cerebrospinal fluid after blast traumatic brain injury.
Vascular endothelial growth factor increases neurogenesis after traumatic brain injury.
Vascular endothelial growth factor is increased in cerebrospinal fluid after traumatic brain injury in infants and children.
Vascular endothelial growth factor is involved in mediating increased de novo hippocampal neurogenesis in response to traumatic brain injury.
VEGI Improves Outcomes in the Early Phase of Experimental Traumatic Brain Injury.
[Nrp-1 expression in healing process of traumatic brain injury combined with tibial fracture].
Brain Injury, Chronic
Huanglian-Jie-Du-Tang Extract Protects against Chronic Brain Injury after Focal Cerebral Ischemia via Hypoxia-Inducible-Factor-1?-Regulated Vascular Endothelial Growth Factor Signaling in Mice.
Brain Ischemia
A novel therapeutic approach using peripheral blood mononuclear cells preconditioned by oxygen-glucose deprivation.
Activated microvessels express vascular endothelial growth factor and integrin alpha(v)beta3 during focal cerebral ischemia.
Adeno-associated viral vector-mediated hypoxia-inducible vascular endothelial growth factor gene expression attenuates ischemic brain injury after focal cerebral ischemia in mice.
Aggravation of hemorrhagic transformation by early intraarterial infusion of low-dose vascular endothelial growth factor after transient focal cerebral ischemia in rats.
Angiopoietin-2 is vasoprotective in the acute phase of cerebral ischemia.
Attenuation of edema and infarct volume following focal cerebral ischemia by early but not delayed administration of a novel small molecule KDR kinase inhibitor.
Basic Fibroblast Growth Factor Protects Astrocytes Against Ischemia/Reperfusion Injury by Upregulating the Caveolin-1/VEGF Signaling Pathway.
Changes in serum vascular endothelial growth factor and endostatin concentrations associated with circulating endothelial progenitor cells after acute ischemic stroke.
Combined treatment of vascular endothelial growth factor and human neural stem cells in experimental focal cerebral ischemia.
Early expressions of hypoxia-inducible factor 1alpha and vascular endothelial growth factor increase the neuronal plasticity of activated endogenous neural stem cells after focal cerebral ischemia.
Effect of bone marrow stromal cell transplantation on neurologic function and expression of VEGF in rats with focal cerebral ischemia.
Effects of anti-VEGF antibody on blood-brain barrier disruption in focal cerebral ischemia.
Effects of Cerebral Ischemia on Levels of Vascular Endothelial Growth Factor (VEGF) and its Soluble Receptors: A Possible Link to Angiogenesis in Arteriovenous Malformations.
Effects of the Thioredoxin-1 Inhibitor PX-12 on Blood-Brain Barrier Permeability in the Early Stage of Focal Cerebral Ischemia.
Effects of VEGF and nitric oxide synthase inhibition on blood-brain barrier disruption in the ischemic and non-ischemic cerebral cortex.
Encapsulated vascular endothelial growth factor-secreting cell grafts have neuroprotective and angiogenic effects on focal cerebral ischemia.
Enhanced expression of vascular endothelial growth factor receptor-3 in the subventricular zone of stroke-lesioned rats.
Enhancement of expression of vascular endothelial growth factor after adeno-associated virus gene transfer is associated with improvement of brain ischemia injury in the gerbil.
Expression of angiopoietin-2 and vascular endothelial growth factor in mice cerebral cortex after permanent focal cerebral ischemia.
Expression of brain-specific angiogenesis inhibitor 2 (BAI2) in normal and ischemic brain: involvement of BAI2 in the ischemia-induced brain angiogenesis.
Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat.
Expression of VEGF and neural repair after alprostadil treatment in a rat model of sciatic nerve crush injury.
Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab.
Fc-saxatilin inhibits VEGF-induced permeability by regulating claudin-5 expression in human brain microvascular endothelial cells.
HIF-1 alpha and VEGF expression after transient global cerebral ischemia.
Huanglian-Jie-Du-Tang Extract Protects against Chronic Brain Injury after Focal Cerebral Ischemia via Hypoxia-Inducible-Factor-1?-Regulated Vascular Endothelial Growth Factor Signaling in Mice.
Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model.
Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia.
Hypoxia-Inducible Factor 1-?-AA-Modified Bone Marrow Stem Cells Protect PC12 Cells from Hypoxia-Induced Apoptosis, Partially Through VEGF/PI3K/Akt/FoxO1 Pathway.
Hypoxic Preconditioning Increases Blood-Brain Barrier Disruption in the Early Stages of Cerebral Ischemia.
Impacts of N-Butylphthalide on expression of growth factors in rats with focal cerebral ischemia.
Implications of vascular endothelial growth factor, sFlt-1, and sTie-2 in plasma, serum and cerebrospinal fluid during cerebral ischemia in man.
Improving Cerebral Blood Flow Through Liposomal Delivery of Angiogenic Peptides: Potential of ¹?F-FDG PET Imaging in Ischemic Stroke Treatment.
Increased protein and mRNA expression of endostatin in the ischemic brain tissue of rabbits after middle cerebral artery occlusion.
Induction of vascular endothelial growth factor and hypoxia-inducible factor-1alpha by global ischemia in rat brain.
Induction of vascular endothelial growth factor receptor-3 expression in perivascular cells of the ischemic core following focal cerebral ischemia in rats.
Induction of vascular endothelial growth factor receptor-3 mRNA in glial cells following focal cerebral ischemia in rats.
Induction of vascular endothelial growth factor receptors and phosphatidylinositol 3'-kinase/Akt signaling by global cerebral ischemia in the rat.
Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment.
Intraventricular vascular endothelial growth factor antibody increases infarct volume following transient cerebral ischemia.
Investigation of the mechanism of dural arteriovenous fistula formation induced by high intracranial venous pressure in a rabbit model.
Met-Controlled Allosteric Module of Neural Generation as A New Therapeutic Target in Rodent Brain Ischemia.
Microglia preconditioned by oxygen-glucose deprivation promote functional recovery in ischemic rats.
Neuroprotective Effect of Chronic Intracranial Toxoplasma gondii Infection in a Mouse Cerebral Ischemia Model.
Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat.
Optimal dose of plasmid vascular endothelial growth factor for enhancement of angiogenesis in the rat brain ischemia model.
Pigment Epithelium-Derived Factor Improves Paracellular Blood-Brain Barrier Integrity in the Normal and Ischemic Mouse Brain.
Reconstituting neurovascular unit with primary neural stem cells and brain microvascular endothelial cells in three-dimensional matrix.
Regenerative repair of Pifithrin-? in cerebral ischemia via VEGF dependent manner.
Retraction: Vascular endothelial growth factor in cerebral ischemia.
The Protective Effects of Juglanin in Cerebral Ischemia Reduce Blood-Brain Barrier Permeability via Inhibition of VEGF/VEGFR2 Signaling.
Transplantation of vascular endothelial growth factor-transfected neural stem cells into the rat brain provides neuroprotection after transient focal cerebral ischemia.
Vascular Endothelial Growth Factor 165-Binding Heparan Sulfate Promotes Functional Recovery From Cerebral Ischemia.
Vascular endothelial growth factor aggravates cerebral ischemia and reperfusion-induced blood-brain-barrier disruption through regulating LOC102640519/HOXC13/ZO-1 signaling.
Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia.
Vascular endothelial growth factor expression in transient focal cerebral ischemia in the rat.
Vascular endothelial growth factor gene expression in middle cerebral artery occlusion in the rat.
Vascular endothelial growth factor gene-transferred bone marrow stromal cells engineered with a herpes simplex virus type 1 vector can improve neurological deficits and reduce infarction volume in rat brain ischemia.
Vascular endothelial growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral ischemia in the rat.
Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia.
Vascular endothelial growth factor in cerebral ischemia.
Vascular endothelial growth factor promotes pericyte coverage of brain capillaries, improves cerebral blood flow during subsequent focal cerebral ischemia, and preserves the metabolic penumbra.
Vascular endothelial growth factor upregulation in transient global ischemia induced by cardiac arrest and resuscitation in rat brain.
VEGF Ameliorates Cognitive Impairment in In Vivo and In Vitro Ischemia via Improving Neuronal Viability and Function.
VEGF promotes angiogenesis and functional recovery in stroke rats.
VEGF protects brain against focal ischemia without increasing blood--brain permeability when administered intracerebroventricularly.
[Effect of Electroacupuncture Combined with Polysaccharide of Gastrodia elata Blume on Ex- pression of Brain Derived Neurotrophic Factor and Vascular Endothelial Growth Factor in the Paraventricular Nucleus of Hypothalamus in Cerebral Ischemia Rat].
[Effect of electroacupuncture on neurovascular unit and Wnt/?-catenin signaling in rats with cerebral ischemia].
[Effect of scalp acupuncture on learning ability and hippocampal VEGF expression in chronic cerebral ischemia rats].
[Effects of Electroacupuncture and Intracerebral Injection of VEGF on Caspase12, Caspase3, and GRP78 Genes in Rats with Cerebral Ischemia-Reperfusion Injury].
[Effects of electroacupuncture combined with compound Salviae Miltiorrhizae tablet on the expressions of brain derived neurotrophic factor and vascular endothelial growth factor in hippocampus CA1 of chronic cerebral ischemia rats].
[Efficiency of integrin ?v?3 inhibitor Cilengitide in acute cerebral ischemia in rats].
[Electroacupuncture Combined with Intracerebral Injection of VEGF Improves Neurological Dysfunction Possibly by Down-regulating Expression of Endoplasmic Reticulum Stress Related Proteins ATF 6, etc. in Cerebral Ischemia-reperfusion Injury Rats].
[Erythropoietin and vascular endothelial growth factor level in normoxia and in cerebral ischemia under pharmacological and hypoxic preconditioning].
[Expression and function of vascular endothelial growth factor and angiopoietins in rat brain after cerebral ischemia].
[Molecular markers of endothelial damage in patients with Parkinson's disease].
[Progranulin].
[Recent advance in experimental study of cerebral ischemia treated by vascular endothelial growth factor]
[Recombinant AAV1 mediated vascular endothelial growth factor gene expression promotes angiogenesis and improves neural function: experiment with rats]
[VEGF-A therapeutic target against hemorrhagic transformation after t-PA treatment].
Brain Neoplasms
A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study.
Angiogenic factors in plasma of brain tumour patients.
Anti-angiogenic therapy in pediatric brain tumors: an effective strategy?
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
Antiangiogenic Therapy of High-Grade Gliomas.
Antidepressant hyperforin up-regulates VEGF in CNS tumour cells.
Antitumor activity of ZD6474 in a metastatic orthotopic brain tumor model.
Apatinib and fractionated stereotactic radiotherapy for the treatment of limited brain metastases from primary lung mucoepidermoid carcinoma: A case report.
Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay.
Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends.
Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series.
Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor.
Changes in VEGF expression and in the vasculature during the growth of early-stage ethylnitrosourea-induced malignant astrocytomas in rats.
Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes.
Comparative efficacy of antiangiogenic treatment for newly diagnosed glioblastoma: A protocol for systematic review and network meta-analysis.
Complex Oncogenic Signaling Networks Regulate Brain Tumor-Initiating Cells and Their Progenies: Pivotal Roles of Wild-Type EGFR, EGFRvIII Mutant and Hedgehog Cascades and Novel Multitargeted Therapies.
Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients.
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Emerging and Investigational Therapties for the Treatment of Adults With Metastatic Brain Tumors.
Correlation of CT perfusion images with VEGF expression in solitary brain metastases.
Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas.
Corticotropin-releasing hormone and the blood-brain-barrier.
Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer.
Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis.
Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice.
Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis.
Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.
Evidence for telomerase involvement in the angiogenesis of astrocytic tumors: expression of human telomerase reverse transcriptase messenger RNA by vascular endothelial cells.
Expression and distribution of vascular endothelial growth factor protein in human brain tumors.
Expression and localization of placenta growth factor and PlGF receptors in human meningiomas.
Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas.
Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors.
Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors.
Expression of vascular endothelial growth factor in human brain tumors.
Expression of vascular endothelial growth factor in tumors and plasma from dogs with primary intracranial neoplasms.
Expression of vascular endothelial growth-factor in the cyst fluid of human cerebral gliomas.
Expression of VEGF and its receptor genes in intracranial schwannomas.
Gene-linked shift in ganglioside distribution influences growth and vascularity in a mouse astrocytoma.
Glucocorticoids in the management of peritumoral brain edema: a review of molecular mechanisms.
Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo.
Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.
Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1.
Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.
Intense focal expression of vascular endothelial growth-factor messenger-RNA in human intracranial neoplasms - association with regions of necrosis.
Lactate administration reproduces specific brain and liver exercise-related changes.
Metastatic brain mass caused by slow-growing small-cell lung cancer: differential vascular endothelial growth factor expression in primary and metastatic tumor.
Patients With Metastatic Breast Cancer Using Bevacizumab as a Treatment: Is There Still a Role for it?
Pilot evaluation of cytokine levels in patients undergoing radiotherapy for brain tumor.
Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumor angiogenesis.
Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;53:376-81.
Relationship between expression of vascular endothelial growth factor and intratumoral hemorrhage in human pituitary adenomas.
Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy.
Serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in children with brain tumours.
Simulating vasogenic brain edema using chronic VEGF infusion.
Targeted Therapies for Breast Cancer Brain Metastases.
The genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor.
Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.
Update on the use of angiogenesis inhibitors in adult patients with brain tumors.
Vascular abnormalities in surgical specimens obtained from the resected focus of intractable epilepsy.
Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression.
Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.
Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.
Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors.
VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly.
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.
VEGF Trap induces antiglioma effect at different stages of disease.
VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells.
VEGF-mediated tight junctions pathological fenestration enhances doxorubicin-loaded glycolipid-like nanoparticles traversing BBB for glioblastoma-targeting therapy.
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Breast Carcinoma In Situ
Angiogenesis and VEGF expression in pre-invasive lesions of the human breast.
[Expression of vascular endothelial growth factor in different breast tissues and clinical significance thereof]
Breast Diseases
Biochemical Investigation of Tissue Oxidative Stress and Angiogenesis with Associated Trace Elements in Breast Disease Patients in Uttarakhand, India.
Breast Neoplasms
17beta-estradiol inhibits forskolin-induced vascular endothelial growth factor promoter in MCF-7 breast adenocarcinoma cells.
99m-Tc-MDP-Scintimammography in the evaluation of breast masses or tumor angiogenesis.
?IIb?3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells.
?vß3-Integrin-Targeted Magnetic Resonance Imaging for the Assessment of Early Antiangiogenic Therapy Effects in Orthotopic Breast Cancer Xenografts.
A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk.
A Common and Functional Gene Variant in the Vascular Endothelial Growth Factor A Predicts Clinical Outcome in Early-Stage Breast Cancer.
A comparison of serum and plasma levels of vascular endothelial growth factor during the menstrual cycle in healthy female volunteers.
A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
A general approach for receptor and antibody-targeted detection of native proteins utilizing split-luciferase reassembly.
A highly-sensitive vascular endothelial growth factor-A(165) immunosensor, as a tool for early detection of cancer.
A Human 3D In Vitro Model to Assess the Relationship Between Osteoporosis and Dissemination to Bone of Breast Cancer Tumor Cells.
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.
A new impedimetric biosensor utilizing VEGF receptor-1 (Flt-1): early diagnosis of vascular endothelial growth factor in breast cancer.
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
A physiologic imaging pilot study of breast cancer treated with AZD2171.
A potential role for vascular endothelial growth factor-D as an autocrine growth factor for human breast carcinoma cells.
A practical and sensitive method of quantitating lymphangiogenesis in vivo.
A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts.
A review on the role of VEGF in Tamoxifen resistance.
Acral cutaneous metastasis from a primary breast carcinoma following chemotherapy with bevacizumab and paclitaxel.
Activation of ?2-Adrenergic Receptor Promotes Growth and Angiogenesis in Breast Cancer by Down-regulating PPAR?.
Activation of GPR120 promotes the metastasis of breast cancer through the PI3K/Akt/NF-?B signaling pathway.
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin.
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Alcohol promotes mammary tumor growth through activation of VEGF-dependent tumor angiogenesis.
Alteration in platelet function in patients with early breast cancer.
An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma.
An open-label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer.
An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
Analysis of the Relationship Between Ultrasound of Breast Cancer DOT-SDI and the Expression of MVD, VEGF and HIF-1?
Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer.
Angiogenesis induction in breast cancer: A paracrine paradigm.
Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer.
Angiopoietin pathway gene expression associated with poor breast cancer survival.
Angiotensin II Type 1 Receptor (AT-1R) Expression Correlates with VEGF-A and VEGF-D Expression in Invasive Ductal Breast Cancer.
Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro.
Anti-angiogenic efficacy in invasive breast carcinoma patients depends on clinicopathological determinants.
Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells.
Anti-angiogenic potential of Gleditsia sinensis fruit extract.
Anti-cancer effects of Piper nigrum via inducing multiple molecular signaling in vivo and in vitro.
Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting.
Antiangiogenic effects of melatonin in endothelial cell cultures.
Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Antiangiogenic strategies, compounds, and early clinical results in breast cancer.
Apatinib for molecular targeted therapy in tumor.
Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation.
Apatinib-induced hyperammonemic encephalopathy.
Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells.
Aptamer-based sensing of breast cancer biomarkers: a comprehensive review of analytical figures of merit.
Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: pre-operative determination of malignant potential.
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.
Association between the Functional Polymorphism of Vascular Endothelial Growth Factor Gene and Breast Cancer: A Meta-Analysis.
Association between vascular endothelial growth factor +936C/T polymorphism and breast cancer risk: a meta-analysis of 18 case-control studies.
Association Between Vascular Endothelial Growth Factor Gene Polymorphisms with Breast Cancer Risk in an Iranian Population.
Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population.
Association of +405C>G and +936C>T polymorphisms of the vascular endothelial growth factor gene with sporadic breast cancer in North Indians.
Association of -2549 insertion/deletion polymorphism of vascular endothelial growth factor with breast cancer in north Indian patients.
Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: a meta-analysis.
Association of ARNT splice variants with estrogen receptor-negative breast cancer, poor induction of vascular endothelial growth factor under hypoxia, and poor prognosis.
Association of the VEGF 936C>T Polymorphism with FDG Uptake, Clinical, Histopathological, and Metabolic Response in Patients with Adenocarcinomas of the Esophagogastric Junction.
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.
Association of vascular endothelial growth factor single nucleotide polymorphisms on the prognosis of breast cancer patients.
Association of VEGF and VEGFR1 polymorphisms with breast cancer risk in North Indians.
Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer.
Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial.
Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.
Autophagy is essential for the endothelial differentiation of breast cancer stem?like cells.
Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?
bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity.
Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line.
Bevacizumab for advanced breast cancer.
Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer.
Bevacizumab in metastatic breast cancer: when may it be used?
Bevacizumab in the treatment of metastatic breast cancer.
Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Bevacizumab: in first-line treatment of metastatic breast cancer.
Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.
Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.
Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Biology of Oestrogen-Receptor Positive Primary Breast Cancer in Older Women with Utilisation of Core Needle Biopsy Samples and Correlation with Clinical Outcome.
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.
Blocking ?v?3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells.
Blood Oxygenation Level-dependent Magnetic Resonance Imaging of Breast Cancer: Correlation with Carbonic Anhydrase IX and Vascular Endothelial Growth Factor.
Breast cancer brain metastases.
Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells.
Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression.
Breast cancer therapy affects the expression of antineonatal Nav1.5 antibodies in the serum of patients with breast cancer.
Breast tumor cells primed by endoplasmic reticulum stress remodel macrophage phenotype.
Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
c-Kit-Positive Adipose Tissue-Derived Mesenchymal Stem Cells Promote the Growth and Angiogenesis of Breast Cancer.
Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: Implications for tumor angiogenesis.
Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer.
CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer.
CCN1 promotes vascular endothelial growth factor secretion through ?v? 3 integrin receptors in breast cancer.
CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo.
Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer.
Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes.
Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer.
Chemically modified siRNA directed against the KDR gene inhibits the proliferation of breast cancer cells.
Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review).
Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer.
Chitosan/short hairpin RNA complexes for vascular endothelial growth factor suppression invasive breast carcinoma.
Circulating levels of angiogenesis-related growth factors in breast cancer: A study to profile proteins responsible for tubule formation.
Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course.
Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFIt-1) in human breast cancer.
Clinical implications of the interleukin 27 serum level in breast cancer.
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Clinical significance of determination of surrogate markers of angiogenesis in breast cancer.
Clinical significance of survivin and vascular endothelial growth factor mRNA detection in the peripheral whole blood of breast cancer patients.
Clinical Study of Tumor Angiogenesis and Perfusion Imaging Using Multi-slice Spiral Computed Tomography for Breast Cancer.
Clinicopathologic and prognostic characteristics of triple-negative breast cancer.
Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand.
Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications.
Co-expression of ?9?1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN.
Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat.
Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma.
Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1.
Combinational Polymorphisms of Seven CXCL12-Related Genes Are Protective against Breast Cancer in Taiwan.
Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer.
Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma.
Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells.
Complex influence of dermatan sulphate on breast cancer cells.
Compounds in clinical Phase III and beyond.
Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer.
Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population.
Correlation between hepatocyte growth factor receptor and vascular endothelial growth factor-A in breast carcinoma.
Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer.
Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma.
Correlation between ultrasonic features and expression levels of C-erbB-2, VEGF and nm23 in breast cancer.
Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma.
Correlation between VEGF expression and angiogenesis in breast carcinoma.
Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
Correlation of serum intercellular adhesion molecule 1 and vascular endothelial growth factor with tumor grading and staging in breast cancer patients.
Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.
Correspondence re: K. Heer et al., serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin. Cancer Res., 7: 3491-3494, 2001.
COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer.
Critical role of CDK11(p58) in human breast cancer growth and angiogenesis.
Crosstalk between IGF signaling and steroid hormone receptors in breast cancer.
Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells.
Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression.
Current evidences on vascular endothelial growth factor polymorphisms and breast cancer susceptibility.
CXCL7-Mediated Stimulation of Lymphangiogenic Factors VEGF-C, VEGF-D in Human Breast Cancer Cells.
Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.
Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer.
Cytokine gene polymorphisms and breast cancer susceptibility and prognosis.
Dauricine inhibits insulin-like growth factor-I-induced hypoxia inducible factor 1alpha protein accumulation and vascular endothelial growth factor expression in human breast cancer cells.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Decorin Antagonizes the Angiogenic Network: CONCURRENT INHIBITION OF MET, HYPOXIA INDUCIBLE FACTOR 1?, VASCULAR ENDOTHELIAL GROWTH FACTOR A, AND INDUCTION OF THROMBOSPONDIN-1 AND TIMP3.
Decreased production of vascular endothelial growth factor in adriamycin-resistant breast cancer cells.
Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells.
Deletion of IL-33R attenuates VEGF expression and enhances necrosis in mammary carcinoma.
Detection of serum VEGF and MMP-9 levels by Luminex multiplexed assays in patients with breast infiltrative ductal carcinoma.
Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis.
Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve.
Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy.
Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E.
Differential stimulation of VEGF-C production by adhesion/growth-regulatory galectins and plant lectins in human breast cancer cells.
Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Divergent Impact of Breast Cancer Laterality on Clinicopathological, Angiogenic, and Hemostatic Profiles: A Potential Role of Tumor Localization in Future Outcomes.
Do serum angiogenic growth factors provide additional information to that of conventional markers in monitoring the course of metastatic breast cancer?
Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?
Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis.
Downregulation of ERR? inhibits angiogenesis in human umbilical vein endothelial cells through regulating VEGF production and PI3K/Akt/STAT3 signaling pathway.
Downregulation of PDGF-D Inhibits Proliferation and Invasion in Breast Cancer MDA-MB-231 Cells.
Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer.
Early nuclear alterations and immunohistochemical expression of Ki-67, Erb-B2, vascular endothelial growth factor (VEGF), transforming growth factor (TGF-beta1) and integrine-linked kinase (ILK) two days after tamoxifen in breast carcinoma.
Early versus late distant metastasis and adjuvant chemotherapy alone versus both radiotherapy and chemotherapy in molecular apocrine breast cancer.
Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells.
Effect of anesthetic technique on serum vascular endothelial growth factor C and transforming growth factor ? in women undergoing anesthesia and surgery for breast cancer.
Effect of cycloxygenase-2 silencing on the malignant biological behavior of MCF-7 breast cancer cells.
Effect of estrogen, tamoxifen and epidermal growth factor on the transcriptional regulation of vascular endothelial growth factor in breast cancer cells.
Effect of matrine against breast cancer by downregulating the vascular endothelial growth factor via the Wnt/?-catenin pathway.
Effect of raloxifene on vascular endothelial growth factor expression in breast carcinomas of postmenopausal women.
Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients.
Effects of 17beta-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messenger RNA in breast cancer cells.
Effects of a Weight Loss Intervention on Body Mass, Fitness, and Inflammatory Biomarkers in Overweight or Obese Breast Cancer Survivors.
Effects of brucine on vascular endothelial growth factor expression and microvessel density in a nude mouse model of bone metastasis due to breast cancer.
Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Effects of PPAR? agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.
Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.
EGCG decreases the expression of HIF-1? and VEGF and cell growth in MCF-7 breast cancer cells.
Elevated plasma levels of tissue factor as a valuable diagnostic biomarker with relevant efficacy for prediction of breast cancer morbidity.
Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer.
Emerging targeted therapies for breast cancer.
Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.
Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis.
Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer.
Enhanced Expression of Rab27A Gene by Breast Cancer Cells Promoting Invasiveness and the Metastasis Potential by Secretion of Insulin-Like Growth Factor-II.
Enhancement of vascular endothelial growth factor release in long-term drug-treated breast cancer via transient receptor potential channel 5-Ca(2+)-hypoxia-inducible factor 1? pathway.
Epidermal growth factor-like domain 7 regulates breast cancer cell proliferation and vascular endothelial growth factor expression via the p38MAPK signaling pathway.
Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells.
Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.
Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells.
ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma.
Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer.
Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins.
Estrogen regulation of VEGF in breast cancer in vitro and in vivo: the role of estrogen receptor {alpha} and c-Myc.
Estrogen-related receptor ? expression and function are associated with vascular endothelial growth factor in human cervical cancer.
Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells.
Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer.
Euterpe oleracea extract inhibits tumorigenesis effect of the chemical carcinogen DMBA in breast experimental cancer.
Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice.
Evaluation of cyclin-dependent kinase-like 1 expression in breast cancer tissues and its regulation in cancer cell growth.
Evaluation of lymphangiogenic factors, vascular endothelial growth factor d and e-cadherin in distinguishing inflammatory from locally advanced breast cancer.
Evaluation of microcirculation of thyroid cancer in Chinese females with breast cancer using contrast-enhanced ultrasound (CEUS) combined with VEGF and microvessel density (MVD).
Evaluation of prognostic value of VEGF-C and VEGF-D in breast cancer--10 years follow-up analysis.
Evaluation of serum concentrations of vascular endothelial growth factor (VEGF) in breast cancer patients.
Evaluation of the correlation between colour power Doppler flow imaging and vascular endothelial growth factor in breast cancer.
Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients.
Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS).
Evaluation of Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-Stage Breast Cancer Patients Treated with Breast-Conserving Therapy.
Evidence for the involvement of ET(B) receptors in ET-1-induced changes in blood flow to the rat breast tumor.
Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Expression of breast cancer anti-estrogen resistance 1 in relation to vascular endothelial growth factor, p53, and prognosis in esophageal squamous cell cancer.
Expression of cluster of differentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic significance.
Expression of Flt-1 and Flk-1 receptors for vascular endothelial growth factor on tumor cells as a new prognostic criterion for locally advanced breast cancer.
Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis.
Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas.
Expression of Metallothionein and Vascular Endothelial Growth Factor Isoforms in Breast Cancer Cells.
Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress.
Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation.
Expression of vascular endothelial growth factor (VEGF) family members in breast cancer.
Expression of vascular endothelial growth factor and caspase-3 in mucinous breast carcinoma and infiltrating ductal carcinoma-not otherwise specified, and the correlation with disease-free survival.
Expression of vascular endothelial growth factor and E26 transformation-specific-1 in breast carcinoma.
Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer.
Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness.
Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas.
Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas.
Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer.
Expression of VEGF, COX-2 and MMP-9 in breast cancer and their relationship with ultrasound findings.
Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.
Expression profile of IL-8 and growth factors in breast cancer cells and adipose-derived stem cells (ASCs) isolated from breast carcinoma.
Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases.
Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: A meta-analysis involving 16,703 individuals.
Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo.
Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts.
Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
Forkhead box protein k1 recruits TET1 to act as a tumor suppressor and is associated with MRI detection.
FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.
FOXP3 inhibits angiogenesis by downregulating VEGF in breast cancer.
Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer.
Genetic Effects of Vascular Endothelial Growth Factor A (VEGF-A) and Its Association with Disease Progression in Breast Cancer Population of Saudi Arabia.
Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian "tumor of breast tissue: incidence, genetics, and environmental risk factors" study.
GPER mediates activation of HIF1?/VEGF signaling by estrogens.
GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin ?5?1 for efficient breast cancer metastasis.
Green tea catechins inhibit angiogenesis through suppression of STAT3 activation.
Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells.
HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
Hexachlorobenzene promotes angiogenesis in vivo, in a breast cancer model and neovasculogenesis in vitro, in the human microvascular endothelial cell line HMEC-1.
HIF-1 stabilization exerts anticancer effects in breast cancer cells in vitro and in vivo.
Higenamine enhances the antitumor effects of cucurbitacin B in breast cancer by inhibiting the interaction of AKT and CDK2.
High basic fibroblast growth factor levels in nipple aspirate fluid are correlated with breast cancer.
High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer.
High serum vascular endothelial growth factor C predicts better relapse-free survival in early clinically node-negative breast cancer.
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer.
High-circulating Tie2 is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.
Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer.
Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer.
HTERT mRNA expression correlates with matrix metalloproteinase-1 and vascular endothelial growth factor expression in human breast cancer: a correlative study using RT-PCR.
Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer.
Hydro-alcoholic Extract of Achillea Wilhelmsii C. Koch Reduces the Expression of Cell Death-Associated Genes while Inducing DNA Damage in HeLa Cervical Cancer Cells.
Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan.
Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer.
Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens.
Hypoxia-induced factor-1 alpha upregulates vascular endothelial growth factor C to promote lymphangiogenesis and angiogenesis in breast cancer patients.
Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital.
Hypoxia-induced vascular endothelial growth factor transcription and protection from apoptosis are dependent on alpha6beta1 integrin in breast carcinoma cells.
Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.
Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer.
Identification of novel biomarkers in chronic immune thrombocytopenia (ITP) by microarray-based serum protein profiling.
Imazamethabenz inhibits human breast cancer cell proliferation, migration and invasion via combination with Pin1.
Immunohistochemical expression of vascular endothelial growth factor and its correlation with tumor grade in breast ductal carcinoma.
Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor.
Impaired lymphatic function accelerates cancer growth.
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer.
In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways.
In vivo measurement of tumor estradiol and vascular endothelial growth factor in breast cancer patients.
Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer.
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.
Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer.
Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis.
Induction of Ras by SAF-1/MAZ through a feed-forward loop promotes angiogenesis in breast cancer.
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis.
Induction of vascular endothelial growth factor by peptidyl-prolyl isomerase Pin1 in breast cancer cells.
Influence of VEGF, COX-2, and MMP-9 expression on the molybdenum-targeted X-ray in breast cancer.
Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor.
Inhibition of Metastatic Potential in Breast Carcinoma In Vivo and In Vitro through Targeting VEGFRs and FGFRs.
Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780.
Inhibition of the renin-angiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells.
Inhibition of the stress response to breast cancer surgery by regional anesthesia and analgesia does not affect vascular endothelial growth factor and prostaglandin E2.
Inhibition of vascular endothelial growth factor by small interfering RNA upregulates differentiation, maturation and function of dendritic cells.
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
INHIBITORY ACTION OF CoCl2-INDUCED MCF-7 CELL HYPOXIA MODEL OF BREAST CANCER AND ITS INFLUENCE ON VASCULAR ENDOTHELIAL GROWTH FACTOR.
Insights into the targeting potential of thymoquinone for therapeutic intervention against triple-negative breast cancer.
Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells.
Interleukin 7 upregulates vascular endothelial growth factor D in breast cancer cells and induces lymphangiogenesis in vivo.
Investigating the Antiangiogenic, Anti-drug Resistance and Apoptotic Effects of Soy Isoflavone Extract Alone or in Combination with Docetaxel on Murine 4T1 Breast Tumor Model.
Investigating the association of vascular endothelial growth factor polymorphisms with breast cancer: a Moroccan case-control study.
Investigation of the therapeutic efficacy of codelivery of psiRNA-vascular endothelial growth factor and pIL-4 into chitosan nanoparticles in the breast tumor model.
Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells.
ISL1 is upregulated in breast cancer and promotes cell proliferation, invasion, and angiogenesis.
JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells.
Lack of association between +405 G/C polymorphism in VEGF and breast cancer risk: A meta-analysis.
Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling.
Leptin signaling in breast cancer: an overview.
LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.
Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells.
Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants.
Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.
Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab.
Loss of Epigenetic Kruppel-like Factor 4 Histone Deacetylase (KLF-4-HDAC)-mediated Transcriptional Suppression Is Crucial in Increasing Vascular Endothelial Growth Factor (VEGF) Expression in Breast Cancer.
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.
Lunasin Attenuates Obesity-Associated Metastasis of 4T1 Breast Cancer Cell through Anti-Inflammatory Property.
Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts.
Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases.
Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature.
Magnetic fluid hyperthermia inhibits the growth of breast carcinoma and downregulates vascular endothelial growth factor expression.
Mammary cancer gene therapy targeting lymphangiogenesis: VEGF-C siRNA and soluble VEGF receptor-2, a splicing variant.
Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression.
Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles.
Measurement of serum vascular endothelial growth factor in breast cancer patients.
Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration.
Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Metastatic breast cancer: an updating.
Metformin Inhibits Advanced Glycation End Products (AGEs)-induced Growth and VEGF Expression in MCF-7 Breast Cancer Cells by Suppressing AGEs Receptor Expression via AMP-activated Protein Kinase.
Methylseleninic acid restricts tumor growth in nude mice model of metastatic breast cancer probably via inhibiting angiopoietin-2.
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.
MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells.
Microvessel density and vascular endothelial growth factor receptors in breast carcinoma under the influence of rapamycin and platelet factor 4.
Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells.
miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells.
miR-27a regulates endothelial differentiation of breast cancer stem like cells.
miR-342 is associated with estrogen receptor-? expression and response to tamoxifen in breast cancer.
MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis.
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis.
Mir526b and Mir655 Promote Tumour Associated Angiogenesis and Lymphangiogenesis in Breast Cancer.
Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress.
Molecular targeted therapies for breast cancer treatment.
Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge Dendrilla nigra inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells.
Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story.
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPAR?.
N-acetylglucosaminidase, myeloperoxidase and vascular endothelial growth factor serum levels in breast cancer patients.
Need for clarification of data in a recent meta-analysis on vascular endothelial growth factor (VEGF) and risk of breast cancer.
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
Neuropeptide Y Y5-receptor activation on breast cancer cells acts as a paracrine system that stimulates VEGF expression and secretion to promote angiogenesis.
Neuropilin-1 expression is associated with lymph node metastasis in breast cancer tissues.
New targeted therapies in breast cancer.
No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery.
Non-angiogenic functions of VEGF in breast cancer.
Non-viral Suicide Gene Therapy: Cytosine Deaminase Gene Directed by VEGF Promoter and 5-fluorocytosine as a Gene Directed Enzyme/prodrug System in Breast Cancer Model.
Novel mechanistic targets of forkhead box Q1 transcription factor in human breast cancer cells.
Oestrogen Inhibits VEGF Expression And Angiogenesis In Triple-Negative Breast Cancer By Activating GPER-1.
Oncolytic Adenovirus rAd.DCN Inhibits Breast Tumor Growth and Lung Metastasis in an Immune-Competent Orthotopic Xenograft Model.
Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis and growth of breast cancer in female mice.
Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.
Osteopontin Regulates VEGFA and ICAM-1 mRNA Expression in Breast Carcinoma.
Over expression of vascular endothelial growth factor in correlation to Ki-67, grade, and stage of breast cancer.
Over-expression of both VEGF-C and Twist predicts poor prognosis in human breast cancer.
Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment.
Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels.
Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo.
p16 Modulates VEGF Expression via Its Interaction With HIF-1alpha in Breast Cancer Cells.
p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma.
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer.
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis.
Paired box 5 is a novel marker of breast cancers that is frequently downregulated by methylation.
Patients With Metastatic Breast Cancer Using Bevacizumab as a Treatment: Is There Still a Role for it?
PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer.
Peripheral enhancement of breast cancers on contrast-enhanced ultrasound: correlation with microvessel density and vascular endothelial growth factor expression.
Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients.
Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model.
Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.
Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells.
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer.
Pivalopril improves anti-cancer efficiency of cDDP in breast cancer through inhibiting proliferation, angiogenesis and metastasis.
Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer.
Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in haematological cancers: a comparison with breast cancer.
Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.
Plasmonic droplet screen for single-cell secretion analysis.
Platelet release of Vascular Endothelial Growth Factor (VEGF) in patients undergoing chemotherapy for breast cancer.
Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways.
Platelet-derived growth factor-D promotes colorectal cancer cell migration, invasion and proliferation by regulating Notch1 and matrix metalloproteinase-9.
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis.
Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort.
Porphyrin-based covalent organic framework as bioplatfrom for detection of vascular endothelial growth factor 165 through fluorescence resonance energy transfer.
Potential Impact of Vascular Endothelial Growth Factor Gene Variation (-2578C>A) on Breast Cancer Susceptibility in Saudi Arabia: a Case-Control Study
Prediction model of lymphovascular invasion based on clinicopathological factors in Chinese patients with invasive breast cancer.
Predictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissue.
Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer.
Predictors of lymphovascular invasion identified from pathological factors in Chinese patients with breast cancer.
Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo.
Preoperative assessment of tumor angiogenesis by vascular endothelial growth factor mRNA expression in homogenate samples of breast carcinoma: fine-needle aspirates vs. resection samples.
Prevalence of +405G>C,-1154G>A Vascular Endothelial Growth Factor Polymorphism in Breast Cancer.
Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer.
ProBDNF is a novel mediator of the interaction between MDA-MB-231 breast cancer cells and brain microvascular endothelial cells.
Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours.
Progesterone in Breast Cancer Angiogenesis.
Progestin regulation of vascular endothelial growth factor in human breast cancer cells.
Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.
Prognosis of invasive breast cancer after adjuvant therapy evaluated with VEGF microvessel density and microvascular imaging.
Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy.
Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer.
Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial.
Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers.
Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer.
Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer.
Prognostic Significance of High VEGF-C Expression for Patients with Breast Cancer: An Update Meta Analysis.
Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.
Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer.
Prognostic value of vascular endothelial growth factor in breast cancer.
Progranulin expression in breast cancer with different intrinsic subtypes.
Progress in targeted therapy for breast cancer.
Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects.
Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer.
Promising molecular targeted therapies in breast cancer.
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways.
Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts.
Protein Kinase A Catalytic Subunit Is a Molecular Switch that Promotes the Pro-tumoral Function of Macrophages.
Quantitation of Vascular Endothelial Growth Factor and Interleukin-6 in Different Stages of Breast Cancer.
Quantitation of vascular endothelial growth factor mRNA levels in human breast tumors and metastatic lymph nodes.
Quantitative analysis of vascular endothelial growth factor in primary breast cancer.
Race to report: are vascular endothelial growth factor genetic polymorphisms associated with outcome in advanced breast cancer patients treated with Paclitaxel plus bevacizumab?
Raised plasma endostatin levels correlate inversely with breast cancer angiogenesis.
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors.
Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis.
Recent advances in aptamer-based sensors for breast cancer diagnosis: special cases for nanomaterial-based VEGF, HER2, and MUC1 aptasensors.
Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.
Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer.
Regenerative Therapy and Cancer: In Vitro and In Vivo Studies of the Interaction Between Adipose-Derived Stem Cells and Breast Cancer Cells from Clinical Isolates.
Regulation of endothelial growth factor expressions in breast cancer.
Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.
Regulation of transcription of hypoxia-inducible factor-1? (HIF-1?) by heat shock factors HSF2 and HSF4.
Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells.
Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients.
Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer.
Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines.
Retraction: Correlation of serum intercellular adhesion molecule 1 and vascular endothelial growth factor with tumor grading and staging in breast cancer patients.
Revaluation of the association between vascular endothelial growth factor gene 936 C/T polymorphism and breast cancer risk.
RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.
RNAi-mediated gene silencing of vascular endothelial growth factor C suppresses growth and induces apoptosis in mouse breast cancer in vitro and in vivo.
Role of Endothelin 1 on Proliferation and Migration of Human MCF-7 Cells.
Role of NF-?B activation in matrix metalloproteinase 9, vascular endothelial growth factor and interleukin 8 expression and secretion in human breast cancer cells.
Role of Notch, IL-1 and leptin expression in colorectal cancer.
Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts.
Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines.
Role of TOPK in lipopolysaccharide-induced breast cancer cell migration and invasion.
Role of vascular endothelial growth factor during breast cancer.
Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells.
Role of vascular endothelial growth factor-C and -D mRNA in breast cancer.
RRM2 elicits the metastatic potential of breast cancer cells by regulating cell invasion, migration and VEGF expression via the PI3K/AKT signaling.
Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer.
Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-beta against ductal breast cancer cells in cellular and xenograft models.
Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect.
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.
Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients.
Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer.
Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer.
Serum vascular endothelial growth factor in breast cancer.
Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.
Serum Vascular Endothelial Growth Factors A, C and D in Human Breast Tumors.
Sesamin Inhibits Macrophage-Induced Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 Expression and Proangiogenic Activity in Breast Cancer Cells.
Sex-steroid regulation of vascular endothelial growth factor in breast cancer.
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.
Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients.
Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer.
Significance of vascular endothelial growth factor, interleukin-18 and nitric oxide in patients with breast cancer: correlation with carbohydrate antigen 15.3.
Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor.
Size optimization of synthetic graft copolymers for in vivo angiogenesis imaging.
Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice.
Soluble vascular endothelial growth factor receptors 2 (sVEGFR-2) and 3 (sVEGFR-3) and breast cancer risk in the Swedish Mammography Cohort.
Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
Stromal Cell-Derived Factor 1? (SDF-1?) in Invasive Breast Cancer: Associations with Vasculo-Angiogenic Factors and Prognostic Significance.
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Study on relationship between angiogenesis and micrometastases of peripheral blood in breast cancer.
Suicide gene therapy-mediated purine nucleoside phosphorylase/fludarabine system for in vitro breast cancer model with emphasis on evaluation of vascular endothelial growth factor promoter efficacy.
Sulfatase 2 facilitates lymphangiogenesis in breast cancer by regulating VEGF-D.
Supported Membrane Platform to Assess Surface Interactions between Extracellular Vesicles and Stromal Cells.
Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models.
Suppression of hypoxia and inflammatory pathways by Phyllanthus niruri extract inhibits angiogenesis in DMBA-induced breast cancer mice.
Suppression of vascular endothelial growth factor expression in breast cancer cells by microRNA-125b-mediated attenuation of serum amyloid A activating factor-1 level.
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells.
Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ER? and VEGFR-2.
Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.
Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery.
Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo.
Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo.
Targeted drugs and Psycho-oncological intervention for breast cancer patients.
Targeted Therapies for Brain Metastases from Breast Cancer.
Targeted Therapies for Breast Cancer Brain Metastases.
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.
Targeting angiogenesis with antibodies for the treatment of cancer.
Targeting AU-rich element-mediated mRNA decay with a truncated active form of the zinc-finger protein TIS11b/BRF1 impairs major hallmarks of mammary tumorigenesis.
Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.
Targeting Notch1 inhibits invasion and angiogenesis of human breast cancer cells via inhibition Nuclear Factor-?B signaling.
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
Tea phytochemicals for breast cancer prevention and intervention: From bench to bedside and beyond.
The 936C>T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake.
The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?
The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development.
The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line.
The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study.
The Association Between VEGF +936C/T and -634G/C Polymorphisms and Breast Cancer Susceptibility, Tumor Growth, and Metastases: Evidence From 20,728 Subjects.
The Association of Serum IL-33 and sST2 with Breast Cancer.
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts.
The chemical environmental pollutants BPA and BPS induce alterations of the proteomic profile of different phenotypes of human breast cancer cells: A proposed interactome.
The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
The contribution of dietary and plasma folate and cobalamin to levels of angiopoietin-1, angiopoietin-2 and Tie-2 receptors depend on vascular endothelial growth factor status of primary breast cancer patients.
The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer.
The Determination of VEGF and MVD, among Patients with Primary Breast Cancer.
The differential regulation of human telomerase reverse transcriptase and vascular endothelial growth factor may contribute to the clinically more aggressive behavior of p63-positive breast carcinomas.
The effect of cancer procoagulant on expression of metastatic and angiogenic markers in breast cancer and embryonic stem cell lines.
The Effect of Coenzyme Q10 Supplementation on Vascular Endothelial Growth Factor and Serum Levels of Interleukin 6 and 8 in Women with Breast Cancer: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
The effect of exercise training on the level of tissue IL-6 and vascular endothelial growth factor in breast cancer bearing mice.
The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer.
The effect of vascular endothelial growth factor C expression in tumor-associated macrophages on lymphangiogenesis and lymphatic metastasis in breast cancer.
The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer.
The efficacy and safety of low-dose Apatinib in the management of stage IV luminal-type breast cancer: a case report and literature review.
The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancer.
The expression of ER beta protein correlates with vascular endothelial growth factor and its prognostic significance in human breast cancer.
The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.
The life, death, and attempted rebirth of bevacizumab in breast cancer.
The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells.
The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer.
The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis.
The natural progression of microvasculature in primary tumor and lymph node metastases in a breast carcinoma model: relationship between microvessel density, vascular endothelial growth factor expression, and metastatic invasion.
The nuclear corepressor 1 and the thyroid hormone receptor ? suppress breast tumor lymphangiogenesis.
The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF.
The pharmacological pathways of GnRH mediating the inhibition of mammary tumours: implications in humans and domestic animals.
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1? and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
The Relationship Between Cytokine Production, CSF2RA, and IL1R2 Expression in Mammary Adenocarcinoma, Tumor Histopathological Parameters, and Lymph Node Metastasis.
The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis.
The role of ?III-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy.
The role of antiangiogenetic agents in the treatment of breast cancer.
The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression.
The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer.
The role of vascular endothelial growth factor a polymorphisms in breast cancer.
The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops.
The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
The ShcA adaptor activates AKT signaling to potentiate breast tumor angiogenesis by stimulating VEGF mRNA translation in a 4E-BP-dependent manner.
The single nucleotide polymorphism +936 C/T VEGF is associated with human epidermal growth factor receptor 2 expression in Moroccan breast cancer women.
The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer.
The Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 Inhibits Aromatase.
Therapy with siRNA for Vegf-c but not for Vegf-d suppresses wide-spectrum organ metastasis in an immunocompetent xenograft model of metastatic mammary cancer.
Three-dimensional contrast-enhanced sonography in the assessment of breast tumor angiogenesis: correlation with microvessel density and vascular endothelial growth factor expression.
Three-dimensional hierarchical plasmonic nano-architecture enhanced surface-enhanced Raman scattering immunosensor for cancer biomarker detection in blood plasma.
Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers.
Toxicodendron vernicifluum Stokes extract inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
Transcriptional analysis of VEGF-D and TGF? genes in MCF7 cells exposed to saponin isolated from Holothuria leucospilota (sea cucumber).
Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis.
Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Transforming growth factor-beta in osteolytic breast cancer bone metastases.
Treatment of premenopausal women with early breast cancer: old challenges and new opportunities.
Triptolide inhibits vascular endothelial growth factor-mediated angiogenesis in human breast cancer cells.
Tristetraprolin: a novel mediator of the anticancer properties of resveratrol.
TRPS1 expression promotes angiogenesis and affects VEGFA expression in breast cancer.
Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression.
Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts.
Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor.
Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers.
Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients.
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
Type 1 TNF receptor forms a complex with and uses Jak2 and c-Src to selectively engage signaling pathways that regulate transcription factor activity.
Ultrasound-mediated destruction of vascular endothelial growth factor (VEGF) targeted and paclitaxel loaded microbubbles for inhibition of human breast cancer cell MCF-7 proliferation.
Ultrasound-mediated vascular endothelial growth factor C (VEGF-C) gene microbubble transfection inhibits growth of MCF-7 breast cancer cells.
Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway.
Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration.
Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: a case-control study.
Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a Chinese population.
Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in Punjabi population from North West India.
Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen.
Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival.
Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients.
Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
Vascular endothelial growth factor +405G/C and -2578C/A polymorphisms and breast cancer risk: a meta-analysis.
Vascular endothelial growth factor +936C/T polymorphism and breast cancer risk: a meta-analysis of 13 case-control studies.
Vascular endothelial growth factor ?634G/C polymorphism is associated with increased breast cancer risk and aggressiveness.
Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma.
Vascular endothelial growth factor A (VEGF-A) mRNA expression levels decrease after menopause in normal breast tissue but not in breast cancer lesions.
Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone.
Vascular endothelial growth factor and bevacitumab in breast cancer.
Vascular endothelial growth factor and breast cancer risk.
Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: a hypothetical consideration.
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer.
Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer.
Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer.
Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3.
Vascular endothelial growth factor encoded by Parapoxviruses can regulate metabolism and survival of triple negative breast cancer cells.
Vascular endothelial growth factor enhances cancer cell adhesion to microvascular endothelium in vivo.
Vascular endothelial growth factor expression and T-regulatory cells in premenopausal breast cancer.
Vascular endothelial growth factor expression in the basal subtype of breast carcinoma.
Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.
Vascular endothelial growth factor gene 936 C/T polymorphism in breast cancer patients.
Vascular endothelial growth factor gene expression in the human breast cancer cell line MX-1 is controlled by O2 availability in vitro and in vivo.
Vascular endothelial growth factor gene polymorphism (-634G/C) and breast cancer risk.
Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.
Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen.
Vascular endothelial growth factor in predicting outcome in breast cancer.
Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery?
Vascular endothelial growth factor in the serum of breast cancer patients.
Vascular endothelial growth factor in tumor tissue and blood serum from patients with breast cancer.
Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients.
Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones.
Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer.
Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression.
Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia.
Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells.
Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma.
Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells.
Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.
Vascular endothelial growth factor levels do not predict efficacy of systemic adjuvant treatment as assessed in 1127 breast cancer patients.
Vascular endothelial growth factor levels in relation to oxidative damage and antioxidant status in patients with breast cancer.
Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.
Vascular Endothelial Growth Factor Mediates the Sprouted Axonogenesis of Breast Cancer in Rat.
Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability.
Vascular endothelial growth factor mRNA levels quantified by reverse transcription-polymerase chain reaction in microdissected breast carcinoma tissues are correlated with histological type and grade of both invasive and intraductal components.
Vascular endothelial growth factor polymorphisms affect gene expression and tumor aggressiveness in patients with breast cancer.
Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis.
Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4.
Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor a.
Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins.
Vascular endothelial growth factor receptor-2 expression is induced by 17beta-estradiol in ZR-75 breast cancer cells by estrogen receptor alpha/Sp proteins.
Vascular endothelial growth factor receptor-2 in breast cancer.
Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo.
Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors.
Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer.
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Vascular endothelial growth factor-C and vascular endothelial growth factor-d messenger RNA expression in breast cancer: association with lymph node metastasis.
Vascular endothelial growth factor-D is a survival factor for human breast carcinoma cells.
Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells.
Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.
VEGF Expression is Associated with Negative Estrogen Receptor Status in Patients with Breast Cancer.
VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve.
VEGF-D and HIF-1alpha in breast cancer.
VEGF-D in Association With VEGFR-3 Promotes Nodal Metastasis in Human Invasive Lobular Breast Cancer.
VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.
VEGFR-2 kinase domain inhibition as a scaffold for anti-angiogenesis: Validation of the anti-angiogenic effects of carotenoids from Spondias mombin in DMBA model of breast carcinoma in Wistar rats.
Visfatin stimulates proliferation of MCF-7 human breast cancer cells.
WITHDRAWN: Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients.
Xenoestrogens modulate vascular endothelial growth factor secretion in breast cancer cells through an estrogen receptor-dependent mechanism.
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
[Association of JMJD3, MMP-2 and VEGF expressions with clinicopathological features of invasive ductal breast carcinoma].
[Change and clinic significance of serum VEGF level before and after breast cancer patients treated]
[Chemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanism]
[Effect and mechanism of apigenin on VEGF expression in human breast cancer cells]
[Effect of different estrogen receptor subtypes on vascular endothelial growth factor protein expression in human breast cancer samples]
[Effect of Runing II on expression of vascular endothelial growth factor in transplanted tumor of mammary cancer MA-891 in TA2 mice]
[Effect of siRNA transfection targeting VEGF gene on proliferation and apoptosis of human breast cancer cells]
[Evaluation of angiogenesis in the tumorigenesis and progression of breast cancer]
[Expression correlation of Ki67 to P53,VEGF,and C-erbB-2 genes in breast cancer and their clinical significances]
[Expression of angiogenesis-related factors in invasive breast cancer and its clinical significance]
[Expression of HIF-1? and correlation with angiogenesis in tissue of breast cancer complicated with diabetes].
[Expression of MMP-9 and VEGF in breast cancer: correlation with other prognostic indicators]
[Expression of vascular endothelial growth factor A and C in human breast cancer and their significance]
[Expression of vascular endothelial growth factor and its receptor (Flt-1) in breast carcinoma]
[Expression of vascular endothelial growth factor and its receptor Flk-1/KDR in benign and malignant breast neoplasms]
[Expression of vascular endothelial growth factor C in human breast cancer cell lines MCF-7 and MCF-7/Adr]
[Expression of vascular endothelial growth factor in different breast tissues and clinical significance thereof]
[Expressions of vascular endothelial growth factor and nm23-H1 gene and their relation to the prognosis of breast cancer in young women.]
[HIF-1alpha expression and relationship involving tumor cell proliferation and angiogenesis in human breast carcinoma]
[Inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway]
[Lymphangiogenes and location of tumor lymphatic vessels induced by VEGF-C in primary breast carcer]
[mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR]
[Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma]
[Relationship between LKB1 gene and invasion-related factors of breast cancer cells]
[Relevance of tumor angiogenesis in occurrence and development of breast cancer]
[Role of matrix metalloproteinase (MMP)-2 and -9 and vascular endothelial growth factor C in lymph node metastasis of breast cancer.]
[Role of RhoA in hypoxia-induced breast cancer cell VEGF secretion and proliferation, migration and tube formation of HUVECs].
[Role of short haipin RNA targeting vascular endothelial growth factor-C on biological characteristics of human breast cancer cell MCF-7]
[Significance of microvascular density and vascular endothelial growth factor in breast cancer]
[Study of mRNA expression of vascular endothelial growth factor-(A, C, D) genes and its effect on prognosis of breast cancer]
[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].
[The prognostic value of vascular endothelial growth factor in breast cancer]
[The relationship between lymphatic metastasis and serum vascular endothelial growth factor C and cyclooxygenase 2 expression in breast cancer]
[The relationship between vascular endothelial growth factor, microvascular density, lymph node metastasis and prognosis of breast carcinoma]
[Tumor angiogenesis in node-negative breast carcinoma]
[Vascular endothelial growth factor (VEGF)-D in association with VEGF receptor-3 in lymphatic metastasis of breast cancer]
[Vascular endothelial growth factor and two types of its receptors in breast cancer]
Bronchial Hyperreactivity
Evaluation of vascular endothelial growth factor A and endostatin levels in induced sputum and relationship to bronchial hyperreactivity in patients with seasonal allergic rhinitis.
Bronchiolitis
Critical Role of VEGF-C/VEGFR-3 Signaling in Innate and Adaptive Immune Responses in Experimental Obliterative Bronchiolitis.
Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis.
Role of vascular endothelial growth factor (VEGF) and its receptors in experimental obliterative bronchiolitis.
Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis.
Bronchitis
Cigarette smoke and ?,?-unsaturated aldehydes elicit VEGF release through the p38 MAPK pathway in human airway smooth muscle cells and lung fibroblasts.
Vascular endothelial growth factor: an angiogenic factor reflecting airway inflammation in healthy smokers and in patients with bronchitis type of chronic obstructive pulmonary disease?
Bronchitis, Chronic
Increased expression of vascular endothelial growth factor and hypoxia inducible factor-1? in lung tissue of patients with chronic bronchitis.
Bronchopulmonary Dysplasia
Alterations of the Thioredoxin System by Hyperoxia: Implications for Alveolar Development.
Association of a vascular endothelial growth factor polymorphism with the development of bronchopulmonary dysplasia in Japanese premature newborns.
Bronchopulmonary dysplasia and early prophylactic inhaled nitric oxide in preterm infants: current concepts and future research strategies in animal models.
Corrected VEGF levels based on platelet count should be calculated. Concerning the article by B.M. Levesque et al.: Low urine vascular endothelial growth factor levels are associated with mechanical ventilation, bronchopulmonary dysplasia and retinopathy of prematurity [Neonatology 2013;104:56-64].
Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia.
Effects of a superoxide dismutase mimetic on biomarkers of lung angiogenesis and alveolarization during hyperoxia with intermittent hypoxia.
Genes Encoding Vascular Endothelial Growth Factor A (VEGF-A) and VEGF Receptor 2 (VEGFR-2) and Risk for Bronchopulmonary Dysplasia.
Genetic Contributions to the Development of Complications in Preterm Newborns.
Genetic risk factors of bronchopulmonary dysplasia.
Interaction between pulmonary vasculature and the patent ductus arteriosus in very premature infants.
Knockdown of miR-203a-3p alleviates the development of bronchopulmonary dysplasia partly via the up-regulation of vascular endothelial growth factor A.
Low urine vascular endothelial growth factor levels are associated with mechanical ventilation, bronchopulmonary dysplasia and retinopathy of prematurity.
Placental growth factor and vascular endothelial growth factor receptor-2 in human lung development.
Upregulation of Vascular Endothelial Growth Factor in Amniotic Fluid Stem Cells Enhances Their Potential to Attenuate Lung Injury in a Preterm Rabbit Model of Bronchopulmonary Dysplasia.
Vascular endothelial growth factor levels and bronchopulmonary dysplasia in preterm infants.
[Dynamic changes in vascular endothelial growth factor and endothelial nitric oxide synthase in lungs of premature rats after hyperoxia exposure]
[Effects of prolonged exposure of high concentration of oxygen on expression of vascular endothelial growth factor and its receptors in neonatal rat lungs]
Bulbo-Spinal Atrophy, X-Linked
Polyglutamine diminishes VEGF; passage to motor neuron death?
Bursitis
Expression of vascular endothelial growth factor and angiogenesis in the diabetic frozen shoulder.
CADASIL
Stem cell factor and granulocyte colony-stimulating factor promote brain repair and improve cognitive function through VEGF-A in a mouse model of CADASIL.
Calcinosis
The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis.
Calciphylaxis
POEMS syndrome and calciphylaxis: an unrecognized cause of abnormal small vessel calcification.
Capillary Leak Syndrome
Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome.
How relevant are vascular endothelial growth factor and intercellular adhesion molecule in the systemic capillary leak syndrome of psoriasis?
Isoform D of vascular endothelial growth factor in systemic capillary leak syndrome: a case report.
Plasma vascular endothelial growth factor level is a predictor of the severity of postoperative capillary leak syndrome in neonates undergoing cardiopulmonary bypass.
Synchronized changes in serum vascular endothelial growth factor during the clinical course of chronic systemic capillary leak syndrome.
Vascular endothelial growth factor in systemic capillary leak syndrome.
[Effect of fluid resuscitation on capillary permeability and vascular endothelial growth factor in dogs with septic shock]
Capsule Opacification
Platelet-derived growth factor D, tissue-specific expression in the eye, and a key role in control of lens epithelial cell proliferation.
Carcinogenesis
1alpha,25-dihydroxycholecalciferol increases the expression of vascular endothelial growth factor in C3H10T1/2 mouse embryo fibroblasts.
5-deoxykaempferol plays a potential therapeutic role by targeting multiple signaling pathways in skin cancer.
?-catenin involvement in arsenite-induced VEGF expression in neuroblastoma SH-SY5Y cells.
?-Solanine inhibits vascular endothelial growth factor expression by down-regulating the ERK1/2-HIF-1? and STAT3 signaling pathways.
A Novel Three-miRNA Signature Identified Using Bioinformatics Predicts Survival in Esophageal Carcinoma.
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.
ADAMTS5 Functions as an Anti-Angiogenic and Anti-Tumorigenic Protein Independent of Its Proteoglycanase Activity.
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.
Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.
Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis.
Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Anterior gradient 2 promotes tumorigenesis through upregulation of CCAAT-enhancer binding protein beta and hypoxia-inducible factor-2? and subsequent secretion of interleukin-6, interleukin-8, and vascular endothelial growth factor in the Caki-1 clear cell renal cell carcinoma cell line.
Anti-VEGF Treatment of Corneal Neovascularization.
Antiangiogenic activity of selenium in cancer chemoprevention: metabolite-specific effects.
Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells.
Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer.
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Antitumorigenic effect of plumbagin by induction of SH2-containing protein tyrosine phosphatase 1 in human gastric cancer cells.
Association between +936 C>T gene polymorphism of vascular endothelial growth factor and lung cancer: a meta-analysis.
Association of clinicopathologic parameters with the expression of inducible nitric oxide synthase and vascular endothelial growth factor in mucoepidermoid carcinoma.
Association of specific single nucleotide variants (SNVs) in the promoter and 3'-Untranslated region of Vascular Endothelial growth factor (VEGF) gene with risk and higher tumour grade of head and neck cancers.
Bioluminescence imaging of vascular endothelial growth factor promoter activity in murine mammary tumorigenesis.
Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study.
C-erbB-2 or mutant Ha-ras induced malignant transformation of immortalized human ovarian surface epithelial cells in vitro.
Cancer prevention and therapy through the modulation of the tumor microenvironment.
Carcinoma ex pleomorphic adenoma of the salivary glands: distinct clinicopathologic features and immunoprofiles between subgroups according to cellular differentiation.
Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
Chemoprevention of colonic tumorigenesis by dietary hydroxylated polymethoxyflavones in azoxymethane-treated mice.
Chlorophyllin abrogates canonical Wnt/?-catenin signaling and angiogenesis to inhibit the development of DMBA-induced hamster cheek pouch carcinomas.
Cigarette smoke modulates binding of the transcription factor MZF1 to the VEGF promoter and regulates VEGF expression in dependence of genetic variation SNP 405.
circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge.
Cocoa polyphenols suppress TNF-?-induced vascular endothelial growth factor expression by inhibiting phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase kinase-1 (MEK1) activities in mouse epidermal cells.
Colorectal polypoid lesions and expression of vascular endothelial growth factor in a consecutive series of endoscopic and surgical patients.
Construction of a two-in-one liposomal system (TWOLips) for tumor-targeted combination therapy.
Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing.
Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma.
COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates.
Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression.
Curcumin reduces pulmonary tumorigenesis in vascular endothelial growth factor (VEGF)-overexpressing transgenic mice.
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis.
Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound.
Dickkopf-3 (DKK-3) obstructs VEGFR-2/Akt/mTOR signaling cascade by interacting of ?2-microglobulin (?2M) in ovarian tumorigenesis.
Dietary Supplementation with Methylseleninic Acid Inhibits Mammary Tumorigenesis and Metastasis in Male MMTV-PyMT Mice.
Dihydroxystilbenes prevent azoxymethane/dextran sulfate sodium-induced colon cancer by inhibiting colon cytokines, a chemokine, and programmed cell death-1 in C57BL/6J mice.
Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis.
DMBA-induced mammary pathologies are angiogenic in vivo and in vitro.
Does hormone therapy, tibolone or raloxifene modify VEGF expression in cervical epithelial cells?
Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice.
Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Effective suppression of azoxymethane-induced aberrant crypt foci formation in mice with citrus peel flavonoids.
Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.
eIF4E expression in tumors: its possible role in progression of malignancies.
Elevated VEGF-D Modulates Tumor Inflammation and Reduces the Growth of Carcinogen-Induced Skin Tumors.
Emerging roles of PDGF-D in EMT progression during tumorigenesis.
Emerging roles of PDGF-D signaling pathway in tumor development and progression.
Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors.
Estimation of vascular endothelial growth factor gene -460 C/T polymorphism as a biomarker in oral squamous cell carcinoma patients from the Indian subcontinent.
Expression and subcellular localization of a novel nuclear acetylcholinesterase protein.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors.
Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours*
Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours.
Expression of hypoxia inducible factor-1 alpha and correlation with preoperative embolization of meningiomas.
Expression of p53, VEGF, Microvessel Density, and Cyclin-D1 in Noncancerous Tissue of Inflammatory Bowel Disease.
Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in Oral Squamous Cell Carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation.
Expression of the von Hippel-Lindau Tumor Suppressor Gene in Nonneoplastic and Neoplastic Lesions of the Thyroid.
Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.
Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop.
Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis.
Expression of vascular endothelial growth factor and its receptors during lung carcinogenesis by N-nitrosobis(2-hydroxypropyl)amine in rats.
Expression of vascular endothelial growth factor and its role in oncogenesis of human gastric carcinoma.
Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis.
Expression of vascular endothelial growth factor and microvessel density in oral tumorigenesis.
Expression of vascular endothelial growth factor in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat bladder carcinogenesis.
Expression of vascular endothelial growth factors VEGF- C and D, VEGFR-3, and comparison of lymphatic vessels density labeled with D2-40 antibodies as a prognostic factors in vulvar intraepithelial neoplasia (VIN) and invasive vul.
Genetic polymorphism of VEGF-1154 (A/G) in laryngeal squamous cell carcinoma.
Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma.
Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.
GM-CSF facilitates the development of inflammation-associated colorectal carcinoma.
Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice.
Haplotype-based association of Vascular Endothelial Growth Factor gene polymorphisms with urothelial bladder cancer risk in Tunisian population.
Helicobacter pylori protein HP0175 transactivates epidermal growth factor receptor through TLR4 in gastric epithelial cells.
Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor.
HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis.
HPV16 E6/E7 upregulates HIF-2? and VEGF by inhibiting LKB1 in lung cancer cells.
Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ ERK1,2 and PI3K/Akt.
Human Skin-Derived Mast Cells Spontaneously Secrete Several Angiogenesis-Related Factors.
Immunoglobulin Fc-Fused Peptide without C-Terminal Arg or Lys Residue Augments Neuropilin-1-Dependent Tumor Vascular Permeability.
Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features.
Immunohistochemical Expression of Vascular Endothelial Growth Factor A in Advanced Gallbladder Carcinoma.
Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Inhibitory effect of clotrimazole on angiogenesis associated with bladder epithelium proliferation in rats.
Inhibitory effects of 1,3-diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Is serous cystadenoma of the pancreas a model of clear-cell-associated angiogenesis and tumorigenesis?
Knockdown GREM1 suppresses cell growth, angiogenesis, and epithelial-mesenchymal transition in colon cancer.
Lactate and cancer: a "lactatic" perspective on spinal tumor metabolism (part 1).
Large-scale production, purification, and function of a tumor multi-epitope vaccine: Peptibody with bFGF/VEGFA.
Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats.
Leukocytic-vascular endothelial growth factor and integrin alphavbeta3 in acute myeloid leukemia: relation to clinical outcome.
Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis.
Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.
Lung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16.
Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling.
Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells.
MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation.
Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
MAZ51 Blocks the Tumor Growth of Prostate Cancer by Inhibiting Vascular Endothelial Growth Factor Receptor 3.
miR-31 is upregulated in oral premalignant epithelium and contributes to the immortalization of normal oral keratinocytes.
Molecular biology of colorectal cancer: new targets.
Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
Mutant IkappaBalpha suppresses hypoxia-induced VEGF expression through downregulation of HIF-1alpha and COX-2 in human glioma cells.
Neuropilin-1 Acts as a Receptor for Complement Split Products.
Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo.
Optimal conditions for cordycepin production in surface liquid-cultured Cordyceps militaris treated with porcine liver extracts for suppression of oral cancer.
Overexpression and Interactions of Interleukin-10, Transforming Growth Factor beta, and Vascular Endothelial Growth Factor in Esophageal Squamous Cell Carcinoma.
PAGOD syndrome and vascular anomalies: is a defect embryonic angiogenesis? A case report and review.
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines.
Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.
Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis.
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).
Phospholipase D activates HIF-1-VEGF pathway via phosphatidic acid.
Pivotal involvement of the CX3CL1-CX3CR1 axis for the recruitment of M2 tumor-associated macrophages in skin carcinogenesis.
Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas.
Platelet-Derived Growth Factor/Vascular Endothelial Growth Factor Receptor Inactivation by Sunitinib Results in Tsc1/Tsc2-Dependent Inhibition of TORC1.
Polymorphisms in the VEGFA promoter are associated with susceptibility to hepatocellular carcinoma by altering promoter activity.
Possible association between polymorphisms of human vascular endothelial growth factor a gene and susceptibility to glioma in a Chinese population.
Possible Role and Therapeutic Target of PDGF-D Signalling in Colorectal Cancer.
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer.
Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer.
Prognostic and clinicopathologic significance of PAQR3 and VEGF-A expression in pulmonary adenocarcinoma.
Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis.
Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis.
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.
Prognostic significance of VEGF immunohistochemical expression in oral cancer: a meta-analysis of the literature.
Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis.
Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis.
Protective effect of berberine on expression pattern of apoptotic, cell proliferative, inflammatory and angiogenic markers during 7,12-dimethylbenz(a)anthracene induced hamster buccal pouch carcinogenesis.
Protein kinase Cbeta is an effective target for chemoprevention of colon cancer.
Quantification of STAT3 and VEGF expression for molecular diagnosis of lymph node metastasis in breast cancer.
Ras gene mutation is not related to tumour invasion during rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide.
Recent developments in colorectal cancer treatment by monoclonal antibodies.
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent.
Resistance to mammary carcinogenesis in Copenhagen rats: potential roles of vascular endothelial growth factor and mast cells.
Role of viral induced vascular endothelial growth factor (VEGF) production in pleural effusion and malignant mesothelioma.
Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer.
Signal Transduction Cross-talk During Colorectal Tumorigenesis.
Silibinin inhibits tumor promotional triggers and tumorigenesis against chemically induced two-stage skin carcinogenesis in Swiss albino mice: possible role of oxidative stress and inflammation.
Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity.
Steroid receptor coactivator-1 interacts with NF-?B to increase VEGFC levels in human thyroid cancer.
Structure activity relationships of chrysoeriol and analogs as dual c?Met and VEGFR2 tyrosine kinase inhibitors.
Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.
Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
Syringic acid modulates molecular marker-involved cell proliferation, survival, apoptosis, inflammation, and angiogenesis in DMBA-induced oral squamous cell carcinoma in Syrian hamsters.
Targeted therapies for thyroid tumors.
Targeted therapy of thyroid cancer.
Targeting the Unfolded Protein Response as a Potential Therapeutic Strategy in Renal Carcinoma Cells Exposed to Cyclosporine A.
Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression.
The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study.
The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma.
The Galpha12/13 family of heterotrimeric G proteins and the small GTPase RhoA link the Kaposi sarcoma-associated herpes virus G protein-coupled receptor to heme oxygenase-1 expression and tumorigenesis.
The immunomodulatory effects of topiramate on azoxymethane-induced colon carcinogenesis in rats: The role of the inflammatory cascade, vascular endothelial growth factor, AKT/mTOR/MAP kinase signaling and the apoptotic markers.
The impact of cigarette smoke on activity of single nucleotide polymorphisms of the vascular endothelial growth factor-promoter gene in cells of the upper aerodigestive tract.
The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer.
The potential role of sunitinib in gastrointestinal cancers other than GIST.
The role of insulin receptor substrate (IRS) proteins in oncogenic transformation.
The RON tyrosine kinase receptor regulates vascular endothelial growth factor production in pancreatic cancer cells.
The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.
The translation initiation factor eIF3i up-regulates vascular endothelial growth factor A, accelerates cell proliferation, and promotes angiogenesis in embryonic development and tumorigenesis.
The von Hippel-Lindau tumor suppressor gene.
Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism.
Tim-4 promotes the growth of colorectal cancer by activating angiogenesis and recruiting tumor-associated macrophages via the PI3K/AKT/mTOR signaling pathway.
Tumor-derived vascular endothelial growth factor (VEGF)-A facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway.
Unique properties of 189 amino acid isoform of vascular endothelial growth factor in tumorigenesis.
Up-Regulation of Vascular Endothelial Growth Factor-D Expression in Clear Cell Renal Cell Carcinoma by CD74: A Critical Role in Cancer Cell Tumorigenesis.
Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease.
Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma.
Vascular endothelial growth factor +936C/T polymorphism and cancer risk in Asians: a meta-analysis.
Vascular endothelial growth factor and breast cancer risk.
Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis.
Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer.
Vascular Endothelial Growth Factor Induced Skin Carcinogenesis depends on Recruitment and Alternative Activation of Macrophages.
Vascular endothelial growth factor mRNA levels as a biomarker for short-term N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder carcinogenesis bioassay.
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.
Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells.
Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo.
Vascular endothelial growth factor-C and vascular endothelial growth factor-d messenger RNA expression in breast cancer: association with lymph node metastasis.
Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy.
VEGF is associated with the poor survival of patients with prostate cancer: a meta-analysis.
VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival.
VEGF receptors are differentially expressed by neuroblastoma cells in culture.
VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis.
VEGFR-2 kinase domain inhibition as a scaffold for anti-angiogenesis: Validation of the anti-angiogenic effects of carotenoids from Spondias mombin in DMBA model of breast carcinoma in Wistar rats.
VEGFR1 and VEGFR2 in lip carcinogenesis and its association with microvessel density.
VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma.
Whole-Exome Sequencing Studies of Nonfunctioning Pituitary Adenomas.
[Activation of CXCR4 in human glioma stem cells promotes tumor angiogenesis]
[Angiogenesis and blood supply during the course of pulmonary carcinogenesis in experimental rat.]
[Circadian variation of clock gene Per2 and cancer-related clock-controlled genes in buccal mucosa carcinoma of golden hamster at different cancer stages].
[Clinical significance and expression of vascular endothelial growth factor in serum of patients with acute leukemia]
[Current progress and management in molecular targeted therapy for advanced thyroid cancer].
[Effect of vascular endothelial growth factor C and collagen triple helix repeat containing 1 expression on prognosis of rectal carcinoma patients].
[Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma]
[Expression and significance of CD44v6, bcl-2, and vascular endothelial growth factor(VEGF) in endometrial adenocarcinoma]
[Expression and significance of inducible nitric oxide synthase and vascular endothelial growth factor in carcinogenesis of hamster cheek pouch]
[Expression of mRNA isoforms of vascular endothelial growth factor in ovarian carcinoma]
[Molecular mechanism of reversing metastatic phenotype in human high-metastatic large cell lung cancer cell line L9981 by nm23-H1]
[Monoclonal antibody preparation and identification of vascular endothelial growth factor 165 expressed in vitro].
[Morphogenesis, structure and properties of lymphatic vessels].
[The clinical value of vascular endothelial growth factor in patients with small cell lung cancer.]
[VEGF--targeted therapy for the treatment of cervical cancer --literature review].
Carcinoid Tumor
Development and characterization of a novel in vivo model of carcinoid syndrome.
GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.
Hypoxia stimulates CXCR4 signalling in ileal carcinoids.
mTOR inhibition, a potential novel approach for bronchial carcinoids.
Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Systemic therapy for advanced carcinoid tumors: where do we go from here?
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
Carcinoma
10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
1alpha,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells.
3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis.
4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells.
A Case of Lung Adenocarcinoma with Marked Improvement of Pulmonary Lymphangitic Carcinomatosis by Adding Bevacizumab to Cisplatin and Pemetrexed.
A comparison of antiangiogenic therapies for the prevention of liver metastases.
A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model.
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.
A multicenter study on expressions of vascular endothelial growth factor, matrix metallopeptidase-9 and tissue inhibitor of metalloproteinase-2 in oral and maxillofacial squamous cell carcinoma.
A Novel Strategy for Advanced Pancreatic Cancer - Progression of Molecular Targeting Therapy.
A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma.
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice.
A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.
A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery.
A study on the inhibition of VEGF expression in salivary gland adenoid cystic carcinoma cells via iNOS gene RNAi in vitro.
A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma.
Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival.
Activation of invasiveness of cervical carcinoma cells by angiotensin II.
Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis.
Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?
Adrenomedullin Up-regulates the Expression of Vascular Endothelial Growth Factor in Epithelial Ovarian Carcinoma Cells via JNK/AP-1 Pathway.
Advances in the research on lymphangiogenesis in carcinoma tissues (Review).
Advances in treatment of metastatic renal cell carcinoma.
AEG-1 Contributes to Metastasis in Hypoxia-Related Ovarian Cancer by Modulating the HIF-1alpha/NF-kappaB/VEGF Pathway.
Alpha-fetoprotein-producing lung carcinoma: report of three cases.
Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Altered Expression of Endogenous Soluble Vascular Endothelial Growth Factor Receptor-2 Is Involved in the Progression of Esophageal Squamous Cell Carcinoma.
An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
An orally administered DNA vaccine targeting vascular endothelial growth factor receptor-3 inhibits lung carcinoma growth.
Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.
Analysis of efficacy of sorafenib combined with vascular endothelial growth factor inhibitor on renal cell carcinoma.
Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity.
Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
Angiogenesis and Expression of Vascular Endothelial Growth Factor, Tumour Necrosis Factor-? and Hypoxia Inducible Factor-1? in Canine Renal Cell Carcinoma.
Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour.
Angiogenesis and VEGF expression in pre-invasive lesions of the human breast.
Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma.
Angiogenesis gene expression profiling in xenograft models to study cellular interactions.
Angiogenesis in liver metastasis of colo-rectal carcinoma.
Angiogenesis in Ocular and Extraocular Sebaceous Carcinoma.
Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis.
Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases.
Angiogenic factors in squamous cell carcinoma of the oral cavity: do they have prognostic relevance?
Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma.
Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro.
Angiogenic growth factors in preinvasive breast disease.
Angiogenic growth factors in tissue homogenates of HNSCC: expression pattern, prognostic relevance, and interrelationships.
Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.
Angiogenic switch occurs during the precancerous stage of human esophageal squamous cell carcinoma.
Angiogenically active vascular endothelial growth factor is over-expressed in malignant human and rat prostate carcinoma cells.
Angiopoietin-2 inhibits the growth of tongue carcinoma without affecting expression of vascular endothelial growth factor.
Angiostatin expression in ovarian cancer.
Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
Anterior gradient 2 promotes tumorigenesis through upregulation of CCAAT-enhancer binding protein beta and hypoxia-inducible factor-2? and subsequent secretion of interleukin-6, interleukin-8, and vascular endothelial growth factor in the Caki-1 clear cell renal cell carcinoma cell line.
Anti-angiogenesis therapy in pancreatic carcinoma.
Anti-Angiogenic Drugs in the Treatment of Metastatic Renal Cell Carcinoma:Advances in Clinical Application.
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model.
Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma.
Antisense oligonucleotides against microRNA-21 reduced the proliferation and migration of human colon carcinoma cells.
Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.
Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody.
Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
Apium graveolens Extract Inhibits Cell Proliferation and Expression of Vascular Endothelial Growth Factor and Induces Apoptosis in the Human Prostatic Carcinoma Cell Line LNCaP.
Application of epidermal growth factor receptor, vascular endothelial growth factor and cyclooxygenase-2 in prognosis of esophageal carcinomas.
Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Ascochlorin inhibits growth factor-induced HIF-1? activation and tumor-angiogenesis through the suppression of EGFR/ERK/p70S6K signaling pathway in human cervical carcinoma cells.
Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results.
Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.
Assessment of VEGF and EGFR in the study of angiogenesis of eyelid carcinomas.
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.
Association between SNPs in vascular endothelial growth factor polymorphisms and risk of renal cell carcinoma: a case-control study.
Association between three VEGF polymorphisms and renal cell carcinoma susceptibility: a meta-analysis.
Association between vascular endothelial growth factor gene polymorphisms and the risk and prognosis of renal cell carcinoma: A systematic review and meta-analysis.
Association of preoperative radiation effect with tumor angiogenesis and vascular endothelial growth factor in oral squamous cell carcinoma.
Association of vascular endothelial growth factor and mast cells with angiogenesis in laryngeal squamous cell carcinoma.
Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.
Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma.
Association of Vascular Endothelial Growth Factor Gene Polymorphism With Renal Cell Carcinoma Risk.
Association of vascular endothelial growth factor polymorphisms with clinical outcome of renal cell carcinoma patients.
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome.
Association of VEGF-A genetic polymorphisms with cancer risk and survival in advanced-stage oral squamous cell carcinoma patients.
Associations between single-nucleotide polymorphisms of the VEGF gene and long-term prognosis of oral squamous cell carcinoma.
Associations between the expression of MTA1 and VEGF-C in esophageal squamous cell carcinoma with lymph angiogenesis and lymph node metastasis.
Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas.
Associations of VEGF-C Genetic Polymorphisms with Urothelial Cell Carcinoma Susceptibility Differ between Smokers and Non-Smokers in Taiwan.
Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production.
Autocrine signaling in carcinoma: VEGF and the alpha6beta4 integrin.
Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
Axitinib plasma pharmacokinetics and ethnic differences.
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.
Axitinib-induced acute pancreatitis: a case report.
Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma.
Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis.
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.
Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Bevacizumab: in first-line treatment of metastatic breast cancer.
Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma.
Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma.
Biological markers and prognosis in recurrent oral cancer after salvage surgery.
Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.
Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond.
Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.
c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases.
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Cabozantinib for the treatment of renal cell carcinoma.
Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells.
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Carcinoma ex pleomorphic adenoma of the salivary glands: distinct clinicopathologic features and immunoprofiles between subgroups according to cellular differentiation.
Carcinoma of the parotid gland: developing prognostic indices.
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.
Cathepsin S Controls Angiogenesis and Tumor Growth via Matrix-derived Angiogenic Factors.
CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells.
CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer.
CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value.
CD40 is overexpressed by HPV16/18-E6 positive cervical carcinoma and correlated with clinical parameters and vascular density.
Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Cepharanthine inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing expression of vascular endothelial growth factor and interleukin-8.
Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: Feasibility and Clinical Outcome.
Characterization of the expression and clinical features of epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in esophageal carcinoma.
Chemokine CCL4 Induces Vascular Endothelial Growth Factor C Expression and Lymphangiogenesis by miR-195-3p in Oral Squamous Cell Carcinoma.
Circulating and imaging markers for angiogenesis.
Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma.
Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios.
Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy.
Circulating proteins as potential biomarkers of sunitinib and interferon-? efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Circulating vascular endothelial growth factor correlates with systemic thrombin generation in patients with pancreatic carcinoma.
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Clinical implications of PTEN and VEGF expression status, as well as microvessel density in esophageal squamous cell carcinoma.
Clinical Implications of VEGF and p53 Expression in Squamous Cell Carcinoma of the Cervix Treated with Radiation Therapy.
Clinical pharmacology of axitinib.
Clinical prognostic values of vascular endothelial growth factor, microvessel density,and p53 expression in esophageal carcinomas.
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).
Clinical significance of hypoxia-inducible factor 1?, and its correlation with p53 and vascular endothelial growth factor expression in resectable esophageal squamous cell carcinoma.
Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients.
Clinical significance of serum levels of vascular endothelial growth factor and its receptor in biliary disease and carcinoma.
Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma.
Clinical significance of urinary vascular endothelial growth factor and microvessel density in patients with renal cell carcinoma.
Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
Clinical significance of vascular endothelial growth factor expression in patients with carcinoma of the mouth floor and tongue.
Clinicopathologic significance of hypoxia-inducible factor 1alpha overexpression in gastric carcinomas.
Clinicopathologic study of neovascularization and VEGF expression in superficial esophageal carcinoma.
Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma.
Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
Clinicopathological implications of vascular endothelial growth factor 165b expression in oral squamous cell carcinoma stroma.
Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas.
Coexpression of heparanase, basic fibroblast growth factor and vascular endothelial growth factor in human esophageal carcinomas.
Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways.
Coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the esophagus.
Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density.
Combination antiangiogenic therapy and radiation in head and neck cancers.
Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial.
Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma.
Combined Analysis of Vascular Endothelial Growth Factor Expression with Cyclooxygenase-2 and Mast Cell Density in Oral Squamous Cell Carcinoma.
Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts.
Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.
Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas.
Comparative analysis of hepatocellular carcinoma in men and dogs.
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
Comparative study of human colonic tumor-derived endothelial cells (HCTEC) and normal colonic microvascular endothelial cells (HCMEC): Hypoxia-induced sVEGFR-1 and sVEGFR-2 levels.
Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer.
Comparison of immunohistochemical expression of vascular endothelial growth factor and CD105 in oral squamous cell carcinoma: Its correlation with prognosis.
Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.
Constitutive upregulation of hypoxia-inducible factor-1alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure.
Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.
Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?
Correction: Simultaneous Expression of Furin and Vascular Endothelial Growth Factor in Human Oral Tongue Squamous Cell Carcinoma Progression.
Correlation and Significance of Urinary Soluble Fas and Vascular Endothelial Growth Factor in Bladder Urothelial Cancer.
Correlation Between Cyclo-oxygenase-2 and Vascular Endothelial Growth Factor Expression in Canine and Feline Squamous Cell Carcinomas.
Correlation between expression of S100A4 and VEGF-C, and lymph node metastasis and prognosis in gastric carcinoma.
Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma.
Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.
Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma.
Correlation between vascular endothelial growth factor C expression and lymph node metastasis in T1 carcinoma of the colon and rectum.
Correlation between vascular endothelial growth factor C expression and prognosis in patients with esophageal squamous cell carcinomas after Ivor-Lewis esophagectomy.
Correlation between Vascular Endothelial Growth Factor C Expressior and Lymph Node Micrometastasis and Prognosis in Patients with pNO Esophageal Squamous Cell Carcinomas.
Correlation between vascular endothelial growth factor expression and presence of lymph node metastasis in advanced squamous cell carcinoma of the larynx.
Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous cell carcinoma.
Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas.
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.
Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma.
Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma.
Correlation of integrin beta3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma.
Correlation of Mast Cell Densities, Angiogenesis and Vascular Endothelial Growth Factor in Proper Muscle Gastric Carcinomas.
Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma.
Correlation of serum levels of vascular endothelial growth factor with TNM staging, histopathologic grading, and surgical therapy for oral squamous cell carcinoma.
Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma.
Correlation of vascular endothelial growth factor and hypoxia-inducible factor-1? expression with pathological renal artery changes in patients with renal cell carcinoma.
Correlation of vascular endothelial growth factor expression to overall survival in feline invasive mammary carcinomas.
Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma.
Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.
COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables.
Cyclo-oxygenase-2 expression is associated with vascular endothelial growth factor C expression and lymph node metastasis in oral squamous cell carcinoma.
Cyclooxygenase-2 expression in an adenoid cystic carcinoma of the uterine cervix.
Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma.
Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma.
Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma.
Cyclooxygenase-2/prostaglandin E(2) pathway mediates icariside II induced apoptosis in human PC-3 prostate cancer cells.
Cyr61 promotes breast tumorigenesis and cancer progression.
Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells.
Cytokines and tumor markers in potentially malignant disorders and oral squamous cell carcinoma: a pilot study.
Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.
Cytoplasmic neuropilin 2 is associated with metastasis and a poor prognosis in early tongue cancer patients.
Decreased lung carcinoma cell functions on select polymer nanometer surface features.
Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma.
Design and synthesis of novel pyridazinoquinazoline derivatives as potent VEGFR-2 inhibitors: In vitro and in vivo study.
Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.
Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma.
Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Differential effects between cyclooxygenase-2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines.
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma.
Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder.
Differential expression of VEGF ligands and receptors in prostate cancer.
Differing Expression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis.
Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src.
Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation.
Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
Downregulation of VEGFA inhibits proliferation, promotes apoptosis, and suppresses migration and invasion of renal clear cell carcinoma.
Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.
Ductal carcinoma in situ of the breast with osteoclast-like giant cells.
DW-MRI for esophageal squamous cell carcinoma, correlations between ADC values with histologic differentiation and VEGF expression: A retrospective study.
Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers.
Editorial Comment on: Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas.
Effect of axitinib on the QT interval in healthy volunteers.
Effect of cis-diammine dichloroplatinum on vascular endothelial growth factor expression in uterine cervical carcinoma.
Effect of down-regulating VEGF on proliferation of colon carcinoma cell HT-29.
Effect of duration of fixation on quantitative reverse transcription polymerase chain reaction analyses.
Effect of endothelial PAS domain protein 1 and hypoxia inducible factor 1alpha on vascular endothelial growth factor expression in human pancreatic carcinoma.
Effect of Kang'ai Injection on serum level of soluble interleukin-2 receptor and vascular endothelial growth factor in patients with esophageal carcinoma during radiotherapy.
Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C.
Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer.
Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma.
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.
Effect of thyroid hormone-nitric oxide interaction on tumor growth, angiogenesis, and aminopeptidase activity in mice.
Effect of VEGF, P53 and telomerase on angiogenesis of gastric carcinoma tissue.
Effect of VEGF-C siRNA and endostatin on ring formation and proliferation of esophageal squamous cell carcinoma lymphatic endothelial cells.
Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis.
Effects of endostatin on expression of vascular endothelial growth factor and its receptors and neovascularization in colonic carcinoma implanted in nude mice.
Effects of Feijining Decoction on vascular endothelial growth factor protein expression and changes of T cell subsets in Lewis lung carcinoma-bearing mice.
Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expression in colon carcinoma cell line HT-29.
Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study.
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-tyrosine Kinase Inhibitor.
Efficacy and Safety of Image-Guided Intensity-Modulated Radiation Therapy and Volumetric Modulated Arc Therapy Combined with Paclitaxel Liposomes and Cisplatin for Locally Advanced Stage IIB-IIIB Cervical Cancer: A Retrospective Study at a Single Center.
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial.
Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Efficacy of Arsenic Trioxide in the Treatment of Malignant Pleural Effusion Caused by Pleural Metastasis of Lung Cancer.
Efficacy of Everolimus in Patients with Advanced Renal Cell Carcinoma Refractory or Intolerant to VEGFR-TKIs and Safety Compared with Prior VEGFR-TKI Treatment.
Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO2@LDH for anti-neuroblastoma therapy.
El-Gazzar R, Macluskey M, Williams H, Ogden GR. Vascularity and expression of vascular endothelial growth factor in oral squamous cell carcinoma, resection margins, and nodal metastases. Br J Oral Maxillofac Surg 2006;44:193-7 [Epub 2005, August 10].
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma.
Elevated Preoperative Carcinoembryonic Antigen and Vascular Endothelial Growth Factor Predict Shorter Survival in Patients with Sigmoid Colon Carcinoma.
Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer.
Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma.
Elevated VEGF-D Modulates Tumor Inflammation and Reduces the Growth of Carcinogen-Induced Skin Tumors.
Elevated VEGFA mRNA levels in oral squamous cell carcinomas and tumor margins: a preliminary study.
Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors.
Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane.
Endostatin gene transfer in murine lung carcinoma cells induces vascular endothelial growth factor secretion resulting in up-regulation of in vivo tumorigenecity.
Endostatin improves cancer-associated systemic syndrome in a lung cancer model.
Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding.
Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor.
Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.
Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion.
Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas.
Enzyme-digested Fucoidan Extracts Derived from Seaweed Mozuku of Cladosiphon novae-caledoniae kylin Inhibit Invasion and Angiogenesis of Tumor Cells.
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy.
Epigenetic regulation of vascular endothelial growth factor a dynamic expression in transitional cell carcinoma.
Estimation of vascular endothelial growth factor gene -460 C/T polymorphism as a biomarker in oral squamous cell carcinoma patients from the Indian subcontinent.
Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.
Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.
Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma.
Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma.
Evaluation of plasma and tissue S100A4 protein and mRNA levels as potential markers of metastasis and prognosis in clear cell renal cell carcinoma.
Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma.
Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast.
Evaluation of the vascular endothelial growth factor (VEGF)-C role in urothelial carcinomas of the bladder.
Evaluation of tissue and serum VEGF in patients with head and neck carcinoma.
Evaluation of tumor metastasis-associated markers for molecular classification in patients with esophageal squamous cell carcinoma.
Evaluation of vascular endothelial growth factor gene and protein expression in canine metastatic mammary carcinomas.
Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study.
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T.
Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
Everolimus.
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?
Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.
Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma.
Exploring the peritoneal surface malignancy phenotype-a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models.
Expression and biological relationship of vascular endothelial growth factor-a and matrix metalloproteinase-9 in gastric carcinoma.
Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma.
Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor.
Expression and prognosis of CyclinA and CDK2 in patients with advanced cervical cancer after chemotherapy.
Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats.
Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Expression and significance of FOXP1, HIF-1a and VEGF in renal clear cell carcinoma.
Expression and significance of vascular endothelial growth factor C from multiple specimen sources in esophageal squamous cell carcinoma.
Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Expression of ?B-Crystallin and Vascular Endothelial Growth Factor in Conjunctival Squamous Cell Carcinoma.
Expression of angiogenesis-related genes in canine cortisol-secreting adrenocortical tumors.
Expression of angiogenesis-related genes in ovarian carcinoma--a clinicopathologic study.
Expression of angiogenic chemokines in ovarian clear cell carcinoma.
Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma.
Expression of angiogenic factors is increased in metastasised renal cell carcinomas.
Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines.
Expression of angiopoietin-2 and vascular endothelial growth factor receptor-3 correlates with lymphangiogenesis and angiogenesis and affects survival of oral squamous cell carcinoma.
Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.
Expression of astrocyte elevated gene-1 closely correlates with the angiogenesis of gastric cancer.
Expression of basic fibroblast growth factor, vascular endothelial growth factor, and thrombospondin-1 related to microvessel density in nonaggressive and aggressive basal cell carcinomas.
Expression of brain?specific angiogenesis inhibitor?1 and association with p53, microvessel density and vascular endothelial growth factor in the tissue of human bladder transitional cell carcinoma.
Expression of cyclooxygenase 2 and vascular endothelial growth factor in gastric carcinoma: Relationship with clinicopathological parameters.
Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression.
Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study.
Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma.
Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma.
Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in oral squamous cell carcinoma: its correlation with angiogenesis and disease progression.
Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma.
Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis.
Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops.
Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma.
Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma.
Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas.
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
Expression of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma.
Expression of inducible nitric oxide synthase is significantly correlated with expression of vascular endothelial growth factor and dendritic cell infiltration in patients with advanced gastric carcinoma.
Expression of interleukin-8, heme oxygenase-1 and vascular endothelial growth factor in DLD-1 colon carcinoma cells exposed to pyrrolidine dithiocarbamate.
Expression of liver-type fatty-acid-binding protein, fatty acid synthase and vascular endothelial growth factor in human lung carcinoma.
Expression of Livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma.
Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis.
Expression of p53 oncoprotein increases intratumoral microvessel formation in human salivary gland carcinomas.
Expression of p53 protein in esophageal squamous cell carcinoma: relation to hypoxia-inducible factor-1alpha, angiogenesis and apoptosis.
Expression of PC cell-derived growth factor and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinicopathologic significance.
Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.
Expression of Rac1, HIF-1?, and VEGF in Gastric Carcinoma: Correlation with Angiogenesis and Prognosis.
Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas.
Expression of the von Hippel-Lindau Tumor Suppressor Gene in Nonneoplastic and Neoplastic Lesions of the Thyroid.
Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung.
Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas.
Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance.
Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival.
Expression of vascular endothelial growth factor (VEGF) in normal oral mucosa, oral dysplasia and oral squamous cell carcinoma.
Expression of vascular endothelial growth factor (VEGF) in patients with oral squamous cell carcinoma and its clinical significance.
Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma.
Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in early gastric carcinoma: correlation with clinicopathological parameters.
Expression of vascular endothelial growth factor (VEGF)-C in preoperative biopsy specimens and metastatic foci of regional lymph nodes in submucosal gastric carcinoma.
Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma.
Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach.
Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer.
Expression of vascular endothelial growth factor and cyclooxygenase-2 in laryngeal squamous cell carcinoma and its significance.
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.
Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells.
Expression of vascular endothelial growth factor and its role in oncogenesis of human gastric carcinoma.
Expression of vascular endothelial growth factor and microvascular density assessment in different histotypes of basal cell carcinoma.
Expression of vascular endothelial growth factor and p53 in pancreatic carcinomas.
Expression of vascular endothelial growth factor and prognosis of oral squamous cell carcinoma.
Expression of vascular endothelial growth factor and receptor flk-1 in colon cancer liver metastases.
Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities.
Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study.
Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas.
Expression of vascular endothelial growth factor by photodynamic therapy with mono-L-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma.
Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis.
Expression of vascular endothelial growth factor C and D (VEGF-C and -D) is an important risk factor for lymphatic metastasis in undifferentiated early gastric carcinoma.
Expression of vascular endothelial growth factor C correlates with a poor prognosis based on analysis of prognostic factors in patients with cervical carcinomas.
Expression of vascular endothelial growth factor C correlates with lymphatic vessel density and prognosis in human gastroesophageal junction carcinoma.
Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with pathological parameters and prognosis.
Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma.
Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas.
Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma.
Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis.
Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer.
Expression of vascular endothelial growth factor in basal cell carcinoma and cutaneous squamous cell carcinoma of the head and neck.
Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin.
Expression of Vascular Endothelial Growth Factor in Canine Inflammatory and Non-inflammatory Mammary Carcinoma.
Expression of vascular endothelial growth factor in human gallbladder lesions.
Expression of vascular endothelial growth factor in human gastric carcinomas.
Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status.
Expression of vascular endothelial growth factor in oral squamous cell carcinoma.
Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression.
Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement.
Expression of vascular endothelial growth factor in renal cell carcinomas.
Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis.
Expression of vascular endothelial growth factor in salivary gland carcinomas correlates with lymph node metastasis.
Expression of vascular endothelial growth factor in thoracic sarcomas.
Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas.
Expression of vascular endothelial growth factor is significantly associated with progression and prognosis of oral squamous cell carcinomas in Taiwan.
Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas.
Expression of vascular endothelial growth factor protein in human renal cell carcinoma.
Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma.
Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer.
Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma.
Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in esophageal squamous cell carcinoma.
Expression of vascular endothelial growth factors A and C in human pancreatic cancer.
Expression of VEGF in Urinary Bladder Transitional Cell Carcinoma in an Iraqi Population Subjected to Depleted Uranium: An Immunohistochemical Study.
Expression of VEGF, HGF, IL-6, IL-8, MMP-9, Telomerase in Peripheral Blood of Patients with Head and Neck Squamous Cell Carcinoma.
Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma.
Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma.
Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma.
Expressional evaluation of vascular endothelial growth factor (VEGF) protein in urinary bladder carcinoma patients exposed to cigarette smoke.
Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome.
Expressions of thymidine phosphorylase (dThdPase) and vascular endothelial growth factor on angiogenesis in intestinal-type gastric carcinoma.
Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells.
Extracts from Huangqi (Radix Astragali Mongoliciplus) and Ezhu (Rhizoma Curcumae Phaeocaulis) inhibit Lewis lung carcinoma cell growth in a xenograft mouse model by impairing mitogen-activated protein kinase signaling, vascular endothelial growth factor production, and angiogenesis.
EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma.
Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas.
First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.
First-line vascular endothelial growth factor inhibitors for advanced renal cell carcinoma and the impact of new agents entering the treatment paradigm.
First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.
Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma.
From gene delivery to gene silencing: plasmid DNA-transfecting cationic lipid 1,3-dimyristoylamidopropane-2-[bis(2-dimethylaminoethane)] carbamate efficiently promotes small interfering RNA-induced RNA interference.
GABARBP down-regulates HIF-1? expression through the VEGFR-2 and PI3K/mTOR/4E-BP1 pathways.
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.
Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer.
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Genomic Fabric Remodeling in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): A New Paradigm and Proposal for a Personalized Gene Therapy Approach.
Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial.
Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma.
Glycoprotein Nonmetastatic Melanoma Protein B as Potential Imaging Marker in Posttherapeutic Metastatic Head and Neck Cancer.
Gonadotropin-regulated lymphangiogenesis in ovarian cancer is mediated by LEDGF-induced expression of VEGF-C.
Granulocyte-colony-stimulating factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 and vascular endothelial growth factor levels.
Granzyme B-truncated VEGF fusion protein represses angiogenesis and tumor growth of OSCC.
Head and neck squamous cell carcinoma lymphatic spread and survival: Relevance of vascular endothelial growth factor family for tumor evaluation.
Heavy-ion beam irradiation inhibits invasion of tongue squamous cell carcinoma Tca8113 cells.
Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells.
Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder.
Heparin octasaccharides inhibit angiogenesis in vivo.
Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes.
Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma.
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
HIF-1? regulated tongue squamous cell carcinoma cell growth via regulating VEGF expression in a xenograft model.
HIF-prolyl hydroxylase is a potential molecular target for esculetin-mediated anti-colitic effects.
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
High expression of CD105 as a prognostic predictor of early tongue cancer.
High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth factor in patients with renal cell carcinoma.
Histochemical study of vascular endothelial growth factor in squamous cell carcinoma of the esophagus.
Histopathological analysis of angiogenic factors in renal cell carcinoma.
Host A(2B) adenosine receptors promote carcinoma growth.
Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF.
Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells.
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents.
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker.
Hypoxia correlates with angiogenesis in cervical cancers.
Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma.
Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma.
Hypoxia promotes vasculogenic mimicry formation by vascular endothelial growth factor A mediating epithelial-mesenchymal transition in salivary adenoid cystic carcinoma.
Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells.
Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells.
Hypoxia-induced angiogenesis of cultured human salivary gland carcinoma cells enhances vascular endothelial growth factor production and basic fibroblast growth factor release.
Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines.
Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study.
Hypoxia-inducible bidirectional shRNA expression vector delivery using PEI/chitosan-TBA copolymers for colorectal Cancer gene therapy.
Hypoxia-inducible factor 1? in combination with vascular endothelial growth factor could predict the prognosis of postoperative patients with oesophageal squamous cell cancer.
Hypoxia-inducible factor-1? protects cervical carcinoma cells from apoptosis induced by radiation via modulation of vascular endothelial growth factor and p53 under hypoxia.
Identification of aryl hydrocarbon receptor signaling pathways altered in TCDD-treated red seabream embryos by transcriptome analysis.
IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma.
Imaging of highly malignant osteosarcoma with iodine-123-vascular endothelial growth factor.
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Immunoexpression of VEGFR-3, but not the immunoexpression of VEGF-C or lymphatic density, is correlated with metastasis in lower lip squamous cell carcinoma.
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.
Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment.
Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma.
Immunohistochemical expression of vascular endothelial growth factor (VEGF) in intestinal type gastric carcinoma.
Immunohistochemical Expression of Vascular Endothelial Growth Factor A in Advanced Gallbladder Carcinoma.
Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas.
Immunohistochemical expression of vascular endothelial growth factor correlates with positive surgical margins and recurrence in T1 and T2 squamous cell carcinoma (SCC) of the lower lip.
Immunohistochemical expression of vascular endothelial growth factor in canine oral squamous cell carcinomas.
Immunohistochemical predictors in squamous cell carcinoma of the tongue and floor of the mouth.
Immunohistochemical study of VEGF expression in oral squamous cell carcinomas: correlation with the mTOR-HIF-1? pathway.
Immunolocalization of VEGF, VEGF receptors, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma.
Immunologics and Chemotherapeutics for Renal Cell Carcinoma.
Impact of Vascular Endothelial Growth Factor Gene Polymorphisms and Their Interactions with Environmental Factors on Susceptibility to Renal Cell Carcinoma.
Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma.
Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma.
In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis.
In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma.
Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma.
Increased pro-angiogenic factors, infiltrating neutrophils and CD163(+) macrophages in bronchoalveolar lavage fluid from lung cancer patients.
Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma.
Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma.
Indirect treatment comparison of bevacizumab + interferon-?-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.
Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients' prognosis.
Induction by carbon-ion irradiation of the expression of vascular endothelial growth factor in lung carcinoma cells.
Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma.
Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.
Inherent phenotypic plasticity facilitates progression of head and neck cancer: Endotheliod characteristics enable angiogenesis and invasion.
Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism.
Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
Inhibition of lung tumor growth in nude mice by siRNA(CD31) targeting PECAM-1.
Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor.
Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells.
Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin.
Inhibition of the VEGF expression and cell growth in hepatocellular carcinoma by blocking HIF-1alpha and Smad3 binding site in VEGF promoter.
Inhibition of VEGF mRNA by 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) antisense oligonucleotides and their influence on off-target gene expressions.
Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors.
Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma.
Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.
Interleukin 8 and vascular endothelial growth factor -- prognostic factors in human gastric carcinomas?
Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk.
Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma.
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma.
Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide.
Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: Implications for alternative response criteria.
Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker.
Intratumoral lymphangiogenesis of esophageal squamous cell carcinoma and relationship with regulatory factors and prognosis.
Intratumoral lymphatics and lymphatic vessel invasion detected by d2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma.
Intratumoral neovascularization and growth pattern in early gastric carcinoma.
Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors.
Involvement of inactive GSK3beta overexpression in tumorigenesis and progression of gastric carcinomas.
Irradiation-induced regulation of plasminogen activator inhibitor type-1 and vascular endothelial growth factor in six human squamous cell carcinoma lines of the head and neck.
Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?
JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.
Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis.
Kidney cancer: current and novel treatment options.
Kidney injury during VEGF inhibitor therapy.
Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets.
Kinase inhibitors in the treatment of renal cell carcinoma.
Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
Lentivirus-Mediated RNAi Silencing of VEGF Inhibits Angiogenesis and Growth of Renal Cell Carcinoma in a Nude Mouse Xenograft Model.
Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Levels and patterns of expression of hypoxia-inducible factor-1?, vascular endothelial growth factor, glucose transporter-1 and CD105 in adenoid cystic carcinomas with high-grade transformation.
Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells.
Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.
Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy.
Long-lasting response with polycythemia to third-line axitinib treatment in metastatic renal cell carcinoma: Very rare case presentation.
Loss of expression of TIMP3 in clear cell renal cell carcinoma.
Loss of ovarian function promotes angiogenesis in human ovarian carcinoma.
Loss of p16INK4a expression is associated with vascular endothelial growth factor expression in squamous cell carcinoma of the esophagus.
Lymphangiogenesis in human gynaecological cancers.
Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases.
Lymphatic dissemination of tumour cells and the formation of micrometastases.
Lymphatic Vessel Density and Vascular Endothelial Growth Factor Expression in Squamous Cell Carcinomas of Lip and Oral Cavity: A Clinicopathological Analysis with Immunohistochemistry Using Antibodies to D2-40, VEGF-C and VEGF-D.
Lymphatic vessel density as a predictor of lymph node metastasis and its relationship with prognosis in urothelial carcinoma of the bladder.
Lymphatic Vessels and High Endothelial Venules are Increased in the Sentinel Lymph Nodes of Patients with Oral Squamous Cell Carcinoma Before the Arrival of Tumor Cells.
Lymphatic vessels and related factors in adenoid cystic carcinoma of the salivary gland.
Magnetic-composite-modified polycrystalline-silicon nanowire field-effect transistor for vascular endothelial growth factor detection and cancer diagnosis.
Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression.
Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.
Management of Metastatic Renal Cell Carcinoma with Variant Histologies.
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.
Manganese (II) induces chemical hypoxia by inhibiting HIF-prolyl hydroxylase: implication in manganese-induced pulmonary inflammation.
Manganese (II) induces chemical hypoxia by inhibiting HIF-prolyl hydroxylase: Implication in manganese-induced pulmonary inflammation.
Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.
Maspin expression in renal cell carcinoma and its correlation with clinicopathologic parameters.
Mast cells and cutaneous malignancies.
Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma.
Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma.
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma.
Mediastinal lymphangiomatosis coexisting with occult thymic carcinoma.
Melatonin inhibits the expression of vascular endothelial growth factor in pancreatic cancer cells.
Melatonin prevents human pancreatic carcinoma cell PANC-1-induced human umbilical vein endothelial cell proliferation and migration by inhibiting vascular endothelial growth factor expression.
Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression.
Metadherin Regulation of Vascular Endothelial Growth Factor Expression Is Dependent Upon the PI3K/Akt Pathway in Squamous Cell Carcinoma of the Head and Neck.
Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab.
Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.
Metastatic renal cell carcinoma: many treatment options, one patient.
MicroRNA-299-3p suppresses proliferation and invasion by targeting VEGFA in human colon carcinoma.
Microvascular density and vascular endothelial growth factor immunoreactivity as predictors of regional lymph node metastasis from betel-associated oral squamous cell carcinoma.
Microvessel density (MVD) and vascular endothelial growth factor expression (VEGF) in human oral squamous cell carcinoma.
Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas.
Microvessel density and vascular endothelial growth factor expression in infiltrating lobular mammary carcinoma.
Microvessel Density Is Associated with VEGF and ?-SMA Expression in Different Regions of Human Gastrointestinal Carcinomas.
Microvessel morphology and vascular endothelial growth factor expression in human colonic carcinoma with or without metastasis.
Migration and vascular lumen formation of endothelial cells in cancer cell spheroids of various sizes.
MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo.
Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29.
Modulation of cellular invasion by VEGF-C expression in squamous cell carcinoma of the head and neck.
Modulatory Effects of Chemoradiation on Angiogenic Factors and Laminin in Cervical Cancer: Link with Treatment Response
Molecular expression of vascular endothelial growth factor, prokineticin receptor-1 and other biomarkers in infiltrating canalicular carcinoma of the breast.
Molecular marker expression in oral and oropharyngeal squamous cell carcinoma.
Molecular markers to predict response to therapy.
Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Monitoring Anti-Angiogenic Therapy in Colorectal Cancer Murine Model using Dynamic Contrast-Enhanced MRI - Comparing Pixel-by-Pixel with Region of Interest Analysis.
Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas.
Mucinous colon carcinomas with microsatellite instability have a lower microvessel density and lower vascular endothelial growth factor expression.
N-(2-Mercaptopropionyl)-glycine, a diffusible antioxidant, activates HIF-1 by inhibiting HIF prolyl hydroxylase-2: implication in amelioration of rat colitis by the antioxidant.
Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.
Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments.
Neoangiogenesis and relationship to nuclear p53 accumulation and vascular endothelial growth factor expression in advanced gastric carcinoma.
Neoangiogenesis in patients with gastric carcinoma in relation to the expression of vascular endothelial growth factor and thymidine phosphorylase.
Nerve growth factor and vascular endothelial growth factor: retrospective analysis of 63 patients with salivary adenoid cystic carcinoma.
Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial ?5 integrin.
New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib.
New agents and new targets for renal cell carcinoma.
New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?
Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production.
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma.
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
Non-clear cell renal cancer: features and medical management.
Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib.
Normalization of the Ovarian Cancer Microenvironment by SPARC.
Notice of retraction: "Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development" (BJUI, Volume 96, Issue 3, pages 286 – 290).
Novel antiangiogenic therapies for renal cell cancer.
Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma.
Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review.
Novel concepts of antiangiogenic therapies in metastatic renal cell cancer.
Oesophageal squamous cell carcinoma in high-risk Chinese populations: Possible role for vascular epithelial growth factor A.
Oncocytoma-like renal tumor with transformation toward high-grade oncocytic carcinoma: a unique case with morphologic, immunohistochemical, and genomic characterization.
Optimal management of gastroesophageal junction cancer.
Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications.
Oral Squamous Cell Carcinoma From Users and Nonusers of Tobacco and Alcohol: Clinicopathologic Features and Immunoreactivity of VEGF, Caspase-3, and P53.
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
Ovarian carcinoma cells effectively inhibit differentiation and maturation of dendritic cells derived from hematopoietic progenitor cells in vitro.
Ovarian serous carcinoma: relationship of p53 and bcl-2 with tumor angiogenesis and VEGF expression.
Over-expression of vascular endothelial growth factor after preoperative radiation therapy for rectal cancer.
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
Overexpression and Interactions of Interleukin-10, Transforming Growth Factor beta, and Vascular Endothelial Growth Factor in Esophageal Squamous Cell Carcinoma.
Overexpression of Antiangiogenic Vascular Endothelial Growth Factor Isoform and Splicing Regulatory Factors in Oral, Laryngeal and Pharyngeal Squamous Cell Carcinomas
Overexpression of c-H-ras p21 is correlated with vascular endothelial growth factor expression and neovascularization in advanced gastric carcinoma.
Overexpression of fibulin-4 is associated with tumor progression and poor prognosis in patients with cervical carcinoma.
Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis.
Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells.
Overexpression of Phosphorylated 4E-BP1 Predicts for Tumor Recurrence and Reduced Survival in Cervical Carcinoma Treated with Postoperative Radiotherapy.
Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development.
Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis.
Overexpression of vascular endothelial growth factor C is related to lymphogenous metastasis in early gastric carcinoma.
Overexpression of vascular endothelial growth factor is responsible for the hematogenous recurrence of early-stage gastric carcinoma.
Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Overview of current and future systemic therapy for metastatic renal cell carcinoma.
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.
p38 Signaling-mediated hypoxia-inducible factor 1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells.
P53 and vascular endothelial growth factor expressions are two important indices for prognosis in gastric carcinoma.
p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells.
PAI-1, CAIX, and VEGFA expressions as prognosis markers in oral squamous cell carcinoma.
Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors.
Pancreatic head carcinoma and vascular endothelial growth factor (VEGF-A) concentration in portal blood: its association with cancer grade, tumor size and probably poor prognosis.
Paraneoplastic hormones: parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma.
Paraneoplastic symptoms: Cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma.
Pathobiological significance of vascular endothelial growth factor and Maspin expressions in human gastric carcinoma.
Pathological response and serum VEGF changes during chemoradiotherapy for esophageal carcinoma.
Patterns of angiogenesis in nonsmall-cell lung carcinoma.
Pazopanib-Induced Severe Acute Pancreatitis.
Pazopanib.
PDGF-D/PDGFR? promotes tongue squamous carcinoma cell (TSCC) progression via activating p38/AKT/ERK/EMT signal pathway.
PECAM-1 (CD31) functions as a reservoir for and a modulator of tyrosine-phosphorylated beta-catenin.
Perfusion Estimated with Rapid Dynamic Contrast-Enhanced Magnetic Resonance Imaging Correlates Inversely with Vascular Endothelial Growth Factor Expression and Pimonidazole Staining in Head-and-Neck Cancer: A Pilot Study.
Perioperative Therapy in Renal Cell Carcinoma: What Do We Know, What Have We Learned, What's Next?
Peripheral blood dendritic cells and vascular endothelial growth factor in oral squamous cell carcinoma: correlation analysis and in vitro study.
Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer.
Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix.
Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib?
Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma.
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma.
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells.
Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma.
Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus.
Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma.
Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases.
Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma.
Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.
Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas.
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Pneumatocele during sorafenib therapy: first report of an unusual complication.
Poly-lactic-glycolic-acid surface nanotopographies selectively decrease breast adenocarcinoma cell functions.
Poor prognostic clinicopathologic features correlate with VEGF expression but not with PTEN expression in squamous cell carcinoma of the larynx.
Population pharmacokinetic analysis of axitinib in healthy volunteers.
Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.
Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
Postoperative efficacy of low-temperature plasma radiofrequency ablation in elderly patients with laryngeal carcinoma and its influences on tumor markers and COX-2 and VEGF expressions in laryngeal carcinoma tissues.
Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2.
Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Potential role for vascular endothelial growth factor-D as an autocrine factor for human gastric carcinoma cells.
Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer.
Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters.
Predictive factor for photodynamic therapy effects on oral squamous cell carcinoma and oral epithelial dysplasia.
Predictive role of vascular endothelial growth factor polymorphisms in the survival of renal cell carcinoma patients.
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib.
Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients.
Predictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomas.
Predictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomas: a case-control study.
Predictors of Response to Targeted Therapy in Renal Cell Carcinoma.
Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma.
Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma.
Pretreatment serum endostatin as a prognostic indicator in metastatic gastric carcinoma.
Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
Prevalence and Clinical Significance of Mammalian Target of Rapamycin Phosphorylation (p-mTOR) and Vascular Endothelial Growth Factor (VEGF) in Clear Cell Carcinoma of the Ovary.
Primary Tumor-Secreted Lymphangiogenic Factors Induce Pre-Metastatic Lymphvascular Niche Formation at Sentinel Lymph Nodes in Oral Squamous Cell Carcinoma.
Proangiogenic effects of ionizing irradiation on squamous cell carcinoma of the hypopharynx.
Profiling of Vascular Endothelial Growth Factor Receptor Heterogeneity Identifies Protein Expression-defined Subclasses of Human Non-small Cell Lung Carcinoma.
Prognostic and predictive value of serum vascular endothelial growth factor (VEGF) in squamous cell carcinoma of the head and neck.
Prognostic Effect of Vascular Endothelial Growth Factor and Angiogenesis in Gastric Carcinoma.
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study.
Prognostic factors for response to chemotherapy in advanced tumors of the uterine cervix: the role of neoangiogenesis.
Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.
Prognostic impact of VEGF and FLT-1 receptor expression in patients with locally advanced squamous cell carcinoma of the head and neck.
Prognostic implications of estrogen receptor 1 and vascular endothelial growth factor A expression in primary gallbladder carcinoma.
Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma.
Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy.
Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens.
Prognostic Role of Protease-Activated Receptors 1 and 4 in Resected Stage IB Non-Small-Cell Lung Cancer.
Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma.
Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma.
Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder.
Prognostic Significance of Human Papillomavirus (HPV) Status and Expression of Selected Markers (HER2/neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on Outcome After (Chemo-) Radiotherapy in Patients with Squamous Cell Carcinoma of Uterine Cervix.
Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy.
Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma.
Prognostic significance of microvessel density and vascular endothelial growth factor expression in sinonasal carcinomas.
Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma.
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma.
Prognostic significance of peritumoral lymphatic vessel density and vascular endothelial growth factor receptor 3 in invasive squamous cell cervical cancer.
Prognostic significance of platelet-derived growth factor receptor-? expression in localized clear cell renal cell carcinoma.
Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor.
Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma.
Prognostic Significance of Vascular Endothelial Growth Factor (VEGF) and Her-2 Protein in the Genesis of Cervical Carcinoma.
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
prognostic significance of vascular endothelial growth factor C in systemic malignancies besides non-small cell lung carcinomas.
Prognostic significance of vascular endothelial growth factor D in gastric carcinoma.
Prognostic significance of vascular endothelial growth factor expression and microvessel density in carcinoma of ampulla of Vater.
Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: comparison with positron emission tomography.
Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma.
Prognostic significance of vascular endothelial growth factor expression in esophageal carcinoma: a meta-analysis.
Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis.
Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma.
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis.
Prognostic significance of vascular endothelial growth factor in squamous cell carcinomas of the tonsil in relation to human papillomavirus status and epidermal growth factor receptor.
Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma.
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Prognostic Value of Epithelial Growth Factor Receptor, Vascular Endothelial Growth Factor, E-Cadherin, and p120 Catenin in Resected Non-Small Cell Lung Carcinoma.
Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.
Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus.
Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma.
Prognostic Value of the VHL, HIF-1?, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas.
Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-? (PDGF-?), and PDGF-? receptor expression in papillary renal cell carcinoma.
Prognostic Value of Vascular Endothelial Growth Factor A in the Prediction of the Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma.
Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer.
Prognostic value of vascular endothelial growth factor expression in gastric carcinoma.
Prognostic value of vascular endothelial growth factor expression in primary lung carcinoma.
Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix.
Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor.
Proliferation, angiogenesis and apoptosis-associated proteins are molecular targets for chemoprevention of MNNG-induced gastric carcinogenesis by ethanolic Ocimum sanctum leaf extract.
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
Properties of a Novel Animal Model of LPR.
Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
Protective effects of mastic oil from Pistacia lentiscus variation chia against experimental growth of lewis lung carcinoma.
Protein kinase C signalling pathway is involved in the regulation of vascular endothelial growth factor expression in human bladder transitional carcinoma cells.
Pulmonary tumor thrombotic microangiopathy caused by a gastric carcinoma expressing vascular endothelial growth factor and tissue factor.
Pulmonary Tumor Thrombotic Microangiopathy Caused by Urothelial Carcinoma Expressing Vascular Endothelial Growth Factor, Platelet-derived Growth Factor, and Osteopontin.
Pulmonary tumour thrombotic microangiopathy.
Quantification by competitive quantitative RT-PCR of VEGF121 and VEGF165 in renal cell carcinoma.
Quantifying the expression of VEGF using qRT-PCR, evaluation of MVD and their correlation with clinicopathological factors in laryngeal squamous cell carcinoma.
Quantitation by competitive PCR assay of vascular endothelial growth factor in non-small cell lung carcinomas.
Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis.
Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
Rap2B promotes angiogenesis via PI3K/AKT/VEGF signaling pathway in human renal cell carcinoma.
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;53:376-81.
Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.
Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.
RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Targeted Therapy.
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
Regulation of aminopeptidase A expression in cervical carcinoma: role of tumor-stromal interaction and vascular endothelial growth factor.
Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent.
Regulation of the expression of pigment epithelium-derived factor, an anti-angiogenic factor in human oral squamous cell carcinoma cell lines.
Regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D expression by the organ microenvironment in human colon carcinoma.
Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase.
Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density.
Regulation of vascular endothelial growth factor transcription by endothelial PAS domain protein 1 (EPAS1) and possible involvement of EPAS1 in the angiogenesis of renal cell carcinoma.
Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Relationship between tumour angiogenesis and expression of cyclo-oxygenase-2 and vascular endothelial growth factor-A in human renal cell carcinoma.
Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas.
Relative Expression of Vascular Endothelial Growth Factor Isoforms in Squamous Cell Carcinoma of the Head and Neck.
Relative quantitative expression of hypoxia-inducible factor-1?, -2? and -3?, and vascular endothelial growth factor A in laryngeal carcinoma.
Renal cell carcinoma.
Renal cell carcinoma: An update for the practicing urologist.
Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
Renal cell carcinoma: relevance of angiogenetic factors.
Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
Resistance to targeted therapy in renal-cell carcinoma.
Resistin promotes the expression of vascular endothelial growth factor in ovary carcinoma cells.
Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.
Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells.
Retraction: "Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells".
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
RhoC, vascular endothelial growth factor and microvascular density in esophageal squamous cell carcinoma.
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.
Risk of Dyslipidemia Associated with VEGF/VEGFR Inhibitors: A Meta-Analysis.
RLIP76 regulates HIF-1 activity, VEGF expression and secretion in tumor cells, and secretome transactivation of endothelial cells.
RNAi-mediated knockdown of vascular endothelial growth factor inhibits vascularization and tumor growth in renal cell carcinoma.
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells.
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence.
RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway.
S-1 inhibits tumorigenicity and angiogenesis of human oral squamous cell carcinoma cells by suppressing expression of phosphorylated Akt, vascular endothelial growth factor and fibroblast growth factor-2.
Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer.
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.
Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions.
Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix.
Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake.
Semaphorin 3F Serves as a Tumor Suppressor in Esophageal Squamous Cell Carcinoma and is Associated With Lymph Node Metastasis in Disease Progression.
Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
Semiquantifiable angiogenesis parameters in association with the malignant transformation of oral leukoplakia.
Serologic angiogenesis factors and microvascular density in renal cell carcinoma: two independent parameters.
Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b.
Serum concentrations of matrix metalloproteinase-9 and vascular endothelial growth factor affect the prognosis of primary hepatic carcinoma patients treated with percutaneous ethanol injection.
Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma.
Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Serum prognostic markers in head and neck cancer.
Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.
Serum vascular endothelial growth factor (VEGF), a prognostic indicator in sarcoma and carcinoma patients.
Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
Serum vascular endothelial growth factor in patients with head and neck squamous cell carcinoma.
Serum vascular endothelial growth factor in patients with pharyngeal and laryngeal squamous cell carcinoma treated with radiotherapy.
Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer.
Serum vascular endothelial growth factor is a candidate biomarker of renal cell carcinoma in hemodialysis patients.
Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis.
Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma.
Signaling inhibitors in metastatic renal cell carcinoma.
Significance and expression of vascular endothelial growth factor and E-cadherin in non-small cell lung Carcinomas.
Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma.
Significance of the expression of integrin ?1, VEGF and MVD in hypopharyngeal squamous cell carcinoma.
Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.
Significance of VEGF and microvascular density in gastric carcinoma.
Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.
Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas.
Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression.
Simultaneous progression of oxidative stress, angiogenesis, and cell proliferation in prostate carcinoma.
Single nucleotide polymorphisms in the 3' untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma.
Single nucleotide polymorphisms of the vascular endothelial growth factor gene associated with incidence of oral squamous cell carcinoma.
Single nucleotide polymorphisms, haplotype association and tumour expression of the vascular endothelial growth factor (VEGF) gene with lung carcinoma.
siRNA-mediated knockdown of VEGF-A, VEGF-C and VEGFR-3 suppresses the growth and metastasis of mouse bladder carcinoma in vivo.
Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by a Mechanism Linked to the Targeting of mTOR/HIF-1 Alpha/VEGF Signaling.
Site-dependent expression of vascular endothelial growth factor, angiogenesis and proliferation in human gastric carcinoma.
Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines.
Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group.
Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study.
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.
Sorafenib stimulates human skin type mast cell degranulation and maturation.
Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities.
Spectral computed tomography in advanced gastric cancer: Can iodine concentration non-invasively assess angiogenesis?
Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.
Stimulatory effect of endogenous tissue inhibitor of metalloproteinases-1 (TIMP-1) overexpression on type IV collagen and laminin gene expression in rat mammary carcinoma cells.
Strobilanthes crispus inhibits migration, invasion and metastasis in breast cancer.
Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma.
Study on Attenuating Angiogenesis and Epithelial-Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC2.
SU11248 and AG013736: current data and future trials in renal cell carcinoma.
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Suppression of VEGF expression through interruption of the HIF?1? and Akt signaling cascade modulates the anti?angiogenic activity of DAPK in ovarian carcinoma cells.
Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report.
Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer.
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations.
Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis.
Targeted therapy for metastatic renal cell carcinoma.
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions.
Targeted therapy in renal cell carcinoma.
Targeted therapy in the treatment of metastatic renal cell cancer.
Targeting angiogenesis in head and neck cancer.
Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma.
Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
Targeting Molecular Pathways in Intracranial Metastatic Disease.
Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.
Targeting Slit-Roundabout signaling inhibits tumor angiogenesis in chemical-induced squamous cell carcinogenesis.
Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma.
Targeting vascular endothelial growth factor in renal cell carcinoma.
Temsirolimus : a safety and efficacy review.
TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma.
Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells.
The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion--the prognostic contribution of related molecular markers.
The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.
The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma.
The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas.
The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.
The association between age-related macular degeneration and renal cell carcinoma: a nested case-control study.
The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer.
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma.
The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis.
The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor.
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.
The differential regulation of human telomerase reverse transcriptase and vascular endothelial growth factor may contribute to the clinically more aggressive behavior of p63-positive breast carcinomas.
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.
The Effect and Mechanism of Vascular Endothelial Growth Factor (VEGF) on Tumor Angiogenesis in Gallbladder Carcinoma.
The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma.
The effect of topiramate on tumor-related angiogenesis and on the serum proteome of mice bearing Lewis lung carcinoma.
The effects of RNA interference mediated VEGF gene silencing on biological behavior of renal cell carcinoma and transplanted renal tumor in nude mice.
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
The effects of vascular endothelial growth factor C knockdown in esophageal squamous cell carcinoma.
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.
The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma.
The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma.
The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.
The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy.
The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition.
The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma.
The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma.
The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma.
The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.
The expression pattern of vascular endothelial growth factor C and D in human esophageal normal mucosa, dysplasia and neoplasia.
The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism.
The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma.
The impact of cyclooxygenase-2 and vascular endothelial growth factor C immunoexpression on the prognosis of penile carcinoma.
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.
The influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase-2 inhibition in head and neck squamous cell carcinoma cell lines.
The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma.
The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients.
The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer.
The lymphatic system and its specific growth factor vascular endothelial growth factor C in kidney tissue and in renal cell carcinoma.
The Monascus metabolite monacolin K reduces tumor progression and metastasis of Lewis lung carcinoma cells.
The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer.
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
The peroxisome proliferator-activated receptor gamma ligand 15-deoxy-Delta12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637.
The place of VEGF inhibition in the current management of renal cell carcinoma.
The predictive value of p53, Ki-67 and angiogenetic factors in primary hypopharyngeal carcinoma.
The prognostic effect of VEGF expression in squamous cell carcinoma of the cervix treated with radiation therapy alone.
The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.
The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis.
The promise of biomarkers for personalized renal cancer care.
The prospects of pazopanib in advanced renal cell carcinoma.
The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.
The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer.
The relationship between the expression of VEGF, EGFR, and HER-2 mRNA in esophageal squamous cell carcinoma (ESCC) and clinicopathological features of different ethnic groups in Xinjiang.
The Relationship of Vascular Endothelial Growth Factor and Coagulation Factor (Fibrin and Fibrinogen) Expression in Clear Cell Renal Cell Carcinoma.
The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female.
The role of macrophages in angiogenesis. Comparison between HIV+ and HIV- populations with anal dysplasia and anal cancer.
The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma.
The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer.
The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma.
The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops.
The role of vascular endothelial growth factor in kidney and prostate cancer.
The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma.
The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell.
The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus.
The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients.
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells.
Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail.
Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
There is no increase in frequency of somatic mutations in metastases compared with primary colorectal carcinomas with microsatellite instability.
Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma.
Thrombospondin-1, vascular endothelial growth factor expression and microvessel density in renal cell carcinoma and their relationship with multifocality.
Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors.
Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.
Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma.
Time-Dependent Pretreatment with Bevacuzimab Increases Tumor Specific Uptake of Cetuximab in Preclinical Oral Cavity Cancer Studies.
TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
Transcription expression and clinical significance of mRNA of vascular endothelial growth factor and endostatin in liquid-based preparation specimens from patients with cervical dysplasia and carcinoma.
Transfection of hypoxia-inducible factor-1 decoy oligodeoxynucleotides suppresses expression of vascular endothelial growth factor in oral squamous cell carcinoma cells.
Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1?-p300 Binding in Renal Cell Carcinoma.
Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma.
Treatment of renal cell carcinoma: Current status and future directions.
Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors.
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Treatment sequences for advanced renal cell carcinoma: A health economic assessment.
Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma.
Tumor angiogenesis in predicting the survival of patients with stage I lung cancer.
Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma.
Tumor necrosis factor-? promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-?B-mediated upregulation of vascular endothelial growth factor-C.
Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation.
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma.
Tumor-Infiltrating Lymphocytes Express Vascular Endothelial Growth Factor in Renal Cell Carcinomas.
Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma.
UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma.
Undifferentiated carcinoma of the gallbladder with endothelial differentiation: A case report and literature review.
Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma.
Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function.
Update on immunotherapy for renal cancer.
Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis.
Upregulated miR-27a-3p Indicates a Poor Prognosis in Pancreatic Carcinoma Patients and Promotes the Angiogenesis and Migration by Epigenetic Silencing of GATA6 and Activating VEGFA/VEGFR2 Signaling Pathway.
Upregulation of hypoxia inducible factor 1alpha mRNA is associated with elevated vascular endothelial growth factor expression and excessive angiogenesis and predicts a poor prognosis in gastric carcinoma.
Upregulation of serum and tissue vascular endothelial growth factor correlates with angiogenesis and prognosis of oral squamous cell carcinoma.
Upregulation of serum vascular endothelial growth factor and matrix metalloproteinase-3 in patients with oral squamous cell carcinoma.
Upregulation of vascular endothelial growth factor (VEGF), its role in progression and prognosis of non-small cell lung carcinoma.
Upregulation of vascular endothelial growth factor mRNA level is significantly related to progression and prognosis of oral squamous cell carcinomas.
Usefulness of contrast-enhanced magnetic resonance imaging for evaluating solitary pulmonary nodules.
Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma: differential diagnosis, tumor progression, and patient survival.
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: A preliminary analysis.
Value of [18F]FDG PET radiomic features and VEGF expression in predicting pelvic lymphatic metastasis and their potential relationship in early-stage cervical squamous cell carcinoma.
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to Cisplatin and radiation in vivo and in vitro.
Vascular endothelial growth factor (VEGF) and microvessel density in squamous cell carcinomas of the larynx: an immunohistochemical study.
Vascular endothelial growth factor (VEGF) and ovarian carcinoma cell supernatant activate signal transducers and activators of transcription (STATs) via VEGF receptor-2 (KDR) in human hemopoietic progenitor cells.
Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma.
Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha(v)beta6.
Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas.
Vascular endothelial growth factor (VEGF) expression correlates with p53 and ki-67 expressions in tongue squamous cell carcinoma.
Vascular Endothelial Growth Factor (VEGF) Expression in Human Pituitary Adenomas and Carcinomas.
Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas.
Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma.
Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells.
Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix.
Vascular endothelial growth factor (VEGF) expression is not associated with prognosis in patients with radically resected ampullary carcinoma.
Vascular endothelial growth factor (VEGF) in sera of oral and oropharyngeal squamous cell carcinoma patients.
Vascular Endothelial Growth Factor (VEGF) Polymorphisms and Serum VEGF Levels in Women With Epithelial Ovarian Cancer, Benign Tumors, and Healthy Ovaries.
Vascular endothelial growth factor (VEGF) receptor antibody bevacizumab (avastin) induces regression of renal cell carcinoma in an adolescent resulting in residual tumorectomy.
Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.
Vascular endothelial growth factor - its relation to neovascularization and their significance as prognostic factors in renal cell carcinoma.
Vascular endothelial growth factor 936 C/T polymorphism is associated with vascular invasion in oral squamous cell carcinoma.
Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma.
Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Vascular endothelial growth factor and basic fibroblast growth factor are released by squamous cell carcinoma cells after irradiation and increase resistance to subsequent irradiation.
Vascular endothelial growth factor and basic fibroblast growth factor in primary lung carcinomas and the incidence of metastases.
Vascular endothelial growth factor and dendritic cells in human squamous cell carcinoma of the oral cavity.
Vascular endothelial growth factor and ki-67 antigen expression in relation to age and gender in oral squamous cell carcinoma.
Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas.
Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Vascular endothelial growth factor and prognosis of cervical carcinoma.
Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma.
Vascular endothelial growth factor and social support in patients with ovarian carcinoma.
Vascular endothelial growth factor and survivin immunostaining in gastric adenocarcinoma.
Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation.
Vascular endothelial growth factor as a biomarker for endostatin gene therapy.
Vascular endothelial growth factor as an angiogenic swich in ovarian carcinoma.
Vascular endothelial growth factor as prognostic factor in renal cell carcinoma.
Vascular endothelial growth factor C and microvessel density in gastric carcinoma: correlation with clinicopathological factors. Our experience and review of the literature.
Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma.
Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck.
Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma.
Vascular endothelial growth factor C is an indicator of lymph node metastasis in thoracic esophageal squamous cellcarcinomas and its role in long-term survival after surgery.
Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in mice.
Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms.
Vascular endothelial growth factor D and intratumoral lymphatics as independent prognostic factors in epithelial ovarian carcinoma.
Vascular endothelial growth factor enhances cancer cell adhesion to microvascular endothelium in vivo.
Vascular endothelial growth factor expression and neovascularization in Barrett's carcinoma.
Vascular Endothelial Growth Factor Expression and Neovascularization in Non-Small Cell Lung Carcinoma.
Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts.
Vascular endothelial growth factor expression and vascular density in oral squamous cell carcinoma (OSCC): A study on clinical and histopathologic significance.
Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck.
Vascular endothelial growth factor expression in early stage ovarian carcinoma.
Vascular endothelial growth factor expression in head and neck squamous cell carcinoma.
Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma.
Vascular endothelial growth factor expression in ovarian serous carcinomas and its effect on tumor proliferation.
Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma.
Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression.
Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas.
Vascular endothelial growth factor expression is increased in renal cell carcinoma.
Vascular endothelial growth factor expression predicts outcome after primary radiotherapy for head and neck squamous cell cancer.
Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus.
Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas.
Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1.
Vascular endothelial growth factor gene polymorphisms and renal cell carcinoma: A systematic review and meta-analysis.
Vascular endothelial growth factor gene polymorphisms and the risk of renal cell carcinoma: Evidence from eight case-control studies.
Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Vascular endothelial growth factor in cervical carcinoma.
Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance.
Vascular Endothelial Growth Factor Induces CXCL1 Chemokine Release via JNK and PI-3K-Dependent Pathways in Human Lung Carcinoma Epithelial Cells.
Vascular Endothelial Growth Factor Inhibitor Therapy And Cardiovascular And Renal Damage In Renal Cell Carcinoma.
Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines.
Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck.
Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.
Vascular Endothelial Growth Factor is a Useful Predictor of Postoperative Distant Metastasis and Survival Prognosis in Esophageal Squamous Cell Carcinoma.
Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma.
Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway.
Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Vascular endothelial growth factor polymorphisms as effect modifiers of oral squamous cell carcinoma risk: A systematic review and meta-analysis.
Vascular endothelial growth factor promotes the expression of cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells.
Vascular endothelial growth factor receptor isoforms: are they present in oral squamous cell carcinoma?
Vascular endothelial growth factor receptor-3 is a favorable prognostic factor in advanced gastric carcinoma.
Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo.
Vascular endothelial growth factor staining and elevated INR in advanced epithelial ovarian carcinoma.
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis.
Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer.
Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas.
Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa.
Vascular Endothelial Growth Factor-D (VEGF-D) is Elevated in Bronchoalveolar Lavage Fluid of Patients with Lung Squamous Carcinoma.
Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma.
Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma.
Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer.
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer.
Vascular endothelial growth factors C and D and lymphangiogenesis at the early stage of esophageal squamous cell carcinoma progression.
Vascular endothelial growth-factor expression and angiogenesis in nonsmall cell lung carcinomas.
Vascularity and expression of vascular endothelial growth factor in oral squamous cell carcinoma, resection margins, and nodal metastases.
VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
VEGF and CD 34: A correlation between tumor angiogenesis and microvessel density-an immunohistochemical study.
VEGF and ki 67 expression in squamous cell carcinoma of the tongue: An immunohistochemical and computerized image analysis study.
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
VEGF as a Predictor for Response to Definitive Chemoradiotherapy and COX-2 as a Prognosticator for Survival in Esophageal Squamous Cell Carcinoma.
VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop.
VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside.
VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population.
VEGF spliced variants: possible role of anti-angiogenesis therapy.
VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma.
VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression.
VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis.
VEGF-C and VEGF-D expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: Implications for use as a prognostic marker.
VEGF-C expression in oral cancer by neurotransmitter-induced activation of beta-adrenergic receptors.
VEGF-D as a marker in the aid of malignant metastatic pleural effusion diagnosis.
VEGF-targeted therapy in metastatic renal cell carcinoma.
VEGF-targeted Therapy in Renal Cell Carcinoma: Active Drugs and Active Choices.
VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix.
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.
VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations.
VEGFR-1 Expression Relates to Fuhrman Nuclear Grade of Clear Cell Renal Cell Carcinoma.
VEGFR1 and VEGFR2 immunohistochemical expression in oral squamous cell carcinoma: a morphometric study.
Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer.
Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Withdrawal: Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma.
Zebularine-induced reduction in VEGF secretion by HIF-1? degradation in oral squamous cell carcinoma.
ZNF750 inhibited the malignant progression of oral squamous cell carcinoma by regulating tumor vascular microenvironment.
[A study of correlation between the blood supply types of PHcc on spiral CT and the level of VEGF expression in PHcc]
[Antiangiogenesis of ginsenoside Rg3 in severe combined immunodeficient mice with human ovarian carcinoma]
[Antiangiogenic and antitumor effects of vascular endothelial growth factor small interfering RNA on Tca8113 human tongue squamous cell carcinoma xenografts in vivo]
[Change in vascular endothelial growth factor level in serum and urine of esophageal carcinoma patients]
[Circadian variation of clock gene Per2 and cancer-related clock-controlled genes in buccal mucosa carcinoma of golden hamster at different cancer stages].
[Clinico-pathological significance of microvessel density and vascular endothelial growth factor expression in adenoid cystic carcinoma of salivary glands]
[Clinicopathologic study of angiogenesis in human hepatocellular carcinoma]
[Cloning and sequencing of human vascular endothelial growth factor-C encoded cDNA]
[Constitutive activation of signal transducers and activators of transcription 3 and expression of its target gene products in human ESCC cell line]
[Correlation analysis of VEGF and PTEN expression in gingival carcinoma].
[Correlation between expression of vascular endothelial growth factor and prognosis of patients with esophageal squamous cell carcinoma]
[Correlation of angiogenesis with expression of vascular endothelial growth factor and its receptors in lung carcinoma]
[Correlation of multislice spiral CT findings with vascular endothelial growth factor expressions and microvessel density in renal cell carcinoma]
[Correlation of neovascularization and vascular endothelial growth factor in human renal cell carcinoma]
[Correlation of tissue factor expression to angiogenesis of gastric carcinoma and its clinical significance]
[Correlations between serum hypoxia inducible factor-1?, vascular endothelial growth factor and computed tomography perfusion imaging at pre-and post-TACE in patients with primary hepatic carcinoma].
[Correlative studies on uPAR receptor mRNA expressions with vascular endothelial growth factor, microvessel density, progression and survival time of gastric carcinomas]
[Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases]
[Effect of interferon-gamma on the expression of vascular endothelial growth factor C on Hep-2 laryngeal carcinoma cell lines]
[Effect of selective cyclooxygenase-2 inhibitor celebrex on expression of vascular endothelial growth factor (VEGF) in pancreatic carcinoma]
[Effect of vascular endothelial growth factor C and collagen triple helix repeat containing 1 expression on prognosis of rectal carcinoma patients].
[Effects of anti-HPV16 E6-ribozyme on invasiveness of cervical carcinoma cell line CaSKi and vascular endothelial growth factor expression]
[Effects of antisense oligodeoxynucleotides on vascular endothelial growth factor expression in Lewis lung carcinoma cells in vitro.]
[Effects of Baihe Recipe on expressions of vascular endothelial growth factor and p53 proteins in tumor tissues of nude mice bearing orthotopically transplanted gastric carcinoma BGC-823.]
[Effects of green tea extract on expression of human papillomavirus type 16 oncoproteins-induced hypoxia-inducible factor-1alpha and vascular endothelial growth factor in human cervical carcinoma cells]
[Effects of HPV 16-E6/E7 oncogene on expression of vascular endothelial growth factor and matrix metalloproteinase 9 in human laryngeal squamous cell carcinoma cell line]
[Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells].
[Effects of vascular endothelial growth factor (VEGF) antisense oligodeoxynucleotide on mRNA and expression of VEGF, flt-1, and kinase insert domain containing receptor and VEGF excretion in human gallbladder carcinoma cells]
[EphA2 mediated vascular endothelial growth factor expression via the p38 MAPK signaling pathway in squamous cell carcinoma of the head and neck].
[Evaluation of angiogenesis in the tumorigenesis and progression of breast cancer]
[Experimental study on the effect of VEGF165 antisense RNA on human squamous cell carcinoma of esophagus]
[Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma]
[Expression and clinical significance of Endostatin, vascular endothelial growth factor and fibroblast growth factor basic-2 in laryngeal carcinoma]
[Expression and clinical significance of hypoxia inducible factor-1alpha, survivin and vascular endothelial growth factor in esophageal squamous cell carcinoma]
[Expression and clinical significance of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinomas]
[Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma]
[Expression and hypoxic regulation of vascular endothelial growth factor and matrix metalloproteinase-9 in esophageal carcinoma]
[Expression of C-erb B-2 and its relation to angiogenesis in nasopharyngeal carcinoma.]
[Expression of HIF-1alpha and VEGF in human laryngeal carcinoma and its relationship with angiogenes].
[Expression of hypoxia inducible factor-1? and correlated target genes in human laryngeal carcinoma].
[Expression of hypoxia-inducible factor-1-alpha, hypoxia-inducible factor-2alpha and vascular endothelial growth factor in sporadic clear cell renal cell renal cell carcinoma and their significance in the pathogenesis thereof]
[Expression of inductive nitric oxide synthase and vascular endothelial growth factor in colonic carcinoma, and their effects on tumor angiogenesis]
[Expression of mRNA isoforms of vascular endothelial growth factor in ovarian carcinoma]
[Expression of p53 and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinical significance]
[Expression of vascular endothelial growth factor and its receptors in laryngeal carcinoma cell and its significance]
[Expression of vascular endothelial growth factor and its significance in pulmonary bronchoalveolar carcinoma.]
[Expression of vascular endothelial growth factor C and cyclooxygenase-2 in non-small-cell lung carcinoma and their clinical significance.]
[Expression of vascular endothelial growth factor C and survivin in gastric carcinoma and their clinical implications]
[Expression of vascular endothelial growth factor D in human esophageal squamous cell carcinoma tissue and its significance].
[Expression of vascular endothelial growth factor in oral squamous cell carcinoma]
[Expression of vascular endothelial growth factor in primary esophageal squamous cell carcinoma and its significance in angiogenesis and prognosis of the tumor]
[Expression of vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and nm23-H1 in oral squamous cell carcinoma]
[Expression of VEGF and VEGF-C in laryngeal carcinoma and their clinical significance]
[Expression of VEGF, EGFR, p16 in lip cancers and oral squamous cell carcinomas and their clinic significance]
[Expression of VEGF-C and VEGF-D in gastric carcinoma and its relationship with lymph node metastases.]
[Expression related to vascular endothelial growth factor C and induced nitride oxide synthesizase in lymph node micrometastasis of oral squamous cell carcinoma]
[Expressions of hypoxia inducible factor-1alpha and vascular endothelial growth factor in human renal cell carcinoma]
[Expressions of receptor-binding cancer antigen expressed on SiSo cells, vascular endothelial growth factor, and matrix metalloproteinase-9 in cervical carcinoma and correlation thereof with the invasion and metastasis of the cancerous tissues]
[Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma.]
[Expressions of VEGF-C and VEGF-D and their correlation with lymphangiogenesis and angiogenesis in gallbladder carcinoma]
[Inhibition of bladder cancer cell growth and angiogenesis by co-blockage of vascular endothelial growth factor and its receptor kdr]
[Interaction of vascular endothelial growth factor-C over-expression with tongue squamous cell carcinoma cell line Tca8113 with peri-carcinoma lymphatics]
[Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
[Microvessel count and vascular endothelial growth factor in renal cell carcinoma]
[Microvessel density and expression of vascular endothelial growth factor in adenoid cystic carcinoma of salivary gland]
[Microvessel density, epithelial-stromal vascular cuffing and expression of vascular endothelial growth factor in human cervical carcinoma]
[Molecular markers of carcinogenesis in the diagnostics of cervical cancer]
[Multistep Process of Establishing Carcinoma Metastases].
[Mutation of von Hippel-Lindau gene and expression of vascular endothelial growth factor in sporadic clear cell renal cell carcinoma and their relationships to angiogenesis]
[Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid.]
[Phosphorylation of signal transducer and activators of transcription 3 induced by vascular endothelial growth factor in ovarian carcinoma cell line in vitro]
[Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor].
[Predictive value of serum levels of basic fibroblast growth factor, vascular endothelial growth factor and matrix metalloproteinase-2 in advanced carcinomas of the head and neck]
[Preliminary effect of VEGF promoter-driven recombinant adenovirus containing double suicide genes on apoptosis of human gastric carcinoma cells]
[Prognostic role of vascular endothelial growth factor in oral carcinoma: a meta analysis].
[Prokaryotic expression of vascular endothelial growth factor-C]
[Relation between vascular endothelial growth factor and reoccurence-metastasis after transcatheter arterial chemoembolization in hepatocellar carcinoma]
[Relation between vascular endothelial growth factor expression and clinical pathological character in laryngeal squamous cell carcinoma]
[Relationship among expression of the VEGF gene and MVD with cervical lymph nodes metastasis in laryngeal squamous cell carcinoma]
[Relationship between fluorodeoxyglucose uptake and vascular endothelial growth factor in early-stage nasophygeal carcinoma.]
[Relationship between the expression of vascular endothelial growth factor, fms-like tyrosine kinase-1 and biological behavior in gastric carcinoma]
[Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma].
[Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]
[Renal cell carcinoma and antiangiogenic therapies]
[Research on the correlation of vascular endothelial growth factor and dendritic cell in patients with oral squamous cell carcinoma]
[Retraction: Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells].
[Roles of vascular endothelial growth factor and platelet-derived growth factor in lymphangiogenesis in epithelial ovarian carcinoma.]
[Screening of anti-tumor parts from the seeds of Livistona chinensis and its anti-angiogenesis effect]
[Study of the anti-tumor effect of anti-vascular endothelial growth factor McAb 5-fluorouracil loaded polylactic acid nanoparticles]
[Study on serum vascular endothelial growth factor level in ovarian malignant tumors]
[Study on the relationship between angiogenesis and cervical lymphatic metastasis in head and neck squamous cell carcinomas]
[Study on the relationship between vascular endothelial growth factor and syndrome type of traditional Chinese medicine in patients with gastric carcinoma]
[The correlation of vascular endothelial growth factor with angiogenesis and p53 gene in laryngeal squamous cell carcinoma]
[The expression of vascular endothelial growth factor, CD44v6 in non-small cell lung carcinoma]
[The relationship of vascular endothelial growth factor and angiogenesis to the progression of gastric carcinoma]
[The roles of VEGF and C-myc in occurrence, development and metastasis of gallbladder carcinoma]
[Therapeutic effect of angiogenesis inhibitors on liver metastases of human colorectal carcinoma]
[Tumor-infiltrating dendritic cells in epithelial ovarian carcinoma and correlation with the expression of vascular endothelial growth factor]
[Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in superficial transitional cell bladder carcinoma]
[Vascular endothelial growth factor D promoting the growth of lymphatic vessel in gastric carcinoma]
[Vascular endothelial growth factor in non-small cell lung carcinoma expression and its significance]
[Vascular endothelial growth factor inhibits dendritic cells from patients with non-small cell lung carcinoma]
[Vascular endothelial growth factor-C (VEGF-C) and vascular endothelial growth factor-D (VEGF-D) in ovarian carcinomas]
[VEGF-D expression in lung adenocarcinoma with or without acquired resistance to gefitinib and normal lung tissue.]
Carcinoma in Situ
Angiogenic growth factors in preinvasive breast disease.
Biomarker expression in normal fimbriae: Comparison of high- and low-grade serous ovarian carcinoma.
Cyclooxygenase-2 expression in an adenoid cystic carcinoma of the uterine cervix.
Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C.
Carcinoma, Acinar Cell
Expression of p53 oncoprotein increases intratumoral microvessel formation in human salivary gland carcinomas.
Carcinoma, Adenoid Cystic
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
A study on the inhibition of VEGF expression in salivary gland adenoid cystic carcinoma cells via iNOS gene RNAi in vitro.
Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma.
Expression of p53 oncoprotein increases intratumoral microvessel formation in human salivary gland carcinomas.
Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome.
Hypoxia promotes vasculogenic mimicry formation by vascular endothelial growth factor A mediating epithelial-mesenchymal transition in salivary adenoid cystic carcinoma.
Levels and patterns of expression of hypoxia-inducible factor-1?, vascular endothelial growth factor, glucose transporter-1 and CD105 in adenoid cystic carcinomas with high-grade transformation.
Lymphatic vessels and related factors in adenoid cystic carcinoma of the salivary gland.
Nerve growth factor and vascular endothelial growth factor: retrospective analysis of 63 patients with salivary adenoid cystic carcinoma.
[Clinico-pathological significance of microvessel density and vascular endothelial growth factor expression in adenoid cystic carcinoma of salivary glands]
[Microvessel density and expression of vascular endothelial growth factor in adenoid cystic carcinoma of salivary gland]
Carcinoma, Adenosquamous
The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer.
Carcinoma, Basal Cell
Expression of basic fibroblast growth factor, vascular endothelial growth factor, and thrombospondin-1 related to microvessel density in nonaggressive and aggressive basal cell carcinomas.
Expression of vascular endothelial growth factor and microvascular density assessment in different histotypes of basal cell carcinoma.
Expression of vascular endothelial growth factor in basal cell carcinoma and cutaneous squamous cell carcinoma of the head and neck.
Mast cells and cutaneous malignancies.
Carcinoma, Bronchogenic
Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?
Carcinoma, Ductal
Angiogenic profile of breast carcinoma determines leukocyte infiltration.
Assessment of Maturation Status of Tumor-Infiltrating Dendritic Cells in Invasive Ductal Carcinoma of the Breast: Relation with Vascular Endothelial Growth Factor Expression.
COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas.
Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression.
Immunohistochemical expression of vascular endothelial growth factor and its correlation with tumor grade in breast ductal carcinoma.
Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer.
Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence.
Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis.
Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density.
Occult breast cancer presenting as axillary metastases.
The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.
The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions.
[Dynamic MRI and tumor angiogenesis of breast cancer]
Carcinoma, Endometrioid
A case of adenocarcinoma of the endometrial type mixed with a clear cell component that metastasized to the vagina.
Expression of aquaporin-1 in normal, hyperplasic, and carcinomatous endometria.
Possible involvement of adipocyte-derived leucine aminopeptidase via angiotensin II in endometrial carcinoma.
The Potential Roles of MELF-Pattern, Microvessel Density, and VEGF Expression in Survival of Patients with Endometrioid Endometrial Carcinoma: A Morphometrical and Immunohistochemical Analysis of 100 Cases.
Carcinoma, Hepatocellular
(-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-formulated, immune-stimulatory vascular endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis.
A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells.
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.
A single nucleotide polymorphism in the vascular endothelial growth factor gene is associated with recurrence of hepatocellular carcinoma after transplantation.
A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery.
Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells.
Alpha-ketoglutarate (AKG) inhibits proliferation of colon adenocarcinoma cells in normoxic conditions.
Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma.
Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice.
Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.
Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
Anti-angiogenic activity of inositol hexaphosphate (IP6).
Antiangiogenic activity of a concentrated effective microorganism fermentation extract.
Antiangiogenic activity of vitexicarpine in experimentally induced hepatocellular carcinoma: Impact on vascular endothelial growth factor pathway.
Antihepatoma activity of chaetocin due to deregulated splicing of hypoxia-inducible factor 1? pre-mRNA in mice and in vitro.
Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma.
Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model.
Apatinib for molecular targeted therapy in tumor.
Apatinib-induced hyperammonemic encephalopathy.
Apparent diffusion coefficient value of diffusion-weighted imaging for hepatocellular carcinoma: correlation with the histologic differentiation and the expression of vascular endothelial growth factor.
Assessment of the clinical significance of serum vascular endothelial growth factor and matrix metalloproteinase-9 in patients with hepatocellular carcinoma.
Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients.
Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients.
Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population.
Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Bilateral above knee amputations after prolonged exposure to sorafenib and trebananib.
Black tea polyphenols target matrix metalloproteinases, RECK, proangiogenic molecules and histone deacetylase in a rat hepatocarcinogenesis model.
Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Branched-chain amino acid deficiency stabilizes insulin-induced vascular endothelial growth factor mRNA in hepatocellular carcinoma cells.
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study.
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells.
Cancer-Associated Fibroblasts Promote Angiogenesis of Hepatocellular Carcinoma by VEGF-Mediated EZH2/VASH1 Pathway.
Cbx4 governs HIF-1? to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity.
CD44 and VEGF expression in extrahepatic metastasis of human hepatocellular carcinoma.
Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial.
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
Characterization of brivanib therapy response in hepatocellular carcinoma xenografts using 1H HR-MAS spectroscopy and histopathology.
Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway.
Circulating levels of VEGF family and their receptors in hepatocellular carcinoma.
Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma.
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.
Clinical implications of the dual blockade of the PD-1/PD-L1 and vascular endothelial growth factor axes in the treatment of hepatocellular carcinoma.
Clinical significance of endothelial progenitor cells in patients with liver cirrhosis with or without hepatocellular carcinoma.
Clinical significance of joint detection of serum VEGF, SIL-2R and HGF in patients with primary hepatocellular carcinoma before and after percutaneous microwave coagulation therapy.
Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.
Clinical significance of the expression of isoform 165 vascular endothelial growth factor mRNA in noncancerous liver remnants of patients with hepatocellular carcinoma.
Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients.
Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.
Clinicopathological features of hepatocellular carcinoma evaluated by vascular endothelial growth factor expression.
Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization.
Cocculus hirsutus: Molecular Docking to Identify Suitable Targets for Hepatocellular Carcinoma by In silico Technique.
Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma.
Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC.
Cooperation of Indian Hedgehog and Vascular Endothelial Growth Factor in Tumor Angiogenesis and Growth in Human Hepatocellular Carcinomas, an Immunohistochemical Study.
Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation.
Correlation Between Vascular Endothelial Growth Factor and Long-Term Occurrence of HCV-Related Hepatocellular Carcinoma After Treatment with Direct-Acting Antivirals.
Correlation between vascular endothelial growth factor levels and prognosis of hepatocellular carcinoma patients receiving radiofrequency ablation.
Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma.
Correlation of vascular endothelial cell proliferation with microvessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in hepatocellular carcinoma.
Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters.
Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma.
Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition.
Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma.
Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor.
Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens.
Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Different expression of VEGF and EGFL7 in human hepatocellular carcinoma.
Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma.
Differential vascular endothelial growth factor A protein expression between small hepatocellular carcinoma and cirrhosis correlates with serum vascular endothelial growth factor A and alpha-fetoprotein.
Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion.
Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor.
Downregulation of Vascular Endothelial Growth Factor Enhances Chemosensitivity by Induction of Apoptosis in Hepatocellular Carcinoma Cells.
Dual action of a selective cyclooxygenase-2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: novel involvement of discoidin domain receptor 2.
Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma.
Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
Effect of c-fos antisense probe on prostaglandin E2-induced upregulation of vascular endothelial growth factor mRNA in human liver cancer cells.
Effect of Fibroblast Growth Factor-2 and its Receptor Gene Polymorphisms on the Survival of Patients With Hepatitis B Virus-associated Hepatocellular Carcinoma.
Effect of hypoxia on hypoxia inducible factor-1?, insulin-like growth factor I and vascular endothelial growth factor expression in hepatocellular carcinoma HepG2 cells.
Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model.
Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Effects of PI3K and p42/p44 MAPK on overexpression of vascular endothelial growth factor in hepatocellular carcinoma.
Effects of VEGF/VEGFR/K-ras signaling pathways on miRNA21 levels in hepatocellular carcinoma tissues in rats.
Efficacy of Ciji Hua'ai Baosheng formula on the expressions of vascular endothelial growth factor, kinase insert domain-containing receptor and basic fibroblast growth factor in mouse models of H(22) hepatocellular carcinoma.
Epidermal growth factor receptor transactivation is involved in the induction of human hepatoma SMMC7721 cell proliferation by insufficient radiofrequency ablation.
Establishment of a sandwich ELISA method for detection of vascular endothelial growth factor in serum samples of hepatocellular carcinoma patients.
Evaluation of transforming growth factor alpha and vascular endothelial growth factor in diagnosis of hepatocellular carcinoma.
Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting ?-catenin-mediated angiogenesis.
Exploration of the relationship between the tumor burden and the concentration of vascular endothelial growth factor in liver-cancer-bearing animals using immunomagnetic reduction assay.
Exploring stemness gene expression and vasculogenic mimicry capacity in well- and poorly-differentiated hepatocellular carcinoma cell lines.
Exposure-Response (Safety) Analysis to Identify Linifanib Dose for a Phase III Study in Patients With Hepatocellular Carcinoma.
Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues.
Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma.
Expression characteristics of KAI1 and vascular endothelial growth factor and their diagnostic value for hepatocellular carcinoma.
Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization.
Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma.
Expression of e-cadherin and vascular endothelial growth factor in noncancerous liver is associated with recurrence of hepatocellular carcinoma after curative resection.
Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival.
Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level.
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.
Expression of vascular endothelial growth factor and matrix metalloproteinase-2 correlates with the invasion and metastasis of hepatocellular carcinoma.
Expression of vascular endothelial growth factor in hepatocellular carcinoma and its relationship to tumor growth and metastasis.
Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver and correlation with MRI findings.
Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver: correlation with angiographically assisted CT.
Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver: correlation with MR imaging and angiographically assisted CT.
Expression of vascular endothelial growth factor in human hepatocellular carcinoma.
Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study.
Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma.
Expression of vascular endothelial growth factor receptors is closely related to the histological grade of hepatocellular carcinoma.
Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter.
Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma.
Ginsenoside Rg3 attenuates hepatoma VEGF overexpression after hepatic artery embolization in an orthotopic transplantation hepatocellular carcinoma rat model.
Hammerhead ribozyme specifically inhibits vascular endothelial growth factor gene expression in a human hepatocellular carcinoma cell line.
Hepatitis B virus X protein activates expression of IGF-IR and VEGF in hepatocellular carcinoma cells.
Hepatocellular carcinoma: correlation between vascular endothelial growth factor level and degree of enhancement by multiphase contrast-enhanced computed tomography.
Hepatocellular Carcinoma: Review of Targeted and Immune Therapies.
High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis.
High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection.
High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma.
High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study.
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features.
Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues.
Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.
Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma.
Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization.
Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma.
Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma.
Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma.
Increased vascular endothelial growth factor transcription in residual hepatocellular carcinoma after open versus laparoscopic hepatectomy in a small animal model.
Increasing matrix stiffness upregulates vascular endothelial growth factor expression in hepatocellular carcinoma cells mediated by integrin ?1.
Inducible nitric oxide synthase expression is related to angiogenesis, bcl-2 and cell proliferation in hepatocellular carcinoma.
Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells.
Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study.
Influence of vascular endothelial growth factor and alpha-fetoprotein on hepatocellular carcinoma.
Inhibition of VEGF expression through blockade of Hif1? and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells.
Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.
Inhibitory effect of antisense vascular endothelial growth factor 165 eukaryotic expression vector on proliferation of hepatocellular carcinoma cells.
Inhibitory effect of antisense vascular endothelial growth factor RNA on the profile of hepatocellular carcinoma cell line in vitro and in vivo.
Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice.
Inhibitory Effect of Semen Litchi Drug Serum on the Proliferation of Human Hepatoma HepG2 Cells and Expression of VEGF and MMP-9.
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression.
Insufficient radiofrequency ablation promotes human hepatoma SMMC7721 cell proliferation by stimulating vascular endothelial growth factor overexpression.
Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma.
Integrin ?v?3-Mediated Effects of Thyroid Hormones on Mesenchymal Stem Cells in Tumor Angiogenesis.
Interplays between genetic and environmental mechanisms trigger tumorigenic VEGF signalling in human HCC cell lines: pilot study.
Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection?
KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Kinetics of tumorigenic vascular endothelial growth factor signalling and its significance in human hepatocellular carcinoma cells.
Levels of HBx, VEGF, and CEACAM1 in HBV-related hepatocellular carcinoma and their correlation with cancer prognosis.
Litchi (Litchi chinensis Sonn.) flower proanthocyanidin fraction exhibited protective efficacy to suppress nickel-induced expression for vascular endothelial growth factor in HepG2 cells.
Low-molecular weight chitosan/vascular endothelial growth factor short hairpin RNA for the treatment of hepatocellular carcinoma.
LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
Lysyl Oxidase Is Predictive of Unfavorable Outcomes and Essential for Regulation of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma.
Magnetic resonance imaging and expression of vascular endothelial growth factor in hepatocellular nodules in cirrhosis and hepatocellular carcinomas.
Medical treatment of advanced hepatocellular carcinoma patients: the issue is not the right drug, but the right patient.
Melatonin maximizes the therapeutic potential of non-preconditioned MSCs in a DEN-induced rat model of HCC.
Metronomic s-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
MicroRNA-205 is downregulated in hepatocellular carcinoma and inhibits cell growth and metastasis via directly targeting vascular endothelial growth factor A.
MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2?/Akt/HIF-1? pathway in hepatocellular carcinoma.
Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma.
miR-100 Suppresses the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells via Targeting CXCR7.
Modified Rat Hepatocellular Carcinoma Models Overexpressing Vascular Endothelial Growth Factor.
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.
MR imaging in hepatocellular carcinoma: correlations between MRI features and molecular marker VEGF.
Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
Multiphase contrast-enhanced CT imaging in hepatocellular carcinoma correlation with immunohistochemical angiogenic activities.
Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/?-catenin signaling.
On-line surface plasmon resonance biosensing of vascular endothelial growth factor signaling in intact-human hepatoma cell lines.
Osthole attenuates angiogenesis in an orthotopic mouse model of hepatocellular carcinoma via the downregulation of nuclear factor-?B and vascular endothelial growth factor.
Overexpression and correlation of HIF-2?, VEGFA and EphA2 in residual hepatocellular carcinoma following high-intensity focused ultrasound treatment: Implications for tumor recurrence and progression.
Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)?2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway.
Overexpression of Caveolin-1 in Hepatocellular Carcinoma with Metastasis and Worse Prognosis: Correlation with Vascular Endothelial Growth Factor, Microvessel Density and Unpaired Artery.
Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients.
Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma.
Peritoneal fluid contains high concentration of hepatocyte growth factor and vascular endothelial growth factor after resection for hepatocellular carcinoma.
Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
Phase II, Open-label Study of Brivanib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.
Pigment Epithelium Derived Factor Effectively Decreases Vascular Endothelial Growth Factor to Pigment Epithelium Derived Factor Messenger RNA Ratio of the Inner Edge of Rat Hepatocellular Carcinoma Induced by Diethyl Nitrosamine - An 'In Vivo' Study.
Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma.
Pneumatocele during sorafenib therapy: first report of an unusual complication.
Polycomb chromobox 4 enhances migration and pulmonary metastasis of hepatocellular carcinoma cell line MHCC97L.
Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment.
pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance.
Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern.
Predictive values of serum VEGF and CRP levels combined with contrast enhanced MRI in hepatocellular carcinoma patients after TACE.
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.
Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging.
Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma.
Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation.
Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis.
Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study.
Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma.
Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis.
Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery.
Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients.
Prognostic Value of Vascular Endothelial Growth Factor Levels in Patients With Hepatocellular Carcinoma.
Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Prognostic values of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma after radiotherapy.
Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival.
PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells: PTEN regulates angiogenesis in HepG2.
Q39, a quinoxaline 1,4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1alpha expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells.
Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma.
Quantitative analysis using ELISA of vascular endothelial growth factor and basic fibroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and hepatocellular carcinoma.
Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma.
Quinazoline derivative compound (11d) as a novel angiogenesis inhibitor inhibiting VEGFR2 and blocking VEGFR2-mediated Akt/mTOR /p70s6k signaling pathway.
Rac activation is associated with hepatocellular carcinoma metastasis by up-regulation of vascular endothelial growth factor expression.
Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial-mesenchymal transition.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.
Recent developments with immunotherapy for hepatocellular carcinoma.
Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy.
Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma.
Relationsip between PTEN and VEGF expression and clinicopathological characteristics in HCC.
Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization.
Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells.
Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-kappa B-mediated mechanism.
Ribozyme mediated suppression of vascular endothelial growth factor gene expression enhances matrix metalloproteinase 1 expression in a human hepatocellular carcinoma cell line.
Role of vascular endothelial growth factor on the invasive potential of hepatocellular carcinoma.
Role of VEGF-C Gene Polymorphisms in Susceptibility to Hepatocellular Carcinoma and Its Pathological Development.
Roles of microRNA-186 and vascular endothelial growth factor in hepatocellular carcinoma complicated with portal vein tumor thrombus.
Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection.
Serum human endothelial cell-specific molecule-1 (endocan) and vascular endothelial growth factor in cirrhotic HCV patients with hepatocellular carcinoma as predictors of mortality.
Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.
Serum vascular endothelial growth factor as a tumor marker for hepatocellular carcinoma in hepatitis C virus-related cirrhotic patients.
Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma.
Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma.
Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma.
Serum vascular endothelial growth factor level in patients with hepatocellular carcinoma undergoing liver transplantation: experience of a single Western center.
Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival.
Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study.
Serum VEGF as a Tumor Marker in Patients with HCV-related Liver Cirrhosis and Hepatocellular Carcinoma.
Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis.
Shenqi Fuzheng Injection (SFI) Enhances IFN-? Inhibitory Effect on Hepatocellular Carcinoma Cells by Reducing VEGF Expression: Validation by Gene Silencing Technique.
Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma.
Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma.
Soluble Vascular Endothelial Growth Factor Receptor-2 as a Predictive Factor for Progression of Illness in Chronic Liver Diseases and Hepatocellular Carcinoma.
Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents.
Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma.
Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis.
Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma.
Sunitinib Induces NK-?B-dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells.
Suppression of Vascular Endothelial Growth Factor via Inactivation of Eukaryotic Elongation Factor 2 by Alkaloids in Coptidis rhizoma in Hepatocellular Carcinoma.
Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma.
Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.
The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization (TACE).
The Effect of High Intensity Focused Ultrasound on Vascular Endothelial Growth Factor and Microvessel Density in Rabbit V-X2 Hepatocellular Carcinoma Models.
The effect of TACE in combination with thalidomide-mediated adjuvant therapy on the levels of VEGF and bFGF in patients with hepatocellular carcinoma.
The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.
The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor.
The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways.
The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma.
The prognostic value of vascular endothelial growth factor in hepatocellular carcinoma for predicting metastasis after curative resection.
The role of vascular endothelial growth factor -634 G/C and its soluble receptor on chronic liver disease and hepatocellular carcinoma.
The value of [(11)C]-acetate PET and [(18)F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab.
The Vascular Endothelial Growth Factor-2549 Insertion/Deletion Polymorphism Is Not Associated with Susceptibility to Hepatocellular Carcinoma in Chinese.
Transfer of the sFLT-1 gene in Morris hepatoma results in decreased growth and perfusion and induction of genes associated with stress response.
Tumor vasculature and glioma stem cells: Contributions to glioma progression.
V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.
Vascular endothelial growth factor and its type 2 receptor in hepatocellular carcinoma.
Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma.
Vascular endothelial growth factor in patients with hepatocellular carcinoma.
Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature.
Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
Vascular endothelial growth factor protects hepatoma cells against oxidative stress-induced cell death.
Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma.
Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells.
Vascular endothelial growth factor: Evidence for autocrine signaling in hepatocellular carcinoma cell lines affecting invasion.
Vascular endothelial growth factors and liver diseases.
VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy.
VEGF Polymorphisms Related to Higher Serum Levels of Protein Identify Patients with Hepatocellular Carcinoma.
VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma.
WNK1 Kinase Stimulates Angiogenesis to Promote Tumor Growth and Metastasis.
[Adenovirus vector encoding human KDR elicits immunity against hepatocellular carcinomas in mice]
[Changes of vascular endothelial growth factor and endothelin-1 and nitric oxide in patients with primary hepatocellular carcinoma]
[Clinical values of vascular endothelial growth factor expression and microvascular density analysis in liver cancer specimens]
[Correlation between epidermal growth factor and overexpression of vascular endothelial growth factor in hepatocellular carcinoma]
[Correlation between PTEN and vascular endothelial growth factor expression and the invasion and metastasis of human hepatocellular carcinomas]
[Effect of ionization on the expression of hypoxia-inducible factor-1alpha and VEGF in hepatocellular carcinoma HepG2 cells under anoxic condition]
[Effects of macrophage migration inhibitor factor gene suppression via siRNA on vascular endothelial growth factor expression in hepatocellular carcinoma.]
[Effects of vascular endothelial growth factor on adhesion molecular expression of hepatocellular carcinoma HepG]
[Expression and clinical impact of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma]
[Expression of liver-type fatty acid-binding protein and vascular endothelial growth factor and their correlation in human hepatocellular carcinoma]
[Expression of vascular endothelial growth factor (VEGF) family members and prognosis after hepatic resection in HBV-related hepatocellular carcinoma]
[Expression of vascular endothelial growth factor correlates with invasion and metastasis of hepatocellular carcinoma]
[Expression rates of three angiogenic factors in hepatocellular carcinoma and their relation with microvessel density and portal vein tumor thrombosis]
[Expressions of inducible nitric oxide synthase and vascular endothelial growth factor and their relationship with microvessel density in hepatocellular carcinoma.]
[Expressions of Survivin and vascular endothelial growth factor in hepatocellular carcinoma and their clinical significance]
[HBx can facilitate the expression of vascular endothelial growth factor in human hepatoma tissue of nude mice]
[HCV DF protein inhibits expression of p16 and p21 in HepG(2); cells.]
[Hypoxia-inducible factor-1? mediates and regulates angiogenesis-related factors expression in hepatocellular carcinoma].
[Inhibitory effects of ampelopsin on angiogenesis]
[Intratumoral microvessel density and expression of vascular endothelial growth factor in hepatocellular carcinoma after chemoembolization]
[Nitric oxide synthase and vascular endothelial growth factor expression in hepatocellular carcinoma and their relation to angiogenesis]
[Prognostic significance of serum level of vascular endothelial growth factor receptor-2 in hepatocellular carcinoma patients after transcatheter arterial chemoembolization].
[Relation between vascular endothelial growth factor and reoccurence-metastasis after transcatheter arterial chemoembolization in hepatocellar carcinoma]
[Relationship between the proliferative activity of cancer cells and microvessel density in portal vein thrombosis and transfer of hepatocellular carcinoma]
[Relationship between vascular endothelial growth factor expression and microvessel density in hepatocellular carcinomas and their surrounding liver tissue]
[Significance of vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma]
[The expression and significance of vascular endothelial growth factor and its receptors in hepatocellular carcinoma cell lines with various metastatic potentialities.]
[The role of angiostatin, vascular endothelial growth factor, matrix metalloproteinase 9 and 12 in the angiogenesis of hepatocellular carcinoma]
[Value of ultrasound-targeted vascular endothelial growth factor receptor-2 in non-invasive monitoring of anti-angiogenic response in nude mice with subcutaneous xenograft model].
Carcinoma, Intraductal, Noninfiltrating
Angiogenesis and VEGF expression in pre-invasive lesions of the human breast.
COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ.
Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer.
Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers.
The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.
The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions.
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast.
Carcinoma, Islet Cell
Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors.
Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Carcinoma, Large Cell
Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.
The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer.
Carcinoma, Lewis Lung
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
Effects of Feijining Decoction on vascular endothelial growth factor protein expression and changes of T cell subsets in Lewis lung carcinoma-bearing mice.
Endostatin improves cancer-associated systemic syndrome in a lung cancer model.
Extracts from Huangqi (Radix Astragali Mongoliciplus) and Ezhu (Rhizoma Curcumae Phaeocaulis) inhibit Lewis lung carcinoma cell growth in a xenograft mouse model by impairing mitogen-activated protein kinase signaling, vascular endothelial growth factor production, and angiogenesis.
Host A(2B) adenosine receptors promote carcinoma growth.
Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.
Protective effects of mastic oil from Pistacia lentiscus variation chia against experimental growth of lewis lung carcinoma.
The effect of topiramate on tumor-related angiogenesis and on the serum proteome of mice bearing Lewis lung carcinoma.
The Monascus metabolite monacolin K reduces tumor progression and metastasis of Lewis lung carcinoma cells.
Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells.
Vascular endothelial growth factor promotes the expression of cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells.
[Effects of antisense oligodeoxynucleotides on vascular endothelial growth factor expression in Lewis lung carcinoma cells in vitro.]
Carcinoma, Lobular
Angiogenesis and VEGF expression in pre-invasive lesions of the human breast.
Axillary metastases from occult breast cancer. Our experience.
Differentiation of tumours of ductal and lobular origin: I. Proteomics of invasive ductal and lobular breast carcinomas.
Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence.
The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions.
Carcinoma, Medullary
Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour.
Angiogenic profile of breast carcinoma determines leukocyte infiltration.
Expression of the von Hippel-Lindau Tumor Suppressor Gene in Nonneoplastic and Neoplastic Lesions of the Thyroid.
Carcinoma, Merkel Cell
Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma.
Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma.
Carcinoma, Mucoepidermoid
Association of clinicopathologic parameters with the expression of inducible nitric oxide synthase and vascular endothelial growth factor in mucoepidermoid carcinoma.
Expression of caveolin-1 in mucoepidermoid carcinoma of the salivary glands: correlation with vascular endothelial growth factor, microvessel density, and clinical outcome.
Expression of p53 oncoprotein increases intratumoral microvessel formation in human salivary gland carcinomas.
Expression of the Vascular Endothelial Growth Factor and Angiopoietins in Mucoepidermoid Carcinoma of Salivary Gland.
Carcinoma, Neuroendocrine
Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas.
Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study.
Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Carcinoma, Non-Small-Cell Lung
A Multicenter, Phase II study of Erlotinib and Sorafenib in Chemotherapy-naive Patients with Advanced Non-Small Cell Lung Cancer.
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.
Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab.
AMP-activated protein kinase ?1 serves a carcinogenic role via regulation of vascular endothelial growth factor expression in patients with non-small cell lung cancer.
Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma.
Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
Angiogenesis in the treatment of non-small cell lung cancer.
Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: Correlations with patient survival and pleural effusion control.
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.
Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer.
Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
Antiangiogenic drugs in non-small cell lung cancer treatment.
Antiangiogenic therapy in nonsmall cell lung cancer.
Antibodies to vascular endothelial growth factor in non-small cell lung cancer.
Antitumor Activity of Elacytarabine Combined with Bevacizumab, Cetuximab and Trastuzumab in Human NSCLC Xenografts.
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma.
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Bevacizumab-induced hypertension: pathogenesis and management.
Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer.
Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
CCL21/CCR7 up-regulate vascular endothelial growth factor-D expression via ERK pathway in human non-small cell lung cancer cells.
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.
Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer.
Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.
Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer.
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.
Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer.
Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Compounds in clinical Phase III and beyond.
Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype.
Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.
Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer.
Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer.
Decreased maspin combined with elevated vascular endothelial growth factor C is associated with poor prognosis in non-small cell lung cancer.
Detection of circulating vascular endothelial growth factor and matrix metalloproteinase-9 in non-small cell lung cancer using Luminex multiplex technology.
Detection of lymphangiogenesis in non-small cell lung cancer and its prognostic value.
Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non-small cell lung cancer.
Differential expression of hypoxia-inducible factor 1? in non-small cell lung cancer and small cell lung cancer.
Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
Effects of autocrine vascular endothelial growth factor (VEGF) in non-small cell lung cancer cell line A549.
Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC.
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.
Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer.
Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients.
Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer.
Elevated SP-1 transcription factor expression and activity drives basal and hypoxia-induced vascular endothelial growth factor (VEGF) expression in non-small cell lung cancer.
ERK Signaling Pathway Is Involved in HPV-16 E6 but not E7 Oncoprotein-Induced HIF-1? Protein Accumulation in NSCLC Cells.
Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer.
Expression of Elf-1 and survivin in non-small cell lung cancer and their relationship to intratumoral microvessel density.
Expression of thymosin beta10 and its role in non-small cell lung cancer.
Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer.
Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas.
Expression of vascular endothelial growth factor (VEGF) and its receptor FLK-1 in non-small cell lung cancer (NSCLC)--a preliminary report.
Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis.
Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer.
Expression of vascular endothelial growth factor and the adhesion molecule E-cadherin in non-small cell lung cancer.
Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas.
Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.
Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells.
High preoperative plasma vasohibin-1 concentration predicts better prognosis in patients with non-small cell lung carcinoma.
Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.
Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.
Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L).
In NSCLC, VEGF-A response to hypoxia may differ between squamous cell and adenocarcinoma histology.
Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma.
Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer.
Inflammatory cytokines and VEGF measured in exhaled breath condensate are correlated with tumor mass in non-small cell lung cancer.
Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.
Influence of vascular endothelial growth factor single nucleotide polymorphisms on non-small cell lung cancer tumor angiogenesis.
Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer.
Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer.
JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.
Levels of Vascular Endothelial Growth Factor in Serum and Pleural Fluid Are Independent Predictors of Survival in Advanced Non-small Cell Lung Cancer: Results of a Prospective Study.
Loss of the endothelial glycocalyx is associated with increased E-selectin mediated adhesion of lung tumour cells to the brain microvascular endothelium.
Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity.
miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A.
Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer.
New antiangiogenetic agents and non-small cell lung cancer.
New Strategies for NSCLC: Is Inhibition of Tumour Vasculature Useful?
Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma.
Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt/?-Catenin signaling pathway.
Paracrine signaling by VEGF-C promotes non-small cell lung cancer cell metastasis via recruitment of tumor-associated macrophages.
Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer.
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).
Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.
Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer.
Platelet VEGF and serum TGF-?1 levels predict chemotherapy response in non-small cell lung cancer patients.
Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy.
Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases.
Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
Profiling of Vascular Endothelial Growth Factor Receptor Heterogeneity Identifies Protein Expression-defined Subclasses of Human Non-small Cell Lung Carcinoma.
Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis.
Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.
Prognostic Value of Epithelial Growth Factor Receptor, Vascular Endothelial Growth Factor, E-Cadherin, and p120 Catenin in Resected Non-Small Cell Lung Carcinoma.
Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer.
Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.
Recruitment of CD11b(+)Ly6C(+) monocytes in non-small cell lung cancer xenografts challenged by anti-VEGF antibody.
Relationship between (18)F-FDG uptake on PET and various biologic molecular markers in benign pulmonary lesion: comparison with primary lung cancer.
Relationship between PTEN and Vascular Endothelial Growth Factor Expression in Non-Small Cell Lung Cancer.
Relationship Between Serum VEGF Level and Radiosensitivity of Patients with Nonsmall Cell Lung Cancer Among Asians: A Meta-Analysis.
Relationship of serum levels of VEGF and TGF-?1 with radiosensitivity of elderly patients with unresectable non-small cell lung cancer.
Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC).
Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells.
Role of lymphangiogenesis in lung cancer.
Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer.
Roles of PI3K/Akt and c-Jun signaling pathways in human papillomavirus type 16 oncoprotein-induced HIF-1?, VEGF, and IL-8 expression and in vitro angiogenesis in non-small cell lung cancer cells.
Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients.
Serum concentrations of vascular endothelial growth factor in advanced non-small cell lung cancer.
Serum endostatin correlates with progression and prognosis of non-small cell lung cancer.
Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients.
Serum tumor markers, hypoxia-inducible factor-1? HIF-1? and vascular endothelial growth factor, in patients with non- small cell lung cancer before and after intervention.
Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer and its relations to the micrometastasis in peripheral blood.
Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer.
Short-term prognostic effects of circulating regulatory T-Cell suppressive function and vascular endothelial growth factor level in patients with non-small cell lung cancer and obstructive sleep apnea.
Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer.
Study on Attenuating Angiogenesis and Epithelial-Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC2.
Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.
The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.
The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
The correlation of expression of VEGF and EGFR with SUV of (18)FDG-PET-CT in non-small cell lung cancer.
The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer.
The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer.
The predictive value of vascular endothelial growth factor and nm23 for the diagnosis of occult metastasis in non-small cell lung cancer.
The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients.
The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer.
The role of serum vascular endothelial growth factor and matrix metalloproteinase-9 in predicting response to chemotherapy in patients with advanced nonsmall cell lung cancer.
The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature.
Time-dependent changes of plasma concentrations of angiopoietins, vascular endothelial growth factor, and soluble forms of their receptors in nonsmall cell lung cancer patients following surgical resection.
Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation.
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Treatment of locally advanced non-small cell lung cancer with combination of chemotherapy and radiation.
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage IIIA).
Tumor angiogenesis in predicting the survival of patients with stage I lung cancer.
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC).
Upregulation of vascular endothelial growth factor (VEGF), its role in progression and prognosis of non-small cell lung carcinoma.
Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers.
Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis.
Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells.
Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer.
Vascular endothelial growth factor B coordinates metastasis of non-small cell lung cancer.
Vascular Endothelial Growth Factor C as a Predictor of Early Recurrence and Poor Prognosis of Resected Stage I Non-small Cell Lung Cancer.
Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.
Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer.
Vascular Endothelial Growth Factor Expression and Neovascularization in Non-Small Cell Lung Carcinoma.
Vascular endothelial growth factor expression in non-small cell lung cancer.
Vascular endothelial growth factor expression in pN2 non-small cell lung cancer: lack of prognostic value.
Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis.
Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer.
Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts.
Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.
Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma.
Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer.
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Vascular endothelial growth factor trap in non small cell lung cancer.
Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer.
VEGF-C in non-small cell lung cancer: meta-analysis.
[Anti-angiogenic agents in the treatment of lung cancer: Indications and toxicities].
[Bevacizumab and arterial hypertension or proteinuria: management]
[Combined Inhibition of Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways in Non-small Cell Lung Cancer Therapy.]
[Correlation of postoperative serum VEGF levels with platelet counts in non-small cell lung cancer]
[Decline of dendritic cells in the peripheral blood of patients with non-small cell lung cancer and its relation to vascular endothelial growth factor.]
[Diagnostic value of enhanced computed tomography plus vascular endothelial growth factor C expression in hilar and mediastinal lymph node metastasis of non-small cell lung cancer].
[Effects of JAK2/STAT3 signaling pathway on angiogenesis in non-small cell lung cancer.]
[Effects of vascular endothelial growth factor in the invasion and metastasis of non-small cell lung cancer.]
[Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma]
[Expression and clinical significance of vascular endothelial growth factor in human non-small cell lung cancer.]
[Expression and significance of Elf-1 and vascular endothelial growth factor in non-small cell lung cancer.]
[Expression and significance of Notch1, Jagged1 and VEGF in human non-small cell lung cancer]
[Expression of CD133 and Notch1 in non-small cell lung cancer and the clinicopathological significance].
[Expression of vascular endothelial growth factor (VEGF) C and VEGF receptor 3 in non-small cell lung cancer]
[Expression of vascular endothelial growth factor C and cyclooxygenase-2 in non-small-cell lung carcinoma and their clinical significance.]
[Expression of vascular endothelial growth factor C and its receptor VEGF-R3 and their significance in non-small cell lung cancer.]
[Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma.]
[Microvessel density and expressions of survivin and vascular endothelial growth factor in non-small cell lung cancer and their correlations to clinicopathologic features]
[Prognostic value of the expression of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha in patients undergoing surgery for non-small cell lung cancer.]
[Recombinant adenovirus expressing wild-type p53 is antiagiogenic--implication for lung cancer gene therapy]
[Research Progress of Small Molecule Anti-angiogenic Drugs ?in Non-small Cell Lung Cancer].
[The clinical significance of detection of vascular endothelial growth factor and CD44v6 expression in human non-small cell lung cancer.]
[The clinical significance of vascular endothelial growth factor and intercellular adhesion molecule-1 expression in non-small cell lung cancer.]
[The Correlation between FDG PET/CT Imaging and Molecule Makers in Non-Small Cell Lung Cancer.]
[The estimation of serum concentration of vascular endothelial growth factor in patients with non-small cell lung cancer]
[The expression of vascular endothelial growth factor, CD44v6 in non-small cell lung carcinoma]
[Vascular endothelial growth factor expression and microvessel density in stage I-II non-small cell lung cancer and their prognostic significances]
[Vascular endothelial growth factor in non-small cell lung carcinoma expression and its significance]
[Vascular endothelial growth factor inhibits dendritic cells from patients with non-small cell lung carcinoma]
[Vascular endothelial growth factor promotes hematogenous metastasis of cancer cells in patients with non-small cell lung cancer]
[Vasoactive intestinal peptide enhances the expression of vascular endothelial growth factor mRNA in non-small cell lung cancer cells.]
Carcinoma, Ovarian Epithelial
Adrenomedullin promotes angiogenesis in epithelial ovarian cancer through upregulating hypoxia-inducible factor-1? and vascular endothelial growth factor.
Adrenomedullin Up-regulates the Expression of Vascular Endothelial Growth Factor in Epithelial Ovarian Carcinoma Cells via JNK/AP-1 Pathway.
An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Angiogenic protein expression in advanced epithelial ovarian cancer.
Association of vascular endothelial growth factor gene polymorphisms with susceptibility to epithelial ovarian cancer.
Bevacizumab and ovarian cancer.
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement]
Clinical significance of growth factor receptor EGFR and angiogenesis regulator VEGF?R2 in patients with ovarian cancer at FIGO stages I-II.
Clinical significance of melanoma cell adhesion molecule CD146 and VEGFA expression in epithelial ovarian cancer.
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
Correlation of the serum concentration of vascular endothelial growth factor (VEGF) and hemoglobin levels in patients with epithelial ovarian cancer.
Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor.
Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.
Expression of the Vascular Endothelial Growth Factor (VEGF) Gene in Epithelial Ovarian Cancer: An Approach to Anti-VEGF Therapy.
Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.
Expression of VEGF-A in Epithelial Ovarian Cancer: Correlation with Morphologic Types, Grade and Clinical Stage.
Expression of VEGF-D in epithelial ovarian cancer and its relationship to lymphatic metastasis.
Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
High levels of circulating CD34+/VEGFR3+ lymphatic/vascular endothelial progenitor cells is correlated with lymph node metastasis in patients with epithelial ovarian cancer.
Hypoxia up-regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells.
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Investigating impact of Vascular Endothelial Growth Factor Polymorphisms in Epithelial Ovarian Cancers: A Study in the Indian Population.
Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment.
MicroRNA?655 inhibits cell proliferation and invasion in epithelial ovarian cancer by directly targeting vascular endothelial growth factor.
MIR-92 stimulates VEGF by inhibiting von Hippel-Lindau gene product in epithelial ovarian cancer.
Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells.
Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer.
Nerve Growth Factor Stimulates Cellular Proliferation of Human Epithelial Ovarian Cancer.
NGF/TRKA Decrease miR-145-5p Levels in Epithelial Ovarian Cancer Cells.
Over-Expression of Semaphorin4D, Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor Is Related to Poor Prognosis in Ovarian Epithelial Cancer.
Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer.
Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer.
Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis.
PARP-1 may be involved in angiogenesis in epithelial ovarian cancer.
Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer.
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.
Platelet-derived growth factor-D expression mediates the effect of differentiated degree on prognosis in epithelial ovarian cancer.
Prechemotherapy serum levels of CD105, transforming growth factor beta2, and vascular endothelial growth factor are associated with prognosis in patients with advanced epithelial ovarian cancer treated with cytoreductive surgery and platinum-based chemotherapy.
Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer.
Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer.
Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor.
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
Reactive oxygen species regulate FSH-induced expression of vascular endothelial growth factor via Nrf2 and HIF1? signaling in human epithelial ovarian cancer.
Role of lymphangiogenesis in epithelial ovarian cancer.
Serum albumin and vascular endothelial growth factor in epithelial ovarian cancer: looking at adnexal tumor drainage.
Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome.
Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer.
The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer.
The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.
The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer.
The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis.
The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer.
Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer.
Tyrosine kinase A receptor (trkA): A potential marker in epithelial ovarian cancer.
Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas.
Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer.
Vascular Endothelial Growth Factor (VEGF) Polymorphisms and Serum VEGF Levels in Women With Epithelial Ovarian Cancer, Benign Tumors, and Healthy Ovaries.
Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients.
Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue.
Vascular endothelial growth factor D and intratumoral lymphatics as independent prognostic factors in epithelial ovarian carcinoma.
Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
Vascular endothelial growth factor polymorphisms and a synchronized examination of plasma and tissue expression in epithelial ovarian cancers.
Vascular endothelial growth factor serum concentrations in ovarian cancer.
Vascular endothelial growth factor staining and elevated INR in advanced epithelial ovarian carcinoma.
Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma.
VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer.
VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma.
[Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value]
[Experimental study of anti-VEGF hairpin ribozyme gene inhibiting expression of VEGF and proliferation of ovarian cancer cells]
[Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer]
[Roles of vascular endothelial growth factor and platelet-derived growth factor in lymphangiogenesis in epithelial ovarian carcinoma.]
[The diagnostic and prognostic values of assay of serum vascular endothelial growth factor in epithelial ovarian cancer]
[Tumor-infiltrating dendritic cells in epithelial ovarian carcinoma and correlation with the expression of vascular endothelial growth factor]
Carcinoma, Pancreatic Ductal
Evaluation of blood flow in pancreatic ductal carcinoma using contrast-enhanced, wide-band Doppler ultrasonography: correlation with tumor characteristics and vascular endothelial growth factor.
Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival.
Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity.
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma.
Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: an in vitro and in vivo study.
Carcinoma, Papillary
Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour.
Delta-like 4/Notch pathway is differentially regulated in benign and malignant thyroid tissues.
Expression of the von Hippel-Lindau Tumor Suppressor Gene in Nonneoplastic and Neoplastic Lesions of the Thyroid.
Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells.
Papillary thyroid carcinoma with heterotopic ossification is a special subtype with extensive progression.
[Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid.]
Carcinoma, Renal Cell
10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma.
A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.
A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma.
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
A phase II study of thalidomide in advanced metastatic renal cell carcinoma.
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.
A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.
A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer.
A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma.
Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis.
Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?
Advances in treatment of metastatic renal cell carcinoma.
An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.
Analysis of efficacy of sorafenib combined with vascular endothelial growth factor inhibitor on renal cell carcinoma.
Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
Angiogenesis and Expression of Vascular Endothelial Growth Factor, Tumour Necrosis Factor-? and Hypoxia Inducible Factor-1? in Canine Renal Cell Carcinoma.
Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases.
Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma.
Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
Anterior gradient 2 promotes tumorigenesis through upregulation of CCAAT-enhancer binding protein beta and hypoxia-inducible factor-2? and subsequent secretion of interleukin-6, interleukin-8, and vascular endothelial growth factor in the Caki-1 clear cell renal cell carcinoma cell line.
Anti-angiogenesis approach to genitourinary cancer treatment.
Anti-Angiogenic Drugs in the Treatment of Metastatic Renal Cell Carcinoma:Advances in Clinical Application.
Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.
Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results.
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.
Association between SNPs in vascular endothelial growth factor polymorphisms and risk of renal cell carcinoma: a case-control study.
Association between three VEGF polymorphisms and renal cell carcinoma susceptibility: a meta-analysis.
Association between vascular endothelial growth factor gene polymorphisms and the risk and prognosis of renal cell carcinoma: A systematic review and meta-analysis.
Association of Vascular Endothelial Growth Factor Gene Polymorphism With Renal Cell Carcinoma Risk.
Association of vascular endothelial growth factor polymorphisms with clinical outcome of renal cell carcinoma patients.
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas.
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
Axitinib plasma pharmacokinetics and ethnic differences.
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.
Axitinib-induced acute pancreatitis: a case report.
Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis.
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma.
Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.
Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond.
Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Cabozantinib for the treatment of renal cell carcinoma.
Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.
CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value.
Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: Feasibility and Clinical Outcome.
Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma.
Circulating proteins as potential biomarkers of sunitinib and interferon-? efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Clinical pharmacology of axitinib.
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).
Clinical significance of urinary vascular endothelial growth factor and microvessel density in patients with renal cell carcinoma.
Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial.
Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas.
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Advanced Renal Cell Carcinoma.
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.
Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.
Correlation of vascular endothelial growth factor and hypoxia-inducible factor-1? expression with pathological renal artery changes in patients with renal cell carcinoma.
Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.
Current management and future perspectives of metastatic renal cell carcinoma.
Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells.
Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma.
Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.
Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma.
Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
Downregulation of microRNA-206 suppresses clear cell renal carcinoma proliferation and invasion by targeting vascular endothelial growth factor A.
Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers.
Editorial Comment on: Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas.
Effect of axitinib on the QT interval in healthy volunteers.
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.
Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-tyrosine Kinase Inhibitor.
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial.
Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Efficacy of Everolimus in Patients with Advanced Renal Cell Carcinoma Refractory or Intolerant to VEGFR-TKIs and Safety Compared with Prior VEGFR-TKI Treatment.
Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.
Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer.
Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane.
Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding.
Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma.
Evaluation of plasma and tissue S100A4 protein and mRNA levels as potential markers of metastasis and prognosis in clear cell renal cell carcinoma.
Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma.
Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study.
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T.
Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
Everolimus.
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?
Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.
Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma.
Expression and significance of FOXP1, HIF-1a and VEGF in renal clear cell carcinoma.
Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Expression of 4E-BP1 and phospho-4E-BP1 correlates with the prognosis of patients with clear cell renal carcinoma.
Expression of angiogenic factors is increased in metastasised renal cell carcinomas.
Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis.
Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice.
Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with pathological parameters and prognosis.
Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression.
Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement.
Expression of vascular endothelial growth factor in renal cell carcinomas.
Expression of vascular endothelial growth factor protein in human renal cell carcinoma.
Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma.
EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma.
First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.
First-line vascular endothelial growth factor inhibitors for advanced renal cell carcinoma and the impact of new agents entering the treatment paradigm.
First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma.
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Genomic Fabric Remodeling in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): A New Paradigm and Proposal for a Personalized Gene Therapy Approach.
Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial.
Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes.
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth factor in patients with renal cell carcinoma.
Histopathological analysis of angiogenic factors in renal cell carcinoma.
How far is the horizon? From current targets to future drugs in advanced renal cancer.
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents.
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma.
Identification of aryl hydrocarbon receptor signaling pathways altered in TCDD-treated red seabream embryos by transcriptome analysis.
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.
Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma.
Immunologics and Chemotherapeutics for Renal Cell Carcinoma.
Impact of Vascular Endothelial Growth Factor Gene Polymorphisms and Their Interactions with Environmental Factors on Susceptibility to Renal Cell Carcinoma.
Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma.
In Vitro Kinetic Characterization of Axitinib Metabolism.
Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma.
Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma.
Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor.
Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma.
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.
Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk.
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: Implications for alternative response criteria.
Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors.
Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?
Kidney cancer: current and novel treatment options.
Kidney injury during VEGF inhibitor therapy.
Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets.
Kinase inhibitors in the treatment of renal cell carcinoma.
Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
Lentivirus-Mediated RNAi Silencing of VEGF Inhibits Angiogenesis and Growth of Renal Cell Carcinoma in a Nude Mouse Xenograft Model.
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy.
Long-lasting response with polycythemia to third-line axitinib treatment in metastatic renal cell carcinoma: Very rare case presentation.
Loss of expression of TIMP3 in clear cell renal cell carcinoma.
Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.
Management of Metastatic Renal Cell Carcinoma with Variant Histologies.
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.
Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.
Maspin expression in renal cell carcinoma and its correlation with clinicopathologic parameters.
Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab.
Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.
Metastatic renal cell carcinoma: many treatment options, one patient.
Molecular markers to predict response to therapy.
Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Monitoring Anti-Angiogenic Therapy in Colorectal Cancer Murine Model using Dynamic Contrast-Enhanced MRI - Comparing Pixel-by-Pixel with Region of Interest Analysis.
Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments.
Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial ?5 integrin.
New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib.
New agents and new targets for renal cell carcinoma.
New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
Non-clear cell renal cancer: features and medical management.
Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib.
Notice of retraction: "Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development" (BJUI, Volume 96, Issue 3, pages 286 – 290).
Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma.
Novel concepts of antiangiogenic therapies in metastatic renal cell cancer.
Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications.
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Overview of current and future systemic therapy for metastatic renal cell carcinoma.
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.
Paraneoplastic hormones: parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma.
Paraneoplastic symptoms: Cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma.
Pazopanib-Induced Severe Acute Pancreatitis.
Pazopanib.
Perioperative Therapy in Renal Cell Carcinoma: What Do We Know, What Have We Learned, What's Next?
Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib?
Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma.
Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma.
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma.
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus.
Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases.
Pneumatocele during sorafenib therapy: first report of an unusual complication.
Population pharmacokinetic analysis of axitinib in healthy volunteers.
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Predictive role of vascular endothelial growth factor polymorphisms in the survival of renal cell carcinoma patients.
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib.
Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients.
Predictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomas.
Predictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomas: a case-control study.
Predictors of Response to Targeted Therapy in Renal Cell Carcinoma.
Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma.
Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study.
Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.
Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma.
Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens.
Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.
Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy.
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma.
Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels.
Prognostic significance of platelet-derived growth factor receptor-? expression in localized clear cell renal cell carcinoma.
Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor.
Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma.
Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma.
Prognostic Value of the VHL, HIF-1?, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-? (PDGF-?), and PDGF-? receptor expression in papillary renal cell carcinoma.
Prognostic Value of Vascular Endothelial Growth Factor A in the Prediction of the Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma.
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma.
Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation.
Quantification by competitive quantitative RT-PCR of VEGF121 and VEGF165 in renal cell carcinoma.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rap2B promotes angiogenesis via PI3K/AKT/VEGF signaling pathway in human renal cell carcinoma.
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;53:376-81.
Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.
Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.
RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Targeted Therapy.
Regulation of vascular endothelial growth factor transcription by endothelial PAS domain protein 1 (EPAS1) and possible involvement of EPAS1 in the angiogenesis of renal cell carcinoma.
Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Relationship between tumour angiogenesis and expression of cyclo-oxygenase-2 and vascular endothelial growth factor-A in human renal cell carcinoma.
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.
Renal cell carcinoma.
Renal cell carcinoma: An update for the practicing urologist.
Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
Renal cell carcinoma: relevance of angiogenetic factors.
Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.
Resveratrol promotes regression of renal carcinoma cells via a renin-angiotensin system suppression-dependent mechanism.
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated With Targeted Therapies.
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.
RNAi-mediated knockdown of vascular endothelial growth factor inhibits vascularization and tumor growth in renal cell carcinoma.
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway.
Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.
Serologic angiogenesis factors and microvascular density in renal cell carcinoma: two independent parameters.
Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b.
Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma.
Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer.
Serum vascular endothelial growth factor is a candidate biomarker of renal cell carcinoma in hemodialysis patients.
Signaling inhibitors in metastatic renal cell carcinoma.
Single nucleotide polymorphisms in the 3' untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma.
Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines.
Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study.
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.
Sorafenib stimulates human skin type mast cell degranulation and maturation.
Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.
STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells.
SU11248 and AG013736: current data and future trials in renal cell carcinoma.
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: Is this an anti-angiogenic potentiation of cancer?
Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report.
Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer.
Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations.
Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis.
Targeted therapy for metastatic renal cell carcinoma.
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions.
Targeted therapy in renal cell carcinoma.
Targeted therapy in the treatment of metastatic renal cell cancer.
Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
Targeting Molecular Pathways in Intracranial Metastatic Disease.
Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma.
Targeting vascular endothelial growth factor in renal cell carcinoma.
Temsirolimus : a safety and efficacy review.
The association between age-related macular degeneration and renal cell carcinoma: a nested case-control study.
The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis.
The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor.
The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.
The effects of RNA interference mediated VEGF gene silencing on biological behavior of renal cell carcinoma and transplanted renal tumor in nude mice.
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.
The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma.
The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma.
The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.
The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy.
The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition.
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.
The lymphatic system and its specific growth factor vascular endothelial growth factor C in kidney tissue and in renal cell carcinoma.
The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis.
The prospects of pazopanib in advanced renal cell carcinoma.
The Relationship of Vascular Endothelial Growth Factor and Coagulation Factor (Fibrin and Fibrinogen) Expression in Clear Cell Renal Cell Carcinoma.
The role of vascular endothelial growth factor in kidney and prostate cancer.
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail.
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma.
Thrombospondin-1, vascular endothelial growth factor expression and microvessel density in renal cell carcinoma and their relationship with multifocality.
Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma.
TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1?-p300 Binding in Renal Cell Carcinoma.
Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma.
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
Treatment of renal cell carcinoma: Current status and future directions.
Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors.
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Treatment sequences for advanced renal cell carcinoma: A health economic assessment.
Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma.
Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib.
Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma.
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma.
Tumor-Infiltrating Lymphocytes Express Vascular Endothelial Growth Factor in Renal Cell Carcinomas.
Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma.
Up-Regulation of Vascular Endothelial Growth Factor-D Expression in Clear Cell Renal Cell Carcinoma by CD74: A Critical Role in Cancer Cell Tumorigenesis.
Update on immunotherapy for renal cancer.
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: A preliminary analysis.
Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Vascular endothelial growth factor (VEGF) receptor antibody bevacizumab (avastin) induces regression of renal cell carcinoma in an adolescent resulting in residual tumorectomy.
Vascular endothelial growth factor - its relation to neovascularization and their significance as prognostic factors in renal cell carcinoma.
Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma.
Vascular endothelial growth factor as a biomarker for endostatin gene therapy.
Vascular endothelial growth factor as prognostic factor in renal cell carcinoma.
Vascular endothelial growth factor expression is increased in renal cell carcinoma.
Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas.
Vascular endothelial growth factor gene polymorphisms and renal cell carcinoma: A systematic review and meta-analysis.
Vascular endothelial growth factor gene polymorphisms and the risk of renal cell carcinoma: Evidence from eight case-control studies.
Vascular Endothelial Growth Factor Inhibitor Therapy And Cardiovascular And Renal Damage In Renal Cell Carcinoma.
Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population.
VEGF spliced variants: possible role of anti-angiogenesis therapy.
VEGF-targeted therapy in metastatic renal cell carcinoma.
VEGF-targeted Therapy in Renal Cell Carcinoma: Active Drugs and Active Choices.
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.
VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations.
VEGFR-1 Expression Relates to Fuhrman Nuclear Grade of Clear Cell Renal Cell Carcinoma.
VEGFR3 and CD31 as Prognostic Factors in Renal Cell Cancer.
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer.
Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
[Correlation of multislice spiral CT findings with vascular endothelial growth factor expressions and microvessel density in renal cell carcinoma]
[Correlation of neovascularization and vascular endothelial growth factor in human renal cell carcinoma]
[Expression of hypoxia-inducible factor-1-alpha, hypoxia-inducible factor-2alpha and vascular endothelial growth factor in sporadic clear cell renal cell renal cell carcinoma and their significance in the pathogenesis thereof]
[Expressions of hypoxia inducible factor-1alpha and vascular endothelial growth factor in human renal cell carcinoma]
[Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
[Microvessel count and vascular endothelial growth factor in renal cell carcinoma]
[Mutation of von Hippel-Lindau gene and expression of vascular endothelial growth factor in sporadic clear cell renal cell carcinoma and their relationships to angiogenesis]
[Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor].
[Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma].
[Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway]
Carcinoma, Small Cell
Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.
VEGF-D as a marker in the aid of malignant metastatic pleural effusion diagnosis.
Carcinoma, Squamous Cell
A multicenter study on expressions of vascular endothelial growth factor, matrix metallopeptidase-9 and tissue inhibitor of metalloproteinase-2 in oral and maxillofacial squamous cell carcinoma.
Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma.
Angiogenic growth factors in tissue homogenates of HNSCC: expression pattern, prognostic relevance, and interrelationships.
Angiogenic switch occurs during the precancerous stage of human esophageal squamous cell carcinoma.
Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma.
Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.
Association of CXCR4, CCR7, VEGF-C and VEGF-D expression with lymph node metastasis in patients with cervical cancer.
Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells.
Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells.
Carcinoma of the parotid gland: developing prognostic indices.
Clinical Implications of VEGF and p53 Expression in Squamous Cell Carcinoma of the Cervix Treated with Radiation Therapy.
Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients.
Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas.
Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways.
Coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the esophagus.
Combination antiangiogenic therapy and radiation in head and neck cancers.
Correction: Simultaneous Expression of Furin and Vascular Endothelial Growth Factor in Human Oral Tongue Squamous Cell Carcinoma Progression.
Correlation Between Cyclo-oxygenase-2 and Vascular Endothelial Growth Factor Expression in Canine and Feline Squamous Cell Carcinomas.
Correlation between vascular endothelial growth factor C expression and prognosis in patients with esophageal squamous cell carcinomas after Ivor-Lewis esophagectomy.
Correlation between Vascular Endothelial Growth Factor C Expressior and Lymph Node Micrometastasis and Prognosis in Patients with pNO Esophageal Squamous Cell Carcinomas.
Correlation between vascular endothelial growth factor expression and presence of lymph node metastasis in advanced squamous cell carcinoma of the larynx.
Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous cell carcinoma.
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.
Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma.
Cytokines and tumor markers in potentially malignant disorders and oral squamous cell carcinoma: a pilot study.
Cytoplasmic neuropilin 2 is associated with metastasis and a poor prognosis in early tongue cancer patients.
Differential effects between cyclooxygenase-2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines.
Differing Expression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis.
Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
Efficacy and Safety of Image-Guided Intensity-Modulated Radiation Therapy and Volumetric Modulated Arc Therapy Combined with Paclitaxel Liposomes and Cisplatin for Locally Advanced Stage IIB-IIIB Cervical Cancer: A Retrospective Study at a Single Center.
El-Gazzar R, Macluskey M, Williams H, Ogden GR. Vascularity and expression of vascular endothelial growth factor in oral squamous cell carcinoma, resection margins, and nodal metastases. Br J Oral Maxillofac Surg 2006;44:193-7 [Epub 2005, August 10].
Elevated VEGF-D Modulates Tumor Inflammation and Reduces the Growth of Carcinogen-Induced Skin Tumors.
Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma.
Evidence for mRNA expression of vascular endothelial growth factor by X-ray irradiation in a lung squamous carcinoma cell line.
Expression and prognosis of CyclinA and CDK2 in patients with advanced cervical cancer after chemotherapy.
Expression of ?B-Crystallin and Vascular Endothelial Growth Factor in Conjunctival Squamous Cell Carcinoma.
Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma.
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
Expression of p53 oncoprotein increases intratumoral microvessel formation in human salivary gland carcinomas.
Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.
Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung.
Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities.
Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study.
Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis.
Expression of vascular endothelial growth factor in basal cell carcinoma and cutaneous squamous cell carcinoma of the head and neck.
Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin.
Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas.
Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma.
Expression of VEGF, HGF, IL-6, IL-8, MMP-9, Telomerase in Peripheral Blood of Patients with Head and Neck Squamous Cell Carcinoma.
Expression of VEGF-C/VEGFR-3 in human laryngeal squamous cell carcinomas and its significance for lymphatic metastasis.
Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.
Glycoprotein Nonmetastatic Melanoma Protein B as Potential Imaging Marker in Posttherapeutic Metastatic Head and Neck Cancer.
Head and neck squamous cell carcinoma lymphatic spread and survival: Relevance of vascular endothelial growth factor family for tumor evaluation.
Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma.
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
HIF-1? regulated tongue squamous cell carcinoma cell growth via regulating VEGF expression in a xenograft model.
High expression of CD105 as a prognostic predictor of early tongue cancer.
Histochemical study of vascular endothelial growth factor in squamous cell carcinoma of the esophagus.
Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF.
Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker.
Hypoxia correlates with angiogenesis in cervical cancers.
Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study.
IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma.
Immunoexpression of VEGFR-3, but not the immunoexpression of VEGF-C or lymphatic density, is correlated with metastasis in lower lip squamous cell carcinoma.
Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas.
Immunohistochemical expression of vascular endothelial growth factor correlates with positive surgical margins and recurrence in T1 and T2 squamous cell carcinoma (SCC) of the lower lip.
Immunohistochemical predictors in squamous cell carcinoma of the tongue and floor of the mouth.
In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Increased pro-angiogenic factors, infiltrating neutrophils and CD163(+) macrophages in bronchoalveolar lavage fluid from lung cancer patients.
Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma.
Inherent phenotypic plasticity facilitates progression of head and neck cancer: Endotheliod characteristics enable angiogenesis and invasion.
Inhibition of epidermoid carcinoma A431 cell growth and angiogenesis in nude mice by early and late treatment with a novel dextran derivative.
Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.
Intratumoral lymphangiogenesis of esophageal squamous cell carcinoma and relationship with regulatory factors and prognosis.
Irradiation-induced regulation of plasminogen activator inhibitor type-1 and vascular endothelial growth factor in six human squamous cell carcinoma lines of the head and neck.
Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells.
Loss of p16INK4a expression is associated with vascular endothelial growth factor expression in squamous cell carcinoma of the esophagus.
Lymphatic Vessel Density and Vascular Endothelial Growth Factor Expression in Squamous Cell Carcinomas of Lip and Oral Cavity: A Clinicopathological Analysis with Immunohistochemistry Using Antibodies to D2-40, VEGF-C and VEGF-D.
Metadherin Regulation of Vascular Endothelial Growth Factor Expression Is Dependent Upon the PI3K/Akt Pathway in Squamous Cell Carcinoma of the Head and Neck.
Modulation of cellular invasion by VEGF-C expression in squamous cell carcinoma of the head and neck.
Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas.
mTHPC-mediated Photodynamic Treatment Up-regulates the Cytokines VEGF and IL-1alpha.
Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review.
Overexpression of Antiangiogenic Vascular Endothelial Growth Factor Isoform and Splicing Regulatory Factors in Oral, Laryngeal and Pharyngeal Squamous Cell Carcinomas
Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development.
PDGF-D/PDGFR? promotes tongue squamous carcinoma cell (TSCC) progression via activating p38/AKT/ERK/EMT signal pathway.
Perfusion Estimated with Rapid Dynamic Contrast-Enhanced Magnetic Resonance Imaging Correlates Inversely with Vascular Endothelial Growth Factor Expression and Pimonidazole Staining in Head-and-Neck Cancer: A Pilot Study.
Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix.
Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma.
Poor prognostic clinicopathologic features correlate with VEGF expression but not with PTEN expression in squamous cell carcinoma of the larynx.
Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2.
Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
Proangiogenic effects of ionizing irradiation on squamous cell carcinoma of the hypopharynx.
Prognostic and predictive value of serum vascular endothelial growth factor (VEGF) in squamous cell carcinoma of the head and neck.
Prognostic impact of VEGF and FLT-1 receptor expression in patients with locally advanced squamous cell carcinoma of the head and neck.
Prognostic Role of Protease-Activated Receptors 1 and 4 in Resected Stage IB Non-Small-Cell Lung Cancer.
Prognostic Significance of Human Papillomavirus (HPV) Status and Expression of Selected Markers (HER2/neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on Outcome After (Chemo-) Radiotherapy in Patients with Squamous Cell Carcinoma of Uterine Cervix.
Prognostic significance of peritumoral lymphatic vessel density and vascular endothelial growth factor receptor 3 in invasive squamous cell cervical cancer.
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis.
Prognostic significance of vascular endothelial growth factor in squamous cell carcinomas of the tonsil in relation to human papillomavirus status and epidermal growth factor receptor.
Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus.
Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas.
Proliferation, angiogenesis and apoptosis-associated proteins are molecular targets for chemoprevention of MNNG-induced gastric carcinogenesis by ethanolic Ocimum sanctum leaf extract.
Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent.
Relative Expression of Vascular Endothelial Growth Factor Isoforms in Squamous Cell Carcinoma of the Head and Neck.
Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells.
Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma.
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence.
Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix.
Serum prognostic markers in head and neck cancer.
Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
Serum vascular endothelial growth factor in patients with head and neck squamous cell carcinoma.
Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma.
Significance of the expression of integrin ?1, VEGF and MVD in hypopharyngeal squamous cell carcinoma.
Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.
Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression.
Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma.
Targeting angiogenesis in head and neck cancer.
The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.
The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas.
The influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase-2 inhibition in head and neck squamous cell carcinoma cell lines.
The prognostic effect of VEGF expression in squamous cell carcinoma of the cervix treated with radiation therapy alone.
The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer.
The role of macrophages in angiogenesis. Comparison between HIV+ and HIV- populations with anal dysplasia and anal cancer.
The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients.
Time-Dependent Pretreatment with Bevacuzimab Increases Tumor Specific Uptake of Cetuximab in Preclinical Oral Cavity Cancer Studies.
Tissue microarray of head and neck squamous carcinoma: validation of the methodology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67.
Tobacco carcinogen mediated up-regulation of AP-1 dependent pro-angiogenic cytokines in head and neck carcinogenesis.
Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma.
Value of [18F]FDG PET radiomic features and VEGF expression in predicting pelvic lymphatic metastasis and their potential relationship in early-stage cervical squamous cell carcinoma.
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to Cisplatin and radiation in vivo and in vitro.
Vascular endothelial growth factor (VEGF) and microvessel density in squamous cell carcinomas of the larynx: an immunohistochemical study.
Vascular endothelial growth factor (VEGF) expression correlates with p53 and ki-67 expressions in tongue squamous cell carcinoma.
Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma.
Vascular endothelial growth factor and basic fibroblast growth factor are released by squamous cell carcinoma cells after irradiation and increase resistance to subsequent irradiation.
Vascular endothelial growth factor and dendritic cells in human squamous cell carcinoma of the oral cavity.
Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation.
Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck.
Vascular Endothelial Growth Factor Expression and Neovascularization in Non-Small Cell Lung Carcinoma.
Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck.
Vascular endothelial growth factor expression in head and neck squamous cell carcinoma.
Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma.
Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus.
Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells.
Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck.
Vascular Endothelial Growth Factor-D (VEGF-D) is Elevated in Bronchoalveolar Lavage Fluid of Patients with Lung Squamous Carcinoma.
VEGF and ki 67 expression in squamous cell carcinoma of the tongue: An immunohistochemical and computerized image analysis study.
VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis.
[Antiangiogenic and antitumor effects of vascular endothelial growth factor small interfering RNA on Tca8113 human tongue squamous cell carcinoma xenografts in vivo]
[Cloning and sequencing of human vascular endothelial growth factor-C encoded cDNA]
[Effect of hypoxia inducible factor-1alpha on vascular endothelial growth factor expression in human tongue squamous carcinoma cells (Tca8113) under hypoxia]
[EphA2 mediated vascular endothelial growth factor expression via the p38 MAPK signaling pathway in squamous cell carcinoma of the head and neck].
[Experimental study on the effect of VEGF165 antisense RNA on human squamous cell carcinoma of esophagus]
[Expression of vascular endothelial growth factor C in laryngeal squamous carcinoma and its role in lymphatic metastasis]
[Expression of VEGF-C and VEGFR-3 in human laryngeal squamous cell carcinomas and cervical metastatic lymph node tissues]
[Interaction of vascular endothelial growth factor-C over-expression with tongue squamous cell carcinoma cell line Tca8113 with peri-carcinoma lymphatics]
[Molecular markers of carcinogenesis in the diagnostics of cervical cancer]
[Prokaryotic expression of vascular endothelial growth factor-C]
[Relationship between clinicopathologic characteristics and expression of VEGF-C and VEGF-D in esophageal squamous cancer]
[Short hairpin RNA silencing of vascular endothelial growth factor, telomerase reverse transcriptase, and Bcl-xl expression in human laryngeal squamous carcinoma xenografted in nude mice]
[Study on the relationship between angiogenesis and cervical lymphatic metastasis in head and neck squamous cell carcinomas]
[Suppression of vascular endothelial growth factor expression by vector-based small interfering RNA in human tongue squamous carcinoma cell line Tca8113]
[The correlation of vascular endothelial growth factor with angiogenesis and p53 gene in laryngeal squamous cell carcinoma]
[The expression of VEGF and iNOS in laryngeal squamous cell carcinoma and its clinical significance]
Carcinoma, Transitional Cell
Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma.
Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder.
Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Epigenetic regulation of vascular endothelial growth factor a dynamic expression in transitional cell carcinoma.
Expression of brain?specific angiogenesis inhibitor?1 and association with p53, microvessel density and vascular endothelial growth factor in the tissue of human bladder transitional cell carcinoma.
Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer.
Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
Expression of VEGF in Urinary Bladder Transitional Cell Carcinoma in an Iraqi Population Subjected to Depleted Uranium: An Immunohistochemical Study.
Intratumoral lymphatics and lymphatic vessel invasion detected by d2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma.
Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma.
Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder.
The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.
The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.
Tumor-Infiltrating Lymphocytes Express Vascular Endothelial Growth Factor in Renal Cell Carcinomas.
Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer.
Carcinosarcoma
Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements.
TNP-470 inhibits growth and the production of vascular endothelial growth factor of uterine carcinosarcoma cells in vitro.
Cardio-Renal Syndrome
Value of Placental Growth Factor as a Predictor of Adverse Events During the Acute Phase of Acute Decompensated Heart Failure.
Cardiomegaly
Aryl hydrocarbon receptor null mice develop cardiac hypertrophy and increased hypoxia-inducible factor-1alpha in the absence of cardiac hypoxia.
Cardiac hypertrophy in chronically anemic fetal sheep: Increased vascularization is associated with increased myocardial expression of vascular endothelial growth factor and hypoxia-inducible factor 1.
Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
Copper stimulates growth of human umbilical vein endothelial cells in a vascular endothelial growth factor-independent pathway.
Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway.
Down-regulation of hypoxia-inducible factor-1 alpha and vascular endothelial growth factor by HEXIM1 attenuates myocardial angiogenesis in hypoxic mice.
Effect of genetic polymorphisms of vascular endothelial growth factor on left ventricular hypertrophy in patients with systemic hypertension.
Expression of vascular endothelial growth factor during the development of cardiac hypertrophy in spontaneously hypertensive rats.
Identification of drug repurposing candidates based on a miRNA-mediated drug and pathway network for cardiac hypertrophy and acute myocardial infarction.
miR-374 promotes myocardial hypertrophy by negatively regulating vascular endothelial growth factor receptor-1 signaling.
Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats: the critical role of ASK1 and VEGF.
Placental growth factor as a protective paracrine effector in the heart.
Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload.
Cardiomyopathies
Cardiomyopathy in the mouse model of Duchenne muscular dystrophy caused by disordered secretion of vascular endothelial growth factor.
Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy.
Decreased cardiac expression of vascular endothelial growth factor and redox imbalance in murine diabetic cardiomyopathy.
Gene electro transfer of plasmid encoding vascular endothelial growth factor for enhanced expression and perfusion in the ischemic swine heart.
Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure.
Impact of cardiac transplantation on molecular pathology of ET-1, VEGF-C, and mitochondrial metabolism and morphology in dilated versus ischemic cardiomyopathic patients.
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.
Inhibition of the Notch1 pathway induces peripartum cardiomyopathy.
Low-energy extracorporeal shock wave ameliorates ischemic acute kidney injury in rats.
Persistent plasminogen activator inhibitor 1 gene expression in cardiac transplant recipients with idiopathic dilated cardiomyopathy.
Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis.
Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy.
Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure.
Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study.
Vascular endothelial growth factor association with angiopoietin 1 promotes improvement in ventricular function after ischemic cardiomyopathy induced in mini pigs.
Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients.
Cardiomyopathy, Dilated
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) inhibition of coronary vasculogenesis is mediated, in part, by reduced responsiveness to endogenous angiogenic stimuli, including vascular endothelial growth factor A (VEGF-A).
Autoantibodies in dilated cardiomyopathy induce vascular endothelial growth factor expression in cardiomyocytes.
Identification of a specific pattern of downregulation in expression of isoforms of vascular endothelial growth factor in dilated cardiomyopathy.
Impact of cardiac transplantation on molecular pathology of ET-1, VEGF-C, and mitochondrial metabolism and morphology in dilated versus ischemic cardiomyopathic patients.
Persistent plasminogen activator inhibitor 1 gene expression in cardiac transplant recipients with idiopathic dilated cardiomyopathy.
Synthetic prostacyclin agonist, ONO1301, enhances endogenous myocardial repair in a hamster model of dilated cardiomyopathy: a promising regenerative therapy for the failing heart.
Transplantation of induced bone marrow mesenchymal stem cells improves the cardiac function of rabbits with dilated cardiomyopathy via upregulation of vascular endothelial growth factor and its receptors.
Cardiomyopathy, Hypertrophic
Vascular Endothelial Growth Factor Is Associated with the Morphologic and Functional Parameters in Patients with Hypertrophic Cardiomyopathy.
Cardiotoxicity
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Cardiotoxicity of Novel Targeted Chemotherapeutic Agents.
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.
Chitosan and Curcumin Nanoformulations against Potential Cardiac Risks Associated with Hydroxyapatite Nanoparticles in Wistar Male Rats.
Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers.
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Molecular biomarkers of cantharidin-induced cardiotoxicity in Sprague-Dawley rats: Troponin T, vascular endothelial growth factor and hypoxia inducible factor-1?.
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.
Resveratrol attenuates doxorubicin-induced cardiotoxicity in rats by up-regulation of vascular endothelial growth factor B.
Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress.
Surviving Cancer without a Broken Heart.
Cardiovascular Abnormalities
Maternal diabetes: effects on embryonic vascular development--a vascular endothelial growth factor-A-mediated process.
Cardiovascular Diseases
10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb.
Aluminum Metasurface with Hybrid Multipolar Plasmons for 1000-Fold Broadband Visible Fluorescence Enhancement and Multiplexed Biosensing.
Angiogenesis. Angiogenic therapy using fibroblast growth factors and vascular endothelial growth factors for ischemic vascular lesions.
Angiogenic effect of the aqueous extract of Cynodon dactylon on human umbilical vein endothelial cells and granulation tissue in rat.
Angiopoietin-2, Angiopoietin-1 and subclinical cardiovascular disease in Chronic Kidney Disease.
Aspirin decreases vascular endothelial growth factor release during myocardial ischemia.
Association between VEGF polymorphisms and homocysteine levels in patients with ischemic stroke and silent brain infarction.
Cancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities.
Chronic Psychological Stress Accelerates Vascular Senescence and Impairs Ischemia-Induced Neovascularization: The Role of Dipeptidyl Peptidase-4/Glucagon-Like Peptide-1-Adiponectin Axis.
Circulating vascular endothelial growth factor and the risk of cardiovascular events.
CORRELATION OF INCREASED SERUM ADIPSIN WITH INCREASED CARDIOVASCULAR RISKS IN ADULT PATIENTS WITH GROWTH HORMONE DEFICIENCY.
Correlations Between Serum Cholesterol and Vascular Lesions in Fabry Disease Patients.
Detection of significantly high vitreous concentrations of fatty acid-binding protein 4 in patients with proliferative diabetic retinopathy.
Does gene therapy become pharmacotherapy?
Enhancement effect of ultrasound-induced microbubble cavitation on branched polyethylenimine-mediated VEGF(165) transfection with varied N/P ratio.
Further evidence for the contribution of the vascular endothelial growth factor gene in coronary artery disease susceptibility.
Gene therapy in vascular medicine: recent advances and future perspectives.
Gene transfer of vascular endothelial growth factor and endothelial nitric oxide synthase--implications for gene therapy in cardiovascular diseases.
Human vascular endothelial growth factor B: characterization of recombinant isoforms and generation of neutralizing monoclonal antibodies.
Hypoxia-inducible VEGF gene delivery to ischemic myocardium using water-soluble lipopolymer.
Impaired myocardial performance in a normotensive rat model of intrauterine growth restriction.
Inhibition of vascular endothelial growth factor activity by transfection with the soluble FLT-1 gene.
Inhibition of VEGFR-2 Phosphorylation and Effects on Downstream Signaling Pathways in Cultivated Human Endothelial Cells by Stilbenes from Vitis Spp.
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Obstructive sleep-disordered breathing and plasma levels of vascular endothelial growth factor in children.
PDGF-C and PDGF-D signaling in vascular diseases and animal models.
Perspective in progress of cardiovascular gene therapy.
Pharmacology down under in 2005--focus on targets.
Platelet-derived growth factor-C and -D in the cardiovascular system and diseases.
Polyethylenimine-mediated gene delivery into human bone marrow mesenchymal stem cells from patients.
Possible association between circulating vascular endothelial growth factor and oxidative stress markers in hemodialysis patients.
Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies.
Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling.
Protein kinase D up-regulates transcription of VEGF receptor-2 in endothelial cells by suppressing nuclear localization of the transcription factor AP2?.
Proteome-wide prediction of targets for aspirin: new insight into the molecular mechanism of aspirin.
Radiotherapy, chemotherapy and atherosclerosis.
Recent progress in gene therapy for cardiovascular disease.
Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.
Resveratrol inhibits angiogenic response of cultured endothelial F-2 cells to vascular endothelial growth factor, but not to basic fibroblast growth factor.
Sensitive, quantitative, and high-throughput detection of angiogenic markers using shape-coded hydrogel microparticles.
Serum from young, sedentary adults who underwent passive heat therapy improves endothelial cell angiogenesis via improved nitric oxide bioavailability.
Six Novel Loci Associated with Circulating VEGF Levels Identified by a Meta-analysis of Genome-Wide Association Studies.
Supplementation with ?-Lipoic Acid Alone or in Combination with Eicosapentaenoic Acid Modulates the Inflammatory Status of Healthy Overweight or Obese Women Consuming an Energy-Restricted Diet.
Suppressed Production of Soluble Fms-Like Tyrosine Kinase-1 Contributes to Myocardial Remodeling and Heart Failure.
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy?
Vascular endothelial growth factor A and cardiovascular disease in rheumatoid arthritis patients.
Vascular endothelial growth factor A gene expression level is higher in patients with major depressive disorder and not affected by cigarette smoking, hyperlipidemia or treatment with statins.
Vascular endothelial growth factor in serum indicates cardiovascular risk in urology patients.
Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance.
Vascular endothelial growth factor-modified macrophages accelerate reendothelialization and attenuate neointima formation after arterial injury in atherosclerosis-prone mice.
Vascular protection: A novel nonangiogenic cardiovascular role for vascular endothelial growth factor.
VEGFR endocytosis regulates the angiogenesis in a mouse model of hindlimb ischemia.
[Changes and clinical implications of the levels of serum NO and VEGF and HIF-1alpha in patients with obstructive sleep apnea-hypopnea syndrome].
[Therapeutic angiogenesis for ischemic diseases]
[Vascular endothelial growth factor and its application in therapy of cardiovascular diseases]
Caroli Disease
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases.
Carotid Artery Diseases
Expression of hypoxia-inducible angiogenic proteins (hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and E26 transformation-specific-1) and plaque hemorrhage in human carotid atherosclerosis.
Vascular Endothelial Growth Factor Gene Polymorphism (rs2010963) and Its Receptor, Kinase Insert Domain-Containing Receptor Gene Polymorphism (rs2071559), and Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus.
Carotid Stenosis
Changes in circulating levels of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 after carotid endarterectomy.
Circulating levels of interleukin-8 and vascular endothelial growth factor in patients with carotid stenosis.
Microvessel Density But Not Neoangiogenesis Is Associated with (18)F-FDG Uptake in Human Atherosclerotic Carotid Plaques.
Production of IL-8, VEGF and Elastase by Circulating and Intraplaque Neutrophils in Patients with Carotid Atherosclerosis.
Carpal Tunnel Syndrome
The role of neoangiogenesis and vascular endothelial growth factor in the development of carpal tunnel syndrome in patients with diabetes.
Castleman Disease
A rare case of renal thrombotic microangiopathy associated with Castleman's disease.
Association of vascular endothelial growth factor and renal thrombotic microangiopathy-like lesions in patients with Castleman's disease.
Castleman Disease: A Rare Condition with Endocrine Manifestations.
Expression of vascular endothelial growth factor in lymphomas and Castleman's disease.
Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease.
Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
POEMS syndrome associated with plasmacytoma of the clivus: "Time discovers the truth".
POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management.
POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management.
POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management.
POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.
POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management.
POEMS syndrome: update on diagnosis, risk-stratification, and management.
Secretion of interleukin-6 and vascular endothelial growth factor by spindle cell sarcoma complicating Castleman's disease (so-called 'vascular neoplasia').
TAFRO Syndrome With Kidney Involvement: A Case Series of Patients With Kidney Biopsies.
Thrombosis revealing POEMS syndrome. About a case.
[POEMS syndrome: Diagnosis, stratification, treatments].
[What's new in internal medicine?].
Cat-Scratch Disease
Differential effects of Bartonella henselae on human and feline macro- and micro-vascular endothelial cells.
Cataract
Aortitis syndrome (Takayasu's arteritis) with cataract and elevated serum level of vascular endothelial growth factor.
Aqueous humor cytokine levels in patients with diabetic macular edema refractory to anti-VEGF treatment.
Aqueous Humor Levels of Cytokines in Patients with Age-Related Macular Degeneration.
Aqueous Vascular Endothelial Growth Factor as a Predictor of Macular Thickening Following Cataract Surgery in Patients with Diabetes Mellitus.
Concentrations of Selected Cytokines and Vascular Endothelial Growth Factor in Aqueous Humor and Serum of Diabetic Patients.
Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema.
Expression levels of aldose reductase enzyme, vascular endothelial growth factor, and intercellular adhesion molecule-1 in the anterior lens capsule of diabetic cataract patients.
Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma.
Intracameral Interleukin 1?, 6, 8, 10, 12p, Tumor Necrosis Factor ? and Vascular Endothelial Growth Factor and Axial Length in Patients with Cataract.
Platelet-derived growth factor D, tissue-specific expression in the eye, and a key role in control of lens epithelial cell proliferation.
Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy.
Safety and Effectiveness of Cataract Surgery with Simultaneous Intravitreal Anti-VEGF in Patients with Previously Treated Exudative Age-Related Macular Degeneration.
Six-month changes in cytokine levels after intravitreal bevacizumab injection for diabetic macular oedema and macular oedema due to central retinal vein occlusion.
The potential health benefits of dietary natural plant products in age related eye diseases.
The Risk of Posterior Capsule Rupture during Phacoemulsification Cataract Surgery in Eyes with Previous Intravitreal Anti Vascular Endothelial Growth Factor Injections.
Vascular endothelial growth factor in anterior chamber liquid patients with diabetic retinopathy, cataract and neovascular glaucoma.
Vascular endothelial growth factor in diabetic and nondiabetic canine cataract patients.
Vascular Endothelial Growth Factor is Increased in Aqueous Humor of Acute Primary Angle-Closure Eyes.
Central Nervous System Diseases
Vascular endothelial growth factor (VEGF) is increased in serum, but not in cerebrospinal fluid in HIV associated CNS diseases.
Vascular endothelial growth factor concentrations in the cerebrospinal fluid of dogs with neoplastic or inflammatory central nervous system disorders.
Vascular endothelial growth factor in cerebral ischemia.
Central Nervous System Neoplasms
The expression of Cyclin D1, VEGF, EZH2, and H3K27me3 in Atypical Teratoid/Rhabdoid Tumors of the CNS: A Possible Role in Targeted Therapy.
Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas.
Vascular endothelial growth factor mRNA expression and peritumoral edema in canine primary central nervous system tumors.
Central Nervous System Vascular Malformations
A pivotal role of the vascular endothelial growth factor signaling pathway in the formation of venous hypertension-induced dural arteriovenous fistulas.
Expression of angiogenic growth factor in the rat DAVF model.
Plasma vascular endothelial growth factor and serum soluble angiopoietin receptor sTIE-2 in patients with dural arteriovenous fistulas: a pilot study.
[Vascular endothelial growth factor expression in the rat dural arteriovenous fistula model]
Central Serous Chorioretinopathy
ANTI-VEGF THERAPY VERSUS PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO CENTRAL SEROUS CHORIORETINOPATHY.
Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy.
Cerebral Hemorrhage
Buyang huanwu decoction promotes angiogenesis via vascular endothelial growth factor receptor-2 activation through the PI3K/Akt pathway in a mouse model of intracerebral hemorrhage.
High serum levels of growth factors are associated with good outcome in intracerebral hemorrhage.
Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage.
Polymorphisms of VEGFA gene and susceptibility to hemorrhage risk of brain arteriovenous malformations in a Chinese population.
Possible pathophysiological role of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in metastatic brain tumor-associated intracerebral hemorrhage.
Primary Central Nervous System Lymphoma Presenting as Growing Intracerebral Hemorrhage.
Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway.
Protection of granulocyte-colony stimulating factor to hemorrhagic brain injuries and its involved mechanisms: effects of vascular endothelial growth factor and aquaporin-4.
Protection of Vascular Endothelial Growth Factor to Brain Edema Following Intracerebral Hemorrhage and Its Involved Mechanisms: Effect of Aquaporin-4.
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;53:376-81.
Role for HIF-1? and Downstream Pathways in Regulating Neuronal Injury after Intracerebral Hemorrhage in Diabetes.
The potential role of vascular endothelial growth factor as a new biomarker in severe intracerebral hemorrhage.
VEGF receptor-2 variants are associated with susceptibility to stroke and recurrence.
[Effects of the scalp acupuncture at baihui (DU20) through qubin (GB7) on the expressions of GDNF VEGF in the brain tissue of rats with acute intracerebral hemorrhage].
Cerebral Infarction
Bone marrow stromal cell transplantation through tail vein injection promotes angiogenesis and vascular endothelial growth factor expression in cerebral infarct area in rats.
Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct.
Effects of dl-3-n-butylphthalide on serum VEGF and bFGF levels in acute cerebral infarction.
Granulocyte colony-stimulating factor and stromal cell-derived factor-1 combination therapy: A more effective treatment for cerebral ischemic stroke.
Heat shock protein 70 expression in the brain of rats with cerebral infarction after receiving vascular endothelial growth factor 165 gene therapy.
Hypoxic preconditioning stimulates angiogenesis in ischemic penumbra after acute cerebral infarction.
MiR-210 suppresses neuronal apoptosis in rats with cerebral infarction through regulating VEGF-notch signaling pathway.
MiR-940 regulates angiogenesis after cerebral infarction through VEGF.
Neuroprotection by platelet-activating factor acetylhydrolase in a mouse model of transient cerebral ischemia.
Neuroprotective effect of ischemic preconditioning in focal cerebral infarction: relationship with upregulation of vascular endothelial growth factor.
Overexpression of lncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-?B signaling pathway in a rat model.
Polymorphisms of human vascular endothelial growth factor gene are associated with acute cerebral infarction in the chinese population.
Protective Effect of Ad-VEGF-Bone Mesenchymal Stem Cells on Cerebral Infarction.
Protective effect of dl-3n-butylphthalide preconditioning on focal cerebral ischaemia-reperfusion injury in rats.
Transplantation of VEGF-mediated Bone Marrow Mesenchymal Stem Cells Promotes Functional Improvement in a Rat Acute Cerebral Infarction Model.
Vascular endothelial growth factor gene-transferred bone marrow stromal cells engineered with a herpes simplex virus type 1 vector can improve neurological deficits and reduce infarction volume in rat brain ischemia.
[Effect of skull acupuncture and scalp acupuncture on serum vascular endothelial growth factor in the patient of acute cerebral infarction]
[Effect of ultra-micronized Buyang Huanwu decoction on neurological function, quality of life, and serum vascular endothelial growth factor in patients convalescent from cerebral infarction.]
[Effects of dl-3n-butylphthalide on the expression of VEGF and bFGF in transient middle cerebral artery occlusion rats]
Cerebral Palsy
Neuroprotection of VEGF-expression neural stem cells in neonatal cerebral palsy rats.
Neuroprotective effect of tanshinone IIA weakens spastic cerebral palsy through inflammation, p38MAPK and VEGF in neonatal rats.
Response of the sensorimotor cortex of cerebral palsy rats receiving transplantation of vascular endothelial growth factor 165-transfected neural stem cells.
Cerebral Small Vessel Diseases
Salvianolic acid B recovers cognitive deficits and angiogenesis in a cerebral small vessel disease rat model via the STAT3/VEGF signaling pathway.
Cerebrovascular Disorders
Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease.
MAP3K6 Mutations in a Neurovascular Disease Causing Stroke, Cognitive Impairment, and Tremor.
Cerebrovascular Trauma
Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: framingham study.
VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway.
Cervical Intraepithelial Neoplasia
Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia.
Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia.
Increased vascular endothelial growth factor expression, CD3-positive cell infiltration, and oxidative stress in premalignant lesions of the cervix.
Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling.
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence.
The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma.
Vascular endothelial growth factor gene polymorphisms and risk of cervical intraepithelial neoplasia.
VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix.
Cheilitis
Evaluation of hypoxia, angiogenesis, and lymphangiogenesis in actinic cheilitis.
Cholangiocarcinoma
Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance.
Anticancer activity of streptochlorin, a novel antineoplastic agent, in cholangiocarcinoma.
Apatinib Inhibits Angiogenesis in Intrahepatic Cholangiocarcinoma by Regulating the Vascular Endothelial Growth Factor Receptor-2/Signal Transducer and Activator of Transcription Factor 3/Hypoxia Inducible Factor 1 Subunit Alpha Signaling Axis.
Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.
Effect of vascular endothelial growth factor-C expression on lymph node metastasis in human cholangiocarcinoma.
Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression.
Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor.
High expression of brain-derived neurotrophic factor in intrahepatic cholangiocarcinoma is associated with intraneural invasion and unfavorable prognosis.
Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma.
miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF).
Molecular Pathogenesis of Cholangiocarcinoma.
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Platelet-derived growth factor D: A new player in the complex cross-talk between cholangiocarcinoma cells and cancer-associated fibroblasts.
Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.
Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Quantitative analysis of VEGF-C mRNA of extrahepatic cholangiocarcinoma with real-time PCR using samples obtained during endoscopic retrograde cholangiopancreatography.
Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.
Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis.
Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells.
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.
Cholangitis
The Impact of Biliary Reconstruction Methods on Small Partial Liver Grafts.
Cholecystitis
[Expressions of VEGF-C and VEGF-D and their correlation with lymphangiogenesis and angiogenesis in gallbladder carcinoma]
Cholestasis
Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report.
Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis.
Cholestasis, Intrahepatic
Expression of vascular endothelial growth factor (VEGF) under hypoxia in placenta with intrahepatic cholestasis of pregnancy and its clinically pathological significance.
[Relationship of vascular endothelial growth factor with bile acid in intrahepatic cholestasis of pregnancy]
Cholesteatoma
Angiogenesis and angiogenic growth factors in middle ear cholesteatoma.
Effect of vascular endothelial growth factor on fibroblasts from external auditory canal cholesteatoma.
Expression of vascular endothelial growth factor in external auditory canal cholesteatoma.
[The significance of keratinocyte in hyperproliferation of middle ear cholesteatoma].
Cholesteatoma, Middle Ear
Angiogenesis and angiogenic growth factors in middle ear cholesteatoma.
[The significance of keratinocyte in hyperproliferation of middle ear cholesteatoma].
Chondroma
Hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in cartilage tumors.
Chondrosarcoma
Basic fibroblast growth factor induces VEGF expression in chondrosarcoma cells and subsequently promotes endothelial progenitor cells-primed angiogenesis.
Brain-derived neurotrophic factor increases vascular endothelial growth factor expression and enhances angiogenesis in human chondrosarcoma cells.
CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells.
CCL5 promotes VEGF-dependent angiogenesis by down-regulating miR-200b through PI3K/Akt signaling pathway in human chondrosarcoma cells.
CORR Insights®: MicroRNA regulates vascular endothelial growth factor expression in chondrosarcoma cells.
CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis.
Do Patient-derived Spheroid Culture Models Have Relevance in Chondrosarcoma Research?
Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells.
HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity.
Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth.
Hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in cartilage tumors.
MicroRNA regulates vascular endothelial growth factor expression in chondrosarcoma cells.
Vascular endothelial growth factor expression as a biomarker of prognosis in patients with chondrosarcoma, Ewing's sarcoma and osteosarcoma. Current concepts.
Vascular pattern in enchondroma and chondrosarcoma: clinical and immunohistologic study.
[Inflammation as molecular target in chondrosarcoma].
Chordoma
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomas.
Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.
Chorioamnionitis
Preterm premature rupture of membranes: vascular endothelial growth factor and its association with histologic chorioamnionitis.
Choriocarcinoma
Endogenous production of nitric oxide by vascular endothelial growth factor down-regulates proliferation of choriocarcinoma cells.
Hypoxia activates the human placental vascular endothelial growth factor system in vitro and in vivo: up-regulation of vascular endothelial growth factor in clinically relevant hypoxic ischemia in birth asphyxia.
Role of regulatory and angiogenic cytokines in invasion of trophoblastic cells.
Choroidal Neovascularization
?2-Adrenergic Receptor Antagonism Attenuates CNV Through Inhibition of VEGF and IL-6 Expression.
A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological Choroidal Neovascularization in Mice.
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.
AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat.
Activated Protein C (APC) and 3K3A-APC-Induced Regression of Choroidal Neovascularization (CNV) Is Accompanied by Vascular Endothelial Growth Factor (VEGF) Reduction.
Adeno-associated virus type 8 vector-mediated expression of siRNA targeting vascular endothelial growth factor efficiently inhibits neovascularization in a murine choroidal neovascularization model.
Analyzing Relative Blood Flow Speeds in Choroidal Neovascularization Using Variable Interscan Time Analysis OCT Angiography.
Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Annexin A2 promotes choroidal neovascularization by increasing vascular endothelial growth factor expression in a rat model of argon laser coagulation-induced choroidal neovascularization.
Antagonistic effects of exogenous Slit2 on VEGF-induced choroidal endothelial cell migration and tube formation.
Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications.
Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside.
Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration.
ANTI-VEGF THERAPY VERSUS PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO CENTRAL SEROUS CHORIORETINOPATHY.
Antiangiogenic effects of axitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on laser-induced choroidal neovascularization in mice.
Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice.
Antineovascular agents in the treatment of eye diseases.
Antiproliferative, Apoptotic, and Autophagic Activity of Ranibizumab, Bevacizumab, Pegaptanib, and Aflibercept on Fibroblasts: Implication for Choroidal Neovascularization.
Antivascular endothelial growth factor agents for neovascular age-related macular degeneration.
Aqueous Concentrations of Vascular Endothelial Growth Factor in Eyes with High Myopia with and without Choroidal Neovascularization.
Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Binding of Gtf2i-?/? transcription factors to the ARMS2 gene leads to increased circulating HTRA1 in AMD patients and in vitro.
Blockade of nitric-oxide synthase reduces choroidal neovascularization.
Broad spectrum antiangiogenic treatment for ocular neovascular diseases.
Bruch's Membrane and the Choroid in Age-Related Macular Degeneration.
Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism.
Cellular and molecular mechanisms of age-related macular degeneration: from impaired autophagy to neovascularization.
CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIA.
Changes in Aqueous Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor after Ranibizumab Alone or Combined with Verteporfin for Exudative Age-related Macular Degeneration.
Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor.
Clinical experience with pegaptanib sodium.
Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization.
Correlation of CD105 and vascular endothelial growth factor in laser-induced choroidal neovascularization in rats.
Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis.
Detection of inducible nitric oxide synthase and vascular endothelial growth factor in choroidal neovascular membranes.
Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD.
Differences in the temporal expression of regulatory growth factors during choroidal neovascular development.
Dioxin promotes vascular endothelial growth factor (VEGF) production in the retina and enhances choroidal neovascularization.
Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization.
Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization.
Early effects of triamcinolone on vascular endothelial growth factor and endostatin in human choroidal neovascularization.
EFFECTS OF VEGF INHIBITION ON RETINAL MORPHOLOGY, NEOVASCULAR NETWORK SIZE, AND VISUAL ACUITY IN PATIENTS WITH VASCULARIZED PIGMENT EPITHELIUM DETACHMENT BECAUSE OF OCCULT CHOROIDAL NEOVASCULARIZATION.
Effects of VEGF levels on anti-VEGF therapy for patients with idiopathic choroidal neovascularization.
Efficacy of ranibizumab combined with photodynamic therapy on wet age-related macular degeneration.
Endogenous osteopontin involvement in laser-induced choroidal neovascularization in mice.
Evolving multidimensional pharmacological approaches to CNV therapy in AMD.
Excessive retinol intake exacerbates choroidal neovascularization through upregulated vascular endothelial growth factor in retinal pigment epithelium in mice.
Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization.
Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization.
Expression of vascular endothelial growth factor in experimental choroidal neovascularization.
Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy.
Fibrotic Changes and Endothelial-to-Mesenchymal Transition Promoted by VEGFR2 Antagonism Alter the Therapeutic Effects of VEGFA Pathway Blockage in a Mouse Model of Choroidal Neovascularization.
Gene therapy for ocular angiogenesis.
Generation and characterization of a recombinant adenovirus expressing vascular endothelial growth factor for studies of neovascularization in the eye.
Glycol Chitosan Engineered Autoregenerative Antioxidant Significantly Attenuates Pathological Damages in Models of Age-Related Macular Degeneration.
Growth-related effects of oxidant-induced stress on cultured RPE and choroidal endothelial cells.
Heat-sensitive TRPV channels in retinal pigment epithelial cells: regulation of VEGF-A secretion.
Human Vascular Endothelial Growth Factor A165 Expression Induces the Mouse Model of Neovascular Age-Related Macular Degeneration.
Imaging of Therapeutic Effects of Anti-Vascular Endothelial Growth Factor Inhibitors by Optical Coherence Tomography Angiography in a Rat Model.
In Vivo Choroidal Neovascularization and Macrophage Studies Provide Further Evidence for a Broad Role of Prostacyclin in Angiogenesis.
Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells.
Inhibition of Hypoxia-Inducible Factor-1? and Vascular Endothelial Growth Factor by Chrysin in a Rat Model of Choroidal Neovascularization.
Inhibition of VEGF expression by targeting HIF-1 alpha with small interference RNA in human RPE cells.
Intense physiological light upregulates vascular endothelial growth factor and enhances choroidal neovascularization via peroxisome proliferator-activated receptor ? coactivator-1? in mice.
Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium.
INTRAOCULAR GROWTH FACTORS AND CYTOKINES IN PATIENTS WITH DRY AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study.
Intravitreal Conbercept for Idiopathic Choroidal Neovascularization in Nursing Women.
Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization.
JNK inhibition reduces apoptosis and neovascularization in a murine model of age-related macular degeneration.
Longitudinal phenotypic study of late-onset retinal degeneration due to a founder variant c.562C>A p.(Pro188Thr) in the C1QTNF5 gene.
Magnetic nanoparticles conjugated with "RPE cell -MCP-1 antibody -VEGF antibody" compounds for the targeted therapy of age-related macular degeneration: a hypothesis.
Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy.
Mechanisms of age-related macular degeneration.
Methallothionein-3 contributes to vascular endothelial growth factor induction in a mouse model of choroidal neovascularization.
MiR-505 promotes M2 polarization in choroidal neovascularization model mice by targeting Transmembrane Protein 229B.
Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate.
Neuropilin-1 expression by endothelial cells and retinal pigment epithelial cells in choroidal neovascular membranes.
New pharmacologic approaches to therapy for age-related macular degeneration.
Nicotine increases VEGF/PEDF ratio in retinal pigment epithelium: a possible mechanism for CNV in passive smokers with AMD.
Non-targeted siRNA suppresses laser-induced choroidal neovascularization.
Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor.
Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells.
Optical Coherence Tomography Angiography during Follow-Up: Qualitative and Quantitative Analysis of Mixed Type I and II Choroidal Neovascularization after Vascular Endothelial Growth Factor Trap Therapy.
Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization.
Oxalomalate reduces expression and secretion of vascular endothelial growth factor in the retinal pigment epithelium and inhibits angiogenesis: Implications for age-related macular degeneration.
Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier.
PKR promotes choroidal neovascularization via upregulating the PI3K/Akt signaling pathway in VEGF expression.
Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders.
Potential protective function of the sterol regulatory element binding factor 1-fatty acid desaturase 1/2 axis in early-stage age-related macular degeneration.
PPAR-alpha Ligands as Potential Therapeutic Agents for Wet Age-Related Macular Degeneration.
Preclinical evaluation of a phosphorothioate oligonucleotide in the retina of rhesus monkey.
Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration.
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.
Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels.
Rac1 activates HIF-1 in retinal pigment epithelium cells under hypoxia.
Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Ranibizumab: a review of its use in myopic choroidal neovascularization.
Re: Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization.
Receptor-associated prorenin system in the pathogenesis of retinal diseases.
Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor.
Reduction of choroidal neovascularization via cleavable VEGF antibodies conjugated to exosomes derived from regulatory T cells.
Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor.
Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization.
Repurposing bortezomib for choroidal neovascularization treatment via antagonizing VEGF-A and PDGF-D mediated signaling.
Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
Resveratrol Inhibits Hypoxia-Induced Vascular Endothelial Growth Factor Expression and Pathological Neovascularization.
Retinal and choroidal angiogenesis: a review of new targets.
Retinal vascular changes and aqueous humor cytokines changes after aflibercept intravitreal injection in treatment-naïve myopic choroidal neovascularization.
Review of choroidal osteomas.
Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.
Short-time effect of intravitreal injections on retinal vascular oxygenation and vessel diameter in patients with diabetic macular oedema or neovascular age-related macular degeneration.
Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys.
Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration.
Successful long-term management of choroidal neovascularization secondary to angioid streaks in a patient with pseudoxanthoma elasticum: a case report.
Sustained and targeted episcleral delivery of celecoxib in a rabbit model of retinal and choroidal neovascularization.
Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration.
The Chinese medicine formula HB01 reduces choroidal neovascularization by regulating the expression of vascular endothelial growth factor.
The expression of growth factors and their receptors in retinal and endothelial cells cocultured in the rotating bioreactor.
The Inhibitory Effects of Gold Nanoparticles on VEGF-A-Induced Cell Migration in Choroid-Retina Endothelial Cells.
The non-antibiotic properties of tetracyclines: Clinical potential in ophthalmic disease.
The role of vascular endothelial growth factor-induced activation of NADPH oxidase in choroidal endothelial cells and choroidal neovascularization.
The use of vascular endothelial growth factor inhibitor for choroidal neovascularization complicating posterior uveitis in eyes with fluocinolone acetonide implants.
Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration.
Tissue kallikrein attenuates choroidal neovascularization via cleavage of vascular endothelial growth factor.
Topical application of PPADS inhibits complement activation and choroidal neovascularization in a model of age-related macular degeneration.
Trimethyl chitosan-hyaluronic acid nano-polyplexes for intravitreal VEGFR-2 siRNA delivery: Formulation and in-vivo efficacy evaluation.
Vandetanib and ADAM inhibitors synergistically attenuate the pathological migration of EBV-infected retinal pigment epithelial cells by regulating the VEGF-mediated MAPK pathway.
Vascular endothelial growth factor expression in choroidal neovascularization in rats.
Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function.
Vascular Endothelial Growth Factor Gene and the Response to Anti-Vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization in High Myopia.
Vascular endothelial growth factor gene polymorphisms and choroidal neovascularization in highly myopic eyes.
Vascular Endothelial Growth Factor in Patients with Exudative Age-Related Macular Degeneration Treated with Ranibizumab.
Vascular endothelial growth factor in the aqueous humour in eyes with myopic choroidal neovascularization.
Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.
Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.
Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.
Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells.
VEGFA variants as prognostic markers for the retinopathy in pseudoxanthoma elasticum.
Vitreous Levels of Proteins Implicated in Angiogenesis Are Modulated in Patients with Retinal or Choroidal Neovascularization.
[Angiogenesis and retinal diseases]
[Choroidal osteoma].
[Expression of integrin alphavbeta3, tissue factor, and vascular endothelial growth factor in experimental choroidal neovascularization.]
[Expression of vascular endothelial growth factor and its receptor in experimental choroidal neovascularization in rat]
[Neovascularization in ocular tissues: mechanisms and role of proangiogenic and antiangiogenic factors]
[Overview of medical practices in wet AMD in France].
[Vascular endothelial growth factor and pigment epithelium-derived factor in aqueous humor of patients with choroidal neovascularization]
[Vascular endothelial growth factor promotes experimental choroidal neovascularization in monkey eyes]
[VEGF inhibitors in ophthalmology]
Chronic Limb-Threatening Ischemia
Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial.
Angiogenesis for the treatment of vascular diseases.
Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2.
Assisted Salvage of Ischemic Fasciocutaneous Flap Using Adipose-Derived Mesenchymal Stem Cells: In-Situ Revascularization.
Corelease of bioactive VEGF and HGF from viscous liquid poly(5-ethylene ketal ?-caprolactone-co-D,L-lactide).
Endogenous vascular endothelial growth factor and angiopoietin-2 expression in critical limb ischemia.
Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve.
Enhanced vascular endothelial growth factor gene expression in ischaemic skin of critical limb ischaemia patients.
Gene therapy in heart disease.
Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia.
Leg ischemia: assessment with MR angiography and spectroscopy.
Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.
Spontaneous recanalization of arterial occlusions: an unusual mechanism for symptomatic improvement.
Therapeutic angiogenesis: theoretic problems using vascular endothelial growth factor.
Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results.
Treatment with Intramuscular Vascular Endothelial Growth Factor Gene Compared with Placebo for Patients with Diabetes Mellitus and Critical Limb Ischemia: A Double-Blind Randomized Trial.
Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial.
Vascular endothelial growth factor in patients with critical limb ischemia before and after amputation.
Vascular endothelial growth factor overexpression does not enhance adipose stromal cell-induced protection on muscle damage in critical limb ischemia.
Chronic Periodontitis
Dental hypofunction alters subgingival microorganisms: a pilot study.
Effects of scaling and root planing on gingival crevicular fluid vascular endothelial growth factor level in chronic periodontitis patients with and without diabetes mellitus: A clinicobiochemical study.
Immunoexpression of angiogenesis, nitric oxide synthase, and proliferation markers in gingival samples of patients with aggressive and chronic periodontitis.
Chronic Urticaria
Analysis of circulating vascular endothelial growth factor and its soluble receptors in patients with different forms of chronic urticaria.
Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria.
Endostatin and Thrombospondin-1 levels are increased in the sera of patients with chronic spontaneous urticaria.
Plasma levels and skin-eosinophil-expression of vascular endothelial growth factor in patients with chronic urticaria.
Vascular endothelial growth factor levels in patients with chronic urticaria.
Vitamin D suppress the production of vascular endothelial growth factor in mast cell by inhibiting PI3K/Akt/p38 MAPK/HIF-1? pathway in chronic spontaneous urticaria.
Churg-Strauss Syndrome
Circulating eosinophils lack ex vivo chemotaxis toward vascular endothelial growth factor in a patient with Churg-Strauss syndrome.
Increased serum vascular endothelial growth factor level in Churg-Strauss syndrome.
Retraction. Increased serum vascular endothelial growth factor level in Churg-Strauss syndrome.
Chylothorax
Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients.
Familial congenital non-immune hydrops, chylothorax, and pulmonary lymphangiectasia.
Retrograde Lymph Flow Leads to Chylothorax in Transgenic Mice with Lymphatic Malformations.
Classical Swine Fever
Coordinated expression of vascular endothelial growth factor A and urokinase-type plasminogen activator contributes to classical swine fever virus Shimen infection in macrophages.
Cleft Lip
Functional identification of a rare vascular endothelial growth factor a (VEGFA) variant associating with the nonsyndromic cleft lip with/without cleft palate.
Cleft Palate
Functional identification of a rare vascular endothelial growth factor a (VEGFA) variant associating with the nonsyndromic cleft lip with/without cleft palate.
Colitis
Active Vaccination With EMMPRIN-Derived Multiple Antigenic Peptide (161-MAP) Reduces Angiogenesis in a Dextran Sodium Sulfate (DSS)-Induced Colitis Model.
Altered expression of angiogenic factors in the VEGF-Ets-1 cascades in inflammatory bowel disease.
Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis.
Cigarette smoke exposure increases ulcerative colitis-associated colonic adenoma formation in mice.
Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound.
Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression in ischaemic colitis and ulcerative colitis.
Intestinal growth factors: Potential use in the treatment of inflammatory bowel disease and their role in mucosal healing.
Piceatannol, a hydroxystilbene natural product, stabilizes HIF-1? protein by inhibiting HIF prolyl hydroxylase.
Ro60 Inhibits Colonic Inflammation and Fibrosis in a Mouse Model of Dextran Sulfate Sodium-Induced Colitis.
Therapeutic action and underlying mechanisms of a combination of two pentacyclic triterpenes, alpha- and beta-amyrin, in a mouse model of colitis.
Vascular endothelial growth factor receptor-2 inhibition in experimental murine colitis.
Ziziphus spina-christi fruit extract suppresses oxidative stress and p38 MAPK expression in ulcerative colitis in rats via induction of Nrf2 and HO-1 expression.
Colitis, Collagenous
Collagenous colitis: implications for the role of vascular endothelial growth factor in repair mechanisms.
Steroids reduce local inflammatory mediator secretion and mucosal permeability in collagenous colitis patients.
Vascular endothelial growth factor (VEGF)--a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis.
Colitis, Ischemic
Hypoxia-inducible factor 1 alpha and vascular endothelial growth factor overexpression in ischemic colitis.
Obliterative arteritis with nitric oxide synthase and HLA-DR expression in Crohn's colitis.
Colitis, Ulcerative
Altered angiogenic balance in ulcerative colitis: a key to impaired healing?
Altered expression of angiogenic factors in the VEGF-Ets-1 cascades in inflammatory bowel disease.
Angiopoietin and vascular endothelial growth factor expression in colorectal disease models.
Expression, localization and systemic concentration of vascular endothelial growth factor (VEGF) and its receptors in patients with ulcerative colitis.
Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease.
Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression in ischaemic colitis and ulcerative colitis.
Increased expression of VEGF and CD146 in patients with inflammatory bowel disease.
Intestinal growth factors: Potential use in the treatment of inflammatory bowel disease and their role in mucosal healing.
Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF.
Obliterative arteritis with nitric oxide synthase and HLA-DR expression in Crohn's colitis.
The Relationship between Ocular Vascular Changes and the Levels of Malondialdehyde and Vascular Endothelial Growth Factor in Patients with Inflammatory Bowel Disease.
Up-Regulation of Intestinal Vascular Endothelial Growth Factor by Afa/Dr Diffusely Adhering Escherichia coli.
Vascular endothelial growth factor - key mediator of angiogenesis and promising therapeutical target in ulcerative colitis.
Vascular endothelial growth factor expression and microvessel parameters of colonic mucosa correlate with sensitivity to steroid in patients with ulcerative colitis.
Vascular endothelial growth factor, endostatin levels and clinical features among patients with ulcerative colitis and irritable bowel syndrome and among healthy controls: a cross-sectional analytical study.
[The associations of ulcerative colitis with vascular endothelial growth factor (-2578C/A) and (+936C/T) single nucleotide polymorphisms].
[Vascular development in inflammatory bowel disease.]
Colitis-Associated Neoplasms
VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer.
VEGFR2 Signaling Prevents Colorectal Cancer Cell Senescence to Promote Tumorigenesis in Mice With Colitis.
Collagen Diseases
Angiogenic cytokines in serum and cutaneous lesions of patients with polyarteritis nodosa.
Serum concentrations of vascular endothelial growth factor in collagen diseases.
Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.
Colonic Diseases
Hypoxia-induced reduction of sVEGFR-2 levels in human colonic microvascular endothelial cells in vitro: Comparative study with HUVEC.
Colonic Neoplasms
15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1? expression in human colon cancer cells.
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor.
?-Catenin and peroxisome proliferator-activated receptor-? coordinate dynamic chromatin loops for the transcription of vascular endothelial growth factor A gene in colon cancer cells.
A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab.
A role for antiangiogenic therapy in breast cancer.
A role of histone H4 hypoacetylation in vascular endothelial growth factor expression in colon mucosa adjacent to implanted cancer in athymic mice cecum.
A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).
A targeted approach for antiangiogenic therapy of metastatic human colon cancer.
Aberrant, ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism.
Activated macrophages induce metastatic behavior of colon cancer cells.
Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer.
Administration of granulocyte colony-stimulating factor with radiotherapy promotes tumor growth by stimulating vascularization in tumor-bearing mice.
ALA-induced photodynamic effect on vitality, apoptosis, and secretion of vascular endothelial growth factor (VEGF) by colon cancer cells in normoxic environment in vitro.
Aldose reductase inhibition prevents hypoxia-induced increase in hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) by regulating 26 S proteasome-mediated protein degradation in human colon cancer cells.
Angiogenesis and Oxidative Stress in Metastatic Tumor Progression: Pathogenesis and Novel Therapeutic Approach of Colon Cancer.
Angiogenesis in normal tissue adjacent to colon cancer.
Angiogenesis of liver metastases: role of sinusoidal endothelial cells.
Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model.
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Antiangiogenic therapy for cancer: an update.
Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.
Antibody against vascular endothelial growth factor (VEGF) inhibits angiogenic switch and liver metastasis in orthotopic xenograft model with site-dependent expression of VEGF.
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.
Antitumor activity of an adenovirus harboring two therapeutic genes, anti-VEGF ribozyme and human IL-24, in colon cancer.
Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy.
Assessment of vascular endothelial growth factor in formalin fixed, paraffin embedded colon cancer specimens by means of a well-based reverse phase protein array.
Association of vascular endothelial growth factor -2578C/A gene polymorphism in Chinese patients with colon cancer.
Astragalus saponins downregulate vascular endothelial growth factor under cobalt chloride-stimulated hypoxia in colon cancer cells.
beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.
Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors.
Bevacizumab-associated hypertension: etiology, incidence, and management.
Bevacizumab-Related Microvascular Angina and Its Management with Nicorandil.
Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer.
Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer.
c-Myc enhances colon cancer cell-mediated angiogenesis through the regulation of HIF-1?.
Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells.
Catalpol suppressed proliferation, growth and invasion of CT26 colon cancer by inhibiting inflammation and tumor angiogenesis.
Chemokine receptor 7 targets the vascular endothelial growth factor via the AKT/ERK pathway to regulate angiogenesis in colon cancer.
Cholesteryl oligoarginine delivering vascular endothelial growth factor sirna effectively inhibits tumor growth in colon adenocarcinoma.
Clinical procedure for colon carcinoma tissue sampling directly affects the cancer marker-capacity of VEGF family members.
Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway.
Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer.
Curcumin and turmeric attenuate arsenic-induced angiogenesis in ovo.
Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins.
D-limonene rich volatile oil from blood oranges inhibits angiogenesis, metastasis and cell death in human colon cancer cells.
Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon adenocarcinoma based on tissue microarrays analysis.
Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate.
Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors.
Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells.
Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src.
Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation.
Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
Effect of prostaglandin E1 on vascular endothelial growth factor production by human macrophages and colon cancer cells.
Effect of thoracic epidural anaesthesia on serum vascular endothelial growth factor C and cytokines in patients undergoing anaesthesia and surgery for colon cancer.
Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis.
Efficacy and adverse reactions of combination therapy of bevacizumab and 5-fluorouracil in patients with metastatic colon cancer.
Elevated TATA-binding protein expression drives vascular endothelial growth factor expression in colon cancer.
Endocrine gland-derived vascular endothelial growth factor strengthens cell invasion ability via prokineticin receptor 2 in colon cancer cell lines.
Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line.
Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.
Expression of chemotaxis- and angiogenesis-related factors in human monocytes following interaction with colon cancer cells is suppressed by low-dose lipopolysaccharide.
Expression of Concern: Aldose reductase inhibition prevents hypoxia-induced increase in hypoxia-inducible factor-1 ? (HIF-1?) and vascular endothelial growth factor (VEGF) by regulating 26 S proteasome-mediated protein degradation in human colon cancer cells.
Expression of delta-like 4 (Drosophila) and vascular endothelial growth factor A in colon cancer and association with tumour angiogenesis.
Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival.
Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.
Expression of vascular endothelial growth factor and receptor flk-1 in colon cancer liver metastases.
Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer.
Expression of VEGF-D, SMAD4, and SMAD7 and Their Relationship with Lymphangiogenesis and Prognosis in Colon Cancer.
Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells.
Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression.
Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C>T) gene and colon cancer in Korea.
Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer.
Heregulin-Induced VEGF Expression via the ErbB3 Signaling Pathway in Colon Cancer.
High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies.
High-mobility group box 1 protein activating nuclear factor-?B to upregulate vascular endothelial growth factor C is involved in lymphangiogenesis and lymphatic node metastasis in colon cancer.
Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells.
Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer.
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer.
Increased expression of angiogenic factors in human colonic angiodysplasia.
Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer.
Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells.
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors.
Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.
Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts.
Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells.
Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis.
Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors.
Knockdown GREM1 suppresses cell growth, angiogenesis, and epithelial-mesenchymal transition in colon cancer.
Knockdown of Hypoxia-Inducible Factor 1? Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts.
l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms.
Long Noncoding RNA ASLNC07322 Functions in VEGF-C Expression Regulated by Smad4 during Colon Cancer Metastasis.
miR?1 inhibits the progression of colon cancer by regulating the expression of vascular endothelial growth factor.
Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story.
Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth.
Mucinous colon carcinomas with microsatellite instability have a lower microvessel density and lower vascular endothelial growth factor expression.
Neoangiogenesis in colon cancer: correlation between vascular density, vascular endothelial growth factor (VEGF) and p53 protein expression.
Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.
Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells.
p53, vessel count, and vascular endothelial growth factor expression in human colon cancer.
PGE2-induced colon cancer growth is mediated by mTORC1.
Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells.
Platelet-derived growth factor-D promotes colorectal cancer cell migration, invasion and proliferation by regulating Notch1 and matrix metalloproteinase-9.
Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer.
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
Postoperative serum Vascular Endothelial Growth Factor is an independent prognostic factor of disease free survival and overall survival in patients with non metastatic colon cancer.
Potential Role of PDGFR?-Associated THBS4 in Colorectal Cancer Development.
Primary and acquired resistance to biologic therapies in gastrointestinal cancers.
Pro-apoptotic and migration-suppressing potential of EGCG, and the involvement of AMPK in the p53-mediated modulation of VEGF and MMP-9 expression.
Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery.
Prognostic value of thymidylate synthase, epidermal growth factor receptors and vascular endothelial growth factor in patients with stage III colon cancer.
Prostaglandin E2 induces the expression of IL-1alpha in colon cancer cells.
Quantitative analysis of vascular endothelial growth factor in colon cancer. Clinical and experimental.
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I.
Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1beta.
Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density.
Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer.
Research progress on common adverse events caused by targeted therapy for colorectal cancer.
RNA interference-mediated gene silencing of vascular endothelial growth factor in colon cancer cells.
Role of biological markers in the clinical outcome of colon cancer.
Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review).
Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells.
Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer.
Smad4 Inhibits VEGF-A and VEGF-C Expressions via Enhancing Smad3 Phosphorylation in Colon Cancer.
Status of targeted therapies in the adjuvant treatment of colon cancer.
Targeting delivery of lipocalin 2-engineered mesenchymal stem cells to colon cancer in order to inhibit liver metastasis in nude mice.
The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion.
The clinical implications of platelet derived growth factor B, vascular endothelial growth factor and basic fibroblast growth factor in colorectal cancer.
The effect of emodin on VEGF receptors in human colon cancer cells.
The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer.
The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines.
Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer.
Transfection of mouse macrophage metalloelastase gene into murine CT-26 colon cancer cells suppresses orthotopic tumor growth, angiogenesis and vascular endothelial growth factor expression.
Triptolide decreases tumor-associated macrophages infiltration and M2 polarization to remodel colon cancer immune microenvironment via inhibiting tumor-derived CXCL12.
Tristetraprolin regulates expression of VEGF and tumorigenesis in human colon cancer.
Tumor?type?dependent effects on the angiogenic abilities of endothelial cells in an in vitro rat cell model.
Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGF-related pathway.
Upregulation of vascular endothelial growth factor by hydrogen peroxide in human colon cancer.
Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer.
Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line.
Vascular endothelial growth factor and p53 expressions in liver and abdominal metastases from colon cancer.
Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy.
Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1.
Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
Vascular endothelial growth factor inhibitors in colon cancer.
Vascular endothelial growth factor polymorphisms -1154 G/A and -460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer.
VEGF and colon cancer growth beyond angiogenesis: Does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism?
VEGF isoforms and mutations in human colorectal cancer.
VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer.
VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients.
VEGF-C and VEGF-D overexpression is more common in left-sided and well-differentiated colon adenocarcinoma.
Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer.
When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab.
Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis.
[Experimental study of human colon cell line Lovo transfected with soluble vascular endothelial growth factor receptor 1 gene]
[Expression and clinical significance of kisspeptin-1, matrix metalloproteinase-2 and vascular endothelial growth factor in tissue of colon cancer].
[Relationship of hypoxia-induced factor with tumor angiogenesis in early liver metastasis in colonic cancer]
[RS3PE syndrome associated with senile Epstein-Barr virus-positive diffuse large B cell lymphoma of a patient with colon cancer].
[Upregulation of vascular endothelial growth factor by peroxide in human colon cancer]
Colorectal Neoplasms
"Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
(-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells.
(99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
A man in his 50s with neurological symptoms during cancer treatment.
A phase ?I study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study).
A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
A Population-Based Study of Complications After Colorectal Surgery in Patients Who Have Received Bevacizumab.
A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases.
A prospective study of the associations among fine particulate matter, genetic variants, and the risk of colorectal cancer.
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
A review on bevacizumab and surgical wound healing: an important warning to all surgeons.
A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
Acute and long-term gastrointestinal consequences of chemotherapy.
Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis.
Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations.
Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.
Alternative splicing of VEGFA, APP and NUMB genes in colorectal cancer.
An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer.
An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer.
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
Analysis of VEGF polymorphisms, tumor expression of VEGF mRNA and colorectal cancer susceptibility in a Swedish population.
Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
Angiogenesis inhibitors in the treatment of colorectal cancer.
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.
Angiopoietin and vascular endothelial growth factor expression in colorectal disease models.
Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Anti-VEGF therapy: a new approach to colorectal cancer therapy.
Antiangiogenesis agents in colorectal cancer.
Antiangiogenic agents in first-line and second-line therapy for advanced colorectal cancer.
Antiangiogenic peptides and proteins: from experimental tools to clinical drugs.
Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Antitumor effects of a covalent cyclin-dependent kinase 7 inhibitor in colorectal cancer.
Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.
Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer.
Association between expression of vascular endothelial growth factor C, chemokine receptor CXCR4 and lymph node metastasis in colorectal cancer.
Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis.
Association of Gankyrin and Stemness Factor Expression in Human Colorectal Cancer.
Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer.
Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6.
Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer.
Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer.
Associations between Single Nucleotide Polymorphisms of MMP2, VEGF, and HIF1A Genes and the Risk of Developing Colorectal Cancer.
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Bevacizumab in the treatment of colorectal cancer.
Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer.
Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
Bevacizumab-Associated Fistula Formation in Postoperative Colorectal Cancer Patients.
Bevacizumab-induced hypertension: pathogenesis and management.
Bevacizumab.
Bevacizumab: a review of its use in metastatic colorectal cancer.
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Biologic therapy for colon cancer.
Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer.
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Bowel perforation from Bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.
Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo.
Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer.
Changes in serum IGF?1 level and tumor VEGF expression in mice with colorectal cancer under hyperglycemic conditions.
Characterisation and identification of the human N(+)-glucuronide metabolite of cediranib.
Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.
Chronic inflammation and colorectal cancer: the role of vascular endothelial growth factor.
circCCT3 Modulates Vascular Endothelial Growth Factor A and Wnt Signaling to Enhance Colorectal Cancer Metastasis Through Sponging miR-613.
Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients.
Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropismin in Patients with Colorectal Cancer.
Circulating vascular endothelial growth factor in patients with colorectal cancer.
Circulating vascular endothelial growth factor six months after primary surgery as a prognostic marker in patients with colorectal cancer.
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.
Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.
Clinical implications of angiogenesis in cancers.
Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.
Clinical relevance of serum vascular endothelial growth factor and interleukin-6 in patients with colorectal cancer.
Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer.
Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery.
Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.
Clinical significance of serum vascular endothelial growth factor and complement 3a levels in patients with colorectal cancer in southern Iran.
Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers.
Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.
Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma.
Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma.
Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer.
Clinicopathological significance of p53, hypoxia-inducible factor 1alpha, and vascular endothelial growth factor expression in colorectal cancer.
Clinicopathological significance of the expression of estrogen receptor-beta and vascular endothelial growth factor-A in colorectal cancer.
Clinicopathological significance of vascular endothelial growth factor, thymidine phosphorylase and microvessel density in colorectal cancer.
Co-existence of cyclin D1 and vascular endothelial growth factor protein expression is a poor prognostic factor for UICC stage I-III colorectal cancer patients after curative resection.
Colorectal cancer.
Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis.
Combined perioperative plasma endoglin and VEGF--a assessment in colorectal cancer patients.
Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients.
Combined treatment with Bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.
Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.
Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival.
Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk.
Comparison of (18)F-fluorodeoxyglucose PET/CT findings with vascular endothelial growth factors and receptors in colorectal cancer.
Comparison of angiogenic factor levels in tumor drainage and peripheral venous blood from colorectal cancer patients.
Compounds in clinical Phase III and beyond.
Concentrations of VEGF and VEGFR1 in paired tumor arteries and veins in patients with rectal cancer.
Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics.
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer.
Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?
Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer.
Correlation of vascular endothelial growth factor (VEGF) and CEA with clinicopathological variables in colorectal cancer patients.
Correlations between SUVmax and expression of GLUT1 and growth factors inducing lymphangiogenesis.
Correlations of serum VEGF and MMP-2 levels with CLM in CRC patients and effects of TACE on their expressions.
Correspondence re: M. L. George et al., Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin. Cancer Res., 6: 3147-3152, 2000.
Correspondence re: M.L. George [correction of H.L. George] et al., Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin. Cancer Res., 6: 3147-3152, 2000.
Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice.
Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.
Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer.
Cyclooxygenase-2 expression and angiogenesis in colorectal cancer.
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.
Cytokeratin 20 and vascular endothelial growth factor as molecular markers in Egyptian patients with colorectal cancer.
Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings.
Development of monoclonal antibodies for the treatment of colorectal cancer.
Development of new agents for the treatment of advanced colorectal cancer.
Diaphragmatic rupture, a new complication of Bevacizumab.
Dietary lipid hydroperoxides induce expression of vascular endothelial growth factor (VEGF) in human colorectal tumor cells.
Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia.
Does immunostaining effectively upstage colorectal cancer by identifying micrometastatic nodal disease?
Does preoperative chemo-radiotherapy enhance the expression of vascular endothelial growth factor in patients with rectal cancer?
Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in ApcMin/+ mice.
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers.
Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer.
Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells.
Effect of FOLFOX6 chemotherapy on serum VEGF expression in advanced colorectal cancer patients.
Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer.
Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma.
Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and its receptor PROKR2 are associated to human colorectal cancer progression and peritoneal carcinomatosis.
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer.
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer.
Endothelial Cell Proliferation and Vascular Endothelial Growth Factor Expression in Primary Colorectal Cancer and Corresponding Liver Metastases.
Establishment of human metastatic colorectal cancer model in rabbit liver: A pilot study.
Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials.
Evaluation of angiogenesis in colorectal carcinoma with multidetector-row CT multislice perfusion imaging.
Exploring the peritoneal surface malignancy phenotype-a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models.
Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer.
Expression and Biological Significance of Leptin, Leptin Receptor, VEGF, and CD34 in Colorectal Carcinoma.
Expression and clinical significance of vascular endothelial growth factor and fms-related tyrosine kinase 1 in colorectal cancer.
Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells.
Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.
Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
Expression of CD44, vascular endothelial growth factor, and proliferating cell nuclear antigen in severe venous invasional colorectal cancer and its relationship to liver metastasis.
Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer.
Expression of GLI1 correlates with expression of lymphangiogenesis proteins, vascular endothelial growth factor C and vascular endothelial growth factor receptor 3, in colorectal cancer.
Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor.
Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
Expression of Raptor and Rictor and their relationships with angiogenesis in colorectal cancer.
Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer.
Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer.
Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma.
Expression of vascular endothelial growth factor C and its correlation with lymph node metastasis in colorectal carcinoma.
Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer.
Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma.
Expression of vascular endothelial growth factor, mitogen-activated protein kinase and p53 in human colorectal cancer.
Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma.
Factors influencing tissue concentration of vascular endothelial growth factor in colorectal carcinoma.
Flt-1-positive cells are cancer-stem like cells in colorectal carcinoma.
From Chemotherapy to Targeted Therapy in Adjuvant Treatment for Stage III Colon Cancer.
Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.
Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.
Gastrointestinal cancer: recent developments in medical oncology.
Gene expression of vascular endothelial growth factor a, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis.
Gut microbial community diversity is associated with systemic vascular endothelial growth factor A levels among colorectal cancer patients.
Hepatic tumor growth: target for angiogenesis inhibition?
Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.
Heterogeneous expression of cyclooxygenase-2 and inducible nitric oxide synthase within colorectal tumors: Correlation with tumor angiogenesis.
HIF-1? expression and high microvessel density are characteristic features in serrated colorectal cancer.
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis.
Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins.
Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer.
Hypoxia Inducible Factor-1 Independent Pathways in Tumor Angiogenesis.
Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.
Immunohistochemical evaluation of vascular endothelial growth factor (VEGF) in colorectal carcinoma.
Immunohistochemical Expression of Fatty Acid Synthase and Vascular Endothelial Growth Factor in Primary Colorectal Cancer: a Clinicopathological Study.
Immunohistochemical expression of vascular endothelial growth factor and microvessel counting as prognostic indicators in node-negative colorectal cancer.
Immunotherapy of tumor by targeting angiogenesis.
Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer.
Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) -- and vascular endothelial growth factor-mediated cellular invasion and tumor growth.
Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma.
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.
In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology.
In vivo release of vascular endothelial growth factor from colorectal carcinomas.
Incidence and management of bevacizumab-related toxicities in colorectal cancer.
Increased expression of nuclear factor-kappaB/RelA is correlated with tumor angiogenesis in human colorectal cancer.
Increased expression of thioredoxin-1, vascular endothelial growth factor, and redox factor-1 is associated with poor prognosis in patients with liver metastasis from colorectal cancer.
Increased serum transforming growth factor-beta1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration.
Individualization of therapy for colorectal cancer based on clinical and molecular parameters.
Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways.
Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma.
Indwelling central venous access port insertion during bevacizumab-based therapy.
Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients.
Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.
Inhibition of VEGF induces cellular senescence in colorectal cancer cells.
Injectable Biodegradable Hydrogels from Vitamin D-Functionalized Polycarbonates for the Delivery of Avastin with Enhanced Therapeutic Efficiency against Metastatic Colorectal Cancer.
Inositol Hexaphosphate and Inositol Inhibit Colorectal Cancer Metastasis to the Liver in BALB/c Mice.
Insulin-like growth factors (IGF), IGF-binding proteins (IGFBP), and vascular endothelial growth factor (VEGF) in blood serum of patients with colorectal cancer.
Integrating systemic and surgical approaches to treating metastatic colorectal cancer.
Integration of novel agents in the treatment of colorectal cancer.
Interaction between stromal fibroblasts and colorectal cancer cells in the expression of vascular endothelial growth factor.
Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma.
Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma.
Interplay between 3'-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans.
Intestinal perforation in colorectal cancers treated with bevacizumab (avastin(r)).
Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells.
Intraperitoneal administration of bevacizumab intraoperatively does not affect abdominal wound healing in rats.
Involvement of cyclooxygenase-2 and vascular endothelial growth factor in vascularization and lymph node metastasis of colorectal cancers with submucosal invasion.
Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers.
Iodine-125 induces apoptosis via regulating p53, microvessel density, and vascular endothelial growth factor in colorectal cancer.
K-ras mutations in colorectal cancer: a practice changing discovery.
Knockdown GREM1 suppresses cell growth, angiogenesis, and epithelial-mesenchymal transition in colon cancer.
KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Lack of association between VEGF -2578C/A polymorphism and risk of colorectal cancer in an Iranian population.
Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
Large Skin Ulcer and Delayed Wound Healing around a Colostomy in a Patient with Metastatic Colorectal Cancer Receiving Vascular Endothelial Growth Factor Receptor-2 Inhibitor Therapy.
Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: An example of pazopanib complication.
Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication.
Long non-coding RNA growth arrest specific transcript 5 acts as a tumour suppressor in colorectal cancer by inhibiting interleukin-10 and vascular endothelial growth factor expression.
Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.
Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells.
Lymphatic microvessel density as prognostic marker in colorectal cancer.
Lymphatic vessel density and its prognostic value in stage I colorectal carcinoma.
Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer.
Macroscopic portal vein tumor thrombi of liver metastasis from colorectal cancer.
Maintenance therapy for colorectal cancer: which regimen and which patients?
Mechanisms of SU5416, an inhibitor of vascular endothelial growth factor receptor, as a radiosensitizer for colon cancer cells.
Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis.
Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy.
Metastatic colorectal cancer: role of target therapies and future perspectives.
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature.
miR-140-5p mediates bevacizumab-induced cytotoxicity to cardiomyocytes by targeting the VEGFA/14-3-3? signal pathway.
miR-148a inhibits early relapsed colorectal cancers and the secretion of VEGF by indirectly targeting HIF-1? under non-hypoxia/hypoxia conditions.
miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer.
Molecular determinants of cetuximab efficacy.
Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives.
Molecular mechanisms and targeting of colorectal cancer.
Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions.
Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion.
Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.
n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway.
N-Terminal Modification of the Tetrapeptide Arg-Leu-Tyr-Glu, a Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Antagonist, Improves Antitumor Activity by Increasing its Stability against Serum Peptidases.
Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
No associations of a set of SNPs in the Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinase (MMP) genes with survival of colorectal cancer patients.
Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
On target? Strategies and progress in developing therapies for colorectal cancer targeted against WNT signalling.
Oncologists' current opinion on the treatment of colon carcinoma.
Optimizing the management of metastatic colorectal cancer.
Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records.
Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
Overexpression of Vascular Endothelial Growth Factor A in Invasive Micropapillary Colorectal Carcinoma.
Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt/?-Catenin signaling pathway.
Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway.
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy.
Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.
Peroxisome-proliferator-activated receptors gamma and beta/delta mediate vascular endothelial growth factor production in colorectal tumor cells.
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer.
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
PINCH mRNA overexpression in colorectal carcinomas correlated with VEGF and FAS mRNA expression.
Placenta growth factor expression is correlated with survival of patients with colorectal cancer.
Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Platelet-activating factor and human thyroid cancer.
Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
Possible Role and Therapeutic Target of PDGF-D Signalling in Colorectal Cancer.
Posterior Reversible Encephalopathy Syndrome (PRES) Presenting as Status Epilepticus: A Case Report and Literature Review.
Potential Role of PDGFR?-Associated THBS4 in Colorectal Cancer Development.
Pre-operative plasma levels of vascular endothelial growth factor A, C and D in patients with colorectal cancer.
Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer.
Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor.
Preclinical data targeting vascular endothelial growth factor in colorectal cancer.
Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer.
Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer.
Predictive value of vascular endothelial growth factor overexpression in early relapse of colorectal cancer patients after curative resection.
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
Preoperative Plasma Vascular Endothelial Growth Factor But Not Nitrite Is a Useful Complementary Tumor Marker in Patients With Colorectal Cancer.
Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.
Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer.
Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer.
Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during long-term follow-up of colorectal cancer patients.
Profile of gene expression of TLR-signaling pathways in colorectal cancer tissues.
Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer.
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.
Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma.
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Prognostic significance of Cytokeratin 20-positive lymph node vascular endothelial growth factor A mRNA and chromodomain helicase DNA binding protein 4 in pN0 colorectal cancer patients.
Prognostic significance of vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer.
Prognostic significance of vascular endothelial growth factor polymorphisms in colorectal cancer patients.
Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer.
Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer.
Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer.
Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients.
Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer.
Protracted Inhibition of Vascular Endothelial Growth Factor Signaling Improves Survival in Metastatic Colorectal Cancer: A Systematic Review.
Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer.
Quantitative analysis of vascular endothelial growth factor receptors 1 and 2 in colorectal cancer.
Quantitative analysis using ELISA of vascular endothelial growth factor and basic fibroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and hepatocellular carcinoma.
Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy.
Recent advances in targeted therapies for colorectal cancer.
Recent concepts of antiangiogenic therapy.
Recent developments in colorectal cancer treatment by monoclonal antibodies.
Recombined human endostatin (Endostar) enhances cisplatin delivery and potentiates chemotherapy by decompressing colorectal cancer vessels.
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
Relationship between plasma levels of vascular endothelial growth factor and serum levels of interleukin-12 in patients with colorectal cancer.
Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer.
Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis.
Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis.
RNA interference-mediated silencing of aquaporin (AQP)-5 hinders angiogenesis of colorectal tumor by suppressing the production of vascular endothelial growth factor.
RNAi-mediated gene silencing of vascular endothelial growth factor inhibits growth of colorectal cancer.
Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
Role of CD34, vascular endothelial growth factor, and p53 in neoangiogenesis as correlated with stage of disease in colorectal carcinoma.
Role of First-Line Anti-Epidermal Growth Factor Receptor Therapy Compared With Anti-Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials.
Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer.
RUNX3 suppresses metastasis and stemness by inhibiting Hedgehog signaling in colorectal cancer.
Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer.
Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool.
Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis.
Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer.
Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.
Serum vascular endothelial growth factor and interleukin-6 in colorectal cancer.
Serum vascular endothelial growth factor-C and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer.
Serum vascular endothelial growth factor-C and vascular endothelial growth factor level in patients with colorectal carcinoma and clinical significance.
Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer.
Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers.
Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer.
Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group.
Sporamin suppresses growth of xenografted colorectal carcinoma in athymic BALB/c mice by inhibiting liver ?-catenin and vascular endothelial growth factor expression.
Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer.
Spotlight on bevacizumab in metastatic colorectal cancer.
Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome.
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.
Study of the vascular endothelial growth factor (VEGF) expression and microvascular density (MVD) in primary colorectal cancer specimens.
Suppression of melanoma-associated neoangiogenesis by bevacizumab.
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
Synchronous vascular endothelial growth factor protein profiles in both tissue and serum identify metastasis and poor survival in colorectal cancer.
Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer.
Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor.
Systemic treatment of advanced colorectal carcinoma.
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?
Targeted Theranostics Against Solid Cancer Using Metal Bond Milk Protein and Aptamers.
Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.
Targeted therapy in rectal cancer.
Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
Targeting Angiogenesis in Colorectal Carcinoma.
Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Targeting vascular endothelial growth factor in colorectal cancer.
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.
The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer.
The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer.
The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression.
The association between preoperative concentration of soluble vascular endothelial growth factor, perioperative blood transfusion, and survival in patients with primary colorectal cancer.
The changing paradigm of colorectal cancer therapy: the impact of vascular endothelial growth factor and epidermal growth factor and epidermal growth factor receptor inhibition. Introduction.
The clinical application of fruquintinib on colorectal cancer.
The clinical implications of platelet derived growth factor B, vascular endothelial growth factor and basic fibroblast growth factor in colorectal cancer.
The combination of nuclear factor kappa B, cyclo-oxygenase-2 and vascular endothelial growth factor expression predicts poor prognosis in stage II and III colorectal cancer.
The correlation between serum vascular endothelial growth factor (VEGF) and tumor VEGF receptor 3 in colorectal cancer.
The correlation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma.
The developing trend of monoclonal antibodies in the treatment of colorectal cancer.
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
The expression of vascular endothelial growth factor determines the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
The impact of gene expression on (18)F-FDG kinetics; a new chapter for diagnostic nuclear medicine.
The importance of -460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer.
The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors.
The malignant progression effects of regorafenib in human colon cancer cells.
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer.
The present and future of angiogenesis-directed treatments of colorectal cancer.
The prognosis was poorer in colorectal cancers that expressed both VEGF and PROK1 (No correlation coefficient between VEGF and PROK1).
The prognostic value of haplotypes in the vascular endothelial growth factor a gene in colorectal cancer.
The relationship between serum vascular endothelial growth factor A and microsatellite instability in colorectal cancer.
The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer.
The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab.
The Therapeutic Potential of Angiotensin-converting enzyme and angiotensin receptor inhibitors in the treatment of colorectal cancer: Rational Strategies and Recent Progress.
Tissue factor (TF) and vascular endothelial growth factor (VEGF) expression in colorectal cancer: relation with cancer recurrence.
Tissue factor and vascular endothelial growth factor expression in colorectal cancer: relation with cancer recurrence.
Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
Translating angiogenesis research into the clinic: the challenges ahead.
Treatment of metastatic colorectal cancer with monoclonal antibody to vascular endothelial growth factor: does the metastatic site make the difference?
Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice.
Treatment with capecitabine + bevacizumab following induction treatment with FOLFIRI + bevacizumab in metastatic colorectal carcinoma.
Tumor-related gene expression levels in pulmonary pleomorphic carcinoma.
Tumour growth increased following antiangiogenic interruption: the challenge of tumour evaluation.
Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma.
Tumour VEGF/Non Tumour VEGF protein expression ratio as a biomarker for survival in colorectal cancer patients.
Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer.
Update on targeted agents for adjuvant treatment of colon cancer in 2006.
Upregulation of activator protein-4 in human colorectal cancer with metastasis.
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Vascular biology support for the use of bevacizumab in colorectal cancer.
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.
Vascular endothelial growth factor (VEGF) gene polymorphisms and colorectal cancer: a meta-analysis of epidemiologic studies.
Vascular endothelial growth factor (VEGF) receptor expression correlates with histologic grade and stage of colorectal cancer.
Vascular endothelial growth factor -2578C/A polymorphism and colorectal cancer risk: A meta-analysis.
Vascular endothelial growth factor 1498C/T, 936C/T polymorphisms associated with increased risk of colorectal adenoma: a Chinese case-control study.
Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer.
Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes.
Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer.
Vascular endothelial growth factor and endoglin expression in colorectal cancer.
Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.
Vascular endothelial growth factor and psychosocial factors in colorectal cancer.
Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence.
Vascular Endothelial Growth Factor C Disrupts the Endothelial Lymphatic Barrier to Promote Colorectal Cancer Invasion.
Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-APR) of healthy controls and colorectal cancer patients.
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Vascular endothelial growth factor expression correlates with hematogenous metastasis and prognosis in colorectal carcinoma.
Vascular endothelial growth factor expression in metastatic pulmonary tumor from colorectal carcinoma: utility as a prognostic factor.
Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator.
Vascular endothelial growth factor gene polymorphisms and colorectal cancer risk: a meta-analysis.
Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer.
Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer.
Vascular endothelial growth factor in colorectal cancer.
Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression.
Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer.
Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?
Vascular endothelial growth factor polymorphisms -1154 G/A and -460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer.
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases.
Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis--correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met.
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
Vascular endothelial growth factor-C (VEGF-C) is a more specific risk factor for lymph node metastasis than VEGF-D in submucosal colorectal cancer.
Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma.
Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy.
Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy.
Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis.
VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells.
VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis.
VEGF, Flt-1, and microvessel density in primary tumors as predictive factors of colorectal cancer prognosis.
VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression.
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.
VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab.
VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer.
Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
X-box binding protein 1 (XBP-1) enhances colorectal cancer cell invasion.
Ziv-aflibercept in metastatic colorectal cancer.
Ziv-aflibercept: A cost-effective, off-label, highly potent antagonist of vascular endothelial growth factor.
ZKSCAN3 Facilitates Liver Metastasis of Colorectal Cancer Associated with CEA-expressing Tumor.
[A Case of Severe Bevacizumab-induced Ischemic Pancolitis, Treated with Conservative Management].
[Angiogenesis and colorectal cancer: a predictive and prognostic role for the vascular endothelial growth factor]
[Association between vascular endothelial growth factor gene 936 T/C polymorphism and colorectal cancer together with anastomotic leakage]
[Clinical research on angiogenesis in colorectal carcinoma and expression of CK20 mRNA in peripheral blood]
[Clinical significance of VEGF levels in serums of colorectal cancer patients at stage IV]
[Construction of adenovirus expressing anti-vascular endothelial growth factor hairpin ribozyme and its inhibition of growth of colorectal cancer HT-29 cells.]
[Determination of vascular endothelial growth factor (VEGF) concentration in serum of patients with colorectal carcinoma]
[Effect of jianpi-jiedu formula on tumor angiogenesis-relevant genes expression in colorectal cancer].
[Effect of siRNA targeting c-Myc and VEGF on human colorectal cancer cells]
[Evaluation of microvessel density and vascular endothelial growth factor in colorectal carcinoma with 64-multidetector-row CT perfusion imaging]
[Expression of angiopoietin-2 and vascular endothelial growth factor in human colon cancer].
[Expression of tissue factor and vascular endothelial growth factor in colorectal carcinoma]
[Expression of vascular endothelial growth factor and metastin in colorectal carcinoma.]
[Expression of vascular endothelial growth factor in colorectal cancer and its clinical significance]
[Expression of vascular growth factors in intestinal tissues in colorectal carcinoma patients with schistosomiasis japonica].
[Expression of vasohibin-1 in colorectal cancer tissue and its correlation with vascular endothelial growth factor A and microvessei density].
[Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis]
[In vitro antitumor effect of adenovirus containing CD-TK fusion gene driven by VEGF promoter on LoVo cells]
[Indication Avastin in ophthalmology].
[Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery]
[Postoperative serum vascular endothelial growth factor can be a marker for colorectal cancer recurrence]
[Relationship between the protein expression of P53, c-erbB-2, vascular endothelial growth factor and CD44 and the survival rates of stage II( colorectal cancer patients without radiochemotherapy after radical resection]
[Role of Ang-2, Tie-2 and VEGFR-2 in angiogenesis in colorectal carcinoma and their prognostic value].
[Serum vascular endothelial growth factor levels in patients with colorectal cancer and its prognostic significance]
[Significance of p53 and VEGF expression in liver metastasis from colorectal cancer]
[Significance of vascular endothelial growth factor expression in colorectal cancer]
[Targeted therapies for metastatic colorectal cancer].
[The cost study of first-?line treatment of metastatic colorectal carcinoma with bevacizumab-?containing regimen in the Czech Republic].
[The expression of vascular endothelial growth factor C, ETS-1, microvessal density, and microlymphaticdensity and their clinicopathologic in colorectal carcinoma]
[The relationship between plasma level of VEGF or soluble Flt-1 and efficacy of hepatic arterial chemotherapy in patients with liver metastasis of colorectal cancer]
[Therapeutic strategies using VEGF inhibitors in colorectal cancer.]
[Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)]
Coma
Decreased vascular endothelial growth factor response to acute hypoglycemia in type 2 diabetic patients with hypoglycemic coma.
Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer.
Communicable Diseases
Clinical significance of vascular endothelial growth factor in patients with primary lung cancer.
Overview of Brain-to-Gut Axis Exposed to Chronic CNS Bacterial Infection(s) and a Predictive Urinary Metabolic Profile of a Brain Infected by Mycobacterium tuberculosis.
Role of Hyperplasia of Gingival Lymphatics in Periodontal Inflammation.
Compartment Syndromes
Local application of VEGF compensates callus deficiency after acute soft tissue trauma-results using a limb-shortening distraction procedure in rabbit tibia.
complement factor d deficiency
A family with complement factor D deficiency.
A Type III Complement Factor D Deficiency: Structural insights for inhibition of the alternative pathway.
A vascular endothelial growth factor deficiency characterises scleroderma lung disease.
Adipsin deficiency does not impact atherosclerosis development in Ldlr-/- mice.
Alterations in sympathetic nervous system activity do not regulate adipsin gene expression in mice.
Complement factor D deficiency in an infant first seen with pneumococcal neonatal sepsis.
Deficiency of vascular endothelial growth factor-D does not affect murine adipose tissue development.
Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections.
Deletion of plasma thromboplastin factor D deficiency.
Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
Genetic deficiencies of the complement system and association with disease--early components.
HFD-induced hepatic lipid accumulation and inflammation are decreased in Factor D deficient mouse.
High in vivo levels of adipsin lead to increased knee tissue degradation in osteoarthritis: data from humans and animal models.
Impairment of adipsin expression is secondary to the onset of obesity in db/db mice.
Mesangial immune complex glomerulonephritis due to complement factor D deficiency.
Reduced adipsin expression in murine obesity: effect of age and treatment with the sympathomimetic-thermogenic drug mixture ephedrine and caffeine.
Vascular Endothelial Growth Factor-D Modulates Calibre And Function Of Initial Lymphatics In The Dermis.
VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis.
[Factor D deficiency]
Conjunctivitis, Allergic
Immunopathogenesis of conjunctival remodelling in vernal keratoconjunctivitis.
Vascular Endothelial Growth Factor (VEGF) Serological and Lacrimal Signaling in Patients Affected by Vernal Keratoconjunctivitis (VKC).
Consciousness Disorders
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.
Contracture
A Nanomedicine Approach to Effectively Inhibit Contracture During Bladder Acellular Matrix Allograft-Induced Bladder Regeneration by Sustained Delivery of Vascular Endothelial Growth Factor.
Vascular endothelial growth factor 121 and 165 in the subacromial bursa are involved in shoulder joint contracture in type II diabetics with rotator cuff disease.
Corneal Diseases
Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.
Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization.
Corneal Injuries
Acute corneal injury in rabbits following nitrogen mustard ocular exposure.
Electrospun formulations of bevacizumab for sustained release in the eye.
Microporous Drug Delivery System for Sustained Anti-VEGF Delivery to the Eye.
Topical dimethyl sulfoxide inhibits corneal neovascularization and stimulates corneal repair in rabbits following acid burn.
Corneal Neovascularization
A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents.
Activin a in the regulation of corneal neovascularization and vascular endothelial growth factor expression.
Apatinib-loaded nanoparticles suppress vascular endothelial growth factor-induced angiogenesis and experimental corneal neovascularization.
Application of plasmid DNA encoding IL-18 diminishes development of herpetic stromal keratitis by antiangiogenic effects.
Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.
Captopril suppresses post-transplantation angiogenic activity in rat allograft coronary vessels.
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization.
Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits.
Corneal neovascularization after excimer keratectomy wounds in matrilysin-deficient mice.
Corneal neovascularization during experimental fungal keratitis.
Delayed neovascularization in inflammation-induced corneal neovascularization in interleukin-10-deficient mice.
Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents.
Effects of HGF and KGF gene silencing on vascular endothelial growth factor and its receptors in rat ultraviolet radiation?induced corneal neovascularization.
Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization.
Effects of nicotine on corneal wound healing following acute alkali burn.
Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.
Effects of VEGF Inhibitor Conbercept on Corneal Neovascularization Following Penetrating Keratoplasty in Rabbit Model.
Efficacy of Subconjunctival Aflibercept Versus Bevacizumab for Prevention of Corneal Neovascularization in a Rat Model.
Essential contribution of CCL3 to alkali-induced corneal neovascularization by regulating vascular endothelial growth factor production by macrophages.
Evaluation of cytotoxic effects of bevacizumab on human corneal cells.
Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization.
Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.
Frontline Science: Aspirin-triggered resolvin D1 controls herpes simplex virus-induced corneal immunopathology.
Genetic loci that control the size of laser-induced choroidal neovascularization.
IL-17A Differentially Regulates Corneal Vascular Endothelial Growth Factor (VEGF)-A and Soluble VEGF Receptor 1 Expression and Promotes Corneal Angiogenesis after HSV Infection.
In vivo significance of ICAM-1--dependent leukocyte adhesion in early corneal angiogenesis.
In-vitro binding analysis of anti-human vascular endothelial growth factor antibodies bevacizumab and aflibercept with canine, feline, and equine vascular endothelial growth factor.
Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.
Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA.
Inhibition of Ocular Angiogenesis by Diced Small Interfering RNAs (siRNAs) Specific to Vascular Endothelial Growth Factor (VEGF).
Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1.
Intrastromal injection of bevacizumab in patients with corneal neovascularization.
KH902, a Recombinant Human VEGF Receptor Fusion Protein, Reduced the Level of Placental Growth Factor in Alkali Burn Induced-Corneal Neovascularization.
Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants.
Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivo.
Macrophage inflammatory protein-2 and vascular endothelial growth factor regulate corneal neovascularization induced by infection with Pseudomonas aeruginosa in mice.
Plumbagin Inhibits Tumor Angiogenesis and Tumor Growth through VEGFR2-mediated Ras Signaling Pathway.
Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro.
Prevention of Corneal Neovascularization by Adenovirus Encoding Human Vascular Endothelial Growth Factor Soluble Receptor (s-VEGFR1) in Lacrimal Gland.
Pterygium Pathology: A Prospective Case-Control Study on Tear Film Cytokine Levels.
Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.
Role of miR-132 in angiogenesis after ocular infection with herpes simplex virus.
Simultaneous in vivo imaging of blood and lymphatic vessel growth in Prox1-GFP/Flk1::myr-mCherry mice.
Soluble vascular endothelial growth factor receptor-3 suppresses allosensitization and promotes corneal allograft survival.
Suppression of Allograft Rejection with Soluble VEGF Receptor 2 Chimeric Protein in a Mouse Model of Corneal Transplantation.
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.
The association between corneal neovascularization and visual acuity: a systematic review.
The effect of bevacizumab on corneal neovascularization in rabbits.
The effect of diabetes on endothelin, interleukin-8 and vascular endothelial growth factor-mediated angiogenesis in rats.
The Hedgehog transcription factor Gli3 modulates angiogenesis.
The impact of tacrolimus on vascular endothelial growth factor in experimental corneal neovascularization.
The role of microRNAs in corneal neovascularization and its relation to VEGF.
Topical dimethyl sulfoxide inhibits corneal neovascularization and stimulates corneal repair in rabbits following acid burn.
Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization.
Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing.
Vascular endothelial growth factor (VEGF) in normal human corneal epithelium: detection and physiological importance.
Vascular Endothelial Growth Factor Inhibitors for Treatment of Corneal Neovascularization: A Meta-Analysis.
VEGF Trap(R1R2) suppresses experimental corneal angiogenesis.
VEGF TrapR1R2 Suspended in the Semifluorinated Alkane F6H8 Inhibits Inflammatory Corneal Hem- and Lymphangiogenesis.
[A synthetic peptide selected by bioinformatics inhibits mouse corneal neovascularization]
[Antisense vascular endothelial growth factor suppressed corneal neovascularization in rats]
[Effect of integrin ?9?1 on corneal neovascularization and vascular endothelial growth factor A expression after corneal suture in rats].
[Small interference RNA targeting vascular endothelial growth factor inhibits rat corneal neovascularization]
[VEGF short hairpin RNA expression plasmid blocks VEGF expression in rat vascular endothelial cell and inhibits rat corneal neovascularization].
Corneal Ulcer
Evaluation of pigment epithelium-derived factor concentration in equine amniotic membrane homogenate and its in-vitro vascular endothelial growth factor inhibition effect in tears of dogs with vascularized ulcerative keratitis.
Coronary Aneurysm
Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease.
Coronary Artery Disease
A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial.
Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state.
AdGVVEGF121.10 (GenVec).
Adipsin deficiency does not impact atherosclerosis development in Ldlr-/- mice.
Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting.
Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.
Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle.
Association between serum adipsin and plaque vulnerability determined by optical coherence tomography in patients with coronary artery disease.
Association of genetic polymorphisms in vascular endothelial growth factor with susceptibility to coronary artery disease: a meta-analysis.
Association of Genetic Variants in miR-217 Gene with Risk of Coronary Artery Disease: A Case-Control Study.
Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease.
Cardiovascular gene therapy: current status and therapeutic potential.
Coronary Artery Disease: Vascular Endothelial Growth Factor and Fibroblast Growth Factor.
Correlation between adiponectin, chemerin, vascular endothelial growth factor and epicardial fat volume in patients with coronary artery disease.
Distinct Characteristics of VEGF-D and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease.
Dysregulation of Vascular Endothelial Growth Factor Receptor-2 by Multiple miRNAs in Endothelial Colony-Forming Cells of Coronary Artery Disease.
Effects of coronary artery disease on expression and microvascular response to VEGF.
Effects of L-arginine on the endogenous angiogenic response in a model of hypercholesterolemia.
Functional vascular endothelial growth factor gene polymorphisms and diabetes: effect on coronary collaterals in patients with significant coronary artery disease.
Further evidence for the contribution of the vascular endothelial growth factor gene in coronary artery disease susceptibility.
Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.
Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results.
Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.
Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease.
Improved expression by cytomegalovirus promoter/enhancer and behavior of vascular endothelial growth factor gene after myocardial injection of naked DNA.
Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis.
Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.
Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD).
Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease.
Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay.
MiR-206 Suppresses the Progression of Coronary Artery Disease by Modulating Vascular Endothelial Growth Factor (VEGF) Expression.
Mobilization of haematopoietic and non-haematopoietic cells by granulocyte-colony stimulating factor and vascular endothelial growth factor gene therapy in patients with stable severe coronary artery disease.
Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of l-arginine in a porcine model of endothelial dysfunction.
Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease.
Periostin gene polymorphisms, protein levels and risk of incident coronary artery disease.
Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.
Plasma haemoxygenase-1 in coronary artery disease. A comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor.
Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary artery disease.
Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents.
Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors.
Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease.
Serum VEGF: Diagnostic Value of Acute Coronary Syndrome from Stable Angina Pectoris and Prognostic Value of Coronary Artery Disease.
Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.
Systemic and intracardiac vascular endothelial growth factor and angiopoietin-1 and -2 levels in coronary artery disease: effects of angioplasty.
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
The association of functional polymorphisms in genes encoding growth factors for endothelial cells and smooth muscle cells with the severity of coronary artery disease.
The impact of vascular endothelial growth factor +405 C/G polymorphism on long-term outcome and severity of coronary artery disease.
The relationship between number and function of EPCs and concentration of VEGF165 and SDF-1 in coronary artery spasm.
The relationship between severity of coronary artery disease and plasma level of vascular endothelial growth factor.
The Role of Vascular Endothelial Growth Factor Gene as the Genetic Marker of Atherothrombotic Disorders and in the Gene Therapy of Coronary Artery Disease.
The role of vascular endothelial growth factor gene as the genetic marker of atherothrombotic disorders and in the gene therapy of coronary artery disease.
Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy?
Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review.
Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease.
Vascular endothelial growth factor and hypoxia-inducible factor-1? gene polymorphisms and coronary collateral formation in patients with coronary chronic total occlusions.
Vascular endothelial growth factor gene polymorphisms in susceptibility to coronary artery disease.
Vascular endothelial growth factor gene transfer therapy for coronary artery disease: A systematic review and meta-analysis.
Vascular endothelial growth factor genetic variability and coronary artery disease in Brazilian population.
Vascular endothelial growth factor polymorphisms and coronary artery disease: a systemic review and meta-analysis.
Vascular endothelial growth factor polymorphisms and extent of coronary atherosclerosis in Chinese population with advanced coronary artery disease.
Vascular Endothelial Growth Factor, Soluble Fms-Like Tyrosine Kinase 1, and the Severity of Coronary Artery Disease.
Vasorelaxation induced by vascular endothelial growth factor in the human internal mammary artery and radial artery.
VEGF gene therapy cooperatively recruits molecules from the immune system and stimulates cell homing and angiogenesis in refractory angina.
[Plaque progression and destabilization in human coronary arteries]
Coronary Disease
Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study.
Association between VEGF polymorphisms (936c/t, -460t/c and -634g/c) with haplotypes and coronary heart disease susceptibility.
Association of Genetic Polymorphisms on Vascular Endothelial Growth Factor and its Receptor Genes with Susceptibility to Coronary Heart Disease.
Comparison of vascular endothelial growth factor and fibroblast growth factor-2 in a swine model of endothelial dysfunction.
Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease.
IsoDA: Isoform-Disease Association Prediction by Multiomics Data Fusion.
MiR-214 regulates the pathogenesis of patients with coronary artery disease by targeting VEGF.
Novel role of lactosylceramide in vascular endothelial growth factor-mediated angiogenesis in human endothelial cells.
Plasma indices of angiogenesis in rheumatoid disease: Relationship to cardiovascular risk factors and cardiac function.
Polymorphisms of KDR gene are associated with coronary heart disease.
Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT).
Serum levels of vascular endothelial growth factor in patients with angina pectoris and acute myocardial infarction.
The influence of genotype on vascular endothelial growth factor and regulation of myocardial collateral blood flow in patients with acute and chronic coronary heart disease.
Vascular endothelial growth factor A polymorphisms are associated with increased risk of coronary heart disease: a meta-analysis.
Vascular endothelial growth factor gene polymorphisms and coronary heart disease: a systematic review and meta-analysis.
[Effect of soluble epoxide hydrolase inhibitor on the function of endothelial progenitor cells in patients with coronary heart disease.]
Coronary Occlusion
Administration of vascular endothelial growth factor adjunctive to fetal cardiomyocyte transplantation and improvement of cardiac function in the rat model.
Exercise training enhances vasodilation responses to vascular endothelial growth factor in porcine coronary arterioles exposed to chronic coronary occlusion.
Coronary Stenosis
Myocardial ischemia enhances the expression of acidic fibroblast growth factor in human pericardial fluid.
Cough
Analysis of vascular endothelial growth factor levels in induced sputum samples from patients with cough variant asthma.
The effect of carvacrol on inflammatory mediators and respiratory symptoms in veterans exposed to sulfur mustard, a randomized, placebo-controlled trial.
The effect of Zataria multiflora on inflammatory cytokine and respiratory symptoms in veterans exposed to sulfur mustard.
COVID-19
A 34-Year-Old Woman from Brazil with Pulmonary Lymphangioleiomyomatosis Diagnosed by Raised Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels and Lung Cysts on Computed Tomography Imaging Presenting with COVID-19 Pneumonia.
Can COVID-19 induce glioma tumorogenesis through binding cell receptors?
Cell Adhesion Molecules and Vascular Endothelial Growth Factor at the Systemic and Alveolar Level in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome.
Comment on: Cell Adhesion Molecules and Vascular Endothelial Growth Factor at the Systemic and Alveolar Level in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome.
Complement dysregulation is associated with severe COVID-19 illness.
COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects.
Direct and Precise Measurement of Bevacizumab Levels in Human Plasma Based on Controlled Methionine Oxidation and Multiple Reaction Monitoring.
Does the compromised sleep and circadian disruption of night and shiftworkers make them highly vulnerable to 2019 coronavirus disease (COVID-19)?
Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19).
Excessive Matrix Metalloproteinase-1 and Hyperactivation of Endothelial Cells Occurred in COVID-19 Patients and Were Associated With the Severity of COVID-19.
Genetic risk for severe COVID-19 correlates with lower inflammatory marker levels in a SARS-CoV-2-negative cohort.
Hypercytokinemia in COVID-19: Tear cytokine profile in hospitalized COVID-19 patients.
Hypotheses about sub-optimal hydration in the weeks before coronavirus disease (COVID-19) as a risk factor for dying from COVID-19.
Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses.
Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients.
Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality.
Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19.
Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology.
Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19.
Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak.
VEGF-D: a novel biomarker for detection of COVID-19 progression.
Craniocerebral Trauma
Neurological surgery at the National Institutes of Health.
Significantly high concentrations of vascular endothelial growth factor in chronic subdural hematoma with trabecular formation.
Craniopharyngioma
Angiogenesis in craniopharyngiomas: Microvascular density and tissue expression of the vascular endothelial growth factor (VEGF) and endostatin.
Expression of Matrix Metalloproteinase-9, Type IV Collagen and Vascular Endothelial Growth Factor in Adamantinous Craniopharyngioma.
Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma.
Phosphorus-32 interstitial radiotherapy for recurrent craniopharyngioma: Expressions of vascular endothelial growth factor and its receptor-2 and imaging features of tumors are associated with tumor radiosensitivity.
Crohn Disease
Altered expression of angiogenic factors in the VEGF-Ets-1 cascades in inflammatory bowel disease.
Anti-TNF-alpha antibody (infliximab) therapy supports the recovery of eNOS and VEGFR2 protein expression in endothelial cells.
Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease.
Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease.
Increased expression of VEGF and CD146 in patients with inflammatory bowel disease.
Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis.
Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease (Br J Surg 2004; 91: 72-77).
Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease.
Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients.
Intestinal growth factors: Potential use in the treatment of inflammatory bowel disease and their role in mucosal healing.
Obliterative arteritis with nitric oxide synthase and HLA-DR expression in Crohn's colitis.
Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients.
Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease.
Subclinical gut inflammation in spondyloarthritis is associated with a pro-angiogenic intestinal mucosal phenotype.
The Relationship between Ocular Vascular Changes and the Levels of Malondialdehyde and Vascular Endothelial Growth Factor in Patients with Inflammatory Bowel Disease.
Up-Regulation of Intestinal Vascular Endothelial Growth Factor by Afa/Dr Diffusely Adhering Escherichia coli.
Vascular endothelial growth factor (VEGF) in Crohn's disease: increased production by peripheral blood mononuclear cells and decreased VEGF165 labeling of peripheral CD14+ monocytes.
Vascular endothelial growth factor secretion from mesenteric adipose tissue and from creeping fat in Crohn's disease.
[Association of vascular endothelial growth factor gene polymorphisms with Crohn's disease among Chinese patients].
[Vascular development in inflammatory bowel disease.]
Cryptogenic Organizing Pneumonia
VEGF and bFGF are highly expressed in intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia.
Cryptorchidism
The relationship between vascular endothelial growth factor and spermatogenesis disturbance in an experimentally-induced unilateral cryptorchidism murine model.
Cystadenocarcinoma
Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
Cystadenocarcinoma, Mucinous
Effects of antisense oligodeoxynucleotide to follicle-stimulating hormone receptor on the expression of proliferating cell nuclear antigen and vascular endothelial growth factor in primary culture cells derived from human ovarian mucinous cystadenocarcinoma.
Cystadenoma
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma.
Cystadenoma, Papillary
Expression of vascular endothelial growth factor in von Hippel-Lindau syndrome-associated papillary cystadenoma of the epididymis.
Cystadenoma, Serous
Serous cystic neoplasms of the pancreas: clinicopathologic and molecular characteristics.
Cystic Fibrosis
Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases.
Elevated vascular endothelial growth factor is correlated with elevated erythropoietin in stable, young cystic fibrosis patients.
Genetics of chronic obstructive pulmonary disease, beyond a1-antitrypsin deficiency.
Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.
Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation.
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Vascular endothelial growth factor increases pulmonary vascular permeability in cystic fibrosis patients undergoing lung transplantation.
Cystitis
Acute stress and intravesical corticotropin-releasing hormone induces mast cell dependent vascular endothelial growth factor release from mouse bladder explants.
Increased vascular endothelial growth factor expression in patients with bladder pain syndrome/interstitial cystitis: its association with pain severity and glomerulations.
Upregulation of vascular endothelial growth factor isoform VEGF-164 and receptors (VEGFR-2, Npn-1, and Npn-2) in rats with cyclophosphamide-induced cystitis.
Uroprotective effect of oleuropein in a rat model of hemorrhagic cystitis.
Cystitis, Interstitial
Angiogenesis in bladder tissues is strongly correlated with urinary frequency and bladder pain in patients with interstitial cystitis/bladder pain syndrome.
Increased Expression of Hypoxia-inducible Factor-1? and Vascular Endothelial Growth Factor Associated With Glomerulation Formation in Patients With Interstitial Cystitis.
Cysts
A 34-Year-Old Woman from Brazil with Pulmonary Lymphangioleiomyomatosis Diagnosed by Raised Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels and Lung Cysts on Computed Tomography Imaging Presenting with COVID-19 Pneumonia.
A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470.
Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
An immunohistochemical and ultrastructural study of pancreatic microcystic serous cyst adenoma with special reference to tumor-associated microvasculature and vascular endothelial growth factor in tumor cells.
CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors.
Chronic treatment with tempol does not significantly ameliorate renal tissue hypoxia or disease progression in a rodent model of polycystic kidney disease.
Comparative analysis of the immunohistochemical expression of vascular endothelial growth factor and matrix metalloproteinase-9 in keratocystic odontogenic tumor, dentigerous cyst and radicular cyst.
Cytohistological diagnosis of pancreatic serous cystadenoma: a multimodal approach.
Cytokines accumulated in acquired renal cysts in long-term hemodialysis patients.
Delayed enlargement of brain edema after resection of intracranial meningioma: two case reports.
Differential effects of interferon-alpha and -beta on the secretion of vascular endothelial growth factor by eutopic and ectopic endometrial stromal cells.
Edema is a precursor to central nervous system peritumoral cyst formation.
Effects of Increased Renal Tubular Vascular Endothelial Growth Factor (VEGF) on Fibrosis, Cyst Formation, and Glomerular Disease.
Endothelial dysfunction and angiogenesis in autosomal dominant polycystic kidney disease.
Endothelial-epithelial communication in polycystic kidney disease: Role of vascular endothelial growth factor signalling.
Enhancing gliotic cyst wall with microvascular proliferation adjacent to a meningioma.
ERK1/2-Dependent Vascular Endothelial Growth Factor Signaling Sustains Cyst Growth in Polycystin-2 Defective Mice.
Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM).
Expression of cyclooxygenase-2 and vascular endothelial growth factor in ovarian endometriotic cysts and their relationship with angiogenesis.
Fulminant liver failure in a patient affected by polycystic liver disease and liver metastases from breast carcinoma.
Heterogeneous appearance of VEGF (vascular endothelial growth factor) immunopositivity in cyst capsules of endometrioma.
Immunohistochemical analysis of vascular endothelial growth factor cellular expression in ovarian endometriomata.
Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
Influence of vascular endothelial growth factor inhibition on simple renal cysts in patients receiving bevacizumab-based chemotherapy.
Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.
Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis.
miR-503, a microRNA epigenetically repressed in endometriosis, induces apoptosis and cell-cycle arrest and inhibits cell proliferation, angiogenesis, and contractility of human ovarian endometriotic stromal cells.
Ovarian Fibrosis: A Phenomenon of Concern.
Pathology, genetics and cell biology of hemangioblastomas.
Polycystic kidney disease: a case of suppressed autophagy?
Posttranslational regulation of polycystin-2 protein expression as a novel mechanism of cholangiocyte reaction and repair from biliary damage.
Schwannoma cells induce a tumor-cell-specific cytotoxic-T-cell response upon transplantation into syngeneic rats but escape elimination through the secretion of immunosuppressive factors.
Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid.
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
Ultramicronized palmitoylethanolamide reduces viscerovisceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis: role of mast cells.
Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression.
Vascular endothelial growth factor in adnexal masses.
Vascular endothelial growth factor in ovarian cyst fluid.
Vascular endothelial growth factor in thyroid cyst fluids.
Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.
Deafness
Defining the Inflammatory Microenvironment in the Human Cochlea by Perilymph Analysis: Toward Liquid Biopsy of the Cochlea.
Dementia
Arterial Blood Pressure Variability and Other Vascular Factors Contribution to the Cognitive Decline in Parkinson's Disease.
Efficacy of the combined use of donepezil with either quetiapine or sodium valproate in patients with Alzheimer's disease with behavioral and psychological symptoms of dementia, and their effects on vascular endothelial growth factors.
Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease.
Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports.
Reduced Vascular Endothelial Growth Factor and Capillary Density in the Occipital Cortex in Dementia with Lewy Bodies.
Taekwondo Enhances Cognitive Function as a Result of Increased Neurotrophic Growth Factors in Elderly Women.
Value of a Panel of 6 Serum Biomarkers to Differentiate between Healthy Controls and Mild Cognitive Impairment Due to Alzheimer Disease.
Dementia, Vascular
Bone marrow mononuclear cell transplantation promotes therapeutic angiogenesis via upregulation of the VEGF-VEGFR2 signaling pathway in a rat model of vascular dementia.
Haplotype analysis of single nucleotide polymorphisms in VEGF gene for vascular dementia.
Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia.
Influences of Bushen Xingnao Decoction on expression of vascular endothelial growth factor, IL-1? and tumor necrosis factor-? in vascular dementia rats.
Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia.
[Acupuncture and moxibustion for vascular dementia and its effect on serum VEGF and AChE].
[Effect of acupuncture technique of Tiaoxin Tongdu on learning-memory ability and expressions of hippocampal VEGF and Ang-1 in rats with vascular dementia].
[Effects of modxibustion on the expressions of hippocampal VEGF, flt-1, bFGF, and bFGF-r in vascular dementia rats].
Demyelinating Diseases
Reduced EGFR signaling in progenitor cells of the adult subventricular zone attenuates oligodendrogenesis after demyelination.
VEGF- and PDGF-dependent proliferation of oligodendrocyte progenitor cells in the medulla oblongata after LPC-induced focal demyelination.
Dengue
Activation of dengue virus-specific T cells modulates vascular endothelial growth factor receptor 2 expression.
Complement protein levels and MBL2 polymorphisms are associated with dengue and disease severity.
Host biomarkers are associated with progression to dengue haemorrhagic fever: a nested case-control study.
Impaired production of immune mediators in dengue virus type 2-infected mononuclear cells of adults with end stage renal disease.
Mast cell mediators in relation to dengue severity: A systematic review and meta-analysis.
Pathogenesis of vascular leak in dengue virus infection.
Profile of time-dependent VEGF upregulation in human pulmonary endothelial cells, HPMEC-ST1.6R infected with DENV-1, -2, -3, and -4 viruses.
Relationship between circulating vascular endothelial growth factor and its soluble receptors in adults with dengue virus infection: a case-control study.
Role of vascular endothelial growth factor (VEGF) in the neurological manifestations of dengue: a preliminary study.
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
The predictive and diagnostic accuracy of vascular endothelial growth factor and pentraxin-3 in severe dengue.
The role of vascular endothelial growth factor leading to vascular leakage in children with dengue virus infection.
VEGF and its receptors in dengue virus infection.
Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic Fever.
Dental Caries
Caffeic Acid Phenethyl Ester (CAPE) Induces VEGF Expression and Production in Rat Odontoblastic Cells.
Clinical antibacterial effectiveness and biocompatibility of gaseous ozone after incomplete caries removal.
Dental Plaque
Dental hypofunction alters subgingival microorganisms: a pilot study.
Dentigerous Cyst
Comparative analysis of the immunohistochemical expression of vascular endothelial growth factor and matrix metalloproteinase-9 in keratocystic odontogenic tumor, dentigerous cyst and radicular cyst.
Immunohistochemical expression of vascular endothelial growth factor in keratocystic odontogenic tumor, dentigerous cyst, and radicular cyst: A comparative study.
VEGF and VEGFR2 in dentigerous cysts associated with impacted third molars.
Dermatitis
Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation.
Major amino acid sequence variants of viral vascular endothelial growth factor are functionally equivalent during Orf virus infection of sheep skin.
Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.
Vascular endothelial growth factor partially induces pruritus via epidermal hyperinnervation in imiquimod-induced psoriasiform dermatitis in mice.
Dermatitis, Allergic Contact
Lesional skin vascular endothelial growth factor levels correlate with clinical severity in patients with cement allergic contact dermatitis.
Dermatitis, Atopic
Association between the -1154 G/A promoter polymorphism of the vascular endothelial growth factor gene and atopic dermatitis.
Content of vascular endothelial growth factor in stratum corneum well correlates to local severity of acute inflammation in patients with atopic dermatitis.
Endostatin and Thrombospondin-1 levels are increased in the sera of patients with chronic spontaneous urticaria.
Expression of vascular endothelial growth factor and other cytokines in atopic dermatitis, and correlation with clinical features.
Increased plasma concentration of vascular endothelial growth factor in patients with atopic dermatitis and its relation to disease severity and platelet activation.
Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis.
Neurotensin serum levels and skin gene expression are increased in atopic dermatitis.
Dermatitis, Contact
Impaired contact hypersensitivity reaction and reduced production of vascular endothelial growth factor in tumor necrosis factor-alpha gene-deficient mice.
Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.
Dermatitis, Exfoliative
Exploring the in situ expression of vascular endothelial growth factor and endoglin in pemphigus foliaceus variants and pemphigus vulgaris.
Increased serum levels of vascular endothelial growth factor in pemphigus foliaceus patients with erythroderma.
Dermatitis, Phototoxic
Effects of yellow intraocular lenses on light-induced upregulation of vascular endothelial growth factor.
Dermatomyositis
Angiogenic cytokines in serum and cutaneous lesions of patients with polyarteritis nodosa.
Dermatomyositis with peripheral nervous system involvement: activation of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) in vasculitic lesions.
Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis.
Diabetes Complications
Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells.
Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes.
Dammarenediol-II Prevents VEGF-Mediated Microvascular Permeability in Diabetic Mice.
Diabetic Retinopathy and Vascular Endothelial Growth Factor Gene Insertion/Deletion Polymorphism.
Effect of insulin on plasma vascular endothelial growth factor in children with new-onset diabetes.
Gold Nanocrystals with Well-Defined Crystallographic {111} Facets Suppress Pathological Neovascularization.
Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus.
Urinary biomarkers involved in type 2 diabetes: a review.
Vascular endothelial growth factor and diabetic complications.
VEGF-B signaling impairs endothelial glucose transcytosis by decreasing membrane cholesterol content.
[Evaluation of the vascular endothelial growth factor in children and adolescents with type 1 diabetes]
Diabetes Mellitus
Activation of Dopamine D1 Receptors in Dermal Fibroblasts Restores Vascular Endothelial Growth Factor-A Production by These Cells and Subsequent Angiogenesis in Diabetic Cutaneous Wound Tissues.
Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells.
Administration of Selenium Decreases Lipid Peroxidation and Increases Vascular Endothelial Growth Factor in Streptozotocin Induced Diabetes Mellitus.
Anti-Angiogenesis Drugs In Diabetic Retinopathy.
Aqueous Vascular Endothelial Growth Factor as a Predictor of Macular Thickening Following Cataract Surgery in Patients with Diabetes Mellitus.
Association between plasma adipsin level and mild cognitive impairment in Chinese patients with type 2 diabetes: a cross-sectional study.
Association between vascular endothelial growth factor and hypertension in children and adolescents type I diabetes mellitus.
Association between VEGF genetic variants and diabetic foot ulcer in Chinese Han population: A case-control study.
Association of the Vascular Endothelial Growth Factor Gene Polymorphism +936 C/T with Diabetic Neuropathy in Mexican Patients with Type 2 Diabetes Mellitus.
Association of VEGF gene family variants with central macular thickness and visual acuity after Aflibercept short-term treatment in diabetic patients: A pilot study.
Changes in Oxidative and Nitrosative Stress Indicators and Vascular Endothelial Growth Factor After Maximum-Intensity Exercise Assessing Aerobic Capacity in Males With Type 1 Diabetes Mellitus.
Changes in TL1A levels and associated cytokines during pathogenesis of diabetic retinopathy.
Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease.
Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition.
Circulating vascular endothelial growth factor (VEGF) levels in advanced stage cancer patients compared to normal controls and diabetes mellitus patients with critical ischemia.
Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus.
Circulating vascular endothelial growth factor is unaffected by acute hyperglycemia and hyperinsulinemia in type 1 diabetes mellitus.
Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus.
Denture stomatitis and salivary vascular endothelial growth factor in immediate complete denture wearers with type 2 diabetes.
Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes.
Diabetic Retinopathy and Vascular Endothelial Growth Factor Gene Insertion/Deletion Polymorphism.
Does conventional laser photocoagulation still have a place in the treatment of diabetic macular edema?
Downregulation of MicroRNA 29a/b exacerbated diabetic retinopathy by impairing the function of Müller cells via Forkhead box protein O4.
Effect of simvastatin on expression of VEGF and TGF-?1 in atherosclerotic animal model of type 2 diabetes mellitus.
Effects of Diabetes Mellitus on VEGF-Induced Proliferation Response in Bone Marrow Derived Endothelial Progenitor Cells.
Effects of laser photocoagulation on serum angiopoietin-1, angiopoietin-2, angiopoietin-1/angiopoietin-2 ratio, and soluble angiopoietin receptor Tie-2 levels in type 2 diabetic patients with proliferative diabetic retinopathy.
Effects of scaling and root planing on gingival crevicular fluid vascular endothelial growth factor level in chronic periodontitis patients with and without diabetes mellitus: A clinicobiochemical study.
Efficacy, safety and influencing factors of intra-calf muscular injection of bone marrow mononuclear cells in the treatment of type 2 diabetes mellitus-induced lower extremity vascular disease.
Elevation of serum apelin-13 associated with proliferative diabetic retinopathy in type 2 diabetic patients.
Endothelial HNF4? potentiates angiogenic dysfunction via enhancement of vascular endothelial growth factor resistance in T2DM.
Erythropoietin attenuates cardiac dysfunction by increasing myocardial angiogenesis and inhibiting interstitial fibrosis in diabetic rats.
Evaluation of VEGF gene polymorphisms and proliferative diabetic retinopathy in Mexican population.
Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in Apis mellifera Lawang propolis extract gel-treated traumatic ulcers in diabetic rats.
Hyperglycemia induced testicular damage in type 2 diabetes mellitus rats exhibiting microcirculation impairments associated with vascular endothelial growth factor decreased via PI3K/Akt pathway.
Hypoxic regulation of vascular endothelial growth factor in retinal cells.
Impaired angiogenesis following hind-limb ischemia in diabetes mellitus mice.
Improvement of insulin sensitivity in response to exercise training in type 2 diabetes mellitus is associated with vascular endothelial growth factor A expression.
Inhibition of glucose-induced vascular endothelial growth factor expression by Salvia miltiorrhiza hydrophilic extract in human microvascular endothelial cells: Evidence for mitochondrial oxidative stress.
Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy.
Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes.
MicroRNA-423 may regulate diabetic vasculopathy.
Modulation of miR29a improves impaired post-ischemic angiogenesis in hyperglycemia.
Myopia and diabetes mellitus as modificatory factors of glaucomatous optic neuropathy.
No effect of yeast-like fungi on lipid metabolism and vascular endothelial growth factor level in children and adolescents with type 1 diabetes mellitus.
Overexpression of lncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-?B signaling pathway in a rat model.
Placental vascular endothelial growth factor expression in pregnancies complicated by type 1 diabetes.
Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus.
Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus.
Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of ?-cell.
Polymorphisms in HIF-1a gene are not associated with diabetic retinopathy in China.
Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes.
Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus.
Protective effects of a novel drug RC28-E blocking both VEGF and FGF2 on early diabetic rat retina.
Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients: a cross-sectional study.
Regulation of transforming growth factor-beta, basic fibroblast growth factor, and vascular endothelial cell growth factor mRNA in peripheral blood leukocytes in patients with diabetic retinopathy.
Relationship between serum adipsin and the first phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance.
Results of intravitreal triamcinolone acetonide in patients with macular edema secondary to branch retinal vein occlusion.
Role of Fetuin-A and vascular endothelial growth factor In type 2 diabetes mellitus patients without and with retinopathy.
Self-Reported Physical Activity and Relations to Growth and Neurotrophic Factors in Diabetes Mellitus: The Framingham Offspring Study.
Sensitive, quantitative, and high-throughput detection of angiogenic markers using shape-coded hydrogel microparticles.
Serum fetuin-A levels are independently correlated with vascular endothelial growth factor and C-reactive protein concentrations in type 2 diabetic patients with diabetic retinopathy.
Serum levels of basic fibroblast growth factor and vascular endothelial growth factor in children and adolescents with type 1 diabetes mellitus.
SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR CONCENTRATION DECREASES IN CORRELATION WITH GLYCATED HEMOGLOBIN LEVELS IN PATIENTS WITH TYPE 2 DIABETES.
Serum vascular endothelial growth factor level is elevated in patients with impaired glucose tolerance and type 2 diabetes mellitus.
Skin capillary permeability in the diabetic foot with critical limb ischaemia: the effects of a phVEGF165 gene product.
Status of serum VEGF and ICAM-1 and its association with external limiting membrane and inner segment-outer segment junction disruption in type 2 diabetes mellitus.
Suppressive effect of aqueous humor from person with Type 2 diabetes with or without retinopathy on reactive oxygen species generation.
The effect of diabetes on endothelin, interleukin-8 and vascular endothelial growth factor-mediated angiogenesis in rats.
The effect of ramipril therapy on cytokines and parameters of incipient diabetic nephropathy in patients with type 1 diabetes mellitus.
The Increased Circulating Plasma Levels of Vascular Endothelial Growth Factor in Patients with Type 1 Diabetes Do Not Correlate to Metabolic Control.
The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes.
The role of NOS2A -954G/C and vascular endothelial growth factor +936C/T polymorphisms in type 2 diabetes mellitus and diabetic nonproliferative retinopathy risk management.
The role of production of adipsin and leptin in the development of insulin resistance in patients with abdominal obesity.
The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus.
The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy.
Three-dimensional-arterial spin labeling perfusion correlation with diabetes-associated cognitive dysfunction and vascular endothelial growth factor in type 2 diabetes mellitus rat.
Thrombotic microangiopathy in patients with diabetic nephropathy is associated with low VEGF expression and end-stage renal disease?.
Transforming growth factor-?1 signalling triggers vascular endothelial growth factor resistance and monocyte dysfunction in type 2 diabetes mellitus.
Treatment with Intramuscular Vascular Endothelial Growth Factor Gene Compared with Placebo for Patients with Diabetes Mellitus and Critical Limb Ischemia: A Double-Blind Randomized Trial.
Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial.
Urinary angiopoietin-2 is associated with albuminuria in patients with type 2 diabetes mellitus.
Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications.
Vascular Endothelial Growth Factor (VEGF) in the Pathogenesis of Diabetic Nephropathy of Type 1 Diabetes Mellitus.
Vascular endothelial growth factor (VEGF) levels of gingiva and gingival crevicular fluid in diabetic and systemically healthy periodontitis patients.
Vascular endothelial growth factor (VEGF)-related polymorphisms rs10738760 and rs6921438 are not risk factors for proliferative diabetic retinopathy (PDR) in patients with type 2 diabetes mellitus (T2DM).
Vascular endothelial growth factor (VEGF)-related single nucleotide polymorphisms rs10738760 and rs6921438 are not associated with diabetic retinopathy (DR) in Slovenian patients with type 2 diabetes mellitus (T2DM).
Vascular endothelial growth factor and its receptors in the placenta of women with type 1 diabetes mellitus.
Vascular endothelial growth factor during hypoglycemia in patients with type 1 diabetes mellitus: relation to cognitive function and renin-angiotensin system activity.
Vascular endothelial growth factor expression levels of gingiva in gingivitis and periodontitis patients with/without diabetes mellitus.
Vascular Endothelial Growth Factor Gene Polymorphism (rs2010963) and Its Receptor, Kinase Insert Domain-Containing Receptor Gene Polymorphism (rs2071559), and Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus.
Vascular endothelial growth factor-D is overexpressed in human cardiac allograft vasculopathy and diabetic atherosclerosis and induces endothelial permeability to low-density lipoproteins in vitro.
VEGF genetic polymorphisms may contribute to the risk of diabetic nephropathy in patients with diabetes mellitus: a meta-analysis.
VEGF levels in plasma in relation to metabolic control, inflammation, and microvascular complications in type-2 diabetes: A cohort study.
VEGF Levels in Plasma in Relation to Platelet Activation, Glycemic Control, and Microvascular Complications in Type 1 Diabetes Mellitus.
[Changes of plasma endothelin-1 and vascular endothelial growth factor in diabetic retinopathy and the clinical application value thereof]
[Concentration of VEGF-A in the intraocular fluid of rats with alloxan model of diabetes mellitus].
[Effect of acute insulin therapy on the concentration of vascular endothelial growth factor A (VEGF-A) in the intraocular fluid in an experiment].
[Role of vascular endothelial growth factor and monocyte chemoattractant protein-1 in the development of endothelial dysfunction in types 1 and 2 diabetes mellitus complicated by diabetic retinopathy].
[Role of vascular endothelial growth factor in the development of diabetic retinopathy in patients with type 1 diabetes mellitus]
[The assessment of the correlation between vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF-alpha), interleukin 6 (IL-6), glycaemic control (HbA1c) and the development of the diabetic retinopathy in children with diabetes mellitus type 1]
Diabetes Mellitus, Type 1
Albuminuria and VEGF as early markers of cardiovascular disturbances in young type 1 diabetic patients.
Changes in Oxidative and Nitrosative Stress Indicators and Vascular Endothelial Growth Factor After Maximum-Intensity Exercise Assessing Aerobic Capacity in Males With Type 1 Diabetes Mellitus.
Chronic treatment with vascular endothelial growth factor preserves agonist-evoked vascular responses in the streptozotocin-induced diabetic rat.
Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition.
Circulating vascular endothelial growth factor is unaffected by acute hyperglycemia and hyperinsulinemia in type 1 diabetes mellitus.
Clinical usefulness of videocapillaroscopy and selected endothelial cell activation markers in people with Type 1 diabetes mellitus complicated by microangiopathy.
Erythropoietin and vascular endothelial growth factor as risk markers for severe hypoglycaemia in type 1 diabetes.
Extracellular matrix-associated (GAGs, CTGF), angiogenic (VEGF) and inflammatory factors (MCP-1, CD40, IFN-?) in type 1 diabetes mellitus nephropathy.
Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria.
Involvement of vascular endothelial growth factor, CD44 and CD133 in periodontal disease and diabetes: an immunohistochemical study.
Modulation of miR29a improves impaired post-ischemic angiogenesis in hyperglycemia.
Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study.
No effect of yeast-like fungi on lipid metabolism and vascular endothelial growth factor level in children and adolescents with type 1 diabetes mellitus.
Placental vascular endothelial growth factor expression in pregnancies complicated by type 1 diabetes.
Podocyte vascular endothelial growth factor (Vegf ( 164 )) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes.
Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus.
Regulation of transforming growth factor-beta, basic fibroblast growth factor, and vascular endothelial cell growth factor mRNA in peripheral blood leukocytes in patients with diabetic retinopathy.
Serum levels of basic fibroblast growth factor and vascular endothelial growth factor in children and adolescents with type 1 diabetes mellitus.
Simultaneous pancreas-kidney transplantation in patients with type 1 diabetes reverses elevated MBL levels in association with MBL2 genotype and VEGF expression.
Single nucleotide polymorphisms of vascular endothelial growth factor gene intron 2 are markers for early progression of diabetic retinopathy in Japanese with type 1 diabetes.
The effect of ramipril therapy on cytokines and parameters of incipient diabetic nephropathy in patients with type 1 diabetes mellitus.
The Increased Circulating Plasma Levels of Vascular Endothelial Growth Factor in Patients with Type 1 Diabetes Do Not Correlate to Metabolic Control.
Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications.
Vascular Endothelial Growth Factor (VEGF) in the Pathogenesis of Diabetic Nephropathy of Type 1 Diabetes Mellitus.
Vascular endothelial growth factor and its receptors in the placenta of women with type 1 diabetes mellitus.
Vascular endothelial growth factor during hypoglycemia in patients with type 1 diabetes mellitus: relation to cognitive function and renin-angiotensin system activity.
[Assessment of growth factor levels in adolescents with type 1 diabetes mellitus and the beginning of diabetic microangiopathy]
[Comparative immunohistochemical evaluation of vascular endothelial growth factor and its receptors in the placental villi in gestational diabetes mellitus and type 1 diabetes].
[Evaluation of the vascular endothelial growth factor in children and adolescents with type 1 diabetes]
[Renal excretion of insulin-like growth factor 1 and vascular endothelial growth factor in patients with type 1 diabetes with nephropathy].
[Role of vascular endothelial growth factor in the development of diabetic retinopathy in patients with type 1 diabetes mellitus]
Diabetes Mellitus, Type 2
Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans.
Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial.
Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection.
Association between plasma adipsin level and mild cognitive impairment in Chinese patients with type 2 diabetes: a cross-sectional study.
Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: a meta-analysis.
Association between VEGF genetic variants and diabetic foot ulcer in Chinese Han population: A case-control study.
Association of polymorphisms in the vascular endothelial growth factor gene and its serum levels with diabetic retinopathy in Chinese patients with type 2 diabetes: a cross-sectional study.
Association of the Vascular Endothelial Growth Factor Gene Polymorphism +936 C/T with Diabetic Neuropathy in Mexican Patients with Type 2 Diabetes Mellitus.
Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes.
Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes.
Association of VEGF gene family variants with central macular thickness and visual acuity after Aflibercept short-term treatment in diabetic patients: A pilot study.
Association of VEGFA variants with altered VEGF secretion and type 2 diabetes: A case-control study.
Associations Between Genetic Polymorphisms in the VEGFA, ACE, and SOD2 Genes and Susceptibility to Diabetic Nephropathy in the Han Chinese.
Both vascular endothelial growth factor and soluble Flt-1 are increased in type 2 diabetes but not in impaired fasting glucose.
Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus.
CONNECTION BETWEEN SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS AND SEVERITY OF MICROANGIOPATHY IN PATIENTS WITH TYPE 2 DIABETES AND OBSTRUCTIVE SLEEP APNEA.
Cutaneous microangiopathy in patients with type 2 diabetes: impaired vascular endothelial growth factor expression and its correlation with neuropathy, retinopathy and nephropathy.
Denture stomatitis and salivary vascular endothelial growth factor in immediate complete denture wearers with type 2 diabetes.
Effect of simvastatin on expression of VEGF and TGF-?1 in atherosclerotic animal model of type 2 diabetes mellitus.
Effects of laser photocoagulation on serum angiopoietin-1, angiopoietin-2, angiopoietin-1/angiopoietin-2 ratio, and soluble angiopoietin receptor Tie-2 levels in type 2 diabetic patients with proliferative diabetic retinopathy.
Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model.
Efficacy, safety and influencing factors of intra-calf muscular injection of bone marrow mononuclear cells in the treatment of type 2 diabetes mellitus-induced lower extremity vascular disease.
Eicosapentaenoic acid down-regulates expression of the selenoprotein P gene by inhibiting SREBP-1c protein independently of the AMP-activated protein kinase pathway in H4IIEC3 hepatocytes.
Elevation of serum apelin-13 associated with proliferative diabetic retinopathy in type 2 diabetic patients.
Evaluation of VEGF gene polymorphisms and proliferative diabetic retinopathy in Mexican population.
Fracture healing and biomarker expression in a diabetic Zucker rat model.
Functional vascular endothelial growth factor -634G>C SNP is associated with proliferative diabetic retinopathy: a case-control study in a Brazilian population of European ancestry.
Hyperglycemia induced testicular damage in type 2 diabetes mellitus rats exhibiting microcirculation impairments associated with vascular endothelial growth factor decreased via PI3K/Akt pathway.
Impact of insulin treatment in diabetic macular edema therapy in type 2 diabetes.
Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease.
Impaired angiogenesis following hind-limb ischemia in diabetes mellitus mice.
Improvement of insulin sensitivity in response to exercise training in type 2 diabetes mellitus is associated with vascular endothelial growth factor A expression.
In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia.
Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.
Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes.
Involvement of vascular endothelial growth factor, CD44 and CD133 in periodontal disease and diabetes: an immunohistochemical study.
Meta-analysis of association between the -2578C/A polymorphism of the vascular endothelial growth factor and retinopathy in type 2 diabetes in Asians and Caucasians.
MicroRNA-423 may regulate diabetic vasculopathy.
Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus.
Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus.
Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of ?-cell.
Polymorphisms in HIF-1a gene are not associated with diabetic retinopathy in China.
Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes.
Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients: a cross-sectional study.
Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes.
Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast.
Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes.
Role of Fetuin-A and vascular endothelial growth factor In type 2 diabetes mellitus patients without and with retinopathy.
Saponins as adipokines modulator: A possible therapeutic intervention for type 2 diabetes.
Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells.
Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy.
Serum exosomal miR-377-3p inhibits retinal pigment epithelium proliferation and offers a biomarker for diabetic macular edema.
Serum fetuin-A levels are independently correlated with vascular endothelial growth factor and C-reactive protein concentrations in type 2 diabetic patients with diabetic retinopathy.
SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR CONCENTRATION DECREASES IN CORRELATION WITH GLYCATED HEMOGLOBIN LEVELS IN PATIENTS WITH TYPE 2 DIABETES.
Serum vascular endothelial growth factor level is elevated in patients with impaired glucose tolerance and type 2 diabetes mellitus.
Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects.
Statins in Low Doses Reduce VEGF and bFGF Serum Levels in Patients with Type 2 Diabetes Mellitus.
Status of serum VEGF and ICAM-1 and its association with external limiting membrane and inner segment-outer segment junction disruption in type 2 diabetes mellitus.
Suppressive effect of aqueous humor from person with Type 2 diabetes with or without retinopathy on reactive oxygen species generation.
The association between MCP-1, VEGF polymorphisms and their serum levels in patients with diabetic foot ulcer.
The impact of T786C and G894T polymorphisms of eNOS on vascular endothelial growth factor serum levels in type 2 diabetes patients.
The impairment of renal function is not associated to altered circulating vascular endothelial growth factor in patients with Type 2 diabetes and hypertension.
The role of insulin-like growth factor I and hypoxia inducible factor 1? in vascular endothelial growth factor expression in type 2 diabetes.
The role of NOS2A -954G/C and vascular endothelial growth factor +936C/T polymorphisms in type 2 diabetes mellitus and diabetic nonproliferative retinopathy risk management.
The role of production of adipsin and leptin in the development of insulin resistance in patients with abdominal obesity.
The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus.
Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.
Three-dimensional-arterial spin labeling perfusion correlation with diabetes-associated cognitive dysfunction and vascular endothelial growth factor in type 2 diabetes mellitus rat.
Transforming growth factor-?1 signalling triggers vascular endothelial growth factor resistance and monocyte dysfunction in type 2 diabetes mellitus.
Urinary angiopoietin-2 is associated with albuminuria in patients with type 2 diabetes mellitus.
Vascular endothelial growth factor (VEGF)-related polymorphisms rs10738760 and rs6921438 are not risk factors for proliferative diabetic retinopathy (PDR) in patients with type 2 diabetes mellitus (T2DM).
Vascular endothelial growth factor (VEGF)-related single nucleotide polymorphisms rs10738760 and rs6921438 are not associated with diabetic retinopathy (DR) in Slovenian patients with type 2 diabetes mellitus (T2DM).
Vascular Endothelial Growth Factor Gene Polymorphism (rs2010963) and Its Receptor, Kinase Insert Domain-Containing Receptor Gene Polymorphism (rs2071559), and Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus.
Vascular Endothelial Growth Factor Inhibition by dRK6 Causes Endothelial Apoptosis, Fibrosis, and Inflammation in the Heart via the Akt/eNOS Axis in db/db Mice.
Vascular endothelial growth factor insertion/deletion gene polymorphism in West Indian patients of type 2 diabetes and diabetic nephropathy.
Visceral Adiposity Index (VAI) Is Predictive of an Altered Adipokine Profile in Patients with Type 2 Diabetes.
[Achievements in molecular genetics studies of diabetes mellitus]
[Changes of plasma endothelin-1 and vascular endothelial growth factor in diabetic retinopathy and the clinical application value thereof]
[No association of vascular endothelial growth factor A gene rs9369425 polymorphism with glucose metabolism in Chinese Han population]
Diabetes, Gestational
Abstracts of the 68th annual meeting in University of Nottingham.
Association of vascular endothelial growth factor expression and polymorphisms with the risk of gestational diabetes mellitus.
Effects of Selenium Supplementation on Gene Expression Levels of Inflammatory Cytokines and Vascular Endothelial Growth Factor in Patients with Gestational Diabetes.
Gestational diabetes mellitus is associated with increased pro-migratory activation of vascular endothelial growth factor receptor 2 and reduced expression of vascular endothelial growth factor receptor 1.
The effects of magnesium supplementation on gene expression related to inflammatory markers, vascular endothelial growth factor, and pregnancy outcomes in patients with gestational diabetes.
The Incidence of Placental Abnormalities, Maternal and Cord Plasma Malondialdehyde and Vascular Endothelial Growth Factor Levels in Women with Gestational Diabetes Mellitus and Nondiabetic Controls.
[Comparative immunohistochemical evaluation of vascular endothelial growth factor and its receptors in the placental villi in gestational diabetes mellitus and type 1 diabetes].
Diabetic Angiopathies
Angiogenic biomarkers in pregnancy: defining maternal and fetal health.
Association of 18bp insertion/deletion polymorphism, at -2549 position of VEGF gene, with diabetic vascular complications in type 2 diabetes mellitus.
Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice.
Microvascular permeability is increased in both types of diabetes and correlates differentially with serum levels of insulin-like growth factor I (IGF-I) and vascular endothelial growth factor (VEGF).
Minor association of kinase insert domain-containing receptor gene polymorphism (rs2071559) with myocardial infarction in Caucasians with type 2 diabetes mellitus: case-control cross-sectional study.
MiR-20a ameliorates diabetic angiopathy in streptozotocin-induced diabetic rats by regulating intracellular antioxidant enzymes and VEGF.
Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox.
Pathophysiology of diabetic sexual dysfunction.
Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3.
Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Role of vascular endothelial growth factor in diabetic vascular complications.
The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients.
The role of insulin-like growth factor I and hypoxia inducible factor 1? in vascular endothelial growth factor expression in type 2 diabetes.
The role of vascular endothelial growth factor in the progression of diabetic vascular complications.
Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells.
[Assessment of growth factor levels in adolescents with type 1 diabetes mellitus and the beginning of diabetic microangiopathy]
Diabetic Cardiomyopathies
Decreased cardiac expression of vascular endothelial growth factor and redox imbalance in murine diabetic cardiomyopathy.
Metallothionein rescues hypoxia-inducible factor-1 transcriptional activity in cardiomyocytes under diabetic conditions.
Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor.
Diabetic Foot
Angiogenic effects of low-intensity cathodal direct current on ischemic diabetic foot ulcers: A randomized controlled trial.
Association between VEGF genetic variants and diabetic foot ulcer in Chinese Han population: A case-control study.
Effect of low-intensity direct current on expression of vascular endothelial growth factor and nitric oxide in diabetic foot ulcers.
Expression and Influence of Matrix Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 and Vascular Endothelial Growth Factor in Diabetic Foot Ulcers.
Growth factors for treating diabetic foot ulcers.
MiR-195-5p and miR-205-5p in extracellular vesicles isolated from diabetic foot ulcer wound fluid decrease angiogenesis by inhibiting VEGFA expression.
Role of growth factors and cytokines in diabetic foot ulcer healing: A detailed review.
The association between MCP-1, VEGF polymorphisms and their serum levels in patients with diabetic foot ulcer.
The relationship of the endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) gene polymorphism in Turkish type 2 diabetic patients with and without diabetic foot ulcers.
Vascular endothelial growth factor gene expression in patients' ischemic skeletal muscle with diabetic foot.
[Analysis of differential gene expressions of inflammatory and repair-related factors in chronic refractory wounds in clinic].
[Effects of Xiaodu Yuji Paste on Protein Expressions of VEGF/SDF-1 a/CXCR4 in Granulation Tissue of Diabetic Foot Patients].
Diabetic Nephropathies
2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice.
A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.
A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism.
Adrenomedullin mediates early phase angiogenesis induced diabetic nephropathy in STZ diabetic rats.
Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats.
Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody.
Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes.
Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model.
Association of Chemerin and Vascular Endothelial Growth Factor (VEGF) with Diabetic Nephropathy.
Association of VEGF-1499C-->T polymorphism with diabetic nephropathy in type 1 diabetes mellitus.
Associations Between Genetic Polymorphisms in the VEGFA, ACE, and SOD2 Genes and Susceptibility to Diabetic Nephropathy in the Han Chinese.
Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats.
Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice.
Combination of Angiotensin Converting Enzyme Insertion/Deletion (I/D) (rs4646994) and VEGF Polymorphism (+405G/C; rs2010963) Synergistically Associated With the Development, of Albuminuria in Iranian Patients With Type 2 Diabetes.
Diabetic nephropathy: serum miR-9 confers a poor prognosis in and is associated with level changes of vascular endothelial growth factor and pigment epithelium-derived factor.
Different expressions of protein kinase C-alpha, betaI and betaII in glomeruli of diabetic nephropathy patients.
Different localization and expression of protein kinase C-beta in kidney cortex of diabetic nephropathy mice and its role in telmisartan treatment.
Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy.
Early Enhanced Leucine-Rich ?-2-Glycoprotein-1 Expression in Glomerular Endothelial Cells of Type 2 Diabetic Nephropathy Model Mice.
Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients.
Effect of pioglitazone on diabetic nephropathy and expression of HIF-1? and VEGF in the renal tissues of type 2 diabetic rats.
Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property.
Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model.
Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy.
Elevated expression levels of serum insulin-like growth factor-1, tumor necrosis factor-? and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy.
Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy.
Extracellular matrix-associated (GAGs, CTGF), angiogenic (VEGF) and inflammatory factors (MCP-1, CD40, IFN-?) in type 1 diabetes mellitus nephropathy.
High glucose induced VEGF expression via PKC and ERK in glomerular podocytes.
Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions.
Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria.
Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.
Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man.
Long-term blockade of vascular endothelial growth factor receptor-2 aggravates the diabetic renal dysfunction associated with inactivation of the Akt/eNOS-NO axis.
Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat.
Microvascular basement membranes in diabetes mellitus.
Novel insights in the treatment of diabetic nephropathy.
Overexpression of calmodulin in pancreatic beta cells induces diabetic nephropathy.
Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy.
Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus.
Plasma vascular endothelial growth factor in Japanese Type 2 diabetic patients with and without nephropathy.
Podocyte vascular endothelial growth factor (Vegf ( 164 )) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes.
Protective effect of tetramethylpyrazine isolated from Ligusticum chuanxiong on nephropathy in rats with streptozotocin-induced diabetes.
Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients: a cross-sectional study.
Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease.
Reactive oxygen species, PKC-beta1, and PKC-zeta mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells.
Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy.
Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss.
Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes.
Response of VEGF to activation of viral receptors and TNF? in human mesangial cells.
Role of vascular endothelial growth factor in diabetic nephropathy.
Simultaneous pancreas-kidney transplantation in patients with type 1 diabetes reverses elevated MBL levels in association with MBL2 genotype and VEGF expression.
Simvastatin alleviates diabetes-induced VEGF-mediated nephropathy via the modulation of Ras signaling pathway.
Study of Angiopoietin-2 and vascular endothelial growth factor as markers of diabetic nephropathy onset in Egyptians diabetic patients with non-albuminuric state.
Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195.
Suramin enhances the urinary excretion of VEGF-A in normoglycemic and streptozotocin-induced diabetic rats.
Targeting angiogenesis and lymphangiogenesis in kidney disease.
Taurine alleviates the progression of diabetic nephropathy in type 2 diabetic rat model.
The effect of ramipril therapy on cytokines and parameters of incipient diabetic nephropathy in patients with type 1 diabetes mellitus.
The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease.
The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy.
The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes.
Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy.
Urinary cystatin C as a biomarker for diabetic nephropathy and its immunohistochemical localization in kidney in Zucker diabetic fatty (ZDF) rats.
Urocortin 1 improves renal function in rats with streptozotocin-induced diabetes by inhibiting overproduction of TGF-beta1 and VEGF.
Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy.
Vascular endothelial growth factor (VEGF) and VEGF receptors in diabetic nephropathy: expression studies in biopsies of type 2 diabetic patients.
Vascular Endothelial Growth Factor (VEGF) in the Pathogenesis of Diabetic Nephropathy of Type 1 Diabetes Mellitus.
Vascular endothelial growth factor and diabetic nephropathy.
Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy.
Vascular endothelial growth factor in diabetic nephropathy.
Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy.
Vascular endothelial growth factor insertion/deletion gene polymorphism in West Indian patients of type 2 diabetes and diabetic nephropathy.
Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats.
Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation.
Vascular endothelial growth factor-receptor 1 inhibition aggravates diabetic nephropathy through eNOS signaling pathway in db/db mice.
Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis.
Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy.
VEGF and the diabetic kidney: More than too much of a good thing.
VEGF genetic polymorphisms may contribute to the risk of diabetic nephropathy in patients with diabetes mellitus: a meta-analysis.
VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy.
[Correlation between expressions of VEGF and TRPC6 and their roles in podocyte injury in rats with diabetic nephropathy].
[Effect of Cordyceps sinensis on expressions of HIF-1? and VEGF in the kidney of rats with diabetic nephropathy].
[Effects of cilazapril on the expression of vascular endothelial growth factor and intercellular adhesion molecule-1 in diabetic rat glomeruli]
[Effects of low molecular weight heparin on vascular endothelial growth factor expression of early diabetic nephropathy]
[Expression of VEGF in kidney of diabetic rats]
Diabetic Neuropathies
Association of the Vascular Endothelial Growth Factor Gene Polymorphism +936 C/T with Diabetic Neuropathy in Mexican Patients with Type 2 Diabetes Mellitus.
Diabetes mellitus influences the expression of NPY and VEGF in neurons of rat trigeminal ganglion.
Electrophysiological changes, plasma vascular endothelial growth factor, fatty acid synthase, and adhesion molecules in diabetic neuropathy.
Gene therapy for the treatment of sensory neuropathy.
Gene Transfer of an Engineered Transcription Factor Promoting Expression of VEGF-A Protects Against Experimental Diabetic Neuropathy.
HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy.
Induction of vascular endothelial growth factor release by transcutaneous frequency modulated neural stimulation in diabetic polyneuropathy.
Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy.
Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage.
Skin biopsy as a diagnostic tool.
The role of growth factors in diabetic peripheral neuropathy.
Vascular Endothelial Growth Factor 936 C/T Gene Polymorphism in Indonesian Subjects with Diabetic Polyneuropathy.
Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats.
Vascular endothelial growth factor gene transfer for diabetic polyneuropathy.
Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial.
VEGF gene polymorphism association with diabetic foot ulcer.
[Biomarkers of the development and progression of diabetic polyneuropathy].
Diabetic Retinopathy
(Pro)renin receptor: Involvement in diabetic retinopathy and development of molecular targeted therapy.
A centrifugal fluidic immunoassay for ocular diagnostics with an enzymatically hydrolyzed fluorogenic substrate.
A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes.
A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
A cross-sectional study of vitreous and serum high mobility group box-1 levels in proliferative diabetic retinopathy.
A genetic variant regulating miR-126 is associated with sight threatening diabetic retinopathy.
A review of anti-VEGF agents for proliferative diabetic retinopathy.
A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.
Ablation of 4E-BP1/2 prevents hyperglycemia-mediated induction of VEGF expression in the rodent retina and in Muller cells in culture.
Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
Adrenomedullin Suppresses Vascular Endothelial Growth Factor-Induced Vascular Hyperpermeability and Inflammation in Retinopathy.
Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide.
Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells.
Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy.
Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications.
ALPHAB-CRYSTALLIN EXPRESSION IN EPIRETINAL MEMBRANE OF HUMAN PROLIFERATIVE DIABETIC RETINOPATHY.
Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey.
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.
An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy.
An endothelin type a receptor antagonist reverses upregulated VEGF and icam-1 levels in streptozotocin-induced diabetic rat retina.
Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy.
Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy.
Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes.
Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy.
ANGPTL-4 correlates with vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
Aniti-angiogenic shift in vitreous after vitrectomy in patients with proliferative diabetic retinopathy.
Anti-Angiogenesis Drugs In Diabetic Retinopathy.
Anti-angiogenic effect of adiponectin in human primary microvascular and macrovascular endothelial cells.
Anti-Diabetic Potential of the Essential Oil of Pinus koraiensis Leaves toward Streptozotocin-Treated Mice and HIT-T15 Pancreatic ? Cells.
Anti-vasopermeability effects of PEDF in retinal-renal disorders.
Antiangiogenic drugs and advanced proliferative diabetic retinopathy.
Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats.
Apelin is a crucial factor for hypoxia-induced retinal angiogenesis.
APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION: Results of a Prospective Trial. Report No. 2.
Aqueous concentrations of VEGF and soluble VEGF receptor-1 in diabetic retinopathy patients.
Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients.
Aqueous Levels of Angiopoietin-like 4 and Semaphorin 3E Correlate with Nonperfusion Area and Macular Volume in Diabetic Retinopathy.
Aqueous levels of VEGF correlate with retinal non-perfusion areas in patients with diabetic macular edema and macular edema secondary to central retinal vein occlusion.
Ascorbic acid prevents VEGF-induced increases in endothelial barrier permeability.
Association between a vascular endothelial growth factor gene polymorphism (rs2146323) and diabetic retinopathy: a meta-analysis.
Association between the Vascular Endothelial Growth Factor Single Nucleotide Polymorphisms and Diabetic Retinopathy Risk: A Meta-analysis.
Association of 150-kDa oxygen-regulated protein with vascular endothelial growth factor in proliferative diabetic retinopathy.
Association of polymorphisms in the vascular endothelial growth factor gene and its serum levels with diabetic retinopathy in Chinese patients with type 2 diabetes: a cross-sectional study.
Association of preoperative vitreous IL-8 and VEGF levels with visual acuity after vitrectomy in proliferative diabetic retinopathy.
Association of vascular endothelial growth factor -634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese.
Association of vascular endothelial growth factor -634G/C and receptor for advanced glycation end products G82S gene polymorphisms with diabetic retinopathy.
Association of Vascular Endothelial Growth Factor Polymorphisms with Nonproliferative and Proliferative Diabetic Retinopathy.
Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes.
Association of VEGF gene family variants with central macular thickness and visual acuity after Aflibercept short-term treatment in diabetic patients: A pilot study.
Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort.
Association of VEGF gene polymorphisms with diabetic retinopathy: a meta-analysis.
Association of VEGF Gene Polymorphisms with Susceptibility to Diabetic Retinopathy: A Systematic Review and Meta-Analysis.
Associations between Vascular Endothelial Growth Factor Gene Polymorphisms and Different Types of Diabetic Retinopathy Susceptibility: A Systematic Review and Meta-Analysis.
Attenuation of streptozotocin-induced diabetic retinopathy with low molecular weight fucoidan via inhibition of vascular endothelial growth factor.
Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
Basal and apical regulation of VEGF-A and placenta growth factor in the RPE/choroid and primary RPE.
Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes.
Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells.
Bioactive lipids in pathological retinopathy.
Bioceramic implant reduces intraocular VEGF levels.
Bioinformatics analysis of diabetic retinopathy using functional protein sequences.
Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Biomarkers in Diabetic Retinopathy.
Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells.
Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Catalogue of soluble proteins in human vitreous humor by one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrospray ionization mass spectrometry including seven angiogenesis-regulating factors.
Change of Vascular Endothelial Growth Factor Levels following Vitrectomy in Eyes with Proliferative Diabetic Retinopathy.
CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab.
Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy.
Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy.
Comparison of aqueous humor levels of PlGF and VEGF in proliferative diabetic retinopathy before and after intravitreal conbercept injection.
Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus.
Concentrations of VEGF and PlGF Decrease in Eyes After Intravitreal Conbercept Injection.
CONNECTION BETWEEN SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS AND SEVERITY OF MICROANGIOPATHY IN PATIENTS WITH TYPE 2 DIABETES AND OBSTRUCTIVE SLEEP APNEA.
Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy.
Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept.
Correlation between Ficolin-3 and Vascular Endothelial Growth Factor-to-Pigment Epithelium-Derived Factor Ratio in the Vitreous of Eyes with Proliferative Diabetic Retinopathy.
Correlation of complement fragment C5a with inflammatory cytokines in the vitreous of patients with proliferative diabetic retinopathy.
Correlation of electroretinography b-wave absolute latency, plasma levels of human basic fibroblast growth factor, vascular endothelial growth factor, soluble fatty acid synthase, and adrenomedullin in diabetic retinopathy.
CORRELATION OF INCREASED INTRAVITREOUS WNT3A WITH VASCULAR ENDOTHELIAL GROWTH FACTOR IN PROLIFERATIVE DIABETIC RETINOPATHY.
Correlation of the aqueous humor total antioxidant capacity, total oxidant status, and levels of IL-6 and VEGF with diabetic retinopathy status.
Correlation of vascular endothelial growth factor plasma levels and glycemic control in patients with diabetic retinopathy.
Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy.
Creation of different bioluminescence resonance energy transfer based biosensors with high affinity to VEGF.
Critical Role of Trophic Factors in Protecting Müller Glia: Implications to Neuroprotection in Age-Related Macular Degeneration, Diabetic Retinopathy, and Anti-VEGF Therapies.
Current and future pharmacological intervention for diabetic retinopathy.
Current status of anti-vascular endothelial growth factor therapy in Europe.
Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration.
Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension.
Dammarenediol-II Prevents VEGF-Mediated Microvascular Permeability in Diabetic Mice.
Detection of significantly high vitreous concentrations of fatty acid-binding protein 4 in patients with proliferative diabetic retinopathy.
Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy.
Diabetic Retinopathy and BDNF: A Review on Its Molecular Basis and Clinical Applications.
Diabetic Retinopathy and Vascular Endothelial Growth Factor Gene Insertion/Deletion Polymorphism.
Diabetic retinopathy and vascular endothelial growth factor.
Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.
Diabetic retinopathy: An update on treatment.
Diabetic retinopathy: current developments in pathogenesis and management.
Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema.
Differences between type 1 and type 2 diabetics in retinal neovascular tissue and vitreous humour.
Different plasma levels of vascular endothelial growth factor and nitric oxide between patients with choroidal and retinal neovascularization.
Differential expression and localization of human tissue inhibitors of metalloproteinases in proliferative diabetic retinopathy.
Distinct downstream signaling and the roles of VEGF and PlGF in high glucose-mediated injuries of human retinal endothelial cells in culture.
Does conventional laser photocoagulation still have a place in the treatment of diabetic macular edema?
Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy.
Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus.
Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularization.
Effect of ?-linolenic acid on streptozotocin-induced diabetic retinopathy indices in vivo.
Effect of atorvastatin on diabetic rat endothelial cells and retinal lesions.
Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina.
Effect of glycemic control and dyslipidemia on plasma vascular endothelial growth factor and pigment epithelium-derived factor in diabetic retinopathy patients in Northern Nigeria.
Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy.
Effect of ozone on vascular endothelial growth factor (VEGF) and related inflammatory cytokines in rats with diabetic retinopathy.
Effect of pan retinal photocoagulation on the serum levels of vascular endothelial growth factor in diabetic patients.
Effect of pan-retinal laser photocoagulation on plasma VEGF, endothelin-1 and nitric oxide in PDR.
Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness.
Effect of VEGF on retinal microvascular endothelial hydraulic conductivity: the role of NO.
Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy.
Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy.
Effects of HIF-1? on diabetic retinopathy angiogenesis and VEGF expression.
Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic Retinopathy.
Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.
Effects of laser photocoagulation on serum angiopoietin-1, angiopoietin-2, angiopoietin-1/angiopoietin-2 ratio, and soluble angiopoietin receptor Tie-2 levels in type 2 diabetic patients with proliferative diabetic retinopathy.
Effects of miRNA-200b on the development of diabetic retinopathy by targeting VEGFA gene.
Effects of quercetin on the expression of MCP-1, MMP-9 and VEGF in rats with diabetic retinopathy.
Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy.
Efficacy of troxerutin on streptozotocin-induced rat model in the early stage of diabetic retinopathy.
Elevated cell proliferation and VEGF production by high-glucose conditions in Müller cells involve XIAP.
Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy.
Elevated LRP6 levels correlate with vascular endothelial growth factor in the vitreous of proliferative diabetic retinopathy.
Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy.
Elevated vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy.
Elevated vitreous Lipocalin-2 levels of patients with proliferative diabetic retinopathy.
Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy.
Enalapril alters expression of key growth factors in experimental diabetic retinopathy.
Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms.
Endothelial and glial cell interaction in diabetic retinopathy via the function of vascular endothelial growth factor (VEGF).
Enhanced recombinant adeno-associated virus-mediated vascular endothelial growth factor expression in the adult mouse retina: a potential model for diabetic retinopathy.
EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown.
ERK1/2 signaling pathways involved in VEGF release in diabetic rat retina.
ERK1/2/COX-2/PGE2 signaling pathway mediates GPR91-dependent VEGF release in streptozotocin-induced diabetes.
Essential Role of Transglutaminase 2 in Vascular Endothelial Growth Factor-Induced Vascular Leakage in the Retina of Diabetic Mice.
Evaluation of the Role of Vascular Endothelial Growth Factor in Diabetic Retinopathy.
Evaluation of vascular endothelial growth factor levels in tears and serum among diabetic patients.
Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation.
Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy.
Expression and significance of HIF-1 ? and VEGF in rats with diabetic retinopathy.
Expression and significance of MiR-126 and VEGF in proliferative diabetic retinopathy.
Expression of angiopoietin-like protein 8 correlates with VEGF in patients with proliferative diabetic retinopathy.
Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes.
Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes.
Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy.
Expression of pigment epithelium-derived factor and vascular endothelial growth factor in fibrovascular membranes from patients with proliferative diabetic retinopathy.
Expression of promyelocytic leukemia protein and vascular endothelial growth factor in aqueous humor and vitreous fluid in patients with proliferative diabetic retinopathy.
Expression of stromal cell-derived factor-1 in diabetic retinopathy.
Expression of the angiogenic mediator, angiopoietin-like 4, in the eyes of patients with proliferative sickle retinopathy.
Expression of vascular endothelial growth factor in proliferative diabetic retinopathy.
Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy.
Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients.
Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy.
Freezing adversely affects measurement of vascular endothelial growth factor levels in human aqueous samples.
Fucoidan as a Potential Therapeutic for Major Blinding Diseases-A Hypothesis.
Functional vascular endothelial growth factor -634G>C SNP is associated with proliferative diabetic retinopathy: a case-control study in a Brazilian population of European ancestry.
Functions of Müller cell-derived vascular endothelial growth factor in diabetic retinopathy.
Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Genetic variation in the hypoxia-inducible factor-1alpha gene is associated with type 2 diabetes in Japanese.
Glucosamine-induced phosphorylation of the alpha-subunit of eukaryotic initiation factor 2 is mediated by the protein kinase R-like endoplasmic-reticulum associated kinase.
Growth factors VEGF and TGF-beta1 in peritoneal dialysis.
Hepatocyte growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy: its relationship with vascular endothelial growth factor and retinopathy activity.
HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
High Glucose and Glucose Deprivation Modulate Müller Cell Viability and VEGF Secretion.
High levels of pigment epithelium-derived factor in the retina of a rat model of type 2 diabetes.
High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins.
High-mobility group box-1 and endothelial cell angiogenic markers in the vitreous from patients with proliferative diabetic retinopathy.
Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4.
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
Hypoxia-Inducible Factor (HIF)/Vascular Endothelial Growth Factor (VEGF) Signaling in the Retina.
Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes.
IL-27 regulates HIF-1?-mediated VEGFA response in macrophages of diabetic retinopathy patients and healthy individuals.
Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy.
Impact of intravitreal pharmacotherapies including antivascular endothelial growth factor and corticosteroid agents on diabetic retinopathy.
Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy.
In vitro and ex vivo retina angiogenesis assays.
Increased expression of KDR/Flk-1 (VEGFR-2) in murine model of ischemia-induced retinal neovascularization.
Increased expression of placenta growth factor in proliferative diabetic retinopathy.
Increased intravitreous interleukin-18 correlated to vascular endothelial growth factor in patients with active proliferative diabetic retinopathy.
Increased levels of alphaB-crystallin in vitreous fluid of patients with proliferative diabetic retinopathy and correlation with vascular endothelial growth factor.
Increased levels of monokine induced by interferon-gamma (Mig) in the vitreous of patients with diabetic retinopathy.
Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy.
Increased levels of vascular endothelial growth factor in aqueous humor of patients with diabetic retinopathy: Is it the whole truth?
Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy.
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes.
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.
Increased Vitreous Chemerin Levels Are Associated with Proliferative Diabetic Retinopathy.
Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study.
Induction of ischemic tolerance protects the retina from diabetic retinopathy.
Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema.
Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier.
Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
Inhibitory mechanism of vascular endothelial growth factor (VEGF) by bucillamine.
Insights into stem cell therapy for diabetic retinopathy: a bibliometric and visual analysis.
Insulin-induced vascular endothelial growth factor expression in retina.
Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy.
Intravitreal anti-VEGF agents and cardiovascular risk.
Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy.
Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab.
Intravitreal neurodegenerative and inflammatory mediators in proliferative diabetic retinopathy.
Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy.
Intravitreous hepatocyte growth factor in patients with proliferative diabetic retinopathy: a case-control study.
Intravitreous high expression level of netrin-1 in patients with proliferative diabetic retinopathy.
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.
Intravitreous Vascular Endothelial Growth Factor and Hypoxia-Inducible Factor 1a in Patients with Proliferative Diabetic Retinopathy.
Investigation of Ocular Neovascularization-Related Genes and Oxidative Stress in Diabetic Rat Eye Tissues After Resveratrol Treatment.
Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy.
KH902 suppresses high glucose-induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PIGF.
Level of Vascular Endothelial Growth Factor in the Vitreous Fluid of Proliferative Diabetic Retinopathy Patients and Prognosis after Vitrectomy.
Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy.
Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model.
Management of proliferative diabetic retinopathy.
Matrix metalloproteinase-14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy.
Müller cell-derived VEGF is a significant contributor to retinal neovascularization.
Melatonin-mediated cytoprotection against hyperglycemic injury in Müller cells.
Meta-analysis of association between the -2578C/A polymorphism of the vascular endothelial growth factor and retinopathy in type 2 diabetes in Asians and Caucasians.
Metalloproteinases mediate diabetes-induced retinal neuropathy and vasculopathy.
MicroRNA-15b Targets VEGF and Inhibits Angiogenesis in Proliferative Diabetic Retinopathy.
MicroRNA-423 may regulate diabetic vasculopathy.
MicroRNA-9 inhibits retinal neovascularization in rats with diabetic retinopathy by targeting vascular endothelial growth factor A.
miR-152/LIN28B axis modulates high-glucose-induced angiogenesis in human retinal endothelial cells via VEGF signaling.
Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients.
Multiplex immunoassay analysis of biomarkers in clinically accessible quantities of human aqueous humor.
Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage.
Müller Glia Are a Major Cellular Source of Survival Signals for Retinal Neurons in Diabetes.
Neuron-derived netrin-1 and netrin-4 proteins are additional effective targets in diabetic retinopathy beyond VEGF.
Neuronal Cell Death in the Inner Retina and the Influence of Vascular Endothelial Growth Factor Inhibition in a Diabetic Rat Model.
Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy.
NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy.
No nephropathy in Type 2 diabetic patient with POEMS syndrome with an elevated plasma VEGF.
Non-physician delivered intravitreal injection service is feasible and safe - a systematic review.
Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor.
Norrin restores blood-retinal barrier properties after vascular endothelial growth factor-induced permeability.
Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization.
Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis.
Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
Oral supplementation with melatonin reduces oxidative damage and concentrations of inducible nitric oxide synthase, VEGF and matrix metalloproteinase 9 in the retina of rats with streptozotocin/nicotinamide induced pre-diabetes.
OSSC1E-K19, a novel phytochemical component of Osteomeles schwerinae, prevents glycated albumin-induced retinal vascular injury in rats.
Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy.
Outcome of vitreous surgery and the balance between vascular endothelial growth factor and endostatin.
Oxidative Stress Induces a VEGF Autocrine Loop in the Retina: Relevance for Diabetic Retinopathy.
Panretinal-Photocoagulation before Pars Plana Vitrectomy Influences Vitreous Level of Interleukin-6 but not of Vascular Endothelial Growth Factor in Patients with Diabetic Retinopathy.
Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.
Pathological role of apelin in angiogenic eye disease.
Pathological Role of Unsaturated Aldehyde Acrolein in Diabetic Retinopathy.
Pathophysiology of Diabetic Retinopathy.
PEDF inhibits VEGF- and EPO- induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation.
PERSISTENT OVERPRODUCTION OF INTRAOCULAR VASCULAR ENDOTHELIAL GROWTH FACTOR AS A CAUSE OF LATE VITREOUS HEMORRHAGE AFTER VITRECTOMY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
Persistent Suppression of Ocular Neovascularization with Intravitreal Administration of AAVrh.10 Coding for Bevacizumab.
Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases.
Pharmacological inhibition of N-methyl d-aspartate receptor promotes secretion of vascular endothelial growth factor in müller cells: effects of hyperglycemia and hypoxia.
Phosphomannopentaose sulfate (PI-88) inhibits retinal leukostasis in diabetic rat.
Phosphorylation of alphaB-crystallin in epiretinal membrane of human proliferative diabetic retinopathy.
Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy.
Pigment epithelium-derived factor exerts opposite effects on endothelial cells of different phenotypes.
Pigment epithelium-derived factor inhibits retinal microvascular dysfunction induced by 12/15-lipoxygenase-derived eicosanoids.
PKCbetaII/HuR/VEGF: A new molecular cascade in retinal pericytes for the regulation of VEGF gene expression.
Plant proteolytic enzyme papain abrogates angiogenic activation of human umbilical vein endothelial cells (HUVEC) in vitro.
Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab.
Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.
Polycomb repressive complex 2 regulates MiR-200b in retinal endothelial cells: potential relevance in diabetic retinopathy.
Polymorphism of the manganese superoxide dismutase gene but not of vascular endothelial growth factor gene is a risk factor for diabetic retinopathy.
Polymorphisms in HIF-1a gene are not associated with diabetic retinopathy in China.
Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes.
Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation.
Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization.
Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy.
Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients.
Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy.
Production of scFv antibody fragments from a hybridoma with functional activity against human vascular endothelial growth factor.
Progesterone induces vascular endothelial growth factor on retinal pigment epithelial cells in culture.
Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy.
Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress, and VEGF in the vitreous body.
Protamine sulfate downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF and its receptor binding in vitro.
Protective actions of microalgae against endogenous and exogenous advanced glycation endproducts (AGEs) in human retinal pigment epithelial cells.
Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway.
Proteolytic cleavage of vascular adhesion protein-1 induced by vascular endothelial growth factor in retinal capillary endothelial cells.
Proteomic Biomarkers of Retinal Inflammation in Diabetic Retinopathy.
Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
Recent advances in the management and understanding of diabetic retinopathy.
Receptor-associated prorenin system contributes to development of inflammation and angiogenesis in proliferative diabetic retinopathy.
Receptor-associated prorenin system in the pathogenesis of retinal diseases.
Reduced serum level of leukocyte cell-derived chemotaxin 2 is associated with the presence of diabetic retinopathy.
Regulated in Development and DNA Damage 1 Is Necessary for Hyperglycemia-induced Vascular Endothelial Growth Factor Expression in the Retina of Diabetic Rodents.
Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin.
Regulation of tight junctions and loss of barrier function in pathophysiology.
Regulation of vascular endothelial growth factor expression by advanced glycation end products.
Regulation of vascular endothelial junction stability and remodeling through Rap1-Rasip1 signaling.
Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy.
Relationship between Serum Vascular Endothelial Growth Factor Levels and Stages of Diabetic Retinopathy and Other Biomarkers.
Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy.
Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy.
Relationship between vitreous levels of matrix metalloproteinases and vascular endothelial growth factor in proliferative diabetic retinopathy.
Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes.
Relationships among Retinal Nonperfusion, Neovascularization, and Vascular Endothelial Growth Factor Levels in Quiescent Proliferative Diabetic Retinopathy.
Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy.
Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation.
Requirement of NOX2 expression in both retina and bone marrow for diabetes-induced retinal vascular injury.
Retinal neovascularization is prevented by blockade of the renin-angiotensin system.
Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines.
Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II.
Risk factors for fellow eye treatment in protocol T.
Role of Angiopoietins and Tie-2 in Diabetic Retinopathy.
Role of NF-?B activation and VEGF gene polymorphisms in VEGF up regulation in non-proliferative and proliferative diabetic retinopathy.
Roles of tissue plasminogen activator and its inhibitor in proliferative diabetic retinopathy.
S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis.
Scutellarin inhibits high glucose-induced and hypoxia-mimetic agent-induced angiogenic effects in human retinal endothelial cells through reactive oxygen species/hypoxia-inducible factor-1?/vascular endothelial growth factor pathway.
Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary.
Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy.
Serum fetuin-A levels are independently correlated with vascular endothelial growth factor and C-reactive protein concentrations in type 2 diabetic patients with diabetic retinopathy.
Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy.
Serum Vascular Endothelial Growth Factor Levels Correlate with Severity of Retinopathy in Diabetic Patients: A Systematic Review and Meta-Analysis.
Short-and Long-Term Expression of Vegf: A Temporal Regulation of a Key Factor in Diabetic Retinopathy.
Significance of nitric oxide and peroxynitrite in permeability changes of the retinal microvascular endothelial cell monolayer induced by vascular endothelial growth factor.
Simvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes.
Single nucleotide polymorphisms of vascular endothelial growth factor gene intron 2 are markers for early progression of diabetic retinopathy in Japanese with type 1 diabetes.
Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor.
Splicing factor polymorphisms, the control of VEGF isoforms and association with angiogenic eye disease.
Streptozotocin induced diabetic retinopathy in rat and the expression of vascular endothelial growth factor and its receptor.
Stretch-induced retinal vascular endothelial growth factor expression is mediated by phosphatidylinositol 3-kinase and protein kinase C (PKC)-zeta but not by stretch-induced ERK1/2, Akt, Ras, or classical/novel PKC pathways.
Study on vascular endothelial growth factor and its receptor in the vitreous of diabetic rats.
Subclinical Hypothyroidism in Patients with Diabetic Retinopathy: Role of Vascular Endothelial Growth Factor.
Suppression of protein kinase C-? attenuates vascular leakage via prevention of tight junction protein decrease in diabetic retinopathy.
Systemic Factors Related to Intraocular Levels of Interleukin-6 and Vascular Endothelial Growth Factor in Diabetic Retinopathy.
Targeting vascular endothelial growth factor using retinal gene therapy.
The 150-kDa oxygen-regulated protein (ORP150) regulates proteinuria in diabetic nephropathy via mediating VEGF.
The ?-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases.
The alpha-helical domain near the amino terminus is essential for dimerization of vascular endothelial growth factor.
The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy.
The Angiogenic Biomarker Endocan is Upregulated in Proliferative Diabetic Retinopathy and Correlates with Vascular Endothelial Growth Factor.
The effect of a systemic angiotensin receptor blocker on vascular endothelial growth factor in the vitreous of patients with proliferative diabetic retinopathy.
The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy.
The Evolving Treatment of Diabetic Retinopathy.
The impact of 1,25-dihydroxy vitamin D3 on the expressions of vascular endothelial growth factor and transforming growth factor-?(1) in the retinas of rats with diabetes.
The Inhibitory Effects of Gold Nanoparticles on VEGF-A-Induced Cell Migration in Choroid-Retina Endothelial Cells.
The kinetics of VEGF and MCP-1 in the second vitrectomy cases with proliferative diabetic retinopathy.
The MAPK signaling pathway mediates the GPR91-dependent release of VEGF from RGC-5 cells.
The oxidative stressor arsenite activates vascular endothelial growth factor mRNA transcription by an ATF4-dependent mechanism.
The P2X7 Receptor: A Promising Pharmacological Target in Diabetic Retinopathy.
The pathogenesis of diabetic retinopathy: old concepts and new questions.
The pathogenesis of early retinal changes of diabetic retinopathy.
The potential health benefits of dietary natural plant products in age related eye diseases.
The Prevention and Treatment of Retinal Complications in Diabetes.
The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas.
The Renin-Angiotensin-Aldosterone System (RAAS) Is One of the Effectors by Which Vascular Endothelial Growth Factor (VEGF)/Anti-VEGF Controls the Endothelial Cell Barrier.
The renin-angiotensin-aldosterone system and the eye in diabetes.
The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy.
Therapeutic Effect of Abelmoschus manihot on Type 2 Diabetic Nonproliferative Retinopathy and the Involvement of VEGF.
Therapeutic Potential of Anti-Angiogenic Multi-Target N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy.
Thioredoxin-interacting protein deficiency ameliorates diabetic retinal angiogenesis.
Transcription factor, SP1, in epiretinal membranes of patients with proliferative diabetic retinopathy.
Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases.
Trial by CCN2: a standardized test for fibroproliferative disease?
Triamcinolone acetonide combined with aminoguanidine inhibits inflammation and oxidative stress, improves vascular endothelial and retinal function and reduces VEGF expression in diabetic retinopathy patients.
Triamcinolone acetonide modulates TGF??2?induced angiogenic and tissue?remodeling effects in cultured human retinal pigment epithelial cells.
Two polymorphisms (rs699947, rs2010963) in the VEGFA gene and diabetic retinopathy: an updated meta-analysis.
Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy.
Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy.
Upregulated CD200 in pre-retinal proliferative fibrovascular membranes of proliferative diabetic retinopathy patients and its correlation with vascular endothelial growth factor.
Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy.
Upregulated VEGF and Robo4 correlate with the reduction of miR-15a in the development of diabetic retinopathy.
Upregulation of retinal vascular endothelial growth factor mRNAs in spontaneously diabetic rats without ophthalmoscopic retinopathy. A possible participation of advanced glycation end products in the development of the early phase of diabetic retinopathy.
Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy.
Using the past to inform the future: anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy.
Vaccinium myrtillus extract prevents or delays the onset of diabetes--induced blood-retinal barrier breakdown.
Vascular endothelial growth factor (VEGF) and VEGF receptors in diabetic nephropathy: expression studies in biopsies of type 2 diabetic patients.
Vascular endothelial growth factor (VEGF)-related polymorphisms rs10738760 and rs6921438 are not risk factors for proliferative diabetic retinopathy (PDR) in patients with type 2 diabetes mellitus (T2DM).
Vascular endothelial growth factor (VEGF)-related single nucleotide polymorphisms rs10738760 and rs6921438 are not associated with diabetic retinopathy (DR) in Slovenian patients with type 2 diabetes mellitus (T2DM).
Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.
Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress.
Vascular endothelial growth factor and fibroblast growth factor 5 are colocalized in vascular and avascular epiretinal membranes.
Vascular endothelial growth factor and its receptors in control and diabetic rat eyes.
Vascular endothelial growth factor and its soluble receptors-1 and -2 in iris neovascularization and neovascular glaucoma.
Vascular endothelial growth factor and retinal neovascularisation: a new therapeutic approach for diabetic retinopathy.
Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy.
Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy.
Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy.
Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2.
Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy.
Vascular endothelial growth factor gene expression in a retinal pigmented cell is up-regulated by glucose deprivation through 3' UTR.
Vascular Endothelial Growth Factor Gene Polymorphism is not Associated with Diabetic Retinopathy in Egyptian Patients.
Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy.
Vascular endothelial growth factor gene regulation and action in diabetic retinopathy.
Vascular endothelial growth factor in anterior chamber liquid patients with diabetic retinopathy, cataract and neovascular glaucoma.
Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.
Vascular endothelial growth factor in diabetic retinopathy.
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy.
Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
Vascular Endothelial Growth Factor in the Vitreous of Proliferative Diabetic Retinopathy Patients: Chasing a Hiding Prey?
Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors.
Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?
Vascular endothelial growth factor inhibition for proliferative diabetic retinopathy: Et tu, Brute?
Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.
Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells.
Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.
Vascular endothelial growth factor level in the serum of diabetic patients with retinopathy.
Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy.
Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels.
Vascular endothelial growth factor promotes cell-cycle transition from G0 to G1 phase in subcultured endothelial cells of diabetic rat thoracic aorta.
Vascular endothelial growth factor regulates primate choroid-retinal endothelial cell proliferation and tube formation through PI3K/Akt and MEK/ERK dependent signaling.
Vascular endothelial growth factors and angiogenesis in eye disease.
Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide.
VEGF -634G>C polymorphism and diabetic retinopathy risk: A meta-analysis.
VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.
VEGF as a Direct Functional Regulator of Photoreceptors and Contributing Factor to Diabetes-Induced Alteration of Photoreceptor Function.
VEGF as a Trophic Factor for Müller Glia in Hypoxic Retinal Diseases.
VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
VEGF increases paracellular transport without altering the solvent-drag reflection coefficient.
VEGF increases retinal vascular ICAM-1 expression in vivo.
VEGF is major stimulator in model of choroidal neovascularization.
VEGF localisation in diabetic retinopathy.
VEGF Mediates Retinal Müller Cell Viability and Neuroprotection through BDNF in Diabetes.
VEGF polymorphisms are associated with severity of diabetic retinopathy.
VEGF-A Is Necessary and Sufficient for Retinal Neuroprotection in Models of Experimental Glaucoma.
VEGF-induced choroidal damage in a murine model of retinal neovascularisation.
VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells.
Vision Loss in Older Adults.
Vitreous and plasma changes of endothelin-1, adrenomedullin and vascular endothelium growth factor in patients with proliferative diabetic retinopathy.
VITREOUS AND PLASMA CONCENTRATIONS OF APELIN AND VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL BEVACIZUMAB IN EYES WITH PROLIFERATIVE DIABETIC RETINOPAHTY.
Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy.
Vitreous and Serum Concentrations of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Proliferative Diabetic Retinopathy.
Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy.
Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema.
Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
Vitreous Levels of Proteins Implicated in Angiogenesis Are Modulated in Patients with Retinal or Choroidal Neovascularization.
Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study.
Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone.
Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy.
Vitreous levels of vascular endothelial growth factor, stromal cell-derived factor-1?, and angiopoietin-like protein 2 in patients with active proliferative diabetic retinopathy.
Vitreous levels of vasohibin-1 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Vitreous renin activity correlates with vascular endothelial growth factor in proliferative diabetic retinopathy.
Vitreous TIMP-1 levels associate with neovascularization and TGF-?2 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathy.
Vitreous Vascular Endothelial Growth Factor Concentrations in Proliferative Diabetic Retinopathy versus Proliferative Vitreoretinopathy.
Worsening of renal function and uncontrolled hypertension from intravitreal bevacizumab injections.
Zinc supplementation does not influence serum levels of VEGF, BDNF, and NGF in diabetic retinopathy patients: a randomized controlled clinical trial.
[(Pro) renin receptor in the pathogenesis of proliferative diabetic retinopathy].
[A comparative study of vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy]
[Angiogenesis and inhibition of angiogenesis in the eye]
[Angiogenesis and retinal diseases]
[Changes of plasma endothelin-1 and vascular endothelial growth factor in diabetic retinopathy and the clinical application value thereof]
[Cytokines in the vitreous fluid of patients with proliferative diabetic retinopathy--vascular endothelial growth factor and platelet-derived growth factor are elevated in proliferative diabetic retinopathy]
[Effects of vascular endothelial growth factor and basic fibroblast growth factor in early stage diabetic retinopathy and their molecular pathological mechanism]
[Erythropoietin administration in diabetic patients]
[Expression of VEGF and PEDF in early-stage retinopathy in diabetic Macaca mulatta].
[Immunodetection of vascular endothelial growth factor in the vitreous of eyes with proliferative diabetic retinopathy]
[Interleukin-12, vascular endothelial growth factor and tumor necrosis factor-alpha in the process of neoangiogenesis of diabetic retinopathy in children]
[Level of vascular endothelial growth factor and interleukin-6 in aqueous humor in diabetic retinopathy patients.]
[Lifestyle-related diseases and anti-aging ophthalmology: suppression of retinal and choroidal pathologies by inhibiting renin-angiotensin system and inflammation]
[Relationship between vascular endothelial growth factors and advanced glycation end products in the human vitreous]
[RhoJ signaling pathway in retinal angiogenesis: promising targets for novel anti-angiogenic therapy].
[Role of vascular endothelial growth factor and monocyte chemoattractant protein-1 in the development of endothelial dysfunction in types 1 and 2 diabetes mellitus complicated by diabetic retinopathy].
[Role of vascular endothelial growth factor in microvascular abnormalities in diabetic retinopathy]
[Role of vascular endothelial growth factor in the development of diabetic retinopathy in patients with type 1 diabetes mellitus]
[Role of vascular endothelial growth factor in the pathogenesis of diabetic retinopathy]
[The assessment of the correlation between vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF-alpha), interleukin 6 (IL-6), glycaemic control (HbA1c) and the development of the diabetic retinopathy in children with diabetes mellitus type 1]
[The expression of vascular endothelial growth factor of vitreous in patients with proliferative diabetic retinopathy]
[Vascular endothelial growth factor in the aqueous humor in diabetic retinopathy and other diseases of the retina]
[Vascular endothelial growth factor in the ocular fluid in diabetic retinopathy and other retinal diseases]
[Vascular endothelial growth factor levels in the aqueous and serum in diabetic retinopathy with or without neovascular glaucoma]
[Vitreous levels of stromal cell-derived factor-1 and vascular endothelial growth factor in diabetic retinopathy]
Diffuse Intrinsic Pontine Glioma
Multiregional tumor drug-uptake imaging by PET and microvascular morphology in end-stage diffuse intrinsic pontine glioma.
DiGeorge Syndrome
Circadian rhythm genes in cancer: insight into their functions and regulation involving noncoding RNAs.
Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome.
Digestive System Neoplasms
Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system.
Diphtheria
Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
Disorders of Excessive Somnolence
[The research progress of relationship between the obstructive sleep apnea hypopnea syndrome and asthma].
Disseminated Intravascular Coagulation
High fever, renal failure, disseminated intravascular coagulation and myelodysplasia accompanied with enhanced angiogenesis possibly due to overexpression of vascular endothelial growth factor.
Pathogenesis of the viral hemorrhagic fevers.
Predictive value of serial platelet count and VEGF determination for the management of DIC in the Crow-Fukase (POEMS) syndrome.
Usefulness of circulating vascular endothelial growth factor and neutrophil elastase as diagnostic markers of disseminated intravascular coagulation in non-cancer patients.
Down Syndrome
Amniotic levels of vascular endothelial growth factor and nitric oxide at the second trimester in Down's syndrome.
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.
First trimester maternal serum placenta growth factor (PIGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18.
The novel axis of YAP1, transcription enhancer factor 3 and Down Syndrome Candidate Region 1 isoform 1L is a common signaling pathway downstream of several angiogenic factors.
The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development.
Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium.
Vascular endothelial growth factor and placenta growth factor concentrations in Down's syndrome and control pregnancies.
Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis.
VEGF and nitric oxide synthase immunoexpression in Down's syndrome amniotic fluid stem cells.
Drug-Related Side Effects and Adverse Reactions
Association Between Aortic Dissection and Systemic Exposure of Vascular Endothelial Growth Factor Pathway Inhibitors in the Japanese Adverse Drug Event Report Database.
Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
Nephrotic syndrome under treatment with dasatinib: be aware of a possible adverse drug reaction.
Dry Eye Syndromes
Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease.
Cytokine expression in tears of patients with glaucoma or dry eye disease: A prospective, observational cohort study.
Effect of trapping vascular endothelial growth factor-A in a murine model of dry eye with inflammatory neovascularization.
The Key Role of VEGF in the Cross Talk between Pterygium and Dry Eye and Its Clinical Significance.
Ductus Arteriosus, Patent
Anatomic Closure of the Premature Patent Ductus Arteriosus: The Role of CD14+/CD163+ Mononuclear Cells and Vascular Endothelial Growth Factor (VEGF) in Neointimal Mound Formation.
Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants.
Duodenal Ulcer
Gene therapy with adenoviral plasmids or naked DNA of vascular endothelial growth factor and platelet-derived growth factor accelerates healing of duodenal ulcer in rats.
Inappropriate Angiogenic Response as a Novel Mechanism of Duodenal Ulceration and Impaired Healing.
Roxatidine suppresses inflammatory responses via inhibition of NF-?B and p38 MAPK activation in LPS-induced RAW 264.7 macrophages.
Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcer.
Dyskinesias
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1?.
Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.
Dyslipidemias
Effect of glycemic control and dyslipidemia on plasma vascular endothelial growth factor and pigment epithelium-derived factor in diabetic retinopathy patients in Northern Nigeria.
Implications of treatment that target protective mechanisms against diabetic nephropathy.
New perspectives on diabetic vascular complications: the loss of endogenous protective factors induced by hyperglycemia.
Retinal oximetry during treatment of retinal vein occlusion by ranibizumab in patients with high blood pressure and dyslipidemia.
[What is new in the treatment of diabetes?--The importance of nephro- and cardioprotective management]
Dysplastic Nevus Syndrome
Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi.
Dyspnea
A 34-Year-Old Woman from Brazil with Pulmonary Lymphangioleiomyomatosis Diagnosed by Raised Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels and Lung Cysts on Computed Tomography Imaging Presenting with COVID-19 Pneumonia.
Echinococcosis
Increase of Vascular Endothelial Growth Factor and Decrease of MCP-1 and Some Updated Epidemiology Aspects of Cystic Echinococcosis Human Cases in Calabria Region.
Ecthyma, Contagious
Major amino acid sequence variants of viral vascular endothelial growth factor are functionally equivalent during Orf virus infection of sheep skin.
Viral vascular endothelial growth factor plays a critical role in orf virus infection.
Ectropion
Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.
Elephantiasis
Soluble cellular adhesion molecules, selectins, VEGF and endothelin-1 in patients with Wuchereria bancrofti infection and association with clinical status.
Embolic Stroke
Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia.
Encephalitis
Expression of platelet-derived growth factor receptor-?/ß, vascular endothelial growth factor receptor-2, c-Abl, and c-Kit in canine granulomatous meningoencephalitis and necrotizing encephalitis.
Increased serum vascular endothelial growth factor is associated with acute viral encephalitis in Bangladeshi children.
Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak.
Encephalitis, Viral
Increased serum vascular endothelial growth factor is associated with acute viral encephalitis in Bangladeshi children.
[Changes and roles of VEGF and VCAM-1 in cerebrospinal fluid of children with viral encephalitis]
Encephalomyelitis
Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) inhibits experimental autoimmune encephalomyelitis in dark Agouti (DA) rats.
Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses.
Focal experimental autoimmune encephalomyelitis in the Lewis rat induced by immunization with myelin oligodendrocyte glycoprotein and intraspinal injection of vascular endothelial growth factor.
Neuroprotective effects of vascular endothelial growth factor A in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
Pertussis toxin attenuates experimental autoimmune encephalomyelitis by upregulating neuronal vascular endothelial growth factor.
Upregulation of Vascular Endothelial Growth Factor Receptor-3 in the Spinal Cord of Lewis Rats with Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) inhibits experimental autoimmune encephalomyelitis in dark Agouti (DA) rats.
Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses.
Focal experimental autoimmune encephalomyelitis in the Lewis rat induced by immunization with myelin oligodendrocyte glycoprotein and intraspinal injection of vascular endothelial growth factor.
Neuroprotective effects of vascular endothelial growth factor A in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
Pertussis toxin attenuates experimental autoimmune encephalomyelitis by upregulating neuronal vascular endothelial growth factor.
Upregulation of Vascular Endothelial Growth Factor Receptor-3 in the Spinal Cord of Lewis Rats with Experimental Autoimmune Encephalomyelitis.
Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats.
Endocardial Cushion Defects
Vascular endothelial growth factor polymorphisms are associated with endocardial cushion defects: a family based case-control study.
Endocarditis
[Role of anti-angiogenic factor chondromodulin-I for maintaining cardiac valvular function]
Endocrine System Diseases
Microvessel density and VEGF expression in pituitaries of pregnant women.
Role of growth factors on human parathyroid adenoma cell proliferation.
Endometrial Hyperplasia
Autophagy in the physiological endometrium and cancer.
Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer.
Endoglin (CD105) expression in endometrial carcinoma.
Enhanced expression of vascular endothelial growth factor and increased microvascular density in women with endometrial hyperplasia: a possible relationship with uterine natural killer cells.
Expression of aquaporin-1 in normal, hyperplasic, and carcinomatous endometria.
Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
Expression of vascular endothelial growth factor and assessment of microvascular density with CD 34 and endoglin in proliferative endometrium, endometrial hyperplasia, and endometrial carcinoma.
Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
Endometrial Neoplasms
205 selective antitumor therapeutic effect of 5-fluorocytosine and interferon-Beta against breast and endometrial cancer cells by engineered stem cells expressing Cytosine deaminase and human interferon-Beta.
A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Angiogenesis and endometrial cancer.
Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels.
Angiostatin expression in endometrial cancer.
Association of growth factors, HIF-1 and NF-?B expression with proteasomes in endometrial cancer.
Association study of vascular endothelial growth factor gene polymorphisms in endometrial carcinomas in a Japanese population.
Autophagy in the physiological endometrium and cancer.
Biologically inhibitory effects of VEGF siRNA on endometrial carcinoma cells.
Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer.
Chemokines mRNA expression in relation to the Macrophage Migration Inhibitory Factor (MIF) mRNA and Vascular Endothelial Growth Factor (VEGF) mRNA expression in the microenvironment of endometrial cancer tissue and normal endometrium: A pilot study.
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Clinical implications of expression of ETS-1 related to angiogenesis in uterine endometrial cancers.
Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers.
Co-expression of vascular endothelial growth factor and thymidine phosphorylase in endometrial cancer.
Correlative expression of cyclooxygenase-1 (cox-1) and human epidermal growth factor receptor type-2 (her-2) in endometrial cancer.
Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase.
Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival.
Effect of p53 gene transfection on vascular endothelial growth factor expression in endometrial cancer cells.
Effects of various steroids on platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA expression in uterine endometrial cancer cells.
EMMPRIN in gynecologic cancers: pathologic and therapeutic aspects.
Endocrine gland-derived vascular endothelial growth factor is expressed in human peri-implantation endometrium, but not in endometrial carcinoma.
Estradiol-17beta regulates vascular endothelial growth factor and Bcl-2 expression in HHUA cells.
Estrogen-induced activation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway.
Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and An-ti-Angiogenic/Lymphangiogenic Effect.
Expression and clinical correlation of NGAL and VEGF in endometrial carcinoma.
Expression of Efp, VEGF and bFGF in normal, hyperplastic and malignant endometrial tissue.
Expression of gastrin-releasing peptide receptors in endometrial cancer.
Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer.
Expression of vascular endothelial growth factor (VEGF) and assessment of microvascular density with CD34 as prognostic markers for endometrial carcinoma.
Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
Expression of vascular endothelial growth factor and assessment of microvascular density with CD 34 and endoglin in proliferative endometrium, endometrial hyperplasia, and endometrial carcinoma.
Expression profile of VEGF-C, VEGF-D, VEGFR-3 in different grades of endometrial cancer.
Expressions of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers.
Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines.
Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins.
Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement.
Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers.
Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma.
Over-expression of platelet-derived growth factor-D promotes tumor growth and invasion in endometrial cancer.
Overexpression of platelet-derived growth factor-D as a poor prognosticator in endometrial cancer.
Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma.
Progestins suppress estrogen-induced expression of vascular endothelial growth factor (VEGF) subtypes in uterine endometrial cancer cells.
Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma.
Regulation of the vascular endothelial growth factor and growth by estrogen and antiestrogens through Efp in Ishikawa endometrial carcinoma cells.
Regulation of Vascular Endothelial Growth Factor in endometrial tumour cells by resveratrol and EGCG.
Sex steroids in uterine endometrial cancers.
Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
Stromal deletion of the APC tumor suppressor in mice triggers development of endometrial cancer.
Suppression of lymph node and lung metastases of endometrial cancer by muscle-mediated expression of soluble vascular endothelial growth factor receptor-3.
Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture.
The Influence of Biologically Active Substances Secreted by the Adipose Tissue on Endometrial Cancer.
The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators.
To evaluate immunoreactivity of cyclooxygenase-2 in cases of endometrial carcinoma and correlate it with expression of p53 and vascular endothelial growth factor.
Vascular endothelial growth factor and intratumoral microvessel density as prognostic factors in endometrial cancer.
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer.
Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma.
Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer.
Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer.
YT521 promotes metastases of endometrial cancer by differential splicing of vascular endothelial growth factor A.
[Estradiol activates MAPK signaling pathway by estrogen induced VEGF and bFGF in endometrial cancer cells].
[Expression and significance of CD44v6, bcl-2, and vascular endothelial growth factor(VEGF) in endometrial adenocarcinoma]
[Expression of Mta-1 and VEGF and their correlation in the endometrial cancer].
[Expression of vascular endothelial growth factor and its receptors in endometrial carcinoma]
[Study on the correlation of Xinjiang endometrial tumor and vascular endothelial growth factor].
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
Endometriosis
17 ?-Estradiol Promotes Vascular Endothelial Growth Factor Expression via the Wnt/?-catenin Pathway during the Pathogenesis of Endometriosis.
2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis.
A mixture of St. John's wort and sea buckthorn oils regresses endometriotic implants and affects the levels of inflammatory mediators in peritoneal fluid of the rat: A surgically induced endometriosis model.
A physiological approach for treating endometriosis by recombinant pigment epithelium-derived factor (PEDF).
A priori implantation potential does not differ in eutopic endometrium of patients with and without endometriosis.
A randomized exploratory trial to assess the effects of resveratrol on VEGF and TNF-? 2 expression in endometriosis women.
Activin a stimulates interleukin 8 and vascular endothelial growth factor release from cultured human endometrial stromal cells: possible implications for the pathogenesis of endometriosis.
All-trans retinoic acid inhibits vascular endothelial growth factor expression in a cell model of neutrophil activation.
Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis.
Antiangiogenesis therapy for endometriosis.
Application of serum markers in diagnosis and staging of ovarian endometriosis.
Application of the nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate for the treatment of endometriosis: an in vitro study.
Association between endometriosis and polymorphisms in endostatin and vascular endothelial growth factor and their serum levels in Korean women.
Association of polymorphisms -1154G/A and -2578C/A in the vascular endothelial growth factor gene with decreased risk of endometriosis in Chinese women.
Association of the vascular endothelial growth factor gene polymorphisms (-460C/T, +405G/C and +936T/C) with endometriosis: a meta-analysis.
Association of vascular endothelial growth factor (VEGF) +405 g>c polymorphism with endometriosis in an Iranian population.
Association of vascular endothelial growth factor (VEGF) Gene polymorphisms and expression with the risk of endometriosis: a case-control study.
Association study of the TNF-? -1031T/C and VEGF?+?450G/C polymorphisms with susceptibility to endometriosis.
Combined effect of vascular endothelial growth factor and its receptor polymorphisms in endometriosis: a case-control study.
Concentrations of receptor for advanced glycation end products, VEGF and CML in plasma, follicular fluid, and peritoneal fluid in women with and without endometriosis.
Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis.
Developing a Noninvasive Procedure Using Labeled Monoclonal Antibody Anti-VEGF (Bevacizumab) for Detection of Endometriosis.
Distinct peritoneal fluid ghrelin and leptin in infertile women with endometriosis and their correlation with interleukin-6 and vascular endothelial growth factor.
Does the Use of the "Proseek® Multiplex Oncology I Panel" on Peritoneal Fluid Allow a Better Insight in the Pathophysiology of Endometriosis, and in Particular Deep-Infiltrating Endometriosis?
Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis.
Dysregulation of Vascular Endothelial Growth Factors and Their Neuropilin Receptors in the Eutopic Endometrium of Women With Endometriosis.
Effect of GnRH analogues on apoptosis and release of interleukin-1beta and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis.
Effect of GnRH-II on the ESC proliferation, apoptosis and VEGF secretion in patients with endometriosis in vitro.
Effect of Hua Yu Xiao Zheng decoction on the expression levels of vascular endothelial growth factor and angiopoietin-2 in rats with endometriosis.
Effect of mistletoe on endometrial stromal cell survival and vascular endothelial growth factor expression in patients with endometriosis.
Effect of monocyte chemoattractant protein-1 and estradiol on the secretion of vascular endothelial growth factor in endometrial stromal cells in vitro.
Effect of pentoxifylline on vascular endothelial growth factor C and flk-1 expression on endometrial implants in the rat endometriosis model.
Effect of vascular endothelial growth factor and interleukin-1beta on apoptosis in endometrial cell cultures from patients with endometriosis and controls.
Effect of Vascular Endothelial Growth Factor Inhibition on Endometrial Implant Development in a Murine Model of Endometriosis.
Effect of Wnt/?-catenin signal pathway on of matrix metalloproteinase-7 and vascular endothelial growth factor gene expressions in endometriosis.
Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia.
Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Effects of peritoneal fluid from endometriosis patients on the release of vascular endothelial growth factor by neutrophils and monocytes.
Effects of prostaglandin E(2) and vascular endothelial growth factor on sperm might lead to endometriosis-associated infertility.
Elevated ghrelin levels in the peritoneal fluid of patients with endometriosis: associations with vascular endothelial growth factor (VEGF) and inflammatory cytokines.
Exosome-mediated microRNA-138 and vascular endothelial growth factor in endometriosis through inflammation and apoptosis via the nuclear factor-?B signaling pathway.
Exploration of the Modulatory Property Mechanism of ELeng Capsule in the Treatment of Endometriosis Using Transcriptomics Combined With Systems Network Pharmacology.
Expression levels of circulatory mir-185-5p, vascular endothelial growth factor, and platelet-derived growth factor target genes in endometriosis.
Expression of CD44s, vascular endothelial growth factor, matrix metalloproteinase-2 and Ki-67 in peritoneal, rectovaginal and ovarian endometriosis.
Expression of MMIF, HIF-1? and VEGF in Serum and Endometrial Tissues of Patients with Endometriosis.
Expression of serum human leukocyte antigen and growth factor levels in a Greek family with familial endometriosis.
Expression of vascular endothelial growth factor (VEGF) and its soluble receptor-1 in endometriosis.
Expression of vascular endothelial growth factor A isoforms is dysregulated in women with endometriosis.
Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis.
Expression of vascular endothelial growth factor C and anti-angiogenesis therapy in endometriosis.
Expression, production, and secretion of vascular endothelial growth factor and interleukin-6 by granulosa cells is comparable in women with and without endometriosis.
Expressions of VEGF and Ki-67 in eutopic endometrium of patients with endometriosis and effect of Quyu Jiedu Recipe on VEGF expression.
Fenofibrate causes regression of endometriotic implants: a rat model.
Follicular fluid vascular endothelial growth factor and tumour necrosis factor alpha concentrations in patients with endometriosis undergoing ICSI.
Genetic polymorphisms and endometriosis: contribution of genes that regulate vascular function and tissue remodeling.
Genetic variants of vascular endothelial growth factor and risk for the development of endometriosis.
Genetic variations in vascular endothelial growth factor but not in angiotensin I-converting enzyme genes are associated with endometriosis in Estonian women.
Green tea epigallocatchin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo.
Heterogeneous appearance of VEGF (vascular endothelial growth factor) immunopositivity in cyst capsules of endometrioma.
Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases.
Hypoxia, cytokines and stromal recruitment: parallels between pathophysiology of encapsulating peritoneal sclerosis, endometriosis and peritoneal metastasis.
Identification of local angiogenic and inflammatory markers in the menstrual blood of women with endometriosis.
Immunoexpression of hepatocyte growth factor and c-Met receptor in the eutopic endometrium predicts the activity of ectopic endometrium.
Increased concentration of vascular endothelial growth factor in the follicular fluid of patients with endometriosis does not affect the outcome of in vitro fertilization-embryo transfer.
Influence of Ovarian Endometrioma on Expression of Steroid Receptor RNA Activator, Estrogen Receptors, Vascular Endothelial Growth Factor, and Thrombospondin 1 in the Surrounding Ovarian Tissues.
Influence of severe endometriosis on gene expression of vascular endothelial growth factor and interleukin-6 in granulosa cells from patients undergoing controlled ovarian hyperstimulation for in vitro fertilization-embryo transfer.
Inhibitory effect of curcumin in human endometriosis endometrial cells via downregulation of vascular endothelial growth factor.
Inhibitory effect of curcumin on angiogenesis in ectopic endometrium of rats with experimental endometriosis.
Involvement of vascular endothelial growth factor -460 C/T, +405 G/C and +936 C/T polymorphisms in the development of endometriosis.
Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis.
Lymphangiogenesis induced by vascular endothelial growth factor receptor 1 signaling contributes to the progression of endometriosis in mice.
Matrix Metalloproteinase-3 mRNA: A Promising Peripheral Blood Marker for Diagnosis of Endometriosis.
Mechanism of elevated vascular endothelial growth factor levels in peritoneal fluids from patients with endometriosis.
Mechanistic and therapeutic implications of angiogenesis in endometriosis.
Methodological concerns regarding levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis.
Methodological concerns regarding levels of vascular endothelial growth factor (VEGF) in serum of women with endometriosis.
Methodological remarks concerning the recent meta-analysis on vascular endothelial growth factor polymorphism and endometriosis risk.
Non-steroidal targets in the diagnosis and treatment of endometriosis.
Ovarian Fibrosis: A Phenomenon of Concern.
Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis.
p27(kip1) overexpression regulates VEGF expression, cell proliferation and apoptosis in cell culture from eutopic endometrium of women with endometriosis.
Paracrine changes in the peritoneal environment of women with endometriosis.
Peritoneal cytokines and adhesion formation in endometriosis: an inverse association with vascular endothelial growth factor concentration.
Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis.
Pigment epithelial-derived factor expression in endometriotic lesions in a rat model of endometriosis.
Polymorphisms and endometriosis: a systematic review and meta-analyses.
Polymorphisms in the vascular endothelial growth factor gene and the risk of familial endometriosis.
Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib.
Regression of Endometrial Implants by Resveratrol in an Experimentally Induced Endometriosis Model in Rats.
Regulation of Matrix Metalloproteinase-2 Activity by COX-2-PGE2-pAKT Axis Promotes Angiogenesis in Endometriosis.
Relation of peritoneal fluid and serum vascular endothelial growth factor levels to endometriosis stage.
Relationship between microvascular density and expression of vascular endothelial growth factor in patients with ovarian endometriosis.
Role of cytokines in progression of endometriosis.
Role of vascular endothelial growth factor polymorphisms (-2578C>A, -460 T>C, -1154G>A, +405G>C and +936C>T) in endometriosis: a case-control study with Brazilians.
Serum and peritoneal fluid levels of vascular endothelial growth factor in women with endometriosis.
Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines.
Serum cytokines as biomarkers for nonsurgical prediction of endometriosis.
Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis.
Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis.
T allele for VEGF gene-460 polymorphism at the 5'-untranslated region: association with a higher susceptibility to endometriosis.
Targeting galectin-1-induced angiogenesis mitigates the severity of endometriosis.
The Association Analysis of Vascular Endothelial Growth Factor -2549 Insertion/ Deletion Variant and Endometriosis Risk.
The association between vascular endothelial growth factor (VEGF) +405G>C genetic polymorphism and endometriosis.
The effects of different doses of melatonin treatment on endometrial implants in an oophorectomized rat endometriosis model.
The effects of resveratrol on the expression of VEGF, TGF-?, and MMP-9 in endometrial stromal cells of women with endometriosis.
The Exosomal Long Noncoding RNA aHIF is Upregulated in Serum From Patients With Endometriosis and Promotes Angiogenesis in Endometriosis.
The expression and significance of leukemia inhibitory factor, interleukin-6 and vascular endothelial growth factor in Chinese patients with endometriosis.
The follicular and endocrine environment in women with endometriosis: local and systemic cytokine production.
The impact of vascular endothelial growth factor single nucleotide polymorphisms in the development and severity of endometriosis: A systematic review of the literature.
The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions.
The role of cytokines in endometriosis.
The vascular endothelial growth factor (VEGF) +405G>C 5'-untranslated region polymorphism and increased risk of endometriosis in South Indian women: a case control study.
The vascular endothelial growth factor (VEGF) polymorphisms and the risk of endometriosis in northern Iran.
The vascular endothelial growth factor +405G>C polymorphism in endometriosis.
Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy.
Transforming Growth Factor-beta 1 Involved in the Pathogenesis of Endometriosis through Regulating Expression of Vascular Endothelial Growth Factor under Hypoxia.
Treatment of endometriosis with a VEGF-targeted conditionally replicative adenovirus.
Understanding the Role of Gui-Zhi-Fu-Ling-Capsules (Chinese Medicine) for Treatment of Endometriosis in the Rat Model: Using NMR Based Metabolomics.
Use of selective PGE2 receptor antagonists on human endometriotic stromal cells and peritoneal macrophages.
Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum.
Vascular endothelial growth factor (-460 C/T, +405 G/C, and +936 C/T) polymorphisms and endometriosis risk in Tunisian population.
Vascular endothelial growth factor (VEGF) and ovarian endometriosis: correlation between VEGF serum levels, VEGF cellular expression, and pelvic pain.
Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis.
Vascular endothelial growth factor (VEGF) in endometriosis.
Vascular endothelial growth factor +405 C/G polymorphism is highly associated with an increased risk of endometriosis in Turkish women.
Vascular endothelial growth factor +936 C/T polymorphism is associated with an increased risk of endometriosis in a Japanese population.
Vascular endothelial growth factor A and C gene expression in endometriosis.
Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis.
Vascular endothelial growth factor and matrix metalloproteinase-2 expedite formation of endometriosis in the early stage ICR mouse model.
Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis.
Vascular endothelial growth factor concentrations in the serum and peritoneal fluid of women with endometriosis.
Vascular endothelial growth factor expression up-regulated by endometrial ischemia in secretory phase plays an important role in endometriosis.
Vascular endothelial growth factor gene +405 C/G polymorphism is associated with susceptibility to advanced stage endometriosis.
Vascular endothelial growth factor gene polymorphisms and endometriosis risk: a meta-analysis.
Vascular endothelial growth factor gene polymorphisms contribute to the risk of endometriosis: an updated systematic review and meta-analysis of 14 case-control studies.
Vascular endothelial growth factor in the plasma, follicular fluid and granulosa cells of women with endometriosis submitted to in vitro fertilization--a pilot study.
Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids.
Vascular endothelial growth factor mRNA in eutopic and ectopic endometrium.
Vascular endothelial growth factor pathway in endometriosis: genetic variants and plasma biomarkers.
Vascular endothelial growth factor polymorphisms (-460C/T, +405G/C, and 936C/T) and endometriosis: their influence on vascular endothelial growth factor expression.
VASCULAR ENDOTHELIAL GROWTH FACTOR SERUM LEVELS IN WOMEN WITH ADVANCED ENDOMETRIOSIS.
Vitamin C and E supplementation effects on secretory and molecular aspects of vascular endothelial growth factor derived from peritoneal fluids of patients with endometriosis.
[Changes of vascular endothelial growth factor and erythropoietin in the peritoneal environment with endometriosis and its significance]
[Effects of Caulis Sargentodoxae Granule on expressions of vascular endothelial growth factor and its receptor-2 in rats with endometriosis.]
[Expression of vascular endothelial growth factor and endostatin in peritoneal fluid of patients with endometriosis]
[Expression of vascular endothelial growth factor and thrombospondin-1 in the ectopic and eutopic endometrium of women with endometriosis]
[Expression of vascular endothelial growth factor in nude mouse models of human endometriosis]
[Expression of vascular endothelial growth factor in the peritoneal fluid and eutopic endometrium of patients with endometriosis]
[Expression of vascular endothelial growth factor receptors in the ectopic and eutopic endometrium of women with endometriosis]
[Inhibition effect and mechanisms of quercetin on surgically induced endometriosis]
[Inhibitory effects of Sanleng pellet on angiogenesis of endometriosis in rats]
[Molecular biological features of ectopic and eutopic endometrium in genital endometriosis].
[Study of tissue morphology and vascular endothelial growth factor and matrix metalloproteinase-9 gene expressions in nude mouse endometriosis model]
[Targeted interruption of COX-2 gene by siRNA inhibits the expression of VEGF, MMP-9, the activity of COX-2 and stimulates the apoptosis in eutopic, ectopic endometrial stromal cells of women with endometriosis].
[Vascular endothelial growth factor gene polymorphisms and the risk of endometriosis:a systematic review].
[Vascular endothelial growth factor is up-regulated by leukemia inhibitory factor and interleukin-6 in human endometriotic stromal cells].
Endophthalmitis
Delayed onset panuveitis following intravitreal aflibercept injection.
ENDOPHTHALMITIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONISTS: A Six-Year Experience at a University Referral Center.
Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.
Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms.
Incidence of endophthalmitis after intravitreal application of anti VEGF therapy at the University Clinical Center in Tuzla, Bosnia and Herzegovina.
Re: Xu et al.: Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors (Ophthalmology. 2018;125:1279-1286).
Endotoxemia
Low-Molecular-Weight Heparin Reduces Ventilation-Induced Lung Injury through Hypoxia Inducible Factor-1? in a Murine Endotoxemia Model.
Plasma obtained during human endotoxemia increases endothelial albumin permeability in vitro.
Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis.
Enterocolitis, Necrotizing
Intestinal microcirculation and necrotizing enterocolitis: The vascular endothelial growth factor system.
Intestinal vascular endothelial growth factor is decreased in necrotizing enterocolitis.
Marked (24-fold) elevation of peritoneal cavity drainage fluid vascular endothelial growth factor after successful "patch, drain, and wait" approach for extensive midgut necrosis in a newborn.
S-layer protein 2 of vaginal Lactobacillus crispatus 2029 enhances growth, differentiation, VEGF production and barrier functions in intestinal epithelial cell line Caco-2.
The effect of vascular endothelial growth factor overexpression in experimental necrotizing enterocolitis.
Eosinophilia
Elevated serum levels of TARC/CCL17, eotaxin-3/CCL26 and vascular endothelial growth factor in a patient with non-episodic angioedema associated with eosinophilia and granulomatous cutaneous reaction.
Inflammatory features and predictors for postsurgical outcomes in patients with nasal polyps stratified by local and systemic eosinophilia.
Vascular endothelial growth factor is involved in angioedema associated with eosinophilia.
Ependymoma
Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
Cyclooxygenase-2 expression in ependymoma of the spinal cord.
Development of an intracranial ependymoma at the site of a pre-existing cavernous malformation.
Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.
Study of Stem cell marker Nestin and its correlation with Vascular endothelial growth factor and microvascular density in Ependymomas.
The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells.
Tumor vessel biology in pediatric intracranial ependymoma.
Epilepsy
Analysis of the Expression of Angioarchitecture-related Factors in Patients with Cerebral Arteriovenous Malformation.
Anti-epileptic activity of daidzin in PTZ-induced mice model by targeting oxidative stress and BDNF/VEGF signaling.
Expression and Functional Relevance of Death-Associated Protein Kinase in Human Drug-Resistant Epileptic Brain: Focusing on the Neurovascular Interface.
Increased placental growth factor in cerebrospinal fluid of patients with epilepsy.
Role of different cytokines and seizure susceptibility: a new dimension towards epilepsy research.
Epiretinal Membrane
ALPHAB-CRYSTALLIN EXPRESSION IN EPIRETINAL MEMBRANE OF HUMAN PROLIFERATIVE DIABETIC RETINOPATHY.
APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION: Results of a Prospective Trial. Report No. 2.
Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes.
Clinical Features and Prognostic Factors in Northern Chinese Patients with Peripheral Granuloma Type of Ocular Toxocariasis: A Retrospective Cohort Study.
Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
Different expression of vascular endothelial growth factor and pigment epithelium-derived factor between diabetic and non-diabetic epiretinal membranes.
ELEVATION OF ANGIOGENIC FACTOR CYSTEINE-RICH 61 LEVELS IN VITREOUS OF PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY.
Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes.
Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes.
Idiopathic epiretinal membranes: cell type, growth factor expression, and fluorescein angiographic and retinal photographic correlations.
Inhibition of CD146 attenuates retinal neovascularization via vascular endothelial growth factor receptor 2 signalling pathway in proliferative diabetic retinopathy.
Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes.
Multimodal imaging of a vascularized idiopathic epiretinal membrane.
Phosphorylation of alphaB-crystallin in epiretinal membrane of human proliferative diabetic retinopathy.
Stromal-derived factor-1 and inflammatory cytokines in retinal vein occlusion.
Transcription factor, SP1, in epiretinal membranes of patients with proliferative diabetic retinopathy.
Vascular endothelial growth factor and fibroblast growth factor 5 are colocalized in vascular and avascular epiretinal membranes.
VEGF localisation in diabetic retinopathy.
Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane.
Epistaxis
Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia.
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
Epistaxis secondary to panitumumab in a patient with colon cancer.
Hereditary hemorrhagic telangiectasia/avastin.
Pentraxin 3 level is elevated in hereditary hemorrhagic telangiectasia and reflects the severity of disease-associated epistaxis.
Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Epstein-Barr Virus Infections
Epstein-Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma.
Erectile Dysfunction
Application of angiogenic factors for therapy of erectile dysfunction: protein and DNA transfer of VEGF 165 into the rat penis.
Chronic Administration of Sildenafil Modified the Impaired VEGF System and Improved the Erectile Function in Rats with Diabetic Erectile Dysfunction.
Correction of diabetic erectile dysfunction with adipose derived stem cells modified with the vascular endothelial growth factor gene in a rodent diabetic model.
Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: a possible cause for erectile dysfunction in diabetes.
Does regular consumption of green tea influence expression of vascular endothelial growth factor and its receptor in aged rat erectile tissue? Possible implications for vasculogenic erectile dysfunction progression.
Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy and reverse venogenic erectile dysfunction in rats.
Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats.
The additive erectile recovery effect of brain-derived neurotrophic factor combined with vascular endothelial growth factor in a rat model of neurogenic impotence.
The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia.
The effect of vascular endothelial growth factor on a rat model of traumatic arteriogenic erectile dysfunction.
Transplantation of endothelial progenitor cells transfected with VEGF165 to restore erectile function in diabetic rats.
Vascular endothelial growth factor restores corporeal smooth muscle function in vitro.
Erythema
A possible additional diagnostic tool for cutaneous melanoma.
Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis.
Non-invasive detection of local tissue responses to predict pressure ulcer development in mouse models.
Primary cutaneous anaplastic large cell lymphoma associated with vascular endothelial growth factor arising from a burn scar.
Recombinant erythroid differentiation regulator 1 inhibits both inflammation and angiogenesis in a mouse model of rosacea.
Transcriptional activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes angiogenesis through VEGF and S100A8.
Vascular endothelial growth factor promotes sensitivity to ultraviolet B-induced cutaneous photodamage.
Erythema Multiforme
Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes.
Esophageal and Gastric Varices
Expression of TNF-alpha and VEGF in the esophagus of portal hypertensive rats.
Esophageal Neoplasms
Aberrant isoform of vascular endothelial growth factor 189 expression is correlated with xenotransplantability of human esophageal cancer.
Advances in targeted therapy for esophageal cancer.
Angiopoietin-1 and vascular endothelial growth factor expression in human esophageal cancer.
Chemically synthesized sugar-cholestanols possess a preferential anticancer activity involving promising therapeutic potential against human esophageal cancer.
Clinical observation and therapeutic evaluation of Rh-endostatin combined with DP regimen in treating patients with advanced esophageal cancer.
Correlation between interleukin 10 and vascular endothelial growth factor expression in human esophageal cancer.
Correlation between Vascular Endothelial Growth Factor C Expressior and Lymph Node Micrometastasis and Prognosis in Patients with pNO Esophageal Squamous Cell Carcinomas.
Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer.
Cyclooxygenase-2 expression after preoperative chemoradiotherapy correlates with more frequent esophageal cancer recurrence.
Effects of Nutrition Intervention on Total and Cancer Mortality: 25-Year Post-trial Follow-up of the 5.25-Year Linxian Nutrition Intervention Trial.
Expression of Stathmin and vascular endothelial growth factor C in esophageal cancer and their combined diagnostic value.
Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Expression of vascular endothelial growth factor C is a prognostic indicator in esophageal cancer.
Immunohistochemical localization of vascular endothelial growth factor in esophageal cancer.
Mucin 1 and Vascular Endothelial Growth Factor C Expression Correlates with Lymph Node Metastatic Recurrence in Patients with N0 Esophageal Cancer After Ivor-Lewis Esophagectomy.
Overexpression of VEGF-C correlates with a poor prognosis in esophageal cancer patients.
Prognostic role of vascular endothelial growth factor and its receptor-1 in patients with esophageal cancer.
Prognostic significance of platelet-derived growth factor-BB expression in human esophageal squamous cell carcinomas.
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis.
Prognostic value of vascular endothelial growth factor-C and podoplanin mRNA expression in esophageal cancer.
Role of +405C>G and +936C>T polymorphisms of the vascular endothelial growth factor gene and risk of esophageal cancer in the Kashmiri population.
Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study.
Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients.
The effect of VEGF rs35569394 in esophageal cancer and response to chemotherapy.
The low expression of CD80 correlated with the vascular endothelial growth factor in esophageal cancer tissue.
Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial.
Tumor-specific expression of shVEGF and suicide gene as a novel strategy for esophageal cancer therapy.
Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis.
Vascular endothelial growth factor C and D expression correlates with lymph node metastasis and poor prognosis in patients with resected esophageal cancer.
Vascular endothelial growth factor in esophageal cancer.
Vascular endothelial growth factor levels in serum and plasma following esophageal cancer resection--relationship to platelet count.
Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis.
[Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases]
[Pathologic response and changes of serum VEGF during chemoradiotherapy may predict prognosis in non-surgical patients with esophageal carcinoma].
Esophageal Squamous Cell Carcinoma
Altered Expression of Endogenous Soluble Vascular Endothelial Growth Factor Receptor-2 Is Involved in the Progression of Esophageal Squamous Cell Carcinoma.
Associations between the expression of MTA1 and VEGF-C in esophageal squamous cell carcinoma with lymph angiogenesis and lymph node metastasis.
Clinical implications of PTEN and VEGF expression status, as well as microvessel density in esophageal squamous cell carcinoma.
Clinical significance of hypoxia-inducible factor 1?, and its correlation with p53 and vascular endothelial growth factor expression in resectable esophageal squamous cell carcinoma.
Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma.
Correlation between vascular endothelial growth factor C expression and prognosis in patients with esophageal squamous cell carcinomas after Ivor-Lewis esophagectomy.
Correlation between Vascular Endothelial Growth Factor C Expressior and Lymph Node Micrometastasis and Prognosis in Patients with pNO Esophageal Squamous Cell Carcinomas.
Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma.
DW-MRI for esophageal squamous cell carcinoma, correlations between ADC values with histologic differentiation and VEGF expression: A retrospective study.
Effect of VEGF-C siRNA and endostatin on ring formation and proliferation of esophageal squamous cell carcinoma lymphatic endothelial cells.
Evaluation of tumor metastasis-associated markers for molecular classification in patients with esophageal squamous cell carcinoma.
Expression and significance of vascular endothelial growth factor C from multiple specimen sources in esophageal squamous cell carcinoma.
Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.
Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma.
Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma.
Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma.
Expression of p53 protein in esophageal squamous cell carcinoma: relation to hypoxia-inducible factor-1alpha, angiogenesis and apoptosis.
Expression of PC cell-derived growth factor and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinicopathologic significance.
Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in esophageal squamous cell carcinoma.
Hypoxia-inducible factor 1? in combination with vascular endothelial growth factor could predict the prognosis of postoperative patients with oesophageal squamous cell cancer.
In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis.
Loss of p16INK4a expression is associated with vascular endothelial growth factor expression in squamous cell carcinoma of the esophagus.
Oesophageal squamous cell carcinoma in high-risk Chinese populations: Possible role for vascular epithelial growth factor A.
Overexpression and Interactions of Interleukin-10, Transforming Growth Factor beta, and Vascular Endothelial Growth Factor in Esophageal Squamous Cell Carcinoma.
Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: comparison with positron emission tomography.
RhoC, vascular endothelial growth factor and microvascular density in esophageal squamous cell carcinoma.
Semaphorin 3F Serves as a Tumor Suppressor in Esophageal Squamous Cell Carcinoma and is Associated With Lymph Node Metastasis in Disease Progression.
TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma.
The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
The effects of vascular endothelial growth factor C knockdown in esophageal squamous cell carcinoma.
The relationship between the expression of VEGF, EGFR, and HER-2 mRNA in esophageal squamous cell carcinoma (ESCC) and clinicopathological features of different ethnic groups in Xinjiang.
Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma.
Vascular endothelial growth factor C is an indicator of lymph node metastasis in thoracic esophageal squamous cellcarcinomas and its role in long-term survival after surgery.
Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression.
Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus.
Vascular Endothelial Growth Factor is a Useful Predictor of Postoperative Distant Metastasis and Survival Prognosis in Esophageal Squamous Cell Carcinoma.
Vascular endothelial growth factors C and D and lymphangiogenesis at the early stage of esophageal squamous cell carcinoma progression.
VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
VEGF as a Predictor for Response to Definitive Chemoradiotherapy and COX-2 as a Prognosticator for Survival in Esophageal Squamous Cell Carcinoma.
VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
[Constitutive activation of signal transducers and activators of transcription 3 and expression of its target gene products in human ESCC cell line]
[Correlation between expression of vascular endothelial growth factor and prognosis of patients with esophageal squamous cell carcinoma]
[Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases]
[Expression and clinical significance of hypoxia inducible factor-1alpha, survivin and vascular endothelial growth factor in esophageal squamous cell carcinoma]
[Expression of p53 and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinical significance]
[Expression of vascular endothelial growth factor D in human esophageal squamous cell carcinoma tissue and its significance].
[Expression of vascular endothelial growth factor in primary esophageal squamous cell carcinoma and its significance in angiogenesis and prognosis of the tumor]
Esophagitis, Peptic
mRNA expression of inducible nitric oxide synthase, endothelial nitric oxide synthase and vascular endothelial growth factor in esophageal mucosa biopsy specimens from patients with reflux esophagitis.
Essential Hypertension
Angiogenesis and Hypertension: The Dual Role of Anti-Hypertensive and Anti-Angiogenic Therapies.
Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension.
Exercise training normalizes skeletal muscle vascular endothelial growth factor levels in patients with essential hypertension.
Expression of Serum Vascular Endothelial Growth Factor and Angiopoietin Receptor Tie-2 in Essential Hypertension.
In vivo platelet activation is responsible for enhanced vascular endothelial growth factor levels in hypertensive patients.
Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension.
The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension.
Vascular endothelial growth factor (VEGF) +405 C/G polymorphism is associated with essential hypertension in a population from Tehran of Iran.
VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension.
Exanthema
Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Myositis, Vasculitis, Hepatic Dysfunction in Adult-Onset Still's Disease.
Exfoliation Syndrome
Aqueous Humor and Plasma Levels of Vascular Endothelial Growth Factor and Nitric Oxide in Patients With Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma.
Eye Diseases
An antisense oligodeoxynucleotide against vascular endothelial growth factor in a nonhuman primate model of iris neovascularization.
Angiogenesis-related factors derived from retinal glial (Müller) cells in hypoxia.
Antiangiogenic Isoforms of VASCULAR ENDOTHELIAL GROWTH FACTOR Predominate in Subretinal Fluid of Patients with Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy.
Arhgef15 promotes retinal angiogenesis by mediating VEGF-induced Cdc42 activation and potentiating RhoJ inactivation in endothelial cells.
Bevacizumab for eye diseases - Legal, regulatory, and ethical overview.
Bevacizumab for ocular neovascular diseases: a systematic review.
Curcumolide, a unique sesquiterpenoid from Curcuma wenyujin displays anti-angiogenic activity and attenuates ischemia-induced retinal neovascularization.
Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes.
ELEVATION OF ANGIOGENIC FACTOR CYSTEINE-RICH 61 LEVELS IN VITREOUS OF PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY.
Fusion Proteins: Aflibercept (VEGF Trap-Eye).
In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye.
Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA.
Manipulating Angiogenesis by Targeting Endothelial Metabolism: Hitting the Engine Rather than the Drivers-A New Perspective?
Non-physician delivered intravitreal injection service is feasible and safe - a systematic review.
Norrin restores blood-retinal barrier properties after vascular endothelial growth factor-induced permeability.
Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis.
Protamine sulfate downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF and its receptor binding in vitro.
The potential health benefits of dietary natural plant products in age related eye diseases.
Thrombospondin-1-Based Antiangiogenic Therapy.
Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model.
Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
Vascular endothelial growth factor in eye disease.
Vascular endothelial growth factors and angiogenesis in eye disease.
VEGF Secreted by Hypoxic Muller Cells Induces MMP-2 Expression and Activity in Endothelial Cells to Promote Retinal Neovascularization in Proliferative Diabetic Retinopathy.
[Alternative splicing of vascular endothelial growth factor A and ocular neovascularization].
[Ophthalmic safety profile of antiangiogenic therapy].
Eye Infections
Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.
Macrophage inflammatory protein-2 and vascular endothelial growth factor regulate corneal neovascularization induced by infection with Pseudomonas aeruginosa in mice.
Eye Injuries
Sulfur Mustard-related Ocular Complications: A Review of Proteomic Alterations and Pathways Involved.
Vascular endothelial growth factor in aqueous humor of patients with perforative eye injuries.
Fabry Disease
Correlations Between Serum Cholesterol and Vascular Lesions in Fabry Disease Patients.
Possible role of transforming growth factor-?1 and vascular endothelial growth factor in Fabry disease nephropathy.
Vascular Endothelial Growth Factor (VEGF-a) in Fabry disease: Association with cutaneous and systemic manifestations with vascular involvement.
Fallopian Tube Neoplasms
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Familial Mediterranean Fever
Analysis of vascular endothelial growth factor gene 936 C/T polymorphism in patients with familial Mediterranean fever.
S100A12 and vascular endothelial growth factor can differentiate Blau syndrome and familial Mediterranean fever from systemic juvenile idiopathic arthritis.
Familial Primary Pulmonary Hypertension
Pulmonary capillary hemangiomatosis: an immunohistochemical analysis of vascular remodeling.
Fanconi Anemia
Identification of novel biomarkers in chronic immune thrombocytopenia (ITP) by microarray-based serum protein profiling.
Fatty Liver
Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study.
Could inflammatory markers help diagnose nonalcoholic steatohepatitis?
Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy.
Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction.
Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease.
Febrile Neutropenia
The use of serum endothelial adhesion molecules in pediatric patients with leukemia with febrile neutropenia to predict bacteremia.
Feline Infectious Peritonitis
Vascular endothelial growth factor (VEGF), produced by feline infectious peritonitis (FIP) virus-infected monocytes and macrophages, induces vascular permeability and effusion in cats with FIP.
Femur Head Necrosis
Effect of Chinese drugs for promoting blood circulation and eliminating blood stasis on vascular endothelial growth factor expression in rabbits with glucocorticoid-induced ischemic necrosis of femoral head.
Effect of Vascular Endothelial Growth Factor 121 Adenovirus Transduction in Rabbit Model of Femur Head Necrosis.
Fetal Death
Amniotic levels of nitric oxide and vascular endothelial growth factor in pregnancy with subsequent intrauterine fetal death.
Fetal death: A condition with a dissociation in the concentrations of soluble vascular endothelial growth factor receptor-2 between the maternal and fetal compartments.
Fetal growth restriction in hypothyroidism is associated with changes in proliferative activity, apoptosis and vascularisation of the placenta.
Prevention of Defective Placentation and Pregnancy Loss by Blocking Innate Immune Pathways in a Syngeneic Model of Placental Insufficiency.
Role of Complement Component C1q in the Onset of Preeclampsia in Mice.
Fetal Growth Retardation
Abnormal fetal growth is not associated with altered chorionic villous expression of vascular endothelial growth factor mRNA.
Angiogenic growth factors in maternal and fetal serum in pregnancies complicated with intrauterine growth restriction.
Are the maternal and umbilical VEGF-A and SVEGF-R1 altered in pregnancies complicated by preeclampsia with or without intrauterine foetal growth retardation? Preliminary communication.
Early fetal hypoxia leads to growth restriction and myocardial thinning.
Effects of KRN633, an inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, on vascular development of placenta and fetus of mid pregnancy in mice.
Effects of pre- and post-natal treatment with KRN633, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on retinal vascular development and patterning in mice.
Ethics and social acceptability of a proposed clinical trial using maternal gene therapy to treat severe early-onset fetal growth restriction.
Expression of genes coding for proangiogenic factors and their receptors in human placenta complicated by preeclampsia and intrauterine growth restriction.
Gene expression patterns of vascular endothelial growth factor (VEGF-A) in human placenta from pregnancies with intrauterine growth restriction.
Glucocorticoids prevent the normal increase in placental vascular endothelial growth factor expression and placental vascularity during late pregnancy in the rat.
Imaging of activated complement using ultrasmall superparamagnetic iron oxide particles (USPIO)--conjugated vectors: an in vivo in utero non-invasive method to predict placental insufficiency and abnormal fetal brain development.
Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction.
Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation.
Mesenteric artery reactivity and small intestine morphology in a chicken model of hypoxia-induced fetal growth restriction.
MicroRNA-206 predicts raised fetal growth retardation risk through the interaction with vascular endothelial growth factor in pregnancies.
miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9.
MiR-590-3p and its targets VEGF, PIGF, and MMP9 in early, middle, and late pregnancy: their longitudinal changes and correlations with risk of fetal growth restriction.
Peri- and Postnatal Effects of Prenatal Adenoviral VEGF Gene Therapy in Growth-Restricted Sheep.
Perinatal and long-term effects of maternal uterine artery adenoviral VEGF-A165 gene therapy in the growth-restricted guinea pig fetus.
Placental expression of vascular endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypoxia at delivery.
Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Pulmonary Vascular Endothelial Growth Factor Expression and Disaturated Phospholipid Content in a Chicken Model of Hypoxia-Induced Fetal Growth Restriction.
Recombinant vascular endothelial growth factor 121 injection for the prevention of fetal growth restriction in a preeclampsia mouse model.
Reduced angiogenic factor expression in intrauterine fetal growth restriction using semiquantitative immunohistochemistry and digital image analysis.
Sustained Endocrine Gland-Derived Vascular Endothelial Growth Factor Levels Beyond the First Trimester of Pregnancy Display Phenotypic and Functional Changes Associated With the Pathogenesis of Pregnancy-Induced Hypertension.
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
The multiple roles of EG-VEGF/PROK1 in normal and pathological placental angiogenesis.
The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction.
Vascular endothelial growth factor, its receptors, and the tie receptors in the placental bed of women with preeclampsia, diabetes, and intrauterine growth retardation.
[Placental gene activity of significant angiogenetic factors in the background of intrauterine growth restriction].
[Vascular endothelial growth factor expression in placenta from intrauterine growth retardation fetus with abnormal umbilical artery flow velocity waveforms]
Fetal Hypoxia
Concentration of cord serum placenta growth factor in normal and diabetic pregnancies.
Fetomaternal Transfusion
Role of the vascular endothelial growth factor in the inverse relationship between increased nuchal translucency thickness and fetomaternal transfusion.
Fibroadenoma
Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas.
Fibromatosis, Aggressive
Abnormalities of the Wnt/?-catenin signalling pathway induce tumour progression in sporadic desmoid tumours: correlation between ?-catenin widespread nuclear expression and VEGF overexpression.
Fibromyalgia
Low plasma levels of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNFalpha), and vascular endothelial growth factor (VEGF) in patients with alpha1-antitrypsin deficiency-related fibromyalgia.
Serum Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-1 Levels in Patients With Fibromyalgia Syndrome.
Fibrosarcoma
Adenoviral vector platform for transduction of constitutive and regulated tricistronic or triple-transcript transgene expression in mammalian cells and microtissues.
Alopecia in patients treated with molecularly targeted anticancer therapies.
Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro.
Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.
Bone marrow-derived cells do not incorporate into the adult growing vasculature.
Disodium Cromolyn and Anti-podoplanin Antibodies Strongly Inhibit Growth of BHK 21/C13-derived Fibrosarcoma in a Chick Embryo Chorioallantoic Membrane Model.
Efficacy and Safety of Apatinib in the Treatment of Postoperative Recurrence of Fibrosarcoma.
Ethanol stimulates tumor progression and expression of vascular endothelial growth factor in chick embryos.
Functional in vivo optical imaging of tumor angiogenesis, growth, and metastasis prevented by administration of anti-human VEGF antibody in xenograft model of human fibrosarcoma HT1080 cells.
Immunohistochemical Expression of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor in Canine Cutaneous Fibrosarcomas.
LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
MALDI-MSI and label-free LC-ESI-MS/MS shotgun proteomics to investigate protein induction in a murine fibrosarcoma model following treatment with a vascular disrupting agent.
Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future.
New-generation multicistronic expression platform: pTRIDENT vectors containing size-optimized IRES elements enable homing endonuclease-based cistron swapping into lentiviral expression vectors.
Radiation oxygen biology with pulse electron paramagnetic resonance imaging in animal tumors.
Relationship of angiogenic and apoptotic activities in soft-tissue sarcoma.
Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.
Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas.
Vascular patterning of subcutaneous mouse fibrosarcomas expressing individual VEGF isoforms can be differentiated using angiographic optical coherence tomography.
Focal Nodular Hyperplasia
Hepatic stellate cells are activated around central scars of focal nodular hyperplasia of the liver--a potential mechanism of central scar formation.
Foot Ulcer
Angiogenic effects of low-intensity cathodal direct current on ischemic diabetic foot ulcers: A randomized controlled trial.
Association between VEGF genetic variants and diabetic foot ulcer in Chinese Han population: A case-control study.
Effect of low-intensity direct current on expression of vascular endothelial growth factor and nitric oxide in diabetic foot ulcers.
Expression and Influence of Matrix Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 and Vascular Endothelial Growth Factor in Diabetic Foot Ulcers.
Growth factors for treating diabetic foot ulcers.
MiR-195-5p and miR-205-5p in extracellular vesicles isolated from diabetic foot ulcer wound fluid decrease angiogenesis by inhibiting VEGFA expression.
Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers.
Role of growth factors and cytokines in diabetic foot ulcer healing: A detailed review.
The association between MCP-1, VEGF polymorphisms and their serum levels in patients with diabetic foot ulcer.
The relationship of the endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) gene polymorphism in Turkish type 2 diabetic patients with and without diabetic foot ulcers.
Frontotemporal Dementia
VEGF Haplotypes are Associated with Increased Risk to Progressive Supranuclear Palsy and Corticobasal Syndrome.
Galactosemias
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Gallbladder Neoplasms
Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer.
Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer.
Inhibition of SCAMP1 suppresses cell migration and invasion in human pancreatic and gallbladder cancer cells.
Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer.
Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
Vascular endothelial growth factor single-nucleotide polymorphism in gall bladder cancer.
Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer.
[Expressions of VEGF-C and VEGF-D and their correlation with lymphangiogenesis and angiogenesis in gallbladder carcinoma]
Ganglioneuroma
VEGF-C, VEGF-D and VEGFR-3 expression in peripheral neuroblastic tumours.
Gastritis
The prognostic significance of growth factors and growth factor receptors in gastric adenocarcinoma.
Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans.
[Effect of Huazhuo Jiedu formula on HIF-1?, VEGF, and PTEN in chronic erosive gastritis patients with syndrome of accumulation of turbidity and toxicity].
[Exploration of the correlation between Chinese medicine syndrome types of verrucous gastritis and the pressions of gastric mucosal hypoxia-inducible factor-1alpha as well as downstream molecules].
Gastritis, Atrophic
Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcer.
[Acupoint catgut embedding improves gastric mucosal injury by down-regulating expression of HIF-1? and VEGF in chronic atrophic gastritis rats].
[Relationship of TCM syndrome type of gastric mucosal epithelial growth factor, vascular endothelial growth factor and proliferative cell nuclear antigen in patients with chronic atrophic gastritis]
Gastroesophageal Reflux
[The research progress of relationship between the obstructive sleep apnea hypopnea syndrome and asthma].
Gastrointestinal Diseases
Prognostic value of serum angiogenic activity in colorectal cancer patients.
Gastrointestinal Neoplasms
Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.
Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer.
Correlations between Serum Levels of Vascular Endothelial Growth Factor and Endostatin with Clinical Pathological Characteristics of Patients with Gastrointestinal Cancers.
Diagnostic and Prognostic Performance of Serum Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor 2, and Osteopontin for Gastrointestinal Cancers.
Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
Endogenous stimulators and inhibitors of angiogenesis in gastrointestinal cancers: basic science to clinical application.
Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells.
Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy.
Serum Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor 2, and Osteopontin: Diagnostic and Prognostic Potential Biomarkers for Gastrointestinal Cancers.
Vascular endothelial growth factor assessment in different blood fractions of gastrointestinal cancer patients and healthy controls.
Vascular endothelial growth factors and liver diseases.
Gastrointestinal Stromal Tumors
Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumors.
Coexpression of cyclooxygenase-2 and vascular endothelial growth factor in gastrointestinal stromal tumor: possible relations to pathological parameters and clinical behavior.
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Expression of matrix metalloproteinase-9, cyclooxygenase-2 and vascular endothelial growth factor are increased in gastrointestinal stromal tumors.
Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach.
Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas.
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
Prognostic significance of angiogenesis in gastrointestinal stromal tumor.
Serum vascular endothelial growth factor and angiogenesis are related to the prognosis of patients with gastrointestinal stromal tumors.
STI571 (Glivec) suppresses the expression of vascular endothelial growth factor in the gastrointestinal stromal tumor cell line, GIST-T1.
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours.
[Correlation between expressions of matrix metalloproteinase-2 & 9 and vasculogenic mimicry in gastrointestinal stromal tumors]
[Detection and clinical significance of plasma vascular endothelial growth factor level in gastrointestinal stromal tumor patients]
Gastroparesis
Increased expression of hypoxia inducible factor-1 alpha and vascular endothelial growth factor is associated with diabetic gastroparesis.
Gaucher Disease
Vascular endothelial growth factor (VEGF), tissue inhibitors of metalloproteinase-1 (TIMP-1) and nail fold capillaroscopy changes in children and adolescents with Gaucher disease; relation to residual disease severity.
Genetic Diseases, Inborn
Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia.
Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Genital Diseases, Female
Vascular endothelial growth factor in cervical carcinoma.
Geographic Atrophy
A Mechanistic PK/PD Model of Factor D Inhibition in Cynomolgus Monkeys by Lampalizumab for the Treatment of Geographic Atrophy.
A PHASE IA DOSE-ESCALATION STUDY OF THE ANTI-FACTOR D MONOCLONAL ANTIBODY FRAGMENT FCFD4514S IN PATIENTS WITH GEOGRAPHIC ATROPHY.
Age-related macular degeneration: a complementopathy?
Complement inhibition as a therapeutic strategy in retinal disorders.
Connexin43 hemichannels: A potential drug target for the treatment of diabetic retinopathy.
Development of a novel ELISA to detect total factor D in the presence of high levels of PEGylated anti-factor D Fab.
Hot Topics in Dry AMD.
Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy.
Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin.
Gestational Trophoblastic Disease
Expression of vascular endothelial growth factor (VEGF), hypoxia inducible factor 1 alpha (HIF-1alpha), and transforming growth factors beta1 (TGFbeta1) and beta3 (TGFbeta3) in gestational trophoblastic disease.
The multiple roles of EG-VEGF/PROK1 in normal and pathological placental angiogenesis.
Giant Cell Arteritis
A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis.
Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells.
Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia.
Vascular endothelial growth factor gene polymorphisms in giant cell arteritis.
Vascular endothelial growth factor levels and rheumatic diseases of the elderly.
Giant Cell Tumor of Bone
Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions.
Giant Cell Tumors
Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions.
Gene expression of vascular endothelial growth factor in giant cell tumors of bone.
Overexpression of hypoxia-inducible factor-1? and vascular endothelial growth factor in sacral giant cell tumors and the correlation with tumor microvessel density.
Gingival Overgrowth
Effect of adjunctive roxithromycin therapy on interleukin-1?, transforming growth factor-?1 and vascular endothelial growth factor in gingival crevicular fluid of cyclosporine A-treated patients with gingival overgrowth.
Increased expression of vascular endothelial growth factor in cyclosporin A-induced gingival overgrowth in rats.
Gingivitis
Vascular endothelial growth factor expression levels of gingiva in gingivitis and periodontitis patients with/without diabetes mellitus.
Glaucoma
Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review.
Anti--vascular endothelial growth factor therapy in glaucoma filtration surgery.
Aqueous Humor and Plasma Levels of Vascular Endothelial Growth Factor and Nitric Oxide in Patients With Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma.
Aqueous humor endothelin-1 (Et-1), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) levels in Mexican glaucomatous patients.
Aqueous Vascular Endothelial Growth Factor and Endothelin-1 Levels in Branch Retinal Vein Occlusion Associated With Normal Tension Glaucoma.
Bevacizumab-Loaded Polyurethane Subconjunctival Implants: Effects on Experimental Glaucoma Filtration Surgery.
Bilateral retinal vein occlusion and rubeosis irides: lessons to learn.
Effect of ripasudil on diabetic macular edema.
Expression of Vascular Endothelial Growth Factor-C in the Trabecular Meshwork of Patients with Neovascular Glaucoma and Primary Open-Angle Glaucoma.
Inhibition of Vascular Endothelial Growth Factor Reduces Scar Formation after Glaucoma Filtration Surgery.
Level of vascular endothelial growth factor in aqueous humor and surgical results of ahmed glaucoma valve implantation in patients with neovascular glaucoma.
Level of Vascular Endothelial Growth Factor in Tenon Tissue and Results of Glaucoma Surgery.
MiR-126 facilitates apoptosis of retinal ganglion cells in glaucoma rats via VEGF-Notch signaling pathway.
Myopia and diabetes mellitus as modificatory factors of glaucomatous optic neuropathy.
Novel engineered, membrane-localized variants of vascular endothelial growth factor (VEGF) protect retinal ganglion cells: a proof-of-concept study.
Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von Willebrand factor in glaucoma.
Prostaglandin use is associated with increased vascular endothelial growth factor in the aqueous humor of glaucoma patients.
Role of mammalian target of rapamycin in regulating HIF-1? and vascular endothelial growth factor signals in glaucoma.
Suppression of Human Tenon Fibroblast Cell Proliferation by Lentivirus-Mediated VEGF Small Hairpin RNA.
The efficiency of subconjunctival bevacizumab in refractory glaucoma - case report.
The potential health benefits of dietary natural plant products in age related eye diseases.
Therapeutic targets of renin-angiotensin system in ocular disorders.
Vascular Endothelial Growth Factor -460 C/T BstUI Gene Polymorphism is associated with Primary Open Angle Glaucoma.
Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes.
Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated.
[Vascular endothelial growth factor (VEGF) and modulation of wound healing after glaucoma surgery]
Glaucoma, Angle-Closure
Vascular Endothelial Growth Factor is Increased in Aqueous Humor of Acute Primary Angle-Closure Eyes.
Glaucoma, Neovascular
Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma.
Aqueous humor endothelin-1 (Et-1), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) levels in Mexican glaucomatous patients.
Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study.
Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma.
Expression of platelet-derived growth factor-C in aqueous humor of patients with neovascular glaucoma and its correlation with vascular endothelial growth factor.
Features of Cutaneous Malignant Melanoma Metastatic to the Retina and Vitreous.
Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma.
Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma.
Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma.
Level of vascular endothelial growth factor in aqueous humor and surgical results of ahmed glaucoma valve implantation in patients with neovascular glaucoma.
Levels of angiogenesis-related vascular endothelial growth factor family in neovascular glaucoma eyes.
Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab.
Neovascular glaucoma treatment with extraction of anterior chamber fibrovascular tissue.
Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
The Measurement of Intraocular Biomarkers in Various Stages of Proliferative Diabetic Retinopathy Using Multiplex xMAP Technology.
Vascular endothelial growth factor and its soluble receptors-1 and -2 in iris neovascularization and neovascular glaucoma.
Vascular endothelial growth factor concentrations in aqueous humor before and after subconjunctival injection of bevacizumab for neovascular glaucoma.
Vascular endothelial growth factor in anterior chamber liquid patients with diabetic retinopathy, cataract and neovascular glaucoma.
Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate.
[Effect of Intravitreal Bevacizumab Injection on Iris and Iridocorneal Angle Neovascularization in Neovascular Glaucoma].
[Neovascular glaucoma--etipathogeny and diagnosis].
[The change of the level of the vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma before and after anterior retinal cryotherapy]
[Vascular endothelial growth factor levels in the aqueous and serum in diabetic retinopathy with or without neovascular glaucoma]
Glaucoma, Open-Angle
Anti--vascular endothelial growth factor therapy in glaucoma filtration surgery.
Aqueous humor endothelin-1 (Et-1), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) levels in Mexican glaucomatous patients.
Cytokine expression in tears of patients with glaucoma or dry eye disease: A prospective, observational cohort study.
Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma.
Level of Vascular Endothelial Growth Factor in Tenon Tissue and Results of Glaucoma Surgery.
Neovascular Glaucoma.
Vascular Endothelial Growth Factor -460 C/T BstUI Gene Polymorphism is associated with Primary Open Angle Glaucoma.
Glioblastoma
8-Cl-cAMP and tiazofurin affect vascular endothelial growth factor production and glial fibrillary acidic protein expression in human glioblastoma cells.
A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes.
A pediatric case of anaplastic astrocytoma with a gliomatosis cerebri; the growth pattern and changes in serum VEGF-121 levels after bevacizumab treatment.
A randomized clinical trial of vascular endothelial growth factor inhibition in the treatment of glioblastoma multiforme.
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma.
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF.
Activation of vascular endothelial growth factor A transcription in tumorigenic glioblastoma cell lines by an enhancer with cell type-specific DNase I accessibility.
Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells.
Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas.
Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway.
Anatomical specificity of vascular endothelial growth factor expression in glioblastomas: a voxel-based mapping analysis.
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Angiogenesis and antiangiogenic therapy for malignant gliomas.
Angiogenic Gene Signature Derived from Subtype Specific Cell Models Segregate Proneural and Mesenchymal Glioblastoma.
Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.
Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma.
Anti-angiogenic therapy for high-grade glioma.
Anti-Invasion and Antiangiogenic Effects of Stellettin B through Inhibition of the Akt/Girdin Signaling Pathway and VEGF in Glioblastoma Cells.
Anti-tumor activity of DLX1008, an anti-VEGFA antibody fragment with low picomolar affinity, in human glioma models.
Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts.
Anti-vascular endothelial growth factor therapy for malignant glioma.
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.
Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas.
Antitumor treatment efficacy by targeting epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in an orthotopic human glioblastoma model.
Association of pSTAT3-VEGF signaling pathway with peritumoral edema in newly diagnosed glioblastoma: an immunohistochemical study.
Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels.
Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.
Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.
Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.
Bevacizumab and micrometastases: Revisiting the preclinical and clinical rollercoaster.
Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.
Bevacizumab for glioblastoma: What can we learn from patterns of progression?
Bevacizumab for malignant gliomas.
Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.
Bevacizumab for the treatment of recurrent glioblastoma.
Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.
Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials?
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study.
Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Biologically active peptides interacting with the G protein-coupled formylpeptide receptor.
Blockade of glioma proliferation through allosteric inhibition of JAK2.
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells.
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Blocking VEGF by Bevacizumab Compromises Electrophysiological and Morphological Properties of Hippocampal Neurons.
CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma.
CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Cell density regulates thrombospondin-1 production in malignant glioma cells.
Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis.
Cell-specific but p53-independent regulation of vascular endothelial growth factor expression by interferons in human glioblastoma cells.
Characterisation and identification of the human N(+)-glucuronide metabolite of cediranib.
Characterization of molecular pathways for targeting therapy in glioblastoma.
Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma.
Combined delivery of BCNU and VEGF siRNA using amphiphilic peptides for glioblastoma.
Comparative efficacy of antiangiogenic treatment for newly diagnosed glioblastoma: A protocol for systematic review and network meta-analysis.
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.
Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
Corticosteroids compromise survival in glioblastoma.
Coupling to a glioblastoma-directed antibody potentiates antitumor activity of curcumin.
Current and Future Drug Treatments for Glioblastomas.
Cutaneous thrombogenic vasculopathy associated with bevacizumab therapy.
Decrease of endogenous vascular endothelial growth factor may not affect glioma cell proliferation and invasion.
Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.
Difference in Immunosuppressive Cells Between Peritumoral Area and Tumor Core in Glioblastoma.
Differential regulation of TGF-?-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma.
Differential regulation of VEGF, HIF1alpha and angiopoietin-1, -2 and -4 by hypoxia and ionizing radiation in human glioblastoma.
Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis.
Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma.
Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Effect of cycloxygenase-2 silencing on the malignant biological behavior of MCF-7 breast cancer cells.
Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2.
Endoglin and TGF-? signaling in glioblastoma.
Enhanced cancer therapy with the combination of EGFR and VEGFR-2 targeting in an orthotopic glioblastoma model.
Enhanced Gene Transfer Efficiency in the Murine Striatum and an Orthotopic Glioblastoma Tumor Model, Using AAV-7- and AAV-8-Pseudotyped Vectors.
Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors.
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.
Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.
Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab.
Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas.
Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis.
Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
Expression of nitric oxide synthase isozymes (NOS I-III) by immunohistochemistry and DNA in situ hybridization. Correlation with macrophage presence, vascular endothelial growth factor (VEGF) and oedema volumetric data in 220 glioblastomas.
Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors.
Expression of vascular endothelial growth factor and its receptors in pilocytic astrocytoma.
Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.
Expression of vascular Notch ligands Delta-like 4 and Jagged-1 in glioblastoma.
Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.
Fos-related antigen 1 modulates malignant features of glioma cells.
Genetic variations in VEGF and VEGFR2 and glioblastoma outcome.
Glial Cell Line-Derived Neurotrophic Factor (GDNF) Promotes Angiogenesis through the Demethylation of the Fibromodulin (FMOD) Promoter in Glioblastoma.
Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors.
Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR.
Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal.
Graphic analysis of microscopic tumor cell infiltration, proliferative potential, and vascular endothelial growth factor expression in an autopsy brain with glioblastoma.
High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment.
Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma.
Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells.
Hydrogel microfluidic co-culture device for photothermal therapy and cancer migration.
Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres.
Identification of Potent VEGF Inhibitors for the Clinical Treatment of Glioblastoma, A Virtual Screening Approach.
Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma.
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology.
Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells.
Influence of vascular endothelial growth factor and radiation on gap junctional intercellular communication in glioblastoma multiforme cell lines.
Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
Integrin Inhibitor Suppresses Bevacizumab-Induced Glioma Invasion.
Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1.
Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.
Intratumoral hemorrhage-related differences in the expression of vascular endothelial growth factor, basic fibroblast growth factor and thioredoxin reductase 1 in human glioblastoma.
Invasion as limitation to anti-angiogenic glioma therapy.
Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways.
Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.
Limited role for transforming growth factor-? pathway activation-mediated escape from VEGF inhibition in murine glioma models.
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression.
MDM2 regulates hypoxic hypoxia-inducible factor 1? stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner.
MicroRNA?566 modulates vascular endothelial growth factor by targeting Von Hippel?Landau in human glioblastoma in vitro and in vivo.
Mitogen-activated protein kinase, ERK1/2, is essential for the induction of vascular endothelial growth factor by ionizing radiation mediated by activator protein-1 in human glioblastoma cells.
Modulation of cerebral endothelial cell function by TGF-? in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition.
Molecular targeted therapies and chemotherapy in malignant gliomas.
Morphological Changes of Cortical and Hippocampal Neurons after Treatment with VEGF and Bevacizumab.
Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.
Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma.
Myoglobin variants are expressed in human glioblastoma cells?hypoxia effect?
Neuropathological diagnosis of brain tumours.
New therapies for recurrent glioblastomas.
Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Novel diagnostic and therapeutic approaches to malignant glioma.
Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: From bedside to bench.
Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines.
Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis.
Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment.
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo.
Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells.
Phosphatase and tensin homolog reconstruction and vascular endothelial growth factor knockdown synergistically inhibit the growth of glioblastoma.
Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans.
PSMB8 inhibition decreases tumor angiogenesis in glioblastoma through vascular endothelial growth factor A reduction.
PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter.
Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines--a clue to radioresistance?
Radiologic Features and Expression of Vascular Endothelial Growth Factor Stratify Survival Outcomes in Patients with Glioblastoma.
Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression.
Repression of vascular endothelial growth factor A in glioblastoma cells using engineered zinc finger transcription factors.
Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression.
Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells
Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells.
Role of vincristine in the inhibition of angiogenesis in glioblastoma.
Rolipram potentiates bevacizumab-induced cell death in human glioblastoma stem-like cells.
Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death.
Silencing microRNA-221/222 cluster suppresses glioblastoma angiogenesis by suppressor of cytokine signaling-3-dependent JAK/STAT pathway.
Spatial expression of VEGF-A in human glioma.
Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation.
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.
Targeting c-Myc on cell growth and vascular endothelial growth factor expression in IN500 glioblastoma cells.
The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines.
The vascular delta-like ligand-4 (DLL4)-Notch4 signaling correlates with angiogenesis in primary glioblastoma: an immunohistochemical study.
Transcriptional upregulation of human cathepsin L by VEGF in glioblastoma cells.
Treatment of recurrent high-grade gliomas.
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.
Tumour-associated macrophage-derived interleukin-1 mediates glioblastoma-associated cerebral oedema.
Two Novel Heparin-binding Vascular Endothelial Growth Factor Splices, L-VEGF144 and L-VEGF138, are Expressed in Human Glioblastoma Cells.
Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.
Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?
Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas.
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells.
Vascular endothelial growth factor.
VEGF Manipulation in Glioblastoma.
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.
VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours.
VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme.
[Effect of nordy on FPR function of malignant human glioma cell line U87]
[Monoclonal antibodies in high-grade gliomas].
Glioma
"Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab.
3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility.
3D-ASL perfusion correlates with VEGF expression and overall survival in glioma patients: Comparison of quantitative perfusion and pathology on accurate spatial location-matched basis.
A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network.
A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes.
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study.
A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma.
A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma.
AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma.
Activation of chemokine receptor CXCR4 in malignant glioma cells promotes the production of vascular endothelial growth factor.
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
All-trans retinoic acid upregulates VEGF expression in glioma cells in vitro.
Anatomical specificity of vascular endothelial growth factor expression in glioblastomas: a voxel-based mapping analysis.
Angiogenesis and antiangiogenic therapy for malignant gliomas.
Angiogenesis in gliomas: biology and molecular pathophysiology.
Angiogenesis in malignant gliomas.
Angiogenesis-related growth factors in brain tumors.
Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors.
Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in gliomas.
Anti-Angiogenic Approaches to Malignant Gliomas.
Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts.
Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo.
Antiangiogenic therapy in malignant glioma: promise and challenge.
Antiangiogenic therapy in malignant gliomas.
Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.
Antisense oligodeoxynucleotide inhibits vascular endothelial growth factor in human glioma cells.
Aquaporin-4 upregulated expression in glioma tissue is a reaction to glioma-associated edema induced by vascular endothelial growth factor.
Association between expression of HOTAIR and invasiveness of gliomas, and its predictive value.
Association of Notch-1, osteopontin and stem-like cells in ENU-glioma malignant process.
Association of pSTAT3-VEGF signaling pathway with peritumoral edema in newly diagnosed glioblastoma: an immunohistochemical study.
Associations of VEGFA and KDR single-nucleotide polymorphisms and increased risk and aggressiveness of high-grade gliomas.
Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels.
Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells.
Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas.
Bevacizumab does not increase the risk of remote relapse in malignant glioma.
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Bevacizumab for the treatment of high-grade glioma.
Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial.
Bevacizumab in recurrent high-grade pediatric gliomas.
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.
Bioprinting of glioma stem cells improves their endotheliogenic potential.
Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma.
Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.
Can dynamic contrast-enhanced MRI evaluate VEGF expression in brain glioma? An MRI-guided stereotactic biopsy study.
Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas.
Carboplatin and bevacizumab for recurrent malignant glioma.
Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme.
CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma.
Cell Heterogeneity Revealed by On-Chip Angiogenic Endothelial Cell Migration.
Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients.
Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
Correlation of Delta-like Ligand 4 (DLL4) with VEGF and HIF-1alpha Expression in Human Glioma.
Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas.
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
CXCL12 in malignant glial tumors: a possible role in angiogenesis and cross-talk between endothelial and tumoral cells.
Decrease in circulating endothelial progenitor cells in treated glioma patients.
Decrease of endogenous vascular endothelial growth factor may not affect glioma cell proliferation and invasion.
Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model.
Decreased Expression of Cystathionine ?-Synthase Promotes Glioma Tumorigenesis.
Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells.
Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma.
Downregulation of LRIG2 expression inhibits angiogenesis of glioma via EGFR/VEGF-A pathway.
Downregulation of VEGF expression attenuates malignant biological behavior of C6 glioma stem cells.
Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Ectopic expression of vascular endothelial growth factor (VEGF) by C6 glioma cells does not increase tumour growth in vivo despite an increase in angiogenesis.
Effect of Hyperbaric Oxygen on the Growth of Intracranial Glioma in Rats.
Effect of vascular endothelial growth factor on remodeling of C6 glioma tissue in vivo.
Effects of all?trans retinoic acid on VEGF and HIF?1? expression in glioma cells under normoxia and hypoxia and its anti?angiogenic effect in an intracerebral glioma model.
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis.
EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas.
Emerging molecular mechanisms of brain tumour oedema.
Engineering of clinical glioma treatment: prediction of pro-invasive molecular events in treated gliomas.
Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
Enhancement of glucose transporter expression of brain endothelial cells by vascular endothelial growth factor derived from glioma exposed to hypoxia.
EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma.
Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.
Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors.
Expression and distribution of vascular endothelial growth factor protein in human brain tumors.
Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis.
Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX.
Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis.
Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression.
Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas.
Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors.
Expression of vascular endothelial growth factor and p53 protein in association with neovascularization in human malignant gliomas.
Expression of vascular endothelial growth factor-b in human astrocytoma.
Expression of VEGF and MMP-9 and MRI imaging changes in cerebral glioma.
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
FLAIR-Only Progression in Bevacizumab-Treated Relapsing Glioblastoma Does Not Predict Short Survival.
FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells.
FtMt promotes glioma tumorigenesis and angiogenesis via lncRNA SNHG1/miR-9-5p axis.
Functional significance of vascular endothelial growth factor receptor expression on human glioma cells.
Galangin inhibits epithelial-mesenchymal transition and angiogenesis by downregulating CD44 in glioma.
Gene transfer of vascular endothelial growth factor plasmid/liposome complexes in glioma cells in vitro: the implication for the treatment of cerebral ischemic diseases.
Generation of neuronal progenitor cells in response to tumors in the human brain.
Genetic variants of vascular endothelial growth factor predict risk and survival of gliomas.
Genistein Suppression of Matrix Metalloproteinase 2 (MMP-2) and Vascular Endothelial Growth Factor (VEGF) Expression in Mesenchymal Stem Cell Like Cells Isolated from High and Low Grade Gliomas
Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.
Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR.
Glioma cells under hypoxic conditions block the brain microvascular endothelial cell death induced by serum starvation.
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1.
Gold nanoparticles carrying or not anti-VEGF antibody do not change glioblastoma multiforme tumor progression in mice.
Growth factor analysis of low-grade glioma CSF: PDGF and VEGF are not detectable.
Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs.
Growth properties of SF188/V+ human glioma in rats in vivo observed by magnetic resonance imaging.
HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways.
Hans Joachim Scherer and His Impact on the Diagnostic, Clinical, and Modern Research Aspects of Glial Tumors.
Heparin affin regulatory peptide/pleiotrophin negatively affects diverse biological activities in C6 glioma cells.
hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines.
High expression of VEGF and PI3K in glioma stem cells provides new criteria for the grading of gliomas.
Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma.
HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas.
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
Human umbilical cord blood stem cells show PDGF-D-dependent glioma cell tropism in vitro and in vivo.
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.
Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells.
Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells.
Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis.
Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion.
Identification of a 190-kDa vascular endothelial growth factor 165 cell surface binding protein on a human glioma cell line.
Identifying the association of contrast enhancement with vascular endothelia growth factor expression in anaplastic gliomas: a volumetric magnetic resonance imaging analysis.
Immunohistochemical characterization of lymphangiogenesis-related biomarkers in primary and recurrent gliomas: A STROBE compliant article.
Impact of
In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice.
Increased levels of tissue endostatin in human malignant gliomas.
Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.
Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine.
Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1.
Induction of WNT11 by hypoxia and hypoxia-inducible factor-1? regulates cell proliferation, migration and invasion.
Inhibition of eIF4F complex loading inhibits the survival of malignant glioma.
Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.
Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas.
Inhibition of Nodal suppresses angiogenesis and growth of human gliomas.
Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.
Inhibition of xenograft human glioma tumor growth by lentivirus-mediated gene transfer of alphastatin.
Inhibitory effect of gefitinib derivative LPY?9 on human glioma.
Inhibitory effect of Siwei Xiaoliuyin on glioma angiogenesis in nude mice.
Interaction of rat tumor cells with blood vessels and lymphatics of the avian chorioallantoic membrane.
Interferon-? inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10.
Intraoperative Contrast Enhanced Ultrasound Evaluates the Grade of Glioma.
Intussusceptive microvascular growth in human glioma.
Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.
Levels of vascular endothelial growth factor and matrix metalloproteinase-9 proteins in patients with glioma.
Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis.
Long non-coding RNA HOTAIR enhances angiogenesis by induction of VEGFA expression in glioma cells and transmission to endothelial cells via glioma cell derived-extracellular vesicles.
Loss of pigment epithelium derived factor expression in glioma progression.
Lower apparent diffusion coefficients indicate distinct prognosis in low-grade and high-grade glioma.
LRIG3 Suppresses Angiogenesis by Regulating the PI3K/AKT/VEGFA Signaling Pathway in Glioma.
Malathion increases apoptotic cell death by inducing lysosomal membrane permeabilization in N2a neuroblastoma cells: a model for neurodegeneration in Alzheimer's disease.
Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines.
Mechanism of SEMA3B gene silencing and clinical significance in glioma.
Mechanisms of action of rapamycin in gliomas.
Metabolic impact of anti-angiogenic agents on U87 glioma cells.
MicroRNA-140-5p inhibits cell proliferation and invasion by regulating VEGFA/MMP2 signaling in glioma.
Migration of mouse-induced pluripotent stem cells to glioma-conditioned medium is mediated by tumor-associated specific growth factors.
miR-21 Is Linked to Glioma Angiogenesis: A Co-Localization Study.
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
Modulation of oxygen consumption rate and vascular endothelial growth factor mRNA expression in human malignant glioma cells by hypoxia.
Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab.
Molecular changes during the genesis of human gliomas.
Molecular mechanisms of developmental and tumor angiogenesis.
Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6 gliomas.
Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.
MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas.
Multiregional tumor drug-uptake imaging by PET and microvascular morphology in end-stage diffuse intrinsic pontine glioma.
Mutant IkappaBalpha suppresses hypoxia-induced VEGF expression through downregulation of HIF-1alpha and COX-2 in human glioma cells.
Neuropathological diagnosis of brain tumours.
Non-Invasive Estimation of Glioma IDH1 Mutation and VEGF Expression by Histogram Analysis of Dynamic Contrast-Enhanced MRI.
Novel anti-angiogenic therapies for malignant gliomas.
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
Overexpression of Limb-Bud and Heart (LBH) promotes angiogenesis in human glioma via VEGFA-mediated ERK signalling under hypoxia.
Overexpression of miR-18a negatively regulates myocyte enhancer factor 2D to increase the permeability of the blood-tumor barrier via Krüppel-like factor 4-mediated downregulation of zonula occluden-1, claudin-5, and occludin.
Overexpression of the neuropilin 1 (NRP1) gene correlated with poor prognosis in human glioma.
Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: a systematic review and meta-analysis.
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
PAX6 suppression of glioma angiogenesis and the expression of vascular endothelial growth factor A.
Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma.
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Pigment epithelium-derived factor inhibits glioma cell growth in vitro and in vivo.
Placental growth factor is a survival factor for tumor endothelial cells and macrophages.
Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells.
Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment.
Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas.
Possible association between polymorphisms of human vascular endothelial growth factor a gene and susceptibility to glioma in a Chinese population.
Possible Relation of Hemin-Induced HO-1 Expression to the Upregulation of VEGF and BDNF mRNA Levels in Rat C6 Glioma Cells.
Post-acute response of 9L gliosarcoma to Photofrintrade mark-mediated PDT in athymic nude mice.
Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models.
Protein kinase C mediates induced secretion of vascular endothelial growth factor by human glioma cells.
PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.
Radiogenomic analysis of vascular endothelial growth factor in patients with diffuse gliomas.
Reduced expression of microRNA-497 is associated with greater angiogenesis and poor prognosis in human gliomas.
Reduced glioma infiltration in Src-deficient mice.
Regulation of IL-8 gene expression in gliomas by microRNA miR-93.
Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma.
Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2.
Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.
Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats.
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
Safety and Efficacy of Bevacizumab with Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas.
SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion.
Selective NTPDase2 expression modulates in vivo rat glioma growth.
Significance of nuclear magnetic resonance combined with Ki-67 and VEGF detection in the diagnosis and prognosis evaluation of brain glioma.
Silencing platelet-derived growth factor receptor-? enhances the radiosensitivity of C6 glioma cells in vitro and in vivo.
Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells.
Specific gene suppression using antisense strategy for growth suppression of glioma.
Stem Cell-like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor.
Survivin promotes glioma angiogenesis through vascular endothelial growth factor and basic fibroblast growth factor in vitro and in vivo.
Synergistic antiglioma activity of radiotherapy and enzastaurin.
Targeted molecular therapy of malignant gliomas.
Targeted Molecular Therapy of Malignant Gliomas.
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Tetrandrine suppresses tumor growth and angiogenesis of gliomas in rats.
The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells.
The emerging role of anti-angiogenic therapy for malignant glioma.
The expression of antisense vascular endothelial growth factor (VEGF) sequences inhibits intracranial C6 glioma growth in vivo by suppressing tumour angiogenesis.
The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival.
The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines.
The role of thrombin in the neo-vascularization of malignant gliomas: an intrinsic modulator for the up-regulation of vascular endothelial growth factor.
The Synergistic Therapeutic Effect of Temozolomide and Hyperbaric Oxygen on Glioma U251 Cell Lines is Accompanied by Alterations in Vascular Endothelial Growth Factor and Multidrug Resistance-associated Protein-1 Levels.
The temporal-spatial expression of VEGF, angiopoietins-1 and 2, and Tie-2 during tumor angiogenesis and their functional correlation with tumor neovascular architecture.
The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.
The VEGF gene polymorphism in glioblastoma may be a new prognostic marker of overall survival.
Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.
Three single nucleotide polymorphisms of the vascular endothelial growth factor (VEGF) gene and glioma risk in a Chinese population.
Thrombin up-regulates vascular endothelial growth factor in experimental gliomas.
Thrombospondin-2 (TSP2) expression is inversely correlated with vascularity in glioma.
Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression.
Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells.
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.
Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR.
Tumor Stromal-Derived Factor-1 Recruits Vascular Progenitors to Mitotic Neovasculature, where Microenvironment Influences Their Differentiated Phenotypes.
Tumor suppressor microRNA?613 inhibits glioma cell proliferation, invasion and angiogenesis by targeting vascular endothelial growth factor A.
Tumor vasculature and glioma stem cells: Contributions to glioma progression.
Tumor-specific activity of cellular regulatory elements is down-regulated upon insertion into the herpes simplex virus genome.
Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis.
Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis.
Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms.
Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/scatter factor stimulation in human glioma cells.
Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain.
Vascular and perivascular GD3 expression in human glioma.
Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression.
Vascular endothelial growth factor +936 C/T gene polymorphism and glioma risk in a Chinese Han population.
Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC).
Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms.
Vascular Endothelial Growth Factor as an Angiogenic Marker in Malignant Astrocytoma and Oligodendroglioma: An Indian Scenario.
Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.
Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours.
Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF.
Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells.
Vascular endothelial growth factor inhibitors in malignant gliomas.
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.
Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro.
Vascular endothelial growth factor-driven glioma growth and vascularization in an orthotopic rat model monitored by magnetic resonance imaging.
Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas.
VEGF and bFGF mRNA are expressed in ethylnitrosourea-induced experimental rat gliomas.
VEGF levels in patients with glioma: a systematic review and meta-analysis.
VEGF mRNA and its receptor flt-1 are expressed in reactive astrocytes following neural grafting and tumor cell implantation in the adult CNS.
VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells.
VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells.
VEGF???-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system.
Vimocin and vidapin, cyclic KTS peptides, are dual antagonists of ?1?1/?2?1 integrins with antiangiogenic activity.
Visualization of experimental glioma C6 by MRI with magnetic nanoparticles conjugated with monoclonal antibodies to vascular endothelial growth factor.
Withania somnifera Suppresses Tumor Growth of Intracranial Allograft of Glioma Cells.
[Activation of CXCR4 in human glioma stem cells promotes tumor angiogenesis]
[Biological profiles of malignant gliomas]
[Effect of nordy on FPR function of malignant human glioma cell line U87]
[Influence of activation of human glioma cell CXCR4 receptor on the expression of vascular endothelial growth factor]
[Treatment of the glioma microenvironment].
[Vascular endothelial growth factor (VEGF) production by a dopamine D2 receptor agonist and its action mechanism in glioma cells]
[Vascular endothelial growth factor gene expression in nasopharyngeal carcinoma cell line induced by hypoxia in vitro]
[Vascular endothelial growth factor shRNA mediated by pEGFP-H1 vector plasmid effectively inhibits glioma proliferation: an experimental study]
Gliosarcoma
Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.
Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps.
Glomerulonephritis
A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis.
Analysis of Relative Expression Level of VEGF ( Vascular Endothelial Growth Factor ), HIF-1? ( Hypoxia Inducible Factor 1? ) and CTGF ( Connective Tissue Growth Factor ) Genes in Chronic Glomerulonephritis (CGN) Patients.
Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis.
Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration.
Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis.
Increased serum levels of vascular endothelial growth factor in human crescentic glomerulonephritis.
Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors.
Induction of progressive glomerulonephritis by podocyte-specific overexpression of platelet-derived growth factor-D.
Inhibition of capillary repair in proliferative glomerulonephritis results in persistent glomerular inflammation with glomerular sclerosis.
Interleukin-18, transforming growth factor-beta, and vascular endothelial growth factor gene polymorphisms and susceptibility to primary glomerulonephritis.
Mesangial immune complex glomerulonephritis due to complement factor D deficiency.
PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis.
Platelet derived growth factor-D may be a possible therapeutic target for advanced IgA nephropathy.
Recurrence of dense deposits in transplanted kidney: II. Serum complement and nephritic factor profiles.
Response of VEGF to activation of viral receptors and TNF? in human mesangial cells.
Serum vascular endothelial growth factor concentration in rapidly progressive glomerulonephritis.
The association between therapeutic outcomes and VEGF G-1154A and C-936T gene polymorphisms in patients with glomerulonephritis.
The influence of vascular endothelial growth factor (VEGF) polymorphism on the progression of chronic glomerulonephritides.
The role of PDGF-D in mesangioproliferative glomerulonephritis.
Triptolide inhibits vascular endothelial growth factor expression and production in endothelial cells.
Urinary cystatin C as a renal biomarker and its immunohistochemical localization in anti-GBM glomerulonephritis rats.
Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis.
[Effect of Yishen capsule on serum vascular endothelial growth factor and cell immunity in patients with chronic glomerulonephritis]
[Molecular factors of angiogenesis in renal tissue of patients with chronic glomerulonephritis: association with nephrosclerosis and anemia]
[Urinary excretion of angiogenesis regulatory factors and renal injury markers in chronic glomerulonephritis: Significance in the assessment of progression].
Glomerulonephritis, IGA
Adrenomedullin gene transcription is decreased in peripheral blood mononuclear cells of patients with IgA nephropathy.
Genetic polymorphism of vascular endothelial growth factor: impact on progression of IgA nephropathy.
Impact of gene polymorphisms of interleukin-18, transforming growth factor-?, and vascular endothelial growth factor on development of IgA nephropathy and thin glomerular basement membrane disease.
Implication of peritubular capillary loss and altered expression of vascular endothelial growth factor in IgA nephropathy.
Platelet derived growth factor-D may be a possible therapeutic target for advanced IgA nephropathy.
[Expression and clinical implication of platelet-derived growth factor-D and platelet-derived growth factor-beta in childhood IgA nephropathy]
Glomerulonephritis, Membranoproliferative
Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
Recurrence of dense deposits in transplanted kidney: II. Serum complement and nephritic factor profiles.
Glomerulonephritis, Membranous
Decreased expression of vascular endothelial growth factor in idiopathic membranous glomerulonephritis: relationships to clinical course.
Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis.
The influence of vascular endothelial growth factor (VEGF) polymorphism on the progression of chronic glomerulonephritides.
Glomerulosclerosis, Focal Segmental
Biomarkers of endothelial injury in focal segmental glomerulosclerotic nephrosis.
Nephrotic Syndrome with Focal Segmental Glomerulosclerosis Induced by Intravitreal Injections of Vascular Endothelial Growth Factor Inhibitor.
Pathogenesis of nonimmune glomerulopathies.
Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction.
Glomus Tumor
Glomus tumors of the fingers: Expression of vascular endothelial growth factor.
Glossitis, Benign Migratory
Salivary levels of interleukin-8 and growth factors are modulated in patients with geographic tongue.
Glucose Intolerance
Adipsin is an adipokine that improves ? cell function in diabetes.
Association Between Serum Adipsin Levels and Insulin Resistance in Subjects With Various Degrees of Glucose Intolerance.
Exploring the role of adipsin in statin-induced glucose intolerance: a prospective open label study.
Reduced insulin secretion and content in VEGF-a deficient mouse pancreatic islets.
Serum vascular endothelial growth factor level is elevated in patients with impaired glucose tolerance and type 2 diabetes mellitus.
Glycogen Storage Disease Type II
Oral Health Status of Patients with Lysosomal Storage Diseases in Poland.
Glycosuria
2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic ZSF1 rats.
Goiter
Complete inhibition of goiter in mice requires combined gene therapy modification of angiopoietin, vascular endothelial growth factor, and fibroblast growth factor signaling.
The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter.
Goiter, Nodular
Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population.
Correlations of HOTAIR expression with pathological stage, CT characteristics and prognosis of patients with papillary thyroid carcinoma.
Role of nitric oxide and vascular endothelial growth factor in fluoride-induced goitrogenesis in rats.
[Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma]
Graft vs Host Disease
Blockade of Vascular Endothelial Growth Factor (VEGF) Aggravates the Severity of Acute Graft-versus-host Disease (GVHD) after Experimental Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT).
The interleukin-6 and vascular endothelial growth factor in hematopoietic stem cell transplantation.
Vascular endothelial growth factor (VEGF) and chronic graft-versus-host disease (cGVHD) in salivary glands of bone marrow transplant (BMT) recipients.
Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation.
Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation.
Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease.
Granuloma
Assessment of angiogenic markers in oral hemangiomas and pyogenic granulomas.
Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis.
Correlation of vascular endothelial growth factor with the clinical regression of tubercular granuloma.
Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants.
Detection and quantification of mast cell, vascular endothelial growth factor, and microvessel density in human inflammatory periapical cysts and granulomas.
Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment.
Expression and localization of vascular endothelial growth factor and its receptor flt in pulmonary sarcoidosis.
Expression of hypoxia-inducible factor (HIF)-1a-vascular endothelial growth factor (VEGF)-inhibitory growth factor (ING)-4- axis in sarcoidosis patients.
Giant cell granuloma of the jawbones--a proliferative vascular lesion? Immunohistochemical study with vascular endothelial growth factor and basic fibroblast growth factor.
Herpes simplex virus type-I and pyogenic granuloma: a vascular endothelial growth factor-mediated association?
Hypoxia, hypoxia-inducible factor-1? and vascular endothelial growth factor in a murine model of Schistosoma mansoni infection.
Increased expression of vascular endothelial growth factor in pyogenic granulomas.
Interferon-gamma-dependent mechanisms of mycobacteria-induced pulmonary immunopathology: the role of angiostasis and CXCR3-targeted chemokines for granuloma necrosis.
Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation.
Local ischemia and increased expression of vascular endothelial growth factor following ocular dissemination of Mycobacterium tuberculosis.
Lymphangiogenesis is induced by mycobacterial granulomas via vascular endothelial growth factor receptor-3 and supports systemic T-cell responses against mycobacterial antigen.
Metaplastic ossification in a cutaneous pyogenic granuloma: a case report.
Niosomes for enhanced activity of praziquantel against Schistosoma mansoni: in vivo and in vitro evaluation.
Obscure gastrointestinal bleeding: resection of a pyogenic granuloma of the ileum via double-balloon enteroscopy.
Paeoniflorin in experimental BALB/c mansoniasis: A novel anti-angiogenic therapy.
Pathogenetic roles of angiogenic factors in pyogenic granulomas in pregnancy are modulated by female sex hormones.
Pathogenetic Roles of Angiogenic Factors in Pyogenic Granulornas in Pregnancy Are Modulated by Female Sex Hormones.
Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis.
Significance of vascular endothelial cell growth factor up-regulation mediated via a chymase-angiotensin-dependent pathway during angiogenesis in hamster sponge granulomas.
The chemokine receptor CXCR4 promotes granuloma formation by sustaining a mycobacteria-induced angiogenesis programme.
The roles of vascular endothelial growth factor and angiopoietin-2 in the regression of pregnancy pyogenic granuloma.
Tympanomastoid cholesterol granulomas: Immunohistochemical evaluation of angiogenesis.
VEGF-A from Granuloma Macrophages Regulates Granulomatous Inflammation by a Non-angiogenic Pathway during Mycobacterial Infection.
[Endogenous prostaglandins and angiogenesis]
[Epithelioid cell granuloma in sarcoidosis: light and electron microscopic morphology]
[Involvement of chymase in angiogenesis in hamster sponge granulomas]
Granuloma, Giant Cell
Giant cell granuloma of the jawbones--a proliferative vascular lesion? Immunohistochemical study with vascular endothelial growth factor and basic fibroblast growth factor.
Granulomatosis with Polyangiitis
Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: analysis using sera from a nationwide prospective cohort study.
Increased serum vascular endothelial growth factor level in Churg-Strauss syndrome.
Serum levels of vascular endothelial growth factor (VEGF) are markedly elevated in patients with Wegener's granulomatosis.
Vascular endothelial growth factor (VEGF)-A and VEGF-A165b are associated with time to remission of granulomatosis with polyangiitis in a nationwide Japanese prospective cohort study.
Granulosa Cell Tumor
Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF.
Serum vascular endothelial growth factor A (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro.
Vascular Endothelial Growth Factor and Its Receptor VEGFR-2 Are Highly Expressed in Ovarian Granulosa Cell Tumors.
Graves Disease
Angiogenic study in Graves' disease treated with thyroid arterial embolization.
Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density.
Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis.
Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features.
Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo.
Vascular endothelial growth factor polymorphisms increase the risk of developing Graves' disease.
Hair Diseases
Heterogeneity in amount of growth factors secreted by platelets in platelet-rich plasma samples from alopecia patients.
Hamartoma
Current concepts on ocular vascular abnormalities in the phakomatoses.
Hamartoma Syndrome, Multiple
Transcatheter embolization of arteriovenous malformations in Cowden disease.
Hantavirus Infections
Elevated vascular endothelial growth factor levels induce hyperpermeability of endothelial cells in hantavirus infection.
Head and Neck Neoplasms
A pilot study of psychosocial functioning and vascular endothelial growth factor in head and neck cancer patients.
Association of specific single nucleotide variants (SNVs) in the promoter and 3'-Untranslated region of Vascular Endothelial growth factor (VEGF) gene with risk and higher tumour grade of head and neck cancers.
Biology of vascular endothelial growth factor and its receptors in head and neck cancer: Beyond angiogenesis.
Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis.
Emerging drugs for head and neck cancer.
Endothelial Microparticles and Vascular Endothelial Growth Factor in Patients With Head and Neck Cancer Undergoing Radiotherapy or Radiochemotherapy.
Genetic variability of vascular endothelial growth factor and prognosis of head and neck cancer in a Brazilian population.
Genetic Variation in the Vascular Endothelial Growth Factor (VEGFA) Gene at rs13207351 Is Associated with Overall Survival of Patients with Head and Neck Cancer.
Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer.
l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms.
Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer.
Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2.
Prognostic value of vascular endothelial growth factor in patients with head and neck cancer: A meta-analysis.
Progression of head and neck cancer in an in vitro model.
Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck.
Serum levels of vascular endothelial growth factor in patients with head and neck cancer.
Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
SIRT2 modulates VEGFD-associated lymphangiogenesis by deacetylating EPAS1 in human head and neck cancer.
Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers.
Vascular endothelial growth factor (VEGF) and Endocrine gland-VEGF (EG-VEGF) are down regulated in head and neck cancer.
Vascular endothelial growth factor (VEGF) gene polymorphisms and risk of head and neck cancer: a meta-analysis involving 2,444 individuals.
[Implication of vascular endothelial growth factor (VEGF) in human head and neck cancer]
[Vascular endothelial growth factor in head and neck cancer]
Hearing Loss
Age-dependent modifications of expression level of VEGF and its receptors in the inner ear.
Hearing Loss, Noise-Induced
Cochlear pericyte responses to acoustic trauma and the involvement of hypoxia-inducible factor-1alpha and vascular endothelial growth factor.
Increased endothelial progenitor cell circulation and VEGF production in a rat model of noise-induced hearing loss.
The redox protein p66(shc) mediates cochlear vascular dysfunction and transient noise-induced hearing loss.
Vascular endothelial growth factor (VEGF) expression in noise-induced hearing loss.
Heart Arrest
Comparison of Vascular Endothelial Growth Factor Concentration in Porcine Kidneys Removed From Living Donors After Cardiac and Brain Death.
HIF-1 alpha and VEGF expression after transient global cerebral ischemia.
Stabilization of HIF-1? modulates VEGF and caspase-3 in hippocampus of rats following transient global ischemia induced by asphyxial cardiac arrest.
Targeted Temperature Management Suppresses Hypoxia-Inducible Factor-1? and Vascular Endothelial Growth Factor Expression in a Pig Model of Cardiac Arrest.
Vascular endothelial growth factor upregulation in transient global ischemia induced by cardiac arrest and resuscitation in rat brain.
Heart Defects, Congenital
Angiogenic biomarkers in children with congenital heart disease: possible implications.
Brain Perfusion Is Increased at Term in the White Matter of Very Preterm Newborns and Newborns with Congenital Heart Disease: Does this Reflect Activated Angiogenesis?
Correlation between vascular endothelial growth factor and leptin in children with cyanotic congenital heart disease.
Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease.
Hypoxia-inducible factor-1?, vascular endothelial growth factor, inducible nitric oxide synthase, and endothelin-1 expression correlates with angiogenesis in congenital heart disease.
Increased vascular endothelial growth factor in patients with cyanotic congenital heart diseases may not be normalized after a Fontan type operation.
Serum vascular endothelial growth factor in cyanotic congenital heart disease functionally contributes to endothelial cell kinetics in vitro.
Single-nucleotide polymorphisms of VEGF gene are associated with risk of congenital valvuloseptal heart defects.
Specific local cardiovascular changes of Nepsilon-(carboxymethyl)lysine, vascular endothelial growth factor, and Smad2 in the developing embryos coincide with maternal diabetes-induced congenital heart defects.
The roles of vascular endothelial growth factor gene polymorphisms in congenital heart diseases: a meta-analysis.
Vascular endothelial growth factor and basic fibroblast growth factor in children with cyanotic congenital heart disease.
Vascular endothelial growth factor in children with congenital heart disease.
Vascular endothelial growth factor in children with cyanotic and acyanotic and congenital heart disease.
VEGFA polymorphisms and cardiovascular anomalies in 22q11 microdeletion syndrome: a case-control and family-based study.
[Changes of serum leptin and vascular endothelial growth factor in children with congenital heart disease.]
[Correlation of serum levels of VEGF and SDF-1 with the number and function of circulating EPCs in children with cyanotic congenital heart disease.]
[Functional State of Vascular Endothelium in Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Diseases].
Heart Diseases
Anatomical features of the right internal jugular vein in infants and young children undergoing heart surgery for congenital disease: comparison between cyanotic and noncyanotic patients.
Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina.
Elevated vascular endothelial growth factor levels are associated with aortopulmonary collateral vessels in patients before and after the Fontan procedure.
Hepatocyte growth factor and vascular endothelial growth factor in ischaemic heart disease.
Hypoxic response elements control expression of human vascular endothelial growth factor(165) genes transferred to ischemia myocardium in vivo and in vitro.
Incidence and risk factors of pleural effusions in patients with POEMS syndrome.
Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family.
The evolving concept of physiological ischemia training vs. ischemia preconditioning.
Vascular endothelial growth factor and basic fibroblast growth factor in children with cyanotic congenital heart disease.
Vascular endothelial growth factor and its soluble receptor in infants with congenital cardiac disease.
Vascular endothelial growth factor in children with cyanotic and acyanotic and congenital heart disease.
Heart Failure
AAV9-mediated VEGF-B gene transfer improves systolic function in progressive left ventricular hypertrophy.
Acute and chronic exercise in patients with heart failure with reduced ejection fraction: evidence of structural and functional plasticity and intact angiogenic signalling in skeletal muscle.
An Expanded View of Progressive Cardiorenal Disorders.
Angiopoietin-2 in adults with congenital heart disease and heart failure.
Aortic dissection during antiangiogenic therapy with sunitinib. A case report.
Cardiac overexpression of human VEGF(165) by recombinant Semliki Forest virus leads to adverse effects in pressure-induced heart failure.
Cardiotoxic effects of angiogenesis inhibitors.
Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure.
Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure.
CELF1 promotes vascular endothelial growth factor degradation resulting in impaired microvasculature in heart failure.
Complementary therapeutic effects of dual delivery of insulin-like growth factor-1 and vascular endothelial growth factor by gelatin microspheres in experimental heart failure.
Congestive heart failure risk in cancer patients treated with VEGFR-TKIs: a systematic review and meta-analysis of 36 clinical trials.
Crow-Fukase syndrome associated with high-output heart failure.
Decreased serum vascular endothelial growth factor concentrations in patients with congestive heart failure.
Design of a small molecule that stimulates vascular endothelial growth factor A enabled by screening RNA fold-small molecule interactions.
Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure.
Effects of exercise training on endothelial progenitor cells in patients with chronic heart failure.
Elevated plasma tyrosine kinases VEGF-D and HER4 in heart failure patients decrease after heart transplantation in association with improved haemodynamics.
Endothelial deletion of protein tyrosine phosphatase-1B protects against pressure overload-induced heart failure in mice.
Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure.
Haplodeficiency of Ataxia Telangiectasia Mutated Accelerates Heart Failure After Myocardial Infarction.
Heart Failure Associated with Sunitinib: Lessons Learned from Animal Models.
Increased expression of VEGF following exercise training in patients with heart failure.
Increased vascular endothelial growth factor D is associated with atrial fibrillation and ischaemic stroke.
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Integrin-linked kinase, a novel component of the cardiac mechanical stretch sensor, controls contractility in the zebrafish heart.
Intramuscular VEGF Repairs the Failing Heart: Role of Host Derived Growth Factors and Mobilization of Progenitor Cells.
Modulation of vascular endothelial gene expression by physical training in patients with chronic heart failure.
Molecular basis of angiogenesis. Role of VEGF and VE-cadherin.
Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure.
Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure.
Randomized clinical trial of physiological ischemic training for patients with coronary heart disease complicated with heart failure: Safety of training, VEGF of peripheral blood and quality of life.
Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure.
Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.
The role of phospho-adenosine monophosphate-activated protein kinase and vascular endothelial growth factor in a model of chronic heart failure.
The skeletal muscle VEGF mRNA response to acute exercise in patients with chronic heart failure.
Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.
Vascular endothelial growth factor and angiogenesis in heart failure.
Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart failure.
Vascular Endothelial Growth Factor B and Its Signaling.
Vascular Endothelial Growth Factor Blockade Prevents the Beneficial Effects of ?-Blocker Therapy on Cardiac Function, Angiogenesis and Remodeling in Heart Failure.
Vascular endothelial growth factor in heart failure.
Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure.
[Highly concentrated vascular endothelial growth factor in Crow-Fukase syndrome with high output heart failure: a case report]
[Response to metoprolol succinate sustained-release tablets in correlation to pulse pressure, serum vascular endothelial growth factor and C-reactive protein in elderly hypertensive patients with chronic heart failure.]
[Targeted therapies and high blood pressure].
Heart Valve Diseases
Development and characterization of a novel in vivo model of carcinoid syndrome.
[Role of anti-angiogenic factor chondromodulin-I for maintaining cardiac valvular function]
HELLP Syndrome
Influence of the vascular endothelial growth factor on the development of severe pre-eclampsia or HELLP syndrome.
Inhibiting PDGF-D alleviates the symptoms of HELLP by suppressing NF-?B activation.
Placenta derived factors involved in the pathogenesis of the liver in the syndrome of haemolysis, elevated liver enzymes and low platelets (HELLP): A review.
Vascular endothelial growth factor (VEGF) polymorphisms in HELLP syndrome patients determined by quantitative real-time PCR and melting curve analyses.
[Plasma VEGF levels are increased in women with severe preeclampsia or HELLP syndrome]
Hemangioblastoma
A case of cerebellar hemangioblastoma with rhabdoid features.
Absence of tight junctions between microvascular endothelial cells in human cerebellar hemangioblastomas.
Antiangiogenic treatment for multiple CNS hemangioblastomas.
Atrial myxoma occurring 15 years after subtotal resection of cerebellar hemangioblastoma.
Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report.
Clinicopathological study of vascular endothelial growth factor (VEGF), p53, and proliferative potential in familial von Hippel-Lindau disease and sporadic hemangioblastomas.
Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function.
Continuous angiogenesis inhibition in the treatment for von Hippel-Lindau-related hemangioblastomas of retina and spinal cord.
Current concepts on ocular vascular abnormalities in the phakomatoses.
Expression of growth factors and growth factor receptors in capillary hemangioblastoma.
Expression of HIF-1 regulated proteins vascular endothelial growth factor, carbonic anhydrase IX and hypoxia inducible gene 2 in hemangioblastomas.
Expression of vascular endothelial growth factor in capillary hemangioblastoma.
Expression of vascular endothelial growth factor in cerebellar hemangioblastomas does not correlate with tumor angiogenesis.
Intratumoral hemorrhage in a patient with cerebellar hemangioblastoma: a case report and review.
Pathology, genetics and cell biology of hemangioblastomas.
Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.
Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas.
Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha.
[Intravitreal anti-VEGF therapy for capillary hemangioblastomas in von Hippel-Lindau disease]
Hemangioendothelioma
Elevated plasma vascular endothelial growth factor levels in 2 patients with hemangioendothelioma.
Telocytes promote VEGF expression and alleviate ventilator-induced lung injury in mice.
Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas.
Hemangioendothelioma, Epithelioid
Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor.
Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management.
Hemangioma
21 cases reports on haemangioma of spleen.
A study of serum vascular endothelial growth factor in infantile hemangiomas.
Adeno-associated viral vector-mediated hypoxia-regulated VEGF gene transfer promotes angiogenesis following focal cerebral ischemia in mice.
Assessment of angiogenic markers in oral hemangiomas and pyogenic granulomas.
Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients.
Circulating Levels of Vascular Endothelial Growth Factor and Basic Fibroblastic Growth Factor in Infantile Hemangioma Versus Vascular Malformations.
Co-suppression of VEGF-A and VEGF-C inhibits development of experimental hemangioma.
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors.
Critical role of microenvironmental factors in angiogenesis.
Current trends in medical management of infantile hemangioma.
Effect of laser therapy on plasma expression of VEGF and bFGF in infants with cutaneous hemangioma.
Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas.
Estimation of vascular endothelial growth factor and placental growth factor serum levels' in infant with hemangioma and population of healthy infants.
Evaluation of Effect of Propranolol on Serum Vascular Endothelial Growth Factor and Tissue Inhibitor of Metalloproteinase-2 Levels in Infantile Hemangioma.
Evaluation of plasma and urinary levels of vascular endothelial growth factor and matrix metalloproteinase-9 in patients with infantile hemangioma.
Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat--angiogenesis and angioma formation.
Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors.
High-throughput flow cytometry purification of transduced progenitors expressing defined levels of vascular endothelial growth factor induces controlled angiogenesis in vivo.
Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor.
Juvenile hemangioma of the testis: analysis of expression of angiogenic factors.
Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth.
Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone.
Ocular Versus Oral Propranolol for Prevention and/or Treatment of Oxygen-Induced Retinopathy in a Rat Model.
One Possible Mechanism of Pulsed Dye Laser Treatment on Infantile Hemangioma: Induction of Endothelial Apoptosis and Serum vascular endothelial growth factor (VEGF) Level Changes.
Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo.
Oxymatrine suppresses proliferation and induces apoptosis of hemangioma cells through inhibition of HIF-1a signaling.
Placental anomalies in children with infantile hemangioma.
Proanthocyanidins as a Potential Novel Way for the Treatment of Hemangioma.
Proliferation hemangiomas formation through dual mechanism of vascular endothelial growth factor mediated endothelial progenitor cells proliferation and mobilization through matrix metalloproteinases 9.
Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis.
Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor.
Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell.
Propranolol Therapy in Infantile Hemangioma: It Is Not Just About the Beta.
Recent progress in studies of infantile hemangioma.
Regulatory mechanisms of skeletal and connective tissue development and homeostasis - lessons from studies of human disorders.
Serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in children with hemangiomas and vascular malformations--preliminary report.
Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol.
Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy.
Signaling mechanisms in infantile hemangioma.
Soluble receptors for vascular endothelial growth factor (sVEGFR1/sVEGFR2) in infantile hemangioma.
Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.
Synergistic effect of estrogen and VEGF on the proliferation of hemangioma vascular endothelial cells.
The potential efficacy of omega-3 fatty acids as anti-angiogenic agents in benign vascular tumors of infancy.
Transgenic rabbits with increased VEGF expression develop hemangiomas in the liver: a new model for Kasabach-Merritt syndrome.
Treatment of hemangioma by transfection of antisense VEGF gene.
Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma.
Vascular complications in Chuvash polycythemia.
Vascular endothelial growth factor confers a growth advantage in vitro and in vivo to stromal cells cultured from neonatal hemangiomas.
Vascular endothelial growth factor expression and pathological changes in the local tissue of facial hemangiomas following injections with pure alcohol.
Vascular endothelial growth factor response with propranolol therapy in patients with infantile hemangioma.
VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma.
von Hippel-Lindau disease type 2A in a family with a duplicated 21-base-pair in-frame insertion mutation in the VHL gene.
[Effect of progesterone on the pathogenesis and development of hemangioma in nude mice].
[Effect of propranolol gel on plasma VEGF, bFGF and MMP-9 in proliferating infantile hemangiomas of superficial type].
[POEMS syndrome with an isolated lytic lesion and glomeruloid hemangiomas: report of one case]
[The change of serum vascular endothelial growth factor and matrix metalloproteinases-9 in proliferative hemangioma treated with propranolol].
Hemangioma, Capillary
CD105 expression in oral capillary hemangiomas and cavernous hemangiomas.
Hemangioma, Cavernous
A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470.
Biological distinctions between juvenile nasopharyngeal angiofibroma and vascular malformation: An immunohistochemical study.
CD105 expression in oral capillary hemangiomas and cavernous hemangiomas.
Chronic encapsulated intracerebral hematoma associated with cavernous angioma: Expression of vascular endothelial growth factor and its receptor.
Growth potential of orbital cavernous hemangioma suggested by vascular endothelial growth factor and its receptor flk-1.
Hemangioma, Cavernous, Central Nervous System
Cerebral cavernous malformations with dynamic and progressive course: correlation study with vascular endothelial growth factor.
Expression of endothelial cell angiogenesis receptors in human cerebrovascular malformations.
Expression of platelet-derived growth factor ligand and receptor in cerebral arteriovenous and cavernous malformations.
Systemic Expression of Vascular Endothelial Growth Factor in Patients with Cerebral Cavernous Malformation Treated by Stereotactic Radiosurgery.
Hemangiosarcoma
A transcriptome signature of endothelial lymphatic cells coexists with the chronic oxidative stress signature in radiation-induced post-radiotherapy breast angiosarcomas.
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.
Analysis of vascular endothelial growth factor (VEGF) and a receptor subtype (KDR/flk-1) in the liver of rats exposed to riddelliine: a potential role in the development of hemangiosarcoma.
Angiogenic growth factor expression in benign and malignant vascular tumours.
Angiosarcoma complicating systemic sclerosis: a case report.
Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update.
Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma.
Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face.
Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor.
Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature.
Combined VEGFR and MAPK pathway inhibition in angiosarcoma.
Contrasting Prognostic Implications of Platelet-Derived Growth Factor Receptor-? and Vascular Endothelial Growth Factor Receptor-2 in Patients with Angiosarcoma.
Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma.
Expression of vascular endothelial growth factor in a human hemangiosarcoma cell line (ISO-HAS).
Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors.
HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma.
In vitro effects of the chemotherapy agent water-soluble micellar paclitaxel (Paccal Vet) on canine hemangiosarcoma cell lines.
Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor.
Inhibition of heat shock protein 90 exerts an antitumour effect in angiosarcoma: involvement of the vascular endothelial growth factor signalling pathway.
MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas.
Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo.
Plasma vascular endothelial growth factor concentrations in healthy dogs and dogs with hemangiosarcoma.
Pregabalin induces hepatic hypoxia and increases endothelial cell proliferation in mice, a process inhibited by dietary vitamin E supplementation.
PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study.
Serum concentrations of vascular endothelial growth factor in angiosarcomas with and without p53 gene mutation.
Sporadic cutaneous angiosarcomas generally lack hypoxia-inducible factor 1alpha: a histologic and immunohistochemical study of 45 cases.
Successful treatment of angiosarcoma of the scalp with apatinib: a case report.
Thalidomide Reduces Vascular Endothelial Growth Factor Immunostaining in Canine Splenic Hemangiosarcoma.
The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: New potential therapeutic targets?
Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases.
Vascular endothelial growth factor in angiosarcoma.
Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas.
Vascular-targeted agents for the treatment of angiosarcoma.
Hematologic Neoplasms
Analysis of neutrophil gelatinase-associated lipocalin, vascular endothelial growth factor, and soluble receptor for advanced glycation end-products in bone marrow supernatant in hematologic malignancies.
Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells.
c-myc but not Hif-1?-dependent downregulation of VEGF influences the proliferation and differentiation of HL-60 cells induced by ATRA.
Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis.
Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.
Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies.
Expression of VEGF and VEGF receptors in childhood precursor B-cell acute lymphoblastic leukemia evaluated by immunohistochemistry.
Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.
High sensitivity CRP and serum amyloid A as expressions of low grade inflammation do not correlate with bFGF or VEGF.
Level of Vascular Endothelial Growth Factor Predicts Both Relapse and Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation.
Nanocomposite-siRNA approach for down-regulation of VEGF and its receptor in myeloid leukemia cells.
Novel therapeutic approaches targeting vascular endothelial growth factor and its receptors in haematological malignancies.
Pigment epithelium-derived factor (PEDF) inhibits survival and proliferation of VEGF-exposed multiple myeloma cells through its anti-oxidative properties.
R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.
Role of Microvessel Density and Vascular Endothelial Growth Factor in Angiogenesis of Hematological Malignancies.
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology.
Targeting the vascular endothelial growth factor (VEGF) in hematological malignancies.
The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia.
The thalidomide saga.
The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies.
Vascular endothelial growth factor as a target opportunity in hematological malignancies.
Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies.
VEGF-induced ROS generation from NAD(P)H oxidases protects human leukemic cells from apoptosis.
[Quantitative analysis of gene expression for vascular endothelial growth factor and its application]
[The expression of vascular endothelial growth factor and its receptor in hematopoietic malignant cell lines HL-60 and Raji]
Hematoma, Subdural
Letter to the editor: Vascular endothelial growth factor in the pathogenesis of chronic spontaneous subdural hematoma.
Hematoma, Subdural, Chronic
Correlation of vascular endothelial growth factor with magnetic resonance imaging in chronic subdural hematomas.
Corticosteroid Suppression of Vascular Endothelial Growth Factor and Recurrence of Chronic Subdural Hematoma.
Development of chronic encapsulated intracerebral hematoma after radiosurgery for a cerebral arteriovenous malformation.
Expression of the TGF-?-ALK-1 Pathway in Dura and the Outer Membrane of Chronic Subdural Hematomas.
Increased concentration of vascular endothelial growth factor (VEGF) in chronic subdural hematoma.
Increased mRNA expression of VEGF within the hematoma and imbalance of angiopoietin-1 and -2 mRNA within the neomembranes of chronic subdural hematoma.
Involvement of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in the mechanism of development of chronic subdural hematoma.
Occurrence and Growth of Chronic Subdural Hematomas: A Complex Interplay between Angiogenic, but also Inflammatory and FibrinolyticProcesses. Possible Targets for Corticosteroid Treatment? In response to "Corticosteroid Suppression of Vascular Endothelial Growth Factor and Recurrence of Chronic Subdural Hematoma' NEU-D-11-01499.
Significantly high concentrations of vascular endothelial growth factor in chronic subdural hematoma with trabecular formation.
Vascular endothelial growth factor concentration in chronic subdural hematoma fluid is related to computed tomography appearance and exudation rate.
Hemianopsia
A man in his 50s with neurological symptoms during cancer treatment.
Hemiplegia
[Embolic stroke immediately after initial administration of intravitreal aflibercept].
Hemochromatosis
Genetics of diabetic retinopathy.
Hemoglobinopathies
Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications.
Hemoglobinuria
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.
Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016.
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Small-molecule factor D inhibitors targeting the alternative complement pathway.
Hemoglobinuria, Paroxysmal
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.
Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016.
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Small-molecule factor D inhibitors targeting the alternative complement pathway.
Hemolytic-Uremic Syndrome
Role of vascular endothelial growth factor and angiopoietin 1 in renal injury in hemolytic uremic syndrome.
Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Hemophilia A
Tissue-inhibitors of metalloproteinase-1 and vascular-endothelial growth-factor in severe haemophilia A children on low dose prophylactic recombinant factor VIII: Relation to subclinical arthropathy.
Hemoptysis
Pulmonary toxicities from targeted therapies: a review.
Serum vascular endothelial growth factor and angiopoietin-2 are associated with the severity of systemic inflammation rather than the presence of hemoptysis in patients with inflammatory lung disease.
Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology.
Hemorrhagic Fever with Renal Syndrome
Relationship between circulating vascular endothelial growth factor and its soluble receptor in patients with hemorrhagic fever with renal syndrome.
The Detection of Vascular Endothelial Growth Factor in Serum of Patients with Hemorrhagic Fever with Renal Syndrome.
[Probable sources of endothelial cells circulating in blood].
Hemorrhagic Septicemia, Viral
An immune responsive complement factor D/adipsin and kallikrein-like serine protease (PoDAK) from the olive flounder Paralichthys olivaceus.
Hemorrhagic Stroke
Circulating lncRNAs HIF1A-AS2 and LINLK-A: Role and Relation to Hypoxia-Inducible Factor-1? in Cerebral Stroke Patients.
Hepatic Veno-Occlusive Disease
Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation.
Hepatitis
A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma.
Evaluating post-transcriptional regulatory elements for enhancing transient gene expression levels in CHO K1 and HEK293 cells.
Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma.
Hepatitis B
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.
Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma.
Expression of vascular endothelial growth factor in liver tissues of hepatitis B.
Hepatitis B virus X protein activates expression of IGF-IR and VEGF in hepatocellular carcinoma cells.
Levels of HBx, VEGF, and CEACAM1 in HBV-related hepatocellular carcinoma and their correlation with cancer prognosis.
Somatic mutation profiling of liver and biliary cancer by targeted next generation sequencing.
The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus.
[Hepatitis B x protein activated vascular endothelial growth factor expression through hypoxia inducible factor-1 pathway]
[Research of signaling pathway of vascular endothelial growth factor regulating by hepatitis B virus X protein]
Hepatitis C
Angiogenic Cytokines in Patients Undergoing Antiviral Treatment for Chronic Hepatitis C Virus Infection.
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.
Autotaxin and vascular endothelial growth factor receptor-2 and -3 are related to vascular development during the progression of chronic viral hepatitis C.
Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients.
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Hepatitis C virus core protein induces hypoxia?inducible factor 1?-mediated vascular endothelial growth factor expression in Huh7.5.1 cells.
Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-?B/hypoxia-inducible factor-1? axis under hypoxic conditions.
Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor.
Influence of vascular endothelial growth factor and alpha-fetoprotein on hepatocellular carcinoma.
NF90-NF45 is a selective RNA chaperone that rearranges viral and cellular riboswitches: biochemical analysis of a virus host factor activity.
OptCDR: a general computational method for the design of antibody complementarity determining regions for targeted epitope binding.
Paraproteinemia and neuropathy.
Paraproteinemic neuropathies.
Relationship of smoking and fibrosis in patients with chronic hepatitis C.
Serum vascular endothelial growth factor as a tumor marker for hepatocellular carcinoma in hepatitis C virus-related cirrhotic patients.
Vascular Endothelial Growth Factor Expression in Hepatitis C Virus-Induced Liver Fibrosis: A Potential Biomarker.
[Effects of HCV core protein on the expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor].
Hepatitis C, Chronic
DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment.
Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C.
Is smoking a prognostic factor in patients with chronic hepatitis C?
Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels.
[Serum levels of vascular endothelial growth factor in chronic hepatitis C patients treated with interferon alpha and ribavirin]
Hepatitis, Chronic
Circulating vascular endothelial growth factor levels are decreased in patients with chronic hepatitis and liver cirrhosis depending on the degree of hepatic damage.
Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Vascular endothelial growth factors and liver diseases.
Hepatoblastoma
Anti-angiogenic potential of Gleditsia sinensis fruit extract.
Hepatolenticular Degeneration
Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children.
Hepatomegaly
Asymmetric optic disc edema in a young patient with POEMS: A rare presentation of a rare disease.
Atypical central retinal artery occlusion as the first presentation of POEMS syndrome: a case report.
Hereditary Breast and Ovarian Cancer Syndrome
Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.
Hereditary Complement Deficiency Diseases
Complement analysis in adult patients with a history of bacteremic pneumococcal infections or recurrent pneumonia.
Serum complement concentrations, nutritional status and the outcome of measles and measles pneumonia.
Hernias, Diaphragmatic, Congenital
Antenatal steroid and tracheal occlusion restore vascular endothelial growth factor receptors in congenital diaphragmatic hernia rat model.
Changes in the expression of vascular endothelial growth factor after fetal tracheal occlusion in an experimental model of congenital diaphragmatic hernia.
Effect of VEGF on the branching morphogenesis of normal and nitrofen-induced hypoplastic fetal rat lung explants.
Enhanced expression of vascular endothelial growth factor in lungs of newborn infants with congenital diaphragmatic hernia and pulmonary hypertension.
Increased vascular endothelial growth factor peptide and gene expression in hypoplastic lung in nitrofen induced congenital diaphragmatic hernia in rats.
Plasma vascular endothelial growth factor A and placental growth factor: novel biomarkers of pulmonary hypertension in congenital diaphragmatic hernia.
Prenatal retinoic acid improves lung vascularization and VEGF expression in CDH rat.
Pulmonary expression of vascular endothelial growth factor and myosin isoforms in rats with congenital diaphragmatic hernia.
Vascular endothelial growth factor accelerates compensatory lung growth by increasing the alveolar units.
VEGF receptor expression decreases during lung development in congenital diaphragmatic hernia induced by nitrofen.
Herpes Simplex
Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.
Cornea lymphatics drive the CD8(+) T cell response to herpes simplex virus-1.
Expression of vascular endothelial growth factor from a defective herpes simplex virus type 1 amplicon vector induces angiogenesis in mice.
Fibroblast growth factor-2 drives and maintains progressive corneal neovascularization following HSV-1 infection.
HSV-1 Targets Lymphatic Vessels in the Eye and Draining Lymph Node of Mice Leading to Edema in the Absence of a Functional Type I Interferon Response.
HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy.
Ocular Neovascularization Caused by Herpes Simplex Virus Type 1 Infection Results from Breakdown of Binding between Vascular Endothelial Growth Factor A and Its Soluble Receptor.
Role of miR-132 in angiogenesis after ocular infection with herpes simplex virus.
Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells.
Vascular endothelial growth factor gene-transferred bone marrow stromal cells engineered with a herpes simplex virus type 1 vector can improve neurological deficits and reduce infarction volume in rat brain ischemia.
[Hypoxia augments the killing effect of herpes simplex virus thymidine kinase gene expression actuated by the promoter of the vascular endothelial growth factor gene on human hepatocellular tumor cells]
Herpes Zoster
Localization of vascular endothelial growth factor in the zona pellucida of developing ovarian follicles in the rat: a possible role in destiny of follicles.
Herpesviridae Infections
Raf-induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpesvirus infection.
Histiocytoma, Malignant Fibrous
Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase.
Expressions of vascular endothelial growth factor and basic fibroblast growth factor in tumors induced by two different cloned cell lines established from transplantable rat malignant fibrous histiocytoma.
Relationship of angiogenic and apoptotic activities in soft-tissue sarcoma.
Histiocytosis
The role of vascular endothelial growth factor in Langerhans cell histiocytosis.
Histiocytosis, Langerhans-Cell
The role of vascular endothelial growth factor in Langerhans cell histiocytosis.
HIV Infections
A Review of Angiogenic Imbalance in HIV-Infected Hypertensive Disorders of Pregnancy.
Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection.
Cytokine pattern in Kaposi's sarcoma associated with immune restoration disease in HIV and tuberculosis co-infected patients.
Maternal endothelial dysfunction in HIV-associated preeclampsia comorbid with COVID-19: a review.
Hoarseness
Hoarseness during treatment with bevacizumab and other vascular endothelial growth factor signalling inhibitors.
Hodgkin Disease
Assessment of endothelial progenitor cells, VEGF-A and SDF-1? in Hodgkin's lymphoma.
Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission.
Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma.
Insights in Hodgkin Lymphoma angiogenesis.
Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL).
Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma.
Re: Doussis-Anagnostopoulou et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002; 197: 677-683.
Role of vascular endothelial growth factor C in classical Hodgkin lymphoma.
Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease.
VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues.
[Plasma levels of VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in patients with newly diagnosed lymphomas].
[Vascular endothelial growth factor and interleukin 6 production by Hodgkin lymphoma]
Huntington Disease
Injectable Hydrogels Providing Sustained Delivery of Vascular Endothelial Growth Factor are Neuroprotective in a Rat Model of Huntington's Disease.
Hydatidiform Mole
Serum and tissue vascular endothelial growth factor levels in hydatidiform mole.
Hydrocephalus
Dissociation between vascular endothelial growth factor receptor-2 and blood vessel density in the caudate nucleus after chronic hydrocephalus.
Exercise-induced changes of cerebrospinal fluid vascular endothelial growth factor in adult chronic hydrocephalus patients.
Vascular endothelial growth factor and erythropoietin concentrations in cerebrospinal fluid of children with hydrocephalus.
Vascular endothelial growth factor and transforming growth factor-beta1 are highly expressed in the cerebrospinal fluid of premature infants with posthemorrhagic hydrocephalus.
VEGF, which is elevated in the CSF of patients with hydrocephalus, causes ventriculomegaly and ependymal changes in rats.
VEGF: a potential target for hydrocephalus.
Hydrops Fetalis
Immunohistochemical distribution of vascular endothelial growth factor in the human placenta associated with hydrops fetalis.
Increased expression of vascular endothelial growth factor in cardiac structures of fetus with hydrops as compared to nonhydropic controls.
Hydrothorax
Diagnostic values of vascular endothelial growth factor and epidermal growth factor receptor for benign and malignant hydrothorax.
Hyperaldosteronism
Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension.
Hyperalgesia
Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis.
Surgery accelerates the development of endometriosis in mouse.
Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer.
Vascular endothelial growth factor and spinal cord injury pain.
Hyperandrogenism
The effect of prednisolone on endometrial VGEF concentrations, Gene polymorphisms and pregnancy outcome in women with polycystic ovary syndrome: A retrospective cohort study.
Hypercalcemia
Paraneoplastic symptoms: Cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma.
Hypercholesterolemia
A VEGF trap inhibits the beneficial effect of bFGF on vasoreactivity in corporal tissues of hypercholesterolemic rabbits.
Association between SNPs of Circulating Vascular Endothelial Growth Factor Levels, Hypercholesterolemia and Metabolic Syndrome.
Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia.
Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia.
Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia.
Successful therapy reduces levels of vascular endothelial growth factor (VEGF) in patients with hypertension and patients with hypercholesterolemia.
The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia.
Vitamins C and E prevent endothelial VEGF and VEGFR-2 overexpression induced by porcine hypercholesterolemic LDL.
Von Willebrand factor, C-reactive protein, nitric oxide, and vascular endothelial growth factor in a dietary reversal model of hypercholesterolemia in rabbit.
[Increased VEGFR-1 immunoreactivity in the choroid-scleral complex in hypercholesterolemia experimental model].
Hyperemia
Modulation of vascular endothelial gene expression by physical training in patients with chronic heart failure.
Triphenylethylene antiestrogens induce uterine vascular endothelial growth factor expression via their partial estrogen agonist activity.
Hypereosinophilic Syndrome
Effect of benzo[a]pyrene on the production of vascular endothelial growth factor by human eosinophilic leukemia EoL-1 cells.
[What's new in internal medicine?].
Hypergammaglobulinemia
Liver cirrhosis in a child associated with Castleman's disease: A case report.
Hyperglycemia
Activation of the VEGF-A/ERK/PLA2 Axis Mediates Early Retinal Endothelial Cell Damage Induced by High Glucose: New Insight from an In Vitro Model of Diabetic Retinopathy.
Adipsin is an adipokine that improves ? cell function in diabetes.
Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans.
Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues.
Biological Activity of c-Peptide in Microvascular Complications of Type 1 Diabetes-Time for Translational Studies or Back to the Basics?
Cell biology of intraocular vascular diseases
Characterization of a mouse model of hyperglycemia and retinal neovascularization.
Circulating vascular endothelial growth factor is unaffected by acute hyperglycemia and hyperinsulinemia in type 1 diabetes mellitus.
Dietary hyperglycemia, glycemic index and metabolic retinal diseases.
Divergent effects of hyper- and hypoglycemia on circulating vascular endothelial growth factor in humans.
Effect of insulin on plasma vascular endothelial growth factor in children with new-onset diabetes.
Effect of saponins from Helicteres isora on lipid and glucose metabolism regulating genes expression.
Endothelial dysfunction in diabetes mellitus: role in cardiovascular disease.
Etiology and effect on outcomes of hyperglycemia in hospitalized patients.
Hyperglycemia induced testicular damage in type 2 diabetes mellitus rats exhibiting microcirculation impairments associated with vascular endothelial growth factor decreased via PI3K/Akt pathway.
Implications of treatment that target protective mechanisms against diabetic nephropathy.
Inhibition of Receptor for Advanced Glycation End Products as New Promising Strategy Treatment in Diabetic Retinopathy.
Insulin may cause deterioration of proliferative diabetic retinopathy.
Lactucaxanthin protects retinal pigment epithelium from hyperglycemia-regulated hypoxia/ER stress/VEGF pathway mediated angiogenesis in ARPE-19 cell and rat model.
Molecular mechanisms of diabetic vascular complications.
New perspectives on diabetic vascular complications: the loss of endogenous protective factors induced by hyperglycemia.
New pharmacologic approaches to treating diabetic retinopathy.
Oral supplementation with melatonin reduces oxidative damage and concentrations of inducible nitric oxide synthase, VEGF and matrix metalloproteinase 9 in the retina of rats with streptozotocin/nicotinamide induced pre-diabetes.
Oral targeting of protein kinase C receptor: promising route for diabetic retinopathy?
Pharmacological inhibition of N-methyl d-aspartate receptor promotes secretion of vascular endothelial growth factor in müller cells: effects of hyperglycemia and hypoxia.
PKC? impaired vessel formation and angiogenic factor expression in diabetic ischemic limbs.
Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus.
Potential Role of Hyperglycemia in Fetoplacental Endothelial Dysfunction in Gestational Diabetes Mellitus.
Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy.
Protein kinase C activation affects, via the mRNA-binding Hu-antigen R/ELAV protein, vascular endothelial growth factor expression in a pericytic/endothelial coculture model.
Role of FAM18B in diabetic retinopathy.
Role of Hypoxia Inducible Factor 1 in Hyperglycemia-Exacerbated Blood-Brain Barrier Disruption in Ischemic Stroke.
The possible mechanism for impaired angiogenesis after transient focal ischemia in type 2 diabetic GK rats: different expressions of angiostatin and vascular endothelial growth factor.
Thioredoxin-interacting protein deficiency ameliorates diabetic retinal angiogenesis.
Thrap3 docks on phosphoserine 273 of PPAR? and controls diabetic gene programming.
[Cell biology of intraocular vascular diseases]
Hyperhomocysteinemia
Arterial Blood Pressure Variability and Other Vascular Factors Contribution to the Cognitive Decline in Parkinson's Disease.
Hyperinsulinism
Circulating vascular endothelial growth factor is unaffected by acute hyperglycemia and hyperinsulinemia in type 1 diabetes mellitus.
Differentiation dependent biphasic regulation of adipsin gene expression by insulin and insulin-like growth factor-1 in 3T3-F442A adipocytes.
EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice.
Impairment of adipsin expression is secondary to the onset of obesity in db/db mice.
Hyperlipidemias
Austrian Moderate Altitude Study (AMAS 2000) - fluid shifts, erythropoiesis, and angiogenesis in patients with metabolic syndrome at moderate altitude (congruent with 1700 m).
Deletion of Lymphangiogenic and Angiogenic Growth Factor VEGF-D Leads to Severe Hyperlipidemia and Delayed Clearance of Chylomicron Remnants.
Effect of folic acid and vitamin B12 on the expression of PPAR?, caspase-3 and caspase-8 mRNA in the abdominal aortas of rats with hyperlipidemia.
Effect of saponins from Helicteres isora on lipid and glucose metabolism regulating genes expression.
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate.
Risk of Dyslipidemia Associated with VEGF/VEGFR Inhibitors: A Meta-Analysis.
The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia.
Vascular endothelial growth factor A gene expression level is higher in patients with major depressive disorder and not affected by cigarette smoking, hyperlipidemia or treatment with statins.
[Effects of simvastatin on vasa vasorum and aortic endothelial function in rats]
Hyperpigmentation
Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone.
Hypersensitivity
Leukotriene B4 Receptor 2 Is Critical for the Synthesis of Vascular Endothelial Growth Factor in Allergen-Stimulated Mast Cells.
Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases.
Possible association of vascular endothelial growth factor with the development of edema in drug-induced hypersensitivity syndrome.
Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer.
Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity.
Hypersensitivity, Delayed
Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease.
Hypertension
2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic ZSF1 rats.
A large-scale retrospective study of the overall survival outcome in nasopharyngeal carcinoma with hypertension in Chinese population.
A Maternally Sequestered, Biopolymer-Stabilized Vascular Endothelial Growth Factor (VEGF) Chimera for Treatment of Preeclampsia.
A pivotal role of the vascular endothelial growth factor signaling pathway in the formation of venous hypertension-induced dural arteriovenous fistulas.
Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)].
Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis.
Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation.
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition.
An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the Literature.
Angiogenic factors and preeclampsia.
Angiogenic growth factors and hypertension.
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
Aortic dissection during antiangiogenic therapy with sunitinib. A case report.
Arterial hypertension in patients under antineoplastic therapy: a systematic review.
Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer.
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.
Association between vascular endothelial growth factor and hypertension in children and adolescents type I diabetes mellitus.
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Bevacizumab in clinical practice.
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study.
Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
Blood pressure control in patients receiving bevacizumab in an outpatient cancer center.
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.
Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
Brain Expression of VEGF and its Receptors in SHR-SP and Effects of an Endothelin Blocker.
Cabozantinib-induced hand-foot skin reaction with subungual splinter hemorrhages and hypertension: a possible association with inhibition of the vascular endothelial growth factor signaling pathway.
Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib.
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Cardiotoxic effects of angiogenesis inhibitors.
Cardiovascular toxic effects of targeted cancer therapy.
Carotid Body Remodelling in l-NAME-Induced Hypertension in the Rat.
Circulating Lymphangiogenic Factors in Preeclampsia.
Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors.
Contribution of VEGF polymorphism rs3025020 to short stature and hypertension in elderly Japanese individuals: a cross-sectional study.
Coronary angiogenesis during experimental hypertension: is it reversible?
Correlative studies on the effects of obesity, diabetes and hypertension on gene expression in omental adipose tissue of obese women.
Cumulative dose of bevacizumab associates with albuminuria rather than podocyturia in cancer patients.
Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension.
Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.
Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats.
Do nutritional supplements lower the risk of stroke or hypertension?
Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab.
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.
Effect of genetic polymorphisms of vascular endothelial growth factor on left ventricular hypertrophy in patients with systemic hypertension.
Effect of vascular endothelial growth factor on retinal ganglion cells of rats with chronic intraocular hypertension.
Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
Effects of androgen on vascular and inflammatory biomarkers in a female hypertensive population.
Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy.
Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients.
Effects of KRN633, an inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, on vascular development of placenta and fetus of mid pregnancy in mice.
Elevated Adipsin Levels are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis.
Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Endothelium and angiogenesis in white coat hypertension.
Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.
Exercise training attenuates placental ischemia-induced hypertension and angiogenic imbalance in the rat.
Expression of hypoxia-inducible factor-1 and vascular endothelial growth factor in response to venous hypertension.
Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab.
Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis.
Functional VEGF haplotypes affect the susceptibility to hypertension.
Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Healing process of autogenous bone graft in spontaneously hypertensive rats treated with losartan: an immunohistochemical and histomorphometric study.
Hydrogen Sulfide Attenuates sFlt1-Induced Hypertension and Renal Damage by Upregulating Vascular Endothelial Growth Factor.
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib.
Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.
Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.
Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression.
Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
Impact of primary hypertension on hematuria of the patients with benign prostatic hyperplasia.
INCREASES OF VITREOUS MONOCYTE CHEMOTACTIC PROTEIN 1 AND INTERLEUKIN 8 LEVELS IN PATIENTS WITH CONCURRENT HYPERTENSION AND DIABETIC RETINOPATHY.
Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients.
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats.
Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab.
Involvement of the lymphatic system in salt-sensitive hypertension in humans.
Is vascular endothelial growth factor a missing link between hypertension and inflammation?
Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction.
Long-term High Salt Diet Causes Hypertension and Decreases Renal Expression of Vascular Endothelial Growth Factor in Sprague-Dawley Rats.
Management of hypertension in angiogenesis inhibitor-treated patients.
Markers of vascular function in hypertension due to Cushing's syndrome.
Mechanisms of endogenous endothelial repair in stroke.
Mechanisms of Hypertension and Renal Injury During Vascular Endothelial Growth Factor Signaling Inhibition.
Molecular basis of hypertension side effects induced by sunitinib.
Molecular mechanisms of preeclampsia.
Multimodal imaging of a vascularized idiopathic epiretinal membrane.
New anticancer strategies targeting HIF-1.
Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
Obese melanocortin-4 receptor-deficient rats exhibit augmented angiogenic balance and vasorelaxation during pregnancy.
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Pathogenesis of nonimmune glomerulopathies.
Peripheral Artery Disease and Stroke.
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.
Physical conditioning modulates rat cardiac vascular endothelial growth factor gene expression in nitric oxide-deficient hypertension.
Placental decidual arteriopathy and vascular endothelial growth factor A (VEGF-A) expression among women with and without HIV.
Placental growth factor, vascular endothelial growth factor, and hypoxia-inducible factor-1? in the placentas of women with pre-eclampsia.
Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy.
Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension.
Plasma N-Terminal Probrain Natriuretic Peptide, Vascular Endothelial Growth Factor, and Cardiac Troponin I as Novel Biomarkers of Hypertensive Disease and Target Organ Damage in Cats.
Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension.
Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension.
Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor.
Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients.
Pregnancy-induced hypertension and preeclampsia: levels of angiogenic factors in malaysian women.
Pro- and antiangiogenic markers in patients with pulmonary complications of systemic scleroderma.
Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition.
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia.
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension.
Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model.
Relaxin in Obstructive Sleep Apnea: Relationship with Blood Pressure and Inflammatory Mediators.
Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis?.
Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib.
Reply to vascular endothelial growth factor: a novel potential therapeutic target for hypertension.
Rescue of hypertension-related impairment of angiogenesis by therapeutic ultrasound.
Resistant Hypertension: Underlying Causes and Treatment.
Retinal oximetry during treatment of retinal vein occlusion by ranibizumab in patients with high blood pressure and dyslipidemia.
Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption.
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
Role of Complement Component C1q in the Onset of Preeclampsia in Mice.
Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans.
Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats.
Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment.
Role of the Aryl Hydrocarbon Receptor in Sugen 5416-induced Experimental Pulmonary Hypertension.
Severe Pulmonary Arterial Hypertension Induced by SU5416 and Ovalbumin Immunization.
Sodium hydrosulfide prevents hypertension and increases in vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in hypertensive pregnant rats.
Sorafenib Dose Escalation is Not Uniformly Associated with Blood Pressure Elevations in Normotensive Patients with Advanced Malignancies.
Stretch-induced retinal vascular endothelial growth factor expression is mediated by phosphatidylinositol 3-kinase and protein kinase C (PKC)-zeta but not by stretch-induced ERK1/2, Akt, Ras, or classical/novel PKC pathways.
Successful therapy reduces levels of vascular endothelial growth factor (VEGF) in patients with hypertension and patients with hypercholesterolemia.
Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.
Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress.
Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor-Signaling Inhibitors.
Syngeneic bone marrow mononuclear cells improve pulmonary arterial hypertension through vascular endothelial growth factor upregulation.
The effect of hypertension on serum nitric oxide and vascular endothelial growth factor concentrations. A study in DOCA-Salt hypertensive ovariectomized rats.
The impairment of renal function is not associated to altered circulating vascular endothelial growth factor in patients with Type 2 diabetes and hypertension.
The relationship between venous hypertension and expression of vascular endothelial growth factor: hemodynamic and immunohistochemical examinations in a rat venous hypertension model.
The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox.
The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients.
The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice.
Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension.
Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use.
Timing of ischemic insult alters fetal growth trajectory, maternal angiogenic balance, and markers of renal oxidative stress in the pregnant rat.
Triple-tyrosine kinase inhibition attenuates pulmonary arterial hypertension and neointimal formation.
Tyrosine Kinase Inhibitor-Induced Hypertension.
Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers.
Vascular Complications of Cancer Chemotherapy.
Vascular endothelial growth factor (VEGF), prostaglandin E2(PGE2) and active renin in hypertension of adrenal origin.
Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer.
Vascular endothelial growth factor administration does not improve microvascular disease in the salt-dependent phase of post-angiotensin II hypertension.
Vascular endothelial growth factor affects dendritic cell activity in hypertensive disorders of pregnancy.
Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension.
Vascular endothelial growth factor and pulmonary hypertension in children with beta thalassemia major.
Vascular Endothelial Growth Factor expression in peripheral blood of patients with pregnancy induced hypertension syndrome and its clinical significance.
Vascular endothelial growth factor gene is associated with hypertensive cerebellar hemorrhage and rehabilitative treatment.
Vascular endothelial growth factor inhibitor induced hypertension: Retrospective analysis of the impact of blood pressure elevations on outcomes.
Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers.
Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors?
Vascular Endothelial Growth Factor Receptor Inhibitor Enhances Dietary Salt-induced Hypertension in Sprague-Dawley (SD) Rats.
Vascular endothelial growth factor: a novel potential therapeutic target for hypertension.
VEGF and sFLT-1 in serum of PIH patients and effects on the foetus.
VEGF receptor expression decreases during lung development in congenital diaphragmatic hernia induced by nitrofen.
Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy.
[Changes and significance of concentrations of serum vascular endothelial growth factor in patients with pregnancy induced hypertension]
[Expression and role of placental vascular endothelial growth factor in patients with pregnancy induced hypertension]
[Expression of vascular endothelial growth factor in placenta from pregnancy complicated with pregnancy induced hypertension]
[Features of hemostasis system and vascular epithelium growth factor in arterial hypertension with high occupational risk].
[Functional State of Vascular Endothelium in Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Diseases].
[Impact of hypertension on angiogenesis in the tissues of benign prostatic hyperplasia]
[Role of vascular endothelial growth factor in the genesis of pregnancy induced hypertension and its relationship with nitric oxide]
[Study on association of vascular endothelial growth factor with the pathogenesis of pregnancy induced hypertension]
[Study on the tumor microenvironment and tumor vascular normalization in integrative treatment of tumor by Chinese medicine and western medicine].
Hypertension, Malignant
Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors.
Hypertension, Portal
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice.
Antioxidant properties of glutamine and its role in VEGF-Akt pathways in portal hypertension gastropathy.
Are humoral factors involved in the colonic mucosal lesion in portal hypertensive rats?
Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment.
Circulating vascular endothelial growth factor and nitric oxide in patients with liver cirrhosis: A possible association with liver function impairment.
Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension.
Intestinal and plasma VEGF levels in cirrhosis: The role of portal pressure.
NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats.
Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses….
Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
Vascular Endothelial Growth Factor Promotes Fibrosis Resolution and Repair in Mice.
[Characteristics of sublingual vein and expressions of vascular endothelial growth factor and hypoxia-inducible factor 1alpha proteins in sublingual tissues of Beagle dogs with portal hypertension.]
Hypertension, Pregnancy-Induced
Assessment of Serum Vascular Endothelial Growth Factor Levels in Pregnancy-Induced Hypertension Patients.
Association of pregnancy-associated plasma protein A and vascular endothelial growth factor with pregnancy-induced hypertension.
Distinct First Trimester Cytokine Profiles for Gestational Hypertension and Preeclampsia.
Efficacy of combined medication of nifedipine and magnesium sulfate on gestational hypertension and the effect on PAPP-A, VEGF, NO, Hcy and vWF.
Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.
Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance.
Plasma markers of angiogenesis in pregnancy induced hypertension.
Sustained Endocrine Gland-Derived Vascular Endothelial Growth Factor Levels Beyond the First Trimester of Pregnancy Display Phenotypic and Functional Changes Associated With the Pathogenesis of Pregnancy-Induced Hypertension.
Vascular Endothelial Growth Factor expression in peripheral blood of patients with pregnancy induced hypertension syndrome and its clinical significance.
Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension.
VEGF and sFLT-1 in serum of PIH patients and effects on the foetus.
[Changes and significance of concentrations of serum vascular endothelial growth factor in patients with pregnancy induced hypertension]
[Expression and role of placental vascular endothelial growth factor in patients with pregnancy induced hypertension]
[Expression of vascular endothelial growth factor in placenta from pregnancy complicated with pregnancy induced hypertension]
[Role of vascular endothelial growth factor in the genesis of pregnancy induced hypertension and its relationship with nitric oxide]
[Study on association of vascular endothelial growth factor with the pathogenesis of pregnancy induced hypertension]
Hypertension, Pulmonary
Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats.
Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.
Antenatal steroid and tracheal occlusion restore vascular endothelial growth factor receptors in congenital diaphragmatic hernia rat model.
Association between levels of anti-angiogenic isoform of vascular endothelial growth factor A and pulmonary hypertension.
Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension.
Changes in Caspase-3, B Cell Leukemia/Lymphoma-2, Interleukin-6, Tumor Necrosis Factor-? and Vascular Endothelial Growth Factor Gene Expression after Human Umbilical Cord Blood Derived Mesenchymal Stem Cells Transfusion in Pulmonary Hypertension Rat Models.
Changes in expression of vascular endothelial growth factor and its receptors in neonatal hypoxia-induced pulmonary hypertension.
Chronic Embolic Pulmonary Hypertension Caused by Pulmonary Embolism and Vascular Endothelial Growth Factor Inhibition.
Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure.
Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema.
Elastase and cell matrix interactions in the pathobiology of vascular disease.
Elastase and the pathobiology of unexplained pulmonary hypertension.
Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia.
Enhanced expression of vascular endothelial growth factor in lungs of newborn infants with congenital diaphragmatic hernia and pulmonary hypertension.
EVE and beyond, retro and prospective insights.
Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension.
Gene transfer of vascular endothelial growth factor reduces bleomycin-induced pulmonary hypertension in immature rabbits.
Hypoxia-inducible factor-1 alpha regulates the role of vascular endothelial growth factor on pulmonary arteries of rats with hypoxia-induced pulmonary hypertension.
Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy.
Impaired TNFalpha-induced VEGF expression in human airway smooth muscle cells from smokers with COPD: role of MAPkinases and histone acetylation--effect of dexamethasone.
Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension.
Intrauterine pulmonary hypertension impairs angiogenesis in vitro: role of vascular endothelial growth factor nitric oxide signaling.
Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension.
New potential diagnostic biomarkers for pulmonary hypertension.
Pathobiology of pulmonary hypertension: Impact on clinical management.
Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation.
Plasma vascular endothelial growth factor A and placental growth factor: novel biomarkers of pulmonary hypertension in congenital diaphragmatic hernia.
Plasma VEGF levels and their relation to right ventricular function in pulmonary hypertension.
POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation.
Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression.
Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn.
Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells.
Rho kinase-mediated vasoconstriction in rat models of pulmonary hypertension.
Role of vascular endothelial growth factor signaling in Schistosoma-induced experimental pulmonary hypertension.
Serum cytokine profiles in patients with chronic obstructive pulmonary disease associated pulmonary hypertension identified using protein array.
Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis.
SETD3 negatively regulates VEGF expression during hypoxic pulmonary hypertension in rats.
Temporal changes of angiopoietins and Tie2 expression in rat lungs after monocrotaline-induced pulmonary hypertension.
Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung.
The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin.
Vascular endothelial growth factor and pulmonary hypertension in children with beta thalassemia major.
Vascular endothelial growth factor improves pulmonary vascular reactivity and structure in an experimental model of chronic pulmonary hypertension in fetal sheep.
Vascular endothelial growth factor in pulmonary hypertension.
Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
[Changes of level and distribution of vascular endothelial growth factor in the lungs of rats with hypoxic pulmonary hypertension]
[Changes of the gene expression of vascular endothelial growth factor in the lung of rats with chronic hypoxic pulmonary hypertension]
[Effect of elastase inhibitor on pulmonary hypertension induced by monocrotaline]
[Effect of VEGF gene transfer on the bleomycin-induced pulmonary hypertension in immature rabbits]
[Effects of feixin decoction on the contents of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in the rat model of hypoxic pulmonary hypertension].
[Gene therapy for pulmonary hypertension]
[Hypoxia-inducible factor 1alpha regulates vascular endothelial growth factor's roles on pulmonary arteries of rats with hypoxia-induced pulmonary hypertension]
[Integripetal rhodiola herb attenuates high altitude-induced pulmonary arterial remodeling and expression of vascular endothelial growth factor in rats].
[Study on relativity of hypoxic pulmonary hypertension with levels of endothelin-1 and vascular endothelial growth factor in plasma of pulmonary artery and carotid artery].
[The role of hypoxia inducible factor-1? and vascular endothelial growth factor in hypoxic pulmonary hypertension in patients with acute high altitude reaction of rescue workers in Yushu earthquake].
[Transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor gene for the treatment of pulmonary hypertension in rats].
Hyperthyroidism
Association between urinary vascular endothelial growth factor excretion and chronic kidney disease in hyperthyroid cats.
Effects of hyperthyroidism on expression of vascular endothelial growth factor (VEGF) and apoptosis in fetal adrenal glands.
Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features.
Hypertrichosis
Monoclonal gammopathy of cutaneous significance: review of a relevant concept.
[Skin Changes in POEMS Syndrome].
Hypertrophy, Left Ventricular
Effect of genetic polymorphisms of vascular endothelial growth factor on left ventricular hypertrophy in patients with systemic hypertension.
Increased superoxide radical with a decrease in vascular endothelial growth factor and inducible nitric oxide synthase level leads to the progression of left ventricular hypertrophy in a pressure-overload rat heart model.
Hypertrophy, Right Ventricular
Gene expression in a swine model of right ventricular hypertrophy: intercellular adhesion molecule, vascular endothelial growth factor and plasminogen activators are upregulated during pressure overload.
Glycoprotein 130 Inhibitor Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats.
Moderate Postnatal Hyperoxia Accelerates Lung Growth and Attenuates Pulmonary Hypertension in Infant Rats After Exposure to Intra-Amniotic Endotoxin.
Hypoalbuminemia
[Interleukin-6-producing paraganglioma mimicking multicentric Castleman disease].
Hypoglycemia
Blood levels of pro-inflammatory and anti-inflammatory cytokines during an oral glucose tolerance test in patients with symptoms suggesting reactive hypoglycemia.
Decreased vascular endothelial growth factor response to acute hypoglycemia in type 2 diabetic patients with hypoglycemic coma.
Divergent effects of hyper- and hypoglycemia on circulating vascular endothelial growth factor in humans.
Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals.
Hypoglycemia Induces Mitochondrial Reactive Oxygen Species Production Through Increased Fatty Acid Oxidation and Promotes Retinal Vascular Permeability in Diabetic Mice.
Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic Beta cells as a regulator of Beta cell mass.
Protective effects of vascular endothelial growth factor in cultured brain endothelial cells against hypoglycemia.
Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes.
Vascular endothelial growth factor during hypoglycemia in patients with type 1 diabetes mellitus: relation to cognitive function and renin-angiotensin system activity.
Vascular endothelial growth factor: a novel endocrine defensive response to hypoglycemia.
Hyponatremia
Different expressions of AQP1, AQP4, eNOS, and VEGF proteins in ischemic versus non-ischemic cerebropathy in rats: potential roles of AQP1 and eNOS in hydrocephalic and vasogenic edema formation.
Hypoparathyroidism
Parathyroid hormone 1-84 alters circulating vascular endothelial growth factor levels in hypoparathyroidism.
Hypopharyngeal Neoplasms
Clinicopathologic significance of CD105 expression in squamous cell carcinoma of the hypopharynx.
Hypotension
Anti-vasopermeability effects of PEDF in retinal-renal disorders.
Combined glucocorticoid resistance and hyperlactatemia contributes to lethal shock in sepsis.
Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats.
Intradialytic hypotension: beyond hemodynamics.
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF.
Hypothyroidism
A case of subclinical hypothyroidism developing marked pleural effusions and peripheral edema with elevated vascular endothelial growth factor.
Blood-brain-barrier disruption in chronic canine hypothyroidism.
Coexistence of Quasi-moyamoya Disease and POEMS Syndrome in a Patient with Intracranial Hemorrhage: A Case Report and Literature Review.
Drug-induced hypothyroidism.
Effect of sunitinib on growth and function of FRTL-5 thyroid cells.
Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer.
Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines.
Hypothyroidism induces uterine hyperplasia and inflammation related to sex hormone receptors expression in virgin rabbits.
Subclinical Hypothyroidism in Patients with Diabetic Retinopathy: Role of Vascular Endothelial Growth Factor.
Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements.
Hypoxia, Brain
Prolonged hypoxia increases vascular endothelial growth factor mRNA and protein in adult mouse brain.
The Anti-Edematous Effect of Ghrelin in Brain Hypoxia is Associated with Decreasing Expression of Vascular Endothelial Growth Factor.
Upregulation of vascular endothelial growth factor in severe chronic brain hypoxia of the rat.
Hypoxia-Ischemia, Brain
Cerebrospinal fluid and serum vascular endothelial growth factor and nitric oxide levels in newborns with hypoxic ischemic encephalopathy.
Erythropoietin improves hypoxic-ischemic encephalopathy in neonatal rats after short-term anoxia by enhancing angiogenesis.
Erythropoietin inhibits basal and stimulated corticotropin-releasing hormone release from the rat hypothalamus via a nontranscriptional mechanism.
Response of the sensorimotor cortex of cerebral palsy rats receiving transplantation of vascular endothelial growth factor 165-transfected neural stem cells.
Idiopathic Pulmonary Fibrosis
Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases.
Differing Expression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis.
Evaluation of chemokines CXCL8 and CCL2, serotonin, and vascular endothelial growth factor serum concentrations in healthy dogs from seven breeds with variable predisposition for canine idiopathic pulmonary fibrosis.
Impaired TNFalpha-induced VEGF expression in human airway smooth muscle cells from smokers with COPD: role of MAPkinases and histone acetylation--effect of dexamethasone.
Lymphangiogenic factors are associated with the severity of hypersensitivity pneumonitis.
MMP expression and abnormal lung permeability are important determinants of outcome in IPF.
Nuclear Localization of VEGF-D and Regulation of c-Myc-Dependent Transcripts in Human Lung Fibroblasts.
Plasma Endothelin-1 and Vascular Endothelial Growth Factor Levels and Their Relationship to Hemodynamics in Idiopathic Pulmonary Fibrosis.
Plasma Vascular Endothelial Growth Factor Concentration and Alveolar Nitric Oxide as Potential Predictors of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis.
Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis.
Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis.
Transforming Growth Factor-?1 Downregulates Vascular Endothelial Growth Factor-D Expression in Human Lung Fibroblasts via the Jun NH2-Terminal Kinase Signaling Pathway.
Vascular Endothelial Growth Factor in Idiopathic Pulmonary Fibrosis. An Imbalancing Act.
[Association of ENA-78, IP-10 and VEGF gene polymorphism with idiopathic pulmonary fibrosis]
IgA Vasculitis
Gene polymorphism of vascular endothelial growth factor in children with Henoch-Schonlein purpura nephritis.
Vascular endothelial growth factor in Henoch-Schonlein purpura.
[Changes of plasma concentration of soluble intercellular adhesion molecule-1 and vascular endothelial growth factor in children with Henoch-Schoenlein purpura]
[Expression of vascular endothelial growth factor is related to microvessel injury of renal interstitium in children with Henoch Sch nlein purpura nephritis.]
[Serum and urine VEGF concentration of different pathological types in children with Henoch Schonlein purpura nephritis]
ikappab kinase deficiency
NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha.
Impotence, Vasculogenic
Intracavernosal injection of vascular endothelial growth factor induces nitric oxide synthase isoforms.
Vascular endothelial growth factor induces IP-10 chemokine expression.
Infarction, Middle Cerebral Artery
Basic Fibroblast Growth Factor Protects Astrocytes Against Ischemia/Reperfusion Injury by Upregulating the Caveolin-1/VEGF Signaling Pathway.
Different expressions of AQP1, AQP4, eNOS, and VEGF proteins in ischemic versus non-ischemic cerebropathy in rats: potential roles of AQP1 and eNOS in hydrocephalic and vasogenic edema formation.
Early Transplantation of Human Cranial Bone-derived Mesenchymal Stem Cells Enhances Functional Recovery in Ischemic Stroke Model Rats.
Effect of Semax and its C-terminal Fragment Pro-Gly-Pro on the Expression of VEGF Family Genes and their Receptors in Experimental Focal Ischemia of the Rat Brain.
Effects of bone marrow mesenchymal stem cells (BM-MSCs) on rat pial microvascular remodeling after transient middle cerebral artery occlusion.
Enhancement of ischemia-induced tyrosine phosphorylation of Kv1.2 by vascular endothelial growth factor via activation of phosphatidylinositol 3-kinase.
Functional recovery after hematic administration of allogenic mesenchymal stem cells in acute ischemic stroke in rats.
Increased protein and mRNA expression of endostatin in the ischemic brain tissue of rabbits after middle cerebral artery occlusion.
Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats.
MicroRNA-384-5p Promotes Endothelial Progenitor Cell Proliferation and Angiogenesis in Cerebral Ischemic Stroke through the Delta-Likeligand 4-Mediated Notch Signaling Pathway.
Neurogenic effect of VEGF is related to increase of astrocytes transdifferentiation into new mature neurons in rat brains after stroke.
Protective effects of sulphonated formononetin in a rat model of cerebral ischemia and reperfusion injury.
Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats.
Reduced ischemic injury after stroke in mice by angiogenic gene delivery via ultrasound-targeted microbubble destruction.
Role of vascular endothelial growth factor in neuronal DNA damage and repair in rat brain following a transient cerebral ischemia.
The influence of Tongqiao Huashuan Decoction on the expression of VEGF and EphB2 in MCAO model rats.
Vascular endothelial growth factor gene expression in middle cerebral artery occlusion in the rat.
Vascular endothelial growth factor mediates atorvastatin-induced mammalian achaete-scute homologue-1 gene expression and neuronal differentiation after stroke in retired breeder rats.
Vascular endothelial growth factor receptor-2 inhibition promotes cell death and limits endothelial cell proliferation in a neonatal rodent model of stroke.
VEGF overexpression enhances striatal neurogenesis in brain of adult rat after a transient middle cerebral artery occlusion.
[Effects of dl-3-n-butylphthalide on expression of VEGF and bFGF in rat brain with permanent focal cerebral ischemia]
[Effects of dl-3n-butylphthalide on the expression of VEGF and bFGF in transient middle cerebral artery occlusion rats]
Infections
A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells.
A family with complement factor D deficiency.
A mechanism for induction of a hypoxic response by vaccinia virus.
Accelerated wound healing of oral soft tissues and angiogenic effect induced by a pool of aminoacids combined to sodium hyaluronate (AMINOGAM).
Activation of hypoxia-inducible factor-1 in bacillary angiomatosis: evidence for a role of hypoxia-inducible factor-1 in bacterial infections.
Alternate receptor usage of neuropilin-1 and glucose transporter protein 1 by the human T cell leukemia virus type 1.
Anti-angiogenic action of the C-terminal domain of tenomodulin that shares homology with chondromodulin-I.
Bartonella quintana variably expressed outer membrane proteins mediate vascular endothelial growth factor secretion but not host cell adherence.
Bartonella vinsonii subsp. berkhoffii and Bartonella henselae as potential causes of proliferative vascular diseases in animals.
C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer.
Characterization of the host response to pichinde virus infection in the Syrian golden hamster by species-specific kinome analysis.
Characterization of two types of vascular endothelial growth factor from Litopenaeus vannamei and their involvements during WSSV infection.
Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis.
Circulation of Orf viruses containing the NZ7-like vascular endothelial growth factor (VEGF-E) gene type in India.
Clinical characterization of two severe cases of hemorrhagic fever with renal syndrome (HFRS) caused by hantaviruses Puumala and Dobrava-Belgrade genotype Sochi.
Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis.
Coexpression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function.
Complement components as uremic toxins and their potential role as mediators of microinflammation.
Complement factor D is linked to platelet activation in human and rodent sepsis.
Complete and partial deficiencies of complement factor D in a Dutch family.
Coordinated expression of vascular endothelial growth factor A and urokinase-type plasminogen activator contributes to classical swine fever virus Shimen infection in macrophages.
Cornea lymphatics drive the CD8(+) T cell response to herpes simplex virus-1.
Correlations among Helicobacter pylori infection and the expression of cyclooxygenase-2 and vascular endothelial growth factor in gastric mucosa with intestinal metaplasia or dysplasia.
CSF inflammatory markers differ in gram-positive versus gram-negative shunt infections.
Cytokine pattern in Kaposi's sarcoma associated with immune restoration disease in HIV and tuberculosis co-infected patients.
Differential effects of Bartonella henselae on human and feline macro- and micro-vascular endothelial cells.
Disruption of in vitro endothelial barrier integrity by Japanese encephalitis virus-Infected astrocytes.
Down-regulation of Jab1, HIF-1alpha, and VEGF by Moloney murine leukemia virus-ts1 infection: a possible cause of neurodegeneration.
Effect of Borrelia burgdorferi OspC at the site of inoculation in mouse skin.
Effect of Vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome.
Elevated levels of vascular endothelial growth factor in adults with severe dengue infection.
Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium.
Epigenetic reader BRD4 supports mycobacterial pathogenesis by co-modulating host lipophagy and angiogenesis.
Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines.
ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biologic therapies: an infectious diseases perspective-cell surface receptors and associated signaling pathways.
Exogenous administration of vascular endothelial growth factor prior to human respiratory syncytial virus a2 infection reduces pulmonary pathology in neonatal lambs and alters epithelial innate immune responses.
Expression of constitutively stable hybrid hypoxia-inducible factor-1alpha protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury.
Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression.
Expression of interleukin-8, heme oxygenase-1 and vascular endothelial growth factor in DLD-1 colon carcinoma cells exposed to pyrrolidine dithiocarbamate.
Expressions of VEGF and miR-21 in tumor tissues of cervical cancer patients with HPV infection and their relationships with prognosis.
Extracellular Hsp90 serves as a co-factor for NF-?B activation and cellular pathogenesis induced by an oncogenic herpesvirus.
Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines.
Fibroblast growth factor-2 drives and maintains progressive corneal neovascularization following HSV-1 infection.
Functional polymorphisms in transforming growth factor-beta-1 (TGF{beta}-1) and vascular endothelial growth factor (VEGF) genes modify risk of renal parenchymal scarring following childhood urinary tract infection.
Gene profiling studies in the neonatal ovine lung show enhancing effects of VEGF on the immune response.
Genetic control of VEGF and TGF-beta1 gene polymorphisms in childhood urinary tract infection and vesicoureteral reflux.
Genetic deficiencies of the complement system and association with disease--early components.
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.
Human parasitic meningitis caused by Angiostrongylus cantonensis infection in Taiwan.
Human rhinovirus infection enhances airway epithelial cell production of growth factors involved in airway remodeling.
Hypotheses about sub-optimal hydration in the weeks before coronavirus disease (COVID-19) as a risk factor for dying from COVID-19.
Hypoxia, hypoxia-inducible factor-1? and vascular endothelial growth factor in a murine model of Schistosoma mansoni infection.
Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.
IL-17A Differentially Regulates Corneal Vascular Endothelial Growth Factor (VEGF)-A and Soluble VEGF Receptor 1 Expression and Promotes Corneal Angiogenesis after HSV Infection.
Immune recovery following bronchiolitis is linked to a drop in cytokine and LTC4 levels.
Increased serum level of vascular endothelial growth factor in Mycobacterium avium complex infection.
Increased vascular endothelial growth factor 165 binding to kinase insert domain-containing receptor after infection of human endothelial cells by recombinant adenovirus encoding the Vegf(165) gene.
Increased Vascular Endothelial Growth Factor in the Ventricular Cerebrospinal Fluid as a Predictive Marker for Subsequent Ventriculoperitoneal Shunt Infection : A Comparison Study among Hydrocephalic Patients.
Infectious angiogenesis: Bartonella bacilliformis infection results in endothelial production of angiopoetin-2 and epidermal production of vascular endothelial growth factor.
Influence of vascular endothelial growth factor and alpha-fetoprotein on hepatocellular carcinoma.
Inhibitory effect of 1?tetradecanol on Helicobacter pylori?induced production of interleukin?8 and vascular endothelial growth factor in gastric epithelial cells.
Interaction of Bartonella henselae with endothelial cells promotes monocyte/macrophage chemoattractant protein 1 gene expression and protein production and triggers monocyte migration.
Intra-amniotic infection upregulates decidual cell vascular endothelial growth factor (VEGF) and neuropilin-1 and -2 expression: implications for infection-related preterm birth.
Macrophage inflammatory protein-2 and vascular endothelial growth factor regulate corneal neovascularization induced by infection with Pseudomonas aeruginosa in mice.
Mast cell mediators in relation to dengue severity: A systematic review and meta-analysis.
Melatonin attenuates inflammation and promotes regeneration in rabbits with fulminant hepatitis of viral origin.
Microcirculatory alteration in low-grade gastric mucosa-associated lymphoma by Helicobacter heilmannii infection: its relation to vascular endothelial growth factor and cyclooxygenase-2.
Molecular characterization, expression and antimicrobial activity of complement factor D in Megalobrama amblycephala.
Mycoplasma pneumoniae Infection Affects the Serum Levels of Vascular Endothelial Growth Factor and Interleukin-5 in Atopic Children.
Necroptosis-based CRISPR knockout screen reveals Neuropilin-1 as a critical host factor for early stages of murine cytomegalovirus infection.
Neuroprotective Effect of Chronic Intracranial Toxoplasma gondii Infection in a Mouse Cerebral Ischemia Model.
Obstructive Lymphangitis Precedes Colitis in Murine Norovirus-Infected Stat1-Deficient Mice.
Ocular cytomegalovirus latency exacerbates the development of choroidal neovascularization.
Ocular Neovascularization Caused by Herpes Simplex Virus Type 1 Infection Results from Breakdown of Binding between Vascular Endothelial Growth Factor A and Its Soluble Receptor.
Overexpression of VEGF165 is associated with poor prognosis of cervical cancer.
Plasma cytokines eotaxin, MIP-1?, MCP-4, and vascular endothelial growth factor in acute lower respiratory tract infection.
Prenatal depression and stress - risk factors for placental pathology and spontaneous abortion.
Prox-1 promotes invasion of kaposiform hemangioendotheliomas.
Raf-induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpesvirus infection.
Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect.
Reconstruction of a Calvarial Wound Complicated by Infection: Comparing the Effects of Biopatterned Bone Morphogenetic Protein 2 and Vascular Endothelial Growth Factor.
Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
Relationship of smoking and fibrosis in patients with chronic hepatitis C.
Respiratory syncytial virus causes increased bronchial epithelial permeability.
Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.
RS3PE: Clinical and Research Development.
Somatic mutation profiling of liver and biliary cancer by targeted next generation sequencing.
Sustained high level of serum VEGF at convalescent stage contributes to the renal recovery after HTNV infection in patients with hemorrhagic fever with renal syndrome.
Sustained-released mixture of vascular endothelial growth factor 165 and fibrin glue strengthens healing of ileal anastomoses in a rabbit model with intraperitoneal infection.
Temporal cytokine profiling of Francisella tularensis-infected human peripheral blood mononuclear cells.
The antibacterial activity of LI-F type peptide against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and inhibition of infections in murine scalded epidermis.
The Impact of Infection in Pregnancy on Placental Vascular Development and Adverse Birth Outcomes.
The interleukin-6 and vascular endothelial growth factor in hematopoietic stem cell transplantation.
Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism.
Tuberculous lymphadenitis is associated with altered levels of circulating angiogenic factors.
Tumor necrosis factor alpha and interleukin-6 facilitate corneal lymphangiogenesis in response to herpes simplex virus 1 infection.
Upregulation of functionally active vascular endothelial growth factor by human cytomegalovirus.
Use of adenovirus vectors for functional gene analysis in the chicken chorioallantoic membrane.
Varicella zoster virus-infected cerebrovascular cells produce a proinflammatory environment.
Vascular endothelial growth factor (VEGF) and lovastatin suppress the inflammatory response to Plasmodium berghei infection and protect against experimental cerebral malaria.
Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway.
Vascular endothelial growth factor augments human herpesvirus-8 (HHV-8/KSHV) infection.
Vascular endothelial growth factor induction by rhinovirus infection.
Vascular endothelial growth factor is associated with blood brain barrier dysfunction in eosinophilic meningitis caused by Angiostrongylus cantonensis infection.
VEGF-A from Granuloma Macrophages Regulates Granulomatous Inflammation by a Non-angiogenic Pathway during Mycobacterial Infection.
VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability.
Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens.
[Induction of VEGF in human monocytes by DENV infection and the regulatory mechanism].
[Infection with L-form of Helicobacter pylori and expressions of MIF, MMP9 and VEGF in gastric carcinoma].
Infertility
An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects.
Analysis of fertility-related soluble mediators in human uterine fluid identifies VEGF as a key regulator of embryo implantation.
Defective Female Reproductive Function in 1,25(OH)2D Deficienct Mice Results from An Indirect Effect Mediated by Extracellular Calcium And/Or Phosphorus.
Distinct peritoneal fluid ghrelin and leptin in infertile women with endometriosis and their correlation with interleukin-6 and vascular endothelial growth factor.
Effects of prostaglandin E(2) and vascular endothelial growth factor on sperm might lead to endometriosis-associated infertility.
Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding.
Evaluation of Diabetes Effects on the Expression of Leukemia Inhibitory Factor and Vascular Endothelial Growth Factor A Genes and Proteins at the Time of Endometrial Receptivity after Superovulation in Rat Model.
Expression of vascular endothelial growth factor receptors during male germ cell differentiation in the mouse.
Follicular fluid vascular endothelial growth factor is associated with type of infertility and interferon alpha correlates with endometrial thickness in natural cycle in vitro fertilization.
Is serum-soluble vascular endothelial growth factor receptor-1 of importance in unexplained infertility?
Loss of vascular endothelial growth factor A (VEGFA) isoforms in the testes of male mice causes subfertility, reduces sperm numbers, and alters expression of genes that regulate undifferentiated spermatogonia.
Review of the role of the plasminogen activator system and vascular endothelial growth factor in subfertility.
Vascular endothelial growth factor and its receptors in male fertility.
[Effect of Qilin Pill Combined Metformin on Polycystic Ovaries Induced Infertility Patients].
Infertility, Male
Effects of silencing epididymal vascular endothelial growth factor (VEGF) expression on hyaluronidase (HYD) activity in arsenic poisoning rats through downregulating VEGF receptor 2 (VEGFR2).
[Experimental varicocele affects VEGF and Flt-1 protein expressions in the testis and epididymis of adolescent rats]
Inflammatory Bowel Diseases
Angiogenic cytokines in serum and cutaneous lesions of patients with polyarteritis nodosa.
Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis.
Elevated serum hepatocyte growth factor in children and young adults with inflammatory bowel disease.
Expression of p53, VEGF, Microvessel Density, and Cyclin-D1 in Noncancerous Tissue of Inflammatory Bowel Disease.
Imbalance of VEGF family serum levels and receptors in patients with inflammatory bowel disease.
Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
Increased expression of VEGF and CD146 in patients with inflammatory bowel disease.
Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease.
Increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease.
Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease.
Inflammation and Lymphatic Function.
Interleukin-4 inhibits the increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease.
Intestinal growth factors: Potential use in the treatment of inflammatory bowel disease and their role in mucosal healing.
Murine colitis treated with multitargeted tyrosine kinase inhibitors.
Pretreatment with anti-VEGF therapy may exacerbate inflammation in experimental acute colitis.
Role of anti-angiogenic factor endostatin in the pathogenesis of experimental ulcerative colitis.
Serum endocan levels are increased in patients with inflammatory bowel disease.
The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients.
The Relationship between Ocular Vascular Changes and the Levels of Malondialdehyde and Vascular Endothelial Growth Factor in Patients with Inflammatory Bowel Disease.
The Role of Vascular Endothelial Growth Factor (VEGF) in Inflammatory Bowel Disease.
Thrombospondin-1 and VEGF in inflammatory bowel disease.
Vascular endothelial growth factor (VEGF) in Crohn's disease: increased production by peripheral blood mononuclear cells and decreased VEGF165 labeling of peripheral CD14+ monocytes.
Vascular endothelial growth factor in inflammatory bowel disease.
Vascular endothelial growth factor in serum of patients with inflammatory bowel disease.
Vascular endothelial growth factor receptor-2 inhibition in experimental murine colitis.
Inflammatory Breast Neoplasms
Blood flow indices by Doppler ultrasonography vary with neoadjuvant chemotherapy but are not related to plasma VEGF levels in locally advanced breast cancer.
Expression of vascular endothelial growth factor (VEGF) family members in breast cancer.
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.
Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer.
Influenza, Human
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Development and validation of a mouse model of contemporary cannabis smoke exposure.
Insulin Resistance
A Narrative Review of Current Understanding of the Pathophysiology of Polycystic Ovary Syndrome: Focus on Plausible Relevance of Vitamin D.
A new effector of lipid metabolism: Complement factor properdin.
Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance.
Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia.
Association between plasma adipsin level and mild cognitive impairment in Chinese patients with type 2 diabetes: a cross-sectional study.
Association Between Serum Adipsin Levels and Insulin Resistance in Subjects With Various Degrees of Glucose Intolerance.
Body fat distribution and circulating adipsin are related to metabolic risks in adult patients with newly diagnosed growth hormone deficiency and improve after treatment.
Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF??B signaling pathway.
Caucasian and south Asian men show equivalent improvements in surrogate biomarkers of cardiovascular and metabolic health following 6-weeks of supervised resistance training.
Cell biology of fat storage.
Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease.
Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome.
Comment on: Elias et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes 2012;61:1801-1813.
CORRELATION OF INCREASED SERUM ADIPSIN WITH INCREASED CARDIOVASCULAR RISKS IN ADULT PATIENTS WITH GROWTH HORMONE DEFICIENCY.
Diabetic nephropathy: serum miR-9 confers a poor prognosis in and is associated with level changes of vascular endothelial growth factor and pigment epithelium-derived factor.
Differences in Metabolic Factors Between Antipsychotic-Induced Weight Gain and Non-pharmacological Obesity in Youths.
Elevated Fetal Adipsin/Acylation-Stimulating Protein (ASP) in Obese Pregnancy: Novel Placental Secretion via Hofbauer Cells.
Endothelial dysfunction in diabetes mellitus: role in cardiovascular disease.
Impact of Gastric Sleeve Surgery on Plasma Retinol Binding Protein 4 and Adipsin Levels in Healthy Male Population.
Improvement of insulin sensitivity in response to exercise training in type 2 diabetes mellitus is associated with vascular endothelial growth factor A expression.
Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome.
Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance.
Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy.
Interactions of smoking with rs833061 polymorphism on the risk of non-alcoholic fat liver disease in Hubei Han population: a preliminary case-control study.
Leptin and other secretory products of adipocytes modulate multiple physiological functions.
Metabolic and Neurocognitive Changes Following Lifestyle Modification: Examination of Biomarkers from the ENLIGHTEN Randomized Clinical Trial.
Muscle-specific vascular endothelial growth factor deletion induces muscle capillary rarefaction creating muscle insulin resistance.
Obesity and cancer.
Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples.
Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction.
Prolonged Fasting and the Effects on Biomarkers of Inflammation and on Adipokines in Healthy Lean Men.
Reduced oxygenation in human obese adipose tissue is associated with impaired insulin suppression of lipolysis.
Regulation of vascular endothelial growth factor expression and vascularization in the myocardium by insulin receptor and PI3K/Akt pathways in insulin resistance and ischemia.
Relationship between serum adipsin and the first phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance.
Response to Comment on: Elias et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes 2012;61:1801-1813.
Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease.
Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment.
Serum Vascular Endothelial Growth Factor in Egyptian Obese Women with Insulin Resistance.
Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects.
Study of the Active Components and Molecular Mechanism of Tripterygium wilfordii in the Treatment of Diabetic Nephropathy.
The role of production of adipsin and leptin in the development of insulin resistance in patients with abdominal obesity.
Thrap3 docks on phosphoserine 273 of PPAR? and controls diabetic gene programming.
Treating diabetes by blocking a vascular growth factor.
Vascular endothelial growth factor +405 G/C,-460 T/C and -2578 A/C polymorphisms are not associated with insulin resistance in polycystic ovary syndrome.
Visceral White Adipose Tissue after Chronic Intermittent and Sustained Hypoxia in Mice.
Weight Reducing and Metabolic Effects of Topiramate in Patients with Migraine - an Observational Study.
[Effect of Qilin Pill Combined Metformin on Polycystic Ovaries Induced Infertility Patients].
[Obesity and cancer].
Insulinoma
Bone marrow-derived mesenchymal stem cells improve rat islet graft revascularization by upregulating ISL1.
Intermittent Claudication
Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
New treatment options in intermittent claudication: the US experience.
Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.
Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
Intervertebral Disc Degeneration
Annular puncture with tumor necrosis factor-alpha injection enhances painful behavior with disc degeneration in vivo.
Expression of vascular endothelial growth factor receptors coincide with blood vessel in-growth and reactive bone remodelling in experimental intervertebral disc degeneration.
Identification of genes associated with disc degeneration using bioinformatics.
Vascular endothelial growth factor gene variations as a risk predictor in disc degeneration.
Intervertebral Disc Displacement
Platelet-derived growth factor and vascular endothelial growth factor expression in disc herniation tissue: and immunohistochemical study.
Vascular endothelial growth factor (VEGF)-induced angiogenesis in herniated disc resorption.
Intestinal Neoplasms
Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in ApcMin/+ mice.
Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.
Intestinal Polyposis
Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice.
Intestinal Volvulus
Marked (24-fold) elevation of peritoneal cavity drainage fluid vascular endothelial growth factor after successful "patch, drain, and wait" approach for extensive midgut necrosis in a newborn.
Intracranial Aneurysm
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Expression of vascular endothelial growth factor receptor-1/-2 and nitric oxide in unruptured intracranial aneurysms.
Vascular endothelial growth factor gene polymorphisms and intracranial aneurysms.
Vascular endothelial growth factor immobilized on platinum microcoils for the treatment of intracranial aneurysms: experimental rat model study.
Intracranial Arteriosclerosis
Angiogenesis in symptomatic intracranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence.
Intracranial Arteriovenous Malformations
Expression of vascular endothelial growth factor in pediatric and adult cerebral arteriovenous malformations: an immunocytochemical study.
Hypoxia inducible factor-1alpha and expression of vascular endothelial growth factor and its receptors in cerebral arteriovenous malformations.
Hypoxia-inducible factor and vascular endothelial growth factor are expressed more frequently in embolized than in nonembolized cerebral arteriovenous malformations.
Plasma levels of vascular endothelial growth factor after treatment for cerebral arteriovenous malformations.
Role of vascular endothelial growth factor in the pathophysiology of intracranial arteriovenous malformations.
Vascular Endothelial Growth Factor Plasma Levels Are Significantly Elevated in Patients with Cerebral Arteriovenous Malformations.
[Immunohistochemical study of vascular endothelial growth factor, relative receptors and ligands in vascular endothelial cells of cerebral arteriovenous malformation]
Intracranial Hemorrhage, Hypertensive
Elevated serum IL-11, TNF ?, and VEGF expressions contribute to the pathophysiology of hypertensive intracerebral hemorrhage (HICH).
Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
Intracranial Hemorrhages
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Expression and methylation status of vascular endothelial growth factor and thrombospondin-1 genes in congenital factor XIII-deficient patients with intracranial hemorrhage.
Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab.
Overexpression of vascular endothelial growth factor in the germinal matrix induces neurovascular proteases and intraventricular hemorrhage.
Intracranial Hypertension
POEMS syndrome with venous sinus thrombosis and visual failure: a case report.
Invasive Pulmonary Aspergillosis
Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis.
Iron Deficiencies
Does iron have a role in breast cancer?
Effects of cellular iron deficiency on the formation of vascular endothelial growth factor and angiogenesis. Iron deficiency and angiogenesis.
Irritable Bowel Syndrome
Vascular endothelial growth factor, endostatin levels and clinical features among patients with ulcerative colitis and irritable bowel syndrome and among healthy controls: a cross-sectional analytical study.
Ischemic Attack, Transient
Comparison of Trophic Factors Changes in the Hippocampal CA1 Region Between the Young and Adult Gerbil Induced by Transient Cerebral Ischemia.
Intraventricular vascular endothelial growth factor antibody increases infarct volume following transient cerebral ischemia.
Role of vascular endothelial growth factor in neuronal DNA damage and repair in rat brain following a transient cerebral ischemia.
Ischemic Stroke
A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab.
A study on the association of rs7950273 polymorphism in the PDGFD with ischaemic stroke in the Chinese Han population.
Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke.
Adipocytokines and the risk of ischemic stroke: the PRIME Study.
Association of cerebral microbleeds in acute ischemic stroke with high serum levels of vascular endothelial growth factor.
Changes in serum vascular endothelial growth factor and endostatin concentrations associated with circulating endothelial progenitor cells after acute ischemic stroke.
Circulating levels of vascular endothelial growth factor and post-stroke long-term functional outcome.
CLEC14A deficiency exacerbates neuronal loss by increasing blood-brain barrier permeability and inflammation.
Contraindications of VEGF-based therapeutic angiogenesis: effects on macrophage density and histology of normal and ischemic brains.
Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke.
Early Post-stroke Activation of Vascular Endothelial Growth Factor Receptor 2 Hinders the Receptor 1-Dependent Neuroprotection Afforded by the Endogenous Ligand.
Early Transplantation of Human Cranial Bone-derived Mesenchymal Stem Cells Enhances Functional Recovery in Ischemic Stroke Model Rats.
Early VEGF inhibition attenuates blood-brain barrier disruption in ischemic rat brains by regulating the expression of MMPs.
Effects of vascular endothelial growth factor in ischemic stroke.
Endogenous regeneration: Engineering growth factors for stroke.
Endothelium-Targeted Deletion of microRNA-15a/16-1 Promotes Post-Stroke Angiogenesis and Improves Long-Term Neurological Recovery.
Growth factors in ischemic stroke.
Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases.
Hypoxia Response Element-Regulated MMP-9 Promotes Neurological Recovery via Glial Scar Degradation and Angiogenesis in Delayed Stroke.
Increased vascular endothelial growth factor D is associated with atrial fibrillation and ischaemic stroke.
Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab.
Lentiviral-mediated silencing of mast cell-expressed membrane protein 1 promotes angiogenesis of rats with cerebral ischemic stroke.
MicroRNA-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain.
MiR-103 regulates the angiogenesis of ischemic stroke rats by targeting vascular endothelial growth factor (VEGF).
N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-? Expressions.
Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke.
Orosomucoid1: Involved in vascular endothelial growth factor-induced blood-brain barrier leakage after ischemic stroke in mouse.
Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke.
Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice.
Reconstituting neurovascular unit with primary neural stem cells and brain microvascular endothelial cells in three-dimensional matrix.
Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke.
Serum vascular endothelial growth factor (VEGF) levels in ischemic stroke patients: a systematic review and meta-analysis of case-control studies.
Serum vascular endothelial growth factor as a biomarker for prognosis of minor ischemic stroke.
Serum VEGF levels in acute ischaemic strokes are correlated with long-term prognosis.
Snakehead fish extract as an enhancer of vascular endothelial growth factor and nitric oxide levels in cerebral angiogenesis: an insight of stroke therapy.
The influence of Tongqiao Huashuan Decoction on the expression of VEGF and EphB2 in MCAO model rats.
The role of vascular endothelial growth factor in ischemic stroke.
Value of measuring serum vascular endothelial growth factor levels in diagnosing acute ischemic stroke.
Vascular endothelial growth factor aggravates cerebral ischemia and reperfusion-induced blood-brain-barrier disruption through regulating LOC102640519/HOXC13/ZO-1 signaling.
Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke.
Vascular endothelial growth factor and poor prognosis after ischaemic stroke.
Vascular Endothelial Growth Factor as Predictive Biomarker for Stroke Severity and Outcome; An Evaluation of a New Clinical Module in Acute Ischemic Stroke.
Vascular Endothelial Growth Factor Isoform-B Stimulates Neurovascular Repair After Ischemic Stroke by Promoting the Function of Pericytes via Vascular Endothelial Growth Factor Receptor-1.
Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after experimental stroke.
[Effect of electroacupuncture on neurovascular unit and Wnt/?-catenin signaling in rats with cerebral ischemia].
[Vascular endothelial growth factor expression in patients with acute ischemic stroke].
Joint Diseases
Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis.
Fat-Produced Adipsin Regulates Inflammatory Arthritis.
Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats.
Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice.
Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints.
TLR-2-mediated induction of vascular endothelial growth factor (VEGF) in cartilage in septic joint disease.
Kashin-Beck Disease
[Serum hyaluronic acid, tumor necrosis factor -alpha, vascular endothelial growth factor, NO, and Se levels in adult patients with Kashin-Beck disease]
Keloid
Altered angiogenic balance in keloids: a key to therapeutic intervention.
Altered circulating endothelial progenitor cells in patients with keloid.
Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation.
Elevated vascular endothelial growth factor in keloids: relevance to tissue fibrosis.
Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion.
Hepatoma-derived growth factor and its role in keloid pathogenesis.
Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts.
Inhibition of vascular endothelial growth factor expression in keloid fibroblasts by vector-mediated vascular endothelial growth factor shRNA: a therapeutic potential strategy for keloid.
Innovative therapies in the treatment of keloids and hypertrophic scars.
Integrated Interaction Network of MicroRNA Target Genes in Keloid Scarring.
Keloid patients have higher peripheral blood endothelial progenitor cell counts and CD34+ cells with normal vasculogenic and angiogenic function that overexpress vascular endothelial growth factor and interleukin-8.
Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor.
Long non-coding RNA H19 promotes the proliferation of fibroblasts in keloid scarring.
Role of vascular endothelial growth factor in keloids: a clinicopathologic study.
The use of corticosteroids to treat keloids: a review.
Upregulation of microRNA-205 suppresses vascular endothelial growth factor expression-mediated PI3K/Akt signaling transduction in human keloid fibroblasts.
Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity.
Verapamil inhibits interleukin-6 and vascular endothelial growth factor production in primary cultures of keloid fibroblasts.
Keratitis
Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.
Corneal neovascularization: updates on pathophysiology, investigations & management.
Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis.
Pathogenesis of herpes simplex keratitis: The host cell response and ocular surface sequelae to infection and inflammation.
Peptidoglycan and muramyl dipeptide from Staphylococcus aureus induce the expression of VEGF-A in human limbal fibroblasts with the participation of TLR2-NF?B and NOD2-EGFR.
Role of miR-132 in angiogenesis after ocular infection with herpes simplex virus.
Serum vascular endothelial growth factor concentration in dogs diagnosed with chronic superficial keratitis.
Keratoacanthoma
Carcinoma-like vascular density in atypic keratoacanthoma suggests malignant progression.
Keratosis, Seborrheic
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
Kernicterus
Cerebellar Axon/Myelin Loss, Angiogenic Sprouting, and Neuronal Increase of Vascular Endothelial Growth Factor in a Preterm Infant with Kernicterus.
Kidney Diseases
Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
PD-1 immunobiology in glomerulonephritis and renal cell carcinoma.
Response of VEGF to activation of viral receptors and TNF? in human mesangial cells.
Role of Vascular Endothelial Growth Factor in Kidney Disease.
Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis.
Urinary biomarkers involved in type 2 diabetes: a review.
VEGF regulates TRPC6 channels in podocytes.
Kidney Failure, Chronic
2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice.
A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease.
Adsorption of complement factor D by polyacrylonitrile dialysis membranes.
Assessment of Levels of Vascular Endothelial Growth Factor in Patients With ESRD and Its Possible Role in Cardiovascular Morbidity and Mortality.
Complement activation by the alternative pathway is modified in renal failure: the role of factor D.
Complement components as uremic toxins and their potential role as mediators of microinflammation.
Decreased activity of complement-mediated immune complex clearance in hemodialysis patients.
Deterioration of immune complex solubilization activity of serum by increased concentration of factor D.
Effect of erythropoietin stimulating agents on vascular endothelial growth factor levels in patients with end stage renal disease.
Effects of excess factor D on early- and late-phase activation of the complement cascade.
Evaluation of the proteolytic activity of factor D accumulated as an active serine protease in patients with chronic renal failure.
Expression of vascular endothelial growth factor and transforming growth factor alpha in rat testis during chronic renal failure.
Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males.
Molecular and functional identification and purification of complement component factor D from urine of patients with chronic renal failure.
Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure.
Sorbents in acute renal failure and end-stage renal disease: middle molecule and cytokine removal.
Sorbents in the treatment of renal failure.
Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease. Associations with laboratory findings, comorbidities, and medications.
Vascular endothelial growth factor gene polymorphisms in North Indian patients with end stage renal disease.
Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients.
[Factor D of complement: Uremic toxin?]
Kidney Neoplasms
A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).
Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Advances on immunotherapy in genitourinary and renal cell carcinoma.
Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development.
Angiogenesis and lymphangiogenesis: highlights of the past year.
Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis.
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.
Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields.
Chemotherapies and immunotherapies for metastatic kidney cancer.
Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer.
Compounds in clinical Phase III and beyond.
Cutaneous thrombogenic vasculopathy associated with bevacizumab therapy.
Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.
Design of clinical trials of radiation combined with antiangiogenic therapy.
Downregulation of microRNA-206 suppresses clear cell renal carcinoma proliferation and invasion by targeting vascular endothelial growth factor A.
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.
Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy.
Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice.
Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib.
Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma.
Identification of binding sites for C-terminal pro-gastrin-releasing peptide (GRP)-derived peptides in renal cell carcinoma: a potential target for future therapy.
Inhibitory effect of resveratrol on the expression of the VEGF gene and proliferation in renal cancer cells.
Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies.
Management of vascular endothelial growth factor and multikinase inhibitor side effects.
Mechanisms of resistance to anti-angiogenesis therapies.
Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine.
Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib.
Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer.
Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.
Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic.
Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Systemic treatment options for untreated patients with metastatic clear cell renal cancer.
Targeted therapy of kidney cancer: keeping the art around the algorithms.
The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer.
Toxicities of targeted agents in advanced renal cell carcinoma.
Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein.
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy.
Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer.
Vascular endothelial growth factor and its type 2 receptor in tumors and serum of patients with renal cancer.
Vascular endothelial growth factor pathway- targeted therapy as initial systemic treatment of patients with renal cancer.
Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer.
Vascular endothelial growth factor platelet counts and renal cancer.
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer.
Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer.
Klatskin Tumor
Inhibiting the proliferation and metastasis of hilar cholangiocarcinoma cells by blocking the expression of vascular endothelial growth factor with small interfering RNA.
Krukenberg Tumor
Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor.
Laryngeal Neoplasms
Increased vascular endothelial growth factor expression predicts a worse prognosis for laryngeal cancer patients: a meta-analysis.
Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy.
Serum vascular endothelial growth factor in patients with pharyngeal and laryngeal squamous cell carcinoma treated with radiotherapy.
The expression of vascular endothelial growth factor (VEGF) and VEGF-C in early laryngeal cancer: relationship with radioresistance.
Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation.
[Role of P53, nm23 proteins and vascular endothelial growth factor in angiogenesis and metastasis of laryngeal cancer]
[The influence of vascular endothelial growth factor and its receptor on the growth of laryngeal cancer cell]
Leg Ulcer
Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds.
Serum concentration of matrix metalloproteinases and angiogenic factors in patients with venous leg ulcers.
Legg-Calve-Perthes Disease
Effects of circulating endothelial progenitor cells, serum vascular endothelial growth factor and hypogammaglobulinemia in Perthes disease.
Is VEGF under-expressed in Indian children with Perthes disease?
Leiomyoma
Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas.
Combined differential gene expression profile and pathway enrichment analyses to elucidate the molecular mechanisms of uterine leiomyoma after gonadotropin-releasing hormone treatment.
Differential expression of visfatin, leptin, stromal cell derived factor-1?, endothelial nitric oxide synthase, and vascular endothelial growth factor in human leiomyomas.
Effect of anesthetic technique on serum vascular endothelial growth factor C and prostaglandin E2 levels in women undergoing surgery for uterine leiomyomas.
Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas.
Effects of Phthalate Esters on Human Myometrial and Fibroid Cells: Cell Culture and NOD-SCID Mouse Data.
Elevated level of plasma vascular endothelial growth factor after gonadotropin-releasing hormone agonist treatment for leiomyomata.
Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome.
Expression of vascular endothelial factor-A, gelatinases (MMP-2, MMP-9) and TIMP-1 in uterine leiomyomas.
Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas.
Expression of vascular endothelial growth factor mRNA in human leiomyomas.
Expression of von Willebrand's factor, CD34, CD31, and vascular endothelial growth factor in uterine leiomyomas.
Familial prevalence of uterine fibroids is associated with distinct clinical and molecular features.
Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.
IGF-1 and VEGF can be used as prognostic indicators for patients with uterine fibroids treated with uterine artery embolization.
Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium.
Impact and clinical significance of Embosphere microsphere artery embolization therapy in serum VEGF expression level of women patients with uterine fibroids.
Increased hyaluronan and CD44 expressions in intravenous leiomyomatosis.
Leiomyoma and vascular endothelial growth factor gene polymorphisms: a systematic review.
Pigment epithelium derived factor as a novel multi-target treatment for uterine fibroids.
Prediction of the shrinking rate of uterine leiomyoma nodules using needle biopsy specimens.
Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells.
Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas.
The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1? signaling pathway in ELT-3 cells.
Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells.
Leiomyosarcoma
Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma.
Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma.
Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas.
Relationship of angiogenic and apoptotic activities in soft-tissue sarcoma.
Vascularity of Nongynecological Leiomyosarcoma Depends on Colony-Stimulating Factor 1 but Not on Vascular Endothelial Growth Factor.
Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Leishmaniasis
Microarray analysis of long non-coding RNA expression profiles in monocytic myeloid-derived suppressor cells in Echinococcus granulosus-infected mice.
Leishmaniasis, Cutaneous
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Leishmaniasis, Diffuse Cutaneous
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Leishmaniasis, Mucocutaneous
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Leishmaniasis, Visceral
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Lens Subluxation
Lens subluxation after plasmin and SF6 injections in rabbit eyes.
Leprosy
Cyclooxygenase 2 and vascular endothelial growth factor-potential targets to manage lepra reactions: A case-control study.
Overexpression of vascular endothelial growth factor and its endothelial cell receptor KDR in type 1 leprosy reaction.
Role of the Vitamin D in Leprosy.
Leukemia
A clinical and basic study of optimal endometrial preparation protocols for patients with infertility undergoing frozen-thawed embryo transfer.
A multiparametric study of the action of mifepristone used in emergency contraception using the Rhesus monkey as a primate model.
A role for endothelial cells in promoting the maturation of astrocytes through the apelin/APJ system in mice.
Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF.
Activation of the vascular niche supports leukemic progression and resistance to chemotherapy.
Adipocyte-derived basement membrane extract with biological activity: applications in hepatocyte functional augmentation in vitro.
Altered gene expression in human cleidocranial dysplasia dental pulp cells.
An In Vivo Characterization of Trophic Factor Production Following Neural Precursor Cell or Bone Marrow Stromal Cell Transplantation for Spinal Cord Injury.
Androgens Induce the Expression of Vascular Endothelial Growth Factor in Human Fetal Prostatic Fibroblasts* *This work was supported by grants-in-aid from the T. J. Martell Foundation for Leukemia, Cancer, and Aids Research; and the Hans E. Schapira, M.D., Foundation for Urologic Research.
Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid.
Angiogenesis in hematologic malignancies.
Angiogenesis in lymphoproliferative disorders.
Angiogenic and lymphangiogenic molecules in hematological malignancies.
Anti-angiogenic effects and mechanisms of polysaccharides from Antrodia cinnamomea with different molecular weights.
Anti-Inflammatory Effects of Diospyrin on Lipopolysaccharide-Induced Inflammation Using RAW 264.7 Mouse Macrophages.
Anti-inflammatory effects of oroxylin A on RAW 264.7 mouse macrophages induced with polyinosinic-polycytidylic acid.
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.
Assessment of biomarkers using multiplex assays in aqueous humor of patients with diabetic retinopathy.
Assessment of endometrial receptivity during implantation window in women with unexplained infertility.
Autocrine pathway of angiopoietins-Tie2 system in AML cells: association with phosphatidyl-inositol 3 kinase.
Autocrine VEGF loops, signaling pathways, and acute leukemia regulation.
Automated Extraction of DNA and RNA from a Single Formalin-Fixed Paraffin-Embedded Tissue Section for Analysis of Both Single-Nucleotide Polymorphisms and mRNA Expression.
Biological approaches to bone regeneration by gene therapy.
Blastocyst-endometrium interaction: intertwining a cytokine network.
Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.
Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor.
Characterization of an immortalized oviduct cell line from the cynomolgus monkey (Macaca fascicularis).
Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia.
Contribution of bone microenvironment to leukemogenesis and leukemia progression.
Detailed characterization of the human aorta-gonad-mesonephros region reveals morphological polarity resembling a hematopoietic stromal layer.
Diacylglycerol kinase-alpha mediates hepatocyte growth factor-induced epithelial cell scatter by regulating Rac activation and membrane ruffling.
Dihydroartemisinin attenuates osteoarthritis by inhibiting abnormal bone remodeling and angiogenesis in subchondral bone.
Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?
Effect of levonorgestrel and mifepristone on endometrial receptivity markers in a three-dimensional human endometrial cell culture model.
Effect of vaginally administered fumagillin on immunohistochemical distribution of leukemia inhibitory factor, interleukin 6, transforming growth factor beta and vascular endothelial growth factor in implantation stage endometrium of the rhesus monkey.
Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro.
Esophageal Adenocarcinoma: Treatment Modalities in the Era of Targeted Therapy.
Ets1-Related Protein Is a Key Regulator of Vasculogenesis in Zebrafish.
Evaluation of Diabetes Effects on the Expression of Leukemia Inhibitory Factor and Vascular Endothelial Growth Factor A Genes and Proteins at the Time of Endometrial Receptivity after Superovulation in Rat Model.
Evaluation of vascular endothelial growth factor A and leukemia inhibitory factor expressions at the time of implantation in diabetic rats following treatment with Metformin and Pioglitazone.
Expression and cellular localization of vascular endothelial growth factor A and its receptors in acute and chronic leukemias: an immunohistochemical study.
Expression and significance of vascular endothelial growth factor A and C in leukemia central nervous system metastasis.
Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia.
Expression of microRNAs and isomiRs in the porcine endometrium: implications for gene regulation at the maternal-conceptus interface.
Expression of promyelocytic leukemia protein and vascular endothelial growth factor in aqueous humor and vitreous fluid in patients with proliferative diabetic retinopathy.
FLORID NEOVASCULARIZATION OF THE RETINA IN A DIABETIC PATIENT UNDERGOING INDUCTION AND CONSOLIDATION THERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA.
Functional regulation of adipose-derived stem cells by PDGF-D.
Gene expression of growth signaling pathways is up-regulated in CD133-positive medulloblastoma cells.
Genetic inhibition of vascular endothelial growth factor receptor?1 significantly inhibits the migration and proliferation of leukemia cells and increases their sensitivity to chemotherapy.
Ginsenoside Rg3 inhibits HIF-1? and VEGF expression in patient with acute leukemia via inhibiting the activation of PI3K/Akt and ERK1/2 pathways.
Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model.
Identification of Novel Biomarker for Early Detection of Diabetic Nephropathy.
Immunostimulatory effect of laminarin on RAW 264.7 mouse macrophages.
In vitro hematopoietic differentiation of human embryonic stem cells induced by co-culture with human bone marrow stromal cells and low dose cytokines.
Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD).
Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence.
Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells
Instructive Role of the Microenvironment in Preventing Renal Fibrosis.
Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways.
Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials.
Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells.
Leukemia inhibitory factor-transfected embryonic fibroblasts and vascular endothelial growth factor successfully improve the skin substitute wound healing by increasing angiogenesis and matrix production.
LIF maintains progenitor phenotype of endothelial progenitor cells via Krüppel-like factor 4.
LRH-A3 and HCG increase pregnancy rate during timed artificial insemination in dairy cows.
Mastic Oil from Pistacia lentiscus var. chia Inhibits Growth and Survival of Human K562 Leukemia Cells and Attenuates Angiogenesis.
Mechanisms of inhibiting human leukemia cell lines by serum of rats treated with compound banmao capsule.
Mesenchymal Stromal Cells Promote Tumor Growth Through the Enhancement of Neovascularization.
Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model.
miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.
Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer.
Neurodegeneration induced by PVC-211 murine leukemia virus is associated with increased levels of vascular endothelial growth factor and macrophage inflammatory protein 1 alpha and is inhibited by blocking activation of microglia.
Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Perturbation of autocrine/paracrine loops of burst-forming units of erythroid-derived cells in rHuEPO-hyporesponsive hemodialysis patients.
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis.
Placenta growth factor stimulates the growth of Philadelphia chromosome positive acute lymphoblastic leukemia cells by both autocrine and paracrine pathways.
Plasmonic droplet screen for single-cell secretion analysis.
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
Rat ovarian prostaglandin endoperoxide synthase-1 and -2: periovulatory expression of granulosa cell-based interleukin-1-dependent enzymes.
Resveratrol inhibits the secretion of vascular endothelial growth factor and subsequent proliferation in human leukemia U937 cells.
Role of fibroblasts and fibroblast-derived growth factors in periprosthetic angiogenesis.
Role of intrauterine administration of transfected peripheral blood mononuclear cells by GM-CSF on embryo implantation and pregnancy rate in mice.
Rubi Fructus Water Extract Alleviates LPS-Stimulated Macrophage Activation via an ER Stress-Induced Calcium/CHOP Signaling Pathway.
Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: Therapeutic implications.
Serum levels of vascular endothelial growth factor in chronic leukemias. A comparative study with emphasis on myeloproliferative disorders.
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Sildenafil citrate-loaded targeted nanostructured lipid carrier enhances receptivity potential of endometrial cells via LIF and VEGF upregulation.
Simultaneous detections of 27 cytokines during cerebral wound healing by multiplexed bead-based immunoassay for wound age estimation.
Specific association of increased vascular endothelial growth factor expression and its receptors with macrophage differentiation of HL-60 leukemia cells.
Stem cells derived from human first-trimester umbilical cord have the potential to differentiate into oocyte-like cells in vitro.
Target-oriented anti-implantation approaches for pregnancy interception: experiences in the rhesus monkey model.
Targeted inhibition of VEGF-modulated survival and arsenic sensitivity in acute myeloid leukemia (AML).
Targeting the vascular endothelial growth factor (VEGF) in hematological malignancies.
Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines.
The expression and significance of leukemia inhibitory factor, interleukin-6 and vascular endothelial growth factor in Chinese patients with endometriosis.
The Impact of Morphine on the Characteristics and Function Properties of Human Mesenchymal Stem Cells.
The important role of ADAM8 in the progression of hepatocellular carcinoma induced by diethylnitrosamine in mice.
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.
The Relationship between Vascular Endothelial Growth Factor 1154G/A Polymorphism and Recurrent Implantation Failure.
The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis.
The therapeutic effects and underlying mechanisms of the intrauterine perfusion of granulocyte colony-stimulating factor on a thin-endometrium rat model.
The use of serum endothelial adhesion molecules in pediatric patients with leukemia with febrile neutropenia to predict bacteremia.
Therapeutic use of growth factors in the musculoskeletal system in sports-related injuries.
Translational control of gene expression: role of IRESs and consequences for cell transformation and angiogenesis.
Up-regulation of VEGF and its receptor in refractory leukemia cells.
Vascular endothelial growth factor acted as autocrine growth factor in an acute promyelocytic leukemia case.
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
Vascular endothelial growth factor and cellular chemotaxis: a possible autocrine pathway in adult T-cell leukemia cell invasion.
Vascular endothelial growth factor at high plasma levels is associated with extranodal involvement in adult T cell leukemia patients.
Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction.
Vascular endothelial growth factor levels in childhood acute lymphoblastic and myeloblastic leukemia.
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Vector-based RNAi approach to isoform-specific downregulation of vascular endothelial growth factor (VEGF)165 expression in human leukemia cells.
VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition.
VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues.
Vitamin E and rutin synergistically inhibit expression of vascular endothelial growth factor through down-regulation of binding activity of activator protein-1 in human promyelocytic leukemia (HL-60) cells.
ZK7, a novel zinc finger gene, is induced by vascular endothelial growth factor and inhibits apoptotic death in hematopoietic cells.
[Angiogenesis and hematologic malignancy]
[Clinical significance and expression of vascular endothelial growth factor in serum of patients with acute leukemia]
[Dynamic observation of vascular endothelial growth factor (VEGF)/VEGF-receptors expression in acute leukemia]
[Effect of vascular endothelial growth factor on apoptosis and expression of Bcl-2 and Mcl-1 in acute leukemia cells]
[Effects of arsenic trioxide on expressions of vascular endothelial growth factor and P-glycoprotein in multidrug resistant leukemia cell line K562/A02]
[Effects of COX-2 inhibitor celecoxib on expressions of VEGF, b-FGF and TGF-? mRNA in acute leukemia cells].
[Effects of histone deacetylase inhibitor on the expression of angiogenesis related factors in Kasumi-1 leukemic cell line.]
[Effects of human fibroblastoid stromal cell line on proliferation of HL-60 cells and expression of VEGF]
[Expression and clinical significance of serum VEGF and bFGF in children with acute leukemia].
[Expression of angiogenin-2 and VEGF in acute leukemia and its significance]
[Expression of bFGF and VEGF in acute leukemia and its effects on HL-60 cell growth]
[Expression of osteopontin and VEGF in acute leukemia and their relationship with angiogenesis].
[High Expression of Bone Marrow VEGF in Patients with Acute Leukemia and Its Correlation with Prognosis].
[Inhibition effect of short hairpin RNA on VEGF receptor flt-1 gene expression in leukemia cell line k562]
[Inhibition of vascular endothelial growth factor gene expression and proliferation of leukemia cells by RNA interference]
[Intracellular mechanisms involved in the angiogenic process in hematological malignancies]
[Mechanisms of enhanced antileukemia activity of conditionally replicating adenovirus (CRAd) ZD55 by interleukin-24]
[Quantitative analysis of gene expression for vascular endothelial growth factor and its application]
[Relationships of Serum Selenium, VEGF and sFas Levels in Leukemia Patients.]
[Research progress of acupuncture and moxibustion for endometrial receptivity in recent 10 years].
[Study on the role of angiogenesis and related factors in leukemias]
[The clinical significance of angiogenesis in the bone marrow of acute leukemia patients]
[The experimental study of transfected sFlt-Ig gene on K562 leukemia cell growth in nude mice]
[The relationship between expression of the vascular endothelial growth factor and acute leukemia subtype]
[Tryptase relation to VEGF in acute leukemia]
[Vascular endothelial growth factor is up-regulated by leukemia inhibitory factor and interleukin-6 in human endometriotic stromal cells].
[vegf shRNA Enhances the Sensitivity of Multidrug-resistant Leukemia Cells to Anticancer Agent.]
Leukemia, B-Cell
Pleomorphic liposarcoma: Clinical observations and molecular variables.
The important role of ADAM8 in the progression of hepatocellular carcinoma induced by diethylnitrosamine in mice.
Leukemia, Lymphocytic, Chronic, B-Cell
A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.
Bone Marrow Stromal Cell-Derived Vascular Endothelial Growth Factor (VEGF) Rather Than Chronic Lymphocytic Leukemia (CLL) Cell-Derived VEGF Is Essential for the Apoptotic Resistance of Cultured CLL Cells.
Cell motility in chronic lymphocytic leukemia: defective Rap1 and alphaLbeta2 activation by chemokine.
Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia.
Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia.
Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia.
Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.
In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells.
Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression.
Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia.
Relationship between cell surface expression of CD38 and of vascular endothelial growth factor in B-cell chronic lymphocytic leukemia.
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).
Survival of chronic lymphocytic leukemia cells: CD40L and the vascular endothelial growth factor (VEGF) connection.
The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.
VEGF and bFGF gene polymorphisms in Polish patients with B-CLL.
VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.
VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.
VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration.
[Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment]
Leukemia, Lymphoid
All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells.
Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia.
P388 Leukemia in CDF1 Mice as the Test System for Studies of Tumor-Associated Neoangiogenesis and Hypercoagulation.
Vascular endothelial growth factor isoforms 121 and 165 are expressed on B-chronic lymphocytic leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells.
Association of Vascular Endothelial Growth Factor A (VEGFA) and its Receptor (VEGFR2) Gene Polymorphisms with Risk of Chronic Myeloid Leukemia and Influence on Clinical Outcome.
Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity.
Chronic myelogenous leukemia cells convert to myofibroblasts in vitro: Effect of vascular endothelial growth factor on development of the microenvironment.
Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis.
Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.
Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells.
Effect of antisense VEGF cDNA transfection on the growth of chronic myeloid leukemia K562 cells in vitro and in nude mice.
Elevated plasma levels of vascular endothelial growth factor is associated with marked splenomegaly in chronic myeloid leukemia.
Expression of VEGF and its effect on cell proliferation in patients with chronic myeloid leukemia.
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia.
Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease.
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia.
Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases.
VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
VEGFA's distal enhancer regulates its alternative splicing in CML.
[Down-regulation of expression of vascular endothelial growth factor induced by arsenic trioxide in bone marrow cells of chronic myeloid leukemia]
[Expression of Vascular Endothelial Growth Factor in the Bone Marrow Cells from Adult Chronic Myelogenous Leukemia]
[Screening of anti-tumor parts from the seeds of Livistona chinensis and its anti-angiogenesis effect]
Leukemia, Myeloid
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.
Nanocomposite-siRNA approach for down-regulation of VEGF and its receptor in myeloid leukemia cells.
[Vascular endothelial growth factor antisense oligodeoxynucleotide enhance drug-sensitivity of myeloid leukemia cells to homoharringtonin.]
Leukemia, Myeloid, Acute
Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome.
Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies.
beta-Tryptase up-regulates vascular endothelial growth factor expression via proteinase-activated receptor-2 and mitogen-activated protein kinase pathways in bone marrow stromal cells in acute myeloid leukemia.
Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia.
CD147 and VEGF co-expression predicts prognosis in patients with acute myeloid leukemia.
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.
Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.
Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels.
Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels.
Down-regulation of cellular vascular endothelial growth factor levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemia.
Effect of thalidomide and arsenic trioxide on the release of tumor necrosis factor-? and vascular endothelial growth factor from the KG-1a human acute myelogenous leukemia cell line.
Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts.
Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia.
Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: incidence and feasibility of immunohistochemical staining.
Expression of vaascular endothelial growth factor in bone marrow cells of patients with acute myeloid leukemia.
Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors.
Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model.
Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category.
In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo.
Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia.
Increased circulating vascular endothelial growth factor in acute myeloid leukemia patients: a systematic review and meta-analysis.
Lactate dehydrogenase, not vascular endothelial growth factor or basic fibroblast growth factor, positively correlates to bone marrow vascularity in acute myeloid leukemia.
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Prognostic impact of ?-like ligand 4 and Notch1 in acute myeloid leukemia.
Prognostic significance of vascular endothelial growth factor expression in adult patients with acute myeloid leukemia: a meta-analysis.
Quantification of VEGF isoforms and VEGFR transcripts by qRT-PCR and their significance in acute myeloid leukemia.
Rational approaches to design of therapeutics targeting molecular markers.
Regulation of the acute myeloid leukemia cell line OCI/AML-2 by endothelial nitric oxide synthase under the control of a vascular endothelial growth factor signaling system.
Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
Soluble flt-1 gene delivery in acute myeloid leukemic cells mediating a nonviral gene carrier.
Soluble hepatocyte growth factor (sHGF) and vascular endothelial growth factor (sVEGF) in adult acute myeloid leukemia: relationship to disease characteristics.
Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come.
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Vascular Endothelial Growth Factor A isoform mRNA expression in pediatric acute myeloid leukemia.
Vascular endothelial growth factor expression in acute myeloid leukemia: a biomarker ready for primetime?
Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients.
Vascular endothelial growth factor signaling in acute myeloid leukemia.
Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia.
Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2.
VEGFC antibody therapy drives differentiation of AML.
What role for angiogenesis in childhood acute lymphoblastic leukaemia?
[Change of vascular endothelial growth factor and its receptors expression in acute myeloid leukemia before and after treatment]
[Dynamic analysis of expression of VEGF and its receptor-2 in mouse model with acute myeloid leukemia.]
[Effect of autocrine vascular endothelial growth factor on the biological activity of acute myeloid leukemia cell line HL-60]
[Effects of human fibroblastoid stromal cell line on proliferation of HL-60 cells and expression of VEGF]
[Expression of angiogenic factors and their clinical significances in acute myeloid leukemia]
[Expression of vascular endothelial growth factor and its receptors KDR and Flt1 in acute myeloid leukemia]
[Inhibitory effect of apatinib on HL-60 cell proliferation and its mechanism].
[Role of vascular endothelial growth factor (VEGF) in development and progress of refractory acute myeloid leukemia]
Leukemia, Myelomonocytic, Chronic
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Leukemia, Plasma Cell
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Leukemia, Prolymphocytic, T-Cell
Production of vascular endothelial growth factor in T-cell prolymphocytic leukemia.
Leukemia, Promyelocytic, Acute
Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid.
FLORID NEOVASCULARIZATION OF THE RETINA IN A DIABETIC PATIENT UNDERGOING INDUCTION AND CONSOLIDATION THERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA.
Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model.
Vascular endothelial growth factor acted as autocrine growth factor in an acute promyelocytic leukemia case.
Leukemia, T-Cell
Tax 1-independent induction of vascular endothelial growth factor in adult T-cell leukemia caused by human T-cell leukemia virus type 1.
Vascular endothelial growth factor at high plasma levels is associated with extranodal involvement in adult T cell leukemia patients.
Leukemia-Lymphoma, Adult T-Cell
Increased microvessel density in involved organs from patients with HTLV-I associated adult T cell leukemia lymphoma.
Tax 1-independent induction of vascular endothelial growth factor in adult T-cell leukemia caused by human T-cell leukemia virus type 1.
Vascular endothelial growth factor and cellular chemotaxis: a possible autocrine pathway in adult T-cell leukemia cell invasion.
Leukocytosis
Brain-targeted hypoxia-inducible factor stabilization reduces neonatal hypoxic-ischemic brain injury.
C-reactive protein in bronchoalveolar lavage fluid is associated with markers of airway inflammation after lung transplantation.
Effects of experimental asthma on inflammation and lung mechanics in sickle cell mice.
Liver cirrhosis in a child associated with Castleman's disease: A case report.
Preoperative Plasma Vascular Endothelial Growth Factor But Not Nitrite Is a Useful Complementary Tumor Marker in Patients With Colorectal Cancer.
Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.
Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome.
Leukoencephalopathies
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Leukomalacia, Periventricular
Vascular endothelial growth factor in brains with periventricular leukomalacia.
Leukoplakia
[The expression characteristics and clinical significance of candidate molecular markers in vocal cord leukoplakia].
Leukostasis
Fenofibrate for Diabetic Retinopathy.
Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy.
Leukostasis and pigment epithelium-derived factor in rat models of diabetic retinopathy.
Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage.
Phosphomannopentaose sulfate (PI-88) inhibits retinal leukostasis in diabetic rat.
Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis.
Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.
Transscleral delivery of bioactive protein to the choroid and retina.
Lichen Planus
Immunohistochemical assessment of angiogenesis and vascular endothelial growth factor expression in cutaneous lichen planus: relation to the degree of inflammation.
Lichen Planus, Oral
Assessment of local angiogenesis and vascular endothelial growth factor in the patients with atrophic-erosive and reticular oral lichen planus.
Serum Level of Vascular Endothelial Growth Factor in Patients with Different Clinical SubtypeS of Oral Lichen Planus.
Upregulation of angiogenesis in oral lichen planus.
[Effect of hypoxia on the proliferation and expressions of hypoxia-inducible factor-1?, vascular endothelial growth factor and matrix metalloproteinase-9 in keratinocytes obtained from oral lichen planus lesions].
Lichen Sclerosus et Atrophicus
Role of angiogenesis in benign, premalignant and malignant vulvar lesions.
Lip Neoplasms
[Expression of VEGF, EGFR, p16 in lip cancers and oral squamous cell carcinomas and their clinic significance]
Lipedema
Increased levels of VEGF-C and macrophage infiltration in lipedema patients without changes in lymphatic vascular morphology.
Lipodystrophy
Complement Factor D (adipsin) Levels Are Elevated in Acquired Partial Lipodystrophy (Barraquer-Simons syndrome).
Lipoma
A Research of Soft Tissue Lipoma Genesis Factor With Immunohistochemical Analysis.
Liposarcoma
Association of sirtuin-1 and vascular endothelial growth factor expression with tumor progression and poor prognosis in liposarcoma.
Relationship of angiogenic and apoptotic activities in soft-tissue sarcoma.
Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
Liver Cirrhosis
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-formulated, immune-stimulatory vascular endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis.
A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-? and vascular endothelial growth factor signalling.
ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.
Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.
Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development.
Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study.
Boosting the hypoxic response in myeloid cells accelerates resolution of fibrosis and regeneration of the liver in mice.
Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment.
Circulating vascular endothelial growth factor and nitric oxide in patients with liver cirrhosis: A possible association with liver function impairment.
Circulating vascular endothelial growth factor levels are decreased in patients with chronic hepatitis and liver cirrhosis depending on the degree of hepatic damage.
Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension.
Clinical significance of endothelial progenitor cells in patients with liver cirrhosis with or without hepatocellular carcinoma.
Collagen-binding vascular endothelial growth factor attenuates CCl4-induced liver fibrosis in mice.
Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma.
Differential Roles of Angiogenesis in the Induction of Fibrogenesis and the Resolution of Fibrosis in Liver.
Dual-Functional Nanoparticles Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate Liver Fibrosis.
Effect of pioglitazone, quercetin, and hydroxy citric acid on vascular endothelial growth factor messenger RNA (VEGF mRNA) expression in experimentally induced nonalcoholic steatohepatitis (NASH).
Elevated circulating endothelial cell-derived microparticle levels in patients with liver cirrhosis: a preliminary report.
Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma.
Expression of angiogenic factors in hepatocarcinogenesis: Identification by antibody arrays.
Expressions of vascular endothelial growth factor in cirrhotic tissues and their relations to proto-oncogene c-fos, c-myc.
Glucobrassicin Metabolites Ameliorate the Development of Portal Hypertension and Cirrhosis in Bile Duct-Ligated Rats.
Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-?B/hypoxia-inducible factor-1? axis under hypoxic conditions.
Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma.
Levistilide A inhibits angiogenesis in liver fibrosis via vascular endothelial growth factor signaling pathway.
Liver sinusoidal endothelial cells are implicated in multiple fibrotic mechanisms.
Mesenchymal Stem Cells and Induced Bone Marrow-Derived Macrophages Synergistically Improve Liver Fibrosis in Mice.
Migration of hepatic stellate cells in fibrotic microenvironment of diseased liver model.
Natural course of splenic artery aneurysm with associated spontaneous splenorenal shunt in non-cirrhotic liver: an 18-year observational follow-up and review of literature.
Neovascularization is a key feature of liver fibrosis progression: anti-angiogenesis as an innovative way of liver fibrosis treatment.
Placental Growth Factor Contributes to Liver Inflammation, Angiogenesis, Fibrosis in Mice by Promoting Hepatic Macrophage Recruitment and Activation.
Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis.
Platelet-derived growth factor-D modulates extracellular matrix homeostasis and remodeling through TIMP-1 induction and attenuation of MMP-2 and MMP-9 gelatinase activities.
Pro-fibrogenic potential of PDGF-D in liver fibrosis.
Relationship of smoking and fibrosis in patients with chronic hepatitis C.
Sensitive, quantitative, and high-throughput detection of angiogenic markers using shape-coded hydrogel microparticles.
Spider angiomas in patients with liver cirrhosis: role of vascular endothelial growth factor and basic fibroblast growth factor.
The herbal formula CGX ameliorates the expression of vascular endothelial growth factor in alcoholic liver fibrosis.
Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis.
Vascular Endothelial Growth Factor Expression in Hepatitis C Virus-Induced Liver Fibrosis: A Potential Biomarker.
Vascular endothelial growth factor levels in liver cirrhosis.
Liver Cirrhosis, Biliary
Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis.
Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis.
Liver Diseases
A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma.
Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma.
Angiogenesis in chronic liver disease.
Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study.
Association of Circulating Adipsin, Visfatin, and Adiponectin with Nonalcoholic Fatty Liver Disease in Adults: A Case-Control Study.
Biomarker profile in stable Fontan patients.
Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease.
Defective intra-platelet vascular endothelial growth factor release is associated with liver dysfunction following partial hepatectomy.
Detection of Autoantibodies to Vascular Endothelial Growth Factor Receptor-3 in Bile Duct Ligated Rats and Correlations with a Panel of Traditional Markers of Liver Diseases.
Genetic polymorphisms of proangiogenic factors seem to favor hepatocellular carcinoma development in alcoholic cirrhosis.
Placental growth factor silencing ameliorates liver fibrosis and angiogenesis and inhibits activation of hepatic stellate cells in a murine model of chronic liver disease.
Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction.
Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndrome.
Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease.
Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease.
Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease.
Serum vascular endothelial growth factor levels in various liver diseases.
Soluble Vascular Endothelial Growth Factor Receptor-2 as a Predictive Factor for Progression of Illness in Chronic Liver Diseases and Hepatocellular Carcinoma.
The Profile of Platelet ?-Granule Released Molecules Affects Postoperative Liver Regeneration.
The role of vascular endothelial growth factor -634 G/C and its soluble receptor on chronic liver disease and hepatocellular carcinoma.
Vascular endothelial growth factor level in chronic liver diseases.
Vascular endothelial growth factor protects hepatoma cells against oxidative stress-induced cell death.
Vascular endothelial growth factors and liver diseases.
VEGF Polymorphisms Related to Higher Serum Levels of Protein Identify Patients with Hepatocellular Carcinoma.
[Diagnostic efficiency of laboratory tests determining the functional status of the endothelium in patients with chronic diffuse liver diseases]
[Hypoxia-inducible factor-1? mediates and regulates angiogenesis-related factors expression in hepatocellular carcinoma].
Liver Failure, Acute
A potent angiogenic factor, vascular endothelial growth factor, improves the survival of the on-going acute hepatic failure in rats.
A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels.
Intravenous Administration is the Best Route of Mesenchymal Stem Cells Migration in Improving Liver Function Enzyme of Acute Liver Failure.
Serum hepatocyte growth factor and vascular endothelial growth factor in children with acute liver failure.
Serum levels of platelet-derived growth factor-BB and vascular endothelial growth factor as prognostic factors for patients with fulminant hepatic failure.
The vascular endothelial growth factor (VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute hepatic failure.
Vascular endothelial growth factor reduces Fas-mediated acute liver injury in mice.
[Effects of bone marrow mesenchymal stem cell transplantation on the expression of stromal cell-derived factor-1? and vascular endothelial growth factor in rats with acute hepatic failure].
[Innovative use of the vascular endothelial growth factor in an experimental model of acute liver failure]
Liver Neoplasms
Amarogentin Inhibits Liver Cancer Cell Angiogenesis after Insufficient Radiofrequency Ablation via Affecting Stemness and the p53-Dependent VEGFA/Dll4/Notch1 Pathway.
An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue.
Apatinib regulates the cell proliferation and apoptosis of liver cancer by regulation of VEGFR2/STAT3 signaling.
Association between the expression of HIF-1? and VEGF and prognostic implications in primary liver cancer.
Association of disease condition with changes in intestinal flora, and plasma endotoxin and vascular endothelial growth factor levels in patients with liver cancer.
Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.
Combination of interventional adenovirus-p53 introduction and ultrasonic irradiation in the treatment of liver cancer.
Correlation between liver cancer pain and the HIF-1 and VEGF expression levels.
Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer.
Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer.
Effect of c-fos antisense probe on prostaglandin E2-induced upregulation of vascular endothelial growth factor mRNA in human liver cancer cells.
Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a.
Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway.
Fructopyrano-(1?4)-glucopyranose inhibits the proliferation of liver cancer cells and angiogenesis in a VEGF/VEGFR dependent manner.
In vivo study on the effects of curcumin on the expression profiles of anti-tumour genes (VEGF, CyclinD1 and CDK4) in liver of rats injected with DEN.
Influence of hepatic arterial blockage on blood perfusion and VEGF, MMP-1 expression of implanted liver cancer in rats.
Inhibition of human hepatocellular carcinoma tumor angiogenesis by siRNA silencing of VEGF via hepatic artery perfusion.
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.
Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer.
Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma.
Prognostic value of the combination of serum levels of vascular endothelial growth factor, C-reactive protein and contrast-enhanced ultrasound in patients with primary liver cancer who underwent transcatheter arterial chemoembolization.
Serum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer.
Serum vascular endothelial growth factor concentrations in hepatocellular cancer patients undergoing percutaneously radiofrequency thermal ablation.
Synthesis of dual-functional targeting probes for cancer theranostics based on iron oxide nanoparticles coated by centipede-like polymer connected with pH-responsive anticancer drug.
The Prognostic Value of Circulating VEGF-A Level in Patients With Hepatocellular Cancer.
Transient increased expression of VEGF and MMP-1 in a rat liver tumor model after hepatic arterial occlusion.
V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.
Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients.
Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats.
[Clinical values of vascular endothelial growth factor expression and microvascular density analysis in liver cancer specimens]
Low Tension Glaucoma
Aqueous Vascular Endothelial Growth Factor and Endothelin-1 Levels in Branch Retinal Vein Occlusion Associated With Normal Tension Glaucoma.
Lung Diseases
A vascular endothelial growth factor deficiency characterises scleroderma lung disease.
Bevacizumab regulates inflammatory cytokines and inhibits VEGFR2 signaling pathway in an ovalbumin-induced rat model of airway hypersensitivity.
Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
Exploring the Role of Matrix Metalloproteinases as Biomarkers in Sporadic Lymphangioleiomyomatosis and Tuberous Sclerosis Complex. A Pilot Study.
Impaired lung vascular endothelial growth factor in extremely premature baboons developing bronchopulmonary dysplasia/chronic lung disease.
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis.
Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn.
Pulmonary Vasculopathy Associated with FIGF Gene Mutation.
Recent advances in diagnosis and management of pulmonary hypertension in chronic lung disease.
Sequestration of Vascular Endothelial Growth Factor (VEGF) Induces Late Restrictive Lung Disease.
Serum vascular endothelial growth factor and angiopoietin-2 are associated with the severity of systemic inflammation rather than the presence of hemoptysis in patients with inflammatory lung disease.
Serum Vascular Endothelial Growth Factor D in Cystic Lung Disease.
Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer and its relations to the micrometastasis in peripheral blood.
Serum vascular endothelial growth factor-d levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.
Serum Vascular Endothelial Growth Factor-D Prospectively Distinguishes Lymphangioleiomyomatosis from Other Diseases.
Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis.
Simultaneous assessment of HGF and VEGF in epithelial lining fluid from patients with COPD.
Soluble vascular endothelial growth factor receptor 1 in tracheal aspirate fluid of preterm neonates at birth may be predictive of bronchopulmonary dysplasia/chronic lung disease.
The role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases.
The trend and the disease prediction of vascular endothelial growth factor and placenta growth factor in nontuberculous mycobacterial lung disease.
Vascular endothelial growth factor accelerates compensatory lung growth by increasing the alveolar units.
Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease.
Vascular endothelial growth factor in pleural effusions of different origin.
Lung Diseases, Interstitial
Decreased VEGF Level Is Associated with Elevated Ferritin Concentration in Bronchoalveolar Lavage Fluid of Children with Interstitial Lung Diseases.
Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis.
Genetic susceptibility to progressive massive fibrosis in coal miners.
Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease.
Lung Diseases, Obstructive
The association of genetic polymorphisms of hypoxia inducible factor-1 alpha and vascular endothelial growth factor with increased risk of chronic obstructive pulmonary disease: A case-control study.
Lung Injury
A Novel Role of VEGFC in Cerebral Ischemia With Lung Injury.
A role for vascular endothelial growth factor in acute and resolving lung injury.
Antioxidative effects of adrenomedullin and vascular endothelial growth factor on lung injury induced by skeletal muscle ischemia-reperfusion.
Cathelicidin attenuates hyperoxia-induced lung injury by inhibiting oxidative stress in newborn rats.
High concentrations of vascular endothelial growth factor reduce stretch-induced apoptosis of alveolar type II cells.
Hydroxyethyl starch reduces high stretch ventilation-augmented lung injury via vascular endothelial growth factor.
Hypoxia-Inducible Factor 1? Signaling Promotes Repair of the Alveolar Epithelium after Acute Lung Injury.
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha are decreased in an experimental model of severe respiratory distress syndrome in preterm lambs.
Integrin alphavbeta5 regulates lung vascular permeability and pulmonary endothelial barrier function.
Intratracheal Clara cell secretory protein (CCSP) administration in preterm infants with or at risk of respiratory distress syndrome.
Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in Idiopathic Pulmonary Fibrosis (IPF).
Mesenchymal stem cells protect against neonatal rat hyperoxic lung injury.
Placental growth factor and vascular endothelial growth factor receptor-2 in human lung development.
Role of Nitric Oxide Isoforms in Vascular and Alveolar Development and Lung Injury in Vascular Endothelial Growth Factor Overexpressing Neonatal Mice Lungs.
The antifibrotic effects of alveolar macrophages 5-HT2C receptors blockade on bleomycin-induced pulmonary fibrosis in rats.
The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury.
Upregulation of Vascular Endothelial Growth Factor in Amniotic Fluid Stem Cells Enhances Their Potential to Attenuate Lung Injury in a Preterm Rabbit Model of Bronchopulmonary Dysplasia.
Vascular Endothelial Growth Factor (VEGF) isoform expression and activity in human and murine lung injury.
Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization.
Vascular endothelial growth factor in epithelial lining fluid of patients with acute respiratory distress syndrome.
Vascular endothelial growth factor increased the permeability of respiratory barrier in acute respiratory distress syndrome model in mice.
Vascular endothelial growth factor is expressed in ovine pulmonary vascular smooth muscle cells in vitro and regulated by hypoxia and dexamethasone.
Vascular endothelial growth factor mediates the therapeutic efficacy of mesenchymal stem cell-derived extracellular vesicles against neonatal hyperoxic lung injury.
Vascular endothelial growth factor overexpression in induced sputum of children with bronchial asthma.
Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury.
VEGF levels in the alveolar compartment do not distinguish between ARDS and hydrostatic pulmonary oedema.
VEGF-C/VEGFR-3 signaling in macrophages ameliorates acute lung injury.
WKYMVm hexapeptide, a strong formyl peptide receptor 2 agonist, attenuates hyperoxia-induced lung injuries in newborn mice.
[Expression of VEGF protein and mRNA in neonatal rats with hyperoxia-induced lung injury]
Lung Neoplasms
-
2'-O,4'-C-ethylene-bridged nucleic acid (ENA) for effective antisense formation.
5,3'-Dihydroxy-6,7,4'-trimethoxyflavanone exerts its anticancer and antiangiogenesis effects through regulation of the Akt/mTOR signaling pathway in human lung cancer cells.
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.
A Multicenter, Phase II study of Erlotinib and Sorafenib in Chemotherapy-naive Patients with Advanced Non-Small Cell Lung Cancer.
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.
A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
Aberrant expression and association of VEGF and Dll4/Notch pathway molecules under hypoxia in patients with lung cancer.
Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer.
Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells.
Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab.
AE-941 (AEterna).
Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial.
AMP-activated protein kinase ?1 serves a carcinogenic role via regulation of vascular endothelial growth factor expression in patients with non-small cell lung cancer.
Amplified LncRNA PVT1 promotes lung cancer proliferation and metastasis by facilitating VEGFC expression.
An orally administered DNA vaccine targeting vascular endothelial growth factor receptor-3 inhibits lung carcinoma growth.
Analysis of Expression of Vascular Endothelial Growth Factor A and Hypoxia Inducible Factor-1alpha in Patients Operated on Stage I Non-Small-Cell Lung Cancer.
Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
Angiogenesis in the treatment of non-small cell lung cancer.
Angiogenesis Inhibitors in Small Cell Lung Cancer.
Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: Correlations with patient survival and pleural effusion control.
Angiogenin and vascular endothelial growth factor expression in lungs of lung cancer patients.
Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor.
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.
Anti-lymphangiogenesis effects of a specific anti-interleukin 7 receptor antibody in lung cancer model in vivo.
Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer.
Antiangiogenesis and damaging blood flow by antisense vascular endothelial growth factor oligodeoxynucleotides to suppress lung cancers.
Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
Antiangiogenic drugs in non-small cell lung cancer treatment.
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.
Antiangiogenic therapy in nonsmall cell lung cancer.
Antibodies to vascular endothelial growth factor in non-small cell lung cancer.
Antitumor Activity of Elacytarabine Combined with Bevacizumab, Cetuximab and Trastuzumab in Human NSCLC Xenografts.
Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.
Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis.
Apatinib for molecular targeted therapy in tumor.
Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
Apatinib-induced hyperammonemic encephalopathy.
Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer.
Application of liquid chromatography-tandem mass spectrometry to study the effect of docetaxel on pharmacokinetics and tissue distribution of apatinib in mice.
ARHGAP15 regulates lung cancer cell proliferation and metastasis via the STAT3 pathway.
ARHGAP6 regulates the proliferation, migration and invasion of lung cancer cells.
Association between +936 C>T gene polymorphism of vascular endothelial growth factor and lung cancer: a meta-analysis.
Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma.
Association between genetic polymorphisms involved in the hypoxia-inducible factor pathway and lung cancer risk: a case-control study in Japan.
Association between VEGF Gene Polymorphisms and the Susceptibility to Lung Cancer: An Updated Meta-Analysis.
Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production.
Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
Basigin-2 upregulated by receptor activator of NF-?B ligand enhances lung cancer-induced osteolytic lesions.
Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma.
Best of the month: a roundup of articles published in recent months.
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
Bevacizumab and micrometastases: Revisiting the preclinical and clinical rollercoaster.
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Bevacizumab-induced hypertension: pathogenesis and management.
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Bevacizumab: in first-line treatment of metastatic breast cancer.
Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer.
Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.
BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation.
Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor.
c-Myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression.
CCL21/CCR7 up-regulate vascular endothelial growth factor-D expression via ERK pathway in human non-small cell lung cancer cells.
CCL25 promotes the migration and invasion of non-small cell lung cancer cells by regulating VEGF and MMPs in a CCR9-dependent manner.
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.
Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer.
Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer.
Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.
Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Clarithromycin is a potent inhibitor of tumor-induced angiogenesis.
Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen.
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
Clinical implications of serum hypoxia inducible factor-1? and vascular endothelial growth factor in lung cancer.
Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9.
Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer.
Clinical significance of defective dendritic cell differentiation in cancer.
Clinical significance of vascular endothelial growth factor in patients with primary lung cancer.
Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients.
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.
Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer.
Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Combined therapeutic effect and molecular mechanisms of metformin and cisplatin in human lung cancer xenografts in nude mice.
Compounds in clinical Phase III and beyond.
Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype.
Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro.
Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.
Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer.
Correlation between vascular endothelial growth factor and quantitative dual-energy spectral CT in non-small-cell lung cancer.
Correlation of gene polymorphisms of vascular endothelial growth factor with grade and prognosis of lung cancer.
Correlation of genetic polymorphism of vascular endothelial growth factor gene with susceptibility to lung cancer.
Correlation of polymorphisms of the vascular endothelial growth factor gene and the risk of lung cancer in an ethnic Han group of North China.
Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer.
Cross-talk between endothelial and tumor cells via basic fibroblast growth factor and vascular endothelial growth factor signaling promotes lung cancer growth and angiogenesis.
Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF).
Current management of advanced non-small cell lung cancer: targeted therapy.
Cyclooxygenase-2 expression is induced by celecoxib treatment in lung cancer cells and is transferred to neighbor cells via exosomes.
Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.
Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer.
Decreased maspin combined with elevated vascular endothelial growth factor C is associated with poor prognosis in non-small cell lung cancer.
Delphinidin inhibits angiogenesis through the suppression of HIF-1? and VEGF expression in A549 lung cancer cells.
Demethylation by 5-aza-2'-deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer cell lines.
Detection of circulating vascular endothelial growth factor and matrix metalloproteinase-9 in non-small cell lung cancer using Luminex multiplex technology.
Detection of lymphangiogenesis in non-small cell lung cancer and its prognostic value.
Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
Diagnostic utility of VEGF mRNA and SP1 mRNA expression in bronchial cells of patients with lung cancer.
Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non-small cell lung cancer.
Differential expression of hypoxia-inducible factor 1? in non-small cell lung cancer and small cell lung cancer.
Differential regulation of human Eag1 channel expression by serum and epidermal growth factor in lung and breast cancer cells.
Diffuse intestinal angiomatosis as a possible paraneoplastic manifestation of small cell lung cancer: a case of small bowel angiomatosis.
Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer.
Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer.
Dual-energy dynamic CT of lung adenocarcinoma: correlation of iodine uptake with tumor gene expression.
Effect of Astragalus Polysaccharide on the Expression of VEGF and EGFR in Mice with Lewis Transplantable Lung Cancer.
Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non-Small-cell Lung Cancer on Progression-free and Overall Survival.
Effect of mast cells on tumor angiogenesis in lung cancer.
Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
Effect of molecular targeted therapy combined with radiotherapy on the expression and prognostic value of COX-2 and VEGF in bone metastasis of lung cancer.
Effect of tetramethylpyrazine combined with cisplatin on VEGF, KLF4 and ADAMTS1 in Lewis lung cancer mice.
Effect of thoracic paraspinal block-propofol intravenous general anesthesia on VEGF and TGF-? in patients receiving radical resection of lung cancer.
Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer.
Effect of YangZheng XiaoJi Extract, DME-25, on Endothelial Cells and their Response to Avastin.
Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
Effects of 3-Tetrazolyl Methyl-3-Hydroxy-Oxindole Hybrid (THOH) on Cell Proliferation, Apoptosis, and G2/M Cell Cycle Arrest Occurs by Targeting Platelet-Derived Growth Factor D (PDGF-D) and the MEK/ERK Signaling Pathway in Human Lung Cell Lines SK-LU-1, A549, and A-427.
Effects of autocrine vascular endothelial growth factor (VEGF) in non-small cell lung cancer cell line A549.
Effects of carbon-ion beam irradiation on the angiogenic response in lung adenocarcinoma A549 cells.
Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells.
Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC.
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Efficacy and toxicity of anti-VEGF agents in patients with castration-resistant prostate cancer: a meta-analysis of prospective clinical studies.
Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer.
Efficacy of radiotherapy on intermediate and advanced lung cancer and its effect on dynamic changes of serum vascular endothelial growth factor and matrix metalloproteinase-9.
Efficient inhibition of non-small-cell lung cancer xenograft by systemic delivery of plasmid-encoding short-hairpin RNA targeting VEGF.
Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients.
Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer.
Elevated SP-1 transcription factor expression and activity drives basal and hypoxia-induced vascular endothelial growth factor (VEGF) expression in non-small cell lung cancer.
Elevated vascular endothelial growth factor levels in sera of patients with lung cancer.
Emerging angiogenesis inhibitors for non-small cell lung cancer.
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma.
Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs).
Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer.
ERK Signaling Pathway Is Involved in HPV-16 E6 but not E7 Oncoprotein-Induced HIF-1? Protein Accumulation in NSCLC Cells.
Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis.
Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer.
Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion.
Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer.
Expression of Elf-1 and survivin in non-small cell lung cancer and their relationship to intratumoral microvessel density.
Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis.
Expression of thymosin beta10 and its role in non-small cell lung cancer.
Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung.
Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer.
Expression of vascular endothelial growth factor (VEGF) and its receptor FLK-1 in non-small cell lung cancer (NSCLC)--a preliminary report.
Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis.
Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer.
Expression of vascular endothelial growth factor and the adhesion molecule E-cadherin in non-small cell lung cancer.
Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.
Formylated honokiol analogs showed antitumor activity against lung carcinoma.
Four Common Vascular Endothelial Growth Factor Polymorphisms (-2578C>A, -460C>T, +936C>T, and +405G>C) in Susceptibility to Lung Cancer: A Meta-Analysis.
Frequent expression of the vascular endothelial growth factor in human non-small-cell lung cancers.
Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer.
Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types.
Further evidence for oxidant-induced vascular endothelial growth factor up-regulation in the bronchoalveolar lavage fluid of lung cancer patients undergoing radio-chemotherapy.
Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells.
Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.
GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.
Heavy-ion beam irradiation inhibits invasion of tongue squamous cell carcinoma Tca8113 cells.
Heparanase expression correlates with angiogenesis and lymphangiogenesis in human lung cancer.
Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
High circulating VEGF level predicts poor overall survival in lung cancer.
High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer.
High preoperative plasma vasohibin-1 concentration predicts better prognosis in patients with non-small cell lung carcinoma.
Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier.
HPV16 E6/E7 upregulates HIF-2? and VEGF by inhibiting LKB1 in lung cancer cells.
Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.
Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells.
Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.
Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L).
Impaired TNFalpha-induced VEGF expression in human airway smooth muscle cells from smokers with COPD: role of MAPkinases and histone acetylation--effect of dexamethasone.
In NSCLC, VEGF-A response to hypoxia may differ between squamous cell and adenocarcinoma histology.
In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies.
Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma.
Increased pro-angiogenic factors, infiltrating neutrophils and CD163(+) macrophages in bronchoalveolar lavage fluid from lung cancer patients.
Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer.
Inflammatory cytokines and VEGF measured in exhaled breath condensate are correlated with tumor mass in non-small cell lung cancer.
Influence of Stromal Components on Lung Cancer Carcinogenesis.
Influence of vascular endothelial growth factor single nucleotide polymorphisms on non-small cell lung cancer tumor angiogenesis.
Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic.
Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC.
Inhibitors of vascular endothelial growth factor and its receptors in the treatment of lung cancer: an update of clinical data from the 2001 American Society of Clinical Oncology meeting.
Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer.
Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer.
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1.
Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.
Leptin promotes the immune escape of lung cancer by inducing proinflammatory cytokines and resistance to apoptosis.
Levels of Vascular Endothelial Growth Factor in Serum and Pleural Fluid Are Independent Predictors of Survival in Advanced Non-small Cell Lung Cancer: Results of a Prospective Study.
Loss of the endothelial glycocalyx is associated with increased E-selectin mediated adhesion of lung tumour cells to the brain microvascular endothelium.
Lung cancer lymph node micrometastasis detection using real-time polymerase chain reaction: correlation with vascular endothelial growth factor expression.
Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity.
Lung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16.
Melittin exerts an antitumor effect on non?small cell lung cancer cells.
Melittin Suppresses VEGF-A-Induced Tumor Growth by Blocking VEGFR-2 and the COX-2-Mediated MAPK Signaling Pathway.
Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Metastatic brain mass caused by slow-growing small-cell lung cancer: differential vascular endothelial growth factor expression in primary and metastatic tumor.
miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A.
Modulation of Vascular Endothelial Growth Factor and Annexin A2 in Response to 4-(Methylnitrosamino)-1-(3-pyridyl)-1-Butanone -Induced Inflammation via Swimming Training.
Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
MUC1 Expression in Pulmonary Metastatic Tumors: A Comparison of Primary Lung Cancer.
Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer.
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer.
Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression.
New antiangiogenetic agents and non-small cell lung cancer.
New Strategies for NSCLC: Is Inhibition of Tumour Vasculature Useful?
New targets and new mechanisms in lung cancer.
Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways.
Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma.
Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis.
Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt/?-Catenin signaling pathway.
Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells.
Paracrine signaling by VEGF-C promotes non-small cell lung cancer cell metastasis via recruitment of tumor-associated macrophages.
Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer.
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
Placental growth factor signaling regulates isoform splicing of vascular endothelial growth factor A in the control of lung cancer cell metastasis.
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.
Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer.
Platelet VEGF and serum TGF-?1 levels predict chemotherapy response in non-small cell lung cancer patients.
Poly(1-vinylimidazole) polyplexes as novel therapeutic gene carriers for lung cancer therapy.
Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy.
Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases.
Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer.
Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients.
Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis.
Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.
Prognostic Role of Protease-Activated Receptors 1 and 4 in Resected Stage IB Non-Small-Cell Lung Cancer.
Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer.
Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
Prognostic value of serum IL-17 and VEGF levels in small cell lung cancer.
Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer.
Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis.
Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer.
Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer.
Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy.
Pulmonary toxicities from targeted therapies: a review.
Purification, partial characterization, crystallization and preliminary X-ray diffraction of a novel cardiotoxin-like basic protein from Naja naja atra (South Anhui) venom.
Quadruplex-forming oligonucleotide targeted to the VEGF promoter inhibits growth of non-small cell lung cancer cells.
Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR.
Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer.
RAR? mediates all-trans-retinoic acid-induced VEGF-C, VEGF-D, and VEGFR3 expression in lung cancer cells.
Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.
Recruitment of CD11b(+)Ly6C(+) monocytes in non-small cell lung cancer xenografts challenged by anti-VEGF antibody.
Relationship between (18)F-FDG uptake on PET and various biologic molecular markers in benign pulmonary lesion: comparison with primary lung cancer.
Relationship between PTEN and Vascular Endothelial Growth Factor Expression in Non-Small Cell Lung Cancer.
Relationship Between Serum VEGF Level and Radiosensitivity of Patients with Nonsmall Cell Lung Cancer Among Asians: A Meta-Analysis.
Relationship between vascular endothelial growth factor -2578C > a gene polymorphism and lung cancer risk: a meta-analysis.
Relationship between vessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro.
Relationship of serum levels of VEGF and TGF-?1 with radiosensitivity of elderly patients with unresectable non-small cell lung cancer.
Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer.
Riboflavin at high doses enhances lung cancer cell proliferation, invasion, and migration.
Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC).
Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Role of dalteparin sodium on the growth of cancer cells and tumor-associated angiogenesis in A549 human lung cancer cell line and grafted mouse model.
Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells.
Role of lymphangiogenesis in lung cancer.
Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer.
Role of the erythropoietin receptor in Lung Cancer cells: erythropoietin exhibits angiogenic potential.
Role of vascular endothelial growth factor in non?small cell lung cancer pathogenesis.
Roles of PI3K/Akt and c-Jun signaling pathways in human papillomavirus type 16 oncoprotein-induced HIF-1?, VEGF, and IL-8 expression and in vitro angiogenesis in non-small cell lung cancer cells.
rs833061 and rs699947 on promoter gene of vascular endothelial growth factor (VEGF) and associated lung cancer susceptibility and survival: a meta-analysis.
Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.
Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer: A case report.
Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis.
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration.
Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients.
Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer.
Serum Angiopoietin-2 as a Clinical Marker for Lung Cancer in Patients with Solitary Pulmonary Nodules.
Serum angiopoietin-2 as a clinical marker for lung cancer.
Serum concentrations of vascular endothelial growth factor in advanced non-small cell lung cancer.
Serum cripto-1 as a clinical marker for lung cancer.
Serum endostatin correlates with progression and prognosis of non-small cell lung cancer.
Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients.
Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer.
Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy.
Serum midkine depends on lymph node involvement and correlates with circulating VEGF-C in oesophageal squamous cell carcinoma.
Serum tumor markers, hypoxia-inducible factor-1? HIF-1? and vascular endothelial growth factor, in patients with non- small cell lung cancer before and after intervention.
Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer.
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer.
Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase.
Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer and its relations to the micrometastasis in peripheral blood.
Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer.
Short-term prognostic effects of circulating regulatory T-Cell suppressive function and vascular endothelial growth factor level in patients with non-small cell lung cancer and obstructive sleep apnea.
Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer.
Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.
Single-nucleotide polymorphisms (SNPs) and haplotype analysis in vascular endothelial growth factor (VEGF) gene in the patients with Parkinson disease and lung cancer.
SNP and Haplotype Analysis of Vascular Endothelial Growth Factor (VEGF) Gene in Lung Cancer Patients of Kashmir
Suppression of lung cancer cell invasion by LKB1 is due to the downregulation of tissue factor and vascular endothelial growth factor, partly dependent on SP1.
Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis.
Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Targeting growth factors and angiogenesis; using small molecules in malignancy.
Targeting vascular endothelial growth factor in lung cancer.
Targeting Vascular Endothelial Growth Factor in Patients With Squamous Cell Lung Cancer.
Tetrandrine suppresses lung cancer growth and induces apoptosis, potentially via the VEGF/HIF-1?/ICAM-1 signaling pathway.
The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients.
The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
The clinical significance of serum adipocytokines level in patients with lung cancer.
The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
The correlation of expression of VEGF and EGFR with SUV of (18)FDG-PET-CT in non-small cell lung cancer.
The effects of sonic hedgehog signaling pathway components on non-small-cell lung cancer progression and clinical outcome.
The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
The emerging role of biomarkers in advanced non-small-cell lung cancer.
The expression of hypoxia inducible factor 1-alpha in lung cancer and its correlation with P53 and VEGF.
The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer.
The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer.
The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.
The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer.
The predictive value of vascular endothelial growth factor and nm23 for the diagnosis of occult metastasis in non-small cell lung cancer.
The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients.
The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer.
The role of anti-angiogenesis in non-small-cell lung cancer: an update.
The role of serum vascular endothelial growth factor and matrix metalloproteinase-9 in predicting response to chemotherapy in patients with advanced nonsmall cell lung cancer.
The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer.
The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature.
Therapeutic targeting of receptor tyrosine kinases in lung cancer.
Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells.
Thromboxane receptor alpha mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells.
Time-dependent changes of plasma concentrations of angiopoietins, vascular endothelial growth factor, and soluble forms of their receptors in nonsmall cell lung cancer patients following surgical resection.
Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation.
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer.
Treatment of advanced non small cell lung cancer.
Treatment of locally advanced non-small cell lung cancer with combination of chemotherapy and radiation.
Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer.
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Tumor angiogenesis and recurrence in stage I non-small cell lung cancer.
Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage IIIA).
Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages.
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
Ulcerative colitis in a patient with non-small-cell lung cancer receiving bevacizumab.
Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC).
Utility of VEGF and sVEGFR-1 in bronchoalveolar lavage fluid for differential diagnosis of primary lung cancer.
Vascular endothelial growth factor (VEGF) -2578C/A and -460C/T gene polymorphisms and lung cancer risk: a meta-analysis involving 11 case-control studies.
Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer.
Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients.
Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers.
Vascular endothelial growth factor -634G/C and vascular endothelial growth factor -2578C/A polymorphisms and lung cancer risk: a case-control study and meta-analysis.
Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer.
Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis.
Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India).
Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells.
Vascular endothelial growth factor and lymph node metastasis in primary lung cancer.
Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53.
Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer.
Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Vascular endothelial growth factor B coordinates metastasis of non-small cell lung cancer.
Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
Vascular Endothelial Growth Factor C as a Predictor of Early Recurrence and Poor Prognosis of Resected Stage I Non-small Cell Lung Cancer.
Vascular endothelial growth factor C complements the ability of positron emission tomography to predict nodal disease in lung cancer.
Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer.
Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.
Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer.
Vascular endothelial growth factor expression in airways of patients with lung cancer: a possible diagnostic tool of responsive angiogenic status on the host side.
Vascular endothelial growth factor expression in non-small cell lung cancer.
Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma.
Vascular endothelial growth factor expression in pN2 non-small cell lung cancer: lack of prognostic value.
Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis.
Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer.
Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer.
Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.
Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer.
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts.
Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer.
Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.
Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients.
Vascular endothelial growth factor polymorphisms and lung cancer risk.
Vascular endothelial growth factor polymorphisms in early-stage non-small-cell lung cancer.
Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer.
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Vascular endothelial growth factor trap in non small cell lung cancer.
Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
Vascular endothelial growth factor-121 mRNA expression and neomicrovessel density in primary lung cancer.
Vascular Endothelial Growth Factor-D (VEGF-D) is Elevated in Bronchoalveolar Lavage Fluid of Patients with Lung Squamous Carcinoma.
VEGF-C in non-small cell lung cancer: meta-analysis.
Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
[Advances on effects of triptolide with non-small cell lung cancer].
[Anti-angiogenic agents in the treatment of lung cancer: Indications and toxicities].
[Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice]
[Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro].
[Association of vascular endothelial growth factor expression with angiogenesis and tumor cell proliferation in human lung cancer]
[Bevacizumab and arterial hypertension or proteinuria: management]
[Combined Inhibition of Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways in Non-small Cell Lung Cancer Therapy.]
[Correlation between the expression of vascular endothelial growth factor and prognosis of lung cancinoma]
[Correlation of postoperative serum VEGF levels with platelet counts in non-small cell lung cancer]
[Decline of dendritic cells in the peripheral blood of patients with non-small cell lung cancer and its relation to vascular endothelial growth factor.]
[Diagnostic value of enhanced computed tomography plus vascular endothelial growth factor C expression in hilar and mediastinal lymph node metastasis of non-small cell lung cancer].
[Effect of irradiation on matrix metalloproteinases, vascular endothelial growth factor and microvessel density of mice bearing Lewis lung cancer]
[Effect of yifei qinghua granule on VEGF, bFGF, angiostatin, and endostatin in lewis lung cancer mice: an experimental study].
[Effects of JAK2/STAT3 signaling pathway on angiogenesis in non-small cell lung cancer.]
[Effects of vascular endothelial growth factor in the invasion and metastasis of non-small cell lung cancer.]
[Effects on lymphangiogenesis and angiogenesis of lung cancer with antisense oligonucleotides of vascular endothelial growth factor C]
[Expression and clinical significance of vascular endothelial growth factor in human non-small cell lung cancer.]
[Expression and significance of Elf-1 and vascular endothelial growth factor in non-small cell lung cancer.]
[Expression and significance of Notch1, Jagged1 and VEGF in human non-small cell lung cancer]
[Expression of CD133 and Notch1 in non-small cell lung cancer and the clinicopathological significance].
[Expression of vascular endothelial growth factor (VEGF) and its receptors KDR, Flt1 in lung cancer and their relationship to prognosis.]
[Expression of vascular endothelial growth factor (VEGF) C and VEGF receptor 3 in non-small cell lung cancer]
[Expression of vascular endothelial growth factor C and its receptor VEGF-R3 and their significance in non-small cell lung cancer.]
[Expressions of cyclooxygenase-2 and vascular endothelial growth factor in human lung cancer tissue.]
[Heparanase and vascular endothelial growth factor expression in non-small-cell lung cancer]
[Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].
[Lung cancer]
[Microvessel density and expressions of survivin and vascular endothelial growth factor in non-small cell lung cancer and their correlations to clinicopathologic features]
[Perforation of the nasal septum: a rare complication of bevacizumab].
[Prognostic value of the expression of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha in patients undergoing surgery for non-small cell lung cancer.]
[Quantitative study of vascular endothelial growth factor expression in primary lung cancer]
[Recombinant adenovirus expressing wild-type p53 is antiagiogenic--implication for lung cancer gene therapy]
[Relation of vascular endothelial growth factor-D expression to microvessel density, microlymphatic vessel density, and lymph-node metastasis of lung adenocarcinoma]
[Relationship between vascular endothelial growth factor C expression level and lymph node metastasis in non small cell lung cancer]
[Research Progress of Small Molecule Anti-angiogenic Drugs ?in Non-small Cell Lung Cancer].
[Study of COX-2 expression and angiogenesis in non-small cell lung cancer.]
[The clinical significance of detection of vascular endothelial growth factor and CD44v6 expression in human non-small cell lung cancer.]
[The clinical significance of vascular endothelial growth factor and intercellular adhesion molecule-1 expression in non-small cell lung cancer.]
[The clinical value of vascular endothelial growth factor in patients with small cell lung cancer.]
[The Correlation between FDG PET/CT Imaging and Molecule Makers in Non-Small Cell Lung Cancer.]
[The effect of VEGF antisense oligonucleotides combined with low molecular weight heparin on the growth and metastasis of mice Lewis lung cancer]
[The estimation of serum concentration of vascular endothelial growth factor in patients with non-small cell lung cancer]
[The evaluation to relationship between serum vascular endothelial growth factor (VEGF) level, metastases and other tumor markers in patients with lung cancer.]
[Vascular endothelial growth factor expression and microvessel density in stage I-II non-small cell lung cancer and their prognostic significances]
[Vascular endothelial growth factor in non-small cell lung carcinoma expression and its significance]
[Vascular endothelial growth factor inhibits dendritic cells from patients with non-small cell lung carcinoma]
[Vascular endothelial growth factor promotes hematogenous metastasis of cancer cells in patients with non-small cell lung cancer]
[Vasoactive intestinal peptide enhances the expression of vascular endothelial growth factor mRNA in non-small cell lung cancer cells.]
Lupus Erythematosus, Systemic
Analysis of correlations between selected endothelial cell activation markers, disease activity, and nailfold capillaroscopy microvascular changes in systemic lupus erythematosus patients.
Assessment of serum vascular endothelial growth factor and nail fold capillaroscopy changes in systemic lupus erythematosus with and without cutaneous manifestations.
Association of Circulating Vascular Endothelial Growth Factor Levels With Autoimmune Diseases: A Systematic Review and Meta-Analysis.
Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus.
Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus.
Comprehensive study of tumour single nucleotide polymorphism array data reveals significant driver aberrations and disrupted signalling pathways in human hepatocellular cancer.
IL-35, TNF-?, BAFF, and VEGF serum levels in patients with different rheumatic diseases.
Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin.
Influence of factor D concentrations on fluid phase C3 activation, lysis of rabbit erythrocytes and solubilization of immune complexes.
Investigating the role of angiogenesis in systemic lupus erythematosus.
Meta-analysis of associations of vascular endothelial growth factor protein levels and -634G/C polymorphism with systemic lupus erythematosus susceptibility.
Neuropilins and semaphorins - from angiogenesis to autoimmunity.
Serum level of complement factor D in systemic lupus erythematosus--an indicator of glomerular filtration rate.
Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.
Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus.
Systemic lupus erythematosus and atherosclerosis: Review of the literature.
The association of single nucleotide polymorphism within vascular endothelial growth factor gene with systemic lupus erythematosus and lupus nephritis.
The VEGFA -1154G/A polymorphism is associated with reduced risk of rheumatoid arthritis but not with systemic lupus erythematosus in Mexican women.
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study).
Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
Vascular endothelial growth factor G1612A (rs10434) gene polymorphism and neuropsychiatric manifestations in systemic lupus erythematosus patients.
Vascular endothelial growth factor in patients with rheumatoid arthritis.
Vascular endothelial growth factor in systemic lupus erythematosus - correlations with disease activity and nailfold capillaroscopy changes.
Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities.
Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.
Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
[A study on relationship between single nucleotide polymorphisms of vascular endothelial growth factor gene and susceptibility to systemic lupus erythematosus in China north Han population].
Lupus Nephritis
Decreased renal expression of vascular endothelial growth factor in lupus nephritis is associated with worse prognosis.
Imbalance between interleukin-6 and adrenomedullin mRNA levels in peripheral blood mononuclear cells of patients with lupus nephritis.
Lupus nephritis: review of the literature.
Serum level of complement factor D in systemic lupus erythematosus--an indicator of glomerular filtration rate.
Serum Vascular Endothelial Growth Factor (VEGF) as a Biomarker for Disease Activity in Lupus Nephritis.
Systemic lupus erythematosus and atherosclerosis: Review of the literature.
The association of single nucleotide polymorphism within vascular endothelial growth factor gene with systemic lupus erythematosus and lupus nephritis.
The detrimental effects of IFN-? on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.
Toll-like receptor 9 and vascular endothelial growth factor levels in human kidneys from lupus nephritis patients.
Vascular endothelial growth factor as a prognostic marker of lupus nephritis.
Lymphadenopathy
Atypical polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome without polyneuropathy: A case report.
Case Report: Challenges in the Diagnosis of Adenopathy and Extensive Skin Patch Overlying a Plasmacytoma Syndrome.
Monoclonal gammopathy of cutaneous significance: review of a relevant concept.
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
The expression and cellular localization of phosphorylated VEGFR2 in lymphoma and non-neoplastic lymphadenopathy: an immunohistochemical study.
Lymphangioleiomyomatosis
A 34-Year-Old Woman from Brazil with Pulmonary Lymphangioleiomyomatosis Diagnosed by Raised Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels and Lung Cysts on Computed Tomography Imaging Presenting with COVID-19 Pneumonia.
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation.
Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.
Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis.
Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM).
Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Methacholine reactivity in lymphangioleiomyomatosis is inversely related to FEV1 and VEGF-D.
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
Lymphangioma
Altered pigment epithelium-derived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence.
Axillary cavernous lymphangioma in pregnancy and puerperium.
Co-expression of VEGF-C and its receptors, VEGFR-2 and VEGFR-3, in endothelial cells of lymphangioma. Implication in autocrine or paracrine regulation of lymphangioma.
Lymphangioma involving the mandible: immunohistochemical expressions for the lymphatic proliferation.
Lymphatic endothelial tumors induced by intraperitoneal injection of incomplete Freund's adjuvant.
Multiple expressions of lymphatic markers and morphological evolution of newly formed lymphatics in lymphangioma and lymph node lymphangiogenesis.
Treatment of Tongue Lymphangioma with Intralesional Combination Injection of Steroid, Bleomycin and Bevacizumab.
Lymphangiomyoma
Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
Involvement of lymphatics in lymphangioleiomyomatosis.
Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Lymphatic Diseases
Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Lymphatic Metastasis
A critical role of vascular endothelial growth factor D in zebrafish embryonic vasculogenesis and angiogenesis.
Angiogenesis and the expression of vascular endothelial growth factors A and C in squamous cell carcinoma of the piriform fossa.
Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels.
Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression.
Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer.
Anti-metastatic Efficacy of Traditional Chinese Medicine (TCM) Ginsenoside Conjugated to a VEFGR-3 Antibody on Human Gastric Cancer in an Orthotopic Mouse Model.
Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C.
Assessment of VEGF-D expression measured by immunohistochemical staining and F-18 FDG uptake on PET as biological prognostic factors for recurrence in patients with surgically resected lung adenocarcinoma.
Association between expression of vascular endothelial growth factor C, chemokine receptor CXCR4 and lymph node metastasis in colorectal cancer.
Association between vascular endothelial growth factor expression and lymph node metastasis in cervical cancer: A meta-analysis.
Association of CXCR4, CCR7, VEGF-C and VEGF-D expression with lymph node metastasis in patients with cervical cancer.
Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma.
Associations between the expression of MTA1 and VEGF-C in esophageal squamous cell carcinoma with lymph angiogenesis and lymph node metastasis.
Associations of VEGF-C Genetic Polymorphisms with Urothelial Cell Carcinoma Susceptibility Differ between Smokers and Non-Smokers in Taiwan.
Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea.
c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation.
CCL21/CCR7 up-regulate vascular endothelial growth factor-D expression via ERK pathway in human non-small cell lung cancer cells.
CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma.
Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer.
circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGF?R1/VEGF-D signaling.
Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance?
Clinical Significance of Vascular Endothelial Growth Factors (VEGF)-C and -D in Resected Non-Small Cell Lung Cancer.
Clinicopathological and prognostic significance of hypoxia-inducible factor-1? in esophageal squamous cell carcinoma: a meta-analysis.
Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas.
Clinicopathological variables associated with lymph node metastasis in submucosal invasive gastric cancer.
Co-expression of ?9?1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN.
Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma.
Combination of IL-24 and cisplatin inhibits angiogenesis and lymphangiogenesis of cervical cancer xenografts in a nude mouse model by inhibiting VEGF, VEGF-C and PDGF-B.
Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma.
Correlation between vascular endothelial growth factor C expression and lymph node metastasis in T1 carcinoma of the colon and rectum.
Correlation between vascular endothelial growth factor expression and presence of lymph node metastasis in advanced squamous cell carcinoma of the larynx.
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.
Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer.
Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma.
Correlations of TNM staging and lymph node metastasis of gastric cancer with MRI features and VEGF expression.
COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer.
Cyclo-oxygenase-2 expression is associated with vascular endothelial growth factor C expression and lymph node metastasis in oral squamous cell carcinoma.
Deguelin-an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by down-regulation of vascular endothelial cell growth factor-D in lung tumor model.
Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases.
Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats.
Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis.
Down-regulation of platelet-derived growth factor-D expression blockades NF-?B pathway to inhibit cell proliferation and invasion as well as induce apoptosis in esophageal squamous cell carcinoma.
Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma.
Effect of local hyperthermia on lymphangiogenic factors VEGF-C and -D in a nude mouse xenograft model of tongue squamous cell carcinoma.
Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer.
Elevated VEGF-D Modulates Tumor Inflammation and Reduces the Growth of Carcinogen-Induced Skin Tumors.
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer.
Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells.
Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer.
Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis.
Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas.
Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma.
Expression of thymosin beta10 and its role in non-small cell lung cancer.
Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma.
Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis.
Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis.
Expression of vascular endothelial growth factor C and D (VEGF-C and -D) is an important risk factor for lymphatic metastasis in undifferentiated early gastric carcinoma.
Expression of vascular endothelial growth factor C and its correlation with lymph node metastasis in colorectal carcinoma.
Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas.
Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma.
Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis.
Expression of vascular endothelial growth factor in salivary gland carcinomas correlates with lymph node metastasis.
Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer.
Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer.
Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.
Expression of vascular endothelial growth factors C and D correlates with lymphangiogenesis and lymph node metastasis in lung adenocarcinoma.
Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma.
Expression of VEGF-C/VEGFR-3 in human laryngeal squamous cell carcinomas and its significance for lymphatic metastasis.
Expression of VEGF-D in epithelial ovarian cancer and its relationship to lymphatic metastasis.
Expression of VEGF-D, SMAD4, and SMAD7 and Their Relationship with Lymphangiogenesis and Prognosis in Colon Cancer.
Expressions of p53, VEGF C, p21: could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma?
Feasibility of MRI-based radiomics features for predicting lymph node metastases and VEGF expression in cervical cancer.
Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
High levels of circulating CD34+/VEGFR3+ lymphatic/vascular endothelial progenitor cells is correlated with lymph node metastasis in patients with epithelial ovarian cancer.
Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer.
Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications.
Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer.
Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma.
Immunohistochemical study of vascular endothelial growth factor (VEGF) and matrilysin (MMP-7) in T1 adenocarcinoma of the colon and rectum to predict lymph node metastases or distant metastases.
Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis.
Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis.
Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor-D.
Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer.
Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker.
Intratumoral lymphatics and lymphatic vessel invasion detected by d2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma.
Involvement of cyclooxygenase-2 and vascular endothelial growth factor in vascularization and lymph node metastasis of colorectal cancers with submucosal invasion.
Involvement of inactive GSK3beta overexpression in tumorigenesis and progression of gastric carcinomas.
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.
Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.
Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma.
Lymphangiogenesis and tumour metastasis.
Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer--A Structured Review with Meta-Analysis.
Lymphatic microvessel density as prognostic marker in colorectal cancer.
Lymphatic Vessel Density and Vascular Endothelial Growth Factor Expression in Squamous Cell Carcinomas of Lip and Oral Cavity: A Clinicopathological Analysis with Immunohistochemistry Using Antibodies to D2-40, VEGF-C and VEGF-D.
Lymphatic vessel density as a predictor of lymph node metastasis and its relationship with prognosis in urothelial carcinoma of the bladder.
Lymphatic vessel density in pulmonary adenocarcinoma immunohistochemically evaluated with anti-podoplanin or anti-D2-40 antibody is correlated with lymphatic invasion or lymph node metastases.
Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer.
Mammary cancer gene therapy targeting lymphangiogenesis: VEGF-C siRNA and soluble VEGF receptor-2, a splicing variant.
Markers of tumour angiogenesis and tumour cells in bone marrow in gastric cancer patients.
Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma.
Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment.
Metastasis-associated in colon cancer-1 upregulates vascular endothelial growth factor-C/D to promote lymphangiogenesis in human gastric cancer.
microRNA-382 suppresses the progression of pancreatic cancer through the PI3K/Akt signaling pathway by inhibition of Anxa3.
Microvascular density and vascular endothelial growth factor immunoreactivity as predictors of regional lymph node metastasis from betel-associated oral squamous cell carcinoma.
Neuropilin-2 expression in papillary thyroid carcinoma: correlation with VEGF-D expression, lymph node metastasis, and VEGF-D-induced aggressive cancer cell phenotype.
Nitric oxide in papillary thyroid carcinoma: induction of vascular endothelial growth factor D and correlation with lymph node metastasis.
Opposing Effects of Heparanase and Heparanase-2 in Head & Neck Cancer.
Over expression of vascular endothelial growth factor in correlation to Ki-67, grade, and stage of breast cancer.
Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.
Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin.
Pathways targeting tumor lymphangiogenesis.
PC4 induces lymphangiogenesis dependent VEGF-C/VEGF-D/VEGFR-3 axis activation in lung adenocarcinoma.
PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer.
Periostin directly and indirectly promotes tumor lymphangiogenesis of head and neck cancer.
Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients.
PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer.
Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.
Predicting lymph node metastasis in patients with papillary thyroid carcinoma by vascular index on power Doppler ultrasound.
Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer.
Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis.
Preoperative serum VEGF-C but not VEGF-A level is correlated with lateral neck metastasis in papillary thyroid carcinoma.
Primary Tumor-Secreted Lymphangiogenic Factors Induce Pre-Metastatic Lymphvascular Niche Formation at Sentinel Lymph Nodes in Oral Squamous Cell Carcinoma.
Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
Prognostic significance of vascular endothelial growth factor D in gastric carcinoma.
Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma.
Prognostic value of the immunohistochemical expression of vascular endothelial growth factors in malignant salivary gland neoplasms: a systematic review and meta-analysis.
Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer.
Quantitative analysis of lymphangiogenic markers in human gastroenteric tumor.
Quantitative analysis of VEGF-C mRNA of extrahepatic cholangiocarcinoma with real-time PCR using samples obtained during endoscopic retrograde cholangiopancreatography.
Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer.
Regulation of vascular endothelial growth factor D by orphan receptors hepatocyte nuclear factor-4 alpha and chicken ovalbumin upstream promoter transcription factors 1 and 2.
Relationship between expression of vascular endothelial growth factor and cervical lymph node metastasis in papillary thyroid cancer: A meta-analysis.
Relationship between vascular endothelial growth factor and Notch1 expression and lymphatic metastasis in tongue cancer.
Role of hypoxia-inducible factor-1?, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer.
Role of lymphangiogenesis in cancer.
Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer.
Role of vascular endothelial growth factor receptor-3/Flt-4 in early-stage cervical cancer.
Role of vascular endothelial growth factor-C and -D mRNA in breast cancer.
Semaphorin 3F Serves as a Tumor Suppressor in Esophageal Squamous Cell Carcinoma and is Associated With Lymph Node Metastasis in Disease Progression.
Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma.
Serum vascular endothelial growth factor-C and vascular endothelial growth factor level in patients with colorectal carcinoma and clinical significance.
Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis.
Serum vascular endothelial growth factor-D levels correlate with cervical lymph node metastases in papillary thyroid carcinoma.
Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma.
Silencing vascular endothelial growth factor C increases the radiosensitivity in nasopharyngeal carcinoma CNE-2 cells.
So05 the nature of nearby lymphatics dictates whether a vascular endothelial growth factor-d (VEGF-d) induces tumor lymphatics and metastasis.
Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
Steroid receptor coactivator-1 interacts with NF-?B to increase VEGFC levels in human thyroid cancer.
Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy.
Suppression of lymph node and lung metastases of endometrial cancer by muscle-mediated expression of soluble vascular endothelial growth factor receptor-3.
Suppression of vascular endothelial growth factor receptor 3 (VEGFR3) and vascular endothelial growth factor C (VEGFC) inhibits hypoxia-induced lymph node metastases in cervix cancer.
Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer.
Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.
The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
The effect of high Sox3 expression on lymphangiogenesis and lymph node metastasis in esophageal squamous cell carcinoma.
The effect of vascular endothelial growth factor C expression in tumor-associated macrophages on lymphangiogenesis and lymphatic metastasis in breast cancer.
The fibrinolysis inhibitor ?2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer.
The natural progression of microvasculature in primary tumor and lymph node metastases in a breast carcinoma model: relationship between microvessel density, vascular endothelial growth factor expression, and metastatic invasion.
The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer.
The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer.
The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma.
The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice.
The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
The VD1 Neutralizing Antibody to Vascular Endothelial Growth Factor-D: Binding Epitope and Relationship to Receptor Binding.
TNF-alpha promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP-1/VEGF-D pathway.
Transcriptional regulation of vascular endothelial growth factor C by oxidative and thermal stress is mediated by lens epithelium-derived growth factor/p75.
Tumor Invasiveness, Not Lymphangiogenesis, Is Correlated with Lymph Node Metastasis and Unfavorable Prognosis in Young Breast Cancer Patients (?35 Years).
Tumor necrosis factor-? promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-?B-mediated upregulation of vascular endothelial growth factor-C.
Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages.
Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients.
Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
Upregulation of Endocrine Gland-Derived Vascular Endothelial Growth Factor in Papillary Thyroid Cancers Displaying Infiltrative Patterns, Lymph Node Metastases, and BRAF Mutation.
Value of [18F]FDG PET radiomic features and VEGF expression in predicting pelvic lymphatic metastasis and their potential relationship in early-stage cervical squamous cell carcinoma.
Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.
Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma.
Vascular endothelial growth factor and lymph node metastasis in primary lung cancer.
Vascular endothelial growth factor and prognosis of cervical carcinoma.
Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis.
Vascular endothelial growth factor C and microvessel density in gastric carcinoma: correlation with clinicopathological factors. Our experience and review of the literature.
Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor.
Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma.
Vascular endothelial growth factor C is an indicator of lymph node metastasis in thoracic esophageal squamous cellcarcinomas and its role in long-term survival after surgery.
Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in mice.
Vascular endothelial growth factor C promotes lymph node metastasis in a rectal cancer orthotopic model.
Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms.
Vascular endothelial growth factor C and D expression correlates with lymph node metastasis and poor prognosis in patients with resected esophageal cancer.
Vascular endothelial growth factor D and intratumoral lymphatics as independent prognostic factors in epithelial ovarian carcinoma.
Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus.
Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis.
Vascular endothelial growth factor-C (VEGF-C) is a more specific risk factor for lymph node metastasis than VEGF-D in submucosal colorectal cancer.
Vascular endothelial growth factor-C and vascular endothelial growth factor-d messenger RNA expression in breast cancer: association with lymph node metastasis.
Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa.
Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas.
Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma.
Vascular endothelial growth factor-D is correlated with hepatic metastasis from gastric cancer after radical gastrectomy.
Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer.
Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy.
Vascular endothelial growth factors C and D and lymphangiogenesis at the early stage of esophageal squamous cell carcinoma progression.
Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis.
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis.
VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer.
VEGF-C and VEGF-D expression and its correlation with lymph node metastasis in esophageal squamous cell cancer tissue.
VEGF-C and VEGF-D expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: Implications for use as a prognostic marker.
VEGF-c expression in an in vivo model of orthotopic endometrial cancer and retroperitoneal lymph node metastasis.
VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors.
VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival.
VEGF-C, VEGF-D and VEGFR-3 expression in peripheral neuroblastic tumours.
VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis.
VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma.
VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab.
VEGF-D in Association With VEGFR-3 Promotes Nodal Metastasis in Human Invasive Lobular Breast Cancer.
VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma.
VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium.
VEGF-D(ilated) Lymphatics as Gateways to Metastasis.
VEGF-D-enhanced lymph node metastasis of ovarian cancer is reversed by vesicular stomatitis virus matrix protein.
VEGF-D-induced draining lymphatic enlargement and tumor lymphangiogenesis promote lymph node metastasis in a xenograft model of ovarian carcinoma.
[Correlation between the vascular endothelial growth factor C expression and lymph node metastasis in human nasopharyngeal carcinoma]
[Correlation of lymphangiogenesis to progression of colorectal cancer]
[Correlation of vascular endothelial growth factor D, microlymphatic density and microvessel density with development and metastasis of rectal cancer]
[Diagnostic value of enhanced computed tomography plus vascular endothelial growth factor C expression in hilar and mediastinal lymph node metastasis of non-small cell lung cancer].
[Expression and clinical significance of vascular endothelial growth factor C and D in nasopharyngeal carcinoma]
[Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma]
[Expression and significance of Bmi-1 in breast cancer]
[Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma]
[Expression of some biomarkers in primary colon adenocarcinomas and their lymph node metastases].
[Expression of vascular endothelial growth factor C in laryngeal squamous carcinoma and its role in lymphatic metastasis]
[Expression of vascular endothelial growth factor C in pancreatic cancer and its effect upon lymph node metastasis]
[Expression of vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and nm23-H1 in oral squamous cell carcinoma]
[Expression of VEGF-C and VEGF-D in gastric carcinoma and its relationship with lymph node metastases.]
[Expressions of VEGF-C and VEGF-D and their correlation with lymphangiogenesis and angiogenesis in gallbladder carcinoma]
[Mesh structure of two-dimensional tumor microvascular architecture phenotype heterogeneity in non-small cell lung cancer]
[New markers for pharmacological targeting in bladder cancer with lymph node metastasis]
[Quantitative study of vascular endothelial growth factor expression in primary lung cancer]
[Relation of vascular endothelial growth factor-D expression to microvessel density, microlymphatic vessel density, and lymph-node metastasis of lung adenocarcinoma]
[Relationship between clinicopathologic characteristics and expression of VEGF-C and VEGF-D in esophageal squamous cancer]
[Relationship between the expressions of KaI1, nm23, ETS-1, VEGF and microvascular density and clinical significance in nasopharyngeal carcinoma]
[Relationship between vascular endothelial growth factor C expression level and lymph node metastasis in non small cell lung cancer]
[Review of relationship between vascular endothelial growth factor C & D and lymph node metastasis of malignant tumor]
[Role of matrix metalloproteinase (MMP)-2 and -9 and vascular endothelial growth factor C in lymph node metastasis of breast cancer.]
[Roles of vascular endothelial growth factor and platelet-derived growth factor in lymphangiogenesis in epithelial ovarian carcinoma.]
[Study of mRNA expression of vascular endothelial growth factor-(A, C, D) genes and its effect on prognosis of breast cancer]
[Study on relationship between VEGF-C and lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.]
[Study on the relationship between angiogenesis and cervical lymphatic metastasis in head and neck squamous cell carcinomas]
[The relationship between lymphatic metastasis and serum vascular endothelial growth factor C and cyclooxygenase 2 expression in breast cancer]
[The relationship between vascular endothelial growth factor, microvascular density, lymph node metastasis and prognosis of breast carcinoma]
[Vascular endothelial growth factor (VEGF)-D in association with VEGF receptor-3 in lymphatic metastasis of breast cancer]
Lymphedema
A genetic Xenopus laevis tadpole model to study lymphangiogenesis.
A model for gene therapy of human hereditary lymphedema.
An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis.
An Important Role of VEGF-C in Promoting Lymphedema Development.
Arap3 is dysregulated in a mouse model of hypotrichosis-lymphedema-telangiectasia and regulates lymphatic vascular development.
Clinical variability in a Japanese hereditary lymphedema type I family with an FLT4 mutation.
Delivery of vascular endothelial growth factor (VEGFC) via engineered exosomes improves lymphedema.
Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Effect of vascular endothelial growth factor C (VEGF-C) gene transfer in rat model of secondary lymphedema.
Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infections.
Erratum to delivery of vascular endothelial growth factor (VEGFC) via engineered exosomes improves lymphedema.
Exogenous VEGF-C augments the efficacy of therapeutic lymphangiogenesis induced by allogenic bone marrow stromal cells in a rabbit model of limb secondary lymphedema.
Familial congenital non-immune hydrops, chylothorax, and pulmonary lymphangiectasia.
Immunohistochemical Evaluation of Histological Change in a Chinese Milroy Disease Family With Venous and Skin Abnormities.
Increased interstitial protein because of impaired lymph drainage does not induce fibrosis and inflammation in lymphedema.
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.
Lymphatic dysfunction, not aplasia, underlies Milroy disease.
Mutation in vascular endothelial growth factor-C, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant milroy-like primary lymphedema.
Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema.
Physiological Perspective on Therapies of Lymphatic Vessels.
Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies.
Primary congenital lymphedema complicated by hydrops fetalis: a case report and review of the literature.
Proteolytic Cleavages in the VEGF Family: Generating Diversity among Angiogenic VEGFs, Essential for the Activation of Lymphangiogenic VEGFs.
Serum level of VEGF-D in patients with primary lymphedema.
Use of Vascular Endothelial Growth Factor-D As a Targeted Therapy in Lymphedema Treatment: A Comprehensive Literature Review.
[Experimental studies of VEGF-C gene for the treatment of chronic obstructive lymphedema in mouse tail model]
Lymphocytosis
Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia.
Lymphohistiocytosis, Hemophagocytic
[Blood cytokine levels as a clinical laboratory test]
Lymphoma
Advances in target therapy in lung cancer.
Alopecia in patients treated with molecularly targeted anticancer therapies.
Amelioration of Dalton's lymphoma-induced angiogenesis by melatonin.
Analyses of novel prognostic factors in neuroblastoma patients.
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.
Angiogenesis in lymphoproliferative disorders.
Angiogenesis in malignant lymphoma.
Angiogenesis in nodal B cell lymphomas: a high throughput study.
Angiogenesis in primary central nervous system lymphoma (PCNSL).
Angiogenic and lymphangiogenic molecules in hematological malignancies.
Angioimmunoblastic T-cell lymphoma with intramedullary production of platelet-derived growth factor and possibly complicating myelofibrosis: report of a case with review of the literature.
Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Beta1 integrins mediate tubule formation induced by supernatants derived from KSHV-infected cells.
Bone marrow-derived mesenchymal stem cells overexpressing MiR-21 efficiently repair myocardial damage in rats.
Clinical development of targeted and immune based anti-cancer therapies.
Clinical significance of serum vascular endothelial growth factor, endostatin, and leptin levels in children with lymphoma.
Clinical Significance of VEGF-A and Microvessel Density in Diffuse Large B-Cell Lymphoma and Low-Grade Follicular Lymphoma.
Co-expression of vascular endothelial growth factor and its receptor, neuropilin-1, in a B cell lymphoma cell line (OHK) with primary effusion lymphoma immunophenotype.
Cocculus hirsutus: Molecular Docking to Identify Suitable Targets for Hepatocellular Carcinoma by In silico Technique.
Correlational study of vascular endothelial growth factor expression and microvessel density in primary malignant gastric lymphoma.
Cryptotanshinone exhibits therapeutical effects on cerebral stroke through the PI3K/AKT?eNOS signaling pathway.
Current and emerging medical treatments for non-small cell lung cancer: A primer for pulmonologists.
Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection.
Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas.
Diacylglycerol kinase-alpha mediates hepatocyte growth factor-induced epithelial cell scatter by regulating Rac activation and membrane ruffling.
Directed Therapies in Lung Cancer: New Hope?
Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?
Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
Effect of high cell density on the growth properties of tumor cells: a role in tumor cytotoxicity of chemotherapeutic drugs.
Effect of Shuangdan Mingmu capsule, a Chinese herbal formula, on oxidative stress-induced apoptosis of pericytes through PARP/GAPDH pathway.
Effects of R type and S type ginsenoside Rg3 on DNA methylation in human hepatocarcinoma cells.
Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in primary central nervous system lymphomas.
Expression of vascular endothelial growth factor and its receptors in canine lymphoma.
Expression of vascular endothelial growth factor in human ocular adnexal lymphoma.
Expression of vascular endothelial growth factor in lymphomas and Castleman's disease.
Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas.
Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation.
HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas.
Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects.
Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?
Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma.
Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD).
Inflammatory Myofibroblastic Tumor of the Urinary Bladder: A Case Report.
Inhibition of prostate cancer RM1 cell growth in vitro by hydroxyapatite nanoparticle?delivered short hairpin RNAs against Stat3.
Intravascular large B-cell lymphoma: report of three cases and analysis of the mTOR pathway.
Kaposi's sarcoma-associated herpesvirus glycoproteins B and K8.1 regulate virion egress and synthesis of vascular endothelial growth factor and viral interleukin-6 in BCBL-1 cells.
Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6.
Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).
Microcirculatory alteration in low-grade gastric mucosa-associated lymphoma by Helicobacter heilmannii infection: its relation to vascular endothelial growth factor and cyclooxygenase-2.
MicroRNA?15a?5p induces pulmonary artery smooth muscle cell apoptosis in a pulmonary arterial hypertension model via the VEGF/p38/MMP?2 signaling pathway.
Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes.
Microvessel density in normal lymph nodes and lymphomas of dogs and their correlation with vascular endothelial growth factor expression.
Model of angiogenesis in mice with severe combined immunodeficiency (SCID) and xenoengrafted with Epstein-Barr virus-transformed B cells.
Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
New targets and new mechanisms in lung cancer.
Novel Therapeutic Targets in Non-small Cell Lung Cancer.
Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms.
Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies.
Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations.
Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation.
Placental Growth Factor and Vascular Endothelial Growth Factor Together Regulate Tumour Progression via Increased Vasculature in Cutaneous T Cell Lymphoma.
Potentially life?threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).
Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six cases.
Primary CNS lymphoma arising in the region of the optic nerve presenting as loss of vision: 2 case reports, including a patient with a massive intracerebral hemorrhage.
Primary cutaneous anaplastic large cell lymphoma associated with vascular endothelial growth factor arising from a burn scar.
Primary cutaneous diffuse large B-cell lymphoma, leg type with features simulating POEMS syndrome.
Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy.
Quantitative analysis of vascular endothelial growth factor expression in chronic lymphocytic leukaemia.
R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.
Recent advances in non-small cell lung cancer biology and clinical management.
Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha.
Relationships between VEGF protein expression and pathological characteristics of diffuse large B cell lymphoma: a meta-analysis.
Relevance of radiobiological concepts in radionuclide therapy of cancer.
Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas.
Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator.
Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma.
Silencing STAT3 with short hairpin RNA enhances radiosensitivity of human laryngeal squamous cell carcinoma xenografts in vivo.
SIRT1 expression is associated with poor prognosis of lung adenocarcinoma.
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
Targeted therapies for lung cancer: clinical experience and novel agents.
Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.
Targeting Multiple Signaling Pathways in Cancer: The Rutin Therapeutic Approach.
Targeting the vascular endothelial growth factor (VEGF) in hematological malignancies.
The expression and cellular localization of phosphorylated VEGFR2 in lymphoma and non-neoplastic lymphadenopathy: an immunohistochemical study.
The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome.
The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.
The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study.
Tumor cell-activated CARD9 signaling contributes to metastasis-associated macrophage polarization.
Up-regulation of SNHG15 facilitates cell proliferation, migration, invasion and suppresses cell apoptosis in breast cancer by regulating miR-411-5p/VASP axis.
Vascular endothelial growth factor expression in low and high grade B-cell non-Hodgkin's lymphomas.
Vascular endothelial growth factor polymorphisms in mantle cell lymphoma.
VEGF and MMP-9: biomarkers for canine lymphoma.
VEGF protein expression is associated with a poor prognosis in cutaneous extranodal NK/T-cell lymphoma patients.
VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues.
VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma.
[Antitumor effect of recombinant Xenopus laevis vascular endothelial growth factor (VEGF) as a vaccine combined with adriamycin on EL4 lymphoma in mice]
[Clinical Significance of TF and VEGF Expressions on Peripheral CD14 Positive Monocytes in Patients with Diffuse Large B Cell Lymphoma].
[Effect of vascular endothelial growth factor antisense oligodeoxynucleotides on angiogenesis in lymphoma of nude mice.]
[Plasma levels of VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in patients with newly diagnosed lymphomas].
[RS3PE syndrome associated with senile Epstein-Barr virus-positive diffuse large B cell lymphoma of a patient with colon cancer].
[Silencing of signal transducer and activator of transcription 3 gene expression using RNAi enhances the efficacy of radiotherapy for laryngeal carcinoma in vivo]
Lymphoma, B-Cell
Abnormal expression of microRNA-575 leads to missed abortion through regulating apoptosis and angiogenesis.
Abnormal vascular endothelial growth factor protein expression may be correlated with poor prognosis in diffuse large B-cell lymphoma: A meta-analysis.
Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma.
Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma.
Anticancer Effects of Gold Nanoparticles by Inducing Apoptosis in Bladder Cancer 5637 Cells.
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Atrial fibrillation is associated with cardiac hypoxia.
Behavior pattern of early-stage ocular surface squamous cell carcinoma in non-HIV patients.
Bevacizumab Modulation of the Interaction Between the MCF-7 Cell Line and the Chick Embryo Chorioallantoic Membrane.
Biology of Oestrogen-Receptor Positive Primary Breast Cancer in Older Women with Utilisation of Core Needle Biopsy Samples and Correlation with Clinical Outcome.
Bone marrow mesenchymal stem cells preconditioned with nitric oxide releasing chitosan/PVA hydrogel attenuate diabetic wound healing in rabbits.
Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas.
Bone marrow-derived mesenchymal stem cells overexpressing MiR-21 efficiently repair myocardial damage in rats.
Circadian rhythm genes in cancer: insight into their functions and regulation involving noncoding RNAs.
Co-expression of vascular endothelial growth factor and its receptor, neuropilin-1, in a B cell lymphoma cell line (OHK) with primary effusion lymphoma immunophenotype.
Combination Efficacy of Astragalus membranaceus and Curcuma wenyujin at Different Stages of Tumor Progression in an Imageable Orthotopic Nude Mouse Model of Metastatic Human Ovarian Cancer Expressing Red Fluorescent Protein.
Daucosterol linolenate from Sweet Potato Suppresses MCF7-Xenograft-Tumor Growth through Regulating PI3K/AKT Pathway.
Differential cytotoxic effects of sodium meta-arsenite on human cancer cells, dental papilla stem cells and somatic cells correlate with telomeric properties and gene expression.
Effect of Shuangdan Mingmu capsule, a Chinese herbal formula, on oxidative stress-induced apoptosis of pericytes through PARP/GAPDH pathway.
Effects of a nutrient mixture on immunohistochemical localization of cancer markers in human cervical cancer HeLa cell tumor xenografts in female nude mice.
Effects of R type and S type ginsenoside Rg3 on DNA methylation in human hepatocarcinoma cells.
EPO Mediates Neurotrophic, Neuroprotective, Anti-Oxidant, and Anti-Apoptotic Effects via Downregulation of miR-451 and miR-885-5p in SH-SY5Y Neuron-Like Cells.
Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells.
Exercise training attenuates dexamethasone-induced hypertension by improving autonomic balance to the heart, sympathetic vascular modulation and skeletal muscle microcirculation.
Exercise Training Prevents Dexamethasone-induced Rarefaction.
Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas.
Extracts of endophytic fungus xkc-s03 from Prunella vulgaris L. spica inhibit gastric cancer in vitro and in vivo.
GOLPH3 Promotes Angiogenesis of Lung Adenocarcinoma by Regulating the Wnt/?-Catenin Signaling Pathway.
Hemorrhage and VEGF expression in a case of primary CNS lymphoma.
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy.
Human colon carcinogenesis is associated with increased interleukin-17-driven inflammatory responses.
Immunoexpression of vascular endothelial growth factor and B-cell lymphoma 2 in the uterine tissue of rats treated with melatonin in the estrus phase1.
Implantation of Endothelial Cells with Mesenchymal Stem Cells Accelerates Dental Pulp Tissue Regeneration/Healing in Pulpotomized Rat Molars.
Inhibition of prostate cancer RM1 cell growth in vitro by hydroxyapatite nanoparticle?delivered short hairpin RNAs against Stat3.
Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-Jun Activation in Renal Cell Carcinoma.
Mechanism of FGF7 gene silencing in regulating viability, apoptosis, invasion of retinoblastoma cell line HXO-Rb44 and angiogenesis.
Melatonin reverses flow shear stress-induced injury in bone marrow mesenchymal stem cells via activation of AMP-activated protein kinase signaling.
Metformin in combination with cisplatin inhibits cell viability and induces apoptosis of human ovarian cancer cells by inactivating ERK 1/2.
microRNA-613 exerts anti-angiogenic effect on nasopharyngeal carcinoma cells through inactivating the AKT signaling pathway by down-regulating FN1.
Microvessel Density and Expression of Vascular Endothelial Growth Factor and its Receptors in Different Subtypes of Primary Cutaneous B-cell Lymphoma.
Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes.
MOXIBUSTION ALLEVIATES GASTRIC PRECANCEROUS LESIONS IN RATS BY PROMOTING CELL APOPTOSIS AND INHIBITING PROLIFERATION-RELATED ONCOGENES.
Nigella sativa and cancer: A review focusing on breast cancer, inhibition of metastasis and enhancement of Natural Killer cell cytotoxicity.
Novel Insights on the Corpus Luteum Function: Role of Vaspin on Porcine Luteal Cell Angiogenesis, Proliferation and Apoptosis by Activation of GRP78 Receptor and MAP3/1 Kinase Pathways.
Overexpression of E74-Like Factor 5 (ELF5) Inhibits Migration and Invasion of Ovarian Cancer Cells.
Ozone increases plasma kynurenine-tryptophan ratio and impacts hippocampal serotonin receptor and neurotrophic factor expression: Role of stress hormones.
Paeonol enhances the sensitivity of human ovarian cancer cells to radiotherapy-induced apoptosis due to downregulation of the phosphatidylinositol-3-kinase/Akt/phosphatase and tensin homolog pathway and inhibition of vascular endothelial growth factor.
Phase II Open Label Study of the oral VEGF-Receptor inhibitor PTK787/ZK222584 (Vatalanib) in Adult Patients with Refractory or Relapsed Diffuse Large B Cell Lymphoma.
Population differences in breast cancer: survey in indigenous african women reveals over-representation of triple-negative breast cancer.
Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers.
Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma.
Primary cutaneous diffuse large B-cell lymphoma, leg type, with expression of both vascular endothelial growth factor and its receptors.
Prognostic significance of hypoxia inducible factor-1? and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab.
Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy.
Protective Effect of Polydeoxyribonucleotide Against Renal Ischemia-Reperfusion Injury in Mice.
Puerarin 6?-O-xyloside possesses significant antitumor activities on colon cancer through inducing apoptosis.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Relationships between VEGF protein expression and pathological characteristics of diffuse large B cell lymphoma: a meta-analysis.
Role of putrescine in ovary and embryo development in fruit bat Cynopterus sphinx during embryonic diapause.
Shuxuetong injection protects cerebral microvascular endothelial cells against oxygen-glucose deprivation reperfusion.
Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma.
Silencing of PTGS2 exerts promoting effects on angiogenesis endothelial progenitor cells in mice with ischemic stroke via repression of the NF-?B signaling pathway.
Silencing STAT3 with short hairpin RNA enhances radiosensitivity of human laryngeal squamous cell carcinoma xenografts in vivo.
Sinoporphyrin Sodium-Mediated Sonodynamic Therapy Inhibits RIP3 Expression and Induces Apoptosis in the H446 Small Cell Lung Cancer Cell Line.
Survivin Signaling in Clinical Oncology: A Multifaceted Dragon.
Syringic acid modulates molecular marker-involved cell proliferation, survival, apoptosis, inflammation, and angiogenesis in DMBA-induced oral squamous cell carcinoma in Syrian hamsters.
Targeting Multiple Signaling Pathways in Cancer: The Rutin Therapeutic Approach.
Tea phytochemicals for breast cancer prevention and intervention: From bench to bedside and beyond.
The aryl hydrocarbon receptor nuclear translocator is an essential regulator of murine hematopoietic stem cell viability.
The effects of doxycycline and micronized purified flavonoid fraction on human vein wall remodeling are not hypoxia-inducible factor pathway-dependent.
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome.
The pro-inflammatory role of high-mobility group box 1 protein (HMGB-1) in photoreceptors and retinal explants exposed to elevated pressure.
The Role of Nrf2 Activity in Cancer Development and Progression.
The transcription factor FOXA1 induces epithelial ovarian cancer tumorigenesis and progression.
Thymoquinone chemosensitizes colon cancer cells through inhibition of NF-?B.
Training counteracts DEX-induced microvascular rarefaction by improving the balance between apoptotic and angiogenic proteins.
Up-regulation of SNHG15 facilitates cell proliferation, migration, invasion and suppresses cell apoptosis in breast cancer by regulating miR-411-5p/VASP axis.
VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma.
[Clinical Significance of TF and VEGF Expressions on Peripheral CD14 Positive Monocytes in Patients with Diffuse Large B Cell Lymphoma].
[Effects of hypoxia-inducible factor 1? on hypoxic tolerance of human amniotic mesenchymal stem cells].
[Effects of severe hypoxia and low concentration of serum protein on the function of human hypertrophic scar fibroblasts].
[Expression of VEGF and its significance in primary diffuse large B-cell lymphoma of the female genital system]
[Silencing of signal transducer and activator of transcription 3 gene expression using RNAi enhances the efficacy of radiotherapy for laryngeal carcinoma in vivo]
Lymphoma, B-Cell, Marginal Zone
New Pharmaceutical Treatment of Gastric MALT Lymphoma: Anti-angiogenesis Treatment using VEGF Receptor Antibodies and Celecoxib.
Lymphoma, Follicular
Peliosis hepatis associated with follicular lymphoma with a rise in vascular endothelial growth factor and anaemia of inflammation.
Lymphoma, Large B-Cell, Diffuse
Abnormal vascular endothelial growth factor protein expression may be correlated with poor prognosis in diffuse large B-cell lymphoma: A meta-analysis.
Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma.
Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas.
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy.
Microvessel Density and Expression of Vascular Endothelial Growth Factor and its Receptors in Different Subtypes of Primary Cutaneous B-cell Lymphoma.
Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes.
Phase II Open Label Study of the oral VEGF-Receptor inhibitor PTK787/ZK222584 (Vatalanib) in Adult Patients with Refractory or Relapsed Diffuse Large B Cell Lymphoma.
Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma.
Primary cutaneous diffuse large B-cell lymphoma, leg type, with expression of both vascular endothelial growth factor and its receptors.
Prognostic significance of hypoxia inducible factor-1? and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab.
Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy.
Relationships between VEGF protein expression and pathological characteristics of diffuse large B cell lymphoma: a meta-analysis.
Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma.
The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome.
VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma.
[Clinical Significance of TF and VEGF Expressions on Peripheral CD14 Positive Monocytes in Patients with Diffuse Large B Cell Lymphoma].
[Expression of VEGF and its significance in primary diffuse large B-cell lymphoma of the female genital system]
Lymphoma, Large-Cell, Anaplastic
Primary cutaneous anaplastic large cell lymphoma associated with vascular endothelial growth factor arising from a burn scar.
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
Lymphoma, Mantle-Cell
Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma.
Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms.
Relevance of radiobiological concepts in radionuclide therapy of cancer.
Vascular endothelial growth factor polymorphisms in mantle cell lymphoma.
Lymphoma, Non-Hodgkin
A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.
Are the high serum interleukin-6 and vascular endothelial growth factor levels useful prognostic markers in aggressive non-hodgkin lymphoma patients?
Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas.
Clinical Significance of Tissue Factor and Vascular Endothelial Growth Factor Expressions on CD14+ Monocytes in Patients with Non Hodgkin Lymphoma.
Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma.
Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma.
Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma.
Levels of bone marrow microvessel density are crucial for evaluating the status of acute myeloid leukemia.
Primary Central Nervous System Lymphoma Presenting as Growing Intracerebral Hemorrhage.
Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma.
Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma.
Relevance of radiobiological concepts in radionuclide therapy of cancer.
Role of gelatinases (MMP-2 and MMP-9), TIMP-1, vascular endothelial growth factor (VEGF), and microvessel density on the clinicopathological behavior of childhood non-Hodgkin lymphoma.
Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.
Vascular endothelial growth factor concentrations from platelets correlate with tumor angiogenesis and grading in a spontaneous canine non-Hodgkin lymphoma model.
Vascular endothelial growth factor expression in low and high grade B-cell non-Hodgkin's lymphomas.
Vascular endothelial growth factor expression in pediatric non-Hodgkin lymphoma: A prospective study.
VEGF overexpression is a valuable prognostic factor for non-Hodgkin's lymphoma evidence from a systemic meta-analysis.
VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues.
[Angiogenesis and hematologic malignancy]
[Clinical Significance of Serum Lactate Dehydrogenase, ?2-microglobulin and Vascular Endothelial Growth Factor Level Detection in Patients with Non-Hodgkin's Lymphoma].
[Plasma levels of VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in patients with newly diagnosed lymphomas].
[Vascular endothelial growth factor (VEGF) serum concentration in non-Hodgkin's lymphoma patients]
Lymphoma, Primary Cutaneous Anaplastic Large Cell
Primary cutaneous anaplastic large cell lymphoma associated with vascular endothelial growth factor arising from a burn scar.
Lymphoma, Primary Effusion
Beta1 integrins mediate tubule formation induced by supernatants derived from KSHV-infected cells.
Co-expression of vascular endothelial growth factor and its receptor, neuropilin-1, in a B cell lymphoma cell line (OHK) with primary effusion lymphoma immunophenotype.
Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas.
Kaposi's sarcoma-associated herpesvirus glycoproteins B and K8.1 regulate virion egress and synthesis of vascular endothelial growth factor and viral interleukin-6 in BCBL-1 cells.
Lymphoma, T-Cell
A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome.
Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways.
Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies.
Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations.
Lymphoma, T-Cell, Cutaneous
Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma.
Placental Growth Factor and Vascular Endothelial Growth Factor Together Regulate Tumour Progression via Increased Vasculature in Cutaneous T Cell Lymphoma.
Vascular endothelial growth factor receptor-3 (VEGFR-3) expression in mycosis fungoides.
Lymphoma, T-Cell, Peripheral
Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified.
Lymphopenia
Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer.
Lymphoproliferative Disorders
Angiogenesis in lymphoproliferative disorders: a therapeutic target?
Borderline Case of TAFRO Syndrome and POEMS Syndrome.
Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders.
The role of angiogenesis in human non-hodgkin lymphomas.
Macular Degeneration
A case of recalcitrant neovascular wet age-related macular degeneration treated with Intravitreal Brolucizumab.
A centrifugal fluidic immunoassay for ocular diagnostics with an enzymatically hydrolyzed fluorogenic substrate.
A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
A Mechanistic and Translational Pharmacokinetic-Pharmacodynamic Model of Abicipar Pegol and VEGF Inhibition.
A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab.
A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes.
A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration.
A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration.
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.
A review of clinical trials of anti-VEGF agents for diabetic retinopathy.
A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.
A view on new drugs for macular degeneration.
AAV2 Delivery of Flt23k Intraceptors Inhibits Murine Choroidal Neovascularization.
Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response.
Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.
Aflibercept for Radiation Maculopathy Study: A Prospective, Randomized Clinical Study.
Aflibercept in wet age-related macular degeneration: a perspective review.
Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Aflibercept.
Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases.
Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration.
Aflibercept: an update on recent milestones achieved.
Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction.
Age-related macular degeneration.
Age-related macular degeneration: current treatment and future options.
Age-related maculopathy - linking aetiology and pathophysiological changes to the ischaemia hypothesis.
Analysis of VEGF--a regulated gene expression in endothelial cells to identify genes linked to angiogenesis.
Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease.
Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases.
Anti-Vascular Endothelial Growth Factors as a Potential Risk for Implant Failure: A Clinical Report.
Antiangiogenic effects of axitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on laser-induced choroidal neovascularization in mice.
Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization.
Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration.
APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration.
Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application.
Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.
Aqueous Humor Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Bevacizumab in Type 3 vs Type 1 and 2 Neovascularization. A Prospective, Case-Control Study.
Aqueous interleukin-6 levels are superior to vascular endothelial growth factor in predicting therapeutic response to bevacizumab in age-related macular degeneration.
Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration.
Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration.
Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration.
Association analysis of genetic polymorphisms and expression levels of selected genes involved in extracellular matrix turnover and angiogenesis with the risk of age-related macular degeneration.
Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.
Association between retinal thickness variation and visual acuity change in neovascular age-related macular degeneration.
Association between vascular endothelial growth factor +936 C/T gene polymorphism and age-related macular degeneration.
Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population.
Association between Vascular Endothelial Growth Factor Polymorphisms and Age-Related Macular Degeneration: An Updated Meta-Analysis.
Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis.
Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor.
Association of Complement Factor D and H Polymorphisms with Recurrent Pregnancy Loss.
Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines.
Basal and apical regulation of VEGF-A and placenta growth factor in the RPE/choroid and primary RPE.
Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes.
Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells.
Binocular Fixation Reduces Fixational Eye Movements in the Worst Eye of Patients with Center-Involving Diabetic Macular Edema.
Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist.
Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Blocking VEGF signaling augments interleukin-8 secretion via MEK/ERK/1/2 axis in human retinal pigment epithelial cells.
Brolucizumab: First Approval.
CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration.
CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIA.
Changes in Aqueous Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor after Ranibizumab Alone or Combined with Verteporfin for Exudative Age-related Macular Degeneration.
Chemical Proteomics Reveals Soluble Epoxide Hydrolase as a Therapeutic Target for Ocular Neovascularization.
Choroidal neovascularization regression on fluorescein angiography after VEGF blockade.
Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients-A cross-sectional study.
Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
Clinical use of Bevacizumab in treating refractory glaucoma.
Clinicopathologic correlation of retinal angiomatous proliferation.
Combination therapy for age-related macular degeneration.
Comparative study of photodynamic therapy monotherapy versus triple management in age-related macular degeneration.
Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
Comparison of intravitreal injections of Ranibizumab and Aflibercept in neovascular age related macular degeneration.
Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration.
Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
Complement factor D in age-related macular degeneration.
Complement Factor H and High-Temperature Requirement A-1 Genotypes and Treatment Response of Age-related Macular Degeneration.
Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications.
Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway.
Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema.
Conbercept for patients with age-related macular degeneration: a systematic review.
Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment.
CONSEQUENCES OF LAPSES IN TREATMENT WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN ROUTINE CLINICAL PRACTICE.
Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration.
Controlled release of anti-VEGF by redox-responsive polydopamine nanoparticles.
Correlation of Indocyanine Green Angiography Findings and Expression of Vascular Endothelial Growth Factor in Surgically Excised Age-related Macular Degeneration-related Choroidal Neovascular Membranes.
Creation of different bioluminescence resonance energy transfer based biosensors with high affinity to VEGF.
Critical Role of Trophic Factors in Protecting Müller Glia: Implications to Neuroprotection in Age-Related Macular Degeneration, Diabetic Retinopathy, and Anti-VEGF Therapies.
Current status of anti-vascular endothelial growth factor therapy in Europe.
Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration.
Cyclic RGD Peptide Targeting Coated Nano Drug Co-Delivery System for Therapeutic Use in Age-Related Macular Degeneration Disease.
Detection of aqueous VEGF concentrations before and after intravitreal injection of anti-VEGF antibody using low-volume sampling paper-based ELISA.
Detection of inducible nitric oxide synthase and vascular endothelial growth factor in choroidal neovascular membranes.
Development of a Sustainable Release System for a Ranibizumab Biosimilar Using Poly(lactic-co-glycolic acid) Biodegradable Polymer-Based Microparticles as a Platform.
Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD.
Development of facile drug delivery platform of ranibizumab fabricated PLGA-PEGylated magnetic nanoparticles for age-related macular degeneration therapy.
Different plasma levels of vascular endothelial growth factor and nitric oxide between patients with choroidal and retinal neovascularization.
Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
Discovery and development of anticancer aptamers.
Disparities in access to anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration.
Distribution of the C-460T polymorphism of the vascular endothelial growth factor gene in age-related macular degeneration.
Dose-Response Relationship between Intravitreal Injections and Retinal Nerve Fiber Layer Thinning in Age-Related Macular Degeneration.
Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.
Dynamic retinal vessel response to flicker in age-related macular degeneration patients before and after vascular endothelial growth factor inhibitor injection.
Dynamics of soluble vascular endothelial growth factor receptors and their ligands in aqueous humour during ranibizumab for age-related macular degeneration.
Effect of posterior vitreous detachment on aqueous humor level of vascular endothelial growth factor in exudative age-related macular degeneration patients.
Effect of Risk Alleles in CFH, C3, and VEGFA on the Response to Intravitreal Bevacizumab in Tunisian Patients with Neovascular Age-related Macular Degeneration.
Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes.
EFFECTS OF VEGF INHIBITION ON RETINAL MORPHOLOGY, NEOVASCULAR NETWORK SIZE, AND VISUAL ACUITY IN PATIENTS WITH VASCULARIZED PIGMENT EPITHELIUM DETACHMENT BECAUSE OF OCCULT CHOROIDAL NEOVASCULARIZATION.
Electrospun formulations of bevacizumab for sustained release in the eye.
Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration.
Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms.
Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration.
Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration.
Evaluation of VEGF-Induced Vascular Permeability in Mice.
Evaluation of Very High- and Very Low-Dose Intravitreal Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.
Evolving multidimensional pharmacological approaches to CNV therapy in AMD.
Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration.
Exudative AMD subtypes and eligibility for treatment with ranibizumab.
Fibrotic Changes and Endothelial-to-Mesenchymal Transition Promoted by VEGFR2 Antagonism Alter the Therapeutic Effects of VEGFA Pathway Blockage in a Mouse Model of Choroidal Neovascularization.
Four-week outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.
Freezing adversely affects measurement of vascular endothelial growth factor levels in human aqueous samples.
Fucoidan as a Potential Therapeutic for Major Blinding Diseases-A Hypothesis.
Fucoidan reduces secretion and expression of vascular endothelial growth factor in the retinal pigment epithelium and reduces angiogenesis in vitro.
Gold Nanocrystals with Well-Defined Crystallographic {111} Facets Suppress Pathological Neovascularization.
Heat-sensitive TRPV channels in retinal pigment epithelial cells: regulation of VEGF-A secretion.
High-affinity VEGF antagonists by oligomerization of a minimal sequence VEGF-binding domain.
Highly bioactive, bevacizumab-loaded, sustained-release PLGA/PCADK microspheres for intravitreal therapy in ocular diseases.
HIV-1-mediated delivery of a short hairpin RNA targeting vascular endothelial growth factor in human retinal pigment epithelium cells.
Human Vascular Endothelial Growth Factor A165 Expression Induces the Mouse Model of Neovascular Age-Related Macular Degeneration.
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
Hypoxia-Inducible Factor (HIF)/Vascular Endothelial Growth Factor (VEGF) Signaling in the Retina.
IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys.
Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation.
Increased electroretinogram a-wave amplitude after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?
Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells.
Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.
Influence of Ranibizumab on Vascular Endothelial Growth Factor Plasma Level and Endothelial Progenitor Cell Mobilization in Age-Related Macular Degeneration Patients: Safety of Intravitreal Treatment for Vascular Homeostasis.
Influence of VEGF-C936T genetic variant on age-related macular degeneration.
Inhibition of Choroidal Neovascularization in a Nonhuman Primate Model by Intravitreal Administration of an AAV2 Vector Expressing a Novel Anti-VEGF Molecule.
Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1.
Inhibitors of factor d may provide a treatment for age-related macular degeneration.
Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.
Initial utilization of aflibercept in exudative age-related macular degeneration.
Insights into stem cell therapy for diabetic retinopathy: a bibliometric and visual analysis.
Interactive expressions of HtrA1 and VEGF in human vitreous humors and fetal RPE cells.
Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration.
Interleukin-1? inhibition prevents choroidal neovascularization and does not exacerbate photoreceptor degeneration.
INTRAOCULAR GROWTH FACTORS AND CYTOKINES IN PATIENTS WITH DRY AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration.
Intravitreal anti-VEGF agents and cardiovascular risk.
Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study.
Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration.
Intravitreal ranibizumab and bevacizumab: a review of risk.
Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial.
IQGAP1-dependent signaling pathway regulates endothelial cell proliferation and angiogenesis.
Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?
Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.
Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use.
Lactoferrin Has a Therapeutic Effect via HIF Inhibition in a Murine Model of Choroidal Neovascularization.
Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice.
Lessons Learned From Avastin and OCT-The Great, the Good, the Bad, and the Ugly: The LXXV Edward Jackson Memorial Lecture.
Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
Long-term alterations of systemic vascular endothelial growth factor levels in patients treated with ranibizumab for age-related macular degeneration.
Long-term anti-VEGF treatment for neovascular age-related macular degeneration. The LATAR Study Report 1: Ten-year, real-world outcomes.
Long-Term Effects of Multiple Intravitreal Anti- Vascular Endothelial Growth Factor Injections on Intraocular Pressure.
Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization.
Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Long-term Stability of Vascular Endothelial Growth Factor Suppression Time Under Ranibizumab Treatment in Age-Related Macular Degeneration.
Longitudinal phenotypic study of late-onset retinal degeneration due to a founder variant c.562C>A p.(Pro188Thr) in the C1QTNF5 gene.
Lutein and Factor D: Two intriguing players in the field of age-related macular degeneration.
MACULAR ATROPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Post Hoc Analysis of Patients With Pigment Epithelial Detachments.
Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Macular Hole Formation After Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration.
Management of retinal vascular diseases: a patient-centric approach.
Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy.
Müller cell-derived VEGF is a significant contributor to retinal neovascularization.
Molecular regulation of vascular endothelial growth factor expression in the retinal pigment epithelium.
Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration.
MYOCARDIAL INFARCTION AFTER INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS: A Whole Population Study.
Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry.
New Therapies of Neovascular AMD beyond Anti-VEGF Injections.
Non-physician delivered intravitreal injection service is feasible and safe - a systematic review.
Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration.
Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization.
Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis.
Ocular Gene Therapy.
Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration.
Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases.
Optical Coherence Tomography Angiography during Follow-Up: Qualitative and Quantitative Analysis of Mixed Type I and II Choroidal Neovascularization after Vascular Endothelial Growth Factor Trap Therapy.
Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months.
Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization.
Oxalomalate reduces expression and secretion of vascular endothelial growth factor in the retinal pigment epithelium and inhibits angiogenesis: Implications for age-related macular degeneration.
Pattern electroretinography in age-related macular degeneration.
PEDF and VEGF plasma level alterations in patients with dry form of age-related degeneration--a possible link to the development of the disease.
Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.
Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany.
Pegaptanib: in exudative age-related macular degeneration.
Persistent Suppression of Ocular Neovascularization with Intravitreal Administration of AAVrh.10 Coding for Bevacizumab.
Pharmacogenetic Aspects in Therapeutic Management of Subfoveal Choroidal Neovascularisation: Role of Factor XIII-A 185 T-Allele.
Pharmacogenetic Associations with Vascular Endothelial Growth Factor Inhibition in Participants with Neovascular Age-Related Macular Degeneration in the IVAN Study.
PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE).
Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor trap-eye).
Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration.
Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.
Plasma levels of complement proteins from the alternative pathway in patients with age-related macular degeneration are independent of Complement Factor H Tyr(402)His polymorphism.
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study.
Pooled-analysis of the associations between three polymorphisms in the VEGF gene and age-related macular degeneration.
Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy.
Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load.
Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.
Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization.
Preclinical evaluation of a phosphorothioate oligonucleotide in the retina of rhesus monkey.
Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration.
Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration.
Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.
PREDICTORS OF Anti-VEGF-ASSOCIATED RETINAL PIGMENT EPITHELIAL TEAR USING FA AND OCT ANALYSIS.
Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study.
Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab.
Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project.
PREVALENCE AND RISK FACTORS FOR THE DEVELOPMENT OF PHYSICIAN-GRADED SUBRETINAL FIBROSIS IN EYES TREATED FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration.
Production of scFv antibody fragments from a hybridoma with functional activity against human vascular endothelial growth factor.
Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration.
Protamine sulfate downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF and its receptor binding in vitro.
Putting theories and results into practice: managing cases.
Quantification of the vascular endothelial growth factor with a bioluminescence resonance energy transfer (BRET) based single molecule biosensor.
Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
Ranibizumab and risk of hospitalisation for ischaemic stroke and myocardial infarction in patients with age-related macular degeneration: a self-controlled case-series analysis.
Ranibizumab for exudative age-related macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors.
Ranibizumab for neovascular age-related macular degeneration.
Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Ranibizumab interacts with the VEGF-A/VEGFR-2 signaling pathway in human RPE cells at different levels.
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration.
Ranibizumab: treatment in patients with neovascular age-related macular degeneration.
Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis.
Rapid One-Step Selection Method for Generating Nucleic Acid Aptamers: Development of a DNA Aptamer against ?-Bungarotoxin.
Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors.
Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration.
Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease.
Recent advances in the management and understanding of macular degeneration.
Receptor-associated prorenin system in the pathogenesis of retinal diseases.
Recombinant human VEGF165b inhibits experimental choroidal neovascularisation.
Recovery of plasma vascular endothelial growth factor concentrations during aflibercept loading phase and after the transition to bimonthly treatment for neovascular age-related macular degeneration.
Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen.
Red Wine Extract Inhibits VEGF Secretion and Its Signaling Pathway in Retinal ARPE-19 Cells to Potentially Disrupt AMD.
Reduction of choroidal neovascularization via cleavable VEGF antibodies conjugated to exosomes derived from regulatory T cells.
Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes.
Regulation of vascular endothelial junction stability and remodeling through Rap1-Rasip1 signaling.
Relationship between aflibercept efficacy and genetic variants of genes associated to neovascular age-related macular degeneration. BIOIMAGE trial.
Retinal and Choroidal Changes after Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration.
Retinal pigment epithelial tear after intravitreal aflibercept for neovascular age-related macular degeneration.
RNA interference as a gene-specific approach for molecular medicine.
Role of Vascular Endothelial Growth Factor Polymorphisms in the Treatment Success in Patients with Wet Age-related Macular Degeneration.
Roles of three common VEGF polymorphisms in the risk of age-related macular degeneration.
Safety and Effectiveness of Cataract Surgery with Simultaneous Intravitreal Anti-VEGF in Patients with Previously Treated Exudative Age-Related Macular Degeneration.
Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.
Safety of ranibizumab therapy in wet AMD and the role of vascular endothelial growth factors in physiological angiogenesis.
SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration.
Selective binding of C-6 OH sulfated hyaluronic acid to the angiogenic isoform of VEGF(165).
Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration.
Senescent retinal pigment epithelial cells are more sensitive to vascular endothelial growth factor: implications for "wet" age-related macular degeneration.
Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
Serum levels of ARMS2, COL8A1, RAD51B, and VEGF and their correlations in Age-Related Macular Degeneration.
SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events.
Serum vascular endothelial growth factor receptor-2 and adropin levels in age-related macular degeneration.
Serum VEGF and CFH in exudative age-related macular degeneration.
Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration.
Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
Short-time effect of intravitreal injections on retinal vascular oxygenation and vessel diameter in patients with diabetic macular oedema or neovascular age-related macular degeneration.
SLC7A11 Reduces Laser-Induced Choroidal Neovascularization by Inhibiting RPE Ferroptosis and VEGF Production.
Small-molecule factor D inhibitors targeting the alternative complement pathway.
SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
SNAI1, an endothelial-mesenchymal transition transcription factor, promotes the early phase of ocular neovascularization.
Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor.
Splicing factor polymorphisms, the control of VEGF isoforms and association with angiogenic eye disease.
StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.
Strategies for inhibiting vascular endothelial growth factor.
Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor.
Sublytic membrane-attack-complex (MAC) activation alters regulated rather than constitutive vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelium monolayers.
Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration.
Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy.
Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration.
SUSTAINED ELEVATION OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL ANTI-VEGF AGENTS: What Is the Evidence?
Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration.
Systemic counterregulatory response of angiopoietin-2 after aflibercept therapy for nAMD: a potential escape mechanism.
Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration.
Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis - implications for cardiovascular safety.
Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
Targeting Lysosomes to Reverse Hydroquinone-Induced Autophagy Defects and Oxidative Damage in Human Retinal Pigment Epithelial Cells.
Targeting vascular endothelial growth factor using retinal gene therapy.
Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions.
The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.
The ?-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases.
The area of fixation covaries with short-term changes in visual acuity after anti-vascular endothelial growth factor treatment in patients with diabetic macular oedema.
The association between age-related macular degeneration and renal cell carcinoma: a nested case-control study.
The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
THE CORRELATION BETWEEN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AND CLINICAL ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
The effect of connexin43 on the level of vascular endothelial growth factor in human retinal pigment epithelial cells.
The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration.
The expression of growth factors and their receptors in retinal and endothelial cells cocultured in the rotating bioreactor.
The function of vascular endothelial growth factor.
The Inhibitory Effects of Gold Nanoparticles on VEGF-A-Induced Cell Migration in Choroid-Retina Endothelial Cells.
The oxidative stressor arsenite activates vascular endothelial growth factor mRNA transcription by an ATF4-dependent mechanism.
The past, present, and future of exudative age-related macular degeneration treatment.
The patients' view: age-related macular degeneration and its effects - a meta-synthesis.
The potential health benefits of dietary natural plant products in age related eye diseases.
The predictive value of subjective symptoms and clinical signs for the presence of treatment-requiring exudative age-related macular degeneration.
The regulation of vascular endothelial growth factors (VEGF-A, -C, and -D) expression in the retinal pigment epithelium.
The relationship between vascular endothelial growth factor -2578C/A polymorphism and age-related macular degeneration.
The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration.
The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration.
Therapeutic Potential of DNA-aptamers Raised Against AGE-RAGE Axis in Diabetes-related Complications.
Therapeutic targeting of the angiopoietin-TIE pathway.
Therapeutic targets of renin-angiotensin system in ocular disorders.
Three Variants of or near VEGF-A Gene are not Associated with Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in a Han Chinese Population.
Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy.
Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes.
Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases.
Treatment for neovascular age related macular degeneration: The state of the art.
Treatment of Exudative Age-Related Macular Degeneration with a Designed Ankyrin Repeat Protein that Binds Vascular Endothelial Growth Factor: a Phase I/II Study.
TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN EVERYDAY PRACTICE: Identification of Health Care Constraints in Germany-The PONS Study.
Tristetraprolin regulates the decay of the hypoxia-induced vascular endothelial growth factor mRNA in ARPE-19 cells.
Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model.
Variability of disease activity in patients treated with ranibizumab for neovascular age-related macular degeneration.
Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis-A possible target for novel therapies?
Vascular endothelial growth factor A polymorphisms and age-related macular degeneration: a systematic review and meta-analysis.
Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy.
Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema.
Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration.
Vascular endothelial growth factor biology: clinical implications for ocular treatments.
Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function.
Vascular endothelial growth factor gene polymorphisms and association with age related macular degeneration in Indian patients.
Vascular Endothelial Growth Factor Gene Polymorphisms and Risk of Neovascular Age-Related Macular Degeneration in a Chinese Cohort.
Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration in a Turkish population.
Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration.
Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration.
Vascular endothelial growth factor genetic polymorphisms and susceptibility to age-related macular degeneration in Tunisian population.
Vascular Endothelial Growth Factor in Patients with Exudative Age-Related Macular Degeneration Treated with Ranibizumab.
Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab.
Vascular endothelial growth factor regulates primate choroid-retinal endothelial cell proliferation and tube formation through PI3K/Akt and MEK/ERK dependent signaling.
Vascular endothelial growth factors and angiogenesis in eye disease.
VEGF and Anti-VEGF drugs have minimal effects on the permeability or selectivity of RPE tight junctions.
VEGF as a Direct Functional Regulator of Photoreceptors and Contributing Factor to Diabetes-Induced Alteration of Photoreceptor Function.
VEGF as a Trophic Factor for Müller Glia in Hypoxic Retinal Diseases.
VEGF differentially regulates transcription and translation of ZO-1alpha(+) and ZO-1alpha(-) and mediates trans-epithelial resistance in cultured endothelial and epithelial cells.
VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration.
VEGF Polymorphisms Among Neovascular Age-Related Macular Degenerative Subjects in a Multiethnic Population.
VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases.
VEGF-A Is Necessary and Sufficient for Retinal Neuroprotection in Models of Experimental Glaucoma.
VEGF-Production by CCR2-Dependent Macrophages Contributes to Laser-Induced Choroidal Neovascularization.
VEGFR2 Trafficking by KIF13B Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration.
Vision Loss in Older Adults.
Vitreous Levels of Proteins Implicated in Angiogenesis Are Modulated in Patients with Retinal or Choroidal Neovascularization.
Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
[A comparison of the mRNA expression of VEGF and its receptor FLK-1 in rabbit iris pigment epithelium cells and retinal pigment epithelial cells]
[Adjuvant stereotactic low energy radiation therapy of exudative age-dependent macular degeneration (Oraya system)].
[Analysis of cardiovascular diseases after the upload phase with intravitreal ranibizumab and bevacizumab in patients with exudative age-related macular degeneration].
[Angiogenesis and retinal diseases]
[Angiography of the ocular fundus without dye: Optical coherence tomography based angiography in exsudative age-related macular degeneration].
[Health services for patients with neovascular age-related macular degeneration in Germany].
[Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD]
[Neovascular form of age-related macular degeneration --current management in Poland and in Europe].
[New drug treatment for age-related macular degeneration]
[RhoJ signaling pathway in retinal angiogenesis: promising targets for novel anti-angiogenic therapy].
[The impact of locally administrated VEGF inhibitors on vascular homeostasis--controversies concerning safety of intravitreal therapy in AMD patients].
[The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes]
[Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication]
[Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis]
[Treatment of wet age-related macular degeneration with vascular endothelial growth factor. A survey of a Cochrane review]
[Unspecific effects of certain siRNA molecules used in the treatment of age related macular degeneration].
[VEGF inhibitors in ophthalmology]
[Volume calculations for current intravitreal injections of Lucentis(R).]
Macular Edema
A Review of Randomized Trials of Approved Pharmaceutical Agents for Macular Edema Secondary to Retinal Vein Occlusion.
Aflibercept Intervention in Experimental Branch Retinal Vein Occlusion Results in Upregulation of DnaJ Homolog Subfamily C Member 17.
Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications.
Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab.
Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders.
Antagonism of Vascular Endothelial Growth Factor for Macular Edema Caused by Retinal Vein Occlusions: Two-Year Outcomes.
Anti-Angiogenesis Drugs In Diabetic Retinopathy.
Anti-vascular endothelial growth factor treatment for retinal vein occlusions.
Anti-VEGF therapy for diabetic macular edema.
Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1).
Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2).
Aqueous concentrations of VEGF and soluble VEGF receptor-1 in diabetic retinopathy patients.
Aqueous flare and inflammatory factors in macular edema with central retinal vein occlusion: a case series.
Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema.
Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion.
Aqueous levels of VEGF correlate with retinal non-perfusion areas in patients with diabetic macular edema and macular edema secondary to central retinal vein occlusion.
Aqueous Soluble Vascular Endothelial Growth Factor Receptor-2 in Macular Edema with Branch Retinal Vein Occlusion.
Aqueous Vascular Endothelial Growth Factor as a Predictor of Macular Thickening Following Cataract Surgery in Patients with Diabetes Mellitus.
Ascorbic acid prevents VEGF-induced increases in endothelial barrier permeability.
Association between macular microcirculation and soluble intercellular adhesion molecule-1 in patients with macular edema and retinal vein occlusion.
Association of Vascular Endothelial Growth Factor Polymorphisms with Nonproliferative and Proliferative Diabetic Retinopathy.
ASSOCIATIONS WITH RECURRENCE OF MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION AFTER THE DISCONTINUATION OF ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR.
Bevacizumab in retinal vein occlusion-results of a prospective case series.
Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities.
Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema.
Changes in foveal thickness after vitrectomy for macular edema with branch retinal vein occlusion and intravitreal vascular endothelial growth factor.
CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Changes of Inflammatory Factors After Intravitreal Triamcinolone Acetonide for Macular Edema with Central Retinal Vein Occlusion.
Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion.
Characteristics of diabetic macular edema patients with serous retinal detachment.
Combined inhibition of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) for the treatment of macular edema of various etiologies: a short-term pilot study.
Comparing Cytokine Kinetics between Ranibizumab and Aflibercept in Central Retinal Vein Occlusion with Macular Edema.
Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema.
Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema.
Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept.
Correlation between vascular endothelial growth factor and nonperfused areas in macular edema secondary to branch retinal vein occlusion.
Correlation of Vitreous Vascular Endothelial Growth Factor and Uric Acid Concentration Using Optical Coherence Tomography in Diabetic Macular Edema.
Critical appraisal of ranibizumab in the treatment of diabetic macular edema.
Current approaches to the management of diabetic macular edema.
Current treatment modalities in diabetic macular edema.
Currently used Biologic Agents in the Management of Behçet's Syndrome.
Cystoid macular edema responds to intravitreal triamcinolone and rebounds after intravitreal bevacizumab.
Cytokines and Pathogenesis of Central Retinal Vein Occlusion.
Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion.
Diabetic Macular Edema Diagnosis and Treatment in the Real World: An Analysis of Medicare Claims Data (2008 to 2010).
Diabetic Macular Edema: Current Understanding, Pharmacologic Treatment Options, and Developing Therapies.
Diabetic macular edema: it is more than just VEGF.
Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion.
Does conventional laser photocoagulation still have a place in the treatment of diabetic macular edema?
Early versus late switch: How long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients?
Effect of ripasudil on diabetic macular edema.
EFFECTS OF SOLUBLE CD14 AND CYTOKINE LEVELS ON DIABETIC MACULAR EDEMA AND VISUAL ACUITY.
Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema.
ELEVATION OF ANGIOGENIC FACTOR CYSTEINE-RICH 61 LEVELS IN VITREOUS OF PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY.
Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy.
Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes.
Gene Therapies for Neovascular Age-Related Macular Degeneration.
Glucose-regulated protein 78 in the aqueous humor in diabetic macular edema patients.
How do we evaluate the role of focal/grid photocoagulation in the treatment of diabetic macular edema?
Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
IGFBP-3 reduces eNOS and PKCzeta phosphorylation, leading to lowered VEGF levels.
Impact of insulin treatment in diabetic macular edema therapy in type 2 diabetes.
Increase of aqueous inflammatory factors in macular edema with branch retinal vein occlusion: a case control study.
Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema.
Increased serum concentration of netrin-1 after intravitreal bevacizumab injection: is it a compensatory mechanism to counteract drug side effects?
Inflammatory cystoid macular edema.
Influence of vitreous factors after vitrectomy for macular edema in patients with central retinal vein occlusion.
Inhibition of Single Routes of Intracellular Signaling is Not Sufficient to Neutralize the Biphasic Disturbance of a Retinal Endothelial Cell Barrier Induced by VEGF-A165.
Insights into stem cell therapy for diabetic retinopathy: a bibliometric and visual analysis.
Intravitreal Aflibercept for Diabetic Macular Edema.
Intravitreal Anti VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery.
Intravitreal anti-VEGF agents and cardiovascular risk.
Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetes.
Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion.
Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas.
Intravitreous vascular endothelial growth factor (VEGF) inhibitor therapy for tamoxifen induced macular edema.
Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 ?g (ILUVIEN®).
Macular infarction following intravitreal bevacizumab for treatment of central retinal vein occlusion.
Macular laser photocoagulation in the management of diabetic macular edema: Still relevant in 2020?
Management of diabetic macular edema patients in clinical practice in Spain.
Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-?/?.
Multimodal Imaging of Microvascular Abnormalities in Retinal Vein Occlusion.
Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema.
New surgical approach for removing massive foveal hard exudates in diabetic macular edema.
Objective of pharmacologic vitreolysis.
Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept.
Ocular Anti-VEGF Therapy for Diabetic Retinopathy: The Role of VEGF in the Pathogenesis of Diabetic Retinopathy.
One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema.
Optic disc edema, cystoid macular edema, and elevated vascular endothelial growth factor in a patient with POEMS syndrome.
Optimal treatment of diabetic retinopathy.
Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6.
Pathophysiology of macular edema.
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.
Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier.
Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties.
Pigment epithelium-derived factor and vascular endothelial growth factor in branch retinal vein occlusion with macular edema.
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Plasmalemma Vesicle-Associated Protein Has a Key Role in Blood-Retinal Barrier Loss.
POSSIBLE MOLECULAR BASIS OF BEVACIZUMAB THERAPY FOR MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION.
Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization.
Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors.
Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy.
Pro-permeability Factors in Diabetic Macular Edema; the Diabetic Macular Edema Treated With Ozurdex Trial.
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells.
Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema.
Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.
Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease.
Relation of diabetic macular edema to cytokines and posterior vitreous detachment.
Relationship between Recurrence of Macular Edema Due to Branch Retinal Vein Occlusion and Changes in Choroidal Thickness.
Relationship between vascular endothelial growth factor and macular edema in retinal vein branch obstruction.
Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: Early versus late switch.
Retinal vascular occlusions: an interdisciplinary challenge.
Role of inflammation in diabetic macular edema.
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion.
Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema.
Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.
Sensitivity of different vascular beds in the eye to neovascularization and blood-retinal barrier breakdown in VEGF transgenic mice.
Significance of monitoring vascular endothelial growth factor, monocyte chemoattractant protein-1 and Interleukin-8 in diabetic macular edema towards early identification of nonresponders to ranibizumab therapy.
Silymarin prevents diabetes-induced hyperpermeability in human retinal endothelial cells.
Soluble Vascular Endothelial Growth Factor Receptor-2 and Inflammatory Factors in Macular Edema with Branch Retinal Vein Occlusion.
Spontaneous resolution of vitreomacular traction following ranibizumab (Lucentis) injection.
The clinical utility of aflibercept for diabetic macular edema.
The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema.
The Evolving Treatment of Diabetic Retinopathy.
The Prevention and Treatment of Retinal Complications in Diabetes.
The use of a vascular endothelial growth factor inhibitor (ranibizumab) in macular edema due to eales disease.
Treatment Choice for Diabetic Macular Edema.
Treatment of Diabetic Macular Edema With a Designed Ankyrin Repeat Protein That Binds Vascular Endothelial Growth Factor: A Phase I/II Study.
Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
Triamcinolone acetonide suppresses interleukin-1 beta-mediated increase in vascular endothelial growth factor expression in cultured rat Müller cells.
Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Up-regulation of vascular endothelial growth factor production by iron chelators.
Update on treatments of diabetic macular edema.
Use of antivascular endothelial growth factor for diabetic macular edema.
Using the past to inform the future: anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy.
Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model.
Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema.
Vascular Endothelial Growth Factor and Diabetic Macular Edema.
Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy.
Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular edema and its correlation with anti-VEGF treatment outcomes.
Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.
Vascular Endothelial Growth Factor Promotes Progressive Retinal Nonperfusion in Patients with Retinal Vein Occlusion.
Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema.
Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.
VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases.
VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.
Vessel Density Changes on Optical Coherence Tomography Angiography after Vascular Endothelial Growth Factor Inhibitor Treatment for Diabetic Macular Edema.
Vision Loss in Older Adults.
Visual acuity and foveal thickness after vitrectomy for macular edema associated with branch retinal vein occlusion: a case series.
Visual acuity and foveal thickness after vitrectomy for macular edema.
Visual prognosis and vitreous molecules after vitrectomy for macular edema with branch retinal vein occlusion.
Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane.
Vitreous Inflammatory Factors and Serous Macular Detachment in Branch Retinal Vein Occlusion.
Vitreous inflammatory factors in macular edema with central retinal vein occlusion.
Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema.
Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion.
Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema.
Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in macular edema with central retinal vein occlusion.
Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema.
Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone.
Wyburn-Mason Syndrome Associated With Cutaneous Reactive Angiomatosis and Central Retinal Vein Occlusion.
[Diabetic maculopathy].
[Diabetic retinopathy and maculopathy].
[From scientific evidence to clinical practice: treatment protocols for diabetic macular edema].
[Strategy for treatment of diabetic retinopathy]
[The Eye in Internal Medicine: Diabetic retinopathy].
[Topical aspects of etiopathogenesis, medicamentous and laser treatment of branch retinal vein occlusion]
Malaria
Altered Cytokine Response of Human Brain Endothelial Cells after Stimulation with Malaria Patient Plasma.
Effects of the vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor SU5416 on in vitro cultures of Plasmodium falciparum.
Elevated Levels of the Endothelial Molecules ICAM-1, VEGF-A, and VEGFR2 in Microscopic Asymptomatic Malaria.
Elevated levels of vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor (VEGFR)-2 in human malaria.
Induction of the vascular endothelial growth factor pathway in the brain of adults with fatal falciparum malaria is a non-specific response to severe disease.
Protective or pathogenic effects of vascular endothelial growth factor (VEGF) as potential biomarker in cerebral malaria.
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Malaria, Cerebral
Protective or pathogenic effects of vascular endothelial growth factor (VEGF) as potential biomarker in cerebral malaria.
Systemic and Cerebral Vascular Endothelial Growth Factor Levels Increase in Murine Cerebral Malaria along with Increased Calpain and Caspase Activity and Can be Reduced by Erythropoietin Treatment.
Vascular endothelial growth factor (VEGF) and lovastatin suppress the inflammatory response to Plasmodium berghei infection and protect against experimental cerebral malaria.
Malformations of Cortical Development
Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB.
Malnutrition
Effects of low level laser therapy on attachment, proliferation, and gene expression of VEGF and VEGF receptor 2 of adipocyte-derived mesenchymal stem cells cultivated under nutritional deficiency.
Elevated serum levels of vascular endothelial growth factor is effective as a marker for malnutrition and inflammation in patients with ovarian cancer.
Metabolic programming of ovarian angiogenesis and folliculogenesis by maternal malnutrition during lactation.
Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system.
Malocclusion
Genes, genetics, and Class III malocclusion.
Mania
Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder.
Neurotrophic factors in bipolar disorders patients with manic episode.
Mastocytoma
Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells.
Effect of radiation on vascular endothelial growth factor expression in the C2 canine mastocytoma cell line.
Mastocytosis
Histopathological and immunohistochemical aspects of mastocytosis.
Vascular endothelial growth factors and angiopoietins as new players in mastocytosis.
Measles
Serum complement concentrations, nutritional status and the outcome of measles and measles pneumonia.
Medulloblastoma
Microvessel density and vascular endothelial growth factor expression as predictors of childrens' survival from cerebellar medulloblastoma.
Pancreatic endoplasmic reticulum kinase activation promotes medulloblastoma cell migration and invasion through induction of vascular endothelial growth factor A.
Prognostic significance of anaplasia and angiogenesis in childhood medulloblastoma: a pediatric oncology group study.
Meigs Syndrome
Markedly elevated levels of vascular endothelial growth factor, fibroblast growth factor, and interleukin 6 in Meigs syndrome.
Pseudo-Meigs' syndrome associated with hydropic degenerating uterine leiomyoma: A case report.
Vascular endothelial growth factor levels in pleural and peritoneal fluid in Meigs' syndrome.
Melanoma
177Lu-DOTA-Bevacizumab: Radioimmunotherapy agent for melanoma.
A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.
A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma.
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
A Pilot Study of Bevacizumab and Interferon-alpha2b in Ocular Melanoma.
A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma.
A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1? and VEGF expressions.
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : A North Central Cancer Treatment Group study, N0775.
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma.
A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin.
Acidic pH via NF-?B favours VEGF-C expression in human melanoma cells.
Acriflavine, a Potent Inhibitor of HIF-1?, Disturbs Glucose Metabolism and Suppresses ATF4-Protective Pathways in Melanoma under Non-Hypoxic Conditions.
Activation of Stat3 in Human Melanoma Promotes Brain Metastasis.
Activin A is anti-lymphangiogenic in a melanoma mouse model.
Alterations of Circulating Bone Marrow-Derived VEGFR-2(+) Progenitor Cells in Isolated Limb Perfusion With or Without rhTNF-?
An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.
An autophagic deficit in the uterine vessel microenvironment provokes hyperpermeability through deregulated VEGFA, NOS1, and CTNNB1.
An integrated approach to measuring tumor oxygen status using human melanoma xenografts as a model.
Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase.
Angiogenesis and vascular growth factor receptor expression in malignant melanoma.
Angiogenesis, lymphangiogenesis, and melanoma metastasis.
Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.
Angiogenic profile of uveal melanoma.
Antiangiogenic and antitumor effects of IMMUNEPOTENT CRP in murine melanoma.
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
Association of vascular endothelial growth factor expression with patohistological parameters of cutaneous melanoma.
Association of Vascular Endothelial Growth Factor Subtypes with Melanoma Patients' Characteristics and Survival: A Semantic Connectivity Map Analysis.
AT1 receptors activation enhances the expression of MMP-2, MMP-13 and VEGF but not MMP-9 in B16F10 melanoma cells.
Autocrine impact of vascular endothelial growth factor (VEGF) A on uveal melanoma cells.
Bartonella henselae Detected in Malignant Melanoma, a Preliminary Study.
Basic fibroblast growth factor-mediated overexpression of vascular endothelial growth factor in 1F6 human melanoma cells is regulated by activation of PI-3K and p38 MAPK.
bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity.
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Beneficial Regulation of Cellular Oxidative Stress Effects, and Expression of Inflammatory, Angiogenic, and the Extracellular Matrix Remodeling Proteins by 1?,25-Dihydroxyvitamin D3 in a Melanoma Cell Line.
Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series.
Bioactivity screening of partially desulfated low-molecular-weight heparins: A structure/activity relationship study.
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.
Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor.
CD147/basigin promotes progression of malignant melanoma and other cancers.
Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of ?v?5 integrin.
Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma.
Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients.
Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma.
Circulating vascular endothelial growth factor in cutaneous malignant melanoma.
Clarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: an explant model study.
Clinicopathological characteristics of vascular endothelial growth factor expression in uveal melanoma: A meta-analysis.
Clotrimazole presents anticancer properties against a mouse melanoma model acting as a PI3K inhibitor and inducing repolarization of tumor-associated macrophages.
Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma.
Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas.
Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma progression: A next-generation Tissue Microarray (ngTMA) automated analysis.
Correspondence re: DC Lev et al., Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther, 2003;2(8):753-63.
Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor.
CXCR7 promotes melanoma tumorigenesis via Src kinase signaling.
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy.
Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-ct following treatment with VEGFR-2 blocking antibodies.
Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma.
DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice.
Does the Use of the "Proseek® Multiplex Oncology I Panel" on Peritoneal Fluid Allow a Better Insight in the Pathophysiology of Endometriosis, and in Particular Deep-Infiltrating Endometriosis?
Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression.
Dual targeting of tumor and endothelial cells by gonadotropin-releasing hormone agonists to reduce melanoma angiogenesis.
Effect of luteolin on apoptosis and vascular endothelial growth factor in human choroidal melanoma cells.
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
Effects of fatty acid synthase inhibitors on lymphatic vessels: an in vitro and in vivo study in a melanoma model.
Effects of high intensity focused ultrasound on vascular endothelial growth factor in melanoma bearing mice.
Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model.
Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis.
Endogenous production of nitric oxide contributes to proliferation effect of vascular endothelial growth factor-induced malignant melanoma cell.
Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.
Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.
Enhanced expression of vascular endothelial growth factor in metastatic melanoma.
Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis.
Erlotinib and bevacizumab have synergistic activity against melanoma.
Establishment, characterization and long-term culture of human endocrine pancreas-derived microvascular endothelial cells.
Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice.
Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma.
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.
Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines.
Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients.
Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis.
EXPRESSION OF THE SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 IN CUTANEOUS MELANOMA: ROLE IN TUMOUR PROGRESSION.
Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours.
Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma.
Expression of vascular endothelial growth factor a, matrix metalloproteinase 9 and extravascular matrix patterns in iris and ciliary body melanomas.
Expression of vascular endothelial growth factor in canine oral malignant melanoma.
Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
Expression of vascular endothelial growth factor in iris melanoma.
Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis.
Expression of vascular endothelial growth factor in uveal melanoma is independent of 6p21-region copy number.
Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.
Features of Cutaneous Malignant Melanoma Metastatic to the Retina and Vitreous.
Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization.
Fingolimod (Gilenya) and melanoma.
Functionalized nanoliposomes loaded with anti survivin and anti angiogenic agents to enhance the activity of chemotherapy against melanoma by 4-pronged action.
Gene expression and promoter methylation of angiogenic and lymphangiogenic factors as prognostic markers in melanoma.
Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.
Glycoprotein Nonmetastatic Melanoma Protein B as Potential Imaging Marker in Posttherapeutic Metastatic Head and Neck Cancer.
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma.
Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma.
HOXB7: a key factor for tumor-associated angiogenic switch.
Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors.
Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.
Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis.
Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma.
Hypoxia-induced up-regulation of angiogenin in human malignant melanoma.
Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma.
Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin.
Identification of aryl hydrocarbon receptor signaling pathways altered in TCDD-treated red seabream embryos by transcriptome analysis.
Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Identification of zinc finger protein of the cerebellum 5 as a survival factor of prostate and colorectal cancer cells.
Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.
Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.
Immunohistochemical expression of platelet growth factor and vascular endothelial growth factor in patients with melanoma with and without redness (Brenner sign).
Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi.
Immunologic escape and angiogenesis in human malignant melanoma.
Immunological monitoring for prediction of clinical response to antitumor vaccine therapy.
In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker.
Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.
Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma.
Inflammatory cytokines induce vascular endothelial growth factor-C expression in melanoma-associated macrophages and stimulate melanoma lymph node metastasis.
Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models.
Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma.
Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach.
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.
Inhibition of melanoma angiogenesis by telomere homolog oligonucleotides.
Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells.
Inhibition of tissue factor by ixolaris reduces primary tumor growth and experimental metastasis in a murine model of melanoma.
Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis.
Intermittent Hypoxia Is Associated With High Hypoxia Inducible Factor-1? but Not High Vascular Endothelial Growth Factor Cell Expression in Tumors of Cutaneous Melanoma Patients.
INTRAOCULAR ACTIVATION OF ANGIOGENIC AND INFLAMMATORY PATHWAYS IN UVEAL MELANOMA.
Investigating associations of cyclooxygenase-2 expression with angiogenesis, proliferation, macrophage and T-lymphocyte infiltration in canine melanocytic tumours.
Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells.
Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells.
Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma.
Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by Vascular Endothelial Growth Factor.
Localization of integrin alpha(v)beta3 and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in cutaneous and oral melanomas of dog.
Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis.
Long noncoding RNA CPS1-IT1 suppresses melanoma cell metastasis through inhibiting Cyr61 via competitively binding to BRG1.
Long-Term Local Injection of RAGE-Aptamer Suppresses the Growth of Malignant Melanoma in Nude Mice.
Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Lymphatic vessel density and VEGF-C expression as independent predictors of melanoma metastases.
Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha.
Macrophage Inhibitory Cytokine-1 Regulates Melanoma Vascular Development.
Mast cells and cutaneous malignancies.
Mastic Oil from Pistacia lentiscus var. chia Inhibits Growth and Survival of Human K562 Leukemia Cells and Attenuates Angiogenesis.
Melanoma Associated Chitinase 3-Like 1 Promoted Endothelial Cell Activation and Immune Cell Recruitment.
Melanoma cell-derived vascular endothelial growth factor induces endothelial tubulogenesis within fibrin gels by a metalloproteinase-mediated mechanism.
Melanoma presenting as circulating tumor cells associated with failed angiogenesis.
Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR.
Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells.
Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma.
Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma.
MicroRNA-145 suppresses uveal melanoma angiogenesis and growth by targeting neuroblastoma RAS viral oncogene homolog and vascular endothelial growth factor.
Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma.
Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression.
Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.
Mitogen-actived protein kinase activation is an early event in melanoma progression.
Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor.
Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis.
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Multiple Sclerosis Treatment and Melanoma Development.
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.
Mutual enhancement between heparanase and vascular endothelial growth factor: a novel mechanism for melanoma progression.
Near-infrared fluorescence lymphatic imaging in vascular endothelial growth factor-C overexpressing murine melanoma.
Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms.
Notch1-MAPK Signaling Axis Regulates CD133(+) Cancer Stem Cell-Mediated Melanoma Growth and Angiogenesis.
Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis.
OPG, OPN, EGF and VEGF Levels at Individual Breslow Score Stages in Malignant Melanoma.
Opposing Roles of JNK and p38 in Lymphangiogenesis in Melanoma.
Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo.
Parthenolide enhances dacarbazine activity against melanoma cells.
Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Pregnancy Promotes Melanoma Metastasis through Enhanced Lymphangiogenesis.
Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis.
Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF.
Prognostic significance of CD163 expression and its correlation with cyclooxygenase-2 and vascular endothelial growth factor expression in cutaneous melanoma.
Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression.
Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression.
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.
Radiation up-regulates the expression of VEGF in a canine oral melanoma cell line.
RAGE-aptamer Attenuates the Growth and Liver Metastasis of Malignant Melanoma in Nude Mice.
Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole.
Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor.
Release of vascular endothelial growth factor from a human melanoma cell line, WM35, is induced by hypoxia but not ultraviolet radiation and is potentiated by activated Ras mutation.
Research on tumorigenicity of cinnamaldehyde in melanoma cell lines and its mechanism.
Resistance of melanoma cells to anticancer treatment: a role of vascular endothelial growth factor.
RLIP76 regulates HIF-1 activity, VEGF expression and secretion in tumor cells, and secretome transactivation of endothelial cells.
Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study.
Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule.
S100A13 is a new angiogenic marker in human melanoma.
Secretion of hepatocyte growth factor and vascular endothelial growth factor during uveal melanoma-monocyte in vitro interactions.
Serum markers in early-stage and locally advanced melanoma.
Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma.
Signet ring cell melanoma, Brenner sign, and elevated vascular endothelial growth factor.
Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma.
Significance of vascular endothelial growth factor expression in skin melanoma.
Simultaneous application of the vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 and ionizing radiation does not further reduce the growth of canine oral melanoma xenografts in nude mice.
Stromal expression of vascular endothelial growth factor C is relevant to predict sentinel lymph node status in melanomas.
Study on Attenuating Angiogenesis and Epithelial-Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC2.
Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy.
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts.
The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor.
The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor.
The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas.
The human melanoma associated protein melanotransferrin promotes endothelial cell migration and angiogenesis in vivo.
The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.
The Melanoma Vascular Mimicry Phenotype Defined in Gene Expression and Microsome Sequencing Analysis.
The role of circulating angiogenic factors in patients operated on for localized malignant melanoma.
The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer.
The stem cell marker prominin-1/CD133 interacts with vascular endothelial growth factor and potentiates its action.
Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling.
Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis.
Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.
Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape.
Tumor lymphangiogenesis and melanoma metastasis.
Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study.
Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth.
Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro.
Vascular endothelial growth factor a in eyes with uveal melanoma.
Vascular endothelial growth factor and basic fibroblast growth factor in melanoma.
Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma.
Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines.
Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window.
Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts.
Vascular Endothelial Growth Factor Receptor-3 Expression Predicts Sentinel Node Status in Primary Cutaneous Melanoma.
Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2.
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
VEGF production, cell proliferation and apoptosis of human IGR 1 melanoma cells under nIFN-alpha/beta and rIFN-gamma treatment.
VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells.
VEGFR-2 expression in human melanoma: Revised assessment.
Wnt1 is anti-lymphangiogenic in a melanoma mouse model.
[Angiogenesis and tumor progression in melanoma]
[Effects of vascular endothelial growth factor D on the signaling cascade of sentinel lymphatic endothelial cells from melanoma patients undergoing sentinel lymphadenectomy]
[Expression of hypoxia-inducible factor-1 alpha and vascular endothelial growth factor in malignant melanoma]
[Importance of lymphangiogenesis and ultrastructure of lymphatic capillaries in metastasis of malignant melanoma].
[Non-specific immunotherapy inhibits angiogenesis - results of the monitoring of serum levels of vascular endothelial growth factor and matrix metalloproteinase 8 in patients with malignant melanoma receiving adjuvant high-dose interferon therapy].
[Targeting microRNA-mediated suppression of vascular endothelial growth factor gene expression and proliferation in malignant melanoma cells in vitro].
[Tc(CO)3]-Radiolabeled Bevacizumab: In vitro and in vivo Evaluation in a Melanoma Model.
[Tumor angiogensis in uveal melanoma. Role of vascular endothelial growth factor (VEGF)]
Melanoma, Experimental
Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion.
Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients.
Melanosis
A clinical, dermoscopic, histopathological and immunohistochemical study of melasma and facial pigmentary demarcation lines in the skin of color.
Clinicopathologic efficacy of copper bromide plus/yellow laser (578 nm with 511 nm) for treatment of melasma in Asian patients.
Melasma Treatment With Combined Chemical Peels and Novel Topical Agent Containing an Anti-estrogen and a Vascular Endothelial Growth Factor Inhibitor.
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.
The vascular characteristics of melasma.
MELAS Syndrome
Peptide-mediated delivery of donor mitochondria improves mitochondrial function and cell viability in human cybrid cells with the MELAS A3243G mutation.
Memory Disorders
VEGF-D Downregulation in CA1 Pyramidal Neurons Exerts Asymmetric Changes of Dendritic Morphology without Correlated Electrophysiological Alterations.
Meningeal Carcinomatosis
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis.
Vascular endothelial growth factor antisense oligonucleotides inhibit leptomeningeal metastasis in vivo.
Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis.
Meningeal Neoplasms
Intertumor heterogeneity in vascularity and invasiveness of artificial melanoma brain metastases.
Meningioma
An audit of immunohistochemical marker patterns in meningioma.
Angiogenesis and brain oedema in intracranial meningiomas: influence of vascular endothelial growth factor.
Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study.
Antiangiogenic agents for nonmalignant brain tumors.
Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs.
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression.
Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.
Canine and feline intracranial meningiomas: An updated review.
Change in plasma vascular endothelial growth factor after gamma knife radiosurgery for meningioma: a preliminary study.
Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation.
Constitutive activation of signal transducer and activator of transcription 3 regulates expression of vascular endothelial growth factor in human meningioma differentiation.
Correlation between dynamic contrast-enhanced perfusion MRI relative cerebral blood volume and vascular endothelial growth factor expression in meningiomas.
Correlation of clinical and biological parameters with peritumoral edema in meningioma.
Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas.
Diversity in tumor territory of meningioma: Protein expression in vascular endothelial growth factor and epidermal growth factor.
Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.
Expression of endothelin 1 and its angiogenic role in meningiomas.
Expression of hypoxia inducible factor-1 alpha and correlation with preoperative embolization of meningiomas.
Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema.
Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas.
Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors.
Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas.
Expression of VEGF and collagen XVIII in meningiomas: correlations with histopathological and MRI characteristics.
Headache in patients with a meningioma correlates with a bone-invasive growth pattern but not with cytokine expression.
Improvement in Visual Fields After Treatment of Intracranial Meningioma With Bevacizumab.
Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas.
Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients.
Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
Intraventricular chordoid meningioma presenting with Castleman disease due to overproduction of interleukin-6. Case report.
Ki-67 and vascular endothelial growth factor expression in intracranial meningiomas in dogs.
Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.
Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches.
MMP-9 expression in meningiomas: a prognostic marker for recurrence risk?
p-CREB expression in human meningiomas: correlation with angiogenesis and recurrence risk.
Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply.
Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway.
Recurrence of meningiomas.
Regulation of vascular endothelial growth factor secretion in human meningioma cells.
Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas.
SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery.
SU11657 Enhances Radiosensitivity of Human Meningioma Cells.
Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?
Tenascin in meningioma: expression is correlated with anaplasia, vascular endothelial growth factor expression, and peritumoral edema but not with tumor border shape.
Tenascin in Meningioma: Expression Is Correlated with Anaplasia, Vascular Endothelial Growth Factor Expression, and Peritumoral Edema But Not with Tumor Border Shape.
The density of microvessels positive for Wilms' tumour-1 protein (WT-1) is an independent predictor of recurrence risk in meningiomas.
The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells.
The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas.
The relationship between vascular endothelial growth factor and histological grade in intracranial meningioma.
The role of somatostatin in vasogenic meningioma associated brain edema.
Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema.
Vascular endothelial growth factor and malignant transformation of a meningioma: case report.
Vascular endothelial growth factor expression and angiogenesis in various grades and subtypes of meningioma.
Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival.
Vascular endothelial growth factor expression under ischemic stress in human meningiomas.
Vascular endothelial growth factor signals through platelet-derived growth factor receptor ? in meningiomas in vitro.
Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy.
Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients.
[Correlation between vascular endothelial growth factor and peritumoural edema in meningiomas]
Meningitis
A family with complement factor D deficiency.
Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis.
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.
Human parasitic meningitis caused by Angiostrongylus cantonensis infection in Taiwan.
Vascular endothelial growth factor is associated with blood brain barrier dysfunction in eosinophilic meningitis caused by Angiostrongylus cantonensis infection.
Meningitis, Bacterial
Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis.
Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain.
Meningitis, Cryptococcal
Intrathecal production and secretion of vascular endothelial growth factor during Cryptococcal Meningitis.
Meningitis, Pneumococcal
Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis.
Meningitis, Viral
Patterns of protein expression in infectious meningitis: a cerebrospinal fluid protein array analysis.
Meningococcal Infections
Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections.
Recommendations for Serogroup B Meningococcal Vaccine for Persons 10 Years and Older.
Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016.
Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease.
Meningoencephalitis
Expression of platelet-derived growth factor receptor-?/ß, vascular endothelial growth factor receptor-2, c-Abl, and c-Kit in canine granulomatous meningoencephalitis and necrotizing encephalitis.
Menorrhagia
Expression of vascular endothelial growth factor receptor-3 in the endometrium in menorrhagia.
Investigation of vascular endothelial growth factor (VEGF) polymorphism in patients with idiopathic heavy menstrual bleeding.
Microvascular density, vascular endothelial growth factor A, and its receptors in endometrial blood vessels in patients with menorrhagia.
Wall discontinuities and increased expression of vascular endothelial growth factor-A and vascular endothelial growth factor receptors 1 and 2 in endometrial blood vessels of women with menorrhagia.
Mesothelioma
A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma.
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
Antiangiogeneic Strategies in Mesothelioma.
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma.
Emerging insights into the biology and therapy of malignant mesothelioma.
Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma.
Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma.
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions.
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Malignant peritoneal mesothelioma. Is there a new treatment?
Molecular targets and targeted therapies for malignant mesothelioma.
Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
Placenta growth factor expression has prognostic value in malignant pleural mesothelioma.
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
Syndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells.
The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor.
The Therapeutic Efficacy of Anti Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice.
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.
Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
VEGF targeting in mesotheliomas using an interleukin-6 signal inhibitor based on adenovirus gene delivery.
Mesothelioma, Malignant
A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma.
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma.
Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1.
Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma.
Expression of vascular endothelial growth factor in malignant mesothelioma.
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.
Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.
PDGF-D/PDGF-?? Receptor-Regulated Chemo-taxis of Malignant Mesothelioma Cells.
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
Role of viral induced vascular endothelial growth factor (VEGF) production in pleural effusion and malignant mesothelioma.
The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor.
The role of gemcitabine in the treatment of malignant mesothelioma.
Urinary trypsin inhibitor suppresses migration of malignant mesothelioma.
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.
Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
VEGF targeting in mesotheliomas using an interleukin-6 signal inhibitor based on adenovirus gene delivery.
Metabolic Diseases
Expression of vascular endothelial growth factor (VEGF)-B and its receptor (VEGFR1) in murine heart, lung and kidney.
Metabolic Syndrome
Adiposity Measurements and Metabolic Syndrome Are Linked Through Circulating Neuregulin 4 and Adipsin Levels in Obese Adults.
Association between SNPs of Circulating Vascular Endothelial Growth Factor Levels, Hypercholesterolemia and Metabolic Syndrome.
Association between the polymorphisms of the vascular endothelial growth factor gene and metabolic syndrome.
Association of a Vascular Endothelial Growth Factor genetic variant with Serum VEGF level in subjects with Metabolic Syndrome.
Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study.
Association of rs6921438 A
Austrian Moderate Altitude Study (AMAS 2000) - fluid shifts, erythropoiesis, and angiogenesis in patients with metabolic syndrome at moderate altitude (congruent with 1700 m).
Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome.
Complement C3 and C4, but not their regulators or activated products, are associated with incident metabolic syndrome: the CODAM study.
Disruption of components of vascular endothelial growth factor angiogenic signalling system in metabolic syndrome. Findings from a study conducted in rural Bangladeshi women.
Increased urine podocyte-associated messenger RNAs in severe obesity are evidence of podocyte injury.
Interplay between 3'-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans.
Mediterranean dietary pattern and VEGF +405 G/C gene polymorphisms in patients with metabolic syndrome: An aspect of gene-nutrient interaction.
Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome.
Promoter polymorphisms of the vascular endothelial growth factor gene are associated with metabolic syndrome susceptibility in Koreans.
Relationship between skin blood flow regulation mechanisms and vascular endothelial growth factor in patients with metabolic syndrome.
Role of adiponectin and proinflammatory gene expression in adipose tissue chronic inflammation in women with metabolic syndrome.
Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease.
Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis.
The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
The contribution of omental adipose tissue to adipokine concentrations in patients with the metabolic syndrome.
The Relationship Between Vascular Endothelial Growth Factor Cis- and Trans-Acting Genetic Variants and Metabolic Syndrome.
VEGF is indirectly associated with NO production and acutely increases in response to hyperglycaemia(1).
[Plasma nitric oxide and vascular endothelial growth factor levels in patients with metabolic syndrome and co-existing vascular complications].
Metrorrhagia
Influence of different hormonal regimens on endometrial microvascular density and VEGF expression in women suffering from breakthrough bleeding.
Microaneurysm
Efficacy of troxerutin on streptozotocin-induced rat model in the early stage of diabetic retinopathy.
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.
Microcephaly
Immune activation in amniotic fluid from Zika virus-associated microcephaly.
Microscopic Polyangiitis
Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: analysis using sera from a nationwide prospective cohort study.
Migraine Disorders
Interaction among nitric oxide (NO)-related genes in migraine susceptibility.
Recurrent Headache Increases Blood-Brain Barrier Permeability and VEGF Expression in Rats.
The effect of intermittent hypoxia training on migraine: a randomized controlled trial.
The role of mast cells in migraine pathophysiology.
Vascular endothelial growth factor genetic polymorphisms and haplotypes in women with migraine.
Milk Hypersensitivity
Elevated serum adipsin may predict unsuccessful treatment for cows' milk allergy but other biomarkers do not.
Miller Fisher Syndrome
Increased serum concentrations of transforming growth factor-?1 (TGF-?1) in patients with Guillain-Barré syndrome.
Mitochondrial Myopathies
Increased capillaries in mitochondrial myopathy: implications for the regulation of oxygen delivery.
Mixed Connective Tissue Disease
Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study.
IL-35, TNF-?, BAFF, and VEGF serum levels in patients with different rheumatic diseases.
Monoclonal Gammopathy of Undetermined Significance
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma.
Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab.
Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
Motor Neuron Disease
Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration.
Elevated serum angiogenin levels in ALS.
From angiogenesis to neuropathology.
Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies.
Unraveling the mechanisms involved in motor neuron degeneration in ALS.
Mouth Neoplasms
Angiogenesis in potentially malignant lesions and carcinomas during experimental oral carcinogenesis: a preliminary study in the hamster cheek pouch.
Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer.
Clinical significance of inflammatory mediators in the pathogenesis of oral cancer.
High expressions of CD105 and VEGF in early oral cancer predict potential cervical metastasis.
Hypoxia-induced up-regulation of angiogenin, besides VEGF, is related to progression of oral cancer.
Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas.
Novel HDGF/HIF-1?/VEGF axis in oral cancer impacts disease prognosis.
Oral squamous cell carcinomas stimulate osteoclast differentiation.
Rapid label-free profiling of oral cancer biomarker proteins using nano-UPLC-Q-TOF ion mobility mass spectrometry.
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo.
The effect of CCND1 +870A>G and VEGF +936C>T polymorphisms on oral cancer development and disease-free survival in a Taiwan population.
Vascular endothelial growth factor 936 c>T polymorphism increased oral cancer risk: evidence from a meta-analysis.
Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer.
Moyamoya Disease
Expression of circulating vascular endothelial growth factor-antagonizing cytokines and vascular stabilizing factors prior to and following bypass surgery in patients with moyamoya disease.
Expression of vascular endothelial growth factor in dura mater of patients with moyamoya disease.
The role of VEGF and KDR polymorphisms in moyamoya disease and collateral revascularization.
Mucocutaneous Lymph Node Syndrome
Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease.
Association of vascular endothelial growth factor C-634 g polymorphism in taiwanese children with Kawasaki disease.
Correlations of complication with coronary arterial lesion with VEGF, PLT, D-dimer and inflammatory factor in child patients with Kawasaki disease.
Disruption of vascular homeostasis in patients with Kawasaki disease: involvement of vascular endothelial growth factor and angiopoietins.
Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease.
Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease.
Increased serum levels of vascular endothelial growth factor in Kawasaki disease.
Lack of association of the vascular endothelial growth factor gene polymorphisms with Kawasaki disease in Taiwanese children.
Marked pleural and pericardial effusion with elevated Vascular Endothelial Growth Factor production: an uncommon complication of Kawasaki disease.
MicroRNA-93 may control vascular endothelial growth factor A in circulating peripheral blood mononuclear cells in acute Kawasaki disease.
Neutrophils and mononuclear cells express vascular endothelial growth factor in acute Kawasaki disease: its possible role in progression of coronary artery lesions.
Platelet vascular endothelial growth factor is a useful predictor for prognosis in Kawasaki syndrome.
Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease.
Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease.
Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease.
Vascular endothelial growth factor gene haplotypes in Kawasaki disease.
Vascular endothelial growth factor in acute Kawasaki disease.
[The role of endogenous vascular elastase in coronary artery reconstruction in Kawasaki disease].
Multiple Endocrine Neoplasia
Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
Multiple Endocrine Neoplasia Type 1
Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
Multiple Myeloma
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.
A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma.
Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma.
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma.
Association of VEGF and VDR gene-gene and gene-smoking interaction on risk of multiple myeloma in Chinese Han population.
Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma.
BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma.
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells.
Biological impact of vascular endothelial growth factor on vessel density and survival in multiple myeloma and plasmacytoma.
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression.
Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells.
Circulating angiogenic cytokines in multiple myeloma and related disorders.
Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma.
Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion.
Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity.
Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies.
Expression of vascular endothelial growth factor receptors VEGFR1 in cultured multiple myeloma cells: correlation with immunophenotype and drug resistance.
Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD).
Increased expression of vascular endothelial growth factor in bone marrow of multiple myeloma patients.
Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera.
Lentiviral shRNA silencing of BDNF inhibits in vivo multiple myeloma growth and angiogenesis via down-regulated stroma-derived VEGF expression in the bone marrow milieu.
Moving disease biology from the lab to the clinic.
Multiple myeloma and human immunodeficiency virus-1 (HIV-1) infection.
Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo.
nm23, TOP2A and VEGF expression: Potential prognostic biologic factors in peripheral T-cell lymphoma, not otherwise specified.
Nonmyelomatous Ascites Resulting from the Increased Secretion of Vascular Endothelial Growth Factor in Multiple Myeloma.
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Pigment epithelium-derived factor (PEDF) inhibits survival and proliferation of VEGF-exposed multiple myeloma cells through its anti-oxidative properties.
Plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myeloma.
Plasma Levels of Vascular Endothelial Growth Factor and Selected Hemostatic Parameters in Association With Treatment Response in Multiple Myeloma.
Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression.
Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.
Prokineticin-1/endocrine gland-derived vascular endothelial growth factor is a survival factor for human multiple myeloma cells.
Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Relationship between tumour necrosis factor-related apoptosis inducing ligand (TRAIL) and vascular endothelial growth factor in human multiple myeloma patients.
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion.
Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor.
Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma.
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma.
Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.
The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis.
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.
Vascular endothelial growth factor and its receptors in multiple myeloma.
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.
[Anti-angiogenesis effect of metronomic chemotherapy in multiple myeloma patients].
[Clinical significance of serum vascular endothelial growth factor and interleukin-17 in patients with multiple myeloma].
[Clinical significance of serum vascular endothelial growth factor and interleukin-6 in multiple myeloma]
[Clinical significance of serum vascular endothelial growth factor in patients with multiple myeloma].
[Correlation between Expression of CXCL12, CXCR4, VEGF, MVD and Prognosis in Patients with Multiple Myeloma].
[Correlation of cytogenetic changes with VEGF and TRacp-5b levels among 60 elderly patients with multiple myeloma].
[Effect of 20 (S)-ginsenoside Rg3 on the proliferation inhibition and secretion of vascular endothelial growth factor of multiple myeloma cell line U266].
[Effect of arsenic trioxide on bone marrow stromal cells of patients with multiple myeloma]
[Effect of shRNA-mediated silencing of BDNF gene on VEGF expression of RPMI8226 cells].
[Expression and clinical significance of vascular endothelial growth factor and its receptors in multiple myeloma]
[Expression of midkine and vascular endothelial growth factor in bone marrow of patients with multiple myeloma and its significance]
[Expression of serum vascular endothelial growth factor correlates with clinical outcome in multiple myeloma]
[Expressions of vascular endothelial growth factor and cyclooxygenase-2 in patients with multiple myeloma and its significance.]
[Gene expression of vascular endothelial growth factors and their receptors in different variants of the course of multiple myeloma].
[In vitro study of human multiple myeloma cell transfected with soluble vascular endothelial growth factor receptor-1 gene]
[Study on the high expression of brain-derived neurotrophic factor in multiple myeloma patients and its possible mechanism]
[The interaction of vascular endothelial growth factor and interleukin-6 in multiple myeloma.]
Multiple Sclerosis
Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) inhibits experimental autoimmune encephalomyelitis in dark Agouti (DA) rats.
Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines.
Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.
Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses.
Elevated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple sclerosis: a Finnish co-twin study.
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients.
Increased serum concentrations of transforming growth factor-?1 (TGF-?1) in patients with Guillain-Barré syndrome.
Neuropilins and semaphorins - from angiogenesis to autoimmunity.
Neuroprotective effects of vascular endothelial growth factor A in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
The Importance of VEGF-KDR Signaling Pathway Genes should Not Be Ignored When the Risk of Developing Multiple Sclerosis is Taken into Consideration.
Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats.
Vascular endothelial growth factor-A mRNA gene expression in clinical phases of multiple sclerosis.
VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Multiple Sclerosis, Chronic Progressive
Vascular endothelial growth factor-A mRNA gene expression in clinical phases of multiple sclerosis.
Multiple Sclerosis, Relapsing-Remitting
Vascular endothelial growth factor-A mRNA gene expression in clinical phases of multiple sclerosis.
Muscle Spasticity
Neuroprotective effect of tanshinone IIA weakens spastic cerebral palsy through inflammation, p38MAPK and VEGF in neonatal rats.
Muscle Weakness
ALS and oxidative stress: the neurovascular scenario.
Biomarkers in Amyotrophic Lateral Sclerosis: Is There a Neurovascular Pathway?
Muscular Atrophy
Effect of vascular endothelial growth factor gene therapy on post-traumatic peripheral nerve regeneration and denervation-related muscle atrophy.
Herbal complex 'Buyang Huanwu Tang' improves motor endplate function of denervated-dependent skeletal muscle atrophy in rat.
Interaction of contractile activity and training history on mRNA abundance in skeletal muscle from trained athletes.
Polyglutamine diminishes VEGF; passage to motor neuron death?
[Effects of electroacupuncture on proangiogenesis process and protein turnover in a mouse model of sarcopenia].
Muscular Dystrophies
Serum levels of vascular endothelial growth factor elevated in patients with muscular dystrophy.
Muscular Dystrophy, Duchenne
ANG1 treatment reduces muscle pathology and prevents a decline in perfusion in DMD mice.
Cardiomyopathy in the mouse model of Duchenne muscular dystrophy caused by disordered secretion of vascular endothelial growth factor.
Nerve growth factor and its receptors TrkA and p75 are upregulated in the brain of mdx dystrophic mouse.
VEGF induces stress fiber formation in fibroblasts isolated from dystrophic muscle.
Myalgia
A 34-Year-Old Woman from Brazil with Pulmonary Lymphangioleiomyomatosis Diagnosed by Raised Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels and Lung Cysts on Computed Tomography Imaging Presenting with COVID-19 Pneumonia.
Effect of low-level laser therapy (LLLT) and light-emitting diodes (LEDT) applied during combined training on performance and post-exercise recovery: protocol for a randomized placebo-controlled trial.
Myasthenia Gravis
Anti-citrullinated protein antibody-positive rheumatoid arthritis associated with RS3PE syndrome-like symptoms and an elevated serum vascular endothelial growth factor level in a patient with myasthenia gravis.
Mycoses
The effect of vacuum sealing drainage after early woundabrasion on wound healing in diabetic patients with deep second degree burn and its influence on the inflammatory response.
Mycosis Fungoides
Podoplanin Expression Correlates with Disease Progression in Mycosis Fungoides.
Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome.
Vascular Endothelial Growth Factor A (Vegfa) Expression In Mycosis Fungoides.
Vascular endothelial growth factor receptor-3 (VEGFR-3) expression in mycosis fungoides.
Myelodysplastic Syndromes
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.
Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome.
Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia.
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes.
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Rational approaches to design of therapeutics targeting molecular markers.
Reduced miR-16 levels are associated with VEGF upregulation in high-risk myelodysplastic syndromes.
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level.
Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications.
[A preliminary observation of bone marrow angiogenesis in patients with myelodysplastic syndromes]
[Expression of cysteine rich 61 and vascular endothelial growth factor genes in patients with myelodysplastic syndromes and their relationship.]
[Serum level of angiogenesis-related cytokins in patients with myelodysplastic syndrome]
Myeloproliferative Disorders
Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD).
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Serum levels of vascular endothelial growth factor in chronic leukemias. A comparative study with emphasis on myeloproliferative disorders.
Soluble angiogenic factors: implications for chronic myeloproliferative disorders.
VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders.
Myocardial Infarction
"All-in-one" in vitro selection of collagen-binding vascular endothelial growth factor.
A relationship between vascular endothelial growth factor, angiogenesis, and cardiac repair after muscle stem cell transplantation into ischemic hearts.
Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study.
Administration of vascular endothelial growth factor adjunctive to fetal cardiomyocyte transplantation and improvement of cardiac function in the rat model.
Angiogenic effects of the extracts from Chinese herbs: Angelica and Chuanxiong.
Apelin and vascular endothelial growth factor are associated with mobilization of endothelial progenitor cells after acute myocardial infarction.
Apelin modulates pathological remodeling of lymphatic endothelium after myocardial infarction.
Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes.
Astragalosides promote angiogenesis via vascular endothelial growth factor and basic fibroblast growth factor in a rat model of myocardial infarction.
Atorvastatin combined with routine therapy on HIF-1, VEGF concentration and cardiac function in rats with acute myocardial infarction.
Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction.
Biodegradable particulate delivery of vascular endothelial growth factor plasmid from polycaprolactone/polyethylenimine electrospun nanofibers for the treatment of myocardial infarction.
Bone marrow mesenchymal stem cell-derived vascular endothelial growth factor attenuates cardiac apoptosis via regulation of cardiac miRNA-23a and miRNA-92a in a rat model of myocardial infarction.
Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor.
Cardioprotective effects of tanshinone IIA on myocardial ischemia injury in rats.
Cell transplantation into ischemic myocardium using mesenchymal stem cells transfected by vascular endothelial growth factor.
Changes of expressions of VEGF, bFGF, and angiogenesis, and effect of benazepril, bFGF on angiogenesis in acute myocardial infarction model of the rabbits.
Changes of soluble CD40 ligand in the progression of acute myocardial infarction associate to endothelial nitric oxide synthase polymorphisms and vascular endothelial growth factor but not to platelet CD62P expression.
Chitosan and Curcumin Nanoformulations against Potential Cardiac Risks Associated with Hydroxyapatite Nanoparticles in Wistar Male Rats.
Collagen-targeting vascular endothelial growth factor improves cardiac performance after myocardial infarction.
Coordinate release of angiogenic growth factors after acute myocardial infarction: evidence of a two-wave production.
Correlation between vascular endothelial growth factor and long-term prognosis in patients with acute myocardial infarction.
Deferoxamine-activated hypoxia-inducible factor-1 restores cardioprotective effects of sevoflurane postconditioning in diabetic rats.
Depressed expression of angiogenic growth factors in the subacute phase of myocardial ischemia: a mechanism behind the remodeling plateau?
Dynamic changes of serum vascular endothelial growth factor levels in a rat myocardial infarction model.
Effect of Basic Fibroblast Growth Factor on the Myocardial Expression of Hypoxia-inducible Factor-1? and Vascular Endothelial Growth Factor Following Acute Myocardial Infarction.
Effect of Heparin on Blood Vascular Endothelial Growth Factor Levels in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Effect of VEGF gene transfer on infarct size, left ventricular function and myocardial perfusion in sheep after two months of coronary artery occlusion.
Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor.
Effects of Myocardial Transplantation of Marrow Mesenchymal Stem Cells Transfected with Vascular Endothelial Growth Factor for the Improvement of Heart Function and Angiogenesis after Myocardial Infarction.
Effects of Radix et Rhizoma Rhodiolae Kirilowii on expressions of von Willebrand factor, hypoxia-inducible factor 1 and vascular endothelial growth factor in myocardium of rats with acute myocardial infarction.
Effects of Rosuvastatin and MiR-126 on Myocardial Injury Induced by Acute Myocardial Infarction in Rats: Role of Vascular Endothelial Growth Factor A (VEGF-A).
Effects of xuesetong soft capsules on angiogenesis and VEGF mRNA expression in ischemic myocardium in rats with myocardial infarction.
Elevated circulating levels of basic fibroblast growth factor and vascular endothelial growth factor in patients with acute myocardial infarction.
Endogenous Progenitors as the Source of Cell Material for Ischemic Damage Repair in Experimental Myocardial Infarction under Conditions of Changed Concentration of Vascular Endothelial Growth Factor.
Enhanced angiogenesis mediated by vascular endothelial growth factor plasmid-loaded thermo-responsive amphiphilic polymer in a rat myocardial infarction model.
Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat--angiogenesis and angioma formation.
Experimental induction of reparative morphogenesis and adaptive reserves in the ischemic myocardium using multipotent mesenchymal bone marrow-derived stem cells.
Expression of vascular endothelial growth factor and its receptors is increased, but microvascular relaxation is impaired in patients after acute myocardial ischemia.
Expression of vascular endothelial growth factor in cardiac repair: Signaling mechanisms mediating vascular protective effects.
Expression of vascular endothelial growth factor in human myocardial infarction.
Expression of vascular endothelial growth factor in patients with acute myocardial infarction.
Gene delivery of hypoxia-inducible VEGF targeting collagen effectively improves cardiac function after myocardial infarction.
Ghrelin ameliorates impaired angiogenesis of ischemic myocardium through GHSR1a-mediated AMPK/eNOS signal pathway in diabetic rats.
Glycogen synthase kinase-3beta/beta-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium.
Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis.
Hepatocyte growth factor and vascular endothelial growth factor in ischaemic heart disease.
Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction.
How can cardiac MR imaging help guide development of gene therapy for treatment of coronary heart disease?
Huoxue Anxin Recipe () promotes myocardium angiogenesis of acute myocardial infarction rats by up-regulating miR-210 and vascular endothelial growth factor.
Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease.
IGFBP-4 enhances VEGF-induced angiogenesis in a mouse model of myocardial infarction.
Imaging of VEGF receptor in a rat myocardial infarction model using PET.
Immunohistochemical Study of the Expression of Vascular Endothelial Growth Factor Receptor-2 (KDR/Flk-1) during Myocardial Infarction.
Impact of low levels of vascular endothelial growth factor after myocardial infarction on 6-month clinical outcome. Results from the Nagoya Acute Myocardial Infarction Study.
Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction.
Infarct stabilization and cardiac repair with a VEGF-conjugated, injectable hydrogel.
Injection of adeno-associated viral vector encoding vascular endothelial growth factor gene in infarcted swine myocardium: MR measurements of left ventricular function and strain.
Interaction Between Smoking and Polymorphism in the Promoter Region of the VEGFA Gene Is Associated with Ischemic Heart Disease and Myocardial Infarction in Rheumatoid Arthritis.
Intramyocardial delivery of VEGF165 via a novel biodegradable hydrogel induces angiogenesis and improves cardiac function after rat myocardial infarction.
Intramyocardial injection of DNA encoding vascular endothelial growth factor in a myocardial infarction model.
Intramyocardial transplantation of fibroblasts expressing vascular endothelial growth factor attenuates cardiac dysfunction.
Intravenous administration of vascular endothelial growth factor improves cardiac performance and inhibits cardiomyocyte apoptosis.
Level changes of serum high-sensitivity C-reactive protein and vascular endothelial growth factor in patients with St-segment elevation myocardial infarction after percutaneous coronary intervention.
Low invasive angiogenic therapy for myocardial infarction by retrograde transplantation of mononuclear cells expressing the VEGF gene.
Low levels of vascular endothelial growth factor B predict left ventricular remodeling after acute myocardial infarction.
Low-energy extracorporeal shock wave therapy promotes vascular endothelial growth factor expression and improves locomotor recovery after spinal cord injury.
Low-Intensity Pulsed Ultrasound Enhances Angiogenesis and Ameliorates Left Ventricular Dysfunction in a Mouse Model of Acute Myocardial Infarction.
Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay.
Mesenchymal Stem Cells Pretreatment With Stromal-Derived Factor-1 Alpha Augments Cardiac Function and Angiogenesis in Infarcted Myocardium.
Mesenchymal stromal cells overexpressing vascular endothelial growth factor in ovine myocardial infarction.
Modified VEGF targets the ischemic myocardium and promotes functional recovery after myocardial infarction.
Morphological Evaluation of Oxidative Phosphorylation System in Myocardial Infarction under Conditions of Modified Vascular Endothelial Growth Factor Concentration.
MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine.
Myeloid-Epithelial-Reproductive Receptor Tyrosine Kinase and Milk Fat Globule Epidermal Growth Factor 8 Coordinately Improve Remodeling After Myocardial Infarction via Local Delivery of Vascular Endothelial Growth Factor.
MYOCARDIAL INFARCTION AFTER INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS: A Whole Population Study.
Myocardial infarction stabilization by cell-based expression of controlled Vascular Endothelial Growth Factor levels.
Outcome improvement of cellular cardiomyoplasty using triple therapy: Mesenchymal stem cell+erythropoietin+vascular endothelial growth factor.
Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival.
PEGylated-PLGA microparticles containing VEGF for long term drug delivery.
Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.
Prostaglandin E2 reduces swine myocardial ischemia reperfusion injury via increased endothelial nitric oxide synthase and vascular endothelial growth factor expression levels.
Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE.
Reactive oxygen species drives myocardial angiogenesis?
Regorafenib-Related Myocardial Injury during Atrial Fibrillation.
Relationship between selected angiographic parameters and the number of CD34+ cells, VEGF, and angiogenin plasma levels in patients with ST-elevation myocardial infarction.
Relationship between vascular endothelial growth factor and left ventricular dimension in patients with acute myocardial infarction.
Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice.
Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1.
Sequential bone marrow-cell delivery of VEGFA/S1P improves vascularization and limits adverse cardiac remodeling after myocardial infarction in mice.
Serial changes in serum VEGF and HGF in patients with acute myocardial infarction.
Serum hepatocyte growth factor predicts ventricular remodeling following myocardial infarction.
Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy.
Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy.
Serum levels of vascular endothelial growth factor in patients with angina pectoris and acute myocardial infarction.
Serum levels of VEGF and basic FGF in the subacute phase of myocardial infarction.
Shexiang Baoxin Pills for Coronary Heart Disease in Animal Models: Preclinical Evidence and Promoting Angiogenesis Mechanism.
Significance of measuring plasma vascular endothelial growth factor in patients with acute myocardial infarction.
Simultaneous regulation of apoptotic gene silencing and angiogenic gene expression for myocardial infarction therapy: Single-carrier delivery of SHP-1 siRNA and VEGF-expressing pDNA.
Stable phase post-MI patients have elevated VEGF levels correlated with inflammation markers, but not with atherosclerotic burden.
Study on the expression of VEGF and HIF-1? in infarct area of rats with AMI.
Targeted delivery of vascular endothelial growth factor improves stem cell therapy in a rat myocardial infarction model.
The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells.
The effects of ethanol on angiogenesis after myocardial infarction, and preservation of angiogenesis with rosuvastatin after heavy drinking.
The Role of Vascular Endothelial Growth Factor Gene as the Genetic Marker of Atherothrombotic Disorders and in the Gene Therapy of Coronary Artery Disease.
The role of vascular endothelial growth factor gene as the genetic marker of atherothrombotic disorders and in the gene therapy of coronary artery disease.
The time course of tumor necrosis factor-alpha, inducible nitric oxide synthase and vascular endothelial growth factor expression in an experimental model of chronic myocardial infarction in rats.
Three-dimensional echocardiography in the diagnosis of myocardial infarction and its correlation with the expressions of serum HIF-1?, HO-1 and VEGF.
TIMP3 or VEGF transfection of aged human MSCs enhances cell therapy after myocardial infarction.
Transmyocardial revascularization and vascular endothelial growth factor administration enhance effect of cell transplantation for myocardial infarct repair in rats.
Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction.
Variation in the vascular endothelial growth factor gene, carotid intima-media thickness and the risk of acute myocardial infarction.
Vascular Complications of Cancer Chemotherapy.
Vascular endothelial growth factor (VEGF)-A: Role on cardiac angiogenesis following myocardial infarction.
Vascular endothelial growth factor expressing mesenchymal stem cells improves cardiac function in chronic myocardial infarction in pigs.
Vascular Endothelial Growth Factor Gene Polymorphisms and Myocardial Infarction.
Vascular endothelial growth factor mRNA synthesis by peripheral blood mononuclear cells in patients with acute myocardial infarction.
Vascular endothelial growth factor-165 gene therapy promotes cardiomyogenesis in reperfused myocardial infarction.
Vascular endothelial growth factor-D mediates fibrogenic response in myofibroblasts.
VEGF and IL-4 gene variability and its association with the risk of coronary heart disease in north Indian population.
VEGF attenuates development from cardiac hypertrophy to heart failure after aortic stenosis through mitochondrial mediated apoptosis and cardiomyocyte proliferation.
VEGF-B Promotes Endocardium-Derived Coronary Vessel Development and Cardiac Regeneration.
VEGF-loaded microsphere patch for local protein delivery to the ischemic heart.
VEGF165 and angiopoietin-1 decreased myocardium infarct size through phosphatidylinositol-3 kinase and Bcl-2 pathways.
[Analysis of genotype combinations at the polymorphic points of the promoter regions of the genes of three matrix metalloproteinases and the gene of vascular endothelial growth factor (VEGF) in patients with history of acute myocardial infarction].
[Angiogenic effect of bone marrow mesenchymal stem cells transfected with human VEGF gene on myocardial infarcts in rats]
[Combined use of transmyocardial stents with gene therapy in the treatment of acute myocardial infarction]
[Dynamic changes of plasma VEGF, SDF-1 and peripheral CD34+ cells in patients with acute myocardial infarction]
[Effect of fulu baoxin oral liquid on lipid peroxidation, plasma nitric oxide and vascular endothelial growth factor in acute myocardial infarction rats]
[Effect of panax quinquefolius saponin on angiogenesis and expressions of VEGF and bFGF in myocardium of rats with acute myocardial infarction]
[Effects of Radix Ginseng and Radix Notoginseng formula on expressions of vascular endothelial growth factor receptor-2 and hypoxia-inducible factor-1alpha in ischemic myocardium of rats with acute myocardial infarction]
[Gelatin microspheres containing vascular endothelial growth factor enhances the efficacy of bone marrow mesenchymal stem cells transplantation in a swine model of myocardial infarction.]
[Promoting effect of granulocyto-colony stimulating factor on neovascularization in rats with myocardial infarction].
[Study of the influence of etoxidol on expression of follistatin-like protein-1 (FSTL-1) in myocardium after experimental infarction in rats].
Myocardial Ischemia
A promising strategy for the treatment of ischemic heart disease: Mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats.
Amelioration of microvascular myocardial ischemia by gene transfer of vascular endothelial growth factor in rabbits.
Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis.
Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs.
Aspirin decreases vascular endothelial growth factor release during myocardial ischemia.
Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium.
Can simvastatin promote tumor growth by inducing angiogenesis similar to VEGF?
Cardiac Magnetic Resonance Imaging for the Assessment of Myocardial Angiogenesis.
Cardiomyocyte hyperplasia after plasmid-mediated vascular endothelial growth factor gene transfer in pigs with chronic myocardial ischemia.
Collagen-targeting vascular endothelial growth factor improves cardiac performance after myocardial infarction.
Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium.
Concentrations of hepatocyte growth factor, basic fibroblast growth factor, and vascular endothelial growth factor in pericardial fluid and plasma.
Effect and mechanism of intermittent myocardial ischemia induced by exercise on coronary collateral formation.
Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia.
Electroacupuncture pretreatment promotes angiogenesis via hypoxia-inducible factor 1? and vascular endothelial growth factor in a rat model of chronic myocardial ischemia.
Elevated circulating levels of basic fibroblast growth factor and vascular endothelial growth factor in patients with acute myocardial infarction.
Experimental model of gene transfection in healthy canine myocardium: perspectives of gene therapy for ischemic heart disease.
Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes.
Expression of vascular endothelial growth factor and its receptors is increased, but microvascular relaxation is impaired in patients after acute myocardial ischemia.
Gene therapy for cardiovascular disease: a case for cautious optimism.
Gene therapy for myocardial angiogenesis.
Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.
Gene therapy in heart disease.
Gene therapy in vascular medicine: recent advances and future perspectives.
Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?
Hypoxia-inducible vascular endothelial growth factor gene therapy using the oxygen-dependent degradation domain in myocardial ischemia.
Identical effects of VEGF and serum-deprivation on phenotype and function of adipose-derived stromal cells from healthy donors and patients with ischemic heart disease.
Impact of low levels of vascular endothelial growth factor after myocardial infarction on 6-month clinical outcome. Results from the Nagoya Acute Myocardial Infarction Study.
Impact of remote physiological ischemic training on vascular endothelial growth factor, endothelial progenitor cells and coronary angiogenesis after myocardial ischemia.
Increased myocardial expression of angiopoietin-2 in patients undergoing urgent surgical revascularization for acute coronary syndromes.
Interaction Between Smoking and Polymorphism in the Promoter Region of the VEGFA Gene Is Associated with Ischemic Heart Disease and Myocardial Infarction in Rheumatoid Arthritis.
Ischemic preconditioning upregulates vascular endothelial growth factor mRNA expression and neovascularization via nuclear translocation of protein kinase C epsilon in the rat ischemic myocardium.
Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia.
Macrophages overexpressing VEGF target to infarcted myocardium and improve neovascularization and cardiac function.
Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.
Markers of Progenitor Cell Recruitment and Differentiation Rise Early During Ischemia and Continue During Resuscitation in a Porcine Acute Ischemia Model.
Microvascular notch signaling is upregulated in response to vascular endothelial growth factor and chronic myocardial ischemia.
Molecular basis of angiogenesis. Role of VEGF and VE-cadherin.
Morphine inhibits VEGF expression in myocardial ischemia.
Mouse model of angiogenesis.
Myocardial ischemia enhances the expression of acidic fibroblast growth factor in human pericardial fluid.
NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study.
Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of l-arginine in a porcine model of endothelial dysfunction.
Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease.
Plasmid-mediated VEGF gene transfer induces cardiomyogenesis and reduces myocardial infarct size in sheep.
Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct.
Post-translational regulation of a hypoxia-responsive VEGF plasmid for the treatment of myocardial ischemia.
Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy.
Primary study of vascular endothelial growth factor immunohistochemical staining in the diagnosis of early acute myocardial ischemia.
Prostaglandin E2 reduces swine myocardial ischemia reperfusion injury via increased endothelial nitric oxide synthase and vascular endothelial growth factor expression levels.
Rapid expression of vascular endothelial growth factor in early acute myocardial ischemia in rats.
Regorafenib-Related Myocardial Injury during Atrial Fibrillation.
Role of angiogenesis in cardiovascular disease: a critical appraisal.
Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT).
Temporal and spatial expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of myocardial ischemia with or without reperfusion.
The biology of vascular endothelial growth factors.
Tongxinluo protects against pressure overload-induced heart failure in mice involving VEGF/Akt/eNOS pathway activation.
Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis.
Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.
Vascular endothelial growth factor administration in chronic myocardial ischemia.
Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules.
Vascular Endothelial Growth Factor and Ischemic Heart Disease Risk: A Mendelian Randomization Study.
Vascular endothelial growth factor and its inhibitors.
Vascular endothelial growth factor C-induced collateral formation in a model of myocardial ischemia.
Vascular endothelial growth factor causes pulmonary vasodilation through activation of the phosphatidylinositol-3-kinase-nitric oxide pathway in the late-gestation ovine fetus.
Vascular endothelial growth factor gene transfer therapy for coronary artery disease: A systematic review and meta-analysis.
Vascular endothelial growth factor promotes cardiomyocyte differentiation of embryonic stem cells.
Vascular endothelial growth factor-165 gene therapy promotes cardiomyogenesis in reperfused myocardial infarction.
VEGF administration in chronic myocardial ischemia in pigs.
VEGF nanoparticles repair the heart after myocardial infarction.
[Effect of dipyridamole on blood levels of fibroblast growth factor and vascular endothelial growth factor in patients with ischemic heart disease]
[Effect of statin therapy on dynamics of vascular endothelial growth factor and fibroblast growth factor in patients with ischemic heart disease]
[Effects of pravastatin and granulocyto-colony stimulating factor in mobilizing endothelial progenitor cells in mice with myocardial ischemia]
[Electroacupuncture for myocardial ischemia injury in rats via AMPK-HDAC5-HIF-1? signaling].
[Therapeutic angiogenesis using genetic transfection. An in vitro quantitative and functional study after gene code transfer for vascular endothelial growth factor]
[Time-dependent expression of vascular endothelial growth factor after acute myocardial ischemia in rats].
Myocarditis
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Myoma
Does vascular endothelial growth factor participate in uterine myoma growth stimulation?
Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies.
Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids: evaluation of the clinical response, the immunohistochemical expression of PDGF, bFGF and VEGF and the vascular pattern.
The pharmacological pathways of GnRH mediating the inhibition of mammary tumours: implications in humans and domestic animals.
Myopia
Aqueous Concentrations of Vascular Endothelial Growth Factor in Eyes with High Myopia with and without Choroidal Neovascularization.
Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.
CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIA.
Correlation of Macular Choroidal Thickness with Concentrations of Aqueous Vascular Endothelial Growth Factor in High Myopia.
Ranibizumab: a review of its use in myopic choroidal neovascularization.
The Inhibitory Effects of Gold Nanoparticles on VEGF-A-Induced Cell Migration in Choroid-Retina Endothelial Cells.
Vascular Endothelial Growth Factor Gene and the Response to Anti-Vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization in High Myopia.
Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.
Myopia, Degenerative
Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.
Myositis
Antiangiogenic VEGF isoform in inflammatory myopathies.
Myxoma
Atrial myxoma occurring 15 years after subtotal resection of cerebellar hemangioblastoma.
Elevated plasma concentration of vascular endothelial growth factor in cardiac myxoma.
Expression of vascular endothelial growth factor and angiogenesis in cardiac myxoma: a study of fifteen patients.
Vascular endothelial growth factor is an autocrine growth factor for cardiac myxoma cells.
Nasal Polyps
Activation of TLR4 induces VEGF expression via Akt pathway in nasal polyps.
Correlation analysis of STAT3 and VEGF expression and eosinophil infiltration in nasal polyps.
Effect of prostaglandin D2 on VEGF release by nasal polyp fibroblasts.
Effect of prostaglandin e2 on vascular endothelial growth factor production in nasal polyp fibroblasts.
Effects of methotrexate on vascular endothelial growth factor, angiopoietin 1, and angiopoietin 2 in nasal polyps.
Expression of Vascular Endothelial Growth Factor in Nasal Polyp and Chronic Rhinosinusitis.
Hypoxia induces cysteine-rich 61, vascular endothelial growth factor, and interleukin-8 expressions in human nasal polyp fibroblasts: An implication of neutrophils in the pathogenesis of nasal polyposis.
Hypoxia-stimulated vascular endothelial growth factor production in human nasal polyp fibroblasts: effect of epigallocatechin-3-gallate on hypoxia-inducible factor-1 alpha synthesis.
Immunohistochemical demonstration and semi-quantitation of vascular endothelial growth factor in recurrent versus non-recurrent nasal polyps.
Immunohistochemical expression of VEGF and VEGF receptors in nasal polyps as compared to normal turbinate mucosa.
Increased expression of hypoxia-inducible factor 1alpha in the nasal polyps.
Inflammatory cells as well as epithelial cells in nasal polyps express vascular endothelial growth factor.
Influence of fluticasone propionate on the production of vascular endothelial growth factor and basic fibroblast growth factor from nasal fibroblasts in vitro.
Inhibition of vascular endothelial growth factor by macrolides in cultured fibroblasts from nasal polyps.
Levocetirizine inhibits rhinovirus-induced up-regulation of fibrogenic and angiogenic factors in nasal polyp fibroblasts.
Nasal polyposis: an update: editorial review.
Osteopontin induced vascular endothelial growth factor production in dispersed nasal polyp cells through the phosphatidylinositol 3-kinase-protein kinase B and the extracellular signal-regulated kinase 1/2 pathways.
Rhinovirus upregulates matrix metalloproteinase-2, matrix metalloproteinase-9, and vascular endothelial growth factor expression in nasal polyp fibroblasts.
Role of vascular endothelial growth factor in the pathogenesis of nasal polyps.
Roles of vascular endothelial growth factor, Angiopoietin 1, and Angiopoietin 2 in nasal polyp.
Steroids inhibit vascular endothelial growth factor expression via TLR4/Akt/NF-?B pathway in chronic rhinosinusitis with nasal polyp.
The effect of corticosteroid therapy on cyclooxygenase 2, vascular endothelial growth factor, and inducible nitric oxide synthase expression levels in nasal polyposis.
Vascular endothelial growth factor and children featuring nasal polyps.
Vascular endothelial growth factor expression in nasal polyps of aspirin-intolerant patients.
Vascular endothelial growth factor in nasal polyps: a comparison of asthmatic and non-asthmatic patients.
[Expression and significance of STAT3 and VEGF with MVD in the nasal polyps]
[Expression and the role of vascular endothelial growth factor mRNA in nasal polyps]
[Expression of hypoxia-inducible factor-1alpha in nasal polyps and it's correlation with vascular endothelial growth factor and inducible nitric oxide synthase]
[Expression of monocyte chemotactic protein 1 and vascular endothelial growth factor in nasal polyps]
[Expression of vascular endothelial growth factor and transforming growth factor-beta 1 in nasal polyps]
[Expressions of vascular endothelial growth factor and basic fibroblast growth factor in nasal polyp and its role]
[Hypoxia effects on vascular endothelial growth factor derived epithelial cells of nasal polyps]
[Vascular cell adhesion molecule-1, eotaxin and vascular endothelial growth factor in nasal polyps after endoscopic surgery]
Nasopharyngeal Carcinoma
A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor.
Apatinib Combined With Radiotherapy Enhances Antitumor Effects in an In Vivo Nasopharyngeal Carcinoma Model.
Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.
Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma.
Berberine radiosensitizes human nasopharyngeal carcinoma by suppressing hypoxia-inducible factor-1? expression.
Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma.
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
Combination of pigment epithelium-derived factor with radiotherapy enhances the antitumor effects on nasopharyngeal carcinoma by downregulating vascular endothelial growth factor expression and angiogenesis.
Correlation Analysis of Nasopharyngeal Carcinoma TNM Staging with Serum EA IgA and VCA IgA in EBV and VEGF-C and -D.
Correlation of quantitative parameters of magnetic resonance perfusion-weighted imaging with vascular endothelial growth factor, microvessel density and hypoxia-inducible factor-1? in nasopharyngeal carcinoma: evaluation on radiosensitivity study.
Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma.
Effect of the vascular endothelial growth factor expression level on angiopoietin-2-mediated nasopharyngeal carcinoma growth.
Efficacy of nedaplatin combined with docetaxel in patients with nasopharyngeal carcinoma and its influence on ECRG4 and VEGF expressions.
Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma.
Elevation of vascular endothelial growth factor in Indonesian advanced stage nasopharyngeal carcinoma.
Functional vascular endothelial growth factor -2578 C/A polymorphism in relation to nasopharyngeal carcinoma risk and tumor progression.
Genetic Variations of VEGFA Gene Are Associated With Infiltration of Adjacent Tissues and the Clinical Outcome of Patients With Nasopharyngeal Carcinoma.
Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma.
Hypoxia Inducible Factor-1alpha and Vascular Endothelial Growth Factor Expression are Associated with a Poor Prognosis in Patients with Nasopharyngeal Carcinoma Receiving Radiotherapy with Carbogen and Nicotinamide.
Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells.
Inhibition of EGF expression and NF-?B activity by treatment with quercetin leads to suppression of angiogenesis in nasopharyngeal carcinoma.
Nasopharyngeal carcinoma.
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells.
Polymorphism of VEGF-2578C/A associated with the risk and aggressiveness of nasopharyngeal carcinoma in a Chinese population.
Prognostic significance of expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma.
Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: More distant metastases and shorter overall survival after treatment.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rhein inhibits invasion and migration of human nasopharyngeal carcinoma cells in vitro by down-regulation of matrix metalloproteinases-9 and vascular endothelial growth factor.
Silencing vascular endothelial growth factor C increases the radiosensitivity in nasopharyngeal carcinoma CNE-2 cells.
Sunitinib Induces NK-?B-dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells.
Suppression of vascular endothelial growth factor via siRNA interference modulates the biological behavior of human nasopharyngeal carcinoma cells.
The long noncoding RNA FOXCUT promotes proliferation and migration by targeting FOXC1 in nasopharyngeal carcinoma.
The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma.
Valsartan inhibits NPC cell line CNE-2 proliferation and invasion and promotes its sensitivity to radiation.
Vascular endothelial growth factor165-regulated nasopharyngeal carcinoma cell lines invasion and migration involve expression and activation of matrix metalloproteinase-2.
VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine.
[Clinical significance of quantitative analysis of serum VEGF, CD44s, and MMP-3 protein in nasopharyngeal carcinoma]
[Clinical value of vascular endothelial growth factor detection in forecasting distant metastasis risk of nasopharyngeal carcinoma]
[Correlation between the vascular endothelial growth factor C expression and lymph node metastasis in human nasopharyngeal carcinoma]
[Correlations of biomolecular markers, such as p53 protein and vascular endothelial growth factor, to radiosensitivity of nasopharyngeal carcinoma.]
[Expression and clinical significance of vascular endothelial growth factor C and D in nasopharyngeal carcinoma]
[Expression and clinical significance of vascular endothelial growth factor in nasopharyngeal carcinoma]
[Expression and relationship of EBV LMP1, COX-2 and VEGF-C in nasopharyngeal carcinoma]
[Expression of vascular endothelial growth factor and nm23 as prognostic factors in nasopharyngeal carcinoma]
[Expression of vascular endothelial growth factor and tumor angiogenesis correlates with biological behaviors of nasopharyngeal carcinoma]
[Expressions and correlation with radiotherapy's effect of five kinds of genes in nasopharyngeal carcinoma]
[Inhibited proliferation and expression of human nasopharyngeal carcinoma line induced by celecoxib in vitro]
[Relationship between fluorodeoxyglucose uptake and vascular endothelial growth factor in early-stage nasophygeal carcinoma.]
[Relationship between the expressions of KaI1, nm23, ETS-1, VEGF and microvascular density and clinical significance in nasopharyngeal carcinoma]
[Significance of serum vascular endothelial growth factor test before radiotherapy in patients with nasopharyngeal carcinoma]
[The study of vascular endothelial growth factor in nasopharyngeal carcinoma patients before and after radiotherapy]
[Vascular endothelial growth factor gene expression in nasopharyngeal carcinoma cell line induced by hypoxia in vitro]
Nasopharyngeal Neoplasms
A Meta-Analysis of Vascular Endothelial Growth Factor for Nasopharyngeal Cancer Prognosis.
Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma--a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor.
Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression.
Nasopharyngitis
[Expression and clinical significance of vascular endothelial growth factor C and D in nasopharyngeal carcinoma]
Neonatal Sepsis
Complement factor D deficiency in an infant first seen with pneumococcal neonatal sepsis.
Neoplasm Metastasis
1,2,3,4,6-Penta-O-galloly-beta-D-glucose Suppresses Hypoxia-Induced Accumulation of Hypoxia-Inducible Factor-1? and Signaling in LNCaP Prostate Cancer Cells.
5-Aza-2'-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells.
A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin.
A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.
A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
A dual role for hypoxia inducible factor-1? in the hepatitis C virus lifecycle and hepatoma migration.
A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer.
A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
A human thyroid cancer cell line, DH-14-3, newly established from poorly differentiated thyroid carcinoma.
A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer.
A monoclonal antibody targeting neuropilin-1 inhibits adhesion of MCF7 breast cancer cells to fibronectin by suppressing the FAK/p130cas signaling pathway.
A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155.
A novel mitochondrial targeted hybrid peptide modified HPMA copolymers for breast cancer metastasis suppression.
A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor.
A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer.
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.
A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma.
A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases.
A role for bone morphogenetic protein-4 in lymph node vascular remodeling and primary tumor growth.
A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library.
A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin.
AAV2-mediated gene transfer of VEGF-Trap with potent suppression of primary breast tumor growth and spontaneous pulmonary metastases by long-term expression.
Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression.
Actions of heparin that may affect the malignant process.
Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Aflibercept a new target therapy in cancer treatment: a review.
An Alternating Irradiation Strategy-Driven Combination Therapy of PDT and RNAi for Highly Efficient Inhibition of Tumor Growth and Metastasis.
An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation.
Analysis of Expression of Vascular Endothelial Growth Factor A and Hypoxia Inducible Factor-1alpha in Patients Operated on Stage I Non-Small-Cell Lung Cancer.
Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab.
Angiogenesis as a target for gastric cancer.
Angiogenesis in liver metastasis of colo-rectal carcinoma.
Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels.
Angiogenesis, lymphangiogenesis, and melanoma metastasis.
Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors.
Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression.
Angiogenic peptides in prostatic disease.
Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis.
Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells.
Anti-metastasis effect of fucoidan from Undaria pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells.
Anti-tumor and anti-metastatic actions of wogonin isolated from Scutellaria baicalensis roots through anti-lymphangiogenesis.
Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma.
Anti-tumor effects of vascular endothelial growth factor/vascular endothelial growth factor receptor binding domain-modified chimeric antigen receptor T cells.
Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer.
Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor.
Antiangiogenesis and damaging blood flow by antisense vascular endothelial growth factor oligodeoxynucleotides to suppress lung cancers.
Antiangiogenic and antitumor activities of IL-27.
Antiangiogenic drugs in non-small cell lung cancer treatment.
Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.
Antibody against vascular endothelial growth factor (VEGF) inhibits angiogenic switch and liver metastasis in orthotopic xenograft model with site-dependent expression of VEGF.
Anticancer Potential of Mefenamic Acid Derivatives with Platelet-Derived Growth Factor Inhibitory Property.
Antimetastatic activity of novel ruthenium (III) pyridine complexes.
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.
Antitumor and radiosensitizing synergistic effects of apigenin and cryptotanshinone against solid Ehrlich carcinoma in female mice.
Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm.
Antitumor effects of bevacizumab in combination with fluoropyrimidine drugs on human oral squamous cell carcinoma.
Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma.
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.
Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C.
Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis.
Assessment of Maturation Status of Tumor-Infiltrating Dendritic Cells in Invasive Ductal Carcinoma of the Breast: Relation with Vascular Endothelial Growth Factor Expression.
Assessment of the associations between three VEGF polymorphisms and risk of prostate cancer.
Assessment of VEGF-D expression measured by immunohistochemical staining and F-18 FDG uptake on PET as biological prognostic factors for recurrence in patients with surgically resected lung adenocarcinoma.
Association between EGF and VEGF functional polymorphisms and sporadic colorectal cancer in the Malaysian population.
Association between expression of vascular endothelial growth factor C, chemokine receptor CXCR4 and lymph node metastasis in colorectal cancer.
Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Association between vascular endothelial growth factor expression and lymph node metastasis in cervical cancer: A meta-analysis.
Association between VEGF-460T/C gene polymorphism and clinical outcomes of nasopharyngeal carcinoma treated with intensity-modulated radiation therapy.
Association of CXCR4, CCR7, VEGF-C and VEGF-D expression with lymph node metastasis in patients with cervical cancer.
Association of Oral Cavity and Oropharyngeal Cancer Biomarkers in Surgical Drain Fluid With Patient Outcomes.
Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer.
Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
Association of single nucleotide polymorphisms in vascular endothelial growth factor gene with bladder cancer risk.
Association of specific single nucleotide variants (SNVs) in the promoter and 3'-Untranslated region of Vascular Endothelial growth factor (VEGF) gene with risk and higher tumour grade of head and neck cancers.
Association of vascular endothelial growth factor -2578C/A gene polymorphism in Chinese patients with colon cancer.
Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma.
Associations between the expression of MTA1 and VEGF-C in esophageal squamous cell carcinoma with lymph angiogenesis and lymph node metastasis.
Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: a meta-analysis.
Associations of VEGF-C Genetic Polymorphisms with Urothelial Cell Carcinoma Susceptibility Differ between Smokers and Non-Smokers in Taiwan.
Basic fibroblast growth factor promotes VEGF-C-dependent lymphangiogenesis via inhibition of miR-381 in human chondrosarcoma cells.
Basigin-2 upregulated by receptor activator of NF-?B ligand enhances lung cancer-induced osteolytic lesions.
BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.
Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer.
Bevacizumab in metastatic breast cancer: when may it be used?
Bevacizumab in the treatment of NSCLC: patient selection and perspectives.
Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer.
Bioactivity screening of partially desulfated low-molecular-weight heparins: A structure/activity relationship study.
Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma.
Biological characterization of subgroups of squamous cell lung carcinomas.
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival.
Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis.
Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Blocking ?v?3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells.
Blocking neuropilin-2 function inhibits tumor cell metastasis.
Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.
Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells.
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Brain-Derived Neurotrophic Factor Activation of TrkB Induces Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Factor-1{alpha} in Neuroblastoma Cells.
Breast cancer brain metastases.
Breast cancer-associated metastasis is significantly increased in a model of autoimmune arthritis.
c-myc but not Hif-1?-dependent downregulation of VEGF influences the proliferation and differentiation of HL-60 cells induced by ATRA.
c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation.
Calcium Phosphate Coating Prepared by Microarc Oxidation Affects hTERT Expression, Molecular Presentation, and Cytokine Secretion in Tumor-Derived Jurkat T Cells.
cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis.
Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis.
CCL21/CCR7 up-regulate vascular endothelial growth factor-D expression via ERK pathway in human non-small cell lung cancer cells.
CD147/basigin promotes progression of malignant melanoma and other cancers.
CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma.
CD44 and VEGF expression in extrahepatic metastasis of human hepatocellular carcinoma.
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy.
Chemical characterization of a procyanidin-rich extract from sorghum bran and its effect on oxidative stress and tumor inhibition in vivo.
Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer.
Chitin hydrolysate stimulates VEGF-C synthesis by MDA-MB-231 breast cancer cells.
Chronic inflammation and colorectal cancer: the role of vascular endothelial growth factor.
circCCT3 Modulates Vascular Endothelial Growth Factor A and Wnt Signaling to Enhance Colorectal Cancer Metastasis Through Sponging miR-613.
Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma.
Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance?
Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma.
Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma.
Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers.
Clinical implications of targeting VEGF in solid tumors.
Clinical outcome and prognostic analysis of meningeal carcinomatosis treated by intrathecal chemotherapy.
Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL).
Clinical Relevance of Increased Endothelial and Mesothelial Expression of Proangiogenic Proteases and VEGFA in the Omentum of Patients with Metastatic Ovarian High-Grade Serous Carcinoma.
Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia.
Clinical significance of platelet derived growth factor-C and -D in gastric cancer.
Clinical significance of vascular endothelial growth factor in patients with primary lung cancer.
Clinical Significance of Vascular Endothelial Growth Factors (VEGF)-C and -D in Resected Non-Small Cell Lung Cancer.
Clinical study on the safety, efficacy, and prognosis of molecular targeted drug therapy for advanced gastric cancer.
Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?
Clinical utility of vascular endothelial growth factor in diagnosing malignant pleural effusions.
Clinicopathologic significance of nuclear factor-?B and vascular endothelial growth factor expression in advanced gastric cancer patients.
Clinicopathological and prognostic significance of hypoxia-inducible factor-1? in esophageal squamous cell carcinoma: a meta-analysis.
Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer.
Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer.
Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas.
Clinicopathological variables associated with lymph node metastasis in submucosal invasive gastric cancer.
Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways.
Colorectal Cancer in the Cotton Top Tamarin (Saguinus oedipus): How Do They Evade Liver Metastasis?
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
Combination of curcuma zedoary and kelp inhibits growth and metastasis of liver cancer in vivo and in vitro via reducing endogenous H2S levels.
Combination of IL-24 and cisplatin inhibits angiogenesis and lymphangiogenesis of cervical cancer xenografts in a nude mouse model by inhibiting VEGF, VEGF-C and PDGF-B.
Combination of mitochondria targeting doxorubicin with Bcl-2 function-converting peptide NuBCP-9 for synergistic breast cancer metastasis inhibition.
Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis.
Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer.
Comparison of (18)F-fluorodeoxyglucose PET/CT findings with vascular endothelial growth factors and receptors in colorectal cancer.
Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer.
Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Emerging and Investigational Therapties for the Treatment of Adults With Metastatic Brain Tumors.
Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma.
Constitutive upregulation of hypoxia-inducible factor-1alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure.
Correlation Analysis of Nasopharyngeal Carcinoma TNM Staging with Serum EA IgA and VCA IgA in EBV and VEGF-C and -D.
Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma.
Correlation between vascular endothelial growth factor C expression and lymph node metastasis in T1 carcinoma of the colon and rectum.
Correlation between vascular endothelial growth factor expression and presence of lymph node metastasis in advanced squamous cell carcinoma of the larynx.
Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.
Correlation of integrin beta3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma.
Correlation of lymphatic vessel density and vascular endothelial growth factor with nodal metastasis in papillary thyroid microcarcinoma.
Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma.
Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy.
Correlation of serum intercellular adhesion molecule 1 and vascular endothelial growth factor with tumor grading and staging in breast cancer patients.
Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma.
Correlations between VEGF-A expression and prognosis in patients with gastric adenocarcinoma.
Correlations of expressions of IMP3 and VEGF with stage of osteosarcoma, microvascular density and pulmonary metastasis.
Correlations of serum VEGF and MMP-2 levels with CLM in CRC patients and effects of TACE on their expressions.
Correlations of TNM staging and lymph node metastasis of gastric cancer with MRI features and VEGF expression.
COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study.
COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer.
CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases.
CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.
Curcumin inhibits the lymphangiogenesis of gastric cancer cells by inhibiton of HMGB1/VEGF-D signaling.
Current role of cabozantinib in metastatic castration-resistant prostate cancer.
Current strategies for modulating lymphangiogenesis signalling pathways in human disease.
Cyclo-oxygenase-2 expression is associated with vascular endothelial growth factor C expression and lymph node metastasis in oral squamous cell carcinoma.
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.
Decorin is responsible for progression of non-small-cell lung cancer by promoting cell proliferation and metastasis.
Decreased Growth Rate of Lung Metastatic Lesions after Splenectomy in Mice.
Decreased serum vascular endothelial growth Factor-D (VEGF-D) levels in metastatic patients with differentiated thyroid carcinoma.
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
Desmoplastic tumour-associated stroma versus neural tissue in central nervous system metastasis: effects of different microenvironments on tumour growth.
Detection of HDM2 and VEGF co-expression in cancer cell lines: novel effect of HDM2 antisense treatment on VEGF expression.
Development and characterization of a novel in vivo model of carcinoid syndrome.
Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve.
Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
Dietary 2-deoxy-D-glucose impairs tumour growth and metastasis by inhibiting angiogenesis.
Dietary oleuropein inhibits tumor angiogenesis and lymphangiogenesis in the B16F10 melanoma allograft model: a mechanism for the suppression of high-fat diet-induced solid tumor growth and lymph node metastasis.
Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors.
Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma.
Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases.
Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma.
Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma.
Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats.
Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.
Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis.
Does preoperative chemo-radiotherapy enhance the expression of vascular endothelial growth factor in patients with rectal cancer?
Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells.
Down-regulation of platelet-derived growth factor-D expression blockades NF-?B pathway to inhibit cell proliferation and invasion as well as induce apoptosis in esophageal squamous cell carcinoma.
Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling.
Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression.
Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.
Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
Effect of anesthetic technique on serum vascular endothelial growth factor C and transforming growth factor ? in women undergoing anesthesia and surgery for breast cancer.
Effect of bevacizumab on the tight junction proteins of vascular endothelial cells.
Effect of Bevacizumab, a Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, on Peritoneal Metastasis of MNK-45P Human Gastric Cancer in Mice.
Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma.
Effect of HIF-1alpha on VEGF-C induced lymphangiogenesis and lymph nodes metastases of pancreatic cancer.
Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Effect of molecular targeted therapy combined with radiotherapy on the expression and prognostic value of COX-2 and VEGF in bone metastasis of lung cancer.
Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma.
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer.
Effect of vascular endothelial growth factor-C expression on lymph node metastasis in human cholangiocarcinoma.
Effect of vegf gene knockdown on growth of the murine sarcoma cell line MS-K.
Effect of Wnt/?-catenin signal pathway on of matrix metalloproteinase-7 and vascular endothelial growth factor gene expressions in endometriosis.
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis.
Effects of brucine on vascular endothelial growth factor expression and microvessel density in a nude mouse model of bone metastasis due to breast cancer.
Effects of ellagic Acid on angiogenic factors in prostate cancer cells.
Effects of melatonin on HIF-1? and VEGF expression and on the invasive properties of hepatocarcinoma cells.
Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
Effects of propofol/remifentanil-based total intravenous anesthesia versus sevoflurane-based inhalational anesthesia on the release of VEGF-C and TGF-? and prognosis after breast cancer surgery: a prospective, randomized and controlled study.
Effects of trichostatin A on HIF-1? and VEGF expression in human tongue squamous cell carcinoma cells in vitro.
Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.
Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model.
Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study.
Efficient inhibition of non-small-cell lung cancer xenograft by systemic delivery of plasmid-encoding short-hairpin RNA targeting VEGF.
EFNS guidelines on disease-specific CSF investigations.
El-Gazzar R, Macluskey M, Williams H, Ogden GR. Vascularity and expression of vascular endothelial growth factor in oral squamous cell carcinoma, resection margins, and nodal metastases. Br J Oral Maxillofac Surg 2006;44:193-7 [Epub 2005, August 10].
Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer.
Elevated VEGF-D Modulates Tumor Inflammation and Reduces the Growth of Carcinogen-Induced Skin Tumors.
Emergency open incarcerated hernia repair with a biological mesh in a patient with colorectal liver metastasis receiving chemotherapy and bevacizumab uncomplicated wound healing.
EMMPRIN in gynecologic cancers: pathologic and therapeutic aspects.
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer.
Endocrine gland-derived vascular endothelial growth factor strengthens cell invasion ability via prokineticin receptor 2 in colon cancer cell lines.
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer.
Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.
Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells.
Endothelial Cell Proliferation and Vascular Endothelial Growth Factor Expression in Primary Colorectal Cancer and Corresponding Liver Metastases.
Engineered Conformation-dependent VEGF Peptide Mimics Are Effective in Inhibiting VEGF Signaling Pathways.
Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis.
Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2.
Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line.
Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs).
Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice.
ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Ethanol stimulates tumor progression and expression of vascular endothelial growth factor in chick embryos.
Evaluation of plasma and tissue S100A4 protein and mRNA levels as potential markers of metastasis and prognosis in clear cell renal cell carcinoma.
Evaluation of stromal metalloproteinases and vascular endothelial growth factors in a spontaneous metastasis model.
Evaluation of vascular endothelial growth factor gene and protein expression in canine metastatic mammary carcinomas.
Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
Exosome miR-155 Derived from Gastric Carcinoma Promotes Angiogenesis by Targeting the c-MYB/VEGF Axis of Endothelial Cells.
Exosome-encapsulated miRNAs contribute to CXCL12/CXCR4-induced liver metastasis of colorectal cancer by enhancing M2 polarization of macrophages.
Exploring stemness gene expression and vasculogenic mimicry capacity in well- and poorly-differentiated hepatocellular carcinoma cell lines.
Exploring the peritoneal surface malignancy phenotype-a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models.
Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer.
Expression and significance of vascular endothelial growth factor A and C in leukemia central nervous system metastasis.
Expression characteristics of KAI1 and vascular endothelial growth factor and their diagnostic value for hepatocellular carcinoma.
Expression of CD44, vascular endothelial growth factor, and proliferating cell nuclear antigen in severe venous invasional colorectal cancer and its relationship to liver metastasis.
Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis.
Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas.
Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma.
Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice.
Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis.
Expression of molecular factors correlated with metastasis in small cell lung cancer and their significance.
Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor.
Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.
Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress.
EXPRESSION OF THE SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 IN CUTANEOUS MELANOMA: ROLE IN TUMOUR PROGRESSION.
Expression of thymosin beta10 and its role in non-small cell lung cancer.
Expression of Tspan-1 gene in patients with advanced gastric cancer.
Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas.
Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance.
Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers.
Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival.
Expression of vascular endothelial growth factor (VEGF) and VEGF-C in serum and tissue of Wilms tumor.
Expression of vascular endothelial growth factor (VEGF) family members in breast cancer.
Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma.
Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
Expression of vascular endothelial growth factor and E26 transformation-specific-1 in breast carcinoma.
Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.
Expression of vascular endothelial growth factor and matrix metalloproteinase-2 correlates with the invasion and metastasis of hepatocellular carcinoma.
Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis.
Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer.
Expression of vascular endothelial growth factor and receptor flk-1 in colon cancer liver metastases.
Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice.
Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis.
Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis.
Expression of vascular endothelial growth factor C and D (VEGF-C and -D) is an important risk factor for lymphatic metastasis in undifferentiated early gastric carcinoma.
Expression of vascular endothelial growth factor C and its correlation with lymph node metastasis in colorectal carcinoma.
Expression of vascular endothelial growth factor can predict distant metastasis and disease-free survival for clinical stage III rectal cancer following 30-Gy/10-f preoperative radiotherapy.
Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas.
Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma.
Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis.
Expression of vascular endothelial growth factor in hepatocellular carcinoma and its relationship to tumor growth and metastasis.
Expression of vascular endothelial growth factor in renal cell carcinomas.
Expression of vascular endothelial growth factor in salivary gland carcinomas correlates with lymph node metastasis.
Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis.
Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis.
Expression of vascular endothelial growth factor mRNA in GI-101A and HL-60 cell lines.
Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma.
Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer.
Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer.
Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.
Expression of vascular endothelial growth factors C and D correlates with lymphangiogenesis and lymph node metastasis in lung adenocarcinoma.
Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma.
Expression of VEGF-C/VEGFR-3 in human laryngeal squamous cell carcinomas and its significance for lymphatic metastasis.
Expression of VEGF-D, SMAD4, and SMAD7 and Their Relationship with Lymphangiogenesis and Prognosis in Colon Cancer.
Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
Expression, purification and functionality of bioactive recombinant human vascular endothelial growth factor VEGF165 in E. coli.
Expression, purification, and characterization of a diabody against the most important angiogenesis cell receptor: Vascular endothelial growth factor receptor 2.
Expressions of p53, VEGF C, p21: could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma?
Extracellular matrix metalloproteinase inducer expression has an impact on survival in human bladder cancer.
Feasibility of MRI-based radiomics features for predicting lymph node metastases and VEGF expression in cervical cancer.
Fingolimod (Gilenya) and melanoma.
Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts.
Flt-1 signaling in macrophages promotes glioma growth in vivo.
Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.
FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma.
Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts.
Gamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusion.
gamma-Tocotrienol modulates the paracrine secretion of VEGF induced by cobalt(II) chloride via ERK signaling pathway in gastric adenocarcinoma SGC-7901 cell line.
Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms-A case-control study in an Omani population.
Gefitinib inhibits malignant melanoma cells through the VEGF/AKT signaling pathway.
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.
Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor.
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk.
Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis.
Glycoprotein Nonmetastatic Melanoma Protein B as Potential Imaging Marker in Posttherapeutic Metastatic Head and Neck Cancer.
GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin ?5?1 for efficient breast cancer metastasis.
Gray level entropy matrix is a superior predictor than multiplex ELISA in the detection of reactive stroma and metastatic potential of high-grade prostatic adenocarcinoma.
Green fluorescent protein (GFP)-expressing tumor model derived from a spontaneous osteosarcoma in a vascular endothelial growth factor (VEGF)-GFP transgenic mouse.
Growth factors as therapeutic targets in HCC.
HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma.
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma.
Heavy-ion beam irradiation inhibits invasion of tongue squamous cell carcinoma Tca8113 cells.
Hedyotis diffusa Willd. inhibits VEGF?C?mediated lymphangiogenesis in colorectal cancer via multiple signaling pathways.
Heparanase regulates in vitro VEGF-C expression and its clinical significance to pancreatic ductal cell adenocarcinoma.
Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice.
Hepatocyte Growth Factor and Macrophage-Stimulating Protein "Hinge" Analogs to Treat Pancreatic Cancer.
High expression of SDF-1 and VEGF is associated with poor prognosis in patients with synovial sarcomas.
High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma.
High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.
High expressions of CD105 and VEGF in early oral cancer predict potential cervical metastasis.
High levels of circulating CD34+/VEGFR3+ lymphatic/vascular endothelial progenitor cells is correlated with lymph node metastasis in patients with epithelial ovarian cancer.
High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma.
High serum levels of Transforming Growth Factor-b1, Interleukin-10 and Vascular Endothelial Growth Factor in pancreatic adenocarcinoma patients.
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
High VEGF-D and Low MMP-2 Serum Levels Predict Nodal-Positive Disease in Invasive Bladder Cancer.
High-mobility group box 1 protein activating nuclear factor-?B to upregulate vascular endothelial growth factor C is involved in lymphangiogenesis and lymphatic node metastasis in colon cancer.
Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier.
Highly sensitive antibody-aptamer sensor for vascular endothelial growth factor based on hybridization chain reaction and pH meter/indicator.
Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer.
Honokiol: A Review of Its Anticancer Potential and Mechanisms.
HTERT mRNA expression correlates with matrix metalloproteinase-1 and vascular endothelial growth factor expression in human breast cancer: a correlative study using RT-PCR.
Human CD133-positive hematopoietic progenitor cells initiate growth and metastasis of colorectal cancer cells.
Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat Rama 37 model cells.
Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer.
Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library.
Hydronephrotic Urine in the Obstructed Kidney Promotes Urothelial Carcinoma Cell Proliferation, Migration, Invasion through the Activation of mTORC2-AKT and ERK Signaling Pathways.
Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker.
Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2.
Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells.
Hypoxia, cytokines and stromal recruitment: parallels between pathophysiology of encapsulating peritoneal sclerosis, endometriosis and peritoneal metastasis.
Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8.
Hypoxia-driven selection of the metastatic phenotype.
Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model.
Hypoxia-Inducible Factor-2{alpha} Regulates GM-CSF-Derived Soluble Vascular Endothelial Growth Factor Receptor 1 Production from Macrophages and Inhibits Tumor Growth and Angiogenesis.
Icariside II from Epimedium koreanum inhibits hypoxia-inducible factor-1alpha in human osteosarcoma cells.
Identification of a prognostic 28-gene expression signature for gastric cancer with lymphatic metastasis.
Identification of HDM2 as a regulator of VEGF expression in cancer cells.
Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications.
Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer.
Immune factors associated with the pathological and therapeutic effects of preoperative chemotherapy in patients with breast cancer.
Immunohistochemical demonstration of angiogenic growth factors and EGF receptor in hepatic metastases and primary human gastric cancer.
Immunohistochemical Expression of Fatty Acid Synthase and Vascular Endothelial Growth Factor in Primary Colorectal Cancer: a Clinicopathological Study.
Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma.
Immunohistochemical study of vascular endothelial growth factor (VEGF) and matrilysin (MMP-7) in T1 adenocarcinoma of the colon and rectum to predict lymph node metastases or distant metastases.
Impact of stress and mast cells on brain metastases.
Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis.
Implication of vascular endothelial growth factor in the development and metastasis of human cancers.
Implication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis.
In vitro and in silico characterization of angiogenic inhibitors from Sophora interrupta.
In Vitro and In Vivo Antimetastatic Effects of ZSTK474 on Prostate Cancer DU145 Cells.
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.
In vivo and in vitro antitumor effect of ascorbic acid, lysine, proline, arginine, and green tea extract on human fibrosarcoma cells HT-1080.
In vivo antitumor effect of ascorbic acid, lysine, proline and green tea extract on human prostate cancer PC-3 xenografts in nude mice: evaluation of tumor growth and immunohistochemistry.
In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment.
Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma.
Increased expression of thioredoxin-1, vascular endothelial growth factor, and redox factor-1 is associated with poor prognosis in patients with liver metastasis from colorectal cancer.
Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies.
Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma.
Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways.
Induction of humoral immune responses and inhibition of metastasis in mice by a VEGF peptide-based vaccine.
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis.
Influence of hepatic arterial blockage on blood perfusion and VEGF, MMP-1 expression of implanted liver cancer in rats.
Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer.
Influence of Stromal Components on Lung Cancer Carcinogenesis.
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors.
Inhibiting the proliferation and metastasis of hilar cholangiocarcinoma cells by blocking the expression of vascular endothelial growth factor with small interfering RNA.
Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism.
Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.
Inhibition of breast cancer proliferation and metastasis by strengthening host immunity with a prolonged oxygen-generating phototherapy hydrogel.
Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor.
Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by d-limonene.
Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
Inhibition of HUVEC tubulogenesis by hederacolchiside-A1 is associated with plasma membrane cholesterol sequestration and activation of the Ha-Ras/MEK/ERK cascade.
Inhibition of liver metastasis of colon cancer by in vivo administration of anti-vascular endothelial growth factor antibody.
Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
Inhibition of the stress response to breast cancer surgery by regional anesthesia and analgesia does not affect vascular endothelial growth factor and prostaglandin E2.
Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.
Inhibition of Vascular Endothelial Growth Factor Receptor 3 Reduces Migration of Gastric Cancer Cells.
Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells.
Inhibitory effects of VEGF-siRNA mediated by adenovirus on osteosarcoma-bearing nude mice.
Inositol Hexaphosphate and Inositol Inhibit Colorectal Cancer Metastasis to the Liver in BALB/c Mice.
Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells.
Interaction between stromal fibroblasts and colorectal cancer cells in the expression of vascular endothelial growth factor.
Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer.
Interleukin-1alpha, 6 regulate the secretion of vascular endothelial growth factor A, C in pancreatic cancer.
Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.
Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker.
Intratumoral lymphatics and lymphatic vessel invasion detected by d2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma.
Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity.
Investigating the Relationship between of Vascular Endothelial Growth Factor and HER-2neu in IHC Staining with Metastasis and Mortality in Patients with Osteosarcoma.
Involvement of cyclooxygenase-2 and vascular endothelial growth factor in vascularization and lymph node metastasis of colorectal cancers with submucosal invasion.
Involvement of inactive GSK3beta overexpression in tumorigenesis and progression of gastric carcinomas.
Knockdown of neuron-specific enolase suppresses the proliferation and migration of NCI-H209 cells.
Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer.
Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression.
Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.
Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by Vascular Endothelial Growth Factor.
Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.
Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression.
lncRNA ROR promotes the progression of renal cell carcinoma through the miR?206/VEGF axis.
Local Delivery of Chitosan/VEGF siRNA Nanoplexes Reduces Angiogenesis and Growth of Breast Cancer In Vivo.
Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics.
Long non-coding RNA HOTAIR is associated with human cervical cancer progression.
Long noncoding RNA CPS1-IT1 suppresses melanoma cell metastasis through inhibiting Cyr61 via competitively binding to BRG1.
Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors.
Lunasin Attenuates Obesity-Associated Metastasis of 4T1 Breast Cancer Cell through Anti-Inflammatory Property.
Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma.
Lymphangiogenesis and tumour metastasis.
Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases.
Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer--A Structured Review with Meta-Analysis.
Lymphatic microvessel density as prognostic marker in colorectal cancer.
Lymphatic Vessel Density and Vascular Endothelial Growth Factor Expression in Squamous Cell Carcinomas of Lip and Oral Cavity: A Clinicopathological Analysis with Immunohistochemistry Using Antibodies to D2-40, VEGF-C and VEGF-D.
Lymphatic vessel density as a predictor of lymph node metastasis and its relationship with prognosis in urothelial carcinoma of the bladder.
Lymphatic vessel density in pulmonary adenocarcinoma immunohistochemically evaluated with anti-podoplanin or anti-D2-40 antibody is correlated with lymphatic invasion or lymph node metastases.
M2-Polarized Tumor-Associated Macrophage Infiltration of Regional Lymph Nodes Is Associated With Nodal Lymphangiogenesis and Occult Nodal Involvement in pN0 Pancreatic Cancer.
Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice.
Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6.
Mammary cancer gene therapy targeting lymphangiogenesis: VEGF-C siRNA and soluble VEGF receptor-2, a splicing variant.
MARKERS OF THE LUNG CANCER COMPLICATIONS.
Markers of tumour angiogenesis and tumour cells in bone marrow in gastric cancer patients.
Mast Cell Infiltration in Human Brain Metastases Modulates the Microenvironment and Contributes to the Metastatic Potential.
Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice.
Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment.
Melatonin maximizes the therapeutic potential of non-preconditioned MSCs in a DEN-induced rat model of HCC.
Melatonin: A regulator of the interplay between FoxO1, miR96, and miR215 signaling to diminish the growth, survival, and metastasis of murine adenocarcinoma.
Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes.
Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis.
Metastasis correlates with production of vascular endothelial growth factor in a murine model of human Wilms' tumor.
Metastasis in melanoma xenografts is associated with tumor microvascular density rather than extent of hypoxia.
Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients.
Metastatic properties of prostate cancer cells are controlled by VEGF.
MIA-dependent angiogenesis and lymphangiogenesis are closely associated with progression, nodal metastasis and poor prognosis in tongue squamous cell carcinoma.
MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells.
MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C.
MicroRNA-205 is downregulated in hepatocellular carcinoma and inhibits cell growth and metastasis via directly targeting vascular endothelial growth factor A.
microRNA-382 suppresses the progression of pancreatic cancer through the PI3K/Akt signaling pathway by inhibition of Anxa3.
Microvascular density and vascular endothelial growth factor immunoreactivity as predictors of regional lymph node metastasis from betel-associated oral squamous cell carcinoma.
Microvascular density of breast cancer in bone metastasis: influence of therapy.
Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation.
Microvessel Density Is Associated with VEGF and ?-SMA Expression in Different Regions of Human Gastrointestinal Carcinomas.
Microvessel morphology and vascular endothelial growth factor expression in human colonic carcinoma with or without metastasis.
Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors.
miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/?-catenin signaling through targeting BCL9.
MiR-22-3p Expression is down-regulated in lung adenocarcinoma.
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis.
Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells.
Modulation of the dual-faced effects of miR-141 with chitosan/miR-141 nanoplexes in breast cancer cells.
Modulation, bioinformatic screening, and assessment of small molecular peptides targeting the vascular endothelial growth factor receptor.
Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
Molecular expression of vascular endothelial growth factor, prokineticin receptor-1 and other biomarkers in infiltrating canalicular carcinoma of the breast.
Molecular mechanisms and targeting of colorectal cancer.
Molecular mechanisms in cancer: what should clinicians know?
Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis.
Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo.
Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer.
Molecular targets for green tea in prostate cancer prevention.
Molecular targets of ?-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: A review.
Monocyte Chemoattractant Protein 1 Promotes VEGF-A Expression in OSCC by Activating ILK and MEK1/2 Signaling and Downregulating miR-29c.
Mulberry leaf extract inhibits invasive potential and downregulates hypoxia-inducible factor-1? (HIF-1?) in SK-N-BE2C neuroblastoma cells.
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
Multifunctional CD40L: pro- and anti-neoplastic activity.
Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.
Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance.
Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways.
Mutual enhancement between heparanase and vascular endothelial growth factor: a novel mechanism for melanoma progression.
Mutually-Reactive, Fluorogenic Hydrocyanine/Quinone Reporter Pairs for In-Solution Biosensing via Nanodroplet Association.
Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition.
Neuropilin-2 contributes to LPS-induced corneal inflammatory lymphangiogenesis.
Neuropilin-2 expression in papillary thyroid carcinoma: correlation with VEGF-D expression, lymph node metastasis, and VEGF-D-induced aggressive cancer cell phenotype.
Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial ?5 integrin.
Nitric oxide donors reduce the invasion ability of ovarian cancer cells in vitro.
Nitric oxide in papillary thyroid carcinoma: induction of vascular endothelial growth factor D and correlation with lymph node metastasis.
Notch1-MAPK Signaling Axis Regulates CD133(+) Cancer Stem Cell-Mediated Melanoma Growth and Angiogenesis.
Novel mutations and role of the LKB1 gene as a tumor suppressor in renal cell carcinoma.
Novel role of lactosylceramide in vascular endothelial growth factor-mediated angiogenesis in human endothelial cells.
NRP-1 silencing suppresses hepatocellular carcinoma cell growth in vitro and in vivo.
Nucleolin Promotes Heat Shock-Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis.
Octreotide and celecoxib synergistically encapsulate VX2 hepatic allografts following transcatheter arterial embolisation.
Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy.
Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma.
Oncolytic Adenovirus rAd.DCN Inhibits Breast Tumor Growth and Lung Metastasis in an Immune-Competent Orthotopic Xenograft Model.
Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation.
Opposing Effects of Heparanase and Heparanase-2 in Head & Neck Cancer.
Opposing Roles of JNK and p38 in Lymphangiogenesis in Melanoma.
Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage.
Osteopontin expression in pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma.
Over expression of vascular endothelial growth factor in correlation to Ki-67, grade, and stage of breast cancer.
Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.
Overexpression of Antiangiogenic Vascular Endothelial Growth Factor Isoform and Splicing Regulatory Factors in Oral, Laryngeal and Pharyngeal Squamous Cell Carcinomas
Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)?2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway.
Overexpression of both platelet-derived growth factor-BB and vascular endothelial growth factor-C and its association with lymphangiogenesis in primary human non-small cell lung cancer.
Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth.
Overexpression of Caveolin-1 in Hepatocellular Carcinoma with Metastasis and Worse Prognosis: Correlation with Vascular Endothelial Growth Factor, Microvessel Density and Unpaired Artery.
Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer.
Overexpression of cyclooxygenase-2 in gastric cancer correlates with the high abundance of vascular endothelial growth factor-C and lymphatic metastasis.
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells.
Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin.
Overexpression of vascular endothelial growth factor C is related to lymphogenous metastasis in early gastric carcinoma.
Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.
p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models.
p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment.
p53, vessel count, and vascular endothelial growth factor expression in human colon cancer.
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.
Paracrine signaling by VEGF-C promotes non-small cell lung cancer cell metastasis via recruitment of tumor-associated macrophages.
Pathobiological significance of vascular endothelial growth factor and Maspin expressions in human gastric carcinoma.
Pathophysiology of ocular surface squamous neoplasia.
Pathways targeting tumor lymphangiogenesis.
PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer.
Periostin directly and indirectly promotes tumor lymphangiogenesis of head and neck cancer.
Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients.
Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
pH, hypoxia and metastasis.
pH-sensitive tangeretin-ZnO quantum dots exert apoptotic and anti-metastatic effects in metastatic lung cancer cell line.
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Phase I safety and pharmacokinetic study of bevacizumab in Chinese patients with advanced cancer.
Photodynamic Therapy Mediated by Aloe-Emodin Inhibited Angiogenesis and Cell Metastasis Through Activating MAPK Signaling Pathway on HUVECs.
Placenta growth factor expression is correlated with survival of patients with colorectal cancer.
Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models.
Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers.
Placental growth factor signaling regulates isoform splicing of vascular endothelial growth factor A in the control of lung cancer cell metastasis.
Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume.
Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours.
Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells.
Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells.
PLGA-encapsulated tea polyphenols enhance the chemotherapeutic efficacy of cisplatin against human cancer cells and mice bearing Ehrlich ascites carcinoma.
PlGF Knockdown Decreases Tumorigenicity and Stemness Properties of Spheroid Body Cells Derived from Gastric Cancer Cells.
PMEPA1/TMEPAI knockout impairs tumour growth and lung metastasis in MDA-MB-231 cells without changing monolayer culture cell growth.
Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Polymorphism of VEGF-460C/T associated with the risk and clinical characteristics of lung cancer in Chinese population.
Poor perfusion of the microvasculature in peritoneal metastases of ovarian cancer.
Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis.
Possible pathophysiological role of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in metastatic brain tumor-associated intracerebral hemorrhage.
Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60.
Potent inhibition of tumoral hypoxia-inducible factor 1 by albendazole.
Pre-operative plasma levels of vascular endothelial growth factor A, C and D in patients with colorectal cancer.
Predicting lymph node metastasis in patients with papillary thyroid carcinoma by vascular index on power Doppler ultrasound.
Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer.
Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer.
Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients.
Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during long-term follow-up of colorectal cancer patients.
Preoperative serum VEGF-C but not VEGF-A level is correlated with lateral neck metastasis in papillary thyroid carcinoma.
Preparation of extracellular domain 3 of human VEGF receptor-2 and the monitoring of its real-time binding to VEGF by biosensors.
Primary Tumor-Secreted Lymphangiogenic Factors Induce Pre-Metastatic Lymphvascular Niche Formation at Sentinel Lymph Nodes in Oral Squamous Cell Carcinoma.
ProBDNF is a novel mediator of the interaction between MDA-MB-231 breast cancer cells and brain microvascular endothelial cells.
Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons.
Progestin regulation of vascular endothelial growth factor in human breast cancer cells.
Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients.
Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis.
Prognostic significance of alpha V integrin and VEGF in osteosarcoma after chemotherapy.
Prognostic Significance of c-erbB-2 and Vascular Endothelial Growth Factor in Colorectal Liver Metastases.
Prognostic significance of placenta growth factor expression in patients with multiple cancers: a meta-analysis.
Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
Prognostic significance of vascular endothelial growth factor D in gastric carcinoma.
Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis.
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.
Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma.
Prognostic significance of VEGF immunohistochemical expression in oral cancer: a meta-analysis of the literature.
Prognostic value of the immunohistochemical expression of vascular endothelial growth factors in malignant salivary gland neoplasms: a systematic review and meta-analysis.
Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis.
Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis.
Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: a systematic review with meta-analysis.
Prohibitin, relocated to the front ends, can control the migration directionality of colorectal cancer cells.
Prophylactic administration of fucoidan represses cancer metastasis by inhibiting vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in Lewis tumor-bearing mice.
Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2.
Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: More distant metastases and shorter overall survival after treatment.
Prostaglandin E? regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells.
Protein kinase C signalling pathway is involved in the regulation of vascular endothelial growth factor expression in human bladder transitional carcinoma cells.
Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer.
Psychological Stress Up-Regulates CD147 Expression Through Beta-Arrestin1/ERK to Promote Proliferation and Invasiveness of Glioma Cells.
Q39, a quinoxaline 1,4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1alpha expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells.
Quantifying heterogeneity in dynamic contrast-enhanced MRI parameter maps.
Quantitative analysis of lymphangiogenic markers in human gastroenteric tumor.
Quantitative analysis of vascular endothelial growth factor in colon cancer. Clinical and experimental.
Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis.
Quantitative analysis of VEGF-C mRNA of extrahepatic cholangiocarcinoma with real-time PCR using samples obtained during endoscopic retrograde cholangiopancreatography.
Quantitative analysis using ELISA of vascular endothelial growth factor and basic fibroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and hepatocellular carcinoma.
Rac activation is associated with hepatocellular carcinoma metastasis by up-regulation of vascular endothelial growth factor expression.
Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial-mesenchymal transition.
RAGE-aptamer Attenuates the Growth and Liver Metastasis of Malignant Melanoma in Nude Mice.
Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin {alpha}v{beta}3.
Re-expression of reduced VEGF activity in liver metastases of experimental pancreatic cancer.
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;53:376-81.
Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.
Recent discovery of non-nucleobase thymidine phosphorylase inhibitors targeting cancer.
Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.
Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer.
Recurrence or metastasis of HCC:predictors, early detection and experimental antiangiogenic therapy.
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma.
Regulation of Gene Expression by Progesterone in Cancer Cells: Effects on Cyclin D1, EGFR and VEGF.
Regulation of genes associated with angiogenesis, growth, and metastasis by specific p53 point mutations in a murine melanoma cell line.
Regulation of vascular endothelial growth factor in prostate cancer.
Regulation of VEGF, MMP-9, and metastasis by CXCR4 in a prostate cancer cell line.
Relationship between expression of vascular endothelial growth factor and cervical lymph node metastasis in papillary thyroid cancer: A meta-analysis.
Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer.
Relationship between vascular endothelial growth factor and Notch1 expression and lymphatic metastasis in tongue cancer.
Relationship between VEGF protein expression and lymph node metastasis in papillary thyroid carcinoma among Asians: a meta-analysis.
Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma.
Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer.
Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis.
Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
Repressing CD147 is a novel therapeutic strategy for malignant melanoma.
Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
RhoC is essential for angiogenesis induced by hepatocellular carcinoma cells via regulation of endothelial cell organization.
Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line.
RNA interference of hypoxia-inducible factor-1 alpha improves the effects of transcatheter arterial embolization in rat liver tumors.
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo.
Role of angiogenesis in the development and growth of liver metastasis.
Role of hypoxia-inducible factor-1?, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer.
Role of lymphangiogenesis in epithelial ovarian cancer.
Role of lymphangiogenesis in lung cancer.
Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule.
Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer.
Role of vascular endothelial growth factor receptor-3/Flt-4 in early-stage cervical cancer.
Role of vascular endothelial growth factor-C and -D mRNA in breast cancer.
Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models.
Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis.
RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer.
S100A13 is a new angiogenic marker in human melanoma.
Salivary levels and immunohistochemical expression of selected angiogenic factors in benign and malignant parotid gland tumours.
SDF-1 Expression is Associated with Poor Prognosis in Osteosarcoma.
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.
Selection, Analysis and Improvement of Anti-Angiogenesis Compounds Identified by an Anti-HIF-1? Screening and Validation System.
Selective cytotoxic and anti-metastatic activity in DU-145 prostate cancer cells induced by Annona muricata L. bark extract and phytochemical, annonacin.
Semaphorin 3F Serves as a Tumor Suppressor in Esophageal Squamous Cell Carcinoma and is Associated With Lymph Node Metastasis in Disease Progression.
Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors.
Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.
Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma.
Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma.
Serum vascular endothelial growth factor in breast cancer.
Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma.
Serum vascular endothelial growth factor-C and vascular endothelial growth factor level in patients with colorectal carcinoma and clinical significance.
Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis.
Serum vascular endothelial growth factor-D levels correlate with cervical lymph node metastases in papillary thyroid carcinoma.
Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival.
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
Siamese crocodile bile induces apoptosis in NCI-H1299 human non-small cell lung cancer cells via a mitochondria-mediated intrinsic pathway and inhibits tumorigenesis.
Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.
Significance and expression of vascular endothelial growth factor and E-cadherin in non-small cell lung Carcinomas.
Significance of MMP-9 and VEGF-C expression in North Indian women with breast cancer diagnosis.
Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma.
Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma.
Silencing vascular endothelial growth factor C increases the radiosensitivity in nasopharyngeal carcinoma CNE-2 cells.
Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells.
Single nucleotide polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma.
siRNA-mediated knockdown of VEGF-A, VEGF-C and VEGFR-3 suppresses the growth and metastasis of mouse bladder carcinoma in vivo.
Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway.
SNP and Haplotype Analysis of Vascular Endothelial Growth Factor (VEGF) Gene in Lung Cancer Patients of Kashmir
So05 the nature of nearby lymphatics dictates whether a vascular endothelial growth factor-d (VEGF-d) induces tumor lymphatics and metastasis.
Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis.
Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) is decreased in lung cancer patients showing progression: a pilot study.
Sorafenib in lung cancer: clinical developments and future directions.
Sp transcription factor family and its role in cancer.
SPECT imaging of neuropilin receptor type-1 expression with 131I-labeled monoclonal antibody.
Stable silencing of dll4 gene suppresses the growth and metastasis of esophagus cancer cells by attenuating Akt phosphorylation.
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.
Strobilanthes crispus inhibits migration, invasion and metastasis in breast cancer.
Stroma-epithelium crosstalk in prostate cancer.
Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy.
Structure-activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents.
Structure-fluctuation-function relationships of seven pro-angiogenic isoforms of VEGFA, important mediators of tumorigenesis.
Studies of pathology and VEGF expression in rabbit cerebrospinal fluid metastasis: application of dynamic contrast-enhanced MRI.
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633.
Suppression of lymph node and lung metastases of endometrial cancer by muscle-mediated expression of soluble vascular endothelial growth factor receptor-3.
Suppression of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2.
Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene.
Suppression of vascular endothelial growth factor receptor 3 (VEGFR3) and vascular endothelial growth factor C (VEGFC) inhibits hypoxia-induced lymph node metastases in cervix cancer.
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Surgical excision promotes tumor growth and metastasis by promoting expression of MMP-9 and VEGF in a breast cancer model.
Surrogate markers of angiogenesis and metastasis.
Survivin and vascular endothelial growth factor are associated with spontaneous pulmonary metastasis of osteosarcoma: Development of an orthotopic mouse model.
Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis.
Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
Synchronous vascular endothelial growth factor protein profiles in both tissue and serum identify metastasis and poor survival in colorectal cancer.
Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.
Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin.
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.
Tangeretin, a citrus pentamethoxyflavone, exerts cytostatic effect via p53/p21 up-regulation and suppresses metastasis in 7,12-dimethylbenz(?)anthracene-induced rat mammary carcinoma.
Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2).
Tanshinone IIA reduces secretion of pro?angiogenic factors and inhibits angiogenesis in human colorectal cancer.
Targeting Angiogenesis in Prostate Cancer.
Targeting delivery of lipocalin 2-engineered mesenchymal stem cells to colon cancer in order to inhibit liver metastasis in nude mice.
Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.
Targeting Notch1 inhibits invasion and angiogenesis of human breast cancer cells via inhibition Nuclear Factor-?B signaling.
Targets of 17beta-oestradiol-induced apoptosis in colon cancer cells: a mechanism for the protective effects of hormone replacement therapy?
The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.
The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion.
The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer.
The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis.
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
The Biology of Brain Metastasis: Challenges for Therapy.
The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway.
The connection between lymphangiogenic signalling and prostglandin biology: A missing link in the metastatsic pathway.
The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor.
The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.
The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1?-dependent and -independent manners.
The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer.
The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis.
The effect of high Sox3 expression on lymphangiogenesis and lymph node metastasis in esophageal squamous cell carcinoma.
The effect of vascular endothelial growth factor-1 expression on survival of advanced colorectal cancer patients.
The effects of exercise training on levels of vascular endothelial growth factor in tumor-bearing mice.
The epidemiology and biology of pulmonary metastases.
The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers().
The fibrinolysis inhibitor ?2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer.
The HOTAIR lncRNA: A remarkable oncogenic promoter in human cancer metastasis.
The natural progression of microvasculature in primary tumor and lymph node metastases in a breast carcinoma model: relationship between microvessel density, vascular endothelial growth factor expression, and metastatic invasion.
The Novel Src Kinase Inhibitor M475271 Inhibits VEGF-Induced Vascular Endothelial-Cadherin and beta-Catenin Phosphorylation but Increases Their Association.
The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K /Akt pathway.
The Potential Role of the Proteases Cathepsin D and Cathepsin L in the Progression and Metastasis of Epithelial Ovarian Cancer.
The predictive value of vascular endothelial growth factor and nm23 for the diagnosis of occult metastasis in non-small cell lung cancer.
The Prognostic Value of Circulating VEGF-A Level in Patients With Hepatocellular Cancer.
The prognostic value of vascular endothelial growth factor in hepatocellular carcinoma for predicting metastasis after curative resection.
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
The Relationship Between Cytokine Production, CSF2RA, and IL1R2 Expression in Mammary Adenocarcinoma, Tumor Histopathological Parameters, and Lymph Node Metastasis.
The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer: A systematic review and meta-analysis.
The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma.
The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer.
The role of EMMPRIN expression in ovarian epithelial carcinomas.
The role of insulin receptor substrate (IRS) proteins in oncogenic transformation.
The role of targeted therapy in the treatment of colorectal cancer.
The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer.
The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells.
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.
The Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and Treatment.
The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer.
The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice.
The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis.
The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer.
The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone.
The Value of Expression of M2-PK and VEGF in Patients with Advanced Gastric Cancer.
The Vascular Endothelial Growth Factor-2549 Insertion/Deletion Polymorphism Is Not Associated with Susceptibility to Hepatocellular Carcinoma in Chinese.
The VD1 Neutralizing Antibody to Vascular Endothelial Growth Factor-D: Binding Epitope and Relationship to Receptor Binding.
Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism.
Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.
Therapy with siRNA for Vegf-c but not for Vegf-d suppresses wide-spectrum organ metastasis in an immunocompetent xenograft model of metastatic mammary cancer.
Three Polymorphisms of Vascular Endothelial Growth Factor (+936C > T, -460C > T, and -2578C > A) and Their Susceptibility to Ovarian Cancer: A Meta-Analysis.
Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer.
Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential.
TIMPs expression in lentigo maligna÷lentigo maligna melanoma versus aged skin - a review of the literature and personal experience.
TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer.
Tissue expression, serum and salivary levels of vascular endothelial growth factor in patients with HNSCC.
Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis.
TNF-alpha and endotoxin increase hypoxia-induced VEGF production by cultured human nasal fibroblasts in synergistic fashion.
TNF-alpha promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP-1/VEGF-D pathway.
Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis.
Transcriptional regulation of vascular endothelial growth factor C by oxidative and thermal stress is mediated by lens epithelium-derived growth factor/p75.
Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling.
Transient increased expression of VEGF and MMP-1 in a rat liver tumor model after hepatic arterial occlusion.
Treatment effect of conversion therapy and its correlation with VEGF expression in unresectable rectal cancer with liver metastasis.
Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non-small cell lung cancer with brain metastasis.
Tricin, 4',5,7-trihydroxy-3',5'-dimethoxyflavone, exhibits potent antiangiogenic activity in vitro.
Troponin I peptide (Glu94-Leu123), a cartilage-derived angiogenesis inhibitor: in vitro and in vivo effects on human endothelial cells and on pancreatic cancer.
Tumor angiogenesis.
Tumor angiogenesis: the pivotal role of vascular endothelial growth factor.
Tumor growth patterns and biological characteristics of early gastric carcinoma.
Tumor interstitial fluid and gastric cancer metastasis: an experimental study to verify the hypothesis of "tumor-phlegm microenvironment".
Tumor location and nature of lymphatic vessels are key determinants of cancer metastasis.
Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability.
Tumor necrosis factor-? promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-?B-mediated upregulation of vascular endothelial growth factor-C.
Tumor refractoriness to anti-VEGF therapy.
Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages.
Tumor-derived vascular endothelial growth factor (VEGF)-A facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway.
Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients.
Tumor-induced lymphangiogenesis: a target for cancer therapy?
Tumor-Microenvironment-Responsive Nanoconjugate for Synergistic Antivascular Activity and Phototherapy.
Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.
Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform.
Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study.
Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread.
Up-regulated EMMPRIN/CD147 protein expression might play a role in colorectal carcinogenesis and its subsequent progression without an alteration of its glycosylation and mRNA level.
Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer.
Up-regulation of hypoxia-inducible factor-1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer.
Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway.
Up-regulation of vascular endothelial growth factor-C by nicotine in cervical cancer cell lines.
Upregulation of Endocrine Gland-Derived Vascular Endothelial Growth Factor in Papillary Thyroid Cancers Displaying Infiltrative Patterns, Lymph Node Metastases, and BRAF Mutation.
Urea-Peptide Hybrids as VEGF-A165/NRP-1 Complex Inhibitors with Improved Receptor Affinity and Biological Properties.
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy.
Vascular biology support for the use of bevacizumab in colorectal cancer.
Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro.
Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha(v)beta6.
Vascular endothelial growth factor (VEGF) expression correlates with p53 and ki-67 expressions in tongue squamous cell carcinoma.
Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma.
Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value.
Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer.
Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.
Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
Vascular endothelial growth factor -634G/C and vascular endothelial growth factor -2578C/A polymorphisms and lung cancer risk: a case-control study and meta-analysis.
Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma.
Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India).
Vascular endothelial growth factor accelerates establishment of a model of hepatic metastasis in walker-256 tumor-bearing rats.
Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone.
Vascular endothelial growth factor and basic fibroblast growth factor in primary lung carcinomas and the incidence of metastases.
Vascular endothelial growth factor and lymph node metastasis in primary lung cancer.
Vascular endothelial growth factor and p53 expressions in liver and abdominal metastases from colon cancer.
Vascular endothelial growth factor and prognosis of cervical carcinoma.
Vascular endothelial growth factor and thymidine phosphorylase expression in salivary gland tumors with distinct metastatic behavior.
Vascular endothelial growth factor antisense oligonucleotides inhibit leptomeningeal metastasis in vivo.
Vascular endothelial growth factor B coordinates metastasis of non-small cell lung cancer.
Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
Vascular endothelial growth factor C (VEGF-C) expression predicts metastasis in tongue cancer.
Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis.
Vascular endothelial growth factor C and microvessel density in gastric carcinoma: correlation with clinicopathological factors. Our experience and review of the literature.
Vascular Endothelial Growth Factor C Disrupts the Endothelial Lymphatic Barrier to Promote Colorectal Cancer Invasion.
Vascular endothelial growth factor C enhances cervical cancer cell invasiveness via upregulation of galectin-3 protein.
Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase.
Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor.
Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma.
Vascular endothelial growth factor C is an indicator of lymph node metastasis in thoracic esophageal squamous cellcarcinomas and its role in long-term survival after surgery.
Vascular endothelial growth factor C promotes cervical cancer cell invasiveness via regulation of microRNA-326/cortactin expression.
Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade.
Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in mice.
Vascular endothelial growth factor C promotes lymph node metastasis in a rectal cancer orthotopic model.
Vascular endothelial growth factor C and D expression correlates with lymph node metastasis and poor prognosis in patients with resected esophageal cancer.
Vascular endothelial growth factor D and intratumoral lymphatics as independent prognostic factors in epithelial ovarian carcinoma.
Vascular endothelial growth factor expression correlates with hematogenous metastasis and prognosis in colorectal carcinoma.
Vascular endothelial growth factor expression in metastatic pulmonary tumor from colorectal carcinoma: utility as a prognostic factor.
Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma.
Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis.
Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.
Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator.
Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus.
Vascular endothelial growth factor gene polymorphisms and colorectal cancer risk: a meta-analysis.
Vascular endothelial growth factor gene polymorphisms and gastric cancer risk: a meta-analysis.
Vascular endothelial growth factor gene polymorphisms and renal cell carcinoma: A systematic review and meta-analysis.
Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer.
Vascular endothelial growth factor in cervical carcinoma.
Vascular endothelial growth factor in colorectal cancer.
Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction.
Vascular endothelial growth factor in thyroid cancers.
Vascular endothelial growth factor induces multidrug resistance-associated protein 1 overexpression through phosphatidylinositol-3-kinase /protein kinase B signaling pathway and transcription factor specificity protein 1 in BGC823 cell line.
Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck.
Vascular Endothelial Growth Factor is a Useful Predictor of Postoperative Distant Metastasis and Survival Prognosis in Esophageal Squamous Cell Carcinoma.
Vascular endothelial growth factor is an autocrine growth factor for cardiac myxoma cells.
Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer.
Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.
Vascular endothelial growth factor promotes the expression of cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells.
Vascular endothelial growth factor signals through platelet-derived growth factor receptor ? in meningiomas in vitro.
Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis.
Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
Vascular endothelial growth factor-C (VEGF-C) is a more specific risk factor for lymph node metastasis than VEGF-D in submucosal colorectal cancer.
Vascular endothelial growth factor-C and vascular endothelial growth factor-d messenger RNA expression in breast cancer: association with lymph node metastasis.
Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa.
Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas.
Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma.
Vascular endothelial growth factor-D is correlated with hepatic metastasis from gastric cancer after radical gastrectomy.
Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer.
Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance.
Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases.
Vascular endothelial growth factors and liver diseases.
Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy.
Vascular endothelial growth factors C and D and lymphangiogenesis at the early stage of esophageal squamous cell carcinoma progression.
Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis.
Vascularity and expression of vascular endothelial growth factor in oral squamous cell carcinoma, resection margins, and nodal metastases.
VEGF -460C>T polymorphism and cancer risk: a meta-analysis.
VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas.
VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI.
VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon.
VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population.
VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome.
VEGF in patients with non-small cell lung cancer during combination chemotherapy of carboplatin and paclitaxel.
VEGF in physiological process and thyroid disease.
VEGF inhibitors in cancer therapy.
VEGF is associated with the poor survival of patients with prostate cancer: a meta-analysis.
VEGF protein expression is associated with a poor prognosis in cutaneous extranodal NK/T-cell lymphoma patients.
VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer.
VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis.
VEGF-C and VEGF-D expression and its correlation with lymph node metastasis in esophageal squamous cell cancer tissue.
VEGF-C and VEGF-D expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: Implications for use as a prognostic marker.
VEGF-c expression in an in vivo model of orthotopic endometrial cancer and retroperitoneal lymph node metastasis.
VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors.
VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival.
VEGF-D and A Preoperative Serum Levels Predict Nodal and Distant Metastases in Differentiated Thyroid Cancer Patients.
VEGF-D as a marker in the aid of malignant metastatic pleural effusion diagnosis.
VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma.
VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab.
VEGF-D in Association With VEGFR-3 Promotes Nodal Metastasis in Human Invasive Lobular Breast Cancer.
VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma.
VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium.
VEGF-D(ilated) Lymphatics as Gateways to Metastasis.
VEGF-D-induced draining lymphatic enlargement and tumor lymphangiogenesis promote lymph node metastasis in a xenograft model of ovarian carcinoma.
VEGF-mediated tumour angiogenesis: a new target for cancer therapy.
VEGF121 promotes lymphangiogenesis in the sentinel lymph nodes of non-small cell lung carcinoma patients.
VEGF: A critical driver for angiogenesis and subsequent tumor growth: An IHC study.
VEGF???-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system.
VEGFA +936C>T polymorphism and cancer risk: a meta-analysis.
VEGFR-2 kinase domain inhibition as a scaffold for anti-angiogenesis: Validation of the anti-angiogenic effects of carotenoids from Spondias mombin in DMBA model of breast carcinoma in Wistar rats.
VEGFR1-activity-independent metastasis formation.
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Visfatin stimulates proliferation of MCF-7 human breast cancer cells.
Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
Wild-type VHL Clear Cell Renal Cell Carcinomas Are a Distinct Clinical and Histologic Entity: A 10-Year Follow-up.
Wnt/??catenin signaling modulates piperine?mediated antitumor effects on human osteosarcoma cells.
YT521 promotes metastases of endometrial cancer by differential splicing of vascular endothelial growth factor A.
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer]
[Advances in molecular mechanisms of tenascin-C in promoting tumor metastasis].
[Clinical significance of serum vascular endothelial growth factor and interleukin-6 in multiple myeloma]
[Clinical value of vascular endothelial growth factor detection in forecasting distant metastasis risk of nasopharyngeal carcinoma]
[Clinical values of vascular endothelial growth factor expression and microvascular density analysis in liver cancer specimens]
[Correlation between PTEN and vascular endothelial growth factor expression and the invasion and metastasis of human hepatocellular carcinomas]
[Correlation between the vascular endothelial growth factor C expression and lymph node metastasis in human nasopharyngeal carcinoma]
[Correlation of vascular endothelial growth factor D, microlymphatic density and microvessel density with development and metastasis of rectal cancer]
[Coxibs for postoperative analgesia].
[Diagnostic value of enhanced computed tomography plus vascular endothelial growth factor C expression in hilar and mediastinal lymph node metastasis of non-small cell lung cancer].
[Effect of irradiation on matrix metalloproteinases, vascular endothelial growth factor and microvessel density of mice bearing Lewis lung cancer]
[Effect of vascular endothelial growth factor antibody avastin on angiogenesis of human gastric cancer growing orthotopically in nude mice.]
[Effects of Baihe Recipe on expressions of vascular endothelial growth factor and p53 proteins in tumor tissues of nude mice bearing orthotopically transplanted gastric carcinoma BGC-823.]
[Effects of suramin in combination with Cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice.]
[Effects of vascular endothelial growth factor in the invasion and metastasis of non-small cell lung cancer.]
[Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma]
[Expression and clinical significance of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinomas]
[Expression and clinical significance of vascular endothelial growth factor C and D in nasopharyngeal carcinoma]
[Expression and significance of Bmi-1 in breast cancer]
[Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma]
[Expression of cyclin D1 and vascular endothelial growth factor(VEGF) in non-small cell lung carcinoma and their association with the prognosis]
[Expression of some biomarkers in primary colon adenocarcinomas and their lymph node metastases].
[Expression of tissue factor and vascular endothelial growth factor in colorectal carcinoma]
[Expression of vascular endothelial growth factor C in laryngeal squamous carcinoma and its role in lymphatic metastasis]
[Expression of vascular endothelial growth factor C in pancreatic cancer and its effect upon lymph node metastasis]
[Expression of vascular endothelial growth factor correlates with invasion and metastasis of hepatocellular carcinoma]
[Expression of VEGF-C and VEGF-D in gastric carcinoma and its relationship with lymph node metastases.]
[Expression patterns in isoforms of vascular endothelial growth-factors in tissue samples of vulval cancer T1 N2M0 stage]
[Expressions of receptor-binding cancer antigen expressed on SiSo cells, vascular endothelial growth factor, and matrix metalloproteinase-9 in cervical carcinoma and correlation thereof with the invasion and metastasis of the cancerous tissues]
[Expressions of VEGF-C and VEGF-D and their correlation with lymphangiogenesis and angiogenesis in gallbladder carcinoma]
[Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer.]
[Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer]
[Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer]
[Mesh structure of two-dimensional tumor microvascular architecture phenotype heterogeneity in non-small cell lung cancer]
[Microvessel density and expression of vascular endothelial growth factor in adenoid cystic carcinoma of salivary gland]
[Molecular mechanism of reversing metastatic phenotype in human high-metastatic large cell lung cancer cell line L9981 by nm23-H1]
[Morphogenesis, structure and properties of lymphatic vessels].
[Multistep Process of Establishing Carcinoma Metastases].
[New markers for pharmacological targeting in bladder cancer with lymph node metastasis]
[Predictive value of vascular endothelial growth factor in metastasis of nephroblastoma]
[Prognostic value of the expression of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha in patients undergoing surgery for non-small cell lung cancer.]
[Quantitative study of vascular endothelial growth factor expression in primary lung cancer]
[Relation between vascular endothelial growth factor and reoccurence-metastasis after transcatheter arterial chemoembolization in hepatocellar carcinoma]
[Relation of vascular endothelial growth factor-D expression to microvessel density, microlymphatic vessel density, and lymph-node metastasis of lung adenocarcinoma]
[Relationship among expression of the VEGF gene and MVD with cervical lymph nodes metastasis in laryngeal squamous cell carcinoma]
[Relationship between clinicopathologic characteristics and expression of VEGF-C and VEGF-D in esophageal squamous cancer]
[Relationship between the expressions of KaI1, nm23, ETS-1, VEGF and microvascular density and clinical significance in nasopharyngeal carcinoma]
[Relationship between vascular endothelial growth factor C expression level and lymph node metastasis in non small cell lung cancer]
[Review of relationship between vascular endothelial growth factor C & D and lymph node metastasis of malignant tumor]
[Role of Ang-2, Tie-2 and VEGFR-2 in angiogenesis in colorectal carcinoma and their prognostic value].
[Role of matrix metalloproteinase (MMP)-2 and -9 and vascular endothelial growth factor C in lymph node metastasis of breast cancer.]
[Role of P53, nm23 proteins and vascular endothelial growth factor in angiogenesis and metastasis of laryngeal cancer]
[Role of vascular endothelial growth factor overexpression in ovarian tumor invasion and mechanism]
[Roles of vascular endothelial growth factor and platelet-derived growth factor in lymphangiogenesis in epithelial ovarian carcinoma.]
[Serum levels of VEGF and nitric oxide in esophageal squamous carcinoma patients and the clinical significance]
[Significance of angiogenesis and clinical application of anti-angiogenesis]
[Significance of p53 and VEGF expression in liver metastasis from colorectal cancer]
[Significance of vascular endothelial growth factor expression in colorectal cancer]
[Significance of vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma]
[Study of mRNA expression of vascular endothelial growth factor-(A, C, D) genes and its effect on prognosis of breast cancer]
[Study on relationship between VEGF-C and lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.]
[The clinical significance of detection of vascular endothelial growth factor and CD44v6 expression in human non-small cell lung cancer.]
[The clinical value of vascular endothelial growth factor in patients with small cell lung cancer.]
[The effect of antibody against vascular endothelial growth factor (VEGF) on tumor metastasis]
[The effect of VEGF antisense oligonucleotides combined with low molecular weight heparin on the growth and metastasis of mice Lewis lung cancer]
[The effects of ?-elemene on rabbit VX2 laryngeal carcinoma and factors associated with tumor growth and metastasis].
[The evaluation to relationship between serum vascular endothelial growth factor (VEGF) level, metastases and other tumor markers in patients with lung cancer.]
[The relationship between lymphangiogenesis and lymphatic metastasis in murine hepatic carcinoma of high and low metastatic potentialities.]
[The relationship between plasma level of VEGF or soluble Flt-1 and efficacy of hepatic arterial chemotherapy in patients with liver metastasis of colorectal cancer]
[The relationship between vascular endothelial growth factor, microvascular density, lymph node metastasis and prognosis of breast carcinoma]
[The roles of VEGF and C-myc in occurrence, development and metastasis of gallbladder carcinoma]
[Therapeutic effect of angiogenesis inhibitors on liver metastases of human colorectal carcinoma]
[Tumor angiogenesis in node-negative breast carcinoma]
[Tumor progression and angiogenesis]
[Tumor-secreted vascular endothelial growth factor A increases the pulmonary metastasis from nasopharyngeal carcinoma].
[Vascular endothelial growth factor D promoting the growth of lymphatic vessel in gastric carcinoma]
[Vascular endothelial growth factor expression and microvessel density in stage I-II non-small cell lung cancer and their prognostic significances]
[Vascular endothelial growth factor promotes hematogenous metastasis of cancer cells in patients with non-small cell lung cancer]
[VEGF-C, VEGF-D and VEGF-receptor 3: novel key regulators of lymphangiogenesis and cancer metastasis]
Neoplasm Micrometastasis
Angiogenesis as a target for gastric cancer.
Bone marrow micrometastases and markers of angiogenesis in esophageal cancer.
Can tumor size be a guide for limited surgical intervention in patients with peripheral non-small cell lung cancer? Assessment from the point of view of nodal micrometastasis.
Correlation between Vascular Endothelial Growth Factor C Expressior and Lymph Node Micrometastasis and Prognosis in Patients with pNO Esophageal Squamous Cell Carcinomas.
Detection of bone marrow micrometastasis in gastric cancer patients by immunomagnetic separation.
Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Lung cancer lymph node micrometastasis detection using real-time polymerase chain reaction: correlation with vascular endothelial growth factor expression.
Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
Prognostic significance of VEGF-C in predicting micrometastasis and isolated tumour cells in N0 oral squamous cell carcinoma.
Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma.
Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer and its relations to the micrometastasis in peripheral blood.
Study on relationship between angiogenesis and micrometastases of peripheral blood in breast cancer.
The future development of bevacizumab in colorectal cancer.
The predictive value of vascular endothelial growth factor and nm23 for the diagnosis of occult metastasis in non-small cell lung cancer.
Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer.
[Clinical research on angiogenesis in colorectal carcinoma and expression of CK20 mRNA in peripheral blood]
[Expression related to vascular endothelial growth factor C and induced nitride oxide synthesizase in lymph node micrometastasis of oral squamous cell carcinoma]
[mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR]
Neoplasm, Residual
Experimental study on residual tumor angiogenesis after cryoablation.
Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation.
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.
Safety and efficacy of radiofrequency ablation with aflibercept and FOLFIRI in a patient with metastatic colorectal cancer.
Vascular endothelial growth factor serum concentrations in ovarian cancer.
Neoplasms
"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.
"On-The-Spot" Arresting of Chondroitin Sulphate Proteoglycans: Implications for Ovarian Adenocarcinoma Recognition and Intervention.
"Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab.
"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.
(-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells.
(-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
(18)F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer.
(18)F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: A clinicopathological study.
(99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
1,2,3,4,6-Penta-O-galloly-beta-D-glucose Suppresses Hypoxia-Induced Accumulation of Hypoxia-Inducible Factor-1? and Signaling in LNCaP Prostate Cancer Cells.
1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents.
10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1? expression in human colon cancer cells.
17beta-estradiol- and lipopolysaccharide-induced changes in nitric oxide, tumor necrosis factor-alpha and vascular endothelial growth factor release from RAW 264.7 macrophages.
18?-Glycyrrhetinic acid suppresses TNF-? induced matrix metalloproteinase-9 and vascular endothelial growth factor by suppressing the Akt-dependent NF-?B pathway.
18F-FDG PET cannot predict expression of clinically relevant histopathological biomarkers in head and neck squamous cell carcinoma: a meta-analysis.
18F-FDG uptake on PET could be a?predictive marker of Excision Repair Cross-Complementation Group 1 (ERCC1) expression in patients with thoracic neoplasms?
18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1?, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells.
2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: possible role of vascular endothelial growth factor.
3-[3-(3-florophenyl-2-propyn-1-ylthio)-1, 2, 5-thiadiazol-4-yl]-1, 2, 5, 6-tetrahydro-1- methylpyridine oxalate, a novel xanomeline derivative, improves neural cells proliferation and survival in adult mice.
3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility.
3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis.
3D in vitro bioengineered tumors based on collagen I hydrogels.
3D Microtissue Models to Analyze the Effects of Ultralow Dose LPS on Vascular Sprouting Dynamics in the Tumor Microenvironment.
4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells.
4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression.
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor.
5-Aza-2'-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells.
8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer.
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
? Opioid systems regulate angiogenesis in development and tumors.
?-Sitosterol-loaded solid lipid nanoparticles ameliorate complete Freund's adjuvant-induced arthritis in rats: involvement of NF-?B and HO-1/Nrf-2 pathway.
?-Solanine inhibits vascular endothelial growth factor expression by down-regulating the ERK1/2-HIF-1? and STAT3 signaling pathways.
A Bayesian view of murine seminal cytokine networks.
A Biomimicking Tumor Tissue Model Using Hepatocellular Carcinoma Cell Sheet in a Collagen Sandwich System.
A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin.
A cancer treatment based on synergy between anti-angiogenic and immune cell therapies.
A case of a sclerosing stromal ovarian tumor that expresses VEGF.
A case of cerebellar hemangioblastoma with rhabdoid features.
A case of complete clearance of chronic subdural hematoma accompanied by recurrent glioblastoma multiforme after administration of bevacizumab.
A CMOS VEGF Sensor for Cancer Diagnosis Using a Peptide Aptamer-Based Functionalized Microneedle.
A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.
A combination of plasmid DNAs encoding murine fetal liver kinase 1 extracellular domain, murine interleukin-12, and murine interferon-gamma inducible protein-10 leads to tumor regression and survival in melanoma-bearing mice.
A Combination with Probiotic Complex, Zinc, and Coenzyme Q10 Attenuates Autoimmune Arthritis by Regulation of Th17/Treg Balance.
A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis.
A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth.
A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis.
A critical role of mir-199a in the cell biological behaviors of colorectal cancer.
A critical role of vascular endothelial growth factor D in zebrafish embryonic vasculogenesis and angiogenesis.
A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays.
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
A dual role for hypoxia inducible factor-1? in the hepatitis C virus lifecycle and hepatoma migration.
A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
A Fatal Brain Stroke in Patient with Advanced Breast Cancer Treated with Bevacizumab: A Case Report.
A feasibility study exploring the role of pre-operative assessment when examining the mechanism of 'chemo-brain' in breast cancer patients.
A flavonoid component from Docynia delavayi (Franch.) Schneid represses transplanted H22 hepatoma growth and exhibits low toxic effect on tumor-bearing mice.
A fluorescence biosensor for VEGF detection based on DNA assembly structure switching and isothermal amplification.
A fluorescent nanoprobe based on graphene oxide fluorescence resonance energy transfer for the rapid determination of oncoprotein vascular endothelial growth factor (VEGF).
A frog cathelicidin peptide effectively promotes cutaneous wound healing in mice.
A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain.
A fusion protein composed of receptor binding domain of vascular endothelial growth factor-A and constant region fragment of antibody: angiogenesis antagonistic activity.
A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model.
A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer.
A group of novel HIF-1? inhibitors, glyceollins, blocks HIF-1? synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding.
A hierarchical assembly strategy to engineer dextran-enveloped polyurethane nanopolyplexes for robust ovarian cancer gene therapy.
A high sensitive electrochemical aptasensor for the determination of VEGF(165) in serum of lung cancer patient.
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.
A high-dose rapamycin treatment alleviates hepatopulmonary syndrome in cirrhotic rats.
A high-performance VEGF aptamer functionalized polypyrrole nanotube biosensor.
A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2.
A Huaier polysaccharide restrains hepatocellular carcinoma growth and metastasis by suppression angiogenesis.
A Human 3D In Vitro Model to Assess the Relationship Between Osteoporosis and Dissemination to Bone of Breast Cancer Tumor Cells.
A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.
A hybrid model of tumor growth and angiogenesis: In silico experiments.
A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma.
A hypoxia-independent up-regulation of hypoxia-inducible factor-1 by AKT contributes to angiogenesis in human gastric cancer.
A large-scale retrospective study of the overall survival outcome in nasopharyngeal carcinoma with hypertension in Chinese population.
A Macrocyclic Ruthenium(III) Complex Inhibits Angiogenesis with Down-Regulation of Vascular Endothelial Growth Factor Receptor-2 and Suppresses Tumor Growth In Vivo.
A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo.
A mathematical model of tumour angiogenesis, regulated by vascular endothelial growth factor and the angiopoietins.
A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer.
A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.
A mesoporous silica nanoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy.
A Meta-Analysis of the Association Between the VEGF +936C>T Gene Polymorphism and Digestive System Cancer Susceptibility.
A Meta-Analysis of Vascular Endothelial Growth Factor for Nasopharyngeal Cancer Prognosis.
A mixture of St. John's wort and sea buckthorn oils regresses endometriotic implants and affects the levels of inflammatory mediators in peritoneal fluid of the rat: A surgically induced endometriosis model.
A model of spontaneous mouse mammary tumor for human estrogen receptor- and progesterone receptor-negative breast cancer.
A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells.
A monoclonal antibody targeting neuropilin-1 inhibits adhesion of MCF7 breast cancer cells to fibronectin by suppressing the FAK/p130cas signaling pathway.
A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model.
A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma.
A multilayered blood vessel/tumor tissue chip to investigate T cell infiltration into solid tumor tissues.
A muscle-specific protein 'myoferlin' modulates IL-6/STAT3 signaling by chaperoning activated STAT3 to nucleus.
A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression.
A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment.
A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis.
A natural food sweetener with anti-pancreatic cancer properties.
A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF(110) in ovarian cancer tumors.
A new indanone from the marine cyanobacterium Lyngbya majuscula that inhibits hypoxia-induced activation of the VEGF promoter in Hep3B cells.
A novel anti-VEGF165 monoclonal antibody-conjugated liposomal nanocarrier system: Physical characterization and cellular uptake evaluation in vitro and in vivo.
A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b.
A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes.
A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis.
A novel dressing seeded with embryonic artery CD133+ cells and loaded with the Sirt1 agonist SRT1720 accelerates the healing of diabetic ischemic ulcers.
A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth.
A novel immunotherapeutic modality with direct hemoperfusion targeting transforming growth factor-beta prolongs the survival of tumor-bearing rats.
A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155.
A novel mechanism in maggot debridement therapy: protease in excretion/secretion promotes hepatocyte growth factor production.
A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF-? derived from ovarian cancer.
A novel mitochondrial targeted hybrid peptide modified HPMA copolymers for breast cancer metastasis suppression.
A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib.
A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor.
A novel splice variant of calcium and integrin-binding protein 1 mediates protein kinase D2-stimulated tumour growth by regulating angiogenesis.
A novel tissue engineered three-dimensional in vitro colorectal cancer model.
A novel tumour suppressor lncRNA F630028O10Rik inhibits lung cancer angiogenesis by regulating miR-223-3p.
A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer.
A novel vascular endothelial growth factor heparin-binding domain substructure binds to glycosaminoglycans in vivo and localizes to tumor microvascular endothelium.
A Nude Mouse Model of Orthotopic Liver Transplantation of Human Hepatocellular Carcinoma HCCLM3 Cell Xenografts and the Use of Imaging to Evaluate Tumor Progression.
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.
A patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour.
A peptide competing with VEGF(165) binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells.
A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells.
A PERITONEAL DIALYSIS REGIMEN LOW IN GLUCOSE AND GLUCOSE DEGRADATION PRODUCTS RESULTS IN INCREASED CANCER ANTIGEN 125 AND PERITONEAL ACTIVATION.
A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability.
A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors.
A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer.
A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer.
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.
A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers.
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma.
A phase II study of thalidomide in advanced metastatic renal cell carcinoma.
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.
A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma.
A physiologic imaging pilot study of breast cancer treated with AZD2171.
A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma.
A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma.
A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism.
A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization.
A polysaccharide from mushroom Huaier retards human hepatocellular carcinoma growth, angiogenesis, and metastasis in nude mice.
A portable oligonucleotide-based microfluidic device for the detection of VEGF165 in a three-step suspended-droplet mode.
A positive relationship between filamin and VEGF in patients with lung cancer.
A potential function of RLIP76 in the ovarian corpus luteum.
A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods.
A prodrug of green tea polyphenol (-)-epigallocatechin-3-gallate (Pro-EGCG) serves as a novel angiogenesis inhibitor in endometrial cancer.
A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1? and VEGF expressions.
A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol for a randomised controlled trial.
A putative G-quadruplex structure in the proximal promoter of VEGFR-2 has implications for drug design to inhibit tumor angiogenesis.
A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
A randomized exploratory trial to assess the effects of resveratrol on VEGF and TNF-? 2 expression in endometriosis women.
A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
A receptor for vascular endothelial growth factor that stimulates endothelial apoptosis.
A Redox-Responsive, In-Situ Polymerized Polyplatinum(IV)-Coated Gold Nanorod as An Amplifier of Tumor Accumulation for Enhanced Thermo-Chemotherapy.
A redox-silent analogue of tocotrienol inhibits cobalt(II) chloride-induced VEGF expression via Yes signaling in mesothelioma cells.
A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy.
A Research of Soft Tissue Lipoma Genesis Factor With Immunohistochemical Analysis.
A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix.
A reusable magnetic graphene oxide-modified biosensor for vascular endothelial growth factor detection in cancer diagnosis.
A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.
A review on the role of VEGF in Tamoxifen resistance.
A role for antiangiogenic therapy in breast cancer.
A Role of Agrin in Maintaining the Stability of Vascular Endothelial Growth Factor Receptor-2 during Tumor Angiogenesis.
A role of cytokines in OK-432 injection therapy for cystic lymphangioma: an approach to the mechanism.
A role of histone H4 hypoacetylation in vascular endothelial growth factor expression in colon mucosa adjacent to implanted cancer in athymic mice cecum.
A safety and immunogenicity study of immunization with hVEGF
A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.
A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics.
A short peptide fragment of the vascular endothelial growth factor as a novel ligand for bevacizumab purification.
A single nucleotide polymorphism in the vascular endothelial growth factor gene is associated with recurrence of hepatocellular carcinoma after transplantation.
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics.
A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery.
A small oxazine compound as an anti-tumor agent: a novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-?.
A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway.
A SORAFENIB INDUCED MODEL OF GLOMERULAR KIDNEY DISEASE.
A spatial model of tumor-host interaction: Application of chemotherapy.
A special linker between macrophage and hematopoietic malignant cells: membrane form of macrophage colony-stimulating factor.
A Specific Inflammatory Profile Underlying Suicide Risk? Systematic Review of the Main Literature Findings.
A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.
A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex.
A Strategy of Killing Three Birds with One Stone for Cancer Therapy through Regulating the Tumor Microenvironment by H2O2-Responsive Gene Delivery System.
A study of 131iodine-labeling of histamine-indomethacin: its in vivo therapeutic effect and anti-tumor mechanisms in Lewis-bearing lung cancer.
A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer.
A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.
A Systematic Study of Mechanism of Sargentodoxa cuneata and Patrinia scabiosifolia Against Pelvic Inflammatory Disease With Dampness-Heat Stasis Syndrome via Network Pharmacology Approach.
A telomerase-derived peptide vaccine inhibits laser-induced choroidal neovascularization in a rat model.
A time-course analysis of mRNA expression during injury healing in human dermal injuries.
A translational view of the molecular pathogenesis of lung cancer.
A tritherapy combination of a fusion protein vaccine with immune-modulating doses of sequential chemotherapies in an optimized regimen completely eradicates large tumors in mice.
A Tunable Nanoplatform of Nanogold Functionalised with Angiogenin Peptides for Anti-Angiogenic Therapy of Brain Tumours.
A two-compartment bone tumor model to investigate interactions between healthy and tumor cells.
A Validated Preclinical Animal Model for Primary Bone Tumor Research.
A vascular endothelial growth factor gene polymorphism predicts malignant potential in intraductal papillary mucinous neoplasm.
A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library.
A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours.
A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers.
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2.
A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients.
AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma.
AAV-Mediated Expression of Human VEGF, TNF-?, and IL-6 Induces Retinal Pathology in Mice.
AAV2-mediated gene transfer of VEGF-Trap with potent suppression of primary breast tumor growth and spontaneous pulmonary metastases by long-term expression.
AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors.
Abdominal Irradiation Ameliorates Obesity in ob/ob Mice.
Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors.
Abnormalities of the Wnt/?-catenin signalling pathway induce tumour progression in sporadic desmoid tumours: correlation between ?-catenin widespread nuclear expression and VEGF overexpression.
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1.
Absence of ethnic difference on single-dose pharmacokinetics of rivoceranib between healthy male Caucasian, Japanese, and Chinese subjects.
Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation.
Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site.
ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro.
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer.
Acacetin inhibits VEGF expression, tumor angiogenesis and growth through AKT/HIF-1? pathway.
Acacia ferruginea inhibits tumor progression by regulating inflammatory mediators-(TNF-a, iNOS, COX-2, IL-1?, IL-6, IFN-?, IL-2, GM-CSF) and pro-angiogenic growth factor- VEGF.
Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of pro-angiogenic and prometastatic factors in murine liver fibrosis.
Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon.
Accelerated tumour metastasis due to interferon-? receptor-mediated dissociation of perivascular cells from blood vessels.
Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines.
Acceleration of tendon-bone healing of anterior cruciate ligament graft using intermittent negative pressure in rabbits.
Acceleration of tumor growth due to dysfunction in M1 macrophages and enhanced angiogenesis in an animal model of autoimmune disease.
Accomplices of the Hypoxic Tumor Microenvironment Compromising Antitumor Immunity: Adenosine, Lactate, Acidosis, Vascular Endothelial Growth Factor, Potassium Ions, and Phosphatidylserine.
ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma.
Acidic pH via NF-?B favours VEGF-C expression in human melanoma cells.
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
Actin-sequestering protein, thymosin beta-4, is a novel hypoxia responsive regulator.
Action of prolactin, IFN-gamma, TNF-alpha and LPS on heme oxygenase-1 expression and VEGF release in human monocytes/macrophages.
Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype.
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia.
Activating transcription factor 4 promotes angiogenesis of breast cancer through enhanced macrophage recruitment.
Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.
Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.
Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression.
Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events.
Activation of Liver X Receptor Improves Viability of Adipose-Derived Mesenchymal Stem Cells to Attenuate Myocardial Ischemia Injury Through TLR4/NF-?B and Keap-1/Nrf-2 Signaling Pathways.
Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy.
Activation of Muscarinic Cholinergic Receptors Induces MCF-7 Cells Proliferation and Angiogenesis by Stimulating Nitric Oxide Synthase Activity.
Activation of peroxisome proliferator-activated receptor alpha (PPAR?) suppresses hypoxia-inducible factor-1? (HIF-1?) signaling in cancer cells.
Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells.
Activation of the phosphatidylinositol 3'-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1.
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.
Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth.
Activation of Toll?like receptor 7 regulates the expression of IFN??1, p53, PTEN, VEGF, TIMP?1 and MMP?9 in pancreatic cancer cells.
Activation of TRPA1 Channel by Antibacterial Agent Triclosan Induces VEGF Secretion in Human Prostate Cancer Stromal Cells.
Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain.
Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells.
Active immunotherapy for mouse breast cancer with irradiated whole-cell vaccine expressing VEGFR2.
Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells.
Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms.
Activin receptor inhibitors-dalantercept.
Activin receptor-like kinase 1 is associated with immune cell infiltration and regulates CLEC14A transcription in cancer.
Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma.
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
Activity Screening of the Herb Caesalpinia sappan and an Analysis of Its Antitumor Effects.
Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer.
Acute Inflammatory Biomarker Responses to Diffuse Traumatic Brain Injury in the Rat Monitored by a Novel Microdialysis Technique.
Acute inflammatory response to prolonged sculling in competitive male rowers.
Acute pericardial effusion representing the TNF-?-mediated severe inflammation but not the coronary artery outcome of Kawasaki disease.
Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.
Acute postischemic treatment with estrogen receptor-alpha agonist or estrogen receptor-beta agonist improves myocardial recovery.
Acute stress and intravesical corticotropin-releasing hormone induces mast cell dependent vascular endothelial growth factor release from mouse bladder explants.
Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers.
ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT.
ADAMTS1 is regulated by interleukin-1beta, not by hypoxia, in chondrosarcoma.
ADAMTS5 Functions as an Anti-Angiogenic and Anti-Tumorigenic Protein Independent of Its Proteoglycanase Activity.
Adeno-associated viral vector-mediated hypoxia-regulated VEGF gene transfer promotes angiogenesis following focal cerebral ischemia in mice.
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth.
Adeno-associated virus-delivered polycistronic microRNA-clusters for knockdown of vascular endothelial growth factor in vivo.
Adeno-associated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer.
Adenosine Inhibits Ovarian Cancer Growth Through Regulating RhoGDI2 Protein Expression.
Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.
Adenovirus mediated knockdown of bone morphogenetic protein 2 inhibits human lung cancer growth and invasion in vitro and in vivo.
Adenovirus-delivered wwox inhibited lung cancer growth in vivo in a mouse model.
Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.
Adenovirus-mediated ING4/IL-24 double tumor suppressor gene co-transfer enhances antitumor activity in human breast cancer cells.
Adipocytokine Levels in Obese and Non-obese Subjects: an Observational Study.
Adipocytokines, inflammatory, epigenetic instability & angiogenesis biomarkers in type 2 diabetic Egyptian women with breast cancer.
Adipokine gene transcription level in adipose tissue of runt piglets.
Adipokines involvement in lung function.
Adiponectin as a biomarker of the metabolic syndrome in children and adolescents.
Adipose Tissue Derived Stem Cells Secretome: Soluble Factors and Their Roles in Regenerative Medicine.
Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markErs in the progreSsion of dIabeteS in obese paTIeNts (The RESISTIN trial).
Adipose tissue extract shows potential for wound healing: in vitro proliferation and migration of cell types contributing to wound healing in the presence of adipose tissue preparation and platelet rich plasma.
Adipose-derived mesenchymal stem cells transplantation facilitate experimental peritoneal fibrosis repair by suppressing epithelial-mesenchymal transition.
Adipose-Derived Stem Cell Transplantation Inhibits Vascular Inflammatory Responses and Endothelial Dysfunction in Rats with Atherosclerosis.
Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin.
Adipsin, the adipocyte serine protease: gene structure and control of expression by tumor necrosis factor.
Adipsin-Dependent Secretion of Hepatocyte Growth Factor Regulates the Adipocyte-Cancer Stem Cell Interaction.
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Adjuvant effects of formalin-inactivated HSV through activation of dendritic cells and inactivation of myeloid-derived suppressor cells in cancer immunotherapy.
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Administration of granulocyte colony-stimulating factor with radiotherapy promotes tumor growth by stimulating vascularization in tumor-bearing mice.
Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
Adrenocortical cancer treatment.
Advanced alveolar soft part sarcoma responds to apatinib.
Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.
Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment.
Advances in the systemic treatment of cutaneous sarcomas.
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.
Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma.
AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Aegle marmelos differentially affects hepatic markers of glycolysis, insulin signalling pathway, hypoxia, and inflammation in HepG2 cells grown in fructose versus glucose-rich environment.
Aerobic Training Improves Angiogenic Potential Independently of Vascular Endothelial Growth Factor Modifications in Postmenopausal Women.
Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?
Aflibercept a new target therapy in cancer treatment: a review.
Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy.
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice.
Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion.
Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis.
Akt mediates an angiogenic switch in transformed keratinocytes.
Alcohol promotes mammary tumor growth through activation of VEGF-dependent tumor angiogenesis.
All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor.
All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.
Alpha lipoic acid priming enhances the hepatoprotective effect of adipose derived stem cells in CCl4 induced hepatic injury in-vitro.
Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery.
Alpha-fetoprotein-producing lung carcinoma: report of three cases.
Alpha-mangostin attenuation of hyperglycemia-induced ocular hypoperfusion and blood retinal barrier leakage in the early stage of type 2 diabetes rats.
Alteration of Cytokines and Chemokines during Febrile Episodes Associated with Endothelial Cell Damage and Plasma Leakage in Dengue Hemorrhagic Fever.
Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis.
Alteration of the Methylation Status of Tumor-Promoting Genes Decreases Prostate Cancer Cell Invasiveness and Tumorigenesis In vitro and In vivo.
Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response.
Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer.
Alterations of Circulating Bone Marrow-Derived VEGFR-2(+) Progenitor Cells in Isolated Limb Perfusion With or Without rhTNF-?
Alterations of gene expression in human neutrophils induced by smoking cessation.
Altered angiogenesis and survival in human tumor-derived endothelial cells.
Altered Biological Potential and Radioresponse of Murine Tumors in Different Microenvironments.
Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice.
Altered Expression of Signaling Genes in Jurkat Cells upon FTY720 Induced Apoptosis.
Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells.
Altered Gene and Protein Expressions in Torn Rotator Cuff Tendon Tissues in Diabetic Patients.
Altered pigment epithelium-derived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence.
Altered plasma cytokine levels in acute and chronic central serous chorioretinopathy.
Altered tear inflammatory profile in Indian keratoconus patients - The 2015 Col Rangachari Award paper.
Alternagin-C (ALT-C), a disintegrin-like protein, attenuates alpha2beta1 integrin and VEGF receptor 2 signaling resulting in angiogenesis inhibition.
Alternating expression levels of WWOX tumor suppressor and cancer-related genes in patients with bladder cancer.
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Amelioration of dry eye syndrome in db/db mice with diabetes mellitus by treatment with Tibetan Medicine Formula Jikan Mingmu Drops.
Ameliorative effects of melatonin against solid Ehrlich carcinoma progression in female mice.
Ameliorative potential of manganese nanoparticles with low-level ionizing radiation against experimentally induced hepatocarcinogenesis.
AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts.
Amicrobial Pustulosis of the Folds Associated with Auto-Immune Disorders. A Case Report with an Analysis of Cytokine Expression Profile in Skin Lesions of Cutaneous Neutrophilic Lupus.
Amino acid deprivation promotes tumor angiogenesis through the GCN2/ATF4 pathway.
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma.
Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells.
An Active and Soft Hydrogel Actuator to Stimulate Live Cell Clusters by Self-folding.
An Alternating Irradiation Strategy-Driven Combination Therapy of PDT and RNAi for Highly Efficient Inhibition of Tumor Growth and Metastasis.
An analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID mice with HIV-1 encephalitis.
An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation.
An analysis of select pathogenic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvesting.
An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.
An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo.
An anti-VEGF ribozyme embedded within the adenoviral VAI sequence inhibits glioblastoma cell angiogenic potential in vitro.
An antibacterial bilayer hydrogel modified by tannic acid with oxidation resistance and adhesiveness to accelerate wound repair.
An aryl hydrocarbon receptor induces VEGF expression through ATF4 under glucose deprivation in HepG2.
An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.
An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells.
An easy way to realize SPR aptasensor: A multimode plastic optical fiber platform for cancer biomarkers detection.
An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression.
An ethanol extract of Senduduk fruit (Melastoma malabathricum L) inhibits the expression of vascular endothelial growth factor and tumour necrosis factor alpha in HeLa cells.
An evaluation of the effects of caffeic acid phenethyl ester and Ankaferd blood stopper on secondary wound healing of oral mucosal tissue
An imbalance in serum concentrations of inflammatory and anti-inflammatory cytokines in hypertension.
An immunohistochemical and ultrastructural study of pancreatic microcystic serous cyst adenoma with special reference to tumor-associated microvasculature and vascular endothelial growth factor in tumor cells.
An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue.
An impedimetric vascular endothelial growth factor biosensor-based PAMAM/cysteamine-modified gold electrode for monitoring of tumor growth.
An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer.
An in silico model for HIF-alpha regulation and hypoxia response in tumor cells.
An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.
An integrated approach to measuring tumor oxygen status using human melanoma xenografts as a model.
An integrative model for vascular endothelial growth factor A as a tumour biomarker.
An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo.
An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma.
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.
An origami paper-based nanoformulated immunosensor detects picograms of VEGF-C per milliliter of blood.
An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice.
An overview of the rare parotid gland cancer.
An ultrastructural and immunohistochemical study of olfactory neuroepithelioma with rhabdomyoblasts.
An Up-to-Date Anti-Cancer Treatment Strategy Focusing on HIF-1alpha Suppression: Its Application for Refractory Ovarian Cancer.
An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects.
An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents.
Analyses of novel prognostic factors in neuroblastoma patients.
Analyses of VEGFC/VEGF-D expressions, density and endothelial lymphatic proliferation in salivary gland neoplasms.
Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease.
Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function.
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer.
Analysis of Expression of Vascular Endothelial Growth Factor A and Hypoxia Inducible Factor-1alpha in Patients Operated on Stage I Non-Small-Cell Lung Cancer.
Analysis of metabolome changes in the HepG2 cells of apatinib treatment by using the NMR-based metabolomics.
Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity.
Analysis of plant-derived phytochemicals as anti-cancer agents targeting cyclin dependent kinase-2, human topoisomerase IIa and vascular endothelial growth factor receptor-2.
Analysis of systemic and airway inflammation in obstructive sleep apnea.
Analysis of Tie2-Expressing Monocytes (TEM) in Patients With Colorectal Cancer.
Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors.
Analysis of tumor-induced lymphangiogenesis and lymphatic vessel invasion of pancreatic carcinoma in the peripheral nerve plexus.
Analysis of VEGF polymorphisms, tumor expression of VEGF mRNA and colorectal cancer susceptibility in a Swedish population.
Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression.
Analysis of VEGF--a regulated gene expression in endothelial cells to identify genes linked to angiogenesis.
Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab.
Analyzing cytokines as biomarkers to evaluate severity of glaucoma.
Analyzing time-series microarray data reveals key genes in spinal cord injury.
Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema.
Anatomical specificity of vascular endothelial growth factor expression in glioblastomas: a voxel-based mapping analysis.
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
Androgens Induce the Expression of Vascular Endothelial Growth Factor in Human Fetal Prostatic Fibroblasts* *This work was supported by grants-in-aid from the T. J. Martell Foundation for Leukemia, Cancer, and Aids Research; and the Hans E. Schapira, M.D., Foundation for Urologic Research.
Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts.
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
Andrographolide reduced VEGFA expression in hepatoma cancer cells by inactivating HIF-1?: The involvement of JNK and MTA1/HDCA.
Angelica sinensis extract promotes neuronal survival by enhancing p38 MAPK-mediated hippocampal neurogenesis and dendritic growth in the chronic phase of transient global cerebral ischemia in rats.
Anginex lipoplexes for delivery of anti-angiogenic siRNA.
Angiogenesis and angiogenic growth factors in Wilms tumor.
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).
Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection.
Angiogenesis and Expression of Vascular Endothelial Growth Factor, Tumour Necrosis Factor-? and Hypoxia Inducible Factor-1? in Canine Renal Cell Carcinoma.
Angiogenesis and extracellular matrix remodelling in bronchioloalveolar carcinomas: distinctive patterns in mucinous and non-mucinous tumours.
Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6.
Angiogenesis and lymphangiogenesis as prognostic factors after therapy in patients with cervical cancer.
Angiogenesis and lymphangiogenesis of gastric cancer.
Angiogenesis and Oxidative Stress in Metastatic Tumor Progression: Pathogenesis and Novel Therapeutic Approach of Colon Cancer.
Angiogenesis and the expression of vascular endothelial growth factors A and C in squamous cell carcinoma of the piriform fossa.
Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.
Angiogenesis and the Tumor Vasculature as Antitumor Immune Modulators: The Role of Vascular Endothelial Growth Factor and Endothelin.
Angiogenesis and tumor metastasis.
Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma.
Angiogenesis does not correlate with prognosis or expression of vascular endothelial growth factor in synovial sarcomas.
Angiogenesis drives psoriasis pathogenesis.
Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response.
Angiogenesis gene expression profiling in xenograft models to study cellular interactions.
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.
Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome.
Angiogenesis in Adipose Tissue: The Interplay Between Adipose and Endothelial Cells.
Angiogenesis in brain tumours.
Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment.
Angiogenesis in cancer: Anti-VEGF escape mechanisms.
Angiogenesis in Colorectal Cancer: Antibodies.
Angiogenesis in Gynecological Cancers: Role of Neurotrophins.
Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study.
Angiogenesis in malignancies of the female genital tract.
Angiogenesis in malignant lymphoma.
Angiogenesis in metastatic verrucous carcinoma of the uterine cervix.
Angiogenesis in myeloproliferative neoplasms, new markers and future directions.
Angiogenesis in neuroblastoma.
Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
Angiogenesis in Ocular and Extraocular Sebaceous Carcinoma.
Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis.
Angiogenesis in primary colorectal cancer and matched metastatic tissues: Biological and clinical implications for anti-angiogenic therapies.
Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour.
Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization.
Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice.
Angiogenesis in vestibular schwannomas: expression of extracellular matrix factors MMP-2, MMP-9, and TIMP-1.
Angiogenesis in vulvar intraepithelial neoplasia.
Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants.
Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy.
Angiogenesis inhibition in prostate cancer: current uses and future promises.
Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis.
Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation.
Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer.
Angiogenesis inhibitors in the treatment of non-small cell lung cancer.
Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia.
Angiogenesis of endocrine gland tumours--new molecular targets in diagnostics and therapy.
Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels.
Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins.
Angiogenesis, lymphangiogenesis, and melanoma metastasis.
Angiogenesis, vascular endothelial growth factor and the endometrium.
Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma.
Angiogenesis-related gene expression profile in clinical cases of canine cancer.
Angiogenesis-related growth factors in brain tumors.
Angiogenesis: From molecular mechanisms to translational implications.
Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis.
Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects.
Angiogenesis: models and modulators.
Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs.
Angiogenesis: the new potential target for the therapy of psoriasis?
Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer.
Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome.
Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance.
Angiogenic and growth factors in gastric cancer.
Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.
Angiogenic and inflammatory properties of psoriatic arthritis.
Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression.
Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas.
Angiogenic cytokines in cartilage tumors.
Angiogenic effect of the aqueous extract of Cynodon dactylon on human umbilical vein endothelial cells and granulation tissue in rat.
Angiogenic factor VEGF is decreased in human colorectal neoplasms showing DNA microsatellite instability.
Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy.
Angiogenic factors in blood serum of bone tumor patients.
Angiogenic factors in squamous cell carcinoma of the oral cavity: do they have prognostic relevance?
Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors.
Angiogenic growth factor mRNA responses in muscle to a single bout of exercise.
Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro.
Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs.
Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy.
Angiogenic molecule expression is downregulated in effusions from breast cancer patients.
Angiogenic molecules in Hodgkin inverted exclamation mark|s disease: results from sequential serum analysis.
Angiogenic peptides in prostatic disease.
Angiogenic profile of uveal melanoma.
Angiogenic protein expression in advanced epithelial ovarian cancer.
Angiogenic signalling pathways.
Angiogenic switch and vascular stability in human Leydig cell tumours.
Angiogenic switch occurs late in squamous cell carcinomas of human skin.
Angiogenically active vascular endothelial growth factor is over-expressed in malignant human and rat prostate carcinoma cells.
Angiogenin outperforms VEGF, EPCs and CECs in predicting Dukes' and AJCC stage in colorectal cancer.
Angioimmunoblastic T-cell lymphoma with intramedullary production of platelet-derived growth factor and possibly complicating myelofibrosis: report of a case with review of the literature.
Angiolipoma of the buccal mucosa: a possible role of mast cell-derived VEGF in its enhanced vascularity.
Angiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis.
Angiomodulin, a marker of cancer vasculature, is upregulated by vascular endothelial growth factor and increases vascular permeability as a ligand of integrin ?v?3.
Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice.
Angiopoietin-1 and vascular endothelial growth factor expression in human esophageal cancer.
Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling.
Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells.
Angiopoietin-2 inhibits the growth of tongue carcinoma without affecting expression of vascular endothelial growth factor.
Angiopoietin-2 is implicated in the regulation of tumor angiogenesis.
Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases.
Angiopoietin-4 inhibits angiogenesis and reduces interstitial fluid pressure.
Angiopoietin/Tie2 signaling transforms capillaries into venules primed for leukocyte trafficking in airway inflammation.
Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma.
Angiopoietins in tumours: the angiogenic switch.
Angiosarcoma complicating systemic sclerosis: a case report.
Angiosarcoma of the tongue: report of a case with immunohistochemical findings.
Angiostatic activity of human plasminogen fragments is highly dependent on glycosylation.
Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression.
Angiostatin expression in endometrial cancer.
Angiostatin expression in ovarian cancer.
Angiostatin suppresses malignant glioma growth in vivo.
Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival.
Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth.
Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor.
Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice.
ANNALS EXPRESS: Cytokine profiles in overweight and obese subjects and normal weight individuals matched for age and gender.
Annular puncture with tumor necrosis factor-alpha injection enhances painful behavior with disc degeneration in vivo.
Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma.
Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Antenatal depression programs cortisol stress reactivity in offspring through increased maternal inflammation and cortisol in pregnancy: The Psychiatry Research and Motherhood - Depression (PRAM-D) Study.
Anterior diffuse retinoblastoma: mutational analysis and immunofluorescence staining.
Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells.
Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis.
Anti-allergic and anti-inflammatory effects of the Bcl-2 inhibitor ABT-737 on experimental allergic rhinitis models.
Anti-angiogenesis approach to genitourinary cancer treatment.
Anti-angiogenesis in cancer therapeutics: the magic bullet.
Anti-angiogenesis therapy in pancreatic carcinoma.
Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.
Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro.
Anti-angiogenic activity of gecko aqueous extracts and its macromolecular components in CAM and HUVE-12 cells.
Anti-angiogenic activity of melatonin in advanced cancer patients.
Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
Anti-angiogenic and anti-inflammatory effects of SERPINA3K on corneal injury.
Anti-angiogenic and anti-lymphangiogenic role of praziquantel and artemether in experimental mansoniasis.
Anti-Angiogenic Approaches to Malignant Gliomas.
Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Anti-angiogenic effect of a chemically sulfated polysaccharide from Phellinus ribis by inhibiting VEGF/VEGFR pathway.
Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice.
Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Anti-angiogenic Effects of Metformin, an AMPK Activator, on Human Umbilical Vein Endothelial Cells and on Granulation Tissue in Rat.
Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture.
Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells.
Anti-angiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts.
Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice.
Anti-angiogenic property of edible berries.
Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.
Anti-angiogenic therapies for advanced esophago-gastric cancer.
Anti-angiogenic therapies in cancer: achievements and open questions.
Anti-angiogenic therapies in the management of glioblastoma.
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.
Anti-angiogenic therapy in the treatment of advanced renal cell cancer.
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect.
Anti-angiogenic treatment (Bevacizumab) improves the responsiveness of photodynamic therapy in colorectal cancer.
Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives.
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale.
Anti-angiogenic treatment of gastrointestinal malignancies.
Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas.
Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor-specific inhibitor.
Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice.
Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells.
Anti-CD73 therapy impairs tumor angiogenesis.
Anti-colorectal cancer targets of resveratrol and biological molecular mechanism: Analyses of network pharmacology, human and experimental data.
Anti-cytokine autoantibodies are ubiquitous in healthy individuals.
Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Anti-fibrosis activity of quercetin attenuates rabbit tracheal stenosis via the TGF-?/AKT/mTOR signaling pathway.
Anti-inflammation Effects of Corn Silk in a Rat Model of Carrageenin-Induced Pleurisy.
Anti-inflammatory activities of a new VEGF blocker, Conbercept.
Anti-inflammatory activity of rhein isolated from the flowers of Cassia fistula L. and possible underlying mechanisms.
Anti-inflammatory and analgesic potency of carboxyamidotriazole, a tumorostatic agent.
Anti-inflammatory and anti-angiogenesis effect of bee pollen methanolic extract using air pouch model of inflammation.
Anti-inflammatory and anti-angiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor.
Anti-inflammatory and anti-fibrotic effects of annexin1 on erectile function after cavernous nerve injury in rats.
Anti-inflammatory effect of glycosaminoglycan derived from Gryllus bimaculatus (a type of cricket, insect) on adjuvant-treated chronic arthritis rat model.
Anti-Inflammatory Effects of Angelica sinensis (Oliv.) Diels Water Extract on RAW 264.7 Induced with Lipopolysaccharide.
Anti-inflammatory effects of flap and lymph node transfer.
Anti-inflammatory effects of oroxylin A on RAW 264.7 mouse macrophages induced with polyinosinic-polycytidylic acid.
Anti-inflammatory effects of the root, stem and leaf extracts of Chloranthus serratus on adjuvant-induced arthritis in rats.
Anti-inflammatory effects of triptolide in human bronchial epithelial cells.
Anti-inflammatory Effects of Z-Ligustilide Nanoemulsion.
Anti-inflammatory, anti-rheumatic and analgesic activities of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-N-propylbenzenesulphonamide (MOPBS) in rodents.
Anti-lymphangiogenesis effects of a specific anti-interleukin 7 receptor antibody in lung cancer model in vivo.
Anti-metastatic effect of Biophytum sensitivum is exerted through its cytokine and immunomodulatory activity and its regulatory effect on the activation and nuclear translocation of transcription factors in B16F-10 melanoma cells.
Anti-metastatic Efficacy of Traditional Chinese Medicine (TCM) Ginsenoside Conjugated to a VEFGR-3 Antibody on Human Gastric Cancer in an Orthotopic Mouse Model.
Anti-neuropilin-1 monoclonal antibody suppresses the migration and invasion of human gastric cancer cells via Akt dephosphorylation.
Anti-oxidant, anti-apoptotic, anti-hypoxic and anti-inflammatory conditions induced by PTY-2 against STZ-induced stress in islets.
Anti-rheumatoid arthritis effects of traditional Chinese herb couple in adjuvant-induced arthritis in rats.
Anti-tissue factor short hairpin RNA inhibits breast cancer growth in vivo.
Anti-Tn Monoclonal Antibody Attenuates Hyperoxia-Induced Lung Injury by Inhibiting Oxidative Stress and Inflammation in Neonatal Mice.
Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model.
Anti-tumor activity of the novel hexahydrocannabinol analog LYR-8 in Human colorectal tumor xenograft is mediated through the inhibition of Akt and hypoxia-inducible factor-1? activation.
Anti-tumor and anti-metastatic actions of wogonin isolated from Scutellaria baicalensis roots through anti-lymphangiogenesis.
Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor.
Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4.
Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma.
Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis.
Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma.
Anti-Tumor Effect of Steamed Codonopsis lanceolata in H22 Tumor-Bearing Mice and Its Possible Mechanism.
Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models.
Anti-tumor effects of all-trans retinoic acid are enhanced by genistein.
Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice.
Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Anti-tumor effects of progesterone in human glioblastoma multiforme: Role of PI3K/Akt/mTOR signaling.
Anti-tumor effects of vascular endothelial growth factor/vascular endothelial growth factor receptor binding domain-modified chimeric antigen receptor T cells.
Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.
Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts.
Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Anti-Vascular Endothelial Growth Factor Targeting by Curcumin and Thalidomide in Acute Myeloid Leukemia Cells
Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer.
Anti-vascular endothelial growth factor therapy for malignant glioma.
Anti-vasospastic Effects of Epidermal Growth Factor Receptor Inhibitors After Subarachnoid Hemorrhage in Mice.
Anti-VEGF antibody enhances the antitumor effect of CD40.
Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor.
Anti-VEGF Anticancer Drugs: Mind the Hypertension.
Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics.
Anti-VEGF therapies in the clinic.
Anti-VEGF therapy: a new approach to colorectal cancer therapy.
Anti-VEGF treatment suppresses remodeling factors and restores epithelial barrier function through the E-cadherin/?-catenin signaling axis in experimental asthma models.
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
Anti?metastatic effects of Aidi on human esophageal squamous cell carcinoma by inhibiting epithelial?mesenchymal transition and angiogenesis.
Antiangiogenesis agents in colorectal cancer.
Antiangiogenesis in neurofibromatosis 1.
Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth.
Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.
Antiangiogenesis, loss of cell adhesion and apoptosis are involved in the antitumoral activity of Proteases from V. cundinamarcensis (C. candamarcensis) in murine melanoma B16F1.
Antiangiogenic Activity of Acer tegmentosum Maxim Water Extract in Vitro and in Vivo.
Antiangiogenic activity of aplidine, a new agent of marine origin.
Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas.
Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators.
Antiangiogenic activity of phthalides-enriched Angelica Sinensis extract by suppressing WSB-1/pVHL/HIF-1?/VEGF signaling in bladder cancer.
Antiangiogenic activity of selenium in cancer chemoprevention: metabolite-specific effects.
Antiangiogenic Activity of the Lipophilic Antimicrobial Peptides from an Endophytic Bacterial Strain Isolated from Red Pepper Leaf.
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development.
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.
Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma.
Antiangiogenic and antitumor effects of IMMUNEPOTENT CRP in murine melanoma.
Antiangiogenic and proapoptotic activities of allyl isothiocyanate inhibit ascites tumor growth in vivo.
Antiangiogenic and Proapoptotic Activities of Atorvastatin and Ganoderma lucidum in Tumor Mouse Model via VEGF and Caspase-3 Pathways.
Antiangiogenic and proapoptotic activity of a novel glycoprotein from U. indica is mediated by NF-kappaB and Caspase activated DNase in ascites tumor model.
Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches.
Antiangiogenic drugs for chemotherapy of bladder tumours.
Antiangiogenic drugs in non-small cell lung cancer treatment.
Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.
Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study.
Antiangiogenic effects of butyric acid involve inhibition of VEGF/KDR gene expression and endothelial cell proliferation.
Antiangiogenic effects of catalpol on rat corneal neovascularization.
Antiangiogenic Effects of Coumarins against Cancer: From Chemistry to Medicine.
Antiangiogenic effects of melatonin in endothelial cell cultures.
Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2.
Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice.
Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Antiangiogenic therapies for advanced hepatocellular carcinoma.
Antiangiogenic therapies in early-stage breast cancer.
Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels.
Antiangiogenic therapy for high-grade gliomas.
Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization.
Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response.
Antiangiogenic Therapy Impedes Infiltration by CD4+ and CD8+ Cells Into an Early Colon Tumor.
Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature.
Antiangiogenic therapy in malignant glioma: promise and challenge.
Antiangiogenic therapy in oncology: current status and future directions.
Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice.
Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
Antiangiogenic treatment for multiple CNS hemangioblastomas.
Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents.
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Antiangiogenics and immunotherapies in cervical cancer: an update and future's view.
Antiapoptotic Seminal Vesicle Protein IV Induces Histamine Release from Human FcepsilonRI+ Cells.
Antibacterial and Antiinflammatory Kinetics of Curcumin as a Potential Antimucositis Agent in Cancer Patients.
Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism.
Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.
Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding.
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis.
Antibody-modified conduits for highly selective cytokine elimination from blood.
Anticancer effects of curcumin on nude mice bearing lung cancer A549 cell subsets SP and NSP cells.
Anticancer effects of the engineered stem cells transduced with therapeutic genes via a selective tumor tropism caused by vascular endothelial growth factor toward HeLa cervical cancer cells.
Anticancer Potential of Mefenamic Acid Derivatives with Platelet-Derived Growth Factor Inhibitory Property.
Antidepressant hyperforin up-regulates VEGF in CNS tumour cells.
Antifibrinolytics attenuate inflammatory gene expression after cardiac surgery.
Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates.
Antihypertensive properties of a traditional Chinese medicine GAO-ZI-YAO in elderly spontaneous hypertensive rats.
Antimetastatic effect of suicide gene therapy for mouse mammary cancers requires T-cell-mediated immune responses.
Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).
Antineoplastic effect of pectic polysaccharides from green sweet pepper (Capsicum annuum) on mammary tumor cells in vivo and in vitro.
Antineoplastic effects of Chlorella pyrenoidosa in the breast cancer model.
Antioxidative response for nitric oxide production in breast carcinoma.
Antiphospholipid antibodies promote tissue factor-dependent angiogenic switch and tumor progression.
Antiproliferative effects of interferon-alphaCon1 on ovarian clear cell adenocarcinoma in vitro and in vivo.
Antisense HIF-1alpha prevents acquired tumor resistance to angiostatin gene therapy.
Antisense hypoxia-inducible factor-1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats.
Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas.
Antisense oligonucleotide of hypoxia-inducible factor-1alpha suppresses growth and tumorigenicity of lung cancer cells A549.
Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells.
Antitumor activity of an adenovirus harboring human IL-24 in colon cancer.
Antitumor activity of an adenovirus harboring two therapeutic genes, anti-VEGF ribozyme and human IL-24, in colon cancer.
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.
Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models.
Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
Antitumor activity of polysaccharide from Laminaria japonica on mice bearing H22 liver cancer.
Antitumor activity of triptolide in SKOV3 cells and SKOV3/DDP in vivo and in vitro.
Antitumor activity of ZD6474 in a metastatic orthotopic brain tumor model.
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Antitumor and antiangiogenic activities of anti-vascular endothelial growth factor hairpin ribozyme in human hepatocellular carcinoma cell cultures and xenografts.
Antitumor and antiangiogenic activities of curcumin in cervical cancer xenografts in nude mice.
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
Antitumor and antiangiogenic effects of GA-13315, a gibberellin derivative.
Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model.
Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.
Antitumor and radiosensitizing synergistic effects of apigenin and cryptotanshinone against solid Ehrlich carcinoma in female mice.
Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model.
Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice.
Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm.
Antitumor effect of a pyrazolone-based-complex [Cu(PMPP-SAL)(EtOH)] against murine melanoma B16 cell in vitro and in vivo.
Antitumor Effect of Bevacizumab in a Xenograft Model of Canine Hemangiopericytoma.
Antitumor Effects and Related Mechanisms of Ethyl Acetate Extracts of Polygonum perfoliatum L.
Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Antitumor effects of bevacizumab in combination with fluoropyrimidine drugs on human oral squamous cell carcinoma.
Antitumor effects of melanin from Lachnum YM226 and its derivative in H22 tumor-bearing mice.
Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma.
Antitumor effects of synthetic VEGF-receptor binding antagonist, VGA1155.
Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.
Antitumor efficacy of hypothemycin, a new Ras-signaling inhibitor.
Antitumor treatment efficacy by targeting epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in an orthotopic human glioblastoma model.
Antitumor/Antiestrogenic Effect of the Chemokine Interferon Inducible Protein 10 (IP-10) Involves Suppression of VEGF Expression in Mammary Tissue.
Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma.
Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models.
Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma.
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.
Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
Apatinib and fractionated stereotactic radiotherapy for the treatment of limited brain metastases from primary lung mucoepidermoid carcinoma: A case report.
Apatinib as targeted therapy for sarcoma.
Apatinib combined with concurrent chemoradiotherapy in patients with subglottic small cell carcinoma: a case report.
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis.
Apatinib for molecular targeted therapy in tumor.
Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma.
Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1?-AKT-mTOR pathway in esophageal squamous cell carcinoma.
Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway.
Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells.
Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.
Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report.
Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma.
Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.
Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.
Apatinib-induced hyperammonemic encephalopathy.
Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer.
Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.
Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy.
Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors.
Apigenin Prevents Development of Medroxyprogesterone Acetate-Accelerated 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Sprague-Dawley Rats.
Apigetrin treatment attenuates LPS-induced acute otitis media though suppressing inflammation and oxidative stress.
Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1? in human ovarian cancer cell lines and a mouse ovarian cancer model.
Apoptosis induction and ERK/NF-?B inactivation are associated with magnolol-inhibited tumor progression in hepatocellular carcinoma in vivo.
Apoptosis of human macrophages by Flt-4 signaling: implications for atherosclerotic plaque pathology.
Apoptotic effects of protocatechuic acid in human breast, lung, liver, cervix, and prostate cancer cells: potential mechanisms of action.
Apoptotic Effects of Rotundic Acid on Human Esophagus and Lung Cancer Cells.
Apparent diffusion coefficient correlation with oesophageal tumour stroma and angiogenesis.
Application of liquid chromatography-tandem mass spectrometry to study the effect of docetaxel on pharmacokinetics and tissue distribution of apatinib in mice.
Application of serum markers in diagnosis and staging of ovarian endometriosis.
Application of the nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate for the treatment of endometriosis: an in vitro study.
Application of weighted gene co-expression network analysis to reveal key modules and hub genes in generalized aggressive periodontitis.
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.
Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors.
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
Aptamer-based biosensors and nanosensors for the detection of vascular endothelial growth factor (VEGF): A review.
Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma.
Aquaporin 3 knockdown suppresses tumour growth and angiogenesis in experimental non-small cell lung cancer.
Aqueous Humor Levels of Different Interleukins 1-?, 2, 6 and 10, Tumor Necrosis Factor-? and Vascular Endothelial Growth Factor in Uveitis Treated with Adalimumab.
Aqueous immune mediators in malignant uveal melanomas in comparison to benign pigmented intraocular tumors.
Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
Are humoral factors involved in the colonic mucosal lesion in portal hypertensive rats?
Are Inflammatory Biomarkers Increased in Varicose Vein Blood?
ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA.
Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis.
ARHGAP6 regulates the proliferation, migration and invasion of lung cancer cells.
Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology.
Arsenic Exposure and Cardiovascular Disorders: An Overview.
Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C.
Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.
Arterially Delivered Mesenchymal Stem Cells Prevent Obstruction-Induced Renal Fibrosis.
Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer.
Arteriovenous malformation and thyroid metastasis from underlying renal cell carcinoma, an unusual presentation of malignancy: A case report.
Aryl Urea Based Scaffolds for Multitarget Drug Discovery in Anticancer Immunotherapies.
Arylurea Derivatives: a Class of Potential Cancer Targeting Agents.
Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites.
Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Aspirin inhibits endothelial nitric oxide synthase (eNOS) and Flk-1 (vascular endothelial growth factor receptor-2) prior to rat colon tumour development.
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis.
Assessing tumor angiogenesis using macromolecular MR imaging contrast media.
Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
Assessment of alterations in gene expression in recurrent malignant glioma after radiotherapy using complementary deoxyribonucleic acid microarrays.
Assessment of angiogenesis in rabbit orthotropic liver tumors using three-dimensional dynamic contrast-enhanced ultrasound compared with two-dimensional DCE-US.
Assessment of angiogenic factor, vascular endothelial growth factor, serum and urine level changes in superficial bladder tumor immunotherapy by intravesical Bacillus Calmette-Guerin.
Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis.
Assessment of biomarkers using multiplex assays in aqueous humor of patients with diabetic retinopathy.
Assessment of endometrial receptivity during implantation window in women with unexplained infertility.
Assessment of Maturation Status of Tumor-Infiltrating Dendritic Cells in Invasive Ductal Carcinoma of the Breast: Relation with Vascular Endothelial Growth Factor Expression.
Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs.
Assessment of the associations between three VEGF polymorphisms and risk of prostate cancer.
Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.
Assessment of vascular endothelial growth factor in formalin fixed, paraffin embedded colon cancer specimens by means of a well-based reverse phase protein array.
Assessment of VEGF and EGFR in the study of angiogenesis of eyelid carcinomas.
Assessment of VEGF-D expression measured by immunohistochemical staining and F-18 FDG uptake on PET as biological prognostic factors for recurrence in patients with surgically resected lung adenocarcinoma.
Association between Aqueous Cytokines and Diabetic Retinopathy Stage.
Association between circulatory levels of adipokines and bone mineral density in postmenopausal women.
Association between EGF and VEGF functional polymorphisms and sporadic colorectal cancer in the Malaysian population.
Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma.
Association between five polymorphisms in vascular endothelial growth factor gene and urinary bladder cancer risk: A systematic review and meta-analysis involving 6671 subjects.
Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma.
Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting.
Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia.
Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population.
Association between the nucleosome footprint of plasma DNA and neoadjuvant chemotherapy response for breast cancer.
Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas.
Association between vascular endothelial growth factor expression and lymph node metastasis in cervical cancer: A meta-analysis.
Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk.
Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients.
Association between vascular endothelial growth factor rs699947 polymorphism and the risk of three major urologic neoplasms (bladder cancer, prostate cancer, and renal cell carcinoma): A meta-analysis involving 11,204 subjects.
Association Between VEGF Expression and Diffusion Weighted Imaging in Several Tumors-A Systematic Review and Meta-Analysis.
Association between VEGF expression in tumour-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients.
Association between VEGF gene promoter polymorphisms and bladder cancer: An updated meta-analysis.
Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population.
Association between VEGF-460T/C gene polymorphism and clinical outcomes of nasopharyngeal carcinoma treated with intensity-modulated radiation therapy.
Association of +405C>G and +936C>T polymorphisms of the vascular endothelial growth factor gene with sporadic breast cancer in North Indians.
Association of 150-kDa oxygen-regulated protein with vascular endothelial growth factor in proliferative diabetic retinopathy.
Association of a Single-Nucleotide Polymorphism in the Promoter Region of the VEGF Gene with the Risk of Renal Cell Carcinoma.
Association of advanced glycoxidation end products and inflammation markers with thrombosis of arteriovenous grafts in hemodialysis patients.
Association of CXCR4, CCR7, VEGF-C and VEGF-D expression with lymph node metastasis in patients with cervical cancer.
Association of fatigue and depression with circulating levels of proinflammatory cytokines and epidermal growth factor receptor ligands: a correlative study of a placebo-controlled fatigue trial.
Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation.
Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.
Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor.
Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Association of preoperative radiation effect with tumor angiogenesis and vascular endothelial growth factor in oral squamous cell carcinoma.
Association of pSTAT3-VEGF signaling pathway with peritumoral edema in newly diagnosed glioblastoma: an immunohistochemical study.
Association of salivary C-reactive protein with the obesity measures and markers in children.
Association of single nucleotide polymorphisms in vascular endothelial growth factor gene with bladder cancer risk.
Association of sirtuin-1 and vascular endothelial growth factor expression with tumor progression and poor prognosis in liposarcoma.
Association of specific single nucleotide variants (SNVs) in the promoter and 3'-Untranslated region of Vascular Endothelial growth factor (VEGF) gene with risk and higher tumour grade of head and neck cancers.
Association of Systemic or Intravitreal Antivascular Endothelial Growth Factor (Anti-VEGF) and Impaired Wound Healing in Pediatric Patients: Collagen to the Rescue.
Association of the serum vascular endothelial growth factor levels with benign prostate hyperplasia and prostate malignancies.
Association of the vascular endothelial growth factor -2578C/A polymorphism with cancer risk: A meta-analysis update.
Association of vascular endothelial growth factor (VEGF) gene polymorphism and increased serum VEGF concentration with pancreatic adenocarcinoma.
Association of vascular endothelial growth factor -2578C/A gene polymorphism in Chinese patients with colon cancer.
Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma.
Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.
Association of vascular endothelial growth factor expression with patohistological parameters of cutaneous melanoma.
Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.
Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer.
Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma.
Association of vascular endothelial growth factor gene polymorphisms with susceptibility to epithelial ovarian cancer.
Association of vascular endothelial growth factor--a gene polymorphisms and haplotypes with breast cancer metastases.
Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans.
Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome.
Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma.
Association of VEGF-A genetic polymorphisms with cancer risk and survival in advanced-stage oral squamous cell carcinoma patients.
Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population.
Association study of the TNF-? -1031T/C and VEGF?+?450G/C polymorphisms with susceptibility to endometriosis.
Associations between Histogram Analysis Parameters Derived from DCE-MRI and Histopathological Features including Expression of EGFR, p16, VEGF, Hif1-alpha, and p53 in HNSCC.
Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study.
Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: a meta-analysis.
Associations Between [18F]FDG-PET and Complex Histopathological Parameters Including Tumor Cell Count and Expression of KI 67, EGFR, VEGF, HIF-1?, and p53 in Head and Neck Squamous Cell Carcinoma.
Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial.
Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas.
Astragalus polysaccharide (PG2) Ameliorates Cancer Symptom Clusters, as well as Improves Quality of Life in Patients with Metastatic Disease, through Modulation of the Inflammatory Cascade.
Astrocyte elevated gene-1 is overexpressed in non-small-cell lung cancer and associated with increased tumour angiogenesis.
Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamide.
Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production.
Atrial myxoma occurring 15 years after subtotal resection of cerebellar hemangioblastoma.
Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis.
Attenuation of the development of murine solid leukemia tumor by physical exercise.
Augmentation of antitumor immunity by fusions of ethanol-treated tumor cells and dendritic cells stimulated via dual TLRs through TGF-?1 blockade and IL-12p70 production.
Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor.
Augmented Macrophage Differentiation and Polarization of Tumor-associated Macrophages Towards M1 Subtype in Listeria-administered Tumor-bearing Host.
Autocrine effects of VEGF-D on endothelial cells after transduction with AD-VEGF-D(DeltaNDeltaC).
Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion.
Autocrine impact of vascular endothelial growth factor (VEGF) A on uveal melanoma cells.
Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells.
Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels.
Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.
Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells.
Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.
Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway.
Autocrine VEGF signalling on M2 macrophages regulates PD-L1 expression for immunomodulation of T cells.
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.
Automated high-throughput RNAi screening in human cells combined with reporter mRNA transfection to identify novel regulators of translation.
Autophagy in the physiological endometrium and cancer.
Autotaxin and vascular endothelial growth factor receptor-2 and -3 are related to vascular development during the progression of chronic viral hepatitis C.
Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer.
Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration.
Avastin® in combination with gemcitabine and cisplatin significantly inhibits tumor angiogenesis and increases the survival rate of human A549 tumor-bearing mice.
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.
Axitinib (AG-013736).
Axitinib exposure triggers endothelial cells senescence through ROS accumulation and ATM activation.
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial.
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer.
B cell activating factor-dependent expression of vascular endothelial growth factor in MH7A human synoviocytes stimulated with tumor necrosis factor-?.
B7-H3 expression in breast cancer and upregulation of VEGF through gene silence.
B?cell translocation 1 gene inhibits cellular metastasis?associated behavior in breast cancer.
BACH1 promotes the progression of esophageal squamous cell carcinoma by inducing the epithelial-mesenchymal transition and angiogenesis.
Bacteria-induced release of white cell--and platelet-derived vascular endothelial growth factor in vitro.
Barrett's mucosa: remodelling by the microenvironment.
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Basic fibroblast growth factor promotes VEGF-C-dependent lymphangiogenesis via inhibition of miR-381 in human chondrosarcoma cells.
Basigin-2 is a cell surface receptor for soluble basigin ligand.
Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells.
Bcl-2 mediated modulation of vascularization in prostate cancer xenografts.
BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Bear Bile Powder Inhibits Growth of Hepatocellular Carcinoma via Suppressing STAT3 Signaling Pathway in Mice.
Beclin 1 deficiency is associated with increased hypoxia-induced angiogenesis.
Bee pollen and propolis improve neuroinflammation and dysbiosis induced by propionic acid, a short chain fatty acid in a rodent model of autism.
Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells.
Beneficial action of resveratrol: How and why?
Beneficial Actions of Orostachys japonica and Its Compounds against Tumors via MAPK Signaling Pathways.
Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5.
Beneficial effects of the Src inhibitor, dasatinib, on breakdown of the blood-retinal barrier.
Beneficial Regulation of Cellular Oxidative Stress Effects, and Expression of Inflammatory, Angiogenic, and the Extracellular Matrix Remodeling Proteins by 1?,25-Dihydroxyvitamin D3 in a Melanoma Cell Line.
Benefits of micronized purified flavonoid fraction as adjuvant therapy on the inflammatory response after sclerotherapy.
Benzodiazepine-Associated Carcinogenesis: Focus on Lorazepam-Associated Cancer Biomarker Changes in Overweight Individuals.
Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
Benzo[a]pyrene-3,6-dione inhibited VEGF expression through inducing HIF-1alpha degradation.
Berberine Ameliorates Collagen-Induced Arthritis in Rats Associated with Anti-inflammatory and Anti-angiogenic Effects.
Berberine inhibits HIF-1alpha expression via enhanced proteolysis.
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
Beta-catenin inversely regulates vascular endothelial growth factor-D mRNA stability.
beta-Eudesmol suppresses tumour growth through inhibition of tumour neovascularisation and tumour cell proliferation.
Bevacizumab and advanced-stage ovarian cancer. Yet another oncological indication, but still best to avoid using this drug.
Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts.
Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis.
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends.
Bevacizumab and near infrared probe conjugated iron oxide nanoparticles for vascular endothelial growth factor targeted MR and optical imaging.
Bevacizumab and ovarian cancer.
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer.
Bevacizumab and Wound-Healing Complications: Mechanisms of Action, Clinical Evidence, and Management Recommendations for the Plastic Surgeon.
Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
Bevacizumab as first-line treatment for advanced non-small cell lung cancer.
Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells.
Bevacizumab combined with low-dose S-1 as maintenance therapy with a long progression-free survival in an elderly patient with heavily pre-treated advanced gastric cancer: A case report.
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.
Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.
Bevacizumab for glioblastoma: What can we learn from patterns of progression?
Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Bevacizumab for patients with metastatic renal cancer: an update.
Bevacizumab for the treatment of glioblastoma.
Bevacizumab for the treatment of recurrent glioblastoma.
Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report.
Bevacizumab in clinical practice.
Bevacizumab in combination chemotherapy for colorectal and other cancers.
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.
Bevacizumab in metastatic breast cancer: when may it be used?
Bevacizumab in non small cell lung cancer.
Bevacizumab in non-small cell lung cancer.
Bevacizumab in the management of solid tumors.
Bevacizumab in the treatment of breast cancer: rationale and current data.
Bevacizumab in the treatment of colorectal cancer.
Bevacizumab in the treatment of NSCLC: patient selection and perspectives.
Bevacizumab in the treatment of ovarian cancer.
Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?
Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.
Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.
Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials?
Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer.
Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.
Bevacizumab reduced auto-phosphorylation of VEGFR2 to protect HDM-induced asthma mice.
Bevacizumab tested for treatment of knee osteoarthritis via inhibition of synovial vascular hyperplasia in rabbits.
Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
Bevacizumab Use in Refractory Adult Pilocytic Astrocytoma: A Single-Center Case Series.
Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
Bevacizumab--current status and future directions.
Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer.
Bevacizumab-associated glomerular microangiopathy.
Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: A case series and systematic review of the literature.
Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database.
Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation.
Bevacizumab: a review of its use in metastatic colorectal cancer.
Bevacizumab: antiangiogenic cancer therapy.
Bevacizumab: in previously treated glioblastoma.
Bevacizumab: more fatal adverse effects.
Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.
bFGF Up-regulation Reduces Spontaneous Necrosis of VX2 Tumors Without Increasing Tumoral Microvascular Density.
BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition.
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer.
Bilirubin modulated cytokines, growth factors and angiogenesis to improve cutaneous wound healing process in diabetic rats.
Bioactivity-guided isolation of flavonoids from Urtica dioica L. and their effect on endometriosis rat model.
Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma.
Biochemical and immunological basis of silymarin effect, a milk thistle (Silybium marianum) against ethanol-induced oxidative damage.
Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist.
Biochemical Evidence for the Antitumor Potential of Garcinia mangostana Linn. On Diethylnitrosamine-Induced Hepatic Carcinoma.
Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution.
Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages toward M1-like Phenotype and Attenuating Tumor Hypoxia.
Biofabrication of a novel leukocyte-fibrin-platelet membrane as a cells and growth factors delivery platform for tissue engineering applications.
Bioinspired Nanonetworks for Targeted Cancer Drug Delivery.
Biologic correlates of (18)F-FDG uptake on PET in pulmonary pleomorphic carcinoma.
Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.
Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors.
Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma.
Biologic therapy in esophageal and gastric malignancies: current therapies and future directions.
Biological agents in gastrointestinal cancers: adverse effects and their management.
Biological and Prognostic Significance of the Morphological Types and Vascular Patterns in Colorectal Liver Metastases (CRLM): Looking Beyond the Tumor Margin.
Biological characterization of subgroups of squamous cell lung carcinomas.
Biological impact of vascular endothelial growth factor on vessel density and survival in multiple myeloma and plasmacytoma.
Biological implications of macrophage infiltration in human tumor angiogenesis.
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Biological Properties of (1???3)-?-d-Glucan-Based Synthetic Oligosaccharides.
Biological stress response in women at risk of postpartum psychosis: The role of life events and inflammation.
Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer.
Biologically active peptides interacting with the G protein-coupled formylpeptide receptor.
Biologically inhibitory effects of VEGF siRNA on endometrial carcinoma cells.
Biologics in gastrointestinal and pancreatic neuroendocrine tumors.
Biology and clinical management challenges in meningioma.
Biology of hepatocellular carcinoma.
Biomarker levels in gingival crevicular fluid of generalized aggressive periodontitis patients after non-surgical periodontal treatment.
Biomarker Profile of Sepsis-Associated Coagulopathy Using Biochip Assay for Inflammatory Cytokines.
Biomarkers in Rheumatoid Arthritis, what is new?
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Biomarkers of pituitary neoplasms.
Biomarkers of pulmonary hypertension in patients with scleroderma: a case-control study.
Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
Biophysical Properties and Motility of Human Mature Dendritic Cells Deteriorated by Vascular Endothelial Growth Factor through Cytoskeleton Remodeling.
Bioprinting of glioma stem cells improves their endotheliogenic potential.
Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.
Bioresponsive functional nanogels as an emerging platform for cancer therapy.
Biosensor incorporating cell barrier architectures on ion selective electrodes for early screening of cancer.
Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer.
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Bismuthoxyiodide Nanoflakes/Titania Nanotubes Arrayed p-n Heterojunction and Its Application for Photoelectrochemical Bioanalysis.
Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia.
BLCA-4 expression is related to MMP-9, VEGF, IL-1? and IL-8 in bladder cancer but not to PEDF, TNF-? or angiogenesis.
Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression.
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.
Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis.
Blockade of NF-?B nuclear translocation results in the inhibition of the invasiveness of human gastric cancer cells.
Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer.
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner.
Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea.
Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma.
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Blocking ?v?3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells.
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
Blocking macrophage migration inhibitory factor activity alleviates mouse acute otitis media in vivo.
Blocking NOTCH Pathway can Enhance the Effect of EGFR Inhibitor through Targeting CD133+ Endometrial Cancer Cells.
Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.
Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?
Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis.
Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1.
Blood levels of pro-inflammatory and anti-inflammatory cytokines during an oral glucose tolerance test in patients with symptoms suggesting reactive hypoglycemia.
Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent emphysema.
Blood vessels as targets in tumor therapy.
Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown.
Blumea balsamifera Oil for the Acceleration of Healing of Burn Injuries.
BMP4/Thrombospondin-1 loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors.
BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation.
Body composition and inflammatory markers in pubertal girls: Comparison between athletes and non-athletic controls.
Body Composition, Inflammation, and 5-Year Outcomes in Colon Cancer.
Body composition, maximal aerobic performance and inflammatory biomarkers in endurance-trained athletes.
Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers.
Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.
Bone marrow angiogenesis and progression in multiple myeloma.
Bone marrow micrometastases and markers of angiogenesis in esophageal cancer.
Bone marrow mononuclear cells enhance anti-inflammatory effects of pravastatin against isoproterenol-induced myocardial infarction in rats.
Bone marrow-derived cells in ocular neovascularization: contribution and mechanisms.
Bone Marrow-Derived Endothelial Progenitor Cells Protect Against Scopolamine-Induced Alzheimer-Like Pathological Aberrations.
Bone marrow-derived endothelial progenitors expressing Delta-like 4 (Dll4) regulate tumor angiogenesis.
Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenetic factors and promote prostate cancer growth.
Bone metastases in hepatocellular carcinoma: an emerging issue.
Bone Metastasis from Renal Cell Carcinoma.
Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis.
Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Bradykinin antagonists as new drugs for prostate cancer.
Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells.
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Brain edema in neurooncology: radiological assessment and management.
Brain gliomas and growth factors: immunohistochemical, immunofluorescence, flow cytometry and RT-PCR profile in pediatric age.
Brain Tumors in Children- Current Therapies and Newer Directions.
Brain-Behavior-Immune Interaction: Serum Cytokines and Growth Factors in Patients with Eating Disorders at Extremes of the Body Mass Index (BMI) Spectrum.
Brain-Derived Neurotrophic Factor Activation of TrkB Induces Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Factor-1{alpha} in Neuroblastoma Cells.
Brain-derived neurotrophic factor, insulin like growth factor-1 and inflammatory cytokine responses to continuous and intermittent exercise in patients with type 1 diabetes.
Breaking the 'harmony' of TNF-? signaling for cancer treatment.
Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.
Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells.
Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression.
Breast cancer therapy affects the expression of antineonatal Nav1.5 antibodies in the serum of patients with breast cancer.
Breast cancer-associated metastasis is significantly increased in a model of autoimmune arthritis.
Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment.
BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.
BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells.
Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases.
Bronchoscopy for bevacizumab-related hemoptysis.
Bullous pemphigoid and pemphigus vulgaris: correlated behaviour of serum VEGF, sE-selectin and TNF-alpha levels.
Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation.
c-Jun kinase mediates expression of VEGF induced at transcriptional level by Rac1 and Cdc42Hs but not by RhoA.
c-Jun NH2-terminal kinase suppression significantly inhibits the growth of transplanted breast tumors in mice.
C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.
c-myc but not Hif-1?-dependent downregulation of VEGF influences the proliferation and differentiation of HL-60 cells induced by ATRA.
c-Myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression.
C/EBP? and Nuclear Factor of Activated T Cells Differentially Regulate Adamts-1 Induction by Stimuli Associated with Vascular Remodeling.
C086, a novel analog of curcumin, induces growth inhibition and down-regulation of NF?B in colon cancer cells and xenograft tumors.
CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors.
Ca(2+) Signalling in Endothelial Progenitor Cells: Friend or Foe?
Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model.
CACNA2D2 promotes tumorigenesis by stimulating cell proliferation and angiogenesis.
Cadexomer as well as cadexomer iodine induces the production of proinflammatory cytokines and vascular endothelial growth factor by human macrophages.
Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells.
Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats.
Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: Implications for tumor angiogenesis.
Calcium Phosphate Coating Prepared by Microarc Oxidation Affects hTERT Expression, Molecular Presentation, and Cytokine Secretion in Tumor-Derived Jurkat T Cells.
Calpastatin Counteracts Pathological Angiogenesis by Inhibiting Suppressor of Cytokine Signaling 3 Degradation in Vascular Endothelial Cells.
Camel milk inhibits inflammatory angiogenesis via downregulation of proangiogenic and proinflammatory cytokines in mice.
Can serum progranulin levels be a biomarker following gastric ulcer therapy?
Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells.
Cancer immunoediting from immunosurveillance to tumor escape in microvillus-formed niche: a study of syngeneic orthotopic rat bladder cancer model in comparison with human bladder cancer.
Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity.
Cancer immunotherapy via targeted TGF-? signalling blockade in TH cells.
Cancer marker: vascular endothelial growth factor.
Cancer Patient-Derived Circulating Microparticles Enhance Lung Metastasis in a Rat Model: Dual-Source CT, Cellular, and Molecular Studies.
Cancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities.
Cancer prevention and therapy through the modulation of the tumor microenvironment.
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.
Cancer Stem Cells and Its Role in Angiogenesis and Vasculogenic Mimicry in Gastrointestinal Cancers.
Cancer stem cells in radiation resistance.
Cancer therapy and cardiovascular risk: focus on bevacizumab.
Cancer treatment scheduling and dynamic heterogeneity in social dilemmas of tumour acidity and vasculature.
Cancer-associated fibroblasts show heterogeneous gene expression and induce vascular endothelial growth factor A (VEGFA) in response to environmental stimuli.
Cancer-derived VEGF plays no role in malignant ascites formation in the mouse.
Cancer-Stromal Cell Interaction and Tumor Angiogenesis in Gastric Cancer.
Cancer: Reduced serum VEGF-D levels in metastatic differentiated thyroid cancer.
Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor.
Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas.
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF.
Carboxymethyl benzylamide dextran inhibits angiogenesis and growth of VEGF-overexpressing human epidermoid carcinoma xenograft in nude mice.
Carboxymethyl chitosan represses tumor angiogenesis in vitro and in vivo.
Carcinoma-like vascular density in atypic keratoacanthoma suggests malignant progression.
Cardiac myxoma: its origin and tumor characteristics.
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.
Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.
Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management.
Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?
Case of high-risk epithelioid hemangioendothelioma of the neck.
Case report of extrarenal rhabdoid tumor of pelvic retroperitoneum molecular profile of angiogenesis and its implication in new treatment strategy.
Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumab.
Case Report: Challenges in the Diagnosis of Adenopathy and Extensive Skin Patch Overlying a Plasmacytoma Syndrome.
Case Report: Non-episodic Angioedema With Eosinophilia in a Young Lactating Woman.
Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer.
Catalyser-21(TM), a mineral water derived from leaf soil, inhibits tumor cell invasion and angiogenesis.
Cathelicidin-deficient (Cnlp -/- ) mice show increased susceptibility to Pseudomonas aeruginosa keratitis.
Cathepsin S Controls Angiogenesis and Tumor Growth via Matrix-derived Angiogenic Factors.
Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells.
Cavernous sinus invasion and effect of immunohistochemical features on remission in growth hormone secreting pituitary adenomas.
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.
CCL27/CCL28-CCR10 CHEMOKINE SIGNALING MEDIATES MIGRATION OF LYMPHATIC ENDOTHELIAL CELLS.
CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients.
CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
CCR6 promotes tumor angiogenesis via the AKT/NF-?B/VEGF pathway in colorectal cancer.
CCR7 enhances the angiogenic capacity of esophageal squamous carcinoma cells in vitro via activation of the NF-?B/VEGF signaling pathway.
CD147 induces up-regulation of vascular endothelial growth factor in U937-derived foam cells through PI3K/AKT pathway.
CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer.
CD147/basigin promotes progression of malignant melanoma and other cancers.
CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma.
CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma.
CD4, IL-17, and COX-2 Are Associated With Subclinical Inflammation in Malar Melasma.
CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma.
CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis.
CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node Metastases.
CD98 expression is associated with the grade of malignancy in thymic epithelial tumors.
CEACAM1/VEGF cross-talk during neuroblastic tumour differentiation.
Cediranib inhibits both the intraosseous growth of PDGF D-Positive prostate cancer cells and the associated bone reaction.
Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
Celastrus Orbiculatus extract inhibits tumor angiogenesis by targeting vascular endothelial growth factor signaling pathway and shows potent antitumor activity in hepatocarcinomas in Vitro and in Vivo.
Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors.
Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor.
Celecoxib can induce vascular endothelial growth factor expression and tumor angiogenesis.
Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.
Cell composition and immunohistochemical detection of VEGF, TGF-beta, and TNF-alpha in proliferative vitreoretinopathy.
Cell mates: paracrine and stromal targets for prostate cancer therapy.
Cell penetrating peptides improve tumor delivery of cargos through neuropilin-1-dependent extravasation.
Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis.
Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis.
Cell-permeable iron inhibits vascular endothelial growth factor receptor-2 signaling and tumor angiogenesis.
Cell-specific but p53-independent regulation of vascular endothelial growth factor expression by interferons in human glioblastoma cells.
Cells designed to deliver anticancer drugs by apoptosis.
Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy.
Cellular proliferative fraction measured with topoisomerase IIalpha predicts malignancy in endocrine pancreatic tumors.
Cellular Source and Amount of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Tumors Determine Response to Angiogenesis Inhibitors.
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ceramide kinase deficiency impairs microendothelial cell angiogenesis in vitro.
Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma.
Cerebrovascular Remodeling and Neuroinflammation is a Late Effect of Radiation-Induced Brain Injury in Non-Human Primates.
Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival.
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis.
Cetirizine and thalidomide synergistically inhibit mammary tumorigenesis and angiogenesis in 7,12-dimethylbenz(a)anthracene-treated rats.
Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy.
Challenges for patient selection with VEGF inhibitors.
Challenges in everyday surgical practice: synchronous bilobar hepatic colorectal metastases--newer multimodality approach.
Change in fibroblast growth factor 2 expression as an early phase radiotherapy-responsive marker in sequential biopsy samples from patients with cervical cancer during fractionated radiotherapy.
Change of proinflammatory cytokines follows certain patterns after induction of endometriosis in a mouse model.
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
Changes in Caspase-3, B Cell Leukemia/Lymphoma-2, Interleukin-6, Tumor Necrosis Factor-? and Vascular Endothelial Growth Factor Gene Expression after Human Umbilical Cord Blood Derived Mesenchymal Stem Cells Transfusion in Pulmonary Hypertension Rat Models.
Changes in circulating immunosuppressive cytokine levels of cancer patients after high intensity focused ultrasound treatment.
Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer.
Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma.
Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo-Adjuvant Hormonal Therapy in Prostate Cancer Patients.
Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer.
Changes in serum IGF?1 level and tumor VEGF expression in mice with colorectal cancer under hyperglycemic conditions.
Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes.
Changes in TL1A levels and associated cytokines during pathogenesis of diabetic retinopathy.
Changes in TNF-?, IL-6, IL-10 and VEGF in rats with ARDS and the effects of dexamethasone.
Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian disease.
Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma.
Changes of CaM-CaMK-CREB signaling pathway and related neuron factors in hippocampus of rats after sevoflurane and propofol administration.
Changes of serum vascular endothelial growth factor of patients with rectal cancer before and after neoadjuvant chemotherapy and tumor progress.
Changes of synovial fluid biomarker levels after opening wedge high tibial osteotomy in patients with knee osteoarthritis.
Chapter 1 trophic factors in the carotid body.
Characterisation of dendritic cell subsets in lung cancer micro-environments.
Characterisation of the inflammatory cytokine and growth factor profile in a rabbit model of proliferative vitreoretinopathy.
Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy.
Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis.
Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.
Characterization of EST Gene in the Bovine Corpus Luteum during the Estrous Cycle.
Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model.
Characterization of mac25/angiomodulin expression by high endothelial venule cells in lymphoid tissues and its identification as an inducible marker for activated endothelial cells.
Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain.
Characterization of proliferative, glial and angiogenic responses after a CoCl2 -induced injury of photoreceptor cells in the adult zebrafish retina.
Characterization of the Bystander Effect of Somatostatin Receptor sst2 After In Vivo Gene Transfer into Human Pancreatic Cancer Cells.
Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells.
Characterization of the endothelium-specific murine vascular endothelial growth factor receptor-2 (Flk-1) promoter.
Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors.
Characterizing the tumor response to treatment with combretastatin A4 phosphate.
Chemerin promotes microangiopathy in diabetic retinopathy via activation of ChemR23 in rat primary microvascular endothelial cells.
Chemical characterization of a procyanidin-rich extract from sorghum bran and its effect on oxidative stress and tumor inhibition in vivo.
Chemical generation of bispecific antibodies.
Chemically modified siRNA directed against the KDR gene inhibits the proliferation of breast cancer cells.
Chemically modified tetracyclines (CMT-3 and CMT-8) enable control of the pathologic remodellation of human aortic valve stenosis via MMP-9 and VEGF inhibition.
Chemiluminescence detection of a protein through the aptamer-controlled catalysis of a porphyrin probe.
Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Chemokine Expression Is Involved in the Vascular Neogenesis of Ewing Sarcoma: A Preliminary Analysis of the Early Stages of Angiogenesis in a Xenograft Model.
Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review).
Chemoprevention of Esophageal Squamous Cell Carcinoma with Berries.
Chemopreventive effect of leflunomide against Ehrlich's solid tumor grown in mice: Effect on EGF and EGFR expression and tumor proliferation.
Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer.
Chemotherapy and antiangiogenic agents in non-small-cell lung cancer.
Chemotherapy and Target Therapy in the Management of Adult High-Grade Gliomas.
Chenodeoxycholic Acid Releases Proinflammatory Cytokines from Small Intestinal Epithelial Cells Through the Farnesoid X Receptor.
Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.
Chitin hydrolysate stimulates VEGF-C synthesis by MDA-MB-231 breast cancer cells.
Chitosan and Curcumin Nanoformulations against Potential Cardiac Risks Associated with Hydroxyapatite Nanoparticles in Wistar Male Rats.
Chlorin e6-loaded sonosensitive magnetic nanoliposomes conjugated with the magnetic field for enhancing anti-tumor effect of sonodynamic therapy.
Cholesteryl oligoarginine delivering vascular endothelial growth factor sirna effectively inhibits tumor growth in colon adenocarcinoma.
Chondrocyte-derived extracellular matrix suppresses pathogenesis of human pterygium epithelial cells by blocking the NF-?B signaling pathways.
Chondroitin sulphate-modified neuropilin 1 is expressed in human tumour cells and modulates 3D invasion in the U87MG human glioblastoma cell line through a p130Cas-mediated pathway.
Chromogranin A-, serotonin-, synaptophysin- and vascular endothelial growth factor-positive endocrine cells and the prognosis of colorectal cancer: an immunohistochemical and ultrastructural study.
Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFC genes.
Chronic inflammation and colorectal cancer: the role of vascular endothelial growth factor.
Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1.
Chronic skin-specific inflammation promotes vascular inflammation and thrombosis.
Chronic Stress Exposure Suppresses Mammary Tumor Growth and Reduces Circulating Exosome TGF-? Content via ?-Adrenergic Receptor Signaling in MMTV-PyMT Mice.
Chronic systemic hypoxia promotes LNCaP prostate cancer growth in vivo.
Chronic thalidomide administration enhances vascular responsiveness to vasopressin in portal-systemic collaterals of bile duct-ligated rats.
Chronobiological approaches to antiangiogenic photodynamic therapy of tumors: the first experimental evaluation.
Chronologic aging decreases tumor angiogenesis and metastasis in a mouse model of head and neck cancer.
Chronology of hemodynamic changes in asymptomatic in vitro fertilization patients and relationship with ovarian steroids and cytokines.
Chronopharmacologic cancer treatment with an angiogenic vessel-targeted liposomal drug.
CIEF and MALDI-TOF-MS methods for analyzing forms of the glycoprotein VEGF 165.
Cigarette smoke differently alters normal and ovalbumin-sensitized bronchial epithelial cells from rat.
Cimetidine inhibits angiogenesis and suppresses tumor growth.
Cinnamic aldehyde suppresses hypoxia-induced angiogenesis via inhibition of hypoxia-inducible factor-1? expression during tumor progression.
Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index.
Circadian clock gene Per2 downregulation in non?small cell lung cancer is associated with tumour progression and metastasis.
CircRNA UBAP2 facilitates the progression of colorectal cancer by regulating miR-199a/VEGFA pathway.
Circulating angiogenesis regulators in cancer patients.
Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma.
Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology.
Circulating Cytokine/Chemokine Concentrations Respond to Ionizing Radiation Doses but not Radiation Dose Rates: Granulocyte-Colony Stimulating Factor and Interleukin-18.
Circulating Fibroblast Growth Factor-21 Levels in Rheumatoid Arthritis: Associations With Disease Characteristics, Body Composition, and Physical Functioning.
Circulating fibronectin controls tumor growth.
Circulating Inflammatory Cytokine Responses to Endurance Exercise in Female Rowers.
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study.
Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNF? inhibitors.
Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFIt-1) in human breast cancer.
Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance?
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy.
Circulating progenitor cells and vascular dysfunction in chronic obstructive pulmonary disease.
Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas.
Circulating TGF-?1 and VEGF and risk of cancer among liver transplant recipients.
Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.
Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma.
Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma.
Circulating vascular endothelial growth factor (VEGF) levels in advanced stage cancer patients compared to normal controls and diabetes mellitus patients with critical ischemia.
Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours.
Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy.
Circulating vascular endothelial growth factor in childhood solid tumors: plasma and serum measurements.
Circulating vascular endothelial growth factor in patients with colorectal cancer.
Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery.
cis-hinokiresinol, a norlignan from Anemarrhena asphodeloides, inhibits angiogenic response in vitro and in vivo.
Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.
Citrus hystrix leaf extract attenuated diabetic-cataract in STZ-rats.
Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors.
Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors.
Clearance of inflammatory cytokines in patients with septic acute kidney injury during renal replacement therapy using the EMiC2 filter (Clic-AKI study).
Cleavable PEGylation and hydrophobic histidylation of polylysine for siRNA delivery and tumor gene therapy.
Clinical advances in the development of novel VEGFR2 inhibitors.
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival in gastric cancer.
Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.
Clinical application of biological markers for treatments of resectable non-small-cell lung cancers.
Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.
Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.
Clinical efficacy of bevacizumab combined with gemcitabine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer.
Clinical experiences with G17DT in gastrointestinal malignancies.
Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
Clinical implications and diagnostic usefulness of correlation between soluble major histocompatibility complex class I chain-related molecule a and protumorigenic cytokines in pancreatic ductal adenocarcinoma.
Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.
Clinical implications of circulating angiogenic factors in cancer patients.
Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers.
Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers.
Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers.
Clinical implications of targeting VEGF in solid tumors.
Clinical Implications of VEGF, TGF-?1, and IL-1? in Patients with Advanced Non-small Cell Lung Cancer.
Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas.
Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.
Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer.
Clinical outcome and prognostic analysis of meningeal carcinomatosis treated by intrathecal chemotherapy.
Clinical prognostic values of vascular endothelial growth factor, microvessel density,and p53 expression in esophageal carcinomas.
Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL).
Clinical Relevance of Increased Endothelial and Mesothelial Expression of Proangiogenic Proteases and VEGFA in the Omentum of Patients with Metastatic Ovarian High-Grade Serous Carcinoma.
Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia.
Clinical relevance of vascular endothelial growth factor for thyroid neoplasms.
Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia.
Clinical Significance and Roles in Angiogenesis of Circulating Microparticles in Oral Cancer.
Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.
Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma.
Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma.
Clinical significance of circulating vascular endothelial growth factor in dogs with mammary gland tumors.
Clinical significance of defective dendritic cell differentiation in cancer.
Clinical Significance of Folate Receptor ?-expressing Tumor-associated Macrophages in Pancreatic Cancer.
Clinical significance of hypoxia-inducible factor 1?, and its correlation with p53 and vascular endothelial growth factor expression in resectable esophageal squamous cell carcinoma.
Clinical significance of plasma D-dimer levels and serum VEGF levels in patients with hepatocellular carcinoma.
Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer.
Clinical significance of platelet derived growth factor-C and -D in gastric cancer.
Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery.
Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients.
Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers.
Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma.
Clinical Significance of Serum Vascular Endothelial Growth Factor, Pigment Epithelium-Derived Factor, Tumor Necrosis Factor Alpha, and Progranulin Levels in Patients with Gastric Cancer and Gastric Precancerous Lesions.
Clinical significance of survivin and vascular endothelial growth factor mRNA detection in the peripheral whole blood of breast cancer patients.
Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.
Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors.
Clinical significance of vascular endothelial growth factor (VEGF) in sera of patients with pediatric malignancies.
Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor.
Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma.
Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumors.
Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma.
Clinical significance of vascular endothelial growth factor expression in gastric cancer.
Clinical significance of vascular endothelial growth factor in patients with primary lung cancer.
Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients.
Clinical significance of VEGFR-2 and (18)F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy.
Clinical study on the safety, efficacy, and prognosis of molecular targeted drug therapy for advanced gastric cancer.
Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?
Clinical utility of vascular endothelial growth factor in diagnosing malignant pleural effusions.
Clinical value of TV-CDS combined with serum tumor markers in diagnosis of ovarian cancer.
Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis.
Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain.
Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer.
Clinicopathologic study of neovascularization and VEGF expression in superficial esophageal carcinoma.
Clinicopathological investigation of vascular endothelial growth factor and von hippel-lindau gene-related protein expression in immunohistochemically negative pituitary adenoma - possible involvement in tumor aggressiveness.
Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer.
Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-? phosphorylation, and microvessel density in gastric cancer.
Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas.
Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach.
Cloning of a cancer cell-producing hepatocyte growth factor, vascular endothelial growth factor, and interleukin-8 from gastric cancer cells.
Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells.
Close correlation between CXCR4 and VEGF expression and frequent CXCR7 expression in rhabdomyosarcoma.
Clotrimazole presents anticancer properties against a mouse melanoma model acting as a PI3K inhibitor and inducing repolarization of tumor-associated macrophages.
Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer.
Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma.
Co-expression of VEGF, c-Met and HGF/SF in secondary pleural tumors.
Co-suppression of VEGF-A and VEGF-C inhibits development of experimental hemangioma.
CO2 Pneumoperitoneum Effects on Molecular Markers of Tumor Invasiveness in SH-SY5Y Neuroblastoma Cells.
Co?O? nanoparticles with multi-enzyme activities and their application in immunohistochemical assay.
Coaxial extrusion bioprinted shell-core hydrogel microfibers mimic glioma microenvironment and enhance the drug resistance of cancer cells.
Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-?1a-treated multiple sclerosis.
Coexpressed High Levels of VEGF-C and Active MMP-9 Are Associated With Lymphatic Spreading and Local Invasiveness of Papillary Thyroid Carcinoma.
Coexpression of cyclooxygenase-2 and vascular endothelial growth factor in gastrointestinal stromal tumor: possible relations to pathological parameters and clinical behavior.
Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function.
Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways.
Coexpression of vascular endothelial growth factor and its receptor KDR on gastric adenocarcinoma MGC803 cell line and stimulation of exogenous VEGF(165) to MGC803 cells.
Coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the esophagus.
Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density.
Collagen VI Ablation Retards Brain Tumor Progression Due to Deficits in Assembly of the Vascular Basal Lamina.
Collateral Damage Intended-Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy.
Colon cancer: a civilization disorder.
Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice.
Colorectal cancer detection by biomarker quantification in noninvasively collected colorectal mucus: preliminary comparison of 24 protein biomarkers.
Colorectal carcinoma cell production of transforming growth factor beta decreases expression of endothelial cell vascular endothelial growth factor receptor 2.
Colorectal carcinoma cells (Caco-2) secrete stroma-inducing growth factors in a stroma-oriented direction.
Colorectal polypoid lesions and expression of vascular endothelial growth factor in a consecutive series of endoscopic and surgical patients.
Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels.
Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
Combination antiangiogenic therapy and radiation in head and neck cancers.
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Combination Efficacy of Astragalus membranaceus and Curcuma wenyujin at Different Stages of Tumor Progression in an Imageable Orthotopic Nude Mouse Model of Metastatic Human Ovarian Cancer Expressing Red Fluorescent Protein.
Combination gene therapy using VEGF-shRNA and fusion suicide gene yCDglyTK inhibits gastric carcinoma growth.
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice.
Combination of curcuma zedoary and kelp inhibits growth and metastasis of liver cancer in vivo and in vitro via reducing endogenous H2S levels.
Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/-) Mice Is Superior to Everolimus Alone.
Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice.
Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis.
Combination of low intensity electromagnetic field with chondrogenic agent induces chondrogenesis in mesenchymal stem cells with minimal hypertrophic side effects.
Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities.
Combination of mild therapeutic hypothermia and adipose-derived stem cells for ischemic brain injury.
Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder.
Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth.
Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1.
Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models.
Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats.
Combination of surgical resection and photodynamic therapy of 9L gliosarcoma in the nude rat.
Combination of vascular endothelial growth factor antisense oligonucleotide therapy and radiotherapy increases the curative effects against maxillofacial VX2 tumors in rabbits.
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model.
Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
Combination Therapy with Low Copper Diet, Penicillamine and Gamma Knife Radiosurgery Reduces VEGF and IL-8 In Patients with Recurrent Glioblastoma
Combination therapy with low molecular weight heparin and Adriamycin results in decreased breast cancer cell metastasis in C3H mice.
Combinations of Bevacizumab With Cancer Immunotherapy.
Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis.
Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy.
Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma.
Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer.
Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation.
Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.
Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement.
Combined effect of sCD40L and PI3K siRNA on transplanted tumours growth and microenvironment in nude mice with gastric cancer.
Combined effect of substance P and curcumin on cutaneous wound healing in diabetic rats.
Combined inhibition of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) for the treatment of macular edema of various etiologies: a short-term pilot study.
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
Combined oral carcinogenicity of HPV-16 and benzo(a)pyrene: an in vitro multistep carcinogenesis model.
Combined silencing of VEGF-A and angiopoietin-2, a more effective way to inhibit the Ishikawa endometrial cancer cell line.
Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis.
Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
Combined Treatment of Non-Small-Cell Lung Cancer Using Shenyi Capsule and Platinum-Based Chemotherapy: A Meta-Analysis and Systematic Review.
Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial.
Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC.
Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.
Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice.
Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis.
Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas.
Comparative analysis of hepatocellular carcinoma in men and dogs.
Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion.
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer.
Comparative gender differences in local and systemic concentrations of pro-inflammatory cytokines in rats with experimental periodontitis.
Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer.
Comparative study between VEGF-A and CA-125 in diagnosis and follow-up of advanced endometriosis after conservative laparoscopic surgery.
Comparative VEGF receptor tyrosine kinase modeling for the development of highly specific inhibitors of tumor angiogenesis.
Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer.
Comparison between 'in vivo' and 'in vitro' methods for evaluating tumor angiogenesis using cervical carcinoma as a model.
Comparison of (18)F-fluorodeoxyglucose PET/CT findings with vascular endothelial growth factors and receptors in colorectal cancer.
Comparison of Adipose-Derived and Bone Marrow Mesenchymal Stromal Cells in a Murine Model of Crohn's Disease.
Comparison of angiogenic factor levels in tumor drainage and peripheral venous blood from colorectal cancer patients.
Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model.
Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Advanced Renal Cell Carcinoma.
Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer.
Comparison of lymphatic vessel density and expression of VEGF-C and VEGF-D lymphangiogenic factors in Warthin's tumours and oncocytic adenomas.
Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix.
Comparison of Photoacoustically Derived Hemoglobin and Oxygenation Measurements with Contrast-Enhanced Ultrasound Estimated Vascularity and Immunohistochemical Staining in a Breast Cancer Model.
Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies.
Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.
Comparison of the effect of intravitreal bevacizumab and intravitreal fasudil on retinal VEGF, TNF?, and caspase 3 levels in an experimental diabetes model.
Comparison of two in vivo models for prostate cancer: orthotopic and intratesticular inoculation of LNCaP or PC-3 cells.
Comparison of VEGF-A secretion from tumor cells under cellular stresses in conventional monolayer culture and microfluidic three-dimensional spheroid models.
Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice.
Compartmentalisation of the inflammatory response following aneurysmal subarachnoid haemorrhage.
Compensatory angiogenesis and tumor refractoriness.
Compensatory Growth Factor and Cytokine Response in Tears After Subconjunctival Bevacizumab Injection.
Complement activation and cytokine response by BioProtein, a bacterial single cell protein.
Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.
Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
Complete remission of psoriasis following bevacizumab therapy for colon cancer.
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma.
Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer.
Composition and Mechanism of Antitumor Effects of Hericium erinaceus Mushroom Extracts in Tumor-Bearing Mice.
Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma.
Comprehensive transcriptome of proteases and protease inhibitors in vascular cells.
Computational Model of Gab1/2-Dependent VEGFR2 Pathway to Akt Activation.
Computational model of VEGFR2 pathway to ERK activation and modulation through receptor trafficking.
Concentrated ascites re-infusion therapy for pseudo-Meigs' syndrome complicated by massive ascites in large pedunculated uterine leiomyoma.
Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors.
Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer.
Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients.
Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas.
Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients.
Concomitant tumour resistance in patients with osteosarcoma. A clue to a new therapeutic strategy.
Concomitant vascular GRP-receptor and VEGF-receptor expression in human tumors: molecular basis for dual targeting of tumoral vasculature.
Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non-small-cell Lung Cancer: Study Protocol for an Open-label Randomized Controlled Trial.
Concurrent expression of angiogenic growth factors and neovascularization during tumourigenesis in colorectal carcinoma patients.
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma.
Concurrent minimal change disease and retroperitoneal liposarcoma successfully treated by tumor resection and steroid therapy.
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.
Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal.
Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF.
Conformational latitude - activity relationship of KPPR tetrapeptide analogues toward their ability to inhibit binding of vascular endothelial growth factor 165 to neuropilin-1.
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Emerging and Investigational Therapties for the Treatment of Adults With Metastatic Brain Tumors.
Connexin 43 suppresses tumor angiogenesis by down-regulation of vascular endothelial growth factor via hypoxic-induced factor-1?.
Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Constitutive and inducible expression and regulation of vascular endothelial growth factor.
Constitutive and stimulated production of VEGF by human megakaryoblastic cell lines: effect on proliferation and signaling pathway.
Constitutive and tumor necrosis factor-?-induced activation of nuclear factor-?B in adenomyosis and its inhibition by andrographolide.
Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma.
Constitutive upregulation of hypoxia-inducible factor-1alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure.
Constitutively active CCK2 receptor splice variant increases Src-dependent HIF-1 alpha expression and tumor growth.
Constructing Tumor Vaccines Targeting for Vascular Endothelial Growth Factor (VEGF) by DNA Shuffling.
Construction of an AuHQ nano-sensitizer for enhanced radiotherapy efficacy through remolding tumor vasculature.
Consumption of Polyphenol-Rich Zingiber Zerumbet Rhizome Extracts Protects against the Breakdown of the Blood-Retinal Barrier and Retinal Inflammation Induced by Diabetes.
Contactin 1: An Important and Emerging Oncogenic Protein Promoting Cancer Progression and Metastasis.
Continuous angiogenesis inhibition in the treatment for von Hippel-Lindau-related hemangioblastomas of retina and spinal cord.
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology.
Contralateral meningeal artery supply of paramedian meningiomas.
Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.
Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.
Contrast-enhanced Ultrasound Imaging of Antiangiogenic Tumor Therapy.
Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Contribution of the clock gene DEC2 to VEGF mRNA upregulation by modulation of HIF1? protein levels in hypoxic MIO-M1 cells, a human cell line of retinal glial (Müller) cells.
Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells.
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.
Control of tumour vascular permeability.
Controlled angiogenesis in the heart by cell-based expression of specific vascular endothelial growth factor levels.
Controlling escape from angiogenesis inhibitors.
Convergence: Lactosylceramide-Centric Signaling Pathways Induce Inflammation, Oxidative Stress, and Other Phenotypic Outcomes.
Converging Perturbed Microvasculature and Microglial Clusters Characterize Alzheimer Disease Brain.
Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells.
Cooperation between ZEB2 and Sp1 promotes cancer cell survival and angiogenesis during metastasis through induction of survivin and VEGF.
Cooperation of Indian Hedgehog and Vascular Endothelial Growth Factor in Tumor Angiogenesis and Growth in Human Hepatocellular Carcinomas, an Immunohistochemical Study.
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.
Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development.
Cordycepin prevents the esophageal stricture formation in the alkali-burn rat model by exerting anti-inflammatory and antifibrotic effects.
Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro.
Correlation Analysis of Nasopharyngeal Carcinoma TNM Staging with Serum EA IgA and VCA IgA in EBV and VEGF-C and -D.
Correlation and Significance of Urinary Soluble Fas and Vascular Endothelial Growth Factor in Bladder Urothelial Cancer.
Correlation between biological marker expression and F-fluorodeoxyglucose uptake in cervical cancer measured by positron emission tomography.
Correlation between CT perfusion parameters and microvessel density and vascular endothelial growth factor in adrenal tumors.
Correlation Between Cyclo-oxygenase-2 and Vascular Endothelial Growth Factor Expression in Canine and Feline Squamous Cell Carcinomas.
Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma.
Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
Correlation Between Magnetic Resonance Imaging-Based Evaluation of Extramural Vascular Invasion and Prognostic Parameters of T3 Stage Rectal Cancer.
Correlation between PAI-1, leptin and ferritin with HOMA in HIV/AIDS patients.
Correlation Between PSMA and VEGF Expression as Markers for LNCaP Tumor Angiogenesis.
Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors.
Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy.
Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas.
Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma.
Correlation between Vascular Endothelial Growth Factor C Expressior and Lymph Node Micrometastasis and Prognosis in Patients with pNO Esophageal Squamous Cell Carcinomas.
Correlation between vascular endothelial growth factor expression and presence of lymph node metastasis in advanced squamous cell carcinoma of the larynx.
Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous cell carcinoma.
Correlation between VEGF expression and angiogenesis in breast carcinoma.
Correlation of a priori DCE-MRI and (1)H-MRS data with molecular markers in neck nodal metastases: Initial analysis.
Correlation of angiogenesis with (18)F-FMT and (18)F-FDG uptake in non-small cell lung cancer.
Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors.
Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma.
Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma.
Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma.
Correlation of gene polymorphisms of vascular endothelial growth factor with grade and prognosis of lung cancer.
Correlation of hypoxia as measured by fluorine-18 fluoroerythronitroimidazole (18F-FETNIM) PET/CT and overall survival in glioma patients.
Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer.
Correlation of intratumoral lymphatic microvessel density, vascular endothelial growth factor C and cell proliferation in salivary gland tumors.
Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer.
Correlation of Serum Biomarkers in Adults with Single Ventricles with Strain and Strain Rate Using 2D Speckle Tracking.
Correlation of serum intercellular adhesion molecule 1 and vascular endothelial growth factor with tumor grading and staging in breast cancer patients.
Correlation of serum levels of vascular endothelial growth factor with TNM staging, histopathologic grading, and surgical therapy for oral squamous cell carcinoma.
Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer.
Correlation of Synovial Fluid Biomarkers With Cartilage Pathology and Associated Outcomes in Knee Arthroscopy.
Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer.
Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma.
Correlation of vascular endothelial growth factor and vascular endothelial growth factor receptor-1 levels in serum and thyroid nodules with histopathological and radiological variables.
Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia.
Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.
Correlation of Vascular Endothelial Growth Factor Expression With Tumor Recurrence and Poor Prognosis in Patients With pN0 Gastric Cancer.
Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas.
Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer.
Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells.
Correlation of VEGF with contrast enhancement on dual-phase dynamic helical CT in liver tumors: preliminary study.
Correlations between CT perfusion parameters and vascular endothelial growth factor expression and microvessel density in implanted VX2 lung tumors.
Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer.
Correlations between VEGF-A expression and prognosis in patients with gastric adenocarcinoma.
Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters.
Correlations of TNM staging and lymph node metastasis of gastric cancer with MRI features and VEGF expression.
Correlations of vascular architecture and angiogenesis with pituitary adenoma histotype.
Correspondence re: DC Lev et al., Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther, 2003;2(8):753-63.
Correspondence re: K. Heer et al., serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin. Cancer Res., 7: 3491-3494, 2001.
Correspondence re: M. L. George et al., Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin. Cancer Res., 6: 3147-3152, 2000.
Correspondence re: M.L. George [correction of H.L. George] et al., Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin. Cancer Res., 6: 3147-3152, 2000.
Correspondence re: P. Salven et al., leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin. Cancer Res., 5: 487-91, 1999.
Costunolide suppresses an inflammatory angiogenic response in a subcutaneous murine sponge model.
Coupling in vitro and in vivo paradigm reveals a dose dependent inhibition of angiogenesis followed by initiation of autophagy by C6-ceramide.
COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study.
COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models.
COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo.
COX?2 inhibition in the endothelium induces glucose metabolism normalization and impairs tumor progression.
CREB3L4 promotes angiogenesis and tumor progression in gastric cancer through regulating VEGFA expression.
Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration.
CRISPR/Cas13a Signal Amplification Linked Immunosorbent Assay for Femtomolar Protein Detection.
Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers.
Critical roles of AMP-activated protein kinase in the carcinogenic metal-induced expression of VEGF and HIF-1 proteins in DU145 prostate carcinoma.
Cross-species array comparative genomic hybridization identifies novel oncogenic events in zebrafish and human embryonal rhabdomyosarcoma.
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.
Cross-talk between endothelial and tumor cells via basic fibroblast growth factor and vascular endothelial growth factor signaling promotes lung cancer growth and angiogenesis.
Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.
Crosstalk between angiogenesis and lymphangiogenesis in tumor progression.
Crystal structure of the complex between VEGF and a receptor-blocking peptide.
CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases.
CT spectral imaging for monitoring the therapeutic efficacy of VEGF receptor kinase inhibitor AG-013736 in rabbit VX2 liver tumours.
Curcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors.
Curcumin delays development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors.
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Curcumin improves prostanoid ratio in diabetic mesenteric arteries associated with cyclooxygenase-2 and NF-?B suppression.
Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer.
Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition.
Curcumin inhibits the lymphangiogenesis of gastric cancer cells by inhibiton of HMGB1/VEGF-D signaling.
Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors.
Curcumin Prevents Experimental Diabetic Retinopathy in Rats Through Its Hypoglycemic, Antioxidant, and Anti-Inflammatory Mechanisms.
Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas.
Current approaches to the management of diabetic retinopathy and diabetic macular oedema.
Current biomarkers of canine mammary tumors.
Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.
Current concepts on ocular vascular abnormalities in the phakomatoses.
Current management and future perspectives of metastatic renal cell carcinoma.
Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer.
Current status of angiogenesis inhibitors combined with radiation therapy.
Current status of anti-vascular endothelial growth factor therapy in Europe.
Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration.
Current strategies for modulating lymphangiogenesis signalling pathways in human disease.
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Cutaneous thrombogenic vasculopathy associated with bevacizumab therapy.
CXC receptor-1 silencing inhibits androgen-independent prostate cancer.
CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer.
CXCL10 promotes invasion-related properties in human colorectal carcinoma cells.
CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization.
CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex.
CXCR4 is a prognostic marker that inhibits the invasion and migration of gastric cancer by regulating VEGF expression.
CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis.
CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway.
CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway.
CXCR7 regulates breast tumor metastasis and angiogenesis in vivo and in vitro.
CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression.
Cyclin I mRNA expression correlates with kinase insert domain receptor expression in human epithelial ovarian cancer.
CyclinD1, p53, E-cadherin, and VEGF discordant expression in paired regional metastatic lymph nodes of esophageal squamous cell carcinoma: A tissue array analysis.
Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer.
Cyclo-oxygenase-2 expression is associated with vascular endothelial growth factor C expression and lymph node metastasis in oral squamous cell carcinoma.
Cycloamylose-nanogel drug delivery system-mediated intratumor silencing of the vascular endothelial growth factor regulates neovascularization in tumor microenvironment.
Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.
Cyclooxygenase 2-mediated apoptotic and inflammatory responses in photodynamic therapy treated breast adenocarcinoma cells and xenografts.
Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma.
Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer.
Cyclooxygenase-2 expression in an adenoid cystic carcinoma of the uterine cervix.
Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase.
Cyclooxygenase-2 inhibitor SC-236 [4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1-pyrazol-1-l] benzenesulfonamide] suppresses nuclear factor-kappaB activation and phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and c-Jun N-terminal kinase in human mast cell line cells.
Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response.
Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer.
Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma.
Cyclooxygenase-2 promotes prostate cancer progression.
Cyclosporin A abrogates the acquired immunity to cutaneous reinfection with the parapoxvirus orf virus.
Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine.
Cyperenoic acid, a sesquiterpene derivative from Croton crassifolius, inhibits tumor growth through anti-angiogenesis by attenuating VEGFR2 signal pathway in breast cancer.
Cyr61 promotes breast tumorigenesis and cancer progression.
Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.
Cytokine and chemokine tear levels in patients with uveitis.
Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Cytokine and growth factor responses after radiotherapy for localized ependymoma.
Cytokine and hormonal profile in blood serum and follicular fluids during ovarian stimulation with the multidose antagonist or the long agonist protocol.
Cytokine dysregulation in children with cerebral palsy.
Cytokine dysregulation persists in childhood post Neonatal Encephalopathy.
Cytokine Effects on Mechano-Induced Electrical Activity in Atrial Myocardium.
Cytokine expression in human osteoblasts after antiseptic treatment: a comparative study between polyhexanide and chlorhexidine.
Cytokine expression in tears of patients with glaucoma or dry eye disease: A prospective, observational cohort study.
Cytokine gene polymorphisms and breast cancer susceptibility and prognosis.
Cytokine pattern in Kaposi's sarcoma associated with immune restoration disease in HIV and tuberculosis co-infected patients.
Cytokine production by infrapatellar fat pad can be stimulated by interleukin 1? and inhibited by peroxisome proliferator activated receptor ? agonist.
Cytokine production in the infrapatellar fat pad: another source of cytokines in knee synovial fluids.
Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro.
Cytokine profile in cases with premature elevation of progesterone serum concentrations during ovarian stimulation.
Cytokine profile in multiple myeloma.
Cytokine profile in synovial fluid from patients with internal derangement of the temporomandibular joint: a preliminary study.
Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis.
Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease.
Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages.
Cytokine release following recruitment maneuvers.
Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells.
Cytokine targets in the treatment of myelodysplastic syndromes.
Cytokines and bullous pemphigoid.
Cytokines and growth factors in mostly atherosclerotic patients on hemodialysis determined by biochip array technology.
Cytokines and Postoperative Delirium in Older Patients Undergoing Major Elective Surgery.
Cytokines and signal transduction.
Cytokines as biochemical markers for knee osteoarthritis.
Cytokines associated with hemorrhage in proliferative diabetic retinopathy.
Cytokines associated with the pathophysiology of aggressive fibromatosis.
Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.
Cytokines in saliva increase in head and neck cancer patients after treatment.
Cytokines profile of reverse cardiac remodeling following transcatheter aortic valve replacement.
Cytokines, Angiogenesis, and Extracellular Matrix Degradation are Augmented by Oxidative Stress in Endometriosis.
Cytokines, matrix metalloproteases, angiogenic and growth factors in tears of normal subjects and vernal keratoconjunctivitis patients.
Cytomegalovirus promotes murine glioblastoma growth via pericyte recruitment and angiogenesis.
Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer.
Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma.
Cytotoxic and Antimicrobial Evaluations of Novel Apoptotic and Anti-Angiogenic Spiro Cyclic 2-Oxindole Derivatives of 2-Amino-tetrahydroquinolin-5-one.
Cytotoxic and proapototic activities of imidoselenocarbamate derivatives are dependent on the release of methylselenol.
Cytotoxic Effect of Immunotoxin Containing The Truncated Form of Pseudomonas Exotoxin A and Anti-VEGFR2 on HUVEC and MCF-7 Cell Lines.
Cytotoxic T lymphocyte-dependent tumor growth inhibition by a vascular endothelial growth factor-superantigen conjugate.
Data Mining, Network Pharmacology, and Molecular Docking Explore the Effects of Core Traditional Chinese Medicine Prescriptions in Patients with Rectal Cancer and Qi and Blood Deficiency Syndrome.
DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop.
Deadly Proliferation and Transformation of Pilocytic Astrocytoma in Pregnancy.
Deciphering the roles of macrophages in developmental and inflammation stimulated lymphangiogenesis.
Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
Decrease of CD68 and MMP-3 expression in synovium by treatment of adalimumab for rheumatoid arthritis.
Decreased adiponectin links elevated adipose tissue autophagy with adipocyte endocrine dysfunction in obesity.
Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.
Decreased expression of carbonyl reductase 1 promotes ovarian cancer growth and proliferation.
Decreased secretion of vascular endothelial growth factor is associated with increased apoptosis in vascular tumor derived endothelial cells.
Decreased serum angiogenin level in Alzheimer's disease.
Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model.
Decreased vascular endothelial growth factor expression associated with tumor regression induced by (E)-2'-deoxy-2'-(fluoromethylene)cytidine (MDL 101,731).
Deeper Penetration into Tumor Tissues and Enhanced in Vivo Antitumor Activity of Liposomal Paclitaxel by Pretreatment with Angiogenesis Inhibitor SU5416.
Defect in early lung defence against Pseudomonas aeruginosa in DBA/2 mice is associated with acute inflammatory lung injury and reduced bactericidal activity in naive macrophages.
Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.
Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors.
Deferoxamine modulates cytokines and growth factors to accelerate cutaneous wound healing in diabetic rats.
Definition of two angiogenic pathways by distinct alpha v integrins.
Deguelin-an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by down-regulation of vascular endothelial cell growth factor-D in lung tumor model.
Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor.
Deletion of IL-33R attenuates VEGF expression and enhances necrosis in mammary carcinoma.
Deletion of Opg Leads to Increased Neovascularization and Expression of Inflammatory Cytokines in the Lumbar Intervertebral Disc of Mice.
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis.
Delphinidin inhibits angiogenesis through the suppression of HIF-1? and VEGF expression in A549 lung cancer cells.
Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Demethylation by 5-aza-2'-deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer cell lines.
Dendrimer-Stabilized Gold Nanostars as a Multifunctional Theranostic Nanoplatform for CT Imaging, Photothermal Therapy, and Gene Silencing of Tumors.
Dendritic cell infiltration in colon cancer.
Dendritic Cell Infiltration in Colon Cancer.
Dengue virus type 2 modulates endothelial barrier function through CD73.
Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Density of Gr1-positive myeloid precursor cells, p-STAT3 expression and gene expression pattern in canine mammary cancer metastasis.
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
Depot-related gene expression in human subcutaneous and omental adipocytes.
Design of Oligonucleotide Carriers: Importance of Polyamine Chain Length.
Design, synthesis and antitumor evaluation of novel thalidomide dithiocarbamate and dithioate analogs against Ehrlich ascites carcinoma-induced solid tumor in Swiss albino mice.
Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors.
Design, synthesis and biological evaluation of uracil derivatives as novel VEGFR-2 inhibitors.
Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents.
Design, synthesis, and evaluation of imidazo[1,2-b]pyridazine derivatives having a benzamide unit as novel VEGFR2 kinase inhibitors.
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
Design, synthesis, and screening of novel ursolic acid derivatives as potential anti-cancer agents that target the HIF-1? pathway.
Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers.
Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b.
Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells.
Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-ct following treatment with VEGFR-2 blocking antibodies.
Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes.
Detection and Quantification of VEGF Isoforms by ELISA.
Detection of bone marrow micrometastasis in esophageal cancer patients by immunomagnetic separation.
Detection of bone marrow micrometastasis in gastric cancer patients by immunomagnetic separation.
Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor.
Detection of extracellular matrix modification in cancer models with inverse spectroscopic optical coherence tomography.
Detection of HDM2 and VEGF co-expression in cancer cell lines: novel effect of HDM2 antisense treatment on VEGF expression.
Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target.
Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings.
Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells.
Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens.
Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients.
Determination of molecular marker expression can predict clinical outcome in colon carcinomas.
Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets.
Development and Characterization of a Camelid Single Domain Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2.
Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice.
Development of a bead-based multiplex assay for the simultaneous detection of porcine inflammation markers using xMAP technology.
Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.
Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.
Development of a molecularly imprinted polymer tailored on disposable screen-printed electrodes for dual detection of EGFR and VEGF using nano-liposomal amplification strategy.
Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization.
Development of a Novel Anti-HIF-1? Screening System Coupled with Biochemical and Biological Validation for Rapidly Selecting Potent Anti-Cancer Compounds.
Development of a phage display-mediated immunoassay for the detection of vascular endothelial growth factor.
Development of an interactive tumor vascular suppression strategy to inhibit multidrug resistance and metastasis with pH/H2O2 responsive and oxygen-producing nanohybrids.
Development of antibody-based c-Met inhibitors for targeted cancer therapy.
Development of monoclonal antibodies for the treatment of colorectal cancer.
Development of POEMS syndrome after an initial manifestation of solitary plasmacytoma.
Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
Development of targeted angiogenic medicine.
Development of time-resolved immunofluorometric assays for vascular endothelial growth factor and application on plasma of patients with gastric tumours.
Development of Two-Component Nanorod Complex for Dual-Fluorescence Imaging and siRNA Delivery.
Development of vitreous haemorrhage during treatment with bevacizumab for metastatic rectal cancer.
Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells.
Dextranated poly(urethane amine)s designed for systemic gene delivery in ovarian cancer therapy.
Diabetic Retinopathy and Vascular Endothelial Growth Factor Gene Insertion/Deletion Polymorphism.
Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma.
Diagnostic and prognostic value of CEP55 in clear cell renal cell carcinoma as determined by bioinformatics analysis.
Diagnostic and therapeutic implications of the vascular endothelial growth factor family in cancer.
Diagnostic potential of differentially regulated microRNAs among endometriosis, endometrioid ovarian cancer, and endometrial cancer.
Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis.
Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non-small cell lung cancer.
Diagnostic value of serum VEGF in women with ovarian tumors.
Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction.
Dietary 2-deoxy-D-glucose impairs tumour growth and metastasis by inhibiting angiogenesis.
Dietary inflammatory index® and cortical bone outcomes in healthy adolescent children.
Dietary oleuropein inhibits tumor angiogenesis and lymphangiogenesis in the B16F10 melanoma allograft model: a mechanism for the suppression of high-fat diet-induced solid tumor growth and lymph node metastasis.
Dietary walnuts inhibit colorectal cancer growth in mice by suppressing angiogenesis.
Difference in Immunosuppressive Cells Between Peritumoral Area and Tumor Core in Glioblastoma.
Differences in Neuregulin 4 Expression in Children: Effects of Fat Depots and Obese Status.
Differences in vascular endothelial growth factor receptor expression and correlation with the degree of enhancement in medulloblastoma.
Different angiogenic pathways characterize superficial and invasive bladder cancer.
Different angiogenic pathways in human cervical cancers.
Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Different combination schedules of gemcitabine with endostar affect antitumor efficacy.
Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells.
Different expression of VEGF and EGFL7 in human hepatocellular carcinoma.
Different expressions of protein kinase C-alpha, betaI and betaII in glomeruli of diabetic nephropathy patients.
Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma.
Different progression of tumor xenografts between mucin-producing and mucin-non-producing mammary adenocarcinoma-bearing mice.
Different responsiveness of endothelial cells to vascular endothelial growth factor and basic fibroblast growth factor added to culture media under gravity and simulated microgravity.
Different role of COX-2 and angiogenesis in canine inflammatory and non-inflammatory mammary cancer.
Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Differential cytokine expression in skin graft healing in inducible nitric oxide synthase knockout mice.
Differential cytotoxic effects of sodium meta-arsenite on human cancer cells, dental papilla stem cells and somatic cells correlate with telomeric properties and gene expression.
Differential effect of hepatocyte growth factor and tumor growth factor-beta on early release of vascular endothelial growth factor from HepG2 cells: possible implications in post-transplant liver regeneration.
Differential Effect of Intraperitoneal Albendazole and Paclitaxel on Ascites Formation and Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Cell-Bearing Athymic Nude Mice.
Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusion.
Differential effects of antiangiogenic compounds in neovascularization, leukocyte recruitment, VEGF production, and tumor growth in mice.
Differential effects of black raspberry and strawberry extracts on BaPDE-induced activation of transcription factors and their target genes.
Differential effects of control and antigen-specific T cells on intracellular mycobacterial growth.
Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma.
Differential Effects of VEGFR-1 and VEGFR-2 Inhibition on Tumor Metastases Based on Host Organ Environment.
Differential Expression and Regulation of the Vascular Endothelial Growth Factor Receptors Neuropilin-1 and Neuropilin-2 in Rat Uterus**This work was supported by Grant HD-27468 (to V.M. and K.M.B.), Grant NS-01636 (to V.M.), and Grant NS-37179 (to K.M.B.). The automated DNA sequencing was performed in the Vermont Cancer Center DNA Analysis Facility and was supported in part by Grant P30-CA-22435 from the NCI. The views expressed are those of the authors and do not represent the views of the NCI.
Differential expression of angiogenic cytokines by cell lines and primary cultures of human prostate cancer.
Differential Expression of CD3, TNF-?, and VEGF Induced by Olanzapine on the Spleen of Adult Male Albino Rats and the Possible Protective Role of Vitamin C.
Differential expression of hypoxia inducible factor-1 alpha and tumor cell proliferation between squamous cell carcinomas and adenocarcinomas among operable non-small cell lung carcinomas.
Differential Expression of mRNA in Human Monocytes following Interaction with Human Colon Cancer Cells.
Differential expression of multidrug resistance?related proteins in adriamycin?resistant (pumc?91/ADM) and parental (pumc?91) human bladder cancer cell lines.
Differential expression of stem cell markers and vascular endothelial growth factor in human retinoblastoma tissue.
Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder.
Differential expression of VEGF ligands and receptors in prostate cancer.
Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats.
Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants.
Differential Protein Expression Profiles in Glaucomatous Trabecular Meshwork: An Evaluation Study on a Small Primary Open Angle Glaucoma Population.
Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors.
Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells.
Differentiation and angiogenic growth factor message in two mammalian lens epithelial cell lines.
Differentiation of tumours of ductal and lobular origin: I. Proteomics of invasive ductal and lobular breast carcinomas.
Diffuse neonatal hemangiomatosis without cutaneous lesions in an adult--a case report.
Dihydroxystilbenes prevent azoxymethane/dextran sulfate sodium-induced colon cancer by inhibiting colon cytokines, a chemokine, and programmed cell death-1 in C57BL/6J mice.
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting.
Dimethyloxalylglycine, a small molecule, synergistically increases the homing and angiogenic properties of human mesenchymal stromal cells when cultured as 3D spheroids.
Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment.
Direct and Precise Measurement of Bevacizumab Levels in Human Plasma Based on Controlled Methionine Oxidation and Multiple Reaction Monitoring.
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.
Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.
Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in?vitro Biological Evaluation.
Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor.
Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
Discovery of novel nonpeptide small-molecule NRP1 antagonists: Virtual screening, molecular simulation and structural modification.
Discovery of novel picolinamide-based derivatives as novel VEGFR-2 kinase inhibitors: synthesis, in vitro biological evaluation and molecular docking.
Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
Discovery of Small Molecules for Repressing Cap-Independent Translation of Human Vascular Endothelial Growth Factor (hVEGF) as Novel Antitumor Agents.
Discovery of Small Molecules that Target Vascular Endothelial Growth Factor Receptor-2 Signalling Pathway Employing Molecular Modelling Studies.
Discovery of structure-based small molecular inhibitor of ?B-crystallin against basal-like/triple-negative breast cancer development in vitro and in vivo.
Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma.
Discrimination of exudative pleural effusions based on multiple biological parameters.
Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients.
Disrupting VEGF-VEGFR1 Interaction: De Novo Designed Linear Helical Peptides to Mimic the VEGF
Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion.
Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition.
Dissecting the roles of Ephrin-A3 in malignant peripheral nerve sheath tumor by TALENs.
Distinct APE1 Activities Affect the Regulation of VEGF Transcription Under Hypoxic Conditions.
Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis.
Distinct signaling pathways confer different vascular responses to VEGF 121 and VEGF 165.
Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour cells after photodynamic therapy.
Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro.
Distribution of VEGF and flt-1 in the normal dog tissues.
Diversity in tumor territory of meningioma: Protein expression in vascular endothelial growth factor and epidermal growth factor.
Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth.
Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
DMBA-induced mammary pathologies are angiogenic in vivo and in vitro.
DNA demethylation of vascular endothelial growth factor-C is associated with gene expression and its possible involvement of lymphangiogenesis in gastric cancer.
Do nutritional supplements lower the risk of stroke or hypertension?
Do serum angiogenic growth factors provide additional information to that of conventional markers in monitoring the course of metastatic breast cancer?
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2.
Does a growing tumour volume induce lymphangiogenesis? A study of oral/oropharyngeal cancer.
Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene.
Does immunostaining effectively upstage colorectal cancer by identifying micrometastatic nodal disease?
Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
Does the compromised sleep and circadian disruption of night and shiftworkers make them highly vulnerable to 2019 coronavirus disease (COVID-19)?
Does the EGFR and VEGF expression predict the prognosis in colon cancer?
Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?
Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia.
Dopamine: an old target in a new therapy.
Dose dependent effects of cadmium on tumor angiogenesis.
Dose-dependency of resveratrol in providing health benefits.
Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis.
Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668.
Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization.
Down-Regulation of Hypoxia-Inducible Factor-1alpha by Hyperbaric Oxygen Attenuates the Severity of Acute Pancreatitis in Rats.
Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells.
Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation.
Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma.
Down-regulation of platelet-derived growth factor-D expression blockades NF-?B pathway to inhibit cell proliferation and invasion as well as induce apoptosis in esophageal squamous cell carcinoma.
Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling.
Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis.
Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition in colon cancer.
Downregulating hypoxia-inducible factor 1 alpha augments transcatheter arterial embolization to treat hepatocellular carcinomas in rats.
Downregulation of angiogenic factors in Ewing tumor xenografts by the combination of human interferon-alpha or interferon-beta with ifosfamide.
Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization.
Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype.
Downregulation of fibroblast growth factor 5 inhibits cell growth and invasion of human nonsmall-cell lung cancer cells.
Downregulation of PDGF-D Inhibits Proliferation and Invasion in Breast Cancer MDA-MB-231 Cells.
Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy.
Downregulation of Tie2 gene by a novel antitumor sulfolipid, 3'-sulfoquinovosyl-1'-monoacylglycerol, targeting angiogenesis.
Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer.
Downregulation of Vascular Endothelial Growth Factor Enhances Chemosensitivity by Induction of Apoptosis in Hepatocellular Carcinoma Cells.
Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells.
Downregulation of VEGF and upregulation of TL1A expression induce HUVEC apoptosis in response to high glucose stimuli.
Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms.
Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Doxorubicin exhibits strong and selective association with VEGF Pu22 G-quadruplex.
Droplet Array-Based 3D Coculture System for High-Throughput Tumor Angiogenesis Assay.
Drug development for cancer chemoprevention: focus on molecular targets.
Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.
Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Dual functions of STAT3 in LPS-induced angiogenesis of hepatocellular carcinoma.
Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside.
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
Dual Inhibition of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor is an Effective Chemopreventive Strategy in the Mouse 4-NQO Model of Oral Carcinogenesis.
Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma.
Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells.
Dual Receptor-Specific Peptides Modified Liposomes as VEGF siRNA Vector for Tumor-Targeting Therapy.
Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.
Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.
Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo.
Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages.
Ductal carcinoma in situ of the breast with osteoclast-like giant cells.
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.
During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium.
Dynamic contrast-enhanced (DCE) MRI assessment of microvascular characteristics in the murine orthotopic pancreatic cancer model.
Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis.
Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.
Dynamic expression of tumor necrosis factor-alpha and vascular endothelial growth factor in rat model of pulmonary emphysema induced by smoke exposure.
Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models.
Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma.
Dysphonia after Bevacizumab Rechallenge: A Case Report.
Dysregulated alveolar function and complications in smokers following oesophagectomy.
Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model.
E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.
Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.
Early Assessment of Tumor Response to Gefitinib Treatment by Noninvasive Optical Imaging of Tumor Vascular Endothelial Growth Factor Expression in Animal Models.
Early blood pressure alterations are associated with pro-inflammatory markers in type 1 diabetes mellitus.
Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study.
Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer.
Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway.
Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G).
Early versus late distant metastasis and adjuvant chemotherapy alone versus both radiotherapy and chemotherapy in molecular apocrine breast cancer.
Early wound healing exhibits cytokine surge without evidence of hypoxia.
Easy Surface Functionalization and Bioconjugation of Peptides as Capture Agents of a Microfluidic Biosensing Platform for Multiplex Assay in Serum.
EBNA3C can modulate the activities of the transcription factor Necdin in association with metastasis suppressor protein Nm23-H1.
Economics of ramucirumab for metastatic colorectal cancer.
Ecto-5'-Nucleotidase (CD73) Deficiency in Mycobacterium tuberculosis-Infected Mice Enhances Neutrophil Recruitment.
Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis.
Ectopic expression of vascular endothelial growth factor (VEGF) by C6 glioma cells does not increase tumour growth in vivo despite an increase in angiogenesis.
EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma.
Effect and clinical significance of fast-track surgery combined with laparoscopic radical gastrectomy on the plasma level of vascular endothelial growth factor in gastric antrum cancer.
Effect and mechanism analysis of siRNA in inhibiting VEGF and its anti-angiogenesis effects in human osteosarcoma bearing rats.
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.
Effect of amentoflavone on the inhibition of pulmonary metastasis induced by B16F-10 melanoma cells in C57BL/6 mice.
Effect of Ampelopsis Radix on wound healing in scalded rats.
Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.
Effect of Asthma on Erectile Dysfunction in Rats as Determined by Biological Network Analysis.
Effect of atorvastatin on diabetic rat endothelial cells and retinal lesions.
Effect of Atorvastatin on Wound Healing in Rats.
Effect of autologous transplant of peripheral blood mononuclear cells in combination with proangiogenic factors during experimental revascularization of lower limb ischemia.
Effect of Avastin on the number and structure of tumor blood vessels of nude mice with A549 lung adenocarcinoma.
Effect of bevacizumab on the tight junction proteins of vascular endothelial cells.
Effect of Biochanin A on Retina Levels of Vascular Endothelial Growth Factor, Tumor Necrosis Factor-Alpha and Interleukin-1Beta in Rats with Streptozotocin-Induced Diabetes.
Effect of biologic therapies targeting TNF-alpha on cutaneous mesenchymal stem cells in psoriasis.
Effect of Blocking of Neuropeptide Y Y2 Receptor on Tumor Angiogenesis and Progression in Normal and Diet-Induced Obese C57BL/6 Mice.
Effect of Bone Marrow Mesenchymal Stem Cell Transplant on Synovial Proliferation in Rats With Type II Collagen-Induced Arthritis.
Effect of CCL2 siRNA on proliferation and apoptosis in the U251 human glioma cell line.
Effect of chitosan particles and dexamethasone on human bone marrow stromal cell osteogenesis and angiogenic factor secretion.
Effect of Chondroitin Sulphate on Pro-Inflammatory Mediators and Disease Activity in Patients with Inflammatory Bowel Disease.
Effect of cineole, alpha-pinene, and camphor on survivability of skin flaps
Effect of cortisol on cell proliferation and the expression of lipoprotein lipase and vascular endothelial growth factor in a human osteosarcoma cell line.
Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids.
Effect of Decorin and Bevacizumab on oxygen-induced retinopathy in rat models: A comparative study.
Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents.
Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis.
Effect of electro-acupuncture on tumor necrosis factor-? and vascular endothelial growth factor in peripheral blood and joint synovia of patients with rheumatoid arthritis.
Effect of endothelial progenitor cells in neovascularization and their application in tumor therapy.
Effect of ER?-regulated ERK1/2 signaling on biological behaviors of prostate cancer cells.
Effect of Ficus carica leaf extract on the gene expression of selected factors in HaCaT cells.
Effect of ginsenoside-Rg3 on the expression of VEGF and TNF-? in retina with diabetic rats.
Effect of high cell density on the growth properties of tumor cells: a role in tumor cytotoxicity of chemotherapeutic drugs.
Effect of Huaier on Melanoma Invasion, Metastasis, and Angiogenesis.
Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models.
Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma.
Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients.
Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors.
Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts.
Effect of Intranasal Instillation of Lipopolysaccharide on Lung Development and Its Related Mechanism in Newborn Mice.
Effect of intraocular surgery and ketamine on aqueous and serum cytokines.
Effect of intratumoral lymphocyte density on the disease-free survival and overall survival in malignant epithelial tumors of the ovary.
Effect of ketoprofen in topical formulation on vascular endothelial growth factor expression and tumor growth in nude mice with osteosarcoma.
Effect of Liuweidihuang pill and Jinkuishenqi pill on inhibition of spontaneous breast carcinoma growth in mice.
Effect of Low Molecular Weight Oligopeptides Isolated from Sea Cucumber on Diabetic Wound Healing in db/db Mice.
Effect of low-frequency low-intensity ultrasound with microbubbles on prostate cancer hypoxia.
Effect of mast cells on tumor angiogenesis in lung cancer.
Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer.
Effect of memantine on the survival of an ischemic random skin flap and the underlying mechanism.
Effect of multimodality therapy on ciculating vascular endothelial growth factor levels in patients with oesophagal cancer.
Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer.
Effect of Niacin on Inflammation and Angiogenesis in a Murine Model of Ulcerative Colitis.
Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma.
Effect of Non-Surgical Periodontal Treatment on Gingival Crevicular Fluid and Serum Endocan, Vascular Endothelial Growth Factor-A, and Tumor Necrosis Factor-Alpha Levels.
Effect of non-surgical periodontal treatment on gingival crevicular fluid hypoxia inducible factor-1 alpha, vascular endothelial growth factor and tumor necrosis factor-alpha levels in generalized aggressive periodontitis patients.
Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo.
Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study.
Effect of p53 gene transfection on vascular endothelial growth factor expression in endometrial cancer cells.
Effect of pazopanib on tumor microenvironment and liposome delivery.
Effect of platelet mediator concentrate (PMC) on Achilles tenocytes: an in vitro study.
Effect of prostaglandin E2 and tumor necrosis factor alpha on the VEGF-receptor system expression in cultured porcine luteal cells.
Effect of PTK/ZK on the angiogenic switch in head and neck tumors.
Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma.
Effect of recombinant vascular endothelial growth factor and translationally controlled tumor protein on 2?hydroxyethyl methacrylate?treated pulp cells.
Effect of Repeated Freezing and Thawing on Biomarker Stability in Plasma and Serum Samples.
Effect of resection of localized pancreaticobiliary adenocarcinoma on angiogenic markers and tissue factor related pro-thrombotic and pro-angiogenic activity.
Effect of resveratrol derivative BTM-0512 on high glucose-induced dysfunction of endothelial cells: role of SIRT1.
Effect of RhoC silencing on multiple myeloma xenografts and angiogenesis in nude mice.
Effect of rutin on retinal VEGF, TNF-?, aldose reductase, and total antioxidant capacity in diabetic rats: molecular mechanism and ocular pharmacokinetics.
Effect of selenium-enriched malt on VEGF and several relevant angiogenic cytokines in diethylnitrosamine-induced hepatocarcinoma rats.
Effect of silibinin on the growth and progression of primary lung tumors in mice.
Effect of siRNA-mediated downregulation of VEGF in Tca8113 cells on the activity of monocyte-derived dendritic cells.
Effect of small hairpin RNA targeting endothelin-converting enzyme-1 in monocrotaline-induced pulmonary hypertensive rats.
Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer.
Effect of sunitinib on growth and function of FRTL-5 thyroid cells.
Effect of Taoren Quyu Decoction on human endometrial cells and its anti-endometriosis activity in rats.
Effect of tetramethylpyrazine combined with cisplatin on VEGF, KLF4 and ADAMTS1 in Lewis lung cancer mice.
Effect of thalidomide and arsenic trioxide on the release of tumor necrosis factor-? and vascular endothelial growth factor from the KG-1a human acute myelogenous leukemia cell line.
Effect of thalidomide in combination with gemcitabine on human pancreatic carcinoma SW-1990 cell lines in vitro and in vivo.
Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo.
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Effect of thyroid hormone-nitric oxide interaction on tumor growth, angiogenesis, and aminopeptidase activity in mice.
Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model.
Effect of two selenium sources on hepatocarcinogenesis and several angiogenic cytokines in diethylnitrosamine-induced hepatocarcinoma rats.
Effect of ultrasound on the production of IL-8, basic FGF and VEGF.
Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo.
Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer.
Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors.
Effect of vegf gene knockdown on growth of the murine sarcoma cell line MS-K.
Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
Effect of VEGF-targeted antisense gene therapy on retinoblastoma cell line SO-RB50 in vitro and in vivo.
Effect of Yiqi Jianpi plus anticancer herbs on spleen deficiency in colorectal cancer and its anti-tumor role.
Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model.
Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.
Effective systemic siRNA delivery using dual-layer protected long-circulating nanohydrogel containing an inorganic core.
Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Effects and mechanism of OK-432 therapy in various neck cystic lesions.
Effects and mechanism of urinary kallidinogenase in the survival of random skin flaps in rats.
Effects of a high-fat diet on spontaneous metastasis of Lewis lung carcinoma in plasminogen activator inhibitor-1 deficient and wild-type mice.
Effects of a new bicarbonate/lactate-buffered neutral peritoneal dialysis fluid for peritoneal failure in patients undergoing peritoneal dialysis.
Effects of a nutrient mixture on immunohistochemical localization of cancer markers in human cervical cancer HeLa cell tumor xenografts in female nude mice.
Effects of active components of Red Paeonia and Rhizoma chuanxiong on angiogenesis in atherosclerosis plaque in rabbits.
Effects of Administration Route of Adipose-Derived Stem Cells on the Survival of Allogeneic Skin Grafts in Mice.
Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis.
Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade.
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model.
Effects of Apelin on RAW264.7 cells under both normal and hypoxic conditions.
Effects of Apigenin Treatment on Random Skin Flap Survival in Rats.
Effects of autocrine vascular endothelial growth factor (VEGF) in non-small cell lung cancer cell line A549.
Effects of Autologous Bone Marrow Mononuclear Cells Implantation on Canine Model of Pulmonary Hypertension.
Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
Effects of bevacizumab combined with oxaliplatin intrathoracic injection on tumor markers and survival rate in patients with malignant pleural effusion of lung cancer.
Effects of bisphenol A and 17?-estradiol on vascular endothelial growth factor A and its receptor expression in the non-cancer and cancer ovarian cell lines.
Effects of brachytherapy on intimal hyperplasia in arteriovenous fistulas in a porcine model.
Effects of carbon-ion beam irradiation on the angiogenic response in lung adenocarcinoma A549 cells.
Effects of chemically modified nanostructured PLGA on functioning of lung and breast cancer cells.
Effects of Copper Reduction on Angiogenesis-Related Factors in Recurrent Glioblastoma Cases
Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial.
Effects of cytokines and chemokines on migration of mesenchymal stem cells following spinal cord injury.
Effects of di(2-ethylhexyl)phthalate exposure on 1,2-dimethyhydrazine-induced colon tumor promotion in rats.
Effects of Diabetes and Obesity on Vascular Reactivity, Inflammatory Cytokines, and Growth Factors.
Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2.
Effects of ellagic Acid on angiogenic factors in prostate cancer cells.
Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells.
Effects of estrogen and phytoestrogens on endometrial leakage in ovariectomized rats and the related mechanisms.
Effects of exogenous VEGF(165)b on invasion and migration of human lung adenocarcinoma A549 cells.
Effects of Far-infrared Ray on Temozolomide-treated Glioma in Rats.
Effects of free and nanoparticulate curcumin on chemically induced liver carcinoma in an animal model.
Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells.
Effects of glycogen synthase kinase-3beta inhibition on the development of cerulein-induced acute pancreatitis in mice*
Effects of glycogen synthase kinase-3beta inhibition on the development of cerulein-induced acute pancreatitis in mice.
Effects of HCG on human epithelial ovarian cancer vasculogenic mimicry formation in vivo.
Effects of heme oxygenase-1 on induction and development of chemically induced squamous cell carcinoma in mice.
Effects of human cyclooxygenase-2 gene silencing on synovial cells of rheumatoid arthritis mediated by lentivirus.
Effects of hyperbaric oxygen exposure on experimental head and neck tumor growth, oxygenation, and vasculature.
Effects of hyperthermia with dextran magnetic fluid on the growth of grafted H22 tumor in mice.
Effects of implantation of bone marrow cells on cytokine levels in the ischemic heart tissue. An experimental study.
Effects of increasing carbon nanofiber density in polyurethane composites for inhibiting bladder cancer cell functions.
Effects of inhalational anaesthetics in experimental allergic asthma.
Effects of initiating time and dosage of
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
Effects of irradiation on tumor cell survival, invasion and angiogenesis.
Effects of ischemic preconditioning and bevacizumab on apoptosis and vascular permeability following retinal ischemia-reperfusion injury.
Effects of low-frequency ultrasound and microbubbles on angiogenesis-associated proteins in subcutaneous tumors of nude mice.
Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice.
Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Effects of melatonin on HIF-1? and VEGF expression and on the invasive properties of hepatocarcinoma cells.
Effects of melatonin on the acute inflammatory response associated with endoscopic retrograde cholangiopancreatography: A randomized, double-blind, placebo-controlled trial.
Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells.
Effects of oral and vaginal administration of levonorgestrel emergency contraception on markers of endometrial receptivity.
Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study.
Effects of Peroxisome Proliferator-Activated Receptor {gamma} and Its Ligand on Blood-Retinal Barrier in a Streptozotocin-Induced Diabetic Model.
Effects of positive end-expiratory pressure, inhaled nitric oxide and surfactant on expression of proinflammatory cytokines and growth factors in preterm piglet lungs.
Effects of prior acute exercise on circulating cytokine concentration responses to a high-fat meal.
Effects of Probiotics on Metabolic Syndrome: A Systematic Review of Randomized Clinical Trials.
Effects of propofol/remifentanil-based total intravenous anesthesia versus sevoflurane-based inhalational anesthesia on the release of VEGF-C and TGF-? and prognosis after breast cancer surgery: a prospective, randomized and controlled study.
Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study.
Effects of pulsed electromagnetic fields on interleukin-1 beta and postoperative pain: a double-blind, placebo-controlled, pilot study in breast reduction patients.
Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Effects of red light emitting diode on apoptosis of HeLa cells and suppression of implanted HeLa cells growth in mice.
Effects of rehabilitative exercise on peripheral muscle TNF{alpha}, IL-6, IGF-I and MyoD expression in patients with COPD.
Effects of rosiglitazone on the growth and lymphangiogenesis of human gastric cancer transplanted in nude mice.
Effects of roxithromycin on tumor necrosis factor-alpha-induced vascular endothelial growth factor expression in human periodontal ligament cells in culture.
Effects of serum matrix on molecular interactions between drugs and target proteins revealed by giant magneto-resistive bio-sensing techniques.
Effects of Short-term Celecoxib Treatment in Patients with Invasive Transitional Cell Carcinoma of the Urinary Bladder.
Effects of silymarin, cabergoline and letrozole on rat model of endometriosis.
Effects of siRNA targeting c-Myc and VEGF on human colorectal cancer Volo cells.
Effects of spironolactone on residual renal function and peritoneal function in peritoneal dialysis patients.
Effects of task-oriented training combined with aerobic training on serum BDNF, GDNF, IGF-1, VEGF, TNF-?, and IL-1? levels in people with Parkinson's disease: A randomized controlled study.
Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.
Effects of the duration of hyperlipidemia on cerebral lipids, vessels and neurons in rats.
Effects of the Thioredoxin-1 Inhibitor PX-12 on Blood-Brain Barrier Permeability in the Early Stage of Focal Cerebral Ischemia.
Effects of the Ultra-High-Frequency Electrical Field Radiofrequency Device on Mouse Skin: A Histologic and Molecular Study.
Effects of thyroid-stimulating hormone on adhesion molecules and pro-inflammatory cytokines secretion in human umbilical vein endothelial cells.
Effects of TNF-alpha and curcumin on the expression of VEGF in Raji and U937 cells and on angiogenesis in ECV304 cells.
Effects of trichostatin A on HIF-1? and VEGF expression in human tongue squamous cell carcinoma cells in vitro.
Effects of tumor microenviromental factors on VEGF expression.
Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.
Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy.
Efficacies of vitamin D and omega-3 polyunsaturated fatty acids on experimental endometriosis.
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Efficacy and safety of (32)P-nanocolloid for treatment of distant lymph node metastasis in VX2 tumor-bearing rabbits.
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study.
Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.
Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials.
Efficacy and safety of bevacizumab for the treatment of glioblastoma.
Efficacy and Safety of Image-Guided Intensity-Modulated Radiation Therapy and Volumetric Modulated Arc Therapy Combined with Paclitaxel Liposomes and Cisplatin for Locally Advanced Stage IIB-IIIB Cervical Cancer: A Retrospective Study at a Single Center.
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Efficacy and toxicity of anti-VEGF agents in patients with castration-resistant prostate cancer: a meta-analysis of prospective clinical studies.
Efficacy of a methyl ester of 5-aminolevulinic acid in photodynamic therapy for ovarian cancers.
Efficacy of Arsenic Trioxide in the Treatment of Malignant Pleural Effusion Caused by Pleural Metastasis of Lung Cancer.
Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo.
Efficacy of Ciji Hua'ai Baosheng formula on the expressions of vascular endothelial growth factor, kinase insert domain-containing receptor and basic fibroblast growth factor in mouse models of H(22) hepatocellular carcinoma.
Efficacy of Coccinia grandis against monosodium glutamate induced hepato-cardiac anomalies by inhibiting NF-kB and caspase 3 mediated signalling in rat model.
Efficacy of endostatin combined with continuous transcatheter arterial infusion and chemoembolization on gastric cancer with liver metastasis and analysis of prognosis.
Efficacy of local delivery of ardipusilloside I using biodegradable implants against cerebral tumor growth.
Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial.
Efficacy of Shouzhangshen (Rhizoma Gymnadeniae Crassinervidis) extract against acute high altitude hypoxia-induced brain injury in mice.
Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
Efficient carboplatin single therapy in a mouse model of human testicular nonseminomatous germ cell tumor.
Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus.
Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO2@LDH for anti-neuroblastoma therapy.
EFNS guidelines on disease-specific CSF investigations.
EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway.
EGCG attenuates pro-inflammatory cytokines and chemokines production in LPS-stimulated L02 hepatocyte.
EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas.
EGFR and ?v?6 as Promising Targets for Molecular Imaging of Cutaneous and Mucosal Squamous Cell Carcinoma of the Head and Neck Region.
EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.
EGFR Inhibition Fails to Suppress Vascular Proliferation and Tumor Growth in a Ewing's Sarcoma Model.
EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1-Independent and HIF-1-Dependent Mechanisms.
Ehrlich ascites carcinoma as model for studying the cardiac protective effects of curcumin nanoparticles against cardiac damage in female mice.
eIF-4E expression and its role in malignancies and metastases.
Electroacupuncture decreases the progression of ovarian hyperstimulation syndrome in a rat model.
Electrocautery snare resection stimulates cellular proliferation of residual colorectal tumor: an increasing gene expression related to tumor growth.
Electrochemiluminescence-Repurposed Abiological Catalysts in Full Protein Tag for Ultrasensitive Immunoassay.
Elevated expression levels of serum insulin-like growth factor-1, tumor necrosis factor-? and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy.
Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis.
Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients.
Elevated Expression of Thymosin ?4, Vascular Endothelial Growth Factor (VEGF), and Hypoxia Inducible Factor (HIF)-1? in Early-Stage Cervical Cancers.
Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors.
Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice.
Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels.
Elevated IL-8 levels in the drainage vein of resectable Dukes' C colorectal cancer indicate high risk for developing hepatic metastasis.
Elevated levels of angiogenic cytokines in the plasma of cancer patients.
Elevated levels of interleukin-1?, interleukin-6, tumor necrosis factor-? and vascular endothelial growth factor in patients with knee articular cartilage injury.
Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.
Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease.
Elevated plasma and synovial fluid interleukin-8 and interleukin-18 may be associated with the pathogenesis of knee osteoarthritis.
Elevated renalase levels in patients with acute coronary microvascular dysfunction - A possible biomarker for ischemia.
Elevated serum IL-11, TNF ?, and VEGF expressions contribute to the pathophysiology of hypertensive intracerebral hemorrhage (HICH).
Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer.
Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer.
Elevated serum levels of vascular endothelial growth factor is effective as a marker for malnutrition and inflammation in patients with ovarian cancer.
Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms.
Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma.
Elevated vascular endothelial growth factor (VEGF) levels in the blood serum of dogs with malignant neoplasms of the oral cavity.
Elevated vascular endothelial growth factor levels in sera of patients with lung cancer.
Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission.
Elevated VEGF-D Modulates Tumor Inflammation and Reduces the Growth of Carcinogen-Induced Skin Tumors.
Elevated VEGFA mRNA levels in oral squamous cell carcinomas and tumor margins: a preliminary study.
Elevation of Nitric Oxide Synthase Activity by Dimethyladenosine from Silkworm Pupae in Aged Rats.
Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer.
Ellagic acid inhibits VEGF/VEGFR2, PI3K/Akt and MAPK signaling cascades in the hamster cheek pouch carcinogenesis model.
Ellagic acid prevents kidney injury and oxidative damage via regulation of Nrf-2/NF-?B signaling in carbon tetrachloride induced rats.
EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma.
Emerging angiogenesis inhibitors for non-small cell lung cancer.
Emerging biomarkers in glioblastoma.
Emerging biotechnological strategies for non-viral antiangiogenic gene therapy.
Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
Emerging drugs for non-small cell lung cancer.
Emerging drugs for renal cell carcinoma.
Emerging molecular mechanisms of brain tumour oedema.
Emerging molecularly targeted therapies in castration refractory prostate cancer.
Emerging role of endothelin-1 in tumor angiogenesis.
Emerging Roles for VEGF-D in Human Disease.
Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis.
Emerging roles of PDGF-D in EMT progression during tumorigenesis.
Emerging roles of PDGF-D signaling pathway in tumor development and progression.
Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.
Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib.
EMMPRIN in gynecologic cancers: pathologic and therapeutic aspects.
EMMPRIN promotes angiogenesis through HIF-2{alpha} mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2.
Enalapril inhibits inflammatory osteolysis induced by wear debris in a mouse model.
Encapsulated three-dimensional bioprinted structure seeded with urothelial cells: a new construction technique for tissue-engineered urinary tract patch.
Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity.
Endocan expression and relationship with survival in human non-small cell lung cancer.
Endocan Measurement for Active Behçet Disease.
Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer.
Endocrine and signalling role of adipose tissue: new perspectives on fat.
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer.
Endocrine glands-derived vascular endothelial growth factor protects pancreatic cancer cells from apoptosis via upregulation of the myeloid cell leukemia-1 protein.
Endogenous erythropoietin and erythropoietin receptors in colorectal cancer; can we answer the questions?
Endogenous growth inhibition of angiogenesis in brain tumors.
Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma.
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer.
Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF.
Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma.
Endoglin for tumor imaging and targeted cancer therapy.
Endolymphatic sac tumor associated with a von Hippel-Lindau disease patient: an immunohistochemical study.
Endometrial secretion analysis identifies a cytokine profile predictive of pregnancy in IVF.
Endoscopic management of colonic perforation owing to angiogenesis inhibitors.
Endoscopic ultrasound guided fine-needle aspiration of a splenic hemangioma with extramedullary hematopoiesis.
Endostatin and vascular endothelial growth factor concentrations in healthy dogs, dogs with selected neoplasia, and dogs with nonneoplastic diseases.
Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane.
Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models.
Endostatin improves cancer-associated systemic syndrome in a lung cancer model.
Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice.
Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells.
Endostatin: a promising drug for antiangiogenic therapy.
Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF.
Endothelial autophagy deficiency induces IL6 - dependent endothelial mesenchymal transition and organ fibrosis.
Endothelial caveolin and its scaffolding domain in cancer.
Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor.
Endothelial cell malignancies: new insights from the laboratory and clinic.
Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Endothelial cell survival and apoptosis in the tumor vasculature.
Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivo.
Endothelial Dll4-Notch signaling in tumor microenvironment: is there any hidden therapeutic opportunity?
Endothelial dysfunction and pathogenesis of diabetic angiopathy.
Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications.
Endothelial Heparan Sulfate 6-O-sulfation Levels Regulate Angiogenic Responses of Endothelial Cells to FGF2 and VEGF.
Endothelial hypoxic metabolism in carcinogenesis and dissemination: HIF-A isoforms are a NO metastatic phenomenon.
Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling.
Endothelial NO synthase and reactive oxygen species mediated effect of simvastatin on vessel structure and function: Pleiotropic and dose-dependent effect on tumor vascular stabilization.
Endothelial progenitor cells and peripheral neuropathy in subjects with type 2 diabetes mellitus.
Endothelial progenitor cells do not contribute to tumor endothelium in primary and metastatic tumors.
Endothelial progenitor cells support tumour growth and metastatisation: implications for the resistance to anti-angiogenic therapy.
Endothelial-Specific Notch Blockade Inhibits Vascular Function and Tumor Growth through an eNOS-Dependent Mechanism.
Endothelin-1 and antiangiogenesis.
Endothelin-1 as a target for therapeutic intervention in prostate cancer.
Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.
Endothelin-1 triggers human peritoneal mesothelial cells' proliferation via ERK1/2-Ets-1 signaling pathway and contributes to endothelial cell angiogenesis.
Endothelins and hypoxia-inducible factor in cancer.
Endothelium-specific over expression of human VEGF-D in mice leads to increased tumor frequency and a reduced lifespan.
Endotoxin-Induced Emphysema Exacerbation: A Novel Model of Chronic Obstructive Pulmonary Disease Exacerbations Causing Cardiopulmonary Impairment and Diaphragm Dysfunction.
Energy imbalance and prostate cancer.
Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression.
Engineered Conformation-dependent VEGF Peptide Mimics Are Effective in Inhibiting VEGF Signaling Pathways.
Engineered mesenchymal cell-based patches as controlled VEGF delivery systems to induce extrinsic angiogenesis.
Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy via tumor microenvironment modulation.
Engineering fully human monoclonal antibodies from murine variable regions.
Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101.
Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy.
Enhanced anticancer effect of ROS-boosted photothermal therapy by using fucoidan-coated polypyrrole nanoparticles.
Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy.
Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis.
Enhanced efficacy of combination therapy with adeno?associated virus-delivered pigment epithelium-derived factor and cisplatin in a mouse model of Lewis lung carcinoma.
Enhanced Efficacy of Doxorubicin by microRNA-499-Mediated Improvement of Tumor Blood Flow.
Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas.
Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen.
Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression.
Enhanced fluorescence diffuse optical tomography with indocyanine green-encapsulating liposomes targeted to receptors for vascular endothelial growth factor in tumor vasculature.
Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2.
Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination.
Enhanced patterns on intraoperative contrast-enhanced ultrasonography predict outcomes after curative liver resection in patients with hepatocellular carcinoma.
Enhanced sensitivity of VEGF detection using catalase-mediated chemiluminescence immunoassay based on CdTe QD/H2O2 system.
Enhanced Systemic Anti-Angiogenic siVEGF Delivery Using PEGylated Oligo-d-arginine.
Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma.
Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line.
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.
Enhancement of antitumor immune response by targeted interleukin-12 electrogene transfer through antiHER2 single-chain antibody in a murine bladder tumor model.
Enhancement of cisplatin efficacy by thalidomide in a 9L rat gliosarcoma model.
Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs).
Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model.
Enhancement of radiation response with bevacizumab.
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species.
Enhancement of vascular endothelial growth factor release in long-term drug-treated breast cancer via transient receptor potential channel 5-Ca(2+)-hypoxia-inducible factor 1? pathway.
Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.
Enhancing integrin function by VEGF/neuropilin signaling: implications for tumor biology.
Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules.
Environmental enrichment protects the retina from early diabetic damage in adult rats.
Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells.
Enzyme-digested Fucoidan Extracts Derived from Seaweed Mozuku of Cladosiphon novae-caledoniae kylin Inhibit Invasion and Angiogenesis of Tumor Cells.
EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts.
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.
Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice.
Epicardial ganglionated plexus stimulation decreases postoperative inflammatory response in humans.
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy.
Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer.
Epidermal growth factor receptor transactivation is involved in the induction of human hepatoma SMMC7721 cell proliferation by insufficient radiofrequency ablation.
Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?
Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.
Epigallocatechin-3-gallate ameliorates LPS-induced inflammation by inhibiting the phosphorylation of Akt and ERK signaling molecules in rat H9c2 cells.
Epigallocatechin-3-gallate inhibits photocarcinogenesis through inhibition of angiogenic factors and activation of CD8+ T cells in tumors.
Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells.
Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival of gastric cancer.
Epigenetic regulation of vascular endothelial growth factor a dynamic expression in transitional cell carcinoma.
Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors.
Epithelial expression of VEGF receptors in colorectal carcinomas and their relationship to metastatic status.
Epithelial to Mesenchymal Transition and Cell Biology of Molecular Regulation in Endometrial Carcinogenesis.
Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells.
Epithelial-mesenchymal transition, proliferation, and angiogenesis in locally advanced cervical cancer treated with chemoradiotherapy.
ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma.
Erratum to "IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer" [Clin. Lab. 2012; 58:501-505].
Erythropoietin prevents the effect of chronic restraint stress on the number of hippocampal CA3c dendritic terminals-relation to expression of genes involved in synaptic plasticity, angiogenesis, inflammation, and oxidative stress in male rats.
Escape Mechanisms from Antiangiogenic Therapy: An Immune Cell's Perspective.
Essential role for oncogenic Ras in tumour maintenance.
Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells.
Establishment of a new human pancreatic cancer cell line, NOR-P1, with high angiogenic activity and metastatic potential.
Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor.
Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes.
Establishment of human metastatic colorectal cancer model in rabbit liver: A pilot study.
Establishment of lymphangioma model and a study on the promoting effect of murine melanoma cell B16-F1 on the lymphangiogenesis in vitro.
Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast.
Estradiol stimulates vascular endothelial growth factor and interleukin-6 in human lactotroph and lactosomatotroph pituitary adenomas.
Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation.
Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts.
Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis.
Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins.
Estrogen regulation of VEGF in breast cancer in vitro and in vivo: the role of estrogen receptor {alpha} and c-Myc.
Estrogen-deficient osteoporosis enhances the recruitment and activity of osteoclasts by breast cancer cells.
Estrogen-induced Ets-1 promotes capillary formation in an in vitro tumor angiogenesis model.
Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways.
Estrogen-related receptor alpha and cancer: axis of evil.
Estrous cycle modulates ovarian carcinoma growth.
ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats.
Ethanol stimulates tumor progression and expression of vascular endothelial growth factor in chick embryos.
Etiology and oncogenesis of pancreatic carcinoma.
Etiology of angiogenesis inhibition-related hypertension.
Ets-1 expression in vascular endothelial cells as an angiogenic and prognostic factor in colorectal carcinoma.
Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.
Ets2-dependent stromal regulation of mouse mammary tumors.
Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression.
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors.
Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice.
Evaluation of angiogenesis with the expression of VEGF and CD34 in human non-small cell lung cancer.
Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer.
Evaluation of angiopoietin 1 and 2, vascular endothelial growth factor, and tumor necrosis factor alpha levels in asthmatic children.
Evaluation of anti-HIF and anti-angiogenic properties of honokiol for the treatment of ocular neovascular diseases.
Evaluation of anti-VEGFR-3 specific scFv antibodies as potential therapeutic and diagnostic tools for tumor lymph-angiogenesis.
Evaluation of Antiangiogenic Efficacy of Emilia sonchifolia (L.) DC on Tumor-Specific Neovessel Formation by Regulating MMPs, VEGF, and Proinflammatory Cytokines.
Evaluation of antitumor effect of oxygen nanobubble water on breast cancer-bearing BALB/c mice.
Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma.
Evaluation of blood flow in pancreatic ductal carcinoma using contrast-enhanced, wide-band Doppler ultrasonography: correlation with tumor characteristics and vascular endothelial growth factor.
Evaluation of cytokines in peripheral blood mononuclear cell supernatants for the diagnosis of tuberculosis.
Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport.
Evaluation of Endoglin as an Angiogenesis Marker in Glioblastoma.
Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis.
Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer.
Evaluation of Ki-67 as prognostic factor for pediatric neuroblastoma and the possibility of molecular-targeted drugs with vascular endothelial growth factor and platelet-derived growth factor receptor.
Evaluation of leptin, interleukin-1beta, tumor necrosis factor-alpha and vascular endothelial growth factor in serum and follicular fluids of women undergoing controlled ovarian hyperstimulation as prognostic markers of ICSI outcome.
Evaluation of Local Injection of Bevacizumab against Triple-Negative Breast Cancer Xenograft Tumors.
Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors.
Evaluation of Neuroprotective Effect of Sevoflurane in Acute Traumatic Brain Injury: An Experimental Study in Rats.
Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma.
Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters.
Evaluation of plasma and tissue expression levels of Endothelins (ET-1, Big ET-1) and VEGF in lobular neoplasia of the breast.
Evaluation of plasma and tissue S100A4 protein and mRNA levels as potential markers of metastasis and prognosis in clear cell renal cell carcinoma.
Evaluation of pro? and anti?tumor effects induced by three colony?stimulating factors, G?CSF, GM?CSF and M?CSF, in bladder cancer cells: Is G?CSF a friend of bladder cancer cells?
Evaluation of selected angiogenic and inflammatory markers in endometriosis before and after danazol treatment.
Evaluation of selected growth factor expression in canine spirocercosis (Spirocerca lupi)-associated non-neoplastic nodules and sarcomas.
Evaluation of serum concentrations of vascular endothelial growth factor (VEGF) in breast cancer patients.
Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast.
Evaluation of Some Cytokines and Gene Expressions in Pre-eclampsia.
Evaluation of stromal metalloproteinases and vascular endothelial growth factors in a spontaneous metastasis model.
Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.
Evaluation of the effect of losartan and methotrexate combined therapy in adjuvant-induced arthritis in rats.
Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI.
Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.
Evaluation of the Therapeutic Effects of the Hydroethanolic Extract of Portulaca oleracea on Surgical-Induced Peritoneal Adhesion.
Evaluation of tissue and serum VEGF in patients with head and neck carcinoma.
Evaluation of Tumor Angiogenesis in a Mouse PC-3 Prostate Cancer Model Using Dynamic Contrast-Enhanced Sonography.
Evaluation of tumor angiogenesis using dynamic enhanced magnetic resonance imaging: comparison of plasma vascular endothelial growth factor, hemodynamic, and pharmacokinetic parameters.
Evaluation of tumor metastasis-associated markers for molecular classification in patients with esophageal squamous cell carcinoma.
Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts.
Evaluation of Vascular Endothelial Growth Factor (VEGF) and Thrombospondin-1 as Biomarkers of Metronomic Chemotherapy in Progressive Pediatric Solid Malignancies.
Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer.
Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein.
Evaluation of VEGF, FGF and PDGF and Serum Levels of Inflammatory Cytokines in Patients with Glioma and Meningioma in Southern Iran.
Evaluation of VEGF-Induced Vascular Permeability in Mice.
Evaluation of wound healing properties of bioactive aqueous fraction from Moringa oleifera Lam on experimentally induced diabetic animal model.
Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.
Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis.
Evidence for mRNA expression of vascular endothelial growth factor by X-ray irradiation in a lung squamous carcinoma cell line.
Evidence for the involvement of miRNA in redox regulated angiogenic response of human microvascular endothelial cells.
Evidence for the involvement of SDF-1 and CXCR4 in the disruption of endothelial cell-branching morphogenesis and angiogenesis by TNF-alpha and IFN-gamma.
Evidence of an anti-inflammatory effect of mycophenolate mofetil in a murine model of pleurisy.
Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome.
Evidence that gene expression of ovarian follicular tight junction proteins is regulated in vivo and in vitro in cattle.
Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting ?-catenin-mediated angiogenesis.
Evolving role of serum biomarkers in the management of ovarian cancer.
Ex vivo simulation of leukocyte function: Stimulation of specific subset of leukocytes in whole blood followed by the measurement of function-associated mRNAs.
Excessive inflammation portends complications: Wound cytokines and head and neck surgery outcomes.
Exenatide inhibits necrosis by enhancing angiogenesis and ameliorating ischemia/reperfusion injury in a random skin flap rat model.
Exosomal neurofilament light: A prognostic biomarker for remote symptoms after mild traumatic brain injury?
Exosome miR-155 Derived from Gastric Carcinoma Promotes Angiogenesis by Targeting the c-MYB/VEGF Axis of Endothelial Cells.
Exosome-encapsulated miRNAs contribute to CXCL12/CXCR4-induced liver metastasis of colorectal cancer by enhancing M2 polarization of macrophages.
Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo.
Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells.
Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers.
Expanded endothelial progenitor cells mitigate lung injury in septic mice.
Expanding the clinical development of bevacizumab.
Experience with bevacizumab in the management of epithelial ovarian cancer.
Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells.
Experimental intermittent ischemia augments exercise-induced inflammatory cytokine production.
Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate.
Experimental study on angiogenesis in a rabbit VX2 early liver tumour by perfusion computed tomography.
Experimental study on residual tumor angiogenesis after cryoablation.
Experimental study on the therapeutic effect of positron emission tomography agent [¹?F]-labeled 2-deoxy-2-fluoro-d-glucose in a colon cancer mouse model.
Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers.
Exploiting the tumor microenvironment in the development of targeted cancer gene therapy.
Exploration of phytochemicals for inhibition of monoamine oxidase-A induced cancer using molecular docking studies.
Exploration of the relationship between the tumor burden and the concentration of vascular endothelial growth factor in liver-cancer-bearing animals using immunomagnetic reduction assay.
Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.
Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study.
Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy.
Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors.
Exploring the limits of benzimidazole DNA-binding oligomers for the hypoxia inducible factor (HIF) site.
Exploring the novel heterocyclic derivatives as lead molecules for design and development of potent anticancer agents.
Exploring the peritoneal surface malignancy phenotype-a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models.
Exposure to prolonged unpredictable light impairs spatial memory via induction of oxidative stress and tumor necrosis factor-alpha in rats.
Exposure-Response (Safety) Analysis to Identify Linifanib Dose for a Phase III Study in Patients With Hepatocellular Carcinoma.
Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer.
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.
Expression and association of VEGF-Notch pathways in infantile hemangiomas.
Expression and characterization of a novel single-chain anti-vascular endothelial growth factor antibody in the goat milk.
Expression and Clinical Significance of Hepatoma-Derived Growth Factor as a Prognostic Factor in Human Hilar Cholangiocarcinoma.
Expression and Clinical Significance of Neuropilin-1 in Patients With Multiple Myeloma.
Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors.
Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells.
Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells.
Expression and hypoxic regulation of angiopoietins in human astrocytomas.
Expression and interaction of TNF-? and VEGF in chronic stress-induced depressive rats.
Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors.
Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas.
Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma.
Expression and purification of functional human vascular endothelial growth factor-a121; the most important angiogenesis factor.
Expression and regulation of neuropilin-1 in human astrocytomas.
Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma.
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer.
Expression characteristics of KAI1 and vascular endothelial growth factor and their diagnostic value for hepatocellular carcinoma.
Expression level and prospective mechanism of miRNA-99a-3p in head and neck squamous cell carcinoma based on miRNA-chip and miRNA-sequencing data in 1, 167 cases.
Expression levels and significance of hypoxia inducible factor-1 alpha and vascular endothelial growth factor in human colorectal adenocarcinoma.
Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma.
Expression levels of serum vasohibin-1 and other biomarkers in type 2 diabetes mellitus patients with different urinary albumin to creatinine ratios.
Expression levels of vascular endothelial growth factors a and C in patients with peptic ulcers and gastric cancer.
Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors.
Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis.
Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer.
Expression of androgen receptor and growth factors in premalignant lesions of the prostate.
Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.
Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia.
Expression of angiogenic factors is increased in metastasised renal cell carcinomas.
Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-kappaB and activating protein-1.
Expression of angiogenic growth factors in paragangliomas.
Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells.
Expression of angiogenic VEGF-A (soluble isoforms 121, 165) and lymphangiogenic VEGF-C in colorectal cancers with micro-satellite instability.
Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy.
Expression of BDNF, TrkB, VEGF and CD105 is associated with pelvic lymph node metastasis and prognosis in IB2-stage squamous cell carcinoma.
Expression of breast cancer anti-estrogen resistance 1 in relation to vascular endothelial growth factor, p53, and prognosis in esophageal squamous cell cancer.
Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck.
Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.
Expression of chemotaxis- and angiogenesis-related factors in human monocytes following interaction with colon cancer cells is suppressed by low-dose lipopolysaccharide.
Expression of cyclic guanosine monophosphate-dependent protein kinase in metastatic colon carcinoma cells blocks tumor angiogenesis.
Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors.
Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression.
Expression of delta-like 4 (Drosophila) and vascular endothelial growth factor A in colon cancer and association with tumour angiogenesis.
Expression of developmentally regulated endothelial cell locus 1 was induced by tumor-derived factors including VEGF.
Expression of e-cadherin and vascular endothelial growth factor in noncancerous liver is associated with recurrence of hepatocellular carcinoma after curative resection.
Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications.
Expression of EMMPRIN in adenoid cystic carcinoma of salivary glands: correlation with tumor progression and patients' prognosis.
Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma.
Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer.
Expression of endostatin in merkel cell carcinoma.
Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors.
Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in oral squamous cell carcinoma: its correlation with angiogenesis and disease progression.
Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours.
Expression of epidermal growth factor receptor and vascular endothelial growth factor in vaginal squamous cell cancer.
Expression of Flt-1 and Flk-1 receptors for vascular endothelial growth factor on tumor cells as a new prognostic criterion for locally advanced breast cancer.
Expression of focal adhesion kinase (p125 FAK) and proline-rich tyrosine kinase 2 (PYK2/CAKb) in cerebral metastases, correlation with VEGF-R-, ecNOS III-labelling and morphometric data.
Expression of Galectin-9 and correlation with disease activity and vascular endothelial growth factor in rheumatoid arthritis.
Expression of granzyme B and perforin in multiple myeloma.
Expression of HAb18G in non-small lung cancer and characterization of activation, migration, proliferation, and apoptosis in A549 cells following siRNA-induced downregulation of HAb18G.
Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications.
Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma.
Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma.
Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast.
Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas.
Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma.
Expression of Hypoxia-Inducible Factor-1? in Human Periodontal Tissue.
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomas.
Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related.
Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas.
Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype.
Expression of IL-6 receptor in pancreatic cancer: involvement in VEGF induction.
Expression of inducible nitric oxide synthase and vascular endothelial growth factor in ameloblastoma.
Expression of interferon-gamma-inducible protein 10 related to angiogenesis in uterine endometrial cancers.
Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice.
Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage.
Expression of interleukin-8, heme oxygenase-1 and vascular endothelial growth factor in DLD-1 colon carcinoma cells exposed to pyrrolidine dithiocarbamate.
Expression of IP-10 related to angiogenesis in uterine cervical cancers.
Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior ?
Expression of liver-type fatty-acid-binding protein, fatty acid synthase and vascular endothelial growth factor in human lung carcinoma.
Expression of maspin in testis tumors with germ cells andits relation with angiogenesis factors.
Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation.
Expression of matrix metalloproteinase-9, cyclooxygenase-2 and vascular endothelial growth factor are increased in gastrointestinal stromal tumors.
Expression of Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases and Vascular Endothelial Growth Factor in Canine Mast Cell Tumours.
Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor.
Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: predominance of vascular endothelial growth factor.
Expression of NOS and VEGF in feline mammary tumours and their correlation with angiogenesis.
Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors.
Expression of p-STAT3 and vascular endothelial growth factor in MNNG-induced precancerous lesions and gastric tumors in rats.
Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer.
Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features.
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.
Expression of platelet-derived growth factor and its receptors in spontaneous canine hemangiosarcoma and cutaneous hemangioma.
Expression of survivin in gastric cancer and its relationship with tumor angiogenesis.
Expression of synovial fluid biomarkers in patients with knee osteoarthritis and meniscus injury.
Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors.
Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.
Expression of the Mig (CXCL9) gene in murine lung carcinoma cells generated angiogenesis-independent antitumor effects.
Expression of the Peptidase "Fibroblast Activation Protein" on Decidual Stromal Cells Facilitating Tissue Remodeling.
Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress.
Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression.
Expression of the Vascular Endothelial Growth Factor (VEGF) Gene in Epithelial Ovarian Cancer: An Approach to Anti-VEGF Therapy.
Expression of the Vascular Endothelial Growth Factor and Angiopoietins in Mucoepidermoid Carcinoma of Salivary Gland.
Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors.
Expression of the vascular endothelial growth factor gene is inhibited by p73.
Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation.
Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: incidence and feasibility of immunohistochemical staining.
Expression of therapeutic targets in Ewing sarcoma family tumors.
Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.
Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.
Expression of TNF-alpha and VEGF in the esophagus of portal hypertensive rats.
Expression of Tspan-1 gene in patients with advanced gastric cancer.
Expression of tumor antigens and heat-shock protein 70 in breast cancer cells after high-intensity focused ultrasound ablation.
Expression of tumor necrosis factor-alpha and vascular endothelial growth factor in different zones of fetal membranes: a possible relation to onset of labor.
Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis.
Expression of type V secretory phospholipase A in myocardial remodelling after infarction.
Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance.
Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.
Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers.
Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours.
Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival.
Expression of vascular endothelial growth factor (VEGF) and its two receptors in diffusely infiltrating astrocytomas and relationship to proliferative activity of tumor cells.
Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue.
Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas.
Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Expression of vascular endothelial growth factor (VEGF) and VEGF-C in serum and tissue of Wilms tumor.
Expression of vascular endothelial growth factor (VEGF) family members in breast cancer.
Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels.
Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms.
Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors.
Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome.
Expression of vascular endothelial growth factor (VEGF) in normal oral mucosa, oral dysplasia and oral squamous cell carcinoma.
Expression of vascular endothelial growth factor (VEGF) in patients with oral squamous cell carcinoma and its clinical significance.
Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma.
Expression of vascular endothelial growth factor (VEGF) in vulvar squamous cancer and VIN.
Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma.
Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in early gastric carcinoma: correlation with clinicopathological parameters.
Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis.
Expression of vascular endothelial growth factor (VEGF)-C in preoperative biopsy specimens and metastatic foci of regional lymph nodes in submucosal gastric carcinoma.
Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma.
Expression of vascular endothelial growth factor and angiogenesis in cardiac myxoma: a study of fifteen patients.
Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach.
Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer.
Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model.
Expression of vascular endothelial growth factor and E26 transformation-specific-1 in breast carcinoma.
Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival.
Expression of vascular endothelial growth factor and hypoxia inducible factor-1alpha in cervical neoplasia.
Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas.
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.
Expression of vascular endothelial growth factor and its receptors in canine lymphoma.
Expression of Vascular Endothelial Growth Factor and Its Receptors in Thyroid Nodular Hyperplasia and Papillary Thyroid Carcinoma: A Tertiary Health Care Centre Based Study
Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells.
Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas.
Expression of vascular endothelial growth factor and microvascular density assessment in different histotypes of basal cell carcinoma.
Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis.
Expression of vascular endothelial growth factor and p53 in pancreatic carcinomas.
Expression of vascular endothelial growth factor and p53 protein in association with neovascularization in human malignant gliomas.
Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders.
Expression of vascular endothelial growth factor and receptor flk-1 in colon cancer liver metastases.
Expression of vascular endothelial growth factor as a predictor of complete response for preoperative chemoradiotherapy in rectal cancer.
Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study.
Expression of vascular endothelial growth factor by cultured endothelial cells from brain microvessels.
Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice.
Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas.
Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis.
Expression of vascular endothelial growth factor C and D (VEGF-C and -D) is an important risk factor for lymphatic metastasis in undifferentiated early gastric carcinoma.
Expression of vascular endothelial growth factor C is a prognostic indicator in esophageal cancer.
Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer.
Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas.
Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma.
Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis.
Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin.
Expression of vascular endothelial growth factor in canine mammary tumors.
Expression of vascular endothelial growth factor in cerebellar hemangioblastomas does not correlate with tumor angiogenesis.
Expression of vascular endothelial growth factor in hepatocellular carcinoma and its relationship to tumor growth and metastasis.
Expression of vascular endothelial growth factor in human hepatocellular carcinoma.
Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status.
Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression.
Expression of vascular endothelial growth factor in lymphomas and Castleman's disease.
Expression of vascular endothelial growth factor in mouse tumours subjected to photodynamic therapy.
Expression of vascular endothelial growth factor in normal and tumour oral tissues assessed with different antibodies.
Expression of vascular endothelial growth factor in normal epidermis, epithelial tumors and cultured keratinocytes.
Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.
Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease.
Expression of vascular endothelial growth factor in pediatric and adult cerebral arteriovenous malformations: an immunocytochemical study.
Expression of vascular endothelial growth factor in pulmonary aspergilloma.
Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression.
Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement.
Expression of vascular endothelial growth factor in renal cell carcinomas.
Expression of vascular endothelial growth factor in retinoblastoma.
Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis.
Expression of vascular endothelial growth factor in the progression of cervical neoplasia and its relation to angiogenesis and p53 status.
Expression of vascular endothelial growth factor in tumors and plasma from dogs with primary intracranial neoplasms.
Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis.
Expression of vascular endothelial growth factor is significantly associated with progression and prognosis of oral squamous cell carcinomas in Taiwan.
Expression of vascular endothelial growth factor mRNA in GI-101A and HL-60 cell lines.
Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas.
Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma.
Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells.
Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer.
Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia.
Expression of vascular endothelial growth factor receptors is closely related to the histological grade of hepatocellular carcinoma.
Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma.
Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors.
Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors.
Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.
Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer.
Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.
Expression of vascular endothelial growth factors VEGF- C and D, VEGFR-3, and comparison of lymphatic vessels density labeled with D2-40 antibodies as a prognostic factors in vulvar intraepithelial neoplasia (VIN) and invasive vul.
Expression of vascular endothelial growth-factor in the cyst fluid of human cerebral gliomas.
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma.
Expression of VEGF and collagen XVIII in meningiomas: correlations with histopathological and MRI characteristics.
Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors.
Expression of VEGF and its receptors by myeloma cells.
Expression of VEGF and its receptors in different brain tumors.
Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.
Expression of VEGF and MMP-9 and MRI imaging changes in cerebral glioma.
Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions.
Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma.
Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas.
Expression of VEGF-D in epithelial ovarian cancer and its relationship to lymphatic metastasis.
Expression of VEGF-D, SMAD4, and SMAD7 and Their Relationship with Lymphangiogenesis and Prognosis in Colon Cancer.
Expression of VEGF???b, VEGFR1, VEGFR2 and CD34 in benign and malignant tumors of parotid glands.
Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.
Expression of Von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis.
Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment.
Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma.
Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.
Expression profile of NF-?B regulated genes in sporadic colorectal cancer patients.
Expression profile of VEGF-C, VEGF-D, VEGFR-3 in different grades of endometrial cancer.
Expression profiles associated with aggressive behavior in Merkel cell carcinoma.
Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
Expression, purification and functionality of bioactive recombinant human vascular endothelial growth factor VEGF165 in E. coli.
Expression, purification, and characterization of a diabody against the most important angiogenesis cell receptor: Vascular endothelial growth factor receptor 2.
Expressional evaluation of vascular endothelial growth factor (VEGF) protein in urinary bladder carcinoma patients exposed to cigarette smoke.
Expressions of ER, PR, HER-2, COX-2, and VEGF in Primary and Relapsed/Metastatic Breast Cancers.
Expressions of miR-29a, TNF-? and Vascular Endothelial Growth Factor in Peripheral Blood of Pulmonary Tuberculosis Patients and Their Clinical Significance.
Expressions of vascular endothelial growth factor and basic fibroblast growth factor in tumors induced by two different cloned cell lines established from transplantable rat malignant fibrous histiocytoma.
Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis.
Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines.
Extracellular matrix metalloproteinase inducer expression has an impact on survival in human bladder cancer.
Extracellular microenvironment and cytokine profile of the ureterovesical junction in children with vesicoureteral reflux.
Extracellular signal-regulated kinases and AP-1 mediate the up-regulation of vascular endothelial growth factor by PDGF in human vascular smooth muscle cells.
Extracorporeal shock wave enhanced extended skin flap tissue survival via increase of topical blood perfusion and associated with suppression of tissue pro-inflammation.
Extracts of endophytic fungus xkc-s03 from Prunella vulgaris L. spica inhibit gastric cancer in vitro and in vivo.
Fabrication of All-Trans Retinoic Acid loaded Chitosan/Tripolyphosphate Lipid Hybrid Nanoparticles as a Novel Oral Delivery Approach for Management of Diabetic Nephropathy in Rats.
Fabrication of vascular endothelial growth factor antibody bioconjugated ultrasmall near-infrared fluorescent Ag2S quantum dots for targeted cancer imaging in vivo.
Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab.
Factors influencing improvement of visual field after trans-sphenoidal resection of pituitary macroadenomas: a retrospective cohort study.
Factors influencing tissue concentration of vascular endothelial growth factor in colorectal carcinoma.
Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts.
Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo.
Fat cell-derived modulators of vascular cell pathophysiology: the list keeps growing.
Fatty acids and expression of adipokines.
Feasibility and tolerability of bevacizumab in children with primary CNS tumors.
Features of Cutaneous Malignant Melanoma Metastatic to the Retina and Vitreous.
Fermentation, purification and immunogenicity of a recombinant tumor multi-epitope vaccine, VBP3.
Fermented goat milk consumption improves cardiovascular health during anemia recovery.
Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Ferulic acid inhibits UVB-radiation induced photocarcinogenesis through modulating inflammatory and apoptotic signaling in Swiss albino mice.
Fetal growth plate: a developmental model of cellular adaptation to hypoxia.
FGF9-induced ovarian cancer cell invasion involves VEGF-A/VEGFR2 augmentation by virtue of ETS1 upregulation and metabolic reprogramming.
FH535, a ?-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis.
FHL family members suppress vascular endothelial growth factor expression through blockade of dimerization of HIF1? and HIF1?.
FHL1 and Smad4 synergistically inhibit vascular endothelial growth factor expression.
Fibrinogen, bFGF and VEGF levels during antibiotic therapy in gynecologic cancer: a preliminary report.
Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells.
Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib.
Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization.
Fibroblast growth factors are required for efficient tumor angiogenesis.
Fibroblasts regulate monocyte response to ECM-derived matrix: the effects on monocyte adhesion and the production of inflammatory, matrix remodeling, and growth factor proteins.
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.
Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas.
Fibulins 3 and 5 antagonize tumor angiogenesis in vivo.
Firefighters' occupational exposure: Contribution from biomarkers of effect to assess health risks.
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
Flavonoids and vitamin E reduce the release of the angiogenic peptide vascular endothelial growth factor from human tumor cells.
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy.
Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo.
Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer.
Flexible FET-Type VEGF Aptasensor Based on Nitrogen-Doped Graphene Converted from Conducting Polymer.
Fli-1 Activation through Targeted Promoter Activity Regulation Using a Novel 3', 5'-diprenylated Chalcone Inhibits Growth and Metastasis of Prostate Cancer Cells.
FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice.
Flow-induced HDAC1 phosphorylation and nuclear export in angiogenic sprouting.
Flow-Related Aneurysm within Glioblastoma: A Case Report and Review of Literature.
Flt-1 signaling in macrophages promotes glioma growth in vivo.
Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
Fluorescence imaging of vascular endothelial growth factor in tumors for mice embedded in a turbid medium.
Fluorescence-Guided Operation in Recurrent Glioblastoma Multiforme Treated with Bevacizumab-Fluorescence of the Noncontrast Enhancing Tumor Tissue?
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
Folate-Targeted and Oxygen/Indocyanine Green-Loaded Lipid Nanoparticles for Dual-Mode Imaging and Photo-sonodynamic/Photothermal Therapy of Ovarian Cancer in Vitro and in Vivo.
Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.
Follicular fluid levels of vascular endothelial growth factor and leptin are associated with pregnancy outcome of normal women participating in intracytoplasmic sperm injection cycles.
Follicular fluid soluble receptor for advanced glycation endproducts (sRAGE): a potential protective role in polycystic ovary syndrome.
Follicular fluid vascular endothelial growth factor and tumour necrosis factor alpha concentrations in patients with endometriosis undergoing ICSI.
Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome.
Fork head box M1 regulates vascular endothelial growth factor-A expression to promote the angiogenesis and tumor cell growth of gallbladder cancer.
Formononetin Antagonizes the Interleukin-1?-Induced Catabolic Effects Through Suppressing Inflammation in Primary Rat Chondrocytes.
Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Fos-icking for control of angiogenesis: increasing the longevity of peritoneal dialysis.
Four Common Vascular Endothelial Growth Factor Polymorphisms (-2578C>A, -460C>T, +936C>T, and +405G>C) in Susceptibility to Lung Cancer: A Meta-Analysis.
Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.
FOXOs in cancer immunity: Knowns and unknowns.
FP3: A Novel VEGF Blocker with Anti-Angiogenic and Anti-Tumor Effects.
FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo.
Fractionated photodynamic therapy for a human oral squamous cell carcinoma xenograft.
Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression.
From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy.
From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer.
Functional and phenotypic differences between glioblastoma multiforme-derived and normal human brain endothelial cells.
Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI.
Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts.
Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Functional in vivo optical imaging of tumor angiogenesis, growth, and metastasis prevented by administration of anti-human VEGF antibody in xenograft model of human fibrosarcoma HT1080 cells.
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.
Functional recovery after hematic administration of allogenic mesenchymal stem cells in acute ischemic stroke in rats.
Functional regulation of adipose-derived stem cells by PDGF-D.
Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity.
Functional vascular endothelial growth factor -2578 C/A polymorphism in relation to nasopharyngeal carcinoma risk and tumor progression.
Functional VEGF and VEGF receptors are expressed in human medulloblastomas.
Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.
Future novel single agent and combination therapies.
G-protein coupled receptor 124 (GPR124) in endothelial cells regulates vascular endothelial growth factor (VEGF)-induced tumor angiogenesis.
G-quadruplex DNAzyme-based electrochemiluminescence biosensing strategy for VEGF165 detection: Combination of aptamer-target recognition and T7 exonuclease-assisted cycling signal amplification.
G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGF?1-induced macrophages.
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Gamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusion.
gamma-Tocotrienol modulates the paracrine secretion of VEGF induced by cobalt(II) chloride via ERK signaling pathway in gastric adenocarcinoma SGC-7901 cell line.
Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
Ganoderma lucidum polysaccharides antagonize the suppression on lymphocytes induced by culture supernatants of B16F10 melanoma cells.
Ganoderma lucidum polysaccharides counteract inhibition on CD71 and FasL expression by culture supernatant of B16F10 cells upon lymphocyte activation.
Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms-A case-control study in an Omani population.
Gastrin stimulates the VEGF-A promotor in a human colon cancer cell line.
Gefitinib inhibits malignant melanoma cells through the VEGF/AKT signaling pathway.
Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells.
Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C>T) gene and patients with stomach cancer.
Gene delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Gene Expression Analysis of the Irrigation Solution Samples Collected during Vitrectomy for Idiopathic Epiretinal Membrane.
Gene expression changes of inflammatory mediators in posterior laryngitis due to laryngopharyngeal reflux and evolution with PPI treatment: a preliminary study.
Gene expression of vascular endothelial growth factor in giant cell tumors of bone.
Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer.
Gene Microarray Analyses of Daboia russelli russelli Daboiatoxin Treatment of THP-1 Human Macrophages Infected with Burkholderia pseudomallei.
Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?
Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor.
Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor--immunotoxin target gene.
Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer.
Gene transfer of kringle 1-5 suppresses tumor development and improves prognosis of mice with hepatocellular carcinoma.
Gene transfer of the vascular endothelial growth factor receptor flt-1 suppresses pulmonary metastasis associated with lung growth.
Gene-linked shift in ganglioside distribution influences growth and vascularity in a mouse astrocytoma.
Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor.
Generation of a Mouse Monoclonal Antibody Recognizing Both the Native and Denatured Forms of Human VEGF.
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.
Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis.
Genetic and environmental determinants of circulating levels of angiogenin in community-based sample.
Genetic and epidemiological risk factors in the development of bronchopulmonary dysplasia.
Genetic and Ethnic Modulation of Cardiovascular Toxicity of Vascular Endothelial Growth Factor Inhibitors.
Genetic Contributions to Childhood Obesity: Association of Candidate Gene Polymorphisms and Overweight/Obesity in Korean Preschool Children.
Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.
Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors.
Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study.
Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian "tumor of breast tissue: incidence, genetics, and environmental risk factors" study.
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk.
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Genetic predisposition to acute kidney injury induced by severe sepsis.
Genetic risk for severe COVID-19 correlates with lower inflammatory marker levels in a SARS-CoV-2-negative cohort.
Genetic susceptibility to progressive massive fibrosis in coal miners.
Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma.
Genetic Variants of VEGF (rs201963 and rs3025039) and KDR (rs7667298, rs2305948, and rs1870377) Are Associated with Glioma Risk in a Han Chinese Population: a Case-Control Study.
Genetic variation determines VEGF-A plasma levels in cancer patients.
Genetics of chronic obstructive pulmonary disease, beyond a1-antitrypsin deficiency.
Genipin inhibits the invasion and migration of colon cancer cells by the suppression of HIF-1? accumulation and VEGF expression.
Genistein suppresses the inflammation and GSK-3 pathway in an animal model of spontaneous ovarian cancer
Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma.
Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 in lung adenocarcinomas.
Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer.
Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer.
Ghrelin-induced gastroprotection against ischemia-reperfusion injury involves an activation of sensory afferent nerves and hyperemia mediated by nitric oxide.
GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.
Gingival crevicular fluid and salivary HIF-1?, VEGF, and TNF-? levels in periodontal health and disease.
Gingival Crevicular Fluid Cytokines in Moderate and Deep Sites of Stage III Periodontitis Patients in Different Rates of Clinical Progression.
Gingival fibroblasts and medication-related osteonecrosis of the jaw: Results by real-time and wound healing in vitro assays.
Gingival Perfusion and Tissue Biomarkers During Early Healing of Post-Extraction Regenerative Procedures: A Prospective Case Series.
Ginkgo biloba Extract Reduces Hippocampus Inflammatory Responses, Improves Cardiac Functions And Depressive Behaviors In A Heart Failure Mouse Model.
Ginsenoside Rf alleviates dysmenorrhea and inflammation through the BDNF-TrkB-CREB pathway in a rat model of endometriosis.
Ginsenoside Rg3 enhances radiosensitization of hypoxic oesophageal cancer cell lines through vascular endothelial growth factor and hypoxia inducible factor 1?
Ginsenoside Rg3 Sensitizes Colorectal Cancer to Radiotherapy through Downregulation of Proliferative and Angiogenic Biomarkers.
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.
Glioblastoma multiforme: clinical findings, magnetic resonance imaging, and pathology in five dogs.
Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches.
Glioma cells under hypoxic conditions block the brain microvascular endothelial cell death induced by serum starvation.
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1.
Glomeruloid microvascular proliferation is superior to intratumoral microvessel density as a prognostic marker in non-small cell lung cancer.
Glomeruloid Microvascular Proliferation, Desmoplasia, and High Proliferative Index as Potential Indicators of High Grade Canine Choroid Plexus Tumors.
Glucocorticoids in the management of peritumoral brain edema: a review of molecular mechanisms.
Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells.
Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma.
Glucose is a key regulator of VEGFR2/KDR in human epithelial ovarian carcinoma cells.
Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF.
Glycine as a potent anti-angiogenic nutrient for tumor growth.
Glycosylation controls cooperative PECAM-VEGFR2-?3 integrin functions at the endothelial surface for tumor angiogenesis.
Glycoxidation and inflammation in renal failure patients.
Gold Nanocrystals with Well-Defined Crystallographic {111} Facets Suppress Pathological Neovascularization.
Gold nanoparticles carrying or not anti-VEGF antibody do not change glioblastoma multiforme tumor progression in mice.
Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma.
GRANULOCYTE INFILTRATION AND EXPRESSION OF THE PRO-ANGIOGENIC BV8 PROTEIN IN EXPERIMENTAL EL4 AND LEWIS LUNG CARCINOMA TUMORS.
Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages.
Granulocyte-colony-stimulating factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 and vascular endothelial growth factor levels.
Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling.
Grape seed proanthocyanidins inhibit colon cancer-induced angiogenesis through suppressing the expression of VEGF and Ang1.
Graphic analysis of microscopic tumor cell infiltration, proliferative potential, and vascular endothelial growth factor expression in an autopsy brain with glioblastoma.
Green fluorescent protein (GFP)-expressing tumor model derived from a spontaneous osteosarcoma in a vascular endothelial growth factor (VEGF)-GFP transgenic mouse.
Green tea catechin inhibits ephrin-A1-mediated cell migration and angiogenesis of human umbilical vein endothelial cells.
Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation.
Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells.
Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.
Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer.
Green Tea Polyphenols Ameliorate Pancreatic Injury in Cerulein-Induced Murine Acute Pancreatitis.
Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Growth and immortalization of human myeloma cells in immunodeficient severe combined immunodeficiency mice: a preclinical model.
Growth factor-mediated interaction between tumor cells and stromal fibroblasts in an experimental model of human small-cell lung cancer.
Growth factors and cytokines in autologous platelet concentrate and their correlation to periodontal regeneration outcomes.
Growth factors and cytokines in wound healing.
Growth factors and their relationship to neoplastic and paraneoplastic disease.
Growth Factors in the Carotid Body-An Update.
Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3.
Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Growth of hepatocellular carcinoma in the regenerating liver.
Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor.
Growth-promoting effect of bisphenol A on neuroblastoma in vitro and in vivo.
H3 Histamine Receptor-Mediated Activation of Protein Kinase C{alpha} Inhibits the Growth of Cholangiocarcinoma In vitro and In vivo.
HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma.
Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group.
Haemoptysis as a prognostic factor in lung adenocarcinoma after curative resection.
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma.
Hans Joachim Scherer and His Impact on the Diagnostic, Clinical, and Modern Research Aspects of Glial Tumors.
Haplotype analysis on chromosome 6p of tumor necrosis factor alpha, vascular endothelial growth factor A, and interleukin-17F alleles associated with corneal transplant rejection.
Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question.
He-Jie-Shen-Shi Decoction as an Adjuvant Therapy on Severe Coronavirus Disease 2019: A Retrospective Cohort and Potential Mechanistic Study.
Head and neck squamous cell carcinoma lymphatic spread and survival: Relevance of vascular endothelial growth factor family for tumor evaluation.
Head-neck cancer drug therapy--could it be improved?
Headache in patients with a meningioma correlates with a bone-invasive growth pattern but not with cytokine expression.
Health Benefits of Polyphenols and Carotenoids in Age-Related Eye Diseases.
Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.
Heat shock protein B6 potently increases non-small cell lung cancer growth.
Heavy metal exposure reverses genetic resistance to Chlamydia-induced arthritis.
Heavy-ion beam irradiation inhibits invasion of tongue squamous cell carcinoma Tca8113 cells.
Hedyotis diffusa Willd. inhibits VEGF?C?mediated lymphangiogenesis in colorectal cancer via multiple signaling pathways.
Helicobacter pylori as an Initiating Factor of Complications in Patients With Cirrhosis: A Single-Center Observational Study.
Hemangiopericytoma of the liver: immunohistochemical observations, expression of angiogenic factors, and review of the literature.
Heme oxygenase-1 expression is associated with tumor aggressiveness and outcomes in patients with bladder cancer: a correlation with smoking intensity.
Hemodiafiltration With Endogenous Reinfusion Improved Microinflammation and Endothelial Damage Compared With Online-Hemodiafiltration: A Hypothesis Generating Study.
Hemoglobin induces the expression and secretion of vascular endothelial growth factor from human malignant cells.
Heparanase and vascular endothelial growth factor expression is increased in hypoxia-induced retinal neovascularization.
Heparanase regulates in vitro VEGF-C expression and its clinical significance to pancreatic ductal cell adenocarcinoma.
Hepatic ischemia-reperfusion increases vascular endothelial growth factor and cancer growth in rats.
Hepatic Radiofrequency Ablation-induced Stimulation of Distant Tumor Growth Is Suppressed by c-Met Inhibition.
Hepatic Thermal Ablation: Effect of Device and Heating Parameters on Local Tissue Reactions and Distant Tumor Growth.
Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice.
Hepatocellular carcinoma cell-derived extracellular vesicles encapsulated microRNA-584-5p facilitates angiogenesis through PCK1-mediated nuclear factor E2-related factor 2 signaling pathway.
Hepatocyte Growth Factor and Macrophage-Stimulating Protein "Hinge" Analogs to Treat Pancreatic Cancer.
Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma.
Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Hepatoma upregulated protein and Ki-67 expression in resectable hepatocellular carcinoma.
Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor.
HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors.
HER-2-positive breast cancer: hope beyond trastuzumab.
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.
Herbal compound "Songyou Yin" reinforced the ability of interferon-alfa to inhibit the enhanced metastatic potential induced by palliative resection of hepatocellular carcinoma in nude mice.
Herbal extract "Songyou Yin" inhibits tumor growth and prolongs survival in nude mice bearing human hepatocellular carcinoma xenograft with high metastatic potential.
Herbal melanin modulates tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) production.
Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines.
Heritability for plasma VEGF concentration in the Stanislas family study.
Herniated and spondylotic intervertebral discs of the human cervical spine: histological and immunohistological findings in 500 en bloc surgical samples. Laboratory investigation.
Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma.
Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor Receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma.
Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation.
Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors.
Heterogeneity of the tumor vasculature.
Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.
Heterogeneous expression of cyclooxygenase-2 and inducible nitric oxide synthase within colorectal tumors: Correlation with tumor angiogenesis.
Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy.
HEXIM1 downregulates Hypoxia Inducible Factor-1 alpha protein stability.
Hhip regulates tumor-stroma-mediated upregulation of tumor angiogenesis.
HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.
HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma.
HIF-1 alpha is required for solid tumor formation and embryonic vascularization.
HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model.
HIF-1alpha and HIF-2alpha are differentially regulated in vivo in neuroblastoma: high HIF-1alpha correlates negatively to advanced clinical stage and tumor vascularization.
HIF-1alpha and VEGF are Associated with Disease Progression in Esophageal Carcinoma.
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.
HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis.
HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array.
High basic fibroblast growth factor levels in nipple aspirate fluid are correlated with breast cancer.
High cell density induces vascular endothelial growth factor expression via protein tyrosine phosphorylation.
High expression levels of Cyr61 and VEGF are associated with poor prognosis in osteosarcoma.
High expression of angiogenic factor AGGF1 is an independent prognostic factor for hepatocellular carcinoma.
High Expression of CCDC34 Is Associated with Poor Survival in Cervical Cancer Patients.
High expression of CD105 as a prognostic predictor of early tongue cancer.
High expression of GADD-45alpha and VEGF induced tumor recurrence via upregulation of IL-2 after photodynamic therapy using NPe6.
High Expression of HuR in Cytoplasm, but Not Nuclei, Is Associated with Malignant Aggressiveness and Prognosis in Bladder Cancer.
High Expression of Neuropilin-1 Associates with Unfavorable Clinicopathological Features in Hepatocellular Carcinoma.
High expression of RELM-? correlates with poor prognosis and promotes angiogenesis in gastric cancer.
High Expression of Retinoblastoma-Binding Protein 2 (RBP2) in Patients with Hepatocellular Carcinoma and Its Prognostic Significance.
High expression of SDF-1 and VEGF is associated with poor prognosis in patients with synovial sarcomas.
High Expression of Solute Carrier Family 2 Member 1 (SLC2A1) in Cancer Cells Is an Independent Unfavorable Prognostic Factor in Pediatric Malignant Peripheral Nerve Sheath Tumor.
High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma.
High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.
High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients.
High glucose promotes tumor cell proliferation and migration in lung adenocarcinoma via the RAGE?NOXs pathway.
High glucose-induced expression of inflammatory cytokines and reactive oxygen species in cultured astrocytes.
High IL-6 and VEGF-A levels correlate with delayed wound healing in cervical lymph node tuberculosis patients.
High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction.
High lactate dehydrogenase 5 expression correlates with high tumoral and stromal vascular endothelial growth factor expression in gastric cancer.
High Leptin/Adiponectin Ratio and Serum Triglycerides Are Associated With an "At-Risk" Phenotype in Young Severely Obese Patients.
High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth factor in patients with renal cell carcinoma.
High level of stabilized angiostatin mediated by adenovirus delivery does not impair the growth of human neuroblastoma xenografts.
High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer.
High Levels of Inflammatory Cytokines in the Reproductive Tract of Women with BV and Engaging in Intravaginal Douching: A Cross-Sectional Study of Participants in the Women Interagency HIV Study.
High levels of oestrogen receptor-alpha in tumorigenesis: inhibition of cell growth and angiogenic factors.
High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection.
High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer.
High microvascular density is correlated with high VEGF, iNOS and COX-2 expression in penetrating growth-type early gastric carcinomas.
High MMP-21 expression in metastatic lymph nodes predicts unfavorable overall survival for oral squamous cell carcinoma patients with lymphatic metastasis.
High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma.
High preoperative plasma vasohibin-1 concentration predicts better prognosis in patients with non-small cell lung carcinoma.
High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.
High salt-induced activation and expression of inflammatory cytokines in cultured astrocytes.
High sensitivity CRP and serum amyloid A as expressions of low grade inflammation do not correlate with bFGF or VEGF.
High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma.
High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study.
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy.
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma.
High urokinase expression contributes to the angiogenic properties of endothelial cells derived from circulating progenitors.
High-affinity VEGF antagonists by oligomerization of a minimal sequence VEGF-binding domain.
High-fat diets promote colon orthotopic transplantation tumor metastasis in BALB/c mice.
High-Fat Meal-Induced Changes in Markers of Inflammation and Angiogenesis in Healthy Adults Who Differ by Age and Physical Activity Level.
High-fat, high-sucrose, and high-cholesterol diets accelerate tumor growth and metastasis in tumor-bearing mice.
High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity.
High-level expression of periostin is significantly correlated with tumor angiogenesis in prostate cancer.
Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases.
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier.
Highly sensitive antibody-aptamer sensor for vascular endothelial growth factor based on hybridization chain reaction and pH meter/indicator.
Highly Sensitive Electrochemical Aptasensor for Detecting the VEGF165 Tumor Marker with PANI/CNT Nanocomposites.
Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors.
Histamine- or vascular endothelial growth factor-induced tissue factor expression and gap formation between vascular endothelial cells are synergistically enhanced by lipopolysaccharide, tumor necrosis factor-?, interleukin (IL)-33 or IL-1?.
Histochemical study of vascular endothelial growth factor in squamous cell carcinoma of the esophagus.
Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations.
Histological analysis of synovium by treatment of etanercept for rheumatoid arthritis.
Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis.
Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin dependent mechanism.
Histopathological, immunohistochemical, and biomechanical effects of splenectomy on Achilles tendon healing in rats.
Honokiol thwarts gastric tumor growth and peritoneal dissemination by inhibiting Tpl2 in an orthotopic model.
Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer.
Hormone-activated nuclear receptors inhibit the stimulation of the JNK and ERK signalling pathways in endothelial cells.
Host A(2B) adenosine receptors promote carcinoma growth.
Host and environmental factors influencing respiratory secretion of pro-wheezing biomarkers in preterm children.
Host response in tumor growth and progression.
Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth.
How far is the horizon? From current targets to future drugs in advanced renal cancer.
How molecular imaging is speeding up antiangiogenic drug development.
Hsp90? promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma.
HTERT mRNA expression correlates with matrix metalloproteinase-1 and vascular endothelial growth factor expression in human breast cancer: a correlative study using RT-PCR.
Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.
Human CD133-positive hematopoietic progenitor cells initiate growth and metastasis of colorectal cancer cells.
Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR.
Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth.
Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis.
Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer.
Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.
Human follicular papilla cells carry out nonadipose tissue production of leptin.
Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen Shedding.
Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.
Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2.
Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism.
Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production.
Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice.
Human periprostatic white adipose tissue is rich in stromal progenitor cells and a potential source of prostate tumor stroma.
Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer.
Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism.
Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients.
Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.
Human Tumor Cells Induce Angiogenesis through Positive Feedback between CD147 and Insulin-Like Growth Factor-I.
Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors.
Human umbilical cord mesenchymal stem cells improve the immune-associated inflammatory and prothrombotic state in collagen type-?-induced arthritic rats.
Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library.
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.
Hyaluronidase treatment of acute lymphedema in a mouse tail model.
Hydrocortisone Suppresses Early Paraneoplastic Inflammation And Angiogenesis To Attenuate Early Hepatocellular Carcinoma Progression In Rats.
Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors.
Hydrogen sulfide modulates epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via HIF-1? activation.
Hydrogen sulfide promotes calcium signals and migration in tumor-derived endothelial cells.
Hydrogen sulfide: potent regulator of vascular tone and stimulator of angiogenesis.
Hydronephrotic Urine in the Obstructed Kidney Promotes Urothelial Carcinoma Cell Proliferation, Migration, Invasion through the Activation of mTORC2-AKT and ERK Signaling Pathways.
Hydroxychloroquine enhances the antitumor effects of BC001 in gastric cancer.
Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-?B signaling pathway in H22 tumor-bearing mice.
Hyperbaric oxygen therapy improves the effect of keloid surgery and radiotherapy by reducing the recurrence rate.
Hypercholesterolemia impairs angiogenesis in patients with breast carcinoma and, therefore, lowers the risk of metastases.
Hypercytokinemia in COVID-19: Tear cytokine profile in hospitalized COVID-19 patients.
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.
Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.
HYPERTENSION DURING VEGF INHIBITION: FOCUS ON NITRIC OXIDE, ENDOTHELIN-1 AND OXIDATIVE STRESS.
Hypertension in cancer patients treated with anti-angiogenic based regimens.
Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.
Hypothalamic ischemia and metabolic syndrome Comment to: Apelin and visfatin: Unique "beneficial" adipokines upregulated in obesity? Jerzy Bełtowski Med Sci Monit, 2006; 12(6): RA112-19.
Hypotheses about sub-optimal hydration in the weeks before coronavirus disease (COVID-19) as a risk factor for dying from COVID-19.
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Hypoxia and reoxygenation augment bone-resorbing factor production from human periodontal ligament cells.
Hypoxia and TGF-?1 lead to endostatin resistance by cooperatively increasing cancer stem cells in A549 transplantation tumors.
Hypoxia and VEGF mRNA expression in human tumors.
Hypoxia in combination with FGF-2 induces tube formation by human microvascular endothelial cells in a fibrin matrix: involvement of at least two signal transduction pathways.
Hypoxia induces pivotal tumor angiogenesis control factors including p53, vascular endothelial growth factor and the NFkappaB-dependent inducible nitric oxide synthase and cyclooxygenase-2.
Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2.
Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells.
Hypoxia Inducible Factor-1 Independent Pathways in Tumor Angiogenesis.
Hypoxia inducible factor-1alpha as a cancer drug target.
Hypoxia promotes tumor growth in linking angiogenesis to immune escape.
Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin.
Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells.
Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells.
Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells.
Hypoxia upregulates Bcl-2 expression and suppresses interferon-gamma induced antiangiogenic activity in human tumor derived endothelial cells.
Hypoxia, angiogenesis, and lung cancer.
Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer.
Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma.
Hypoxia-induced decreases in SOCS3 increase STAT3 activation and upregulate VEGF gene expression.
Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines.
Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis.
Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model.
Hypoxia-induced reactive oxygen species cause chromosomal abnormalities in endothelial cells in the tumor microenvironment.
Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells.
Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer.
Hypoxia-inducible bidirectional shRNA expression vector delivery using PEI/chitosan-TBA copolymers for colorectal Cancer gene therapy.
Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis.
Hypoxia-inducible factor 1 in lower limb ischemia.
Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma.
Hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in cartilage tumors.
Hypoxia-inducible factor 1? in combination with vascular endothelial growth factor could predict the prognosis of postoperative patients with oesophageal squamous cell cancer.
Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer.
Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer.
Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.
Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth.
Hypoxia-inducible factor-1alpha is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor.
Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts.
Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice.
Hypoxia-Inducible Factor-2{alpha} Regulates GM-CSF-Derived Soluble Vascular Endothelial Growth Factor Receptor 1 Production from Macrophages and Inhibits Tumor Growth and Angiogenesis.
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins.
Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase.
Hypoxia-specific downregulation of endogenous human VEGF-A gene by hypoxia-driven expression of artificial transcription factor.
Hypoxic Conditioned Medium From Human Adipose-Derived Stem Cells Promotes Mouse Liver Regeneration Through JAK/STAT3 Signaling.
Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements.
Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc.
ID2-VEGF-related pathways in the pathogenesis of Kaposi's sarcoma: a link disrupted by rapamycin.
Identification and In Vitro Characterization of Phage-Displayed VHHs Targeting VEGF.
Identification and validation of differential plasma proteins levels in epithelial ovarian cancer.
Identification of binding sites for C-terminal pro-gastrin-releasing peptide (GRP)-derived peptides in renal cell carcinoma: a potential target for future therapy.
Identification of Biomarkers for Footpad Dermatitis Development and Wound Healing.
Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration.
Identification of cis- and trans-Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels.
Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.
Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor.
Identification of HDM2 as a regulator of VEGF expression in cancer cells.
Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.
Identification of local angiogenic and inflammatory markers in the menstrual blood of women with endometriosis.
Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
Identification of novel biomarkers in neuroblastoma associated with the risk for bone marrow metastasis: a pilot study.
Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding.
Identification of RSK and TTK as Modulators of Blood Vessel Morphogenesis Using an Embryonic Stem Cell-Based Vascular Differentiation Assay.
Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein.
Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity.
Identified a disintegrin and metalloproteinase with thrombospondin motifs 6 serve as a novel gastric cancer prognostic biomarker by bioinformatics analysis.
Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.
Identifying the association of contrast enhancement with vascular endothelia growth factor expression in anaplastic gliomas: a volumetric magnetic resonance imaging analysis.
IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma.
IgG-recognizing shed tumor-associated antigens can promote tumor invasion and metastasis.
IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program.
IL-17, IL-1beta and TNF-alpha stimulate VEGF production by dedifferentiated chondrocytes.
IL-1? Upregulates IL-8 Production in Human Müller Cells Through Activation of the p38 MAPK and ERK1/2 Signaling Pathways.
IL-1?, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients.
IL-3 is a novel target to interfere with tumor vasculature.
IL-35, TNF-?, BAFF, and VEGF serum levels in patients with different rheumatic diseases.
IL-4 and interferon-gamma differentially modulate vascular endothelial growth factor release from normal human keratinocytes and fibroblasts.
IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells.
IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer.
ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer.
Imaging acute effects of bevacizumab on tumor vascular kinetics in a preclinical orthotopic model of U251 glioma.
Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy.
Imaging key biomarkers of tumor angiogenesis.
Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model.
Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.
Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications.
Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells.
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Imiquimod Inhibits Melanoma Development by Promoting pDC Cytotoxic Functions and Impeding Tumor Vascularization.
Immune dysfunction in cancer patients.
Immune factors associated with the pathological and therapeutic effects of preoperative chemotherapy in patients with breast cancer.
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
Immune regulation in multiple myeloma: the host-tumour conflict.
Immune response against 3LL Lewis lung carcinoma potentiates the therapeutic efficacy of endostatin.
Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
Immune responses in the lungs of patients with tuberculous pleural effusion without pulmonary tuberculosis.
Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues.
Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen.
Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models.
Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates.
Immunogenicity moderation effect of interleukin-24 on myelogenous leukemia cells.
Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature.
Immunoglobulin E induces VEGF production in mast cells and potentiates their pro-tumorigenic actions through a Fyn kinase-dependent mechanism.
Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis.
Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation.
Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas.
Immunohistochemical analysis of vascular endothelial growth factor (VEGF) and p53 expression in pterygium from Tunisian patients.
Immunohistochemical characterization of lymphangiogenesis-related biomarkers in primary and recurrent gliomas: A STROBE compliant article.
Immunohistochemical demonstration of angiogenic growth factors and EGF receptor in hepatic metastases and primary human gastric cancer.
Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate.
Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
Immunohistochemical detection of the 150-kDa oxygen-regulated protein in bladder cancer.
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas.
Immunohistochemical evaluation of prostaglandin E2 and vascular endothelial growth factor in canine cutaneous mast cell tumours.
Immunohistochemical evaluation of vascular endothelial growth factor (VEGF) in colorectal carcinoma.
Immunohistochemical Expression of Epithelial-Mesenchymal Transition Markers in Early Gastric Cancer: Cancer Tissue versus Noncancer Tissue.
Immunohistochemical Expression of Fatty Acid Synthase and Vascular Endothelial Growth Factor in Primary Colorectal Cancer: a Clinicopathological Study.
Immunohistochemical expression of granzyme B and vascular endothelial growth factor (VEGF) in normal uterine cervices and low and high grade squamous intraepithelial lesions.
Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions.
Immunohistochemical expression of vascular endothelial growth factor (VEGF) and p53 in breast lesions.
Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus.
Immunohistochemical Expression of Vascular Endothelial Growth Factor A in Advanced Gallbladder Carcinoma.
Immunohistochemical expression of vascular endothelial growth factor and its correlation with tumor grade in breast ductal carcinoma.
Immunohistochemical expression of vascular endothelial growth factor and microvessel counting as prognostic indicators in node-negative colorectal cancer.
Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas.
Immunohistochemical Expression of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor in Canine Cutaneous Fibrosarcomas.
Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in canine simple mammary gland adenocarcinomas.
Immunohistochemical Expression of Vascular Endothelial Growth Factor as a Prognostic Marker for Canine Mast Cell Tumors.
Immunohistochemical expression of vascular endothelial growth factor correlates with positive surgical margins and recurrence in T1 and T2 squamous cell carcinoma (SCC) of the lower lip.
Immunohistochemical Expression of Vascular Endothelial Growth Factor in Canine Mammary Tumours.
Immunohistochemical expression of vascular endothelial growth factor in canine oral squamous cell carcinomas.
Immunohistochemical investigation of hormone receptors and vascular endothelial growth factor concentration in vestibular schwannoma.
Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Immunohistochemical markers for prognosis of ependymal neoplasms.
Immunohistochemical markers for prognosis of oligodendroglial neoplasms.
Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor.
Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue.
Immunohistochemical profile of the dural tail in intracranial meningiomas.
Immunohistochemical selection of biomarkers for tumor-targeted image-guided surgery of myxofibrosarcoma.
Immunohistochemical study of vascular endothelial growth factor (VEGF), tumor suppressor protein (p53) and intercellular adhesion molecule (ICAM-1) in the conjunctiva of diabetic patients.
Immunohistochemical Vascular Factor Expression in Canine Inflammatory Mammary Carcinoma.
Immunohistochemistry Evaluation of the Effect in Vivo of Tumor Necrosis Factor (TNF)-alpha on Blood Vessel Density in Murine Fibrosarcoma.
Immunohistological analysis of synovium treated with abatacept in rheumatoid arthritis.
Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors.
Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: A pilot study.
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Immunomodulatory effect of captopril and local irradiation on myeloid-derived suppressor cells.
Immunomodulatory Effects of (24R)-Pseudo-Ginsenoside HQ and (24S)-Pseudo-Ginsenoside HQ on Cyclophosphamide-Induced Immunosuppression and Their Anti-Tumor Effects Study.
Immunomodulatory effects of cigarette smoke condensate in mouse macrophage cell line.
Immunomodulatory glc/man-directed Dolichos lablab lectin (DLL) evokes anti-tumour response in vivo by counteracting angiogenic gene expressions.
Immunoprofile from tissue microarrays to stratify familial breast cancer patients.
Immunosuppression in Cows following Intramammary Infusion of Mycoplasma bovis.
Immunotherapy and potential molecular targets for the treatment of pituitary adenomas resistant to standard therapy: a critical review of potential therapeutic targets and current developments.
Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC.
Immunotherapy in patients with less than complete response to chemotherapy.
Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2.
Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.
Impact of acetylsalicylic acid on tumor angiogenesis and lymphangiogenesis through inhibition of VEGF signaling in a murine sarcoma model.
Impact of HLA-DPB1 Haplotypes on Outcome of 10/10 Matched Unrelated Hematopoietic Stem Cell Donor Transplants Depends on MHC-Linked Microsatellite Polymorphisms.
Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer.
Impact of polyphenols on mast cells with special emphasis on the effect of quercetin and luteolin.
Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.
Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer.
Impact of systemic hypoxemia on cancer aggressiveness and circulating vascular endothelial growth factors A and C in gastroesophageal cancer patients with chronic respiratory insufficiency.
Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma.
Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L).
Impact of tumor removal on the systemic oxidative profile of patients with breast cancer discloses lipid peroxidation at diagnosis as a putative marker of disease recurrence.
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms.
Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis.
Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer.
Impact of vascular endothelial growth factor release on radiation resistance.
Impact of VEGF expression on the physiological characteristics of clonal cell lines.
Impact of VEGF-C gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan.
Impact of video-assisted thoracoscopic major lung resection on immune function.
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Impaired contact hypersensitivity reaction and reduced production of vascular endothelial growth factor in tumor necrosis factor-alpha gene-deficient mice.
Impaired healing of fragility fractures in type 2 diabetes: clinical and radiographic assessments and serum cytokine levels.
Impaired production of immune mediators in dengue virus type 2-infected mononuclear cells of adults with end stage renal disease.
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth.
Impaired Vascular Endothelial Growth Factor A and Inflammation in Patients With Peripheral Artery Disease.
Implication of vascular endothelial growth factor in the development and metastasis of human cancers.
Importance of MACC1 expression in breast cancer and its relationship with pathological prognostic markers.
Importance of the putative furin recognition site 742RNRR745 for antiangiogenic Sema3C activity in vitro.
Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model.
Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium.
Improvement of the survival and therapeutic effects of implanted mesenchymal stem cells in a rat model of coronary microembolization by rosuvastatin treatment.
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy.
Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor.
Improving VEGF-targeted therapies through inhibition of COX-2/PGE2 signaling.
In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis.
In pursuit of new anti-angiogenic therapies for cancer treatment.
In situ construction of nanonetworks from transformable nanoparticles for anti-angiogenic therapy.
In the adult mesenchymal stem cell population, source gender is a biologically relevant aspect of protective power.
In vitro and in silico characterization of angiogenic inhibitors from Sophora interrupta.
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.
In vitro anti-inflammatory and wound-healing potential of a Phyllostachys edulis leaf extract--identification of isoorientin as an active compound.
In Vitro AuNPs' Cytotoxicity and Their Effect on Wound Healing.
In Vitro Characterization of the Metabolic Pathways and Cytochrome P450 Inhibition and Induction Potential of BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor.
In vitro chemotherapeutic and antiangiogenic properties of cardenolides from Acokanthera oblongifolia (Hochst.) Codd.
In vitro cytokine release profile: Predictive value for metastatic potential in head and neck squamous cell carcinomas.
In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.
In vitro effects of therapeutic ultrasound on cell proliferation, protein synthesis, and cytokine production by human fibroblasts, osteoblasts, and monocytes.
In vitro evaluation of migratory capacity of human liver stem cells influenced by soluble factors.
In vitro evaluation of optimized liposomes for delivery of small interfering RNA.
In Vitro Kinetic Characterization of Axitinib Metabolism.
In vitro studies on the effect of particle size on macrophage responses to nanodiamond wear debris.
In vitro study of biofunctional indicators after exposure to asbestos-like fluoro-edenite fibres.
In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors.
In vivo and in vitro Approach to Anti-arthritic and Anti-inflammatory Effect of Crocetin by Alteration of Nuclear Factor-E2-Related Factor 2/hem Oxygenase (HO)-1 and NF-?B Expression.
In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model.
In vivo assessment of vascular endothelial growth factor-induced angiogenesis.
In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models.
In Vivo Choroidal Neovascularization and Macrophage Studies Provide Further Evidence for a Broad Role of Prostacyclin in Angiogenesis.
In vivo effect of an luteinizing hormone-releasing hormone analog on vascular endothelial growth factor and epidermal growth factor receptor expression in mammary tumors.
In Vivo Evidences of Nanosecond Pulsed Electric Fields for Melanoma Malignancy Treatment on Tumor-bearing BALB/c Nude Mice.
In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin.
In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies.
In vivo measurement of tumor estradiol and vascular endothelial growth factor in breast cancer patients.
In vivo neutralization of vascular endothelial growth factor (VEGF) vascular permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth.
In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment.
In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice.
In Vivo Recognition of Human Vascular Endothelial Growth Factor by Molecularly Imprinted Polymers.
In vivo release of vascular endothelial growth factor from colorectal carcinomas.
In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
In Vivo, Dual-Modality OCT/LIF Imaging Using a Novel VEGF Receptor-Targeted NIR Fluorescent Probe in the AOM-Treated Mouse Model.
In-silico fragment-based identification of novel angiogenesis inhibitors.
In-vivo anti-tumor activity of a novel poloxamer-based thermosensitive in situ gel for sustained delivery of norcantharidin.
In-vivo wound healing activity of a novel composite sponge loaded with mucilage and lipoidal matter of Hibiscus species.
Inactivation of endothelial cell phosphoinositide 3-kinase ? inhibits tumor angiogenesis and tumor growth.
Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.
Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Incidence and risk factors of pleural effusions in patients with POEMS syndrome.
Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.
Incisor degeneration in rats induced by vascular endothelial growth factor/fibroblast growth factor receptor tyrosine kinase inhibition.
Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm.
Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia.
Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia.
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.
Increased CCL2, CCL3, CCL5, and IL-1? cytokine concentration in piriform cortex, hippocampus, and neocortex after pilocarpine-induced seizures.
Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia.
Increased circulating vascular endothelial growth factor in acute myeloid leukemia patients: a systematic review and meta-analysis.
Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma.
Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma.
Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma.
Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma.
Increased expression of placental growth factor in high-grade endometrial carcinoma.
Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis.
Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study.
Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies.
Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma.
Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma.
Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma.
Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma.
Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms.
Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme.
Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma.
Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis.
Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression.
Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer.
Increased hypoxia-inducible factor 1alpha expression in lung cells of horses with recurrent airway obstruction.
Increased interleukin-6 but not tumour necrosis factor-alpha predicts mortality in the population of elderly heart failure patients.
Increased Levels of NF-kB-Dependent Markers in Cancer-Associated Deep Venous Thrombosis.
Increased levels of plasma haemoxygenase-1 in prostate cancer.
Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease.
Increased levels of tissue endostatin in human malignant gliomas.
Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?
Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor.
Increased matrix metalloproteinase-2 expression and reduced tissue factor pathway inhibitor-2 expression correlate with angiogenesis and early postoperative recurrence of pancreatic carcinoma.
Increased miR-155-5p expression in dermal mesenchymal stem cells of psoriatic patients: comparing the microRNA expression profile by microarray.
Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer.
Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study.
Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice.
Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma.
Increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease.
Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis.
Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera.
Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer.
Increased serum transforming growth factor-beta1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration.
Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription.
Increased vascular endothelial growth factor D is associated with atrial fibrillation and ischaemic stroke.
Increased vascular endothelial growth factor expression, CD3-positive cell infiltration, and oxidative stress in premalignant lesions of the cervix.
Increased vascular endothelial growth factor transcription in residual hepatocellular carcinoma after open versus laparoscopic hepatectomy in a small animal model.
Increased VEGF levels in one case of papillary tumor of the pineal region with intracranial haemorrhage at presentation: a potential surrogate indicator of tumor angiogenesis and aggressiveness?
Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice.
Increased VEGF-A in solid type of lung adenocarcinoma reduces the patients' survival.
Increasing levels of TNFalpha are associated with increased brain perfusion.
Increasing production of matrix metalloproteinases, tumor necrosis factor-?, vascular endothelial growth factor and prostaglandin E2 in rheumatoid arthritis synovial fibroblasts by different adiponectin isoforms in a concentration-dependent manner.
Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab: from bench to bedside?
Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo.
Induced migration of endothelial cells into 3D scaffolds by chemoattractants secreted by pro-inflammatory macrophages in situ.
Inducible expression of endothelial PAS domain protein-1 by hypoxia in human lung adenocarcinoma A549 cells. Role of Src family kinases-dependent pathway.
Inducible nitric oxide synthase-vascular endothelial growth factor axis: a potential target to inhibit tumor angiogenesis by dietary agents.
Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways.
Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells.
Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin).
Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer.
Induction of fibroblast growth factor-9 and interleukin-1alpha gene expression by motorcycle exhaust particulate extracts and benzo(a)pyrene in human lung adenocarcinoma cells.
Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation.
Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells.
Induction of PDGF-B in TCA-treated epidermal keratinocytes.
Induction of prosurvival molecules during treatment: rethinking therapy options for photodynamic therapy.
Induction of Senescence in Cancer Cells by a Novel Combination of Cucurbitacin B and Withanone: Molecular Mechanism and Therapeutic Potential.
Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents.
Induction of vascular endothelial growth factor (VEGF) by hyperthermia and/or an angiogenesis inhibitor.
Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element.
Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma.
Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1.
Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis.
Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma.
Infiltrating angiolipoma of the lower lip: A case report and literature review.
Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence.
Inflammation and cancer: how friendly is the relationship for cancer patients?
Inflammation and cancer: tumor initiation, progression and metastasis, and Chinese botanical medicines.
Inflammation and tumor progression: signaling pathways and targeted intervention.
Inflammation, a Double-Edge Sword for Cancer and Other Age-Related Diseases.
Inflammation, metalloproteinases, and growth factors in the development of carotid atherosclerosis in renal transplant patients.
Inflammation: gearing the journey to cancer.
Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD.
Inflammatory biomarkers and spontaneous preterm birth among obese women.
Inflammatory cytokines and VEGF measured in exhaled breath condensate are correlated with tumor mass in non-small cell lung cancer.
Inflammatory cytokines induce vascular endothelial growth factor-C expression in melanoma-associated macrophages and stimulate melanoma lymph node metastasis.
Inflammatory markers and bone mass in children with overweight/obesity: the role of muscular fitness.
Inflammatory Markers and Severity of Intracerebral Hemorrhage.
Inflammatory markers as risk factors for microangiopathy in type 1 diabetic patients on functional intensive insulin therapy from the onset of the disease.
Inflammatory Markers in Anorexia Nervosa: An Exploratory Study.
Inflammatory mediators and posterior segment involvement in ocular Behcet disease.
Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis.
Inflammatory mediators reduce surface PrPc on human BMVEC resulting in decreased barrier integrity.
Inflammatory Myofibroblastic Tumor of the Urinary Bladder: A Case Report.
Inflammatory response to acute hypoxia in humans.
Inflammatory Serum Biomarkers in Colorectal Cancer in Kazakhstan Population.
Influence of antibiotic therapy on the level of selected angiogenic factors in patients with benign gynecologic tumors--preliminary report.
Influence of Cellular Composition and Exogenous Activation on Growth Factor and Cytokine Concentrations in Canine Platelet-Rich Plasmas.
Influence of cytokine and ICAM-1 gene polymorphisms on susceptibility to chronic pancreatitis.
Influence of cytokine gene polymorphisms on the development of prostate cancer.
Influence of Different Irradiation Protocols on Vascularization and Bone Formation Parameters in Rat Femora.
Influence of growth factors on proliferation and morphogenesis of rabbit ovarian mesothelial cells in vitro.
Influence of heme oxygenase 1 modulation on the progression of murine collagen-induced arthritis.
Influence of hepatic arterial blockage on blood perfusion and VEGF, MMP-1 expression of implanted liver cancer in rats.
Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC.
Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer.
Influence of L-thyroxine administration on poor-platelet plasma VEGF concentrations in patients with induced short-term hypothyroidism, monitored for thyroid carcinoma.
Influence of miR-199a on rats with non-small cell lung cancer via regulating the HIF-1?/VEGF signaling pathway.
Influence of polymorphisms in VEGF, TNF-?, and GSTP1 genes on retinopathy of prematurity risk: a Meta-analysis.
Influence of renin-angiotensin-aldosterone system-blocking drugs on peritoneal membrane in peritoneal dialysis patients.
Influence of Stromal Components on Lung Cancer Carcinogenesis.
Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models.
Influence of vascular endothelial growth factor and radiation on gap junctional intercellular communication in glioblastoma multiforme cell lines.
Influence of vascular endothelial growth factor single nucleotide polymorphisms on non-small cell lung cancer tumor angiogenesis.
Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma.
Influences of brain tumor-associated pH changes and hypoxia on epileptogenesis.
Influences of Bushen Xingnao Decoction on expression of vascular endothelial growth factor, IL-1? and tumor necrosis factor-? in vascular dementia rats.
Influenza A H1N1 pdm09-associated myocarditis during zanamivir therapy.
Inhalation Delivery of a Novel Diindolylmethane Derivative for the Treatment of Lung Cancer.
Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
Inhibiting angiogenesis: interview with Dr Jean Plouët. Interview by Emma Quigley.
Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor.
Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.
Inhibition effect of triptolide on human epithelial ovarian cancer via adjusting cellular immunity and angiogenesis.
Inhibition effects of all trans-retinoic acid on the growth and angiogenesis of esophageal squamous cell carcinoma in nude mice.
Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism.
Inhibition of AGS Cancer Cell Proliferation following siRNA-Mediated Downregulation of VEGFR2.
Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a).
Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.
Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate.
Inhibition of angiogenesis and tumor growth by a novel 1,4-naphthoquinone derivative.
Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo.
Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells.
Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats.
Inhibition of angiogenesis by a novel neutralizing antibody targeting human VEGFR-3.
Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice.
Inhibition of angiogenesis by humulone, a bitter acid from beer hop.
Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin.
Inhibition of angiogenic factor production from murine mast cells by an antiallergic agent (epinastine hydrochloride) in vitro.
Inhibition of Angiogenic Factor Productions by Quercetin In Vitro and In Vivo.
Inhibition of blood-brain barrier efflux transporters promotes seizure in pregnant rats: Role of circulating factors.
Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.
Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.
Inhibition of breast cancer proliferation and metastasis by strengthening host immunity with a prolonged oxygen-generating phototherapy hydrogel.
Inhibition of Caco-2 colon, MCF-7 and Hs578T breast, and DU 145 prostatic cancer cell proliferation by water-soluble black bean condensed tannins.
Inhibition of Carrageenan/Kaolin-Induced Arthritis in Rats and of Inflammatory Cytokine Expressions in Human IL-1?-Stimulated Fibroblast-like Synoviocytes by a Benzylideneacetophenone Derivative.
Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole.
Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus.
Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis.
Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor.
Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling Lee A, Frischer J, Serur A, Huang J, Bae JO, Kornfield ZN, Eljuga L, Shawber CJ, Feirt N, Mansukhani M, Stempak D, Baruchel S, Bender JG, Kandel JJ, Yamashiro DJ, Department of Pediatrics, College of Physicians and Surgeons of Columbia University, New York, NY.
Inhibition of Cyclooxygenase-2 Disrupts Tumor Vascular Mural Cell Recruitment and Survival Signaling.
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.
Inhibition of Ehrlich ascites cancer, hypoxia-inducible factor-1 alpha, and the kinase insert domain-containing receptor/fms-like tyrosine kinase-binding domains of vascular endothelial growth factor by Thiazole Acetamide Derivatives.
Inhibition of endothelial cell differentiation and proinflammatory cytokine production during angiogenesis by allyl isothiocyanate and phenyl isothiocyanate.
Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin.
Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.
Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms.
Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by d-limonene.
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.
Inhibition of heme oxygenase-1 interferes with the transforming activity of the Kaposi sarcoma herpesvirus-encoded G protein-coupled receptor.
Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma.
Inhibition of human breast cancer xenograft growth by cruciferous vegetable constituent benzyl isothiocyanate.
Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
Inhibition of HUVEC tubulogenesis by hederacolchiside-A1 is associated with plasma membrane cholesterol sequestration and activation of the Ha-Ras/MEK/ERK cascade.
Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas.
Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis.
Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity.
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.
Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.
Inhibition of inflammatory angiogenesis by distant subcutaneous tumor in mice.
Inhibition of Jun NH2-Terminal Kinases Suppresses the Growth of Experimental Head and Neck Squamous Cell Carcinoma.
Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence.
Inhibition of liver metastasis of colon cancer by in vivo administration of anti-vascular endothelial growth factor antibody.
Inhibition of lung cancer cell proliferation mediated by human mesenchymal stem cells.
Inhibition of MAP kinase in synovium by treatment with tocilizumab in rheumatoid arthritis.
Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells.
Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
Inhibition of neuropilin-1 by RNA-interference and its angiostatic potential in the treatment of hepatocellular carcinoma.
Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation.
Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice.
Inhibition of Oxygen-Induced Hypoxia-Inducible Factor-1{alpha} Degradation Unmasks Estradiol Induction of Vascular Endothelial Growth Factor Expression in ECC-1 Cancer Cells in Vitro.
Inhibition of pancreatic carcinoma growth by adenovirus-mediated human interleukin-24 expression in animal model.
Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy.
Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas.
Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor.
Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants.
Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.
Inhibition of tissue factor by ixolaris reduces primary tumor growth and experimental metastasis in a murine model of melanoma.
Inhibition of TRAF6 alleviates choroidal neovascularization in vivo.
Inhibition of Triple-Negative Breast Cancer Tumor Growth by Electroacupuncture with Encircled Needling and Its Mechanisms in a Mice Xenograft Model.
Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor.
Inhibition of tumor angiogenesis by interferon-? by suppression of tumor-associated macrophage differentiation.
Inhibition of tumor angiogenesis by oral etoposide.
Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases.
Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.
Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor.
Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.
Inhibition of Tumorigenesis by the Thyroid Hormone Receptor ? in Xenograft Models.
Inhibition of Ultraviolet B-Induced Expression of the Proinflammatory Cytokines TNF-? and VEGF in the Cornea by Fucoxanthin Treatment in a Rat Model.
Inhibition of vacuolar ATPase subunit in tumor cells delays tumor growth by decreasing the essential macrophage population in the tumor microenvironment.
Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.
Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts.
Inhibition of Vascular Endothelial Growth Factor (VEGF)-A Causes a Paradoxical Increase in Tumor Blood Flow and Up-Regulation of VEGF-D.
Inhibition of vascular endothelial growth factor a and hypoxia-inducible factor 1? maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature.
Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients.
Inhibition of vascular endothelial growth factor in the treatment of solid tumors.
Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature.
Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
Inhibition of Vascular Endothelial Growth Factor Receptor-1/Wnt/{beta}-catenin Crosstalk Leads to Tumor Cell Death.
Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist.
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.
Inhibition of VEGF expression in tongue squamous cancer cells via RNA interference silencing of iNOS gene.
Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies.
Inhibition of VEGF transcription through blockade of the hypoxia inducible factor-1?-p300 interaction by a small molecule.
Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.
Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors.
Inhibition of VEGF-Induced VEGFR-2 Activation and HUVEC Migration by Melatonin and Other Bioactive Indolic Compounds.
Inhibition of VEGFA Increases the Sensitivity of Ovarian Cancer Cells to Chemotherapy by Suppressing VEGFA-Mediated Autophagy.
Inhibition of VEGFR-2 Phosphorylation and Effects on Downstream Signaling Pathways in Cultivated Human Endothelial Cells by Stilbenes from Vitis Spp.
Inhibition of xenograft human glioma tumor growth by lentivirus-mediated gene transfer of alphastatin.
Inhibitor of DNA binding 1 activates vascular endothelial growth factor through enhancing the stability and activity of hypoxia-inducible factor-1alpha.
Inhibitors of HIF-1? and CXCR4 Mitigate the Development of Radiation Necrosis in Mouse Brain.
Inhibitors of vascular endothelial growth factor in cancer.
Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer.
Inhibitory effect of atractylenolide I on angiogenesis in chronic inflammation in vivo and in vitro.
Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
Inhibitory effect of dexamethasone on Lewis mice lung cancer cells.
Inhibitory effect of dexamethasone on residual Lewis lung cancer cells in mice following palliative surgery.
Inhibitory effect of electrolyzed reduced water on tumor angiogenesis.
Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene.
Inhibitory effect of nifedipine on tumor necrosis factor alpha-induced neovascularization in cultured choroidal explants of streptozotocin-diabetic rat.
Inhibitory Effects of Anti-VEGF Antibody on the Growth and Angiogenesis of Estrogen-induced Pituitary Prolactinoma in Fischer 344 Rats: Animal Model of VEGF-targeted Therapy for Human Endocrine Tumors.
Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells
Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis.
Inhibitory effects of Chanling Gao on the proliferation and liver metastasis of transplanted colorectal cancer in nude mice.
Inhibitory effects of human lactoferrin on U14 cervical carcinoma through upregulation of the immune response.
Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells.
Inhibitory effects of Lang-du extract on the in vitro and in vivo growth of melanoma cells and its molecular mechanisms of action.
Inhibitory effects of polysaccharide extract from Spirulina platensis on corneal neovascularization.
Inhibitory effects of S100A4 gene silencing on alkali burn-induced corneal neovascularization: an in vivo study.
Inhibitory effects of VEGF-siRNA mediated by adenovirus on osteosarcoma-bearing nude mice.
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression.
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer.
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
Injectable Biodegradable Hydrogels from Vitamin D-Functionalized Polycarbonates for the Delivery of Avastin with Enhanced Therapeutic Efficiency against Metastatic Colorectal Cancer.
Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention.
Innate immune cells induce hemorrhage in tumors during thrombocytopenia.
Inositol Hexaphosphate and Inositol Inhibit Colorectal Cancer Metastasis to the Liver in BALB/c Mice.
Insight into the Role of Angiopoietins in Ageing-Associated Diseases.
Insights in Hodgkin Lymphoma angiogenesis.
Insulin and hypoxia-inducible factor-1 cooperate in pancreatic cancer cells to increase cell viability.
Insulin increases tristetraprolin and decreases VEGF gene expression in mouse 3T3-L1 adipocytes.
Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.
Insulin-like growth factor binding protein-7 (IGFBP7) blocks vascular endothelial cell growth factor (VEGF)-induced angiogenesis in human vascular endothelial cells.
Insulin-Like Growth Factor I (IGF-I) Expressed from an AAV1 Vector Leads to a Complete Reversion of Liver Cirrhosis in Rats.
Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
Integral role of transcription factor 8 in the negative regulation of tumor angiogenesis.
Integrated therapy of kidney cancer.
Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma.
Intense focal expression of vascular endothelial growth-factor messenger-RNA in human intracranial neoplasms - association with regions of necrosis.
Interaction of vascular endothelial growth factor and heparin quantified by single molecule force spectroscopy.
Interactions between osteopontin and vascular endothelial growth factor: Implications for cancer.
Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
Interferon ?-inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival.
Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice.
Interferon gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells.
Interferon-? efficiently inhibited endothelial progenitor cell-induced tumor angiogenesis.
Interferon-alpha as angiogenesis inhibitor: learning from tumor models.
Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Interferon-Gamma and Tumor Necrosis Factor-Related Weak Inducer of Apoptosis Expression in Neoangiogenesis in Colorectal Polypoid Lesions.
Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer.
Interleukin 12-activated lymphocytes influence tumor genetic programs.
Interleukin 4, interleukin 6 and osteopontin-serological markers of head and neck malignancy in primary diagnostics: A pilot study.
Interleukin-12 deficiency is permissive for angiogenesis in UV radiation-induced skin tumors.
Interleukin-13 and age-related macular degeneration.
Interleukin-17 potently increases non-small cell lung cancer growth.
Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival.
Interleukin-1? promotes ovarian tumorigenesis through a p53/NF-?B-mediated inflammatory response in stromal fibroblasts.
Interleukin-1alpha, 6 regulate the secretion of vascular endothelial growth factor A, C in pancreatic cancer.
Interleukin-1beta regulates angiopoietin-1 expression in human endothelial cells.
Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.
Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk.
Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma.
Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions.
Interleukin-6: An angiogenic target in solid tumours.
Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations.
Intermittent hypoxia increases kidney tumor vascularization in a murine model of sleep apnea.
Intermittent Hypoxia Is Associated With High Hypoxia Inducible Factor-1? but Not High Vascular Endothelial Growth Factor Cell Expression in Tumors of Cutaneous Melanoma Patients.
Interplay of VEGFa and MMP2 regulates invasion of glioblastoma.
Interpretation of Pin-1 and VEGF-C expression in breast infiltrating duct carcinoma.
Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma.
Interruption of the HGF paracrine loop by NK4, an HGF antagonist, reduces VEGF expression of CT26 cells.
Intra-amniotic infection upregulates decidual cell vascular endothelial growth factor (VEGF) and neuropilin-1 and -2 expression: implications for infection-related preterm birth.
Intra-arterial injection of human adipose-derived stem cells improves viability of the random component of axial skin flaps in nude mice.
Intra-Arterial Transplantation of Adult Bone Marrow Cells Restores Blood Flow and Regenerates Skeletal Muscle in Ischemic Limbs.
Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels.
Intracameral Interleukin 1?, 6, 8, 10, 12p, Tumor Necrosis Factor ? and Vascular Endothelial Growth Factor and Axial Length in Patients with Cataract.
Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib.
Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189.
Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells.
Intraductal papillary mucinous neoplasms of the pancreas: an analysis of protein expression and clinical features.
Intralesional bevacizumab as in-add adjuvant to immunocryosurgery for locally advanced basal cell carcinoma.
Intramuscular gene transfer of soluble tumor necrosis factor-alpha receptor 1 activates vascular endothelial growth factor receptor and accelerates angiogenesis in a rat model of hindlimb ischemia.
Intranasal delivery of self-assembled nanoparticles of therapeutic peptides and antagomirs elicits anti-tumor effects in an intracranial glioblastoma model.
Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: Implications for alternative response criteria.
Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age-related macular degeneration, glaucoma and cataract.
Intraocular use of bevacizumab in India: An issue resolved?
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
Intraperitoneal administration of bevacizumab intraoperatively does not affect abdominal wound healing in rats.
Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108.
Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway.
Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: the first step before intraperitoneal anti-vascular endothelial growth factor treatment?
Intraperitoneal Vascular Endothelial Growth Factor: A Prognostic Factor and the Potential for Intraperitoneal Bevacizumab Use in Peritoneal Surface Malignancies.
Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?
Intraplatelet Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor: New Biomarkers in Carcinoembryonic Antigen-Negative Colorectal Cancer?
Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice.
Intratumoral delivery and therapeutic efficacy of nanoparticle-encapsulated anti-tumor siRNA following intrapulmonary administration for potential treatment of lung cancer.
Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts.
Intratumoral hemorrhage in a patient with cerebellar hemangioblastoma: a case report and review.
Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors.
Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer.
Intratumoral lymphangiogenesis and prognostic significance of VEGFC expression in gastric cancer.
Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx.
Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer.
Intravenous Administration Is an Effective and Safe Route for Cancer Gene Therapy Using the Bifidobacterium-Mediated Recombinant HSV-1 Thymidine Kinase and Ganciclovir.
Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains.
Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity.
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration.
Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury.
Intravitreal neurodegenerative and inflammatory mediators in proliferative diabetic retinopathy.
Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors.
Intussusceptive Angiogenesis in Human Metastatic Malignant Melanoma.
Intussusceptive microvascular growth in human glioma.
Invasion as limitation to anti-angiogenic glioma therapy.
Invasive Pituitary Adenoma-Derived Tumor-Associated Fibroblasts Promote Tumor Progression both In Vitro and In Vivo.
Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer.
Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors.
Investigating associations of cyclooxygenase-2 expression with angiogenesis, proliferation, macrophage and T-lymphocyte infiltration in canine melanocytic tumours.
Investigating the antiproliferative activity of high affinity DNA aptamer on cancer cells.
Investigating the effects of carvacrol in rats using oxygen-induced retinopathy model.
Investigating the role of angiogenesis in systemic lupus erythematosus.
Investigation of circulating endothelial progenitor cells and angiogenic and inflammatory cytokines during recovery from an episode of major depression.
Investigation of gene expression profiles in a rat adjuvant arthritis model suggests an effective role of triptolide via PI3K-AKT signaling.
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
Investigation of pulmonary involvement in inflammatory bowel disease in an experimental model of colitis.
Investigation of the maternal and cord plasma levels of IL-1 beta, TNF-alpha and VEGF in early membrane rupture.
Investigation of the therapeutic efficacy of codelivery of psiRNA-vascular endothelial growth factor and pIL-4 into chitosan nanoparticles in the breast tumor model.
Involvement of cyclooxygenase-2 and vascular endothelial growth factor in vascularization and lymph node metastasis of colorectal cancers with submucosal invasion.
Involvement of hypoxia-inducible factor 1 in human cancer.
Involvement of inactive GSK3beta overexpression in tumorigenesis and progression of gastric carcinomas.
Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis.
Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells.
Involvement of Tumor Lymphatic System in Translocation of Intratumorally Injected Liposomes.
Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis.
Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma.
Ionizing radiation induces tumor cell lysyl oxidase secretion.
IQGAP1-dependent signaling pathway regulates endothelial cell proliferation and angiogenesis.
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.
Irisin and inflammatory cytokines in elite male rowers: adaptation to volume-extended training period.
Irradiated VEGF164-modified tumor cell vaccine protected mice from the parental tumor challenge.
Is Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) a Subset of Rheumatoid Arthritis?
Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?
Is there a Role for Bevacizumab in Non-Glial Tumors?
Is there a role of platelet-activating factor in human lung cancer?
Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?
Is YKL-40 a new therapeutic target in cancer?
Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?
Ischemic Stroke May Activate Bone Marrow Mononuclear Cells to Enhance Recovery After Stroke.
Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development.
Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature.
Isolation and Identification of Proteins Secreted by Cells Cultured within Synthetic Hydrogel-Based Matrices.
Isolation and purification of vascular endothelial growth factor (VEGF) from ascitic fluid of ovarian cancer patients.
Isomers of conjugated linoleic acid differ in their effects on angiogenesis and survival of mouse mammary adipose vasculature.
Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells.
ISSLS PRIZE IN BASIC SCIENCE 2018: Growth differentiation factor-6 attenuated pro-inflammatory molecular changes in the rabbit anular-puncture model and degenerated disc-induced pain generation in the rat xenograft radiculopathy model.
It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies.
IVF outcome in women with endometriosis in relation to tumour necrosis factor and anti-Müllerian hormone.
Jagged Ligands Enhance the Pro-Angiogenic Activity of Multiple Myeloma Cells.
JMJD6 exerts function in neuropathic pain by regulating NF??B following peripheral nerve injury in rats.
JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells.
Juvenile hemangioma of the testis: analysis of expression of angiogenic factors.
Juxtaglomerular cell tumor: Clinical and immunohistochemical features.
K20E, an oxidative-coupling compound of methyl caffeate, exhibits anti-angiogenic activities through down-regulations of VEGF and VEGF receptor-2.
Kallistatin protects against bleomycin-induced idiopathic pulmonary fibrosis by inhibiting angiogenesis and inflammation.
Kallistatin suppresses cancer development by multi-factorial actions.
Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist.
Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression.
Kawasaki disease seasonality in Venezuela supports an arbovirus infection trigger.
KDR activation in astrocytic neoplasms.
KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Key roles for the lipid signaling enzyme phospholipase d1 in the tumor microenvironment during tumor angiogenesis and metastasis.
Keystone symposia: antibody-based therapeutics for cancer.
Kidney injury during VEGF inhibitor therapy.
Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor.
Kinetics of viral load and cytokines in severe fever with thrombocytopenia syndrome.
Kisspeptin/Kiss1r system and angiogenic and immunological mediators at the maternal-fetal interface of domestic cats.
Knockdown of HMGN5 increases the chemosensitivity of human urothelial bladder cancer cells to cisplatin by targeting PI3K/Akt signaling.
Knockdown of VEGFR2 inhibits proliferation and induces apoptosis in hemangioma-derived endothelial cells.
KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth.
KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties.
l-Cysteine decorated nanoscale metal-organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy.
L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma.
L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas.
l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms.
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Lack of association between VEGF -2578C/A polymorphism and risk of colorectal cancer in an Iranian population.
Lack of Effect of Brivanib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, Administered Intravenously and Orally in Healthy Participants.
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.
Lack of immunohistochemical detection of VEGF in prostate carcinoma.
Lactate administration reproduces specific brain and liver exercise-related changes.
Lactate Consumption via Cascaded Enzymes Combined VEGF siRNA for Synergistic Anti-Proliferation and Anti-Angiogenesis Therapy of Tumors.
Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer.
Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis.
Laminin alpha2 chain (merosin M chain) distribution and VEGF, FGF(2), and TGFbeta1 gene expression in angiogenesis of supraglottic, lung, and breast carcinomas.
Landscape of Molecular Events in Pituitary Apoplexy.
Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea.
Large-scale production, purification, and function of a tumor multi-epitope vaccine: Peptibody with bFGF/VEGFA.
Lathyrus sativus diamine oxidase reduces Clostridium difficile toxin A-induced toxicity in Caco-2 cells by rescuing RhoA-GTPase and inhibiting pp38-MAPK/NF-?B/HIF-1? activation.
LDH-A influences hypoxia-inducible factor 1? (HIF1 ?) and is critical for growth of HT29 colon carcinoma cells in vivo.
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells.
Lentivirus-Mediated RNAi Silencing of VEGF Inhibits Angiogenesis and Growth of Renal Cell Carcinoma in a Nude Mouse Xenograft Model.
Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied.
Lenvatinib: A Review in Refractory Thyroid Cancer.
Leptin and other secretory products of adipocytes modulate multiple physiological functions.
Leptin serves as angiogenic/mitogenic factor in melanoma tumor growth.
Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2).
Leptin-induced transphosphorylation of vascular endothelial growth factor receptor increases Notch and stimulates endothelial cell angiogenic transformation.
Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer.
Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.
Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1.
Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro.
Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor.
Leukotriene D4 enhances tumor necrosis factor-?-induced vascular endothelial growth factor production in human monocytes/macrophages.
Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma.
Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma.
Levels of endothelial substances in patients with newly identified hypertension compared with healthy controls.
Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.
LHRH Receptor-Mediated Delivery of siRNA Using Polyelectrolyte Complex Micelles Self-Assembled from siRNA-PEG-LHRH Conjugate and PEI.
Licochalcone E present in licorice suppresses lung metastasis in the 4T1 mammary orthotopic cancer model.
Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors.
LINC00628 suppresses migration and invasion of hepatocellular carcinoma by its conserved region interacting with the promoter of VEGFA.
Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and -186 expression: Novel mechanism of VEGF modulation in prostate cancer.
Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference.
Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor.
Lipid hydroperoxide-induced tumor necrosis factor (TNF)-alpha, vascular endothelial growth factor and neovascularization in the rabbit cornea: effect of TNF inhibition.
Lipid profile and serum characteristics of the blind subterranean mole rat, Spalax.
Lipopolysaccharide preconditioning of adipose-derived stem cells improves liver-regenerating activity of the secretome.
Lipopolysaccharide-Induced Profiles of Cytokine, Chemokine, and Growth Factors Produced by Human Decidual Cells Are Altered by Lactobacillus rhamnosus GR-1 Supernatant.
Lipopolysaccharide-Squamous Cell Carcinoma-Monocyte Interactions Induce Cancer-Supporting Factors Leading to Rapid STAT3 Activation.
Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer.
Liposome-encapsulated curcumin suppresses neuroblastoma growth through nuclear factor-kappa B inhibition.
Liposome-mediated gene transfer of K1-5 suppresses tumor development and improves the prognosis of hepatocellular carcinoma in mice.
Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis.
Liquiritigenin Inhibits Serum-induced HIF-1? and VEGF Expression via the AKT/mTOR-p70S6K Signalling Pathway in HeLa Cells.
Liquiritigenin inhibits tumor growth and vascularization in a mouse model of HeLa cells.
LncRNA DANCR promotes tumor growth and angiogenesis in ovarian cancer through direct targeting of miR-145.
LncRNA MAGI2-AS3 inhibits tumor progression and angiogenesis by regulating ACY1 via interacting with transcription factor HEY1 in clear cell renal cell carcinoma.
Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation.
Local application of low-dose insulin in improving wound healing after deep burn surgery.
Local Delivery of Chitosan/VEGF siRNA Nanoplexes Reduces Angiogenesis and Growth of Breast Cancer In Vivo.
Local delivery of thalidomide to inhibit neointima formation in rat model with artery injury.
Localization of basic fibroblast growth factor and vascular endothelial growth factor in human glial neoplasms.
Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features.
Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis.
Localized and metastatic myxoid/round cell liposarcoma: Clinical and molecular observations.
Localized controlled release of bevacizumab and doxorubicin by thermo-sensitive hydrogel for normalization of tumor vasculature and to enhance the efficacy of chemotherapy.
Long non-coding RNA growth arrest specific transcript 5 acts as a tumour suppressor in colorectal cancer by inhibiting interleukin-10 and vascular endothelial growth factor expression.
Long non?coding RNA MEG?3 suppresses gastric carcinoma cell growth, invasion and migration via EMT regulation.
Long Term Survival of Mice With Hepatocellular Carcinoma after Pulse Power Ablation with Nanosecond Pulsed Electric FieldsT.
Long-term alpha-tocopherol supplementation is associated with lower serum vascular endothelial growth factor levels.
Long-term follow-up of immunocytochemical analysis of vascular endothelial growth factor (VEGF), and its two receptors, VEGF-R1 (Flt-1) and VEGF-R2 (Flk-1/KDR), in oesophagogastric cancer.
Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review.
Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment.
Long-term therapy with bevacizumab in a young patient affected by NF-2: a case report and review of the literature.
LONG-TERM VISUAL ACUITY PRESERVATION IN SORSBY FUNDUS DYSTROPHY WITH CORTICOSTEROID TREATMENT.
Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo.
Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions.
Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin ?v? 3 and vascular endothelial growth factor.
Longitudinal phenotypic study of late-onset retinal degeneration due to a founder variant c.562C>A p.(Pro188Thr) in the C1QTNF5 gene.
Loss of Epigenetic Kruppel-like Factor 4 Histone Deacetylase (KLF-4-HDAC)-mediated Transcriptional Suppression Is Crucial in Increasing Vascular Endothelial Growth Factor (VEGF) Expression in Breast Cancer.
Loss of expression of TIMP3 in clear cell renal cell carcinoma.
Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.
Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis.
Loss of p16INK4a expression is associated with vascular endothelial growth factor expression in squamous cell carcinoma of the esophagus.
Loss of Serglycin Promotes Primary Tumor Growth and Vessel Functionality in the RIP1-Tag2 Mouse Model for Spontaneous Insulinoma Formation.
Loss of the endothelial glycocalyx is associated with increased E-selectin mediated adhesion of lung tumour cells to the brain microvascular endothelium.
Loss of vascular endothelial growth factor a activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation.
Loss of vascular endothelial growth factor expression reduces vascularization, but not growth, of tumors lacking the Von Hippel-Lindau tumor suppressor gene.
Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis.
Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer.
Low grade inflammation inhibits VEGF induced HUVECs migration in p53 dependent manner.
Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis?
Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors.
Low plasma levels of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNFalpha), and vascular endothelial growth factor (VEGF) in patients with alpha1-antitrypsin deficiency-related fibromyalgia.
Low plasma vascular endothelial growth factor (VEGF) associated with completed suicide.
Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma.
Low TGF-?1 in Wound Exudate Predicts Surgical Site Infection After Axillary Lymph Node Dissection.
Low-concentration detergent sclerosants stimulate white blood cells and release proinflammatory and proangiogenic cytokines in vitro.
Low-Dose Docetaxel Combined with (-)-Epigallocatechin-3-Gallate Inhibits Angiogenesis and Tumor Growth in Nude Mice with Gastric Cancer Xenografts.
Low-frequency ultrasound enhances vascular endothelial growth factor expression, thereby promoting the wound healing in diabetic rats.
Low-frequency ultrasound-induced VEGF suppression and synergy with dendritic cell-mediated anti-tumor immunity in murine prostate cancer cells in vitro.
Low-level laser therapy alleviates neuropathic pain and promotes function recovery in rats with chronic constriction injury-possible involvements in hypoxia-inducible factor 1? (HIF-1?).
Low-molecular weight chitosan/vascular endothelial growth factor short hairpin RNA for the treatment of hepatocellular carcinoma.
Low-Molecular-Weight Heparin Reduces Ventilation-Induced Lung Injury through Hypoxia Inducible Factor-1? in a Murine Endotoxemia Model.
Loxoprofen sodium suppresses mouse tumor growth by inhibiting vascular endothelial growth factor.
LQFM030 reduced Ehrlich ascites tumor cell proliferation and VEGF levels.
LSD1 demethylates HIF1? to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis.
Lung tumor growth-promoting function of peroxiredoxin 6.
Lung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16.
Luteolin inhibits human keratinocyte activation and decreases NF-?B induction that is increased in psoriatic skin.
Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells.
Luteolysis and the Auto-, Paracrine Role of Cytokines From Tumor Necrosis Factor ? and Transforming Growth Factor ? Superfamilies.
Lycopene inhibits experimental metastasis of human hepatoma SK-Hep-1 cells in athymic nude mice.
Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes.
Lymphangiogenesis and anti-tumor immune responses.
Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Lymphangiogenesis and Podoplanin Expression in Oral Squamous Cell Carcinoma and the Associated Lymph Nodes.
Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma.
Lymphangiogenesis and tumour metastasis.
Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis.
Lymphangiogenesis in human gynaecological cancers.
Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
Lymphangiogenesis in regional lymph nodes predicts nodal recurrence in pathological N0 squamous cell carcinoma of the tongue.
Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas.
Lymphangiogenic growth factors as markers of tumor metastasis.
Lymphatic dissemination of tumour cells and the formation of micrometastases.
Lymphatic microvessel density as prognostic marker in colorectal cancer.
Lymphatic vessel density and VEGF-C expression as independent predictors of melanoma metastases.
Lymphatic vessel density in pulmonary adenocarcinoma immunohistochemically evaluated with anti-podoplanin or anti-D2-40 antibody is correlated with lymphatic invasion or lymph node metastases.
Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer.
Lymphatic Vessels and High Endothelial Venules are Increased in the Sentinel Lymph Nodes of Patients with Oral Squamous Cell Carcinoma Before the Arrival of Tumor Cells.
Lymphatics at the crossroads of angiogenesis and lymphangiogenesis.
Lysine methylation promotes VEGFR-2 activation and angiogenesis.
Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.
Lysophosphatidic acid induces reactive oxygen species generation by activating protein kinase C in PC-3 human prostate cancer cells.
Lysozyme-Antimicrobial Peptide Fusion Protein Promotes the Diabetic Wound Size Reduction in Streptozotocin (STZ)-Induced Diabetic Rats.
Lysyl oxidase assists tumor?initiating cells to enhance angiogenesis in hepatocellular carcinoma.
Macrophage CCL22 expression promotes lymphangiogenesis in patients with tongue squamous cell carcinoma via IL-4/STAT6 in the tumor microenvironment.
Macrophage colony-stimulating factor induces vascular endothelial growth factor production in skeletal muscle and promotes tumor angiogenesis.
Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer.
Macrophage inflammatory protein-2 promotes angiogenesis, cell migration, and tumor growth in hepatic metastasis.
Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma.
Macrophage-derived inflammatory cytokines regulate growth factors and pain-related molecules in mice with intervertebral disc injury.
Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice.
Macrophages promote angiogenesis in human breast tumour spheroids in vivo.
Macrophages Promote Growth of Squamous Cancer Independent of T cells.
Macroscopic portal vein tumor thrombi of liver metastasis from colorectal cancer.
Magnetic fluid hyperthermia inhibits the growth of breast carcinoma and downregulates vascular endothelial growth factor expression.
Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor.
Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor.
Magnetic-composite-modified polycrystalline-silicon nanowire field-effect transistor for vascular endothelial growth factor detection and cancer diagnosis.
Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods.
Major surgery increases serum levels of vascular endothelial growth factor only temporarily.
MALDI-MSI and label-free LC-ESI-MS/MS shotgun proteomics to investigate protein induction in a murine fibrosarcoma model following treatment with a vascular disrupting agent.
Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6.
Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.
Malignant pleural effusion cells show aberrant glucose metabolism gene expression.
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma.
Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro.
Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells.
Mammalian tumor xenografts induce neovascularization in zebrafish embryos.
Mammary cancer gene therapy targeting lymphangiogenesis: VEGF-C siRNA and soluble VEGF receptor-2, a splicing variant.
Management of advanced medullary thyroid cancer.
Management of Hyperglycaemia by Ethyl Acetate Extract of Balanites aegyptiaca (Desert Date).
Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus.
Managing patients treated with bevacizumab combination therapy.
Managing patients with metastatic colorectal cancer on bevacizumab.
Manipulating Angiogenesis by Targeting Endothelial Metabolism: Hitting the Engine Rather than the Drivers-A New Perspective?
Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity.
MAP kinases and hypoxia in the control of VEGF expression.
MAPKAPK2 plays a crucial role in the progression of head and neck squamous cell carcinoma by regulating transcript stability.
Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker.
Markers of angiogenesis and clinical features in patients with sarcoma.
Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer.
Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
Markers of degeneration and regeneration in Duchenne muscular dystrophy.
Markers of response for the antiangiogenic agent bevacizumab.
Markers of systemic inflammation in periodontal patients: chronic versus aggressive periodontitis. An explorative cross-sectional study.
MARKERS OF THE LUNG CANCER COMPLICATIONS.
Markers of tumour angiogenesis and tumour cells in bone marrow in gastric cancer patients.
Massive ascites as the initial manifestation of mantle cell lymphoma: a challenge for the gastroenterologist.
Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis.
Mast cells contribute to Enterovirus 71 infection-induced pulmonary edema in neonatal mice.
Maternal plasma levels of cytokines in normal and preeclamptic pregnancies and their relationship with diastolic blood pressure and fibronectin levels.
Maternal serum adipokines and inflammatory markers at late gestation and newborn weight in mothers with and without gestational diabetes mellitus.
Mathematical Model Predicts Effective Strategies to Inhibit VEGF-eNOS Signaling.
Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Maximal exercise, limb ischemia, and endothelial progenitor cells.
MAZ51 Blocks the Tumor Growth of Prostate Cancer by Inhibiting Vascular Endothelial Growth Factor Receptor 3.
MCF7-MSC co-culture assay: approach to assess the co-operation between MCF-7s and MSCs in tumor-induced angiogenesis.
Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas.
MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia.
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Measuring permeability with a whole cell-based biosensor as an alternate assay for angiogenesis: comparison with common in vitro assays.
Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
Mechanical loading of intervertebral disc modulates microglia proliferation, activation, and chemotaxis.
Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor.
Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1.
Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts.
Mechanism of vascular endothelial growth factor expression mediated by cisplatin in human ovarian cancer cells.
Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling.
Mechanisms Governing Anaphylaxis: Inflammatory Cells, Mediators, Endothelial Gap Junctions and Beyond.
Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer.
Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.
Mechanisms of human amniotic epithelial cell transplantation in treating stage III pressure ulcer in a rat model.
Mechanisms of hypertension associated with BAY 43-9006.
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.
Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs.
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells.
Mechanistic analysis of pancreatic ductal carcinogenesis in hamsters.
Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer.
Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment.
Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma.
Medical management of high-grade astrocytoma: current and emerging therapies.
Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.
MEK mediates the novel cross talk between TNFR2 and TGF-EGFR in enhancing vascular endothelial growth factor (VEGF) secretion from human mesenchymal stem cells.
MEK, P38 AND PI-3K MEDIATE CROSS TALK BETWEEN EGFR AND TNFR IN ENHANCING HEPATOCYTE GROWTH FACTOR PRODUCTION FROM HUMAN MESENCHYMAL STEM CELLS.
Melanoma antigen-encoding gene-1 expression in invasive gastric carcinoma: correlation with stage of disease.
Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF.
Melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis--the role of platelet-derived growth factor.
Melanoma cells use Thy-1 (CD90) on endothelial cells for metastasis formation.
Melanoma presenting as circulating tumor cells associated with failed angiogenesis.
Melanoma-Derived Soluble DC-HIL/GPNMB Promotes Metastasis by Excluding T-Lymphocytes from the Pre-Metastatic Niches.
Melatonin and pancreatic cancer: Current knowledge and future perspectives.
Melatonin decreases muscular oxidative stress and inflammation induced by strenuous exercise and stimulates growth factor synthesis.
Melatonin inhibits angiogenesis in SH-SY5Y human neuroblastoma cells by downregulation of VEGF.
Melatonin prevents human pancreatic carcinoma cell PANC-1-induced human umbilical vein endothelial cell proliferation and migration by inhibiting vascular endothelial growth factor expression.
Melittin suppresses tumor progression by regulating tumor-associated macrophages in a Lewis lung carcinoma mouse model.
Melittin Suppresses VEGF-A-Induced Tumor Growth by Blocking VEGFR-2 and the COX-2-Mediated MAPK Signaling Pathway.
Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes.
Membrane-bound estrogen receptor-alpha expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients.
Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema.
Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells.
Mesenchymal stem cell prevention of vascular remodeling in high flow-induced pulmonary hypertension through a paracrine mechanism.
Mesenchymal stem cell therapy inhibited inflammatory and profibrotic pathways induced by partial bladder outlet obstruction and prevented high-pressure urine storage.
Mesenchymal Stem Cells From Bone Marrow, Adipose Tissue, and Lung Tissue Differentially Mitigate Lung and Distal Organ Damage in Experimental Acute Respiratory Distress Syndrome.
Mesenchymal stem cells pretreated with platelet-rich plasma modulate doxorubicin-induced cardiotoxicity.
Mesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor ?1.
Mesenchymal Stromal Cells Are More Effective Than Their Extracellular Vesicles at Reducing Lung Injury Regardless of Acute Respiratory Distress Syndrome Etiology.
MET and VEGF: synergistic targets in castration-resistant prostate cancer.
MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation.
Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome.
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case-control studies.
Metabolic and molecular relative percentage coreduction in patients with locally advanced rectal cancer treated with neoadjuvant therapy.
Metabolic endotoxaemia in childhood obesity.
Metabolic profile of a peptide-conjugated chlorin-type photosensitizer targeting neuropilin-1: an in vivo and in vitro study.
Metabolic response evaluation for colorectal liver metastases and correlation to pathologic response and tumour markers.
Metabolic Response to Claudication in Peripheral Arterial Disease: a Microdialysis pilot study.
Metabolo-volumetric parameters of 18F-FDG-PET can predict expression of EGFR and HIF 1alpha in uterine cervical cancer.
Metastasis associated protein 1 correlates with Hypoxia inducible-factor 1 alpha expression and lymphangiogenesis in esophageal cancer.
Metastasis correlates with production of vascular endothelial growth factor in a murine model of human Wilms' tumor.
Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways.
Metastasis-promoting role of extravasated platelet activation in tumor.
Metastatic brain mass caused by slow-growing small-cell lung cancer: differential vascular endothelial growth factor expression in primary and metastatic tumor.
Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy.
Metastatic papillary craniopharyngioma: case study and study of tumor angiogenesis.
Metastatic properties of prostate cancer cells are controlled by VEGF.
Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor.
Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer.
Metformin attenuated histopathological ocular deteriorations in a streptozotocin-induced hyperglycemic rat model.
Metformin Prevents the Development of Chronic Heart Failure in the SHHF Rat Model.
Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Methoxyluteolin Inhibits Neuropeptide-stimulated Proinflammatory Mediator Release via mTOR Activation from Human Mast Cells.
Methylseleninic acid restricts tumor growth in nude mice model of metastatic breast cancer probably via inhibiting angiopoietin-2.
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
Metronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft.
Micro-positron emission tomography imaging of angiogenesis based on 18F-RGD for assessing liver metastasis of colorectal cancer.
Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia.
Microparticles from VEGF inhibitor-treated cancer patients mediate endothelial cell injury.
MicroRNA-195 vector influence on the development of gradually induced hepatocellular carcinoma in murine model.
MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
MicroRNA-27b, microRNA-101 and microRNA-128 inhibit angiogenesis by down-regulating vascular endothelial growth factor C expression in gastric cancers.
MicroRNA-381 Favors Repair of Nerve Injury Through Regulation of the SDF-1/CXCR4 Signaling Pathway via LRRC4 in Acute Cerebral Ischemia after Cerebral Lymphatic Blockage.
MicroRNA-9 overexpression suppresses vulnerable atherosclerotic plaque and enhances vascular remodeling through negative regulation of the p38MAPK pathway via OLR1 in acute coronary syndrome.
MicroRNA-93 regulates the neurological function, cerebral edema and neuronal apoptosis of rats with intracerebral hemorrhage through TLR4/NF-?B signaling pathway.
MicroRNA?15a?5p induces pulmonary artery smooth muscle cell apoptosis in a pulmonary arterial hypertension model via the VEGF/p38/MMP?2 signaling pathway.
MicroRNA?944 targets vascular endothelial growth factor to inhibit cell proliferation and invasion in osteosarcoma.
MicroRNAs in tumor angiogenesis.
Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis.
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression.
Microvascular density of breast cancer in bone metastasis: influence of therapy.
Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma.
Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression.
Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study.
Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes.
Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer.
Microvessel density and vascular endothelial growth factor expression as predictors of childrens' survival from cerebellar medulloblastoma.
Microvessel density and vascular endothelial growth factor expression in human tumors of different localization.
Microvessel density and vascular endothelial growth factor receptors in breast carcinoma under the influence of rapamycin and platelet factor 4.
Microvessel density and VEGF/VEGF receptor status and their role in sarcomas of the pulmonary artery.
Microvessel Density Is Associated with VEGF and ?-SMA Expression in Different Regions of Human Gastrointestinal Carcinomas.
Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters.
Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors.
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.
Migration-Inducing Gene 7 promotes tumorigenesis and angiogenesis and independently predicts poor prognosis of epithelial ovarian cancer.
Mild Heat Stress Enhances Angiogenesis in a Co-culture System Consisting of Primary Human Osteoblasts and Outgrowth Endothelial Cells.
Milk fat globule-epidermal growth factor-factor VIII (MFGE8)/lactadherin promotes bladder tumor development.
Mimetic peptide of ubiquitin-interacting motif of epsin as a cancer therapeutic-perspective in brain tumor therapy through regulating VEGFR2 signaling.
Mingmu Xiaomeng Tablets Restore Autophagy and Alleviate Diabetic Retinopathy by Inhibiting PI3K/Akt/mTOR Signaling.
Minimal contribution of marrow-derived endothelial precursors to tumor vasculature.
Minimally invasive surgery may result in lower peak levels of circulating vascular endothelial growth factor.
Minocycline attenuates hypoxia-inducible factor-1? expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies.
Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.
miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF).
miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/?-catenin signaling through targeting BCL9.
miR-140-5p mediates bevacizumab-induced cytotoxicity to cardiomyocytes by targeting the VEGFA/14-3-3? signal pathway.
miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.
MiR-155 Inhibitor-Laden Exosomes Reverse Resistance to Cisplatin in a 3D Tumor Spheroid and Xenograft Model of Oral Cancer.
miR-195 suppresses abdominal aortic aneurysm through the TNF-?/NF-?B and VEGF/PI3K/Akt pathway.
miR-21 Is Linked to Glioma Angiogenesis: A Co-Localization Study.
MiR-548c-3p suppressed the progression of papillary thyroid carcinoma via inhibition of the HIF1?-mediated VEGF signaling pathway.
miR-570 Inhibits Proliferation, Angiogenesis, and Immune Escape of Hepatocellular Carcinoma.
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis.
miR?20b negatively regulates VEGF expression by targeting STAT3 in H22 hepatocellular carcinoma cells.
miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer.
Mitochondrial UQCRB regulates VEGFR2 signaling in endothelial cells.
Mitogen-activated protein 3 kinase 6 mediates angiogenic and tumorigenic effects via vascular endothelial growth factor expression.
Mitogen-activated protein kinase, ERK1/2, is essential for the induction of vascular endothelial growth factor by ionizing radiation mediated by activator protein-1 in human glioblastoma cells.
MKK4 is a novel target for the inhibition of tumor necrosis factor-alpha-induced vascular endothelial growth factor expression by myricetin.
MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells.
MMP-2 AND MMP-9 SECRETION BY RPE IS STIMULATED BY ANGIOGENIC MOLECULES FOUND IN CHOROIDAL NEOVASCULAR MEMBRANES.
MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer.
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis.
Mo polyoxometalate nanoparticles inhibit tumor growth and vascular endothelial growth factor induced angiogenesis.
Modafinil improves monocrotaline-induced pulmonary hypertension rat model.
Model for Risk-Based Screening of Diabetic Retinopathy in People With Newly-Diagnosed Type 2 Diabetes Mellitus.
Modeling the VEGF-Bcl-2-CXCL8 pathway in intratumoral agiogenesis.
Moderate Aerobic Training Improves Cardiorespiratory Parameters in Elastase-Induced Emphysema.
Modes of resistance to anti-angiogenic therapy.
Modification of Antitumor Immunity and Tumor Microenvironment by Resveratrol in Mouse Renal Tumor Model.
Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model.
Modified model of VX2 tumor overexpressing vascular endothelial growth factor.
Modified Rat Hepatocellular Carcinoma Models Overexpressing Vascular Endothelial Growth Factor.
Modulating the tumor microenvironment to increase radiation responsiveness.
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
Modulation of cellular invasion by VEGF-C expression in squamous cell carcinoma of the head and neck.
Modulation of cytokine production by monocytes and developing-dendritic cells under the influence of leukemia and lymphoma cell products.
Modulation of growth factor and cytokine expression by nitric oxide during rat colon anastomotic healing.
Modulation of human NK cell lines by vascular endothelial growth factor and receptor VEGFR-1 (FLT-1).
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Modulation of neoangiogenesis in bronchial preneoplastic lesions.
Modulation of p75 neurotrophin receptor under hypoxic conditions induces migration and invasion of C6 glioma cells.
Modulation of pericytes by a fusion protein comprising of a PDGFR?-antagonistic affibody and TNF? induces tumor vessel normalization and improves chemotherapy.
Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
Modulation of tumor induced angiogenesis in Ehrlich ascites tumor.
Modulation, bioinformatic screening, and assessment of small molecular peptides targeting the vascular endothelial growth factor receptor.
Molecular and immunohistochemical profile of a basaloid (cloacogenic) carcinoma of the sigmoid colon: possible predictive value for clinical outcomes.
Molecular Basis of the Beneficial Actions of Resveratrol.
Molecular biomarkers of vascular dysfunction in obstructive sleep apnea.
Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells.
Molecular Characterization of Lipoaspirates Used in Regenerative Head and Neck Surgery.
Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts.
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.
Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
Molecular epidemiology and phylogenetic analysis of a marine fish infectious spleen and kidney necrosis virus-like (ISKNV-like) virus.
Molecular expression of vascular endothelial growth factor, prokineticin receptor-1 and other biomarkers in infiltrating canalicular carcinoma of the breast.
Molecular hierarchy of heparin-binding epidermal growth factor-like growth factor-regulated angiogenesis in triple negative breast cancer.
Molecular imaging of breast cancer.
Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors.
Molecular Imaging of Inducible VEGF Expression and Tumor Progression in a Breast Cancer Model.
Molecular magnetic resonance probe targeting VEGF165: preparation and in vitro and in vivo evaluation.
Molecular markers of radiation effectiveness in head and neck squamous cell carcinoma.
Molecular mechanism of epigallocatechin-3-gallate in human esophageal squamous cell carcinoma in vitro and in vivo.
Molecular mechanisms and targeting of colorectal cancer.
Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Molecular mechanisms in cancer: what should clinicians know?
Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules.
Molecular mechanisms of developmental and tumor angiogenesis.
Molecular Mechanisms of Resistance to Anti-Angiogenic Drugs.
Molecular mechanisms of resistance to tumour anti-angiogenic strategies.
Molecular mechanisms of topical anti-inflammatory effects of lipoxin A(4) in endotoxin-induced uveitis.
Molecular MRI of VEGFR-2 reveals intra-tumor and inter-tumor heterogeneity.
Molecular pathogenesis of fracture nonunion.
Molecular pathology of non-invasive urothelial carcinomas (part I).
Molecular pathway for cancer metastasis to bone.
Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases.
Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization.
Molecular pathways underlying tissue injuries in the bladder with ketamine cystitis.
Molecular Pathways: Can Activin-Like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors?
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.
Molecular predictors of response to antiangiogenesis therapies.
Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy.
Molecular profiling of sinonasal undifferentiated carcinoma.
Molecular signal networks and regulating mechanisms of the unfolded protein response.
Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis.
Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
Molecular targeted therapies for solid tumors: management of side effects.
Molecular targets and targeted therapies for malignant mesothelioma.
Molecular targets for anti-angiogenic therapy.
Molecular targets from VHL studies into the oxygen-sensing pathway.
Molecular Targets in Malignant Pleural Mesothelioma Treatment.
Molecular targets of ?-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: A review.
Molecular Ultrasound Imaging.
Molecular-biological analysis of acute lung injury (ALI) induced by heat exposure and/or intravenous administration of oleic acid.
Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge Dendrilla nigra inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells.
Molecularly Imprinted Nanocavities Capable of Ligand-Binding Domain and Size/Shape Recognition for Selective Discrimination of Vascular Endothelial Growth Factor Isoforms.
Molecularly targeted therapy for gastrointestinal cancer.
Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound.
Monitoring early tumor response to drug therapy with diffuse optical tomography.
Monitoring Ocular Drug Therapy by Analysis of Aqueous Samples.
Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging.
Monitoring therapeutic monoclonal antibodies in brain tumor.
Monoclonal antibodies for the treatment of osteoarthritis.
Monoclonal antibodies in gynecological cancer: a critical point of view.
Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.
Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story.
Monocyte Chemoattractant Protein 1 Promotes VEGF-A Expression in OSCC by Activating ILK and MEK1/2 Signaling and Downregulating miR-29c.
Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas.
Monocyte chemotactic protein-1 deficiency reduces spontaneous metastasis of Lewis lung carcinoma in mice fed a high-fat diet.
Monomethyl selenium--specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation.
Morphine decreases the pro-angiogenic interaction between breast cancer cells and macrophages in vitro.
Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth.
Morphologic changes and altered gene expression in an epithelioid hemangioendothelioma during a ten-year course of disease.
Morphologic changes and molecular regulation of angiogenesis in pituitary adenomas.
Morphological, histological and molecular investigations on canine uterine tissue after ovariectomy.
Motesanib diphosphate in progressive differentiated thyroid cancer.
Mouse models for studying angiogenesis and lymphangiogenesis in cancer.
Moving cupping therapy for plaque psoriasis: A PRISMA-compliant study of 16 randomized controlled trials.
Moving disease biology from the lab to the clinic.
MOXIBUSTION ALLEVIATES GASTRIC PRECANCEROUS LESIONS IN RATS BY PROMOTING CELL APOPTOSIS AND INHIBITING PROLIFERATION-RELATED ONCOGENES.
Moxibustion Enhances Chemotherapy of Breast Cancer by Affecting Tumor Microenvironment.
mPGES-1-expressing bone marrow-derived cells enhance tumor growth and angiogenesis in mice.
MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas.
MRI and fluorescence microscopy of the acute vascular response to VEGF165: vasodilation, hyper-permeability and lymphatic uptake, followed by rapid inactivation of the growth factor.
MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report.
mRNA Expression Analysis of E-Cadherin, VEGF, and MMPs in Gastric Cancer: a Pilot Study.
MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression.
mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.
MUC1 Expression in Pulmonary Metastatic Tumors: A Comparison of Primary Lung Cancer.
MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.
Mulberry leaf extract inhibits invasive potential and downregulates hypoxia-inducible factor-1? (HIF-1?) in SK-N-BE2C neuroblastoma cells.
Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
Multifocal angiostatic therapy: an update.
Multifunctional Albumin-MnO2 Nanoparticles Modulate Solid Tumor Microenvironment by Attenuating Hypoxia, Acidosis, Vascular Endothelial Growth Factor and Enhance Radiation Response.
Multifunctional CD40L: pro- and anti-neoplastic activity.
Multifunctional Polymeric Nanosystems for Dual-Targeted Combinatorial Chemo/Angiogenesis Therapy of Tumors.
Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
Multimodal doxorubicin loaded magnetic nanoparticles for VEGF targeted theranostics of breast cancer.
Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
Multimodality molecular imaging of tumor angiogenesis.
Multiple effects of 2ME2 and D609 on the cortical expression of HIF-1alpha and apoptotic genes in a middle cerebral artery occlusion-induced focal ischemia rat model.
Multiple mechanisms are responsible for transactivation of the epidermal growth factor receptor in mammary epithelial cells.
Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance.
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.
Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival.
Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer.
Multiplexing Angiogenic Receptor Quantification via Quantum Dots.
Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration.
Multiregional tumor drug-uptake imaging by PET and microvascular morphology in end-stage diffuse intrinsic pontine glioma.
Multiscale Modeling of Glioblastoma Suggests that the Partial Disruption of Vessel/Cancer Stem Cell Crosstalk Can Promote Tumor Regression Without Increasing Invasiveness.
Multispecies Probiotic Supplementation Favorably Affects Vascular Function and Reduces Arterial Stiffness in Obese Postmenopausal Women-A 12-Week Placebo-Controlled and Randomized Clinical Study.
Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti-angiogenesis activity in a preclinical cancer model.
Murine chemokine CXCL2/KC is a surrogate marker for angiogenic activity in the inflammatory granulation tissue.
Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice.
Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Mutual enhancement between heparanase and vascular endothelial growth factor: a novel mechanism for melanoma progression.
Mutually-Reactive, Fluorogenic Hydrocyanine/Quinone Reporter Pairs for In-Solution Biosensing via Nanodroplet Association.
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity.
Myeloid heme oxygenase-1 promotes metastatic tumor colonization in mice.
Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2.
Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model.
Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice.
Myocardial Infarction-Associated SNP at 6p24 Interferes With MEF2 Binding and Associates With PHACTR1 Expression Levels in Human Coronary Arteries.
Myocyte Enhancer Factor 2C as a New Player in Human Breast Cancer Brain Metastases.
Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression.
Myoglobin variants are expressed in human glioblastoma cells?hypoxia effect?
n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway.
N-acetylglucosaminyltransferase I activity of bovine oviduct epithelial cells: stimulation by luteinizing hormone, vascular endothelial growth factor and tumor necrosis factor alpha.
N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-? Expressions.
N-Terminal Modification of the Tetrapeptide Arg-Leu-Tyr-Glu, a Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Antagonist, Improves Antitumor Activity by Increasing its Stability against Serum Peptidases.
Na+/H+ exchanger blockade inhibits the expression of vascular endothelial growth factor in SGC7901 cells.
NADPH oxidase 1 plays a critical mediating role in oncogenic Ras-induced vascular endothelial growth factor expression.
NADPH oxidase 4 mediates reactive oxygen species induction of CD146 dimerization in VEGF signal transduction.
NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment.
Nano-Gold Loaded with Resveratrol Enhance the Anti-Hepatoma Effect of Resveratrol In Vitro and In Vivo.
Nanoengineered biomimetic Cu-based nanoparticles for multifunational and efficient tumor treatment.
Nanoparticle Delivered VEGF-A siRNA Enhances Photodynamic Therapy for Head and Neck Cancer Treatment.
Nanoparticles for Colorectal Cancer-Targeted Drug Delivery and MR Imaging: Current Situation and Perspectives.
Nanosecond Pulsed Electric Fields as A Novel drug free Therapy for Breast Cancer: an in vivo study.
NaoXinTong Capsule Inhibits Carrageenan-Induced Thrombosis in Mice.
Nasopharyngeal carcinoma.
Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.
Naturally Available Extracts Inhibiting Cancer Progression: A Systematic Review.
NDRG1 activates VEGF-A-induced angiogenesis through PLC?1/ERK signaling in mouse vascular endothelial cells.
NDV-D90 suppresses growth of gastric cancer and cancer-related vascularization.
Near-infrared fluorescence lymphatic imaging in vascular endothelial growth factor-C overexpressing murine melanoma.
Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh.
Neem Leaf Glycoprotein Restrains VEGF Production by Direct Modulation of HIF1?-Linked Upstream and Downstream Cascades.
Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis.
Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.
Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production.
Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression.
Neoangiogenesis in colon cancer: correlation between vascular density, vascular endothelial growth factor (VEGF) and p53 protein expression.
Neoneurogenesis and the neuro-neoplastic synapse.
Neovascularization in Glioblastoma: Current Pitfall in Anti-angiogenic therapy.
Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor.
Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer.
Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
Nephrotoxicity of Anti-Angiogenic Therapies.
Network analysis of inflammatory genes and their transcriptional regulators in coronary artery disease.
Neuraminidase-1: A novel therapeutic target in multistage tumorigenesis.
Neuregulin?1 protects cardiac function in septic rats through multiple targets based on endothelial cells.
Neuro-oncologists have spoken - the role of bevacizumab in the inpatient setting. A clinical and economic conundrum.
Neuroblastoma-targeted nanoparticles and novel nanotechnology-based treatment methods.
Neurocytoma is a tumor of adult neuronal progenitor cells.
Neuroendocrine apendicopathy in morphologically normal appendices of patients with diagnosis of acute appendicitis: Diagnostic study.
Neuroendocrine pancreatic tumors: guidelines for management and update.
Neurological surgery at the National Institutes of Health.
Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma.
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth.
Neuropilin 1 guides regulatory T cells into VEGF-producing melanoma.
Neuropilin-1 and neuropilin-2 expression in the adenoma-carcinoma sequence of colorectal cancer.
Neuropilin-1 and VEGF correlate with somatostatin expression and microvessel density in ovarian tumours.
Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity.
Neuropilin-1 Expression on CD4 T Cells Is Atherogenic and Facilitates T Cell Migration to the Aorta in Atherosclerosis.
Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding.
Neuropilin-1 in acute myeloid leukemia: expression and role in proliferation and migration of leukemia cells.
Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis.
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.
Neuropilin-1 is involved in regulation of apoptosis and migration of human colon cancer.
Neuropilin-1 is overexpressed in osteosarcoma and contributes to tumor progression and poor prognosis.
Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition.
Neuropilin-2 contributes to LPS-induced corneal inflammatory lymphangiogenesis.
Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma.
Neuropilin-2 expression in cancer.
Neuropilin-2 expression in papillary thyroid carcinoma: correlation with VEGF-D expression, lymph node metastasis, and VEGF-D-induced aggressive cancer cell phenotype.
Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial ?5 integrin.
Neuropilin2 expressed in gastric cancer endothelial cells increases the proliferation and migration of endothelial cells in response to VEGF.
Neuropilins Controlling Cancer Therapy Responsiveness.
Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes.
Neuroprotective effect of melatonin against hypoxia-induced retinal ganglion cell death in neonatal rats.
Neurotrophic and inflammatory markers in bipolar disorder: A prospective study.
Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo.
Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma.
Neutrophil-derived cytokines: potential therapeutic targets in inflammation.
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
New antiangiogenetic agents and non-small cell lung cancer.
New antibody to stop tumor angiogenesis and lymphatic spread by blocking receptor partnering.
New anticancer strategies targeting HIF-1.
New concepts in the understanding of the ovarian hyperstimulation syndrome.
New drug development in digestive neuroendocrine tumors.
New Insights Into Immunological Therapy for Retinal Disorders.
New isoforms of VEGF are translated from alternative initiation CUG codons located in its 5'UTR.
New markers of early cardiovascular risk in multiple sclerosis patients: Oxidized-LDL correlates with clinical staging.
New Model of In-situ Xenograft Lymphangiogenesis by a Human Colonic Adenocarcinoma Cell Line in Nude Mice.
New oxaliplatin-based combinations in the treatment of colorectal cancer.
New peptide MY1340 revert the inhibition effect of VEGF on dendritic cells differentiation and maturation via blocking VEGF-NRP-1 axis and inhibit tumor growth in vivo.
New targeted probes for radioimaging of angiogenesis.
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFR?/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
Next target of tranilast: Inhibition of corneal neovascularization.
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents.
NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells.
NF-kappaB blockade upregulates Bax, TSP-1, and TSP-2 expression in rat granulation tissue.
NF-YA promotes invasion and angiogenesis by upregulating EZH2-STAT3 signaling in human melanoma cells.
NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin.
Niaspan treatment induces neuroprotection after stroke.
Nicorandil enhances the efficacy of mesenchymal stem cell therapy in isoproterenol-induced heart failure in rats.
Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells.
Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation.
Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2.
Nilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response.
Nitric oxide and adverse events of vascular endothelial growth factor inhibitors.
Nitric oxide donors reduce the invasion ability of ovarian cancer cells in vitro.
Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production.
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
Nitroxyl inhibits breast tumor growth and angiogenesis.
No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population.
No significant effects of Poly(I:C) on human umbilical cord-derived mesenchymal stem cells in the treatment of B6.MRL-Fas(lpr) mice.
Nobiletin alleviates endometriosis via down-regulating NF-?B activity in endometriosis mouse model.
NOD-like receptor C4 Inflammasome Regulates the Growth of Colon Cancer Liver Metastasis in NAFLD.
NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype.
Non-coding RNA and lung cancer progression.
Non-invasive analysis of rat ovarian angiogenesis by MRI.
Non-invasive Biomarkers of Liver Inflammation and Cell Death in Response to Alcohol Detoxification.
Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer.
Non-paralleled increase of hepatocyte growth factor and vascular endothelial growth factor in the eyes with angiogenic and nonangiogenic fibroproliferation.
Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens.
Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review).
Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?
Nonangiogenic function of VEGF and enhanced radiosensitivity of HeLa cells by inhibition of VEGF expression.
Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review.
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice.
Noninvasive indirect imaging of vascular endothelial growth factor gene expression using bioluminescence imaging in living transgenic mice.
Noninvasive intravital high-resolution imaging of pancreatic neuroendocrine tumours.
Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor.
Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1? protein-dependent mechanism.
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells.
Normalization of the vasculature for treatment of cancer and other diseases.
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner.
Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras.
Notoginsenoside Ft1 Promotes Fibroblast Proliferation via PI3K/Akt/mTOR Signaling Pathway and Benefits Wound Healing in Genetically Diabetic Mice.
Novel 1,2,4-triazole derivatives as antitumor agents against hepatocellular carcinoma.
Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking.
Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.
Novel Agents in the Management of Lung Cancer.
Novel Anti-Angiogenic and Anti-Tumour Activities of the N-Terminal Domain of NOEY2 via Binding to VEGFR-2 in Ovarian Cancer.
Novel anti-angiogenic therapies for malignant gliomas.
Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization.
Novel antiangiogenic therapies for renal cell cancer.
Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma.
Novel approaches to target pancreatic cancer.
Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
Novel biochemical markers of psychosocial stress in women.
Novel biological radiochemotherapy approaches in locally advanced-stage cervical cancer management.
Novel biologically based therapies for myeloma.
Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review.
Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus.
Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy.
Novel dual inhibitors of vascular endothelial growth factor and VEGFR2 receptor.
Novel Fish Oil-based Bigel System for Controlled Drug Delivery and its Influence on Immunomodulatory Activity of Imiquimod Against Skin Cancer.
Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR).
Novel Markers of Angiogenesis in the Setting of Cognitive Impairment and Dementia.
Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy.
Novel mutations and role of the LKB1 gene as a tumor suppressor in renal cell carcinoma.
Novel polysaccharide extracted from Sipunculus nudus inhibits HepG2 tumour growth in vivo by enhancing immune function and inducing tumour cell apoptosis.
Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?
Novel role of lactosylceramide in vascular endothelial growth factor-mediated angiogenesis in human endothelial cells.
Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy.
Novel Selective Detection Method of Tumor Angiogenesis Factors Using Living Nano-Robots.
Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application.
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Novel therapeutic approaches for targeting tumor angiogenesis.
Novel therapeutic approaches targeting vascular endothelial growth factor and its receptors in haematological malignancies.
Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
Novel therapies for intracerebral hemorrhage.
Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation.
Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.
Novel treatments for metastatic renal cell carcinoma.
Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development?
NRP-1 expression is strongly associated with the progression of pituitary adenomas.
NRP-1 silencing suppresses hepatocellular carcinoma cell growth in vitro and in vivo.
NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft model.
NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms.
Nuclear accumulation of p53 protein in gastric cancer strongly correlates with enlargement of nuclear area of cancer cells.
Nuclear factor 90 promotes angiogenesis by regulating HIF-1?/VEGF-A expression through the PI3K/Akt signaling pathway in human cervical cancer.
Nuclear factor kappaB dependency of platelet-activating factor-induced angiogenesis.
Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo.
Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression.
Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity.
Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation.
Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells.
Nucleated red blood cells participate in myocardial regeneration in the toad Bufo Gargarizan Gargarizan.
Nucleolin Promotes Heat Shock-Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis.
Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat.
Number of Circulating CD 73-Expressing Lymphocytes Correlates With Survival After Cardiac Arrest.
Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha.
Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, and zeaxanthin decrease A2E accumulation and VEGF expression in the retinas of Ccl2/Cx3cr1-deficient mice on Crb1rd8 background.
Oat Attenuation of Hyperglycemia-Induced Retinal Oxidative Stress and NF-?B Activation in Streptozotocin-Induced Diabetic Rats.
Obesity Does Not Exacerbate the Protumorigenic Systemic Environment in Sarcoma Subjects.
Obesity-associated NLRC4 inflammasome activation drives breast cancer progression.
Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation.
Obstructive Lymphangitis Precedes Colitis in Murine Norovirus-Infected Stat1-Deficient Mice.
Obstructive sleep apnea as an independent stroke risk factor: possible mechanisms.
Obstructive Sleep Apnea Monocytes Exhibit High Levels of Vascular Endothelial Growth Factor Secretion, Augmenting Tumor Progression.
Octacosanol isolated from Tinospora cordifolia downregulates VEGF gene expression by inhibiting nuclear translocation of NF-B and its DNA binding activity.
Ocular surface cytokine profile in chronic Stevens-Johnson syndrome and its response to mucous membrane grafting for lid margin keratinisation.
Oesophageal squamous cell carcinoma in high-risk Chinese populations: Possible role for vascular epithelial growth factor A.
Okadaic acid stimulates the expression of vascular endothelial growth factor gene.
Old Drug Scaffold, New Activity: Thalidomide-Correlated Compounds Exert Different Effects on Breast Cancer Cell Growth and Progression.
Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: Preclinical and clinical evidence.
Oleanolic acid inhibits colorectal cancer angiogenesis by blocking the VEGFR2 signaling pathway.
Oligoclonal selection of nanobodies targeting vascular endothelial growth factor.
Oligomer procyanidins (F2) isolated from grape seeds inhibits tumor angiogenesis and cell invasion by targeting HIF-1? in vitro.
Olive oil compounds inhibit vascular endothelial growth factor receptor-2 phosphorylation.
Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1-7).
Oltipraz and dithiolethione congeners inhibit hypoxia-inducible factor-1alpha activity through p70 ribosomal S6 kinase-1 inhibition and H2O2-scavenging effect.
Omega-3 fatty acid supplementation reduces tumor growth and vascular endothelial growth factor expression in a model of progressive non-metastasizing malignancy.
Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial.
Oncocytic papillary renal cell carcinoma with inverted nuclear pattern: distinct subtype with an indolent clinical course.
Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts.
Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy.
Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates.
Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.
Oncogenic Ras and transforming growth factor-beta synergistically regulate AU-rich element-containing mRNAs during epithelial to mesenchymal transition.
Oncological management of advanced neuroendocrine tumours (Review).
Oncology nursing in a new era: optimizing treatment with bevacizumab.
Oncolytic Adenovirus rAd.DCN Inhibits Breast Tumor Growth and Lung Metastasis in an Immune-Competent Orthotopic Xenograft Model.
Oncolytic adenovirus-mediated E1A gene therapy induces tumor-cell apoptosis and reduces tumor angiogenesis leading to inhibition of hepatocellular carcinoma growth in animal model.
Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region.
Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety.
Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo.
Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation.
Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells.
Ontogeny of adipokine expression in neonatal pig adipose tissue.
Openwork@Dendritic Mesoporous Silica Nanoparticles for Lactate Depletion and Tumor Microenvironment Regulation.
Ophthalmological Aspects of von-Hippel-Lindau Syndrome.
Opioids and Cancer Mortality.
Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed.
Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice.
Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor.
Opposing roles for complement component c5a in tumor progression and the tumor microenvironment.
Opposing roles for HIF-1{alpha} and HIF-2{alpha} in the regulation of angiogenesis by mononuclear phagocytes.
Optical Tomographic and Magnetic Resonance Imaging of Tumor Growth and Regression in Mice treated with VEGF Blockade.
Optimal conditions for cordycepin production in surface liquid-cultured Cordyceps militaris treated with porcine liver extracts for suppression of oral cancer.
Optimal management of gastroesophageal junction cancer.
Optimal ratio of 18?- and 18?-glycyrrhizic acid for preventing alcoholic hepatitis in rats.
Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: Analysis of response and progression-free survival in the RECORD-1 study.
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature.
Orai1 and Transient Receptor Potential Channels as Novel Molecular Targets to Impair Tumor Neovascularisation in Renal Cell Carcinoma and other Malignancies.
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
Oral administration of NSP-116, a free radical scavenger, suppresses the symptoms of retinal vein occlusion in the murine model.
Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis and growth of breast cancer in female mice.
Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis.
Oral Health Status of Patients with Lysosomal Storage Diseases in Poland.
Orally administered green tea polyphenols prevent ultraviolet radiation-induced skin cancer in mice through activation of cytotoxic T cells and inhibition of angiogenesis in tumors.
Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers.
Organoarsenic Roxarsone Promotes Angiogenesis In Vivo.
Osteonecrosis of the jaw associated with ziv-aflibercept.
Osteonecrosis of the mandible associated with bevacizumab therapy.
Osteopontin b and c Splice isoforms in Leukemias and Solid Tumors: Angiogenesis Alongside Chemoresistance
Osteopontin expression in pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma.
Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.
Osteosarcoma arising in the breast.
Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model.
Ovarian cancer biology and immunotherapy.
Ovarian hyperstimulation syndrome.
Ovarian Metabolic activity in Dehydroepiandrosterone-Induced Polycystic Ovary in Wistar rats Treated with Aspirin.
Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.
Over-expression of platelet-derived growth factor-D promotes tumor growth and invasion in endometrial cancer.
Over-Expression of Semaphorin4D, Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor Is Related to Poor Prognosis in Ovarian Epithelial Cancer.
Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis.
Over-expression of VEGF and MMP-9 in residual tumor cells of hepatocellular carcinoma after embolization with lipidol.
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.
Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment.
Overcoming Radioresistance in Tumor Therapy by Alleviating Hypoxia and Using the HIF-1 Inhibitor.
Overcoming resistance to antiangiogenic therapies.
Overexpressed HSPA2 correlates with tumor angiogenesis and unfavorable prognosis in pancreatic carcinoma.
Overexpression and correlation of HIF-2?, VEGFA and EphA2 in residual hepatocellular carcinoma following high-intensity focused ultrasound treatment: Implications for tumor recurrence and progression.
Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer.
Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors.
Overexpression of Antiangiogenic Vascular Endothelial Growth Factor Isoform and Splicing Regulatory Factors in Oral, Laryngeal and Pharyngeal Squamous Cell Carcinomas
Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
Overexpression of both platelet-derived growth factor-BB and vascular endothelial growth factor-C and its association with lymphangiogenesis in primary human non-small cell lung cancer.
Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth.
Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer.
Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma.
Overexpression of cyclooxygenase-2 in gastric cancer correlates with the high abundance of vascular endothelial growth factor-C and lymphatic metastasis.
Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression.
Overexpression of fibulin-4 is associated with tumor progression and poor prognosis in patients with cervical carcinoma.
Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice.
Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis.
Overexpression of homeobox B-13 correlates with angiogenesis, aberrant expression of EMT markers, aggressive characteristics and poor prognosis in pancreatic carcinoma.
Overexpression of hypoxia-inducible factor-1? and vascular endothelial growth factor in sacral giant cell tumors and the correlation with tumor microvessel density.
Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer.
Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer.
Overexpression of matriptase in tumor stroma is a poor prognostic indicator of extrahepatic bile duct cancer.
Overexpression of miR-18a negatively regulates myocyte enhancer factor 2D to increase the permeability of the blood-tumor barrier via Krüppel-like factor 4-mediated downregulation of zonula occluden-1, claudin-5, and occludin.
Overexpression of Phosphorylated 4E-BP1 Predicts for Tumor Recurrence and Reduced Survival in Cervical Carcinoma Treated with Postoperative Radiotherapy.
Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo.
Overexpression of Romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients.
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells.
Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer.
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels.
Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer.
Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo.
Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors.
Overexpression of vascular endothelial growth factor is responsible for the hematogenous recurrence of early-stage gastric carcinoma.
Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis.
Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis.
Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions.
Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo.
Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients.
Overexpression of VEGF-C and MMP-9 predicts poor prognosis in Kazakh patients with esophageal squamous cell carcinoma.
Overexpression of VEGF183 promotes murine breast cancer cell proliferation in vitro and induces dilated intratumoral microvessels.
Overproduction of N(epsilon)-(carboxymethyl)lysine-induced neovascularization in cultured choroidal explant of aged rat.
Overproduction of N(epsilon)-(carboxymethyl)lysine-induced neovascularization in cultured choroidal explant of streptozotocin-diabetic rat.
Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor.
Oxidative stress in tumor angiogenesis- therapeutic targets.
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.
Oxidized low density lipoprotein-induced senescence of retinal pigment epithelial cells is followed by outer blood-retinal barrier dysfunction.
Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions.
Oxygen sensing by H+: implications for HIF and hypoxic cell memory.
Oxygen-charged HTK-F6H8 emulsion reduces ischemia-Reperfusion injury in kidneys from brain-dead Pigs.
Oxyresveratrol prevents murine H22 hepatocellular carcinoma growth and lymph node metastasis via inhibiting tumor angiogenesis and lymphangiogenesis.
P-21-activated kinase 1 contributes to tumor angiogenesis upon photodynamic therapy via the HIF-1?/VEGF pathway.
P-Selectin-Mediated Adhesion between Platelets and Tumor Cells Promotes Intestinal Tumorigenesis in Apc(Min/+) Mice.
P-selectin-mediated platelet adhesion promotes tumor growth.
p16 Modulates VEGF Expression via Its Interaction With HIF-1alpha in Breast Cancer Cells.
p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models.
P27 deletion enhances hematopoiesis by paracrine action of IL22 secreted from bone marrow mesenchymal stem cells.
p28(GANK) overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1? pathways.
p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1? pathways.
P388 Leukemia in CDF1 Mice as the Test System for Studies of Tumor-Associated Neoangiogenesis and Hypercoagulation.
p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts.
p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease.
P53 and vascular endothelial growth factor expressions are two important indices for prognosis in gastric carcinoma.
p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells.
p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer.
P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients.
p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene.
p53 functional deficiency in human colon cancer cells promotes fibroblast-mediated angiogenesis and tumor growth.
p53 Inhibits Vascular Endothelial Growth Factor Expression in Solid Tumor.
p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway.
P53 tumor suppressor factor, plasminogen activator inhibitor, and vascular endothelial growth factor gene polymorphisms and recurrent implantation failure.
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models.
Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations.
Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment.
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis.
PAF receptor antagonist Ginkgolide B inhibits tumourigenesis and angiogenesis in colitis-associated cancer.
Paired box 5 is a novel marker of breast cancers that is frequently downregulated by methylation.
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.
Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation.
Pancreatic Cyst Fluid Vascular Endothelial Growth Factor A and Carcinoembryonic Antigen: A Highly Accurate Test for the Diagnosis of Serous Cystic Neoplasm.
Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
Pancreatic endoplasmic reticulum kinase activation promotes medulloblastoma cell migration and invasion through induction of vascular endothelial growth factor A.
Pancreatic head carcinoma and vascular endothelial growth factor (VEGF-A) concentration in portal blood: its association with cancer grade, tumor size and probably poor prognosis.
Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice.
Pannus inflammation in sacroiliitis following immune pathological injury and radiological structural damage: a study of 193 patients with spondyloarthritis.
Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis.
Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells.
Papillary thyroid carcinoma with lymph node metastases.
Paracrine effect of canine allogenic umbilical cord blood-derived mesenchymal stromal cells mixed with beta-tricalcium phosphate on bone regeneration in ectopic implantations.
Paracrine upregulation of VEGF receptor mRNA in endothelial cells by hypoxia-exposed hep G2 cells.
Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy.
Paraproteinaemias: pathophysiology.
Parathyroid Tumor Microenvironment.
Parathyroid-induced angiogenesis is VEGF-dependent.
Parylene peel-off arrays to probe the role of cell-cell interactions in tumour angiogenesis.
Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited.
Pathogenetic roles of angiogenic factors in pyogenic granulomas in pregnancy are modulated by female sex hormones.
Pathogenetic Roles of Angiogenic Factors in Pyogenic Granulornas in Pregnancy Are Modulated by Female Sex Hormones.
Pathological angiogenesis in a murine model of human Wilms' tumor.
Pathological crosstalk in vitro between T lymphocytes and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact.
Pathological neoangiogenesis depends on oxidative stress regulation by ATM.
Pathological significance of vascular endothelial growth factor A isoform expression in human cancer.
Pathology, genetics and cell biology of hemangioblastomas.
Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors.
Pathophysiology of ocular surface squamous neoplasia.
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
Pathways targeting tumor lymphangiogenesis.
Patients with tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) are hypersensitive to Toll-like receptor 9 stimulation.
Patterns of angiogenesis in nonsmall-cell lung carcinoma.
Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo.
Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours.
PC4 induces lymphangiogenesis dependent VEGF-C/VEGF-D/VEGFR-3 axis activation in lung adenocarcinoma.
PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.
PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer.
PDGF-D is a potent transforming and angiogenic growth factor.
PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway.
PDGF-D promotes dermal fibroblast invasion in 3-dimensional extracellular matrix via Snail-mediated MT1-MMP upregulation.
PDGF-D signaling: a novel target in cancer therapy.
PDGF-D/PDGFR? promotes tongue squamous carcinoma cell (TSCC) progression via activating p38/AKT/ERK/EMT signal pathway.
PDGFR-?, PDGFR-?, VEGFR-2 and CD117 expression in canine mammary tumours and evaluation of the in vitro effects of toceranib phosphate in neoplastic mammary cell lines.
PEA3 activates VEGF transcription in T47D and SKBR3 breast cancer cells.
Pectic polysaccharide from corn (Zea mays L.) effectively inhibited multi-step mediated cancer cell growth and metastasis.
Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival.
PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis.
PEG-detachable cationic polyaspartamide derivatives bearing stearoyl moieties for systemic siRNA delivery toward subcutaneous BxPC3 pancreatic tumor.
PEI-g-PEG-RGD/Small Interference RNA Polyplex-Mediated Silencing of Vascular Endothelial Growth Factor Receptor and Its Potential as an Anti-Angiogenic Tumor Therapeutic Strategy.
Penduliflaworosin, a Diterpenoid from Croton crassifolius, Exerts Anti-Angiogenic Effect via VEGF Receptor-2 Signaling Pathway.
Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways.
Pentameric procyanidins isolated from Theobroma cacao seeds selectively downregulate ErbB2 in human aortic endothelial cells.
Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor.
Pentraxin 3 in serum and synovial fluid of patients with rheumatoid arthritis with and without autoantibodies.
Peptide-conjugated chlorin-type photosensitizer binds neuropilin-1 in vitro and in vivo.
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy.
Performing IVIM-DWI using the multifunctional nanosystem for the evaluation of the antitumor microcirculation changes.
Perfusion Estimated with Rapid Dynamic Contrast-Enhanced Magnetic Resonance Imaging Correlates Inversely with Vascular Endothelial Growth Factor Expression and Pimonidazole Staining in Head-and-Neck Cancer: A Pilot Study.
Pericytes: a double-edged sword in cancer therapy.
Perindopril: possible use in cancer therapy.
Periodontal treatment down-regulates protease-activated receptor-2 in human gingival crevicular fluid cells.
Periostin directly and indirectly promotes tumor lymphangiogenesis of head and neck cancer.
Peripheral and cranial nerve sheath tumors.
Peripheral blood concentrations of vascular endothelial growth factor and its soluble receptors (R1 and R2) in patients with adrenal cortex tumours treated by surgery.
Peripheral blood mononuclear CD133 mRNA levels correlates with response to treatment in patients with gastrointestinal stromal tumors.
Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid.
Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis.
Peripheral enhancement of breast cancers on contrast-enhanced ultrasound: correlation with microvessel density and vascular endothelial growth factor expression.
Peripheral T cell lymphoma, not otherwise specified with myelofibrosis: report of a case with review of the literature.
Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations.
Peripheral washout phenomenon in an animal tumour model: comparison of dynamic magnetic resonance imaging using a small molecular contrast medium with histology.
Periprosthetic UHMWPE Wear Debris Induces Inflammation, Vascularization, and Innervation After Total Disc Replacement in the Lumbar Spine.
Peritoneal cytokines and adhesion formation in endometriosis: an inverse association with vascular endothelial growth factor concentration.
Peritoneal vascular density assessment using narrow-band imaging and vascular analysis software, and cytokine analysis in women with and without endometriosis.
Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients.
Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix.
Perivascular Adipose Tissue, Vascular Reactivity and Hypertension.
Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF).
Permeable endothelium and the interstitial space of brain.
Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer.
Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3.
Persistent Inflammation and Angiogenesis during Wound Healing in K14-Directed Hoxb13 Transgenic Mice.
Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab.
Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Personalizing therapy for colorectal cancer.
PET Imaging of Receptor Tyrosine Kinases in Cancer.
PET Imaging of VEGFR with a Novel 64Cu-Labeled Peptide.
PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.
PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways.
PGE2-induced colon cancer growth is mediated by mTORC1.
Phage display peptide probes for imaging early response to bevacizumab treatment.
Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review.
Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.
Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice.
Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
Pharmacogenetics of EGFR and VEGF inhibition.
Pharmacokinetic and anti-cancer properties of high dose ascorbate in solid tumours of ascorbate-dependent mice.
Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies.
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse.
Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
Pharmacologic Blockade of Angiopoietin-2 Is Efficacious against Model Hemangiomas in Mice.
Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1.
Pharmacological activation of cannabinoid 2 receptor attenuates inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing.
Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells.
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis.
Pharmacology down under in 2005--focus on targets.
Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib?
Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.
Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Phase I safety and pharmacokinetic study of bevacizumab in Chinese patients with advanced cancer.
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy.
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.
Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma.
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance).
Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.
Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network.
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers.
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.
Phase II trial of thalidomide in renal-cell carcinoma.
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
PHD3 affects gastric cancer progression by negatively regulating HIF1A.
Phenethyl isothiocyanate inhibits hypoxia-induced accumulation of HIF-1? and VEGF expression in human glioma cells.
Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo.
pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth.
Philinopside E, a new sulfated saponin from sea cucumber, blocks the interaction between kinase insert domain-containing receptor (KDR) and alphavbeta3 integrin via binding to the extracellular domain of KDR.
Phlorizin Supplementation Attenuates Obesity, Inflammation, and Hyperglycemia in Diet-Induced Obese Mice Fed a High-Fat Diet.
Phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 (P-Rex-1), a guanine nucleotide exchange factor for Rac, mediates angiogenic responses to stromal cell-derived factor-1/chemokine stromal cell derived factor-1 (SDF-1/CXCL-12) linked to Rac activation, endothelial cell migration, and in vitro angiogenesis.
Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1?
Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.
Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.
Phospholipase Cepsilon promotes intestinal tumorigenesis of Apc(Min/+) mice through augmentation of inflammation and angiogenesis.
Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases.
Phosphorus-32 interstitial radiotherapy for recurrent craniopharyngioma: Expressions of vascular endothelial growth factor and its receptor-2 and imaging features of tumors are associated with tumor radiosensitivity.
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis.
Photoacoustic imaging of tumour vascular permeability with indocyanine green in a mouse model.
Photodynamic therapy combined with a cysteine proteinase inhibitor synergistically decrease VEGF production and promote tumour necrosis in a rat mammary carcinoma.
Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel.
Physiological and pathological angiogenesis in the endocrine system.
Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ.
Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression.
Phytochemical profiling and ameliorative effects of Achillea cretica L. on rat model of endometriosis.
Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy.
Phytotherapeutic approach: a new hope for polycyclic aromatic hydrocarbons induced cellular disorders, autophagic and apoptotic cell death.
PI3K/AKT/mTOR Pathway in Angiogenesis.
PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis.
Picrorhiza kurroa Inhibits Experimental Arthritis Through Inhibition of Pro-inflammatory Cytokines, Angiogenesis and MMPs.
Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity.
Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis.
Pilot assessment of vascular endothelial growth factor receptors and trafficking pathways in recurrent and metastatic canine subcutaneous mast cell tumours.
Pilot evaluation of cytokine levels in patients undergoing radiotherapy for brain tumor.
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.
Pioglitazone does not increase the risk of type II diabetes in patients with bladder cancer: A retrospective study.
Pirfenidone enhances the efficacy of combined radiation and sunitinib therapy.
Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.
Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis.
PKC? activation mediates angiogenesis via NADPH oxidase activity in PC-3 prostate cancer cells.
Placenta growth factor is not required for exercise-induced angiogenesis.
Placenta growth factor is over-expressed and has prognostic value in human breast cancer.
Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma.
Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models.
Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers.
Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441.
Placental Growth Factor and Vascular Endothelial Growth Factor Together Regulate Tumour Progression via Increased Vasculature in Cutaneous T Cell Lymphoma.
Placental growth factor is a survival factor for tumor endothelial cells and macrophages.
Placental growth factor promotes metastases of ovarian cancer through MiR-543-regulated MMP7.
Placental growth factor signaling regulates isoform splicing of vascular endothelial growth factor A in the control of lung cancer cell metastasis.
Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. II. Physico-chemical properties and structure elucidation.
Plant proteolytic enzyme papain abrogates angiogenic activation of human umbilical vein endothelial cells (HUVEC) in vitro.
Plant-derived medicines for treatment of endometriosis: A comprehensive review of molecular mechanisms.
Plants as source of new therapies for endometriosis: a review of preclinical and clinical studies.
Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study.
Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders.
Plasma Cytokine Concentrations Indicate That In Vivo Hormonal Regulation of Immunity Is Altered During Long-Duration Spaceflight.
Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer.
Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients.
Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema.
Plasma level of miR-93 is associated with higher risk to develop type 2 diabetic retinopathy.
Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients.
Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer.
Plasma levels of hypoxia-regulated factors in patients with age-related macular degeneration.
Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers.
Plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myeloma.
Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in haematological cancers: a comparison with breast cancer.
Plasma levels of vascular endothelial growth factor (VEGF) in haematological cancers.
Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer.
Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease.
Plasma obtained during human endotoxemia increases endothelial albumin permeability in vitro.
Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours.
Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor.
Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma.
Plasma vascular endothelial growth factors A and C in patients undergoing prostatic biopsy and TURP for suspected prostatic neoplasia.
Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions.
Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factors.
Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.
Plasminogen kringle 5 suppresses gastric cancer via regulating HIF-1? and GRP78.
Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas.
Platelet Normalized Serum Vascular Endothelial Growth Factor Levels in Progressive Pediatric Solid Malignancies.
Platelet Normalized Serum Vascular Endothelial Growth Factor Levels in Progressive Pediatric Solid Malignancies: Authors' Reply.
Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.
Platelet phenotype changes associated with breast cancer and its treatment.
Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer.
Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas.
Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment.
Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways.
Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells.
Platelet-derived growth factor-D promotes colorectal cancer cell migration, invasion and proliferation by regulating Notch1 and matrix metalloproteinase-9.
Platelet-Derived Growth Factor/Vascular Endothelial Growth Factor Receptor Inactivation by Sunitinib Results in Tsc1/Tsc2-Dependent Inhibition of TORC1.
Platelet: transporter of vascular endothelial growth factor.
Platelets and cancer: implications for antiangiogenic therapy.
Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor.
Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study.
Platycodin D exerts anti-tumor efficacy in H22 tumor-bearing mice via improving immune function and inducing apoptosis.
Playing Tag with HIF: The VHL Story.
Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta as regulators of angiogenesis and cancer.
Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
Pleomorphic hyalinizing angiectatic tumor of renal hilum.
Pleomorphic hyalinizing angiectatic tumor of soft parts: immunohistochemical study including the expression of vascular endothelial growth factor.
Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review.
Pleural fluid cytokines correlate with tissue inflammatory expression in tuberculosis.
PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo.
PlGF Knockdown Decreases Tumorigenicity and Stemness Properties of Spheroid Body Cells Derived from Gastric Cancer Cells.
PluS Nanoparticles Loaded with Sorafenib: Synthetic Approach and Their Effects on Endothelial Cells.
PO-23 - Expression of heparanase in cancer as biomarker of malignancies: overexpression in an aggressive, poor survival gastric cancer "gastric signet ring cell carcinoma" compared with that of other gastric cancers.
Podoplanin expression in cancer-associated fibroblasts correlates with VEGF-C expression in cancer cells of invasive ductal breast carcinoma.
Polycystic kidney disease: a case of suppressed autophagy?
Polydeoxyribonucleotide Exerts Therapeutic Effect by Increasing VEGF and Inhibiting Inflammatory Cytokines in Ischemic Colitis Rats.
Polydeoxyribonucleotide improves angiogenesis and wound healing in experimental thermal injury.
Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Polymers for induction of revascularization in the rat fascial flap: application of vascular endothelial growth factor and pancreatic islet cells.
Polymorphism of vascular endothelial growth factor -1154G>A (rs1570360) with cancer risk: a meta-analysis of 16 case-control studies.
Polymorphism of vascular endothelial growth factor -2578C/A with cancer risk: evidence from 11263 subjects.
Polymorphism of VEGF-460C/T associated with the risk and clinical characteristics of lung cancer in Chinese population.
Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer.
Polymorphisms in the genes related to angiogenesis are associated with uterine cervical cancer.
Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort.
Polymorphisms in the VEGFA promoter are associated with susceptibility to hepatocellular carcinoma by altering promoter activity.
Polyplex nanomicelle promotes hydrodynamic gene introduction to skeletal muscle.
Polysialic acid blocks mononuclear phagocyte reactivity, inhibits complement activation, and protects from vascular damage in the retina.
Polyunsaturated fatty acids augment tumoricidal action of 5-fluorouracil on gastric cancer cells by their action on vascular endothelial growth factor, tumor necrosis factor-? and lipid metabolism related factors.
Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.
Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women.
Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis.
Porphyrin-based covalent organic framework as bioplatfrom for detection of vascular endothelial growth factor 165 through fluorescence resonance energy transfer.
Portal Cytokine Response and Metabolic Markers in the Early Stages of Abdominal Sepsis in Pigs.
Positive association between vascular endothelial growth factor (VEGF) -2578 C/A variant and prostate cancer.
Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer.
Positive feedback and angiogenesis in tumor growth control.
Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab.
Positron emission tomography elucidates transport system and tumor proliferation in meningiomas.
Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
Positron Emission Tomography Imaging of Vascular Endothelial Growth Factor Receptor Expression with (61)Cu-Labeled Lysine-Tagged VEGF(121).
Possible association between polymorphisms of human vascular endothelial growth factor a gene and susceptibility to glioma in a Chinese population.
Possible pathophysiological role of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in metastatic brain tumor-associated intracerebral hemorrhage.
Possible protective effect of TNF-? inhibition and triad NO/cGMP/VEGF activation on gastric ulcer in rats.
Possible Role and Therapeutic Target of PDGF-D Signalling in Colorectal Cancer.
Post-acute response of 9L gliosarcoma to Photofrintrade mark-mediated PDT in athymic nude mice.
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis.
Postoperative autovaccinotherapy for patients with gastric cancer and expression of some proteins in tumor tissue.
Postoperative efficacy of low-temperature plasma radiofrequency ablation in elderly patients with laryngeal carcinoma and its influences on tumor markers and COX-2 and VEGF expressions in laryngeal carcinoma tissues.
Potent and long-term antiangiogenic efficacy mediated by FP3-expressing oncolytic adenovirus.
Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60.
Potent anti-cancer effect of 3'-hydroxypterostilbene in human colon xenograft tumors.
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium.
Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
Potent inhibition of tumoral hypoxia-inducible factor 1 by albendazole.
Potent inhibition of VEGFR-2 activation by tight binding of green tea epigallocatechin gallate and apple procyanidins to VEGF: Relevance to angiogenesis.
Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.
Potential Anti-Cancer Flavonoids Isolated From Caesalpinia bonduc Young Twigs and Leaves: Molecular Docking and In Silico Studies.
Potential Anticancer Effects of Polyphenols from Chestnut Shell Extracts: Modulation of Cell Growth, and Cytokinomic and Metabolomic Profiles.
Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2.
Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation.
Potential contribution of naïve immune effectors to oral tumor resistance: role in synergistic induction of VEGF, IL-6, and IL-8 secretion.
Potential impact of quercetin and idebenone against immuno- inflammatory and oxidative renal damage induced in rats by titanium dioxide nanoparticles toxicity.
Potential lung carcinogenicity induced by chronic exposure to PM2.5 in the rat.
Potential new therapeutics for Waldenstrom's macroglobulinemia.
Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report.
Potential Regulation Mechanisms of P-gp in the Blood-Brain Barrier in Hypoxia.
Potential regulatory molecules in the human trabecular meshwork of patients with glaucoma: immunohistochemical profile of a number of inflammatory cytokines.
Potential role for vascular endothelial growth factor-D as an autocrine factor for human gastric carcinoma cells.
Potential Role of PDGFR?-Associated THBS4 in Colorectal Cancer Development.
Potential role of Saudi red propolis in alleviating lung damage induced by methicillin resistant Staphylococcus aureus virulence in rats.
Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer.
Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer.
PPAR? agonists suppress angiogenesis in a VEGFR2-dependent manner.
PRDX6 promotes lung tumor progression via its GPx and iPLA2 activities.
Pre-operative plasma levels of vascular endothelial growth factor A, C and D in patients with colorectal cancer.
Pre-Therapeutic VEGF Level in Plasma Is a Prognostic Bio-Marker in Head and Neck Squamous Cell Carcinoma (HNSCC).
Prechemotherapy serum levels of CD105, transforming growth factor beta2, and vascular endothelial growth factor are associated with prognosis in patients with advanced epithelial ovarian cancer treated with cytoreductive surgery and platinum-based chemotherapy.
Precision medicine: Uses and challenges.
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Preclinical data targeting vascular endothelial growth factor in colorectal cancer.
Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.
Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer.
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.
Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry.
Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling.
Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms.
Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels.
Prediction model of lymphovascular invasion based on clinicopathological factors in Chinese patients with invasive breast cancer.
Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.
Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer.
Predictive Value of Growth Factors and Interleukins for Future Liver Remnant Volume and Colorectal Liver Metastasis Volume Growth Following Portal Vein Embolization and Autologous Stem Cell Application.
Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancer.
Predictive value of serum VEGF, IL-1 and TNF-? in the treatment of thromboangiitis obliterans by revascularization.
Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy.
Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern.
Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer.
Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients.
Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer.
Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis.
Preferential Effect of Synchrotron Microbeam Radiation Therapy on Intracerebral 9L Gliosarcoma Vascular Networks.
Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival.
Pregnancy Promotes Melanoma Metastasis through Enhanced Lymphangiogenesis.
Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma.
Preliminary study of plasma vascular endothelial growth factor (VEGF) during low- and high-dose radiation therapy of dogs with spontaneous tumors.
Preliminary study of the effect of FK506 nanospheric-suspension eye drops on rejection of penetrating keratoplasty.
Preoperative administration of erythropoietin stimulates tumor recurrence after surgical excision of colon cancer in mice by a vascular endothelial growth factor-independent mechanism.
Preoperative assessment of tumor angiogenesis by vascular endothelial growth factor mRNA expression in homogenate samples of breast carcinoma: fine-needle aspirates vs. resection samples.
Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer.
Preoperative Plasma Vascular Endothelial Growth Factor But Not Nitrite Is a Useful Complementary Tumor Marker in Patients With Colorectal Cancer.
Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.
Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.
Preparation and Characterization of RGDS/Nanodiamond as a Vector for VEGF-siRNA Delivery.
Preparation and functional characterization of human vascular endothelial growth factor-melittin fusion protein with analysis of the antitumor activity in vitro and in vivo.
Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab.
Preparation of artificial red cell and its application on alleviation of tumor hypoxia.
Preparation of asiaticoside-loaded coaxially electrospinning nanofibers and their effect on deep partial-thickness burn injury.
Preparation of curcumin micelles and the in vitro and in vivo evaluation for cancer therapy.
Preparation of extracellular domain 3 of human VEGF receptor-2 and the monitoring of its real-time binding to VEGF by biosensors.
Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies.
Preparation, antiangiogenic and antitumoral activities of the chemically sulfated glucan from Phellinus ribis.
Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function.
Preterm birth, infection, and inflammation advances from the study of animal models.
Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer.
Preventive effects of fluvastatin in rat mammary carcinogenesis.
Preventive effects of the angiotensin-converting enzyme inhibitor, captopril, on the development of azoxymethane-induced colonic preneoplastic lesions in diabetic and hypertensive rats.
Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six cases.
Primary CNS lymphoma arising in the region of the optic nerve presenting as loss of vision: 2 case reports, including a patient with a massive intracerebral hemorrhage.
Primary T cells for mRNA-mediated immunotoxin delivery.
Primary tumor induces sentinel lymph node lymphangiogenesis in oral squamous cell carcinoma.
Primary Tumor-Secreted Lymphangiogenic Factors Induce Pre-Metastatic Lymphvascular Niche Formation at Sentinel Lymph Nodes in Oral Squamous Cell Carcinoma.
Pro-angiogenic cytokines and their role in tumor angiogenesis.
Pro-angiogenic effects of MDM2 through HIF-1? and NF-?B mediated mechanisms in LNCaP prostate cancer cells.
Pro-Apoptotic and Anti-Angiogenesis Effects of Olive Leaf Extract on Spontaneous Mouse Mammary Tumor Model by Balancing Vascular Endothelial Growth Factor and Endostatin Levels.
Proangiogenic effects of ionizing irradiation on squamous cell carcinoma of the hypopharynx.
Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis.
Proanthocyanidins: novel treatment for psoriasis that reduces oxidative stress and modulates Th17 and Treg cells.
Procalcitonin Impairs Endothelial Cell Function and Viability.
Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons.
Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF.
Production of pro-inflammatory polypeptides by airway mucous glands and its potential significance.
Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.
Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer.
Profile of gene expression of TLR-signaling pathways in colorectal cancer tissues.
Profile of nintedanib in the treatment of solid tumors: the evidence to date.
Profiling of Vascular Endothelial Growth Factor Receptor Heterogeneity Identifies Protein Expression-defined Subclasses of Human Non-small Cell Lung Carcinoma.
Profiling the cytokines in gingival crevicular fluid using a cytokine antibody array.
Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer.
Progesterone Inhibits the Growth of Human Neuroblastoma: In Vitro and In Vivo Evidence.
Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics.
Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy.
Prognostic and diagnostic implications of MMP-2, MMP-9, and VEGF-? expressions in colorectal cancer.
Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial.
Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers.
Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer.
Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology.
Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells.
Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer.
Prognostic impact of VEGF and FLT-1 receptor expression in patients with locally advanced squamous cell carcinoma of the head and neck.
Prognostic Impact of VEGF and VEGF Receptor 1 (FLT1) Expression in Patients Irradiated for Stage II/III Non-Small Cell Lung Cancer (NSCLC).
Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.
Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer.
Prognostic implications of estrogen receptor 1 and vascular endothelial growth factor A expression in primary gallbladder carcinoma.
Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy.
Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome.
Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma.
Prognostic index expression of cyclin-D1, cerbB-2 and VEGF: metastases vs corresponding primary cancers and metastatic vs non-metastatic adenocarcinomas.
Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer.
Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers.
Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma.
Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer.
Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.
Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis.
Prognostic significance of angiogenesis in gastrointestinal stromal tumor.
Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma.
Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma.
Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery.
Prognostic Significance of Human Papillomavirus (HPV) Status and Expression of Selected Markers (HER2/neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on Outcome After (Chemo-) Radiotherapy in Patients with Squamous Cell Carcinoma of Uterine Cervix.
Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer.
Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung.
Prognostic significance of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma.
Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer.
Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer.
Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma.
Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma.
Prognostic significance of placenta growth factor expression in patients with multiple cancers: a meta-analysis.
Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels.
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma.
Prognostic Significance of Serum Levels of Vascular Endothelial Growth Factor and Insulin-Like Growth Factor-1 in Advanced Gastric Cancer Patients Treated with FOLFOX Chemotherapy.
Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma.
Prognostic Significance of Serum Vascular Endothelial Growth Factor Per Platelet Count in Unresectable Advanced Gastric Cancer Patients.
Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer.
Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor.
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
prognostic significance of vascular endothelial growth factor C in systemic malignancies besides non-small cell lung carcinomas.
Prognostic significance of vascular endothelial growth factor D in gastric carcinoma.
Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: comparison with positron emission tomography.
Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up.
Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.
Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma.
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer.
Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma.
Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy.
Prognostic Significance of VEGF-C Expression in Patients with Breast Cancer: A Meta-Analysis.
Prognostic significance of VEGF-C in predicting micrometastasis and isolated tumour cells in N0 oral squamous cell carcinoma.
Prognostic significance of VEGF-C, semaphorin 3F, and neuropilin-2 expression in oral squamous cell carcinomas and their relationship with lymphangiogenesis.
Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer.
Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan.
Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia.
Prognostic Value of Molecular Markers and Implication for Molecular Targeted Therapies in Nasopharyngeal Carcinoma: An Update in an Era of New Targeted Molecules Development.
Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus.
Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer.
Prognostic value of serum Tie-2 and vascular endothelial growth factor levels in cancer patients.
Prognostic value of the cancer oncogene Kelch-like 6 in gastric cancer.
Prognostic value of the immunohistochemical expression of vascular endothelial growth factors in malignant salivary gland neoplasms: a systematic review and meta-analysis.
Prognostic value of TNF a mRNA and VEGF mRNA expression in patients with chronic hepatitis C genotype-4, with and without cirrhosis and hepatocellular carcinoma to predict disease outcome.
Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression.
Prognostic Value of Vascular Endothelial Growth Factor A in the Prediction of the Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma.
Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1? in canine malignant mammary tumors.
Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer.
Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours.
Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients.
Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: a systematic review with meta-analysis.
Prognostic value of vascular endothelial growth factor expression in primary lung carcinoma.
Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients.
Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer.
Prognostic value of vascular endothelial growth factor-C and podoplanin mRNA expression in esophageal cancer.
Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer.
Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
Progress in magnetic resonance imaging of brain tumours.
Progress in targeted therapeutic drugs for oral squamous cell carcinoma.
Progress in the treatment of solid tumors with apatinib: a systematic review.
Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma.
Progression difference between cancers of the larynx and hypopharynx is not due to tumor size and vascularization.
Progression From Atypical/Dysplastic Intraepidermal Proliferations and Carcinoma In Situ to Invasive Tumors: A Pathway Based on Current Knowledge.
Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations.
Progressive enlargement of a mass lesion in late cerebral radionecrosis.
Proinflammatory cytokines predict the incidence of diabetic peripheral neuropathy over 5 years in Chinese type 2 diabetes patients: A prospective cohort study.
Proinflammatory cytokines upregulate mRNA expression and secretion of vascular endothelial growth factor in cultured human airway smooth muscle cells.
Prokaryotic Soluble Overexpression and Purification of Human VEGF165 by Fusion to a Maltose Binding Protein Tag.
Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects.
Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas.
Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis.
Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer.
Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2).
Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
Promiscuous transcription of vascular endothelial growth factor and survival of tumors.
Promising activity of Anthemis austriaca Jacq. on the endometriosis rat model and isolation of its active constituents.
Promising effect of chemotherapy with bevacizumab for patients with pulmonary pleomorphic carcinoma: Two case reports and a literature review.
Promoter methylation status of VEGF receptor genes: A possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
Promotion of Primary Murine Breast Cancer Growth and Metastasis by Adipose-Derived Stem Cells Is Reduced in the Presence of Autologous Fat Graft.
Properties and gene expression profiling of acquired radioresistance in mouse breast cancer cells.
Prophylactic administration of carnosine and melatonin abates the incidence of apoptosis, inflammation, and DNA damage induced by titanium dioxide nanoparticles in rat livers.
Prophylactic administration of fucoidan represses cancer metastasis by inhibiting vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in Lewis tumor-bearing mice.
Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
Propionibacterium acnes Augments Antitumor, Anti-Angiogenesis and Immunomodulatory Effects of Melatonin on Breast Cancer Implanted in Mice.
Propofol inhibits pancreatic cancer proliferation and metastasis by up-regulating miR-328 and down-regulating ADAM8.
Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2.
Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
Prostaglandin E(2) induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway.
Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line.
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Prostaglandin E2 regulates tumor angiogenesis in prostate cancer.
Prostaglandin E? regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells.
Protease-activated receptor-2 accelerates intestinal tumor formation through activation of nuclear factor-?B signaling and tumor angiogenesis in ApcMin/+ mice.
Protection Against Titanium Particle-Induced Inflammatory Osteolysis by the Proteasome Inhibitor Bortezomib In Vivo.
Protection of mesenchymal stem cells on acute kidney injury.
Protective effect of citicoline on random flap survival in a rat mode.
Protective effect of gentiopicroside from Gentiana macrophylla Pall. in ethanol-induced gastric mucosal injury in mice.
Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity.
Protective effect of norcantharidin on collagen-induced arthritis rats.
Protective effect of resveratrol and vitamin E against ethanol-induced oxidative damage in mice: biochemical and immunological basis.
Protective effect of telmisartan treatment against arsenic-induced testicular toxicity in rats.
Protective effect of teprenone on gastric mucosal injury induced by dual antiplatelet therapy in rats.
Protective effects of dexmedetomidine on the survival of random flaps.
Protective Effects of Silymarin, Alone or in Combination with Chlorogenic Acid and/or Melatonin, Against Carbon Tetrachloride-induced Hepatotoxicity.
Protective effects of the Chinese herbal medicine prescription Zhujing pill on retina of streptozotocin-induced diabetic rats.
Protective role for CD1d-reactive invariant natural killer T cells in cauterization-induced corneal inflammation.
Protective role of cytochrome P450 1A1 (CYP1A1) against benzo[a]pyrene-induced toxicity in mouse aorta.
Protective role of SIRT1-mediated Sonic Hedgehog signaling pathway in the preeclampsia rat models.
Protein detection using tunable pores: resistive pulses and current rectification.
Protein Expression and Genetic Variation of
Protein Kinase A Catalytic Subunit Is a Molecular Switch that Promotes the Pro-tumoral Function of Macrophages.
Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis.
Protein kinase C signalling pathway is involved in the regulation of vascular endothelial growth factor expression in human bladder transitional carcinoma cells.
Protein kinase D up-regulates transcription of VEGF receptor-2 in endothelial cells by suppressing nuclear localization of the transcription factor AP2?.
Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases.
Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors.
Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility.
Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
Proteolytic Cleavages in the VEGF Family: Generating Diversity among Angiogenic VEGFs, Essential for the Activation of Lymphangiogenic VEGFs.
Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer.
Proteome-wide prediction of targets for aspirin: new insight into the molecular mechanism of aspirin.
Proteomics based drug repositioning applied to improve in vitro fertilization implantation: an artificial intelligence model.
Pseudo-Meigs' syndrome caused by uterine smooth muscle tumor of uncertain malignant potential with low vascular endothelial growth factor expression.
Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation.
PSMB8 inhibition decreases tumor angiogenesis in glioblastoma through vascular endothelial growth factor A reduction.
Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation.
Psychological Stress Up-Regulates CD147 Expression Through Beta-Arrestin1/ERK to Promote Proliferation and Invasiveness of Glioma Cells.
PTEN regulate angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells.
PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells: PTEN regulates angiogenesis in HepG2.
PTEN's regulation of VEGF and VEGFR1 expression and its clinical significance in myeloid leukemia.
PTEN/PI3K/Akt/VEGF signaling and the cross talk to KRIT1, CCM2, and PDCD10 proteins in cerebral cavernous malformations.
Pterostilbene Inhibits Adipocyte Conditioned-Medium-Induced Colorectal Cancer Cell Migration through Targeting FABP5-Related Signaling Pathway.
Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab.
Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines.
Pulmonary large cell carcinoma with rhabdoid phenotype.
Pulmonary tumor thrombotic microangiopathy caused by a gastric carcinoma expressing vascular endothelial growth factor and tissue factor.
Pulmonary tumor thrombotic microangiopathy caused by an ovarian cancer expressing tissue factor and vascular endothelial growth factor.
Pulmonary tumor thrombotic microangiopathy caused by lung adenocarcinoma: Case report with review of the literature.
Pulmonary Tumor Thrombotic Microangiopathy Caused by Urothelial Carcinoma Expressing Vascular Endothelial Growth Factor, Platelet-derived Growth Factor, and Osteopontin.
Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature.
Putative mechanism for anticancer properties of Ag-PP (NPs) extract.
Pyogenic granuloma in a finger of a rheumatoid arthritis patient.
Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
QSAR modelling on a series of arylsulfonamide-based hydroxamates as potent MMP-2 inhibitors.
Quadruplex-forming oligonucleotide targeted to the VEGF promoter inhibits growth of non-small cell lung cancer cells.
Quantification by competitive quantitative RT-PCR of VEGF121 and VEGF165 in renal cell carcinoma.
Quantification of angiogenesis stimulators in children with solid malignancies.
Quantification of antiangiogenic treatment effects on tissue heterogeneity in glioma tumour xenograft model using a combination of DCE-MRI and 3D-ultramicroscopy.
Quantification of Malignant Breast Cancer Cell MDA-MB-231 Transmigration Across Brain and Lung Microvascular Endothelium.
Quantification of tumour and circulating vascular endothelial growth factor (VEGF) in patients with oesophagogastric cancer: a long-term follow-up study.
Quantification of vascular endothelial growth factor, interleukin-8, and basic fibroblast growth factor in plasma of cancer patients and healthy volunteers - comparison of ELISA and microsphere-based multiplexed immunoassay.
Quantitation of angiogenesis and its correlation with vascular endothelial growth factor expression in astrocytic tumors.
Quantitation of Vascular Endothelial Growth Factor and Interleukin-6 in Different Stages of Breast Cancer.
Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma.
Quantitative analysis of lymphangiogenic markers in human colorectal cancer.
Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression.
Quantitative analysis of vascular endothelial growth factor expression in chronic lymphocytic leukaemia.
Quantitative analysis of vascular endothelial growth factor in colon cancer. Clinical and experimental.
Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma.
Quantitative analysis of VEGF-isoforms in head and neck squamous cell carcinoma cell lines: relation to xenotransplantability and tumour progression in mice.
Quantitative and semiquantitative immunoassay of growth factors and cytokines in the conditioned medium of STO and CF-1 mouse feeder cells.
Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors.
Quantitative assessment of the integrity of the blood-retinal barrier in mice.
Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma.
Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin alphaV and integrin beta3 in human neuroendocrine tumors.
Quantitative immunohistochemistry (IHC) analysis of biomarker combinations for human esophageal squamous cell carcinoma.
Quantitative PET imaging of VEGF receptor expression.
Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies.
Quantum dots-bevacizumab complexes for in vivo imaging of tumors.
Quercetin accelerated cutaneous wound healing in rats by increasing levels of VEGF and TGF-?1.
Quercetin loaded chitosan tripolyphosphate nanoparticles accelerated cutaneous wound healing in Wistar rats.
Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis.
Quercus infectoria gall extract aids wound healing in a streptozocin-induced diabetic mouse model.
R-Ras Inhibits Autophosphorylation of VEGF Receptor-2 in Endothelial Cells and Suppresses the Receptor Activation in Tumor Vasculature.
Rac activation is associated with hepatocellular carcinoma metastasis by up-regulation of vascular endothelial growth factor expression.
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
Radiation Exposure-Induced Changes in the Immune Cells and Immune Factors of Mice With or Without Primary Lung Tumor.
Radiation-synthesis of chitosan/poly (acrylic acid) nanogel for improving the antitumor potential of rutin in hepatocellular carcinoma.
Radioimmunotherapy with (131)i-bevacizumab as a specific molecule for cells with overexpression of the vascular endothelial growth factor.
Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft model.
Radioiodination of Pimonidazole as a Novel Theranostic Hypoxia Probe.
Radiolabeled RGD peptides as integrin alpha(v)beta3-targeted PET tracers.
Radiolabeling of VEGF165 with 99mTc to evaluate VEGFR expression in tumor angiogenesis.
Radiologic Features and Expression of Vascular Endothelial Growth Factor Stratify Survival Outcomes in Patients with Glioblastoma.
Radionuclide imaging of tumor angiogenesis.
Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.
Radiopharmaceuticals for renal positron emission tomography imaging.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
RAGE-aptamer Attenuates the Growth and Liver Metastasis of Malignant Melanoma in Nude Mice.
Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.
Ramucirumab and its use in gastric cancer treatment.
Ramucirumab: A vascular endothelial growth factor receptor-2 inhibitor with activity in several malignancies.
Ramucirumab: first global approval.
Randomized clinical trial investigating the stress response from two different methods of analgesia after laparoscopic colorectal surgery.
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non?Small-Cell Lung Cancer.
Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration.
RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression.
Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin {alpha}v{beta}3.
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.
Rapamycin is an effective inhibitor of human renal cancer metastasis.
Rapamycin prevents mesenteric neo-angiogenesis and reduces splanchnic blood flow in portal hypertensive mice.
Rapamycin unbalances the polarization of human macrophages to M1.
Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models.
Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart.
Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay.
Rapid tumor growth with glial differentiation of central neurocytoma after stereotactic radiosurgery.
Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants.
Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis.
Rat ovarian prostaglandin endoperoxide synthase-1 and -2: periovulatory expression of granulosa cell-based interleukin-1-dependent enzymes.
Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma.
Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma.
Ratios of biochemical markers in peritoneal fluid to those in venous blood for the diagnosis of ruptured tubal pregnancy: A prospective study.
Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors.
Re-expression of reduced VEGF activity in liver metastases of experimental pancreatic cancer.
Reactive oxygen generated by Nox1 triggers the angiogenic switch.
Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.
Reactive oxygen species (ROS)-responsive nanomedicine for RNAi-based cancer therapy.
Reactive oxygen species activation of MAPK pathway results in VEGF upregulation as an undesired irradiation response.
Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy.
Reactive oxygen species production has a critical role in hypoxia-induced Stat3 activation and angiogenesis in human glioblastoma.
Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor.
Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis.
Real-time visualization and quantitation of vascular permeability in vivo: implications for drug delivery.
Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
REC8 suppresses tumor angiogenesis by inhibition of NF-?B-mediated vascular endothelial growth factor expression in gastric cancer cells.
Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1.
Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy.
Recent advances in management of patients with platinum-refractory testicular germ cell tumors.
Recent advances in mechanisms and treatments of airway remodeling in asthma: a message from the bench side to the clinic.
Recent Advances in Molecular Imaging of Colorectal Tumors.
Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.
Recent advances in ultrasound-based diagnosis and therapy with micro- and nanometer-sized formulations.
Recent advances in understanding and managing rosacea.
Recent Developments in Chimeric NSAIDs as Anticancer Agents: Teaching an Old Dog a New Trick.
Recent developments in colorectal cancer treatment by monoclonal antibodies.
Recent developments of targeted therapies in the treatment of non-small cell lung cancer.
Recent discovery of non-nucleobase thymidine phosphorylase inhibitors targeting cancer.
Recent progress in studies of infantile hemangioma.
Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19.
Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression.
Reciprocal activation between ATPase inhibitory factor 1 and NF-?B drives hepatocellular carcinoma angiogenesis and metastasis.
Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2.
RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Targeted Therapy.
Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
Recombinant fusion protein by lysozyme and antibacterial peptide enhances ischemic wound healing via angiogenesis and reduction of inflammation in diabetic db/db mice.
Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models.
Recombinant human growth hormone (rhGH) treatment of MKN-45 xenograft mice improves nutrition status and strengthens immune function without promoting tumor growth.
Recombinant human insulin-like growth factor-1: a new cardiovascular disease treatment option?
Recombined human endostatin (Endostar) enhances cisplatin delivery and potentiates chemotherapy by decompressing colorectal cancer vessels.
Recruitment of CD11b(+)Ly6C(+) monocytes in non-small cell lung cancer xenografts challenged by anti-VEGF antibody.
Rectal cancer with paraneoplastic nephropathy: association of vascular endothelial growth factor.
Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose-volume analysis.
Recurrence or metastasis of HCC:predictors, early detection and experimental antiangiogenic therapy.
Reduced Choroidal Neovascular Membrane Formation in Cyclooxygenase-2 Null Mice.
Reduced glioma infiltration in Src-deficient mice.
Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism.
Reducing peritoneal vascular endothelial growth factor concentration and inhibiting cancer scattering in a mouse model of laparoscopy.
Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470.
Reference genes for quantitative real time PCR in UVB irradiated keratinocytes.
Refined Deep-Sea Water Suppresses Inflammatory Responses via the MAPK/AP-1 and NF-?B Signaling Pathway in LPS-Treated RAW 264.7 Macrophage Cells.
Refining the use of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells.
Refractory generalized seizures as a possible side effect of bevacizumab in a colon cancer patient.
Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor.
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
Regorafenib diminishes the expression and secretion of angiogenesis and metastasis associated proteins and inhibits cell invasion via NF-?B inactivation in SK-Hep1 cells.
Regorafenib-loaded poly (lactide-co-glycolide) microspheres designed to improve transarterial chemoembolization therapy for hepatocellular carcinoma.
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.
Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.
Regulated expression of cytokines in human endometrium throughout the menstrual cycle: dysregulation in habitual abortion.
Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia.
Regulation of angiogenic factors by the PI3K/Akt pathway in A549 lung cancer cells under hypoxic conditions.
Regulation of cancer-related growth factor expression by artificial zinc-finger proteins.
Regulation of cell-cell interactions by phosphatidic acid phosphatase 2b/VCIP.
Regulation of extracellular-superoxide dismutase in rat retina pericytes.
Regulation of glucose transporter protein-1 and vascular endothelial growth factor by hypoxia inducible factor 1? under hypoxic conditions in Hep-2 human cells.
Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.
Regulation of nicotine-induced apoptosis of pulmonary artery endothelial cells by treatment of N-acetylcysteine and vitamin E.
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies.
Regulation of sepsis-induced apoptosis of pulmonary cells by posttreatment of erdosteine and N-aceylcysteine.
Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis.
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.
Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience.
Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription.
Regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D expression by the organ microenvironment in human colon carcinoma.
Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene.
Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia.
Regulation of vascular endothelial growth factor D by orphan receptors hepatocyte nuclear factor-4 alpha and chicken ovalbumin upstream promoter transcription factors 1 and 2.
Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells.
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas.
Regulation of vascular endothelial growth factor expression by insulin-like growth factor-II in human keratinocytes, differential involvement of mitogen-activated protein kinases and feedback inhibition of protein kinase C.
Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase.
Regulation of vascular endothelial growth factor expression in human gastric cancer cells by interleukin-1beta.
Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids.
Regulation of Vascular Endothelial Growth Factor in endometrial tumour cells by resveratrol and EGCG.
Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1.
Regulation of vascular endothelial junction stability and remodeling through Rap1-Rasip1 signaling.
Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells.
Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment.
Regulators of vascular endothelial growth factor expression in cancer.
Regulatory T cells, leptin and angiogenesis.
Reinforcing endothelial junctions prevents microvessel permeability increase and tumor cell adhesion in microvessels in vivo.
Relation between cell-to-cell adhesion and angiogenesis and clinico-morphological prognostic factors in patients with gastric cancer.
Relation between expression of TNF alpha, iNOS, VEGF mRNA and development of heart failure after experimental myocardial infarction in rats.
Relation of fibroblast growth factor receptor 2 expression to hepatocellular carcinoma recurrence after liver resection.
Relationship between (18)F-FDG uptake on PET and various biologic molecular markers in benign pulmonary lesion: comparison with primary lung cancer.
Relationship between (18)F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.
Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP.
Relationship between gingival angiopoietin-1 concentrations and depth of the adjacent gingival sulcus.
Relationship Between Loneliness and Proangiogenic Cytokines in Newly Diagnosed Tumors of Colon and Rectum.
Relationship between plasma levels of vascular endothelial growth factor and serum levels of interleukin-12 in patients with colorectal cancer.
Relationship between preoperative serum TSH levels and expression of VEGF in papillary thyroid carcinoma.
Relationship between PTEN and Vascular Endothelial Growth Factor Expression in Non-Small Cell Lung Cancer.
Relationship between the expression of VEGF signal components and matrix metalloproteinases in ovarian tumors.
Relationship between tumor vascularity and vascular endothelial growth factor as prognostic factors for patients with neuroblastoma.
Relationship between tumour angiogenesis and expression of cyclo-oxygenase-2 and vascular endothelial growth factor-A in human renal cell carcinoma.
Relationship between tumour necrosis factor-related apoptosis inducing ligand (TRAIL) and vascular endothelial growth factor in human multiple myeloma patients.
Relationship between vascular endothelial growth factor and Notch1 expression and lymphatic metastasis in tongue cancer.
Relationship between vascular endothelial growth factor and nuclear factor-kappaB in renal cell tumors.
Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas.
Relationship between venous thromboembolism and vascular endothelial growth factor in cancer.
Relationship of angiogenic and apoptotic activities in soft-tissue sarcoma.
Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas.
Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors.
Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer.
Relationsip between PTEN and VEGF expression and clinicopathological characteristics in HCC.
Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer.
Relaxin, a potent microcirculatory effector, is not angiogenic.
Relaxin-like peptides in cancer.
Release in vitro of adipsin, vascular cell adhesion molecule 1, angiotensin 1-converting enzyme, and soluble tumor necrosis factor receptor 2 by human omental adipose tissue as well as by the nonfat cells and adipocytes.
Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.
Relevance of MicroRNA-18a and MicroRNA-199a-5p to hepatocellular carcinoma recurrence after living donor liver transplantation.
Remission of infantile generalized myofibromatosis after interferon alpha therapy.
Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer.
Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis.
Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children.
Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
Renal cancer genetics: von Hippel Lindau and other syndromes.
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications.
Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma.
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
Repeated thoracenteses affect proinflammatory cytokines, vascular endothelial growth factor, and fibrinolytic activity in pleural transudates.
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
Repression of the Notch pathway prevents liver damage in streptozotocin-induced diabetic mice.
Repression of vascular endothelial growth factor A in glioblastoma cells using engineered zinc finger transcription factors.
Reproducibility of fluid-phase measurements in PBS-treated sputum supernatant of healthy and stable COPD subjects.
Repurposing of a monoamine oxidase A inhibitor?heptamethine carbocyanine dye conjugate for paclitaxel?resistant non?small cell lung cancer.
Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.
Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab.
Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor.
Resistance exercise training-induced muscle hypertrophy was associated with reduction of inflammatory markers in elderly women.
Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer.
Resistance of a VEGF-producing tumor to anti-VEGF antibody: unimpeded growth of human rhabdoid tumor xenografts.
Resistance of melanoma cells to anticancer treatment: a role of vascular endothelial growth factor.
Resistance of SMMC-7721 hepatoma cells to etoposide in hypoxia is reversed by VEGF inhibitor.
Resistance to angiogenesis inhibitors in renal cell carcinoma.
Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs.
Resistance to high-fat diet-induced obesity and altered expression of adipose-specific genes in HSL-deficient mice.
Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.
Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.
Response gene to complement 32, a novel hypoxia-regulated angiogenic inhibitor.
Response letter regarding the interpretation of gene expression data.
Response of Primary Renal Cell Carcinoma to Systemic Therapy.
Response of tumour cells to hypoxia: role of p53 and NFkB.
Response surface methodology to extraction of tea polysaccharide and its antitumour activity.
Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion.
Restoration of corpus luteum angiogenesis in immature hypothyroid rdw rats after thyroxine treatment: morphologic and molecular evidence.
Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells.
Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).
Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.
Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
Resveratrol ameliorated endothelial injury of thoracic aorta in diabetic mice and Gly-LDL-induced HUVECs through inhibiting TLR4/HIF-1?.
Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis.
Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo.
Resveratrol inhibits VEGF-induced angiogenesis in human endothelial cells associated with suppression of aerobic glycolysis via modulation of PKM2 nuclear translocation.
Resveratrol plays dual roles in pancreatic cancer cells.
Resveratrol protects mitochondrial quantity by activating SIRT1/PGC-1? expression during ovarian hypoxia.
Retinal heparanase expression in streptozotocin-induced diabetic rats.
Retinoic acid modulates the ability of macrophages to participate in the induction of the angiogenic phenotype in head and neck squamous cell carcinoma.
Retraction: Correlation of serum intercellular adhesion molecule 1 and vascular endothelial growth factor with tumor grading and staging in breast cancer patients.
Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer.
Revascularization and muscle adaptation to limb demand ischemia in diet-induced obese mice.
Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology.
Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer.
Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated With Targeted Therapies.
Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis.
Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy.
Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.
Rho GTPases and the regulation of endothelial permeability.
RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
RhoC is essential for angiogenesis induced by hepatocellular carcinoma cells via regulation of endothelial cell organization.
Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? a brief review.
rHuEPo reduces ischemia-reperfusion injury and improves survival after transplantation of fatty livers in rats.
Riboflavin at high doses enhances lung cancer cell proliferation, invasion, and migration.
Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC).
Ribozyme mediated suppression of vascular endothelial growth factor gene expression enhances matrix metalloproteinase 1 expression in a human hepatocellular carcinoma cell line.
Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels.
Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials.
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.
Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis.
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era.
Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis.
Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis.
RNA interference of hypoxia-inducible factor-1 alpha improves the effects of transcatheter arterial embolization in rat liver tumors.
RNA interference targeting NRP-1 inhibits human glioma cell proliferation and enhances cell apoptosis.
RNAi-mediated gene silencing of vascular endothelial growth factor inhibits growth of colorectal cancer.
RNAi-mediated inhibition of PDGF-D leads to decreased cell growth, invasion and angiogenesis in the SGC-7901 gastric cancer xenograft model.
RNAi-mediated knockdown of vascular endothelial growth factor inhibits vascularization and tumor growth in renal cell carcinoma.
RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Ro60 Inhibits Colonic Inflammation and Fibrosis in a Mouse Model of Dextran Sulfate Sodium-Induced Colitis.
Role and Mechanisms of RAGE-Ligand Complexes and RAGE-Inhibitors in Cancer Progression.
Role of adiponectin and proinflammatory gene expression in adipose tissue chronic inflammation in women with metabolic syndrome.
Role of angiogenesis in benign, premalignant and malignant vulvar lesions.
Role of angiogenesis in the development and growth of liver metastasis.
Role of angiogenesis in tumor growth and metastasis.
Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma.
Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.
Role of AP-1 and HIF-1 transcription factors in TGF-beta activation of VEGF expression.
Role of biological markers in the clinical outcome of colon cancer.
Role of CD34, vascular endothelial growth factor, and p53 in neoangiogenesis as correlated with stage of disease in colorectal carcinoma.
Role of copper in tumour angiogenesis--clinical implications.
Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma.
Role of Cytokines and Chemokines in Renal Ischemia-Reperfusion Injury.
Role of cytokines in lavage or drainage fluid after hemithyroidectomy in wound healing: Involvement of histamine in the acceleration and delay of wound healing.
Role of cytokines in myocardial ischemia and reperfusion.
Role of cytokines in progression of endometriosis.
Role of deformable cancer cells on wall shear stress-associated-VEGF secretion by endothelium in microvasculature.
Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors.
Role of endogenous angiogenesis inhibitors in Down syndrome.
Role of endothelin-1 in neovascularization of ovarian carcinoma.
Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells.
Role of HIF signaling on tumorigenesis in response to chronic low-dose arsenic administration.
Role of HIF-1? in response of tumors to a combination of hyperthermia and radiation in vivo.
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.
Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors.
Role of hypoxia in tumor angiogenesis-molecular and cellular angiogenic crosstalk.
Role of inflammation and oxidative stress in atrial fibrillation.
Role of Intravitreal Inflammatory Cytokines and Angiogenic Factors in Proliferative Diabetic Retinopathy.
Role of intravoxel incoherent motion MRI in preoperative evaluation of DNA mismatch repair status in rectal cancers.
Role of lymphangiogenesis in epithelial ovarian cancer.
Role of macrophage colony-stimulating factor (M-CSF)-dependent macrophages in gastric ulcer healing in mice.
Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants.
Role of mesenchymal stem cells on cornea wound healing induced by acute alkali burn.
Role of Microvessel Density and Vascular Endothelial Growth Factor in Angiogenesis of Hematological Malignancies.
Role of miR-497 in VEGF-A-mediated cancer cell growth and invasion in non-small cell lung cancer.
Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with ?5?1 integrin in glioma.
Role of modulation of vascular endothelial growth factor and tumor necrosis factor-alpha in gastric ulcer healing in diabetic rats.
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis.
Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis.
Role of Nanomechanics in Canonical and Noncanonical Pro-angiogenic Ligand/VEGF Receptor-2 Activation.
Role of Notch, IL-1 and leptin expression in colorectal cancer.
Role of nuclear receptor NR4A2 in gastrointestinal inflammation and cancers.
Role of oxygen in the regulation of Leydig tumor derived MA-10 cell steroid production: the effect of cobalt chloride.
Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.
Role of plasma membrane caveolae/lipid rafts in VEGF-induced redox signaling in human leukemia cells.
Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells.
Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression and HIF1alpha activation.
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements.
Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer.
Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells.
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Role of the VEGF/VEGFR axis in cancer biology and therapy.
Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule.
Role of TOPK in lipopolysaccharide-induced breast cancer cell migration and invasion.
Role of tumour angiogenesis in haematological malignancies.
Role of Vascular Endothelial Growth Factor (VEGF) in Thymus of Mice under Normal Conditions and with Tumor Growth.
Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study.
Role of vascular endothelial growth factor C in classical Hodgkin lymphoma.
Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization.
Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.
Role of vascular endothelial growth factor receptor-3/Flt-4 in early-stage cervical cancer.
Role of vascular endothelial growth factor-C and -D mRNA in breast cancer.
Role of VEGF-A and Its Receptors in Sporadic and MEN2-Associated Pheochromocytoma.
Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer.
Role of VEGF-C Gene Polymorphisms in Susceptibility to Hepatocellular Carcinoma and Its Pathological Development.
Role of VHL gene mutation in human renal cell carcinoma.
Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo.
Role of wnts in prostate cancer bone metastases.
Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis.
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence.
Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis.
Roles of arrest-defective protein 1(225) and hypoxia-inducible factor 1alpha in tumor growth and metastasis.
Roles of endogenous monocyte chemoattractant protein-1 in ischemia-induced neovascularization.
Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.
Roles of main pro- and anti-angiogenic factors in tumor angiogenesis.
Roles of microRNA-186 and vascular endothelial growth factor in hepatocellular carcinoma complicated with portal vein tumor thrombus.
Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
Roles of omental and bone marrow adipocytes in tumor biology.
Roles of p38? and p38? mitogen?activated protein kinase isoforms in human malignant melanoma A375 cells.
Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer.
Roles of VEGF-Flt-1 signaling in malignant behaviors of oral squamous cell carcinoma.
Rolipram potentiates bevacizumab-induced cell death in human glioblastoma stem-like cells.
Roquin2 suppresses breast cancer progression by inhibiting tumor angiogenesis via selectively destabilizing proangiogenic factors mRNA.
ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy.
Rosmarinic acid inhibits inflammation and angiogenesis of hepatocellular carcinoma by suppression of NF-?B signaling in H22 tumor-bearing mice.
Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung.
Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: Role of iNOS and VEGF.
Roxatidine suppresses inflammatory responses via inhibition of NF-?B and p38 MAPK activation in LPS-induced RAW 264.7 macrophages.
Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice.
Roxithromycin inhibits tumor necrosis factor-alpha-induced matrix metalloproteinase-1 expression through regulating mitogen-activated protein kinase phosphorylation and Ets-1 expression.
RSUME inhibits VHL and regulates its tumor suppressor function.
RT-PCR method to quantify vascular endothelial growth factor expression.
Rubi Fructus Water Extract Alleviates LPS-Stimulated Macrophage Activation via an ER Stress-Induced Calcium/CHOP Signaling Pathway.
Runt-related gene 2 is involved in the inhibition of matrix metalloproteinase-13 expression by roxithromycin in human gingival epithelial cell cultures.
Rupatadine Inhibits Proinflammatory Mediator Secretion from Human Mast Cells Triggered by Different Stimuli.
S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase.
Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9.
Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization as a Bridging Therapy in Patients with Early Stage Hepatocellular Carcinoma and Child-Pugh Stage B Eligible for Liver Transplant.
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies.
Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis.
Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.
Salivary levels and immunohistochemical expression of selected angiogenic factors in benign and malignant parotid gland tumours.
Salmonella inhibits tumor angiogenesis by downregulation of vascular endothelial growth factor.
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
Sanhuang Decoction Controls Tumor Microenvironment by Ameliorating Chronic Stress in Breast Cancer: A Report of Ninety Cases.
Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice.
Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.
Sclerosing stromal tumor of the ovaries overexpressing vascular endothelial growth factor: two cases.
Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer.
Screening of novel alkaloid inhibitors for vascular endothelial growth factor in cancer cells: an integrated computational approach.
SCUBE3 is an endogenous TGF-? receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer.
scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis.
SDF-1 Expression is Associated with Poor Prognosis in Osteosarcoma.
Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface.
Secreted Threonyl-tRNA synthetase stimulates endothelial cell migration and angiogenesis.
Secretion of extracellular superoxide dismutase from muscle transduced with recombinant adenovirus inhibits the growth of B16 melanomas in mice.
Secretion of the angiogenic factor VEGF after photodynamic therapy with ALA under hypoxia-like conditions in colon cancer cells.
Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix.
Secretion of vascular endothelial growth factor in ovarian cancer.
Secretion of VEGF-165 has unique characteristics, including shedding from the plasma membrane.
Secretion rates and levels of vascular endothelial growth factor in clone A or HCT-8 human colon tumour cells as a function of oxygen concentration.
Segmental heterogeneity of vasa vasorum neovascularization in human coronary atherosclerosis.
Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors.
Selected gene profiles of stressed NSC-34 cells and rat spinal cord following peripheral nerve reconstruction and minocycline treatment.
Selecting bioactive phenolic compounds as potential agents to inhibit proliferation and VEGF expression in human ovarian cancer cells.
Selection and characterization of DNA aptamers against VEGF165 with aptamer blotting method and its application.
Selection of DNA aptamers against VEGF(165) using a protein competitor and the aptamer blotting method.
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
Selection of Reference Genes for Studies of Human Retinal Endothelial Cell Gene Expression by Reverse Transcription-Quantitative Real-Time Polymerase Chain Reaction.
Selection, Analysis and Improvement of Anti-Angiogenesis Compounds Identified by an Anti-HIF-1? Screening and Validation System.
Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.
Selective and Specific Macrophage Ablation Is Detrimental to Wound Healing in Mice.
Selective binding of C-6 OH sulfated hyaluronic acid to the angiogenic isoform of VEGF(165).
Selective imaging of VEGFR-1 and VEGFR-2 receptors using 89Zr-labeled single-chain VEGF mutants.
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
Selective NTPDase2 expression modulates in vivo rat glioma growth.
Selective release of cytokines, chemokines, and growth factors by minced skin in vitro supports the effectiveness of autologous minced micrografts technique for chronic ulcer repair.
Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma.
Selenium Induces an Anti-tumor Effect Via Inhibiting Intratumoral Angiogenesis in a Mouse Model of Transplanted Canine Mammary Tumor Cells.
Selenium Status Is Not Associated with Cognitive Performance: A Cross-Sectional Study in 154 Older Australian Adults.
Self-Assembled Nanoconstructs Modified with Amplified Aptamers Inhibited Tumor Growth and Retinal Vascular Hyperpermeability via Vascular Endothelial Growth Factor Capturing.
Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect.
Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells.
Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression.
Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration.
Semiquantitative immunohistochemical marker staining and localization in canine thyroid carcinoma and normal thyroid gland.
Sensitive, quantitative, and high-throughput detection of angiogenic markers using shape-coded hydrogel microparticles.
Sequential dynamics of inflammatory cytokine, angiogenesis inducing factor and matrix degrading enzymes during spontaneous resorption of the herniated disc.
Sequential Treatment of Bioresponsive Nanoparticles Elicits Antiangiogenesis and Apoptosis and Synergizes with a CD40 Agonist for Antitumor Immunity.
Sequestering and inhibiting a vascular endothelial growth factor in vivo by systemic administration of a synthetic polymer nanoparticle.
Serial analysis of cytokine and chemokine profiles and viral load in severe fever with thrombocytopenia syndrome: Case report and review of literature.
Serial Assessment of Growth Factors Associated with Liver Regeneration in Patients Operated with Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy.
Serial cytokine alterations and abnormal neuroimaging in newborn infants with encephalopathy.
Serial in vivo imaging using a fluorescence probe allows identification of tumor early response to cetuximab immunotherapy.
Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
Serous cystic neoplasms of the pancreas: clinicopathologic and molecular characteristics.
Serous effusions in malignant lymphomas: A review.
Serum albumin and vascular endothelial growth factor in epithelial ovarian cancer: looking at adnexal tumor drainage.
Serum and gene expression profile of cytokines in first-episode psychosis.
Serum and renal tissue markers of nephropathy in rats under immunosuppressive therapy: cyclosporine versus sirolimus.
Serum angiopoietin-2 as a clinical marker for lung cancer.
Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer.
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.
Serum biomarkers for Modic changes in patients with chronic low back pain.
Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck.
Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer.
Serum cripto-1 as a clinical marker for lung cancer.
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab.
Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy.
Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy.
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.
Serum cytokines and growth factor levels in Japanese patients with psoriasis.
Serum cytokines as biomarkers for nonsurgical prediction of endometriosis.
Serum cytokines in follicular lymphoma. Correlation of TGF-beta and VEGF with survival.
Serum endocan levels are increased in patients with inflammatory bowel disease.
Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors.
Serum IL-17F combined with VEGF as potential diagnostic biomarkers for oral squamous cell carcinoma.
Serum inflammatory factors in patients with idiopathic choroidal neovascularization.
Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Serum levels of angiogenic cytokines decrease after antineoplastic radiotherapy.
Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas.
Serum levels of angiogenin (ANG) in invasive cervical cancer and in cervical intraepithelial neoplasia (CIN).
Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors.
Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis.
Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Serum levels of vascular endothelial growth factor and cancer antigen 125 are related to the prognosis of adenomyosis patients after interventional therapy.
Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system.
Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer.
Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer.
Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy.
Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors.
Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy.
Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis.
Serum Placental Growth Factor (PIGF), Vascular Endothelial Growth Factor (VEGF), Soluble VEGF Receptor -1 and -2 Levels In Periodontal Disease and Adverse Pregnancy Outcomes.
Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer.
Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy.
Serum tumor markers, hypoxia-inducible factor-1? HIF-1? and vascular endothelial growth factor, in patients with non- small cell lung cancer before and after intervention.
Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.
Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer.
Serum vascular endothelial growth factor (VEGF), a prognostic indicator in sarcoma and carcinoma patients.
Serum vascular endothelial growth factor A (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro.
Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome.
Serum vascular endothelial growth factor and adiponectin levels in patients with benign and malignant gynecological diseases.
Serum vascular endothelial growth factor and angiogenesis are related to the prognosis of patients with gastrointestinal stromal tumors.
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Serum vascular endothelial growth factor as a significant marker of treatment response in pediatric malignancies.
Serum vascular endothelial growth factor as a tumor marker for hepatocellular carcinoma in hepatitis C virus-related cirrhotic patients.
Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma.
Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma.
Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma.
Serum vascular endothelial growth factor concentrations in hepatocellular cancer patients undergoing percutaneously radiofrequency thermal ablation.
Serum vascular endothelial growth factor in breast cancer.
Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.
Serum vascular endothelial growth factor in dogs with haemangiosarcoma and haematoma.
Serum vascular endothelial growth factor in patients with head and neck squamous cell carcinoma.
Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer.
Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma.
Serum vascular endothelial growth factor is often elevated in disseminated cancer.
Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer.
Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase.
Serum vascular endothelial growth factor levels in patients with medullary thyroid carcinoma.
Serum vascular endothelial growth factor load and interleukin-6 in cancer patients - reply.
Serum vascular endothelial growth factor load and interleukin-6 in cancer patients.
Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival.
Serum vascular endothelial growth factor receptor-3 levels in patients with esophageal squamous cell cancer.
Serum vascular endothelial growth factor-C and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer.
Serum vascular endothelial growth factor-C levels: A possible diagnostic marker for lymph node metastasis in patients with primary non-small cell lung cancer.
Serum Vascular Endothelial Growth Factors A, C and D in Human Breast Tumors.
Serum vascular endothelial growth factors C and D in patients with oesophageal cancer.
Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer.
Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis.
Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival.
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis.
Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB.
Severe depletion of peripheral blood dendritic cell subsets in obstructive sleep apnea patients: A new link with cancer?
Severe exacerbation of Crohn's disease during sunitinib treatment.
Severe OSA associated with higher risk of mortality in stage III and IV lung cancer.
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade.
Sex dimorphism in antitumor response of chemotherapeutic drug cisplatin in a murine host-bearing a T-cell lymphoma.
Sex dimorphisms in activated mesenchymal stem cell function.
Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability.
Sexual dimorphism in gene expression after aneurysmal subarachnoid hemorrhage.
Shaping of monocyte and macrophage function by adenosine receptors.
Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet a-granule content and primary activation.
Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: relationship to platelet alpha-granule content and primary activation.
Shift in VEGFA isoform balance towards more angiogenic variants is associated with tumor stage and differentiation of human hepatocellular carcinoma.
Shock Wave Application Increases the Antineoplastic Effect of Molecular Iodine Supplement in Breast Cancer Xenografts.
Short Hairpin RNA (shRNA) Ether à go-go 1 (Eag1) Inhibition of Human Osteosarcoma Angiogenesis via VEGF/PI3K/AKT Signaling.
Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer.
Short-term one-lung ventilation does not influence local inflammatory cytokine response after lung resection.
Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.
Showing NAFLD, as a key connector disease between Alzheimer's disease and diabetes via analysis of systems biology.
ShRNA knock-down of CXCR7 inhibits tumour invasion and metastasis in hepatocellular carcinoma after transcatheter arterial chemoembolization.
Shuxuetong injection protects cerebral microvascular endothelial cells against oxygen-glucose deprivation reperfusion.
Sialyl Lewis X Expression and Lymphatic Microvessel Density in Primary Tumors of Node-negative Colorectal Cancer Patients Predict Disease Recurrence.
Siamese crocodile bile induces apoptosis in NCI-H1299 human non-small cell lung cancer cells via a mitochondria-mediated intrinsic pathway and inhibits tumorigenesis.
Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways.
Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma.
Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.
Signaling Pathways and Emerging Therapies in Multiple Myeloma.
Signaling pathways in HPV-associated cancers and therapeutic implications.
Signalling role of adipose tissue: adipokines and inflammation in obesity.
Significance and expression of vascular endothelial growth factor and E-cadherin in non-small cell lung Carcinomas.
Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma.
Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma.
Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers.
Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer.
Significance of Glioma Stem-Like Cells in the Tumor Periphery That Express High Levels of CD44 in Tumor Invasion, Early Progression, and Poor Prognosis in Glioblastoma.
Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy.
Significance of heparin-binding growth factor expression on cells of solid pediatric tumors.
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.
Significance of MMP-9 and VEGF-C expression in North Indian women with breast cancer diagnosis.
Significance of phospho-vascular endothelial growth factor receptor-2 expression in pancreatic cancer.
Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer.
Significance of serum connective tissue growth factor in patients with hepatocellular carcinoma and relationship with angiogenesis.
Significance of survivin expression: Prognostic value and survival in stage III non-small cell lung cancer.
Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma.
Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma.
Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer.
Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma.
Significance of vascular endothelial growth factor, interleukin-18 and nitric oxide in patients with breast cancer: correlation with carbohydrate antigen 15.3.
Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.
Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report.
Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors.
Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis.
Silencing of CCR7 inhibits the growth, invasion and migration of prostate cancer cells induced by VEGFC.
Silencing of hypoxia-inducible factor-1? induces anti-tumor effects in hepatoma cell lines under tumor hypoxia.
Silencing of long noncoding RNA H19 alleviates pulmonary injury, inflammation, and fibrosis of acute respiratory distress syndrome through regulating the microRNA-423-5p/FOXA1 axis.
Silencing of long noncoding RNA LEF1-AS1 prevents the progression of hepatocellular carcinoma via the crosstalk with microRNA-136-5p/WNK1.
Silencing of PTGS2 exerts promoting effects on angiogenesis endothelial progenitor cells in mice with ischemic stroke via repression of the NF-?B signaling pathway.
Silencing vascular endothelial growth factor C increases the radiosensitivity in nasopharyngeal carcinoma CNE-2 cells.
Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice.
Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells.
Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling.
Simulating sleep apnea by exposure to intermittent hypoxia induces inflammation in the lung and liver.
Simulating vasogenic brain edema using chronic VEGF infusion.
Simulation of tumor-induced angiogenesis and its response to anti-angiogenic drug treatment: mode of drug delivery and clearance rate dependencies.
Simultaneous Analyses of Vitreous Levels of 27 Cytokines in Eyes with Retinopathy of Prematurity.
Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis.
Simultaneous Detection of VEGF and CEA by Time-Resolved Chemiluminescence Enzyme-Linked Aptamer Assay.
Simultaneous detections of 27 cytokines during cerebral wound healing by multiplexed bead-based immunoassay for wound age estimation.
Simultaneous EGFR and VEGF Alterations in Non-Small Cell Lung Carcinoma Based on Tissue Microarrays.
Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.
Simultaneous Follicular Lymphoma and Myelofibrosis: Report of a Case with Review of the Literature.
Simultaneous inhibition of Src and Aurora kinases by SU6656 induces therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo.
Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
Simultaneous quantitative detection of multiple tumor markers in microfluidic nanoliter-volume droplets.
Simultaneous Sensing of Multiple Cancer Biomarkers by a Single DNA Nanoprobe in a Nanopore.
Simultaneous silencing of VEGF and KSP by siRNA cocktail inhibits proliferation and induces apoptosis of hepatocellular carcinoma Hep3B cells.
Simultaneous targeting of VEGF message and VEGF receptor signaling as a therapeutic anticancer approach.
Simvastatin Alleviates Pathology in a Rat Model of Preeclampsia Involving ERK/MAPK Pathway.
Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature.
Single nucleotide polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma.
Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer.
Single nucleotide polymorphisms of the vascular endothelial growth factor gene associated with incidence of oral squamous cell carcinoma.
Single nucleotide polymorphisms, haplotype association and tumour expression of the vascular endothelial growth factor (VEGF) gene with lung carcinoma.
Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors.
Single-chain vascular endothelial growth factor variant with antagonist activity.
Sinonasal hemangiopericytoma-like tumor with true pericytic myoid differentiation: a clinicopathologic and immunohistochemical study of five cases.
Sinoporphyrin Sodium-Mediated Sonodynamic Therapy Inhibits RIP3 Expression and Induces Apoptosis in the H446 Small Cell Lung Cancer Cell Line.
siRNA and chemotherapeutic molecules entrapped into a redox-responsive platform for targeted synergistic combination therapy of glioma.
SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth.
siRNA-mediated knockdown of VEGF-A, VEGF-C and VEGFR-3 suppresses the growth and metastasis of mouse bladder carcinoma in vivo.
SIRT6 overexpression inhibits HIF1? expression and its impact on tumor angiogenesis in lung cancer.
Site-dependent angiogenic cytokine production in human tumor xenografts.
Site-dependent expression of vascular endothelial growth factor, angiogenesis and proliferation in human gastric carcinoma.
Six Novel Loci Associated with Circulating VEGF Levels Identified by a Meta-analysis of Genome-Wide Association Studies.
Size effect in molecular imaging of vascular endothelial growth factor.
Sjögren's syndrome pathological neovascularization is regulated by VEGF-A-stimulated TACE-dependent crosstalk between VEGFR2 and NF-?B.
SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy.
Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway.
Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis.
Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization.
Small Particle-Size Talc Is Associated with Poor Outcome and Increased Inflammation in Thoracoscopic Pleurodesis.
Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines.
Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia.
Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma.
SNP and Haplotype Analysis of Vascular Endothelial Growth Factor (VEGF) Gene in Lung Cancer Patients of Kashmir
SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor.
So05 the nature of nearby lymphatics dictates whether a vascular endothelial growth factor-d (VEGF-d) induces tumor lymphatics and metastasis.
Social isolation stress augments angiogenesis induced by colon 26-L5 carcinoma cells in mice.
Social Relationships, Inflammation, and Cancer Survival.
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer.
Solitary plasmacytoma of the skull: immunohistochemical study of angiogenic factors and syndecan-1--two case reports.
Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.
Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity.
Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia.
Soluble factors differ in platelets derived from separate niches: a pilot study comparing the secretome of peripheral blood and bone marrow platelets.
Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.
Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis.
Soluble Flt-1 Has Cytotoxic Effects on BeWo Choriocarcinoma Cells.
Soluble Fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice.
Soluble forms of the Notch ligands Delta1 and Jagged1 promote in vivo tumorigenicity in NIH3T3 fibroblasts with distinct phenotypes.
Soluble production and function of vascular endothelial growth factor/basic fibroblast growth factor complex peptide.
Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis.
Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS).
Soluble Vascular Endothelial Growth Factor Decoy Receptor FP3 Exerts Potent Antiangiogenic Effects.
Soluble vascular endothelial growth factor in various blood transfusion components.
Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group.
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) is decreased in lung cancer patients showing progression: a pilot study.
Soluble vascular endothelial growth factor receptors 2 (sVEGFR-2) and 3 (sVEGFR-3) and breast cancer risk in the Swedish Mammography Cohort.
Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target.
Sonodynamic therapy inhibits angiogenesis and tumor growth in a xenograft mouse model.
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Sorafenib and Thyroid Cancer.
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma.
Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2.
Sorafenib Dose Escalation is Not Uniformly Associated with Blood Pressure Elevations in Normotensive Patients with Advanced Malignancies.
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.
Sorafenib improves the postoperative effect of early stage renal cell carcinoma.
Sorafenib in lung cancer: clinical developments and future directions.
Sorafenib in melanoma.
Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
Sorafenib.
Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Sorafenib: targeting multiple tyrosine kinases in cancer.
Sorbents in acute renal failure and end-stage renal disease: middle molecule and cytokine removal.
Sp transcription factor family and its role in cancer.
Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities.
Sp1 inhibition-mediated upregulation of VEGF(165)b induced by rh-endostatin enhances antiangiogenic and anticancer effect of rh-endostatin in A549.
Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism.
Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression.
SPAD aptasensor for the detection of circulating protein biomarkers.
SPARC expression is negatively correlated with clinicopathological factors of gastric cancer and inhibits malignancy of gastric cancer cells.
SPARC suppresses lymph node metastasis by regulating the expression of VEGFs in ovarian carcinoma.
Spatial and temporal expression of angiogenic molecules during tumor growth and progression.
Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside.
Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine.
Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.
Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology.
Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.
SPECT imaging of neuropilin receptor type-1 expression with 131I-labeled monoclonal antibody.
Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases.
Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF.
Spontaneous elicitation of potent antitumor immunity and eradication of established tumors by administration of DNA encoding soluble transforming growth factor-beta II receptor without active antigen-sensitization.
Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer.
Spotlight on bevacizumab in metastatic colorectal cancer.
Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression.
Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.
SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition.
Stabilization of HIF-2? Induces sVEGFR-1 Production from Tumor-Associated Macrophages and Decreases Tumor Growth in a Murine Melanoma Model.
Stabilization of VEGF G-quadruplex and inhibition of angiogenesis by quindoline derivatives.
Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma.
Stable silencing of dll4 gene suppresses the growth and metastasis of esophagus cancer cells by attenuating Akt phosphorylation.
Stage-dependent expression of an angiogenic agent and vascular organization in experimental skin tumor development.
Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Standardised pomegranate peel extract lavage prevents postoperative peritoneal adhesion by regulating TGF-? and VEGF levels.
STAT proteins as novel targets for cancer drug discovery.
STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells.
Statins and cancers.
Statins for the treatment of antiphospholipid syndrome?
Stem cell factor induces HIF-1alpha at normoxia in hematopoietic cells.
Stem Cell-like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor.
Steroids and cytokines in endometrial angiogenesis.
Stevens-johnson syndrome induced by vandetanib.
STI571 (Glivec) suppresses the expression of vascular endothelial growth factor in the gastrointestinal stromal tumor cell line, GIST-T1.
Stimulation of tissue factor expression in human microvascular and macrovascular endothelial cells by cultured vascular smooth muscle cells in vitro.
Stimulation of vascular endothelial growth factor gene transcription by all trans retinoic acid through Sp1 and Sp3 sites in human bronchioloalveolar carcinoma cells.
Stimulatory effect of endogenous tissue inhibitor of metalloproteinases-1 (TIMP-1) overexpression on type IV collagen and laminin gene expression in rat mammary carcinoma cells.
STRATEGIES OF TREATING CANCER BY CYTOKINE REGULATION OF CHROMOSOME END REMODELLING.
Strategies targeting angiogenesis in advanced non-small cell lung cancer.
Strategy for Treatment of Infected Diabetic Foot Ulcers.
Strobilanthes crispus inhibits migration, invasion and metastasis in breast cancer.
Stroke in tuberculous meningitis.
Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor.
Stromal cells and integrins: conforming to the needs of the tumor microenvironment.
Stromal expression of vascular endothelial growth factor C is relevant to predict sentinel lymph node status in melanomas.
Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases.
Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer.
Stromal impact on tumor growth and lymphangiogenesis in human carcinoma xenografts.
Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-? signalling.
Stromal-derived factor-1 and inflammatory cytokines in retinal vein occlusion.
Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis.
Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma.
Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma.
Structure activity relationships of chrysoeriol and analogs as dual c?Met and VEGFR2 tyrosine kinase inhibitors.
Structure-based identification of potent VEGFR-2 inhibitors from in vivo metabolites of a herbal ingredient.
Structure-fluctuation-function relationships of seven pro-angiogenic isoforms of VEGFA, important mediators of tumorigenesis.
Strychnine inhibits inflammatory angiogenesis in mice via down regulation of VEGF, TNF-? and TGF-?
Studies of pathology and VEGF expression in rabbit cerebrospinal fluid metastasis: application of dynamic contrast-enhanced MRI.
Study of aqueous cytokines in patients with different patterns of diabetic macular edema based on optical coherence tomography.
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Study of DNA synthesis and mitotic activity of hepatocytes and its relation to angiogenesis in hepatectomised tumour bearing mice.
Study of endothelin-1 and vascular endothelial growth factor in patients with cancer colon.
Study of gastric fluid induced cytokine and chemokine expression in airway smooth muscle cells and airway remodeling.
Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues.
Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
Study on Attenuating Angiogenesis and Epithelial-Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC2.
Study on breast cancer animal model of tumor-micro vessel variation before and after the chemotherapy by contrast enhanced ultrasound quantitative analysis.
Study on the alleviation of Fengshi Gutong capsule on rheumatoid arthritis through integrating network pharmacology and experimental exploration.
Study on the effect of perfusion weighted imaging on guiding the operation implementation for non-enhanced glioma.
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Subcutaneous Injections of the Mannose-Sensitive Hemagglutination Pilus Strain of Pseudomonas aeruginosa Stimulate Host Immunity, Reduce Bladder Cancer Size and Improve Tumor Survival in Mice.
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Subserous invasion of VEGF-C-producing cancer cells is a possible risk factor for ileal ulceration in the non-metastatic mucosal layer during bevacizumab-combined chemotherapy for recurrent ovarian cancer: A case report.
Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells.
Substance P promotes diabetic wound healing by modulating inflammation and restoring cellular activity of mesenchymal stem cells.
Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation.
Sulforaphane Attenuates Endometriosis in Rat Models Through Inhibiting PI3K/Akt Signaling Pathway.
Sulindac sulfide inhibits colon cancer cell growth and downregulates specificity protein transcription factors.
Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice.
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence.
Sunitinib in pancreatic neuroendocrine tumors.
Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts.
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.
Sunitinib.
Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose.
Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis.
Suppression of angiogenesis and tumor growth by recombinant T4 phages displaying extracellular domain of vascular endothelial growth factor receptor 2.
Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis.
Suppression of choriocarcinoma invasion and metastasis following blockade of BDNF/TrkB signaling.
Suppression of ERK/NF-?B Activation Is Associated With Amentoflavone-Inhibited Osteosarcoma Progression In Vivo.
Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production.
Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633.
Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis.
Suppression of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2.
Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector.
Suppression of PLC{beta}2 by Endotoxin Plays a Role in the Adenosine A2A Receptor-Mediated Switch of Macrophages from an Inflammatory to an Angiogenic Phenotype.
Suppression of signal transducers and activators of transcription 1 in hepatocellular carcinoma is associated with tumor progression.
Suppression of STAT3 Phosphorylation and RelA/p65 Acetylation Mediated by MicroRNA134 Plays a Pivotal Role in the Apoptotic Effect of Lambertianic Acid.
Suppression of the Production of Transforming Growth Factor ?1, Interleukin-10, and Vascular Endothelial Growth Factor in the B16F10 Cells by Ganoderma lucidum Polysaccharides.
Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene.
Suppression of vascular endothelial growth factor abrogates the immunosuppressive capability of murine gastric cancer cells and elicits antitumor immunity.
Suppression of Vascular Endothelial Growth Factor via Inactivation of Eukaryotic Elongation Factor 2 by Alkaloids in Coptidis rhizoma in Hepatocellular Carcinoma.
Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer.
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Surface air plasma-induced cell death and cytokine release of human keratinocytes in the context of psoriasis.
Surgery and cancer promotion: are we trading beauty for cancer?
Surgical excision promotes tumor growth and metastasis by promoting expression of MMP-9 and VEGF in a breast cancer model.
Surgical procedure as an inducer of tumor angiogenesis.
Surrogate markers of angiogenesis and metastasis.
Survivin and vascular endothelial growth factor are associated with spontaneous pulmonary metastasis of osteosarcoma: Development of an orthotopic mouse model.
Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced ?-catenin/Tcf-Lef dependent transcription.
Survivin knockdown and concurrent 4-HPR treatment controlled human glioblastoma in vitro and in vivo.
Sustain, Adapt, and Overcome-Hypoxia Associated Changes in the Progression of Lymphatic Neoplasia.
Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth.
Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: Is this an anti-angiogenic potentiation of cancer?
Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation.
Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis.
Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo.
Syndecan-1 overexpression promotes tumor growth and angiogenesis in an endometrial cancer xenograft model.
Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer.
Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma.
Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.
Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection.
Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
Synergistic effect of regulatory T cells and proinflammatory cytokines in angiogenesis in the endometriotic milieu.
Synergistic effect of thymoquinone and melatonin against breast cancer implanted in mice.
Synergistic effects of multiple myeloma cells and tumor-associated macrophages on vascular endothelial cells in vitro.
Synergistic induction of endothelial tissue factor by tumor necrosis factor and vascular endothelial growth factor: functional analysis of the tumor necrosis factor receptors.
Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.
Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma.
Synergistic Suppression of Tumor Angiogenesis by the Co-delivering of Vascular Endothelial Growth Factor Targeted siRNA and Candesartan Mediated by Functionalized Carbon Nanovectors.
Synergistic tumor suppression by adenovirus-mediated ING4/PTEN double gene therapy for gastric cancer.
Synergistic tumor suppression by adenovirus-mediated inhibitor of growth 4 and interleukin-24 gene cotransfer in hepatocarcinoma cells.
Synergy between tumor immunotherapy and antiangiogenic therapy.
Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression. analysis of a proof-of-concept randomized clinical trial of cytokine blockade.
Synthesis and biological activity of 5-chloro-N(4)-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents.
Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ER? and VEGFR-2.
Synthesis and Biological Evaluation of Glycyrrhetic Acid Derivatives as Potential VEGFR2 Inhibitors.
Synthesis and Biological Evaluation of Oleanolic Acid Derivatives as Selective Vascular Endothelial Growth Factor Promoter i-Motif Ligands.
Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
Synthesis and evaluation of 99mTc chelate-conjugated Bevacizumab.
Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Synthesis of factor D by gastric cancer-derived cell lines.
Synthesis, Characterization, and In Vivo Anti-Cancer Activity of New Metal Complexes Derived from Isatin-N(4)antipyrinethiosemicarbazone Ligand Against Ehrlich Ascites Carcinoma Cells.
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.
Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice.
Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
Systematic investigation of ethanolic extract from Leea macrophylla Implications in wound healing.
Systematic Quality Control Analysis of LINCS Data.
Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.
Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma.
Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.
Systemic and Tumor Th1 and Th2 Inflammatory Profile and Macrophages in Lung Cancer: Influence of Underlying Chronic Respiratory Disease.
Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy.
Systemic capillary leak syndrome triggered by anti-programmed death 1 checkpoint inhibitor in psoriasis.
Systemic delivery of a breast cancer-detecting adenovirus using targeted microbubbles.
Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth.
Systemic factors related to soluble (pro)renin receptor in plasma of patients with proliferative diabetic retinopathy.
Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors.
Systemic hypoxia potentiates anti-tumor effects of metformin in hepatocellular carcinoma in mice.
Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029.
Systemic inflammatory response to non-surgical treatment in hypertensive patients with periodontal infection.
Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin.
Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth.
Systemic therapy for advanced carcinoid tumors: where do we go from here?
Systemic therapy for patients with advanced, unresectable ormetastatic renal cell carcinoma: moving to guidelines.
Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor.
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis - implications for cardiovascular safety.
T cell-derived matrix metalloproteinase-9 in breast cancer: friend or foe?
T11TS impedes glioma angiogenesis by inhibiting VEGF signaling and pro-survival PI3K/Akt/eNOS pathway with concomitant upregulation of PTEN in brain endothelial cells.
Tacrolimus downregulates inflammation by regulating pro?/anti?inflammatory responses in LPS?induced keratitis.
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.
Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo.
Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo.
Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.
Tangeretin, a citrus pentamethoxyflavone, exerts cytostatic effect via p53/p21 up-regulation and suppresses metastasis in 7,12-dimethylbenz(?)anthracene-induced rat mammary carcinoma.
Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2).
Tanshinone IIA inhibits HIF-1? and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.
TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression.
Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate.
Targeted agents and esophageal cancer--the next step?
Targeted agents for the treatment of advanced renal cell carcinoma.
Targeted approaches for treating advanced clear cell renal carcinoma.
Targeted delivery of biodegradable nanoparticles with ultrasound-targeted microbubble destruction-mediated hVEGF-siRNA transfection in human PC-3 cells in vitro.
Targeted Genetic Disruption of Peroxisome Proliferator-Activated Receptor-{delta} and Colonic Tumorigenesis.
Targeted inhibition of tumor survival, metastasis and angiogenesis by Acacia ferruginea mediated regulation of VEGF, inflammatory mediators, cytokine profile and inhibition of transcription factor activation.
Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice.
Targeted molecular therapy of malignant gliomas.
Targeted Molecular Therapy of Malignant Gliomas.
Targeted radiotherapy of pigmented melanoma with 131I-5-IPN.
Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Targeted Theranostics Against Solid Cancer Using Metal Bond Milk Protein and Aptamers.
Targeted therapies in metastatic esophageal cancer: Advances over the past decade.
Targeted therapies in non-small cell lung cancer.
Targeted therapies in solid tumours: results and promises.
Targeted therapies in the management of colorectal carcinoma: role of bevacizumab.
Targeted therapies with chemoradiation in esophageal cancer: development and future directions.
Targeted therapy for colorectal cancer.
Targeted therapy for metastatic renal cell carcinoma.
Targeted therapy in advanced non-small-cell lung cancer.
Targeted therapy in renal cell carcinoma.
Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
Targeted therapy using novel agents in the treatment of non-small-cell lung cancer.
Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer.
Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy.
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
Targeting Angiogenesis for Treatment of NSCLC Brain Metastases.
Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor.
Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Targeting angiogenesis in cancer: clinical development of bevacizumab.
Targeting angiogenesis in head and neck cancer.
Targeting Angiogenesis in Prostate Cancer.
Targeting angiogenesis with antibodies for the treatment of cancer.
Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment.
Targeting cell signaling pathways for drug discovery: an old lock needs a new key.
Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.
Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents.
Targeting expression of the catalytic domain of the kinase insert domain receptor (KDR) in the peroxisomes of Pichia pastoris.
Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma.
Targeting Fluorescent Nanodiamonds to Vascular Endothelial Growth Factor Receptors in Tumor.
Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
Targeting growth factors and angiogenesis; using small molecules in malignancy.
Targeting growth factors to the kidney: myth or reality?
Targeting HIF-1? and VEGF by lentivirus-mediated RNA interference reduces liver tumor cells migration and invasion under hypoxic conditions.
Targeting Hypoxia-Inducible Factor 1? in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.
Targeting leukostasis for the treatment of early diabetic retinopathy.
Targeting lymphangiogenesis to prevent tumour metastasis.
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.
Targeting Multiple Signaling Pathways in Cancer: The Rutin Therapeutic Approach.
Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
Targeting myeloid cells in the tumor sustaining microenvironment.
Targeting neovascularization and respiration of tumor grafts grown on chick embryo chorioallantoic membranes.
Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
Targeting neuropilin 1 as an antitumor strategy in lung cancer.
Targeting neuropilin-1 interactions is a promising anti-tumor strategy.
Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development.
Targeting Notch1 inhibits invasion and angiogenesis of human breast cancer cells via inhibition Nuclear Factor-?B signaling.
Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis.
Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro.
Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides.
Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab.
Targeting PPAR? Signaling Cascade for the Prevention and Treatment of Prostate Cancer.
Targeting regulation of the tumour microenvironment induces apoptosis of breast cancer cells by an affinity hemoperfusion adsorbent.
Targeting Rheumatoid Tenosynovial Angiogenesis with Cytokine Inhibitors.
Targeting Slit-Roundabout signaling inhibits tumor angiogenesis in chemical-induced squamous cell carcinogenesis.
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways.
Targeting stromal-cancer cell interactions with siRNAs.
Targeting the IKK?/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer.
Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor.
Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate.
Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.
Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Targeting tumor angiogenesis.
Targeting tumor neovasculature in non-small-cell lung cancer.
Targeting tumor-infiltrating Ly6G
Targeting tumor-related immunosuppression for cancer immunotherapy.
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies.
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.
Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy.
Targeting VEGF receptors with non-neutralizing cyclopeptides for imaging applications.
Targeting VEGF-neuropilin interactions: a promising antitumor strategy.
Targeting VEGF/VEGFR to Modulate Antitumor Immunity.
Taurine improves functional and histological outcomes and reduces inflammation in traumatic brain injury.
Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation.
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
Tear and aqueous humour cytokine profile in primary open-angle glaucoma.
Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease.
Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost.
Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids.
Tectorigenin inhibits inflammation and pulmonary fibrosis in allergic asthma model of ovalbumin-sensitized guinea pigs.
Tenascin in meningioma: expression is correlated with anaplasia, vascular endothelial growth factor expression, and peritumoral edema but not with tumor border shape.
Tenascin in Meningioma: Expression Is Correlated with Anaplasia, Vascular Endothelial Growth Factor Expression, and Peritumoral Edema But Not with Tumor Border Shape.
Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression.
Tetra-sulfonate phthalocyanine zinc-bovine serum albumin conjugate-mediated photodynamic therapy of human glioma.
Tetrahedral framework nucleic acids promote scarless healing of cutaneous wounds via the AKT-signaling pathway.
Texture Analysis of Non-Contrast-Enhanced Computed Tomography for Assessing Angiogenesis and Survival of Soft Tissue Sarcoma.
TGF-? secreted by tumor-associated macrophages promotes proliferation and invasion of colorectal cancer via miR-34a-VEGF axis.
TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma.
Thalidomide affects experimental endometriosis: a randomized controlled study in the rat.
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Thalidomide for the treatment of idiopathic myelofibrosis.
Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod-induced Psoriatic Mouse Model.
Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic Rats.
Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Thalidomide treatment reduces colon injury induced by experimental colitis.
The "game" of glial fibrillary acidic and S100 proteins in pituitary adenomas: two players or several?
The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade.
The Acellular Fraction of Stored Platelets Promotes Tumor Cell Invasion.
The activation of TLR7 regulates the expression of VEGF, TIMP1, MMP2, IL-6, and IL-15 in Hela cells.
The Activity Screening of Hmong Herbs Caesalpiniaminax and an Antitumor Effect Study.
The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster.
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis.
The alpha-helical domain near the amino terminus is essential for dimerization of vascular endothelial growth factor.
The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies.
The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications.
The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.
The Angiogenic Capacity from Ligamentum Flavum subsequent to Inflammation : a Critical component of the Pathomechanism of Hypertrophy.
The angiogenic responses induced by release of angiogenic proteins from tumor cell-activated platelets are regulated by distinct molecular pathways.
The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme.
The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer.
The angiopoietin/Tie2 axis mediates malignant pleural effusion formation.
The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.
The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling.
The Anti-Breast Cancer Effects of Green-Synthesized Zinc Oxide Nanoparticles Using Carob Extract.
The Anti-Cancer Effects of a Zotarolimus and 5-Fluorouracil Combination Treatment on A549 Cell-Derived Tumors in BALB/c Nude Mice.
The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo.
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
The antiangiogenic activity of a soluble fragment of the VEGFR extracellular domain.
The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice.
The antibacterial activity of LI-F type peptide against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and inhibition of infections in murine scalded epidermis.
The antifibrotic effects of alveolar macrophages 5-HT2C receptors blockade on bleomycin-induced pulmonary fibrosis in rats.
The antioxidant role of agomelatine and gallic acid on oxidative stress in STZ induced type I diabetic rat testes.
The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
The antitumor and antimetastatic effects of N-trimethyl chitosan-encapsulated camptothecin on ovarian cancer with minimal side effects.
The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells.
The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates.
The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line.
The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.
The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis.
The associations between serum vascular endothelial growth factor, tumor necrosis factor and interleukin 4 with the markers of blood-brain barrier breakdown in patients with paraneoplastic neurological syndromes.
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.
The biology of vascular endothelial growth factors.
The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1).
The C-terminus of viral vascular endothelial growth factor-E partially blocks binding to VEGF receptor-1.
The calendar of cytokines: Seasonal variation of circulating cytokines in chronic venous insufficiency.
The cancer's nervous tooth: Considering the neuronal crosstalk within tumors.
The Caspase-3/PKC?/Akt/VEGF-A Signaling Pathway Mediates Tumor Repopulation during Radiotherapy.
The CD154-CD40 T-cell co-stimulation pathway in liver ischemia and reperfusion inflammatory responses.
The challenges of modeling drug resistance to antiangiogenic therapy.
The Changes of HIF-1? and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma.
The changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma.
The chemokine receptor CXCR7 is a critical regulator for the tumorigenesis and development of papillary thyroid carcinoma by inducing angiogenesis in vitro and in vivo.
The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
The circular RNA 001971/miR-29c-3p axis modulates colorectal cancer growth, metastasis, and angiogenesis through VEGFA.
The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.
The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites.
The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
The clinical significance of serum adipocytokines level in patients with lung cancer.
The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
The combination of nuclear factor kappa B, cyclo-oxygenase-2 and vascular endothelial growth factor expression predicts poor prognosis in stage II and III colorectal cancer.
The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer.
The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice.
The Complex Relationship between Diabetic Retinopathy and High-Mobility Group Box: A Review of Molecular Pathways and Therapeutic Strategies.
The complex roles of Wnt antagonists in RCC.
The complexity of tumour angiogenesis based on recently described molecules.
The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway.
The connection between lymphangiogenic signalling and prostglandin biology: A missing link in the metastatsic pathway.
The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells.
The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors.
The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis.
The coordinated effects of Apatinib and Tripterine on the proliferation, invasiveness and apoptosis of human hepatoma Hep3B cells.
The correlation between serum vascular endothelial growth factor (VEGF) and tumor VEGF receptor 3 in colorectal cancer.
The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization.
The critical role of vascular endothelial growth factor in tumor angiogenesis.
The crucial role of miR-126 on suppressing progression of esophageal cancer by targeting VEGF-A.
The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.
The cytokine IL-17A as a marker of treatment resistance in major depressive disorder?
The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1?-dependent and -independent manners.
The development and use of vascular targeted therapy in ovarian cancer.
The development of bevacizumab in noncolorectal gastrointestinal malignancies: gastroesophageal, pancreatic, and hepatocellular carcinoma.
The development of porcine models of obesity and the metabolic syndrome.
The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography.
The Different Effect of VEGF Polymorphisms on the Prognosis of Non-Small Cell Lung Cancer according to Tumor Histology.
The differential regulation of human telomerase reverse transcriptase and vascular endothelial growth factor may contribute to the clinically more aggressive behavior of p63-positive breast carcinomas.
The direct effects of anti-vascular endothelial growth factor therapy on tumor cells.
The Drosophila Perlecan gene trol regulates multiple signaling pathways in different developmental contexts.
The dynamic roles of angiopoietins in tumor angiogenesis.
The Effect and Mechanism of Vascular Endothelial Growth Factor (VEGF) on Tumor Angiogenesis in Gallbladder Carcinoma.
The effect of acute respiratory distress syndrome on bone marrow-derived mesenchymal stem cells.
The Effect of an Aloe Polymannose Multinutrient Complex on Cognitive and Immune Functioning in Alzheimer's Disease.
The Effect of Androgens on Proinflammatory Cytokine Secretion from Human Ocular Surface Epithelial Cells.
The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis.
The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
The effect of carvacrol on inflammatory mediators and respiratory symptoms in veterans exposed to sulfur mustard, a randomized, placebo-controlled trial.
The effect of CELLFOODTM on radiotherapy or combined chemoradiotherapy: preclinical evidence.
The effect of chronic stress on anti-angiogenesis of sunitinib in colorectal cancer models.
The effect of etanercept on vascular endothelial growth factor production by cutaneous mesenchymal stem cells from patients with psoriasis.
The effect of fibroblast activation on vascularization in transplanted pancreatic islets.
The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice.
The effect of insulin-loaded linear poly(ethylene glycol)-brush-like poly(l-lysine) block copolymer on renal ischemia/reperfusion-induced lung injury through downregulating hypoxia-inducible factor.
The Effect of Recombinant HopH Protein of Helicobacter pylori on the VEGF Expression in Metastatic Breast Cancer Model.
The effect of RNAi silencing of p62 using an osmotic polysorbitol transporter on autophagy and tumorigenesis in lungs of K-rasLA1 mice.
The effect of thalidomide on vascular endothelial growth factor and tumor necrosis factor-alpha levels in retinal ischemia/reperfusion injury.
The effect of topiramate on tumor-related angiogenesis and on the serum proteome of mice bearing Lewis lung carcinoma.
The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired study.
The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospectivematched-paired study.
The effect of von hippel-lindau gene transfer on human vascular smooth muscle cell proliferation and apoptosis.
The effect of Zataria multiflora on inflammatory cytokine and respiratory symptoms in veterans exposed to sulfur mustard.
The effects of anticancer medicinal herbs on vascular endothelial growth factor based on pharmacological aspects: a review study.
The Effects of Chromium Supplementation on Gene Expression of Insulin, Lipid, and Inflammatory Markers in Infertile Women With Polycystic Ovary Syndrome Candidate for in vitro Fertilization: A Randomized, Double-Blinded, Placebo-Controlled Trial.
The effects of exercise training on levels of vascular endothelial growth factor in tumor-bearing mice.
The Effects of Korea Red Ginseng on Inflammatory Cytokines and Apoptosis in Rat Model with Chronic Nonbacterial Prostatitis.
The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells.
The effects of P. gingivalis and E. coli LPS on the expression of proinflammatory mediators in human mast cells and their relevance to periodontal disease.
The Effects of Probiotic Supplementation on Genetic and Metabolic Profiles in Patients with Gestational Diabetes Mellitus: a Randomized, Double-Blind, Placebo-Controlled Trial.
The effects of propofol on the growth behavior of hepatoma xenografts in Balb/c mice.
The effects of RNA interference mediated VEGF gene silencing on biological behavior of renal cell carcinoma and transplanted renal tumor in nude mice.
The effects of sonic hedgehog signaling pathway components on non-small-cell lung cancer progression and clinical outcome.
The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer.
The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells.
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
The effects of VEGF and VEGFR-2 on survival in patients with gastric cancer.
The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study.
The efficacy and safety of cold atmospheric plasma as a novel therapy for diabetic wound in vitro and in vivo.
The efficacy of Paclitaxel on solid tumour analysed by ATP bioluminescence assay and VEGF expression: a translational research study.
The emerging role of lenalidomide in the management of lymphoid malignancies.
The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs.
The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: Up-regulation of EG-VEGF/prokineticin 1 with malignancy.
The epidemiology and biology of pulmonary metastases.
The epidermal growth factor receptor as a target for cancer therapy.
The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers().
The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
The expression of antisense vascular endothelial growth factor (VEGF) sequences inhibits intracranial C6 glioma growth in vivo by suppressing tumour angiogenesis.
The expression of CXCR4 and its relationship with matrix metalloproteinase-9/vascular endothelial growth factor in esophageal squamous cell cancer.
The expression of Cyclin D1, VEGF, EZH2, and H3K27me3 in Atypical Teratoid/Rhabdoid Tumors of the CNS: A Possible Role in Targeted Therapy.
The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma.
The expression of glycophorin A and osteoprotegerin is locally increased in carotid atherosclerotic lesions of symptomatic compared to asymptomatic patients.
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival.
The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma.
The expression of thymidine phosphorylase and its correlation with angiogenesis in gastric adenocarcinoma.
The expression of vascular endothelial growth factor (VEGF) and VEGF-C in early laryngeal cancer: relationship with radioresistance.
The expression of vascular endothelial growth factor and proliferative activity of cancer cells in gastric cancer.
The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults.
The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.
The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
The expression pattern of vascular endothelial growth factor C and D in human esophageal normal mucosa, dysplasia and neoplasia.
The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis.
The Farnesyltransferase Inhibitor LB42708 Suppresses VEGF-induced Angiogenesis by Inhibiting Ras-dependent MAPK and PI3K/Akt Signal Pathways.
The Features of Inflammation Factors Concentrations in Aqueous Humor of Polypoidal Choroidal Vasculopathy.
The fibrinolysis inhibitor ?2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer.
The flt-1 promoter for transcriptional targeting of teratocarcinoma.
The Foxc2 transcription factor regulates tumor angiogenesis.
The function of vascular endothelial growth factor.
The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1?/pAKT in prostate cancer.
The functional proteomics analysis of VEGF-treated human epithelial ovarian cancer cells.
The future development of bevacizumab in colorectal cancer.
The genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor.
The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy.
The growth and aggressive behavior of human osteosarcoma is regulated by a CaMKII-controlled autocrine VEGF signaling mechanism.
The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor.
The heparins and cancer: review of clinical trials and biological properties.
The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.
The HIF1?-PDGFD-PDGFR? axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin.
The horizon of antiangiogenic therapy for colorectal cancer.
The HOTAIR lncRNA: A remarkable oncogenic promoter in human cancer metastasis.
The human tri-peptide GHK and tissue remodeling.
The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma.
The immune influence of a parabiosis model on tumour-bearing mice.
The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.
The impact of different gas mixtures on inflammatory responses in advanced recreational divers.
The impact of exercise on growth factors (VEGF and FGF2): results from a 12-month randomized intervention trial.
The impact of FGFR1 and FRS2? expression on sorafenib treatment in metastatic renal cell carcinoma.
The impact of gene polymorphisms in angiotensin receptor 1 and aldosterone synthase in peritoneal dialysis patients.
The Impact of Physical Activity on Serum Inflammatory Markers in Overweight Pubertal Boys: 24-Month Follow-Up Study.
The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery.
The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies.
The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.
The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study.
The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis.
The increased number of tumor-associated macrophage is associated with overexpression of VEGF-C, plays an important role in Kazakh ESCC invasion and metastasis.
The indirect antiangiogenic effect of IL-37 in the tumor microenvironment.
The Inflammatory Cytokine Profile of Patients with Malignant Pleural Effusion Treated with Pleurodesis.
The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer.
The influence of fractionated radiation therapy on plasma vascular endothelial growth factor (VEGF) concentration in dogs with spontaneous tumors and its impact on outcome.
The Influence of Lipid and Proinflammatory Status on Maternal Uterine Blood Flow in Women With Late Onset Gestational Diabetes.
The Influence of Naproxen on Biological Factors in Leukocyte-Rich Platelet-Rich Plasma: A Prospective Comparative Study.
The influence of systemic renin-angiotensin-inhibition on ocular cytokines related to proliferative vitreoretinopathy.
The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).
The inhibitory effects of rh-endostatin (YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the underlying mechanisms.
The Inhibitory Properties of Ethanol Extracts of Some Culinary-Medicinal Mushrooms on the Secretion of Interleukin-8 and Vascular Endothelial Growth Factor by PC3 Cancer Cells.
The interaction between KDR and interleukin-3 receptor (IL-3R) beta common modulates tumor neovascularization.
The Intraocular Cytokine Profile and Therapeutic Response in Persistent Neovascular Age-Related Macular Degeneration.
The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients.
The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression.
The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.
The levels of 12 cytokines and growth factors in tears: hyperthyreosis vs euthyreosis.
The levels of steroid hormones and cytokines in individual follicles are not associated with the fertilization outcome after intracytoplasmic sperm injection.
The life, death, and attempted rebirth of bevacizumab in breast cancer.
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer.
The lymphatic system and its specific growth factor vascular endothelial growth factor C in kidney tissue and in renal cell carcinoma.
The malignant progression effects of regorafenib in human colon cancer cells.
The MAPK-AP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF.
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts.
The molecular balance between receptor tyrosine kinases Tie1 and Tie2 is dynamically controlled by VEGF and TNF? and regulates angiopoietin signalling.
The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways.
The morphological analysis of vasculature and angiogenic potential in meningiomas: immunoexpression of CD31 and VEGF antibodies.
The Morphopathogenetic Aspects of Intraabdominal Adhesions in Children under One Year of Age.
The mRNA expression of cytokines and their receptors in cultured iris pigment epithelial cells: a comparison with retinal pigment epithelial cells.
The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis.
The multifactorial role of leptin in driving the breast cancer microenvironment.
The natural alkaloid berberine targets multiple pathways to induce cell death in cultured human colon cancer cells.
The natural compound chebulagic acid inhibits vascular endothelial growth factor A mediated regulation of endothelial cell functions.
The natural progression of microvasculature in primary tumor and lymph node metastases in a breast carcinoma model: relationship between microvessel density, vascular endothelial growth factor expression, and metastatic invasion.
The neuroendocrine impact of chronic stress on cancer.
The Neuropilin-1 Ligand, Sema3A, Acts as a Tumor Suppressor in the Pathogenesis of Acute Leukemia.
The novel axis of YAP1, transcription enhancer factor 3 and Down Syndrome Candidate Region 1 isoform 1L is a common signaling pathway downstream of several angiogenic factors.
The novel non-immunological role and underlying mechanisms of B7-H3 in tumorigenesis.
The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib.
The Novel Src Kinase Inhibitor M475271 Inhibits VEGF-Induced Vascular Endothelial-Cadherin and beta-Catenin Phosphorylation but Increases Their Association.
The Nrf2 inhibitor brusatol has a protective role in a rat model of oxygen-induced retinopathy of prematurity.
The nuclear corepressor 1 and the thyroid hormone receptor ? suppress breast tumor lymphangiogenesis.
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
The pathophysiology of ovarian hyperstimulation syndrome--views and ideas.
The pharmacological pathways of GnRH mediating the inhibition of mammary tumours: implications in humans and domestic animals.
The phenolic profiles of Radix Tetrastigma after solid phase extraction (SPE) and their antitumor effects and antioxidant activities in H22 tumor-bearing mice.
The plasma levels of 12 cytokines and growth factors in patients with gastric cancer.
The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes.
The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma.
The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer.
The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma.
The Potential Roles of MELF-Pattern, Microvessel Density, and VEGF Expression in Survival of Patients with Endometrioid Endometrial Carcinoma: A Morphometrical and Immunohistochemical Analysis of 100 Cases.
The preserved expression of neuropilin (NRP) 1 contributes to a better prognosis in colon cancer.
The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.
The pro-inflammatory role of high-mobility group box 1 protein (HMGB-1) in photoreceptors and retinal explants exposed to elevated pressure.
The pro-oxidant buthionine sulfoximine (BSO) reduces tumor growth of implanted Lewis lung carcinoma in mice associated with increased protein carbonyl, tubulin abundance, and aminopeptidase activity.
The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer.
The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
The prognostic relevance of preoperative transcatheter arterial chemoembolization (TACE) and PCNA/VEGF expression in patients with Wilms' tumour.
The prognostic significance of growth factors and growth factor receptors in gastric adenocarcinoma.
The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients.
The Prognostic Value of Circulating VEGF-A Level in Patients With Hepatocellular Cancer.
The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer.
The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.
The prognostic value of vascular endothelial growth factor in hepatocellular carcinoma for predicting metastasis after curative resection.
The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis.
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma.
The Propeptides of VEGF-D Determine Heparin Binding, Receptor Heterodimerization, and Effects on Tumor Biology.
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
The protective effect of fenofibrate, triptorelin, and their combination against premature ovarian failure in rats.
The protective effects of naproxen against interleukin-1? (IL-1?)- induced damage in human umbilical vein endothelial cells (HUVECs).
The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex-interactive agents.
The radionuclide molecular imaging and therapy of neuroendocrine tumors.
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
The ratio of plasma angiopoietin-2 to angiopoietin-1 as a prognostic biomarker in patients with sepsis.
The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma.
The recombinant kringle domain of urokinase plasminogen activator inhibits in vivo malignant glioma growth.
The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.
The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.
The regulatory effect of SC-236 (4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1-pyrazol-1-l]benzenesulfonamide) on stem cell factor induced migration of mast cells.
The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells.
The related transcriptional enhancer factor-1 isoform, TEAD4(216), can repress vascular endothelial growth factor expression in mammalian cells.
The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer.
The Relationship Between Cytokine Production, CSF2RA, and IL1R2 Expression in Mammary Adenocarcinoma, Tumor Histopathological Parameters, and Lymph Node Metastasis.
The relationship between GLUT-1 and vascular endothelial growth factor expression and 18F-FDG uptake in esophageal squamous cell cancer patients.
The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer: A systematic review and meta-analysis.
The relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome.
The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas.
The relationship between serum vascular endothelial growth factor A and microsatellite instability in colorectal cancer.
The Relationship between Vascular Endothelial Growth Factor 1154G/A Polymorphism and Recurrent Implantation Failure.
The relationship of erythropoietin receptor expression and prognosis in glioblastoma multiforme patients.
The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.
The relationships between systemic cytokine profiles and inflammatory markers in colorectal cancer and the prognostic significance of these parameters.
The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer.
The relevance of cell type- and tumor zone-specific VEGFR-2 activation in locally advanced colon cancer.
The risk of circulating angiogenic T cells and subsets in patients with systemic sclerosis.
The RNA-binding protein RBPMS1 represses AP-1 signaling and regulates breast cancer cell proliferation and migration.
The role of a drug-loaded poly (lactic co-glycolic acid) (PLGA) copolymer stent in the treatment of ovarian cancer.
The role of adrenomedullin in angiogenesis.
The role of androgens on periodontal repair in female rats.
The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival.
The role of angiogenesis in human non-hodgkin lymphomas.
The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer.
The Role of Ankaferd Blood Stopper and Oxytocin as Potential Therapeutic Agents in Endometriosis: A Rat Model.
The role of antiangiogenesis therapy: bevacizumab and beyond.
The role of antiangiogenetic agents in the treatment of breast cancer.
The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
The Role of Cancer Stem Cells (CD133+) in Malignant Gliomas.
The role of CD55 in protecting the tumour environment from complement attack.
The Role of Connexin and Pannexin Channels in Perinatal Brain Injury and Inflammation.
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer.
The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer.
The role of cytokines in endometriosis.
The Role of Cytokines, Chemokines, and Growth Factors in the Pathogenesis of Pityriasis Rosea.
The role of EMMPRIN expression in ovarian epithelial carcinomas.
The role of fibroblast growth factors in tumor growth.
The role of fibroblast growth factors in vascular development.
The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis.
The Role of FoxC2 Transcription Factor in Tumor Angiogenesis.
The role of growth factors in the malignant and invasive progression of intrinsic brain tumours.
The role of growth factors in the pathogenesis of diabetic retinopathy.
The role of HER2 in angiogenesis.
The role of human leukocyte antigen and tumor necrosis factor D as a prognostic, preventive and therapeutic factor in gastric cancer.
The role of hypoxia-inducible factor 1 in tumor immune evasion.
The role of insulin-like growth factor I and hypoxia inducible factor 1? in vascular endothelial growth factor expression in type 2 diabetes.
The role of leptin and its short-form receptor in inflammation in db/db mice infused with peritoneal dialysis fluid.
The role of macrophages in angiogenesis. Comparison between HIV+ and HIV- populations with anal dysplasia and anal cancer.
The Role of Mast Cells in Alzheimer's Disease.
The role of melatonin in angio-miR-associated inhibition of tumorigenesis and invasion in human glioblastoma tumour spheroids.
The Role of miR-378a in Metabolism, Angiogenesis, and Muscle Biology.
The Role of MRgLITT in Overcoming the Challenges in Managing Infield Recurrence After Radiation for Brain Metastasis.
The role of nitric oxide in mediating tumour blood flow.
The Role of Nrf2 Activity in Cancer Development and Progression.
The role of peroxisome proliferator-activated receptor gamma in bladder cancer in relation to angiogenesis and progression.
The role of pro-inflammatory and immunoregulatory cytokines in tendon healing and rupture: new insights.
The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression.
The role of semaphorin 4D as a potential biomarker for antiangiogenic therapy in colorectal cancer.
The role of six biomarkers in diagnosis of hemophilic arthropathy: review of the literature.
The Role of Smoking and Gingival Crevicular Fluid Markers on Coronally Advanced Flap Outcomes.
The role of SPARC in the TRAMP model of prostate carcinogenesis and progression.
The role of targeted therapy in the treatment of colorectal cancer.
The role of the Angiopoietins in vascular morphogenesis.
The role of the EGFR signaling in tumor microenvironment.
The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer.
The role of the vascular endothelial growth factor/vascular endothelial growth factor receptors axis mediated angiogenesis in curcumin-loaded nanostructured lipid carriers induced human HepG2 cells apoptosis.
The Role of the VEGF Family in Coronary Heart Disease.
The role of the VEGF-C/VEGFR-3 axis in cancer progression.
The Role of the VEGF-C/VEGFRs Axis in Tumor Progression and Therapy.
The Role of Tumor-Associated Neutrophils in Colorectal Cancer.
The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors.
The role of vascular endothelial growth factor a polymorphisms in breast cancer.
The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops.
The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study.
The role of vascular endothelial growth factor genetic variability in cancer.
The role of vascular endothelial growth factor in a murine chronic granulomatous tissue air pouch model of angiogenesis.
The Role of Vascular Endothelial Growth Factor in Metastatic Prostate Cancer to the Skeleton.
The role of vascular endothelial growth factor in proliferation of odontogenic cysts and tumors: An immunohistochemical study.
The Role of Vascular Endothelial Growth Factor in Small-airway Remodelling in a Rat Model of Chronic Obstructive Pulmonary Disease.
The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.
The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells.
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.
The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy.
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
The role of VEGF and other parameters in tracking the clinical course in metronomic chemotherapy.
The Role of VEGF and TNF-Alpha on Epithelialization of Diabetic Foot Ulcers after Hyperbaric Oxygen Therapy.
The role of VEGF in melanoma progression.
The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non?small cell lung cancer (Review).
The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma.
The Role of Wnt Signalling in Angiogenesis.
The role of Zeb1 in the pathogenesis of morbidly adherent placenta.
The roles of CD147 in the progression of gliomas.
The Roles of Non-Coding RNAs in Tumor-Associated Lymphangiogenesis.
The Ron receptor promotes prostate tumor growth in the TRAMP mouse model.
The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer.
The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
The safety of bevacizumab.
The secretion of endothelin-1 by microvascular endothelial cells from human benign prostatic hyperplasia is inhibited by vascular endothelial growth factor.
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice.
The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects.
The selective P-TEFb inhibitor CAN508 targets angiogenesis.
The Semaphorin 4D-Plexin-B1-RhoA signaling axis recruits pericytes and regulates vascular permeability through endothelial production of PDGF-B and ANGPTL4.
The seminal work of Werner Risau in the study of the development of the vascular system.
The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis.
The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population.
The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man.
The stem cell marker prominin-1/CD133 interacts with vascular endothelial growth factor and potentiates its action.
The study of the extended haplotypes of rare HLA-B*2730 allele using microsatellite loci.
The supernatant of apoptotic cells causes transcriptional activation of hypoxia-inducible factor-1alpha in macrophages via sphingosine-1-phosphate and transforming growth factor-beta.
The suppression of hypoxia-inducible factor and vascular endothelial growth factor by siRNA does not affect the radiation sensitivity of multicellular tumor spheroids.
The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent.
The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer.
The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine.
The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer.
The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.
The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.
The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging.
The time course of tumor necrosis factor-alpha, inducible nitric oxide synthase and vascular endothelial growth factor expression in an experimental model of chronic myocardial infarction in rats.
The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis.
The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer.
The tumor suppressive effect of angiotensin II type 1 receptor antagonist in a murine osteosarcoma model.
The tyrosine kinase inhibitors effects on metastatic tumor graft in the chick chorioallantoic membrane assay.
The use of bevacizumab in non-small cell lung cancer: an update.
The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab.
The use of Doppler ultrasound in evaluation of breast cancer metastasis to axillary lymph nodes.
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
The usefulness of immunohistochemistry in sporadic colorectal cancer.
The Value of Expression of M2-PK and VEGF in Patients with Advanced Gastric Cancer.
The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients.
The vascular delta-like ligand-4 (DLL4)-Notch4 signaling correlates with angiogenesis in primary glioblastoma: an immunohistochemical study.
The vascular endothelial growth factor mRNA contains an internal ribosome entry site.
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
The Vascular Endothelial Growth Factor-2549 Insertion/Deletion Polymorphism Is Not Associated with Susceptibility to Hepatocellular Carcinoma in Chinese.
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.
The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration.
The VD1 Neutralizing Antibody to Vascular Endothelial Growth Factor-D: Binding Epitope and Relationship to Receptor Binding.
The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells.
The VEGF family in cancer and antibody-based strategies for their inhibition.
The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.
The VEGF pathway in cancer and disease: responses, resistance, and the path forward.
The VEGF pathway in lung cancer.
The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.
The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance.
The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: New potential therapeutic targets?
The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy.
The VEGFR-2 protein and the VEGFR-2 rs1870377 A>T genetic polymorphism are prognostic factors for gastric cancer.
The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women.
The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.
The von Hippel-Lindau tumor suppressor gene.
The WHO Grade I Collagen-forming Meningioma Produces Angiogenic Substances. A New Meningioma Entity.
Theranostic Designed Near-Infrared Fluorescent Poly (Lactic-co-Glycolic Acid) Nanoparticles and Preliminary Studies with Functionalized VEGF-Nanoparticles.
Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production.
Therapeutic anti-VEGF antibodies.
Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism.
Therapeutic effect of thalidomide combined with temozolomide and three-dimensional conformal radiotherapy for patients with high-grade gliomas after operation.
Therapeutic effects of adipose-derived stem cells-based microtissues on erectile dysfunction in streptozotocin-induced diabetic rats.
Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema.
Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis.
Therapeutic Effects of Three Human-derived Materials in a Mouse Corneal Alkali Burn Model.
Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells.
Therapeutic monoclonal antibodies in ophthalmology.
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer.
Therapeutic Potential of a Monoclonal Antibody Blocking the Wnt Pathway in Diabetic Retinopathy.
Therapeutic Potential of Andrographolide Isolated from the Leaves of Andrographis paniculata Nees for Treating Lung Adenocarcinomas.
Therapeutic potential of inhibitory VEGF splice variants.
Therapeutic potential of thiazolidinediones as anticancer agents.
Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.
Therapeutic response of rosacea to dobesilate.
Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review).
Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts.
Therapeutic targeting of the angiopoietin-TIE pathway.
Therapeutic targets and molecular mechanism of calycosin for the treatment of cerebral ischemia/reperfusion injury.
Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.
Therapies directed at vascular endothelial growth factor.
Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis.
Thiazolidinediones abrogate cervical cancer growth.
Thioredoxin-Interacting Protein Mediates TRX1 Translocation to the Plasma Membrane in Response to Tumor Necrosis Factor-{alpha}: A Key Mechanism for Vascular Endothelial Growth Factor Receptor-2 Transactivation by Reactive Oxygen Species.
Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer.
Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension.
Three Polymorphisms of Vascular Endothelial Growth Factor (+936C > T, -460C > T, and -2578C > A) and Their Susceptibility to Ovarian Cancer: A Meta-Analysis.
Three vascular endothelial growth factor polymorphisms (-460C>T, -2578C>A, 1612G>A) with cancer risk: a meta-analysis based on 30 case-control studies.
Three-dimensional cell cultures: from molecular mechanisms to clinical applications.
Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation.
Thrombin Induces Secretion of Multiple Cytokines and Expression of Protease-Activated Receptors in Mouse Mast Cell Line.
Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium.
Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells.
Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood.
Thrombomodulin promotes focal adhesion kinase activation and contributes to angiogenesis by binding to fibronectin.
Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.
Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers.
Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor.
Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism.
Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis.
Thromboxane receptor alpha mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells.
Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma.
Thymidine phosphorylase promotes angiogenesis and tumour growth in intrahepatic cholangiocarcinoma.
Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma.
Thymosin ?4: A Potential Molecular Target for Tumor Therapy.
Thymosin alpha-1 blocks the accumulation of myeloid suppressor cells in NSCLC by inhibiting VEGF production.
Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines.
Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors.
Thyroxine treatment stimulated ovarian follicular angiogenesis in immature hypothyroid rats.
Tie2-mediated vascular remodeling by ferritin-based protein C nanoparticles confers antitumor and anti-metastatic activities.
Time-Dependent Pretreatment with Bevacuzimab Increases Tumor Specific Uptake of Cetuximab in Preclinical Oral Cavity Cancer Studies.
TIPE regulates VEGFR2 expression and promotes angiogenesis in colorectal cancer.
Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer.
Tissue biomarkers as prognostic variables of cervical cancer.
Tissue expression of VEGF in cervical intraepithelial neoplasia and cervical cancer.
Tissue expression, serum and salivary levels of vascular endothelial growth factor in patients with HNSCC.
Tissue factor (TF) and vascular endothelial growth factor (VEGF) expression in colorectal cancer: relation with cancer recurrence.
Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis.
Tissue factor and vascular endothelial growth factor expression in colorectal cancer: relation with cancer recurrence.
Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma.
Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis.
Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy.
Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis.
Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer.
Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours.
Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents.
Tissue reconstruction process in the area of peri-tumoural oedema caused by glioblastoma--immunohistochemical and graphical analysis using brain obtained at autopsy.
TLR family gene expression in relation to the HIF1? and the VEGFR pathway activation in endometrial cancer.
TNF-? blockade suppresses pericystic inflammation following anthelmintic treatment in porcine neurocysticercosis.
TNF-?-Induced VEGF and MMP-9 Expression Promotes Hemorrhagic Transformation in Pituitary Adenomas.
TNF-alpha and endotoxin increase hypoxia-induced VEGF production by cultured human nasal fibroblasts in synergistic fashion.
TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage.
TNF-alpha secretion and apoptosis of lymphocytes mediated by gene transfer.
TNFR-1 on tumor cells contributes to the sensitivity of fibrosarcoma to chemotherapy.
TNP-470 blockage of VEGF synthesis is dependent on MAPK/COX-2 signaling pathway in PDGF-BB-activated hepatic stellate cells.
TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease model.
To explore the clinical efficacy of Traditional Chinese Medicine bath in the treatment of psoriasis vulgaris with blood-heat syndrome and its effect on related cytokines based on different temperature and different concentration.
Tobacco exposure and wound healing in head and neck surgical wounds.
Tocotrienol as a potential anticancer agent.
Tocotrienol Inhibits Secretion of Angiogenic Factors from Human Colorectal Adenocarcinoma Cells by Suppressing Hypoxia-Inducible Factor-1{alpha}
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Tongxinluo mitigates atherogenesis by regulating angiogenic factors and inhibiting vasa vasorum neovascularization in apolipoprotein E-deficient mice.
Topical application of substance P promotes wound healing in streptozotocin-induced diabetic rats.
Topical co-administration of Teucrium polium hydroethanolic extract and Aloe vera gel triggered wound healing by accelerating cell proliferation in diabetic mouse model.
Topical Topiramate Improves Wound Healing in an Animal Model of Hyperglycemia.
Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice.
Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Total alkaloids of Rubus alceifolius Poir inhibit tumor angiogenesis through suppression of the Notch signaling pathway in a mouse model of hepatocellular carcinoma.
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy.
TPS, CA 19-9, VEGF-A, and CEA as Diagnostic and Prognostic Factors in Patients with Mass Lesions in the Pancreatic Head.
Tracking tumor cells in lymphatics in a mice xenograft model by magnetic resonance imaging.
TRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions.
Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.
Transarterial oily chemoembolization with lidamycin shows potent therapeutic efficacy in VX2 rabbit liver tumor.
Transcription of the vascular endothelial growth factor receptor-3 (VEGFR3) gene is regulated by the zinc finger proteins Sp1 and Sp3 and is under epigenetic control : Transcription of vascular endothelial growth factor receptor 3.
Transcriptional activity of human epidermal growth factor receptor family and angiogenesis effectors in locoregionally recurrent head and neck squamous cell carcinoma and correlation with patient outcome.
Transcriptional factor OCT4 promotes esophageal cancer metastasis by inducing epithelial-mesenchymal transition through VEGF-C/VEGFR-3 signaling pathway.
Transcriptional regulation of the VEGF gene in dependence of individual genomic variations.
Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Transcriptional regulation of vascular endothelial growth factor C by oxidative and thermal stress is mediated by lens epithelium-derived growth factor/p75.
Transcriptional regulation of vascular endothelial growth factor in cancer.
Transcriptional-based screens for pathway-specific, high-throughput target discovery in endothelial cells.
Transfection of hypoxia-inducible factor-1 decoy oligodeoxynucleotides suppresses expression of vascular endothelial growth factor in oral squamous cell carcinoma cells.
Transfection of mouse macrophage metalloelastase gene into murine CT-26 colon cancer cells suppresses orthotopic tumor growth, angiogenesis and vascular endothelial growth factor expression.
Transfection of NF-?B decoy oligodeoxynucleotide suppresses pulmonary metastasis by murine osteosarcoma.
Transfection of wtp53 and Rb94 genes into retinoblastomas of nude mice by ultrasound-targeted microbubble destruction.
Transfer of mesenchymal stem cells and cyclosporine A on alkali-injured rabbit cornea using nanofiber scaffolds strongly reduces corneal neovascularization and scar formation.
Transformation by oncogenic Ras expands the early genomic response to transforming growth factor beta in intestinal epithelial cells.
Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells.
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Transforming growth factor-beta (TGF-beta)-inducible gene TMEPAI converts TGF-beta from a tumor suppressor to a tumor promoter in breast cancer.
Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages.
Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis.
Transforming growth factor-beta in osteolytic breast cancer bone metastases.
Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice.
Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma.
Transgenic expression of VEGF in intestinal epithelium drives mesenchymal cell interactions and epithelial neoplasia.
Transient expression of anti-VEFGR2 nanobody in Nicotiana tabacum and N. benthamiana.
Transient increased expression of VEGF and MMP-1 in a rat liver tumor model after hepatic arterial occlusion.
Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma.
Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis.
Translational Impact of Nanoparticle-Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer.
Treatment Effects of Jinlingzi Powder and Its Extractive Components on Gastric Ulcer Induced by Acetic Acid in Rats.
Treatment of a burn animal model with functionalized tridimensional electrospun biomaterials.
Treatment of Auricular Hematomas by OK-432: How and Why It Works.
Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody.
Treatment of gastrointestinal bleeding in left ventricular assist devices: A comprehensive review.
Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer.
Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity.
Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice.
Treatment of xenografted ovarian carcinoma using paclitaxel-loaded ultrasound microbubbles.
Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease.
Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor.
Treatment-related mortality with aflibercept in cancer patients: a meta-analysis.
Treatment-related toxicities of apatinib in solid tumors: a meta-analysis.
Trehalose 6,6'-dimycolate (cord factor) of Mycobacterium tuberculosis induces corneal angiogenesis in rats.
Triamcinolone acetonide protects the rat retina from STZ-induced acute inflammation and early vascular leakage.
Triamcinolone Acetonide Suppresses Inflammation and Facilitates Vascular Barrier Function in Human Retinal Microvascular Endothelial Cells.
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.
Trichostatin A resistance is facilitated by HIF-1? acetylation in HeLa human cervical cancer cells under normoxic conditions.
Tricin, 4',5,7-trihydroxy-3',5'-dimethoxyflavone, exhibits potent antiangiogenic activity in vitro.
Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.
Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations.
Triptolide Downregulates Treg Cells and the Level of IL-10, TGF-?, and VEGF in Melanoma-Bearing Mice.
Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells.
Tristetraprolin Inhibits Ras-dependent Tumor Vascularization by Inducing Vascular Endothelial Growth Factor mRNA Degradation.
TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model.
Tubular deficiency of von Hippel-Lindau attenuates renal disease progression in anti-GBM glomerulonephritis.
Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma.
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
Tumor and lymph node lymphangiogenesis--impact on cancer metastasis.
Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Tumor angiogenesis and anti-angiogenic therapies.
Tumor angiogenesis and anti-angiogenic therapy.
Tumor angiogenesis and its clinical significance in pediatric malignant liver tumor.
Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma.
Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage IIIA).
Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression.
Tumor angiogenesis in predicting the survival of patients with stage I lung cancer.
Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression.
Tumor angiogenesis of non-small cell lung cancer.
Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
Tumor angiogenesis.
Tumor angiogenesis: the pivotal role of vascular endothelial growth factor.
Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade.
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
Tumor cell-activated CARD9 signaling contributes to metastasis-associated macrophage polarization.
Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma.
Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma.
Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma.
Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer.
Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment.
Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib.
Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk-1) promoter/enhancer sequences.
Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype.
Tumor gene therapy by systemic delivery of plasmid DNA with cell-penetrating peptides.
Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts.
Tumor growth factor expression in obesity and changes in expression with weight loss: another cause of increased virulence and incidence of cancer in obesity.
Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.
Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor.
Tumor growth patterns and biological characteristics of early gastric carcinoma.
Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma.
Tumor Growth: A Putative Role for Platelets?
Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers.
Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies.
Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor.
Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.
Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A.
Tumor interstitial fluid and gastric cancer metastasis: an experimental study to verify the hypothesis of "tumor-phlegm microenvironment".
Tumor interstitial fluid as modulator of cancer inflammation, thrombosis, immunity and angiogenesis.
Tumor interstitial fluid pressure-a link between tumor hypoxia, microvascular density, and lymph node metastasis.
Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy.
Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment.
Tumor location and nature of lymphatic vessels are key determinants of cancer metastasis.
Tumor lymphangiogenesis and metastatic spread-new players begin to emerge.
Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability.
Tumor microenvironment modifications induced by soluble VEGF receptor expression in a rat liver metastasis model.
Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR.
Tumor necrosis factor and vascular endothelial growth factor induce endothelial integrin repertories, regulating endovascular differentiation and apoptosis in a human extravillous trophoblast cell line.
Tumor necrosis factor-? promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-?B-mediated upregulation of vascular endothelial growth factor-C.
Tumor necrosis factor-alpha promotes malignant pleural effusion.
Tumor necrosis factor-alpha promotes tumor growth by inducing vascular endothelial growth factor.
Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells.
Tumor necrosis factor-alpha regulates vascular endothelial growth factor secretion by human oviductal epithelial cells and stromal fibroblasts.
Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy.
Tumor refractoriness to anti-VEGF therapy.
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas.
Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody.
Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer.
Tumor Stromal-Derived Factor-1 Recruits Vascular Progenitors to Mitotic Neovasculature, where Microenvironment Influences Their Differentiated Phenotypes.
Tumor suppressive microRNA?429 regulates cellular function by targeting VEGF in clear cell renal cell carcinoma.
Tumor suppressor microRNA?613 inhibits glioma cell proliferation, invasion and angiogenesis by targeting vascular endothelial growth factor A.
Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma.
Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma.
Tumor vasculature and glioma stem cells: Contributions to glioma progression.
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma.
Tumor vessel biology in pediatric intracranial ependymoma.
Tumor-Adhesive and pH-Degradable Microgels by Microfluidics and Photo-Cross-Linking for Efficient Antiangiogenesis and Enhanced Cancer Chemotherapy.
Tumor-associated fibroblasts and mesenchymal stem cells: more similarities than differences.
Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis.
Tumor-associated stromal cells as key contributors to the tumor microenvironment.
Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function.
Tumor-Derived Factors and Reduced p53 Promote Endothelial Cell Centrosome Over-Duplication.
Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages.
Tumor-derived vascular endothelial growth factor (VEGF)-A facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway.
Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients.
Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.
Tumor-induced lymphangiogenesis: a target for cancer therapy?
Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors.
Tumor-Infiltrating Lymphocytes Express Vascular Endothelial Growth Factor in Renal Cell Carcinomas.
Tumor-Microenvironment-Responsive Nanoconjugate for Synergistic Antivascular Activity and Phototherapy.
Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment.
Tumor-specific gene expression using the survivin promoter is further increased by hypoxia.
Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.
Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase.
Tumor-Targeted Immunotherapy by Using Primary Adipose-Derived Stem Cells and an Antigen-Specific Protein Vaccine.
Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.
Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas.
Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model.
Tumor-Treating Fields Inhibit the Metastatic Potential of Osteosarcoma Cells.
Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy.
Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.
Tumorigenic Development of Induced Pluripotent Stem Cells in Ischemic Mouse Brain.
Tumorigenicity depends on angiogenic potential of tumor cells: dominant role of vascular endothelial growth factor and/or fibroblast growth factors produced by tumor cells.
Tumour expressions of hypoxic markers predict the response to neo-adjuvant chemotherapy in children with inoperable rhabdomyosarcoma.
Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform.
Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study.
Tumour suppressive effects of WEE1 gene silencing in neuroblastomas.
Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma.
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.
Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma?
Tumour vasculature as a target for anticancer therapy.
Tumour VEGF/Non Tumour VEGF protein expression ratio as a biomarker for survival in colorectal cancer patients.
Tumour-associated host cells participating at invasion and metastasis : targets for therapy?
Tumour-associated macrophages are associated with vascular endothelial growth factor expression in canine mammary tumours.
Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis.
Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3.
Two Novel Heparin-binding Vascular Endothelial Growth Factor Splices, L-VEGF144 and L-VEGF138, are Expressed in Human Glioblastoma Cells.
Tyroserleutide-based gene vector for suppressing VEGF expression in cancer therapy.
Tyrosine kinase A receptor (trkA): A potential marker in epithelial ovarian cancer.
Tyrosine kinase expression in pulmonary metastases and paired primary tumors.
Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: A comparative review.
Tyrosine Kinase Receptor Flt/VEGFR Family: Its Characterization Related to Angiogenesis and Cancer.
Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGF-related pathway.
Ultrasensitive immuno-detection using viral nanoparticles with modular assembly using genetically-directed biotinylation.
Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics.
Ultrasound-mediated destruction of oxygen and paclitaxel loaded dual-targeting microbubbles for intraperitoneal treatment of ovarian cancer xenografts.
Ultrasound-Targeted Microbubble Destruction Enhances Inhibitory Effect of Apatinib on Angiogenesis in Triple Negative Breast Carcinoma Xenografts.
Ultrasound-targeted microbubble destruction improved the antiangiogenic effect of Endostar in triple-negative breast carcinoma xenografts.
Ultrastructural and cytobiological studies on possible interactions between PTHrP-secreting tumor cells, stromal cells, and bone cells.
Ultrastructural localization of platelet endothelial cell adhesion molecule (PECAM-1, CD31) in vascular endothelium.
Ultraviolet-A-induced transactivation of the vascular endothelial growth factor gene in HaCaT keratinocytes is conveyed by activator protein-2 transcription factor.
Umbilical cord-matrix stem cells induce the functional restoration of vascular endothelial cells and enhance skin wound healing in diabetic mice via the polarized macrophages.
Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis.
Understanding the biology of angiogenesis: review of the most important molecular mechanisms.
Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist.
Undifferentiated spindle-cell sarcoma of the chest wall with vascular endothelial growth factor expression: report of a case.
Unexpected neuronal protection of SU5416 against 1-Methyl-4-phenylpyridinium ion-induced toxicity via inhibiting neuronal nitric oxide synthase.
Unfavorable effect of calcitriol and its low-calcemic analogs on metastasis of 4T1 mouse mammary gland cancer.
Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro.
Up-regulated autocrine VEGF/VEGFR-2 loop prevents apoptosis in hemangioma-derived endothelial cells.
Up-regulated EMMPRIN/CD147 protein expression might play a role in colorectal carcinogenesis and its subsequent progression without an alteration of its glycosylation and mRNA level.
Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer.
Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Up-regulation of interleukin-6 and vascular endothelial growth factor-A in the synovial fluid of temporomandibular joints affected by synovial chondromatosis.
Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor.
Up-regulation of pVHL along with down-regulation of HIF-1? by NDRG2 expression attenuates proliferation and invasion in renal cancer cells.
Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function.
Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis.
Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway.
Up-regulation of vascular endothelial growth factor production by iron chelators.
Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases.
Up-Regulation of Vascular Endothelial Growth Factor-D Expression in Clear Cell Renal Cell Carcinoma by CD74: A Critical Role in Cancer Cell Tumorigenesis.
Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels.
Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer.
Update on clinical trials targeting vascular endothelial growth factor in cancer.
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma.
Update on novel therapeutic agents for cervical cancer.
Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis.
Upregulation of Endocrine Gland-Derived Vascular Endothelial Growth Factor in Papillary Thyroid Cancers Displaying Infiltrative Patterns, Lymph Node Metastases, and BRAF Mutation.
Upregulation of hypoxia inducible factor 1alpha mRNA is associated with elevated vascular endothelial growth factor expression and excessive angiogenesis and predicts a poor prognosis in gastric carcinoma.
Upregulation of hypoxia-inducible factor-1alpha mRNA and its clinical significance in non-small cell lung cancer.
Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling.
Upregulation of microfibrillar-associated protein 2 is closely associated with tumor angiogenesis and poor prognosis in hepatocellular carcinoma.
Upregulation of serum vascular endothelial growth factor in patients with salivary gland tumor.
Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines.
Upregulation of vascular endothelial growth factor by hydrogen peroxide in human colon cancer.
Upregulation of VEGF by 15-deoxy-Delta12,14-prostaglandin J2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells.
Urea-Peptide Hybrids as VEGF-A165/NRP-1 Complex Inhibitors with Improved Receptor Affinity and Biological Properties.
URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-?B signaling pathway.
Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer.
Urinary biomarkers involved in type 2 diabetes: a review.
Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy.
Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation.
Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix.
Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Uroprotective effect of oleuropein in a rat model of hemorrhagic cystitis.
Ursodeoxycholic acid ameliorates diabetic retinopathy via reducing retinal inflammation and reversing the breakdown of blood-retinal barrier.
Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy.
Use of intravitreal bevacizumab in a patient with a Von Hippel-Lindau-associated retinal haemangioblastoma of the optic nerve head: a case report.
Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity.
Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma.
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
Usefulness of contrast-enhanced magnetic resonance imaging for evaluating solitary pulmonary nodules.
Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma: differential diagnosis, tumor progression, and patient survival.
Usefulness of thallium-201 SPECT in the evaluation of tumor natures in intracranial meningiomas.
Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours.
Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma.
Using semi-quantitative dynamic contrast-enhanced magnetic resonance imaging parameters to evaluate tumor hypoxia: a preclinical feasibility study in a maxillofacial VX2 rabbit model.
Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival.
Uterine dehiscence in term pregnant patients with one previous cesarean delivery: growth factor immunoexpression and collagen content in the scarred lower uterine segment.
Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor.
UTERINE WOUND HEALING: A COMPLEX PROCESS MEDIATED BY PROTEINS AND PEPTIDES.
Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer.
Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19.
UV radiation induces the release of angiopoietin-2 from dermal microvascular endothelial cells.
UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression.
V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.
V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression.
Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy.
Vaccine CIGB 247 is potentially safe for use as a novel therapeutic vaccine against cancer in Chlorocebus aethiops monkeys.
Validation of commercial ELISAs for quantifying anabolic growth factors and cytokines in canine ACD-A anticoagulated plasma.
Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.
Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray.
Value of perfusion CT parameters, microvessl density and VEGF expression in differentiation of benign and malignant prostate tumours.
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies.
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.
Variations in inflammatory genes are associated with periodontitis.
Vasa nervorum angiogenesis in prostate cancer with perineural invasion.
Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma.
Vascular channels formed by subpopulations of PECAM1+ melanoma cells.
Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic.
Vascular dysfunction and increased metastasis of B16F10 melanomas in Shb deficient mice as compared with their wild type counterparts.
Vascular effects of cancer treatments.
Vascular endocan is preferentially expressed in tumor endothelium.
Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Vascular endothelial growth factor (VEGF) & tumour angiogenesis.
Vascular endothelial growth factor (VEGF) activates Raf-1, mitogen-activated protein (MAP) kinases, and S6 kinase (p90rsk) in cultured rat cardiac myocytes.
Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies.
Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro.
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma.
Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha(v)beta6.
Vascular endothelial growth factor (VEGF) expression and microvascular density in salivary gland tumours.
Vascular endothelial growth factor (VEGF) expression correlates with p53 and ki-67 expressions in tongue squamous cell carcinoma.
Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation.
Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma.
Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia.
Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells.
Vascular endothelial growth factor (VEGF) expression in the lung in toxic septic shock.
Vascular endothelial growth factor (VEGF) expression regulates angiogenesis accompanying tumor growth in a peritoneal disseminated tumor model.
Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a Chinese population.
Vascular endothelial growth factor (VEGF) genotype and serum concentration in patients with pancreatic adenocarcinoma and chronic pancreatitis.
Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway.
Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival.
Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis-A possible target for novel therapies?
Vascular endothelial growth factor (VEGF) inhibition--a critical review.
Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors.
Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression.
Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease.
Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells.
Vascular endothelial growth factor (VEGF) levels as a tool to discriminate between malignant and nonmalignant ascites.
Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors.
Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies.
Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.
Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.
Vascular Endothelial Growth Factor (VEGF) Polymorphisms and Serum VEGF Levels in Women With Epithelial Ovarian Cancer, Benign Tumors, and Healthy Ovaries.
Vascular endothelial growth factor (VEGF) receptor neuropilin-1's distribution in astrocytic tumors.
Vascular endothelial growth factor (VEGF) serum levels during cancer immunotherapy with IL-2: preliminary considerations.
Vascular endothelial growth factor (VEGF) signaling in tumor progression.
Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.
Vascular endothelial growth factor (VEGF) splice isoforms may hold the key to targeting tumour angiogenesis in oesophageal cancer.
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers.
Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells.
Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy.
Vascular endothelial growth factor (VEGF), mast cells and inflammation.
Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Vascular endothelial growth factor (VEGF)--a valuable serum tumour marker in patients with colorectal cancer?
Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A.
Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
Vascular endothelial growth factor +936C/T and +405G/C polymorphisms and cancer risk: a meta-analysis.
Vascular endothelial growth factor +936C/T polymorphism and cancer risk in Asians: a meta-analysis.
Vascular endothelial growth factor - its relation to neovascularization and their significance as prognostic factors in renal cell carcinoma.
Vascular endothelial growth factor -634 G/C polymorphism and risk of cancer: an updated meta-analysis.
Vascular endothelial growth factor -634G/C and vascular endothelial growth factor -2578C/A polymorphisms and lung cancer risk: a case-control study and meta-analysis.
Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer.
Vascular endothelial growth factor 936 C/T polymorphism in cancer patients.
Vascular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin {alpha}9{beta}1: identification of a specific {alpha}9{beta}1 binding site.
Vascular Endothelial Growth Factor A and Leptin Expression Associated with Ectopic Proliferation and Retinal Dysplasia in Zebrafish Optic Pathway Tumors.
Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India).
Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer.
Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer.
Vascular endothelial growth factor A, secreted in response to transforming growth factor-?1 under hypoxic conditions, induces autocrine effects on migration of prostate cancer cells.
Vascular endothelial growth factor accelerates establishment of a model of hepatic metastasis in walker-256 tumor-bearing rats.
Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3.
Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone.
Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells.
Vascular endothelial growth factor affects permeability of brain microvessel endothelial cells in vitro.
Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules.
Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumours.
Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus.
Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma.
Vascular endothelial growth factor and basic fibroblast growth factor in patients with squamous cell oesophageal cancer.
Vascular endothelial growth factor and basic fibroblast growth factor in primary lung carcinomas and the incidence of metastases.
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
Vascular endothelial growth factor and bevacitumab in breast cancer.
Vascular endothelial growth factor and cyclooxygenase-2 are overexpressed in ileal pouch-anal anastomosis.
Vascular endothelial growth factor and dendritic cells in human squamous cell carcinoma of the oral cavity.
Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer.
Vascular endothelial growth factor and endoglin expression in colorectal cancer.
Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms.
Vascular endothelial growth factor and HDAC 6: a neuroprotective signalling pathway against cancer therapy-induced neuropathy.
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.
Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients.
Vascular endothelial growth factor and its inhibitors.
Vascular Endothelial Growth Factor and Its Receptor VEGFR-2 Are Highly Expressed in Ovarian Granulosa Cell Tumors.
Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers.
Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Vascular endothelial growth factor and its type 2 receptor in hepatocellular carcinoma.
Vascular endothelial growth factor and its type 2 receptor in tumors and serum of patients with renal cancer.
Vascular endothelial growth factor and Kaposi's sarcoma cells in human skin grafts.
Vascular endothelial growth factor and ki-67 antigen expression in relation to age and gender in oral squamous cell carcinoma.
Vascular endothelial growth factor and KIT expression in relation with microvascular density and tumor grade in supratentorial astrocytic tumors.
Vascular endothelial growth factor and neovascularization in astrocytic tumors.
Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53.
Vascular Endothelial Growth Factor and not Cyclooxygenase 2 Promotes Endothelial Cell Viability in the Pancreatic Tumor Microenvironment.
Vascular endothelial growth factor and osteopontin in tumor biology.
Vascular endothelial growth factor and other signaling pathways in developmental and pathologic angiogenesis.
Vascular endothelial growth factor and oxidative damage in cancer.
Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer.
Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions.
Vascular endothelial growth factor and protein level in pleural effusion for differentiating malignant from benign pleural effusion.
Vascular endothelial growth factor and social support in patients with ovarian carcinoma.
Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade.
Vascular endothelial growth factor and survivin immunostaining in gastric adenocarcinoma.
Vascular endothelial growth factor and thymidine phosphorylase expression in salivary gland tumors with distinct metastatic behavior.
Vascular endothelial growth factor and tumor necrosis factor genes polymorphisms in Turkish patients with sarcoidosis.
Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation.
Vascular endothelial growth factor and vascular targeting of solid tumors.
Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats.
Vascular endothelial growth factor antisense oligonucleotides inhibit leptomeningeal metastasis in vivo.
Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin.
Vascular endothelial growth factor as a biomarker for the early detection of cancer using a whole cell-based biosensor.
Vascular endothelial growth factor as a marker of tumor endothelium.
Vascular endothelial growth factor as a survival factor for human islets: effect of immunosuppressive drugs.
Vascular endothelial growth factor as a target for cancer gene therapy.
Vascular endothelial growth factor as a therapeutic target in cancer.
Vascular endothelial growth factor as an age-dependent prognostic factor in gastric cancer patients.
Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy.
Vascular endothelial growth factor as prognostic factor in renal cell carcinoma.
Vascular endothelial growth factor assessment in different blood fractions of gastrointestinal cancer patients and healthy controls.
Vascular endothelial growth factor blockade elicits a stable metabolic shift in tumor cells: therapeutic implications.
Vascular Endothelial Growth Factor Blockade Induces Dermal Endothelial Cell Apoptosis in a Clinically Relevant Skin Organ Culture Model.
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Vascular endothelial growth factor C (VEGF-C) expression in pT2 gastric cancer.
Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma.
Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells.
Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma.
Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3.
Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms.
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.
Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor.
Vascular endothelial growth factor C936T polymorphism in cancer patients with thrombosis.
Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells.
Vascular endothelial growth factor concentrations from platelets correlate with tumor angiogenesis and grading in a spontaneous canine non-Hodgkin lymphoma model.
Vascular Endothelial Growth Factor Concentrations in Dogs with Spirocercosis.
Vascular endothelial growth factor concentrations in the cerebrospinal fluid of dogs with neoplastic or inflammatory central nervous system disorders.
Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-APR) of healthy controls and colorectal cancer patients.
Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma.
Vascular endothelial growth factor C and D expression correlates with lymph node metastasis and poor prognosis in patients with resected esophageal cancer.
Vascular endothelial growth factor D and intratumoral lymphatics as independent prognostic factors in epithelial ovarian carcinoma.
Vascular endothelial growth factor D is a biomarker of fluid overload in haemodialysis patients.
Vascular endothelial growth factor D is dispensable for development of the lymphatic system.
Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.
Vascular endothelial growth factor enhances cancer cell adhesion to microvascular endothelium in vivo.
Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance.
Vascular endothelial growth factor expressed by mast cells rather than tumour cells in angiomyofibroblastoma of the vaginal wall.
Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts.
Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas.
Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck.
Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.
Vascular endothelial growth factor expression in metastatic pulmonary tumor from colorectal carcinoma: utility as a prognostic factor.
Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma.
Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival.
Vascular Endothelial Growth Factor Expression in Osteosarcoma.
Vascular endothelial growth factor expression in osteosarcoma.
Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
Vascular endothelial growth factor expression in ovarian serous carcinomas and its effect on tumor proliferation.
Vascular endothelial growth factor expression in pN2 non-small cell lung cancer: lack of prognostic value.
Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression.
Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis.
Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis.
Vascular endothelial growth factor expression in transient focal cerebral ischemia in the rat.
Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas.
Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.
Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours.
Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma.
Vascular endothelial growth factor expression predicts outcome after primary radiotherapy for head and neck squamous cell cancer.
Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus.
Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy.
Vascular endothelial growth factor gene polymorphism and protein expression in the pathogenesis of pterygium.
Vascular endothelial growth factor gene polymorphisms and colorectal cancer risk: a meta-analysis.
Vascular endothelial growth factor gene polymorphisms and gastric cancer risk: a meta-analysis.
Vascular endothelial growth factor gene polymorphisms and renal cell carcinoma: A systematic review and meta-analysis.
Vascular endothelial growth factor gene polymorphisms and risk of cervical intraepithelial neoplasia.
Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer.
Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer.
Vascular endothelial growth factor gene polymorphisms in ovarian cancer.
Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer.
Vascular endothelial growth factor immunoexpression is increased in malignant salivary gland tumors.
Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.
Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways.
Vascular endothelial growth factor in angiosarcoma.
Vascular endothelial growth factor in cervical carcinoma.
Vascular endothelial growth factor in esophageal cancer.
Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction.
Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen.
Vascular endothelial growth factor in ovarian cyst fluid.
Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery?
Vascular endothelial growth factor in salivary pleomorphic adenomas: one of the reasons for their poorly vascularized stroma.
Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker.
Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen.
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts.
Vascular endothelial growth factor in thyroid cancers.
Vascular endothelial growth factor in tumor tissue and blood serum from patients with breast cancer.
Vascular endothelial growth factor induces multidrug resistance-associated protein 1 overexpression through phosphatidylinositol-3-kinase /protein kinase B signaling pathway and transcription factor specificity protein 1 in BGC823 cell line.
Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors.
Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation.
Vascular endothelial growth factor inhibition: Conflicting roles in tumor growth.
Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies.
Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals.
Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.
Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck.
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.
Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.
Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression.
Vascular endothelial growth factor is an autocrine growth factor for cardiac myxoma cells.
Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia.
Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma.
Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites.
Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells.
Vascular endothelial growth factor levels in bile distinguishes pancreatic cancer from other etiologies of biliary stricture: a pilot study.
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity.
Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
Vascular endothelial growth factor levels in pleural and peritoneal fluid in Meigs' syndrome.
Vascular endothelial growth factor levels in serum and plasma following esophageal cancer resection--relationship to platelet count.
Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?
Vascular endothelial growth factor mRNA expression and peritumoral edema in canine primary central nervous system tumors.
Vascular endothelial growth factor mRNA levels quantified by reverse transcription-polymerase chain reaction in microdissected breast carcinoma tissues are correlated with histological type and grade of both invasive and intraductal components.
Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.
Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Vascular endothelial growth factor overproduced by tumour cells acts predominantly as a potent angiogenic factor contributing to malignant progression.
Vascular endothelial growth factor partially inhibits the trastuzumab-mediated antibody-dependent cellular cytotoxicity of human monocytes.
Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis.
Vascular endothelial growth factor polymorphisms -1154 G/A and -460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer.
Vascular endothelial growth factor polymorphisms affect gene expression and tumor aggressiveness in patients with breast cancer.
Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival.
Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors.
Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro.
Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors.
Vascular endothelial growth factor production is induced by histone deacetylase 1 and suppressed by von Hippel-Lindau protein in HaCaT cells.
Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro.
Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application.
Vascular endothelial growth factor promotes macrophage apoptosis through stimulation of tumor necrosis factor superfamily member 14 (TNFSF14/LIGHT).
Vascular endothelial growth factor promotes the expression of cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells.
Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth.
Vascular endothelial growth factor receptor 1, a therapeutic target in cancer, inflammation and other disorders.
Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.
Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice.
Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Vascular Endothelial Growth Factor Receptor Inhibitor SU5416 Suppresses Lymphocyte Generation and Immune Responses in Mice by Increasing Plasma Corticosterone.
Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer.
Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1).
Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases.
Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma.
Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.
Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells.
Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas.
Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo.
Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here?
Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.
Vascular endothelial growth factor receptors: expression and function in solid tumors.
Vascular endothelial growth factor reduces mural cell coverage of endothelial cells and induces sprouting rather than luminal division in an HT1080 tumour angiogenesis model.
Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors.
Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2.
Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process.
Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature.
Vascular endothelial growth factor serum concentrations in ovarian cancer.
Vascular endothelial growth factor serum levels in children with newly diagnosed rhabdomyosarcoma.
Vascular endothelial growth factor signals through platelet-derived growth factor receptor ? in meningiomas in vitro.
Vascular endothelial growth factor single-nucleotide polymorphism in gall bladder cancer.
Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer.
Vascular endothelial growth factor staining and elevated INR in advanced epithelial ovarian carcinoma.
Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion.
Vascular endothelial growth factor stimulates protein kinase C-dependent phospholipase D activity in endothelial cells.
Vascular endothelial growth factor synergistically enhances induction of E-selectin by tumor necrosis factor-alpha.
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling.
Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.
Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells.
Vascular endothelial growth factor with tumour growth factor-beta, endostatin, proteinases or cytokines might be useful for differential diagnosis of pleural effusions.
Vascular endothelial growth factor, a specific regulator of angiogenesis.
Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy.
Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival.
Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients.
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
Vascular endothelial growth factor--a positive and negative regulator of tumor growth.
Vascular endothelial growth factor--marker for proliferation in thyroid diseases?
Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.
Vascular endothelial growth factor-c (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway.
Vascular endothelial growth factor-C and vascular endothelial growth factor-d messenger RNA expression in breast cancer: association with lymph node metastasis.
Vascular endothelial growth factor-C expression as a biomarker of poor prognosis in esophageal squamous cell carcinoma: a meta-analysis.
Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis.
Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma.
Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma.
Vascular endothelial growth factor-D is correlated with hepatic metastasis from gastric cancer after radical gastrectomy.
Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer.
Vascular Endothelial Growth Factor-D-Mediated Blockade of Regulatory T Cells within Tumors Is Induced by Hematopoietic Stem Cell Transplantation.
Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance.
Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.
Vascular endothelial growth factor-induced tumor angiogenesis and tumorigenicity in relation to metastasis in a HT1080 human fibrosarcoma cell model.
Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype.
Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases.
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses.
Vascular endothelial growth factor.
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer.
Vascular endothelial growth factor/semaphorin-3A ratio and SEMA3A expression in cutaneous malignant melanoma.
Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma.
Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.
Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer.
Vascular endothelial growth factor: Evidence for autocrine signaling in hepatocellular carcinoma cell lines affecting invasion.
Vascular endothelial growth factor: much more than an angiogenesis factor.
Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy.
Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients.
Vascular endothelial growth factors and liver diseases.
Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells.
Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis.
Vascular Endothelial Growth Factors, Angiogenesis, and Survival in Human Ileal Enterochromaffin Cell Carcinoids.
Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma.
Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy.
Vascular normalization: a real benefit?
Vascular patterning of subcutaneous mouse fibrosarcomas expressing individual VEGF isoforms can be differentiated using angiographic optical coherence tomography.
Vascular permeability and drug delivery in cancers.
Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications.
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia.
Vascular permeability factor (VPF, VEGF) in tumor biology.
Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia.
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.
Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation.
Vascular proliferation is important for clinical progress of endometrial cancer.
Vascular stenosis in a child with visual pathway glioma treated with bevacizumab: a case report and review of literature.
Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein.
Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor.
Vascular toxicity associated with anti-angiogenic drugs.
Vascular-targeted agents for the treatment of angiosarcoma.
Vascularity and expression of vascular endothelial growth factor in oral squamous cell carcinoma, resection margins, and nodal metastases.
Vasculo-toxic and pro-inflammatory action of unbound haemoglobin, haem and iron in transfusion-dependent patients with haemolytic anaemias.
Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma.
Vasohibin-2 modulates tumor onset in the gastrointestinal tract by normalizing tumor angiogenesis.
Vector-based RNAi approach to isoform-specific downregulation of vascular endothelial growth factor (VEGF)165 expression in human leukemia cells.
Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer.
VEGF +405G/C (rs2010963) polymorphisms and digestive system cancer risk: a meta-analysis.
VEGF -460C>T polymorphism and cancer risk: a meta-analysis.
VEGF 936C > T Polymorphism and Association of BI-RADS Score in Women with Suspected Breast Cancer.
VEGF and 17-?-estradiol levels after tamoxifen administration in canine hepatoid gland adenomas and hepatoid gland epitheliomas.
VEGF and Bcl-2 interact via MAPKs signaling pathway in the response to hypoxia in neuroblastoma.
VEGF and bFGF expression and microvessel density of maxillary sinus squamous cell carcinoma in relation to p53 status, spontaneous apoptosis and prognosis.
VEGF and cortactin expression are independent predictors of tumor recurrence following curative resection of gastric cancer.
VEGF and Id-1 in pancreatic adenocarcinoma: Prognostic significance and impact on angiogenesis.
VEGF and IL-18 in induced sputum of lung cancer patients.
VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma.
VEGF and prostatic cancer: a systematic review.
VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.
VEGF and the quest for tumour angiogenesis factors.
VEGF and tPA co-expressed in malignant glioma.
VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate.
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas.
VEGF as a mediator of tumor-associated immunodeficiency.
VEGF as a target of therapy in gastrointestinal oncology.
VEGF as a therapeutic target in cancer.
VEGF concentrations in tumour arteries and veins from patients with rectal cancer.
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2.
VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2.
VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop.
VEGF expression and angiogenesis in oral squamous cell carcinoma: an immunohistochemical and morphometric study.
VEGF expression and its reguration by p53 gene transfection in endometrial carcinoma cells.
VEGF expression from human dysplastic or malignant oral epithelium may be related to mast cell density and the subsequent angiogenetic phenomena.
VEGF expression in dog mastocytoma.
VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI.
VEGF Expression is Associated with Negative Estrogen Receptor Status in Patients with Breast Cancer.
VEGF expression is augmented by hypoxia?induced PGIS in human fibroblasts.
VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population.
VEGF hypersecretion as a plausible mechanism for pseudo-meigs' syndrome in advanced colorectal cancer.
VEGF Immunoexpression in Prostate Adenocarcinoma.
VEGF immunopositivity related to malignancy degree, proliferative activity and angiogenesis in ENU-induced gliomas.
VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome.
VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review).
VEGF in patients with non-small cell lung cancer during combination chemotherapy of carboplatin and paclitaxel.
VEGF in physiological process and thyroid disease.
VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly.
VEGF increases paracellular transport without altering the solvent-drag reflection coefficient.
VEGF inhibitors in cancer therapy.
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.
VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine.
VEGF is essential for the growth and migration of human hepatocellular carcinoma cells.
VEGF kinase inhibitors: How do they cause hypertension?
VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.
VEGF levels in patients with glioma: a systematic review and meta-analysis.
VEGF mRNA expression in jugulotympanic paraganglioma.
VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines.
VEGF overexpression is associated with optic nerve involvement and differentiation of retinoblastoma: A PRISMA-compliant meta-analysis.
VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells.
VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population.
VEGF Promotes Glycolysis in Pancreatic Cancer via HIF1? Up-Regulation.
VEGF Promotes Proliferation of Human Glioblastoma Multiforme Stem-Like Cells through VEGF Receptor 2.
VEGF protein expression is associated with a poor prognosis in cutaneous extranodal NK/T-cell lymphoma patients.
VEGF receptor expression and signaling in human bladder tumors.
VEGF receptor signal transduction - A brief update.
VEGF receptor signaling in tumor angiogenesis.
VEGF Restores Delayed Tumor Progression in Tumors Depleted of Macrophages.
VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines.
VEGF silencing inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via PI3K/AKT signaling pathway.
VEGF Silencing Inhibits Human Osteosarcoma Angiogenesis and Promotes Cell Apoptosis via PI3K/AKT Signaling Pathway.
VEGF spliced variants: possible role of anti-angiogenesis therapy.
VEGF stimulated the angiogenesis by promoting the mitochondrial functions.
VEGF stimulates PKD-mediated CREB-dependent orphan nuclear receptor Nurr1 expression: Role in VEGF-induced angiogenesis.
VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-?B-induced endothelial activation.
VEGF targets the tumour cell.
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.
VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo.
VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts.
VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix.
VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.
VEGF, Flt-1, and microvessel density in primary tumors as predictive factors of colorectal cancer prognosis.
VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent.
VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells.
VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course.
VEGF-A Induces Angiogenesis by Perturbing the Cathepsin-Cysteine Protease Inhibitor Balance in Venules, Causing Basement Membrane Degradation and Mother Vessel Formation.
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis.
VEGF-A Is Necessary and Sufficient for Retinal Neuroprotection in Models of Experimental Glaucoma.
VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling.
VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression.
VEGF-A/VEGF-B/VEGF-C expressions in non-hereditary, non-metastatic phaeochromocytoma.
VEGF-A/VEGFR-2 and FGF-2/FGFR-1 but not PDGF-BB/PDGFR-? play important roles in promoting immature and inflammatory intraplaque angiogenesis.
VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis.
VEGF-C and VEGF-D expression and its correlation with lymph node metastasis in esophageal squamous cell cancer tissue.
VEGF-C and VEGF-D overexpression is more common in left-sided and well-differentiated colon adenocarcinoma.
VEGF-C antisense oligoxydeonucleotide suppression of invasive ability of the A-549 lung carcinoma cell line.
VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients.
VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors.
VEGF-C Is a Thyroid Marker of Malignancy Superior to VEGF-A in the Differential Diagnostics of Thyroid Lesions.
VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival.
VEGF-C, VEGF-D and VEGFR-3 expression in peripheral neuroblastic tumours.
VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours.
VEGF-C/Flt-4 axis in tumor cells contributes to the progression of oral squamous cell carcinoma via upregulating VEGF-C itself and contactin-1 in an autocrine manner.
VEGF-D as a marker in the aid of malignant metastatic pleural effusion diagnosis.
VEGF-D in Association With VEGFR-3 Promotes Nodal Metastasis in Human Invasive Lobular Breast Cancer.
VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme.
VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues.
VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.
VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma.
VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium.
VEGF-D(ilated) Lymphatics as Gateways to Metastasis.
VEGF-D-enhanced lymph node metastasis of ovarian cancer is reversed by vesicular stomatitis virus matrix protein.
VEGF-D-induced draining lymphatic enlargement and tumor lymphangiogenesis promote lymph node metastasis in a xenograft model of ovarian carcinoma.
VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis.
VEGF-Induced Growth Cone Enhancement Is Diminished by Inhibiting Tyrosine-Residue 1214 of VEGFR-2.
VEGF-induced neoangiogenesis is mediated by NAADP and two-pore channel-2-dependent Ca2+ signaling.
VEGF-mediated tumour angiogenesis: a new target for cancer therapy.
VEGF-neuropilin-2 signaling promotes stem-like traits in breast cancer cells by TAZ-mediated repression of the Rac GAP ?2-chimaerin.
VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these malignant tumors.
VEGF-specific siRNAs modified with 2'-deoxy effectively suppress VEGF expression and inhibit growth of nasopharyngeal carcinoma xenograft in a mouse model.
VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs.
VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma.
VEGF-targeted therapy: mechanisms of anti-tumour activity.
VEGF-Trap: a VEGF blocker with potent antitumor effects.
VEGF-VEGF receptor complexes as markers of tumor vascular endothelium.
VEGF-VEGFR Signals in Health and Disease.
VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence.
VEGF/Neuropilin Signaling in Cancer Stem Cells.
VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-?B and ?-catenin.
VEGF111b, a new member of VEGFxxxb isoforms and induced by mitomycin C, inhibits angiogenesis.
VEGF121 and VEGF165 differentially promote vessel maturation and tumor growth in mice and humans.
VEGF121 promotes lymphangiogenesis in the sentinel lymph nodes of non-small cell lung carcinoma patients.
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.
VEGF: A critical driver for angiogenesis and subsequent tumor growth: An IHC study.
VEGF: an essential mediator of both angiogenesis and endochondral ossification.
VEGF: From Discovery to Therapy: The Champalimaud Award Lecture.
VEGF???-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system.
VEGFA +936C>T polymorphism and cancer risk: a meta-analysis.
VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities.
VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide in vivo.
VEGFR-1 Expression Relates to Fuhrman Nuclear Grade of Clear Cell Renal Cell Carcinoma.
VEGFR-1 Regulates EGF-R to Promote Proliferation in Colon Cancer Cells.
VEGFR-2 expression in malignant tumours of the canine mammary gland: a prospective survival study.
VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).
VEGFR-2 kinase domain inhibition as a scaffold for anti-angiogenesis: Validation of the anti-angiogenic effects of carotenoids from Spondias mombin in DMBA model of breast carcinoma in Wistar rats.
VEGFR-3, VEGF-C and VEGF-D mRNA quantification by RT-PCR in different human cell types.
VEGFR-Mediated Cytotoxic Activity of Pulicaria undulata Isolated Metabolites: A Biological Evaluation and In Silico Study.
VEGFR1 and VEGFR2 immunohistochemical expression in oral squamous cell carcinoma: a morphometric study.
VEGFR1 promotes cell migration and proliferation through PLC? and PI3K pathways.
VEGFR1-activity-independent metastasis formation.
VEGFR2 inhibition hampers breast cancer cell proliferation via enhanced mitochondrial biogenesis.
VEGFR2 Signaling Prevents Colorectal Cancer Cell Senescence to Promote Tumorigenesis in Mice With Colitis.
VEGFR3 and CD31 as Prognostic Factors in Renal Cell Cancer.
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor.
Vernolide-A inhibits radiation-induced hypoxia-mediated tumor angiogenesis by regulating HIF-1?, MMP-2, MMP-9, and VEGF.
Versican/PG-M G3 domain promotes tumor growth and angiogenesis.
Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis.
Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma.
VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma.
Viburnum opulus L.: A remedy for the treatment of endometriosis demonstrated by rat model of surgically-induced endometriosis.
Videocapillaroscopic findings in the microcirculation of the psoriatic plaque during etanercept therapy.
Vinculin associates with endothelial VE-cadherin junctions to control force-dependent remodeling.
Vinorelbine is effective for the malignant pleural effusion associated with lung cancer in mice.
Virus Mimetic Shell-Sheddable Chitosan Micelles for siVEGF Delivery and FRET-Traceable Acid-Triggered Release.
Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody.
Vitamin D and the insulin-like growth factor system: Implications for colorectal neoplasia.
Vitamin D Inflammatory Cytokines and Coronary Events: A Comprehensive Review.
Vitamin D restores angiogenic balance and decreases tumor necrosis factor-? in a rat model of pre-eclampsia.
Vitamin D Status is Linked to Biomarkers of Oxidative Stress, Inflammation, and Endothelial Activation in Obese Children.
Vitamin D3 repressed astrocyte activation following lipopolysaccharide stimulation in vitro and in neonatal rats.
Vitex negundo and its medicinal value.
Vitexin, an inhibitor of hypoxia-inducible factor-1?, enhances the radiotherapy sensitization of hyperbaric oxygen on glioma.
Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment.
Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis.
von Hippel-Lindau disease.
Von Hippel-Lindau disease.
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
Weight Reducing and Metabolic Effects of Topiramate in Patients with Migraine - an Observational Study.
Wharton's Jelly-Derived Mesenchymal Stromal Cells and Fibroblast-Derived Extracellular Matrix Synergistically Activate Apoptosis in a p21-Dependent Mechanism in WHCO1 and MDA MB 231 Cancer Cells In Vitro.
What is the response profile of deciduous pulp fibroblasts stimulated with E. coli LPS and E. faecalis LTA?
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.
Where It's at Really Matters: In Situ In Vivo Vascular Endothelial Growth Factor Spatially Correlates with Electron Paramagnetic Resonance pO(2) Images in Tumors of Living Mice.
Where to now with the VEGF signalling pathway in cancer?
Whole-Body Vibration Training Increases Stem/Progenitor Cell Circulation Levels and May Attenuate Inflammation.
Why some tumours trigger neovascularisation and others don't: the story thus far.
Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor.
Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Wild-type VHL Clear Cell Renal Cell Carcinomas Are a Distinct Clinical and Histologic Entity: A 10-Year Follow-up.
Wilms' tumor gene (WT1) expression correlates with vascular epithelial growth factor (VEGF) in newly acute leukemia patients undergoing chemotherapy.
Window of opportunity: A new insight into sequential bevacizumab and paclitaxel in two cases of metastatic triple-negative breast cancer.
Withania somnifera Suppresses Tumor Growth of Intracranial Allograft of Glioma Cells.
Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis.
Wnt5a attenuates the pathogenic effects of the Wnt/?-catenin pathway in human retinal pigment epithelial cells via down-regulating ?-catenin and Snail.
Wogonin inhibits tumor angiogenesis via degradation of HIF-1? protein.
Wogonin Inhibits Tumor-derived Regulatory Molecules by Suppressing STAT3 Signaling to Promote Tumor Immunity.
Worsening of renal function and uncontrolled hypertension from intravitreal bevacizumab injections.
Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors.
WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia.
Xanthan/chitosan gold chip for metal enhanced protein biomarker detection.
Xanthones from Securidaca inappendiculata Exert Significant Therapeutic Efficacy on Adjuvant-Induced Arthritis in Mice.
Xanthorrhizol Suppresses Vascular Endothelial Growth Factor-Induced Angiogenesis by Modulating Akt/eNOS Signaling and the NF-[Formula: see text]B-Dependent Expression of Cell Adhesion Molecules.
Xenoestrogens modulate vascular endothelial growth factor secretion in breast cancer cells through an estrogen receptor-dependent mechanism.
Xenografts of human solid tumors frequently express cellular-associated isoform of vascular endothelial growth factor (VEGF) 189.
YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors.
YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established Tumors.
YT521 promotes metastases of endometrial cancer by differential splicing of vascular endothelial growth factor A.
Yucca schidigera extract modulates the lead-induced oxidative damage, nephropathy and altered inflammatory response and glucose homeostasis in Japanese quails.
ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.
ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.
ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells.
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.
ZD6474--clinical experience to date.
ZEB-1, a Repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells.
Zebrafish G protein gamma2 is required for VEGF signaling during angiogenesis.
Zebrafish scube1 and scube2 cooperate in promoting Vegfa signaling during embryonic vascularization.
ZKSCAN3 Facilitates Liver Metastasis of Colorectal Cancer Associated with CEA-expressing Tumor.
ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity.
ZNF750 inhibited the malignant progression of oral squamous cell carcinoma by regulating tumor vascular microenvironment.
ZnPPIX inhibits peritoneal metastasis of gastric cancer via its antiangiogenic activity.
Zoledronic acid prevents the hepatic changes associated with high fat diet in rats; the potential role of mevalonic acid pathway in nonalcoholic steatohepatitis.
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
[A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine]
[A case of skull metastasis from hepatocellular carcinoma at the site of skull fracture]
[A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab].
[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine]
[A colorimetric method for vascular endothelial growth factor detection based on aptamer and magnetic beads].
[A quantitative pathological study on angiogenesis, vascular endothelial growth factor and inducible nitric oxide synthase in astrocytomas]
[Accumulative regularity of tumor-associated noncellular components in supernatant of stored packed red cells].
[Adipose tissue as an endocrine organ]
[Adjuvant phlebotrophic therapy and its effect on anti-inflammatory response after sclerotherapy].
[Advances in molecular mechanisms of tenascin-C in promoting tumor metastasis].
[Advances in the study of the role of vascular endothelial growth factor and its receptor in tumor angiogenesis and its relation with anti-angiogenesis effect]
[Advances of research on vascular endothelial growth factor receptors in epidermal neoplasm]
[An experimental study of energy controllable steep pulse in the treatment of rat with subcutaneous transplantive tumor]
[An oral DNA vaccine against VEGFR2 inhibits angiogenesis of Lewis lung carcinoma in C57BL/6 mice.]
[Analysis of differential gene expressions of inflammatory and repair-related factors in chronic refractory wounds in clinic].
[Analysis of the relationship between the changes of lung function and serum proinflammatory cytokines in workers occupationally exposed to toluene diisocyanate].
[Angiogenesis and antiangiogenic cancer therapy]
[Angiogenesis and blood supply during the course of pulmonary carcinogenesis in experimental rat.]
[Angiogenesis and breast cancer]
[Angiogenesis and Metastasis of carcinoma.]
[Angiogenesis in the chronic inflammatory diseases and malignancies]
[Anti-angiogenesis strategies in cancer]
[Anti-angiogenic treatment and colorectal cancer]
[Anti-vascular endothelial growth factor (VEGF) therapy: a new cause of secondary hypertension]
[Anti-VEGF therapy for peritoneal dissemination model of gastric cancer considering of pharmacokinetics]
[Anti-VEGF therapy with bevacizumab in breast cancer]
[Antiangiogenic and anti-immunosuppressive therapeutic strategies in human head and neck squamous cell carcinoma (HNSCC)]
[Antiangiogenic effect of continuous low-dose chemotherapy on Lewis lung carcinoma.]
[Application of bevacizumab on metastatic breast cancer].
[Are there alternative forms of therapy in breast carcinoma? Status and perspectives for the treatment of metastasized breast carcinoma]
[Association of vascular endothelial growth factor expression with angiogenesis and tumor cell proliferation in human lung cancer]
[Bevacizumab and arterial hypertension or proteinuria: management]
[Biological profiles of malignant gliomas]
[Blocking enhancive effect of vascular endothelial growth factor on proliferation of rhabdomyosarcoma cell line RH4 by avastin]
[Blood cytokine levels as a clinical laboratory test]
[Chronic inflammation in patients with acute coronary syndrome and chronic kidney disease].
[Clinical and prognostic significance of serum MMP-9, endostatin and VEGF in patients with advanced non-small cell lung cancer.]
[Clinical efficacy and influencing factors of different modes of continuous negative pressure wound therapy on venous ulcer wounds of lower limbs].
[Clinical research on angiogenesis in colorectal carcinoma and expression of CK20 mRNA in peripheral blood]
[Clinical significance of serum vascular endothelial growth factor and interleukin-6 in multiple myeloma]
[Clinical significance of survivin expression in colorectal cancer and its relationship with cell apoptosis and angiogenesis.]
[Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors]
[Clinical value of vascular endothelial growth factor detection in forecasting distant metastasis risk of nasopharyngeal carcinoma]
[Clinicopathologic features and expression of epidermal growth factor receptor and vascular endothelial growth factor in adrenocortical tumors].
[Cloning and sequencing of human vascular endothelial growth factor-C encoded cDNA]
[Coexpression of vascular endothelial growth factor and its receptors in human tumor cell lines]
[Colorectal cancer: current treatment options]
[Construction of a DNA vaccine against extracellular domain 1-3 of Flk1 and its inhibitory effect on growth of liver cancer cell line H22.]
[Construction of recombinant adenoviruses encoding TK suicide gene driven by VEGF promoter using efficient AdEasier-1 system]
[Construction, expression and bioactivity characterization of targeting toxin DT-VEGF]
[Correlation between expressions of matrix metalloproteinase-2 & 9 and vasculogenic mimicry in gastrointestinal stromal tumors]
[Correlation of expression of vascular endothelial growth factor and matrix matalloproteinase-2 to invasion of ovarian tumor cells in vitro]
[Correlation of tumor angiogenesis with clinicopathologic prognostic parameters in choroidal melanoma]
[Coxibs for postoperative analgesia].
[CT and MRI imaging in tumoral angiogenesis.]
[Current progression of bevacizumab in advanced non-small cell lung cancer].
[Current strategies in the treatment of renal-cell cancer: targeted therapies]
[Dectection of G3BP and CD44v6 in the tissues of laryngeal squamous cell carcinoma and their clinical significance].
[Deiscenza di anastomosi colorettale dopo terapia neoadiuvante con bevacizumab. Case report.]
[Demonstration of the angiogenic cytokine vascular endothelial growth factor (VEGF) by non radioactive in situ hybridization]
[Design of Synthetic Polymer Nanoparticles That Capture and Neutralize Target Molecules].
[Detection and clinical significance of plasma vascular endothelial growth factor level in gastrointestinal stromal tumor patients]
[Diagnosis and treatment of tumor metastases]
[Diagnostic value of the determination of angiogenic factors and cytokine composition parameters in the serum and urine of patients with scleroderma systematica].
[Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy?]
[Drug-induced uveitis].
[Dynamic study on effect of Chinese medicine compound Yiliuyin on angiogenesis in transplanted S180 tumor of mouse]
[Effect of acellular process on small intestinal submucosa cell residue and growth factor content]
[Effect of different estrogen receptor subtypes on vascular endothelial growth factor protein expression in human breast cancer samples]
[Effect of ionization on the expression of hypoxia-inducible factor-1alpha and VEGF in hepatocellular carcinoma HepG2 cells under anoxic condition]
[Effect of irradiation on matrix metalloproteinases, vascular endothelial growth factor and microvessel density of mice bearing Lewis lung cancer]
[Effect of mild hypothermia on behaviors of rats with intracerebral hemorrhage and the possible mechanism].
[Effect of progesterone on the pathogenesis and development of hemangioma in nude mice].
[Effect of Runing II on expression of vascular endothelial growth factor in transplanted tumor of mammary cancer MA-891 in TA2 mice]
[Effect of the levels of vascular endothelial growth factor-A and C on the prognosis of patients with larynx carcinoma].
[Effect of vascular endothelial growth factor and tumor necrosis factor receptor for treatment of avascular necrosis of the femoral head in rabbits]
[Effect of yifei qinghua granule on VEGF, bFGF, angiostatin, and endostatin in lewis lung cancer mice: an experimental study].
[Effects of 1alpha, 25-dihydroxyvitamin D3 on the acute immune rejection and corneal neovascularization in high-risk penetrating keratoplasty in rats]
[Effects of Baihe Recipe on expressions of vascular endothelial growth factor and p53 proteins in tumor tissues of nude mice bearing orthotopically transplanted gastric carcinoma BGC-823.]
[Effects of dioscornin tablet containing serum on NF-kappaB p65, STAT3, and VEGF mRNA expressions in rats' synovial cell strain RSC-364 induced by IL-17 and TNF-alpha].
[Effects of interleukin-12 transfection on proliferation of ovarian cancer SKOV3 cells in vitro and in vivo]
[Effects of moxibustion on serum cytokines in experimental animals with rheumatoid arthritis: a systematic review and meta-analysis].
[Effects of parthenolide on estradiol-synthesizing enzyme, ER isoforms and VEGF in human endometriotic stromal cells].
[Effects of sophoridine on the growth and expressions of p53 and vascular endothelial growth factor of transplanted solid tumor SW480 in nude mice]
[Effects of suramin in combination with Cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice.]
[EFFECTS OF Tempol ON SURVIVAL OF RANDOM PATTERN SKIN FLAPS IN RATS].
[Effects of transcatheter arterial chemoembolization with pingyangmycin-lipiodol emulsion on VX2 liver tumors in rabbits].
[Effects of treatment based on different target mean arterial pressure on gastrointestinal function in septic shock patients with hypertension].
[Effects of triptolide and TNF-alpha on the expression of VEGF in Raji cells and on angiogenesis in ECV304 cells]
[Effects of vascular endothelial growth factor D on the signaling cascade of sentinel lymphatic endothelial cells from melanoma patients undergoing sentinel lymphadenectomy]
[Electrochemotherapy for tumor and mechanism analysis]
[Endostatin in different administration routes combined with adriamycin chemotherapy in the treatment of liver cancer xenograft in mice.]
[Epigallocatechin-3-gallate inhibits growth and angiogenesis of gastric cancer and its molecular mechanism]
[Evaluation of angiogenesis in the tumorigenesis and progression of breast cancer]
[Evolution of angiogenesis following anthracycline-based neoadjuvant chemotherapy in breast cancer]
[Experimental study of anti-vascular endothelial growth factor hairpin ribozyme gene inhibiting growth of xenografted tumor of ovarian cancer cells]
[Experimental study of anti-VEGF hairpin ribozyme gene inhibiting expression of VEGF and proliferation of ovarian cancer cells]
[Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model]
[Experimental study on anti-angiogenesis in mice with Lewis lung carcinoma by low-dose of cyclophosphamide combined with ginsenoside Rg3]
[Exploratory study on influence of biopsy to biological behavior of Tca8113 transplanted tumor].
[Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma]
[Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma]
[Expression and Clinical Significance of VEGF and Its Receptors Flt-1 and KDR in Nasopharyngeal Carcinoma.]
[Expression and clinical significance of VEGF and MMP-9 in hepatocellular carcinoma]
[Expression and significance of Bmi-1 in breast cancer]
[Expression and significance of Elf-1 and vascular endothelial growth factor in non-small cell lung cancer.]
[Expression and significance of inducible nitric oxide synthase and vascular endothelial growth factor in carcinogenesis of hamster cheek pouch]
[Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma]
[Expression and subtype analysis of vascular endothelial growth factor (VEGF) and its receptor (flt-1) in human ovarian tumors]
[Expression of carbonic anhydrase IX in NSCLC and its relationship with VEGF and Ki67 expression]
[Expression of CD133 and Notch1 in non-small cell lung cancer and the clinicopathological significance].
[Expression of cyclin D1 and vascular endothelial growth factor(VEGF) in non-small cell lung carcinoma and their association with the prognosis]
[Expression of extracellular domain of VEGF receptor KDR with recombinant AAV]
[Expression of hepatocyte growth factor, transcription factor SP1, vascular endothelial growth factor and CD34 in serosa-infiltrative gastric cancer and their relations with defluxion of gastric cancercell and prognosis]
[Expression of inductive nitric oxide synthase and vascular endothelial growth factor in colonic carcinoma, and their effects on tumor angiogenesis]
[Expression of p53 and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinical significance]
[Expression of PTEN, Cx43, and VEGF in hepatocellular carcinoma]
[Expression of tissue factor and vascular endothelial growth factor in colorectal carcinoma]
[Expression of transforming growth factor alpha, tumor necrosis factor alpha, and vascular endothelial growth factor of human pheochromocytoma tissues]
[Expression of vascular endothelial growth factor (VEGF) and its receptors KDR, Flt1 in lung cancer and their relationship to prognosis.]
[Expression of vascular endothelial growth factor (VEGF) family members and prognosis after hepatic resection in HBV-related hepatocellular carcinoma]
[Expression of vascular endothelial growth factor and its receptors in endometrial carcinoma]
[Expression of vascular endothelial growth factor and metastin in colorectal carcinoma.]
[Expression of vascular endothelial growth factor and microvessel density in ovarian tumor]
[Expression of vascular endothelial growth factor and tumor angiogenesis correlates with biological behaviors of nasopharyngeal carcinoma]
[Expression of vascular endothelial growth factor in primary esophageal squamous cell carcinoma and its significance in angiogenesis and prognosis of the tumor]
[Expression of Vascular Endothelial Growth Factor in the Bone Marrow Cells from Adult Chronic Myelogenous Leukemia]
[Expression of VEGF, KDR, p53, E6 HPV16 and HPV18 in vulvar and cervix cancer]
[Expression of VEGF-C and VEGF-D in gastric carcinoma and its relationship with lymph node metastases.]
[Expression rates of three angiogenic factors in hepatocellular carcinoma and their relation with microvessel density and portal vein tumor thrombosis]
[Expressions of cyclooxygenase-2 and vascular endothelial growth factor in human lung cancer tissue.]
[Expressions of human epidermal growth factor receptor 2 and vascular endothelial growth factor in primary or recurrent metastatic breast cancers]
[Expressions of inducible nitric oxide synthase and vascular endothelial growth factor and their relationship with microvessel density in hepatocellular carcinoma.]
[Expressions of receptor-binding cancer antigen expressed on SiSo cells, vascular endothelial growth factor, and matrix metalloproteinase-9 in cervical carcinoma and correlation thereof with the invasion and metastasis of the cancerous tissues]
[Expressions of VEGF-C and VEGF-D and their correlation with lymphangiogenesis and angiogenesis in gallbladder carcinoma]
[Functions and the regulation of cytokines and growth factors in the thrombotic event of arteries and veins]
[Gamma-hydroxybutyric acid, a metabolite of UFT, shows anti-angiogenic activities and antitumor effect]
[Gene expression of vascular endothelial growth factors and their receptors in different variants of the course of multiple myeloma].
[HIF-1alpha expression and relationship involving tumor cell proliferation and angiogenesis in human breast carcinoma]
[Hormones, autocrine and paracrine regulators of tumor growth in osteosarcoma]
[Hypoxia augments the killing effect of herpes simplex virus thymidine kinase gene expression actuated by the promoter of the vascular endothelial growth factor gene on human hepatocellular tumor cells]
[Immunohistochemical analysis of expression of angiogenic factors and tumor angiogenesis in superficial bladder cancer]
[Implication of vascular endothelial growth factor (VEGF) in human head and neck cancer]
[Influence of antisense VEGF oligodeoxynucleotides formulated in cationic liposome on microvessel density and VEGF expression of lung cancer.]
[Inhibitive effect of polypeptide extract from scorpion venom on repopulation in H22 tumor cell during chemotherapy]
[Inhibitive effects of mifepristone on growth of breast cancer: experiment with rats]
[Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer]
[Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer]
[Inhibitory effect of low molecular weight heparin on the secretion of vascular endothelial growth factor by tumor cells in vitro]
[Inhibitory effects of Sanleng pellet on angiogenesis of endometriosis in rats]
[Inhibitory effects of TNP-470 in combination with 5-fluorouracil on growth of human colon cancer]
[Interleukin-12, vascular endothelial growth factor and tumor necrosis factor-alpha in the process of neoangiogenesis of diabetic retinopathy in children]
[Intervention effect of feiji recipe on immune escape of lung cancer]
[Justifying genetic and immune markers of efficiency and sensitivity under combined exposure to risk factors in mining industry workers].
[Lung cancer]
[Lymphangiogenes and location of tumor lymphatic vessels induced by VEGF-C in primary breast carcer]
[Mechanism of Danggui Sini Decoction in treatment of primary dysmenorrhea based on network pharmacology and molecular docking].
[Mechanisms and role of lymphangiogenesis in cancer metastasis]
[Mesh structure of two-dimensional tumor microvascular architecture phenotype heterogeneity in non-small cell lung cancer]
[Molecular basis of targeted therapy in metastatic renal cancer.]
[Molecular markers of carcinogenesis in the diagnostics of cervical cancer]
[Molecular mechanism of liver metastasis from colorectal cancer]
[Monoclonal antibody preparation and identification of vascular endothelial growth factor 165 expressed in vitro].
[mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR]
[Neuroprotective mechanisms of vascular endothelial growth factor]
[Notch1 expression in esophageal squamous cell carcinoma and its relation with microvascular angiogenesis]
[Novelties of treatment in advanced renal-cell cancer.]
[Optimal therapeutic strategies in ovarian epithelial cancer in 1997]
[Osteosarcoma: biochemical and endocrinological studies as a basis for its pathogenetic treatments]
[Pathologic response and changes of serum VEGF during chemoradiotherapy may predict prognosis in non-surgical patients with esophageal carcinoma].
[Perspectives of the stomach cancer treatment: the introduction of molecular targeted therapy and the hope for cure].
[Preacondicionamiento isquémico remoto sobre viabilidad del injerto hepático].
[Predictive Biomarkers for Bevacizumab in Anti-tumor Therapy].
[Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients]
[Prognostic significance of angiogenesis and blood vessel invasion in stage I non-small cell lung cancer after complete surgical resection.]
[Prognostic value of the expression of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha in patients undergoing surgery for non-small cell lung cancer.]
[Prospects for molecular research in urological oncology: bladder cancer]
[Quantitative analysis of gene expression for vascular endothelial growth factor and its application]
[Radiotherapy, chemotherapy and target therapy for treatment of head and neck cancer : new developments]
[Related biomarkers in the diagnosis of prostate cancer].
[Relation between the expression of hypoxia inducible factor-1alpha and angiogenesis in ovarian cancer using tissue microarray]
[Relationship between clinicopathologic characteristics and expression of VEGF-C and VEGF-D in esophageal squamous cancer]
[Relationship between early enhanced helical CT and tumor angiogenesis in bladder cancer]
[Relationship between plasma vascular endothelial growth factor and tumor necrosis factor-alpha and obstructive sleep apnea hypopnea syndrome in children].
[Relationship between the expression of vascular endothelial growth factor, fms-like tyrosine kinase-1 and biological behavior in gastric carcinoma]
[Relationship of hypoxia-induced factor with tumor angiogenesis in early liver metastasis in colonic cancer]
[Relationships of Serum Selenium, VEGF and sFas Levels in Leukemia Patients.]
[Renal cell carcinoma and antiangiogenic therapies]
[Renovascular effects of antiangiogenic drugs].
[Research on effects of bone marrow mononuclear cells implantation on model of experimental pulmonary artery hypertension].
[Review of relationship between vascular endothelial growth factor C & D and lymph node metastasis of malignant tumor]
[Role of vascular endothelial growth factor overexpression in ovarian tumor invasion and mechanism]
[Roles of vascular endothelial growth factor and platelet-derived growth factor in lymphangiogenesis in epithelial ovarian carcinoma.]
[Serum hyaluronic acid, tumor necrosis factor -alpha, vascular endothelial growth factor, NO, and Se levels in adult patients with Kashin-Beck disease]
[Serum levels of VEGF and nitric oxide in esophageal squamous carcinoma patients and the clinical significance]
[Serum tumor necrosis factor alpha (TNF-alpha) concentration correlates with soluble adhesion molecules and vascular endothelial growth factor (VEGF) in rheumatoid arthritis]
[Serum vascular endothelial growth factor levels in patients with colorectal cancer and its prognostic significance]
[Significance of angiogenesis and clinical application of anti-angiogenesis]
[Specific anti-glioma angiogenesis immune response induced by attenuated Salmonella typhimurium vaccine expressing vascular endothelial growth factor receptor-2]
[Study about the clinical and pathological characteristics of salivary duct carcinoma]
[Study of angiogenesis in human colorectal carcinoma and its modulation by p53 and K-ras gene]
[Study of thalidomide on the growth and angiogenesis of ovary cancer SKOV3 transplanted subcutaneously in nude mice]
[Study on relationship between VEGF-C and lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.]
[Study on serum vascular endothelial growth factor level in ovarian malignant tumors]
[Study on the expression and their relationship among P27, Bcl-2 and VEGF in lung cancer.]
[Study on the relationship between angiogenesis and cervical lymphatic metastasis in head and neck squamous cell carcinomas]
[Study on the tumor microenvironment and tumor vascular normalization in integrative treatment of tumor by Chinese medicine and western medicine].
[Synergism between Ang-2 and VEGF and its application of anti-angiogenesis in tumor therapy - review]
[Tc(CO)3]-Radiolabeled Bevacizumab: In vitro and in vivo Evaluation in a Melanoma Model.
[Tetraspanins: A new target for antiangiogenic therapy?]
[The assessment of the correlation between vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF-alpha), interleukin 6 (IL-6), glycaemic control (HbA1c) and the development of the diabetic retinopathy in children with diabetes mellitus type 1]
[The clinical value of vascular endothelial growth factor in patients with small cell lung cancer.]
[The correlation of vascular endothelial growth factor with angiogenesis and p53 gene in laryngeal squamous cell carcinoma]
[The effect of all-trans retinoid acid and sodium selenite (Na2SeO3) on VEGF and its receptor expression in HL-60 cells]
[The effect of antibody against vascular endothelial growth factor (VEGF) on tumor metastasis]
[The effect of antibody against vascular endothelial growth factor on tumor growth]
[The effect of TNP-470 on the proliferation and apoptosis of lung adenocarcinoma cells]
[The effect of VEGF antisense oligonucleotides combined with low molecular weight heparin on the growth and metastasis of mice Lewis lung cancer]
[The effects of ?-elemene on rabbit VX2 laryngeal carcinoma and factors associated with tumor growth and metastasis].
[The effects of vascular endothelial growth factor on dendritic cells in esophageal tumor tissue]
[The evaluation to relationship between serum vascular endothelial growth factor (VEGF) level, metastases and other tumor markers in patients with lung cancer.]
[The expressions and functions of inflammatory cytokines, growth factors and apoptosis factors in the late stage of pressure ulcer chronic wounds].
[The expressions of CTLA-4 and PD-1 on CD(4)(+) T cells and the level of plasma VEGF in patients with obstructive sleep apnea hypopnea syndrome].
[The importance of tumor angiogenesis as a prognostic indicator in primary breast cancer]
[The relationship between lymphatic metastasis and serum vascular endothelial growth factor C and cyclooxygenase 2 expression in breast cancer]
[The role of cyclooxygenase-2 and vascular endothelial growth factor-C in lymphatic metastasis of gastric cancer]
[The role of transforming growth factor-beta in the pathogenesis of diabetic retinopathy]
[The role of tumor markers in prognosing transitional bladder cancer.]
[The use of bevacizumab in refractory peritoneal dissemination of gastric cancer with malignant ascites-two case reports].
[The Vascular Endothelial Growth Factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?]
[Therapeutic regimens using monoclonal antibodies in gastroenterology].
[Therapeutic strategies using VEGF inhibitors in colorectal cancer.]
[Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway]
[Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)]
[Tumor angiogenesis in node-negative breast carcinoma]
[Tumor angiogensis in uveal melanoma. Role of vascular endothelial growth factor (VEGF)]
[Tumor inhibitory factors in urologic malignancies]
[Tumor progression and angiogenesis]
[Tumor targeting gene transfer mediated by electroporation for growth suppression of retinoblastoma in vivo]
[Tumor-infiltrating dendritic cells in epithelial ovarian carcinoma and correlation with the expression of vascular endothelial growth factor]
[Two perspectives on venous thromboembolism in oncology].
[Tyrosine kinases in soft tissue tumors].
[Upregulation of vascular endothelial growth factor by peroxide in human colon cancer]
[Value of ultrasound-targeted vascular endothelial growth factor receptor-2 in non-invasive monitoring of anti-angiogenic response in nude mice with subcutaneous xenograft model].
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
[Vascular endothelial growth factor and the effects of endostatin on the inhibition of tumor angiogenesis in treating hepatocarcinomas]
[Vascular endothelial growth factor D promoting the growth of lymphatic vessel in gastric carcinoma]
[Vascular endothelial growth factor expression and microvessel density in stage I-II non-small cell lung cancer and their prognostic significances]
[Vascular endothelial growth factor expression in cerebral neoplasms]
[Vascular endothelial growth factor gene expression in nasopharyngeal carcinoma cell line induced by hypoxia in vitro]
[Vascular endothelial growth factor promotes hematogenous metastasis of cancer cells in patients with non-small cell lung cancer]
[Vascular endothelial growth factor].
[Vasoactive intestinal peptide enhances the expression of vascular endothelial growth factor mRNA in non-small cell lung cancer cells.]
[VEGF-C and lymphatic vessels: a double-edged sword in tumor development and metastasis].
[VEGF-C, VEGF-D and VEGF-receptor 3: novel key regulators of lymphangiogenesis and cancer metastasis]
[Von Willebrand factor as an intermediate between hemostasis and angiogenesis of tumor origin]
{beta}2-Microglobulin Is a Signaling and Growth-Promoting Factor for Human Prostate Cancer Bone Metastasis.
¹?F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.
Neoplasms, Germ Cell and Embryonal
Efficient carboplatin single therapy in a mouse model of human testicular nonseminomatous germ cell tumor.
Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease.
Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor.
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFR?/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.
Recent advances in management of patients with platinum-refractory testicular germ cell tumors.
Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors.
Neoplasms, Glandular and Epithelial
Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms.
Neoplasms, Neuroepithelial
First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity.
Neoplasms, Plasma Cell
Case Report: Challenges in the Diagnosis of Adenopathy and Extensive Skin Patch Overlying a Plasmacytoma Syndrome.
Neoplasms, Squamous Cell
Expression of breast cancer anti-estrogen resistance 1 in relation to vascular endothelial growth factor, p53, and prognosis in esophageal squamous cell cancer.
Expression of epidermal growth factor receptor and vascular endothelial growth factor in vaginal squamous cell cancer.
Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma.
Hypoxia-inducible factor 1? in combination with vascular endothelial growth factor could predict the prognosis of postoperative patients with oesophageal squamous cell cancer.
Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx.
Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck.
Serum vascular endothelial growth factor receptor-3 levels in patients with esophageal squamous cell cancer.
The expression of CXCR4 and its relationship with matrix metalloproteinase-9/vascular endothelial growth factor in esophageal squamous cell cancer.
The relationship between GLUT-1 and vascular endothelial growth factor expression and 18F-FDG uptake in esophageal squamous cell cancer patients.
Vascular endothelial growth factor expression predicts outcome after primary radiotherapy for head and neck squamous cell cancer.
VEGF-C and VEGF-D expression and its correlation with lymph node metastasis in esophageal squamous cell cancer tissue.
Neoplastic Cells, Circulating
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.
Current biomarkers of canine mammary tumors.
Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study.
Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.
Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.
The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
Neoplastic Processes
The role of macrophages in angiogenesis. Comparison between HIV+ and HIV- populations with anal dysplasia and anal cancer.
[Vascular endothelial growth factor (VEGF) and its role in neoplastic processes]
Nephritis
A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis.
Activated mesangial cells induce glomerular endothelial cells proliferation in rat anti-Thy-1 nephritis through VEGFA/VEGFR2 and Angpt2/Tie2 pathway.
Gene polymorphism of vascular endothelial growth factor in children with Henoch-Schonlein purpura nephritis.
Infusion of angiotensin II reduces loss of glomerular capillary area in the early phase of anti-Thy-1.1 nephritis possibly via regulating angiogenesis-associated factors.
The role of PDGF-D in mesangioproliferative glomerulonephritis.
[Expression of vascular endothelial growth factor is related to microvessel injury of renal interstitium in children with Henoch Sch nlein purpura nephritis.]
[Serum and urine VEGF concentration of different pathological types in children with Henoch Schonlein purpura nephritis]
[Triptolide inhibits vascular endothelial growth factor expression and production by endothelial cells]
Nephrosclerosis
Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis.
High-glucose-Induced O-GlcNAcylated Carbohydrate Response Element-binding Protein (ChREBP) Mediates Mesangial Cell Lipogenesis and Fibrosis : The Possible Role of the Development of Diabetic Nephropathy.
[Molecular factors of angiogenesis in renal tissue of patients with chronic glomerulonephritis: association with nephrosclerosis and anemia]
Nephrosis
Biomarkers of endothelial injury in focal segmental glomerulosclerotic nephrosis.
Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis.
Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis.
Nephrosis, Lipoid
Pseudothrombus deposition accompanied with minimal change nephrotic syndrome and chronic kidney disease in a patient with Waldenström's macroglobulinemia: A case report.
Rectal cancer with paraneoplastic nephropathy: association of vascular endothelial growth factor.
Nephrotic Syndrome
Anti-vasopermeability effects of PEDF in retinal-renal disorders.
Circulating vascular endothelial growth factor is not increased during relapses of steroid-sensitive nephrotic syndrome.
Circulating VEGF and TGF-beta1 in children with idiopathic nephrotic syndrome.
Elevated vascular endothelial growth factor levels in the urine of patients with minimal-change nephrotic syndrome.
Glucocorticoid receptor and vascular endothelial growth factor in nephrotic syndrome.
Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Nephrotic syndrome under treatment with dasatinib: be aware of a possible adverse drug reaction.
Nephrotic Syndrome with Focal Segmental Glomerulosclerosis Induced by Intravitreal Injections of Vascular Endothelial Growth Factor Inhibitor.
Pseudothrombus deposition accompanied with minimal change nephrotic syndrome and chronic kidney disease in a patient with Waldenström's macroglobulinemia: A case report.
Rectal cancer with paraneoplastic nephropathy: association of vascular endothelial growth factor.
Relapse of minimal change nephrotic syndrome after intravitreal bevacizumab.
Serum hemolytic factor D values in children with steroid-responsive idiopathic nephrotic syndrome.
Steroid-sensitive nephrotic syndrome and vascular endothelial growth factor gene polymorphisms.
Vascular Endothelial Growth Factor (VEGF) and Neopterin Levels in Children with Steroid-sensitive and Steroid-resistant Nephrotic Syndrome.
Vascular endothelial growth factor (VEGF-C1)-dependent inflammatory response of podocytes in nephrotic syndrome glomerulopathies in children: an immunohistochemical approach.
Vascular endothelial growth factor in children with nephrotic syndrome treated with cyclosporine A.
Nerve Sheath Neoplasms
Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
Nervous System Diseases
Enhanced neuroprotective efficacy of bone marrow mesenchymal stem cells co-overexpressing BDNF and VEGF in a rat model of cardiac arrest-induced global cerebral ischemia.
Immunohistochemical localization of vascular endothelial growth factor receptors-1, -2 and -3 in human spinal cord: altered expression in amyotrophic lateral sclerosis.
Nervous System Neoplasms
Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function.
Neuralgia
Diabetes-induced microvascular complications at the level of the spinal cord: a contributing factor in diabetic neuropathic pain.
Low-level laser therapy alleviates neuropathic pain and promotes function recovery in rats with chronic constriction injury-possible involvements in hypoxia-inducible factor 1? (HIF-1?).
Relationship of Bladder Pain With Clinical and Urinary Markers of Neuroinflammation in Women With Urinary Urgency Without Urinary Incontinence.
Vascular endothelial growth factor signaling in injured nerves underlies peripheral sensitization in neuropathic pain.
[Stimulating Frequency-dependent Analgesic Effect of Electroacupuncture via Down-regulating Expression of VEGF in Dorsal Horns of Lumbar Spinal Cord in Post Herpetic Neuralgia Rats].
[Vascular endothelial growth factor antibody attenuates diabetic peripheral neuropathic pain in rats].
Neurilemmoma
Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.
Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas.
Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas.
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Hypoxia-induced miR-210 promoter demethylation enhances proliferation, autophagy and angiogenesis of schwannoma cells.
Long-term therapy with Bevacizumab in a young patient affected by NF2. Stop or continue treatment? An update of a case report and review of the literature.
Neuroblastoma
A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
Angiogenesis in neuroblastoma.
Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US.
Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.
Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease.
Brain-Derived Neurotrophic Factor Activation of TrkB Induces Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Factor-1{alpha} in Neuroblastoma Cells.
Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.
Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
Enhancing the anti-angiogenic action of histone deacetylase inhibitors.
Evaluation of Ki-67 as prognostic factor for pediatric neuroblastoma and the possibility of molecular-targeted drugs with vascular endothelial growth factor and platelet-derived growth factor receptor.
Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma.
Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas.
Expression of vascular endothelial growth factor and its receptor Flk-1 in human neuroblastoma using in situ hybridization.
Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma.
High level of stabilized angiostatin mediated by adenovirus delivery does not impair the growth of human neuroblastoma xenografts.
Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma.
Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.
Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor-D.
Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.
Inhibition of thrombin-induced vascular endothelial growth factor production in human neuroblastoma (NB-1) cells by argatroban.
Isolation and characterization of canine placenta-derived mesenchymal stromal cells for the treatment of neurological disorders in dogs.
Longterm recombinant adeno-associated, virus-mediated, liver-generated expression of an angiogenesis inhibitor improves survival in mice with disseminated neuroblastoma.
Melatonin inhibits angiogenesis in SH-SY5Y human neuroblastoma cells by downregulation of VEGF.
MicroRNA miR-93-5p regulates expression of IL-8 and VEGF in neuroblastoma SK-N-AS cells.
MicroRNA-145 suppresses uveal melanoma angiogenesis and growth by targeting neuroblastoma RAS viral oncogene homolog and vascular endothelial growth factor.
microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells.
Modulation of extracellular signal-regulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell.
Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.
Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
Neuroblastoma-targeted nanoparticles and novel nanotechnology-based treatment methods.
Nucleoside 5'-phosphorothioate derivatives are highly effective neuroprotectants.
PAGOD syndrome and vascular anomalies: is a defect embryonic angiogenesis? A case report and review.
Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity.
Prospects for therapeutic inhibition of neuroblastoma angiogenesis.
Protein kinase C regulates bombesin-induced rapid VEGF secretion in neuroblastoma cells.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Relationship between tumor vascularity and vascular endothelial growth factor as prognostic factors for patients with neuroblastoma.
Reply to Langer et al. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas.
Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma.
SU5416 and EGCG Work Synergistically and Inhibit Angiogenic and Survival Factors and Induce Cell Cycle Arrest to Promote Apoptosis in Human Malignant Neuroblastoma SH-SY5Y and SK-N-BE2 Cells.
The angiogenic growth factors HGF and VEGF in serum and plasma from neuroblastoma patients.
The studies on the correlation for gene expression of tyrosine-kinase receptors and vascular endothelial growth factor in human neuroblastomas.
Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma.
Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma.
Vascular endothelial growth factor (VEGF)-C - a potent risk factor in children diagnosed with stadium 4 neuroblastoma.
Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma.
Vascular endothelial growth factor expression in human neuroblastoma: up-regulation by hypoxia.
Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
Vascular endothelial growth factor in children with neuroblastoma: a retrospective analysis.
VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells.
VEGF-C, VEGF-D and VEGFR-3 expression in peripheral neuroblastic tumours.
[Effects of TrkB-BDNF signal pathway on synthesis and secretion of vascular endothelial growth factor in human neuroblastoma cells.]
[Secretion and expression of vascular endothelial growth factor and interleukin-8 by SH-SY5Y human neuroblastoma cells].
Neurocytoma
Neurocytoma is a tumor of adult neuronal progenitor cells.
Neurodegenerative Diseases
Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease.
Clinical and fundamental aspects of angiogenesis and anti-angiogenesis.
Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients.
Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis.
Heritability for plasma VEGF concentration in the Stanislas family study.
Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways.
Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases.
Naringin: a protector of the nigrostriatal dopaminergic projection.
Neutralizing Endogenous VEGF Following Traumatic Spinal Cord Injury Modulates Microvascular Plasticity but not Tissue Sparing or Functional Recovery.
Role of VEGF gene variability in longevity: a lesson from the Italian population.
The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease.
Vascular endothelial growth factor and transforming growth factor-beta1 are highly expressed in the cerebrospinal fluid of premature infants with posthemorrhagic hydrocephalus.
Vascular endothelial growth factor gene variability is associated with increased risk for AD.
Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases.
VEGF genetic variability is associated with increased risk of developing Alzheimer's disease.
Neuroectodermal Tumors, Primitive
c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation.
Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice.
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
Neuroendocrine Tumors
A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
A phase II study of axitinib in advanced neuroendocrine tumors.
Activity of sunitinib in patients with advanced neuroendocrine tumors.
Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors.
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
Biologics in gastrointestinal and pancreatic neuroendocrine tumors.
Combined Mammalian Target of Rapamycin and Vascular Endothelial Growth Factor Pathway Inhibition in Pancreatic Neuroendocrine Tumors: More Than the Sum of Its Parts?
Current treatment options for neuroendocrine tumors.
Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors.
Expression of vascular endothelial growth factor and epidermal growth factor receptor in pancreatic ductal adenocarcinomas, neuroendocrine tumours and chronic pancreatitis.
Expression of vascular endothelial growth factor in digestive neuroendocrine tumours.
Gastrointestinal neuroendocrine tumors: a role for targeted therapies?
Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours.
Polypeptide growth factors in gastroenteropancreatic neuroendocrine tumours.
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin alphaV and integrin beta3 in human neuroendocrine tumors.
Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors
Stimulatory effect of growth hormone-releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitro.
Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential.
Sunitinib in pancreatic neuroendocrine tumors.
Systemic treatment of neuroendocrine tumors with hepatic metastases.
The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.
Neurofibroma
Analysis of vascularity of human neurofibromas.
Antiangiogenesis in neurofibromatosis 1.
Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.
NF1 gene silencing induces upregulation of vascular endothelial growth factor expression in both Schwann and non-Schwann cells.
Peripheral and cranial nerve sheath tumors.
Neurofibromatoses
Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas.
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.
Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
Why increased nuchal translucency is associated with congenital heart disease; a systematic review on genetic mechanisms.
Neurofibromatosis 1
Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
Why increased nuchal translucency is associated with congenital heart disease; a systematic review on genetic mechanisms.
Neurofibromatosis 2
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.
Neurofibrosarcoma
A patient with a large intrathoracic malignant schwannoma who showed a complete clinical response to rAd-p53-combined with radiotherapy.
Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.
Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas.
Relationship of angiogenic and apoptotic activities in soft-tissue sarcoma.
Neuroinflammatory Diseases
Association of Plasma Biomarkers for Angiogenesis and Proteinopathy in Indian Amyotrophic Lateral Sclerosis Patients.
Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection.
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Inhibition of blood-brain barrier efflux transporters promotes seizure in pregnant rats: Role of circulating factors.
Intercellular Adhesion Molecule-1-Induced Posttraumatic Brain Injury Neuropathology in the Prefrontal Cortex and Hippocampus Leads to Sensorimotor Function Deficits and Psychological Stress.
Multiple therapeutic effects of progranulin on experimental acute ischaemic stroke.
Role of PDGF-D and PDGFR-? in neuroinflammation in experimental ICH mice model.
The Mechanisms of Cerebral Vascular Dysfunction and Neuroinflammation by MMP-Mediated Degradation of VEGFR-2 in Alcohol Ingestion.
The Role of Mast Cells in Alzheimer's Disease.
VEGF-C Induces Alternative Activation of Microglia to Promote Recovery from Traumatic Brain Injury.
[Progranulin].
Neurologic Manifestations
Role of vascular endothelial growth factor (VEGF) in the neurological manifestations of dengue: a preliminary study.
Neuroma, Acoustic
Antiangiogenic agents for nonmalignant brain tumors.
Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
Expression of vascular endothelial growth factor and basic fibroblast growth factor in sporadic vestibular schwannomas correlates to growth characteristics.
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate.
Immunohistochemical investigation of hormone receptors and vascular endothelial growth factor concentration in vestibular schwannoma.
Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue.
Immunohistochemical Profiles of Matrix Metalloproteinases and Vascular Endothelial Growth Factor Overexpression in the Antoni B Area of Vestibular Schwannomas.
Peripheral and cranial nerve sheath tumors.
The Relationship Between Peritumoral Brain Edema and the Expression of Vascular Endothelial Growth Factor in Vestibular Schwannoma.
Therapeutics for Childhood Neurofibromatosis Type 1 and Type 2.
[Neurotrophic factor expression in vestibular schwannoma. An overview]
Neutropenia
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
Nevus
Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
Mitogen-actived protein kinase activation is an early event in melanoma progression.
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.
Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: Evaluation of potential chemopreventive activity.
Spitz Nevi Arising in Speckled Lentiginous Nevus: Clinical, Histologic, and Molecular Evaluation of Two Cases.
Nevus, Pigmented
Expression of vascular endothelial growth factor in melanocytic nevi.
Non-alcoholic Fatty Liver Disease
Adipokines in nonalcoholic fatty liver disease.
Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study.
Association of Circulating Adipsin, Visfatin, and Adiponectin with Nonalcoholic Fatty Liver Disease in Adults: A Case-Control Study.
Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease.
Effect of pioglitazone, quercetin, and hydroxy citric acid on vascular endothelial growth factor messenger RNA (VEGF mRNA) expression in experimentally induced nonalcoholic steatohepatitis (NASH).
NOD-like receptor C4 Inflammasome Regulates the Growth of Colon Cancer Liver Metastasis in NAFLD.
Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction.
Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models.
Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease.
Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease.
Vascular Endothelial Growth Factor Promotes Proliferation of Epithelial Cell Adhesion Molecule-Positive Cells in Nonalcoholic Steatohepatitis.
Non-ST Elevated Myocardial Infarction
Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction.
Noonan Syndrome
Vascular endothelial growth factor (VEGF) levels in short, GH treated children: a distinct pattern of VEGF-C in Noonan syndrome.
Obesity
Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study.
Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance.
Adipsin and an endogenous pathway of complement from adipose cells.
Adipsin and complement factor D activity: an immune-related defect in obesity.
Adipsin deficiency does not impact atherosclerosis development in Ldlr-/- mice.
Adipsin expression and growth in rats as influenced by insulin and somatotropin.
Adipsin mRNA amounts are not decreased in the genetically obese Zucker rat.
Adipsin: regulation and dysregulation in obesity and other metabolic states.
Adrenal glucocorticoids regulate adipsin gene expression in genetically obese mice.
Adverse Effects of Selected Markers on the Metabolic and Endocrine Profiles of Obese Women With and Without PCOS.
Alterations in sympathetic nervous system activity do not regulate adipsin gene expression in mice.
Association between plasma adipsin level and mild cognitive impairment in Chinese patients with type 2 diabetes: a cross-sectional study.
Association of Circulating Adipsin, Visfatin, and Adiponectin with Nonalcoholic Fatty Liver Disease in Adults: A Case-Control Study.
Association of salivary C-reactive protein with the obesity measures and markers in children.
Austrian Moderate Altitude Study (AMAS 2000) - fluid shifts, erythropoiesis, and angiogenesis in patients with metabolic syndrome at moderate altitude (congruent with 1700 m).
Battle of the bulge: the yin and yang of vascular endothelial growth factor in obesity.
Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells.
BODY MASS INDEX AS A PROGNOSTIC FACTOR FOR DISEASE PROGRESSION IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH BEVACIZUMAB BASED SYSTEMIC THERAPY.
Comment on: Elias et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes 2012;61:1801-1813.
Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass.
Control of the adipsin gene in adipocyte differentiation. Identification of distinct nuclear factors binding to single- and double-stranded DNA.
CORRELATION OF INCREASED SERUM ADIPSIN WITH INCREASED CARDIOVASCULAR RISKS IN ADULT PATIENTS WITH GROWTH HORMONE DEFICIENCY.
Correlative studies on the effects of obesity, diabetes and hypertension on gene expression in omental adipose tissue of obese women.
Differential expression of miRNAs related to angiogenesis and adipogenesis in subcutaneous fat of obese and nonobese women.
Differentiation dependent biphasic regulation of adipsin gene expression by insulin and insulin-like growth factor-1 in 3T3-F442A adipocytes.
Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.
Effect of vascular endothelial growth factor on fetal vessels among obese pregnant women.
Elevated Fetal Adipsin/Acylation-Stimulating Protein (ASP) in Obese Pregnancy: Novel Placental Secretion via Hofbauer Cells.
Extracellular matrix in obesity - cancer interactions.
Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab.
Impairment of adipsin expression is secondary to the onset of obesity in db/db mice.
Improvement of obesity phenotype by Chinese sweet leaf tea (Rubus suavissimus) components in high-fat diet-induced obese rats.
Independent regulation of adipose tissue-specificity and obesity response of the adipsin promoter in transgenic mice.
Induction of IL-17A Precedes Development of Airway Hyperresponsiveness during Diet-Induced Obesity and Correlates with Complement Factor D.
Involvement of serum vascular endothelial growth factor family members in the development of obesity in mice and humans.
Lipotoxicity versus adipotoxicity-The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes.
Long-term endurance exercise decreases antiangiogenic endostatin signalling in overweight men aged 50-60 years.
miR-20b, miR-296, and Let-7f Expression in Human Adipose Tissue is Related to Obesity and Type 2 Diabetes.
Modulation of angiogenesis during adipose tissue development in murine models of obesity.
No causal impact of serum vascular endothelial growth factor level on temporal changes in body mass index in Japanese male workers: a five-year longitudinal study.
Obesity is associated with increased levels of circulating hepatocyte growth factor.
Obesity, adipokines, and prostate cancer (review).
Obesity-associated NLRC4 inflammasome activation drives breast cancer progression.
Obesity-linked regulation of the adipsin gene promoter in transgenic mice.
Oleic Acid increases synthesis and secretion of VEGF in rat vascular smooth muscle cells: role of oxidative stress and impairment in obesity.
PDGF-D activation by macrophage-derived uPA promotes AngII-induced cardiac remodeling in obese mice.
Perivascular Adipose Tissue-Derived PDGF-D Contributes to Aortic Aneurysm Formation During Obesity.
Prolonged Fasting and the Effects on Biomarkers of Inflammation and on Adipokines in Healthy Lean Men.
Reduced adipsin expression in murine obesity: effect of age and treatment with the sympathomimetic-thermogenic drug mixture ephedrine and caffeine.
Regulation of adipsin and body composition in the monosodium glutamate (MSG)-treated mouse.
Regulation of Adipsin Expression by Endoplasmic Reticulum Stress in Adipocytes.
Relation between human LPIN1, hypoxia and endoplasmic reticulum stress genes in subcutaneous and visceral adipose tissue.
Repression of adipose vascular endothelial growth factor reduces obesity through adipose browning.
Response to Comment on: Elias et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes 2012;61:1801-1813.
Salivary Amylase Gene Copy Number Is Associated with the Obesity and Inflammatory Markers in Children.
Severely impaired adipsin expression in genetic and acquired obesity.
Systemic vascular endothelial growth factor-A (VEGF-A) neutralization ameliorates diet induced metabolic dysfunction.
The beneficial role of vitamin D in obesity: possible genetic and cell signaling mechanisms.
The role of production of adipsin and leptin in the development of insulin resistance in patients with abdominal obesity.
Vascular endothelial growth factor and its receptors in the placenta of pregnant women with obesity.
Vascular Endothelial Growth Factor-D (VEGF-D) Overexpression and Lymphatic Expansion in Murine Adipose Tissue Improves Metabolism in Obesity.
[The research progress of relationship between the obstructive sleep apnea hypopnea syndrome and asthma].
Obesity, Abdominal
The contribution of omental adipose tissue to adipokine concentrations in patients with the metabolic syndrome.
The role of production of adipsin and leptin in the development of insulin resistance in patients with abdominal obesity.
Obesity, Maternal
Elevated Fetal Adipsin/Acylation-Stimulating Protein (ASP) in Obese Pregnancy: Novel Placental Secretion via Hofbauer Cells.
Obstetric Labor, Premature
Role of Notch signaling during lipopolysaccharide-induced preterm labor.
Second-Trimester Serum Cytokines in Women Who Develop Spontaneous Preterm Labor at Less than 28 Weeks' Gestation versus Term Labor.
Ocular Hypertension
Effect of ripasudil on diabetic macular edema.
Odontogenic Cysts
Expression of Vascular Endothelial Growth Factor in Odontogenic Cysts: Is There Any Impression on Clinical Outcome?
Immunohistochemical expression of vascular endothelial growth factor (VEGF) in different types of odontogenic cysts.
Odontogenic keratocyst expresses vascular endothelial growth factor: an immunohistochemical study.
The role of vascular endothelial growth factor in proliferation of odontogenic cysts and tumors: An immunohistochemical study.
Odontogenic Tumors
Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas.
Comparative analysis of the immunohistochemical expression of vascular endothelial growth factor and matrix metalloproteinase-9 in keratocystic odontogenic tumor, dentigerous cyst and radicular cyst.
Evaluation and Comparison of Vascular Endothelial Growth Factor Expression between Ameloblastoma and Keratocystic Odontogenic Tumor.
Immunohistochemical expression of vascular endothelial growth factor in keratocystic odontogenic tumor, dentigerous cyst, and radicular cyst: A comparative study.
Oligodendroglioma
Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas.
Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
Neuropathological diagnosis of brain tumours.
The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.
Vascular endothelial growth factor (VEGF) likely contributes to oligodendroglioma angiogenesis.
Vascular Endothelial Growth Factor as an Angiogenic Marker in Malignant Astrocytoma and Oligodendroglioma: An Indian Scenario.
Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival.
Optic Atrophy, Autosomal Dominant
Exogenous hydrogen sulphide supplement accelerates skin wound healing via oxidative stress inhibition and vascular endothelial growth factor enhancement.
Optic Neuropathy, Ischemic
Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia.
VEGF Induces Neuroglial Differentiation in Bone Marrow-Derived Stem Cells and Promotes Microglia Conversion Following Mobilization with GM-CSF.
Oral Submucous Fibrosis
Role of angiogenesis in oral submucous fibrosis using vascular endothelial growth factor and CD34: An immunohistochemical study.
Single nucleotide polymorphisms and serologic levels of hypoxia-inducible factor1 ? and vascular endothelial growth factor are associated with increased risk of oral submucous fibrosis in gutka users among a North Indian population.
Oropharyngeal Neoplasms
Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx.
Vascular endothelial growth factor (VEGF) in sera of oral and oropharyngeal squamous cell carcinoma patients.
Osteoarthritis
Cartilage repair in a rat model of osteoarthritis through intraarticular transplantation of muscle-derived stem cells expressing bone morphogenetic protein 4 and soluble flt-1.
Changes in the antiangiogenic properties of articular cartilage in osteoarthritis.
Chondrogenic progenitor cells promote vascular endothelial growth factor expression through stromal-derived factor-1.
CITED2 mediates the mechanical loading-induced suppression of adipokines in the infrapatellar fat pad.
Detection of vascular endothelial growth factor (VEGF) in moderate osteoarthritis in a rabbit model.
Differential Expression of Renin-Angiotensin System-related Components in Patients with Rheumatoid Arthritis and Osteoarthritis.
Distinct signaling pathways are involved in hypoxia- and IL-1-induced VEGF expression in human articular chondrocytes.
Effect of large-size dialysis membrane and hemofiltration/hemodiafiltration methods on long-term dialysis patients.
Effects of hyaluronan on vascular endothelial growth factor and receptor-2 expression in a rabbit osteoarthritis model.
Elevated VEGF levels contribute to the pathogenesis of osteoarthritis.
Evaluating the Effects of Platelet-Rich Plasma and Amniotic Viscous Fluid on Inflammatory Markers in a Human Coculture Model for Osteoarthritis.
Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis.
Expression of platelet-derived growth factors C and D in the synovial membrane of patients with rheumatoid arthritis and osteoarthritis.
Expression of vascular endothelial growth factor (VEGF) associated with histopathological changes in rodent models of osteoarthritis.
Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis.
Expression of vascular endothelial growth factor on chondrocytes increases with osteoarthritis - an animal experimental investigation.
High in vivo levels of adipsin lead to increased knee tissue degradation in osteoarthritis: data from humans and animal models.
Hyaluronic acid modulates gene expression of connective tissue growth factor (CTGF), transforming growth factor-beta1 (TGF-beta1), and vascular endothelial growth factor (VEGF) in human fibroblast-like synovial cells from advanced-stage osteoarthritis in vitro.
IL-17, IL-1beta and TNF-alpha stimulate VEGF production by dedifferentiated chondrocytes.
In vivo protective effect of adipsin-deficiency on spontaneous knee osteoarthritis in aging mice.
Increased expression of endocan in arthritic synovial tissues: effects of adiponectin on the expression of endocan in fibroblast-like synoviocytes.
Inhibition of vascular endothelial growth factor with shRNA in chondrocytes ameliorates osteoarthritis.
Injecting vascular endothelial growth factor into the temporomandibular joint induces osteoarthritis in mice.
Injection of vascular endothelial growth factor into knee joints induces osteoarthritis in mice.
Intraperitoneal injection of thalidomide alleviates early osteoarthritis development by suppressing vascular endothelial growth factor expression in mice.
Local intra?articular injection of vascular endothelial growth factor accelerates articular cartilage degeneration in rat osteoarthritis model.
Mechanical forces induce changes in VEGF and VEGFR-1/sFlt-1 expression in human chondrocytes.
Osteopontin induces vascular endothelial growth factor expression in articular cartilage through PI3K/AKT and ERK1/2 signaling.
Oxidized LDL binding to LOX-1 upregulates VEGF expression in cultured bovine chondrocytes through activation of PPAR-gamma.
Platelet rich plasma enhances the immunohistochemical expression of platelet derived growth factor and vascular endothelial growth factor in the synovium of the meniscectomized rat models of osteoarthritis.
Procyanidins Mitigate Osteoarthritis Pathogenesis by, at Least in Part, Suppressing Vascular Endothelial Growth Factor Signaling.
Sphingosine-1-phosphate modulates expression of vascular endothelial growth factor in human articular chondrocytes: a possible new role in arthritis.
Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.
The effect of vascular endothelial growth factor (VEGF) on mouse condylar articular cartilage cultured in vitro.
The expression of vascular endothelial growth factor and Syndecan-4 in cartilage from osteoarthritic knees.
The levels of the adipokines adipsin and leptin are associated with knee osteoarthritis progression as assessed by MRI and incidence of total knee replacement in symptomatic osteoarthritis patients: a post hoc analysis.
The Relationship between HIF-2? and VEGF with Radiographic Severity in the Primary Osteoarthritic Knee.
TNF-? increases the expression of inflammatory factors in synovial fibroblasts by inhibiting the PI3K/AKT pathway in a rat model of monosodium iodoacetate-induced osteoarthritis.
Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development.
Vascular endothelial growth factor (VEGF) is expressed during articular cartilage growth and re-expressed in osteoarthritis.
Vascular Endothelial Growth Factor in Cartilage Development and Osteoarthritis.
Vascular endothelial growth factor in patients with rheumatoid arthritis.
Vascular Endothelial Growth Factor Is Regulated by the Canonical and Noncanonical Transforming Growth Factor-? Pathway in Synovial Fibroblasts Derived from Osteoarthritis Patients.
Vascular endothelial growth factor plays an important autocrine/paracrine role in the progression of osteoarthritis.
Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.
VEGF Production by Osteoarthritic Chondrocytes Cultured in Micromass and Stimulated by IL-17 and TNF-alpha.
Visfatin Increases VEGF-dependent Angiogenesis of Endothelial Progenitor Cells during Osteoarthritis Progression.
[Characteristics of vascular morphology and vascular endothelial growth factor in patients with osteoarthritis and rheumatoid arthritis].
[Effects of Yanghe Decoction on vascular endothelial growth factor in cartilage cells of osteoarthritis rabbits]
[Expression of hypoxia-inducible factor-1? and vascular endothelial growth factor in the synovium of patients with osteoarthritis].
Osteoarthritis, Knee
Effects of ultrasound on vascular endothelial growth factor in cartilage, synovial fluid, and synovium in rabbit knee osteoarthritis.
Increase levels of apo-A1 and apo B are associated in knee osteoarthritis: lack of association with VEGF-460 T/C and +405 C/G polymorphisms.
Relationship of plasma and synovial fluid vascular endothelial growth factor with radiographic severity in primary knee osteoarthritis.
The levels of the adipokines adipsin and leptin are associated with knee osteoarthritis progression as assessed by MRI and incidence of total knee replacement in symptomatic osteoarthritis patients: a post hoc analysis.
Vascular endothelial growth factor expression and their action in the synovial membranes of patients with painful knee osteoarthritis.
[Characteristics of vascular morphology and vascular endothelial growth factor in patients with osteoarthritis and rheumatoid arthritis].
[Effect of eletroacupuncture with close-to-bone needling treatment on expression of Sox9, VEGF and ColX in impaired cartilage of rabbits with knee osteoarthritis].
Osteochondrodysplasias
Expression and identification of recombinant chicken vascular endothelial growth factor in Pichia pastoris and its role in the pathogenesis of tibial dyschondroplasia.
In Vitro Effect of Apigenin and Danshen in Tibial Dyschondroplasia Through Inhibition of Heat-Shock Protein 90 and Vascular Endothelial Growth Factor Expressions in Avian Growth Plate Cells.
Osteogenesis Imperfecta
Collagen content and growth factor immunoexpression in uterine lower segment of type IA osteogenesis imperfecta: Relationship with recurrent uterine rupture in pregnancy.
Osteolysis
Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.
Blockade of vascular endothelial growth factor activity suppresses wear debris-induced inflammatory osteolysis.
Comparison of VEGF-producing cells in periprosthetic osteolysis.
Effects of SU5416 and a vascular endothelial growth factor neutralizing antibody on wear debris-induced inflammatory osteolysis in a mouse model.
Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies.
Periprosthetic osteolysis: induction of vascular endothelial growth factor from human monocyte/macrophages by orthopaedic biomaterial particles.
Targeting vascular endothelial growth factor ameliorates PMMA-particles induced inflammatory osteolysis in murine calvaria.
[Inhibitory effects of vascular endothelial growth factor antibody on wear particle-induced osteolysis].
Osteoma
Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma.
Osteomyelitis
Angiogenic gene therapy as a potential therapeutic agent in chronic osteomyelitis.
Effects of transpositional muscle flaps transfected with vascular endothelial growth factor gene in the treatment of experimental osteomyelitis.
Osteonecrosis
Association between vascular endothelial growth factor gene polymorphisms and the risk of osteonecrosis of the femoral head: Systematic review.
Association of osteonecrosis and peripheral neuropathy in HIV-1-infected patients: possible roles of nerve growth factor and vascular endothelial growth factor.
Changes in femoral head blood supply and vascular endothelial growth factor in rabbits with steroid-induced osteonecrosis.
Decreased levels of insulin-like growth factor-1 and vascular endothelial growth factor relevant to the ossification disturbance in femoral heads spontaneous hypertensive rats.
Differential Expression of Vascular Endothelial Growth Factor in Glucocorticoid-related Osteonecrosis of the Femoral Head.
Erythropoietin Enhances Bone Repair Effects via the Hypoxia-Inducible Factor Signal Pathway in Glucocorticoid-Induced Osteonecrosis of the Femoral Head.
Genetic association between VEGF polymorphisms and BRONJ in the Korean population.
Interleukin-6 deletion stimulates revascularization and new bone formation following ischemic osteonecrosis in a murine model.
Localization of vascular endothelial growth factor during the early reparative phase of the rats' vessels deprivation-induced osteonecrosis of the femoral heads.
Low expression of vascular endothelial growth factor and high serum level of cyclic guanine monophosphate as the risk factors of femoral head osteonecrosis in alcohol-exposed Wistar rat.
Nonoperative and Operative Bone and Cartilage Regeneration and Orthopaedic Biologics of the Hip: An Orthoregeneration Network (ON) Foundation Hip Review.
Osteonecrosis Of The Jaw In A Patient Receiving Cabozantinib.
Porous, lithium-doped calcium polyphosphate composite scaffolds containing vascular endothelial growth factor (VEGF)-loaded gelatin microspheres for treating glucocorticoid-induced osteonecrosis of the femoral head.
Promoter polymorphisms of the vascular endothelial growth factor gene is associated with an osteonecrosis of the femoral head in the Korean population.
The association between VEGF -634C/G polymorphisms and osteonecrosis of femoral head: a meta-analysis.
Treatment of Osteonecrosis of the Femoral Head with VEGF(165) Transgenic Bone Marrow Mesenchymal Stem Cells in Mongrel Dogs.
Vascular endothelial growth factor -634G/C polymorphism associated with osteonecrosis of the femoral head in a Chinese population.
Vascular endothelial growth factor for the treatment of femoral head osteonecrosis: An experimental study in canines.
Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws.
Vascular endothelial growth factor in rabbits during development of corticosteroid-induced osteonecrosis: a controlled experiment.
Vascular endothelial growth factor polymorphisms in patients with steroid-induced femoral head osteonecrosis.
[Effects of different stress force stimulations on the expression of vascular endothelial growth factor in Beagle dogs in the repairing process of osteonecrosis of the femoral head].
[Study on biological activity of recombinant adeno-associated virus vector co-expressing human vascular endothelial growth factor 165 and human bone morphogenetic protein 7 genes in vitro]
[Study on time effect of gene expression of recombinant adeno-associated virus vector co-expressing human vascular endothelial growth factor 165 and human bone morphogenetic protein 7 genes]
Osteophyte
Development and regulation of osteophyte formation during experimental osteoarthritis.
Osteoporosis
Circulating vascular endothelial growth factor concentrations in patients with postmenopausal osteoporosis.
Effect of fluvastatin on vascular endothelial growth factor in rats with osteoporosis in process of fracture healing.
Genetic Scores of eNOS, ACE and VEGFA Genes Are Predictive of Endothelial Dysfunction Associated Osteoporosis in Postmenopausal Women.
Genetically Decreased Circulating Vascular Endothelial Growth Factor and Osteoporosis Outcomes: A Mendelian Randomization Study.
Obesity: Friend or foe for osteoporosis.
Plasma vascular endothelial growth factor levels are similar in subjects with and without osteoporosis.
Reduced local blood supply to the tibial metaphysis is associated with ovariectomy-induced osteoporosis in mice.
SPTBN1 Prevents Primary Osteoporosis by Modulating Osteoblasts Proliferation and Differentiation and Blood Vessels Formation in Bone.
The effect of parathyroid hormone (1-84) treatment on serum bone morphogenetic protein 4 and vascular endothelial growth factor in postmenopausal women with established osteoporosis.
[Study on relationship between osteoporosis and mRNA expressions of vascular endothelial growth factor and bone morphogenetic protein 2 in nontraumatic avascular necrosis of femoral head]
Osteoporosis, Postmenopausal
Circulating vascular endothelial growth factor concentrations in patients with postmenopausal osteoporosis.
Factors regulating circulating vascular endothelial growth factor (VEGF): Association with bone mineral density (BMD) in post-menopausal osteoporosis.
Osteosarcoma
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.
A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma.
A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.
Analyzing time-series microarray data reveals key genes in spinal cord injury.
Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma.
Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Association of the vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphisms with osteosarcoma susceptibility in a Chinese population.
Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma.
Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-? as angiogenic factors in mouse osteosarcoma.
CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma.
Circular RNA circ_001621 promotes osteosarcoma cells proliferation and migration by sponging miR-578 and regulating VEGF expression.
Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model.
Comment on Zhuang YF et al.: impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis.
Comparison of VEGF-A secretion from tumor cells under cellular stresses in conventional monolayer culture and microfluidic three-dimensional spheroid models.
Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.
Correlation between the changes of serum COX 2, APE1, VEGF, TGF-? and TSGF levels and prognosis in patients with osteosarcoma before and after treatment.
Correlation between the expression of vegf and survival in osteosarcoma.
Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma.
Correlations of expressions of IMP3 and VEGF with stage of osteosarcoma, microvascular density and pulmonary metastasis.
CXCL8 promotes the invasion of human osteosarcoma cells by regulation of PI3K/Akt signaling pathway.
Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of osteosarcoma cells by switching on suppressor microRNAs and inactivating of Notch-1 signaling.
Difference in pre- and postchemotherapy vascular endothelial growth factor levels as a prognostic indicator in osteosarcoma.
Downregulation of Adrenomedullin Leads to the Inhibition of the Tumorigenesis via VEGF Pathway in Human and Nude Mice Osteosarcoma Models.
Effect and mechanism analysis of siRNA in inhibiting VEGF and its anti-angiogenesis effects in human osteosarcoma bearing rats.
Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice.
Effect of cortisol on cell proliferation and the expression of lipoprotein lipase and vascular endothelial growth factor in a human osteosarcoma cell line.
Effect of ketoprofen in topical formulation on vascular endothelial growth factor expression and tumor growth in nude mice with osteosarcoma.
Effect of polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients.
Effects of resveratrol on vascular endothelial growth factor expression in osteosarcoma cells and cell proliferation.
Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.
Essential role of SH3GL1 in interleukin-6(IL-6)- and vascular endothelial growth factor (VEGF)-triggered p130(cas)-mediated proliferation and migration of osteosarcoma cells.
Expression of macrophage migration inhibitory factor relates to survival in high-grade osteosarcoma.
Expression of NOS and VEGF in feline mammary tumours and their correlation with angiogenesis.
Expression of vascular endothelial growth factor (VEGF) in human osteosarcoma cells transfected with adeno-associated virus-antisense VEGF.
Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma.
Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.
Expression profile of Twist, vascular endothelial growth factor and CD34 in patients with different phases of osteosarcoma.
Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma.
Green fluorescent protein (GFP)-expressing tumor model derived from a spontaneous osteosarcoma in a vascular endothelial growth factor (VEGF)-GFP transgenic mouse.
High-level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma.
Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Immunohistochemical expression of vegf and her-2 proteins in osteosarcoma biopsies.
Impact of common SNPs in VEGF gene on the susceptibility of osteosarcoma.
Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis.
Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma.
Inhibiting GIT1 reduces the growth, invasion, and angiogenesis of osteosarcoma.
Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab.
Inhibitory effects of VEGF-siRNA mediated by adenovirus on osteosarcoma-bearing nude mice.
Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma.
Interstitial fluid pressure as an alternate regulator of angiogenesis independent of hypoxia driven HIF-1? in solid tumors.
Investigating the Relationship between of Vascular Endothelial Growth Factor and HER-2neu in IHC Staining with Metastasis and Mortality in Patients with Osteosarcoma.
Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes.
Microarray analysis of retinal gene expression in Egr-1 knockout mice.
MicroRNA-134 inhibits osteosarcoma angiogenesis and proliferation by targeting the VEGFA/VEGFR1 pathway.
MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells.
MicroRNA-150-5p inhibits proliferation and invasion of osteosarcoma cells by down-regulating VEGFA.
MicroRNA-638 expression change in osteosarcoma patients via PLD1 and VEGF expression.
MicroRNA?944 targets vascular endothelial growth factor to inhibit cell proliferation and invasion in osteosarcoma.
Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.
Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells.
Polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients.
Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma.
Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.
Prognostic significance of alpha V integrin and VEGF in osteosarcoma after chemotherapy.
Prospective Preliminary In Vitro Investigation of a Magnetic Iron Oxide Nanoparticle Conjugated with Ligand CD80 and VEGF Antibody As a Targeted Drug Delivery System for the Induction of Cell Death in Rodent Osteosarcoma Cells.
Quantitative RT-PCR assay detecting the transcriptional induction of vascular endothelial growth factor under hypoxia.
Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma.
Resistance of epiphyseal cartilage to invasion by osteosarcoma is likely to be due to expression of antiangiogenic factors.
Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study.
Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma.
Silencing of Eag1 Gene Inhibits Osteosarcoma Proliferation and Migration by Targeting STAT3-VEGF Pathway.
Suppression of ERK/NF-?B Activation Is Associated With Amentoflavone-Inhibited Osteosarcoma Progression In Vivo.
Survivin and vascular endothelial growth factor are associated with spontaneous pulmonary metastasis of osteosarcoma: Development of an orthotopic mouse model.
The associations of vascular endothelial growth factor gene polymorphisms with susceptibility to osteosarcoma: evidence from a meta-analysis.
The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma.
The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma.
The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review.
Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma.
Vascular endothelial growth factor expression as a biomarker of prognosis in patients with chondrosarcoma, Ewing's sarcoma and osteosarcoma. Current concepts.
Vascular Endothelial Growth Factor Expression in Osteosarcoma.
Vascular endothelial growth factor expression in osteosarcoma.
Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.
Vascular endothelial growth factor polymorphisms are associated with osteosarcoma susceptibility.
Vector-based Ape1 small interfering RNA enhances the sensitivity of human osteosarcoma cells to endostatin in vivo.
VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma.
VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI.
VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro.
VEGFR2 Promotes Metastasis and PD-L2 Expression of Human Osteosarcoma Cells by Activating the STAT3 and RhoA-ROCK-LIMK2 Pathways.
[Cryptotanshinone down-regulates the expression of VEGF and inhibits angiogenesis in U2OS osteosarcoma cells].
[Effect of silencing HIF-1alpha by RNA interference on expression of vascular endothelial growth factor in osteosarcoma cell line SaOS-2 under hypoxia]
[Expression of Ether à go-go 1 and its molecular mechanism of regulating the malignant phenotype of osteosarcoma].
[Morphological changes in osteosarcoma xenografts in nude mice after inhibiting angiogenesis by Ad-VEGF-siRNA.]
[Osteosarcoma: biochemical and endocrinological studies as a basis for its pathogenetic treatments]
[Relationship between vascular endothelial growth factor expression and angiogenesis in osteosarcoma]
[Targeted inhibition of vascular endothelial growth factor (VEGF) expression in human osteosarcoma cell line by antisense VEGF165 cDNA promoted by hypoxia reaction element]
Otitis Media
Apigetrin treatment attenuates LPS-induced acute otitis media though suppressing inflammation and oxidative stress.
Effect of recombinant vascular endothelial growth factor on experimental otitis media with effusion.
Effect of vascular endothelial growth factor and its receptors in adult otitis media with effusion.
Expression of vascular endothelial growth factor in otitis media.
Expression of vascular endothelial growth factor receptors in experimental otitis media in the rat.
Hypoxia-Inducible Factor and Vascular Endothelial Growth Factor Pathway for the Study of Hypoxia in a New Model of Otitis Media with Effusion.
The expression of VEGF and VEGFR in endotoxin induced otitis media with effusion in rats.
The role of vascular endothelial growth factor in pediatric otitis media with effusion.
Vascular endothelial growth factor and transforming growth factor ? in hypertrophic adenoids in children suffering from otitis media with effusion.
[The significance of keratinocyte in hyperproliferation of middle ear cholesteatoma].
Otitis Media with Effusion
Effect of recombinant vascular endothelial growth factor on experimental otitis media with effusion.
Effect of vascular endothelial growth factor and its receptors in adult otitis media with effusion.
Expression of vascular endothelial growth factor in otitis media.
Expression of vascular endothelial growth factor receptors in experimental otitis media in the rat.
Hypoxia-Inducible Factor and Vascular Endothelial Growth Factor Pathway for the Study of Hypoxia in a New Model of Otitis Media with Effusion.
The expression of VEGF and VEGFR in endotoxin induced otitis media with effusion in rats.
The role of vascular endothelial growth factor in pediatric otitis media with effusion.
Vascular endothelial growth factor and transforming growth factor ? in hypertrophic adenoids in children suffering from otitis media with effusion.
Ovarian Cysts
Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology.
Vascular endothelial growth factor in ovarian cyst fluid.
Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation.
Ovarian Diseases
Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian disease.
Ovarian Hyperstimulation Syndrome
A potential role of endoplasmic reticulum stress in development of ovarian hyperstimulation syndrome.
Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.
Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability.
Advances in ultrasound assessment in the establishment and development of pregnancy.
Angiogenic cytokine and interleukin 8 levels in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients.
Association of -460C/T and +405 G/C polymorphisms of vascular endothelial growth factor gene and susceptibility to ovarian hyperstimulation syndrome.
Authors' reply re: Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome.
Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program.
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction.
Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.
Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists.
Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol.
Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome.
Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome.
Endocrine gland-derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome in women undergoing controlled ovarian hyperstimulation.
Etiology of OHSS and use of dopamine agonists.
Follicular fluid levels of vascular endothelial growth factor. Are they predictive markers for ovarian hyperstimulation syndrome?
GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study.
Growth differentiation factor 9 inhibits vascular endothelial growth factor expression in human granulosa cells.
High levels of soluble vascular endothelial growth factor receptor 1/sFlt1 and low levels of vascular endothelial growth factor in follicular fluid on the day of oocyte retrieval correlate with ovarian hyperstimulation syndrom regardless of the stimulation protocol.
Human albumin enhances expression of vascular endothelial growth factor in cultured human luteinizing granulosa cells: importance in ovarian hyperstimulation syndrome.
Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor.
Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study.
Increased risk of ovarian hyperstimulation syndrome following controlled ovarian hyperstimulation in patients with vascular endothelial growth factor +405 cc genotype.
Insights into angiogenic imbalances during pregnancy.
Investigation of short- and long-term effects of ovarian hyperstimulation syndrome on ovarian reserve: an experimental study.
Is vascular endothelial growth factor (VEGF) the main mediator in ovarian hyperstimulation syndrome (OHSS)?
Local VEGF inhibition prevents ovarian alterations associated with ovarian hyperstimulation syndrome.
Lysophosphatidic acid up-regulates expression of interleukin-8 and -6 in granulosa-lutein cells through its receptors and nuclear factor-kappaB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndrome.
New concepts in the understanding of the ovarian hyperstimulation syndrome.
Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats.
Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.
Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.
Plasma and follicular fluid osteopontin levels during ovarian cycle and their correlation with follicular fluid vascular endothelial growth factor levels.
Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration.
Preventing ovarian hyperstimulation syndrome by inhibiting the effects of vascular endothelial growth factor.
Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
Re: Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndrome.
Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome.
Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries.
Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome.
Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception.
Serum vascular endothelial growth factor levels before starting gonadotropin treatment in women who have developed moderate forms of ovarian hyperstimulation syndrome.
Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
Severe ovarian hyperstimulation syndrome: serum and ascitic fluid concentrations of vascular endothelial growth factor.
Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways.
sRAGE downregulates the VEGF expression in OHSS ovarian granulosa cells.
Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
The effectiveness of cabergoline for the prevention of ovarian hyperstimulation syndrome.
The effects of 'coasting' on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome.
The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study.
The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome.
The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.
The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor.
THE ROLE OF HIGH FOLLICULAR LEVELS OF ANGIOTENSIN II AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN ANTICIPATING THE DEVELOPMENT OF SEVERE OVARIAN HYPERSTIMULATION SYNDROME IN PATIENTS WITH PROPHYLACTIC CABERGOLINE THERAPY UNDERGOING AN IN VITRO FERTILIZATION PROCEDURE.
The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.
Transient receptor potential melastatin 2 ion channel activity in ovarian hyperstimulation syndrome physiopathology
Urinary vascular endothelial growth factor concentrations in women undergoing gonadotrophin treatment.
Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome.
Variations in serum vascular endothelial growth factor binding profiles and the development of ovarian hyperstimulation syndrome.
Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome.
Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization.
Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF.
Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome.
Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome.
Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.
Vascular endothelial growth factor response to exogenous chorionic gonadotropic hormone in the luteal phase of women with a history of severe ovarian hyperstimulation syndrome.
Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome.
Vascular endothelial growth factor, polycystic ovary syndrome, and ovarian hyperstimulation syndrome.
Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report.
VEGF, IVF clinical variables and ovarian hyperstimulation syndrome: a prospective study of the preimplantation luteal phase.
Vitamin D Decreases Serum VEGF Correlating with Clinical Improvement in Vitamin D-Deficient Women with PCOS: A Randomized Placebo-Controlled Trial.
What's new in the pathogenesis and prevention of ovarian hyperstimulation syndrome?
[Function of vascular endothelial growth factor in ovarian hyperstimulation syndrome]
[Preliminary study on the role of vascular endothelial growth factor in pathogenesis of ovarian hyperstimulation syndrome]
[The Predictive Role of Vascular Endothelial Growth Factor and Estradiol in Infertile Patients with Ovarian Hyperstimulation Syndrome]
Ovarian Neoplasms
24PReactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients.
9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells.
A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer.
A new link in ovarian cancer angiogenesis: lysophosphatidic acid and vascular endothelial growth factor expression.
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer.
AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer.
Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation.
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.
Adenosine Inhibits Ovarian Cancer Growth Through Regulating RhoGDI2 Protein Expression.
Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial.
Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model.
Angiogenesis in epithelian ovarian cancer.
Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival.
Antiangiogenic therapy for ovarian cancer.
Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding.
Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression.
Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways.
Association of four genetic polymorphisms in the vascular endothelial growth factor-A gene and development of ovarian cancer: a meta-analysis.
Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer.
Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma.
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Bevacizumab in ovarian cancer: A critical review of phase III studies.
Bevacizumab in the treatment of ovarian cancer.
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer.
Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8.
Calcitriol Combined With Platinum-based Chemotherapy Suppresses Growth and Expression of Vascular Endothelial Growth Factor of SKOV-3 Ovarian Cancer Cells.
Cediranib in ovarian cancer: state of the art and future perspectives.
Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian disease.
Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy.
Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.
Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers.
Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.
Clinical value of TV-CDS combined with serum tumor markers in diagnosis of ovarian cancer.
Combined anti-angiogenic therapy against VEGF and integrin alpha(V)beta(3) in an orthotopic model of ovarian cancer.
Concentrated ascites re-infusion therapy for pseudo-Meigs' syndrome complicated by massive ascites in large pedunculated uterine leiomyoma.
Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer.
Correlation of the expression of vascular endothelial growth factor and its receptors with microvessel density in ovarian cancer.
Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice.
Current status of anti-angiogenic agents in the treatment of ovarian carcinoma.
Current Status on Biologic Therapies in the Treatment of Epithelial Ovarian Cancer.
CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer.
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers.
CXCL12 promotes human ovarian cancer cell invasion through suppressing ARHGAP10 expression.
Differential Effect of Intraperitoneal Albendazole and Paclitaxel on Ascites Formation and Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Cell-Bearing Athymic Nude Mice.
Do preoperative serum vascular endothelial growth factor and migration-inhibitory factor predict the nature of the adnexal masses? A prospective-controlled trial.
Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?
Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells.
Effect of estradiol on the expression of angiogenic factors in epithelial ovarian cancer.
Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo.
Effects of bisphenol A and 17?-estradiol on vascular endothelial growth factor A and its receptor expression in the non-cancer and cancer ovarian cell lines.
Elevated serum levels of vascular endothelial growth factor is effective as a marker for malnutrition and inflammation in patients with ovarian cancer.
Enhanced siRNA delivery using a combination of an arginine-grafted bioreducible polymer, ultrasound, and microbubbles in cancer cells.
Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients.
Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite.
Experience with bevacizumab in the management of epithelial ovarian cancer.
Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.
Expression levels of PTEN, HIF-1?, and VEGF as prognostic factors in ovarian cancer.
Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer.
Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas.
Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels.
Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model.
Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.
Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
Extracellular vesicle-encapsulated microRNA-424 exerts inhibitory function in ovarian cancer by targeting MYB.
Fludarabine reduces survivability of HepG2 cells through VEGF under hypoxia.
Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
Frontline use of bevacizumab in ovarian cancer: Experience from India.
FSH receptor binding inhibitor impacts K-Ras and c-Myc of ovarian cancer and signal pathway.
Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion.
Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma.
Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer.
Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients.
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.
Inhibitory effect of 2'-o-methoxyethyl-modified antisense oligonucleotides targeting vascular endothelial growth factor A on SKOV3 human ovarian cancer cells.
Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.
Interferon-? produced by tumor-infiltrating NK cells and CD4(+) T cells downregulates TNFSF15 expression in vascular endothelial cells.
Interleukin-1? promotes ovarian tumorigenesis through a p53/NF-?B-mediated inflammatory response in stromal fibroblasts.
Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer.
Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation.
Isolation and purification of vascular endothelial growth factor (VEGF) from ascitic fluid of ovarian cancer patients.
Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc.
LncRNA DANCR promotes tumor growth and angiogenesis in ovarian cancer through direct targeting of miR-145.
Loss of ovarian function promotes angiogenesis in human ovarian carcinoma.
Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.
Lysophosphatidic acid signaling in ovarian cancer.
Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.
Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor.
Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells.
Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
Major clinical research advances in gynecologic cancer in 2020.
Mechanism of vascular endothelial growth factor expression mediated by cisplatin in human ovarian cancer cells.
MicroRNA-126 affects ovarian cancer cell differentiation and invasion by modulating expression of vascular endothelial growth factor.
MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer.
Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells.
Multiple anticancer activities of EF24, a novel curcumin analog, on human ovarian carcinoma cells.
Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance.
Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.
Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer.
New treatments in ovarian cancer.
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells.
Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer.
Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer.
Overview of anti-angiogenic agents in development for ovarian cancer.
Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt/?-Catenin signaling pathway.
Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment.
Paeonol enhances the sensitivity of human ovarian cancer cells to radiotherapy-induced apoptosis due to downregulation of the phosphatidylinositol-3-kinase/Akt/phosphatase and tensin homolog pathway and inhibition of vascular endothelial growth factor.
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
PI3K Catalytic Isoform Alteration Promotes the LIMK1-related Metastasis Through the PAK1 or ROCK1/2 Activation in Cigarette Smoke-exposed Ovarian Cancer Cells.
Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.
Platelet-derived growth factor-D expression mediates the effect of differentiated degree on prognosis in epithelial ovarian cancer.
Platinum-based chemotherapy and bevacizumab instigate the destruction of human ovarian cancers via different signaling pathways.
Positive Feedback between Vascular Endothelial Growth Factor-A and Autotaxin in Ovarian Cancer Cells.
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Potential predictors of chemotherapy response in ovarian cancer--how do we define chemosensitivity?
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer.
Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.
Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer.
Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer.
Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma.
Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up.
Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer.
Prognostic value of vascular endothelial growth factor expression in women with ovarian cancer: A meta-analysis.
Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
Pseudo-Meigs' syndrome associated with hydropic degenerating uterine leiomyoma: A case report.
Pulmonary tumor thrombotic microangiopathy caused by an ovarian cancer expressing tissue factor and vascular endothelial growth factor.
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Reactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients.
Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor.
Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells.
Real-time monitoring biomarker expression of carcinoma cells by surface plasmon resonance biosensors.
Recent progress in the diagnosis and treatment of ovarian cancer.
RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
Role of lymphangiogenesis in epithelial ovarian cancer.
Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization.
Secretion of vascular endothelial growth factor in ovarian cancer.
Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer.
Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.
Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.
Significance of serum c-erbB-2 oncoprotein, insulin-like growth factor-1 and vascular endothelial growth factor levels in ovarian cancer.
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.
Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism.
SPARC suppresses lymph node metastasis by regulating the expression of VEGFs in ovarian carcinoma.
Strategies for suppressing angiogenesis in gynecological cancers.
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines.
Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family.
Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth.
Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis.
Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
The effects of Curcuma longa and curcumin on reproductive systems.
The effects of ovarian cancer cell-derived exosomes on vascular endothelial growth factor expression in endothelial cells.
The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer.
The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells.
The Novel I?B Kinase ? Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice.
The Potential Role of the Proteases Cathepsin D and Cathepsin L in the Progression and Metastasis of Epithelial Ovarian Cancer.
The prognostic significance of high/positive expression of tissue VEGF in ovarian cancer.
The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis.
The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.
The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer.
The Role of Cediranib in Ovarian Cancer.
The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts.
The role of VEGFR-2 expression in outcomes and survival of patients with peritoneal carcinomatosis from appendiceal cancer.
The Wilms' Tumor Gene WT1 - 17AA/- KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model.
Three Polymorphisms of Vascular Endothelial Growth Factor (+936C > T, -460C > T, and -2578C > A) and Their Susceptibility to Ovarian Cancer: A Meta-Analysis.
TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.
trans-3,4,5'-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells.
Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.
Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer.
Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer.
Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival.
Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer.
Vascular endothelial growth factor gene polymorphisms in ovarian cancer.
Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Vascular endothelial growth factor in ovarian cancer.
Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
Vascular endothelial growth factor serum concentrations in ovarian cancer.
Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer.
Vascular endothelial growth factor staining and elevated INR in advanced epithelial ovarian carcinoma.
Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion.
Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer.
Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts.
Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer.
VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon.
VEGF Expression to Support Targeted Therapy in Ovarian Surface Epithelial Neoplasms.
VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine.
VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent.
VEGF-D-induced draining lymphatic enlargement and tumor lymphangiogenesis promote lymph node metastasis in a xenograft model of ovarian carcinoma.
[Down-regulation of vascular endothelial growth factor expression in ovarian cancer cell line SKOV3 by interferon-gamma]
[Experimental study of anti-vascular endothelial growth factor hairpin ribozyme gene inhibiting growth of xenografted tumor of ovarian cancer cells]
[Expression and significance of VEGF, miR-205 and target protein Ezrin and Lamin A/C in ovarian cancer].
[Inhibitory effects of artesunate on angiogenesis]
[Optimal therapeutic strategies in ovarian epithelial cancer in 1997]
[Relationship of hypoxia-inducible factor-1alpha expression and vascular endothelial growth factor in SKOV-3 ovarian cancer model]
[Screening of anti-tumor parts from the seeds of Livistona chinensis and its anti-angiogenesis effect]
[Study on serum vascular endothelial growth factor level in ovarian malignant tumors]
[The vascular endothelial growth factor in patients with advanced ovarian cancer on the background of chemotherapy according to the AP scheme.]
Overweight
Adipsin Concentrations Are Associated with Back Pain Independently of Adiposity in Overweight or Obese Adults.
Angiogenic factors are elevated in overweight and obese individuals.
Benzodiazepine-Associated Carcinogenesis: Focus on Lorazepam-Associated Cancer Biomarker Changes in Overweight Individuals.
Biomarkers for Overweight in Adult-Onset Asthma.
Effects of a Weight Loss Intervention on Body Mass, Fitness, and Inflammatory Biomarkers in Overweight or Obese Breast Cancer Survivors.
Effects of exercise training with weight loss on skeletal muscle expression of angiogenic factors in overweight and obese older men.
Genetic Contributions to Childhood Obesity: Association of Candidate Gene Polymorphisms and Overweight/Obesity in Korean Preschool Children.
No causal impact of serum vascular endothelial growth factor level on temporal changes in body mass index in Japanese male workers: a five-year longitudinal study.
Serum bFGF levels are reduced in Japanese overweight men and restored by a 6-month exercise education.
Paget Disease, Extramammary
Concordant over-expression of transcription factor Sp1 and vascular endothelial growth factor in extramammary Paget's disease.
Expression of vascular endothelial growth factor and basic fibroblast growth factor in extramammary Paget disease.
Pancreatic Cyst
Pancreatic Cyst Fluid Vascular Endothelial Growth Factor A and Carcinoembryonic Antigen: A Highly Accurate Test for the Diagnosis of Serous Cystic Neoplasm.
Vascular endothelial growth factor detection in serous pancreatic cysts: have we really reached a breakthrough?
Vascular endothelial growth factor, a novel and highly accurate pancreatic fluid biomarker for serous pancreatic cysts.
Pancreatic Diseases
A vascular endothelial growth factor gene polymorphism predicts malignant potential in intraductal papillary mucinous neoplasm.
Pancreatic Neoplasms
A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer.
A Novel Strategy for Advanced Pancreatic Cancer - Progression of Molecular Targeting Therapy.
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Action of antiproteases on pancreatic cancer cells.
Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling.
Anti-angiogenesis therapy in pancreatic carcinoma.
Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro.
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer.
Association of vascular endothelial growth factor (VEGF) gene polymorphism and increased serum VEGF concentration with pancreatic adenocarcinoma.
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer.
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy.
Clinical significance of vascular endothelial growth factor and connexin43 for predicting pancreatic cancer clinicopathologic parameters.
Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer.
Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E2.
Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer.
De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop.
Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells.
Dynamic contrast-enhanced (DCE) MRI assessment of microvascular characteristics in the murine orthotopic pancreatic cancer model.
Effect of antisense oligodeoxynucleotide of vascular endothelial growth factor C on lymphangiogenesis and angiogenesis of pancreatic cancer.
Effect of HIF-1alpha on VEGF-C induced lymphangiogenesis and lymph nodes metastases of pancreatic cancer.
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Effects of Helicobacter pylori infection on human pancreatic cancer cell line.
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.
Endocrine gland?derived vascular endothelial growth factor modulates proliferation, apoptosis and migration in pancreatic cancer cells.
Endocrine glands-derived vascular endothelial growth factor protects pancreatic cancer cells from apoptosis via upregulation of the myeloid cell leukemia-1 protein.
Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity.
Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression.
Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer.
Escin inhibits angiogenesis by suppressing interleukin?8 and vascular endothelial growth factor production by blocking nuclear factor??B activation in pancreatic cancer cell lines.
Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer.
Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis.
Expression of vascular endothelial growth factors A and C in human pancreatic cancer.
Function of nuclear factor kappaB in pancreatic cancer metastasis.
Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor.
Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer.
Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer.
Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis.
In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2.
Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer.
Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells.
Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.
Interleukin-1alpha, 6 regulate the secretion of vascular endothelial growth factor A, C in pancreatic cancer.
Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer.
Keratinocyte growth factor induces vascular endothelial growth factor-A expression in colorectal cancer cells.
Low molecular weight heparin suppresses lymphatic endothelial cell proliferation induced by vascular endothelial growth factor C in vitro.
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma.
Melatonin inhibits the expression of vascular endothelial growth factor in pancreatic cancer cells.
Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors.
Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a.
MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes.
Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma.
Molecular and genetic bases of pancreatic cancer.
Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer.
Neoadjuvant therapy and biliary decompression lower biliary and pancreatic juice vascular endothelial growth factor levels in patients with periampullary adenocarcinoma.
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Novel approaches to target pancreatic cancer.
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells.
p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models.
Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo.
Pancreatic cancer: what the oncologist can offer for palliation.
Pancreatic head carcinoma and vascular endothelial growth factor (VEGF-A) concentration in portal blood: its association with cancer grade, tumor size and probably poor prognosis.
Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma.
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results.
Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells.
Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer.
Prognostic significance of S100A4 and vascular endothelial growth factor expression in pancreatic cancer.
Propofol attenuates pancreatic cancer malignant potential via inhibition of NMDA receptor.
Propofol inhibits pancreatic cancer proliferation and metastasis by up-regulating miR-328 and down-regulating ADAM8.
Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer.
Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins.
Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation.
Retraction: Down-regulation of Notch-1 Inhibits Invasion by Inactivation of Nuclear Factor-?B, Vascular Endothelial Growth Factor, and Matrix Metalloproteinase-9 in Pancreatic Cancer Cells.
Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line.
RNA interference?mediated inhibition of survivin and VEGF in pancreatic cancer cells in vitro.
Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells.
Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis.
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer.
Significance of phospho-vascular endothelial growth factor receptor-2 expression in pancreatic cancer.
Sonic hedgehog derived from human pancreatic cancer cells augments angiogenic function of endothelial progenitor cells.
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.
Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis.
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.
The RON tyrosine kinase receptor regulates vascular endothelial growth factor production in pancreatic cancer cells.
Thiol-ene hydrogels as desmoplasia-mimetic matrices for modeling pancreatic cancer cell growth, invasion, and drug resistance.
Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer.
TPS, CA 19-9, VEGF-A, and CEA as Diagnostic and Prognostic Factors in Patients with Mass Lesions in the Pancreatic Head.
Traditional Chinese medicine Astragalus polysaccharide enhanced antitumor effects of the angiogenesis inhibitor apatinib in pancreatic cancer cells on proliferation, invasiveness, and apoptosis.
Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF.
Troponin I peptide (Glu94-Leu123), a cartilage-derived angiogenesis inhibitor: in vitro and in vivo effects on human endothelial cells and on pancreatic cancer.
Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer.
Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer.
Vascular endothelial growth factor levels in bile distinguishes pancreatic cancer from other etiologies of biliary stricture: a pilot study.
Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray.
Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer.
VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature.
VEGF Promotes Glycolysis in Pancreatic Cancer via HIF1? Up-Regulation.
VEGF-A/VEGFR-2 Signaling Plays an Important Role for the Motility of Pancreas Cancer Cells.
VEGF-C ShRNA inhibits pancreatic cancer growth and lymphangiogenesis in an orthotopic fluorescent nude mouse model.
VEGF-RII influences the prognosis of pancreatic cancer.
Xanthohumol inhibits angiogenesis by suppressing nuclear factor-?B activation in pancreatic cancer.
Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells.
ZIP4 upregulates the expression of neuropilin-1, vascular endothelial growth factor, and matrix metalloproteases in pancreatic cancer cell lines and xenografts.
[Exogenous PTEN enhances apoptosis in pancreas cancer cell line ASPC-1 induced by hypoxia]
[Expression of vascular endothelial growth factor C in pancreatic cancer and its effect upon lymph node metastasis]
[Gene therapy for pancreatic cancer]
Pancreaticobiliary Maljunction
Immunohistochemical analysis of cyclooxygenase-2 and vascular endothelial growth factor in pancreaticobiliary maljunction.
Pancreatitis
A Rare Case of Acquired Thrombotic Thrombocytopenic Purpura Triggered by Acute Pancreatitis.
Effect of ischemic preconditioning on pancreatic regeneration and pancreatic expression of vascular endothelial growth factor and platelet-derived growth factor-A in ischemia/reperfusion-induced pancreatitis.
EFFECTS OF THALIDOMIDE IN A MOUSE MODEL OF CERULEIN-INDUCED ACUTE PANCREATITIS.
Effects of thalidomide in a mouse model of cerulein-induced acute pancreatitis.
Everolimus Improves Microcirculatory Derangements in Experimental Postischemic Pancreatitis Modulating the Expression of Vascular Endothelial Growth Factor, Interleukin 6, and Toll-Like Receptor 4.
Host Gene Expression in the Colon of Gnotobiotic Interleukin-2-Deficient Mice Colonized with Commensal Colitogenic or Noncolitogenic Bacterial Strains: Common Patterns and Bacteria Strain Specific Signatures.
Protective effects of vascular endothelial growth factor on intestinal epithelial apoptosis and bacterial translocation in experimental severe acute pancreatitis.
Serum levels of mast cell tryptase, vascular endothelial growth factor and basic fibroblast growth factor in patients with acute pancreatitis.
Serum levels of mast cell tryptase, vascular endothelial growth factor, and basic fibroblast growth factor in patients with acute pancreatitis.
Vascular endothelial growth factor increases in serum and protects against the organ injuries in severe acute pancreatitis.
[Role of vascular endothelial growth factor in rats with severe acute pancreatitis].
Pancreatitis, Chronic
Expression of vascular endothelial growth factor and epidermal growth factor receptor in pancreatic ductal adenocarcinomas, neuroendocrine tumours and chronic pancreatitis.
Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma: differential diagnosis, tumor progression, and patient survival.
Vascular endothelial growth factor (VEGF) genotype and serum concentration in patients with pancreatic adenocarcinoma and chronic pancreatitis.
Papilledema
Anti-VEGF therapy prevents Müller intracellular edema by decreasing VEGF-A in diabetic retinopathy.
Atypical polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome without polyneuropathy: A case report.
Correlation of Vascular Endothelial Growth Factor Production with Photochemical Reaction-induced Retinal Edema.
Effects of an Aquaporin 4 Inhibitor, TGN-020, on Murine Diabetic Retina.
Induction of ischemic tolerance protects the retina from diabetic retinopathy.
Ocular Findings in Patients with Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.
Optic disc edema, cystoid macular edema, and elevated vascular endothelial growth factor in a patient with POEMS syndrome.
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome.
POEMS Syndrome: an Enigma.
Restoring retinal neurovascular health via substance P.
Targeting leukostasis for the treatment of early diabetic retinopathy.
Treatment of Leukoencephalopathy With Calcifications and Cysts With Bevacizumab.
Papilloma
Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function.
Associations between Histogram Analysis Parameters Derived from DCE-MRI and Histopathological Features including Expression of EGFR, p16, VEGF, Hif1-alpha, and p53 in HNSCC.
Associations Between [18F]FDG-PET and Complex Histopathological Parameters Including Tumor Cell Count and Expression of KI 67, EGFR, VEGF, HIF-1?, and p53 in Head and Neck Squamous Cell Carcinoma.
Biologics for the Treatment of Recurrent Respiratory Papillomatosis.
Immunoexpression of vascular endothelial growth factor in gingival mucosa with papilloma and condyloma acuminata.
The expression of epidermal growth factor receptor, vascular endothelial growth factor, matrix metalloproteinase-2, and cyclooxygenase-2 in relation to human papilloma viral load and persistence of human papillomavirus after conization with negative margins.
Tissue biomarkers as prognostic variables of cervical cancer.
Papilloma, Inverted
The elevated expression of osteopontin and vascular endothelial growth factor in sinonasal inverted papilloma and its relationship with clinical severity.
[Significance and expression of VEGF and its receptor in nasal inverted papillomas and the correlation with malignant phenotype].
[The significance and expression of vascular endothelial growth factor on nasal inverted papillomas]
Paraganglioma
Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma.
Endoglin as a marker in cervical paragangliomas.
Expression of angiogenic growth factors in paragangliomas.
Vascular endothelial growth factor expression, vascularization and proliferation in paragangliomas.
VEGF mRNA expression in jugulotympanic paraganglioma.
Paralysis
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.
Vascular endothelial growth factor gene therapy improves nerve regeneration in a model of obstetric brachial plexus palsy.
Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration.
Paraneoplastic Syndromes
Diffuse intestinal angiomatosis as a possible paraneoplastic manifestation of small cell lung cancer: a case of small bowel angiomatosis.
Oocyte cryopreservation in the setting of a vascular endothelial growth factor (VEGF)-producing paraneoplastic syndrome: a case report and review of literature.
Paraneoplastic symptoms: Cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma.
Paraparesis
Hind-limb paraparesis in a rat model for neurolathyrism associated with apoptosis and an impaired vascular endothelial growth factor system in the spinal cord.
Paraparesis, Tropical Spastic
Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism.
Paraproteinemias
Asymmetric optic disc edema in a young patient with POEMS: A rare presentation of a rare disease.
Atypical polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome without polyneuropathy: A case report.
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
Changes in subfoveal choroidal thickness and reduction of serum levels of vascular endothelial growth factor in patients with POEMS syndrome.
Coexistence of Quasi-moyamoya Disease and POEMS Syndrome in a Patient with Intracranial Hemorrhage: A Case Report and Literature Review.
Correlation between peripapillary retinal thickness and serum level of vascular endothelial growth factor in patients with POEMS syndrome.
Correlation between serum level of vascular endothelial growth factor and subfoveal choroidal thickness in patients with POEMS syndrome.
Correlation of changes in serum level of VEGF and peripapillary retinal thickness in patients with POEMS syndrome.
Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma.
Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan.
Efficacy of lenalidomide in POEMS syndrome: A retrospective study of 20 patients.
Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity.
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Increase of serum vascular endothelial growth factors in wet beriberi: two case reports.
Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial.
Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome.
Optic disc edema, cystoid macular edema, and elevated vascular endothelial growth factor in a patient with POEMS syndrome.
POEMS syndrome and calciphylaxis: an unrecognized cause of abnormal small vessel calcification.
POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation.
Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis.
Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab.
Remarkable expression of vascular endothelial growth factor in bone marrow plasma cells of patients with POEMS syndrome.
Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome.
Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
Skin and Nerve Neovascularization in POEMS Syndrome: Insights From a Small Cohort.
Skin manifestations and vascular endothelial growth factor levels in POEMS syndrome: impact of autologous hematopoietic stem cell transplantation.
Successful Treatment of a Patient with POEMS Syndrome by Tandem High-Dose Chemotherapy with Autologous CD34+ Purged Stem Cell Rescue.
The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study.
Vascular endothelial growth factor helps differentiate neuropathies in rare plasma cell dyscrasias.
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.
[Crow-Fukase (POEMS) syndrome: pathophysiology and treatments].
[POEMS syndrome presenting with transient immunoglobulin isotype switching after successful treatment with autologous peripheral blood stem cell transplantation]
Parasitemia
Elevated Levels of the Endothelial Molecules ICAM-1, VEGF-A, and VEGFR2 in Microscopic Asymptomatic Malaria.
Parathyroid Neoplasms
Angiogenesis and lymphangiogenesis in parathyroid proliferative lesions.
Biomarkers of parathyroid carcinoma.
Immunohistochemical expression of Insulin-like growth factor-1, Transforming growth factor-beta1, and Vascular endothelial growth factor in parathyroid adenoma and hyperplasia.
Paresis
Value of measuring serum vascular endothelial growth factor levels in diagnosing acute ischemic stroke.
Parkinson Disease
Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease.
Angiogenic and neurotrophic effects of vascular endothelial growth factor (VEGF165): studies of grafted and cultured embryonic ventral mesencephalic cells.
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1?.
Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease.
Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease.
Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease.
Intrastriatal gene transfer of vascular endothelial growth factor rescues dopaminergic neurons in a rat Parkinson's disease model.
Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
PI3-K/Akt and ERK pathways activated by VEGF play opposite roles in MPP(+)-induced neuronal apoptosis.
Single-nucleotide polymorphisms (SNPs) and haplotype analysis in vascular endothelial growth factor (VEGF) gene in the patients with Parkinson disease and lung cancer.
The Effects of Deep Brain Stimulation of the Subthalamic Nucleus on Vascular Endothelial Growth Factor, Brain-Derived Neurotrophic Factor, and Glial Cell Line-Derived Neurotrophic Factor in a Rat Model of Parkinson's Disease.
The role of ?-adrenergic blockers in Parkinson's disease: possible genetic and cell-signaling mechanisms.
Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease.
Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.
[Adenovirus mediated vascular endothelial growth factor gene transfer protects dopaminergic neurons in Parkinson's disease: experiment with rats]
Parkinsonian Disorders
Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian.
Pediatric Obesity
Vascular Endothelial Growth Factor Haplotypes Associated with Childhood Obesity.
Peliosis Hepatis
"Have you seen this?" peliosis hepatis.
Peliosis hepatis associated with follicular lymphoma with a rise in vascular endothelial growth factor and anaemia of inflammation.
Pemphigoid, Bullous
Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes.
Pemphigus
Exploring the in situ expression of vascular endothelial growth factor and endoglin in pemphigus foliaceus variants and pemphigus vulgaris.
Increased serum levels of vascular endothelial growth factor in pemphigus foliaceus patients with erythroderma.
Peptic Ulcer
Can serum progranulin levels be a biomarker following gastric ulcer therapy?
Effect of polymorphisms in the 3' untranslated region (3'-UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan.
Peri-Implantitis
Expression of Vascular Endothelial Growth Factor (VEGF) mRNA in healthy bone tissue around implants and in peri-implantitis.
Influence of amine fluoride/stannous fluoride mouthwashes with and without chlorhexidine on secretion of proinflammatory molecules by peri-implant crevicular fluid cells.
Periapical Granuloma
A potential role for the silent information regulator 2 homologue 1 (SIRT1) in periapical periodontitis.
Immunoexpression of vascular endothelial growth factor in periapical granulomas, radicular cysts, and residual radicular cysts.
Periapical Periodontitis
Vascular endothelial growth factors and receptors are up-regulated during development of apical periodontitis.
Pericardial Effusion
Idiopathic remitting seronegative symmetrical synovitis with pitting edema syndrome associated with bilateral pleural and pericardial effusions: a case report.
Influenza A H1N1 pdm09-associated myocarditis during zanamivir therapy.
Marked pleural and pericardial effusion with elevated Vascular Endothelial Growth Factor production: an uncommon complication of Kawasaki disease.
Preliminary Investigation of the Clinical Value of Vascular Endothelial Growth Factor and Hypoxia-Inducible Factor-1alpha in Pericardial Fluid in Diagnosing Malignant and Tuberculous Pericardial Effusion.
Vascular Endothelial Growth Factor in Malignant and Benign Pericardial Effusion.
Periodontal Diseases
A disintegrin-like And metalloproteinase with thrombospondin-1 (ADAMTS-1) levels in gingival crevicular fluid correlate with vascular endothelial growth factor-A, hypoxia-inducible factor-1?, and clinical parameters in patients with advanced periodontitis.
Cyclooxygenase-2-derived prostaglandin E(2) is involved in vascular endothelial growth factor production in interleukin-1alpha-stimulated human periodontal ligament cells.
Effect of Non-Surgical Periodontal Treatment on Gingival Crevicular Fluid and Serum Endocan, Vascular Endothelial Growth Factor-A, and Tumor Necrosis Factor-Alpha Levels.
Expression of VEGF in Periodontal Tissues of Type II Diabetes Mellitus Patients with Chronic Periodontitis -an Immunohistochemical Study.
Gingival crevicular fluid and serum vascular endothelial growth factor: Their relationship in periodontal health, disease and after treatment.
Involvement of vascular endothelial growth factor, CD44 and CD133 in periodontal disease and diabetes: an immunohistochemical study.
Leptin within healthy and diseased human gingiva.
Potential role of vascular endothelial growth factor, interleukin-8 and monocyte chemoattractant protein-1 in periodontal diseases.
Serum Placental Growth Factor (PIGF), Vascular Endothelial Growth Factor (VEGF), Soluble VEGF Receptor -1 and -2 Levels In Periodontal Disease and Adverse Pregnancy Outcomes.
Short-term induction of thrombocytopenia delays periodontal healing in rats with periodontal disease: participation of endostatin and vascular endothelial growth factor.
The expression of vascular endothelial growth factor in a rat model at destruction and healing stages of periodontal disease.
Uncoupling of Vascular Endothelial Growth Factor (VEGF) and Inducible Nitric Oxide Synthase (iNOS) in Gingival Tissue of Type 2 Diabetic Patients.
Vascular endothelial cadherin and vascular endothelial growth factor in periodontitis and smoking.
Vascular endothelial growth factor (VEGF) levels of gingiva and gingival crevicular fluid in diabetic and systemically healthy periodontitis patients.
Vascular endothelial growth factor in human periodontal disease.
Periodontitis
A disintegrin-like And metalloproteinase with thrombospondin-1 (ADAMTS-1) levels in gingival crevicular fluid correlate with vascular endothelial growth factor-A, hypoxia-inducible factor-1?, and clinical parameters in patients with advanced periodontitis.
Association of cytokines, high sensitive C-reactive protein, VEGF and beta-defensin-1 gene polymorphisms and their protein expressions with chronic periodontitis in the Chinese population.
COX-2 inhibition decreases VEGF expression and alveolar bone loss during the progression of experimental periodontitis in rats.
Effect of rhPDGF-BB Delivery on Mediators of Periodontal Wound Repair.
Effect of rhPDGF-BB delivery on mediators of periodontal wound repair.
Effect of VEGFC on lymph flow and inflammation-induced alveolar bone loss.
Effects of nicotine administration in rats on MMP2 and VEGF levels in periodontal membrane.
Gingival Crevicular Fluid Cytokines in Moderate and Deep Sites of Stage III Periodontitis Patients in Different Rates of Clinical Progression.
Hypoxia and collagen crosslinking in the healthy and affected sites of periodontitis patients.
Involvement of vascular endothelial growth factor, CD44 and CD133 in periodontal disease and diabetes: an immunohistochemical study.
Role of fibroblast populations in peri-implantitis.
Role of Hyperplasia of Gingival Lymphatics in Periodontal Inflammation.
Vascular endothelial cadherin and vascular endothelial growth factor in periodontitis and smoking.
Vascular endothelial growth factor (VEGF) levels of gingiva and gingival crevicular fluid in diabetic and systemically healthy periodontitis patients.
Vascular endothelial growth factor and microvessel density in periodontitis patients with and without diabetes.
Vascular endothelial growth factor expression levels of gingiva in gingivitis and periodontitis patients with/without diabetes mellitus.
Vascular endothelial growth factor in gingival tissues and crevicular fluids of diabetic and healthy periodontal patients.
Peripheral Arterial Disease
Activation of Flk-1/KDR mediates angiogenesis but not hypotension.
Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve.
Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle.
Antiangiogenic VEGF-A in peripheral artery disease.
Correlation between increasing tissue ischemia and circulating levels of angiogenic growth factors in peripheral artery disease.
Effect of training on the response of plasma vascular endothelial growth factor to exercise in patients with peripheral arterial disease.
Endogenous vascular endothelial growth factor and angiopoietin-2 expression in critical limb ischemia.
Gene therapy for cardiovascular disease: the potential of VEGF.
Hybrid Nitric Oxide Donor and its Carrier for the Treatment of Peripheral Arterial Diseases.
Imaging VEGF Receptors and ?v?3 Integrins in a Mouse Hindlimb Ischemia Model of Peripheral Arterial Disease.
Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease.
Impact of VEGF polymorphisms on the severity of peripheral artery disease in diabetic patients.
Impaired Vascular Endothelial Growth Factor A and Inflammation in Patients With Peripheral Artery Disease.
Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia.
Is gene therapy for limb ischemia a reality?
Low-energy extracorporeal shock wave therapy promotes vascular endothelial growth factor expression and improves locomotor recovery after spinal cord injury.
Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia.
Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.
Reactive hyperemia and BOLD MRI demonstrate that VEGF inhibition, age, and atherosclerosis adversely affect functional recovery in a murine model of peripheral artery disease.
Recent progress in gene therapy for cardiovascular disease.
Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial.
Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
Repeated, but not single, VEGF gene transfer affords protection against ischemic muscle lesions in rabbits with hindlimb ischemia.
Serum concentrations of vascular endothelial growth factor and monocyte-colony stimulating factor in peripheral arterial disease.
Sustained elevation of circulating vascular endothelial growth factor after percutaneous angioplasty for peripheral arterial diseases.
The association between circulating anti-angiogenic isoform of vascular endothelial growth factor and clinical profiles in patients with peripheral artery disease.
Treatment of mouse limb ischemia with an integrative hypoxia-responsive vector expressing the vascular endothelial growth factor gene.
Vascular complications and gene therapy.
Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis?
[The effect of vascular endothelia growth factor encapsulated in nanoparticles on chronic limb ischemia]
[Therapeutic angiogenesis for diabetes mellitus related ischemic disease]
[Vascular endothelial growth factor gene therapy for peripheral artery disease: experimental study]
Peripheral Nerve Injuries
Effects of vascular endothelial growth factor on nerve regeneration in acellular nerve grafts.
Vascularization via activation of VEGF-VEGFR signaling is essential for peripheral nerve regeneration.
X-ray irradiation has positive effects for the recovery of peripheral nerve injury maybe through the vascular smooth muscle contraction signaling pathway.
Peripheral Nervous System Diseases
Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth.
Association of osteonecrosis and peripheral neuropathy in HIV-1-infected patients: possible roles of nerve growth factor and vascular endothelial growth factor.
Association of the Vascular Endothelial Growth Factor Gene Polymorphism +936 C/T with Diabetic Neuropathy in Mexican Patients with Type 2 Diabetes Mellitus.
Chylothorax in POEMS syndrome.
Ethnic differences in the +405 and -460 vascular endothelial growth factor polymorphisms and peripheral neuropathy in patients with diabetes residing in a North London, community in the United Kingdom.
Interactions between and Shared Molecular Mechanisms of Diabetic Peripheral Neuropathy and Obstructive Sleep Apnea in Type 2 Diabetes Patients.
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome.
POEMS syndrome associated with plasmacytoma of the clivus: "Time discovers the truth".
Relationship between single nucleotide polymorphisms in the 3'-untranslated region of the vascular endothelial growth factor gene and susceptibility to diabetic peripheral neuropathy in China.
Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome.
Successful Treatment of a Patient with POEMS Syndrome by Tandem High-Dose Chemotherapy with Autologous CD34+ Purged Stem Cell Rescue.
The therapeutic potential of gene transfer for the treatment of peripheral neuropathies.
[Pathology of Crow-Fukase syndrome]
[Treatment of POEMS syndrome with lenalidomide and dexamethasone].
Peripheral Nervous System Neoplasms
Peripheral and cranial nerve sheath tumors.
Peripheral Vascular Diseases
AdGVVEGF121.10 (GenVec).
An engineered VEGF-activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced-age mice.
Does gene therapy become pharmacotherapy?
Gene therapy in vascular medicine: recent advances and future perspectives.
Peripheral vascular disease: preclinical models and emerging therapeutic targeting of the vascular endothelial growth factor ligand-receptor system.
Perspective in progress of cardiovascular gene therapy.
Recent progress in gene therapy for cardiovascular disease.
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Vascular endothelial growth factor causes pulmonary vasodilation through activation of the phosphatidylinositol-3-kinase-nitric oxide pathway in the late-gestation ovine fetus.
Vascular permeability effect of adenovirus-mediated vascular endothelial growth factor gene transfer to the rabbit and rat skeletal muscle.
[Gene therapy for peripheral arterial diseases]
[Overview on diagnosis, treatment and therapeutic angiogenesis for arteriosclerosis obliterans]
[Therapeutic angiogenesis using genetic transfection. An in vitro quantitative and functional study after gene code transfer for vascular endothelial growth factor]
Peritoneal Diseases
Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
Peritoneal Fibrosis
Calcitriol decreases TGF-?1 and angiotensin II production and protects against chlorhexide digluconate-induced liver peritoneal fibrosis in rats.
Effect of bevacizumab, a vascular endothelial growth factor inhibitor, on a rat model of peritoneal sclerosis.
Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model.
HIF1A and VEGF regulate each other by competing endogenous RNA mechanism and involve in the pathogenesis of peritoneal fibrosis.
Hypoxia, cytokines and stromal recruitment: parallels between pathophysiology of encapsulating peritoneal sclerosis, endometriosis and peritoneal metastasis.
Inhibition effect of small interfering RNA of connective tissue growth factor on the expression of vascular endothelial growth factor and connective tissue growth factor in cultured human peritoneal mesothelial cells.
Interstitial Fibrosis Restricts Osmotic Water Transport in Encapsulating Peritoneal Sclerosis.
Patients with encapsulating peritoneal sclerosis have increased peritoneal expression of connective tissue growth factor (CCN2), transforming growth factor-?1, and vascular endothelial growth factor.
Peritoneal dialysis in diabetic patients.
Preventive effect of Notch signaling inhibition by a gamma-secretase inhibitor on peritoneal dialysis fluid-induced peritoneal fibrosis in rats.
Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis.
Tetramethylpyrazine Ameliorates Peritoneal Angiogenesis by Regulating VEGF/Hippo/YAP Signaling.
The impact of gene polymorphisms in angiotensin receptor 1 and aldosterone synthase in peritoneal dialysis patients.
WNT Signaling Is Required for Peritoneal Membrane Angiogenesis.
Peritoneal Neoplasms
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and its receptor PROKR2 are associated to human colorectal cancer progression and peritoneal carcinomatosis.
Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: the first step before intraperitoneal anti-vascular endothelial growth factor treatment?
Intraperitoneal Vascular Endothelial Growth Factor: A Prognostic Factor and the Potential for Intraperitoneal Bevacizumab Use in Peritoneal Surface Malignancies.
Prognostic Significance of Serum Vascular Endothelial Growth Factor Per Platelet Count in Unresectable Advanced Gastric Cancer Patients.
Peritonitis
Acute peritonitis in a C57BL/6 mouse model of peritoneal dialysis.
Enhanced local production of vascular endothelial growth factor is not sufficient to increase peritoneal permeability to protein during acute peritonitis.
Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
Increased production of vascular endothelial growth factor in peritoneal macrophages of cirrhotic patients with spontaneous bacterial peritonitis.
The role of vascular endothelial growth factor in peritoneal hyperpermeability during CAPD-related peritonitis.
Vascular endothelial growth factor (VEGF), produced by feline infectious peritonitis (FIP) virus-infected monocytes and macrophages, induces vascular permeability and effusion in cats with FIP.
Vascular endothelial growth factor in dialysate in relation to intensity of peritoneal inflammation.
Persistent Hyperplastic Primary Vitreous
Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease.
Pheochromocytoma
Bioactivity of small intestinal submucosa and oxidized regenerated cellulose/collagen.
Distinct protein kinase C isoforms mediate regulation of vascular endothelial growth factor expression by A2A adenosine receptor activation and phorbol esters in pheochromocytoma PC12 cells.
Down-regulation of vascular endothelial growth factor expression after A(2A) adenosine receptor activation in PC12 pheochromocytoma cells.
Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation.
Effect of norepinephrine on RhoA, MAP kinase, proliferation and VEGF expression in human umbilical vein endothelial cells.
Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas.
In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor.
Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells.
The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway.
The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development.
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.
[Expression of transforming growth factor alpha, tumor necrosis factor alpha, and vascular endothelial growth factor of human pheochromocytoma tissues]
Phlebitis
Effects of anisodamine on the expressions of vascular endothelial growth factor and intercellular adhesion molecule 1 in experimental infusion phlebitis.
Phyllodes Tumor
Expression of vascular endothelial growth factor, CD10, and factor 8 in phyllodes tumor: A 5-year study of 38 cases.
Phyllodes tumours of the breast: the role of CD34, vascular endothelial growth factor and ?-catenin in histological grading and clinical outcome.
Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases.
Pituitary ACTH Hypersecretion
Neurological surgery at the National Institutes of Health.
Pituitary Apoplexy
Landscape of Molecular Events in Pituitary Apoplexy.
Pituitary Apoplexy After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitor: A Novel Complication.
Pituitary Neoplasms
2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: possible role of vascular endothelial growth factor.
Analysis of Circulating Endostatin and Vascular Endothelial Growth Factor in Patients with Pituitary Adenoma Treated by Stereotactic Radiosurgery: A Preliminary Study.
Angiogenesis in normal and neoplastic pituitary tissues.
Angiogenesis in pituitary adenomas: human studies and new mutant mouse models.
Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour.
Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: case report and literature review.
Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors.
Biomarkers of pituitary neoplasms: a review (Part II).
Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1.
Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy.
Clinicopathological investigation of vascular endothelial growth factor and von hippel-lindau gene-related protein expression in immunohistochemically negative pituitary adenoma - possible involvement in tumor aggressiveness.
Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas.
Effects of somatostatin on vascular endothelial growth factor (VEGF) secretion from non-functioning pituitary tumoral cells incubated in vitro.
Estradiol stimulates vascular endothelial growth factor and interleukin-6 in human lactotroph and lactosomatotroph pituitary adenomas.
Estrogen-dependent growth of a rat pituitary tumor involves, but does not require, a high level of vascular endothelial growth factor.
Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.
Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas.
Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior ?
Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment.
Expression of vascular endothelial growth factor in normal pituitary cells and pituitary adenomas producing adrenocorticotropic hormone.
Hypoxia induces hemorrhagic transformation in pituitary adenomas via the HIF-1? signaling pathway.
Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice.
Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas.
Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas.
Molecular Network Basis of Invasive Pituitary Adenoma: A Review.
Morphologic changes and molecular regulation of angiogenesis in pituitary adenomas.
Multiple Endocrine Neoplasia Type 1 (MEN1) knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia.
Non-Small Cell Bronchial Carcinoma Metastasizing into a Prolactin-Producing Pituitary Adenoma.
NRP-1 expression is strongly associated with the progression of pituitary adenomas.
Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.
Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence.
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
Pituitary tumor transforming gene: an update.
Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas.
Relationship between expression of vascular endothelial growth factor and intratumoral hemorrhage in human pituitary adenomas.
Relationship between intratumoral hemorrhage and overexpression of vascular endothelial growth factor (VEGF) in pituitary adenoma.
Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas.
siRNA-mediated silencing of bFGF gene inhibits the proliferation, migration, and invasion of human pituitary adenoma cells.
Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection.
The "game" of glial fibrillary acidic and S100 proteins in pituitary adenomas: two players or several?
The association of the expression of vascular endothelial growth factor with the cystic component and haemorrhage in pituitary adenoma.
The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas.
TNF-?-Induced VEGF and MMP-9 Expression Promotes Hemorrhagic Transformation in Pituitary Adenomas.
Trophic and neurotrophic factors in human pituitary adenomas (Review).
Vascular Endothelial Growth Factor (VEGF) Expression in Human Pituitary Adenomas and Carcinomas.
Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours.
Vascular endothelial growth factor expression in pituitary adenomas.
Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro.
Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors.
[Expressive level of vascular endothelial growth factor in peripheral blood in patients with pituitary adenomas]
Placenta Accreta
Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta.
Placenta Previa
Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast.
Increased expression of high mobility group box protein 1 and vascular endothelial growth factor in placenta previa.
Placental Insufficiency
Achieving orphan designation for placental insufficiency: annual incidence estimations in Europe.
Imaging of activated complement using ultrasmall superparamagnetic iron oxide particles (USPIO)--conjugated vectors: an in vivo in utero non-invasive method to predict placental insufficiency and abnormal fetal brain development.
Timing of ischemic insult alters fetal growth trajectory, maternal angiogenic balance, and markers of renal oxidative stress in the pregnant rat.
Plasmacytoma
Autologous peripheral blood stem cell transplantation for POEMS syndrome.
Biological impact of vascular endothelial growth factor on vessel density and survival in multiple myeloma and plasmacytoma.
Case Report: Challenges in the Diagnosis of Adenopathy and Extensive Skin Patch Overlying a Plasmacytoma Syndrome.
Coexistence of Quasi-moyamoya Disease and POEMS Syndrome in a Patient with Intracranial Hemorrhage: A Case Report and Literature Review.
Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome.
Monoclonal gammopathy of cutaneous significance: review of a relevant concept.
POEMS syndrome associated with plasmacytoma of the clivus: "Time discovers the truth".
Solitary plasmacytoma of the skull: immunohistochemical study of angiogenic factors and syndecan-1--two case reports.
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.
Vascular endothelial growth factor (VEGF) expression in plasmacytoma.
[A case of Crow-Fukase syndrome with extramedullary plasmacytoma: marked clinical deterioration following a biopsy to plasmacytoma]
[Electrophysiologic aspects of Crow-Fukase (POEMS) syndrome--significance in early diagnosis and insights into the pathophysiology]
[New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy]
[POEMS syndrome: monoclonal plasma cell disorder with polyneuropathy]
Pleural Diseases
Evaluation of ovarian cancer biomarkers in subjects with benign asbestos-related pleural diseases.
Pleural Effusion
A case of cardiac amyloidosis with diuretic-refractory pleural effusions treated with bevacizumab.
A case of subclinical hypothyroidism developing marked pleural effusions and peripheral edema with elevated vascular endothelial growth factor.
Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: Correlations with patient survival and pleural effusion control.
Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions.
Angiopoietin-2 levels are elevated in exudative pleural effusions.
Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
Clinical significance of vascular endothelial growth factor in patients with primary lung cancer.
Clinical value of vascular endothelial growth factor combined with interferon-gamma in diagnosing malignant pleural effusion and tuberculous pleural effusion.
Diagnostic Significance of Measuring Vascular Endothelial Growth Factor for the Differentiation between Malignant and Tuberculous Pleural Effusion.
Diagnostic utility of LUNX mRNA and VEGF mRNA in pleural fluid for differentiating benign from malignant origin.
Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions.
Diagnostic Value of Vascular Endothelial Growth Factor, Transforming Growth Factor-?, Interleukin-8, and the Ratio of Lactate Dehydrogenase to Adenosine Deaminase in Pleural Effusion.
Discrimination of exudative pleural effusions based on multiple biological parameters.
Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs).
Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion.
High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer.
Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor.
Incidence and risk factors of pleural effusions in patients with POEMS syndrome.
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.
Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone.
Pleural mesothelial cells in pleural and lung diseases.
Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome.
Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors.
Residual Pleural Thickening Is Related to Vascular Endothelial Growth Factor Levels in Parapneumonic Pleural Effusions.
Role of viral induced vascular endothelial growth factor (VEGF) production in pleural effusion and malignant mesothelioma.
Serum vascular endothelial growth factor in pediatric patients with community-acquired pneumonia and pleural effusion.
Syndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells.
Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.
The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
The importance of serum and pleural fluid level of vascular endothelial growth factor (VEGF) and VEGF fluid/serum ratio in the differential diagnosis of malignant mesothelioma-related pleural effusion.
Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer.
Transforming growth factor beta induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro.
Utility of VEGF and sVEGFR-1 in bronchoalveolar lavage fluid for differential diagnosis of primary lung cancer.
Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions.
Vascular endothelial growth factor and protein level in pleural effusion for differentiating malignant from benign pleural effusion.
Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Vascular endothelial growth factor correlates with matrix metalloproteinase-9 in the pleural effusion.
Vascular endothelial growth factor in malignant and tuberculous pleural effusions.
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Vascular endothelial growth factor in pleural effusions and correlation with radiologic and biochemical parameters.
Vascular endothelial growth factor in pleural effusions of different origin.
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications.
Vascular endothelial growth factor level correlates with transforming growth factor-beta isoform levels in pleural effusions.
Vascular endothelial growth factor levels in pleural and peritoneal fluid in Meigs' syndrome.
Vascular endothelial growth factor levels in pleural fluid and serum of patients with tuberculous pleural effusions.
Vascular endothelial growth factor levels in post-CABG pleural effusions are associated with pleural inflammation and permeability.
Vascular endothelial growth factor with tumour growth factor-beta, endostatin, proteinases or cytokines might be useful for differential diagnosis of pleural effusions.
Vascular endothelial growth factor: the key mediator in pleural effusion formation.
VEGF increases the permeability of sheep pleura ex vivo through VEGFR2 stimulation.
VEGF-D as a marker in the aid of malignant metastatic pleural effusion diagnosis.
[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP]
[Effect of anti-vascular endothelial growth factor antibody on pleurodesis induced by transforming growth factor-beta or doxycycline in rabbits]
[Role of c-c chemokines in the determination of pleural effusion etiology]
Pleural Effusion, Malignant
A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: Correlations with patient survival and pleural effusion control.
Angiogenic molecule expression is downregulated in effusions from breast cancer patients.
Clinical utility of vascular endothelial growth factor in diagnosing malignant pleural effusions.
Clinical value of vascular endothelial growth factor combined with interferon-gamma in diagnosing malignant pleural effusion and tuberculous pleural effusion.
Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer.
Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: A meta-analysis.
Diagnostic Significance of Measuring Vascular Endothelial Growth Factor for the Differentiation between Malignant and Tuberculous Pleural Effusion.
Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions.
Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions.
Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusions.
Levels of Vascular Endothelial Growth Factor in Serum and Pleural Fluid Are Independent Predictors of Survival in Advanced Non-small Cell Lung Cancer: Results of a Prospective Study.
Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.
Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules.
Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study.
Potential role of AQP1 and VEGF in the development of malignant pleural effusion in mice.
Role of VEGF-stromal cell-derived factor-1alpha/CXCL12 axis in pleural effusion of lung cancer.
Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer.
Systematic review and meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions.
The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.
Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer.
Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions.
Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer.
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.
[Vascular endothelial growth factor in benign and malignant pleural effusions]
Pleurisy
Anti-inflammation Effects of Corn Silk in a Rat Model of Carrageenin-Induced Pleurisy.
Biological characteristics of carcinomatosa pleuritis in orthotopic model systems using immune-deficient rats.
Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions.
Pneumonia
A 34-Year-Old Woman from Brazil with Pulmonary Lymphangioleiomyomatosis Diagnosed by Raised Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels and Lung Cysts on Computed Tomography Imaging Presenting with COVID-19 Pneumonia.
Development of Lymphatic Capillary Network Along the Alveolar Walls of Autopsied Human Lungs with Pneumonia.
Early increase of VEGF-A is associated with resolution of ventilator-associated pneumonia: Clinical and experimental evidence.
Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis.
Manganese (II) induces chemical hypoxia by inhibiting HIF-prolyl hydroxylase: implication in manganese-induced pulmonary inflammation.
Manganese (II) induces chemical hypoxia by inhibiting HIF-prolyl hydroxylase: Implication in manganese-induced pulmonary inflammation.
Mesenchymal stem cells protect against neonatal rat hyperoxic lung injury.
Monocytic/Macrophagic pneumonitis after intrabronchial deposition of vascular endothelial growth factor in neonatal lambs.
Mycoplasma pneumoniae Infection Affects the Serum Levels of Vascular Endothelial Growth Factor and Interleukin-5 in Atopic Children.
Protective Role of Liriodendrin in Sepsis-Induced Acute Lung Injury.
Recombinant human Clara cell secretory protein treatment increases lung mRNA expression of surfactant proteins and vascular endothelial growth factor in a premature lamb model of respiratory distress syndrome.
Serum vascular endothelial growth factor in pediatric patients with community-acquired pneumonia and pleural effusion.
WKYMVm hexapeptide, a strong formyl peptide receptor 2 agonist, attenuates hyperoxia-induced lung injuries in newborn mice.
Pneumonia, Mycoplasma
Increased serum interleukin-5 and vascular endothelial growth factor in children with acute mycoplasma pneumonia and wheeze.
Mycoplasma pneumoniae Infection Affects the Serum Levels of Vascular Endothelial Growth Factor and Interleukin-5 in Atopic Children.
Pneumonia, Ventilator-Associated
Early increase of VEGF-A is associated with resolution of ventilator-associated pneumonia: Clinical and experimental evidence.
Pneumoperitoneum
Effects of low versus standard pressure pneumoperitoneum on renal syndecan-1 shedding and VEGF receptor-2 expression in living-donor nephrectomy: a randomized controlled study.
Pneumothorax
Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
POEMS Syndrome
Acutely deteriorated extravascular volume overload during peripheral blood stem cell mobilization in POEMS syndrome: A case series with cytokine analysis.
Advances in the Treatment of Paraproteinemic Neuropathy.
Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome.
Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support.
Arterial obliteration in POEMS syndrome: possible role of vascular endothelial growth factor.
Asymmetric optic disc edema in a young patient with POEMS: A rare presentation of a rare disease.
Atypical polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome without polyneuropathy: A case report.
Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist.
Borderline Case of TAFRO Syndrome and POEMS Syndrome.
Case Report: Challenges in the Diagnosis of Adenopathy and Extensive Skin Patch Overlying a Plasmacytoma Syndrome.
Changes in subfoveal choroidal thickness and reduction of serum levels of vascular endothelial growth factor in patients with POEMS syndrome.
Circulating levels of MMP-1, -2, -3, -9, and TIMP-1 are increased in POEMS syndrome.
Coexistence of Quasi-moyamoya Disease and POEMS Syndrome in a Patient with Intracranial Hemorrhage: A Case Report and Literature Review.
Correlation between peripapillary retinal thickness and serum level of vascular endothelial growth factor in patients with POEMS syndrome.
Correlation between serum level of vascular endothelial growth factor and subfoveal choroidal thickness in patients with POEMS syndrome.
Correlation of changes in serum level of VEGF and peripapillary retinal thickness in patients with POEMS syndrome.
Development of POEMS syndrome after an initial manifestation of solitary plasmacytoma.
Discrepancy between disease activity and levels of vascular endothelial growth factor in a patient with POEMS syndrome successfully treated with autologous stem-cell transplantation.
Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs.
Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan.
Efficacy of lenalidomide in POEMS syndrome: A retrospective study of 20 patients.
Expression of vascular endothelial growth factor by plasma cells in the sclerotic bone lesion of a patient with POEMS syndrome.
Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome.
Growth factors and proinflammatory cytokines in the renal involvement of POEMS syndrome.
Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor.
Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome.
Increase of serum vascular endothelial growth factors in wet beriberi: two case reports.
Increased expression of vascular endothelial growth factor and its receptor, Flt-1, in glomeruloid haemangioma associated with Crow-Fukase syndrome.
Increased serum level of vascular endothelial growth factor in Crow-Fukase syndrome.
Intractable ascites, changes in serum vascular endothelial growth factor levels and thalidomide treatment in POEMS syndrome.
Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial.
Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome.
Monoclonal gammopathy of cutaneous significance: review of a relevant concept.
Multiple vascular abnormalities and a paradoxical combination of vitamin B12 deficiency and thrombocytosis in a case with POEMS syndrome.
New treatment strategy for Crow-Fukase (POEMS) syndrome.
OCULAR MANIFESTATIONS AND TREATMENT OUTCOMES IN CHINESE PATIENTS WITH POEMS SYNDROME.
Optic disc edema, cystoid macular edema, and elevated vascular endothelial growth factor in a patient with POEMS syndrome.
Pentraxin-3 and VEGF in POEMS syndrome: a 2-year longitudinal study.
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome.
POEMS syndrome associated with plasmacytoma of the clivus: "Time discovers the truth".
POEMS syndrome complicated by follicular lymphoma.
POEMS syndrome demonstrating VEGF decrease by ticlopidine.
POEMS syndrome presenting with abdominal distension, lower limb edema and shortness of breath: A case report and literature review.
POEMS Syndrome Showing Left Ventricular Dysfunction and Extracellular Edema Assessed by Cardiac Magnetic Resonance Imaging.
POEMS syndrome with Guillan-Barre syndrome-like acute onset: a case report and review of neurological progression in 30 cases.
POEMS syndrome with idiopathic portal hypertension: autopsy case and review of the literature.
POEMS syndrome with prominent acute axonal lesions.
POEMS Syndrome: A Multisystem Clonal Disorder.
POEMS syndrome: clinical update.
POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation.
Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome refractory to complete serum vascular endothelial growth factor (VEGF) blockade: insights from sequential VEGF monitoring.
Predictive value of serial platelet count and VEGF determination for the management of DIC in the Crow-Fukase (POEMS) syndrome.
Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome.
Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome.
Ratio of serum vascular endothelial growth factor to platelet count correlates with disease activity in a patient with POEMS syndrome.
Recurrent Crow-Fukase syndrome associated with increased serum levels of vascular endothelial growth factor: a case report and review of the literature.
Relapse of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome without increased level of vascular endothelial growth factor following successful autologous peripheral blood stem cell transplantation.
Remarkable expression of vascular endothelial growth factor in bone marrow plasma cells of patients with POEMS syndrome.
Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome.
Serum vascular endothelial growth factor (VEGF) in the differential diagnosis of amyloid neuropathy and POEMS syndrome.
Serum vascular endothelial growth factor (VEGF) level can be used as a diagnostic marker in POEMS syndrome.
Skin and Nerve Neovascularization in POEMS Syndrome: Insights From a Small Cohort.
Skin manifestations and vascular endothelial growth factor levels in POEMS syndrome: impact of autologous hematopoietic stem cell transplantation.
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome.
Thrombosis revealing POEMS syndrome. About a case.
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.
Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study.
Vascular endothelial growth factor promoted endothelial progenitor cell mobilization into the peripheral blood of a patient with POEMS syndrome.
VEGF is causative for pulmonary hypertension in a patient with Crow-Fukase (POEMS) syndrome.
[A case of Crow-Fukase syndrome with extramedullary plasmacytoma: marked clinical deterioration following a biopsy to plasmacytoma]
[A case of POEMS syndrome with enlarged pancreas due to IgG4-related autoimmune pancreatitis].
[Advances and perspectives in treatment for refractory neuropathies; with special foci upon immune-mediated neuropathies and Crow-Fukase syndrome]
[Blood cytokine levels as a clinical laboratory test]
[Crow-Fukase (POEMS) syndrome]
[Diagnostic performance and clinical correlation of serum vascular endothelial growth factor levels in patients with newly diagnosed POEMS syndrome].
[Electrophysiologic aspects of Crow-Fukase (POEMS) syndrome--significance in early diagnosis and insights into the pathophysiology]
[Highly concentrated vascular endothelial growth factor in Crow-Fukase syndrome with high output heart failure: a case report]
[Increased vascular endothelial growth factor (VEGF) is causative in Crow-Fukase syndrome]
[New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy]
[POEMS syndrome diagnosed by detection of M-protein on immunofixation and increased level of vascular endothelial growth factor].
[POEMS syndrome presenting with transient immunoglobulin isotype switching after successful treatment with autologous peripheral blood stem cell transplantation]
[POEMS syndrome revealed by a scleroderma-like skin thickening]
[POEMS syndrome with increased vascular endothelial growth factor (VEGF) and multiple osteosclerotic lesion]
[POEMS syndrome with increased vascular endothelial growth factor (VEGF)]
[POEMS syndrome: advances in molecular pathophysiology and treatment].
[Two cases of POEMS syndrome with increased vascular endothelial growth factor (VEGF)]
[Vascular endothelial growth factor and Crow-Fukase syndrome]
Polycystic Kidney Diseases
Anti-VEGF treatment accelerates polycystic kidney disease.
Endothelial-epithelial communication in polycystic kidney disease: Role of vascular endothelial growth factor signalling.
Influence of factor D concentrations on fluid phase C3 activation, lysis of rabbit erythrocytes and solubilization of immune complexes.
Targeting angiogenesis and lymphangiogenesis in kidney disease.
Vascular Endothelial Growth Factor (VEGF) Gene Promoter Polymorphisms and Disease Progression in North Indian Cohort with Autosomal Dominant Polycystic Kidney Disease.
Vascular endothelial growth factor as an angiogenesis biomarker for the progression of autosomal dominant polycystic kidney disease.
Vascular Endothelial Growth Factor C for Polycystic Kidney Diseases.
Polycystic Kidney, Autosomal Dominant
Angiogenesis in autosomal-dominant polycystic kidney disease.
Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease.
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases.
Endothelial dysfunction and angiogenesis in autosomal dominant polycystic kidney disease.
Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid.
The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
Vascular Endothelial Growth Factor (VEGF) Gene Promoter Polymorphisms and Disease Progression in North Indian Cohort with Autosomal Dominant Polycystic Kidney Disease.
Vascular endothelial growth factor as an angiogenesis biomarker for the progression of autosomal dominant polycystic kidney disease.
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.
Polycystic Ovary Syndrome
Adverse Effects of Selected Markers on the Metabolic and Endocrine Profiles of Obese Women With and Without PCOS.
Analysis of VEGF gene polymorphisms and serum VEGF protein levels contribution in polycystic ovary syndrome of patients.
Analysis of VEGFA Variants and Changes in VEGF Levels Underscores the Contribution of VEGF to Polycystic Ovary Syndrome.
Association between the vascular endothelial growth factor gene polymorphisms and the risk of polycystic ovary syndrome in Northern Chinese women.
Association between vascular endothelial growth factor gene polymorphisms and PCOS risk: a meta-analysis.
Association of serum levels of vascular endothelial growth factor and thrombospondin-1 to body mass index in polycystic ovary syndrome: a case-control study.
Association of vascular endothelial growth factor polymorphisms with polycystic ovarian syndrome risk: a meta-analysis.
Association study between single nucleotide polymorphisms in the VEGF gene and polycystic ovary syndrome.
Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovaries.
Correlation between endometrial receptivity with expressions of IL-1 and VEGF in rats with polycystic ovary syndrome.
Decreased levels of sRAGE in follicular fluid from patients with PCOS.
Effect of laparoscopic ovarian drilling on vascular endothelial growth factor and ovarian stromal blood flow using 3-dimensional power Doppler.
Effect of Vitamin E on Serum Levels of Vascular Endothelial Growth Factor and Angiopoietin-1 in Women with Polycystic Ovary Syndrome: A Pilot Randomized, Placebo-Controlled Trial.
Effects of laparoscopic ovarian drilling on serum vascular endothelial growth factor and on insulin responses to the oral glucose tolerance test in women with polycystic ovary syndrome.
Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.
Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries.
Evaluation of the impact of laparoscopic ovarian drilling on Doppler indices of ovarian stromal blood flow, serum vascular endothelial growth factor, and insulin-like growth factor-1 in women with polycystic ovary syndrome.
Follicular fluid-specific distribution of vascular endothelial growth factor isoforms and sFlt-1 in patients undergoing IVF and their correlation with treatment outcomes.
Follicular oestradiol and VEGF after GnRH antagonists or GnRH agonists in women with PCOS.
Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome.
Insulin and insulin-like growth factor stimulation of vascular endothelial growth factor production by luteinized granulosa cells: comparison between polycystic ovarian syndrome (PCOS) and non-PCOS women.
Local administration of platelet-derived growth factor B (PDGFB) improves follicular development and ovarian angiogenesis in a rat model of Polycystic Ovary Syndrome.
Ovarian Fibrosis: A Phenomenon of Concern.
Prolonged HCG action affects angiogenic substances and improves follicular maturation, oocyte quality and fertilization competence in patients with polycystic ovarian syndrome.
Role of vascular endothelial growth factor in women with PCO and PCOS: a systematic review.
Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment.
Serum visfatin, vascular endothelial growth factor and matrix metalloproteinase-9 in women with polycystic ovary syndrome.
Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome.
The Higher Response of Vascular Endothelial Growth Factor and Angiotensin-II to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome.
The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor.
The VEGF +405 G>C 5' untranslated region polymorphism and risk of PCOS: a study in the South Indian Women.
Vascular endothelial growth factor (VEGFA) gene variation in polycystic ovary syndrome in a Tunisian women population.
Vascular endothelial growth factor +405 G/C,-460 T/C and -2578 A/C polymorphisms are not associated with insulin resistance in polycystic ovary syndrome.
Vascular endothelial growth factor -2578 A/C, -460 T/C and +405 G/C polymorphisms in polycystic ovary syndrome.
Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation.
Vascular endothelial growth factor and insulin-like growth factor-1 in polycystic ovary syndrome and their relation to ovarian blood flow.
Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF.
Vascular endothelial growth factor, polycystic ovary syndrome, and ovarian hyperstimulation syndrome.
Vitamin D Decreases Serum VEGF Correlating with Clinical Improvement in Vitamin D-Deficient Women with PCOS: A Randomized Placebo-Controlled Trial.
Polycythemia
Angiogenic activity in the sera of patients with post-kidney transplant erythrocytosis.
Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia.
Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.
Paraneoplastic symptoms: Cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma.
Successful Treatment of a Patient with POEMS Syndrome by Tandem High-Dose Chemotherapy with Autologous CD34+ Purged Stem Cell Rescue.
Polycythemia Vera
Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity.
Elevated serum vascular endothelial growth factor levels in patients with polycythemia vera and thrombotic complications.
Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera.
Vascular endothelial growth factor and thrombopoietin in patients with essential thrombocythemia and polycythemia vera and thrombotic complications.
Polymyalgia Rheumatica
Vascular endothelial growth factor levels and rheumatic diseases of the elderly.
Vascular endothelial growth factor production in polymyalgia rheumatica.
Polymyositis
STROBE: The correlation of Cyr61, CTGF, and VEGF with polymyositis/dermatomyositis.
Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis.
Polyneuropathies
Atypical central retinal artery occlusion as the first presentation of POEMS syndrome: a case report.
Atypical polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome without polyneuropathy: A case report.
Early onset vitreous amyloidosis in familial amyloidotic polyneuropathy with a transthyretin Glu54Gly mutation is associated with elevated vitreous VEGF.
Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan.
Efficacy of lenalidomide in POEMS syndrome: A retrospective study of 20 patients.
POEMS syndrome complicated by follicular lymphoma.
POEMS syndrome with prominent acute axonal lesions.
Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis.
Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey.
TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report.
Thrombosis revealing POEMS syndrome. About a case.
[A case of Crow-Fukase syndrome with extramedullary plasmacytoma: marked clinical deterioration following a biopsy to plasmacytoma]
[A case of POEMS syndrome with enlarged pancreas due to IgG4-related autoimmune pancreatitis].
[Thiamine deficiency polyneuropathy after gastrectomy associated with high level of serum vascular endothelial growth factor (VEGF). A case report]
Polyradiculoneuropathy
Increased serum concentrations of transforming growth factor-?1 (TGF-?1) in patients with Guillain-Barré syndrome.
POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management.
POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management.
POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management.
POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.
POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management.
POEMS syndrome: update on diagnosis, risk-stratification, and management.
[POEMS syndrome: Diagnosis, stratification, treatments].
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Increased serum concentrations of transforming growth factor-?1 (TGF-?1) in patients with Guillain-Barré syndrome.
Polyuria
Angiotensin II promotes development of the renal microcirculation through AT1 receptors.
Porcine Reproductive and Respiratory Syndrome
Clarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: an explant model study.
Port-Wine Stain
The expression of vascular endothelial growth factor and its receptors in port-wine stains.
Posterior Leukoencephalopathy Syndrome
Could increased vascular endothelial growth factor induced by interleukin 17 be the cause of posterior reversible encephalopathy syndrome in systemic lupus erythematosus?
Posterior reversible encephalopathy syndrome (PRES) with immune system activation, VEGF up-regulation, and cerebral amyloid angiopathy.
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Role of interleukin-6 and vascular endothelial growth factor in Henoch-Schönlein purpura with posterior reversible encephalopathy syndrome.
Pouchitis
Vascular endothelial growth factor and cyclooxygenase-2 are overexpressed in ileal pouch-anal anastomosis.
Pre-Eclampsia
A critical review of early-onset and late-onset preeclampsia.
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
A Maternally Sequestered, Biopolymer-Stabilized Vascular Endothelial Growth Factor (VEGF) Chimera for Treatment of Preeclampsia.
A meta-analysis of the vascular endothelial growth factor polymorphisms associated with the risk of pre-eclampsia.
A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia.
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.
A Review of Angiogenic Imbalance in HIV-Infected Hypertensive Disorders of Pregnancy.
A review of the mechanism for poor placentation in early-onset preeclampsia: the role of autophagy in trophoblast invasion and vascular remodeling.
A role for Nrf2 in redox signalling of the invasive extravillous trophoblast in severe early onset IUGR associated with preeclampsia.
Abnormal fetal growth is not associated with altered chorionic villous expression of vascular endothelial growth factor mRNA.
Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis.
Adenosine A2A receptor regulates expression of vascular endothelial growth factor in feto-placental endothelium from normal and late-onset pre-eclamptic pregnancies.
Aldosterone, Vascular Endothelial Growth Factor, and Preeclampsia: A Mystery Solved?
Allelic variations in angiogenic pathway genes are associated with preeclampsia.
Altered angiogenesis in preeclampsia: evaluation of a new test system for measuring placental growth factor.
Amniotic vascular endothelial growth factor (VEGF) and nitric oxide (NO) in women with subsequent preeclampsia.
An analysis on the roles of angiogenesis-related factors including serum vitamin D, soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF) in the diagnosis and severity of late-onset preeclampsia.
An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array.
Angiogenic and antiangiogenic factors in preeclampsia.
Angiogenic factor screening in women with mild preeclampsia - New and significant proteins in plasma.
Angiogenic factors and preeclampsia.
Angiogenic factors in preeclampsia: implications for clinical practice.
Angiogenic imbalance as a contributor of preeclampsia.
Angiogenin and vascular endothelial growth factor in pregnancies complicated by preeclampsia.
Angiopoietin-2: A Promising Indicator for the Occurrence of Severe Preeclampsia.
Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy.
Are the maternal and umbilical VEGF-A and SVEGF-R1 altered in pregnancies complicated by preeclampsia with or without intrauterine foetal growth retardation? Preliminary communication.
Assessment of the diagnostic value of a urinary adipsin rapid strip test for pre-eclampsia: A prospective multicenter study.
Association between Vascular Endothelial Growth Factor Gene Polymorphisms and Pre-Eclampsia Susceptibility: An Updated Meta-Analysis.
Associations between vascular endothelial growth factor gene polymorphisms and pre-eclampsia susceptibility: a meta-analysis.
Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study.
Circulating angiogenic factors and their association with birth outcomes in preeclampsia.
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia.
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies.
Circulating Lymphangiogenic Factors in Preeclampsia.
Clinical assessment of the specificity of an adipsin rapid test for the diagnosis of preeclampsia.
Correlation of MiR-152 expression with VEGF expression in placental tissue of preeclampsia rat and its influence on apoptosis of trophoblast cells.
CYR61 modulates the vascular endothelial growth factor c expression of decidual NK cells via PI3K/AKT pathway.
Cytokines, angiogenic, and antiangiogenic factors and bioactive lipids in preeclampsia.
Decreased circulating soluble Tie2 levels in preeclampsia may result from inhibition of vascular endothelial growth factor (VEGF) signaling.
Decreased expression of annexin A2 and loss of its association with vascular endothelial growth factor leads to the deficient trophoblastic invasion in preeclampsia.
Decreased expressions of vascular endothelial growth factor and visfatin in the placental bed of pregnancies complicated by preeclampsia.
Decreased placental miR-126 expression and vascular endothelial growth factor levels in patients with pre-eclampsia.
Decreased proportion of peripheral blood vascular endothelial growth factor-expressing T and natural killer cells in preeclampsia.
Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia.
Developing potential biomarkers for preeclampsia: Why is the current strategy failing?
Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy.
Different Polymorphisms of Vascular Endothelial Growth Factor Gene in Patients with Pre-Eclampsia among The Iranian Women Population.
Differential expression of VE-cadherin and VEGFR2 in placental syncytiotrophoblast during preeclampsia - New perspectives to explain the pathophysiology.
Differential expressions of stromal cell-derived factor-1? and vascular endothelial growth factor in the placental bed of pregnancies complicated by preeclampsia.
Distinct First Trimester Cytokine Profiles for Gestational Hypertension and Preeclampsia.
DNA methylation profiles of genes associated with angiogenesis in the samples of placenta in pregnancies complicated by intrauterine growth restriction.
Early pregnancy protein multiplex screening reflects circulating and urinary divergences associated with the development of preeclampsia.
Effect of Recombinant Placental Growth Factor 2 on Hypertension Induced by Full-Length Mouse Soluble fms-Like Tyrosine Kinase 1 Adenoviral Vector in Pregnant Mice.
Effect of vascular endothelial growth factors A, C, and D in HIV-associated pre-eclampsia.
Effects of KRN633, an inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, on vascular development of placenta and fetus of mid pregnancy in mice.
Effects of maternal and fetal vascular endothelial growth factor a single nucleotide polymorphisms on pre-eclampsia: A hybrid design study.
Effects of pre- and post-natal treatment with KRN633, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on retinal vascular development and patterning in mice.
Elevated miR-200a and miR-141 inhibit endocrine gland-derived vascular endothelial growth factor expression and ciliogenesis in preeclampsia.
Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia.
Elevated serum concentrations of the angiogenesis inhibitor endostatin in preeclamptic women.
Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia.
Elevated serum sFlt-1/Ang-2 ratio in women with preeclampsia.
Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia.
Elevation of urinary adipsin in preeclampsia: correlation with urine protein concentration and the potential use for a rapid diagnostic test.
Endothelial dysfunction in the pathogenesis of pre-eclampsia in Ghanaian women.
Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events?
Enhanced Angiogenic Capacity of Human Umbilical Vein Endothelial Cells From Women With Preeclampsia.
Evaluation of physiological alterations of the placenta through analysis of cell-free messenger ribonucleic acid concentrations of angiogenic factors.
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award.
Excess soluble fms-like tyrosine kinase 1 and low platelet counts in premature neonates of preeclamptic mothers.
Exogenous vascular endothelial growth factor can induce preeclampsia-like symptoms in pregnant mice.
Exogenous vascular endothelial growth factor supplementation can restore the podocyte barrier-forming capacity disrupted by sera of preeclamptic women.
Expression and oxygen regulation of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 and its receptors in human placenta during early pregnancy.
Expression and significance of miR155 and vascular endothelial growth factor in placenta of rats with preeclampsia.
Expression levels of seven candidate genes in human peripheral blood mononuclear cells and their association with preeclampsia.
Expression of genes coding for proangiogenic factors and their receptors in human placenta complicated by preeclampsia and intrauterine growth restriction.
Ferulic acid alleviates symptoms of preeclampsia in rats by upregulating vascular endothelial growth factor.
Feto-placental nitric oxide, asymmetric dimethylarginine and vascular endothelial growth factor (VEGF) levels and VEGF gene polymorphisms in severe preeclampsia.
First-trimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia.
Fractional excretion of angiogenic factors in women with severe preeclampsia.
Genetic markers for preeclampsia in Peruvian women.
Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia.
Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis.
High levels of urinary vascular endothelial growth factor in women with severe preeclampsia.
Hypermethylation of delta-like homolog 1/maternally expressed gene 3 loci in human umbilical veins: insights into offspring vascular dysfunction born after preeclampsia.
Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression.
Hypoadiponectinemia and circulating angiogenic factors in overweight patients complicated with pre-eclampsia.
Hypoxia activates the human placental vascular endothelial growth factor system in vitro and in vivo: up-regulation of vascular endothelial growth factor in clinically relevant hypoxic ischemia in birth asphyxia.
Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast.
Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.
Immunohistochemical expression of endothelial nitric oxide synthase and C-kit in the placenta of complete hydatidiform mole.
Impaired A(2A) adenosine receptor/nitric oxide/VEGF signaling pathway in fetal endothelium during late- and early-onset preeclampsia.
In vivo rat model of preeclampsia.
Increase of serum angiopoietin-2 during pregnancy is suppressed in women with preeclampsia.
Influence of the vascular endothelial growth factor on the development of severe pre-eclampsia or HELLP syndrome.
Interplay between vascular endothelial growth factor (VEGF) and nuclear factor erythroid 2-related factor-2 (Nrf2): implications for preeclampsia.
Investigation of polymorphisms in pre-eclampsia related genes VEGF and IL1A.
Investigation of role of vascular endothelial growth factor, Annexin A5 and Apelin by immunohistochemistry method in placenta of preeclampsia patients.
Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies.
Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age.
Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre-eclampsia.
Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia.
Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance.
Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction.
Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation.
Maternal/newborn VEGF-C936T interaction and its influence on the risk, severity and prognosis of preeclampsia, as well as on the maternal angiogenic profile.
Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia.
microRNA-646 inhibits angiogenesis of endothelial progenitor cells in pre-eclamptic pregnancy by targeting the VEGF-A/HIF-1? axis.
Midgestation maternal serum 25-hydroxyvitamin D level and soluble fms-like tyrosine kinase 1/placental growth factor ratio as predictors of severe preeclampsia.
miR-219a suppresses human trophoblast cell invasion and proliferation by targeting vascular endothelial growth factor receptor 2 (VEGFR2).
miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9.
Nephrin and endothelial injury.
New scope in angiogenesis: role of vascular endothelial growth factor (VEGF), NO, lipid peroxidation, and vitamin E in the pathophysiology of pre-eclampsia among Egyptian females.
No association between polymorphisms/haplotypes of the vascular endothelial growth factor gene and preeclampsia.
No association of the genetic polymorphisms of endothelial nitric oxide synthase, dimethylarginine dimethylaminohydrolase, and vascular endothelial growth factor with preeclampsia in Korean populations.
Nutraceutical Targeting of Placental Synthesis of Soluble Fms-Like Tyrosine Kinase-1 (sFlt-1) as Strategy for Preventing and Controlling Pre-eclampsia.
Obese melanocortin-4 receptor-deficient rats exhibit augmented angiogenic balance and vasorelaxation during pregnancy.
Outcome of pregnancy in patients with isolated proteinuria.
Phosphorylation of Ser-279/282 and Tyr-265 positions on Cx43 as possible mediators of VEGF-165 inhibition of pregnancy-adapted Ca2+ burst function in ovine uterine artery endothelial cells.
Placental expression of EG-VEGF and its receptors PKR1 (prokineticin receptor-1) and PKR2 throughout mouse gestation.
Placental expression of vascular endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypoxia at delivery.
Placental expression of vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 correlates with severity of clinical preeclampsia and villous hypermaturity.
Placental expression of VEGF is increased in pregnancies with hydatidiform mole: Possible association with developing very early onset preeclampsia.
Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension.
Placental growth factor and vascular endothelial growth factor serum levels in Tunisian Arab women with suspected preeclampsia.
Placental growth factor, vascular endothelial growth factor, and hypoxia-inducible factor-1? in the placentas of women with pre-eclampsia.
Placental NRP1 and VEGF expression in pre-eclamptic women and in a homocysteine-treated mouse model of pre-eclampsia.
Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity.
Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.
Potential role of A2B adenosine receptors on proliferation/migration of fetal endothelium derived from preeclamptic pregnancies.
PP011. Increased placental expression of angiogenin inhibitor (Ribonuclease inhibitor), a novel gene in pre-eclampsia.
PP016. Circulating lymphangiogenic factors in preeclampsia.
Pre-eclampsia and the vascular endothelial growth factor: a new aspect.
Pre-eclampsia: clinical manifestations and molecular mechanisms.
Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance.
Preeclampsia Downregulates MicroRNAs in Fetal Endothelial Cells: Roles of miR-29a/c-3p in Endothelial Function.
Preeclampsia is associated with lower production of vascular endothelial growth factor by peripheral blood mononuclear cells.
Preeclampsia: new insights.
Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor.
Pregnancy-induced hypertension and preeclampsia: levels of angiogenic factors in malaysian women.
Pro-angiogenic therapeutics for preeclampsia.
Recombinant Vascular Endothelial Growth Factor 121 Attenuates Autoantibody-Induced Features of Pre-eclampsia in Pregnant Mice.
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia.
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension.
Recombinant vascular endothelial growth factor 121 injection for the prevention of fetal growth restriction in a preeclampsia mouse model.
Reduced angiogenic factor expression in intrauterine fetal growth restriction using semiquantitative immunohistochemistry and digital image analysis.
Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model.
Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia.
Regulation of miR-375 and Sonic hedgehog on vascular endothelial growth factor in preeclampsia rats and its effect on trophoblast cells.
Renal dysfunction and podocyturia in pre-eclampsia may be explained by increased urinary VEGF.
Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats.
Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment.
Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia.
Serum Adipsin Levels throughout Normal Pregnancy and Preeclampsia.
Serum endostatin and vascular endothelial growth factor levels in patients with pre-eclampsia.
Serum hyperglycosylated human chorionic gonadotrophin at 14-17?weeks of gestation does not predict preeclampsia.
Serum Levels of Angiogenic Factors Distinguish Between Women with Preeclampsia and Normotensive Pregnant Women But Not Severity of Preeclampsia in an Obstetric Center in Turkey.
Serum levels of asymmetric dimethylarginine, vascular endothelial growth factor, and nitric oxide metabolite levels in preeclampsia patients.
Serum VEGF and PGF may be significant markers in prediction of severity of preeclampsia.
Soluble and membranous vascular endothelial growth factor receptor-2 in pregnancies complicated by pre-eclampsia.
Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor.
Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop.
Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF.
Stress responses and pre-eclampsia.
Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia.
Sustained Endocrine Gland-Derived Vascular Endothelial Growth Factor Levels Beyond the First Trimester of Pregnancy Display Phenotypic and Functional Changes Associated With the Pathogenesis of Pregnancy-Induced Hypertension.
Targeting angiogenesis and lymphangiogenesis in kidney disease.
The effects of magnesium sulfate on placental vascular endothelial growth factor expression in preeclampsia.
The effects of vascular endothelial growth factor on endothelial cells: a potential role in preeclampsia.
The function of adipsin and C9 protein in the complement system in HIV-associated preeclampsia.
The immunohistochemical evaluation of VEGF in placenta biopsies of pregnancies complicated by preeclampsia.
The kidney in normal pregnancy and preeclampsia.
The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia.
The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation.
The multiple roles of EG-VEGF/PROK1 in normal and pathological placental angiogenesis.
The prediction of early preeclampsia: Results from a longitudinal proteomics study.
The relationship between circulating tissue transglutaminase, soluble fms-like tyrosine kinase-1, soluble endoglin and vascular endothelial growth factor in pre-eclampsia.
Timing of ischemic insult alters fetal growth trajectory, maternal angiogenic balance, and markers of renal oxidative stress in the pregnant rat.
Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?
Ultra-high sensitive C-reactive protein during normal pregnancy and in preeclampsia: a pilot study.
Ultrastructure and histomorphometric analysis of human umbilical cord vessels in preeclampsia: a potential role of VEGF, VEGFR-1 and VEGFR-2.
Umbilical cord serum vascular endothelial growth factor (VEGF) levels in normal pregnancies and in pregnancies complicated by preterm delivery or pre-eclampsia.
Unexplained fetal death: another anti-angiogenic state.
Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia.
Uteroplacental blood flow and placental vascular endothelial growth factor in normotensive and pre-eclamptic pregnancy.
Vascular endothelial growth factor (VEGF) polymorphisms in HELLP syndrome patients determined by quantitative real-time PCR and melting curve analyses.
Vascular endothelial growth factor (VEGF)-634G/C polymorphism was associated with severe pre-eclampsia and lower serum VEGF level.
Vascular endothelial growth factor +936C/T, -634G/C, -2578C/A, and -1154G/A polymorphisms with risk of preeclampsia: a meta-analysis.
Vascular endothelial growth factor and endothelin-1 levels in normal pregnant women and pregnant women with pre-eclampsia.
Vascular endothelial growth factor and its receptors in the placental villi of pregnant patients with pre-eclampsia.
Vascular endothelial growth factor and placental growth factor release in cultured trophoblast cells under different oxygen tensions.
Vascular endothelial growth factor C participates in regulation of maspin in extravillous trophoblast cell migration and invasion.
Vascular endothelial growth factor C/A 2578 gene polymorphism and umbilical artery Doppler in preeclamptic women.
Vascular endothelial growth factor expression is unaltered in placentae and myometrial resistance arteries from pre-eclamptic patients.
Vascular endothelial growth factor family gene polymorphisms in preeclampsia in Sinhalese women in Sri-Lanka.
Vascular endothelial growth factor gene +813CC polymorphism of foetus is associated with preterm labour but not with pre-eclampsia in Turkish pregnant women.
Vascular endothelial growth factor gene +936 C/T polymorphism is associated with preeclampsia in Korean women.
Vascular endothelial growth factor gene polymorphisms and pre-eclampsia.
Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension.
Vascular endothelial growth factor induced functional and morphologic signs of endothelial dysfunction in isolated arteries from normal pregnant women.
Vascular endothelial growth factor is increased in patients with preeclampsia.
Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome.
Vascular endothelial growth factor serum levels in pregnancy and preeclampsia.
Vascular endothelial growth factor single nucleotide polymorphisms and haplotypes in pre-eclampsia: A case-control study.
Vascular endothelial growth factor, its receptors, and the tie receptors in the placental bed of women with preeclampsia, diabetes, and intrauterine growth retardation.
Vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and genistein-induced changes in the vascular reactivity of rat's aorta.
Vascular Endothelial Growth Factor-121 Administration Mitigates Halogen Inhalation-Induced Pulmonary Injury and Fetal Growth Restriction in Pregnant Mice.
Vasoactivity to and endogenous release of vascular endothelial growth factor in the in vitro perfused human placental lobule from pregnancies complicated by preeclampsia.
VEGF (Vascular Endothelial Growth Factor) Functionalized Magnetic Beads in a Microfluidic Device to Improve the Angiogenic Balance in Preeclampsia.
VEGF and VEGFR1 levels in different regions of the normal and preeclampsia placentae.
VEGF deficit is involved in endothelium dysfunction in preeclampsia.
VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia.
VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy: implications in the pathogenesis of preeclampsia.
VEGF-A and VEGFR1 SNPs associate with preeclampsia in a Philippine population.
Whole mount immunofluorescence analysis of placentas from normotensive versus preeclamptic pregnancies.
[Different effects of pravastatin on sFlt-1, PlGF and VEGF in different preeclampsia-like mouse models].
[Effect of vascular endothelial growth factor on pre-eclampsia in pregnant rats]
[Expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and sFlt-1 in preeclampsia placenta]
[Immunohistochemical evaluation of the distribution of vascular endothelial growth factor in the placenta, placental bed in normal pregnancy and in women with preeclampsia]
[Plasma VEGF levels are increased in women with severe preeclampsia or HELLP syndrome]
[Vasohibin and VEGF protein levels in placentae from pregnancies complicated by severe pre-eclampsia].
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Exit of pediatric pre-B acute lymphoblastic leukaemia cells from the bone marrow to the peripheral blood is not associated with cell maturation or alterations in gene expression.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Analysis of the expression levels of survivin and VEGF in patients with acute lymphoblastic leukemia.
Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Assessment of Angiogenesis in Children with Acute Lymphoblastic Leukemia Based on Serum Vascular Endothelial Growth Factor Assay.
Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor.
Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.
Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia.
Effect of heat shock protein-90 (HSP90) and vascular endothelial growth factor (VEGF) on survival in acute lymphoblastic leukemia: an immunohistochemical study.
Increased Angiogenesis-associated Poor Outcome in Acute Lymphoblastic Leukemia: A Single Center Study.
Induction of vascular endothelial growth factor secretion by childhood acute lymphoblastic leukemia cells via the FLT-3 signaling pathway.
Overexpression of heme oxygenase-1 in microenvironment mediates vincristine resistance of B-cell acute lymphoblastic leukemia by promoting vascular endothelial growth factor secretion.
Serum Vascular Endothelial Growth Factor-A Levels During Induction Therapy in Children with Acute Lymphoblastic Leukemia.
Vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (NOS3) polymorphisms are associated with high relapse risk in childhood acute lymphoblastic leukemia (ALL).
Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction.
Vascular endothelial growth factor-C and its receptor type-3 expressed in acute lymphocytic leukemia cases with t(1;19).
VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia.
[Plasma concentrations of vascular endothelial growth factor and tissue factor in children with acute lymphoblastic leukemia]
Prediabetic State
Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial.
Association Between Serum Adipsin Levels and Insulin Resistance in Subjects With Various Degrees of Glucose Intolerance.
Pregnancy Complications
Circulating angiogenic factors and HIV among pregnant women in Zambia: a nested case-control study.
Human chorionic gonadotropin and vascular endothelial growth factor in normal and complicated pregnancies.
miR-219a suppresses human trophoblast cell invasion and proliferation by targeting vascular endothelial growth factor receptor 2 (VEGFR2).
Pregnancy, Ectopic
Association of serum levels of vascular endothelial growth factor and early ectopic pregnancy.
Association study of vascular endothelial growth factor and polymorphisms of its gene with ectopic pregnancy.
Association study of vascular endothelial growth factor gene polymorphisms with ectopic pregnancy in Chinese women.
Levels of vascular endothelial growth factor are elevated in patients with ectopic pregnancy: is this a novel marker?
Maternal serum vascular endothelial growth factor levels in early ectopic and intrauterine pregnancies after in vitro fertilization treatment.
Predicting first trimester pregnancy outcome: derivation of a multiple marker test.
Serum concentration of vascular endothelial growth factor and depth of trophoblastic invasion in ampullary ectopic pregnancy.
Serum vascular endothelial growth factor as a possible marker for early ectopic pregnancy.
Soluble fms-Like Tyrosine Kinase-1 (sFlt-1) and Serum Placental Growth Factor (PlGF) as Biomarkers for Ectopic Pregnancy and Missed Abortion.
The value of a single combined measurement of VEGF, glycodelin, progesterone, PAPP-A, HPL and LIF for differentiating between ectopic and abnormal intrauterine pregnancy.
The value of vascular endothelial growth factor, pregnancy-associated plasma protein-A, and progesterone for early differentiation of ectopic pregnancies, normal intrauterine pregnancies, and spontaneous miscarriages.
Vascular endothelial growth factor (VEGF) and discrimination between abnormal intrauterine and ectopic pregnancy.
Vascular endothelial growth factor and beta-human chorionic gonadotropin are associated with trophoblastic invasion into the tubal wall in ectopic pregnancy.
[Association of vascular endothelial growth factor gene polymorphisms with ectopic pregnancy among Chinese women].
Prehypertension
Effects of androgen on vascular and inflammatory biomarkers in a female hypertensive population.
Premature Birth
Association of VEGFA gene polymorphisms and VEGFA plasma levels with spontaneous preterm birth.
Detection of angiogenic factors in midtrimester amniotic fluid and the prediction of preterm birth.
Effect of preterm birth on hypoxia-inducible factors and vascular endothelial growth factor in primate lungs.
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha are decreased in an experimental model of severe respiratory distress syndrome in preterm lambs.
Identification of biomarkers for preterm delivery in mid-trimester amniotic fluid.
Inflammatory biomarkers and spontaneous preterm birth among obese women.
Intra-amniotic infection upregulates decidual cell vascular endothelial growth factor (VEGF) and neuropilin-1 and -2 expression: implications for infection-related preterm birth.
Production of vascular endothelial growth factor and endothelin in the placenta and umbilical cord during normal and complicated pregnancy.
Pressure Ulcer
Non-invasive detection of local tissue responses to predict pressure ulcer development in mouse models.
Prediction of healing in Category I pressure ulcers by skin blotting with plasminogen activator inhibitor 1, interleukin-1?, vascular endothelial growth factor C, and heat shock protein 90?: A pilot study.
The angiogenic peptide vascular endothelial growth factor (VEGF) is expressed in chronic sacral pressure ulcers.
The angiogenic peptide vascular endothelial growth factor-basic fibroblast growth factor signaling is up-regulated in a rat pressure ulcer model.
The exudate of pressure ulcers contains a substantial amount of vascular endothelial growth factor.
[Analysis of differential gene expressions of inflammatory and repair-related factors in chronic refractory wounds in clinic].
[Expressions of vascular endothelial growth factor and basic fibroblast growth factor in the late stage of pressure ulcer].
Primary Myelofibrosis
Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia.
Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia.
Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity.
Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis.
Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor.
Modern management of myelofibrosis.
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases.
Primary Ovarian Insufficiency
An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects.
Association of Variants in Vascular Endothelial Growth Factor A Gene and VEGFA Serum Levels with the Risk of Primary Ovarian Insufficiency: A Case-Control Study.
Ovarian Fibrosis: A Phenomenon of Concern.
Vascular endothelial growth factor gene polymorphisms in Korean patients with premature ovarian failure.
Proctitis
Expression of vascular endothelial growth factor and its correlation with clinical symptoms and endoscopic findings in patients with chronic radiation proctitis.
Progeria
Dysfunction of iPSC-derived endothelial cells in human Hutchinson-Gilford progeria syndrome.
Prolactinoma
Angiogenesis in pituitary adenomas: human studies and new mutant mouse models.
Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour.
Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Prostatic Hyperplasia
Angiogenic peptides in prostatic disease.
Differential research of inflammatory and related mediators in BPH, histological prostatitis and PCa.
Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer.
Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.
MicroRNA and vascular endothelial growth factor (VEGF) as new useful markers in the diagnosis of benign prostatic hyperplasia in dogs.
Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia.
The effects of ROS in prostatic stromal cells under hypoxic environment.
The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer.
The secretion of endothelin-1 by microvascular endothelial cells from human benign prostatic hyperplasia is inhibited by vascular endothelial growth factor.
Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.
Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia.
[Vascular endothelial growth factor in patients with prostate cancer and benign prostatic hyperplasia]
Prostatic Intraepithelial Neoplasia
Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model.
Expression of androgen receptor and growth factors in premalignant lesions of the prostate.
Prostatic Neoplasms
(-)-Gossypol, a Natural BH3 Mimetic, Suppresses the Growth of Human Prostate Cancer Xenografts via Modulating VEGF Signaling-Mediated Angiogenesis.
A chemiluminescent dual-aptasensor capable of simultaneously quantifying prostate specific antigen and vascular endothelial growth factor.
A critical role of the PTEN/PDGF signaling network for the regulation of radiosensitivity in adenocarcinoma of the prostate.
A novel 1-((3-(2-toluyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-(trifluoromethyl)pyrimidin-2(1H)-one activates intrinsic mitochondria-dependent pathway and decreases angiogenesis in PC-3 cells.
A novel resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1? and VEGF expression, and migration in human prostate cancer cells.
A potential autocrine role for vascular endothelial growth factor in prostate cancer.
A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression.
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer.
Activation of TRPA1 Channel by Antibacterial Agent Triclosan Induces VEGF Secretion in Human Prostate Cancer Stromal Cells.
Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells.
Adiponectin inhibits VEGF-A in prostate cancer cells.
Alpha-tocopheryl succinate (alpha-TOS) modulates human prostate LNCaP xenograft growth and gene expression in BALB/c nude mice fed two levels of dietary soybean oil.
An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.
Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site.
Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts.
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Angiogenesis and prostate cancer: identification of a molecular progression switch.
Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
Angiogenic peptides in prostatic disease.
Anti-angiogenesis approach to genitourinary cancer treatment.
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
Antitumor Agent Cabozantinib Decreases RANKL Expression in Osteoblastic Cells and Inhibits Osteoclastogenesis and PTHrP-Stimulated Bone Resorption.
Antitumor effect of reduction of 150-kDa oxygen-regulated protein expression on human prostate cancer cells.
Assessment of 54 biomarkers for biopsy-detectable prostate cancer.
Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting.
Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population.
Association between vascular endothelial growth factor rs699947 polymorphism and the risk of three major urologic neoplasms (bladder cancer, prostate cancer, and renal cell carcinoma): A meta-analysis involving 11,204 subjects.
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
Associations Between Gene Polymorphisms of Vascular Endothelial Growth Factor and Prostate Cancer.
Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: a meta-analysis.
Associations of nm23H1, VEGF-C, and VEGF-3 receptor in human prostate cancer.
Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells.
Butein suppresses the expression of nuclear factor-kappa B-mediated matrix metalloproteinase-9 and vascular endothelial growth factor in prostate cancer cells.
cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis.
Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2.
Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer.
Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells.
CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer.
Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields.
Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo-Adjuvant Hormonal Therapy in Prostate Cancer Patients.
Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis.
Cigarette smoke induces nuclear translocation of heme oxygenase 1 (HO-1) in prostate cancer cells: nuclear HO-1 promotes vascular endothelial growth factor secretion.
Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer.
Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth.
Combined Dynamic Alterations in Urinary VEGF Levels and Tissue ADAM9 Expression as Markers for Lethal Phenotypic Progression of Prostate Cancer.
Correlates of thrombin generation in patients with advanced prostate cancer.
Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.
Current role of cabozantinib in metastatic castration-resistant prostate cancer.
Development of angiogenesis inhibition as therapy for prostate cancer.
Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models.
Differential expression of the semaphorin 3A pathway in prostatic cancer.
Differential expression of VEGF ligands and receptors in prostate cancer.
Differential research of inflammatory and related mediators in BPH, histological prostatitis and PCa.
Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer.
Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
Dynamic regulation of platelet-derived growth factor D (PDGF-D) activity and extracellular spatial distribution by matriptase-mediated proteolysis.
Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
Effect of low-frequency low-intensity ultrasound with microbubbles on prostate cancer hypoxia.
Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade.
Efficacy and toxicity of anti-VEGF agents in patients with castration-resistant prostate cancer: a meta-analysis of prospective clinical studies.
Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer.
Emodin inhibits the proliferation of PC3 prostate cancer cells in vitro via the Notch signaling pathway.
Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: an in vitro model for assessment.
Enhancement of prostate cancer xenograft growth with whole-body radiation and vascular endothelial growth factor.
Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies.
Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma.
Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice.
Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage.
Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer.
Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer.
Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome.
Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis.
Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer.
Expression of vascular endothelial growth factor receptors in human prostate cancer.
Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor.
Histone methyltransferase NSD2/MMSET mediates constitutive NF-?B signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.
Hypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings.
Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells.
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor.
Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression.
Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer.
Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA.
Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer.
Inhibition of growth and regulation of IGFs and VEGF in human prostate cancer cell lines by shikonin analogue 93/637 (SA).
Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
Inhibition of Stromal PlGF Suppresses the Growth of Prostate Cancer Xenografts.
INPP4B overexpression suppresses migration, invasion and angiogenesis of human prostate cancer cells.
Insulin-like growth factor-I induces chemoresistence to docetaxel by inhibiting miR-143 in human prostate cancer.
Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.
Interrelationships between dietary restriction, the IGF-I axis, and expression of vascular endothelial growth factor by prostate adenocarcinoma in rats.
Issues and promises of bevacizumab in prostate cancer treatment.
Kochia scoparia seed extract suppresses VEGF-induced angiogenesis via modulating VEGF receptor 2 and PI3K/AKT/mTOR pathways.
L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer.
Low-frequency ultrasound-induced VEGF suppression and synergy with dendritic cell-mediated anti-tumor immunity in murine prostate cancer cells in vitro.
LPA1/3 signaling mediates tumor lymphangiogenesis through promoting CRT expression in prostate cancer.
Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells.
Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen.
Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer.
MET and VEGF: synergistic targets in castration-resistant prostate cancer.
Metastatic properties of prostate cancer cells are controlled by VEGF.
Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer.
miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.
MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.
Molecular markers and death from prostate cancer.
Molecular pathway for cancer metastasis to bone.
Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer.
Molecular targets for green tea in prostate cancer prevention.
Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.
NADPH oxidase subunit p22(phox)-mediated reactive oxygen species contribute to angiogenesis and tumor growth through AKT and ERK1/2 signaling pathways in prostate cancer.
Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis.
No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population.
Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells.
Obesity and prostate cancer: a role for adipokines.
Obesity, adipokines, and prostate cancer (review).
Opposite functions of HIF-? isoforms in VEGF induction by TGF-?1 under non-hypoxic conditions.
Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage.
Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).
Pentosan polysulfate (Elmiron): in vitro effects on prostate cancer cells regarding cell growth and vascular endothelial growth factor production.
Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1?.
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer.
Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer.
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells.
Positive association between vascular endothelial growth factor (VEGF) -2578 C/A variant and prostate cancer.
Potential role of inhibiting the vascular endothelial growth factor pathway in advanced prostate cancer.
Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.
Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer.
Predictive values of vascular endothelial growth factor and microvessel-density levels in initial biopsy for prostate cancer.
Preparation of Titanocene-Gold Compounds Based on Highly Active Gold(I)-N-Heterocyclic Carbene Anticancer Agents: Preliminary in?vitro Studies in Renal and Prostate Cancer Cell Lines.
Prognostic role of vascular endothelial growth factor in prostate cancer: a systematic review and meta-analysis.
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: a systematic review with meta-analysis.
Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer.
Prostaglandin E(2) induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway.
Prostate cancer cell-specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes.
Protein kinase inhibitors for the treatment of prostate cancer.
PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy.
Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.
Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel.
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
Regulation of vascular endothelial growth factor in prostate cancer.
Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1.
Regulation of VEGF, MMP-9, and metastasis by CXCR4 in a prostate cancer cell line.
Relationship between the expression of CD133, HIF-1?, VEGF and the proliferation and apoptosis in hypoxic human prostate cancer cells.
Retraction: Inhibition of Angiogenesis and Invasion by 3,3'-Diindolylmethane Is Mediated by the Nuclear Factor-?B Downstream Target Genes MMP-9 and uPA that Regulated Bioavailability of Vascular Endothelial Growth Factor in Prostate Cancer.
Role of vascular endothelial growth factor in clinically localized prostate cancer treated with radiation therapy.
Role of vascular endothelial growth factor in prostate cancer.
Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC).
Serum levels of vascular endothelial growth factor in patients undergoing prostate biopsy for suspicion of prostate cancer.
Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia.
Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer.
Silencing of CCR7 inhibits the growth, invasion and migration of prostate cancer cells induced by VEGFC.
Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer.
SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition.
Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Stroma-epithelium crosstalk in prostate cancer.
Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy.
SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro.
The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer.
The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
The identification and internal validation of a preoperative serum biomarker panel to determine extracapsular extension in patients with prostate cancer.
The peroxisome proliferator-activated receptor gamma ligand 15-deoxy-Delta12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637.
The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy.
The relation of p53 protein nuclear accumulation and angiogenesis in human prostatic carcinoma.
The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer.
The role of vascular endothelial growth factor in kidney and prostate cancer.
The Role of Vascular Endothelial Growth Factor in Metastatic Prostate Cancer to the Skeleton.
The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells.
Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.
Transformation dependent signalling pathways leading to transcriptional induction of vascular endothelial growth factor in prostate cancer.
Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies.
Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
Untargeted metabolomics reveals distinct metabolic reprogramming in endothelial cells co-cultured with CSC and non-CSC prostate cancer cell subpopulations.
Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.
Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression.
Value of perfusion CT parameters, microvessl density and VEGF expression in differentiation of benign and malignant prostate tumours.
Vascular endothelial growth factor (VEGF) and prostate pathology.
Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells.
Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610.
Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia.
Vascular endothelial growth factor A, secreted in response to transforming growth factor-?1 under hypoxic conditions, induces autocrine effects on migration of prostate cancer cells.
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer.
Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.
Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts.
Vascular endothelial growth factor expression in head and neck squamous cell carcinoma.
Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer.
Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer.
Vascular endothelial growth factor in prostate cancer.
Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase.
Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.
Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer.
Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells.
Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo.
VIP induces NF-?B1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.
Vitamin E and the Y4 agonist BA-129 decrease prostate cancer growth and production of vascular endothelial growth factor.
[Curcumin inhibits the expression of vascular endothelial growth factor and androgen-independent prostate cancer cell line PC-3 in vitro]
[Diffusion weighted MRI helps evaluate angiogenesis and vascular endothelial growth factor expression in prostate cancer]
[Elucidating the molecular mechanism of prostate cancer progression under chronic hypoxia and development of the novel therapeutic approach].
[Expression of cyclooxygenase-2 and vascular endothelial growth factor in human prostate cancer and its significance]
[Expression of hypoxia-inducible factor lalpha and vascular endothelial growth factor in prostate cancer and its significance]
[Expressions of telomerase reverse transcriptase and vascular endothelial growth factor and their correlation in prostate cancer]
[Inhibitory effect of dihydroartemisinin on the growth of human prostate cancer PC-3M cells and its mechanism].
[Related biomarkers in the diagnosis of prostate cancer].
[The inhibitory action of the antisense oligodeoxynucleotide to the expression of vascular endothelial growth factor by radiotherapy in a prostate cancer cell line]
[Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ]
[Vascular endothelial growth factor in patients with prostate cancer and benign prostatic hyperplasia]
{beta}2-Microglobulin Is a Signaling and Growth-Promoting Factor for Human Prostate Cancer Bone Metastasis.
Prostatitis
Differential research of inflammatory and related mediators in BPH, histological prostatitis and PCa.
protein acetyllysine n-acetyltransferase deficiency
SIRT3 deficiency delays diabetic skin wound healing via oxidative stress and necroptosis enhancement.
Sirt3 deficiency impairs neurovascular recovery in ischemic stroke.
protein-long-chain fatty-acyl-lysine deacylase (nad+) deficiency
Sirtuin-6 deficiency exacerbates diabetes-induced impairment of wound healing.
Protein-Losing Enteropathies
Increased expression of vascular endothelial growth factor in a case of protein-losing enteropathy with undifferentiated connective tissue disease.
Proteinuria
2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic ZSF1 rats.
Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity.
Angiogenic factors and preeclampsia.
Angiotensin receptor blockade attenuates glomerulosclerosis progression by promoting VEGF expression and bone marrow-derived cells recruitment.
Bevacizumab in clinical practice.
Bevacizumab increases risk for severe proteinuria in cancer patients.
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study.
Calcium Dobesilate Restores Autophagy by Inhibiting the VEGF/PI3K/AKT/mTOR Signaling Pathway.
Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Circulating angiogenic factors in diabetes patients in a tertiary hospital in Ghana.
Circulating VEGF and TGF-beta1 in children with idiopathic nephrotic syndrome.
Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway.
Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab.
Effect of cholecalciferol supplementation on urine podocyte-associated messenger RNAs in patients with chronic kidney disease.
Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes.
Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model.
ELEVATED SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND PROTEINURIA IN RENAL ALLOGRAFT RECIPIENTS TREATED WITH mTOR INHIBITORS.
Experience of bevacizumab in a patient with colorectal cancer after renal transplantation.
Expression of angiogenesis-related genes in the cellular component of the blood of preeclamptic women.
Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis.
Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.
Fractional excretion of angiogenic factors in women with severe preeclampsia.
From placenta to podocyte: vascular and podocyte pathophysiology in preeclampsia.
Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia.
Glomerular mesangial cell and podocyte injuries in diabetic nephropathy.
Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis.
Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant.
Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.
Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency.
Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab.
Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Molecular mechanisms of preeclampsia.
Nephrin and endothelial injury.
Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria.
Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib.
Outcome of pregnancy in patients with isolated proteinuria.
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Placental growth factor, vascular endothelial growth factor, and hypoxia-inducible factor-1? in the placentas of women with pre-eclampsia.
Preeclampsia: new insights.
Proteinuria and vascular changes after renal irradiation: the role of reactive oxygen species (ROS) and vascular endothelial growth factor (Vegf).
Rapamycin promotes podocyte migration through the up-regulation of urokinase receptor.
Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
Reactive oxygen species, PKC-beta1, and PKC-zeta mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells.
Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model.
Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes.
Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis?.
Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib.
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis.
Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment.
Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus.
Sam68-like mammalian protein 2, identified by digital differential display as expressed by podocytes, is induced in proteinuria and involved in splice site selection of vascular endothelial growth factor.
Semaphorin3a disrupts podocyte foot processes causing acute proteinuria.
Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
Study of Angiopoietin-2 and vascular endothelial growth factor as markers of diabetic nephropathy onset in Egyptians diabetic patients with non-albuminuric state.
The cardiorenal syndrome in diabetes mellitus.
The glomerular injury of preeclampsia.
The study on the relationship between serum vascular endothelial growth factor and proteinuria in adriamycin-induced nephrotic rats.
Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension.
Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use.
Vascular Complications of Cancer Chemotherapy.
Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation.
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
VEGF-A165 b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF-A splice isoforms from the kidney.
Vitamin D and Glomerulonephritis.
Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy.
Yi qi qing re gao attenuates podocyte injury and inhibits vascular endothelial growth factor overexpression in puromycin aminonucleoside rat model.
[A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab].
[Renal excretion of insulin-like growth factor 1 and vascular endothelial growth factor in patients with type 1 diabetes with nephropathy].
Prurigo
Effective Control of Recalcitrant Pruritus by Bevacizumab: A Possible Role for Vascular Endothelial Growth Factor in Chronic Itch?
Pruritus
Effect of large-size dialysis membrane and hemofiltration/hemodiafiltration methods on long-term dialysis patients.
Effective Control of Recalcitrant Pruritus by Bevacizumab: A Possible Role for Vascular Endothelial Growth Factor in Chronic Itch?
Vascular endothelial growth factor partially induces pruritus via epidermal hyperinnervation in imiquimod-induced psoriasiform dermatitis in mice.
Pseudolymphoma
Microvessel Density and Expression of Vascular Endothelial Growth Factor and its Receptors in Different Subtypes of Primary Cutaneous B-cell Lymphoma.
Pseudomyxoma Peritonei
Exploring the peritoneal surface malignancy phenotype-a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models.
Pseudoxanthoma Elasticum
Successful long-term management of choroidal neovascularization secondary to angioid streaks in a patient with pseudoxanthoma elasticum: a case report.
Vascular endothelial growth factor gene polymorphisms as prognostic markers for ocular manifestations in pseudoxanthoma elasticum.
Psoriasis
A new selective vascular endothelial growth factor receptor 2 inhibitor ablates disease in a mouse model of psoriasis.
A Preliminary Study of the Effect of Semaphorin 3A and Acitretin on the Proliferation, Migration, and Apoptosis of HaCaT Cells.
Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis.
An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.
Angiogenesis drives psoriasis pathogenesis.
Angiogenesis: the new potential target for the therapy of psoriasis?
Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy.
Angiogenic and inflammatory properties of psoriatic arthritis.
Antiangiogenic Effect of Methotrexate and PUVA on Psoriasis.
Association of psoriasis with the VEGF gene polymorphism in the northern Polish population.
Association of the CTG (-2578/-460/+405) haplotype within the vascular endothelial growth factor gene with early-onset psoriasis.
Calcitonin gene-related peptide regulates the expression of vascular endothelial growth factor in human HaCaT keratinocytes by activation of ERK1/2 MAPK.
Can signal peptide-CUB-EGF domain-containing protein (SCUBE) levels be a marker of angiogenesis in patients with psoriasis?
Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation.
Clinical, pathological and immunological features of psoriatic-like lesions affecting keratin 14-vascular endothelial growth factor transgenic mice.
Cocoa polyphenols suppress TNF-?-induced vascular endothelial growth factor expression by inhibiting phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase kinase-1 (MEK1) activities in mouse epidermal cells.
Components of the alternative complement pathway in patients with psoriasis.
Correlation between vascular endothelial growth factor and subclinical atherosclerosis in patients with psoriasis.
Corticotropin-releasing hormone attenuates vascular endothelial growth factor release from human HaCaT keratinocytes.
Deciphering Gut Microbiota Dysbiosis and Corresponding Genetic and Metabolic Dysregulation in Psoriasis Patients Using Metagenomics Sequencing.
Differential expression of the angiogenesis growth factors in psoriasis vulgaris.
Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re-PUVA and narrow-band UVB.
Effect of biologic therapies targeting TNF-alpha on cutaneous mesenchymal stem cells in psoriasis.
Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study.
Effects of Narrow Band Ultraviolet B on Serum Levels of Vascular Endothelial Growth Factor and Interleukin-8 in Patients with Psoriasis.
Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis.
Endostatin and Thrombospondin-1 levels are increased in the sera of patients with chronic spontaneous urticaria.
Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: implications for the pathogenesis of psoriasis.
Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis.
Excessive angiogenesis associated with psoriasis as a cause for cardiovascular ischaemia.
Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds.
Expression of Angiogenic Factors in Psoriasis Vulgaris.
Four Polymorphisms of VEGF (+405C>G, -460T>C, -2578C>A, and -1154G>A) in Susceptibility to Psoriasis: A Meta-Analysis.
Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Genetic interaction between placenta growth factor (PGF) and vascular endothelial growth factor A (VEGFA) in psoriasis.
Genetic Risk Factors for Psoriasis in Turkish Population: -1540 C/A, -1512 Ins18, and +405 C/G Polymorphisms within the Vascular Endothelial Growth Factor Gene.
Hypoxia-inducible factor-1: A potential pharmacological target to manage psoriasis.
Imiquimod Increases Cutaneous VEGF Expression in Imiquimod-induced Psoriatic Mouse Model.
Immunohistochemical study of psoriatic plaques and perilesional skin in psoriasis vulgaris patients: A pilot study.
Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice.
Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.
Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasis.
Investigation of +405 and -460 polymorphisms of vascular endothelial growth factor in psoriasis and short-term responsiveness to efalizumab therapy.
Investigation of Immunovascular Polymorphisms and Intersections in Psoriasis.
Investigational VEGF antagonists for psoriasis.
Involvement of TNF-? converting enzyme in the development of psoriasis-like lesions in a mouse model.
Keratinocytes treated with peptidoglycan from Staphylococcus aureus produce vascular endothelial growth factor, and its expression is amplified by the subsequent production of interleukin-13.
Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis.
Luteolin inhibits human keratinocyte activation and decreases NF-?B induction that is increased in psoriatic skin.
Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor.
Multidisciplinary focus on cyclosporin A.
Network Pharmacology-Based Analysis on the Mechanism of Action of Ephedrae Herba-Cinnamomi Ramulus Couplet Medicines in the Treatment for Psoriasis.
Notch-1 mediates endothelial cell activation and invasion in psoriasis.
Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis.
Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF.
Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions.
Paradoxical exacerbation of chronic plaque psoriasis by sorafenib.
Reduced Number of Circulating Endothelial Progenitor Cells (CD133+/KDR+) in Patients with Plaque Psoriasis.
Regulation of vascular endothelial growth factor expression by insulin-like growth factor-II in human keratinocytes, differential involvement of mitogen-activated protein kinases and feedback inhibition of protein kinase C.
Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids.
Serum cytokines and growth factor levels in Japanese patients with psoriasis.
Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis.
Serum Vascular Endothelial Growth Factor, Transforming Growth Factor ?1, and Nitric Oxide Levels in Patients With Psoriasis Vulgaris: Their Correlation to Disease Severity.
Severe generalized pustular psoriasis accompanied by bullae formation with increased serum vascular endothelial growth factor level.
Significance of vascular endothelial growth factor and CD31 and morphometric analysis of microvessel density by CD31 receptor expression as an adjuvant tool in diagnosis of psoriatic lesions of skin.
Silencing KRT16 inhibits keratinocyte proliferation and VEGF secretion in psoriasis via inhibition of ERK signaling pathway.
Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.
Skin Surface Protein Detection by Transdermal Analysis Patches in Pediatric Psoriasis.
SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis.
Targeting VEGF/VEGFR in the treatment of psoriasis.
Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod-induced Psoriatic Mouse Model.
The alpha-helical domain near the amino terminus is essential for dimerization of vascular endothelial growth factor.
The association of serum vascular endothelial growth factor levels and psoriasis vulgaris: A protocol for systematic review and meta-analysis.
The effect of etanercept on vascular endothelial growth factor production by cutaneous mesenchymal stem cells from patients with psoriasis.
The efficacy of in vivo administration of Apremilast on mesenchymal stem cells derived from psoriatic patients.
The mesenchymal stem cell profile in psoriasis.
The role of endothelial cell apoptosis in the effect of etanercept in psoriasis.
The vascular endothelial growth factor +405 G/C polymorphism in psoriasis.
To explore the clinical efficacy of Traditional Chinese Medicine bath in the treatment of psoriasis vulgaris with blood-heat syndrome and its effect on related cytokines based on different temperature and different concentration.
Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes.
Upregulation of hypoxia-inducible factors in normal and psoriatic skin.
Vascular endothelial growth factor (VEGF) gene polymorphisms (rs699947, rs833061, and rs2010963) and psoriatic risk in South Indian Tamils.
Vascular Endothelial Growth Factor Blockade Induces Dermal Endothelial Cell Apoptosis in a Clinically Relevant Skin Organ Culture Model.
Vascular endothelial growth factor driving aberrant keratin expression pattern contributes to the pathogenesis of psoriasis.
Vascular endothelial growth factor gene polymorphisms and psoriasis susceptibility: a meta-analysis.
Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis.
Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control.
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis.
Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase-2 expression in psoriasis.
Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation.
Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes.
VEGF-A promotes IL-17A-producing ?? T cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells.
Videocapillaroscopic findings in the microcirculation of the psoriatic plaque during etanercept therapy.
[Expression of vascular endothelial growth factor in skin lesions and sera from patients with psoriasis vulgaris].
[Qinzhu Liangxue Decoction in treatment of blood-heat type psoriasis vulgaris: a randomized controlled trial]
Pterygium
A randomized controlled prospective study to assess the role of subconjunctival bevacizumab in primary pterygium surgery in Indian patients.
Angiogenesis in pterygium: morphometric and immunohistochemical study.
Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1.
Connective tissue growth factor in pterygium: simultaneous presence with vascular endothelial growth factor - possible contributing factor to conjunctival scarring.
Correlation of vascular endothelial growth factor and CD105-microvascular density in primary pterygium.
Cyclooxygenase-2-expressing macrophages in human pterygium co-express vascular endothelial growth factor.
Elevated blood/lymphatic vessel ratio in pterygium and its relationship with vascular endothelial growth factor (VEGF) distribution.
Evaluation of transforming growth factor and vascular endothelial growth factor polymorphisms in Taiwan Chinese patients with pterygium.
Expression of Vascular Endothelial Growth Factor (VEGF) in Macrophages, Fibroblasts, and Endothelial Cells in Pterygium Treated with 5-Fluorouracil.
Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia.
Expression of vascular endothelial growth factor C in human pterygium.
Immunohistochemical analysis of vascular endothelial growth factor (VEGF) and p53 expression in pterygium from Tunisian patients.
Management of primary pterygium with intra-lesional injection of 5 flurouracil and bevacizumab (Avastin).
Overexpression of low-density lipoprotein receptors stimulated by vascular endothelial growth factor in fibroblasts from pterygium.
Overexpression of vascular endothelial growth factor receptor 2 in pterygia may have a predictive value for a higher postoperative recurrence rate.
Pterygium Pathology: A Prospective Case-Control Study on Tear Film Cytokine Levels.
Relationship between expression of cyclooxygenase 2 and neovascularization in human pterygia.
Role of oxidative stress and vascular endothelial growth factor expression in pterygium pathogenesis and prevention of pterygium recurrence after surgical excision.
Semaphorin 7a participants in pterygium by regulating vascular endothelial growth factor.
Targeted delivery of mitomycin C-loaded and LDL-conjugated mesoporous silica nanoparticles for inhibiting the proliferation of pterygium subconjunctival fibroblasts.
The expression of vascular endothelial growth factor in pterygium tissue of atopic patients.
The Key Role of VEGF in the Cross Talk between Pterygium and Dry Eye and Its Clinical Significance.
Treatment of inflamed pterygia or residual pterygial bed.
Vascular endothelial growth factor gene 460 polymorphism is associated with pterygium formation in female patients.
Vascular endothelial growth factor gene polymorphism and protein expression in the pathogenesis of pterygium.
[Blood vessel multiply and significance of expression of Cox-2, VEGF in pterygium]
Pulmonary Arterial Hypertension
Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
Elevated Adipsin Levels are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis.
Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis.
Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
Pro- and antiangiogenic markers in patients with pulmonary complications of systemic scleroderma.
Role of the Aryl Hydrocarbon Receptor in Sugen 5416-induced Experimental Pulmonary Hypertension.
Severe Pulmonary Arterial Hypertension Induced by SU5416 and Ovalbumin Immunization.
Syngeneic bone marrow mononuclear cells improve pulmonary arterial hypertension through vascular endothelial growth factor upregulation.
The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox.
Triple-tyrosine kinase inhibition attenuates pulmonary arterial hypertension and neointimal formation.
[Functional State of Vascular Endothelium in Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Diseases].
Pulmonary Disease, Chronic Obstructive
Adenosine receptors in COPD and asymptomatic smokers: effects of smoking cessation.
Angiogenesis and vascular endothelial growth factor in COPD.
Apoptotic mechanisms in the pathogenesis of COPD.
Association of VEGFA polymorphisms with chronic obstructive pulmonary disease in Chinese Han and Mongolian populations.
Azithromycin Attenuates Fibroblast Growth Factors Induced Vascular Endothelial Growth Factor Via p38(MAPK) Signaling in Human Airway Smooth Muscle Cells.
Basement membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a cross-sectional study.
Bevacizumab regulates inflammatory cytokines and inhibits VEGFR2 signaling pathway in an ovalbumin-induced rat model of airway hypersensitivity.
Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent emphysema.
Cigarette smoke and ?,?-unsaturated aldehydes elicit VEGF release through the p38 MAPK pathway in human airway smooth muscle cells and lung fibroblasts.
Cigarette Smoke Triggers IL-33-Associated Inflammation in a Model of Late Stage COPD.
Circulating progenitor cells and vascular dysfunction in chronic obstructive pulmonary disease.
Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease.
Comparison of arterial and venous blood biomarker levels in chronic obstructive pulmonary disease.
Decreased airway expression of vascular endothelial growth factor in cigarette smoke-induced emphysema in mice and COPD patients.
Elevated oxidative stress and reciprocal reduction of vascular endothelial growth factor levels with severity of COPD.
Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease.
Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease.
Evaluation of the severity of small airways obstruction and alveolar destruction in chronic obstructive pulmonary disease.
Functional Studies of Single-Nucleotide Polymorphisms Suggest Heterogeneity in Chronic Obstructive Pulmonary Disease due to Susceptibility of Different Cell Types.
Impaired TNFalpha-induced VEGF expression in human airway smooth muscle cells from smokers with COPD: role of MAPkinases and histone acetylation--effect of dexamethasone.
Increased expression of vascular endothelial growth factor and hypoxia inducible factor-1? in lung tissue of patients with chronic bronchitis.
Longitudinal Measurement of Serum Vascular Endothelial Growth Factor in Patients with Chronic Obstructive Pulmonary Disease.
Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease.
Prostaglandin E2 possesses different potencies in inducing Vascular Endothelial Growth Factor and Interleukin-8 production in COPD human lung fibroblasts.
Remodeling in asthma and chronic obstructive pulmonary disease.
Role of Inhaled Steroids in Vascular Airway Remodelling in Asthma and COPD.
Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants.
Role of the HIF-1 signaling pathway in chronic obstructive pulmonary disease.
Role of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease.
Serum cytokine profiles in patients with chronic obstructive pulmonary disease associated pulmonary hypertension identified using protein array.
Serum levels of vascular endothelial growth factor in chronic obstructive pulmonary disease.
Serum vascular endothelial growth factor and its receptor level in patients with chronic obstructive pulmonary disease.
Smad3 mediates cigarette smoke extract (CSE) induction of VEGF release by human fetal lung fibroblasts.
Studies of vascular endothelial growth factor in asthma and chronic obstructive pulmonary disease.
The association of genetic polymorphisms of hypoxia inducible factor-1 alpha and vascular endothelial growth factor with increased risk of chronic obstructive pulmonary disease: A case-control study.
The Role of Vascular Endothelial Growth Factor in Small-airway Remodelling in a Rat Model of Chronic Obstructive Pulmonary Disease.
Therapeutic perspectives in vascular remodeling in asthma and chronic obstructive pulmonary disease.
TNF-?-induced NF-?B activation stimulates skeletal muscle glycolytic metabolism through activation of HIF-1?
Variants in multiple genes polymorphism association analysis of COPD in the Chinese Li population.
Vascular biomarkers in asthma and COPD.
Vascular endothelial growth factor and the risk of smoking-related COPD.
Vascular endothelial growth factor as a non-invasive marker of pulmonary vascular remodeling in patients with bronchitis-type of COPD.
Vascular endothelial growth factor in the human diaphragm: new insight into adaptation mechanisms in chronic obstructive pulmonary disease patients.
Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
Vascular endothelial growth factor: an angiogenic factor reflecting airway inflammation in healthy smokers and in patients with bronchitis type of chronic obstructive pulmonary disease?
[Expressions of and the effect of smoking on vascular endothelial growth factor and induced nitric oxide synthase in lung tissues of chronic obstructive pulmonary disease patients]
Pulmonary Edema
Elevated VEGF Levels in Pulmonary Edema Fluid and PBMCs from Patients with Acute Hantavirus Pulmonary Syndrome.
Genetic Delivery of Bevacizumab to Suppress VEGF-induced High-permeability Pulmonary Edema.
Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema.
Opposing effects of isoflurane and sevoflurane on neurogenic pulmonary edema development in an animal model.
Pathogenesis of high altitude pulmonary edema: does alveolar epithelial lining fluid vascular endothelial growth factor exacerbate capillary leak?
Vascular endothelial growth factor in patients with high-altitude pulmonary edema.
Vascular endothelial growth factor receptor and coreceptor expression in human acute respiratory distress syndrome.
[Effect of phosgene on apoptosis of alveolar type II cells and vascular endothelial growth factor in exposed mice]
Pulmonary Embolism
Chronic Embolic Pulmonary Hypertension Caused by Pulmonary Embolism and Vascular Endothelial Growth Factor Inhibition.
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Pulmonary toxicities from targeted therapies: a review.
Pulmonary Emphysema
Airway administration of vascular endothelial growth factor siRNAs induces transient airspace enlargement in mice.
Airway Hyperresponsiveness, Inflammation, and Pulmonary Emphysema in Rodent Models Designed to Mimic Exposure to Fuel Oil-Derived Volatile Organic Compounds Encountered during an Experimental Oil Spill.
Differing Expression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis.
Dynamic expression of tumor necrosis factor-alpha and vascular endothelial growth factor in rat model of pulmonary emphysema induced by smoke exposure.
Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells.
Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity.
[Restoration of pathological changes of emphysema by angiogenesis factors: experiment of rats]
Pulmonary Eosinophilia
Increased vascular endothelial growth factor in acute eosinophilic pneumonia.
Pulmonary Fibrosis
A Lipidomics Approach to Identifying Key Lipid Species Involved in VEGF-Inhibitor Mediated Attenuation of Bleomycin-Induced Pulmonary Fibrosis.
Angiogenic cytokines in induced sputum of patients with sarcoidosis.
Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis.
Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis.
Indole alkaloids from leaves of Alstonia scholaris (L.) R. Br. protect against emphysema in mice.
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis.
Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.
Potential regulatory role of circular RNA in idiopathic pulmonary fibrosis.
Pro- and antiangiogenic markers in patients with pulmonary complications of systemic scleroderma.
[Discovery of intervention effect of Chinese herbal formulas on COVID-19 pulmonary fibrosis treated by VEGFR and FGFR inhibitors].
[Effects of sense vascular endothelial growth factor cDNA transfection on mononuclear chemotaxis protein-1 expression in rat pulmonary microvessel endothelial cells]
Pulmonary Valve Insufficiency
DNA Microarray and Quantitative Analysis Reveal Enhanced Myocardial VEGF Expression with Stunted Angiogenesis in Human Tetralogy of Fallot.
Pulpitis
Lipopolysaccharide enhances the production of vascular endothelial growth factor by human pulp cells in culture.
Purpura
Association between functional haplotypes of vascular endothelial growth factor and renal complications in Henoch-Schönlein purpura.
Role of interleukin-6 and vascular endothelial growth factor in Henoch-Schönlein purpura with posterior reversible encephalopathy syndrome.
[Expression of vascular endothelial growth factor is related to microvessel injury of renal interstitium in children with Henoch Sch nlein purpura nephritis.]
[Serum and urine VEGF concentration of different pathological types in children with Henoch Schonlein purpura nephritis]
Purpura, Thrombocytopenic, Idiopathic
[Blood cytokine levels as a clinical laboratory test]
Pyelonephritis
[The clinical diagnostic importance of detection of vascular endothelial growth factor in evaluation of progression of pyelonephritis in children].
Pyoderma Gangrenosum
Disseminated pyoderma gangrenosum: role for vascular endothelial growth factor and hypoxia inducible factor-2.
Radiation Pneumonitis
Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy.
Radicular Cyst
Comparative analysis of the immunohistochemical expression of vascular endothelial growth factor and matrix metalloproteinase-9 in keratocystic odontogenic tumor, dentigerous cyst and radicular cyst.
Detection and quantification of mast cell, vascular endothelial growth factor, and microvessel density in human inflammatory periapical cysts and granulomas.
Immunoexpression of vascular endothelial growth factor in periapical granulomas, radicular cysts, and residual radicular cysts.
Immunohistochemical expression of vascular endothelial growth factor and matrix metalloproteinase-9 in radicular and residual radicular cysts.
Immunohistochemical expression of vascular endothelial growth factor in keratocystic odontogenic tumor, dentigerous cyst, and radicular cyst: A comparative study.
Microvessel density and vascular endothelial growth factor (VEGF) expression in human radicular cysts.
The extra domain A of fibronectin facilitates osteoclastogenesis in radicular cysts through vascular endothelial growth factor.
Radiodermatitis
Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.
Rectal Neoplasms
An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation.
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy.
Changes of serum vascular endothelial growth factor of patients with rectal cancer before and after neoadjuvant chemotherapy and tumor progress.
Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy.
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy.
Expression of vascular endothelial growth factor as a predictor of complete response for preoperative chemoradiotherapy in rectal cancer.
Expression of vascular endothelial growth factor can predict distant metastasis and disease-free survival for clinical stage III rectal cancer following 30-Gy/10-f preoperative radiotherapy.
Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer.
Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer.
Interleukin-24 is correlated with differentiation and lymph node numbers in rectal cancer.
Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study.
Molecular prognostic factors in rectal cancer treated by radiation and surgery.
MRI In rectal cancer: Correlations between MRI features and molecular markers Ki-67, HIF-1?, and VEGF.
Nomogram for prediction of pathologic complete remission using biomarker expression and endoscopic finding after preoperative chemoradiotherapy in rectal cancer.
Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer.
Over-expression of vascular endothelial growth factor after preoperative radiation therapy for rectal cancer.
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging in patients with rectal cancer: correlation with microvascular density and vascular endothelial growth factor expression.
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.
Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy.
Pretreatment Expression of 13 Molecular Markers as a Predictor of Tumor Responses After Neoadjuvant Chemoradiation in Rectal Cancer.
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy.
Rectal cancer with paraneoplastic nephropathy: association of vascular endothelial growth factor.
ROLE OF GELATINASES (MMP-2 AND MMP-9), VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND ENDOSTATIN ON CLINICOPATHOLOGICAL BEHAVIOR OF RECTAL CANCER.
Role of intravoxel incoherent motion MRI in preoperative evaluation of DNA mismatch repair status in rectal cancers.
The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery.
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Treatment effect of conversion therapy and its correlation with VEGF expression in unresectable rectal cancer with liver metastasis.
Vascular endothelial growth factor C promotes lymph node metastasis in a rectal cancer orthotopic model.
VEGF concentrations in tumour arteries and veins from patients with rectal cancer.
VEGF hypersecretion as a plausible mechanism for pseudo-meigs' syndrome in advanced colorectal cancer.
[Correlation of vascular endothelial growth factor D, microlymphatic density and microvessel density with development and metastasis of rectal cancer]
[Effect of vascular endothelial growth factor C and collagen triple helix repeat containing 1 expression on prognosis of rectal carcinoma patients].
[Molecular epidemiologic analysis of the levels of metalloproteases and cyclooxygenase-2 in colorectal cancer]
Relative Energy Deficiency in Sport
MicroRNA 210 Mediates VEGF Upregulation in Human Periodontal Ligament Stem Cells Cultured on 3DHydroxyapatite Ceramic Scaffold.
Renal Insufficiency
Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease.
Complement activation by the alternative pathway is modified in renal failure: the role of factor D.
Complement depletion during haemofiltration with polyacrilonitrile membranes.
High fever, renal failure, disseminated intravascular coagulation and myelodysplasia accompanied with enhanced angiogenesis possibly due to overexpression of vascular endothelial growth factor.
Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function.
Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure.
Interaction of poly(2-acrylamido 2-methylpropane sulfonate)-grafted polystyrene beads with cationic complement proteins.
Metabolism of complement factor D in renal failure.
Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone.
Purification of human complement factor D from the peritoneal fluid of patients on chronic ambulatory peritoneal dialysis.
The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
The role of PDGF-D in mesangioproliferative glomerulonephritis.
[Factor D of complement: Uremic toxin?]
Renal Insufficiency, Chronic
Albumin suppresses vascular endothelial growth factor via alteration of hypoxia-inducible factor/hypoxia-responsive element pathway.
An Expanded View of Progressive Cardiorenal Disorders.
Association between urinary vascular endothelial growth factor excretion and chronic kidney disease in hyperthyroid cats.
Blockade of vascular endothelial growth factor-A/receptor 2 exhibits a protective effect on angiotensin-II stimulated podocytes.
Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients.
CONNECTION BETWEEN SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS AND SEVERITY OF MICROANGIOPATHY IN PATIENTS WITH TYPE 2 DIABETES AND OBSTRUCTIVE SLEEP APNEA.
Endostatin and vascular endothelial growth factor: potential regulators of endothelial progenitor cell number in chronic kidney disease.
Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males.
Macrophages Regulate Unilateral Ureteral Obstruction-Induced Renal Lymphangiogenesis through C-C Motif Chemokine Receptor 2-Dependent Phosphatidylinositol 3-Kinase-AKT-Mechanistic Target of Rapamycin Signaling and Hypoxia-Inducible Factor-1?/Vascular Endothelial Growth Factor-C Expression.
Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease.
The GA genotype of the -1154 G/A (rs1570360) vascular endothelial growth factor (VEGF) is protective against hypertension-related chronic kidney disease incidence.
The GG genotype of the -152 G/A vascular endothelial growth factor (VEGF) polymorphism predisposes to hypertension-related chronic kidney disease.
The predictive value of urinary vascular endothelial growth factor (VEGF) on worsening kidney function in proteinuric chronic kidney disease.
Urinary and circulating levels of the anti-angiogenic isoform of vascular endothelial growth factor-A in patients with chronic kidney disease.
Urinary excretion of endothelin-1 (ET-1), transforming growth factor- beta1 (TGF- beta1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial.
Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer.
Value of Placental Growth Factor as a Predictor of Adverse Events During the Acute Phase of Acute Decompensated Heart Failure.
Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?
Vascular endothelial growth factor C levels are modulated by dietary salt intake in proteinuric chronic kidney disease patients and in healthy subjects.
Vascular endothelial growth factor polymorphism (-460 T/C) is related to hypertension-associated chronic kidney disease.
VEGF-A165 b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF-A splice isoforms from the kidney.
Reperfusion Injury
Antioxidative effects of adrenomedullin and vascular endothelial growth factor on lung injury induced by skeletal muscle ischemia-reperfusion.
Bosentan protects the spinal cord from ischemia reperfusion injury in rats through vascular endothelial growth factor receptors.
Carbon monoxide ameliorates renal cold ischemia-reperfusion injury with an upregulation of vascular endothelial growth factor by activation of hypoxia-inducible factor.
Dual role of vascular endothelial growth factor in hepatic ischemia-reperfusion injury.
Effect of Berberine on Angiogenesis and HIF-1α / VEGF Signal Transduction Pathway in Rats with Cerebral Ischemia - Reperfusion Injury.
Effect of systemic piracetam treatment on flap survival and vascular endothelial growth factor expression after ischemia-reperfusion injury.
Effects of VEGF administration following ischemia on survival of the gracilis muscle flap in the rat.
Expression of vascular endothelial growth factor and its receptor, KDR, following retinal ischemia-reperfusion injury in the rat.
Immunohistochemical identification of vascular endothelial growth factor in pig latissimus dorsi musculocutaneous flaps following ischemia-reperfusion injury.
Influence of an Early Application of Mammalian Target of Rapamycin Inhibitors Everolimus and Sirolimus on Acute Vascular Inflammatory Responses After Ischemia-Reperfusion Injury.
Ischemia-reperfusion injury induces occludin phosphorylation/ubiquitination and retinal vascular permeability in a VEGFR-2-dependent manner.
Monitoring of renal ischemia reperfusion injury in rabbits by ultrasonic contrast and its relationship with expression of VEGF in renal tissue.
Observation of human retinal remodeling in octogenarians with a resveratrol based nutritional supplement.
Prostaglandin E2 reduces swine myocardial ischemia reperfusion injury via increased endothelial nitric oxide synthase and vascular endothelial growth factor expression levels.
Protective effect of vascular endothelial growth factor on histologic changes in testicular ischemia-reperfusion injury.
Protective effects of acupuncture and LGNHFD on expressions of vascular endothelial growth factor, basic fibroblast growth factor, and cluster of differentiation 34 in rats with cerebral ischemia-reperfusion injury.
Protective effects of sulphonated formononetin in a rat model of cerebral ischemia and reperfusion injury.
The effect of adipose-derived stem cells on ischemia-reperfusion injury: immunohistochemical and ultrastructural evaluation.
Trace element levels in ischemia-reperfusion injury after left colonic anastomosis in rats and effects of papaverine and pentoxiphylline on vascular endothelial growth factor in anastomosis healing.
Triple-marker cardiac MRI detects sequential tissue changes of healing myocardium after a hydrogel-based therapy.
Vascular endothelial growth factor attenuates myocardial ischemia-reperfusion injury.
Vascular endothelial growth factor expression in pig latissimus dorsi myocutaneous flaps after ischemia reperfusion injury.
Vascular Endothelial Growth Factor Up-regulation in Human Amniotic Fluid Stem Cell Enhances Nephroprotection After Ischemia-Reperfusion Injury in the Rat.
VEGF and Ang-1 promotes endothelial progenitor cells homing in the rat model of renal ischemia and reperfusion injury.
VEGF mitigates histone-induced pyroptosis in the remote liver injury associated with renal allograft ischemia-reperfusion injury in rats.
[Effect of electroacupuncture on plasma endogenous endothelial progenitor cell counts in cerebral ischemia-reperfusion rats]
[Effects of Electroacupuncture and Intracerebral Injection of VEGF on Caspase12, Caspase3, and GRP78 Genes in Rats with Cerebral Ischemia-Reperfusion Injury].
[Electroacupuncture Combined with Intracerebral Injection of VEGF Improves Neurological Dysfunction Possibly by Down-regulating Expression of Endoplasmic Reticulum Stress Related Proteins ATF 6, etc. in Cerebral Ischemia-reperfusion Injury Rats].
[Protective effect of electroacupuncture intervention on neurovascular unit in rats with focal cerebral ischemia-reperfusion injury].
[The impact of different duration of EA-pretreatment on expression of MMP-9 and VEGF in blood-brain barrier in rats with cerebral ischemia-reperfusion injury].
Respiratory Distress Syndrome
A role for vascular endothelial growth factor in acute and resolving lung injury.
Anti-vasopermeability effects of PEDF in retinal-renal disorders.
Association Between Vascular Endothelial Growth Factor + 936 Genotype and Acute Respiratory Distress Syndrome in a Chinese Population.
Cell Adhesion Molecules and Vascular Endothelial Growth Factor at the Systemic and Alveolar Level in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome.
Changes in TNF-?, IL-6, IL-10 and VEGF in rats with ARDS and the effects of dexamethasone.
Comment on: Cell Adhesion Molecules and Vascular Endothelial Growth Factor at the Systemic and Alveolar Level in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome.
Decreased VEGF concentration in lung tissue and vascular injury during ARDS.
Exogenous surfactant protects against endotoxin induced acute respiratory distress syndrome in rodents via vascular endothelial growth factor.
Genetic Contributions to the Development of Complications in Preterm Newborns.
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha are decreased in an experimental model of severe respiratory distress syndrome in preterm lambs.
Molecular-biological analysis of acute lung injury (ALI) induced by heat exposure and/or intravenous administration of oleic acid.
Monitoring of vascular endothelial growth factor and its soluble receptor levels in early trauma.
Placental growth factor and vascular endothelial growth factor receptor-2 in human lung development.
Recombinant human Clara cell secretory protein treatment increases lung mRNA expression of surfactant proteins and vascular endothelial growth factor in a premature lamb model of respiratory distress syndrome.
Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury.
Sp1-mediated nonmuscle myosin light chain kinase expression and enhanced activity in vascular endothelial growth factor-induced vascular permeability.
Structural and molecular regulation of lung maturation by intratracheal vascular endothelial growth factor administration in the normally grown and placentally restricted fetus.
Systemic Endothelial Activation Is Associated With Early Acute Respiratory Distress Syndrome in Children With Extrapulmonary Sepsis.
Targeted Antagonism of Vascular Endothelial Growth Factor Reduces Mortality of Mice with Acute Respiratory Distress Syndrome.
The role of VEGF and its soluble receptor VEGFR-1 in preterm newborns of preeclamptic mothers with RDS.
Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?
Vascular endothelial growth factor gene polymorphism and acute respiratory distress syndrome.
Vascular endothelial growth factor in acute lung injury and acute respiratory distress syndrome.
Vascular endothelial growth factor in epithelial lining fluid of patients with acute respiratory distress syndrome.
Vascular endothelial growth factor in preterm infants with respiratory distress syndrome.
Vascular endothelial growth factor increased the permeability of respiratory barrier in acute respiratory distress syndrome model in mice.
Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome.
Vascular endothelial growth factor receptor and coreceptor expression in human acute respiratory distress syndrome.
Vascular endothelial growth factor: a possible mediator of endothelial activation in acute respiratory distress syndrome.
[Effects of xuebijing on nitric oxide and VEGF-A in exhaled breath condensate of patients with ALI/ARDS].
Respiratory Hypersensitivity
A prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, regulates vascular permeability by reducing vascular endothelial growth factor expression in asthma.
Respiratory Insufficiency
Impact of systemic hypoxemia on cancer aggressiveness and circulating vascular endothelial growth factors A and C in gastroesophageal cancer patients with chronic respiratory insufficiency.
Vascular endothelial growth factor and amyotrophic lateral sclerosis: The Interplay with exercise and non-invasive ventilation.
VEGF levels in humans and animal models with RDS and BPD: Temporal relationships.
Respiratory Syncytial Virus Infections
Pretreatment with recombinant human vascular endothelial growth factor reduces virus replication and inflammation in a perinatal lamb model of respiratory syncytial virus infection.
Respiratory Tract Infections
Plasma cytokines eotaxin, MIP-1?, MCP-4, and vascular endothelial growth factor in acute lower respiratory tract infection.
Reticuloendotheliosis, Avian
Gene Expression Analysis of the Irrigation Solution Samples Collected during Vitrectomy for Idiopathic Epiretinal Membrane.
Retinal Degeneration
Impact of obesity with impaired glucose tolerance on retinal degeneration in a rat model of metabolic syndrome.
Longitudinal phenotypic study of late-onset retinal degeneration due to a founder variant c.562C>A p.(Pro188Thr) in the C1QTNF5 gene.
Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Upregulation of vascular endothelial growth factor (VEGF) in the retinas of transgenic mice overexpressing interleukin-1beta (IL-1beta) in the lens and mice undergoing retinal degeneration.
Retinal Detachment
Amino acid and vascular endothelial growth factor levels in subretinal fluid in rhegmatogenous retinal detachment.
Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1.
Antiangiogenic Isoforms of VASCULAR ENDOTHELIAL GROWTH FACTOR Predominate in Subretinal Fluid of Patients with Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy.
APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION: Results of a Prospective Trial. Report No. 2.
Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion.
Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity.
Characteristics of diabetic macular edema patients with serous retinal detachment.
Clinical Features and Prognostic Factors in Northern Chinese Patients with Peripheral Granuloma Type of Ocular Toxocariasis: A Retrospective Cohort Study.
Comparison of vitreous and plasma levels of vascular endothelial growth factor, interleukin-6 and hepatocyte growth factor in diabetic and non-diabetic retinal detachment cases.
Concentration of vascular endothelial growth factor in the subretinal fluid of retinal detachment.
CONCURRENT SCLERAL BUCKLE AND INTRAVITREAL BEVACIZUMAB FOR ADVANCED RETINOPATHY OF PREMATURITY-RELATED RETINAL DETACHMENT.
Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor.
Elevated erythropoietin and vascular endothelial growth factor levels in an adolescent with retinal neovascularization from a chronic rhegmatogenous retinal detachment.
Genetic polymorphisms of vascular endothelial growth factor and risk for retinopathy of prematurity in South of Iran.
Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment.
Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment.
Inhibition of integrin ?5?1 ameliorates VEGF-induced retinal neovascularization and leakage by suppressing NLRP3 inflammasome signaling in a mouse model.
Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
Review of choroidal osteomas.
SUCCESSFUL TREATMENT OF REFRACTORY PROLIFERATIVE RETINOPATHY OF INCONTINENTIA PIGMENTI BY INTRAVITREAL RANIBIZUMAB AS ADJUNCT THERAPY IN A 4-YEAR-OLD CHILD.
The influence of systemic renin-angiotensin-inhibition on ocular cytokines related to proliferative vitreoretinopathy.
Vascular endothelial growth factor and interleukin-6 are correlated with serous retinal detachment in central retinal vein occlusion.
Vitreous Inflammatory Factors and Serous Macular Detachment in Branch Retinal Vein Occlusion.
Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment.
[Concentration of vascular endothelial growth factor within the subretinal space and vitreous fluid in rhegmatogenous retinal detachment]
[Correlation from Undiluted Vitreous Cytokines of Untreated Central Retinal Vein Occlusion with Spectral Domain Optical Coherence Tomography].
Retinal Diseases
A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes.
An Evidence-Based Meta-analysis of Vascular Endothelial Growth Factor Inhibition in Pediatric Retinal Diseases: Part 1. Retinopathy of Prematurity.
An Evidence-Based Review of Vascular Endothelial Growth Factor Inhibition in Pediatric Retinal Diseases: Part 2. Coats' Disease, Best Disease, and Uveitis With Childhood Neovascularization.
Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD.
Angiogenic growth factors and their inhibitors in diabetic retinopathy.
Antiproliferative, Apoptotic, and Autophagic Activity of Ranibizumab, Bevacizumab, Pegaptanib, and Aflibercept on Fibroblasts: Implication for Choroidal Neovascularization.
Apelin is a crucial factor for hypoxia-induced retinal angiogenesis.
Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade.
Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications.
Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis.
Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF).
Effects of ischemic preconditioning and bevacizumab on apoptosis and vascular permeability following retinal ischemia-reperfusion injury.
Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms.
Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Galectins in the Pathogenesis of Common Retinal Disease.
HIV-1-mediated delivery of a short hairpin RNA targeting vascular endothelial growth factor in human retinal pigment epithelium cells.
Human plasminogen-derived N-acetyl-Arg-Leu-Tyr-Glu antagonizes VEGFR-2 to prevent blood-retinal barrier breakdown in diabetic mice.
Hypoxia-Inducible Factor (HIF)/Vascular Endothelial Growth Factor (VEGF) Signaling in the Retina.
Hypoxia-inducible factor expression in human RPE cells.
Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes.
Indications for intravitreal bevacizumab in ibadan, sub-saharan Africa.
Inhibitory mechanism of vascular endothelial growth factor (VEGF) by bucillamine.
Interactive expressions of HtrA1 and VEGF in human vitreous humors and fetal RPE cells.
Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry.
Intravitreal Anti Vascular Endothelial Growth Factor Agents in The Management of Retinal Diseases: An Audit.
Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation.
Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach.
Objective of pharmacologic vitreolysis.
Pathological angiogenesis in a murine model of human Wilms' tumor.
Pathological role of apelin in angiogenic eye disease.
Potential role of the methylation of VEGF gene promoter in response to hypoxia in oxygen-induced retinopathy: beneficial effect of the absence of AQP4.
Structure-Guided Molecular Engineering of a Vascular Endothelial Growth Factor Antagonist to Treat Retinal Diseases.
Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy.
Systemic effects of intravitreal vascular endothelial growth factor inhibitors.
The omnipresence of vascular endothelial growth factor in retinal diseases.
Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension.
Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease.
Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema.
Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Pigment Epithelium-Derived Factor Expression in the Neovascular Iris in Retinal Diseases.
VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases.
Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic vitreoretinopathy.
[Angiogenesis and retinal diseases]
[Basic in vitro Studies on VEGF Inhibition with Aflibercept: Similarities and Differences to Other VEGF-Binding Therapeutic Proteins.]
[Pathological and therapeutic possibilities in inhibiting ocular angionesis].
[Pharmacokinetics of intravitreally administered VEGF inhibitors].
[Vascular endothelial growth factor in the ocular fluid in diabetic retinopathy and other retinal diseases]
Retinal Dysplasia
Vascular Endothelial Growth Factor A and Leptin Expression Associated with Ectopic Proliferation and Retinal Dysplasia in Zebrafish Optic Pathway Tumors.
Retinal Dystrophies
Longitudinal phenotypic study of late-onset retinal degeneration due to a founder variant c.562C>A p.(Pro188Thr) in the C1QTNF5 gene.
Retinal Necrosis Syndrome, Acute
INTRAOCULAR AND SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN ACUTE RETINAL NECROSIS AND OCULAR TOXOPLASMOSIS.
Retinal Neoplasms
Aggressive retinal astrocytoma associated with tuberous sclerosis.
EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION IN A CASE OF FOCAL NODULAR GLIOSIS OF THE RETINA.
Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapy with bevacizumab in vasoproliferative retinal tumors.
INCREASED VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL IN THE SUBRETINAL FLUID OF EYE WITH VASOPROLIFERATIVE RETINAL TUMORS.
Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy.
Zingiber officinale attenuates retinal microvascular changes in diabetic rats via anti-inflammatory and antiangiogenic mechanisms.
[Retinal angiomatosis]
Retinal Neovascularization
A novel ex vivo murine retina angiogenesis (EMRA) assay.
Activation of cytosolic phospholipase A2 downstream of the Src-phospholipase D1 (PLD1)-protein kinase C ? (PKC?) signaling axis is required for hypoxia-induced pathological retinal angiogenesis.
Adeno-Associated Virus-Mediated Expression of Vascular Endothelial Growth Factor Peptides Inhibits Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy.
Adeno-associated virus-mediated expression of vascular endothelial growth factor peptides inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy.
Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells.
An Endostatin-lentivirus (ES-LV)-EPC gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model.
Angiogenesis-Inflammation Cross Talk in Diabetic Retinopathy: Novel Insights From the Chick Embryo Chorioallantoic Membrane/Human Vitreous Platform.
Anti-VEGF therapies and blood pressure: more than meets the eye.
Anti-VEGF Treatment of Corneal Neovascularization.
Antiangiogenic effect of betaine on pathologic retinal neovascularization via suppression of reactive oxygen species mediated vascular endothelial growth factor signaling.
Antiangiogenic effect of silicate nanoparticle on retinal neovascularization induced by vascular endothelial growth factor.
Antiangiogenic therapy for ischemic retinopathies.
Antineovascular agents in the treatment of eye diseases.
Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity.
Blockade of nitric-oxide synthase reduces choroidal neovascularization.
CCAAT/Enhancer-Binding Protein ? Mediates Oxygen-Induced Retinal Neovascularization via Retinal Vascular Damage and Vascular Endothelial Growth Factor.
Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model.
Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells.
Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice.
Development and Validation of Analytical Method for SH-1242 in the Rat and Mouse Plasma by Liquid Chromatography/Tandem Mass Spectrometry.
Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium--derived factor in brown norway and sprague dawley rats contributing to different susceptibilities to retinal neovascularization.
Different plasma levels of vascular endothelial growth factor and nitric oxide between patients with choroidal and retinal neovascularization.
Downregulation of vascular endothelial growth factor and integrinbeta3 by endostatin in a mouse model of retinal neovascularization.
Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.
Effects of long non-coding RNA myocardial infarction-associated transcript on retinal neovascularization in a newborn mouse model of oxygen-induced retinopathy.
Effects of tetrathiomolybdate in a mouse model of retinal neovascularization.
Elevated erythropoietin and vascular endothelial growth factor levels in an adolescent with retinal neovascularization from a chronic rhegmatogenous retinal detachment.
Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.
Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation.
Expression of thrombospondin-1 in ischemia-induced retinal neovascularization.
Fluorescein angiography, optical coherence tomography, and histopathologic findings in a VEGF(165) animal model of retinal angiogenesis.
Fumaric acid: a possible new therapy for macular edema?
Genetic polymorphisms of vascular endothelial growth factor and risk for retinopathy of prematurity in South of Iran.
Genistein inhibited retinal neovascularization and expression of vascular endothelial growth factor and hypoxia inducible factor 1alpha in a mouse model of oxygen-induced retinopathy.
Heparanase and vascular endothelial growth factor expression is increased in hypoxia-induced retinal neovascularization.
High-resolution, in vivo multimodal photoacoustic microscopy, optical coherence tomography, and fluorescence microscopy imaging of rabbit retinal neovascularization.
Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis.
Impact of Lycium Barbarum Polysaccharide and Danshensu on vascular endothelial growth factor in the process of retinal neovascularization of rabbit.
In vitro and ex vivo retina angiogenesis assays.
Induced Expression of VEGFC, ANGPT, and EFNB2 and Their Receptors Characterizes Neovascularization in Proliferative Diabetic Retinopathy.
Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation.
Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy.
Inhibition of ocular neovascularization by hedgehog blockade.
Inhibition of retinal neovascularization by siRNA targeting VEGF(165).
Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization.
Intravitreal thalidomide reduces experimental preretinal neovascularization without induction of retinal toxicity.
Involvement of Bradykinin B2 Receptor in Pathological Vascularization in Oxygen-Induced Retinopathy in Mice and Rabbit Cornea.
Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis.
Leptin stimulates ischemia-induced retinal neovascularization: possible role of vascular endothelial growth factor expressed in retinal endothelial cells.
Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor.
Local injection of receptor tyrosine kinase inhibitor MAE 87 reduces retinal neovascularization in mice.
Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer.
Matrix metalloproteinase-9 and vascular endothelial growth factor expression change in experimental retinal neovascularization.
MicroRNA-126 inhibits pathological retinal neovascularization via suppressing vascular endothelial growth factor expression in a rat model of retinopathy of prematurity.
MicroRNA-410 reduces the expression of vascular endothelial growth factor and inhibits oxygen-induced retinal neovascularization.
MicroRNA-9 inhibits retinal neovascularization in rats with diabetic retinopathy by targeting vascular endothelial growth factor A.
Pathogenesis of retinopathy of prematurity.
Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model.
Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization.
Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth.
Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy.
Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits.
Reduction of choroidal neovascularization via cleavable VEGF antibodies conjugated to exosomes derived from regulatory T cells.
Regulation of vascular endothelial growth factor expression by advanced glycation end products.
Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.
Remodeling retinal neovascularization by ALK1 gene transfection in vitro.
Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.
Retinal hypoxia and angiogenesis with methamphetamine.
Retinopathy of prematurity: molecular pathology and therapeutic strategies.
Rofecoxib inhibits retinal neovascularization via down regulation of cyclooxygenase-2 and vascular endothelial growth factor expression.
Role of NADPH oxidase in retinal vascular inflammation.
Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy.
Small interference RNA targeting vascular endothelial growth factor gene effectively attenuates retinal neovascularization in mice model.
Soluble Tei2 fusion protein inhibits retinopathy of prematurity occurrence via regulation of the Ang/Tie2 pathway.
Subchoroidal Release of VEGF and bFGF Produces Choroidal Neovascularization in Rabbit.
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
Targeting of Integrin-Linked Kinase with Small Interfering RNA Inhibits VEGF-Induced Angiogenesis in Retinal Endothelial Cells.
The Inhibitory Effects of Gold Nanoparticles on VEGF-A-Induced Cell Migration in Choroid-Retina Endothelial Cells.
The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes.
The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas.
The VEGF paradox: Does diabetic retinopathy protect from age related macular degeneration?
TIMP-1 promotes VEGF-induced neovascularization in the retina.
Tissue Kallikrein Inhibits Retinal Neovascularization via the Cleavage of Vascular Endothelial Growth Factor 165.
Trans-Chalcone Prevents VEGF Expression and Retinal Neovascularization in the Ischemic Retina.
Transcription factor Ets-1 mediates ischemia- and vascular endothelial growth factor-dependent retinal neovascularization.
Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases.
Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization.
Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization.
Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat.
Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease.
Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model.
Vascular endothelial growth factor (VEGF) in normal human corneal epithelium: detection and physiological importance.
Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.
Vascular endothelial growth factor upregulates expression of ADAMTS1 in endothelial cells through protein kinase C signaling.
Vascular endothelial growth factor upregulates expression of annexin A2 in vitro and in a mouse model of ischemic retinopathy.
VEGF is major stimulator in model of choroidal neovascularization.
VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.
[Inhibitory effect of interfering RNA targeting HIF-1alpha and VEGF on retinal neovascularization in the mouse]
[New drug VEGF Trap-Eye--Eylea--and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia].
[Pathogenesis of retinal neovascularization in a rat model of oxygen fluctuations-induced retinopathy]
[PPAR gamma: a novel pharmacological target against retinal and choroidal neovascularization]
Retinal Perforations
Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGF?1 in diabetic eyes undergoing vitrectomy.
Aqueous flare and inflammatory factors in macular edema with central retinal vein occlusion: a case series.
Clinical Features and Prognostic Factors in Northern Chinese Patients with Peripheral Granuloma Type of Ocular Toxocariasis: A Retrospective Cohort Study.
Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment.
Inhibition of CD146 attenuates retinal neovascularization via vascular endothelial growth factor receptor 2 signalling pathway in proliferative diabetic retinopathy.
Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
Role of inflammation in diabetic macular edema.
Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion.
Soluble Vascular Endothelial Growth Factor Receptor-2 and Inflammatory Factors in Macular Edema with Branch Retinal Vein Occlusion.
Retinal Telangiectasis
An Evidence-Based Review of Vascular Endothelial Growth Factor Inhibition in Pediatric Retinal Diseases: Part 2. Coats' Disease, Best Disease, and Uveitis With Childhood Neovascularization.
Associations of cytokine concentrations in aqueous humour with retinal vascular abnormalities and exudation in Coats' disease.
Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab.
Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium.
Expression of vascular endothelial growth factor in eyes with Coats' disease.
Increased Nitric Oxide and Vascular Endothelial Growth Factor Levels in the Aqueous Humor of Patients with Coats' Disease.
INTRAVITREAL RANIBIZUMAB AS AN ADJUNCTIVE TREATMENT FOR COATS DISEASE (6-YEAR FOLLOW-UP).
Treatment of Leukoencephalopathy With Calcifications and Cysts With Bevacizumab.
Two-year results of intravitreal injections of aflibercept in Coats' Disease; a case report.
Vascular endothelial growth factor in Coats' disease.
Retinal Vasculitis
EFFECT OF INTRAVITREAL METHOTREXATE AND AQUEOUS HUMOR CYTOKINE LEVELS IN REFRACTORY RETINAL VASCULITIS IN BEHCET DISEASE.
Low-Dose Recombinant Adeno-Associated Virus-Mediated Inhibition of Vascular Endothelial Growth Factor Can Treat Neovascular Pathologies Without Inducing Retinal Vasculitis.
Retinal Vein Occlusion
Aflibercept Intervention in Experimental Branch Retinal Vein Occlusion Results in Upregulation of DnaJ Homolog Subfamily C Member 17.
Aflibercept: an update on recent milestones achieved.
Antagonism of Vascular Endothelial Growth Factor for Macular Edema Caused by Retinal Vein Occlusions: Two-Year Outcomes.
Anti-VEGF Therapy for Retinal Vein Occlusions.
Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2).
AQUEOUS HUMOR CYTOKINE LEVELS AND REBOUND MACULAR EDEMA AFTER CONBERCEPT TREATMENT IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION.
Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion.
Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion.
Aqueous levels of VEGF correlate with retinal non-perfusion areas in patients with diabetic macular edema and macular edema secondary to central retinal vein occlusion.
Aqueous Soluble Vascular Endothelial Growth Factor Receptor-2 in Macular Edema with Branch Retinal Vein Occlusion.
Aqueous Vascular Endothelial Growth Factor and Endothelin-1 Levels in Branch Retinal Vein Occlusion Associated With Normal Tension Glaucoma.
Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion.
Association between macular microcirculation and soluble intercellular adhesion molecule-1 in patients with macular edema and retinal vein occlusion.
Association of electroretinographic parameters and inflammatory factors in branch retinal vein occlusion with macular oedema.
ASSOCIATIONS WITH RECURRENCE OF MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION AFTER THE DISCONTINUATION OF ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR.
Brolucizumab: First Approval.
Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema.
Changes in foveal thickness after vitrectomy for macular edema with branch retinal vein occlusion and intravitreal vascular endothelial growth factor.
Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion.
Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion.
Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion.
Changes of Inflammatory Factors After Intravitreal Triamcinolone Acetonide for Macular Edema with Central Retinal Vein Occlusion.
Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion.
Chorioretinal Anastomosis for Central Retinal Vein Occlusion: A Review of Its Development, Technique, Complications, and Role in Management.
Comparing Cytokine Kinetics between Ranibizumab and Aflibercept in Central Retinal Vein Occlusion with Macular Edema.
Comparison of vascular endothelial growth factor inhibitors on macular oedema secondary central retinal vein occlusion.
Correlation between vascular endothelial growth factor and nonperfused areas in macular edema secondary to branch retinal vein occlusion.
Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.
Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion.
Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion.
Effects of apelin and vascular endothelial growth factor on central retinal vein occlusion in monkey eyes intravitreally injected with bevacizumab: a preliminary study.
Electroretinograms and level of aqueous vascular endothelial growth factor in eyes with hemicentral retinal vein occlusion or branch retinal vein occlusion.
Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors.
Freezing adversely affects measurement of vascular endothelial growth factor levels in human aqueous samples.
Hypoxic regulation of vascular endothelial growth factor in retinal cells.
Increase of aqueous inflammatory factors in macular edema with branch retinal vein occlusion: a case control study.
Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular oedema and central retinal vein occlusion.
Influence of vitreous factors after vitrectomy for macular edema in patients with central retinal vein occlusion.
Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion.
Levels of VEGF but not VEGF(165b) are Increased in the Vitreous of Patients With Retinal Vein Occlusion.
Long-Term Effects of Multiple Intravitreal Anti- Vascular Endothelial Growth Factor Injections on Intraocular Pressure.
Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 ?g (ILUVIEN®).
Macular infarction following intravitreal bevacizumab for treatment of central retinal vein occlusion.
Management of retinal vascular diseases: a patient-centric approach.
Multimodal Imaging of Microvascular Abnormalities in Retinal Vein Occlusion.
Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6.
Photocoagulation of the Retinal Nonperfusion Area Prevents the Expression of the Vascular Endothelial Growth Factor in an Animal Model.
Pigment epithelium-derived factor and vascular endothelial growth factor in branch retinal vein occlusion with macular edema.
Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.
POSSIBLE MOLECULAR BASIS OF BEVACIZUMAB THERAPY FOR MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION.
Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization.
Quantification of the vascular endothelial growth factor with a bioluminescence resonance energy transfer (BRET) based single molecule biosensor.
Relationship between Recurrence of Macular Edema Due to Branch Retinal Vein Occlusion and Changes in Choroidal Thickness.
Relationship between vascular endothelial growth factor and macular edema in retinal vein branch obstruction.
RETINAL BLOOD FLOW CORRELATES TO AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR IN CENTRAL RETINAL VEIN OCCLUSION.
Retinal oximetry during treatment of retinal vein occlusion by ranibizumab in patients with high blood pressure and dyslipidemia.
Retinal vascular occlusions: an interdisciplinary challenge.
Retinal vascular oximetry during ranibizumab treatment of central retinal vein occlusion.
Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion.
Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema.
Significant Correlation between Electroretinogram Parameters and Ocular Vascular Endothelial Growth Factor Concentration in Central Retinal Vein Occlusion Eyes.
Significant Correlation between Retinal Venous Tortuosity and Aqueous Vascular Endothelial Growth Factor Concentration in Eyes with Central Retinal Vein Occlusion.
Soluble Vascular Endothelial Growth Factor Receptor-2 and Inflammatory Factors in Macular Edema with Branch Retinal Vein Occlusion.
Vascular endothelial growth factor and interleukin-6 are correlated with serous retinal detachment in central retinal vein occlusion.
Vascular endothelial growth factor levels in tears of patients with retinal vein occlusion.
Vascular Endothelial Growth Factor Promotes Progressive Retinal Nonperfusion in Patients with Retinal Vein Occlusion.
Vascular Endothelial Growth Factor Receptor-2 in Macular Oedema with Retinal Vein Occlusion.
Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.
Vascular endothelial growth factor upregulation in human central retinal vein occlusion.
Visual acuity and foveal thickness after vitrectomy for macular edema associated with branch retinal vein occlusion: a case series.
Visual acuity and foveal thickness after vitrectomy for macular edema.
Visual prognosis and vitreous cytokine levels after arteriovenous sheathotomy in branch retinal vein occlusion associated with macular oedema.
Visual prognosis and vitreous molecules after vitrectomy for macular edema with branch retinal vein occlusion.
Vitreous Inflammatory Factors and Serous Macular Detachment in Branch Retinal Vein Occlusion.
Vitreous inflammatory factors in macular edema with central retinal vein occlusion.
Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion.
Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in macular edema with central retinal vein occlusion.
[Retinal vein occlusion: anti-VEGF treatments.]
Retinitis Pigmentosa
Aqueous humor levels of vascular endothelial growth factor in retinitis pigmentosa.
Selective binding of C-6 OH sulfated hyaluronic acid to the angiogenic isoform of VEGF(165).
Retinoblastoma
Adventitial gene transfer to arterial wall.
Biomarkers of parathyroid carcinoma.
Defective heat shock factor 1 inhibits the growth of fibrosarcoma derived from simian virus 40/T antigen?transformed MEF cells.
Differential expression of stem cell markers and vascular endothelial growth factor in human retinoblastoma tissue.
Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours.
Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma.
Expression of vascular endothelial growth factor in retinoblastoma.
Gene therapy for the treatment of peripheral vascular disease and coronary artery disease.
Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies.
Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
Inhibitory effect of carboplatin in combination with bevacizumab on human retinoblastoma in an
Involvement of RB gene family in tumor angiogenesis.
Lack of Effect of SU1498, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2, in a Transgenic Murine Model of Retinoblastoma.
Leucine-Rich ?-2-Glycoprotein-1 (LRG-1) Expression in Retinoblastoma.
microRNA-497 overexpression decreases proliferation, migration and invasion of human retinoblastoma cells via targeting vascular endothelial growth factor A.
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
PEDF inhibits growth of retinoblastoma by anti-angiogenic activity.
Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.
Rubeosis iridis in retinoblastoma. Histologic findings and the possible role of vascular endothelial growth factor in its induction.
Vascular gene transfer for the treatment of restenosis and atherosclerosis.
Vascular gene transfer.
VEGF expression in residual tumor cells in orbital retinoblastoma (IRSS stage III) treated with NACT: A prospective study.
VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma.
[Analysis of angiogenesis associated factors of retinoblastoma cell line and tumor tissues]
[Anti-sense nucleic acid of CyclinD1 induces apoptosis of lung adenocarcinoma cancer cell A549.]
[Clinicopathologic features of retinoblastoma and expression of VEGF and Ki-67 after comprehensive treatment.]
[Expression and clinical implication of Matrix Metalloproteinase-1 and Vascular Endothelial Growth Factor in retinoblastoma.]
[HIF-1alpha, HPSE and VEGF promote malignant progression of retinoblastoma.]
[Inhibition of VEGF expression by plasmid-based RNA interference in the retinoblastoma cells]
Retinopathy of Prematurity
2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.
A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.
Acute and chronic effects of intravitreal bevacizumab on lung biomarkers of angiogenesis in the rat exposed to neonatal intermittent hypoxia.
Adenosine receptors and caffeine in retinopathy of prematurity.
An Evidence-Based Meta-analysis of Vascular Endothelial Growth Factor Inhibition in Pediatric Retinal Diseases: Part 1. Retinopathy of Prematurity.
Anti-angiogenic effect of luteolin on retinal neovascularization via blockade of reactive oxygen species production.
Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab.
Association between VEGF polymorphisms (-460 T/C and +936 C/T) and retinopathy of prematurity risk: A meta-analysis.
Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity.
Association of retinal vascular endothelial growth factor with avascular retina in a rat model of retinopathy of prematurity.
Association of VEGF gene polymorphisms with advanced retinopathy of prematurity: a meta-analysis.
Associations of VEGF/VEGF-receptor and HGF/c-Met promoter polymorphisms with progression/regression of retinopathy of prematurity.
Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.
Colocalization of Tie2, angiopoietin 2 and vascular endothelial growth factor in fibrovascular membrane from patients with retinopathy of prematurity.
Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
CONCURRENT SCLERAL BUCKLE AND INTRAVITREAL BEVACIZUMAB FOR ADVANCED RETINOPATHY OF PREMATURITY-RELATED RETINAL DETACHMENT.
Corrected VEGF levels based on platelet count should be calculated. Concerning the article by B.M. Levesque et al.: Low urine vascular endothelial growth factor levels are associated with mechanical ventilation, bronchopulmonary dysplasia and retinopathy of prematurity [Neonatology 2013;104:56-64].
Do platelets have a role in the pathogenesis of aggressive posterior retinopathy of prematurity?
Effect of laser photocoagulation on plasma levels of VEGF-A, VEGFR-2, and Tie2 in infants with retinopathy of prematurity.
Effect of Resveratrol on Bcl-2 and VEGF Expression in Oxygen-Induced Retinopathy of Prematurity.
Effects of long non-coding RNA myocardial infarction-associated transcript on retinal neovascularization in a newborn mouse model of oxygen-induced retinopathy.
Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.
Elimination of Signaling by the Luteinizing Hormone Receptor Reduces Ocular VEGF and Retinal Vascularization during Mouse Eye Development.
Expression of Total Vascular Endothelial Growth Factor and the Anti-angiogenic VEGF 165 b Isoform in the Vitreous of Patients with Retinopathy of Prematurity.
Expression of vascular endothelial growth factor and pigment epithelial-derived factor in a rat model of retinopathy of prematurity.
Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy.
Genetic Contributions to the Development of Complications in Preterm Newborns.
Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity.
Genetic polymorphisms of vascular endothelial growth factor and risk for retinopathy of prematurity in South of Iran.
Genetic variation of vascular endothelial growth factor pathway does not correlate with the severity of retinopathy of prematurity.
Haem relieves hyperoxia-mediated inhibition of HMEC-1 cell proliferation, migration and angiogenesis by inhibiting BACH1 expression.
Histopathologic Characterization of the Expression of Vascular Endothelial Growth Factor in a Case of Retinopathy of Prematurity Treated With Ranibizumab.
Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity.
How does preeclampsia affect neonates? Highlights in the disease's immunity.
Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model.
Hypoxia-induced retinal neovascularization in zebrafish embryos: a potential model of retinopathy of prematurity.
Hypoxic regulation of vascular endothelial growth factor in retinal cells.
Increased angiogenic factors associated with peripheral avascular retina and intravitreous neovascularization: a model of retinopathy of prematurity.
Infantile Hemangiomas, Retinopathy of Prematurity and Cancer: A Common Pathogenetic Role of the ?-Adrenergic System.
Influence of polymorphisms in VEGF, TNF-?, and GSTP1 genes on retinopathy of prematurity risk: a Meta-analysis.
Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy.
Inhibition of vascular endothelial growth factor-induced retinal neovascularization by retinoic acid in experimental retinopathy of prematurity.
Inhibitory Effects On Retinal Neovascularization by Ranibizumab and sTie2-Fc in An Oxygen-Induced Retinopathy Mouse Model.
Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity.
Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity.
Intravitreal bevacizumab alters type IV collagenases and exacerbates arrested alveologenesis in the neonatal rat lungs.
Intravitreal Delivery of VEGF-A165-loaded PLGA Microparticles Reduces Retinal Vaso-Obliteration in an In Vivo Mouse Model of Retinopathy of Prematurity.
Lack of association of the VEGF gene promoter (-634 G-->C and -460 C-->T) polymorphism and the risk of advanced retinopathy of prematurity.
Low urine vascular endothelial growth factor levels are associated with mechanical ventilation, bronchopulmonary dysplasia and retinopathy of prematurity.
Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer.
Müller cell-derived VEGF is a significant contributor to retinal neovascularization.
Meta analysis on the relationship between gene polymorphisms of vascular endothelial growth factor and retinal prognosis risk of prematurity.
MicroRNA-126 inhibits pathological retinal neovascularization via suppressing vascular endothelial growth factor expression in a rat model of retinopathy of prematurity.
Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity.
Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity.
Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease.
Ocular Versus Oral Propranolol for Prevention and/or Treatment of Oxygen-Induced Retinopathy in a Rat Model.
Oxidative stress in the newborn--a 30-year perspective.
Oxygen and retinopathy of prematurity.
Pericytes and the pathogenesis of diabetic retinopathy.
Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.
PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION.
Polymorphisms of Vascular Endothelial Growth Factor and Retinopathy of Prematurity.
Present-day conservative treatment retinopathy of prematurity.
Prevention of retinopathy of prematurity.
Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial.
Reduced occurrence of programmed cell death and gliosis in the retinas of juvenile rabbits after shortterm treatment with intravitreous bevacizumab.
Regression of Cystoid Macular Edema Three Weeks After Laser for Retinopathy of Prematurity.
Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity.
Relationship between the 5'UTR of vascular endothelial growth factor polymorphism and retinopathy of prematurity in Chinese premature newborns.
RETHINKING STOP-ROP: IS IT WORTHWHILE TRYING TO MODULATE EXCESSIVE VEGF LEVELS IN PRETHRESHOLD ROP EYES BY SYSTEMIC INTERVENTION?: A Review of the Role of Oxygen, Light Adaptation State, and Anemia in Prethreshold ROP.
Retinal neovascularization is prevented by blockade of the renin-angiotensin system.
Retinal neuronal cell loss prevents abnormal retinal vascular growth in a rat model of retinopathy of prematurity.
Role of Serum Levels of Vascular Endothelial Growth Factor and Its Receptor in Retinopathy of Prematurity.
Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity.
SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.
Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity.
Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity.
Serum erythropoietin, insulin-like growth factor 1, and vascular endothelial growth factor in etiopathogenesis of retinopathy of prematurity.
Serum Levels of Vascular Endothelial Growth Factor and Related Factors After Intravitreous Bevacizumab Injection for Retinopathy of Prematurity.
SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity.
Short Hairpin RNA-Mediated Knockdown of VEGFA in Müller Cells Reduces Intravitreal Neovascularization in a Rat Model of Retinopathy of Prematurity.
SNAI1, an endothelial-mesenchymal transition transcription factor, promotes the early phase of ocular neovascularization.
Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis).
Suppression of transient receptor potential canonical channel 4 inhibits vascular endothelial growth factor-induced retinal neovascularization.
Systemic conbercept pharmacokinetics and VEGF pharmacodynamics following intravitreal injections of conbercept in patients with retinopathy of prematurity.
Systemic Solutions in Retinopathy of Prematurity.
Targeted Knockdown of Overexpressed VEGFA or VEGF164 in Müller cells maintains retinal function by triggering different signaling mechanisms.
The ?-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases.
The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review.
The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity.
The effect of sevoflurane on retinal angiogenesis in a mouse model of oxygen-induced retinopathy.
The lack of association between vascular endothelial growth factor and retinopathy of prematurity in an observational study.
The Serum Levels of Asymmetric Dimethylarginine, Vascular Endothelial Growth Factor, and Insulin-Like Growth Factor-1 in Preterms with Retinopathy of Prematurity.
The Short-Term Effects of Intravitreal Injection of Bevacizumab on the Plasma Levels of Vascular Endothelial Growth Factor, Insulin-Like Growth Factor-1, and Growth Parameters in Infants with Retinopathy of Prematurity.
Thrombocytopenia and retinopathy of prematurity.
Toward better evidence: Meta-analysis of vascular endothelial growth factor (VEGF) polymorphisms in retinopathy of prematurity.
Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors.
Up-regulation of VEGF by retinoic acid during hyperoxia prevents retinal neovascularization and retinopathy.
Variations of Vascular Endothelial Growth Factor and Pigment Epithelial-derived Factor Are Related to Retinopathy of Prematurity in Human Babies.
Variations of Vascular Endothelial Growth Factor and Pigment Epithelial-derived Factor are Related to the Retinopathy of Prematurity in Human Babies.
Vascular endothelial growth factor (VEGF-634G/C) polymorphism and retinopathy of prematurity: a meta-analysis.
Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity.
Vascular endothelial growth factor and apelin in plasma of patients with retinopathy of prematurity.
Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity.
Vascular endothelial growth factor and insulin-like growth factor-1 in preterm infants with retinopathy of prematurity.
Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.
Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab.
VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases.
Vitreous Levels of Erythropoietin and Vascular Endothelial Growth Factor in Eyes with Retinopathy of Prematurity.
Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity.
[Changes of serum vascular endothelial growth factor in newborn infants and its relationship with retinopathy of prematurity].
[Expression and action of vascular endothelial growth factor and its receptor in a rat model of retinopathy of prematurity]
Rhabdomyosarcoma
Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
Distinct Effects of Ligand-Induced PDGFR? and PDGFR? Signaling in the Human Rhabdomyosarcoma Tumor Cell and Stroma Cell Compartments.
Increased fat oxidation and regulation of metabolic genes with ultraendurance exercise.
Relationship of angiogenic and apoptotic activities in soft-tissue sarcoma.
Tumour expressions of hypoxic markers predict the response to neo-adjuvant chemotherapy in children with inoperable rhabdomyosarcoma.
Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
Vascular endothelial growth factor serum levels in children with newly diagnosed rhabdomyosarcoma.
[Blocking enhancive effect of vascular endothelial growth factor on proliferation of rhabdomyosarcoma cell line RH4 by avastin]
Rhabdomyosarcoma, Alveolar
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rhabdomyosarcoma, Embryonal
Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
Rheumatic Diseases
Biomarkers in Rheumatoid Arthritis, what is new?
Immunohistochemical analysis of TGF-?1 and VEGF in gingival and periodontal tissues: a role of these biomarkers in the pathogenesis of scleroderma and periodontal disease.
Levels of vascular endothelial growth factor and hepatocyte growth factor in sera of patients with rheumatic diseases.
Sjögren's syndrome pathological neovascularization is regulated by VEGF-A-stimulated TACE-dependent crosstalk between VEGFR2 and NF-?B.
Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases.
Vascular endothelial growth factor levels and rheumatic diseases of the elderly.
Rheumatic Heart Disease
[Role of anti-angiogenic factor chondromodulin-I for maintaining cardiac valvular function]
Rhinitis, Allergic
Allergic rhinitis and vascular endothelial growth factor.
Evaluation of circulating vascular endothelial growth factor and its soluble receptors in patients suffering from persistent allergic rhinitis.
In vitro and in vivo antiangiogenic activity of carebastine: a plausible mechanism affecting airway remodelling.
Protective effects of rutin through regulation of vascular endothelial growth factor in allergic rhinitis.
Serum adipsin levels in patients with seasonal allergic rhinitis: preliminary data.
Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus.
The effect of academic exam stress on mucosal and cellular airway immune markers among healthy and allergic individuals.
Vascular endothelial growth factor in allergen-induced nasal inflammation.
Vascular endothelial growth factor produced in nasal glands of perennial allergic rhinitis.
[Effect of RORC inhibitor on HIF-1? and VEGF in nasal mucosa of allergic rhinitis of mice].
Rhinitis, Allergic, Seasonal
Evaluation of vascular endothelial growth factor A and endostatin levels in induced sputum and relationship to bronchial hyperreactivity in patients with seasonal allergic rhinitis.
Increased expression of tissue vascular endothelial growth factor and foetal liver kinase-1 receptor in seasonal allergic rhinitis and relevance to asthma component.
Serum adipsin levels in patients with seasonal allergic rhinitis: preliminary data.
rna-directed rna polymerase deficiency
Aminoacyl-Transfer RNA Synthetase Deficiency Promotes Angiogenesis via the Unfolded Protein Response Pathway.
Rosacea
Citron Essential Oils Alleviate the Mediators Related to Rosacea Pathophysiology in Epidermal Keratinocytes.
Determination of tear and serum inflammatory cytokines in patients with rosacea using multiplex bead technology.
Effects of dextran sulfate, 4-t-butylcyclohexanol, pongamia oil and hesperidin methyl chalcone on inflammatory and vascular responses implicated in rosacea.
Expression of vascular endothelial growth factor and its receptors in rosacea.
Lymphangiogenesis and angiogenesis in non-phymatous rosacea.
Sodium Bituminosulfonate Used to Treat Rosacea Modulates Generation of Inflammatory Mediators by Primary Human Neutrophils.
Vascular endothelial growth factor gene polymorphisms in patients with rosacea: A case-control study.
Sacroiliitis
Efficacy of wIRA in the treatment of sacroiliitis in male patients with ankylosing spondylitis and its effect on serum VEGF levels.
Salivary Gland Neoplasms
An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents.
Analyses of VEGFC/VEGF-D expressions, density and endothelial lymphatic proliferation in salivary gland neoplasms.
Prognostic value of the immunohistochemical expression of vascular endothelial growth factors in malignant salivary gland neoplasms: a systematic review and meta-analysis.
Salmonella Infections
Microarray analysis of long non-coding RNA expression profiles in monocytic myeloid-derived suppressor cells in Echinococcus granulosus-infected mice.
Sarcoidosis
Evaluation of carotid intima-media thickness with vascular endothelial growth factor and malondialdehyde levels in patients with sarcoidosis.
Expression and localization of vascular endothelial growth factor and its receptor flt in pulmonary sarcoidosis.
Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities.
Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis.
Vascular endothelial growth factor and tumor necrosis factor genes polymorphisms in Turkish patients with sarcoidosis.
Vascular endothelial growth factor gene polymorphisms in Japanese patients with sarcoidosis.
Vascular endothelial growth factor gene polymorphisms in Turkish patients with sarcoidosis.
VEGF gene haplotypes are associated with sarcoidosis.
Sarcoidosis, Pulmonary
Different activity of the biological axis VEGF-Flt-1 (fms-like tyrosine kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: a bronchoalveolar lavage study.
Expression and localization of vascular endothelial growth factor and its receptor flt in pulmonary sarcoidosis.
Proangiogenic and Profibrotic Markers in Pulmonary Sarcoidosis.
Sarcoma
A multi?targeted tyrosine kinase inhibitor lenvatinib for the treatment of mice with advanced glioblastoma.
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.
AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor.
Alterations of Circulating Bone Marrow-Derived VEGFR-2(+) Progenitor Cells in Isolated Limb Perfusion With or Without rhTNF-?
An update on clinical trials of targeted therapies in thyroid cancer.
Analysis of HIF-1alpha and its regulator, PHD2, in retroperitoneal sarcomas: Clinico-pathologic implications.
Angiogenesis and antiangiogenic approaches to sarcomas.
Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma.
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
Circulating levels of angiogenic factors and their association with preeclampsia among pregnant women at Mulago National Referral Hospital in Uganda.
Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas.
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.
Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas.
Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.
Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma.
Effects of vascular endothelial growth factor and E-selectin on angiogenesis in the murine metastatic RCT sarcoma.
Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients.
Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.
EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer.
EWS/Fli-1 chimeric fusion gene up-regulates vascular endothelial growth factor-A.
Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas.
Expression of vascular endothelial growth factor in thoracic sarcomas.
Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1 receptor inhibitor, in AIDS-Kaposi's sarcoma.
Identified a disintegrin and metalloproteinase with thrombospondin motifs 6 serve as a novel gastric cancer prognostic biomarker by bioinformatics analysis.
Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas.
Immunohistochemical selection of biomarkers for tumor-targeted image-guided surgery of myxofibrosarcoma.
Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.
Impaired lymphatic function accelerates cancer growth.
In vivo imaging of cell proliferation in meningioma using 3'-deoxy-3'-[18F]fluorothymidine PET/MRI.
Increased number of mesenchymal stem cell-like cells in peripheral blood of patients with bone sarcomas.
Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma.
Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine.
Inhibition of vascular endothelial growth factor a and hypoxia-inducible factor 1? maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature.
l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms.
Markers of angiogenesis and clinical features in patients with sarcoma.
Microvessel density does not predict outcome in high grade soft tissue sarcoma.
Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1? inhibition, and hypoxia-activated chemotherapy.
Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1?
Pazopanib-Induced Severe Acute Pancreatitis.
Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma.
Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas.
Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements Towards Individualizing the Treatment.
Precision medicine: Uses and challenges.
Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma.
Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-?B and matrix metalloproteinase-2/-9 signaling pathways.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Secretion of interleukin-6 and vascular endothelial growth factor by spindle cell sarcoma complicating Castleman's disease (so-called 'vascular neoplasia').
Serum endostatin levels are elevated in patients with soft tissue sarcoma.
Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma.
Serum vascular endothelial growth factor (VEGF), a prognostic indicator in sarcoma and carcinoma patients.
Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma.
Serum vascular endothelial growth factor in dogs with soft tissue sarcomas.
Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family.
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Targeted therapy of soft tissue sarcomas.
Targeting angiogenesis for the treatment of sarcoma.
The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma.
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis.
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
Undifferentiated spindle-cell sarcoma of the chest wall with vascular endothelial growth factor expression: report of a case.
Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade.
Vascular endothelial growth factor expression and microvascular density in soft tissue sarcomas in dogs.
Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.
Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas.
Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
[Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
[Electrochemotherapy for tumor and mechanism analysis]
[Hormones, autocrine and paracrine regulators of tumor growth in osteosarcoma]
Sarcoma 180
Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor.
Cytotoxic T lymphocyte-dependent tumor growth inhibition by a vascular endothelial growth factor-superantigen conjugate.
Purification and characterization of two collagenase inhibitors from mouse sarcoma 180 conditioned medium.
Sarcoma, Ewing
A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
CAPER-? alternative splicing regulates the expression of vascular endothelial growth factor(165) in ewing sarcoma cells.
Disodium Cromolyn and Anti-podoplanin Antibodies Strongly Inhibit Growth of BHK 21/C13-derived Fibrosarcoma in a Chick Embryo Chorioallantoic Membrane Model.
E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model.
EWS/Fli-1 chimeric fusion gene up-regulates vascular endothelial growth factor-A.
Expression of Vascular endothelial growth factor in Ewing's sarcoma.
Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo.
Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature.
Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor.
Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
Vascular endothelial growth factor expression as a biomarker of prognosis in patients with chondrosarcoma, Ewing's sarcoma and osteosarcoma. Current concepts.
Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma.
Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.
Sarcoma, Kaposi
A phase 1b/pharmacokinetic trial of PTC299, a novel post-transcriptional VEGF inhibitor, for AIDS-related Kaposi's sarcoma: AIDS Malignancy Consortium trial 059.
AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor.
Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma.
c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells.
Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells.
Cationic liposomes/lipids for oligonucleotide delivery: application to the inhibition of tumorigenicity of Kaposi's sarcoma by vascular endothelial growth factor antisense oligodeoxynucleotides.
Chemically modified tetracyclines inhibit VEGF secretion by breast cancer cell lines.
Classic Kaposi's sarcoma and vascular endothelial growth factor.
Common vascular endothelial growth factor variants and risk for posttransplant Kaposi sarcoma.
Cytokine pattern in Kaposi's sarcoma associated with immune restoration disease in HIV and tuberculosis co-infected patients.
Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells.
Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma.
Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus through interaction with Daxx.
Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells.
Intralesional bevacizumab in patients with Human immunodeficiency virus-associated Kaposi's sarcoma in the upper airway.
Involvement of vascular endothelial growth factor in Kaposi's sarcoma associated with acquired immunodeficiency syndrome.
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma.
Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3.
Signal transduction targets in Kaposi's sarcoma.
Sirolimus (rapamycin): from the soil of Easter Island to a bright future.
Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor.
The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha.
The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B.
The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma.
Vascular endothelial growth factor (VEGF165) plasma level increase with immunodepression in AIDS patients with Kaposi's sarcoma.
Vascular endothelial growth factor A polymorphism and risk of Kaposi's sarcoma herpesvirus viremia in kidney allograft recipients.
Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development.
Vascular endothelial growth factor and Kaposi's sarcoma cells in human skin grafts.
Vascular endothelial growth factor levels in serum do not increase following HIV type 1 and HHV8 seroconversion and lack correlation with AIDS-related Kaposi's sarcoma.
Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas.
Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma.
Sarcoma, Synovial
Angiogenesis does not correlate with prognosis or expression of vascular endothelial growth factor in synovial sarcomas.
Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.
Relationship of angiogenic and apoptotic activities in soft-tissue sarcoma.
Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Sarcopenia
Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib.
Schistosomiasis
Vascular endothelial growth factor promotes the activation of hepatic stellate cells in chronic schistosomiasis.
[Expression of vascular growth factors in intestinal tissues in colorectal carcinoma patients with schistosomiasis japonica].
Schistosomiasis mansoni
Endothelial Markers in Schistosomiasis Patients With or Without Portal Hypertension.
Hypoxia, hypoxia-inducible factor-1? and vascular endothelial growth factor in a murine model of Schistosoma mansoni infection.
Immunological indicators of morbidity in human schistosomiasis mansoni: role of vascular endothelial growth factor and anti-soluble egg antigen IgG4 in disease progression.
Scleroderma, Systemic
A PRISMA-driven systematic review for predictive risk factors of digital ulcers in systemic sclerosis patients.
A vascular endothelial growth factor deficiency characterises scleroderma lung disease.
Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.
Angiogenic cytokines in serum and cutaneous lesions of patients with polyarteritis nodosa.
Association of Acroosteolysis With Enhanced Osteoclastogenesis and Higher Blood Levels of Vascular Endothelial Growth Factor in Systemic Sclerosis.
Association of Circulating Vascular Endothelial Growth Factor Levels With Autoimmune Diseases: A Systematic Review and Meta-Analysis.
Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways.
CD21low B cells in systemic sclerosis: A possible marker of vascular complications.
Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis.
Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis--association with pulmonary involvement.
Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic sclerosis.
Elevated Adipsin Levels are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis.
Elevated vascular endothelial growth factor in systemic sclerosis.
Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis.
Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin.
Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients.
Myocardial fibrosis in systemic sclerosis assessed by cardiac magnetic resonance is associated with vascular endothelial growth factor expression.
Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvement.
Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1.
Overexpression of VEGF165b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Leads to Insufficient Angiogenesis in Patients With Systemic Sclerosis.
Parasympathetic activity increases with digital microvascular damage and vascular endothelial growth factor in systemic sclerosis.
Peripheral blood mononuclear cells from patients with systemic sclerosis spontaneously secrete increased amounts of vascular endothelial growth factor (VEGF) already in the early stage of the disease.
Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations.
Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab.
Renal parenchymal thickness is both related to vascular endothelial growth factor and intrarenal stiffness in systemic sclerosis.
Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis.
Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis.
Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement.
Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis.
The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis.
The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis.
Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis.
Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis.
Vascular endothelial growth factor in patients with rheumatoid arthritis.
Vascular Endothelial Growth Factor in Tear Samples of Patients with Systemic Sclerosis.
Vascular endothelial growth factor profile and Vitamin D level in Systemic Sclerosis Egyptian patients.
Seizures
CSF and plasma adipokines after tonic-clonic seizures.
Depression of synaptic transmission by vascular endothelial growth factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures.
Inhibition of blood-brain barrier efflux transporters promotes seizure in pregnant rats: Role of circulating factors.
Role of different cytokines and seizure susceptibility: a new dimension towards epilepsy research.
Vascular endothelial growth factor (VEGF) in seizures: a double-edged sword.
VEGF regulates hippocampal neurogenesis and reverses cognitive deficits in immature rats after status epilepticus through the VEGF R2 signaling pathway.
Seminoma
[Expressions of STAT3, VEGF and C-myc in seminoma and their significance]
Sepsis
A PROSPECTIVE, OBSERVATIONAL STUDY OF SOLUBLE FLT-1 AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN SEPSIS.
A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis.
ANGIOGENESIS INHIBITOR ENDOSTATIN PROTECTS MICE WITH SEPSIS FROM MULTIPLE ORGAN DYSFUNCTION SYNDROME.
Angiopoietin-2 is increased in sepsis and inversely associated with nitric oxide-dependent microvascular reactivity.
Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis.
Cardiovascular Collapse and Vascular Permeability Changes in an Ovine Model of Methicillin-Resistant Staphylococcus aureus Sepsis.
Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1.
Circulating angiopopietin-1 correlates with the clinical course of multiple organ dysfunction syndrome and mortality in patients with severe sepsis.
Combined glucocorticoid resistance and hyperlactatemia contributes to lethal shock in sepsis.
Complement factor D is linked to platelet activation in human and rodent sepsis.
Decreased Expression of Serum and Microvascular Vascular Endothelial Growth Factor Receptor-2 in Meningococcal Sepsis.
Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis.
Elevated levels of placental growth factor represent an adaptive host response in sepsis.
elSerum vascular endothelial growth factor in adult haematological patients with neutropenic fever: a comparison with C-reactive protein.
Endothelial progenitor cells (EPC) in sepsis with acute renal dysfunction (ARD).
Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis.
Enhanced vascular endothelial growth factor and inflammatory cytokine removal with online hemodiafiltration over high-flux hemodialysis in sepsis-related acute kidney injury patients.
Evaluation of plasma angiopoietin-2 and vascular endothelial growth factor in healthy dogs and dogs with systemic inflammatory response syndrome or sepsis.
Glutamine Administration Modulates Endothelial Progenitor Cell and Lung Injury in Septic Mice.
Influence of diabetes on endothelial cell response during sepsis.
Interleukin-18 and fibroblast growth factor 2 in combination is a useful diagnostic biomarker to distinguish adult-onset Still's disease from sepsis.
Is VEGF a marker of severity of scrub typhus infection?
Lipopolysaccharide-induced Notch signaling activation through JNK-dependent pathway regulates inflammatory response.
Novel PKC signaling is required for LPS-induced soluble Flt-1 expression in macrophages.
Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study.
Plasma vascular endothelial growth factor in severe sepsis.
Pulmonary expression of vascular endothelial growth factor in sepsis.
Role of kidney injury in sepsis.
Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis.
Sorbents in acute renal failure and end-stage renal disease: middle molecule and cytokine removal.
Sorbents in the treatment of renal failure.
Systemic Endothelial Activation Is Associated With Early Acute Respiratory Distress Syndrome in Children With Extrapulmonary Sepsis.
The Diagnostic and Prognostic Role of Vascular Endothelial Growth Factor C in Sepsis and Septic Shock.
Time-Dependent Alterations of VEGF and Its Signaling Molecules in Acute Lung Injury in a Rat Model of Sepsis.
Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor as Novel Biomarkers for Poor Outcomes in Children With Severe Sepsis and Septic Shock.
Vascular endothelial growth factor blockade reduces plasma cytokines in a murine model of polymicrobial sepsis.
Vascular endothelial growth factor in severe sepsis and septic shock.
Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells.
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality.
Vascular endothelial growth factor modulates contractile response in microvascular lung pericytes.
[A clinical study of the serum vascular endothelial growth factor in patients with severe sepsis.]
[Effects of changes of endothelial function on prognosis in patients with severe sepsis].
[Research advances on the molecular mechanisms of vascular permeability in sepsis].
[Significance of the ratio of plasma vascular endothelial growth factor level to platelet count in the prognosis of patients with sepsis].
Severe Combined Immunodeficiency
?vß3-Integrin-Targeted Magnetic Resonance Imaging for the Assessment of Early Antiangiogenic Therapy Effects in Orthotopic Breast Cancer Xenografts.
bFGF and VEGF improve the quality of vitrified-thawed human ovarian tissues after xenotransplantation to SCID mice.
Biochemical indicators of implantation success of tissue-engineered oral mucosa.
Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma.
miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF).
Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma.
SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
Severe Dengue
Elevated levels of vascular endothelial growth factor in adults with severe dengue infection.
Relationship between circulating vascular endothelial growth factor and its soluble receptors in adults with dengue virus infection: a case-control study.
Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection.
The predictive and diagnostic accuracy of vascular endothelial growth factor and pentraxin-3 in severe dengue.
Shock, Septic
Activation of Vascular Endothelial Growth Factor Receptor-3 in Macrophages Restrains TLR4-NF-?B Signaling and Protects against Endotoxin Shock.
Angiopoietin balance in septic shock patients treated by direct hemoperfusion with polymyxin b-immobilized fiber.
Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome.
The Diagnostic and Prognostic Role of Vascular Endothelial Growth Factor C in Sepsis and Septic Shock.
Vascular endothelial growth factor (VEGF) expression in the lung in toxic septic shock.
Vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in septic shock patients treated with direct hemoperfusion with a polymyxin B-immobilized fiber column.
Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor as Novel Biomarkers for Poor Outcomes in Children With Severe Sepsis and Septic Shock.
Vascular endothelial growth factor in severe sepsis and septic shock.
Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability.
[Effect of fluid resuscitation on capillary permeability and vascular endothelial growth factor in dogs with septic shock]
[The correlation between vascular endothelial growth factor and degree of hypoxia in dogs with septic shock.]
Silicosis
Ginsenoside Rg1 enhances lymphatic transport of intrapulmonary silica via VEGF-C/VEGFR-3 signaling in silicotic rats.
Sinus Thrombosis, Intracranial
Expression of angiogenic growth factors in dural arteriovenous fistula.
POEMS syndrome with venous sinus thrombosis and visual failure: a case report.
Skin Diseases
Genetic interaction between placenta growth factor (PGF) and vascular endothelial growth factor A (VEGFA) in psoriasis.
Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice.
The spectrum of neutrophilic dermatoses associated with monoclonal gammopathy: Association with IgA isotype and inflammatory profile.
Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis.
[Advancements in expression of vascular endothelial growth factor receptors in skin diseases]
Skin Neoplasms
Multiple roles for VEGF in non-melanoma skin cancer: angiogenesis and beyond.
Skin Ulcer
Clinical evaluation of allogeneic cultured dermal substitutes for intractable skin ulcers after tumor resection.
Impaired lymphangiogenesis due to excess vascular endothelial growth factor-D/Flt-4 signalling in the skin of patients with systemic sclerosis.
Large Skin Ulcer and Delayed Wound Healing around a Colostomy in a Patient with Metastatic Colorectal Cancer Receiving Vascular Endothelial Growth Factor Receptor-2 Inhibitor Therapy.
Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis.
[Effect of mild-warm moxibustion on microcirculation in the raw surface tissue of chronic refractory wound in skin ulcer rats].
[Effects and action mechanisms of Buyang Huanwu Decoction in wound healing of chronic skin ulcers of rats]
[Effects of Chinese herbs for replenishing qi and resolving stagnation on hypoxia-inducible factor-1alpha and vascular endothelial growth factor in granulation tissue of skin ulcers in rats with diabetes]
[Effects of reinforcing qi and nourishing blood recipes on vascular endothelial growth factor and microvessel count in granulation tissue in rats with chronic skin ulcers.]
Sleep Apnea Syndromes
Circulating plasma levels of vascular endothelial growth factor in patients with sleep disordered breathing.
Essential roles of angiotensin II in vascular endothelial growth factor expression in sleep apnea syndrome.
Ischemic preconditioning as a possible explanation for the age decline relative mortality in sleep apnea.
Obstructive sleep-disordered breathing and plasma levels of vascular endothelial growth factor in children.
Plasma vascular endothelial growth factor in sleep apnea syndrome: effects of nasal continuous positive air pressure treatment.
Vascular endothelial growth factor and sleep apnea: clutching at straws in the night.
Sleep Apnea, Obstructive
Altered in vitro endothelial repair and monocyte migration in obstructive sleep apnea: implication of VEGF and CRP.
Association of elevated levels of vascular endothelial growth factor in obstructive sleep apnea syndrome with patient age rather than with obstructive sleep apnea syndrome severity.
Circulating vascular endothelial growth factor levels in patients with obstructive sleep apnea.
CONNECTION BETWEEN SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS AND SEVERITY OF MICROANGIOPATHY IN PATIENTS WITH TYPE 2 DIABETES AND OBSTRUCTIVE SLEEP APNEA.
Effects of continuous positive airway pressure on exhaled transforming growth factor-? and vascular endothelial growth factor in patients with obstructive sleep apnea.
Effects of oxygen administration on the circulating vascular endothelial growth factor (VEGF) levels in patients with obstructive sleep apnea syndrome.
Hypoxia-sensitive molecules may modulate the development of atherosclerosis in sleep apnoea syndrome.
Impact of continuous positive airway pressure on vascular endothelial growth factor in patients with obstructive sleep apnea: a meta-analysis.
Obstructive Sleep Apnea Monocytes Exhibit High Levels of Vascular Endothelial Growth Factor Secretion, Augmenting Tumor Progression.
Relaxin in Obstructive Sleep Apnea: Relationship with Blood Pressure and Inflammatory Mediators.
Serum level of vascular endothelial growth factor in patients with obstructive sleep apnea hypopnea syndrome.
Serum Levels of Vascular Endothelial Growth Factor and Insulin-like Growth Factor Binding Protein-3 in Obstructive Sleep Apnea Patients: Effect of Continuous Positive Airway Pressure Treatment.
Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe night time hypoxia.
Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia.
Short-term prognostic effects of circulating regulatory T-Cell suppressive function and vascular endothelial growth factor level in patients with non-small cell lung cancer and obstructive sleep apnea.
Vascular endothelial growth factor genotypes and haplotypes contribute to the susceptibility of obstructive sleep apnea syndrome.
Vascular endothelial growth factor levels in patients with obstructive sleep apnea: a meta-analysis.
[Changes and clinical implications of the levels of serum NO and VEGF and HIF-1alpha in patients with obstructive sleep apnea-hypopnea syndrome].
[Cyclooxygenase-2 overexpression and vascular endothelial growth factor expression in pharyngeal tissue of patients with OSAHS correlates with angiogenesis].
[Relationship between plasma vascular endothelial growth factor and tumor necrosis factor-alpha and obstructive sleep apnea hypopnea syndrome in children].
[The research progress of relationship between the obstructive sleep apnea hypopnea syndrome and asthma].
Sleep Deprivation
Does the compromised sleep and circadian disruption of night and shiftworkers make them highly vulnerable to 2019 coronavirus disease (COVID-19)?
Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): A pilot study.
Relationship between rosacea and sleep.
Sleep Wake Disorders
The expression of vascular endothelial growth factor in skeletal muscle of patients with sleep disorders.
Small Cell Lung Carcinoma
-
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.
An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.
Angiogenesis Inhibitors in Small Cell Lung Cancer.
Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.
Differential expression of hypoxia-inducible factor 1? in non-small cell lung cancer and small cell lung cancer.
Diffuse intestinal angiomatosis as a possible paraneoplastic manifestation of small cell lung cancer: a case of small bowel angiomatosis.
Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma.
Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells.
Increased pro-angiogenic factors, infiltrating neutrophils and CD163(+) macrophages in bronchoalveolar lavage fluid from lung cancer patients.
Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients.
Prognostic value of serum IL-17 and VEGF levels in small cell lung cancer.
Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer.
Relationship between vessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro.
Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients.
Serum tumor markers, hypoxia-inducible factor-1? HIF-1? and vascular endothelial growth factor, in patients with non- small cell lung cancer before and after intervention.
Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer.
Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase.
Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients.
Vascular endothelial growth factor trap in non small cell lung cancer.
[Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro].
[Relationship between vascular endothelial growth factor C expression level and lymph node metastasis in non small cell lung cancer]
[The clinical value of vascular endothelial growth factor in patients with small cell lung cancer.]
Small Fiber Neuropathy
Skin biopsy as a diagnostic tool.
Smoldering Multiple Myeloma
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma.
Smooth Muscle Tumor
Pseudo-Meigs' syndrome caused by uterine smooth muscle tumor of uncertain malignant potential with low vascular endothelial growth factor expression.
Solitary Pulmonary Nodule
Dynamic enhancement patterns of solitary pulmonary nodules at multi-detector row CT and correlation with vascular endothelial growth factor and microvessel density.
Serum Angiopoietin-2 as a Clinical Marker for Lung Cancer in Patients with Solitary Pulmonary Nodules.
Solitary pulmonary nodules: comparison of multi-slice computed tomography perfusion study with vascular endothelial growth factor and microvessel density.
Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density.
Spasm
The relationship between number and function of EPCs and concentration of VEGF165 and SDF-1 in coronary artery spasm.
Spinal Cord Diseases
Potential role of growth factors in diminishing radiation therapy neural tissue injury.
Vascular Endothelial Growth Factor Enhanced the Angiogenesis Response of Human Umbilical Cord-Derived Mesenchymal Stromal Cells in a Rat Model of Radiation Myelopathy.
Spinal Cord Injuries
2-Methoxyestradiol inhibits the up-regulation of AQP4 and AQP1 expression after spinal cord injury.
879 Hypoxia-inducible Gene Expression System for Vascular Endothelial Growth Factor Gene Therapy for the Rat Spinal Cord Injury Model.
A pilot study of cell-mediated gene therapy for spinal cord injury in mini pigs.
Batroxobin protects against spinal cord injury in rats by promoting the expression of vascular endothelial growth factor to reduce apoptosis.
Combined Method of Neuronal Cell-Inducible Vector and Valproic Acid for Enhanced Gene Expression under Hypoxic Conditions.
Effect of hypoxia-inducible factor-1/vascular endothelial growth factor signaling pathway on spinal cord injury in rats.
Effect of vascular endothelial growth factor treatment in experimental traumatic spinal cord injury: in vivo longitudinal assessment.
Effects of vascular endothelial growth factor on ischemic spinal cord injury caused by aortic cross-clamping in rabbits.
Ex vivo VEGF delivery by neural stem cells enhances proliferation of glial progenitors, angiogenesis, and tissue sparing after spinal cord injury.
Ferulic Acid Improves Functional Recovery after Acute Spinal Cord Injury in Rats by Inducing Hypoxia to Inhibit microRNA-590 and Elevate Vascular Endothelial Growth Factor Expressions.
Growth factors and cytokines in patients with long bone fractures and associated spinal cord injury.
Hyperbaric oxygen intervention on expression of hypoxia-inducible factor-1? and vascular endothelial growth factor in spinal cord injury models in rats.
Hypoxia-inducible expression of vascular endothelial growth factor for the treatment of spinal cord injury in a rat model.
Hypoxia-specific VEGF-expressing neural stem cells in spinal cord injury model.
Influences of HIF-l? on Bax/Bcl-2 and VEGF expressions in rats with spinal cord injury.
LncRNA MIAT activates vascular endothelial growth factor A through RAD21 to promote nerve injury repair in acute spinal cord injury.
Low-energy extracorporeal shock wave therapy for promotion of vascular endothelial growth factor expression and angiogenesis and improvement of locomotor and sensory functions after spinal cord injury.
Low-energy extracorporeal shock wave therapy promotes vascular endothelial growth factor expression and improves locomotor recovery after spinal cord injury.
Nerve growth factor combined with vascular endothelial growth factor enhances regeneration of bladder acellular matrix graft in spinal cord injury-induced neurogenic rat bladder.
Neural Stem Cells Modified by a Hypoxia-Inducible VEGF Gene Expression System Improve Cell Viability under Hypoxic Conditions and Spinal Cord Injury.
Reduced Vascular Endothelial Growth Factor Expression In Contusive Spinal Cord Injury.
Sustained Expression of Vascular Endothelial Growth Factor and Angiopoietin-1 Improves Blood-Spinal Cord Barrier Integrity and Functional Recovery after Spinal Cord Injury.
The correlation between nitric oxide and vascular endothelial growth factor in spinal cord injury.
Therapeutic Use of 3?-[N-(N',N'-Dimethylaminoethane) Carbamoyl] Cholesterol-Modified PLGA Nanospheres as Gene Delivery Vehicles for Spinal Cord Injury.
Transplantation of Recombinant Vascular Endothelial Growth Factor (VEGF)189-Neural Stem Cells Downregulates Transient Receptor Potential Vanilloid 1 (TRPV1) and Improves Motor Outcome in Spinal Cord Injury.
Triple-Gene Therapy for Stroke: A Proof-of-Concept
Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 following acute spinal cord contusion in rats.
Vascular endothelial growth factor activates neural stem cells through epidermal growth factor receptor signal after spinal cord injury.
Vascular endothelial growth factor and spinal cord injury pain.
Vascular endothelial growth factor enhances axonal outgrowth in organotypic spinal cord slices via vascular endothelial growth factor receptor 1 and 2.
Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury.
Vascular Endothelial Growth Factor-Transfected Bone Marrow Mesenchymal Stem Cells Improve the Recovery of Motor and Sensory Functions of Rats With Spinal Cord Injury.
VEGF inhibits the inflammation in spinal cord injury through activation of autophagy.
VEGF mRNA induction correlates with changes in the vascular architecture upon spinal cord damage in the rat.
VEGF-transfected BMSC Improve the Recovery of Motor and Sensory Functions of Rats With Spinal Cord Injury.
[Effects of bone marrow mesenchymal stem cells transplantation on expression of vascular endothelial growth factor gene and angiogenesis after spinal cord injury in rats].
[Neuroprotective effects of recombinant adeno-associated virus expressing vascular endothelial growth factor on rat traumatic spinal cord injury and its mechanism].
[Protective effect of olfactory ensheathing cells in combination with intrathecal injection of vascular endothelial growth factor on injured spinal cord in rats].
Spinal Cord Ischemia
Intrathecal granulocyte colony-stimulating factor modulate glial cell line-derived neurotrophic factor and vascular endothelial growth factor A expression in glial cells after experimental spinal cord ischemia.
Spinal Stenosis
Expression of Hypoxia-inducible Factor-1?, Vascular Endothelial Growth Factor, and Matrix Metalloproteinases 1, 3, and 9 in Hypertrophied Ligamentum Flavum.
Spinocerebellar Ataxias
Self-assembling vascular endothelial growth factor nanoparticles improve function in spinocerebellar ataxia type 1.
Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1.
Spondylarthropathies
High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies.
Spondylitis, Ankylosing
Associations of the VEGF level, VEGF rs2010963 G/C gene polymorphism and ankylosing spondylitis risk in a Chinese Han population.
Efficacy of wIRA in the treatment of sacroiliitis in male patients with ankylosing spondylitis and its effect on serum VEGF levels.
Elevated serum level of IL-27 and VEGF in patients with ankylosing spondylitis and associate with disease activity.
Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor.
Influence of VEGF gene polymorphisms on the severity of ankylosing spondylitis.
Serum levels of Dkk-1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parameters.
Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab.
[Changes in the serum concentrations of adhesion molecules and vascular endothelial growth factor in active ankylosing spondylitis patients taking amtolmetin guacil: Results of a 56-week prospective ???n-label controlled observational study].
Squamous Cell Carcinoma of Head and Neck
A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer.
A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma.
A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
Angiogenic factors in squamous cell carcinoma of the oral cavity: do they have prognostic relevance?
Angiogenic growth factors in tissue homogenates of HNSCC: expression pattern, prognostic relevance, and interrelationships.
Angiogenin-mediated ribosomal RNA transcription as a molecular target for treatment of head and neck squamous cell carcinoma.
Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma.
Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.
Assessment of gene expression in head and neck carcinoma using laser capture microdissection and real-time reverse transcription polymerase chain reaction.
Association of preoperative radiation effect with tumor angiogenesis and vascular endothelial growth factor in oral squamous cell carcinoma.
Association of vascular endothelial growth factor and mast cells with angiogenesis in laryngeal squamous cell carcinoma.
Association of VEGF-A genetic polymorphisms with cancer risk and survival in advanced-stage oral squamous cell carcinoma patients.
Associations between single-nucleotide polymorphisms of the VEGF gene and long-term prognosis of oral squamous cell carcinoma.
Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
Bleeding complications in patients with squamous cell carcinoma of the head and neck.
Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells.
Cepharanthine inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing expression of vascular endothelial growth factor and interleukin-8.
Chemokine CCL4 Induces Vascular Endothelial Growth Factor C Expression and Lymphangiogenesis by miR-195-3p in Oral Squamous Cell Carcinoma.
Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
Clinicopathological implications of vascular endothelial growth factor 165b expression in oral squamous cell carcinoma stroma.
Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways.
Combination antiangiogenic therapy and radiation in head and neck cancers.
Combined Analysis of Vascular Endothelial Growth Factor Expression with Cyclooxygenase-2 and Mast Cell Density in Oral Squamous Cell Carcinoma.
Comparison of immunohistochemical expression of vascular endothelial growth factor and CD105 in oral squamous cell carcinoma: Its correlation with prognosis.
Correction: Simultaneous Expression of Furin and Vascular Endothelial Growth Factor in Human Oral Tongue Squamous Cell Carcinoma Progression.
Correlation between vascular endothelial growth factor expression and presence of lymph node metastasis in advanced squamous cell carcinoma of the larynx.
Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous cell carcinoma.
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.
Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma.
Correlation of serum levels of vascular endothelial growth factor with TNM staging, histopathologic grading, and surgical therapy for oral squamous cell carcinoma.
Cyclo-oxygenase-2 expression is associated with vascular endothelial growth factor C expression and lymph node metastasis in oral squamous cell carcinoma.
Cytokines and tumor markers in potentially malignant disorders and oral squamous cell carcinoma: a pilot study.
Cytokines in saliva increase in head and neck cancer patients after treatment.
Differential effects between cyclooxygenase-2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines.
Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.
Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study.
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.
El-Gazzar R, Macluskey M, Williams H, Ogden GR. Vascularity and expression of vascular endothelial growth factor in oral squamous cell carcinoma, resection margins, and nodal metastases. Br J Oral Maxillofac Surg 2006;44:193-7 [Epub 2005, August 10].
Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma.
Elevated VEGFA mRNA levels in oral squamous cell carcinomas and tumor margins: a preliminary study.
Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.
Estimation of vascular endothelial growth factor gene -460 C/T polymorphism as a biomarker in oral squamous cell carcinoma patients from the Indian subcontinent.
Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma.
Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts.
Expression level and prospective mechanism of miRNA-99a-3p in head and neck squamous cell carcinoma based on miRNA-chip and miRNA-sequencing data in 1, 167 cases.
Expression of angiopoietin-2 and vascular endothelial growth factor receptor-3 correlates with lymphangiogenesis and angiogenesis and affects survival of oral squamous cell carcinoma.
Expression of c-erbB receptors, MMPs and VEGF in head and neck squamous cell carcinoma.
Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck.
Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study.
Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in oral squamous cell carcinoma: its correlation with angiogenesis and disease progression.
Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.
Expression of vascular endothelial growth factor (VEGF) in normal oral mucosa, oral dysplasia and oral squamous cell carcinoma.
Expression of vascular endothelial growth factor (VEGF) in patients with oral squamous cell carcinoma and its clinical significance.
Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma.
Expression of vascular endothelial growth factor and cyclooxygenase-2 in laryngeal squamous cell carcinoma and its significance.
Expression of vascular endothelial growth factor and prognosis of oral squamous cell carcinoma.
Expression of vascular endothelial growth factor by photodynamic therapy with mono-L-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma.
Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis.
Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status.
Expression of vascular endothelial growth factor in oral squamous cell carcinoma.
Expression of vascular endothelial growth factor is significantly associated with progression and prognosis of oral squamous cell carcinomas in Taiwan.
Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma.
Expression of VEGF, HGF, IL-6, IL-8, MMP-9, Telomerase in Peripheral Blood of Patients with Head and Neck Squamous Cell Carcinoma.
Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.
Glycoprotein Nonmetastatic Melanoma Protein B as Potential Imaging Marker in Posttherapeutic Metastatic Head and Neck Cancer.
Granzyme B-truncated VEGF fusion protein represses angiogenesis and tumor growth of OSCC.
Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-{kappa}B and STAT3 pathways in head and neck cancer cells.
Head and neck squamous cell carcinoma lymphatic spread and survival: Relevance of vascular endothelial growth factor family for tumor evaluation.
Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma.
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells.
Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study.
IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma.
Immunohistochemical expression of vascular endothelial growth factor in canine oral squamous cell carcinomas.
Immunohistochemical study of VEGF expression in oral squamous cell carcinomas: correlation with the mTOR-HIF-1? pathway.
In vitro cytokine release profile: Predictive value for metastatic potential in head and neck squamous cell carcinomas.
In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab: from bench to bedside?
Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients' prognosis.
Inherent phenotypic plasticity facilitates progression of head and neck cancer: Endotheliod characteristics enable angiogenesis and invasion.
Inhibition of mTOR in Head and Neck Cancer Cells Alters Endothelial Cell Morphology in a Paracrine Fashion.
Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.
Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker.
Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells.
Lymphatic Vessels and High Endothelial Venules are Increased in the Sentinel Lymph Nodes of Patients with Oral Squamous Cell Carcinoma Before the Arrival of Tumor Cells.
Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
Microvascular density and vascular endothelial growth factor immunoreactivity as predictors of regional lymph node metastasis from betel-associated oral squamous cell carcinoma.
Microvessel density (MVD) and vascular endothelial growth factor expression (VEGF) in human oral squamous cell carcinoma.
Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas.
Molecular marker expression in oral and oropharyngeal squamous cell carcinoma.
Oral Squamous Cell Carcinoma From Users and Nonusers of Tobacco and Alcohol: Clinicopathologic Features and Immunoreactivity of VEGF, Caspase-3, and P53.
PAI-1, CAIX, and VEGFA expressions as prognosis markers in oral squamous cell carcinoma.
Peripheral blood dendritic cells and vascular endothelial growth factor in oral squamous cell carcinoma: correlation analysis and in vitro study.
PET monitoring of therapy response in head and neck squamous cell carcinoma.
Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma.
Poor prognostic clinicopathologic features correlate with VEGF expression but not with PTEN expression in squamous cell carcinoma of the larynx.
Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2.
Predictive factor for photodynamic therapy effects on oral squamous cell carcinoma and oral epithelial dysplasia.
Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma.
Primary Tumor-Secreted Lymphangiogenic Factors Induce Pre-Metastatic Lymphvascular Niche Formation at Sentinel Lymph Nodes in Oral Squamous Cell Carcinoma.
Proangiogenic effects of ionizing irradiation on squamous cell carcinoma of the hypopharynx.
Prognostic and predictive value of serum vascular endothelial growth factor (VEGF) in squamous cell carcinoma of the head and neck.
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis.
Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma.
Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma.
Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas.
Quantifying the expression of VEGF using qRT-PCR, evaluation of MVD and their correlation with clinicopathological factors in laryngeal squamous cell carcinoma.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent.
Regulation of the expression of pigment epithelium-derived factor, an anti-angiogenic factor in human oral squamous cell carcinoma cell lines.
S-1 inhibits tumorigenicity and angiogenesis of human oral squamous cell carcinoma cells by suppressing expression of phosphorylated Akt, vascular endothelial growth factor and fibroblast growth factor-2.
Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions.
Semiquantifiable angiogenesis parameters in association with the malignant transformation of oral leukoplakia.
Serum vascular endothelial growth factor in patients with head and neck squamous cell carcinoma.
Serum vascular endothelial growth factor in patients with pharyngeal and laryngeal squamous cell carcinoma treated with radiotherapy.
Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma.
Significance of the expression of integrin ?1, VEGF and MVD in hypopharyngeal squamous cell carcinoma.
Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression.
Single nucleotide polymorphisms of the vascular endothelial growth factor gene associated with incidence of oral squamous cell carcinoma.
Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma.
Targeting angiogenesis in head and neck cancer.
Targeting Slit-Roundabout signaling inhibits tumor angiogenesis in chemical-induced squamous cell carcinogenesis.
The effects of reactive species on the tumorigenic phenotype of human head and neck squamous cell carcinoma (HNSCC) cells.
The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma.
The influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase-2 inhibition in head and neck squamous cell carcinoma cell lines.
The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer.
The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma.
Tissue expression, serum and salivary levels of vascular endothelial growth factor in patients with HNSCC.
Transfection of hypoxia-inducible factor-1 decoy oligodeoxynucleotides suppresses expression of vascular endothelial growth factor in oral squamous cell carcinoma cells.
Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma.
Upregulation of serum and tissue vascular endothelial growth factor correlates with angiogenesis and prognosis of oral squamous cell carcinoma.
Upregulation of serum vascular endothelial growth factor and matrix metalloproteinase-3 in patients with oral squamous cell carcinoma.
Upregulation of vascular endothelial growth factor mRNA level is significantly related to progression and prognosis of oral squamous cell carcinomas.
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to Cisplatin and radiation in vivo and in vitro.
Vascular endothelial growth factor (VEGF) in sera of oral and oropharyngeal squamous cell carcinoma patients.
Vascular endothelial growth factor 936 C/T polymorphism is associated with vascular invasion in oral squamous cell carcinoma.
Vascular endothelial growth factor and ki-67 antigen expression in relation to age and gender in oral squamous cell carcinoma.
Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation.
Vascular endothelial growth factor expression and vascular density in oral squamous cell carcinoma (OSCC): A study on clinical and histopathologic significance.
Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck.
Vascular endothelial growth factor expression in head and neck squamous cell carcinoma.
Vascular endothelial growth factor polymorphisms as effect modifiers of oral squamous cell carcinoma risk: A systematic review and meta-analysis.
Vascular endothelial growth factor receptor isoforms: are they present in oral squamous cell carcinoma?
Vascularity and expression of vascular endothelial growth factor in oral squamous cell carcinoma, resection margins, and nodal metastases.
VEGF and CD 34: A correlation between tumor angiogenesis and microvessel density-an immunohistochemical study.
VEGF-C and VEGF-D expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: Implications for use as a prognostic marker.
VEGF-C expression in oral cancer by neurotransmitter-induced activation of beta-adrenergic receptors.
VEGFR1 and VEGFR2 immunohistochemical expression in oral squamous cell carcinoma: a morphometric study.
Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
Zebularine-induced reduction in VEGF secretion by HIF-1? degradation in oral squamous cell carcinoma.
[Antiangiogenic and anti-immunosuppressive therapeutic strategies in human head and neck squamous cell carcinoma (HNSCC)]
[Effects of HPV 16-E6/E7 oncogene on expression of vascular endothelial growth factor and matrix metalloproteinase 9 in human laryngeal squamous cell carcinoma cell line]
[Expression and clinical significance of Endostatin, vascular endothelial growth factor and fibroblast growth factor basic-2 in laryngeal carcinoma]
[Expression and clinical significance of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinomas]
[Expression of vascular endothelial growth factor in oral squamous cell carcinoma]
[Expression of vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and nm23-H1 in oral squamous cell carcinoma]
[Expression of VEGF, EGFR, p16 in lip cancers and oral squamous cell carcinomas and their clinic significance]
[Expression related to vascular endothelial growth factor C and induced nitride oxide synthesizase in lymph node micrometastasis of oral squamous cell carcinoma]
[Relation between vascular endothelial growth factor expression and clinical pathological character in laryngeal squamous cell carcinoma]
[Relationship among expression of the VEGF gene and MVD with cervical lymph nodes metastasis in laryngeal squamous cell carcinoma]
[Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]
[Research on the correlation of vascular endothelial growth factor and dendritic cell in patients with oral squamous cell carcinoma]
[Study on the relationship between angiogenesis and cervical lymphatic metastasis in head and neck squamous cell carcinomas]
[The correlation of vascular endothelial growth factor with angiogenesis and p53 gene in laryngeal squamous cell carcinoma]
Starvation
Effects of serum starvation and vascular endothelial growth factor stimulation on the expression of Notch signalling pathway components.
Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells.
Fibroblast growth factor rescues brain endothelial cells lacking presenilin 1 from apoptotic cell death following serum starvation.
Myeloid angiogenic cells exhibit impaired migration, reduced expression of endothelial markers, and increased apoptosis in idiopathic pulmonary arterial hypertension 1.
New proangiogenic activity on vascular endothelial cells for C-terminal mechano growth factor.
Normalization of the vasculature for treatment of cancer and other diseases.
Status Epilepticus
Increased expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 after pilocarpine-induced status epilepticus in mice.
Leptomycin B ameliorates vasogenic edema formation induced by status epilepticus via inhibiting p38 MAPK/VEGF pathway.
Peroxisome Proliferator-Activated Receptor ? Coactivator 1? Activates Vascular Endothelial Growth Factor That Protects Against Neuronal Cell Death Following Status Epilepticus through PI3K/AKT and MEK/ERK Signaling.
Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus.
Vascular endothelial growth factor receptor-3 regulates astroglial glutamate transporter-1 expression via mTOR activation in reactive astrocytes following pilocarpine-induced status epilepticus.
VEGF as a target for neuroprotection.
VEGF treatment during status epilepticus attenuates long-term seizure-associated alterations in astrocyte morphology.
Still's Disease, Adult-Onset
[Blood cytokine levels as a clinical laboratory test]
Stillbirth
Decreased expression of pigment epithelium derived factor (PEDF), an inhibitor of angiogenesis, in placentas of unexplained stillbirths.
Stomach Neoplasms
(-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer.
A Case Report of Gastrointestinal Hemorrhage and Perforation During Apatinib Treatment of Gastric Cancer.
A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab.
A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin1 predicts survival in patients with advanced gastric cancer.
A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
Active Targeted Nanoparticles for Oral Administration of Gastric Cancer Therapy.
Alpha-fetoprotein-producing gastric cancer: histochemical analysis of cell proliferation, apoptosis, and angiogenesis.
Angiogenesis and lymphangiogenesis of gastric cancer.
Angiogenesis as a target for gastric cancer.
Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer.
Anti-metastatic Efficacy of Traditional Chinese Medicine (TCM) Ginsenoside Conjugated to a VEFGR-3 Antibody on Human Gastric Cancer in an Orthotopic Mouse Model.
Anti-neuropilin-1 monoclonal antibody suppresses the migration and invasion of human gastric cancer cells via Akt dephosphorylation.
Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody.
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma.
Apatinib for molecular targeted therapy in tumor.
Apatinib for the treatment of gastric cancer.
Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation.
Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1?-AKT-mTOR pathway in esophageal squamous cell carcinoma.
Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report.
Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report.
Apatinib-induced hyperammonemic encephalopathy.
Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo.
Association between color doppler vascularity index, angiogenesis-related molecules, and clinical outcomes in gastric cancer.
Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer.
Association between the expression of T-cadherin and vascular endothelial growth factor and the prognosis of patients with gastric cancer.
Association of Vascular Endothelial Growth Factor ( VEGF) Gene Polymorphisms With Gastric Cancer and Its Development, Prognosis, and Survival.
Aurora-A as an independent molecular prognostic marker in gastric cancer.
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer.
Bevacizumab combined with low-dose S-1 as maintenance therapy with a long progression-free survival in an elderly patient with heavily pre-treated advanced gastric cancer: A case report.
Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.
C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer.
Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression.
Cancer-Stromal Cell Interaction and Tumor Angiogenesis in Gastric Cancer.
Cetuximab combined with cisplatin improves the prognosis of gastric cancer patients and its effect on P38 MAPK expression.
Chemotherapy regimen based on sorafenib combined with 5-FU on HIF-1? and VEGF expression and survival in advanced gastric cancer patients.
Circulating stromal cell derived factor-1alpha (SDF-1alpha) is predictive of distant metastasis in gastric carcinoma.
Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery.
Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival in gastric cancer.
Clinical Correlations and Prognostic Relevance of Tissue Angiogenic Factors in Patients with Gastric Cancer.
Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma.
Clinical significance of platelet derived growth factor-C and -D in gastric cancer.
Clinical Significance of Serum Vascular Endothelial Growth Factor, Pigment Epithelium-Derived Factor, Tumor Necrosis Factor Alpha, and Progranulin Levels in Patients with Gastric Cancer and Gastric Precancerous Lesions.
Clinical significance of vascular endothelial growth factor expression in gastric cancer.
Clinical study on the safety, efficacy, and prognosis of molecular targeted drug therapy for advanced gastric cancer.
Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer.
Clinicopathologic significance of nuclear factor-?B and vascular endothelial growth factor expression in advanced gastric cancer patients.
Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer.
Clinicopathological variables associated with lymph node metastasis in submucosal invasive gastric cancer.
Cloning of a cancer cell-producing hepatocyte growth factor, vascular endothelial growth factor, and interleukin-8 from gastric cancer cells.
Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft.
Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade.
Combined effect of sCD40L and PI3K siRNA on transplanted tumours growth and microenvironment in nude mice with gastric cancer.
Combined targeting of vascular endothelial growth factor C (VEGFC) and P65 using miR-27b-3p agomir and lipoteichoic acid in the treatment of gastric cancer.
Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients.
Concurrent apatinib and local radiation therapy for advanced gastric cancer: A case report and review of the literature.
Contrast-enhanced power Doppler endosonography and pathological assessment of vascularization in advanced gastric carcinomas--a feasibility study.
Correlation between Vascular Endothelial Growth Factor and Somatostatin Receptor with Progression and Prognosis in Gastric Cancer.
Correlation of Vascular Endothelial Growth Factor Expression With Tumor Recurrence and Poor Prognosis in Patients With pN0 Gastric Cancer.
Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma.
Correlations of serum homocysteine, VEGF and gastrin 17 with gastric cancer and precancerous lesions.
Correlations of TNM staging and lymph node metastasis of gastric cancer with MRI features and VEGF expression.
Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer.
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.
Curcumin inhibits the lymphangiogenesis of gastric cancer cells by inhibiton of HMGB1/VEGF-D signaling.
CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer.
Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer.
Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma.
Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer.
Differential expression of angiogenesis-related genes in human gastric cancers with and those without high-frequency microsatellite instability.
Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts.
Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients.
Dynamic contrast-enhanced MRI of gastric cancer: Correlations of the pharmacokinetic parameters with histological type, Lauren classification, and angiogenesis.
Effect of arsenic trioxide on vascular endothelial cell proliferation and expression of vascular endothelial growth factor receptors Flt-1 and KDR in gastric cancer in nude mice.
Effect of Bevacizumab, a Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, on Peritoneal Metastasis of MNK-45P Human Gastric Cancer in Mice.
Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase-2 in patients with gastric cancer.
Effect of polymorphisms in the 3' untranslated region (3'-UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan.
Effect of Weikangning on gastric cancer cell growth and expression of vascular endothelial growth factor and its receptors KDR and Flt-1.
Effects of all-trans-retinoic on human gastric cancer cells BGC-823.
Effects of Nutrition Intervention on Total and Cancer Mortality: 25-Year Post-trial Follow-up of the 5.25-Year Linxian Nutrition Intervention Trial.
Effects of recombinant human endostatin on the expression of vascular endothelial growth factor in human gastric cancer cell line MGC-803.
Effects of shRNA targeting VEGF on VEGF mRNA expression in gastric cancer cells.
Effects of vascular endothelial growth factor and epidermal growth factor on biological properties of gastric cancer cells.
Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis.
Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma.
Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor.
Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer.
Experimental and clinicopathological analysis of HOXB9 in gastric cancer.
Expression and clinical significance of aquaporin-1, vascular endothelial growth factor and microvessel density in gastric cancer.
Expression and significances of contactin-1 in human gastric cancer.
Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer.
Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma.
Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer.
Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer.
Expression of Differentiation Inhibiting Factor 1 and Vascular Endothelial Growth Factor and the Relation between them and Microvessel Density in Gastric Cancer Tissue.
Expression of inducible nitric oxide synthase is significantly correlated with expression of vascular endothelial growth factor and dendritic cell infiltration in patients with advanced gastric carcinoma.
Expression of midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival.
Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer.
Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer.
Expression of survivin in gastric cancer and its relationship with tumor angiogenesis.
Expression of Tspan-1 gene in patients with advanced gastric cancer.
Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.
Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma.
Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells.
Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms-A case-control study in an Omani population.
Gastric Cancer: New Drugs - New Strategies.
Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C>T) gene and patients with stomach cancer.
Genetic polymorphisms of vascular endothelial growth factor (VEGF) associated with gastric cancer recurrence after curative resection with adjuvant chemotherapy.
Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer.
Helicobacter pylori promotes VEGF expression via the p38 MAPK?mediated COX?2?PGE2 pathway in MKN45 cells.
Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism.
Hepatoma-derived growth factor regulates the bad-mediated apoptotic pathway and induction of vascular endothelial growth factor in stomach cancer cells.
High density of peritumoral lymphatic vessels measured by D2-40/podoplanin and LYVE-1 expression in gastric cancer patients: an excellent prognostic indicator or a false friend?
High Expression of Angiogenic Factor with G-Patch and FHA Domain1 (AGGF1) Predicts Poor Prognosis in Gastric Cancer.
High lactate dehydrogenase 5 expression correlates with high tumoral and stromal vascular endothelial growth factor expression in gastric cancer.
High lymphatic vessel density correlates with overexpression of VEGF-C in gastric cancer.
High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.
Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer.
Hydroxychloroquine enhances the antitumor effects of BC001 in gastric cancer.
Immunohistochemical demonstration of angiogenic growth factors and EGF receptor in hepatic metastases and primary human gastric cancer.
In Vivo RNAi Efficacy of Palmitic Acid-Conjugated Dicer-Substrate siRNA in a Subcutaneous Tumor Mouse Model.
In-silico based identification of phytochemicals from Houttuynia cordata Thunb. as potential inhibitors for overexpressed HER2 and VEGFR2 cancer genes.
Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer.
Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients.
Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells.
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
Inhibition of the hypoxia-induced factor-1? and vascular endothelial growth factor expression through ginsenoside Rg3 in human gastric cancer cells.
Inhibition of Vascular Endothelial Growth Factor Receptor 3 Reduces Migration of Gastric Cancer Cells.
Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer.
Inhibitory effect of vascular endothelial growth factors-targeted small interfering RNA on proliferation of gastric cancer cells.
Interleukin-1alpha enhances angiogenesis and is associated with liver metastatic potential in human gastric cancer cell lines.
Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer.
Isoprenaline/?2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis.
KLK6 Promotes Growth, Migration, and Invasion of Gastric Cancer Cells.
Lentivirus-Mediated VEGF Knockdown Suppresses Gastric Cancer Cell Proliferation and Tumor Growth in vitro and in vivo.
Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma.
Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer.
Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis.
Markers of tumour angiogenesis and tumour cells in bone marrow in gastric cancer patients.
Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway.
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Metastasis-associated in colon cancer-1 upregulates vascular endothelial growth factor-C/D to promote lymphangiogenesis in human gastric cancer.
MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C.
microRNA-1228(?) impairs the pro-angiogenic activity of gastric cancer cells by targeting macrophage migration inhibitory factor.
MicroRNA-27b, microRNA-101 and microRNA-128 inhibit angiogenesis by down-regulating vascular endothelial growth factor C expression in gastric cancers.
MicroRNA-4316 inhibits gastric cancer proliferation and migration via directly targeting VEGF-A.
miR-125a regulates angiogenesis of gastric cancer by targeting vascular endothelial growth factor A.
Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer.
Monocyte chemoattractant protein 1 and CD40 ligation have a synergistic effect on vascular endothelial growth factor production through cyclooxygenase 2 upregulation in gastric cancer.
ncRuPAR inhibits gastric cancer progression by down-regulating protease-activated receptor-1.
Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
No Association of Vascular Endothelial Growth Factor-A (VEGF-A) and VEGF-C Expression with Survival in Patients with Gastric Cancer.
Overexpression of cyclooxygenase-2 and tumor angiogenesis in human gastric cancer.
p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer.
PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system.
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray.
Polyunsaturated fatty acids augment tumoricidal action of 5-fluorouracil on gastric cancer cells by their action on vascular endothelial growth factor, tumor necrosis factor-? and lipid metabolism related factors.
Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer.
Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers.
Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer.
Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer.
Predictive Significance of Serum Level of Vascular Endothelial Growth Factor in Gastric Cancer Patients.
Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancer.
Prognostic Significance of Serum Levels of Vascular Endothelial Growth Factor and Insulin-Like Growth Factor-1 in Advanced Gastric Cancer Patients Treated with FOLFOX Chemotherapy.
Prognostic Significance of Serum Vascular Endothelial Growth Factor Per Platelet Count in Unresectable Advanced Gastric Cancer Patients.
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.
Prognostic value of CD83-positive mature dendritic cells and their relation to vascular endothelial growth factor in advanced human gastric cancer.
Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis.
Prognostic value of vascular endothelial growth factor expression in resected gastric cancer.
Progress and current status of molecule-targeted therapy and drug resistance in gastric cancer.
Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis.
Protease-activated receptor-2 induces expression of vascular endothelial growth factor and cyclooxygenase-2 via the mitogen-activated protein kinase pathway in gastric cancer cells.
Pulmonary tumor thrombotic microangiopathy caused by an ovarian cancer expressing tissue factor and vascular endothelial growth factor.
Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Re: vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival by Tzanakis N, Gazouli M, Rallis G, et al.
REC8 suppresses tumor angiogenesis by inhibition of NF-?B-mediated vascular endothelial growth factor expression in gastric cancer cells.
Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A.
Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients.
Reduction of prostaglandin transporter predicts poor prognosis associated with angiogenesis in gastric adenocarcinoma.
Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8.
Regulation of Vascular Endothelial Growth Factor (VEGF) Production and Angiogenesis by Tissue Factor (TF) in SGC-7901 Gastric Cancer Cells.
Regulation of vascular endothelial growth factor expression in human gastric cancer cells by interleukin-1beta.
Relation between cell-to-cell adhesion and angiogenesis and clinico-morphological prognostic factors in patients with gastric cancer.
Relationship between clinicopathological features and HIF-2? in gastric adenocarcinoma.
Relationship between expression of NADPH oxidase 2 and invasion and prognosis of human gastric cancer.
Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP.
Relationship between LYVE-1, VEGFR-3 and CD44 gene expressions and lymphatic metastasis in gastric cancer.
Relationship of p53 and vascular endothelial growth factor expression of clinicopathological factors in human scirrhous gastric cancer.
Relationships between local and systemic expression of interleukin-12 and plasma levels of vascular endothelial growth factor in patients with gastric cancer.
Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer.
RNAi-mediated inhibition of PDGF-D leads to decreased cell growth, invasion and angiogenesis in the SGC-7901 gastric cancer xenograft model.
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients.
Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer.
Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer.
Roles of circulating endothelial progenitor cells and endothelial cells in gastric carcinoma.
RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer.
Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?
Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer.
Serum levels of vascular endothelial growth factor in gastric cancer patients.
Serum VEGF levels in gastric cancer patients: correlation with clinicopathological parameters.
Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX.
Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
Significance of preoperative tissue levels of vascular-endothelial cadherin, liver-intestine cadherin and vascular endothelial growth factor in gastric cancer.
Significance of vascular endothelial growth factor expression and its correlation with inducible nitric oxide synthase in gastric cancer.
Significance of vascular endothelial growth factor messenger RNA expression in gastric cancer.
Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.
Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report.
STAT3 regulation the expression of VEGF-D in HGC-27 gastric cancer cell.
Suppression of vascular endothelial growth factor abrogates the immunosuppressive capability of murine gastric cancer cells and elicits antitumor immunity.
Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor.
Targeting receptor tyrosine kinases in gastric cancer.
Targeting the Vascular Endothelial Growth Factor Pathway in Gastric Cancer: A Hit or a Miss?
Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: Preclinical and clinical aspects.
The Clinical Study of Urokinase-Type Plasminogen Activator and Vascular Endothelial Growth Factor in Gastric Cancer.
The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer.
The expression of vascular endothelial growth factor and proliferative activity of cancer cells in gastric cancer.
The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.
The role of circulating IL-8 and VEGF protein in the progression of gastric cancer.
The role of human leukocyte antigen and tumor necrosis factor D as a prognostic, preventive and therapeutic factor in gastric cancer.
The role of leptin in gastric cancer: Clinicopathologic features and molecular mechanisms.
The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer.
The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer.
Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism.
Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial.
Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis: A case report.
Tumor interstitial fluid and gastric cancer metastasis: an experimental study to verify the hypothesis of "tumor-phlegm microenvironment".
Vascular endothelial growth factor (VEGF) +936 C/T gene polymorphism and gastric cancer risk: appraisal of a recent meta-analysis.
Vascular endothelial growth factor (VEGF) +936 C/T gene polymorphisms and gastric cancer risk: a meta-analysis involving 4,138 subjects.
Vascular endothelial growth factor (VEGF) gene polymorphisms and gastric cancer risk in a Chinese Han population.
Vascular endothelial growth factor +936C/T polymorphism and gastric cancer risk: A meta-analysis.
Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer.
Vascular Endothelial Growth Factor and Cluster of Differentiation 34 for Assessment of Perioperative Bleeding Risk in Gastric Cancer Patients.
Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer.
Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans.
Vascular Endothelial Growth Factor and Soluble Forms of Its Receptors 1 and 2 in Gastric Cancer.
Vascular endothelial growth factor as an age-dependent prognostic factor in gastric cancer patients.
Vascular endothelial growth factor C (VEGF-C) expression in pT2 gastric cancer.
Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
Vascular endothelial growth factor expression and microvessel density--two useful tools for the assessment of prognosis and survival in gastric cancer patients.
Vascular endothelial growth factor expression is an independent poor prognostic factor for human epidermal growth factor receptor 2 positive gastric cancer.
Vascular endothelial growth factor gene polymorphisms and gastric cancer risk: a meta-analysis.
Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer.
Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival.
Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival.
Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
VEGF and cortactin expression are independent predictors of tumor recurrence following curative resection of gastric cancer.
VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice.
VEGF-D Correlates with Metastatic Disease in Gastric Cancer Patients Undergoing Surgery.
VEGFA+936C/T and -634G/C polymorphisms and gastric cancer risk: a meta-analysis.
VEGFR-2 Inhibitor Apatinib Hinders Endothelial Cells Progression Triggered by Irradiated Gastric Cancer Cells-derived Exosomes.
Wogonin Inhibits Tumor-derived Regulatory Molecules by Suppressing STAT3 Signaling to Promote Tumor Immunity.
Xiaotan Sanjie decoction attenuates tumor angiogenesis by manipulating Notch-1-regulated proliferation of gastric cancer stem-like cells.
Xiaotan Sanjie decoction inhibits angiogenesis in gastric cancer through Interleukin-8-linked regulation of the vascular endothelial growth factor pathway.
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
Zerumbone inhibits tumor angiogenesis via NF-?B in gastric cancer.
[(-)-Epigallocatechin-3-gallate reduces vascular endothelial growth factor expression in gastric cancer cells via suppressing activity].
[Chinese herbal medicine Jianpi Jiedu Formula down-regulates the expression of vascular endothelial growth factor in human gastric cell line MKN45 induced by Helicobacter pylori by inhibiting cyclooxygenase-2.]
[Effect of vascular endothelial growth factor antibody avastin on angiogenesis of human gastric cancer growing orthotopically in nude mice.]
[Effects of quercetin on the expression of VEGF-C and VEGFR-3 in human cancer MGC-803 cells.]
[Effects of weikangning contained serum on growth of gastric cancer cell, expression of vascular endothelial growth factor and its receptors including KDR and fit-1]
[Experimental research of the inhibition of vascular endothelial growth factor C expression in gastric cancer by targeting RNA interference]
[Expression of hepatocyte growth factor, transcription factor SP1, vascular endothelial growth factor and CD34 in serosa-infiltrative gastric cancer and their relations with defluxion of gastric cancercell and prognosis]
[Expression of transcription factor SP1, vascular endothelial growth factor and CD34 in serosa-infiltrating gastric cancer and their relationship with biological behavior and prognosis]
[Expression of VEGF-C and VEGF-D in gastric carcinoma and its relationship with lymph node metastases.]
[Expressions of TGIF, MMP9 and VEGF proteins and their clinicopathological relationship in gastric cancer]
[Impacts of Bevacizumab on vascular endothelial growth factor and Sp1 expression in gastric cancer xenografts].
[Infection with L-form of Helicobacter pylori and expressions of MIF, MMP9 and VEGF in gastric carcinoma].
[Mechanism of hsa-miR-302a-3p-targeted VEGFA in the Inhibition of Proliferation of Gastric Cancer Cell].
[Preliminary results regarding vascular endothelial growth factor (VEGF-A) levels in the serum of gastric cancer patients].
[Research status quo and progression in targeted therapy for advanced gastric cancer].
Stomach Ulcer
A vascular endothelial growth factor mimetic accelerates gastric ulcer healing in an iNOS-dependent manner.
Antioxidant-mediated preventative effect of Dragon-pearl tea crude polyphenol extract on reserpine-induced gastric ulcers.
Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance.
Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido)ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa.
Effect of Jianweiyuyang granule on gastric ulcer recurrence and expression of VEGF mRNA in the healing process of gastric ulcer in rats.
Evaluation of gastric ulcerogenic and healing impairment effects of bisphosphonates: adverse gastric reactions of bisphosphonate.
Expression of vascular endothelial growth factor at the human gastric ulcer margin and in cultured gastric fibroblasts: a new angiogenic factor for gastric ulcer healing.
Gastric ulcerogenic and healing impairment actions of alendronate, a nitrogen-containing bisphosphonate - prophylactic effects of rebamipide.
Gene therapy for gastric diseases.
Gene therapy for ulcerations of the gastrointestinal tract.
Helicobacter pylori down-regulates the receptors of vascular endothelial growth factor and angiopoietin in vascular endothelial cells: implications in the impairment of gastric ulcer healing.
Influence of vascular endothelial growth factor (VEGF) on gastroprotection in stress-induced gastric mucosal ulcers in rats.
Leptin promotes gastric ulcer healing via upregulation of vascular endothelial growth factor.
Platelets accelerate gastric ulcer healing through presentation of vascular endothelial growth factor.
Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release.
Prostaglandin E(2) stimulates VEGF expression in primary rat gastric fibroblasts through EP4 receptors.
Relation of Hypoxia-Inducible Factor-1alpha to Vascular Endothelial Growth Factor and Vasoactive Factors During Healing of Gastric Ulcers.
Relationship between vascular endothelial growth factor and angiogenesis in spontaneous and indomethacin-delayed healing of acetic acid-induced gastric ulcers in rats.
Role of modulation of vascular endothelial growth factor and tumor necrosis factor-alpha in gastric ulcer healing in diabetic rats.
Roles of Cyclooxygenase, Prostaglandin E2 and EP Receptors in Mucosal Protection and Ulcer Healing in the Gastrointestinal Tract.
Russelioside B; A pregnane glycoside for treatment of gastric ulcer via modulation of heat shock protein-70 and vascular endothelial growth factor.
The possible role of vascular endothelial growth factor (VEGF) in gastric ulcer healing: effect of sofalcone on VEGF release in vitro.
The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor.
Stomatitis
Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols.
Stomatitis, Aphthous
Expression of endocan and vascular endothelial growth factor in recurrent minor aphthous ulcers.
High-level expression of vascular endothelial growth factor and its receptors in an aphthous ulcer.
Stomatitis, Denture
Denture stomatitis and salivary vascular endothelial growth factor in immediate complete denture wearers with type 2 diabetes.
Stroke
A Feedback Loop Involving MicroRNA-150 and MYB Regulates VEGF Expression in Brain Microvascular Endothelial Cells After Oxygen Glucose Deprivation.
Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke.
Anti-Nogo-A antibodies prevent vascular leakage and act as pro-angiogenic factors following stroke.
Association of a Vascular Endothelial Growth Factor genetic variant with Serum VEGF level in subjects with Metabolic Syndrome.
AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.
Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice.
Bone Marrow Stromal Cells Combined With Sodium Ferulate and n-Butylidenephthalide Promote the Effect of Therapeutic Angiogenesis via Advancing Astrocyte-Derived Trophic Factors After Ischemic Stroke.
Bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor.
Brief overview: Protective roles of astrocyte-derived pentraxin-3 in blood-brain barrier integrity.
Candesartan stimulates reparative angiogenesis in ischemic retinopathy model: role of hemeoxygenase-1 (HO-1).
Circulating MiRNA-195-5p and -451a in Diabetic Patients with Transient and Acute Ischemic Stroke in the Emergency Department.
Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia.
Coupling of angiogenesis and neurogenesis in cultured endothelial cells and neural progenitor cells after stroke.
Early expressions of hypoxia-inducible factor 1alpha and vascular endothelial growth factor increase the neuronal plasticity of activated endogenous neural stem cells after focal cerebral ischemia.
Effect of gene-gene and gene-environment interaction on the risk of first-ever stroke and poststroke death.
Electroacupuncture induces acute changes in cerebral cortical miRNA profile, improves cerebral blood flow and alleviates neurological deficits in a rat model of stroke.
Enhanced Migration of Bone Marrow-Derived Mesenchymal Stem Cells with Tetramethylpyrazine and Its Synergistic Effect on Angiogenesis and Neurogenesis After Cerebral Ischemia in Rats.
Enhanced neurogenesis and cell migration following focal ischemia and peripheral stimulation in mice.
Enhanced Neurogenesis and Collaterogenesis by Sodium Danshensu Treatment After Focal Cerebral Ischemia in Mice.
Erythropoietin Prevents Blood Brain Barrier Damage Induced by Focal Cerebral Ischemia in Mice.
Evidence for epistatic gene interactions between growth factor genes in stroke outcome.
Exercise-induced overexpression of angiogenic factors and reduction of ischemia/reperfusion injury in stroke.
Expression of angiopoietin-1, angiopoietin-2, and tie receptors after middle cerebral artery occlusion in the rat.
From angiogenesis to neuropathology.
Granulocyte colony-stimulating factor and stromal cell-derived factor-1 combination therapy: A more effective treatment for cerebral ischemic stroke.
Growth factor treatment of stroke.
HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: potential roles of oligodendrogenesis, VEGF, and anti-inflammation.
Higher level of acute serum VEGF and larger infarct volume are more frequently associated with post-stroke cognitive impairment.
HIV is associated with endothelial activation despite ART, in a sub-Saharan African setting.
Human Urinary Kallidinogenase Improves Outcome of Stroke Patients by Shortening Mean Transit Time of Perfusion Magnetic Resonance Imaging.
Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
Hypoxia-inducible factor and vascular endothelial growth factor are targets of dietary soy during acute stroke in female rats.
Illuminating the Effects of Stroke on the Diabetic Brain: Insights From Imaging Neural and Vascular Networks in Experimental Animal Models.
Increased vascular endothelial growth factor D is associated with atrial fibrillation and ischaemic stroke.
Induction of vascular endothelial growth factor receptor-3 mRNA in glial cells following focal cerebral ischemia in rats.
Inhibition of HIF-1? Reduced Blood Brain Barrier Damage by Regulating MMP-2 and VEGF During Acute Cerebral Ischemia.
Inhibition of prolyl hydroxylases by dimethyloxaloylglycine after stroke reduces ischemic brain injury and requires hypoxia inducible factor-1?.
INJECTABLE VEGF HYDROGELS PRODUCE NEAR COMPLETE NEUROLOGICAL AND ANATOMICAL PROTECTION FOLLOWING CEREBRAL ISCHEMIA IN RATS.
Intranasal Delivery of Apelin-13 Is Neuroprotective and Promotes Angiogenesis After Ischemic Stroke in Mice.
iPSC Transplantation increases regeneration and functional recovery after ischemic stroke in neonatal rats.
Long-term cerebral cortex protection and behavioral stabilization by gonadal steroid hormones after transient focal hypoxia.
Long-term Survival and Regeneration of Neuronal and Vasculature Cells inside the Core Region after Ischemic Stroke in Adult Mice.
Microneedle-mediated vascular endothelial growth factor delivery promotes angiogenesis and functional recovery after stroke.
Neural Stem Cell Transplantation Induces Stroke Recovery by Upregulating Glutamate Transporter GLT-1 in Astrocytes.
Neuronal deficiency of HIF prolyl 4-hydroxylase 2 in mice improves ischemic stroke recovery in an HIF dependent manner.
Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis.
Neuroprotective Effect of Human Placenta-derived Cell Treatment of Stroke in Rats.
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Niaspan treatment induces neuroprotection after stroke.
Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat.
Peripheral Artery Disease and Stroke.
Pituitary Apoplexy After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitor: A Novel Complication.
Plasma indices of angiogenesis in rheumatoid disease: Relationship to cardiovascular risk factors and cardiac function.
Positron emission tomography imaging of poststroke angiogenesis.
Postacute ischemia vascular endothelial growth factor transfer by transferrin-targeted liposomes attenuates ischemic brain injury after experimental stroke in rats.
Progesterone Changes VEGF and BDNF Expression and Promotes Neurogenesis After Ischemic Stroke.
Promoting neuroregeneration after perinatal arterial ischemic stroke: neurotrophic factors and mesenchymal stem cells.
Protective effects of angiopoietin-like 4 on the blood-brain barrier in acute ischemic stroke treated with thrombolysis in mice.
Protective effects of D-Limonene against transient cerebral ischemia in stroke-prone spontaneously hypertensive rats.
Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE.
Reduced ischemic injury after stroke in mice by angiogenic gene delivery via ultrasound-targeted microbubble destruction.
Regulation of hypoxia-inducible factor 1alpha and induction of vascular endothelial growth factor in a rat neonatal stroke model.
Reported Prestroke Physical Activity Is Associated with Vascular Endothelial Growth Factor Expression and Good Outcomes after Stroke.
Role of vasodilator stimulated phosphoprotein in VEGF induced blood-brain barrier permeability in endothelial cell monolayers.
Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: framingham study.
Serum VEGF levels in acute ischaemic strokes are correlated with long-term prognosis.
Shenmayizhi Formula Combined with Ginkgo Extract Tablets for the Treatment of Vascular Dementia: A Randomized, Double-Blind, Controlled Trial.
Small vessel disease and biomarkers of endothelial dysfunction after ischaemic stroke.
Snakehead fish extract as an enhancer of vascular endothelial growth factor and nitric oxide levels in cerebral angiogenesis: an insight of stroke therapy.
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke.
Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
TGF-?2/Smad3 Signaling Pathway Activation Through Enhancing VEGF and CD34 Ameliorates Cerebral Ischemia/Reperfusion Injury After Isoflurane Post-conditioning in Rats.
The association between vascular endothelial growth factor gene polymorphisms and stroke: a meta-analysis.
The association between vascular endothelial growth factor gene polymorphisms and stroke: A PRISMA-compliant meta-analysis.
The dose-effectiveness of intranasal VEGF in treatment of experimental stroke.
The impact of experimental preconditioning using vascular endothelial growth factor in stroke and subarachnoid hemorrhage.
The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis.
The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia.
The possible mechanism for impaired angiogenesis after transient focal ischemia in type 2 diabetic GK rats: different expressions of angiostatin and vascular endothelial growth factor.
The role of vascular endothelial growth factor in angiogenesis and brain circulation after stroke.
The role of vascular endothelial growth factor in ischemic stroke.
Therapeutic effect of human umbilical cord multipotent mesenchymal stromal cells in a rat model of stroke.
Time Course of Flow-Mediated Dilation and Vascular Endothelial Growth Factor following Acute Stroke.
Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.
Towards a multi protein and mRNA expression of biological predictive and distinguish model for post stroke depression.
Treatment efficacy of arterial urokinase thrombolysis combined with mechanical thrombectomy for acute cerebral infarction and its influence on neuroprotective factors and factors for neurological injury.
Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats.
Uric acid treatment after stroke modulates the Krüppel-like factor 2-VEGF-A axis to protect brain endothelial cell functions: Impact of hypertension.
Value of measuring serum vascular endothelial growth factor levels in diagnosing acute ischemic stroke.
Vascular endothelial growth factor and angiopoietins in neurovascular regeneration and protection following stroke.
Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke.
Vascular Endothelial Growth Factor as Predictive Biomarker for Stroke Severity and Outcome; An Evaluation of a New Clinical Module in Acute Ischemic Stroke.
Vascular endothelial growth factor in cerebral ischemia.
Vascular endothelial growth factor mediates atorvastatin-induced mammalian achaete-scute homologue-1 gene expression and neuronal differentiation after stroke in retired breeder rats.
Vascular endothelial growth factor receptor-2 inhibition promotes cell death and limits endothelial cell proliferation in a neonatal rodent model of stroke.
Vascular endothelial growth factor-A and -C protein up-regulation and early angiogenesis in a rat photothrombotic ring stroke model with spontaneous reperfusion.
VEGF protein associates to neurons in remote regions following cortical infarct.
VEGF receptor-2 variants are associated with susceptibility to stroke and recurrence.
VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia.
[Vascular endothelial growth factor expression in patients with acute ischemic stroke].
Stroke, Lacunar
Increased VEGF and Decreased SDF-1? in Patients with Silent Brain Infarction Are Associated with Better Prognosis after First-Ever Acute Lacunar Stroke.
Subarachnoid Hemorrhage
'What is the restorative effect of VEGF inhibitor bevacuzimab against subarachnoid hemorrhage in an experimental model'.
Anti-Vascular Endothelial Growth Factor Treatment Suppresses Early Brain Injury After Subarachnoid Hemorrhage in Mice.
Expression of the receptors of VEGF and the influence of extract of Ginkgo biloba after cisternal injection of autologus arterial hemolysate in rats.
Extract of Ginkgo biloba promotes the expression of VEGF following subarachnoid hemorrhage in rats.
Neurological surgery at the National Institutes of Health.
Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
The impact of experimental preconditioning using vascular endothelial growth factor in stroke and subarachnoid hemorrhage.
Vascular endothelial growth factor A promotes platelet adhesion to collagen IV and causes early brain injury after subarachnoid hemorrhage.
Vascular endothelial growth factor gene polymorphisms and intracranial aneurysms.
Vascular Endothelial Growth Factor in Brain Edema Formation After Subarachnoid Hemorrhage.
Superior Vena Cava Syndrome
Bevacizumab and Glioblastoma Multiforme: A Thrombosis and Bleeding Dilemma (A Case Report and a Brief Review of the Literature).
Sweet Syndrome
Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases.
Synovitis
A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome.
Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators.
Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Idiopathic remitting seronegative symmetrical synovitis with pitting edema syndrome associated with bilateral pleural and pericardial effusions: a case report.
Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints.
Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate.
Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis.
Subclinical gut inflammation in spondyloarthritis is associated with a pro-angiogenic intestinal mucosal phenotype.
The levels of vascular endothelial growth factor in the synovial fluid correlated with the severity of arthroscopically observed synovitis and clinical outcome after temporomandibular joint irrigation in patients with chronic closed lock.
The Relationship between Remitting Seronegative Symmetrical Synovitis with Pitting Edema and Vascular Endothelial Growth Factor and Matrix Metalloproteinase 3.
The role of interleukin 6 in the pathophysiology of rheumatoid arthritis.
Vascular endothelial growth factor levels and rheumatic diseases of the elderly.
VEGF-C Gene Polymorphisms Increase Susceptibility to Rheumatoid Arthritis.
Syphilis
Clinicopathologic features, microvessel density, and immunohistochemical expression of ICAM-1 and VEGF in 15 cases of secondary syphilis with oral manifestations.
Syringomyelia
Neurological surgery at the National Institutes of Health.
Systemic Vasculitis
Increased serum vascular endothelial growth factor level in Churg-Strauss syndrome.
Increased serum vascular endothelial growth factor levels in microscopic poly angiitis with pulmonary involvement.
Myositis, Vasculitis, Hepatic Dysfunction in Adult-Onset Still's Disease.
t-plasminogen activator deficiency
Tissue-type plasminogen activator deficiency delays bone repair: roles of osteoblastic proliferation and vascular endothelial growth factor.
Takayasu Arteritis
Aortitis syndrome (Takayasu's arteritis) with cataract and elevated serum level of vascular endothelial growth factor.
Endothelial progenitor cells and vascular endothelial growth factor in patients with Takayasu's arteritis.
Telangiectasia, Hereditary Hemorrhagic
Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.
Effects of VEGF on phenotypic severity in children with hereditary hemorrhagic telangiectasia.
Hereditary hemorrhagic telangiectasia/avastin.
Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression.
Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
Pentraxin 3 level is elevated in hereditary hemorrhagic telangiectasia and reflects the severity of disease-associated epistaxis.
Plasma level and tissue expression of angiogenic factors in patients with hereditary hemorrhagic telangiectasia.
Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Vascular endothelial growth factor and transforming growth factor in hereditary hemorrhagic telangiectasia.
Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia.
[Analysis of angiogenesis related proteins and its implication in type-2 hereditary hemorrhagic telangiectasia]
[What's new in internal medicine?].
Telangiectasis
Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.
Effects of VEGF on phenotypic severity in children with hereditary hemorrhagic telangiectasia.
Hereditary hemorrhagic telangiectasia/avastin.
Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression.
Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
Pentraxin 3 level is elevated in hereditary hemorrhagic telangiectasia and reflects the severity of disease-associated epistaxis.
Plasma level and tissue expression of angiogenic factors in patients with hereditary hemorrhagic telangiectasia.
POOR LONG-TERM OUTCOME OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2.
Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Vascular endothelial growth factor and transforming growth factor in hereditary hemorrhagic telangiectasia.
Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia.
[Analysis of angiogenesis related proteins and its implication in type-2 hereditary hemorrhagic telangiectasia]
[What's new in internal medicine?].
Temporomandibular Joint Disorders
Dickkopf?related protein 1 induces angiogenesis by upregulating vascular endothelial growth factor in the synovial fibroblasts of patients with temporomandibular joint disorders.
Expression of Dickkopf-related Protein 1 in Patients with Temporomandibular Osteoarthritis after Treatment with Hyaluronic Acid.
Tendinopathy
cDNA-arrays and real-time quantitative PCR techniques in the investigation of chronic Achilles tendinosis.
Gene Therapy Using Plasmid DNA Encoding Vascular Endothelial Growth Factor 164 and Fibroblast Growth Factor 2 Genes for the Treatment of Horse Tendinitis and Desmitis: Case Reports.
Investigation of angiogenesis genes with anterior cruciate ligament rupture risk in a South African population.
Low-level laser therapy in experimental model of collagenase-induced tendinitis in rats: effects in acute and chronic inflammatory phases.
Photobiomodulation therapy on collagen type I and III, vascular endothelial growth factor, and metalloproteinase in experimentally induced tendinopathy in aged rats.
Role of VEGF, Nitric Oxide, and Sympathetic Neurotransmitters in the Pathogenesis of Tendinopathy: A Review of the Current Evidences.
Vascular Endothelial Growth Factor Receptor-2 Polymorphisms Have Protective Effect against the Development of Tendinopathy in Volleyball Athletes.
Teratoma
Analyses of novel prognostic factors in neuroblastoma patients.
Effects of Kaposi's sarcoma-associated herpesvirus ORF K1 on differentiating endothelium in murine embryoid bodies and teratomas.
Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth.
Testicular Neoplasms
Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor.
Pazopanib induced unilateral posterior reversible encephalopathy syndrome.
Serum and plasma vascular endothelial growth factor levels in testicular cancer patients.
Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors.
Tetralogy of Fallot
Haploinsufficiency of vascular endothelial growth factor related signaling genes is associated with tetralogy of Fallot.
Thalassemia
Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia.
Thiamine Deficiency
HIF1-?-mediated gene expression induced by vitamin B1 deficiency.
[Thiamine deficiency polyneuropathy after gastrectomy associated with high level of serum vascular endothelial growth factor (VEGF). A case report]
Thromboangiitis Obliterans
Predictive value of serum VEGF, IL-1 and TNF-? in the treatment of thromboangiitis obliterans by revascularization.
Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results.
[Comprehensive treatment of a patient with Buerger's disease using genetically engineered complexes VEGF-165].
Thrombocythemia, Essential
Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia.
Vascular endothelial growth factor and thrombopoietin in patients with essential thrombocythemia and polycythemia vera and thrombotic complications.
Thrombocytopenia
Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1 receptor inhibitor, in AIDS-Kaposi's sarcoma.
Innate immune cells induce hemorrhage in tumors during thrombocytopenia.
Short-term induction of thrombocytopenia delays periodontal healing in rats with periodontal disease: participation of endostatin and vascular endothelial growth factor.
The case for a subcutaneous magnesium product and delivery device for space missions.
Vascular endothelial growth factor and angiogenin levels during fetal development and in maternal diabetes.
Thrombocytosis
Angiogenesis in chronic myeloproliferative diseases.
Atypical central retinal artery occlusion as the first presentation of POEMS syndrome: a case report.
Atypical polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome without polyneuropathy: A case report.
Neurologic Complications of Lymphoma, Leukemia, and Paraproteinemias.
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome.
POEMS Syndrome: an Enigma.
Thrombosis revealing POEMS syndrome. About a case.
Thromboembolism
Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
Peripheral Artery Disease and Stroke.
The effects of sonic hedgehog signaling pathway components on non-small-cell lung cancer progression and clinical outcome.
Vascular Complications of Cancer Chemotherapy.
Thrombophilia
ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.
Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation.
Thrombosis
A novel semisynthesized small molecule icaritin reduces incidence of steroid-associated osteonecrosis with inhibition of both thrombosis and lipid-deposition in a dose-dependent manner.
Adenovirus-mediated VEGF gene therapy enhances venous thrombus recanalization and resolution.
Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents.
Association of advanced glycoxidation end products and inflammation markers with thrombosis of arteriovenous grafts in hemodialysis patients.
Bevacizumab and Glioblastoma Multiforme: A Thrombosis and Bleeding Dilemma (A Case Report and a Brief Review of the Literature).
Circulating microRNA expression and their target genes in deep vein thrombosis: A systematic review and bioinformatics analysis.
Clinical significance of endothelial progenitor cells in patients with liver cirrhosis with or without hepatocellular carcinoma.
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors.
Construction of human VEGF165 gene eukaryotic expression plasmid and its effect on proliferation of vascular endothelial cells.
Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma.
Could VEGF-D level have a role in clinical risk scoring, estimation of thrombus burden, and treatment in acute pulmonary thromboembolism?
Cytokines Associated with Increased Erythropoiesis in Sprague-Dawley Rats Administered a Novel Hyperglycosylated Analog of Recombinant Human Erythropoietin.
Design, preparation and performance of a novel drug-eluting stent with multiple layer coatings.
Endoglin (CD105) expression in the development of haemorrhoids.
Evaluation of circulating vascular endothelial growth factor and soluble adhesion molecules as reliable predictors of native arteriovenous fistula thrombosis in chronic hemodialysis patients.
Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma.
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.
Expression of VEGFs and its receptors in abdominal aortic aneurysm.
Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab.
Hypoxia and Upregulation of Hypoxia-Inducible Factor 1{alpha} Stimulate Venous Thrombus Recanalization.
Interleukin-8 administration enhances venous thrombosis resolution in a rat model.
New anticancer strategies targeting HIF-1.
Osteopontin expression in pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma.
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Quantum molecular resonance technology in hard-to-heal extremity wounds: histological and clinical results.
Recurrent first trimester pregnancy loss: revised definitions and novel causes.
Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review).
Role of vascular mitogens in subarachnoid hemorrhage-associated cerebral vasculopathy.
Roles of microRNA-186 and vascular endothelial growth factor in hepatocellular carcinoma complicated with portal vein tumor thrombus.
Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS).
Synthesis and antiangiogenic activity of N-alkylated levamisole derivatives.
Thrombotic risk factors in patients with superior vena cava syndrome undergoing chemotherapy via femoral inserted central catheter.
Upregulation of hypoxia-inducible factor 1 alpha in local vein wall is associated with enhanced venous thrombus resolution.
Utility of placental growth factor for prediction of 30-day adverse event in emergency department population with non-ST elevation acute coronary syndrome.
Vascular Complications of Cancer Chemotherapy.
Vascular endothelial growth factor (VEGF)-eluting stents: in vivo effects on thrombosis, endothelialization and intimal hyperplasia.
Vascular endothelial growth factor C936T polymorphism in cancer patients with thrombosis.
Vascular endothelial growth factor enhances venous thrombus recanalisation and organisation.
Vascular endothelial growth factor naked DNA gene transfer enhances thrombus recanalization and resolution.
Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma.
[Expression rates of three angiogenic factors in hepatocellular carcinoma and their relation with microvessel density and portal vein tumor thrombosis]
[Relationship between the proliferative activity of cancer cells and microvessel density in portal vein thrombosis and transfer of hepatocellular carcinoma]
Thrombotic Microangiopathies
ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.
Antineoplastic agents and thrombotic microangiopathy.
Antineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted Therapies.
Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Interference with Gs?-Coupled Receptor Signaling in Renin-Producing Cells Leads to Renal Endothelial Damage.
Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab.
Nintedanib-Induced Renal Thrombotic Microangiopathy.
Pulmonary tumor thrombotic microangiopathy caused by a gastric carcinoma expressing vascular endothelial growth factor and tissue factor.
Pulmonary tumor thrombotic microangiopathy caused by an ovarian cancer expressing tissue factor and vascular endothelial growth factor.
Pulmonary Tumor Thrombotic Microangiopathy Caused by Urothelial Carcinoma Expressing Vascular Endothelial Growth Factor, Platelet-derived Growth Factor, and Osteopontin.
Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.
Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use.
Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy.
Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy.
VEGF inhibition and renal thrombotic microangiopathy.
Thymoma
Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.
Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors.
Deciphering mechanisms controlling placental artery endothelial cell migration stimulated by vascular endothelial growth factor.
p28(GANK) overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1? pathways.
p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1? pathways.
Progress in targeted therapy for breast cancer.
SNPs, linkage disequilibrium, and chronic mountain sickness in Tibetan Chinese.
Spherical bullet formation via E-cadherin promotes therapeutic potency of mesenchymal stem cells derived from human umbilical cord blood for myocardial infarction.
Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma.
[Correlation of CKP and VEGF expression and microvessel density to spiral CT manifestations of thymoma.]
[Minimal change nephrotic syndrome complicated with recurrence of malignant thymoma: an interesting case with remission due to steroid therapy of both nephrotic syndrome and thymoma]
Thyroid Cancer, Papillary
Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis.
Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population.
Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas.
Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Expression of NIS, VEGF-A and Thyroid Autoantibody in Papillary Thyroid Carcinoma with or without Hashimoto's Disease.
Expression of Vascular Endothelial Growth Factor and Its Receptors in Thyroid Nodular Hyperplasia and Papillary Thyroid Carcinoma: A Tertiary Health Care Centre Based Study
Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma.
Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.
Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer.
Neuropilin-2 expression in papillary thyroid carcinoma: correlation with VEGF-D expression, lymph node metastasis, and VEGF-D-induced aggressive cancer cell phenotype.
Nitric oxide in papillary thyroid carcinoma: induction of vascular endothelial growth factor D and correlation with lymph node metastasis.
Personalization of targeted therapy in advanced thyroid cancer.
Phase II trial of sorafenib in metastatic thyroid cancer.
Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer.
Preoperative serum VEGF-C but not VEGF-A level is correlated with lateral neck metastasis in papillary thyroid carcinoma.
Relationship between expression of vascular endothelial growth factor and cervical lymph node metastasis in papillary thyroid cancer: A meta-analysis.
Relationship between VEGF protein expression and lymph node metastasis in papillary thyroid carcinoma among Asians: a meta-analysis.
Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma.
Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer.
Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model.
The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults.
The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma.
Upregulation of Endocrine Gland-Derived Vascular Endothelial Growth Factor in Papillary Thyroid Cancers Displaying Infiltrative Patterns, Lymph Node Metastases, and BRAF Mutation.
Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma.
Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma.
VEGF in physiological process and thyroid disease.
VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma.
[Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma]
[Expression of VEGF-C and angiogenesis, and lymphangiogenesis in papillary thyroid carcinoma]
[Value of VEGF-C, VEGF-D and VEGFR-3 levels combined with serum TSH in diagnosis of papillary thyroid carcinoma].
Thyroid Carcinoma, Anaplastic
A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-à-go-go-related gene silencing in anaplastic thyroid carcinoma cells.
A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: 125 I Seed Implantation Plus Apatinib After Surgery.
CLM3, a Multitarget Tyrosine Kinase Inhibitor With Antiangiogenic Properties, Is Active Against Primary Anaplastic Thyroid Cancer In Vitro and In Vivo.
Effect of mesoporous silica nanoparticles co?loading with 17?AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
Extensive tracheal necrosis after treatment of anaplastic thyroid cancer with vascular endothelial growth factor inhibitors.
Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma.
Initial Therapy of Advanced Anaplastic Thyroid Cancer via Targeting VEGFR-2: A Case Report.
Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.
Thyroid Diseases
Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features.
Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases.
[Immunohistochemical profile of angiogenesis in the thyroid gland in various thyroid diseases].
Thyroid Neoplasms
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
An update on clinical trials of targeted therapies in thyroid cancer.
Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
Antitumor Activity of Motesanib in a Medullary Thyroid Cancer Model.
Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population.
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Cancer: Reduced serum VEGF-D levels in metastatic differentiated thyroid cancer.
CD74 expression and its therapeutic potential in thyroid carcinoma.
Changes and Prognostic Value of Serum Vascular Endothelial Growth Factor in Patients with Differentiated Thyroid Cancer.
Clinical relevance of vascular endothelial growth factor for thyroid neoplasms.
Correlations of HOTAIR expression with pathological stage, CT characteristics and prognosis of patients with papillary thyroid carcinoma.
Decreased serum vascular endothelial growth Factor-D (VEGF-D) levels in metastatic patients with differentiated thyroid carcinoma.
Delta-like 4/Notch pathway is differentially regulated in benign and malignant thyroid tissues.
Downregulation of vascular endothelial growth factor receptor-2 under oxidative stress conditions is mediated by ?-transduction repeat-containing protein via glycogen synthase kinase-3? signaling.
Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study.
Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways.
Evaluation of microcirculation of thyroid cancer in Chinese females with breast cancer using contrast-enhanced ultrasound (CEUS) combined with VEGF and microvessel density (MVD).
Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS).
Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop.
Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms.
Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade.
Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma.
Interactions of vascular endothelial growth factor and p53 with miR-195 in thyroid carcinoma: possible therapeutic targets in aggressive thyroid cancers.
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer.
Motesanib diphosphate in progressive differentiated thyroid cancer.
Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
New molecular targeted therapies in thyroid cancer.
Personalization of targeted therapy in advanced thyroid cancer.
Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Phase II trial of sorafenib in advanced thyroid cancer.
Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function.
Platelet-activating factor and human thyroid cancer.
Pneumatocele during sorafenib therapy: first report of an unusual complication.
Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissue.
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas.
Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.
Serum vascular endothelial growth factor levels in patients with medullary thyroid carcinoma.
Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma.
Silencing of hypoxia-inducible factor-1? promotes thyroid cancer cell apoptosis and inhibits invasion by downregulating WWP2, WWP9, VEGF and VEGFR2.
Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): From bench to bedside.
The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter.
The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults.
Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines.
Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors.
Vandetanib: first global approval.
Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.
Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma.
Vascular endothelial growth factor gene polymorphisms in thyroid cancer.
Vascular endothelial growth factor in thyroid cancers.
VEGF-D and A Preoperative Serum Levels Predict Nodal and Distant Metastases in Differentiated Thyroid Cancer Patients.
[Current progress and management in molecular targeted therapy for advanced thyroid cancer].
[Expression and significance of VEGF-C and VEGF-D in differentiated thyroid carcinoma]
[The inhibitory effect of vascular endothelial growth factor antisense oligonucleotides in angiogenesis of thyroid carcinoma]
Thyroid Nodule
Correlation of vascular endothelial growth factor and vascular endothelial growth factor receptor-1 levels in serum and thyroid nodules with histopathological and radiological variables.
Serum vascular endothelial growth factor-D levels correlate with cervical lymph node metastases in papillary thyroid carcinoma.
Thyroid volumes and serum VEGF levels in dyslipidemic patients: effects of statin treatment
VEGF-C Is a Thyroid Marker of Malignancy Superior to VEGF-A in the Differential Diagnostics of Thyroid Lesions.
Thyroiditis
Drug-induced hypothyroidism.
Expression of NIS, VEGF-A and Thyroid Autoantibody in Papillary Thyroid Carcinoma with or without Hashimoto's Disease.
Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis.
Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features.
THE CORRELATION BETWEEN INFLAMMATORY AND METABOLIC PARAMETERS WITH THYROID FUNCTION IN PATIENTS WITH HASHIMOTO'S THYROIDITIS: THE POTENTIAL ROLE OF INTERLEUKIN 23 (IL-23) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) - 1.
The effects of Nigella sativa on thyroid function, serum Vascular Endothelial Growth Factor (VEGF) - 1, Nesfatin-1 and anthropometric features in patients with Hashimoto's thyroiditis: a randomized controlled trial.
The relationship between transforming growth factor-beta1, vascular endothelial growth factor, nitric oxide and Hashimoto's thyroiditis.
Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma.
Tongue Neoplasms
Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression.
Lymphangiogenesis in regional lymph nodes predicts nodal recurrence in pathological N0 squamous cell carcinoma of the tongue.
Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF).
MIA-dependent angiogenesis and lymphangiogenesis are closely associated with progression, nodal metastasis and poor prognosis in tongue squamous cell carcinoma.
RE: Correlational of oral tongue cancer inversion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression, by Kim S-H, Cho NH, Kim K, et al.
Relationship between vascular endothelial growth factor and Notch1 expression and lymphatic metastasis in tongue cancer.
Vascular endothelial growth factor C (VEGF-C) expression predicts metastasis in tongue cancer.
[In vivo short hairpin RNA interference of vascular endothelial growth factor on drug-resistant tongue cancer cells].
[The effect of VEGF-ASODN transfection on expression of VEGF and growth in tongue squamous cancer cell line Tca8113]
Tooth, Unerupted
Bone marrow combined with dental bud cells promotes tooth regeneration in miniature pig model.
Fibrin glue mixed with platelet-rich fibrin as a scaffold seeded with dental bud cells for tooth regeneration.
Toxocariasis
Clinical Features and Prognostic Factors in Northern Chinese Patients with Peripheral Granuloma Type of Ocular Toxocariasis: A Retrospective Cohort Study.
Toxoplasmosis, Ocular
INTRAOCULAR AND SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN ACUTE RETINAL NECROSIS AND OCULAR TOXOPLASMOSIS.
VEGF Production Is Regulated by the AKT/ERK1/2 Signaling Pathway and Controls the Proliferation of Toxoplasma gondii in ARPE-19 Cells.
Tracheal Stenosis
Anti-fibrosis activity of quercetin attenuates rabbit tracheal stenosis via the TGF-?/AKT/mTOR signaling pathway.
Trachoma
Expression of growth factors in the conjunctiva from patients with active trachoma.
Transfusion-Related Acute Lung Injury
Platelet Vascular Endothelial Growth Factor is a Potential Mediator of Transfusion-Related Acute Lung Injury.
Trauma, Nervous System
Human platelet-rich plasma promotes axon growth in brain-spinal cord coculture.
The HIF-1 inhibitor YC-1 decreases reactive astrocyte formation in a rodent ischemia model.
Treatment of traumatic brain injury using zinc-finger protein gene therapy targeting VEGF-A.
Vascular endothelial growth factor in central nervous system injuries - a vascular growth factor getting nervous?
Triple Negative Breast Neoplasms
A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer.
An isoflavone derivative potently inhibits the angiogenesis and progression of triple-negative breast cancer by targeting the MTA2/SerRS/VEGFA pathway.
Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China.
Induction of Ras by SAF-1/MAZ through a feed-forward loop promotes angiogenesis in breast cancer.
Oestrogen Inhibits VEGF Expression And Angiogenesis In Triple-Negative Breast Cancer By Activating GPER-1.
Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer.
Significance of aeg-1 expression in correlation with vegf, microvessel density and clinicopathological characteristics in triple-negative breast cancer.
Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathological characteristics in triple-negative breast cancer.
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.
Study of diffusion-weighted magnetic resonance imaging in the evaluation of the response to AAV2-VEGF-Trap neoadjuvant treatment in a triple-negative breast cancer animal model.
Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy.
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer.
The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.
Tumor necrosis factor ? inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer.
Vascular endothelial growth factor encoded by Parapoxviruses can regulate metabolism and survival of triple negative breast cancer cells.
Trisomy 18 Syndrome
First trimester maternal serum placenta growth factor (PIGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18.
Tuberculoma
Dynamic contrast-enhanced (DCE) derived transfer coefficient (ktrans) is a surrogate marker of matrix metalloproteinase 9 (MMP-9) expression in brain tuberculomas.
Relative cerebral blood volume is a measure of angiogenesis in brain tuberculoma.
Tuberculosis
Cytokine pattern in Kaposi's sarcoma associated with immune restoration disease in HIV and tuberculosis co-infected patients.
Epigenetic reader BRD4 supports mycobacterial pathogenesis by co-modulating host lipophagy and angiogenesis.
Expression, purification, and characterization of soluble RpfD with high bioactivity as a recombinant protein in Mycobacterium vaccae.
Human tuberculosis brain promotes neuronal apoptosis but not in astrocytes with high expression of vascular endothelial growth factor.
Local ischemia and increased expression of vascular endothelial growth factor following ocular dissemination of Mycobacterium tuberculosis.
Mycobacterium Tuberculosis Modulates Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Ocular Tuberculosis.
Overview of Brain-to-Gut Axis Exposed to Chronic CNS Bacterial Infection(s) and a Predictive Urinary Metabolic Profile of a Brain Infected by Mycobacterium tuberculosis.
Vascular endothelial growth factor in pleural effusions of different origin.
[Evaluation of vascular endothelial growth factor (VEGF) in neoplastic and tuberculosis effusions--preliminary results]
Tuberculosis, Meningeal
Expression of vascular endothelial growth factor in tuberculous meningitis.
Overview of Brain-to-Gut Axis Exposed to Chronic CNS Bacterial Infection(s) and a Predictive Urinary Metabolic Profile of a Brain Infected by Mycobacterium tuberculosis.
Vascular endothelial growth factor and blood-brain barrier disruption in tuberculous meningitis.
Vascular endothelial growth factor in tuberculous meningitis.
Tuberculosis, Ocular
Mycobacterium Tuberculosis Modulates Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Ocular Tuberculosis.
Tuberculosis, Pulmonary
Angiopoietins as biomarkers of disease severity and bacterial burden in pulmonary tuberculosis.
Expression of vascular endothelial growth factor in tuberculous meningitis.
Expressions of miR-29a, TNF-? and Vascular Endothelial Growth Factor in Peripheral Blood of Pulmonary Tuberculosis Patients and Their Clinical Significance.
Immune responses in the lungs of patients with tuberculous pleural effusion without pulmonary tuberculosis.
Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis.
Serum levels of vascular endothelial growth factor and cavity formation in active pulmonary tuberculosis.
Vascular endothelial growth factor levels in active pulmonary tuberculosis.
Tuberous Sclerosis
Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients.
Elevated Expression of VEGF-C and Its Receptors, VEGFR-2 and VEGFR-3, in Patients with Mesial Temporal Lobe Epilepsy.
Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex.
Novel Anti-Angiogenic and Anti-Tumour Activities of the N-Terminal Domain of NOEY2 via Binding to VEGFR-2 in Ovarian Cancer.
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis.
Sirolimus (rapamycin): from the soil of Easter Island to a bright future.
Sirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient.
Turner Syndrome
Brain-Derived Neurotropic Factor, Vascular Endothelial Growth Factor and Matrix Metalloproteinases as Markers of Metabolic Status in Non-Growth Hormone-Treated Girls With Turner Syndrome.
Potential involvement of vascular endothelial growth factor in pathophysiology of Turner syndrome.
Tympanic Membrane Perforation
The importance of vascular endothelial growth factor in the healing of acute tympanic membrane perforation.
Undifferentiated Connective Tissue Diseases
Increased expression of vascular endothelial growth factor in a case of protein-losing enteropathy with undifferentiated connective tissue disease.
Uremia
Complement factor D in uremia.
Influence of factor D concentrations on fluid phase C3 activation, lysis of rabbit erythrocytes and solubilization of immune complexes.
Number and function impairment of resident C-Kit+ cardiac stem cells in mice with renal dysfunction caused by 5/6 nephrectomy.
Peritoneal microvascular endothelial function and the microinflammatory state are associated with baseline peritoneal transport characteristics in uremic patients.
Ureteral Obstruction
Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubulointerstitial injury.
Rapamycin reduces renal hypoxia, interstitial inflammation and fibrosis in a rat model of unilateral ureteral obstruction.
Role of Mesenchymal Stem Cells Transfected With Vascular Endothelial Growth Factor in Maintaining Renal Structure and Function in Rats with Unilateral Ureteral Obstruction.
Vascular endothelial growth factor-C ameliorates renal interstitial fibrosis through lymphangiogenesis in mouse unilateral ureteral obstruction.
Vascular endothelial growth factor-C and -D are involved in lymphangiogenesis in mouse unilateral ureteral obstruction.
Urinary Bladder Neck Obstruction
Mesenchymal stem cell therapy inhibited inflammatory and profibrotic pathways induced by partial bladder outlet obstruction and prevented high-pressure urine storage.
Urinary Bladder Neoplasms
A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer.
Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.
Analytical validation of ONCURIA™ a multiplex bead-based immunoassay for the non-invasive bladder cancer detection.
Anti-angiogenesis approach to genitourinary cancer treatment.
Antiangiogenic activity of phthalides-enriched Angelica Sinensis extract by suppressing WSB-1/pVHL/HIF-1?/VEGF signaling in bladder cancer.
Antiangiogenic drugs for chemotherapy of bladder tumours.
Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo.
Arsenic Trioxide Downregulates Specificity Protein (Sp) Transcription Factors And Inhibits Bladder Cancer Cell And Tumor Growth.
Assessment of angiogenic factor, vascular endothelial growth factor, serum and urine level changes in superficial bladder tumor immunotherapy by intravesical Bacillus Calmette-Guerin.
Association between five polymorphisms in vascular endothelial growth factor gene and urinary bladder cancer risk: A systematic review and meta-analysis involving 6671 subjects.
Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk.
Association of single nucleotide polymorphisms in vascular endothelial growth factor gene with bladder cancer risk.
Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia.
Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival.
Bladder transitional cell carcinoma: correlation of contrast enhancement on computed tomography with histological grade and tumour angiogenesis.
BLCA-4 expression is related to MMP-9, VEGF, IL-1? and IL-8 in bladder cancer but not to PEDF, TNF-? or angiogenesis.
Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells.
Circ0001429 regulates progression of bladder cancer through binding miR-205-5p and promoting VEGFA expression.
circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGF?R1/VEGF-D signaling.
Cis-dichlorodiammineplatinum Upregulates Angiotensin II Type 1 Receptors through Reactive Oxygen Species Generation and Enhances VEGF Production in Bladder Cancer.
Clinical significance of the VEGF level in urinary bladder carcinoma.
Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors.
Clinical value of vascular endothelial growth factor and endostatin in urine for diagnosis of bladder cancer.
Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer.
Comparison of seven screening methods in the diagnosis of bladder cancer.
Copper and zinc levels in plasma and cancerous tissues and their relation with expression of VEGF and HIF-1 in the pathogenesis of muscle invasive urothelial bladder cancer: a case-controlled clinical study.
Correlation of APE1 with VEGFA and CD163+ macrophage infiltration in bladder cancer and their prognostic significance.
Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma.
Curcumin decreases specificity protein expression in bladder cancer cells.
Cytotoxic necrotizing factor 1 promotes bladder cancer angiogenesis through activating RhoC.
Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells.
Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.
Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C.
Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer.
Effects of bevacizumab on autocrine VEGF stimulation in bladder cancer cell lines.
Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression.
Expression and clinical significance of microRNA-21, maspin and vascular endothelial growth factor-C in bladder cancer.
Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer.
Expression of vascular endothelial growth factor in primary superficial bladder cancer.
Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer.
Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer.
Haplotype-based association of Vascular Endothelial Growth Factor gene polymorphisms with urothelial bladder cancer risk in Tunisian population.
HB-EGF is a potent inducer of tumor growth and angiogenesis.
High VEGF-D and Low MMP-2 Serum Levels Predict Nodal-Positive Disease in Invasive Bladder Cancer.
Immunohistochemical detection of the 150-kDa oxygen-regulated protein in bladder cancer.
Impact of vascular endothelial growth factor gene-gene and gene-smoking interaction and haplotype combination on bladder cancer risk in Chinese population.
Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer.
Investigating Colorimetric Protein Array Assay Schemes for Detection of Recurrence of Bladder Cancer.
Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?
Knockdown of HMGN5 increases the chemosensitivity of human urothelial bladder cancer cells to cisplatin by targeting PI3K/Akt signaling.
Loss of GATA3 in bladder cancer promotes cell migration and invasion.
Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia.
Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D.
Mechanisms of Disease: angiogenesis in urologic malignancies.
MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C.
miR-101 Suppresses Vascular Endothelial Growth Factor C That Inhibits Migration and Invasion and Enhances Cisplatin Chemosensitivity of Bladder Cancer Cells.
Molecular mediators of angiogenesis in bladder cancer.
Molecular pathology of non-invasive urothelial carcinomas (part I).
Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application.
p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.
Pigment epithelium-derived factor expression is down-regulated in bladder tumors and correlates with vascular endothelial growth factor and matrix metalloproteinase-9.
Pioglitazone does not increase the risk of type II diabetes in patients with bladder cancer: A retrospective study.
Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A.
Prognostic significance of angiogenesis in superficial bladder cancer.
Prognostic Value of Tissue Vascular Endothelial Growth Factor Expression in Bladder Cancer: a Meta-analysis.
Proliferation activity in bladder tumors does not correlate with the pathological grading.
Re: Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C.
Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines.
Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo.
Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel.
Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer.
Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
Targeting angiogenesis in bladder cancer.
The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism.
The diagnostic efficacy of urinary TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology.
The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy.
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer.
The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer.
The role of peroxisome proliferator-activated receptor gamma in bladder cancer in relation to angiogenesis and progression.
The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.
Tumour-associated macrophages mediate the invasion and metastasis of bladder cancer cells through CXCL8.
Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer.
Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.
Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression.
Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin.
Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.
Vascular Endothelial Growth Factor, Carbonic Anhydrase 9, and Angiogenin as Urinary Biomarkers for Bladder Cancer Detection.
Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer.
Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer.
VEGF gene rs3025039C/T and rs833052C/A variants are associated with bladder cancer risk in Asian descendants.
VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival.
[Down-regulation effect of TGF-beta1 on expression of VEGF in bladder cancer cell line].
[Effects of transforming growth factor-?1 gene silencing on the expression of vascular endothelial growth factor in human bladder cancer cell lines].
[Expression of VEGF and tumor angiogenesis in bladder cancer]
[Inhibition of bladder cancer cell growth and angiogenesis by co-blockage of vascular endothelial growth factor and its receptor kdr]
[Molecular markers for the diagnosis of non-muscle-invasive bladder cancer].
[New markers for pharmacological targeting in bladder cancer with lymph node metastasis]
[Screening of anti-tumor parts from the seeds of Livistona chinensis and its anti-angiogenesis effect]
[Study of the angiogenesis as prognostic factor of pT1G3 bladder tumours]
[The role of tumor markers in prognosing transitional bladder cancer.]
Urinary Bladder, Neurogenic
Nerve growth factor combined with vascular endothelial growth factor enhances regeneration of bladder acellular matrix graft in spinal cord injury-induced neurogenic rat bladder.
Urinary Incontinence
Bioactive Porous Beads as an Injectable Urethral Bulking Agent : Their In Vitro Evaluation on Smooth Muscle Cell Differentiation.
Urinary Tract Infections
Functional polymorphisms in transforming growth factor-beta-1 (TGF{beta}-1) and vascular endothelial growth factor (VEGF) genes modify risk of renal parenchymal scarring following childhood urinary tract infection.
Genetic control of VEGF and TGF-beta1 gene polymorphisms in childhood urinary tract infection and vesicoureteral reflux.
Urogenital Neoplasms
Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas.
Urologic Neoplasms
Association between vascular endothelial growth factor rs699947 polymorphism and the risk of three major urologic neoplasms (bladder cancer, prostate cancer, and renal cell carcinoma): A meta-analysis involving 11,204 subjects.
Urticaria
Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria.
Vitamin D suppress the production of vascular endothelial growth factor in mast cell by inhibiting PI3K/Akt/p38 MAPK/HIF-1? pathway in chronic spontaneous urticaria.
Uterine Cervical Neoplasms
A quantitative analysis of the reduction in oxygen levels required to induce up-regulation of vascular endothelial growth factor (VEGF) mRNA in cervical cancer cell lines.
Angiogenesis and lymphangiogenesis as prognostic factors after therapy in patients with cervical cancer.
Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome.
Anticancer effects of the engineered stem cells transduced with therapeutic genes via a selective tumor tropism caused by vascular endothelial growth factor toward HeLa cervical cancer cells.
Association between vascular endothelial growth factor expression and lymph node metastasis in cervical cancer: A meta-analysis.
Association of CXCR4, CCR7, VEGF-C and VEGF-D expression with lymph node metastasis in patients with cervical cancer.
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
CCDC7 Activates Interleukin-6 and Vascular Endothelial Growth Factor to Promote Proliferation via the JAK-STAT3 Pathway in Cervical Cancer Cells.
Celecoxib radiosensitizes the human cervical cancer HeLa cell line via a mechanism dependent on reduced cyclo-oxygenase-2 and vascular endothelial growth factor C expression.
Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival.
Chemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancer.
Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers.
Clinical Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Invasive Cervical Cancer.
Concentration of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in the serum of patients with cervical cancer: prediction of response.
Correlation of serum vascular endothelial growth factor with clinicopathological parameters in cervical cancer.
Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia.
Effects and significance of formononetin on expression levels of HIF-1? and VEGF in mouse cervical cancer tissue.
Effects of shRNA-mediated Silencing of PSMA7 on Cell Proliferation and Vascular Endothelial Growth Factor Expression via the Ubiquitin-Proteasome Pathway in Cervical Cancer.
Effects of tetrahydrocurcumin on hypoxia-inducible factor-1? and vascular endothelial growth factor expression in cervical cancer cell-induced angiogenesis in nude mice.
Effects of VEGF suppression by small hairpin RNA interference combined with radiotherapy on the growth of cervical cancer.
Emerging Biological Treatments for Uterine Cervical Carcinoma.
Estrogen-related receptor ? expression and function are associated with vascular endothelial growth factor in human cervical cancer.
Evaluation of tissue-specific promoters in carcinomas of the cervix uteri.
Expression and prognosis of CyclinA and CDK2 in patients with advanced cervical cancer after chemotherapy.
Expression of Angiopoietin and VEGF in Cervical Cancer and its Clinical Significance.
Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes.
Expression of IP-10 related to angiogenesis in uterine cervical cancers.
Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers.
Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis.
Expression of vascular endothelial growth factor C correlates with a poor prognosis based on analysis of prognostic factors in patients with cervical carcinomas.
Expressions of VEGF and miR-21 in tumor tissues of cervical cancer patients with HPV infection and their relationships with prognosis.
Feasibility of MRI-based radiomics features for predicting lymph node metastases and VEGF expression in cervical cancer.
Function of inducible nitric oxide synthase in the regulation of cervical cancer cell proliferation and the expression of vascular endothelial growth factor.
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
Grading of uterine cervical cancer by using the ADC difference value and its correlation with microvascular density and vascular endothelial growth factor.
Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells.
Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
Human telomerase reverse transcriptase regulates vascular endothelial growth factor expression via human papillomavirus oncogene E7 in HPV-18-positive cervical cancer cells.
Improved survival with bevacizumab in advanced cervical cancer.
Influence of serum VEGF levels on therapeutic outcome and diagnosis/prognostic value in patients with cervical cancer.
Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal.
Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor.
Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.
Interleukin?17A and heparanase promote angiogenesis and cell proliferation and invasion in cervical cancer.
Monoclonal antibodies in gynecological cancer: a critical point of view.
Overexpression of astrocyte elevated gene-1 (AEG-1) in cervical cancer and its correlation with angiogenesis.
Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells.
Overexpression of VEGF165 is associated with poor prognosis of cervical cancer.
Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.
Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling.
Pretreatment levels of serum vascular endothelial growth factor do not correlate with outcome in patients with locally advanced cervical cancer.
Prognostic role of vascular endothelial growth factor in cervical cancer: a meta-analysis.
Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix.
Relationship of common vascular endothelial growth factor polymorphisms and haplotypes with the risk of cervical cancer in Tunisians.
Role of hypoxia-inducible factor-1?, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer.
Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.
Role of vascular endothelial growth factor receptor-3/Flt-4 in early-stage cervical cancer.
Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix.
Serum vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer.
Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer.
Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-B.
Serum vascular endothelial growth factor: a prognostic factor in cervical cancer.
Significance of hypoxia in uterine cervical cancer. Multicentre study.
STRATEGIES OF TREATING CANCER BY CYTOKINE REGULATION OF CHROMOSOME END REMODELLING.
Suppression of vascular endothelial growth factor receptor 3 (VEGFR3) and vascular endothelial growth factor C (VEGFC) inhibits hypoxia-induced lymph node metastases in cervix cancer.
The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer.
The mechanism and inhibitory effect of recombinant human P53 adenovirus injection combined with paclitaxel on human cervical cancer cell HeLa.
The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus.
The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients.
Thymosin Beta-4, Actin-Sequestering Protein Regulates Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Nitric Oxide Production in HeLa Cervical Cancer Cells.
Up-regulation of vascular endothelial growth factor-C by nicotine in cervical cancer cell lines.
Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival.
Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1?/VEGF signals.
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers.
Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer.
Vascular endothelial growth factor C enhances cervical cancer cell invasiveness via upregulation of galectin-3 protein.
Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase.
Vascular endothelial growth factor C expression is closely correlated with lymph node recurrence and poor prognosis in patients with early stage cervical cancer.
Vascular endothelial growth factor C promotes cervical cancer cell invasiveness via regulation of microRNA-326/cortactin expression.
Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade.
Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis.
Vascular endothelial growth factor exression in uterine cervical cancer: correlation with clinicopathologic characteristics and survival.
Vascular endothelial growth factor in cervical carcinoma.
Vascular endothelial growth factor is implicated in early invasion in cervical cancer.
Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women.
VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix.
[Effects of anti-HPV16 E6-ribozyme on invasiveness of cervical carcinoma cell line CaSKi and vascular endothelial growth factor expression]
[Influence of hypoxia inducible factor-1alpha on cervical cancer cell line HeLa in vitro]
[Molecular markers of carcinogenesis in the diagnostics of cervical cancer]
[Serum galectin-9 in cervical cancer]
[VEGF--targeted therapy for the treatment of cervical cancer --literature review].
Uterine Cervicitis
CD40 is overexpressed by HPV16/18-E6 positive cervical carcinoma and correlated with clinical parameters and vascular density.
Uterine Hemorrhage
Angiogenic effects of norplant contraception on endometrial histology and uterine bleeding.
Decidualized human endometrial stromal cells mediate hemostasis, angiogenesis, and abnormal uterine bleeding.
Vascular endothelial growth factor mRNA and its protein expression in decidua after terminating early pregnancy by mifepristone plus misoprostol.
Uterine Neoplasms
The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus.
Uterine Rupture
Collagen content and growth factor immunoexpression in uterine lower segment of type IA osteogenesis imperfecta: Relationship with recurrent uterine rupture in pregnancy.
Uveitis
Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(-) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study.
An Evidence-Based Review of Vascular Endothelial Growth Factor Inhibition in Pediatric Retinal Diseases: Part 2. Coats' Disease, Best Disease, and Uveitis With Childhood Neovascularization.
Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema.
Aqueous humor IL-8, IL-10, and VEGF levels in Fuchs' uveitis syndrome and Behçet's uveitis.
Aqueous Humor Levels of Different Interleukins 1-?, 2, 6 and 10, Tumor Necrosis Factor-? and Vascular Endothelial Growth Factor in Uveitis Treated with Adalimumab.
Increased vascular endothelial growth factor levels in aqueous humor and serum of patients with quiescent uveitis.
Mycobacterium Tuberculosis Modulates Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Ocular Tuberculosis.
Vascular endothelial growth factor inhibition in uveitis: a systematic review.
[Drug-induced uveitis].
Uveitis, Posterior
The use of vascular endothelial growth factor inhibitor for choroidal neovascularization complicating posterior uveitis in eyes with fluocinolone acetonide implants.
Vaccinia
A mechanism for induction of a hypoxic response by vaccinia virus.
Cytokines and their inhibitors in orf virus infection.
Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy.
Ovine diseases. Orf.
Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway.
Varicocele
Activation of adenosine A(2A) receptors by polydeoxyribonucleotide increases vascular endothelial growth factor and protects against testicular damage induced by experimental varicocele in rats.
Effects of experimental left varicocele repair on hypoxia-inducible factor-1? and vascular endothelial growth factor expressions and angiogenesis in rat testis.
Experimental varicocele induces hypoxia inducible factor-1alpha, vascular endothelial growth factor expression and angiogenesis in the rat testis.
Expression of vascular endothelial growth factor and its receptors in infertile men with varicocele.
Increased expression of the sonic hedgehog and vascular endothelial growth factor with co-localization in varicocele veins.
Involvement of vascular endothelial growth factor on spermatogenesis in testis with varicocele.
[Experimental varicocele affects VEGF and Flt-1 protein expressions in the testis and epididymis of adolescent rats]
Varicose Ulcer
Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endothelial growth factor transcription in the ulcer bed.
Increased but ineffectual angiogenic drive in nonhealing venous leg ulcers.
Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers.
Varicose Veins
Are Inflammatory Biomarkers Increased in Varicose Vein Blood?
Behavior of Smooth Muscle Cells under Hypoxic Conditions: Possible Implications on the Varicose Vein Endothelium.
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors.
Intense remodeling of extracellular matrix within the varicose vein: the role of gelatinases and vascular endothelial growth factor.
Serum concentration of procoagulant, endothelial and oxidative stress markers in early primary varicose veins.
Varicose veins: loss of release of vascular endothelial growth factor and reduced plasma nitric oxide.
Vascular complications in Chuvash polycythemia.
Vascular Diseases
Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases.
Aflibercept: an update on recent milestones achieved.
AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion.
Angiogenesis in the pathobiology and treatment of vascular and malignant diseases.
Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences.
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Cardiovascular gene therapy: current status and therapeutic potential.
Colorimetric immunoassays for the screening and specificity evaluation of molecules disturbing VEGFs/VEGFRs interactions.
Critical Role of Trophic Factors in Protecting Müller Glia: Implications to Neuroprotection in Age-Related Macular Degeneration, Diabetic Retinopathy, and Anti-VEGF Therapies.
Cyclic stretch induces VEGFA alternative splicing via Serine/Arginine-Rich Splicing Factor 1.
Efficacy, safety and influencing factors of intra-calf muscular injection of bone marrow mononuclear cells in the treatment of type 2 diabetes mellitus-induced lower extremity vascular disease.
Elastase and cell matrix interactions in the pathobiology of vascular disease.
Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease.
Evidence that C-reactive protein or IL-6 are not surrogates for all inflammatory cardiovascular risk factors in hemodialysis patients.
Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor.
Expression of angiogenesis and angiogenic factors in human aortic vascular disease.
Expression of the angiogenic mediator, angiopoietin-like 4, in the eyes of patients with proliferative sickle retinopathy.
Expression of vascular endothelial growth factor and its receptor, KDR, following retinal ischemia-reperfusion injury in the rat.
Expression of vascular endothelial growth factor in renal vascular disease and renal allografts.
Fat cell-derived modulators of vascular cell pathophysiology: the list keeps growing.
Gene therapy for the treatment of peripheral vascular disease and coronary artery disease.
Gene transfer of vascular endothelial growth factor plasmid/liposome complexes in glioma cells in vitro: the implication for the treatment of cerebral ischemic diseases.
Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis.
Impact of VEGF polymorphisms on the severity of peripheral artery disease in diabetic patients.
Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease.
Increased expression of the sonic hedgehog and vascular endothelial growth factor with co-localization in varicocele veins.
Inhibition of glucose-induced vascular endothelial growth factor expression by Salvia miltiorrhiza hydrophilic extract in human microvascular endothelial cells: Evidence for mitochondrial oxidative stress.
Lipopolysaccharide-Induced VEGF Production and Ambient Oxidative Stress in Type 2 Diabetes.
Long-acting protein drugs for the treatment of ocular diseases.
Lowering homocysteine decreases levels and expression of VEGF(165) and endostatin.
Management of retinal vascular diseases: a patient-centric approach.
Molecular targets for retinal vascular diseases.
Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding.
Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells.
Novel role of lactosylceramide in vascular endothelial growth factor-mediated angiogenesis in human endothelial cells.
PDGF-C and PDGF-D signaling in vascular diseases and animal models.
Phosphorylation of STAT3 and ERBB2 mediates hypoxia?induced VEGF release in ARPE?19 cells.
Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.
Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease.
Role of vascular endothelial growth factor in diabetic vascular complications.
Soluble fms-like tyrosine kinase-1 and the progression of carotid intima-media thickness – 24-month follow-up study –.
The impact of experimental preconditioning using vascular endothelial growth factor in stroke and subarachnoid hemorrhage.
The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease.
Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development.
Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.
Vascular endothelial growth factor a in intraocular vascular disease.
Vascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertension.
VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.
VEGFR1 promotes cell migration and proliferation through PLC? and PI3K pathways.
Zebrafish (Danio rerio) embryo as a platform for the identification of novel angiogenesis inhibitors of retinal vascular diseases.
[Advances of study on the relationship between vascular endothelial growth factor and ischemic cerebral vascular disease]
[Intraocular antiangiogenic drugs in clinical application advantages and disadvantages].
[Protective effect of electroacupuncture intervention on neurovascular unit in rats with focal cerebral ischemia-reperfusion injury].
Vascular Malformations
Cellular markers that distinguish the phases of hemangioma during infancy and childhood.
Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients.
Circulating Levels of Vascular Endothelial Growth Factor and Basic Fibroblastic Growth Factor in Infantile Hemangioma Versus Vascular Malformations.
Emerging importance of molecular pathogenesis of vascular malformations in clinical practice and classifications.
Endoglin prevents vascular malformation by regulating flow-induced cell migration and specification through VEGFR2 signalling.
Expression of angiogenic factors and structural proteins in central nervous system vascular malformations.
Neuropilin-2 and vascular endothelial growth factor receptor-3 are up-regulated in human vascular malformations.
Pericytes in Hereditary Hemorrhagic Telangiectasia.
Serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in children with hemangiomas and vascular malformations--preliminary report.
The pathology of scleroderma vascular disease.
The Use of Sirolimus for Treatment of Orbital Lymphatic Malformations: A Systematic Review.
Vascular endothelial growth factor and type 2 receptor for this factor in vascular malformations.
Vascular endothelial growth factor concentrations in serum of patients with extensive slow-flow vascular malformations.
Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.
Vascular Neoplasms
A phase II study of axitinib in advanced neuroendocrine tumors.
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
Vascular System Injuries
A defective angiogenesis in chronic kidney disease.
A20 inhibits post-angioplasty restenosis by blocking macrophage trafficking and decreasing adventitial neovascularization.
Acute Rejection After Kidney Transplantation Associates With Circulating MicroRNAs and Vascular Injury.
Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5.
Bone Marrow Rejuvenation Accelerates Re-Endothelialization and Attenuates Intimal Hyperplasia After Vascular Injury in Aging Mice.
Endothelial cell-targeted pVEGF165 polyplex plays a pivotal role in inhibiting intimal thickening after vascular injury.
Fat cell-derived modulators of vascular cell pathophysiology: the list keeps growing.
Hypoxia-inducible factor and vascular endothelial growth factor are targets of dietary soy during acute stroke in female rats.
Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy.
Inhibition of intimal thickening after vascular injury with a cocktail of vascular endothelial growth factor and cyclic Arg-Gly-Asp peptide.
Metabolic endotoxaemia in childhood obesity.
Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells.
Osteopontin expression and adventitial angiogenesis induced by local vascular endothelial growth factor 165 reduces experimental aortic calcification.
Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis.
Vascular endothelial growth factor causes endothelial proliferation after vascular injury.
Vasculitis
Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia.
Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: analysis using sera from a nationwide prospective cohort study.
Increased serum vascular endothelial growth factor levels in microscopic poly angiitis with pulmonary involvement.
Interleukin-6, vascular endothelial growth factor and transforming growth factor beta 1 in canine steroid responsive meningitis-arteritis.
Myositis, Vasculitis, Hepatic Dysfunction in Adult-Onset Still's Disease.
Overexpression of circulating vascular endothelial growth factor (VEGF) in leukocytoclastic vasculitis.
The detrimental effects of IFN-? on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.
Vascular endothelial growth factor gene polymorphisms and vasculitis susceptibility: A meta-analysis.
Vascular endothelial growth factor may provide additional values to C-reactive protein and anti-myeloperoxidase titer as a parameter for evaluating disease activity in anti-myeloperoxidase associated vasculitis.
[What's new in internal medicine?].
Vasospasm, Intracranial
Neurological surgery at the National Institutes of Health.
Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Venous Insufficiency
Analysis of vascular endothelial growth factor gene expression in the tissues of patients with chronic venous insufficiency.
Increased expression of platelet-derived growth factor receptor alpha and beta and vascular endothelial growth factor in the skin of patients with chronic venous insufficiency.
Venous Thromboembolism
Cardiotoxic effects of angiogenesis inhibitors.
Relationship between venous thromboembolism and vascular endothelial growth factor in cancer.
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS).
The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired study.
The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospectivematched-paired study.
Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer.
VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients.
Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy.
Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor.
[Two perspectives on venous thromboembolism in oncology].
Venous Thrombosis
Arterial and venous thrombosis are associated with different angiogenic cytokine patterns in patients with the antiphospholipid syndrome.
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review).
Thrombotic risk factors in patients with superior vena cava syndrome undergoing chemotherapy via femoral inserted central catheter.
Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet's patients with venous thrombosis.
Ventilator-Induced Lung Injury
Roles of lung-recruited monocytes and pulmonary Vascular Endothelial Growth Factor (VEGF) in resolving Ventilator-Induced Lung Injury (VILI).
Ventricular Dysfunction, Left
Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients.
Vesico-Ureteral Reflux
Extracellular microenvironment and cytokine profile of the ureterovesical junction in children with vesicoureteral reflux.
Genetic control of VEGF and TGF-beta1 gene polymorphisms in childhood urinary tract infection and vesicoureteral reflux.
Structural changes of the intravesical ureter in children with vesicoureteral reflux-does ischemia have a role?
Vesicular Stomatitis
Matrix protein of vesicular stomatitis virus: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation.
Viremia
Vascular endothelial growth factor A polymorphism and risk of Kaposi's sarcoma herpesvirus viremia in kidney allograft recipients.
Virus Diseases
A Novel Vascular Endothelial Growth Factor Receptor Participates in White Spot Syndrome Virus Infection in
Andes virus infection of lymphatic endothelial cells causes giant cell and enhanced permeability responses that are rapamycin and vascular endothelial growth factor C sensitive.
Capsicum annuum WRKY transcription factor d (CaWRKYd) regulates hypersensitive response and defense response upon Tobacco mosaic virus infection
Capsicum annuum WRKY transcription factor d (CaWRKYd) regulates hypersensitive response and defense response upon Tobacco mosaic virus infection.
Host Response Cytokine Signatures in Viral and Nonviral Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Pretreatment with recombinant human vascular endothelial growth factor reduces virus replication and inflammation in a perinatal lamb model of respiratory syncytial virus infection.
Relationship between circulating vascular endothelial growth factor and its soluble receptors in adults with dengue virus infection: a case-control study.
Serum complement concentrations, nutritional status and the outcome of measles and measles pneumonia.
Study of serum VEGF levels in patients with severe dengue infection admitted in a tertiary care hospital in Kolkata.
The role of vascular endothelial growth factor leading to vascular leakage in children with dengue virus infection.
Vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGFbeta), and interleukin-6 (IL-6) in experimental herpesvirus retinopathy: association with inflammation and viral infection.
Vascular endothelial growth factor levels in dobrava/belgrade virus infections.
Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic Fever.
Vision Disorders
A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes.
Curcumolide, a unique sesquiterpenoid from Curcuma wenyujin displays anti-angiogenic activity and attenuates ischemia-induced retinal neovascularization.
Hot Topics in Dry AMD.
Ranibizumab: a review of its use in myopic choroidal neovascularization.
Ranibizumab: in diabetic macular oedema.
SGLT2 Inhibitor-Induced Low-Grade Ketonemia Ameliorates Retinal Hypoxia in Diabetic Retinopathy-A Novel Hypothesis.
The patients' view: age-related macular degeneration and its effects - a meta-synthesis.
Therapeutic Potential of Anti-Angiogenic Multi-Target N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy.
[Overview of medical practices in wet AMD in France].
Vitamin D Deficiency
Interactions between and Shared Molecular Mechanisms of Diabetic Peripheral Neuropathy and Obstructive Sleep Apnea in Type 2 Diabetes Patients.
Vitelliform Macular Dystrophy
An Evidence-Based Review of Vascular Endothelial Growth Factor Inhibition in Pediatric Retinal Diseases: Part 2. Coats' Disease, Best Disease, and Uveitis With Childhood Neovascularization.
Vitiligo
Is the +405 G/C single nucleotide polymorphism of the vascular endothelial growth factor (VEGF) gene associated with late-onset vitiligo?
Vitreoretinopathy, Proliferative
Antiangiogenic Isoforms of VASCULAR ENDOTHELIAL GROWTH FACTOR Predominate in Subretinal Fluid of Patients with Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy.
Antiproliferative Wirkung von Genistein auf kultivierte retinale Pigmentepithelzellen vom Schwein.
Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
Changes in retinal gene expression in proliferative vitreoretinopathy: glial cell expression of HB-EGF.
Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment.
Intravitreal connective tissue growth factor neutralizing antibody or bevacizumab alone or in combination for prevention of proliferative vitreoretinopathy in an experimental model.
Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
Overexpression of CD163 in vitreous and fibrovascular membranes of patients with proliferative diabetic retinopathy: possible involvement of periostin.
Placenta growth factor and vascular endothelial growth factor in the vitreous of patients with proliferative vitreoretinopathy.
Triamcinolone acetonide modulates TGF??2?induced angiogenic and tissue?remodeling effects in cultured human retinal pigment epithelial cells.
Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor ? to promote proliferative vitreoretinopathy.
Vascular endothelial growth factor and fibroblast growth factor 5 are colocalized in vascular and avascular epiretinal membranes.
Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy.
Vitreous Vascular Endothelial Growth Factor Concentrations in Proliferative Diabetic Retinopathy versus Proliferative Vitreoretinopathy.
Vitreous Detachment
Effect of posterior vitreous detachment on aqueous humor level of vascular endothelial growth factor in exudative age-related macular degeneration patients.
Effects of posterior vitreous detachment on aqueous humour levels of VEGF and inflammatory cytokines.
Plasmin treatment accelerates vascular endothelial growth factor clearance from rabbit eyes.
Relation of diabetic macular edema to cytokines and posterior vitreous detachment.
Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema.
Vitreous Hemorrhage
Intravitreous VEGF-A in eyes with massive vitreous hemorrhage.
PERSISTENT OVERPRODUCTION OF INTRAOCULAR VASCULAR ENDOTHELIAL GROWTH FACTOR AS A CAUSE OF LATE VITREOUS HEMORRHAGE AFTER VITRECTOMY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
RANDOMIZED CONTROLLED STUDY OF INTRAVITREAL BEVACIZUMAB 0.16 MG INJECTED ONE DAY BEFORE SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
von Hippel-Lindau Disease
Clinicopathological study of vascular endothelial growth factor (VEGF), p53, and proliferative potential in familial von Hippel-Lindau disease and sporadic hemangioblastomas.
Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome.
Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease.
Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes.
Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.
Serous cystic neoplasms of the pancreas: clinicopathologic and molecular characteristics.
Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Vulvar Diseases
Angiogenesis in benign, pre-malignant and malignant vulvar lesions.
Vulvar Lichen Sclerosus
Distribution of transforming growth factor-beta isoforms TGF-beta 1, TGF-beta 2 and TGF-beta 3 and vascular endothelial growth factor in vulvar lichen sclerosus.
Vulvar Neoplasms
Role of angiogenesis in benign, premalignant and malignant vulvar lesions.
Serum concentrations of vascular endothelial growth factor in vulvar cancer.
[Expression patterns in isoforms of vascular endothelial growth-factors in tissue samples of vulval cancer T1 N2M0 stage]
Warts
Expression of angiopoietin-1, angiopoietin-2, and their receptor Tie2 in verruca vulgaris (common skin warts).
Wet Macular Degeneration
Clinical application of therapies targeting VEGF.
Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration.
Macugen treatment for wet age-related macular degeneration.
White Coat Hypertension
Endothelium and angiogenesis in white coat hypertension.
Whooping Cough
Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver.
Pertussis toxin attenuates experimental autoimmune encephalomyelitis by upregulating neuronal vascular endothelial growth factor.
Wilms Tumor
Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor.
Antiangiogenic therapy for Wilms tumor in an adult and literature review.
Coexpression of hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in Wilms' tumor.
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
Early changes in gene expression that influence the course of primary glomerular disease.
Effect of antiepileptic drug (Topiramate) and cold pressed ginger oil on testicular genes expression, sexual hormones and histopathological alterations in mice.
Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma.
Expression of vascular endothelial growth factor (VEGF) and VEGF-C in serum and tissue of Wilms tumor.
HIF-2?, acting via miR-191, is involved in angiogenesis and metastasis of arsenite-transformed HBE cells.
In vivo and in vitro analysis of the vasculogenic potential of avian proepicardial and epicardial cells.
Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Metastasis correlates with production of vascular endothelial growth factor in a murine model of human Wilms' tumor.
Modified scanning electron microscopy reveals pathological crosstalk between endothelial cells and podocytes in a murine model of membranoproliferative glomerulonephritis.
p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease.
Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction.
Suppression of tumorigenicity of rhabdoid tumor derived G401 cells by the multivalent HB-19 pseudopeptide that targets surface nucleolin.
TGF-?-Activated Kinase 1 Is Crucial in Podocyte Differentiation and Glomerular Capillary Formation.
The prognostic significance of angiogenesis and the effect of vascular endothelial growth factor on angiogenic process in Wilms' tumour.
The significance of VEGF-C/VEGFR-2 interaction in the neovascularization and prognosis of nephroblastoma (Wilms' tumour).
The Wilms' Tumor Gene WT1 - 17AA/- KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model.
Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis.
Wilms' tumor gene (WT1) expression correlates with vascular epithelial growth factor (VEGF) in newly acute leukemia patients undergoing chemotherapy.
Zebrafish no isthmus reveals a role for pax2.1 in tubule differentiation and patterning events in the pronephric primordia.
[Expression of Stat3, HIF-1alpha and VEGF in Wilms' tumor]
[Predictive value of vascular endothelial growth factor in metastasis of nephroblastoma]
Xeroderma Pigmentosum
The helicase XPD unwinds bubble structures and is not stalled by DNA lesions removed by the nucleotide excision repair pathway.
Xerostomia
Inhibition of experimental Sjögren's syndrome through immunization with HSP60 and its peptide amino acids 437-460.
Yellow Fever
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Yersinia Infections
Vascular endothelial growth factor in yersiniosis. A study on 157 military recruits.